THE NATIONAL CLEARINGHOUSE FOR MENTAL HEALTH INFORMATION

VOL. 12 - Cumulative Index - June 1975

PSYCHOPHARMACOLOGY ABSTRACTS

NATIONAL INSTITUTE OF MENTAL HEALTH

PSYCHOPHARMACOLOGY ABSTRACTS is a publication of the National Clearinghouse for Mental Health Information of the National Institute of Mental Health. It is a specialized information medium designed to assist the Institute in meeting its obligation to foster and support laboratory and clinical research into the nature and causes of mental disorders and methods of treatment and prevention. Specifically, this information service is designed to meet the needs of investigators in the field of psychopharmacology for rapid and comprehensive information about new developments and research results. For information or correspondence with the National Institute of Mental Health concerning *Psychopharmacology Abstracts,* changes of address, or removal of names from the mailing list see the inside back cover page.

The Secretary of Health, Education, and Welfare has determined that the publication of this periodical is necessary in the transaction of the public business required by law of this Department. Use of funds for printing this periodical has been approved by the Director of the Office of Management and Budget through December 31, 1976.

NATIONAL CLEARINGHOUSE FOR MENTAL HEALTH INFORMATION
PSYCHOPHARMACOLOGY ABSTRACTS

Volume 12

Cumulative Index

July 1975

	Page
Author Index	A1
Subject Index	S1

Carrie Lee Rothgeb, *Editor*
Bette L. Shannon, *Managing Editor*

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
Public Health Service

Alcohol, Drug Abuse and Mental Health Administration
5600 Fishers Lane
Rockville, Maryland 20852

Publication No. (ADM) 75-150
Printed 1975

For sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402. Subscription price per year in the United States, Canada, and Mexico: $16.90; other countries, $21.15. Single copy $3.70. Index issue $2.25. The Clearinghouse does not sell copies of *Psychopharmacology Abstracts*. Persons wishing to subscribe by the year or to purchase single copies should send their orders, accompanied by check or money order, directly to the Superindendent of Documents.

AUTHOR INDEX

(The 6-digit number is the abstract accession number. The next two digits are the issue number; digits after hyphen are the category number.)

A

ABBATIELLO ER 172374 01-04
ABDALLAH A 192014 04-04
ABDALLAH AH 171007 01-13, 189613 04-04
ABE T 171282 01-11
ABEL EL 176880 02-03, 186570 03-03, 187928 04-03
ABLON SL 181274 02-09
ABRAMS LS 183899 03-03
ABRAMS R 170627 01-09
ABRAMSON DC 174568 01-11
ABSAVA GI 183518 03-01, 191122 04-03
ABUZZAHAB FS 171695 01-09
ACETO MD 191907 04-14
ACHEE FM 191300 04-03
ADACHI K 168302 01-17
ADAMS MD 191971 04-03
ADAMS RN 190239 04-08
ADIKUSUMO A 170753 01-11
ADKINS EK 186681 03-03
ADLER M 183897 03-03
ADLER R 184291 03-14
ADOLPHE M 188864 04-03
AFIFI A 183600 03-01
AFIFI AH 182159 02-03
AFLALO M 183201 03-11
AGARWAL VK 185035 03-01
AGHAJANIAN GK 177407 02-12, 182141 02-03, 188750 04-03, 191931 04-03, 191949 04-03
AGHJANIAN GK 191948 04-03
AGID Y 183794 03-03
AGRESTI E 182788 03-09
AHLENIUS S 171611 01-04, 171614 01-04
AHTEE L 183606 03-04, 191421 04-03
AIRAKSINEN MM 171613 01-03
AJMANI S 175410 02-09
AKABORI F 176456 02-11
AKERA T 182184 02-03
AKISKAL HS 187866 04-11
AKPINAR S 174131 01-08, 180064 02-10
AL-BAKER A 187076 03-05
AL-HACHIM GM 187076 03-05
AL-KAISI AH 185191 03-14
ALBANUS L 171632 01-03
ALBIN MS 188689 04-05
ALBRIGHT JD 185033 03-04
ALDERMAN JL 191988 04-03
ALEKSANDROWICZ MK 183706 03-17
ALES M 168976 01-14
ALEXANDER K 169817 01-13, 170838 01-13
ALEXANDER N 188198 04-03
ALEXANDER RW 191511 04-13
ALGERI S 189752 04-03
ALI B 169818 01-01, 182727 03-03, 185980 03-01, 191942 04-03
ALI N 185005 03-08
ALIVISATOS SGA 191956 04-03
ALLEN BS 185927 03-04
ALLEN C 185927 03-04
ALLEN CR 167334 01-07
ALLEN GS 182088 02-03
ALLIKMETS LK 191783 04-02, 191785 04-02, 191788 04-04
ALLSOP JL 187618 04-11
ALLTOP LB 171500 01-09
ALMLI CR 168859 01-03
ALTMAN H 176676 02-17
ALTSHULER HL 191939 04-04
ALVES CN 167362 01-04
ALVIN J 177731 02-03
AMADUCCI L 168578 01-13
AMAKUSA T 181378 02-08
AMAMOTO T 191670 04-09
AMAN MG 185861 03-14
AMBANI LM 170662 01-13
AMERY W 183194 03-09
AMIELANCZYK W 174784 01-15
AMIN M 167774 01-09, 168807 01-11, 191138 04-14
AMIT Z 183470 03-04, 183790 03-04, 184238 03-04, 186586 03-04
AMMAR EM 183600 03-01
AMMON HPT 168440 01-03
AMORI T 173548 01-05
ANAGNOSTE B 182256 03-03
ANANTH JV 168313 01-08, 168319 01-15, 177676 02-17, 180243 02-15, 180247 02-15, 192412 04-17
ANDEN N 171611 01-04, 171622 01-03, 171623 01-03, 189571 04-03
ANDERSON A 189924 04-17
ANDERSON EG 168436 01-03, 188751 04-03, 189832 04-03
ANDERSON PF 180057 02-03
ANDERSON R 182157 02-03
ANDERSON RE 185330 03-14
ANDERSON SW 177674 02-14
ANDJELKOVIC D 180058 02-03
ANDO K 182110 02-04
ANDREANI G 175540 02-11
ANDREWS CJ 187615 04-11
ANGEL C 187868 04-04, 190696 04-04
ANGELETTI PU 177338 02-03
ANGRIST B 185875 03-11, 186744 03-14
ANGRIST BM 177826 02-13, 191507 04-13
ANNAU Z 191917 04-04
ANSELL GB 171971 01-01
ANTELMAN SM 182212 03-03
ANTON AH 191920 04-03
ANTONACCIO MJ 177406 02-03
ANTONELLI F 168809 01-11
ANTOPOL W 189582 04-05
ANUSUYA SR 169633 01-11
AOKI N 182552 03-15
AONO T 181377 02-15
APFELBACH R 183863 03-04
APOSHIAN D 190476 04-03
APPEL JB 174034 01-04, 185752 03-04
AQUILONIUS S 171600 01-03, 171606 01-03
ARA T 176541 02-08
ARAKI Y 181384 02-04
ARAT M 174131 01-08
ARBRUS M 191771 04-03
ARCHIBALD JL 187940 04-01
AREVALO L 169467 01-03
ARIOKA I 176472 02-08
ARITOME T 171275 01-15
ARORA RC 191956 04-03
AROURA S 191997 04-03
ARRANZ T 183955 03-08
ARRIGO A 167336 01-13
ARUSHANYAN EB 183521 03-17
ASANO Y 184178 03-03
ASAO Y 176472 02-09
ASBERG M 192873 04-09
ASCHKENASE LJ 192565 04-04
ASHKENAZI R 174319 01-03
ASHTON H 182763 03-14, 187350 04-13
ASKEW WE 185582 03-03, 188167 04-03
ASO S 176727 02-08
ASPER H 191418 04-03
ATKINSON M 187565 04-11
ATKINSON RC 189406 04-14
ATRENS DM 186164 03-04
AUCLAIR MC 188864 04-03
AUDIO-VISUAL SERVICES LH 189297 04-17
AURES D 189597 04-03
AUYONG TK 182727 03-03
AVIS HH 183615 03-14, 190264 04-04
AXELROD J 170082 01-03, 177128 02-03, 177403 02-16, 178747 02-03, 181468 02-03, 187397 04-03
AYD FJ 188312 04-15, 191044 04-08, 191119 04-09
AYUSO GUTIERREZ JL 187536 04-09
AZARNOFF DL 190258 04-15

B

BABBINI M 178756 02-04
BABOR TF 169084 01-13
BACHRACH AJ 186630 03-04
BADER A 186026 03-12
BAENNINGER R 185463 03-04
BAER L 169869 01-15
BAEZ LA 186582 03-03
BAEZ S 182185 02-03
BAGADIA VN 172444 01-08, 174588 01-08, 174589 01-08, 175393 02-11, 175460 02-08, 175967 02-10, 180153 02-08
BAGCHI SP 184838 03-04
BAGGIOLINI M 191418 04-03
BAILEY DN 177394 02-15
BAILEY DW 185751 03-03
BAILEY J 192577 04-09
BAILEY LC 176871 02-16
BAKER JD 190194 04-11
BAKER KM 189073 01-01
BAKER M 185928 03-09
BAKER TG 191906 04-03
BAKER WW 167329 01-03, 182129 02-03
BALASSA M 180672 02-11
BALAZS T 191982 04-15
BALDAUF A 182900 03-11
BALDESSARINI RJ 169120 01-03, 191035 04-15
BALDET M 180723 02-03
BALDWIN BA 189409 04-04
BALLINGER BR 185195 03-17
BALOCH N 189042 04-15
BALTER MB 177699 02-17, 181713 02-17
BALZAMO E 191629 04-04
BAMJI AN 191320 04-08
BAN TA 167774 01-09, 168313 01-08, 168804 01-16, 168805 01-11, 168806 01-11, 168807 01-11, 169296 01-09, 170293 01-11, 183360 03-13, 191138 04-14, 191139 04-17, 192412 04-17
BAN TS 180243 02-15
BANCROFT J 190061 04-11
BANDMAN AL 174257 01-03
BANDO M 182872 03-03
BANEN DM 167496 01-11
BANERJEE SP 191290 04-08
BANERJEE U 172921 01-04
BARATTI CM 169467 01-03
BARCHAS JD 183891 03-03
BARDAKHCH'YAN EA 183520 03-01
BARFKNECHT CF 172915 01-03, 177734 02-03, 188121 04-12
BARKER JL 168485 01-03, 177976 02-03, 189033 04-03, 190727 04-03
BARKER LA 182237 03-04, 192000 04-03
BARKER LM 190265 04-04
BARNARD M 182219 03-03
BARNETT A 182240 03-04
BARO F 192431 04-08
BAROFSKY I 182244 03-03
BARONDES SH 188605 04-04
BARRACLOUGH BM 174561 01-15
BARRATT E 167334 01-07
BARRER B 178255 02-08
BARRETT R 182204 02-03
BARRETT RJ 179990 02-04, 189521 04-04, 191914 04-04
BARRY H 182190 02-04, 182243 03-03, 185748 03-04, 188228 04-06, 189525 04-04, 191946 04-03
BARSUHN C 186578 03-03
BARTHOLINI G 184229 03-03, 186677 03-03, 189602 04-03
BARTHWAL JP 183601 03-03
BARTOLETTI M 178756 02-04
BARUK H 180724 02-04
BASKIN SI 182184 02-03
BATES DE 177671 02-11
BATTIG K 174043 01-14, 190333 04-04
BATTISTA AF 191932 04-03
BAUER RB 189502 04-11
BAUER W 169462 01-14
BAUGH EL 171306 01-04
BAUM M 183470 03-04
BAUMANN IR 184227 03-03
BAUMANN P 181471 02-03
BAUMANN PA 172917 01-03
BAUMEL IP 182721 03-03
BAUMGARTEN HG 188287 04-03, 188977 04-03
BAXTER BL 182215 03-04
BAXTER JH 189895 04-03
BAYLOR MR 189177 04-02
BAYOMI SM 183600 03-01
BAYULKEM F 171121 01-17

BAZHIN EF 181778 02-08
BAZO AJ 173190 01-11
BEAHRS JO 184021 03-12
BEARD JD 187866 04-11
BEATON JM 187260 04-04, 189519 04-04
BEATTIE CW 175650 02-03
BEATTIE IA 182762 03-04
BEAUBIEN AR 191925 04-03
BEAVEN MA 189895 04-03
BECHTEREVA NP 178787 02-13
BECK AT 191857 04-09
BECK H 168369 01-11, 190095 04-11
BECKETT AH 183796 03-13, 190902 04-06
BECKNER JS 191968 04-03, 191970 04-03
BECKSTEAD HD 192787 04-17
BEDERKA JP 174606 01-12
BELANGER PM 183796 03-13
BELESLIN DB 186640 03-03
BELGRADE J 187700 04-04
BELIN M 179988 02-13
BELKNAP JK 175895 02-03
BELL DS 186702 03-04
BELL JA 170874 01-03, 174480 01-12
BEN-ISHAY D 173256 01-04
BEN-ZVI Z 187574 04-01
BENDER DA 191320 04-08
BENEDITO MAC 184212 03-04
BENESOVA O 192430 04-04
BENNETT EL 174036 01-03
BENNETT JL 188750 04-03
BENTLEY R 172741 01-08
BENVENUTI P 168578 01-13
BERARDI AC 183609 03-03
BERG D 185463 03-04
BERGER BD 182210 02-04
BERGER FM 182770 03-17
BERGNER PE 187255 03-08
BERGONZI P 186643 03-14
BERKOWITCH S 183201 03-11
BERKOWITZ BA 189390 04-03
BERNARD BK 182241 03-04
BERNDT S 181467 02-03
BERNHEIM J 180699 02-14
BERNSTEIN JG 187257 04-14
BERNTSON GG 182238 03-04
BERRY FA 182762 03-04
BERT J 191629 04-04
BERTHOD H 183406 03-01
BERTILSSON L 169074 01-01
BERTRAND N 189023 04-02
BESBRIS H 191281 04-03
BESSON MJ 184230 03-03
BEUMONT PJV 183807 03-10, 184436 03-15, 184437 03-13
BEYEL V 185877 03-08, 187840 04-17
BEYER EC 181158 02-09
BHARGAVA HN 182159 02-03, 191769 04-03, 191985 04-03
BHARGAVA KP 177021 02-03
BHASKARAN K 171985 01-08, 180154 02-08
BHATE S 185005 03-08
BHATIA SC 174376 01-09
BHATNAGAR SP 187800 04-03
BIALER I 177771 02-14
BIANCHI C 177729 02-13, 186377 03-06
BIANCHI GN 186584 03-10
BICKEL MH 192423 04-03
BIEGER D 177785 02-04
BIEL JH 174760 01-03, 191499 04-01
BIENER R 182722 03-13
BIERWAGEN ME 187573 04-03
BIGELOW A 181958 02-13
BIGELOW LB 177669 02-08, 177818 02-08
BIGELOW VTN 173791 01-04
BIGGIO G 168748 01-03
BIGGS JT 191924 04-13
BILLINGS EG 174566 01-09
BINAZZI A 168578 01-13
BINDRA D 182123 02-03
BIRCHALL PMA 175219 02-13
BIRCHLER A 188093 04-11
BIRDSONG JH 184195 03-11
BISCHOFF S 168750 01-03, 189396 04-03
BISCOE TJ 188201 04-03
BISHOP G 174137 01-08
BISHOP MP 174137 01-08
BITE A 185933 03-03
BIXLER EO 172114 01-15
BJEGOVIC M 170747 01-03
BJERKE K 172735 01-07
BJORUM N 172402 01-09
BLACK WC 188760 04-04
BLACKWELL B 167341 01-08, 189924 04-17
BLAIR AW 168523 01-14
BLAKEMORE C 185008 03-11
BLAMPIED NM 190334 04-04
BLANC G 188978 04-03
BLASIG J 169474 01-03
BLATCHLEY R 188121 04-12
BLESSED G 185005 03-08
BLOOM F 168817 01-03
BLOOM FE 187132 03-06, 187498 04-04, 187499 04-04, 191762 04-03
BLOUNT JF 185034 03-01
BLOZOVSKI D 169473 01-04
BLOZOVSKI M 169473 01-04
BLUM A 185873 03-09
BLUM JE 179021 02-05
BLUM K 169782 01-03, 192013 04-05
BOAL D 191522 04-13
BOBON DP 172972 01-13, 174044 01-11
BOBON J 174044 01-11, 183189 03-09, 183190 03-07
BOCK K 180676 02-11
BOEHMES DH 183602 03-01
BOELKINS RC 178867 02-04
BOGETTO F 184975 03-03
BOGGAN W 183891 03-03
BOGGAN WO 174034 01-04, 182167 02-03, 187698 04-04
BOHUON C 190337 04-03
BOISSE NR 191953 04-04
BOISSIER JR 167449 01-03
BOJANOVSKY J 182591 03-14
BOLT AG 168770 04-01
BOND AJ 168831 01-14
BONDARTCHUK AN 178787 02-13
BONILLA E 185993 03-03
BONISCH H 189604 04-03
BONN JA 182764 03-10
BOOHER R 187130 03-03
BOOM AJ 183194 03-09
BOPP B 174760 01-03
BORBELY AA 177477 02-04, 184227 03-03
BORBERG S 185954 03-04
BORCHARDT RT 190716 04-01, 190717 04-01
BORDA RP 177645 02-16
BORENSTEIN P 184955 03-17
BORG S 186565 03-08
BORGEN LA 182191 02-04, 183788 03-03, 191967 04-04
BORGMAN RJ 189177 04-02
BOROWITZ JL 189583 04-05, 189591 04-03
BOROWSKI R 184228 03-03
BORSY J 192416 04-03
BOSCO JJ 178127 02-17
BOST R 189072 04-08
BOSWORTH JE 188404 04-03
BOTALLA L 188350 04-13
BOUCSEIN W 184617 03-07
BOUERI-ATEM S 168923 01-11
BOULU R 169469 01-04
BOURDOUXHE S 174044 01-11, 183190 03-07
BOURGEOIS M 176432 02-15
BOURGOIN S 188164 04-03, 188976 04-03
BOUVET D 183794 03-03
BOVER CE 182128 02-04
BOVET D 186590 03-04
BOWDEN CL 172486 01-10
BOWERS MB 170662 01-13, 177736 02-13
BOWMAN RE 192565 04-04
BOYD EH 186666 03-03
BOYD ES 186666 03-03
BOYD R 177318 02-14
BOYSON S 191771 04-03
BRADBARD G 185324 03-14
BRADLEY RJ 187260 04-04
BRADLEY SG 177834 02-05
BRAESTRUP C 180059 02-03
BRAHAMANKAR D 188873 04-03
BRAHIM D 168923 01-11
BRAHM E 167774 01-09
BRAMBILLA F 191190 04-14
BRANCH B 183324 03-03
BRANCH BJ 181576 02-03
BRANCH MN 183890 03-04, 187066 03-04
BRAND L 182156 02-03
BRANDAU K 181468 02-03
BRASE DA 184179 03-03
BRASSEUR R 172978 01-09, 172979 01-09
BRASTED M 186676 03-03
BRAUD WG 186583 03-04
BRAUDE MC 182192 02-04, 188872 04-05, 189516 04-04, 189598 04-05, 191965 04-03, 191966 04-04
BRAUN P 167336 01-13
BRAUZER B 190195 04-09
BRAYTENBAH EA 182232 03-03
BREESE GR 186634 03-04, 186699 03-03, 187696 04-04, 189515 04-04, 191518 04-03, 191526 04-03, 191905 04-03, 191955 04-03, 191984 04-03
BREITBART H 177835 02-03
BRENNAN T 181811 02-13, 185083 03-12
BRESLER DE 185753 03-04
BREULET M 174044 01-11, 183190 03-07
BREZENOFF HE 182130 02-03
BRIDGE TP 192229 04-09
BRIDGER WH 178575 02-04, 190266 04-04
BRIDGERS WF 187260 04-04
BRIGHT TP 191993 04-05
BRISTOW RL 182160 02-03
BRODIE BB 188865 04-05
BRODIE RE 189564 04-05
BRODY JA 169376 01-15, 179996 02-13
BRODY TM 182184 02-03
BROEKKAMP CLE 174763 01-04, 187666 04-04
BRONAUGH RL 175232 02-03
BI NHEIM LA 167774 01-09, 191138 04-14
BROOKS E 185324 03-14
BROVERMAN DM 187149 03-13
BROWN CC 190146 04-07
BROWN CR 177320 02-11
BROWN DJ 191991 04-04, 191993 04-05
BROWN LE 186666 03-03
BROWN RA 178255 02-08
BROWN RM 171612 01-04
BROWN SS 172397 01-16
BROWN TS 184834 03-04
BROWNE IW 181811 02-13
BRUCKWICK EA 191511 04-13
BRUMLEVE SJ 169818 01-01, 183598 03-02, 183601 03-03, 191942 04-03
BRUNNGRABER EG 181815 02-03
BRUS R 178558 02-03
BRUUN RD 188431 04-11
BRYANT RW 191768 04-03
BUCCI L 186590 03-04
BUCH O 192420 04-13
BUCHANAN DC 178638 02-04, 184242 03-04
BUCHAR E 170072 01-03
BUCHENAUER D 183894 03-03
BUCHOWSKA I 174777 01-10
BUCHSBAUM M 169861 01-11
BUCKHOLTZ N 182229 03-03
BUCKLEY JP 182243 03-03, 183795 03-03, 185748 03-04
BUCKMAN J 189074 04-17
BUCKNER CK 186633 03-03
BUENING MK 184180 03-03
BUHRICH N 182765 03-09
BUNEGIN L 188689 04-05
BUNNELL PR 191966 04-04
BUNNEY BS 191948 04-03
BUNNEY WE 174479 01-14, 185928 03-09
BURES J 191411 04-03
BURI P 180700 02-15
BURKE W 187835 04-03
BURKHALTER A 188178 04-03
BURKI HR 191418 04-03
BURKMAN AM 182131 02-04
BURKS TF 188202 04-03
BURNER M 172977 01-11
BURNS M 189358 04-14
BUROV YV 183206 03-04
BURROWS G 187582 04-10
BURSTEIN S 169067 01-03, 187574 04-01
BURTON RM 192426 04-03
BUSH MT 177731 02-03, 177732 02-03, 191057 04-03
BUTCHER S 182250 03-03, 189597 04-03
BUTLER WM 188865 04-05
BUTTERWORTH AT 188584 04-11
BUYNISKI JP 187573 04-03
BYERS MR 191324 04-03
BYMASTER FP 191951 04-03
BYRD LD 183889 03-04

C

CAFFEY EM 171926 01-09, 172831 01-08, 186188 03-09, 186191 03-09, 189735 04-09
CAIRNS RB 173039 01-04
CALDWELL DF 191536 04-13
CALHOUN W 169782 01-03
CALLERY PS 175759 02-03, 190718 04-03
CALOBRISI A 174299 01-09
CAMPBELL BA 174860 01-04
CAMPBELL HE 192410 04-17
CAMPBELL JT 185957 03-04
CAMPBELL M 175872 02-17
CANALES ES 175245 02-13
CANDY J 168832 01-10
CANFIELD DR 182212 03-03
CANNON E 173398 01-03
CANTWELL DP 177778 02-11
CARDAUNS H 178619 02-05
CARDELLINI M 180098 02-01
CARENZI A 191766 04-03
CARL JL 177135 02-03
CARLIN AS 184021 03-12
CARLINI EA 167362 01-04, 169472 01-03, 183609 03-03
CARLSON ET 192059 04-17
CARLSON GP 167361 01-05
CARLSON HE 186580 03-09
CARLSSON A 191513 04-03
CARMAN JS 187985 04-11
CARNEY J 182195 02-04, 191983 04-04
CARON LB 183359 03-03
CARPENTER JF 186638 03-04
CARPER WR 178812 02-03
CARR CB 171241 01-14
CARR PJ 183807 03-10
CARROLL BJ 191532 04-09
CARROLL FI 182156 02-03
CARSKADON M 171496 01-11
CARTER SB 168286 01-13
CASE G 184175 03-10
CASE WG 172993 01-10
CASELLI G 175540 02-11
CASS J 190061 04-11
CASTAGNOLI N 175759 02-03, 187941 04-01, 190718 04-03
CASTAIGNE P 171134 01-13
CASTELLANO C 185751 03-03, 186705 03-04
CASTLES TR 182160 02-03
CASTREN O 171613 01-03
CATE JC 177393 02-15
CATOVIC S 184200 03-04
CAVANAGH RL 191906 04-03
CAVANAUGH GL 185873 03-09
CAVANAUGH JH 184654 03-13
CAVERO I 183795 03-03
CAVNESS C 189884 04-14
CEBIROGLU R 182431 03-11
CECCHETTI G 188196 04-03, 191422 04-03
CELY W 174608 01-05, 175238 02-03, 191994 04-03
CENTURY B 175859 02-03
CHABOT D 168619 01-15, 177511 02-11
CHAN TL 168836 01-08
CHANAL J 180723 02-03
CHAND N 177021 02-03
CHANDRA S 182828 03-02
CHANG HK 171259 01-04, 173078 01-04
CHANG LW 186476 03-05, 192565 04-04
CHANG WK 189178 04-02
CHANLEY JD 174995 02-09
CHAPALLAZ S 183786 03-15
CHAPOUTHIER G 168838 01-04
CHARALAMPOUS KD 190196 04-09
CHARLTON CG 191918 04-03
CHASE TN 169376 01-15, 169377 01-13, 177975 02-11, 179996 02-13, 186029 03-11, 187985 04-11, 191524 04-13
CHATURVEDI AK 183598 03-02
CHAU-WONG M 182127 02-03, 187802 04-03, 189400 04-03
CHAUDHARY A 183598 03-02
CHAUDHRY ZA 170622 01-09
CHAWLA R 174588 01-08, 175460 02-08
CHAYKIN LB 167335 01-11
CHEAH JS 167460 01-13
CHEN G 186581 03-04
CHEN SS 187802 04-03
CHENEY D 188891 04-03
CHENEY DL 180582 02-03, 182226 03-03, 184553 03-03, 187526 04-03
CHENG HC 177734 02-03, 188204 04-03
CHENG R 185192 03-11
CHENOWETH MB 182258 03-04
CHEON YS 180507 02-03
CHERNICK WS 191962 04-03
CHESHER GB 180057 02-03, 189513 04-03
CHESSEN DH 187837 04-15
CHIEL H 174764 01-03
CHIEN C 173006 01-09
CHIKVAIDZE VN 183142 03-13
CHIN L 191992 04-03
CHIN S 177674 02-14
CHINN C 183866 03-03
CHIODINI PG 188350 04-13
CHIUEH CC 176874 02-03, 189397 04-03, 191897 04-03
CHIURULLA C 186643 03-14
CHO AK 182203 02-06, 191921 04-03, 191923 04-03
CHO DW 176676 02-17
CHO HY 171259 01-04
CHO YN 173080 01-15
CHOE J 186678 03-03
CHOI L 189597 04-03
CHOPDE CT 188873 04-03
CHOROSH J 168420 01-12
CHOUINARD G 167343 01-08
CHOUVET G 179988 02-13
CHRISTENSEN AV 171607 01-04, 186371 03-04
CHRISTENSEN HD 182223 03-03
CHRISTIANSEN C 188889 04-11
CHRISTIANSEN J 183604 03-13
CHUN RWM 173205 01-11
CHUNG HR 167773 01-10, 172993 01-10, 185747 03-09
CIANCHETTI C 186643 03-14
CICCARELLI G 183199 03-11
CICERO TJ 183895 03-03, 191367 04-04
CIOFALO FR 183896 03-03
CISIN IH 177699 02-17
CLARE RA 183793 03-13
CLARIDGE GS 175219 02-13
CLARK DL 187640 04-04
CLARK EL 188144 04-10
CLARK ML 173402 01-08, 174348 01-14, 184177 03-11
CLARK SC 187812 04-13
CLARK WC 177674 02-14
CLARK WG 183608 03-03, 189587 04-05
CLARKE CC 183897 03-03
CLARKE PA 185005 03-08
CLIFFORD JM 192575 04-13
CLOUET DH 182228 03-03, 184329 03-03
COAN M 182239 03-04
COCCHI D 188200 04-03
COCHIN J 191996 04-03
COHEN A 167335 01-11
COHEN G 182130 02-03, 182150 02-03, 182204 02-03, 182723 03-03
COHEN I 186706 03-03
COHEN J 184238 03-04
COHEN MJ 181887 02-13, 190308 04-14
COHEN ML 186693 03-03
COHEN S 177373 02-11
COHEN SM 187113 03-08
COHN M 182155 02-03, 183789 03-03
COHN ML 182155 02-03, 183789 03-03
COINTY C 189023 04-02
COLASANTI BK 189407 04-03
COLBURN RW 181810 02-03
COLE JO 173006 01-09, 176673 02-08, 184630 03-17, 185874 03-10, 190144 04-17, 192066 04-10
COLE SO 184839 03-03
COLEMAN M 188429 04-11
COLEMAN MP 181392 02-13
COLLARD J 178946 02-11, 183189 03-09, 183198 03-11
COLLINGS VB 176307 02-03
COLLINS AC 185210 03-10
COLLINS RJ 191940 04-04
COLOMBEL M 189517 04-05
COLONNA L 180725 02-07
CONSOLO S 185995 03-03, 189893 04-03, 191423 04-03
CONSROE PF 187640 04-04, 191992 04-03
COOK DA 176597 02-17
COOK MP 189564 04-05
COOKSON JH 192575 04-13
COOLS AR 186700 03-04
COOPER BR 186634 03-04, 189515 04-04, 191518 04-03, 191526 04-03, 191905 04-03, 191955 04-03, 191984 04-03
COOPER CW 186570 03-03
COOPER SD 192005 04-11
COOPER TB 187255 03-08
COPER H 180056 02-05, 184199 03-03, 185931 03-03, 189573 04-04
COPPEN A 192577 04-09
CORCORAN ME 183790 03-04, 186586 03-04
CORKER CS 184437 03-13
CORNATZER WE 185980 03-01
CORR PB 174008 01-04
CORREIA J 182244 03-03
CORRODI H 189611 04-03
COSCINA DV 182725 03-03
COSTA E 170086 01-03, 170755 01-03, 173381 01-03, 179986 02-03, 180582 02-03, 182344 03-03, 184553 03-03, 186673 03-03, 187526 04-03, 187527 04-03, 188891 04-03, 191515 04-03, 191764 04-03, 191766 04-03, 192335 04-03
COSTA M 189027 04-03
COSTALL B 171305 01-03, 176877 02-04, 185958 03-04, 186577 03-03
COTE J 187799 04-03
COTMAN CW 181406 02-04
COTT JM 189515 04-04
COTTEE LJ 187835 04-03
COTTEREAU M 184962 03-09
COTTRELL JC 170464 01-05
COTZIAS GC 189587 04-05
COUCH JR 191950 04-03
COURRIERE P 183406 03-01
COUSENS K 174041 01-14
COUSSE H 180723 02-03
COVI L 169089 01-10, 171925 01-10, 177671 02-11
COWAN N 187380 04-03
COX T 186637 03-04
COYLE JT 173380 01-03
CRAIG CR 189407 04-03
CRAIG JC 182445 03-01
CRANE A 192000 04-03
CRANE GE 171974 01-15, 189923 04-13
CRAVENS J 177716 02-14, 177717 02-14, 177718 02-14
CRAWFORD TI 167338 01-11
CRAYTON JW 187114 03-09
CREE JE 171731 01-13
CREMASCOLI G 188350 04-13
CRESON D 167334 01-07
CRISCUOLI PM 168975 01-13
CROFFORD M 182164 02-03
CROOK TH 171502 01-09
CROOKS PA 174828 01-03
CROSBY DM 192878 04-01
CROUCHER T 172780 01-03
CROUGHAN JL 174496 01-12
CROWLEY HJ 181575 02-03
CROWN P 169068 01-13
CROY DJ 176873 02-04
CSANALOSI I 172993 01-10, 184175 03-10, 185747 03-09
CUELLO AC 177131 02-03
CULLEN J 181811 02-13
CULLEN SC 182159 02-03
CULVER B 176867 02-06
CURI O 168923 01-11
CURRY SH 192871 04-14
CUSHMAN P 182166 02-13
CUTLER RWP 189031 04-03
CYRUS J 191233 04-13
CZERMACK M 167676 01-08
CZERWINSKI AW 174348 01-14, 184177 03-11
CZLONKOWSKI A 170126 01-04, 178757 02-04

D

D'ANGELI P 182791 03-09
DACHARY JM 183124 03-11
DAFNY N 187362 04-03
DAHL LK 173256 01-04
DAHLBERG CC 168420 01-12, 192084 04-15
DAILEY J 171626 01-03
DALTON B 191961 04-13

DALTON C 181575 02-03
DALTON WS 191989 04-14
DALY JW 177252 02-03
DANDIYA PC 174038 01-04, 174768 01-04, 182828 03-02
DANIELS AC 188426 04-03
DANTZER R 189409 04-04
DARLEY CF 177720 02-14, 189406 04-14
DARVAS F 190714 04-01
DASBERG H 171124 01-10
DASBERG HH 186184 03-13
DASILVA J 187115 03-09
DATA JB 185979 03-01
DATTA RK 189582 04-05
DAVE KP 174589 01-08, 175393 02-11, 175967 02-10
DAVID J 187931 04-03
DAVID RJ 189032 04-03
DAVID-REMACLE M 186704 03-04
DAVIDSON ST 177699 02-17
DAVIES AL 174059 01-08
DAVIES B 187582 04-10, 192510 04-09
DAVIES J 189750 04-03
DAVIES JA 174829 01-04, 174830 01-04, 186636 03-04
DAVIES NH 185330 03-14
DAVIS DA 176863 02-04, 191982 04-15
DAVIS J 191531 04-09
DAVIS JM 172272 01-11, 175935 02-15, 177450 02-14, 184654 03-13, 188542 04-14, 189650 04-09, 191508 04-08, 191530 04-09
DAVIS KH 176747 02-03, 180670 02-01, 182223 03-03
DAVIS WM 172454 01-04, 182191 02-04, 183788 03-03, 191899 04-04
DAWSON S 173521 01-14, 178578 02-08, 188115 04-08
DAWSON V 186613 03-04
DAY RP 182255 03-03
DAYKIN S 183790 03-04
DE ALBURQUERQUE IC 169932 01-06
DE ALBURQUERQUE MA 169932 01-06
DE BIASE G 182788 03-09
DE BOER B 191942 04-03
DE CHAMPLAIN J 172598 01-05, 187807 04-03
DE GREGORIO M 168809 01-11
DE GUZMAN T 191413 04-03
DE JONG W 188393 04-03
DE KOROSY F 167448 01-09
DE L. HORNE DJ 184976 03-14
DE LA CRUZ A 175245 02-13
DE LEENHEER AP 183599 03-02
DE MARCHI F 178756 02-04
DE MELLO DN 188120 04-13
DE SILVA JAF 169817 01-13
DE SILVA KL 167572 01-15
DE SOUZA NJ 185978 03-01
DE WIED D 177836 02-04, 187697 04-04, 188166 04-04, 188393 04-03
DEARDORFF CM 185330 03-14
DEBERDT R 183197 03-11
DEBUS G 180065 02-14
DECKERT FW 185866 03-03
DEEM MA 176238 02-15
DEFELICE EA 167335 01-11
DEFEO JJ 182721 03-03
DEFEUDIS FV 168418 01-03
DEGIOVANNI A 184961 03-17
DEGUCHI T 176447 02-08, 177128 02-03
DEISENHAMMER E 180672 02-11
DEJACO R 180063 02-15
DEL CARPIO W. J 190670 04-11
DELAUNAY J 184965 03-07
DELBARRE B 186576 03-04
DELERM B 189215 04-04
DELGADO JMR 183863 03-04
DELINI-STULA A 192420 04-13
DELLE M 184243 03-03
DELNEKY P 182157 02-03
DELUCA DC 187868 04-04, 190696 04-04
DEMARS JP 192083 04-10
DEMBERT ML 181813 02-03
DEMBIEC D 182150 02-03
DEMENT WC 171496 01-11
DEMISCH L 181944 02-03
DEMISSIANOS HV 176108 02-13
DEMMELER R 185902 03-03
DEMPSEY GM 185873 03-09
DENEAU GA 191939 04-04
DENIKER P 169945 01-17, 180725 02-07, 184962 03-09
DENNIS SG 187701 04-04
DEQUATTRO V 188198 04-03
DER-KARABETIAN A 186164 03-04
DERDA D 188426 04-03
DERKACH P 177785 02-04
DEROGATIS LR 169089 01-10, 171925 01-10
DEROSA ER 171507 01-08
DESAI PD 185978 03-01
DESI I 188874 04-05
DEUTSCH R 174877 01-03
DEVRED D 182902 03-09
DEWAR AJ 181942 02-03
DEWAR JH 188348 04-09
DEWEY WL 174607 01-04, 182217 03-04, 191960 04-03, 191963 04-03, 191968 04-03, 191970 04-03, 191971 04-03
DEWS P 181399 02-04
DEWSBURY DA 168718 01-04
DHASMANA KM 178557 02-03
DHAWAN BN 176881 02-03
DI ROSA AE 171794 01-13
DI TRAPANI G 182790 03-11
DI VITTORIO P 168748 01-03
DIAMANT EY 177835 02-03
DIBONA GF 184243 03-03
DICK DAT 187644 04-15
DICK EG 187644 04-15
DICK P 169468 01-09, 180700 02-15
DIEZ-EWALD M 185993 03-03
DIGENIS GA 190715 04-01
DIGIACOMO J 169491 01-09
DIGIACOMO JN 176675 02-14
DIGREGORIO GJ 191962 04-03
DIMASCIO A 169087 01-09, 171924 01-10, 173006 01-09, 174041 01-14, 185898 03-17
DIMITRIJEVIC M 186640 03-03
DINGELL JV 192003 04-03
DINGERDISSEN JJ 192879 04-01
DINOFF M 183635 03-17
DINOVO EC 182722 03-13
DIONISIO A 168809 01-11
DITMAN KS 177373 02-11
DITTRICH A 174043 01-14
DLABAC A 192430 04-04
DOBOS C 170744 01-11
DOENICKE A 184618 03-14
DOGGETT NS 178640 02-03
DOHADWALLA AN 185978 03-01
DOHERTY JD 191315 04-03
DOHI T 188199 04-03
DOIG MT 171792 01-05, 178113 02-09
DOLFINI M 191422 04-03
DOM R 192431 04-08
DOMINO EF 182227 03-03, 186703 03-04, 191935 04-04
DONALD JM 185193 03-11
DONLON PT 177748 02-08, 187869 04-08, 189095 04-08
DONNELLY C 191502 04-13
DORE F 187799 04-03
DORLE AK 188873 04-03
DORNBUSH R 169068 01-13
DORRIS RL 181809 02-03
DOSHI SU 175460 02-08
DOTEUCHI M 182344 03-03
DOUMAS BT 190194 04-11
DOUST JWL 174134 01-08
DOUVAN I 189178 04-02
DOWNES K 189855 04-03
DOWNING RW 171299 01-14, 172993 01-10, 177376 02-10, 181273 02-10, 189919 04-10
DOWNS DA 191972 04-04
DOWSON JH 167359 01-03, 172924 01-03
DRAFFAN GH 183793 03-13
DRAGOVICH JA 182133 02-04
DRAKONTIDES AB 186395 03-14
DRAWBAUGH RB 180021 02-04, 187699 04-04
DREESMANN H 171299 01-14
DREW RT 189600 04-05
DREW WG 171306 01-04
DRISCOLL P 190333 04-04
DUBAS TC 183363 03-03
DUBINSKY B 170162 01-04, 182188 02-04, 192016 04-04
DUDDERIDGE HJ 186573 03-04
DUDLEY AW 186476 03-05
DUDZINSKI DS 189031 04-03
DUFFICY RG 169746 01-11
DUFOUR H 167675 01-09
DUFRASNE M 178946 02-11, 183544 03-17
DUGGAN AW 188201 04-03
DUMMER GE 182162 02-03
DUNLEAVY DLF 183547 03-09
DUNN WJ 174606 01-12
DUNNER DL 174093 01-09, 187933 04-13
DUPEYRON JP 169469 01-04
DYBING E 179989 02-13
DYER DC 172915 01-03, 182716 03-03
DYKSTRA LA 185752 03-04

E

EADES CG 176312 02-03, 186665 03-03, 191904 04-03
EARL J 169462 01-14
EBARA T 180301 02-11
EBE M 191613 04-03
EBERTS FS 191900 04-02
EBSTEIN R 191932 04-03
EBSTEIN RP 191510 04-13
ECKERT H 192425 04-03
ECKMAN WW 170112 01-06
ECKMANN F 180070 02-15
EDEN PL 191943 04-14
EDMONDS HL 186632 03-03
EDWARDS C 188291 04-03
EGOROVA NL 183517 03-04
EHLERS W 192428 04-13, 192429 04-14
EHRENSING RH 171501 01-09, 189076 04-09
EHRNEBO M 191444 04-13
EICHELMAN BS 182441 03-03
EIDUSON S 191498 04-01
EILERS MK 189924 04-17
EISENRING JJ 169468 01-09
EISSENBERG EM 173133 01-03
EKIERT H 174777 01-10
EKWALL T 171601 01-03
EL-YOUSEF MK 172272 01-11, 177450 02-14, 188542 04-14, 191508 04-08, 191959 04-15
ELEFTHERIOU BE 185751 03-03
ELEK SD 178549 02-11
ELIASSON M 171617 01-04, 188611 04-04
ELISEO M 168975 01-13, 168976 01-14
ELLAMAA AN 191790 04-07
ELLEN P 167954 01-08
ELLINWOOD EH 182248 03-03, 187116 03-13, 191505 04-04
ELLIOTT HW 183899 03-03, 185881 03-14
ELLIS KO 186638 03-04
ELLIS MJ 181853 02-14
ELLISON GD 185753 03-04
ELONEN E 171629 01-03
EMMERICH DS 167817 01-08
ENCINOZA O 189173 04-15
ENDO T 182106 02-17
ENGEL J 171611 01-04, 171614 01-04, 185899 03-03
ENGELBRECHT J 189395 04-03
ENGELHARDT DM 177754 02-08, 177782 02-17, 184174 03-11
ENGISCH R 169298 01-11
ENGLEHARDT DM 183275 03-08
ENGLERT LF 183787 03-03, 187578 04-03
ENSOR CR 186581 03-04
EPLOV L 171627 01-03
EPPS LD 169070 01-13
ERANKO L 189027 04-03
ERANKO O 189027 04-03
ERDMANN E 189567 04-03
ERENBERG G 190138 04-11
ERICKSON CK 186375 03-03
ERIKSSON H 171614 01-04
ERTEL RJ 183795 03-03
ERVIN G 191955 04-03, 191984 04-03
ERVIN GN 182136 02-04, 191905 04-03
ERWIN VG 175232 02-03
ESCHENHOF E 179022 02-13
ESCOBAR JI 192065 04-13
ESCUETA AV 188738 04-05, 189032 04-03
ESSIEN EE 190902 04-06
ESTEVEZ VS 187578 04-03
ESTRADA HR 182890 03-11
ETEVENON P 167449 01-03
ETIENNE T 182432 03-10
ETSURAKU M 176474 02-10
EUBANKS JD 192013 04-05

EUN CS 178109 02-17
EVANS JI 183490 03-13
EVANS MA 191990 04-14
EVENSON RC 176676 02-17
EVERDS JP 183629 03-08
EVERITT BS 186584 03-10
EYMARD P 180722 02-07

F

FABER J 192419 04-11
FAHN S 188560 04-11
FAHNDRICH C 180056 02-05, 185931 03-03
FAINGOLD CL 182121 02-03, 191927 04-03
FALK JL 191768 04-03
FALK MA 167345 01-10
FANN WE 184654 03-13, 189403 04-11, 190314 04-13, 190380 04-11, 191533 04-11, 191978 04-10, 192227 04-10
FARAGALLA FF 182171 02-03
FARBER MG 191993 04-05
FARKAS I 188874 04-05
FARNEBO L 182347 03-03
FAURBYE A 172735 01-07
FAVAZZA AR 192068 04-11
FAYEZ MBE 192875 04-12
FECHTER LD 173136 01-04
FEDER HH 186686 03-04
FEDYNSKYJ NM 189589 04-03
FEINBERG I 189884 04-14
FEIST HW 184618 03-14
FEJER D 167585 01-17
FELDMAN HS 185747 03-09
FELDMAN RS 185934 03-04
FELDMAN SM 182185 02-03
FELIX AM 180097 02-03
FELLENIUS E 171631 01-03
FENNESSY MR 186584 03-10
FENSTERMACHER JD 170112 01-06
FERGUSON GG 167287 01-03
FERGUSON MM 172397 01-16
FERNANDES M 189573 04-04
FERNANDEZ J 181811 02-13, 185083 03-12
FERNGREN HG 182595 03-11
FERRARO DP 171886 01-04, 186567 03-04, 186645 03-04, 189405 04-04, 191375 04-04
FERRO FM 182791 03-09
FEURST SI 167339 01-10
FIBIGER HC 175241 02-03
FIEVE RR 169494 01-09, 169495 01-09, 174093 01-09, 182443 03-09
FIGLER MH 177722 02-04
FILCZEWSKI M 169471 01-03
FILE SE 171308 01-04, 189514 04-04, 191211 04-04
FINK BR 191324 04-03
FINK M 169068 01-13
FINK RD 187866 04-11
FINN G 176673 02-08
FINNERTY RJ 185874 03-10, 192066 04-10
FIRTH H 189043 04-14
FISCH ML 174071 01-11
FISCHER E 192521 04-09
FISCHER I 181811 02-13
FISCHER JF 186706 03-03
FISCHER R 189744 04-12, 191936 04-03, 191938 04-03
FISCHER-PERROUDON C 187237 03-14
FISHER AE 182212 03-03
FISHER BA 191943 04-14
FJALLAND B 186368 03-04, 186369 03-04, 186370 03-04
FLANARY HG 186665 03-03
FLEISCHMAN RW 188872 04-05
FLEISHMAN RW 191965 04-03
FLEISS JL 192084 04-15
FLEMENBAUM A 167342 01-08, 186745 03-13, 189775 04-09
FLENTGE F 171600 01-03
FLYNN K 190147 04-13
FONLUPT V 182900 03-11
FONTANA AE 180139 02-12, 180140 02-12, 180142 02-12, 180143 02-12, 180144 02-12
FOPPEN FH 177338 02-03
FORBIS OL 169457 01-14
FORCIONE M 185979 03-01
FORD RB 181158 02-09
FORD RD 182193 02-04
FORIST AA 187577 04-01
FORNEY RB 191989 04-14, 191990 04-14, 191991 04-04
FORREST AD 182766 03-10
FORREST IS 173875 01-03, 175751 02-03
FORREST JN 169486 01-15
FORREST WH 177320 02-11
FOSHEE DP 167954 01-08
FOSTER FG 171503 01-09
FOUTS JR 189600 04-05
FOWLER GW 188424 04-03
FOX S 173516 01-14
FRACCHIA J 185877 03-08, 187840 04-17
FRAIPONT J 178946 02-11
FRANCK KF 171608 01-04
FRANCO S 182126 02-03
FRANGOS E 183196 03-08
FRANK IM 169070 01-13
FRANKLIN KBJ 189025 04-04
FRANKLIN LM 186473 03-15
FRANTZ AG 191506 04-13
FRANZ DN 191937 04-03
FRASER HF 187254 03-15
FRATTA W 168748 01-03, 188519 04-03
FRAZER A 174994 02-14
FREED ME 187940 04-01
FREEDMAN AM 182741 03-14, 184630 03-17, 189059 04-07
FREEDMAN DX 174034 01-04, 182167 02-03, 183891 03-03, 188120 04-13
FREEDMAN LS 191510 04-13
FREEDMAN R 187496 04-03
FREEMAN JJ 174963 01-03
FREEMESSER GF 190196 04-09
FREEMON FR 172615 01-11, 187929 04-14
FREIBERGS V 176963 02-04
FREIDMAN E 191998 04-03
FREY H 170073 01-03, 171610 01-03, 172923 01-03, 181469 02-03
FRI C 186566 03-16
FRIED I 171631 01-03
FRIEDHOFF AJ 184630 03-17
FRIEDL H 180063 02-15
FRIEDLER G 191902 04-04
FRIEDMAN AS 169088 01-09
FRIEDMAN E 182254 03-03
FRIEDMAN MA 191963 04-03
FRIESEN HG 184436 03-15, 184437 03-13, 188428 04-13, 189076 04-09
FRIGERIO A 169073 01-01
FRISTROM S 171613 01-03
FROHMAN CE 191536 04-13
FROMENT J 189023 04-02
FROMMER EA 182428 03-10
FROST JB 168314 01-11
FROST M 175725 02-08
FUCHIMOTO H 177019 02-04, 177020 02-04
FUENTES JA 191500 04-03
FUJIMORI K 182093 02-03
FUJIMOTO A 176564 02-11
FUJITA S 177569 02-11
FUJITANI Y 182549 03-03
FUJIWARA M 182114 02-04
FUKUDA N 181658 02-02
FUKUDA T 189843 04-03
FUKUMOTO M 174853 01-16, 181588 02-13, 181593 02-03
FULLER RW 183869 03-03, 187831 04-03, 190346 04-03
FUNDERBURK WH 182124 02-03, 182125 02-03
FURUKAWA T 178725 02-03, 182109 02-04
FUXE K 171605 01-03, 189026 04-03, 189611 04-03, 191932 04-03
FYRO B 186565 03-08

G

GABAY S 174318 01-03, 191300 04-03
GABELLA G 191326 04-03
GAEBELEIN C 167398 01-04
GAFFNEY D 177318 02-14
GAFFNEY S 177318 02-14
GAFFNEY T 177395 02-15
GAGNON M 183359 03-03
GAGNON MA 183361 03-09
GAIARDI M 178756 02-04
GAINER H 168485 01-03
GAJWANI AK 180406 02-09
GALANTER M 173516 01-14, 175003 02-14
GALE K 192018 04-04
GALLAGER DAW 172015 01-03
GALLAGER DW 182140 02-03, 191949 04-03
GALLANT DM 172749 01-03, 174137 01-08, 189072 04-08
GALVAN L 168806 01-11, 191138 04-14, 191139 04-17
GAMAIKE N 178053 02-08
GARATTINI S 179983 02-17, 185995 03-03, 191422 04-03, 191423 04-03
GARD H 177395 02-15
GARDEY-LEVASSORT C 185996 03-03
GARDJITO SO 176582 02-11
GARDOS G 176673 02-08
GARELIS E 176254 02-13
GARNETT JE 191367 04-04
GARRETT ER 169673 01-16, 188256 04-01
GARSKE G 182242 03-04
GASCO P 182789 03-10
GASPARINO AM 180144 02-12
GATTONI RC 167403 01-04
GAUGER D 182242 03-04
GAURON EF 192116 04-04
GAUT ZN 191770 04-13
GAUTHIER G 188093 04-11
GAUTHIER P 187807 04-03
GAUTHIER R 183359 03-03
GAUTIER J 178187 02-08, 178193 02-11, 188406 04-03, 191142 04-15
GAY PE 173727 01-04, 184839 03-03
GAY VL 173257 01-03
GAZTANAGA P 170627 01-09
GEHA DG 187837 04-15
GEIGER PF 167287 01-03
GELDER MG 183807 03-10, 184436 03-15
GELLER I 176861 02-04, 176873 02-04
GENT M 168318 01-09
GERALD MC 182232 03-03, 187937 04-01
GERBER CJ 189403 04-11, 190314 04-13
GERBER HR 191920 04-03
GERBER N 177732 02-03
GERHARDS HJ 191766 04-03
GERLACH J 185929 03-11, 190310 04-03
GERSHON S 168836 01-08, 172485 01-10, 174138 01-09, 177710 02-15, 177826 02-13, 181957 02-10, 182254 03-03, 185875 03-11, 186744 03-14, 186920 03-09, 191507 04-13, 191531 04-09, 191977 04-04, 191998 04-03
GERVASI A 184291 03-14
GESSA GL 168748 01-03, 188519 04-03
GESSNER PK 183897 03-03, 192006 04-03
GEYER MA 186674 03-03
GHATE VR 169152 01-11
GHEZZI D 188196 04-03
GHOSH JJ 189582 04-05
GIACHETTI A 182234 03-03
GIANTURCO D 192229 04-09
GIANUTSOS G 180021 02-04
GIBB JW 184180 03-03, 188231 04-03
GIBBONS JL 182190 02-04
GIBBS JT 188107 04-09
GIBSON TP 184243 03-03
GILBERT MM 169632 01-10
GILBERT PE 176312 02-03
GILL EW 172596 01-03, 177333 02-03, 181941 02-03
GILLIN JC 173398 01-03, 176480 02-12, 178432 02-09, 187642 04-14
GILLIS CN 177332 02-03, 182717 03-03
GILLIS RA 187923 04-03
GILMAN S 187362 04-03
GINESTET D 169945 01-17, 180725 02-07, 184962 03-09
GINTZLER AR 186698 03-03
GITTELMAN-KLEIN R 189512 04-15
GIURGEA C 173495 01-02
GLASS D 183490 03-13
GLASSMAN AH 169869 01-15, 172271 01-13, 192872 04-10
GLATZEL J 180675 02-08
GLAUBIGER GA 186029 03-11
GLENNE PO 171630 01-16
GLESER GC 181072 02-10
GLICK SD 177409 02-04, 182208 02-04, 186620 03-04, 187261 04-04, 192000 04-03
GLOBUS G 177318 02-14
GLOOR P 188374 04-03
GLOW PH 168837 01-04, 181605 02-04
GLOWINSKI J 183794 03-03, 184230 03-03, 188164 04-03, 188976 04-03, 188978 04-03

GLUCK JP 186567 03-04, 186645 03-04, 191375 04-04
GLUCKMAN MI 182215 03-04
GODSE DD 182725 03-03
GOENECHEA S 172397 01-16
GOETZ P 175043 02-04
GOGERTY JH 191943 04-14
GOGOL Z 174777 01-10
GOGOLAK G 178947 02-03
GOLD BI 167326 01-03
GOLD S 183602 03-01
GOLDBERG AM 184953 03-04, 191954 04-05
GOLDBERG DM 191926 04-04
GOLDBERG H 185898 03-17
GOLDBERG HL 185874 03-10, 192066 04-10
GOLDBERG IK 188149 04-17
GOLDBERG JB 176109 02-14
GOLDBERG ME 170162 01-04, 171304 01-04, 182188 02-04
GOLDBERG SC 184977 03-08
GOLDBERG SR 191916 04-04, 191926 04-04
GOLDIN A 179983 02-17
GOLDMAN H 191936 04-03
GOLDMAN L 185033 03-04
GOLDSTEIN A 182161 02-03
GOLDSTEIN BJ 190195 04-09
GOLDSTEIN L 176864 02-04
GOLDSTEIN M 182256 03-03, 183891 03-03, 191510 04-13, 191932 04-03
GOLLUB LR 181400 02-04, 186376 03-06, 187066 03-04
GOLUB M 184371 03-04
GOMER FE 185955 03-04
GOMITA Y 181384 02-04, 182115 02-04
GONCZI L 188874 04-05
GONZALEZ FA 191916 04-04
GOODELL H 175426 02-11
GOODMAN FR 172925 01-03
GOODMAN MN 191771 04-03
GOODWIN BL 167445 01-03
GOODWIN DW 182719 03-13
GOODWIN FK 170079 01-09, 170083 01-03, 170084 01-09, 170621 01-09, 174094 01-09, 174329 01-09, 181274 02-09, 181358 02-09, 183546 03-10, 184160 03-09, 185928 03-09, 187398 04-13, 187642 04-14
GOOTMAN PM 182185 02-03
GORDON PE 167773 01-10
GORELICK DA 190266 04-04, 191934 04-04
GORODETZKY CW 187256 03-15
GORRY T 178502 02-04
GOTHERT M 188977 04-03
GOTO A 180986 02-10
GOTO T 176471 02-11
GOTTFRIES C 192527 04-11
GOTTLIEB JS 191536 04-13
GOTTSCHALK LA 177671 02-11, 181072 02-10, 182722 03-13, 185881 03-14
GOUDIE AJ 187925 04-04, 187926 04-04, 190335 04-04
GOWARDMAN M 178255 02-08
GRABOWSKI SW 169634 01-11
GRAEFF FG 186692 03-04
GRAF CL 190275 04-04
GRAHAM DT 186375 03-03
GRAHAM J 191961 04-13
GRAHAM JM 184235 03-03
GRAHAM LT 167358 01-03
GRAM LF 182434 03-09, 183604 03-13, 191026 04-09
GRANCHELLI FE 174967 02-01
GRANT LD 186634 03-04, 187696 04-04
GRATTAROLA FR 167594 01-10
GRAVES J 178432 02-09
GRAY D 190265 04-04
GRAY JA 168834 01-04, 186573 03-04
GREEN DE 175751 02-03
GREEN DO 190242 04-07
GREEN JR 192391 04-07
GREEN R 178578 02-08, 188115 04-08
GREEN RS 181270 02-14
GREEN TK 189398 04-03
GREENBERG D 188114 04-15, 191290 04-08
GREENBERG I 168230 01-04
GREENBERG L 191400 04-14
GREENBERG LM 176238 02-15
GREENBERG S 189394 04-03, 189395 04-03
GREENBLATT DJ 192190 04-14
GREENE C 187812 04-13
GREENGARD P 191896 04-03
GREENLAND RD 191957 04-05
GREENSTEIN S 186620 03-04
GREENWOOD L 170079 01-09
GREENWOOD MH 184082 03-14
GREGER J 174101 01-08
GRETCHIN VB 178787 02-13
GREVEN J 184222 03-03
GREWAL RS 187931 04-03
GRIFFITH JD 171241 01-14
GRIFFITH RK 187937 04-01
GRIFFITHS PJ 185992 03-03
GRIGOR J 181192 02-08
GRILLY DM 171886 01-04, 189405 04-04
GROBLEWSKI GE 182239 03-04
GROFF S 189512 04-15
GROSS MD 169295 01-11
GROSSMAN SP 187698 04-04
GROSSMANN W 172926 01-03, 185901 03-03
GROSZ HJ 188760 04-04
GROTH HP 188977 04-03
GROVE J 183793 03-13
GROVE RN 191941 04-04
GROVES PM 185264 03-03
GRUBB MN 188202 04-03
GUDELSKY G 192009 04-04
GUELEN PJR 186184 03-13
GUERINOT F 190337 04-03
GUERRA FC 192426 04-03
GUERRERO-FIGUEROA E 172749 01-03, 177749 02-03
GUERRERO-FIGUEROA R 172749 01-03, 174137 01-08, 177749 02-03
GUERRINI A 191190 04-14
GUIBERT S 184965 03-07
GUIDOTTI A 170086 01-03, 170755 01-03, 170876 01-03, 173381 01-03, 186675 03-03, 191515 04-03, 191764 04-03
GUILLEMIN R 190104 04-13
GUILLEMINAULT C 171134 01-13, 171496 01-11
GUILLEMOT J 176963 02-04
GULATI OD 191933 04-03
GULDBERG HC 191319 04-03
GUMULKA W 178757 02-04
GUPTA ML 177021 02-03
GUPTA TK 177021 02-03
GUTIERROZ CO 172916 01-03
GYLYS JA 191906 04-03
GYORGY L 185933 03-03

H

HAAVIK CO 170163 01-03, 182220 03-03
HABER B 174319 01-03
HABER BT 176873 02-04
HABLITZ JJ 177645 02-16
HACKMAN R 176879 02-04
HACKMANN E 171307 01-03
HADFIELD MG 188404 04-03
HADLEY KW 180670 02-01
HAEFELY W 179021 02-05, 184197 03-03, 184202 03-03
HAEUSLER G 186677 03-03
HAHN I 181470 02-03
HAIDER I 176286 02-10, 180146 02-10, 180147 02-15, 180148 02-15, 180149 02-15, 180152 02-15
HAIG JR 190321 04-14
HAIGLER HJ 177407 02-12, 182141 02-03
HAILEY DM 171731 01-13
HAIN JD 189074 04-17
HAKKINEN S 189619 04-14
HALARIS A 188120 04-13
HALARIS AE 182168 02-03
HALL EH 182763 03-14
HALL M 172745 01-04
HALL P 185008 03-11
HALL R 188348 04-09
HALMAGYI GM 187618 04-11
HALMI KA 174132 01-14
HALPERN B 171122 01-11
HAM CH 169286 01-10
HAMADA H 191686 04-08
HAMILTON LW 167401 01-04
HAMON M 188164 04-03, 188976 04-03
HAN DS 182574 03-17
HANABUSA Y 178725 02-03
HANBAUER I 170876 01-03
HANCOCK JC 191995 04-03
HANDLEY SL 185750 03-03
HANE DL 180097 02-03
HANEDA T 185213 03-08
HANENSON I 177395 02-15
HANIN I 180582 02-03, 182226 03-03
HANLON TE 184653 03-09
HANO J 167813 01-04
HANSEN CE 187639 04-16, 188832 04-09
HANSEN S 191331 04-03
HANSL NR 184581 03-02
HANSON B 185322 03-10
HANSOTIA P 172439 01-11
HARA A 174853 01-16, 181588 02-13, 181593 02-03, 182555 03-03, 182556 03-13
HARADA K 188450 04-15
HARBISON RD 189598 04-05
HARCLERODE J 181813 02-03
HARDMAN HF 170163 01-03, 182220 03-03, 191997 04-03
HARMS D 183183 03-15
HARPER MA 172741 01-08
HARRIS GW 184436 03-15
HARRIS LS 182153 02-03, 183893 03-04, 186570 03-03, 187928 04-03, 191960 04-03, 191963 04-03, 191968 04-03, 191970 04-03, 191971 04-03
HARRIS RT 187638 04-04
HARRISON SD 177334 02-03
HARTL O 180063 02-15
HARTLEY D 187565 04-11
HARTMAN ER 189407 04-03
HARTMAN R 187380 04-03
HARTMANN E 177716 02-14, 177717 02-14, 177718 02-14
HARTMANN EL 181393 02-14
HARTMANN R 176861 02-04
HARTMANN RJ 176873 02-04
HARTMANN W 174101 01-08
HARTSE KM 191389 04-03
HARVEY JA 189398 04-03, 191947 04-05
HARVEY WM 178695 02-17
HASCHKE RH 191324 04-03
HASEGAWA N 181771 02-07
HASH AM 182124 02-03
HASSELBACH W 184223 03-03
HATANAKA H 178623 02-09
HATTAB JR 167340 01-11
HATTORI T 176454 02-11, 183228 03-03
HAUBRICH DR 192001 04-03
HAVLIK I 170072 01-03
HAWALDAR PP 172439 01-11
HAWKING F 179983 02-17
HAYAKAWA J 176726 02-08
HAYES RL 191944 04-04
HEADLEY PM 188201 04-03
HEBBAR YV 175460 02-08
HEFFNER TG 187699 04-04
HEFNER MA 171304 01-04
HEIBER S 182156 02-03
HEIKKILA RE 182723 03-03
HEISE GA 181394 02-14
HELDMAN J 182178 02-06
HELLER B 192521 04-09
HELLING DK 189902 04-15
HENINGER GR 169486 01-15
HENOMATSU H 182634 03-02
HENRIKSSON BG 175884 02-04, 178813 02-04
HENRY DP 168862 01-05
HENRY GM 169504 01-09
HERBACZYNSKA-CEDRO K 172835 01-03
HERBERG LJ 189025 04-04
HERMAN ZS 178558 02-03, 186571 03-04, 190311 04-03
HERNACKA B 174778 01-09
HERNDON BL 182187 02-03
HERNDON JG 185705 03-04
HERRERO FA 168505 01-15
HERRING BS 192413 04-03
HERXHEIMER A 183812 03-15
HERZ A 169474 01-03
HESBACHER P 188144 04-10
HESTER JB 185032 03-01
HEUBEL F 191607 04-17
HEYL MG 171792 01-05, 178113 02-09
HEYMAN IA 189588 04-05, 191966 04-04
HIBI S 189884 04-14
HIEP A 181192 02-08
HIGHMAN B 188865 04-05
HIGUCHI M 181771 02-07

HILDICK-SMITH M 175459 02-15
HILL SY 182719 03-13
HILLEL J 183361 03-09
HILTON AM 177392 02-15
HINDMARCH I 172780 01-03
HINE B 191977 04-04
HINTON J 184438 03-14
HIRAI T 184314 03-13
HIRAIWA T 181386 02-04
HIRATA J 175069 02-09, 181388 02-11
HIRAYAMA M 178224 02-08
HIRONAKA T 191686 04-08
HIROSE K 168498 01-05
HIRSCHHORN ID 191944 04-04
HIRSH K 183887 03-03
HITZEMANN RJ 182253 03-04, 186671 03-03, 189586 04-03
HO BT 183787 03-03, 187578 04-03, 187932 04-04, 188167 04-03
HO G 179985 02-03
HO IK 182231 03-03, 191898 04-03
HODGSON JR 182160 02-03
HODSHON BJ 191921 04-03
HOEKMAN T 187923 04-03
HOFFER A 188446 04-11
HOFFER BJ 187496 04-03, 187498 04-04
HOFFMAN SP 177754 02-08, 183275 03-08, 184174 03-11
HOFFMEISTER F 177719 02-04
HOFMANN A 189101 04-12
HOKFELT T 191932 04-03
HOLCOMB RR 177732 02-03
HOLDEN EM 169376 01-15, 179996 02-13
HOLLAND JB 180096 02-03
HOLLENBECK RA 182234 03-03
HOLLISTER AS 186699 03-03, 191905 04-03
HOLLISTER LE 171505 01-08, 174347 01-13, 175914 02-17, 177720 02-14
HOLTZMAN SG 168439 01-04, 182859 03-04, 183892 03-04, 186373 03-04
HOLZ RW 173380 01-03, 177128 02-03
HOLZBAUER M 191497 04-03
HOLZER B 184291 03-14
HOMMA I 191613 04-03
HONDA O 178019 02-15
HONECKER H 177337 02-03
HONG SA 171599 01-04
HONG SY 173078 01-04
HONIG WMM 174763 01-04
HONMA K 191685 04-17
HONTELA S 168805 01-11
HOOGHE-PETERS EL 167324 01-04
HOPF A 192425 04-03
HOPWOOD J 191400 04-14
HORAKOVA Z 189895 04-03
HORI N 182092 02-03
HORIBE M 182108 02-04, 192415 04-04
HORITA A 192018 04-04
HORN A 190545 04-03
HORN AS 175233 02-03, 177131 02-03
HORNBUCKLE PA 176307 02-03
HORNYKIEWICZ O 177785 02-04
HOULIHAN JP 182524 03-08
HOUSER FL 171302 01-04
HOUSER VP 171301 01-02, 171302 01-04, 178720 02-03, 189381 04-03
HOWARD JL 187696 04-04
HOWARD JS 181153 02-08
HOWARD L 189394 04-03, 189395 04-03
HOWARD-JONES N 186474 03-17
HOWES JF 191964 04-03
HOYT HJ 174348 01-14
HOZAKI H 185235 03-17
HRDINA PD 182170 02-03
HSU LL 180020 02-03
HSU SY 182232 03-03, 187937 04-01
HSU W 180064 02-10
HUANG CC 182143 02-03
HUANG J 187932 04-04
HUANG JT 182245 03-03
HUBER HP 192428 04-13, 192429 04-14
HUBER JA 190717 04-01
HUBER W 184177 03-11
HUDICK JP 182224 03-03
HUGHES RN 190334 04-04
HUI FW 182164 02-03
HUISMAN NG 183194 03-09
HUMPHRIES J 177318 02-14
HUNT CA 188256 04-01
HUNT WA 182348 03-03
HUNTER KR 168286 01-13
HUNTER P 188348 04-09
HURST PM 174210 01-14
HURWIC MJ 172271 01-13
HUSSAIN MZ 170622 01-09
HUSTON JP 177477 02-04
HUSZKA L 174134 01-08
HVIDBERG EF 188832 04-09
HYNES MD 180021 02-04

I

IDE-JOHANSON L 187700 04-04
IFFLAND R 178619 02-05
IGISU H 189843 04-03
IGUCHI K 180301 02-11
IIDA N 188517 04-09
IIDA S 182091 02-03
IISALO E 184978 03-13
IIZUKA R 191677 04-17
IIZUKA Y 168499 01-07
IKEDA K 181657 02-02
IKUTA T 174505 01-13
IKUTOMI H 191593 04-08
ILIUKHINA VA 178787 02-13
IMLAH NW 172435 01-08
INADA H 176468 02-08
INAMORI J 176472 02-08
INANAGA K 175550 02-08, 184314 03-13
INAZU Y 168499 01-07
INOUE K 176454 02-11
INOUE T 177336 02-03
INUI M 175119 02-08
INUI T 174680 01-08
INWANG EE 187112 03-03
IORDANISHVILI GS 183142 03-13
IRWIN S 190236 04-17, 190237 04-17
ISENBERG PL 189640 04-17
ISHIBASHI F 176473 02-10
ISHIDA M 191723 04-09
ISHIGANE M 191693 04-17
ISHIGE K 171246 01-11
ISHII H 173548 01-05
ISHII N 170660 01-13
ISHIKAWA H 174681 01-08
ISHIKAWA T 176469 02-08
ISHIYAMA Y 191613 04-03
ISHIZU H 191670 04-09
ISOZAKI H 184314 03-13
ISRAEL Y 192005 04-11
ISWARIAH V 189673 04-14
ITIL T 180064 02-10
ITIL TM 174131 01-08, 181958 02-13, 187115 03-09
ITO H 177567 02-09, 184845 03-10
ITO K 191693 04-17
ITO M 177837 02-04
ITO R 181386 02-04, 182634 03-02
ITO S 176542 02-11, 177994 02-08
ITO Y 188934 04-08, 191720 04-08
ITOI K 176471 02-11
ITSKOVITZ HD 190194 04-11
IVERSEN L 190545 04-03
IVERSEN LL 180060 02-03, 189616 04-03
IVERSEN SD 187420 04-04, 188620 04-04
IWAJIMA Y 176467 02-08
IWAMOTO N 188517 04-09
IWAMOTO T 182093 02-03
IWASAWA K 176467 02-08
IWASAWA Y 182717 03-03
IWATA H 182113 02-03
IWATA N 174603 01-03
IYER DS 180249 02-10
IZQUIERDO I 167403 01-04, 168749 01-03, 186575 03-03, 189608 04-03, 189609 04-03
IZQUIERDO JA 169467 01-03
IZUMI K 189843 04-03

J

JACK ML 169817 01-13, 170838 01-13
JACKSON B 186636 03-04
JACKSON DM 180057 02-03, 189513 04-03
JACKSON FB 172021 01-03
JACOB JJ 189517 04-05
JACOBOWITZ DM 182211 03-04, 187380 04-03
JACOBS LS 175245 02-13
JACOBSON AF 190195 04-09
JACOBSON G 191035 04-15
JACOBY JH 180022 02-03
JACQUES D 183030 03-11
JAFFE J 168420 01-12, 177674 02-14, 192084 04-15
JAGGER J 188164 04-03
JAIN PC 176881 02-03
JAIN RC 168319 01-15
JAKUBCZAK LF 185955 03-04
JAKUBOVIC A 183228 03-03, 189590 04-03
JALANBO H 188200 04-03
JALFRE M 179021 02-05
JAMES B 168901 01-14, 169745 01-14
JAMES NM 168901 01-14, 169745 01-14
JAMROZIK Z 178558 02-03
JANDHYALA ML 182243 03-03
JANIEC W 190311 04-03
JANKE W 180065 02-14, 184617 03-07
JANNETTA PJ 188689 04-05
JANOWSKI DS 191508 04-08
JANOWSKY D 191530 04-09, 191531 04-09
JANOWSKY DS 172272 01-11, 177450 02-14, 184654 03-13, 188542 04-14, 189650 04-09
JAQUETTE DL 188202 04-03
JARBE TUC 175884 02-04, 178813 02-04
JARBOE CH 180096 02-03
JARVIK LF 181395 02-15, 192084 04-15
JARVIK ME 181401 02-04
JASINSKI DR 171241 01-14, 174473 01-13, 174479 01-14, 182163 02-03
JATLOW PI 177393 02-15, 177394 02-15
JAUCH TE 169462 01-14
JAVOY F 183794 03-03
JEFFERSON JW 176674 02-15
JEND H- 184199 03-03
JERUSSI TP 177409 02-04
JESTE DV 174588 01-08
JEWETT RE 168439 01-04
JHA BK 171985 01-08, 174851 01-09, 180154 02-08
JITSUICHI S 191670 04-09
JOBE PC 167287 01-03
JOHANSSON G 180044 02-04
JOHNSON DAW 173866 01-15, 192513 04-15
JOHNSON DN 182124 02-03, 182125 02-03
JOHNSON F 167575 01-10
JOHNSON G 189793 04-09
JOHNSON JC 182228 03-03
JOHNSON RD 167445 01-03
JONES B 191992 04-03
JONES BC 187640 04-04
JONES G 181941 02-03
JONSSON G 171605 01-03, 189026 04-03
JONSSON J 171634 01-03, 191921 04-03
JONSSON M 171632 01-03
JORI A 188196 04-03, 191422 04-03
JOSHI PC 169818 01-01, 185980 03-01
JOST F 187958 04-11
JOUBERT PH 189606 04-15
JOUVET M 187237 03-14, 189023 04-02
JOY RM 181818 02-03, 186632 03-03
JUGE O 188093 04-11
JULIEN RM 188424 04-03
JUORIO AV 191326 04-03
JURNA I 172926 01-03, 185901 03-03
JUS A 167587 01-15, 178187 02-08, 178193 02-11, 183693 03-17, 188406 04-03, 191142 04-15
JUS K 167587 01-15, 178187 02-08, 178193 02-11, 183693 03-17, 188406 04-03

K

KADZIELAWA K 187075 03-03
KAHLING J 187805 04-01
KAHN J 190266 04-04
KAISER DG 187577 04-01
KAJFEZ F 187942 04-01
KAJIYAMA S 180986 02-10
KALANT H 179985 02-03, 192020 04-03
KALES A 172114 01-15
KALES JD 172114 01-15
KAMANO DK 175877 02-04
KAMBAROVA DK 178787 02-13
KAMIOKA T 168499 01-07, 180490 02-02
KAMIZAKI Y 178623 02-09
KANEKO T 180102 02-17
KANEKO Z 175119 02-08
KANETO H 182103 02-04

KANTO J 171633 01-03, 184978 03-13
KAPADIA GJ 170839 01-06, 192875 04-12
KAPELSKI Z 174778 01-09
KAPLAN J 173521 01-14, 173522 01-12, 176480 02-12, 178578 02-08, 188115 04-08
KAPLAN SA 169817 01-13, 170838 01-13
KARASUMOTO K 176542 02-11
KARBOWSKI MJ 182158 02-03
KARIYA T 178224 02-08
KARIYAMA N 176454 02-11
KARLER R 174608 01-05, 175238 02-03, 191994 04-03
KARNIK NR 175967 02-10
KARNIOL IG 169472 01-03
KARON BP 173534 01-08, 178677 02-17
KAROUM F 179986 02-03, 192335 04-03
KARPOWICZ JK 170162 01-04, 192016 04-04
KARR GW 187812 04-13
KARU LE 191787 04-02
KASHIMOTO T 191510 04-13
KASSIR S 169869 01-15
KASTIN AJ 171501 01-09, 189076 04-09
KATIRA MN 180249 02-10
KATO G 182624 03-11
KATO I 170638 01-13
KATO M 178021 02-08
KATO T 192084 04-15
KATSUDA N 182092 02-03
KATZ J 192565 04-04
KAUCHTSCHISCHWILI GM 167336 01-13
KAUFMANN JS 184654 03-13
KAWAHARA R 182550 03-11
KAWAKAMI K 181771 02-07
KAWAKAMI T 180102 02-17
KAWAKITA Y 177567 02-09
KAWAMURA Y 189219 04-03
KAWANO K 181653 02-06
KAWANO M 182731 03-10
KAWANO Y 180490 02-02
KAWATHEKAR P 169633 01-11
KAY DC 174496 01-12
KAY NE 192510 04-09
KAYMAKCALAN S 186585 03-03
KAZAMA K 178725 02-03
KAZDOVA E 192430 04-04
KEATING J 192426 04-03
KEDZIOR J 174783 01-11
KEEGAN DL 191192 04-11
KEHNE CW 176810 02-11
KEHR W 191513 04-03
KEIPER CG 190743 04-14
KELFER DA 186568 03-04
KELLEY DL 190260 04-04
KELLNER R 168316 01-10, 185210 03-10
KELLOGG C 187551 04-04
KELLY D 168832 01-10
KELLY KA 187129 03-04
KELLY MG 192589 04-11
KENNEDY J 191331 04-03
KENNEDY MJ 177749 02-03
KENNEY J 189178 04-02
KEPNER LA 171521 01-04
KERMANI E 172485 01-10
KERPEL-FRONIUS S 180591 02-04
KERTESZ D 167448 01-09
KETTER KA 184243 03-03
KETTLER R 186677 03-03
KHACHATURIAN ZS 191946 04-03
KHANNA JM 179985 02-03
KHO TK 180298 02-17
KHORANA AB 167346 01-10, 186553 03-11
KHORRAMZADEH E 175282 02-07
KHOUW V 192005 04-11
KIDO A 181588 02-13, 181593 02-03, 182555 03-03, 182556 03-13
KIDO M 175072 02-17
KIEV A 178544 02-10
KILBEY MM 172745 01-04
KILIAN M 170073 01-03, 181469 02-03
KILLAM KF 181396 02-04
KILOH LG 169140 01-15
KIM ST 171159 01-17
KIMBALL AP 188167 04-03
KIMBELL I 171505 01-08
KIMISHIMA K 181650 02-03, 182549 03-03, 189209 04-05
KIMURA H 182154 02-03
KIMURA K 182094 02-03, 191593 04-08
KIMURA M 182620 03-09
KIMURA Y 176448 02-10, 182094 02-03
KINEMUCHI H 175239 02-03
KING AR 187697 04-04
KING LJ 177135 02-03
KINGSTONE E 184259 03-15
KINOKUNI Y 178019 02-15
KIRALY I 192416 04-03
KIRK L 172735 01-07, 191026 04-09
KIRKBY RJ 186702 03-04
KIROV K 186081 03-08
KIRSHNER N 191512 04-13
KIRVEN LE 170129 01-11
KISARA K 182112 02-04
KIVITY-EPHRAIM S 189174 04-11
KJELLBERG B 180061 02-04
KLAIBER EL 187149 03-13
KLEIN DF 169492 01-15, 189512 04-15
KLEIN M 168838 01-04
KLEINROK Z 177721 02-04
KLERMAN G 169087 01-09
KLERMAN GL 169748 01-17, 171924 01-10, 185322 03-10
KLETT CJ 171926 01-09, 172831 01-08, 186188 03-09, 189735 04-09
KLINE NS 167344 01-09, 180297 02-09
KLINGMAN JD 187677 04-03
KLINGNER A 167774 01-09, 168807 01-11, 183360 03-13, 191138 04-14
KLOTTER J 187839 04-09
KLUGE H 174101 01-08
KLUWE S 189573 04-04
KMIECIAK-KOLADA K 186571 03-04
KNAPP D 177395 02-15
KNAPP S 175149 02-13, 186674 03-03, 191516 04-03
KNEFFEL Z 188874 04-05
KNOBEL M 168808 01-11
KNOBLOCH LC 188876 04-05
KNOTT DH 187866 04-11
KOBAYASHI I 177569 02-11
KOBAYASHI K 176564 02-11
KOBAYASHI M 182105 02-03, 182108 02-04
KOBAYASHI S 168499 01-07
KOBAYASHI Y 187149 03-13
KOBYASHI T 170638 01-13
KOCH-WESER J 179987 02-13
KOCHANSKY GE 169086 01-14
KOCHAR MS 190194 04-11
KODAMA H 191670 04-09
KOEPKE HH 169632 01-10
KOERKER RL 190907 04-03
KOGANTY RR 190715 04-01
KOHL H 185978 03-01
KOHLI RP 186569 03-03
KOIZUMI S 181377 02-15
KOJIMA S 188199 04-03
KOJO J 181653 02-06
KOKETSU K 182637 03-02
KOLAKOWSKA T 184437 03-13
KOLIS SJ 170837 01-03
KOMISKEY H 186633 03-03
KONDO H 167919 01-09
KONERMANN G 185900 03-03
KONUMA M 182755 03-15
KOPELL BS 177720 02-14, 185932 03-13
KOPIN I 191495 04-03
KOPIN IJ 168862 01-05, 178747 02-03, 179983 02-17, 181810 02-03, 187397 04-03, 187488 04-17
KOPPANYI T 169688 01-05
KORCZAK-DZIUBA K 190311 04-03
KORDUBA CA 175240 02-03
KORF J 184652 03-09
KORN M 172976 01-09
KORNBLIT G 180123 02-12
KORNBLIT GA 180142 02-12
KORNETSKY C 181402 02-04, 184371 03-04, 190330 04-04, 191975 04-04
KOROLENKO TA 191121 04-03
KOSERSKY DS 182221 03-03, 183893 03-04
KOSHINO Y 191625 04-13, 191667 04-13
KOSLOW SH 170747 01-03
KOSTOWSKI W 170126 01-04, 178757 02-04
KOTIN J 170621 01-09, 183546 03-10, 184160 03-09, 185928 03-09
KOTORII M 167921 01-14
KOTWANI PN 175393 02-11
KOUROUNAKIS P 183611 03-03
KOVAC T 187942 04-01
KOWA Y 182107 02-04
KOYUNCUOGLU H 187645 04-03
KOZATO Y 181654 02-04
KRAGH-SORENSEN P 188832 04-09
KRAKOWSKI AJ 169298 01-11
KRAMER JC 172109 01-17
KRAMER M 167341 01-08, 177747 02-07
KRAUSS JA 171007 01-13
KRAYNACK B 182155 02-03
KREBS H 168817 01-03, 182123 02-03
KRENDAL FP 183682 03-03
KREUTER C 185715 03-14
KREUZ DS 177403 02-16
KRIEGLSTEIN G 181470 02-03
KRIEGLSTEIN J 181470 02-03, 186589 03-06
KRIP G 187552 04-03
KRIVOY W 183324 03-03
KROEGER D 183324 03-03
KROEGER EA 188915 04-03
KROP S 191976 04-04
KRSIAK M 174604 01-04
KRUEGER GAW 174136 01-09
KRUK ZL 170177 01-04
KRUNNFUSZ RW 180739 02-01
KSIR CJ 186372 03-04
KUCZENSKI R 167325 01-03
KUDO Y 177567 02-09, 183195 03-08
KUDRIN AN 183682 03-03
KUEHNLE J 187257 04-14
KUGLER J 184618 03-14
KUHAR MJ 191999 04-03
KUHN CM 191922 04-03
KUHN R 182429 03-10
KUHN V 182429 03-10
KUIPERS H 183194 03-09
KULESHA ID 180097 02-03
KULKARNI AS 189613 04-04
KULKARNI SK 174038 01-04
KULKARNI SS 167346 01-10
KULLBERG MP 187256 03-15
KULSHRESTHA VK 186569 03-03
KUMAKURA S 168499 01-07
KUMASHIRO H 181377 02-15, 181388 02-11
KUMBAR M 174605 01-12
KUNIGI T 188893 04-09
KUPFER DJ 171503 01-09
KUPIETZ S 177771 02-14
KURATOMO M 176475 02-09
KURIOKA Y 171296 01-15, 188838 04-13
KURLAND AA 176109 02-14, 177319 02-07
KUROKAWA E 191716 04-09
KUROMARU S 181590 02-11
KURTIN SB 169492 01-15
KURTZ P 188248 04-04
KURTZ SM 189587 04-05
KUSCHINSKY K 176746 02-03, 184198 03-03
KUSHIKU K 178725 02-03
KUSSIN D 168806 01-11
KUTSCHER AH 188149 04-17

L

LA FLORE JE 175242 02-04
LABRECQUE G 182227 03-03
LACNY J 168315 01-11
LADER M 187022 03-17, 190336 04-11
LADER MH 168831 01-14, 184082 03-14, 188887 04-10
LADINSKY H 185995 03-03, 189893 04-03, 191423 04-03
LAGALI S 169633 01-11
LAHTI RA 176870 02-03, 186578 03-03, 189584 04-02
LAJTHA A 182224 03-03, 191413 04-03
LAKE CR 189403 04-11, 190314 04-13, 190380 04-11, 191533 04-11, 192227 04-10
LAL H 171300 01-04, 180021 02-04, 182230 03-03, 182721 03-03, 184225 03-03, 190306 04-03
LAL S 186587 03-04, 188428 04-13
LALLEY PM 167329 01-03
LAMM SS 174071 01-11
LAMPRECHT F 173520 01-09
LANDAUER AA 189408 04-14
LANDIS SC 191762 04-03
LANDIS WB 167773 01-10
LANGFELDT T 184979 03-04
LAO L 177135 02-03
LAPIERRE YD 183362 03-10, 191137 04-14

LARA PP 172992 01-15
LAROCHELLE L 177785 02-04
LARSEN N 187639 04-16, 188832 04-09
LARSSON K 186683 03-04
LASSEN JB 171609 01-04, 185959 03-04, 190309 04-04
LASTING PG 191776 04-14
LATIES VG 181403 02-04
LAUDER J 168817 01-03
LAVALLEE J 183362 03-10
LAVOINE JR 184963 03-14, 184964 03-11
LAWRENCE DK 172596 01-03, 177333 02-03
LE BRUN Y 191522 04-13
LE POIDEVIN D 185193 03-11
LEANDER JD 177410 02-04, 182194 02-04
LEASK BGS 167445 01-03
LEBLANC AE 189519 04-04
LEBLANC J 187799 04-03
LECHAT P 185996 03-03, 188864 04-03
LEDNICER D 189584 04-02
LEE CK 173563 01-08
LEE HK 186744 03-14
LEE JE 175426 02-11
LEE JH 187255 03-08
LEE KH 173080 01-15
LEE T 187801 04-03, 189401 04-03
LEE WY 173502 01-08
LEEDS AA 167706 01-17
LEEMING FC 181408 02-04
LEFF JP 172963 01-08
LEFORT H 176432 02-15
LEGG NJ 184445 03-10
LEGROS P 176432 02-15
LEHMANN HE 167774 01-09, 168313 01-08, 168804 01-16, 170293 01-11, 180243 02-15, 183360 03-13, 191138 04-14, 192412 04-17
LEHTINEN V 184978 03-13
LEIBOWITZ SF 182216 03-03, 182238 03-04
LEITE JR 183609 03-03
LEITH NJ 189521 04-04, 191914 04-04
LELORD G 182432 03-10
LEMBERGER L 173516 01-14, 181810 02-03, 182773 03-17, 191961 04-13, 191989 04-14, 191990 04-14
LEMMER B 184232 03-03
LEON AS 170837 01-03
LEPORE F 176963 02-04
LERMAN P 189174 04-11
LESLIE J 183862 03-04
LESSER LI 177778 02-11
LESTER D 177733 02-03
LETERRIER FR 176703 02-03
LEUNER H 186025 03-12
LEVINE EM 191313 04-03
LEVINE FM 167817 01-08, 170744 01-11
LEVINE J 170292 01-11, 181713 02-17
LEVINE JM 175317 02-04
LEVINE RR 182715 03-03
LEVITAN H 189033 04-03
LEVITT M 187933 04-13
LEVY JA 191960 04-03
LEVY RA 189832 04-03
LEVY RH 185977 03-16, 192391 04-07
LEVY ST 169486 01-15
LEVY W 187787 04-15
LEW JY 191932 04-03
LEWANDER T 169470 01-13, 171602 01-03, 191503 04-03
LEY JP 188976 04-03
LIBERATORE F 180098 02-01
LICHTSTEINER M 171307 01-03
LIDBRINK P 171604 01-03, 182347 03-03, 189026 04-03, 189611 04-03
LIDEN S 192527 04-11
LIEBERMAN A 191522 04-13
LIEBERMAN AN 188414 04-15
LIEBLING DS 178575 02-04
LIMACHER JJ 187806 04-03
LIN GS 172921 01-04
LIN R 187576 04-03
LINDEKE B 182203 02-06, 191921 04-03
LINDQUIST M 191513 04-03
LINDSTROM LH 171616 01-04
LING GM 182170 02-03, 183358 03-03
LINKOUS P 192231 04-09
LINNOILA M 184848 03-14, 189619 04-14
LIPMAN RS 169089 01-10, 170292 01-11, 171925 01-10
LIPPA AS 182212 03-03
LIPPER S 189734 04-13
LIPTON MA 182223 03-03, 191534 04-09
LISCIANI R 168802 01-13
LISO G 180098 02-01
LISTER RE 182762 03-04
LITTLE HJ 174828 01-03
LITTLE MH 174134 01-08
LITTLETON JM 185992 03-03
LIU JC 185112 03-03
LIU RK 169675 01-03
LIU Y 186583 03-04
LIUZZI A 177338 02-03, 188350 04-13
LIVINGSTON A 190698 04-04
LLEWELLYN M 191983 04-04
LLOYD KG 189602 04-03
LOBER CW 189425 04-03
LOCH J 169462 01-14
LOCKE S 182150 02-03
LODGE D 188201 04-03
LOEFFLER LJ 170840 01-06
LOFFT JG 192083 04-10
LOFSTRANDH S 170747 01-03
LOH H 173872 01-03
LOH HH 182231 03-03, 182253 03-04, 184179 03-03, 186670 03-04, 186671 03-03, 189586 04-03, 191898 04-03
LONEY J 180992 02-11
LONG JP 177734 02-03, 188204 04-03
LOO H 180725 02-07, 184962 03-09
LOPEC CA 183402 03-13
LOPES DA SILVA FH 188166 04-04
LOPEZ-IBOR ALINO JJ 187536 04-09
LOPEZ-IBOR ALINO JM 183957 03-08
LORANGER AW 175426 02-11
LORENS SA 163835 01-04
LORENZ RJ 181576 02-03
LOREZ HP 186677 03-03
LORKOVIC H 188914 04-03
LOSEY EG 176870 02-03
LOSKOTA WS 189597 04-03
LOSKUTOVA ZF 191123 04-05
LOTFY AO 175282 02-07
LOVECKY DV 168718 01-04
LOVELL RA 182168 02-03
LOVENBERG W 188287 04-03, 191511 04-13
LOVSTAD RA 177335 02-13
LOW GL 168318 01-09
LOW PA 187618 04-11
LU LJW 191935 04-04
LUCAS RW 182214 03-03
LUCKENS MM 167328 01-03
LUERS H 184585 03-05
LUKANINA SK 183683 03-08
LULLMANN-RAUCH R 189605 04-03
LUNDBORG P 185899 03-03
LUNDE DT 185932 03-13
LUNDHOLM B 171606 01-03
LUNTS LHC 187565 04-11
LURIA J 168420 01-12, 185600 03-14
LUTHRA YK 189599 04-03
LUTTGES MW 175230 02-03
LUTZ MP 186703 03-04
LUYCKX A 183200 03-15
LYDELL KW 182192 02-04
LYDIARD RB 186695 03-03
LYNN CW 171500 01-09
LYON M 174035 01-04
LYTLE LD 180022 02-03, 182246 03-03

M

MABRY PD 174860 01-04
MACCANNELL KL 187812 04-13
MACDONALD ML 175862 02-17
MACFARLANE MD 191281 04-03
MACHLEIDT H 187805 04-01
MACINNES JW 175230 02-03
MACKAY AVP 171785 01-03
MACKINNON PCB 184436 03-15
MACPHAIL RC 173748 01-04, 186376 03-06
MAEDA H 176722 02-08
MAEDA S 191663 04-09
MAGNUSSON T 171622 01-03, 189571 04-03
MAGOUR S 180056 02-05, 185931 03-03
MAGYAR R 173398 01-03
MAHIER DH 191959 04-15
MAHNKE MW 189640 04-17
MAHUZIER G 184955 03-17
MAICKEL RP 177334 02-03, 182134 02-03, 187381 04-03, 189589 04-03
MAITRE L 172917 01-03, 181471 02-03
MAJIMA T 181378 02-08
MAJORS LF 192227 04-10
MAKI E 182111 02-04
MAKI M 184848 03-14
MAKIHARA H 178021 02-08
MAKINO K 174855 01-05
MAKINOSE M 184223 03-03
MALARKEY WB 191233 04-13
MALETZKY BM 187839 04-09
MALICK JB 182240 03-04
MALING HM 169688 01-05, 188865 04-05
MALITZ S 177674 02-14, 188149 04-17
MALKIN MD 171506 01-15
MALLACH HJ 178948 02-06
MALMNAS CO 171618 01-04
MALONE MH 167328 01-03
MALPAS A 184445 03-10
MALSBURY CW 183790 03-04
MANDEL LR 191535 04-12
MANDELBROTE BM 184436 03-15, 184437 03-13
MANDELL AJ 175149 02-13, 180020 02-03, 180047 02-13, 186674 03-03, 191516 04-03
MANFREDINI G 182789 03-10
MANHEIMER DI 177699 02-17, 181713 02-17
MANIAN AA 182243 03-03, 182444 03-01, 185748 03-04, 188977 04-03, 189589 04-03
MANIGAULT I 182224 03-03
MANION AA 191908 04-03
MANNO BR 182218 03-03
MANNO JE 182218 03-03
MANSCHRECK T 191035 04-15
MANTEGAZZA P 188200 04-03
MANTILLA-PLATA B 189598 04-05
MAO CC 191764 04-03
MARAMIS WF 171150 01-11, 176446 02-08
MARASA J 181958 02-13
MARCH J 189884 04-14
MARCHINI P 180098 02-01
MARCOTTE DB 167775 01-09
MARCUS R 190330 04-04, 191975 04-04
MARCY R 185749 03-06
MARGETTS G 182768 03-10
MARGULES AS 182133 02-04
MARGULES DL 182133 02-04
MARIAUD J 176703 02-03
MARIGNAN R 180723 02-03
MARK LC 182156 02-03
MARKOWITZ RA 191975 04-04
MARKS JH 168418 01-03
MARKS V 192577 04-09
MARQUIS WJ 176869 02-04
MARRAZZI AS 182121 02-03, 182143 02-03
MARRIOTT PF 181192 02-08
MARS H 187877 04-13
MARSANICO RG 186620 03-04, 187261 04-04
MARSELLA AJ 190240 04-17
MARSHALL FN 171007 01-13
MARSHALL J 184437 03-13
MARSHALL JM 188915 04-03
MARSHALL KE 173749 01-04
MARSHMAN J 179985 02-03
MARTIN A 182901 03-11
MARTIN BR 191968 04-03, 191970 04-03
MARTIN DF 171792 01-05, 178113 02-09, 178812 02-03
MARTIN ICA 185007 03-09
MARTIN IL 171971 01-01
MARTIN JB 188428 04-13
MARTIN P 192068 04-11
MARTIN WR 170874 01-03, 174480 01-12, 174496 01-12, 176312 02-03, 186024 03-12, 186665 03-03, 187254 03-15, 191904 04-03
MARTIN YC 180096 02-03, 191499 04-01
MARTINEZ JB 180123 02-12, 180141 02-12
MARTINEZ OA 190147 04-13
MARTIS L 185977 03-16
MARTZ R 191989 04-14, 191990 04-14
MARUKO K 171246 01-11, 181377 02-15
MASEK K 170072 01-03
MASKIN MB 168619 01-15, 177511 02-11
MASLAND RL 191096 04-13
MASLIYAH E 186164 03-04
MASON AS 173433 01-11
MASON P 186681 03-03
MASON ST 187420 04-04
MASSA A 175628 02-11

MASSON J 182901 03-11
MASSOPUST LC 188689 04-05
MASTEN LW 188178 04-03
MASTER RS 167346 01-10
MASTERSON J 185083 03-12
MASUDA K 191670 04-09
MASUDA T 181315 02-16, 182623 03-06
MASUR J 184212 03-04
MATHEU H 181811 02-13
MATHIEU LF 191925 04-03
MATIN SB 190718 04-03
MATRIANO D 192000 04-03
MATSUMOTO K 178623 02-09, 181653 02-06, 190095 04-11
MATSUMOTO Y 177190 02-17
MATSUMURA F 191315 04-03
MATSUSHITA K 178623 02-09, 181653 02-06
MATSUZAKI M 191952 04-04
MATTHEWS JD 182227 03-03
MATTILA MJ 171629 01-03, 186579 03-03
MATTIS PA 189587 04-05
MATZ R 174138 01-09
MAULE M 182766 03-10
MAXWELL RA 191978 04-10
MAYEVSKY A 177835 02-03
MAZURKIEWICZ-KWILECKI IM 169471 01-03
MAZURSKY MB 183683 03-08
MCALLISTER DR 190146 04-07
MCCABE OL 186994 03-08
MCCARTHY DA 186581 03-04
MCCARTHY KD 188231 04-03
MCCLAIN LD 187260 04-04
MCCLELLAND HA 185005 03-08
MCCLOSKEY KL 191937 04-03
MCCLURE DJ 167584 01-13, 168318 01-09
MCCLURE WO 182772 03-17
MCCONAHEY OLS 185604 03-14
MCCOY DJ 191991 04-04
MCCURDY L 167775 01-09
MCDOWELL FH 175426 02-11, 188421 04-13
MCGAUGH JL 169467 01-03, 181404 02-04
MCGEE JJ 171507 01-08
MCGEER EG 175241 02-03
MCGEER PL 183228 03-03, 189590 04-03
MCGLASHAN T 175332 02-16
MCGOWAN-SASS BK 182119 02-03
MCGUIRE RA 182246 03-03
MCGUIRE RJ 185191 03-14
MCHENRY JT 189502 04-11
MCHUGH PR 183648 03-09
MCKEARNEY JW 191767 04-03
MCKELVEY RK 190743 04-14
MCKENZIE GM 182128 02-04, 185997 03-04, 189403 04-11, 190314 04-13, 191517 04-03, 191533 04-11
MCKERNAN JB 172017 01-03
MCKIM WA 168833 01-04
MCKINNEY AS 184195 03-11
MCLAUGHLIN JL 192874 04-12, 192878 04-01, 192879 04-01, 192882 04-01
MCLELLAN DL 178618 02-11
MCLENDON D 187638 04-04
MCMAHON SA 176238 02-15
MCMASTER SE 191947 04-05
MCMILLAN DE 177410 02-04, 181405 02-04, 182194 02-04, 183893 03-04, 187928 04-03
MCNAIR DM 190305 04-17
MCPHILLIPS JJ 189177 04-02
MCQUILLAN LM 183402 03-13
MEAD PG 177533 02-04
MEADOW R 189778 04-11
MEDRANO JF 185993 03-03
MEHAR GS 191141 04-04
MEHTA NB 191978 04-10
MEKHILANE LS 191784 04-02, 191785 04-02, 191786 04-02, 191788 04-04
MELGES FT 185330 03-14
MELIKIAN AP 173875 01-03
MELISKA CJ 186701 03-03
MELLERUP ET 174133 01-04
MELLINGER GD 177699 02-17
MELLO WF 173032 01-04
MELTZER HL 182443 03-09
MELTZER HY 174609 01-14, 187114 03-09, 191506 04-13
MENDELS J 169093 01-09, 169491 01-09, 174994 02-14
MENDELSON JH 187257 04-14
MENDLEWICZ J 169494 01-09, 169495 01-09
MENON MK 183608 03-03, 189587 04-05
MENON MS 174587 01-08, 180248 02-15
MERCURO G 168748 01-03
MERLIS S 185877 03-08, 187840 04-17
MERRITT J 169782 01-03
MERSKEY H 182765 03-09
MESSIHA FS 184653 03-09, 185998 03-13, 189210 04-03
MESSINA C 171794 01-13
MESTER R 175251 02-17
METZLER CM 176108 02-13
MEYER ER 183895 03-03
MEYER H 172923 01-03
MEYER J 171731 01-13
MEYERSON BJ 171615 01-04, 171616 01-04, 171617 01-04, 171618 01-04
MEYLER L 183812 03-15
MICHAELSON IA 191957 04-05
MICHANEK A 171617 01-04
MICHIELS W 180699 02-14
MICZEK KA 182190 02-04, 189525 04-04
MIDDAUGH L 182229 03-03
MIDGLEY AR 173257 01-03
MIDORIKAWA Y 176448 02-10
MIELKE DH 189072 04-08
MIHARA M 182552 03-15
MIKEJIRI K 176471 02-11
MIKODA R 181654 02-04
MILES H 187130 03-03
MILHAUD C 168838 01-04
MILLENSON JR 183862 03-04
MILLER CA 191313 04-03
MILLER E 169220 01-11, 184196 03-11
MILLER EM 174297 01-15, 188561 04-11
MILLER FP 182242 03-04
MILLER H 185928 03-09
MILLER LL 171306 01-04
MILLER R 190545 04-03
MILLER RE 175317 02-04
MILLER RJ 177131 02-03, 180060 02-03, 189616 04-03
MILLER RR 192190 04-14
MILLER WC 167775 01-09
MILLMAN JE 187350 04-13
MILLNER JR 188412 04-04
MILLOY S 182208 02-04
MILLS PJ 182192 02-04
MILSTEIN SL 187812 04-13
MILSTEIN V 191188 04-15
MILZOFF JR 174964 01-03
MINSKER EI 183683 03-08
MIRMAN MJ 184175 03-10
MIRSKY IA 175317 02-04
MISKA RS 183601 03-03
MITA T 176468 02-08
MITCHELL CL 168835 01-04, 181397 02-04, 187077 03-03
MITTAG TW 192000 04-03
MIWA GT 191923 04-03
MIYADERA T 180487 02-01, 180488 02-01, 180489 02-01, 180490 02-02
MIYAMOTO K 176470 02-08
MIYAMOTO T 191932 04-03
MIYAMURA A 170638 01-13
MIYASHITA S 188450 04-15
MIZUNO K 177099 02-02
MOAMAI N 178189 02-17
MOAN E 185877 03-08
MOCHIZUKI Y 176565 02-09
MODELL W 176011 02-11
MODIGH K 168751 01-03, 171623 01-03
MOGLIA A 167336 01-13
MOHAN J 188094 04-15
MOLDOWAN MJ 173601 01-03
MOLINOFF PB 191509 04-03
MOLLENAUER S 187703 04-04
MOLNAR GW 186187 03-13
MONTANINI R 182789 03-10
MONTEBELLI ML 175540 02-11
MONTEJO IGLESIAS L 187536 04-09
MONTEL H 182345 03-03, 189568 04-03, 189569 04-03
MONTERO EF 170129 01-11
MONTGOMERY S 192577 04-09
MONTI JM 186574 03-11
MONTI L 186574 03-11
MOODY JP 187644 04-15
MOON HS 173502 01-08
MOON IJ 173078 01-04
MOORE JW 172745 01-04, 185934 03-04
MOORE KE 176874 02-03, 177840 02-03, 186635 03-04, 189397 04-03, 191521 04-04, 191897 04-03, 192012 04-04
MOORE RA 172834 01-11
MOORE RH 168130 01-03, 191935 04-04
MOOSMAYER A 178948 02-06
MORACCI FM 180098 02-01
MORALES F 186574 03-11
MORALISHVILI E 192084 04-15
MOREAU D 172980 01-11
MORGAN JP 185998 03-13
MORGANDO E 167594 01-10
MORGENROTH VH 191519 04-03, 191908 04-03
MORI A 177568 02-08, 188893 04-09, 191716 04-09
MORI M 170660 01-13, 174603 01-03
MORIN LP 186686 03-04
MORISHITA H 178725 02-03
MORITA K 182113 02-03
MORMONT C 183190 03-07, 190312 04-14
MOROJI T 184178 03-03, 191685 04-17
MOROT-GAUDRY Y 188976 04-03
MORRIS JB 191857 04-09
MORRIS LA 192704 04-17
MORRIS M 172741 01-08
MORRISON CF 190331 04-04, 190332 04-04
MORRITT C 186288 03-08
MORROW CW 186567 03-04
MORSE WH 191926 04-04
MORSELLI PL 169073 01-01
MOSKOWITZ H 189358 04-14, 189359 04-14
MOSNAIM AD 179992 02-03, 187112 03-03
MOSS J 168862 01-05, 191495 04-03
MOTULSKY AG 188826 04-11
MOUNTFORD D 190260 04-04
MOUNTJOY CQ 188348 04-09
MOURET J 187237 03-14
MOUZAS GL 174880 01-17
MOWAT AP 168526 01-15
MOWBRAY R 187582 04-10
MULLEN C 185112 03-03
MULLER EE 188200 04-03
MULLER P 187804 04-03
MULLER PJ 167572 01-15
MULLER W 189595 04-13
MULLER-CALGAN H 192424 04-04
MULLER-LIMMROTH W 179023 02-13
MUNGAVIN JM 182769 03-10
MUNKVAD I 186588 03-04
MUNSON AE 177834 02-05, 191960 04-03
MUNSON AF 191963 04-03
MURABAYASHI R 180986 02-10
MURAD F 182154 02-03
MURAKAMI T 180986 02-10
MURAYAMA S 182097 02-03
MURAZAKI M 176565 02-09
MURPHREE OD 187868 04-04, 190696 04-04
MURPHY DL 169504 01-09, 173387 01-03, 178432 02-09, 185928 03-09, 186580 03-09, 191502 04-13
MURPHY JE 182768 03-10
MURPHY LR 184834 03-04
MURRAY MAF 184437 03-13
MUSACCHIO JM 186698 03-03
MUTALIPASSI LR 171506 01-15
MYAGI MA 191777 04-07, 191790 04-07
MYTILINEOU C 182204 02-03

N

NADEAU R 172598 01-05
NADEAU RA 187807 04-03
NADITCH MP 167832 01-15
NADLER RD 187935 04-03
NAESTOFT J 188832 04-09
NAFTCHI NE 182178 02-06
NAGAI T 176467 02-08
NAGAMI GT 182250 03-03
NAGARAJA J 182870 03-17
NAGASAKA G 176564 02-11
NAGASWAMI R 169461 01-11
NAGASWAMI S 169461 01-11, 188094 04-15
NAGAWA Y 173548 01-05, 177099 02-02, 181654 02-04, 181657 02-02, 181658 02-02
NAGLE BT 191962 04-03
NAGY A 183603 03-13
NAHORSKI SR 188291 04-03

NAIR NPV 168805 01-11, 168806 01-11, 191138 04-14
NAITO H 182547 03-03
NAITO Y 182096 02-03
NAJ L 180123 02-12
NAKAGUCHI T 177097 02-05
NAKAHARA T 178725 02-03
NAKAHARA Y 177336 02-03
NAKAJIMA H 170754 01-17
NAKAJIMA R 181654 02-04
NAKAMURA M 182637 03-02
NAKANE M 185241 03-14
NAKANISHI H 182103 02-04
NAKANO S 182118 02-14
NAKASHIMA Y 180301 02-11
NAKAYA K 167917 01-09, 167918 01-09
NAKAYAMA K 168499 01-07
NAKAZAWA Y 167921 01-14, 176722 02-08
NAMBA T 171282 01-11, 182624 03-11
NAMIKI M 181771 02-07
NANDI DN 175410 02-09
NANIVADEKAR AS 167346 01-10
NARAHASHI T 186672 03-03
NARANJO C 178064 02-12
NARASIMHACHARI N 187576 04-03
NARAYANAN HS 183418 03-14
NASH JB 191969 04-03
NATHANSON JE 184175 03-10
NAUMOV NN 183520 03-01
NAVARATNAM V 174830 01-04
NAYLOR GJ 185193 03-11, 187644 04-15
NAYLOR RJ 171305 01-03, 176877 02-04, 185958 03-04, 186577 03-03
NEFF NH 168437 01-03, 176254 02-13, 182718 03-03, 186668 03-03, 191500 04-03
NEIBURG HA 174297 01-15
NEILL DB 187698 04-04
NELSEN JM 176864 02-04
NELSON DL 191509 04-03
NELSON LM 187116 03-13
NELSON MF 180022 02-03
NELSON WL 190719 04-02
NEUBURG J 187119 03-04
NEUVONEN PJ 176879 02-04
NEVSIMALOVA S 192419 04-11
NEWMARK CS 183635 03-17
NG LKY 181810 02-03
NICHOLS A 187113 03-08
NICHOLS DE 172915 01-03, 173588 01-03, 177734 02-03
NICKANDER R 187130 03-03
NICOLL RA 177976 02-03, 190727 04-03
NIEBURG HA 169220 01-11
NIELSEN EB 174035 01-04
NIELSEN IM 186368 03-04, 186369 03-04, 186370 03-04, 186371 03-04
NIELSEN M 171627 01-03, 190310 04-03
NIEMEGEERS CJE 185961 03-04, 190306 04-03, 192421 04-04
NISHI H 182095 02-03
NISHIDA K 171282 01-11, 182624 03-11
NISHIE K 187575 04-04
NISHIJIMA Y 174603 01-03
NISHIKAWA T 188199 04-03
NISHIKIORI T 178655 02-17
NISHIMURA K 176472 02-08
NISHIOKA M 182112 02-04
NISHIURA N 188517 04-09
NISHIZAKI H 181386 02-04
NISHIZONO M 170415 01-11, 177066 02-17, 180319 02-08
NITYANAND S 176881 02-03
NIWAGUCHI T 177336 02-03
NO YI 182574 03-17
NOBLE EP 182722 03-13
NOGUCHI T 180986 02-10, 191716 04-09
NOMA T 167918 01-09, 181388 02-11
NOMURA J 176454 02-11
NOMURA M 177097 02-05
NOMURA S 191670 04-09
NOON JP 191896 04-03
NORHEIM G 172398 01-16
NORRED WP 187575 04-04
NORRMAN S 171632 01-03
NORTON S 176867 02-06
NOSE F 183199 03-11
NOWAKOWSKI H 174783 01-11
NOYES R 174132 01-14, 185873 03-09
NOZAWA A 182624 03-11
NURNBERG FL 175003 02-14
NUTT JG 174473 01-13, 174479 01-14, 182163 02-03
NUTTER R 188107 04-09
NYBACK HV 191931 04-03
NYMARK M 186368 03-04

O

O'BRIEN A 190718 04-03
O'BRIEN CP 176675 02-14
O'BRIEN GS 176677 02-03
O'BRIEN PMJ 185190 03-11
O'CONNELL RA 187786 04-15
O'DEA MH 187939 04-01
O'LEARY J 174059 01-08
O'NEAL EC 192704 04-17
OATES JA 184654 03-13
OBE G 184585 03-05
OBERMAJEROVA H 170072 01-03
OBOURN R 190241 04-09
OCHI Y 167919 01-09
ODLE D 171502 01-09
ODSTRCHEL G 182186 02-03
OERIPSANTOSO S 172809 01-17
OESCH F 182720 03-03
OFFERMEIER J 191420 04-03
OGATA M 167921 01-14, 178019 02-15
OGAWA H 182116 02-04, 182117 02-04
OGAWA N 168272 01-17, 181384 02-04, 182114 02-04, 182115 02-04, 182118 02-14, 185350 03-17
OGLESBY MW 176866 02-04, 184980 03-04
OGUCHI T 176565 02-09
OGURA C 181650 02-03, 182549 03-03
OGURA M 188450 04-15
OH D 181957 02-10
OH JS 171599 01-04
OH YP 172018 01-03
OHATA K 182094 02-03
OHMI S 176472 02-08
OHMOTO T 190095 04-11
OHSAWA I 175120 02-09
OHSHIMA T 168499 01-07
OHTANI T 183369 03-10
OHUCHIDA S 175120 02-09
OIKAWA T 182549 03-03
OKA M 182089 02-03
OKADA F 170638 01-13
OKADA M 176889 02-09, 191716 04-09
OKAMOTO M 191952 04-04, 191953 04-04
OKAMOTO Y 178019 02-15
OKLOBDZIJA M 187942 04-01
OKUBO N 182731 03-10
OKUMURA Y 176470 02-08
OKUSE S 176473 02-10
OLDS ME 177837 02-04
OLGIATI S 174299 01-09
OLIVERIO A 185751 03-03
OLIVIER JA 189606 04-15
OLLERICH DA 176476 02-05
OLLMANN JE 187937 04-01
OMAR NM 183600 03-01
OMENN GS 188826 04-11
ONDRUSEK G 175895 02-03
ONO M 176474 02-10
ONO N 178725 02-03, 182109 02-04
ORCI L 168440 01-03
ORCUTT JC 191509 04-03
ORDONA TT 180992 02-11
ORDONEZ LA 191771 04-03
ORELAND L 175239 02-03
ORGANISCIAK DT 187677 04-03
ORITA S 177097 02-05
ORKIN LR 182185 02-03
ORNSTON D 189075 04-13
ORSULAK P 191523 04-01
ORTIZ A 185992 03-03
ORZACK MH 176673 02-08
ORZECHOWSKI RF 188875 04-05
OSANIUS B 171632 01-03
OSAWA S 191720 04-08
OSGOOD PP 191964 04-03
OSHIMA M 175550 02-08
OSKOUI M 182222 03-03
OSTAPTZEFF G 184963 03-14, 184964 03-11
OSTAPTZEFF M 184963 03-14, 184964 03-11
OSTERHOLM KC 187572 04-04
OSTOW M 174495 01-10
OSTRENGA JA 177396 02-15
OSWALD I 183547 03-09
OTA H 178053 02-08
OTA KY 177319 02-07
OTANI T 182872 03-03
OTIS LS 175751 02-03
OTSUKA R 191625 04-13, 191667 04-13
OTSUKI S 167917 01-09, 167918 01-09, 180301 02-11
OU GT 180321 02-17
OVERALL JE 171505 01-08
OVERO KF 191026 04-09
OVERSTREET DH 185265 03-04
OVERTON DA 169071 01-03
OWEN CA 176936 02-03, 185330 03-14
OWEN JE 185957 03-04

P

PADJEN A 177976 02-03, 190727 04-03
PAESALU EI 191789 04-03
PAGE JG 189587 04-05
PALAZZO G 168801 01-01
PALFAI T 188248 04-04, 188412 04-04
PANTELEYEVA GP 183683 03-08
PANTON Y 189744 04-12
PAOLINO RM 182241 03-04
PAPESCHI R 183868 03-03, 186587 03-04, 186588 03-04
PARE CM 191496 04-03
PARE WP 171301 01-02, 178720 02-03
PAREKH CS 172439 01-11
PARENT M 174044 01-11, 183190 03-07
PARISH LC 184175 03-10
PARK CW 171259 01-04, 171599 01-04
PARK DH 191510 04-13
PARK S 168836 01-08
PARKER DC 190104 04-13
PARKER JM 183363 03-03, 191141 04-04
PARKER Z 191192 04-11
PARMAR SS 169818 01-01, 182727 03-03, 183598 03-02, 183601 03-03, 185980 03-01, 191942 04-03
PARRY HJ 177699 02-17
PARVEZ H 178815 02-03
PARVEZ S 178815 02-03
PATCH VD 169085 01-14
PATEL G 182721 03-03
PATHAK D 185210 03-10
PATLAK CS 170112 01-06
PATNI SK 174768 01-04
PATON DM 168747 01-03
PATON WDM 181941 02-03
PATRICK GA 172019 01-03, 182153 02-03
PATTISON JH 171925 01-10
PAUL AG 192876 04-12
PAULI AI 174763 01-04
PAULSON GW 168777 01-13, 191233 04-13
PAYKEL ES 185322 03-10
PAZZAGLI A 168578 01-13
PEARCE J 167572 01-15
PEARLE DL 187923 04-03
PEARLMAN S 167382 01-17
PEARSON E 172485 01-10
PEDEMONTE WA 179992 02-03
PEDERSEN V 171607 01-04, 186368 03-04
PEET M 192577 04-09
PEGRAM GV 187260 04-04
PEKUNOVA LG 183683 03-08
PELTON EW 177975 02-11
PENG T 186678 03-03
PENN RG 182761 03-17
PENNINGROTH RP 186780 03-10
PENSABENE JW 187575 04-04
PENTIKAINEN P 176879 02-04
PEREIRA-OGAN JA 167773 01-10, 172993 01-10, 176107 02-10, 184175 03-10
PEREL JH 192872 04-10
PEREL JM 172271 01-13, 187933 04-13
PEREZ-REYES M 176747 02-03, 182223 03-03, 188119 04-13
PERI G 189893 04-03, 191423 04-03
PERKINS R 184438 03-14
PERL M 177835 02-03
PERLOFF MM 176107 02-10, 188144 04-10
PERON-MAGNAN J 176438 02-17
PERON-MAGNAN P 180725 02-07
PERRIER C 184177 03-11
PERRON D 191142 04-15

PERRY KW 187831 04-03
PERRY TL 191331 04-03
PERSSON G 172401 01-09
PERT A 190264 04-04
PERT CB 190476 04-03
PERTWEE RG 181941 02-03
PERUZZI G 188200 04-03
PETERS DAV 181945 02-03
PETERS MA 182165 02-03, 183894 03-03
PETERSEN BH 191961 04-13
PETERSON GR 182225 03-03, 188178 04-03
PETITJEAN F 189023 04-02
PETROZZI M. C 190670 04-11
PETRYSHYN WR 187702 04-04
PETTIGREW A 191192 04-11
PFEIFFER E 192229 04-09
PHILIPPU A 184230 03-03, 185902 03-03
PHILLIPS J 186584 03-10
PHILLIPS RN 174961 01-05
PHILLIS JW 187806 04-03, 191380 04-03
PHOEBUS E 177318 02-14
PICCHONI A 191992 04-03
PICKENS R 185960 03-04
PIERCE JV 170840 01-06
PIHLAJAMAKI K 171633 01-03
PILBRANT A 171630 01-16
PINARD G 167343 01-08, 183359 03-03, 183361 03-09
PINCO R 172109 01-17
PINDER R 190545 04-03
PINEAU R 178193 02-11, 188406 04-03
PINEDA MR 190379 04-09
PINKEY B 186092 03-15
PINTO A 171507 01-08
PINTO F 182790 03-11, 182791 03-09
PIPPENGER CE 191096 04-13
PIRCH JH 187572 04-04, 191969 04-03
PIRES P 178187 02-08, 178193 02-11, 188406 04-03
PITTERMAN A 182721 03-03
PITTMAN KA 178641 02-03
PLANAS P 183955 03-08
PLENGE P 172402 01-09, 174133 01-04
PLETSCHER A 184229 03-03
PLOTNIK R 187703 04-04
PLOTNIKOFF N 180096 02-03
PLOTNIKOFF NP 176677 02-03, 187938 04-01
POCOCK DA 189408 04-14
PODOSIN RL 177778 02-11
POHORECKY LA 182238 03-04
POITOU P 190337 04-03
POKORNY A 171505 01-08
POKORNY AD 190381 04-09
POLC P 179021 02-05
POLIZOS P 177754 02-08, 183275 03-08, 184174 03-11
POLLARD H 168750 01-03, 189396 04-03
POLLIN W 187113 03-08
POLVAN O 182431 03-11
PONG SF 167358 01-03
PONZIO F 189752 04-03
POOL WR 180097 02-03
POPE FE 168361 01-17
POPE JH 189514 04-04
PORRINO LJ 169086 01-14
PORTER AL 184380 03-04
POSCHEL BPH 186581 03-04, 191527 04-04
POSHIVALOV VP 191120 04-04
POST RM 170084 01-09, 170621 01-09, 174094 01-09, 183546 03-10, 184160 03-09, 187398 04-13, 187642 04-14
POSTEL J 167676 01-08
POSTEL M 167676 01-08
POSTMA E 170837 01-03
POTKIN SG 192229 04-09
POTTER WZ 189589 04-03
POUPIER G 182900 03-11
POWELL BJ 182719 03-13
POWER M 185083 03-12
PRADHAN PV 175967 02-10
PRADHAN SN 191528 04-04
PRANGE AJ 171500 01-09, 172992 01-15, 191534 04-09
PRASADIO T 176446 02-08, 178038 02-10
PRECHTL HFR 168523 01-14
PREPAS S 183608 03-03
PRESLEY JM 167954 01-08
PRESS M 177771 02-14
PRESTON AC 186702 03-04
PRICE JS 188348 04-09
PRICE-WILLIAMS D 190240 04-17
PRIEN R 186189 03-09
PRIEN RF 169065 01-11, 169090 01-09, 171926 01-09, 172831 01-08, 186188 03-09, 186190 03-09, 186191 03-09, 189735 04-09, 190381 04-09
PRIEST RG 173307 01-16
PRIJOSEMBODO W 171161 01-09
PROAKIS AG 189583 04-05
PROTT FW 189408 04-14
PROUDFIT HK 188751 04-03
PRUITT DB 188202 04-03
PRUSOFF B 171924 01-10, 185322 03-10
PRYOR GT 182192 02-04
PTITO M 176963 02-04
PUGLISI CV 169817 01-13
PUHAKKA P 180047 02-13
PUIG M 184229 03-03
PUJOL J 179988 02-13
PULLIAM AL 187577 04-01
PULLMAN B 183406 03-01
PURGYI P 180063 02-15
PURI SK 171300 01-04, 182230 03-03, 184225 03-03

Q

QUENTIN J 182901 03-11
QUENZER LF 185934 03-04
QUERMONNE MA 185749 03-06
QUIMBY KL 192565 04-04
QUINN PO 185324 03-14
QUITKIN F 169492 01-15

R

RACAGNI G 180582 02-03, 184553 03-03, 187526 04-03, 188891 04-03
RADA RT 177748 02-08, 187869 04-08
RADCLIFFE GJ 176868 02-04
RADLOW RR 174210 01-14
RADULOVACKI M 181815 02-03
RAFAELSEN OJ 172402 01-09, 174133 01-04, 182434 03-09
RAFALOVICH EG 181778 02-08
RAFT D 183635 03-17
RAJAN KS 176763 02-06
RAKE AV 185927 03-04
RAMACHANDRAN V 174587 01-08, 180248 02-15
RAND MJ 182088 02-03
RANDALL CL 177733 02-03
RANDALL LO 182771 03-17
RANDRUP A 180061 02-04, 185929 03-11, 186587 03-04, 186588 03-04, 190310 04-03
RAO BSS 183418 03-14
RAO DB 185560 03-15
RAO GS 170839 01-06
RAO VA 176881 02-03
RAPOPORT JL 185324 03-14
RAPOPORT R 190718 04-03
RASKIN A 171502 01-09, 171923 01-09
RAU JH 181270 02-14
RAY AK 185560 03-15
RAY I 168317 01-09
RAY OS 178638 02-04, 184242 03-04, 189521 04-04
RAZANI J 189916 04-10
READ RC 186187 03-13
READING HW 181942 02-03
REATIG N 171502 01-09
REBEC GV 185264 03-03
RECH RH 176869 02-04, 187930 04-04, 192009 04-04
RECHTSCHAFFEN A 191389 04-03
REDDY GNN 183418 03-14
REDFERN PH 174829 01-04, 174830 01-04, 186636 03-04
REES JMH 174828 01-03
REES WL 176926 02-17
REGINA EG 190743 04-14
REID AH 185193 03-11
REIGLE TG 174962 01-03
REILLY E 174132 01-14
REIMER DR 188094 04-15, 190242 04-07
REINHARD JF 187939 04-01
REINHOLD K 169474 01-03
REINIS S 171904 01-03, 171905 01-04
REINTOFT M 187236 03-11
REISBY N 185929 03-11
REISS D 189743 04-14
REISS M 187255 03-08
REITZ RH 171007 01-13
RENAULT P 181879 02-13
RENAULT PF 188120 04-13
RESCHKE RW 178545 02-08
RESNICK O 167496 01-11
RESNICK RB 189059 04-07
REVUSKY S 178502 02-04
REYNOLDS CF 171503 01-09
REYNOLDS EH 184439 03-15
REYNOLDS R 181853 02-14
REYNOSO RM 180142 02-12, 180143 02-12
REYNTJENS A 183194 03-09
REYNTJENS AM 183191 03-11, 183192 03-11, 183193 03-11
RHO KS 171599 01-04
RICCIARDI F 191190 04-14
RICCIO DC 167398 01-04
RICHARDS DW 185725 03-03
RICHARDSON JS 173520 01-09, 182211 03-04, 187380 04-03
RICKELS K 167773 01-10, 171299 01-14, 172993 01-10, 176107 02-10, 177376 02-10, 181273 02-10, 184175 03-10, 185747 03-09, 188144 04-10, 189919 04-10
RICKLES W 169070 01-13
RICKLES WH 181887 02-13, 190308 04-14
RIDDLE KD 185324 03-14
RIDGERS A 168834 01-04
RIEGER F 176703 02-03
RIEGLE T 191523 04-01
RIFKIN A 169492 01-15
RIGGI F 191190 04-14
RIKLAN M 168619 01-15, 177511 02-11
RIMON R 180046 02-08
RIMON 4 180047 02-13
RINGLE DA 182187 02-03
RITCHIE AC 187565 04-11
RITTER S 173029 01-03, 182210 02-04
RIVIER J 190104 04-13
ROACH MK 191939 04-04
ROBB D 184372 03-03
ROBBINS J 186580 03-09
ROBBINS T 188620 04-04
ROBERTS CD 181959 02-14
ROBERTSON JF 191215 04-15
ROBICHAUD RC 171304 01-04, 182188 02-04, 192016 04-04
ROBIN J 178950 02-11
ROBIN SS 178127 02-17
ROBINSON RG 187498 04-04
ROBINSON S 171124 01-10
ROBY DM 171007 01-13
RODBRO P 188889 04-11
RODDA BE 191989 04-14, 191990 04-14
RODRIGUES VR 178811 02-10
ROE TS 171260 01-06
ROENSBERG G 185902 03-03
ROFFMAN M 191523 04-01
ROGER B 176431 02-11
ROGERS KJ 188291 04-03
ROGERS ME 187938 04-01
ROIZEN MF 168862 01-05, 191495 04-03
ROIZIN L 185112 03-03
ROMERO RJ 189754 04-12
ROMI JC 169297 01-07
ROMMELSPACHER H 177337 02-03
ROOLAYD EA 191790 04-07
ROSCAM ABBING PJ 170847 01-17
ROSE WC 177834 02-05
ROSECRANS JA 191944 04-04
ROSEN AJ 175242 02-04, 186568 03-04
ROSENBERG CM 189926 04-11
ROSENBLATT JE 177450 02-14
ROSENBLATT S 174995 02-09
ROSENBLUM MP 183602 03-01
ROSENFELD H 185747 03-09, 188144 04-10
ROSENKRANTZ H 188872 04-05, 189516 04-04, 189588 04-05, 189599 04-03, 191965 04-03, 191966 04-04
ROSENTHAL R 177669 02-08
ROSENTHAL SH 172486 01-10
ROSENZWEIG MR 174036 01-03
ROSIER YA 172980 01-11
ROSSI AM 187257 04-14
ROSSI GV 167329 01-03
ROSSI V 188875 04-05

ROSSIGNOL P 169469 01-04
ROSSMAN LG 190104 04-13
ROTH B 192419 04-11
ROTH JA 177332 02-03
ROTH RH 191519 04-03, 191896 04-03, 191908 04-03, 191931 04-03
ROTH T 167341 01-08, 177747 02-07
ROTH W 191957 04-05
ROTH WT 177720 02-14, 189406 04-14
ROTHSTEIN E 172275 01-11
ROWE TC 173158 01-04
ROWLEY VN 192116 04-04
ROY A 182898 03-15
ROY JY 183361 03-09
RUCH W 191418 04-03
RUDERMAN NB 191771 04-03
RUDMAN S 180064 02-10
RUDZIK AD 185032 03-01
RUPP JM 178948 02-06
RUSCH DN 173589 01-01
RUSSELL A 168837 01-04, 181605 02-04
RUSSELL RW 181406 02-04
RUSSELL SC 190379 04-09
RUSTERHOLZ DB 172915 01-03
RUTHVEN CRJ 167445 01-03
RUTLEDGE CO 186669 03-03
RYBAKOWSKI J 174778 01-09

S

SAARIKOSKI S 171613 01-03
SAARNIVAARA L 186579 03-03
SAAVEDRA JM 173382 01-03
SABELLI HC 179992 02-03, 187112 03-03
SABY J 184955 03-17
SACCO FA 167575 01-10
SACHAR EJ 191506 04-13
SACK RL 170083 01-03, 174329 01-09, 181358 02-09
SADOF M 185997 03-04
SADONO B 174618 01-17
SAFER D 188567 04-11
SAITO H 182872 03-03
SAITO K 176468 02-08
SAITO M 176722 02-08, 178002 02-17
SAITO N 176468 02-08, 176473 02-10
SAITO S 182626 03-01
SAITO T 182624 03-11
SAJI Y 177099 02-02, 181654 02-04
SAKALIS G 168836 01-08, 172485 01-10, 181957 02-10
SAKATA T 177019 02-04, 177020 02-04
SAKSONOV PP 191123 04-05
SAKURADA S 182112 02-04
SAKURAI T 176722 02-08
SALAN R 176582 02-11
SALELKAR GK 182829 03-10
SALETU B 174131 01-08, 181958 02-13, 187115 03-09
SALETU M 187115 03-09
SALKIND MR 182767 03-10
SALLER R 184232 03-03
SALMINEN J 184978 03-13
SALZMAN C 169086 01-14, 187837 04-15, 189743 04-14
SAM J 182446 03-01, 187938 04-01
SAMANIN R 188196 04-03
SAMARDZIC R 186640 03-03
SAMEJIMA K 177097 02-05
SAMESHIMA T 176722 02-08
SAMOUR CM 187939 04-01
SAMPATH SS 182718 03-03
SANCILIO FD 185034 03-01
SANDERS-BUSH E 182140 02-03
SANDLER M 167445 01-03, 168286 01-13, 191496 04-03
SANDQUIST VL 176312 02-03
SANGIOVANNI F 170627 01-09
SANKAV DVS 174605 01-12
SANO I 185182 03-17
SANO M 182105 02-03, 182108 02-04
SANTOS CA 182229 03-03
SANTOS MR 169297 01-07
SARA SJ 186704 03-04
SARAF KR 174588 01-08, 175393 02-11, 175460 02-08, 189512 04-15
SARAI K 191670 04-09
SARANTAKIS D 177836 02-04
SARBIN TR 173056 01-13
SARGES R 175762 02-17
SASAMOTO S 176542 02-11
SASSE EA 190194 04-11
SATHANANTHAN GL 174138 01-09, 177710 02-15
SATINDER KP 187702 04-04
SATO E 185241 03-14
SATO K 176565 02-09
SATO M 182105 02-03, 182108 02-04
SATO Y 177567 02-09
SATTERFIELD JH 177778 02-11
SAUL RE 177778 02-11
SAUL W 188865 04-05
SAULLE RD 181152 02-14
SAVAGE C 184653 03-09
SAVAGE RD 182763 03-14
SAWA A 191686 04-08
SAWADA H 174853 01-16, 181588 02-13, 181593 02-03, 182555 03-03, 182556 03-13
SAWADA T 182096 02-03
SAWICKY TE 186701 03-03
SAYERS AC 185750 03-03
SCARBORO MB 182193 02-04
SCATTAREGIA F 182155 02-03
SCELLES F 184955 03-17
SCERNI R 182215 03-04
SCHAEFER GJ 178638 02-04, 184242 03-04
SCHAEFFER JC 182250 03-03
SCHAEPPI U 189516 04-04
SCHALCH DS 189076 04-09
SCHALLEK W 181575 02-03, 182771 03-17
SCHALLY AV 175245 02-13, 189076 04-09
SCHANBERG SM 191512 04-13, 191922 04-03
SCHARER K 179021 02-05
SCHARF M 172114 01-15
SCHEEL-KRUGER J 171627 01-03
SCHERRER P 182898 03-15, 182899 03-17
SCHIELE BC 192065 04-13
SCHILDKRAUT JJ 169091 01-13, 178114 02-09, 191523 04-01
SCHINTOMI K 182107 02-04
SCHLEDE E 184228 03-03
SCHLOSSER W 182126 02-03, 182771 03-17
SCHMALTZ G 189215 04-04
SCHMIDBAUER W 175537 02-17
SCHMIDT KT 181153 02-08
SCHMITT H 186576 03-04
SCHMITT R 167334 01-07
SCHNEIDER B 176107 02-10
SCHNEIDER FH 190907 04-03
SCHNEIDER J 185112 03-03
SCHNITZER RJ 179983 02-17
SCHNOLL SH 182186 02-03
SCHOLES NW 169689 01-03
SCHOLFIELD CN 191945 04-03
SCHOLZ SD 173039 01-04
SCHONER W 189567 04-03
SCHOU M 167675 01-09, 182433 03-09, 185192 03-11
SCHREIBER RA 184235 03-03
SCHROEDER CS 190321 04-14
SCHROEDER DH 191978 04-10
SCHROEDER SR 190321 04-14
SCHUBERT DSP 169635 01-15
SCHUBERT J 168839 01-03
SCHUBERTH J 171600 01-03
SCHULTERBRANDT JG 171502 01-09
SCHULTES RE 189101 04-12
SCHULZ R 171610 01-03, 182161 02-03
SCHULZE G 177337 02-03
SCHUMPELICK V 178945 02-03
SCHUSTER CR 181879 02-13, 188120 04-13
SCHWABE U 181467 02-03
SCHWARTZ J 168750 01-03, 189396 04-03
SCHWARTZ JL 177747 02-07
SCHWARTZ M 170837 01-03, 173398 01-03, 189075 04-13
SCHWARTZ NB 175650 02-03
SCHWARTZBAUM JS 173032 01-04, 187700 04-04
SCHWIN R 182719 03-13
SCOGGINS BA 187582 04-10
SCOTT DF 184445 03-10
SCOTT J 191400 04-14
SCOTT JE 174966 01-15
SCUDDER CL 188637 04-04
SEDVALL G 171626 01-03, 186565 03-08, 186566 03-16
SEEMAN P 182127 02-03, 187801 04-03, 187802 04-03, 187803 04-03, 187804 04-03, 187805 04-01, 189400 04-03, 189401 04-03
SEEVERS MH 191603 04-16
SEGAL A 176107 02-10
SEGAL DS 185264 03-03
SEGAL M 187499 04-04, 190829 04-03, 191996 04-03
SEGAWA Y 191670 04-09
SEHON AH 187129 03-04
SEIDEN LS 171612 01-04
SEIFERT J 170072 01-03
SEIFTER E 182254 03-03
SEIFTER J 182254 03-03
SEILER K 184226 03-03
SEILER N 181944 02-03
SEISER RL 189381 04-03
SEKERKE HJ 172272 01-11
SELBY G 191614 04-11
SELIGER DL 167415 01-03
SELIVANOVA AT 183517 03-04
SELLERS EM 179987 02-13, 192005 04-11
SELYE H 183611 03-03
SEMEL C 178578 02-08
SENAULT B 186374 03-04
SENGUPTA S 187805 04-01
SERAFETINIDES EA 173402 01-08, 174135 01-16, 181918 02-13, 184177 03-11
SERRANO AC 169457 01-14
SERRANO M 167343 01-08
SETH SK 187937 04-01
SETHI ML 170839 01-06
SETHNA ER 185078 03-10
SETHNA KJ 175620 02-17
SETHY VH 188429 04-11
SETYONEGORO K 180299 02-11
SETYONEGORO RK 170412 01-11, 170753 01-11, 171162 01-10
SHAGASS C 169092 01-09
SHAH BK 167344 01-09
SHAH LP 172444 01-08, 174588 01-08, 174589 01-08, 175393 02-11, 175967 02-10, 180153 02-08
SHAH NS 191933 04-03
SHAMBHU MB 190715 04-01
SHAPIRO AK 188431 04-11
SHARMA S 180406 02-09, 189359 04-14
SHARPE LG 191367 04-04
SHARPLESS NS 176936 02-03
SHASTRI PC 174589 01-08, 180153 02-08
SHAVELZON A 180140 02-12
SHEA R 189358 04-14
SHEEHAN DV 177681 02-12
SHEERIN E 170802 01-17
SHEHORN J 184021 03-12
SHELLENBERGER MK 191988 04-03
SHELLEY E 169495 01-09
SHELTON JW 176868 02-04
SHEPPARD C 185877 03-08, 187840 04-17
SHEPPARD H 180097 02-03, 181575 02-03
SHERMAN AD 187077 03-03
SHERMAN WR 191924 04-13
SHERWOOD BE 190719 04-02
SHIBATA Y 168302 01-17
SHIBUYA T 182106 02-17
SHIELDS WE 189640 04-17
SHIGEYOSHI T 176473 02-10
SHIH JC 189597 04-03, 191498 04-01
SHIH T 191946 04-03
SHIH TM 182222 03-03
SHIMAZU Y 178224 02-08
SHIMIZU H 182099 02-03
SHIMIZU K 177022 02-03
SHIMIZU S 182091 02-03
SHIMURA M 182634 03-02
SHIN KCL 180507 02-03
SHINOHARA M 182105 02-03
SHINTOMI K 183610 03-03
SHIOZAKI M 176727 02-08
SHIRRON C 182256 03-03
SHOJI O 181388 02-11
SHOPSIN B 169094 01-09, 181957 02-10, 186920 03-09, 191531 04-09
SHORE PA 181809 02-03, 182234 03-03
SHOSHKES M 192511 04-13
SHOSTAK M 173536 01-06
SHOULSON I 187985 04-11
SHROFF AP 176871 02-16
SHROFF PF 177320 02-11

SHULGIN AT 192877 04-12
SHULMAN RS 185210 03-10
SHUMWAY J 191967 04-04
SHUPACK JL 188414 04-15
SHUSTER L 182225 03-03
SICHEL J 182900 03-11
SIEMENS AJ 179985 02-03, 192020 04-03
SIEROSLAWSKA J 167813 01-04
SIERRA MR 189754 04-12
SIGGINS GR 187496 04-03
SIGWALD J 171134 01-13
SIKIC B 188120 04-13
SILBERGELD EK 184953 03-04, 191954 04-05
SILER TM 190104 04-13
SILVA D 189597 04-03
SILVERMAN I 167382 01-17
SILVESTRINI B 168802 01-13
SILVESTRINI F 188350 04-13
SIMEON J 187115 03-09
SIMON G 188874 04-05
SIMON JR 191999 04-03
SIMON M 189597 04-03
SIMOPOULOS AM 171507 01-08
SIMPSON FO 183234 03-09
SIMPSON GM 187255 03-08
SINGER K 171485 01-17, 185192 03-11
SINGH AN 168320 01-08, 191140 04-11
SINGH GB 176881 02-03
SINGH N 186569 03-03
SINGHAL BS 172439 01-11
SINGHAL RL 183358 03-03
SINNETT ER 178695 02-17
SINYUKHIN VN 183519 03-03
SIRCOVICH O 171122 01-11
SIRIS JH 191096 04-13
SIZARET P 184961 03-17
SJO O 188889 04-11
SJOQUIST B 171626 01-03
SJOQVIST F 169074 01-01
SJOSTROM R 169470 01-13
SKOLNICK P 177252 02-03
SKOPKOVA H 175047 02-11
SKORINA JK 186833 03-14
SKOUSEN WC 192092 04-17
SLATER IH 190346 04-03
SLEDGE K 192016 04-04
SLEDGE KL 171304 01-04
SLEIGH MJ 188770 04-01
SLETTEN I 180064 02-10
SLETTEN IW 176676 02-17
SLOAN JW 186024 03-12
SLOBODA W 181959 02-14
SLOMINSKA-ZUREK J 186571 03-04
SLOTNICK VB 177319 02-07
SMALL E 192787 04-17
SMALL JG 191188 04-15
SMALLING KF 190196 04-09
SMART R 167585 01-17
SMATHERS CC 189856 04-03
SMEETS RA 189923 04-13
SMIRNOVA LV 174257 01-03
SMITH AA 182164 02-03
SMITH BM 189074 04-17
SMITH CB 177406 02-03, 182255 03-03
SMITH D 182156 02-03
SMITH DC 189075 04-13
SMITH GM 190743 04-14
SMITH GP 182136 02-04
SMITH GR 192231 04-09
SMITH HJ 187640 04-04
SMITH JE 171925 01-10
SMITH JS 169140 01-15
SMITH ML 187573 04-03
SMITH RB 188875 04-05
SMITH RD 186634 03-04
SMITH SG 172454 01-04, 191899 04-04
SMITH WM 185727 03-04
SMITHLOFF BR 183895 03-03
SMYTH WF 190902 04-06
SMYTHIES JR 187260 04-04
SNEED GA 172749 01-03, 177749 02-03
SNIDER SR 184201 03-03
SNODDY HD 183869 03-03, 190346 04-03
SNYDER E 187703 04-04
SNYDER S 188114 04-15
SNYDER SH 188121 04-12, 190476 04-03, 191290 04-08
SOBCHINSKAYA NM 183142 03-13
SOBOTKA TJ 189564 04-05
SODERSTEN P 171614 01-04, 186683 03-04, 186691 03-04
SOFIA RD 188876 04-05
SOFRONOV GA 174257 01-03
SOHEL MS 188873 04-03
SOHN SS 170464 01-05
SOKOLA A 178558 02-03
SOLOMON TA 183795 03-03
SOLYOM L 184259 03-15
SOMERVILLE B 187615 04-11
SOSKIN RA 181461 02-12
SOUBRIER J 184959 03-17
SOURKES TL 188769 04-03
SOVNER RD 183648 03-09
SOYKA LF 185866 03-03
SPARBER SB 168438 01-04, 186695 03-03
SPARF B 171600 01-03, 171632 01-03
SPATZ H 192521 04-09
SPAULDING TC 174607 01-04, 182217 03-04
SPECTOR S 189390 04-03
SPEHLMANN R 188426 04-03, 189855 04-03, 189856 04-03
SPENCER HW 182727 03-03
SPERANSKAYA NP 183206 03-04
SPERO L 187804 04-03
SPIGUEL RD 172916 01-03
SPILKER BA 178557 02-03
SPIRTES MA 189072 04-08
SPITALNIK R 170744 01-11
SPOHN HE 183629 03-08
SPRAGUE RL 181853 02-14, 185861 03-14, 187581 04-14
SPREAVICE R 191604 04-17
SPRINCE H 183602 03-01
SPRING C 191400 04-14
SPRING GK 191187 04-15
SQUIRE LR 188605 04-04
SQUIRES R 171628 01-03
SRAM RJ 175043 02-04
SRIMAL RC 176881 02-03
SRINIWAS P 169633 01-11
STACK JJ 182430 03-09
STADLER H 189602 04-03
STADNICKI SW 189516 04-04
STAEHELIN M 181471 02-03
STAHL SM 174609 01-14, 188426 04-03
STAIMAN A 182127 02-03, 187802 04-03, 187803 04-03, 189400 04-03
STALLONE F 169494 01-09, 169495 01-09
STANCAK A 178817 02-13
STANCER HC 168312 01-17, 182725 03-03
STARKE K 182345 03-03, 189568 04-03, 189569 04-03
STEELE CA 174137 01-08
STEENBERG ML 185748 03-04
STEIN DG 191378 04-04
STEIN L 173029 01-03, 182210 02-04, 191529 04-13
STEINBOOK RM 190195 04-09
STEINER M 184977 03-08
STEINKE J 168440 01-03
STEINMEYER CH 186780 03-10
STERANKA LR 179990 02-04
STERN GM 168286 01-13
STERN H 178549 02-11
STERN M 184200 03-04
STERN P 184200 03-04
STERN S 189075 04-13
STERNBACH LH 185034 03-01
STEVENS BC 169438 01-08
STEVENSON I 189074 04-17
STEWART WJ 190334 04-04
STIKELEATHER RA 171500 01-09
STILL CN 169286 01-10
STILLE G 191418 04-03
STILLMAN R 173516 01-14, 173522 01-12, 175003 02-14, 176480 02-12
STITZEL RE 189177 04-02
STOCK G 189571 04-03
STOCK R 186589 03-06
STODDARD DD 178812 02-03
STOFF DM 173162 01-04, 178575 02-04
STOKES JD 188637 04-04
STOLK JM 182442 03-05, 183891 03-03
STONE RA 191512 04-13
STONE TW 188739 04-03
STONE WN 181072 02-10
STORM-MATHISEN J 191319 04-03
STORY DF 182088 02-03
STORY NL 186204 03-15
STOTSKY BA 190144 04-17
STRADA SJ 171973 01-03
STRAHILEVITZ M 187129 03-04
STRASSER H 179023 02-13
STRAUSS SM 177337 02-03
STRAW RN 176108 02-13
STREFFER C 185900 03-03
STRICKER EM 168484 01-03, 182213 03-03, 187695 04-03, 191520 04-04
STROJNY N 169817 01-13
STRONG KH 189902 04-15
STULL RE 167287 01-03
STUMPF C 178947 02-03
SU C 189597 04-03
SUAREZ EM 190265 04-04
SUDILOVSKY A 182248 03-03, 187116 03-13
SUEHIRO K 182620 03-09
SUEMITSU S 181388 02-11
SUETA T 182551 03-10, 182552 03-15
SUETSUGU T 178021 02-08
SUGANO H 182620 03-09
SUGIMURA N 176889 02-09
SUGIYAMA K 178021 02-08
SUK JH 182581 03-08
SULE SM 172444 01-08, 180153 02-08
SULSER F 171973 01-03, 192003 04-03
SUM C 182203 02-06
SUNDWALL A 171600 01-03, 171630 01-16
SUNJIC V 187942 04-01
SURIA A 170748 01-03, 182249 03-03, 186673 03-03
SUTHERLAND VC 182253 03-04
SUURHASKO BVA 171624 01-03
SUWA N 170638 01-13
SUZUKI J 181771 02-07
SUZUKI T 182097 02-03
SUZUKI Y 168498 01-05, 177063 02-17, 189587 04-05
SVENSSON TH 191948 04-03
SWANSON WC 189072 04-08
SWEET RD 175426 02-11, 188421 04-13, 188431 04-11, 188433 04-03
SWEETMAN BJ 191057 04-03
SYMCHOWICZ S 175240 02-03
SYMES AL 188769 04-03
SZABO S 183611 03-03
SZEKELY JI 192416 04-03

T

TABAKOFF B 182157 02-03
TABER CA 168436 01-03
TABOR RG 192013 04-05
TACHIBANA H 167921 01-14, 175550 02-08
TACHIKAWA R 180487 02-01, 180488 02-01, 180489 02-01
TADANO T 182112 02-04
TADOKORO S 182116 02-04, 182117 02-04
TAEN S 176889 02-09
TAGASHIRA E 182104 02-04
TAGLIAMONTE A 168748 01-03, 188519 04-03
TAGUCHI K 167917 01-09, 167918 01-09, 180301 02-11
TAHA AM 183600 03-01
TAIT AC 192422 04-09
TAIT RM 189590 04-03
TAKAGI H 168499 01-07, 180490 02-02, 182094 02-03
TAKAGI M 189209 04-05
TAKAHASHI H 175119 02-08
TAKAHASHI R 177567 02-09, 185241 03-14
TAKAHASHI S 167919 01-09, 170638 01-13, 174125 01-04
TAKAHASHI T 191677 04-17
TAKAHASHI Y 181377 02-15
TAKAI A 181386 02-04
TAKAMORI M 170660 01-13
TAKANO K 177097 02-05
TAKASHINA K 176726 02-08
TAKASU S 176473 02-10
TAKAYA Y 171246 01-11
TAKAYAMA I 182731 03-10
TAKE Y 181657 02-02, 181658 02-02
TAKEI H 191716 04-09
TAKEMURA N 176889 02-09, 191686 04-08
TAKENOSHITA M 182099 02-03
TAN T 172114 01-15

TANABE K 181650 02-03, 182111 02-04, 182549 03-03, 189209 04-05
TANABE T 182872 03-03
TANAKA A 182551 03-10
TANAKA K 176470 02-08, 180307 02-17, 191686 04-08
TANAKA M 184314 03-13
TANAKA R 178019 02-15
TANAKA S 174680 01-08
TANAKA T 178053 02-08
TANASE H 168498 01-05
TANAYAMA S 181654 02-04
TANDA M 173548 01-05
TANDOU OP 170414 01-11
TANEDA M 176565 02-09
TANG M 191768 04-03
TANIMUKAI H 174680 01-08, 175119 02-08
TANIWA M 171296 01-15
TANNHAUSER M 168749 01-03, 183609 03-03, 189609 04-03
TANSELLA M 190336 04-11
TARSY D 169120 01-03
TARTARA A 167336 01-13
TARVE US 191789 04-03
TARVER JJ 189390 04-03
TASSIN JP 188978 04-03
TATEBE A 183369 03-10
TAYLOR AN 181576 02-03, 183324 03-03
TAYLOR CW 192231 04-09
TAYLOR D 183787 03-03
TAYLOR FH 183789 03-03
TAYLOR IJ 191119 04-09
TAYLOR M 187925 04-04, 187926 04-04, 190335 04-04
TAYLOR MA 170627 01-09
TAYLOR ML 185979 03-01
TAYLOR WA 174959 01-03
TEJA JS 174376 01-09
TELFORD R 182763 03-14, 187350 04-13
TELLER DN 191413 04-03
TEMPESTA E 186643 03-14
TEMPLE DM 184223 03-03
TENNANT FS 177452 02-15
TENNENT G 190061 04-11
TEOH PC 167460 01-13
TERADA A 180487 02-01, 180488 02-01, 180489 02-01, 180490 02-02
TESAROVA O 180062 02-10
TESSEL RE 191915 04-04
TESSMANN R 180674 02-11
TESTA G 188374 04-03
TETREAULT L 167343 01-08, 183359 03-03, 183361 03-09, 183362 03-10
THEOBALD W 192420 04-13
THEORELL K 168523 01-14
THERES C 172926 01-03, 185901 03-03
THETFORD PE 183629 03-08
THIELE W 187959 04-17
THIELEMANS G 183201 03-11
THIERRY AM 188978 04-03
THIESSEN PN 176597 02-17
THOA NB 178747 02-03, 187397 04-03
THOMAS E 182154 02-03
THOMAS JA 183358 03-03
THOMAS M 182835 03-17, 189059 04-07
THOMPSON DM 174008 01-04, 177408 02-04
THOMPSON GR 188872 04-05, 191965 04-03
THOMPSON H 174138 01-09
THOMPSON JA 176312 02-03, 186665 03-03
THOMPSON JH 189597 04-03
THOMPSON JW 182763 03-14, 187350 04-13
THOMPSON WO 186665 03-03, 187254 03-15
THONG YH 174568 01-11
THORNBURG JE 177840 02-03, 182209 02-04, 186635 03-04, 192012 04-04
THORNER R 177730 02-13
THORNTON BP 174298 01-11
THORNTON WE 174298 01-11
THUT PD 187119 03-04
TILSON HA 168438 01-04, 176869 02-04, 182251 03-03, 187930 04-04, 191906 04-03
TIMIRAS PS 182119 02-03
TIMMONS MC 176747 02-03, 182223 03-03, 188119 04-13
TINKLENBERG JR 177720 02-14, 185330 03-14, 185932 03-13, 189406 04-14
TIPTON RK 182134 02-03
TISSARI AH 171624 01-03
TISSOT R 169468 01-09
TITOVA VG 191121 04-03
TJANDRA J 170412 01-11
TO DH 180320 02-17
TOBIAS LL 175862 02-17
TOBIN T 182184 02-03
TODRICK A 192422 04-09
TOGULGA G 191300 04-03
TOLIS G 188428 04-13
TOLLE R 182591 03-14
TOMAS D 182435 03-11
TOMASELLO F 171794 01-13
TOMASI L 177729 02-13, 186377 03-06
TOMINAGA H 191723 04-09
TONAMI M 176470 02-08
TONGE SR 191383 04-03
TONGYONK J 172800 01-11
TORAIWA S 176726 02-08
TORAN-ALLERAND CD 186033 03-03
TORMAY A 192000 04-03
TORRE E 184975 03-03
TORRE M 184975 03-03
TORRELIO M 169467 01-03
TORRIELLI MV 178756 02-04
TOSELAND PA 183793 03-13
TOSI EC 167340 01-11
TOSI GC 167340 01-11
TOSOVSKY J 192419 04-11
TOUYAA HJ 180145 02-12
TOWNEND RA 185007 03-09
TRABER DL 167334 01-07
TRABUCCHI M 180582 02-03, 184553 03-03, 187526 04-03, 187527 04-03, 188891 04-03
TRANZER JP 186677 03-03
TRAPPE B 180048 02-10
TRAVERS RD 184439 03-15
TREIBER L 183603 03-13
TREMBLAY EC 189517 04-05
TRENCHI HM 186574 03-11
TRENDELENBURG U 189604 04-03
TREVOR AJ 186693 03-03
TROUPIN AS 192391 04-07
TRUEMAN HR 185194 03-08
TS'O TOT 182258 03-04, 191974 04-04
TSCHAKALOFF C 178947 02-03
TSCHENTSCHER K 181470 02-03
TSENG L 184179 03-03, 186670 03-04
TSENG LF 182253 03-04, 186671 03-03
TSUCHIE F 182103 02-04
TSUI PT 187129 03-04
TSUJIMOTO A 188199 04-03
TSUKAMOTO R 176474 02-10
TSUTSUI S 171282 01-11, 182624 03-11
TSUTSUI'KOVSKAYA MY 183683 03-08
TUBAS T 191141 04-04
TUOMISTO J 180055 02-06
TUPIN JP 189095 04-08
TURECEK LE 187582 04-10
TUREK I 184653 03-09, 190146 04-07
TUREK IS 177670 02-11
TURKANIS SA 174608 01-05, 175238 02-03, 191994 04-03
TURKER MN 186585 03-03
TURKER RK 186585 03-03
TURNBOW M 183894 03-03
TURNER AJ 189752 04-03
TURNER CE 180670 02-01
TWYCROSS RG 191606 04-17
TYCE GM 176936 02-03
TYE N 186637 03-04
TYRER P 168832 01-10
TYRER PJ 188887 04-10

U

UBAGO JG 189754 04-12
UCHA R 191139 04-17
UCHIMURA Y 176889 02-09
UDABE RU 168803 01-11, 189331 04-17
UDESCHINI G 188200 04-03
UEKI S 181384 02-04, 182095 02-03, 182114 02-04, 182115 02-04
UEMURA H 182097 02-03
UHLENHUTH EH 171507 01-08
ULIANA R 177671 02-11
ULIANA RL 185881 03-14
UNGAR F 191956 04-03
UNGER S 188121 04-12
UNWIN A 172741 01-08
URBAN I 188166 04-04
URCUYO L 185875 03-11
URETSKY NJ 186694 03-03
URQUHART N 191331 04-03
USDIN E 170302 01-06
USHER DR 183358 03-03
USHIJIMA I 182109 02-04
USHIZIMA I 178725 02-03
USUI H 178021 02-08
UTSUMI S 182096 02-03
UYENO ET 182189 02-04

V

VAHIA NS 187477 04-09
VAHIA V 187477 04-09
VAKHING VA 191786 04-02
VALENTINE MG 185194 03-08
VAN DAM DP 187381 04-03
VAN DEN BRINK FG 191420 04-03
VAN DER KLEIJN E 186184 03-13
VAN DER POEL AM 187259 04-04, 187641 04-04
VAN DER STEEN JA 187835 04-03
VAN DER WIEL HJ 183194 03-09
VAN KAMMEN DP 178432 02-09
VAN LEEUWEN WS 188166 04-04
VAN LOMMEL R 192431 04-08
VAN PRAAG HM 169095 01-09, 184652 03-09
VAN RENYNGHE DE VOXVRIE G 183202 03-09
VAN ROSSUM JM 174763 01-04, 187666 04-04
VAN TYLE WK 174960 01-03, 182131 02-04
VAN WOERT MH 170662 01-13, 188429 04-11
VANDENBOS GR 173534 01-08, 178677 02-17
VANDERVORT W 176107 02-10
VANPUTTEN T 171506 01-15
VANWERSCH RAP 171521 01-04
VANWYKE PE 185676 03-14
VAPAATALO H 176879 02-04
VAQUEZ AJ 187552 04-03
VARDARIS RM 167398 01-04
VARGA E 187255 03-08
VARGAS JR 189076 04-09
VARMA B 182088 02-03
VARMA LP 180155 02-14
VASKO MR 186703 03-04
VAUGHAN T 173521 01-14, 188115 04-08
VAUGHAN TB 175003 02-14
VAZQUEZ AJ 179992 02-03
VEACH HO 188447 04-11
VEALS J 175240 02-03
VEAUVY N 182432 03-10
VELDKAMP W 176108 02-13
VENABLES PH 183630 03-17
VENALAINEN E 180047 02-13
VENCOVSKY E 178029 02-17
VENTAFRIDDA V 191604 04-17
VENTOURAS K 180700 02-15
VENTURA DF 182254 03-03
VENTURA MS 188533 04-17
VERGARA L 191138 04-14, 191139 04-17
VERMEYLEN J 183201 03-11
VERNADAKIS A 178814 02-03, 184372 03-03
VERRIER J 182901 03-11
VESELL ES 181398 02-13
VESSMAN J 171630 01-16
VETULANI J 192003 04-03
VIBAL JR 183402 03-13
VICHAIYA V 183749 03-15
VICTOR SJ 188287 04-03
VIDA JA 187939 04-01
VIGNALOU J 168369 01-11
VIIK K 182128 02-04
VILLARREAL JE 182162 02-03
VILLENEUVE A 167587 01-15, 178187 02-08, 178193 02-11, 188406 04-03, 191142 04-15
VILLENEUVE R 167587 01-15, 178193 02-11, 188406 04-03
VINAR O 168800 01-17
VINDING T 173452 01-17
VIVONIA CA 189587 04-05
VOGEL E 184585 03-05
VOGEL RA 191917 04-04
VOGEL W 187149 03-13
VOGEL WH 170464 01-05, 182186 02-03, 183602 03-01, 186706 03-03
VOLAVKA J 169068 01-13, 189059 04-07
VOLICER L 167326 01-03
VOLLMER RR 183795 03-03
VOM SCHEIDT J 175537 02-17
VON BAHR C 171631 01-03

VON SCHWARTZENFELD I 191411 04-03
VON VIETINGHOFF-RIESCH F 186164 03-04
VON ZEPPLIN I 174043 01-14
VORE M 191057 04-03
VORONTSOV VA 183520 03-01
VRBANAC JJ 182251 03-03
VUGRINCIC C 182157 02-03, 191956 04-03
VYSOTSKAYA NB 183518 03-01

W

WADA T 176473 02-10
WADDINGHAM S 175895 02-03
WAGLE GP 187931 04-03
WAGNER LA 190907 04-03
WAHLSTROM G 171601 01-03
WAIZER J 177754 02-08, 183275 03-08, 184174 03-11
WAJDA IJ 182224 03-03
WAKAMATSU Y 182105 02-03
WALDECK B 184201 03-03
WALDMEIER PC 172917 01-03
WALFORD RL 169675 01-03
WALKER CA 191918 04-03
WALKER JB 187110 03-03
WALL EM 176747 02-03
WALL ME 182223 03-03, 188119 04-13
WALLACE JE 169782 01-03, 192013 04-05
WALLACH M 191977 04-04
WALLACH MB 191504 04-04
WALLE T 177395 02-15
WALSH CT 182715 03-03
WALSH DB 177392 02-15
WALSH JM 186630 03-04
WALTER LA 189178 04-02
WALTERS JR 191519 04-03, 191931 04-03
WAMPLER KS 178695 02-17
WANG H 192229 04-09
WANG S 180097 02-03
WANG SC 183887 03-03
WANG TST 187939 04-01
WARD JW 182124 02-03, 182125 02-03
WARSH JJ 182725 03-03
WASER PG 184227 03-03
WASSERMAN O 184226 03-03
WASTERLAIN CG 188433 04-03
WATANABE E 170638 01-13
WATANABE S 167917 01-09, 167918 01-09, 180301 02-11, 182095 02-03
WATERS W 187638 04-04
WATKINS JC 189750 04-03
WATTS G 169138 01-11
WATTS RD 188584 04-11
WAUQUIER A 185961 03-04, 190306 04-03
WAY EL 182159 02-03, 182231 03-03, 184179 03-03, 188178 04-03, 191769 04-03, 191898 04-03, 191985 04-03
WEAVER SS 191939 04-04
WEBB RW 182134 02-03
WEBB W 176675 02-14
WEBER F 189568 04-03, 189569 04-03
WEBER LJ 183866 03-03
WEBSTER CD 189519 04-04, 192413 04-03
WECKOWICZ TE 188107 04-09
WEDIG JH 173257 01-03
WEEKS JR 191940 04-04
WEI E 173872 01-03
WEIDNER MF 174210 01-14
WEINER N 191514 04-06
WEINFELD RE 169817 01-13, 170838 01-13
WEINGARTNER H 169504 01-09, 173516 01-14, 175003 02-14
WEINSTEIN B 177836 02-04
WEISE CC 185747 03-09
WEISS AA 171124 01-10
WEISS BL 171503 01-09
WEISS GB 172925 01-03
WEISS LR 191976 04-04
WEISSMAN L 169817 01-13
WEISSMAN M 171924 01-10
WEISSMAN MM 185322 03-10
WELBEL L 174777 01-10
WELLER M 188348 04-09
WENDER P 169861 01-11
WENGER GR 186669 03-03, 191973 04-04
WERBENEC J 180722 02-07
WERNER WL 191096 04-13
WERRY JS 187581 04-14
WEST AP 189099 04-15
WEST LG 192882 04-01
WEST NR 183602 03-01
WESTFALL TC 186676 03-03
WESTON MJ 172741 01-08
WHALEN EM 185747 03-09
WHALLEY C 179992 02-03
WHANGER A 192229 04-09
WHEELER TJ 190335 04-04
WHITAKER CA 177720 02-14
WHITE HD 189613 04-04, 192014 04-04
WHITEHEAD WE 181879 02-13
WHITSETT TL 174348 01-14
WHYTE CR 185190 03-11
WIBISONO S 180299 02-11
WICKHAM PE 192575 04-13
WIECZOREK V 174101 01-08
WIENER L 188561 04-11
WIESEL F 186566 03-16
WIG NN 167346 01-10
WIJSENBEEK H 184977 03-08
WILBUR WR 187939 04-01
WILES DH 184437 03-13
WILEY RA 181391 02-01
WILK S 177826 02-13
WILLIAMS BI 191969 04-03
WILLIAMS DA 182244 03-03
WILLIAMS FM 183793 03-13
WILLIAMS MA 188865 04-05
WILLIAMS SE 169140 01-15
WILLINSKY MD 192413 04-03
WILLIS D 174135 01-16
WILLIS JC 174319 01-03
WILLIS WD 174319 01-03
WILLSON N 185112 03-03
WILSON A 191935 04-04
WILSON IC 171500 01-09, 172992 01-15, 191534 04-09
WILSON MC 169028 01-04
WILSON RD 167334 01-07
WILSON WA 188738 04-05, 189032 04-03
WILSON WR 189394 04-03, 189395 04-03
WINAKTU OA 170413 01-11
WINBLADH B 171606 01-03
WINNIK HZ 171122 01-11
WINOCUR G 184838 03-04
WINSBERG BG 177771 02-14
WINSTEAD DK 189924 04-17
WINSTON RA 172020 01-03
WINTER DP 180097 02-03
WINTER JC 176866 02-04, 184980 03-04, 186667 03-04, 188229 04-12
WIRZ-JUSTICE A 171307 01-03
WISE CD 182210 02-04, 191529 04-13
WISE JG 191995 04-03
WISE RA 186613 03-04
WISNIEWSKI K 187787 04-15
WITIAK DT 187937 04-01
WITT PA 181853 02-14
WITT PN 182193 02-04
WITTNER WK 185932 03-13
WODE-HELGODT B 186565 03-08
WOLCOTT GJ 173205 01-11
WOLCOTT LJ 185932 03-13
WOLF HH 181407 02-05
WOLFF BB 177735 02-06
WOLGIN DL 173775 01-03
WOLLERT U 189595 04-13
WOLTHUIS OL 171521 01-04
WONG DT 191951 04-03
WOODROW K 178578 02-08
WOODS AC 186029 03-11
WOODS HF 191497 04-03
WOODS JH 191915 04-04, 191972 04-04
WOODS JM 191983 04-04
WOODS P 192577 04-09
WOODWARD JK 182214 03-03
WOOLLEY E 174641 01-17
WOOTEN GF 178747 02-03, 187397 04-03
WORKMAN M 176312 02-03
WORSHAM E 167401 01-04
WRAY M 167341 01-08
WRIGHT DC 188226 04-14
WU SC 174036 01-03
WU YS 190716 04-01, 190717 04-01
WURSCH MS 175751 02-03
WURTMAN RJ 174764 01-03, 183797 03-03, 189399 04-04, 191771 04-03
WUTTKE W 177719 02-04
WYATT R 173516 01-14, 173521 01-14, 173522 01-12, 178432 02-09, 187113 03-08, 192335 04-03
WYATT RJ 173398 01-03, 175003 02-14, 176480 02-12, 187642 04-14, 188115 04-08

Y

YABE Y 180487 02-01, 180488 02-01, 180489 02-01
YAGI G 170637 01-08
YAGIELA JA 188231 04-03
YAMADA E 176564 02-11
YAMAGUCHI N 176475 02-09
YAMAGUCHI S 186476 03-05
YAMAKAGE N 176542 02-11
YAMAKI T 182185 02-03
YAMAMOTO H 182108 02-04
YAMAMOTO I 182113 02-03, 191898 04-03
YAMAMOTO J 188501 04-07
YAMAMOTO K 182096 02-03
YAMAMOTO N 183369 03-10
YAMAMOTO T 181384 02-04, 189219 04-03
YAMAMURA HI 188114 04-15, 191290 04-08
YAMAMURA M 182107 02-04, 183610 03-03
YAMANAKA T 182552 03-15
YAMASHITA I 170638 01-13, 191665 04-09
YAMASHITA J 174855 01-05
YAMAUCHI I 171245 01-08
YAMAUCHI Y 182637 03-02
YAMAURA H 176471 02-11
YAMAZAKI M 181650 02-03, 182549 03-03, 189209 04-05
YAMAZAKI Y 182553 03-04, 182554 03-04
YANAGITA T 174125 01-04, 182110 02-04
YANAURA S 182104 02-04
YANG DC 174071 01-11
YANG H-T 186668 03-03
YANG HT 168437 01-03, 191500 04-03
YANNIOTIS G 169468 01-09
YANO H 181588 02-13, 181593 02-03, 182555 03-03, 182556 03-13
YARYURA-TOBIAS JA 192521 04-09
YASHIMA Y 171246 01-11
YASUHARA M 182547 03-03
YAUCHI N 178053 02-08
YEH JZ 186672 03-03
YEHUDA S 174764 01-03, 183797 03-03, 189399 04-04
YELLOWLEY TW 167575 01-10
YEN F 192084 04-15
YEN SSC 190104 04-13
YEN-KOO HC 191982 04-15
YEN-KOO HCY 176863 02-04
YOKEL RA 185960 03-04, 191919 04-04
YOKOTAN H 177097 02-05
YOKOTANI H 173548 01-05
YOKOYAMA S 167918 01-09
YOMAIDA I 182872 03-03
YOO BY 175239 02-03
YORIOKA N 176564 02-11
YOSHIDA S 176470 02-08, 178623 02-09
YOSHIMI T 167919 01-09
YOSHIMURA M 167919 01-09
YOSHIMUTA T 182731 03-10
YOUDIM MBH 191496 04-03, 191497 04-03
YOUNG J 185008 03-11
YU JL 168131 01-03
YUNGER LM 191947 04-05

Z

ZABIK JE 187381 04-03
ZARA MM 172512 01-11
ZARAGOZA H 172977 01-11
ZARATE A 175245 02-13
ZAREMBA AL 189924 04-17
ZARIFIAN E 184962 03-09
ZAVATSKY E 182126 02-03
ZEBROWSKA-LUPINA I 177721 02-04
ZEIDENBERG P 177674 02-14
ZEMP JW 182229 03-03, 184235 03-03
ZETLER G 177730 02-13
ZIEGLGANSBERGER S 169474 01-03
ZIGMOND MJ 168484 01-03, 182213 03-03, 187695 04-03, 187699 04-04, 191520 04-04
ZIGMOND RE 171785 01-03
ZILM DH 192005 04-11
ZIMMERMAN-TANSELLA C 190336 04-11

ZIMMERMANN E 183324 03-03
ZIMMERMANN R 192065 04-13
ZIRZOW G 182239 03-04
ZISKIND D 183470 03-04
ZIVANOVIC D 182129 02-03
ZIVKOVIC B 170086 01-03, 170755 01-03, 173381 01-03, 191515 04-03
ZMORSKI T 187958 04-11
ZNANIECKA V 181192 02-08
ZOCH C 191138 04-14, 191139 04-17
ZOLFAGHARI M 191522 04-13
ZSIGMOND EK 190147 04-13
ZUANAZZI GF 183199 03-11
ZUDOVA Z 175043 02-04
ZUNG WWK 168419 01-14, 175286 02-10, 192229 04-09
ZWEIG JS 175759 02-03, 187941 04-01, 190718 04-03

SUBJECT INDEX

[The Subject Index is machine generated. Keywords in the titles of abstracts appear alphabetically in the left hand margin; under each keyword is a list of titles in which the keyword appears. The spelling of words in the titles of abstracts has not been changed; hence, two spellings of the same word may appear in this index -- for example, BEHAVIOR and BEHAVIOUR.]

ABDOMINAL
THE EFFECT OF DIAZEPAM ON SOME CARDIOVASCULAR AND RESPIRATORY REFLEXES ELICITED BY AFFERENT ABDOMINAL VAGUS STIMULATION.
178945 02-03

ABERRATION
EMERGENCY TREATMENT OF AN ACUTE STATE OF MENTAL ABERRATION.
191723 04-09

ABILITY
A ROLE OF THE DIETARY LIPID IN THE ABILITY OF PHENOBARBITAL TO STIMULATE DRUG DETOXIFICATION.
175859 02-03

ABLATIONS
EFFECTS OF PSYCHOTROPIC DRUGS ON DISCRIMINATION AVOIDANCE CONDITIONING IN RATS WITH OLFACTORY BULB ABLATIONS.
182115 02-04
SHIFTING OF THE D-AMPHETAMINE DOSE-RESPONSE CURVE IN RATS WITH FRONTAL CORTICAL ABLATIONS.
187261 04-04

ABNORMAL
BEHAVIOURAL STATE CYCLES IN ABNORMAL INFANTS.
168523 01-14
THOUGHTS ON TREATMENT BY PRIVATE PHYSICIANS OF ABNORMAL SEX DRIVES.
180674 02-11
EFFECTS OF PSYCHOTROPIC DRUGS ON ABNORMAL BEHAVIOR INDUCED BY DELTA9-TETRAHYDROCANNABINOL.
182114 02-04

ABNORMALITIES
THE ELECTROCARDIOGRAPHIC ABNORMALITIES INDUCED BY PSYCHOTROPIC DRUGS.
170638 01-13
MUSCLE ABNORMALITIES IN PSYCHOTIC PATIENTS: II. SERUM CPK ACTIVITY, FIBER ABNORMALITIES, AND BRANCHING AND SPROUTING OF SUBTERMINAL NERVES.
187114 03-09
ABNORMALITIES IN TRYPTOPHAN METABOLITES IN SCHIZOPHRENIA.
191536 04-13

ABNORMALITY
THE ELECTROCARDIOGRAPHIC ABNORMALITY INDUCED BY CHLORPROMAZINE.
171296 01-15

ABRUPT
THE ABRUPT WITHDRAWAL OF ANTIPARKINSONIAN DRUGS IN SCHIZOPHRENIC PATIENTS.
185005 03-08

ABSENCE
CNS DEPRESSION IN THE ABSENCE OF PROLACTIN RELEASE FOLLOWING INTRAARTERIAL INJECTIONS OF SODIUM PENTOTHAL IN THE PROESTROUS RAT.
173257 01-03
ABSENCE OF DEGENERATION OF ADRENERGIC NEURONS AFTER PROLONGED TREATMENT WITH DEBRISOQUIN.
186677 03-03
ABSENCE OF REM REBOUND AFTER BARBITURATE WITHDRAWAL.
189884 04-14

ABSORPTION
STUDIES ON METABOLISM OF BROMAZEPAM (III): ABSORPTION, EXCRETION, AND METABOLISM OF BROMAZEPAM IN MAN.
181588 02-13
DIRECT DETERMINATION OF LITHIUM IN SERUM BY ATOMIC ABSORPTION SPECTROSCOPY.
181653 02-06
ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF BROMAZEPAM IN RABBIT.
182555 03-03
DRUG ABSORPTION IN RATS PRETREATED WITH ANTIBIOTICS.
182715 03-03
THE ABSORPTION AND DISTRIBUTION OF THE NEW ANTIDEPRESSANT AZAPHEN IN THE ORGANS.
183519 03-03
ABSORPTION AND CLEARANCE OF SECOBARBITAL, HEPTABARBITAL, METHAQUALONE, AND ETHINAMATE.
192575 04-13

ABSTINENT
RESPONSE TO INCREMENTAL DOSES OF DITRAN IN ABSTINENT ALCOHOLICS AND DRUG USERS.
185875 03-11

ABSTRACT
CLINICAL STUDIES OF ACUTE PSYCHOSIS ON THE BASIS OF CHRONIC HYPNOTICA INTOXICATION -- AN ABSTRACT REPORT.
182755 03-15

ABUSE
THE ROLE OF RESEARCH IN DRUG ABUSE INTERVENTION: STREET DRUG ANALYSES.
167382 01-17
ABUSE POTENTIAL OF ETORPHINE (M99) I. SUBJECTIVE EFFECTS AND PHYSICAL DEPENDENCE. (UNPUBLISHED PAPER).
171241 01-14
USE AND ABUSE OF DRUGS IN PSYCHIATRY.
175620 02-17
COMPLICATIONS OF METHAQUALONE DIPHENHYDRAMINE (MANDRAX) ABUSE.
177452 02-15
DRUG ABUSE -- OVERDOSE AND RECOVERY.
180147 02-15
VALIDITY OF SCREENING METHODS FOR DRUGS OF ABUSE IN BIOLOGICAL FLUIDS. II. HEROIN IN PLASMA AND SALIVA.
187256 03-15

ACCOUNTING
PERIPHERAL VERSUS CENTRAL MECHANISMS ACCOUNTING FOR ANTIANXIETY EFFECTS OF PROPRANOLOL.
181072 02-10

ACCUMULATION
A CENTRAL EFFECT OF LOCAL ANESTHETICS: PREVENTION AGAINST THE ACCUMULATION OF CYCLIC AMP IN BRAIN SLICES.
182099 02-03
THE INHIBITION OF (3H) BIOGENIC AMINE ACCUMULATION INTO RAT BRAIN TISSUE SLICES BY VARIOUS TRYPTAMINE DERIVATIVES.
182723 03-03
ON THE CEREBRAL ACCUMULATION OF KETAMINE AND THE RELATIONSHIP BETWEEN METABOLISM OF THE DRUG AND ITS PHARMACOLOGICAL EFFECTS.
186693 03-03
PLASMA AND CEREBROSPINAL FLUID PROBENECID CONCENTRATIONS AS RELATED TO ACCUMULATION OF ACIDIC BIOGENIC AMINE METABOLITES IN MAN.
187933 04-13
SELECTIVE RESERPINE RESISTANT ACCUMULATION OF CATECHOLAMINES IN CENTRAL DOPAMINE NEURONES AFTER DOPA ADMINISTRATION.
189026 04-03
EXTRANEURONAL REMOVAL, ACCUMULATION AND O-METHYLATION OF ISOPRENALINE IN THE PERFUSED HEART.
189604 04-03

ACEPERONE
EFFECTS OF PHENOXYBENZAMINE, ACEPERONE AND CLONIDINE ON THE LEVEL OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL, (MOPEG) IN RAT BRAIN.
180059 02-03

ACETALDEHYDE
A COMPARISON OF THE EFFECTS OF CHRONIC ADMINISTRATION OF ETHANOL AND ACETALDEHYDE TO MICE: EVIDENCE FOR A ROLE OF ACETALDEHYDE IN ETHANOL DEPENDENCE.
185992 03-03

ACETAMIDE
N-(2-DIETHYLAMINOETHYL) 2 (P-HYDROXYPHENOXY) ACETAMIDE, A METABOLITE OF MEFEXAMIDE IN MAN.
187577 04-01

ACETATE
ALTERATION OF MATERNAL BEHAVIOR IN MICE FOLLOWING ADMINISTRATION OF CYPROTERONE ACETATE.
172374 01-04
EFFECTS OF CYPROTERONE ACETATE IN THE MALE JAPANESE QUAIL.
186681 03-03

ACETIC
STUDIES ON BENZODIAZEPINOOXAZOLES. V. REACTIONS OF BENZODIAZEPINOOXAZOLE DERIVATIVES WITH ACETIC ANHYDRIDE.
180489 02-01

ACETOPHENONE
INTERACTION OF SEROTONIN ANTAGONISTS WITH 3,4-DICHLORO-2-(2-IMIDAZOLIN-2-YL-THIO) 2 ACETOPHENONE HYDROBROMIDE (DITA) AND D-AMPHETAMINE HYDROBROMIDE (DITA) AND D-AMPHETAMINE ON CERTAIN BEHAVIORAL PARAMETERS OF MALE MICE.
192014 04-04

ACETYLASE
EFFECTS OF FOOD DEPRIVATION, DISCRIMINATION EXPERIENCE AND PHYSOSTIGMINE ON CHOLINE ACETYLASE AND ACETYLCHOLINE ESTERASE IN THE DORSAL HIPPOCAMPUS AND FRONTAL CORTEX OF RATS.
169467 01-03

ACETYLCHOLINE
EFFECTS OF FOOD DEPRIVATION, DISCRIMINATION EXPERIENCE AND PHYSOSTIGMINE ON CHOLINE ACETYLASE AND ACETYLCHOLINE

ESTERASE IN THE DORSAL HIPPOCAMPUS AND FRONTAL CORTEX OF RATS.
169467 01-03

SYNTHESIS OF ACETYLCHOLINE IN BRAIN NERVE TERMINALS DURING CONSCIOUSNESS AND BARBITURATE ANESTHESIA.
171600 01-03

INTERACTION BETWEEN ATROPINE AND OXOTREMORINE ON CORTICAL ACETYLCHOLINE AND MOTOR ACTIVITY.
171606 01-03

THE EFFECT OF PSYCHOTROPIC AGENTS ON SOME ASPECTS OF ACETYLCHOLINE METABOLISM IN CAT BRAINS.
174257 01-03

ACETYLCHOLINE TURNOVER IN BRAIN OF MICE AND RATS: EFFECTS OF VARIOUS DOSE REGIMENS OF MORPHINE. (UNPUBLISHED PAPER).
180582 02-03

THE EFFECT OF CATECHOLAMINES, ACETYLCHOLINE AND SEROTONIN ON THE MORPHINE TOLERANT LONGITUDINAL MUSCLE STRIP OF THE GUINEA-PIG ILEUM.
182161 02-03

EFFECTS OF NARCOTIC ANALGESICS ON ENZYMES OF ACETYLCHOLINE METABOLISM IN CULTURED CHICK BRAIN CELLS.
182225 03-03

EFFECT OF ACUTE AND CHRONIC MORPHINE ON SPECIFIC RADIOACTIVITIES OF CHOLINE AND ACETYLCHOLINE IN MOUSE BRAIN.
182226 03-03

EFFECTS OF MORPHINE, NALORPHINE AND NALOXONE ON RAT BRAIN RELEASE OF ACETYLCHOLINE.
182227 03-03

EFFECTS OF VARIOUS MORPHINE TREATMENT SCHEDULES ON ACETYLCHOLINE TURNOVER RATE IN RAT BRAIN PARTS.
184553 03-03

PENTOBARBITAL AND IN VIVO TURNOVER RATE OF ACETYLCHOLINE IN MOUSE BRAIN AND IN REGIONS OF RAT BRAIN. (UNPUBLISHED PAPER).
187526 04-03

EVIDENCE FOR AN INHIBITORY ROLE FOR ACETYLCHOLINE, CATECHOLAMINES, AND SEROTONIN ON THE CEREBRAL CORTEX.
187552 04-03

EFFECT OF TETRAHYDROCANNABINOLS ON BRAIN ACETYLCHOLINE.
188167 04-03

ACETYLCHOLINE AND DEPRESSION.
188542 04-14

THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. I. NEURONAL RESPONSES TO STIMULATION OF THE RETICULAR FORMATION.
189855 04-03

THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. II. COMPARISON OF THE NEURONAL RESPONSES TO RETICULAR AND OTHER STIMULI.
189856 04-03

EFFECT OF DIAZEPAM ON MOUSE WHOLE BRAIN AND BRAIN AREA ACETYLCHOLINE AND CHOLINE LEVELS.
191423 04-03

BALANCE BETWEEN ACETYLCHOLINE, SEROTONIN, NOREPINEPHRINE, AND DOPAMINE IN SELF-STIMULATION.
191528 04-04

ROLE OF ACETYLCHOLINE AND DOPAMINE IN MANIC BEHAVIOR.
191532 04-09

INFLUENCE OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTS OF ELECTRICAL STIMULATION AND MICROINJECTION OF ACETYLCHOLINE, SEROTONIN AND NORADRENALINE INTO THE MESENCEPHALON.
191786 04-02

MORPHINE TOLERANCE, DEPENDENCE AND WITHDRAWAL AND BRAIN ACETYLCHOLINE.
191985 04-03

TETRAHYDROCANNABINOLS: INHIBITION IN ACETYLCHOLINE SYNTHESIS IN REGIONAL RAT BRAIN SLICES.
191998 04-03

INHIBITION IN VIVO OF ACETYLCHOLINE SYNTHESIS IN MOUSE BRAIN BY INHIBITORS OF CHOLINE ACETYLTRANSFERASE.
192001 04-03

ACETYLCHOLINESTERASE

CHANGES IN BRAIN ACETYLCHOLINESTERASE ACTIVITY OF YOUNG RATS AFTER CHRONIC TREATMENT WITH TREMORINE.
178814 02-03

ACETYLCHOLINESTERASE INHIBITION AND MYELINOGENESIS IN VITRO.
186033 03-03

ACETYLPHENYLHYDRAZINE

PHARMACOLOGICAL AND BIOCHEMICAL ACTIONS OF THE HEMOLYTIC AGENTS ACETYLPHENYLHYDRAZINE AND PHENYLHYDRAZINE ON MONOAMINE OXIDASE IN THE RAT.
188769 04-03

ACETYLTRANSFERASE

CHOLINE ACETYLTRANSFERASE ACTIVITY IN THE CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
180047 02-13

REGIONAL AND SUBCELLULAR DISTRIBUTION OF CHOLINE ACETYLTRANSFERASE IN THE BRAIN OF NORMAL AND MORPHINE TREATED RATS.
182224 03-03

DRUGS, BEHAVIOR AND CHOLINE ACETYLTRANSFERASE.
182237 03-04

TRANSSYNAPTIC INDUCTION OF CHOLINE ACETYLTRANSFERASE IN THE PREGANGLIONIC NEURON OF THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM.
182720 03-03

INHIBITION IN VIVO OF ACETYLCHOLINE SYNTHESIS IN MOUSE BRAIN BY INHIBITORS OF CHOLINE ACETYLTRANSFERASE.
192001 04-03

ACH

THE EFFECT OF METHAMPHETAMINE ON BRAIN ACH CONSUMPTION AND AGGRESSIVENESS IN MICE STRESSED MILDLY BY LONG-TERM ISOLATION.
182108 02-04

EFFECT OF DIVALENT CATIONS ON ACH CONTRACTURES OF DEPOLARIZED DENERVATED RAT MUSCLES.
188914 04-03

ACID

POTENTIATION OF THERAPEUTIC EFFECTS OF NICOTINIC ACID BY PYRIDOXINE IN CHRONIC SCHIZOPHRENICS.
168313 01-08

LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND GAMMA-AMINOBUTYRIC ACID (GABA) INTERACTION ON SPONTANEOUS POTENTIALS AND THE EVOKED RESPONSE IN THE AVIAN TECTUM.
169689 01-03

INFLUENCES OF DRUGS ON THE INCREASES IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OF GAMMA-HYDROXYBUTYRIC ACID (GHBA).
171622 01-03

INFLUENCE OF PHENOBARBITAL AND SEX HORMONES ON ENZYMES IN ASCORBIC ACID BIOSYNTHESIS IN MALE AND FEMALE RATS. (PH.D. DISSERTATION).
172017 01-03

POTENTIAL PSYCHOTOMIMETICS: BROMOMETHOXYAMPHETAMINES AND STRUCTURAL CONGENERS OF LYSERGIC ACID. (PH.D. DISSERTATION).
173588 01-03

BEHAVIORAL EFFECTS OF A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR (FUSARIC ACID) IN MAN. (UNPUBLISHED PAPER
174329 01-09

THE EFFECTS OF AMPHETAMINE, 2-AMINOINDANE AND 2-AMINOTETRALIN ON THE CONCENTRATIONS OF WHOLE BRAIN NORADRENALINE, DOPAMINE, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC ACID IN THE MOUSE.
174828 01-03

STUDIES ON ENZYMATIC DEALKYLATION OF D-LYSERGIC ACID DIETHYLAMIDE (LSD).
177336 02-03

LYSERGIC ACID DIETHYLAMIDE AND SEROTONIN: A COMPARISON OF EFFECTS ON SEROTONERGIC NEURONS AND NEURONS RECEIVING A SEROTONERGIC INPUT.
177407 02-12

AMITRIPTYLINE IN MAN: DECREASED FORMATION OF CENTRAL 5-HYDROXYINDOLEACETIC ACID.
177736 02-13

THE EFFECT OF PROBENECID AND LARGE DOSE AMPHETAMINE ADMINISTRATION ON CEREBROSPINAL FLUID HOMOVANILLIC ACID.
177826 02-13

ACTION OF CONVULSANTS ON ROOT POTENTIALS AND AMINO ACID RESPONSES IN ISOLATED FROG SPINAL CORD. (UNPUBLISHED PAPER).
177976 02-03

NICOTINIC ACID INDUCED SYSTEMIC LUPUS-ERYTHEMATOSUS.
180243 02-15

STUDY WITH RADIOTRACERS OF THE DISTRIBUTION OF A NEW PSYCHOTROPE IN MICE: L-2-PYRROLIDONE-5-CARBOXYLATE DIMETHYLAMINOETHANOL. I. COMPARISON WITH L-GLUTAMIC AND L-2-PYRROLIDONE-5-CARBOXYLIC ACID.
180723 02-03

INCREASED GASTRIC ACID DURING SHOCK AVOIDANCE IN MAN.
181879 02-13

COMPARISON OF THE CHRONIC AND ACUTE EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) TREATMENT ON RAT BRAIN SEROTONIN AND NOREPINEPHRINE.
181945 02-03

A COMPARISON OF EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) AND SEROTONIN ON PRE- AND POSTSYNAPTIC CELLS IN THE SEROTONIN SYSTEM.
182141 02-03

EFFECT OF GAMMA-AMINOBUTYRIC ACID (GABA) ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
182231 03-03

SYNTHESIS OF COMPOUNDS RELATED TO LYSERGIC ACID.
182445 03-01

EVIDENCE FOR THE ACTION OF D-LYSERGIC ACID DIETHYLAMIDE, MESCALINE AND BUFOTENINE ON 5-HYDROXYTRYPTAMINE RECEPTORS IN UMBILICAL VASCULATURE.
182716 03-03

THE ELIMINATION OF 5-HYDROXYINDOLEACETIC ACID FROM CEREBROSPINAL FLUID: CHARACTERISTICS OF THE ACID TRANSPORT SYSTEM OF THE CHOROID PLEXUS.
182718 03-03

NICOTINIC ACID AND CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN SCHIZOPHRENIA.
183360 03-13

CATALEPSY AND STEREOTYPED BEHAVIOUR IN RATS TREATED CHRONICALLY WITH METHADONE: RELATION TO BRAIN HOMOVANILLIC ACID CONTENT.
183606 03-04

A NOVEL SPASMOLYTIC AND CNS ACTIVE AGENT: 3-(2-BENZYLMETHYLAMINOETHYL) BENZOIC ACID METHYL ESTER HYDROCHLORIDE.
184581 03-02

EFFECT OF LSD-25 AND 1-METHYL-D-LYSERGIC ACID BUTANOLAMIDE ON RAT BRAIN AND PLATELET SEROTONIN LEVELS.
184975 03-03

THE SITE OF ACTION ON THE OPTICAL ISOMERS OF 1-METHYL-5-PHENYL-5-PROPYL BARBITURIC ACID.
185901 03-03

THE EFFECT OF CHLORPROMAZINE ON HOMOVANILLIC ACID LEVELS IN CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS.
186565 03-08

MASS FRAGMENTOGRAPHIC ANALYSIS OF HOMOVANILLIC ACID AND ITS HOMOISO ANALOGUE IN CEREBROSPINAL FLUID USING THE ALPHA DIDEUTERO ACID AS INTERNAL STANDARD.
186566 03-16

THE EFFECTS OF CHRONIC RESERPINE AND NIALAMIDE TREATMENT ON THE FREE AMINO ACID LEVELS OF RAT BRAIN.
187645 04-03

METHIOTHEPIN ELEVATION OF 5-HYDROXYINDOLEACETIC ACID LEVELS IN VARIOUS ANATOMIC REGIONS OF RAT BRAIN.
187831 04-03

MESCALINE INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON THE BINDING OF AMINOACYL TRANSFER RIBONUCLEIC ACID TO RIBOSOMES OF BRAIN TISSUE.
189582 04-05

THE ROLE OF GAMMA-AMINOBUTYRIC ACID AS A MEDIATOR OF POSITIVE DORSAL ROOT POTENTIALS.
189832 04-03

POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES: 1. MODIFICATION OF THE AMINO ACID PORTION OF S-ADENOSYLHOMOCYSTEINE.
190716 04-01

STUDIES ON CONVULSANTS IN THE ISOLATED FROG SPINAL CORD. I. ANTAGONISM OF AMINO ACID RESPONSES. (UNPUBLISHED PAPER)
190727 04-03

THE METABOLISM OF 1-N-BUTYL-5,5 DIETHYLBARBITURIC ACID (N-N BUTYLBARBITAL) IN THE RAT.
191057 04-03

EFFECT OF PIRIBEDIL AND ONE OF ITS METABOLITES ON THE CONCENTRATION OF HOMOVANILLIC ACID IN THE RAT BRAIN.
191422 04-03

DIAZEPAM, CYCLIC NUCLEOTIDES AND AMINO ACID NEUROTRANSMITTERS IN RAT CEREBELLUM. (UNPUBLISHED PAPER).
191764 04-03

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
191944 04-04

THE EFFECT OF INCREASED GAMMA-AMINOBUTYRIC ACID ON ALPHA-METHYLTYROSINE INDUCED DECREASE IN CATECHOLAMINES IN RAT BRAIN.
191988 04-03

CHROMOSOME EXAMINATIONS AFTER MEDICALLY ADMINISTERED LYSERGIC ACID DIETHYLAMIDE AND DEXTROAMPHETAMINE.
192084 04-15

ACIDIC

PLASMA AND CEREBROSPINAL FLUID PROBENECID CONCENTRATIONS AS RELATED TO ACCUMULATION OF ACIDIC BIOGENIC AMINE METABOLITES IN MAN.
187933 04-13

ACIDS

BRAIN AMINO ACIDS DURING CONVULSIONS.
177135 02-03

EFFECTS OF CHLORPROMAZINE AND ACTINOMYCIN D ON UPTAKE AND INCORPORATION OF CERTAIN AMINO ACIDS, HYPOXANTHINE AND THYMIDINE IN CULTURES OF HUMAN SKIN EPITHELIAL CELLS.
179989 02-13

ANALGESICS. I. SELECTED 5-SUBSTITUTED 5-PROPIONOXYBARBITURIC ACIDS.
187939 04-01

ACOUSTIC

CENTRAL MONOAMINES AND THE ACOUSTIC STARTLE REACTION IN RATS. (PH.D. DISSERTATION).
173136 01-04

ACQUISITION

ACQUISITION AND RETENTION OF AVOIDANCE BEHAVIORS FOLLOWING SEPTAL LESIONS OR SCOPOLAMINE INJECTIONS IN RATS.
1(401 01-04

THE EFFECT OF DOPAMINE ANTAGONISTS AND AMANTADINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
174829 01-04

ACQUISITION AND PERFORMANCE OF AN ATTENTION TASK BY RATS SUBJECTED TO CHRONIC NICOTINE TREATMENT.
176864 02-04

REPEATED ACQUISITION OF BEHAVIORAL CHAINS UNDER CHRONIC DRUG CONDITIONS.
177408 02-04

OPEN-FIELD BEHAVIOR AND ACQUISITION OF DISCRIMINATIVE RESPONSE CONTROL IN DELTA9-THC TOLERANT RATS.
178813 02-04

AN ANALYSIS OF D-AMPHETAMINE PRODUCED FACILITATION OF AVOIDANCE ACQUISITION IN RATS AND PERFORMANCE CHANGES SUBSEQUENT TO DRUG TERMINATION.
179990 02-04

THE EFFECT OF AMANTADINE, L-DOPA, (..) AMPHETAMINE AND APOMORPHINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE.
186636 03-04

STRUCTURE-ACTIVITY RELATIONS OF SOME INDOLEALKYLAMINES IN COMPARISON TO PHENETHYLAMINES ON MOTOR ACTIVITY AND ACQUISITION OF AVOIDANCE BEHAVIOR.
186703 03-04

EFFECTS OF INTRACISTERNAL 6-HYDROXYDOPAMINE TREATMENT ON ACQUISITION AND PERFORMANCE OF RATS IN A DOUBLE T-MAZE.
187696 04-04

EFFECTS OF CYCLOHEXIMIDE ON ACQUISITION AND RETENTION OF AVOIDANCE LEARNING IN THE RAT: RECOVERY OF MEMORY.
189215 04-04

AN ANALYSIS OF THE FACILITATION OF AVOIDANCE ACQUISITION BY D-AMPHETAMINE AND SCOPOLAMINE.
189521 04-04

ACRIDAN

CONFORMATIONAL ANALYSIS OF ACRIDAN DERIVATIVES BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY. A RELATIONSHIP BETWEEN CONFORMATION AND PHARMACOLOGICAL ACTIVITY.
190715 04-01

ACROMEGALY

INHIBITORY EFFECT OF DOPAMINERGIC STIMULATION ON GH RELEASE IN ACROMEGALY.
188350 04-13

ACTH

ONTOGENESIS OF CIRCADIAN PITUITARY ADRENAL PERIODICITY IN RATS AFFECTED BY NEONATAL TREATMENT WITH ACTH.
181576 02-03

FAILURE OF ACTH TO INFLUENCE AVOIDANCE EXTINCTION IN A ONE-WAY AVOIDANCE SITUATION.
183470 03-04

EFFECT OF VARIOUS STEROIDS AND ACTH ON METHYPRYLON PLASMA LEVELS AND SLEEPING TIME IN RATS.
183611 03-03

A FREQUENCY SHIFT IN THE HIPPOCAMPAL THETA ACTIVITY: AN ELECTRICAL CORRELATE OF CENTRAL ACTION OF ACTH ANALOGUES IN THE DOG
188166 04-04

ACTING

TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER).
170876 01-03

STUDY ON THE PSYCHOPHARMACOLOGICAL ASSAY OF CENTRALLY ACTING DRUGS IN RATS.
171260 01-06

EFFECTS OF CENTRALLY ACTING DRUGS ON ADENYL CYCLASE ACTIVITY AND CYCLIC AMP LEVELS OF MOUSE BRAIN. (PH.D. DISSERTATION).
172019 01-03

EFFECTS OF SELECTED CENTRALLY ACTING AGENTS ON ADENYL CYCLASE ACTIVITY IN MOUSE BRAIN.
182153 02-03

DRUGS ACTING ON THE CENTRAL NERVOUS SYSTEM.
182835 03-17

THE ISOLATED PERFUSED RAT BRAIN AS A MODEL FOR STUDYING DRUGS ACTING ON THE CNS.
186589 03-06

A NEW PROLONGED ACTING TYPE OF CHLORPROMAZINE: BEHAVIORAL EFFECTS AND PROLONGED ACTIONS ON NERVE MEMBRANES.
187805 04-01

CENTRALLY ACTING MUSCLE RELAXANTS. ISOMERIC 9,10 DIHYDROXYOCTAHYDROPHENANTHRENES AND THEIR CARBAMATE ESTERS.
190719 04-02

BEHAVIORAL EFFECTS OF DIRECT AND INDIRECT ACTING DOPAMINERGIC AGONISTS.
191521 04-04

ACTINOMYCIN

EFFECTS OF CHLORPROMAZINE AND ACTINOMYCIN D ON UPTAKE AND INCORPORATION OF CERTAIN AMINO ACIDS, HYPOXANTHINE AND THYMIDINE IN CULTURES OF HUMAN SKIN EPITHELIAL CELLS.
179989 02-13

ACTION

PROSTAGLANDINS AND CANNABIS: A POSSIBLE MODE OF ACTION FOR THC.
169067 01-03

EVALUATION OF THE HYPOTHERMIC ACTION OF TETRAHYDROCANNABINOLS IN MICE AND SQUIRREL MONKEYS.
170163 01-03

THE EFFECT OF L-TRYPTOPHAN (TP) ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) REFLEXES IN ACUTE DECEREBRATE SPINAL CATS AND THE EFFECT OF PRETREATMENT WITH P-CHLOROPHENYLALANINE (PCPA) ON THE ACTION OF TP. (UNPUBLISHED PAPER).
170874 01-03

IS THERE A RELATIONSHIP BETWEEN THE INVOLVEMENT OF EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS WITH THE CATALEPTIC ACTION OF NEUROLEPTIC AGENTS AND THEIR CLINICAL ANTIPSYCHOTIC EFFECT?
171305 01-03

STUDY INTO THE MECHANISM OF THE ANORECTIC ACTION OF AMPHETAMINE AND ITS P-CHLORO ANALOGUE.
171610 01-03

A DIFFERENTIAL INHIBITORY ACTION OF LSD AND AMPHETAMINE ON COPULATORY BEHAVIOR IN THE FEMALE RAT.
171617 01-04

COMPARISON OF TRICYCLIC ANTIDEPRESSANTS AS TO THEIR CARDIOTOXIC ACTION IN CONSCIOUS RABBITS.
171629 01-03

SEROTONINERGIC MECHANISMS IN THE CENTRAL ACTION OF PSYCHOTROPIC DRUGS. (PH.D. DISSERTATION).
172015 01-03

STUDY OF THE PSYCHOTROPIC ACTION OF TEGRETOL IN PATIENTS WITH EPILEPSY.
172439 01-11

ON THE MECHANISM OF CENTRAL ACTION OF AMPHETAMINE: THE ROLE OF CATECHOLAMINES.
172921 01-04

DEPENDENCE OF ANTICONVULSANT DRUG ACTION ON CENTRAL MONOAMINES.
172923 01-03

SLEEP: A TOOL TO STUDY CHLORPROMAZINES ACTION. (UNPUBLISHED PAPER).
173521 01-14

BEHAVIORAL PARAMETERS OF DRUG ACTION: SIGNALED AND RESPONSE INDEPENDENT REINFORCEMENT.
174008 01-04

APOMORPHINE INDUCED BITING AND FIGHTING BEHAVIOUR IN RESERPINIZED RATS AND AN APPROACH TO THE MECHANISM OF ACTION.
174768 01-04

AMPHETAMINE TRICYCLIC INTERACTIONS: ROLE OF THE HYDROXYLATION OF AMPHETAMINE IN ITS CENTRAL AND PERIPHERAL MODE OF ACTION. (PH.D. DISSERTATION).
174963 01-03

MEASURING THE PHARMACOLOGICAL ACTION OF IMIPRAMINE IN THE TREATMENT OF DEPRESSIONS.
174995 02-09

THE MECHANISM OF ACTION OF THE MONOAMINE OXIDASE INHIBITOR PARGYLINE.
175239 02-03

ACTION OF CONVULSANTS ON ROOT POTENTIALS AND AMINO ACID RESPONSES IN ISOLATED FROG SPINAL CORD. (UNPUBLISHED PAPER).
177976 02-03

ROLE OF 5-HT IN THE ACTION OF SOME DRUGS AFFECTING EXTRAPYRAMIDAL SYSTEM.
178757 02-04

THE FIRST LONG-ACTING (RETARD) THYMOANALEPTIC OR ANTIDEPRESSANT: THE TIME-RELEASED DIBENZEPINE WITH PROLONGED ACTION.
178946 02-11

FURTHER EVIDENCE FOR A ROLE OF 2-PHENYLETHYLAMINE IN THE MODE OF ACTION OF DELTA9-TETRAHYDROCANNABINOL.
179992 02-03

THE MECHANISMS OF ACTION OF HALLUCINOGENS.
180142 02-12

A FEW GALENIC METHOD TO PROLONG THE ACTION OF LITHIUM SULFATE.
180700 02-15

CENTRAL NERVOUS ACTION OF BROMAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.
181650 02-03

INFLUENCES OF LITHIUM ON THE BEHAVIORAL ACTION OF METHAMPHETAMINE AND TETRABENAZINE.
182109 02-04

STUDIES ON THE ANOREXIGENIC ACTION OF PHENTERMINE.
182134 02-03

HYPOTHERMIC ACTION OF DELTA9-TETRAHYDROCANNABINOL, 11-OH-DELTA9-TETRAHYDROCANNABINOL AND 11-OH-DELTA8-TETRAHYDROCANNABINOL (DELTA9-THC, 11-OH-DELTA9-THC AND 11-OH-DELTA8-THC) IN MICE.
182220 03-03

ACTION OF OPIPRAMOL (G-33040) IN DEPRESSIVE SYNDROMES IN CHILDREN AND ADOLESCENTS.
182432 03-10

RUBIDIUM SALTS: BASIC MECHANISMS OF ACTION.
182441 03-03

CENTRAL NERVOUS ACTION OF FLURAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.
182549 03-03

EVIDENCE FOR THE ACTION OF D-LYSERGIC ACID DIETHYLAMIDE, MESCALINE AND BUFOTENINE ON 5-HYDROXYTRYPTAMINE RECEPTORS IN UMBILICAL VASCULATURE.
182716 03-03

MECHANISMS UNDERLYING POTENTIATION OF BARBITURATE ACTION BY SODIUM NITRITE IN THE MOUSE: THE ROLE OF METHEMOGLOBIN INDUCED HYPOXIA.
182721 03-03

A SMALL CONTROLLED STUDY TO DETERMINE THE TIME OF ONSET OF ACTION OF OXYPERTINE AFTER ORAL ADMINISTRATION IN NORMAL SUBJECTS.
182763 03-14

THE ACTION OF NEMBUTAL ON THE ULTRA ARCHITECTONICS OF THE NEUROHYPOPHYSIS.
183520 03-01

ANTIPSYCHOTIC ACTION OF NEUROLEPTIC AGENTS AND THE FUNCTION OF BASAL GANGLIA (SURVEY OF LITERATURE).
183521 03-17

A COMPARATIVE STUDY OF THE ANTIPSYCHOTIC ACTION OF SOME NEUROLEPTICS BASED ON THE MODEL OF LSD PSYCHOSES.
183682 03-03

SELECTIVE RESPIRATORY STIMULATING ACTION OF DOXAPRAM COMPARED TO PENTYLENETETRAZOL.
183887 03-03

MECHANISM OF ACTION OF SUBSTANCE-P.
184200 03-04

A PRELIMINARY STUDY ON THE ACTION OF THYROTROPINE RELEASING HORMONE OR TRH IN DEPRESSIVE STATES.
184962 03-09

THE ANALYSIS OF THE POTENTIAL ACTION OF A MEDICATION.
184963 03-14

THE ACTION OF D-AMPHETAMINE ON SPONTANEOUS ACTIVITY IN THE CAUDATE NUCLEUS AND RETICULAR FORMATION OF THE RAT.
185264 03-03

THE SITE OF ACTION ON THE OPTICAL ISOMERS OF 1-METHYL-5-PHENYL-5-PROPYL BARBITURIC ACID.
185901 03-03

CLINICAL PHARMACOLOGY AS AN APPROACH TO THE STUDY OF BIOCHEMICAL SLEEP MECHANISMS: THE ACTION OF L-DOPA.
186643 03-14

NONCHOLINERGIC MECHANISM OF ACTION OF CHOLINERGIC DRUGS ON SQUID AXON MEMBRANES.
186672 03-03

THE ACTION OF ALPHA-METHYLDOPA IN THE CERVEAU ISOLE PREPARATION.
187075 03-03

COMPARISON OF THE LOCOMOTOR STIMULANT MECHANISMS OF ACTION OF D-AMPHETAMINE AND D-AMPHETAMINE PLUS L-DOPA: POSSIBLE INVOLVEMENT OF SEROTONIN.
187119 03-04

ALPHA-L-ACETYLMETHADOL AND ITS N-DEMTHYLATED METABOLITES HAVE POTENT OPIATE ACTION IN THE GUINEA-PIG ISOLATED ILEUM.
187130 03-03

ONE CASE OF AGRYPNIA (4 MONTHS WITHOUT SLEEP) IN A MORVAN DISEASE: FAVORABLE ACTION OF 5-HYDROXYTRYPTOPHAN.
187237 03-14

A POSSIBLE MECHANISM FOR THE ANTISCHIZOPHRENIC ACTION OF CHLORPROMAZINE: INHIBITION OF THE FORMATION OF DIMETHYLTRYPTAMINE BY CHLORPROMAZINE METABOLITES.
187576 04-03

A FREQUENCY SHIFT IN THE HIPPOCAMPAL THETA ACTIVITY: AN ELECTRICAL CORRELATE OF CENTRAL ACTION OF ACTH ANALOGUES IN THE DOG
188166 04-04

STUDIES ON THE ACTION OF CERTAIN PHARMACOLOGICAL AGENTS ON TARDIVE DYSKINESIA AND ON THE RABBIT SYNDROME.
188406 04-03

TREATMENT OF ACTION MYOCLONUS WITH L-5-HYDROXYTRYPTOPHAN.
188429 04-11

FURTHER EVIDENCE FOR A DOPAMINE RECEPTOR STIMULATING ACTION OF AN ERGOT ALKALOID.
188739 04-03

ANTICONVULSANT ACTION OF VITAMIN-D IN EPILEPTIC PATIENTS? A CONTROLLED PILOT STUDY.
188889 04-11

INVOLVEMENT OF BRAIN CHOLINERGIC MECHANISMS IN THE ACTION OF CHLORPROMAZINE.
188891 04-03

MECHANISM OF THE VASOCONSTRICTOR ACTION OF PROSTAGLANDIN B.
189394 04-03

ENHANCEMENT OF AMPHETAMINE ACTION AFTER INTERRUPTION OF ASCENDING SEROTONERGIC PATHWAYS.
189398 04-03

THE ACTION OF CHLORPROMAZINE ON EXPLORATION IN PAIRS OF RATS.
189514 04-04

DOPAMINERGIC INHIBITION OF STRIATAL CHOLINERGIC NEURONS: SYNERGISTIC BLOCKING ACTION OF GAMMA-BUTYROLACTONE AND NEUROLEPTIC DRUGS.
189602 04-03

THE ACTION OF BETA-PHENYL-GABA DERIVATIVES ON NEURONES OF THE CAT CEREBRAL CORTEX.
189750 04-03

DIPSOGENIC ACTION OF DIAZOXIDE: A PHARMACOLOGIC ANALYSIS.
191768 04-03

CORRELATION BETWEEN THE TRANQUILIZING AND SEDATIVE ACTION OF NEUROLEPTICS, ANTIDEPRESSANTS AND ANTICHOLINERGIC DRUGS.
191783 04-02

THE ACTION OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTOR CENTERS OF EMOTIONS IN THE HYPOTHALAMUS.
191785 04-02

ACTION OF HALOPERIDOL AND TRIFLUOPERAZINE ON THE MOTOR RESPONSES ELICITED BY ELECTRICAL STIMULATION OF THE BRAIN IN RABBITS.
191787 04-02

ADENOSINE ACTION ON SYNAPTIC TRANSMISSION IN BRAIN SLICES.
191945 04-03

ANALYSIS OF HYPOTHERMIC ACTION OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) IN MICE.
191997 04-03

ACTIONS

PARADOXICAL BLOCKADE BY P-CHLOROPHENYLALANINE OF 5-HYDROXYTRYPTOPHAN FACILITATORY ACTIONS ON SPINAL REFLEXES.
168436 01-03

QUANTUM CHEMICAL STUDIES ON DRUG ACTIONS: IV. CORRELATION OF SUBSTITUENT STRUCTURES AND ANTISEROTONIN ACTIVITY IN LYSERGAMIDE SERIES.
174605 01-12

DISSOCIATIVE CHANGE IN ANTIAGGRESSIVE AND MUSCLE RELAXANT ACTIONS OF S-TRIAZOLOBENZODIAZEPINE (D-40TA) BY REPEATED ADMINISTRATION AND PHENOBARBITAL PRETREATMENT, AND ITS RELATION TO METABOLISM.
181654 02-04

NEURONE BLOCKING ACTIONS OF ANTIPSYCHOTIC DRUGS.
182127 02-03

SEPARATION OF THE DEPENDENCE PRODUCING ACTIONS FROM THE DIRECT ACTIONS OF NARCOTICS ON GUINEA-PIG ILEUM.
182162 02-03

THE ACTIONS OF SEVERAL PSYCHOACTIVE AGENTS UPON THE MUSCARINIC MECHANISMS IN THE SUPERIOR CERVICAL GANGLION OF THE CAT.
183866 03-03

THE POSSIBLE ROLE OF TRYPTAMINE IN BRAIN FUNCTION AND ITS RELATIONSHIP TO THE ACTIONS OF LSD-LIKE HALLUCINOGENS.
186024 03-12

A ROLE FOR THE AMYGDALA IN THE DEVELOPMENT OF THE CATALEPTIC AND STEREOTYPIC ACTIONS OF THE NARCOTIC AGONISTS AND ANTAGONISTS IN THE RAT.
186577 03-03

ON THE BEHAVIORAL AND NEUROCHEMICAL ACTIONS OF 6-HYDROXYDOPA AND 5,6 DIHYDROXYTRYPTAMINE IN RATS.
187380 04-03

ACTIONS OF ATROPINE, HEMICHOLINIUM-3, AND PHYSOSTIGMINE ON CHLORPROMAZINE INDUCED CHANGES IN RAT BRAIN MONOAMINES.
187800 04-03

A NEW PROLONGED ACTING TYPE OF CHLORPROMAZINE: BEHAVIORAL EFFECTS AND PROLONGED ACTIONS ON NERVE MEMBRANES.
187805 04-01

STEREOSPECIFIC ACTIONS OF DOET (2,5 DIMETHOXY-4-ETHYLAMPHETAMINE) IN MAN.
188121 04-12

PHARMACOLOGICAL AND BIOCHEMICAL ACTIONS OF THE HEMOLYTIC AGENTS ACETYLPHENYLHYDRAZINE AND PHENYLHYDRAZINE ON MONOAMINE OXIDASE IN THE RAT.
188769 04-03

INFLUENCE OF ADRENERGIC BLOCKERS AND ANTILIPEMIC AGENTS ON PHARMACODYNAMIC ACTIONS OF MORPHINE IN CARBON TETRACHLORIDE TREATED RATS.
188873 04-03

THE NERVE IMPULSE BLOCKING ACTIONS OF TRANQUILIZERS AND THE BINDING OF NEUROLEPTICS TO SYNAPTOSOME MEMBRANES.
189400 04-03

THE DOPAMINE RELEASING ACTIONS OF NEUROLEPTICS AND ETHANOL.
189401 04-03

CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE METABOLITE, NORFENFLURAMINE: AN EVALUATION OF ITS ROLE IN THE ACTIONS OF FENFLURAMINE.
190335 04-04

EFFECTS OF VARIOUS DRUGS ON THE ACTIONS OF 5,7 DIHYDROXYTRYPTAMINE.
191955 04-03

DIFFERENTIAL INCREASE OF BEHAVIORAL AND EXTRAPYRAMIDAL STIMULATING ACTIONS OF NEUROLEPTICS BY ALPHA-METHYLTYROSINE PRETREATMENT IN RATS.
192016 04-04

ACTIVATED

CHANGE OF ESTROGEN ACTIVATED BEHAVIOR BY CYCLOHEXIMIDE IN THE FEMALE RAT.
171615 01-04

EFFECTS OF LSD AND MONOAMINE SYNTHESIS INHIBITORS ON HORMONE ACTIVATED COPULATORY BEHAVIOR IN THE FEMALE RAT.
188611 04-04

ACTIVATING

IS OXYPERTINE AN ACTIVATING TRANQUILLIZER?
182765 03-09

INABILITY TO CONDITION A PERIPHERAL ACTIVATING DRUG.
190698 04-04

ACTIVATION

SPECIFIC ACTIVATION OF STRIATAL TYROSINE HYDROXYLASE (TH) BY NEUROLEPTICS. (UNPUBLISHED PAPER).
170755 01-03

ACTIVATION OF COPULATORY BEHAVIOR BY PILOCARPINE AND OXOTREMORINE IN THE FEMALE RAT.
171616 01-04

MONOAMINES AND COPULATORY ACTIVATION IN THE CASTRATED MALE RAT.
171618 01-04

INHIBITION BY MORPHINE OF REPETITIVE ACTIVATION OF CAT SPINAL MOTONEURONES.
172926 01-03

DRUG-INDUCED ACTIVATION OF STRIATAL TYROSINE HYDROXYLASE: CHANGES IN THE AFFINITY FOR PTERIDINE COFACTORS. (UNPUBLISHED PAPER).
173381 01-03

CHOLINE ACTIVATION OF LITHIUM TRANSPORT.
178812 02-03

MARIJUANA DIMINISHES GSR ACTIVATION PEAKING.
181887 02-13

DOSE EFFECTS OF METHYLPHENIDATE ON BEHAVIORAL INHIBITION AND ACTIVATION IN HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
185676 03-14

CENTRAL HYPOTHERMIA BY 2-DEOXY-D-GLUCOSE: ANTAGONISM BY ALPHA-ADRENERGIC ACTIVATION.
188200 04-03

IN VIVO CHANGES OF CEREBRAL CYCLIC ADENOSINE 3,5 MONOPHOSPHATE INDUCED BY BIOGENIC AMINES: ASSOCIATION WITH PHOSPHORYLASE ACTIVATION.
188291 04-03

ACTIVATION OF STRIATAL HYDROXYLASE BY HYDROXYLATED METABOLITES OF CHLORPROMAZINE.
191908 04-03

ACTIVE

EFFECTS OF INTRAPERITONEAL AND INTRAVENTRICULAR D-AMPHETAMINE ADMINISTRATION ON ACTIVE AVOIDANCE PERFORMANCE IN THE RAT.
175242 02-04

INTERACTION OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A PURPORTED HASHISH AND LSD ANTAGONIST, WITH SEVERAL CENTRAL NEUROCHEMICAL SYSTEMS.
182217 03-04

EFFECTS OF NEONATAL STRYCHNINE ADMINISTRATION ON ACTIVE AVOIDANCE IN RATS.
184242 03-04

A NOVEL SPASMOLYTIC AND CNS ACTIVE AGENT: 3-(2-BENZYLMETHYLAMINOETHYL) BENZOIC ACID METHYL ESTER HYDROCHLORIDE.
184581 03-02

PHARMACOLOGICAL DISTINCTIONS BETWEEN ACTIVE AND PASSIVE AVOIDANCE MEMORY FORMATION AS SHOWN BY MANIPULATION OF BIOGENIC AMINE ACTIVE COMPOUNDS.
185927 03-04

LOCALIZED BEHAVIORAL EFFECTS OF VASOPRESSIN ON MAINTENANCE OF AN ACTIVE AVOIDANCE RESPONSE IN RATS.
187697 04-04

COMPARATIVE EFFECTS OF SOME CNS ACTIVE DRUGS ON LEARNED AND UNLEARNED BEHAVIOR IN THE HAMSTER.
191976 04-04

ACTIVITIES

A STUDY OF THE RELATIVE ANTICONVULSANT AND TOXIC ACTIVITIES OF DELTA9-TETRAHYDROCANNABINOL AND ITS CONGENERS.
174608 01-05

A SENSITIVE, SIMPLE METHOD FOR MEASUREMENT OF TYROSINE HYDROXYLASE AND TRYPTOPHAN-5-HYDROXYLASE ACTIVITIES.
182178 02-06

EFFECTS OF ALKALI METALS ON SPONTANEOUS MOTOR ACTIVITIES OF MICE.
182637 03-02

CONTROL OF MENTAL ACTIVITIES.
185235 03-17

THE EFFECT OF PRETREATMENT WITH IPRONIAZID ON THE BEHAVIORAL ACTIVITIES OF BETA-PHENYLETHYLAMINE IN RATS.
187932 04-04

ACTIVITY

EFFECT OF PRENATAL MATERNAL ADMINISTRATION OF D-AMPHETAMINE ON RAT OFFSPRING ACTIVITY AND PASSIVE AVOIDANCE LEARNING.
167415 01-03

EFFECTS OF ATROPINE ON EXPLORATION, LEARNING AND ELECTROCORTICAL ACTIVITY IN THE DEVELOPING RAT.
169473 01-04

THE ACTIVITY OF SOME NEUROLEPTIC DRUGS AND AMPHETAMINE IN NORMAL AND ISOLATED RATS.
170126 01-04

TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER).
170876 01-03

INTERACTION BETWEEN ATROPINE AND OXOTREMORINE ON CORTICAL ACETYLCHOLINE AND MOTOR ACTIVITY.
171606 01-03

EFFECTS OF CENTRALLY ACTING DRUGS ON ADENYL CYCLASE ACTIVITY AND CYCLIC AMP LEVELS OF MOUSE BRAIN. (PH.D. DISSERTATION).
172019 01-03

THE NOOTROPIC APPROACH TO THE PHARMACOLOGY OF THE INTEGRATIVE ACTIVITY OF THE BRAIN.
173495 01-02

DIURETIC ACTIVITY OF A NEW NARCOTIC ANTAGONIST IN MAN (BRISTOL-COMPOUND-2605). (UNPUBLISHED PAPER).
174473 01-13

QUANTUM CHEMICAL STUDIES ON DRUG ACTIONS: IV. CORRELATION OF SUBSTITUENT STRUCTURES AND ANTISEROTONIN ACTIVITY IN LYSERGAMIDE SERIES.
174605 01-12

THE ROLE OF HYDROPHOBICITY IN THE ANTISEROTONIN ACTIVITY OF LSD ANALOGS.
174606 01-12

PLATELET MONOAMINE OXIDASE ACTIVITY AND SUBSTRATE PREFERENCES IN SCHIZOPHRENIC PATIENTS.
174609 01-14

THE ANTICONVULSANT ACTIVITY OF CANNABIDIOL AND CANNABINOL.
175238 02-03

OBSER:.ATIONS ON THE THERAPEUTIC ACTIVITY OF CLOPENTHIXOL IN PSYCHIATRY.
175540 02-11

A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY IN MAN OF INTRAVENOUSLY ADMINISTERED DELTA9-TETRAHYDROCANNABINOL, CANNABINOL, AND CANNABIDIOL.
176747 02-03

A STUDY OF ANTIOVULATORY ACTIVITY OF HALOPERIDOL IN RABBITS.
177021 02-03

ANTICONVULSIVE ACTIVITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) AND ITS EFFECT ON LIMBIC SYSTEM.
177099 02-02

DOPAMINE IN THE MESOLIMBIC SYSTEM OF THE RAT BRAIN: ENDOGENOUS LEVELS AND THE EFFECTS OF DRUGS ON THE UPTAKE MECHANISM AND STIMULATION OF ADENYLATE CYCLASE ACTIVITY.
177131 02-03

L-DOPA CHLORPROMAZINE ANTAGONISM ON RUNNING ACTIVITY IN MICE.
177785 02-04

INFLUENCE OF N1-2-HYDROXYETHYL SUBSTITUTION ON CENTRAL ACTIVITY OF OXAZEPAM AND LORAZEPAM.
178756 02-04

CHANGES IN BRAIN ACETYLCHOLINESTERASE ACTIVITY OF YOUNG RATS AFTER CHRONIC TREATMENT WITH TREMORINE.
178814 02-03

ANTICONVULSANT ACTIVITY OF CLONAZEPAM AND RO-8-4192 AGAINST PENICILLIN AND LIDOCAINE INDUCED SEIZURES.
178947 02-03

STIMULATION OF BRAIN AROMATIC ALKYLAMINE N-METHYLTRANSFERASE ACTIVITY BY FAD AND METHYLCOBALAMIN.
180020 02-03

CHOLINE ACETYLTRANSFERASE ACTIVITY IN THE CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
180047 02-13

SYNTHESIS AND ANTIRESERPINE ACTIVITY OF PEPTIDES OF L-DOPA.
180097 02-03

EFFECTS OF NEUROLEPTICS AND THYMOLEPTICS ON PHOSPHODIESTERASE ACTIVITY AND ON CYCLIC 3,5 AMP LEVELS IN RAT BRAIN.
181467 02-03

REGIONAL CYCLIC NUCLEOTIDES PHOSPHODIESTERASE ACTIVITY IN CAT CENTRAL NERVOUS SYSTEM: EFFECTS OF BENZODIAZEPINES.
181575 02-03

METHYLPHENIDATE AND THE ACTIVITY OF HYPERACTIVES IN THE INFORMAL SETTING.
181853 02-14

EFFECT OF PROCAINE, LIDOCAINE AND PENTOBARBITAL ON ELECTRICAL ACTIVITY OF GUINEA-PIG OLFACTORY CORTEX IN VITRO.
182092 02-03

MODULATORY EFFECTS OF CORTICOSTEROIDS ON EVOKED ACTIVITY IN THE HIPPOCAMPUS AND THALAMUS OF THE RAT.
182119 02-03

EFFECTS OF NEUROPHARMACOLOGICAL AGENTS ON HYPOTHALAMIC NEURONAL ACTIVITY: A MICROELECTROPHORETIC STUDY.
182123 02-03

EFFECTS OF SELECTED CENTRALLY ACTING AGENTS ON ADENYL CYCLASE ACTIVITY IN MOUSE BRAIN.
182153 02-03

PHARMACOLOGIC ACTIVITY AND BIOTRANSFORMATION OF R_ AND S-BARBITURATE ENANTIOMERS IN MOUSE AND MAN.
182156 02-03

CHROMATIN TEMPLATE ACTIVITY DURING MORPHINE-INDUCED ANALGESIA AND THE DEVELOPMENT OF ANALGESIC TOLERANCE.
182160 02-03

TOLERANCE TO THE ACTIVITY ENHANCING EFFECTS OF D-AMPHETAMINE.
182208 02-04

RELATIVE IMPORTANCE OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS FOR THE STIMULATION OF LOCOMOTOR ACTIVITY INDUCED BY AMPHETAMINE AND OTHER DRUGS.
182209 02-04

ANTIPYRETIC, ANALGESIC AND ANTIINFLAMMATORY ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL IN THE RAT.
182221 03-03

A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL AND ITS MONOHYDROXYLATED METABOLITES IN MAN.
182223 03-03

EFFECTS OF METHADONE ON ACTIVITY AND ON BRAIN MONOAMINES IN TWO MOUSE STRAINS.
182229 03-03

EFFECT OF MORPHINE, HALOPERIDOL, APOMORPHINE AND BENZTROPINE ON DOPAMINE TURNOVER IN RAT CORPUS-STRIATUM: EVIDENCE SHOWING MORPHINE-INDUCED REDUCTION IN CNS DOPAMINERGIC ACTIVITY.
182230 03-03

BEHAVIORAL AND PHYSIOLOGICAL ACTIVITY OF DEAMINATED METABOLITES OF MESCALINE.
182244 03-03

COMPARATIVE EFFECTS OF DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE ON CENTRAL CATECHOLAMINES AND LOCOMOTOR ACTIVITY.
182253 03-04

THE INFLUENCE OF NEUROTROPIC DRUGS ON MONOAMINE OXIDASE (MAO) AND 5-OXYTRYPTOPHANE DECARBOXYLASE (5-OTD) ACTIVITY IN THE BRAIN.
183142 03-13

EFFECTS OF CHRONICALLY ADMINISTERED DELTA1-TETRAHYDROCANNABINOL OF ADRENAL AND GONADAL ACTIVITY OF MALE RATS.
183358 03-03

NICOTINIC ACID AND CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN SCHIZOPHRENIA.
183360 03-13

THE EFFECTS OF PSYCHIC STIMULANTS ON THE ACTIVITY OF POTASSIUM AND SODIUM ION STIMULATED ATPASE IN THE MICROSOMAL FRACTIONS OF THE BRAIN OF RATS.
183518 03-01

SUBSTITUTED PIPERAZINOQUINAZOLONES: RELATIONSHIP BETWEEN SELECTIVE INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND ANTICONVULSANT ACTIVITY.
183598 03-02

SUBSTITUTED BENZOXAZOLE/BENZTHIAZOLE-2-THIONES: INTERRELATIONSHIP BETWEEN ANTICONVULSANT ACTIVITY AND INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND MONOAMINE OXIDASE.
183601 03-03

ALPHA-ADRENERGIC BLOCKING AGENTS: ANTINOCICEPTIVE ACTIVITY AND ENHANCEMENT OF MORPHINE-INDUCED ANALGESIA.
183895 03-03

INFLUENCE OF METHAMPHETAMINE AND NEUROLEPTIC DRUGS ON TYROSINE HYDROXYLASE ACTIVITY.
184180 03-03

DECREASED EFFECT OF PHENOBARBITAL TREATMENT ON MICROSOMAL DRUG METABOLIZING ENZYME ACTIVITY DURING GESTATION.
184228 03-03

INDICATIONS AND DOSAGE FOR MAXIMAL ACTIVITY OF ORNITHINE-CARBAMYL-TRANSFERASE IN THE PSYCHIATRIC ENVIRONMENT.
184955 03-17

QUINAZOLINES AND 1,4 BENZODIAZEPINES.64.COMPARISON OF THE STEREOCHEMISTRY OF DIAZEPAM WITH THAT OF CLOSE ANALOGS WITH MARGINAL BIOLOGICAL ACTIVITY.
185034 03-01

ANTICONVULSANT ACTIVITY OF SUBSTITUTED INDOLEALKYLAMINES.
185035 03-01

THE ACTION OF D-AMPHETAMINE ON SPONTANEOUS ACTIVITY IN THE CAUDATE NUCLEUS AND RETICULAR FORMATION OF THE RAT.
185264 03-03

THE EFFECTS OF CHRONIC TREATMENT WITH D-AMPHETAMINE ON FOOD INTAKE, BODYWEIGHT, LOCOMOTOR ACTIVITY AND SUBCELLULAR DISTRIBUTION OF THE DRUG IN RAT BRAIN.
185931 03-03

ON CATALEPSY AND CATATONIA AND THE PREDICTABILITY OF THE CATALEPSY TEST FOR NEUROLEPTIC ACTIVITY.
185958 03-04

SYNTHESIS AND CNS ACTIVITY OF 3-SUBSTITUTED 7-CHLORO-5-PHENYLBENZOTRIAZEPIN-2-ONES.
185978 03-01

ANTICONVULSANT ACTIVITY AND INHIBITION OF RESPIRATION IN RAT BRAIN HOMOGENATES BY SUBSTITUTED OXADIAZOLES.
185980 03-01

A NEW RECORDING APPARATUS FOR MEASUREMENT OF LOCOMOTOR ACTIVITY OF MICE. EXPERIMENTAL OBSERVATIONS ON ITS USE.
186377 03-06

EFFECTS OF METHAMPHETAMINE, PIPRADROL, AND METHYLPHENIDATE ON INSTRUMENTAL CONDITIONING AND SPONTANEOUS MOTOR ACTIVITY IN THE IMMATURE RAT.
186568 03-04

A COMPARISON OF EFFECTS OF APOMORPHINE AND ET-495 ON LOCOMOTOR ACTIVITY AND CIRCLING BEHAVIOUR IN MICE.
186635 03-04

SIGNIFICANCE OF DOPAMINE RECEPTOR ACTIVITY IN DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY.
186670 03-04

EFFECTS OF AMPHETAMINES ON REGIONAL TRYPTOPHAN HYDROXYLASE ACTIVITY AND SYNAPTOSOMAL CONVERSION OF TRYPTOPHAN TO 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
186674 03-03

EVIDENCE FOR A CRITICAL PERIOD FOR POSTNATAL ELEVATION OF BRAIN TYROSINE HYDROXYLASE ACTIVITY RESULTING FROM RESERPINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT.
186695 03-03

COMPARISON OF TYROSINE HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION WITH THE EFFECTS OF VARIOUS 6-HYDROXYDOPAMINE TREATMENTS ON D-AMPHETAMINE INDUCED MOTOR ACTIVITY.
186699 03-03

STRUCTURE-ACTIVITY RELATIONS OF SOME INDOLEALKYLAMINES IN COMPARISON TO PHENETHYLAMINES ON MOTOR ACTIVITY AND ACQUISITION OF AVOIDANCE BEHAVIOR.
186703 03-04

MUSCLE ABNORMALITIES IN PSYCHOTIC PATIENTS: II. SERUM CPK ACTIVITY, FIBER ABNORMALITIES, AND BRANCHING AND SPROUTING OF SUBTERMINAL NERVES.
187114 03-09

BLOCKING OF THE EFFECT OF A DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC) ON SPONTANEOUS MOTOR ACTIVITY IN THE RAT BY IMMUNIZATION WITH A PROTEIN CONJUGATE OF DELTA1-THC.
187129 03-04

EFFECTS OF LOCUS-COERULEUS STIMULATION ON HIPPOCAMPAL UNIT ACTIVITY AND ON BEHAVIOR IN UNRESTRAINED RATS. (UNPUBLISHED PAPER).
187499 04-04

DELTA9-TETRAHYDROCANNABINOL: EFFECTS OF ROUTE OF ADMINISTRATION ON ONSET AND DURATION OF ACTIVITY AND TOLERANCE DEVELOPMENT.
187928 04-03

3-ARYL-3-HYDROXYQUINOLIZIDINES WITH POTENTIAL HYPOTENSIVE, ANTIDEPRESSANT, AND ANALGETIC ACTIVITY.
187938 04-01

A FREQUENCY SHIFT IN THE HIPPOCAMPAL THETA ACTIVITY: AN ELECTRICAL CORRELATE OF CENTRAL ACTION OF ACTH ANALOGUES IN THE DOG
188166 04-04

EFFECT OF ORAL ADMINISTRATION OF METHADONE ON HEPATIC MICROSOMAL MIXED FUNCTION OXIDASE ACTIVITY IN MICE.
188178 04-03

INTERACTIONS OF CHLORPHENIRAMINE ETHANOL COMBINATIONS: ACUTE TOXICITY AND ANTIHISTAMINIC ACTIVITY.
188875 04-05

SYNTHESIS AND CENTRAL NERVOUS SYSTEM ACTIVITY OF 1,2,3,4-TETRAHYDRO-1-AMINO-4-PHENYLNAPHTHALENES.
189178 04-02

INTERACTION OF D-AMPHETAMINE WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY OF MICE.
189613 04-04

EFFECT OF PHENOTHIAZINE NEUROLEPTIC DRUGS AND TRICYCLIC ANTIDEPRESSANTS ON PHOSPHODIESTERASE ACTIVITY IN RAT CEREBRAL CORTEX.
190311 04-03

CONFORMATIONAL ANALYSIS OF ACRIDAN DERIVATIVES BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY. A RELATIONSHIP BETWEEN CONFORMATION AND PHARMACOLOGICAL ACTIVITY.
190715 04-01

EFFECT OF ATROPINE SULFATE ON THE SLEEP RELATED EEG SPIKE ACTIVITY OF THE TORTOISE, GEOCHELONE-CARBONARIA.
191389 04-03

ELECTRODERMAL ACTIVITY IN HYPERACTIVE BOYS WHO ARE METHYLPHENIDATE RESPONDERS.
191400 04-14

PHYSICOCHEMICAL PROPERTIES, DEVELOPMENT, AND REGULATION OF CENTRAL AND PERIPHERAL MONOAMINE OXIDASE ACTIVITY.
191497 04-03

HUMAN SERUM DOPAMINE-BETA-HYDROXYLASE: RELATIONSHIP TO SYMPATHETIC ACTIVITY IN PHYSIOLOGICAL AND PATHOLOGICAL STATES.
191510 04-13

AN EVALUATION OF SERUM DOPAMINE-BETA-HYDROXYLASE AS AN INDEX OF SYMPATHETIC NERVE ACTIVITY IN MAN.
191511 04-13

EFFECTS OF NOMIFENSINE (HOE-984), D-AMPHETAMINE AND APOMORPHINE ON MOTOR ACTIVITY, CATECHOLAMINE TURNOVER AND CAMP CONCENTRATIONS IN RAT BRAIN. (UNPUBLISHED PAPER).
191766 04-03

CHANGES IN RHYTHMS OF BIOELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX IN HUMANS UNDER THE INFLUENCE OF ETHYMISOL.
191790 04-07

NORADRENERGIC NEURONS: EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON SINGLE UNIT ACTIVITY.
191931 04-03

THE LOCALIZATION AND CHARACTERIZATION OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE ACTIVITY IN SPECIFIC REGIONS OF THE CNS.
191932 04-03

A PREDICTABLE LABORATORY MODEL FOR SEDATIVE/HYPNOTIC ACTIVITY IN MAN.
191943 04-14

CHLORDIAZEPOXIDE INDUCED BETA SPINDLE ACTIVITY IN RATS.
192416 04-03

LABORATORY ASSESSMENTS OF ANTIDEPRESSIVE ACTIVITY -- THEIR VALUE FOR CLINICAL PSYCHIATRY AND THE UNDERSTANDING OF DEPRESSION.
192422 04-09

THE EFFECTS OF HOE-36801 ON MUSCLE ACTIVITY AND BLOOD PRESSURE, ON ATTENTION AND CONCENTRATION, ON TIME JUDGMENT AND SUBJECTIVE RESPONSES IN NEUROTICS AND NORMALS.
192429 04-14

ACUTE

METIAPINE IN ACUTE SCHIZOPHRENIC PATIENTS.
167341 01-08

EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF CANNABIS-SATIVA EXTRACT ON THE MOUSE-KILLING BEHAVIOR OF RATS.
167362 01-04

ACUTE DRUG-INDUCED EXTRAPYRAMIDAL SYNDROMES.
167572 01-15

ACUTE ADVERSE REACTIONS TO PSYCHOACTIVE DRUGS, DRUG USAGE, AND PERSONALITY. (UNPUBLISHED PAPER).
167832 01-15

USE OF PSYCHOTHERAPEUTIC DRUGS IN THE ACUTE DETOXIFICATION OF HEROIN ADDICTS.
169746 01-11

THE EFFECT OF L-TRYPTOPHAN (TP) ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) REFLEXES IN ACUTE DECEREBRATE SPINAL CATS AND THE EFFECT OF PRETREATMENT WITH P-CHLOROPHENYLALANINE (PCPA) ON THE ACTION OF TP. (UNPUBLISHED PAPER).
170874 01-03

ACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MICE, RATS, RABBITS AND DOGS.
173548 01-05

ACUTE SCHIZOPHRENIA.
175725 02-08

ACUTE CEREBELLAR DISTURBANCE ASSOCIATED WITH DIAZEPAM THERAPY -- A CASE REPORT AND FURTHER INVESTIGATION. 177392 02-15

ACUTE LETHALITY FOR MICE FOLLOWING ADMINISTRATION OF CYCLOPHOSPHAMIDE WITH BARBITURATES. 177834 02-05

PARENTERAL HALOPERIDOL FOR RAPID CONTROL OF SEVERE, DISRUPTIVE SYMPTOMS OF ACUTE SCHIZOPHRENIA. 178545 02-08

ACUTE NITRAZEPAM (MOGADON) POISONING: AN ELECTROENCEPHALOGRAPHIC STUDY. 180148 02-15

ELECTROENCEPHALOGRAPHIC CHANGES IN ACUTE PHENOBARBITONE POISONING. 180149 02-15

THE ELECTROENCEPHALOGRAPHIC CHANGES IN ACUTE BARBITURATE POISONING. 180152 02-15

COMPARISON OF THE CHRONIC AND ACUTE EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) TREATMENT ON RAT BRAIN SEROTONIN AND NOREPINEPHRINE. 181945 02-03

EFFECT OF ACUTE AND CHRONIC MORPHINE ON SPECIFIC RADIOACTIVITIES OF CHOLINE AND ACETYLCHOLINE IN MOUSE BRAIN. 182226 03-03

STUDIES ON THE EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT ON CATECHOLAMINE LEVELS AND TURNOVER IN DISCRETE BRAIN AREAS OF RATS. 182228 03-03

DIAZEPAM TREATMENT FOR ACUTE CONVULSIONS IN CHILDREN: A REPORT OF 41 PATIENTS, THREE WITH PLASMA LEVELS. 182595 03-11

CLINICAL STUDIES OF ACUTE PSYCHOSIS ON THE BASIS OF CHRONIC HYPNOTICA INTOXICATION -- AN ABSTRACT REPORT. 182755 03-15

ACUTE POISONING BY NITRAZEPAM (MOGADON). 183786 03-15

THE EFFECTS OF ACUTE ADMINISTRATION OF PROPRANOLOL AND PRACTOLOL ON THE UPTAKE, CONTENT, RELEASE AND TURNOVER OF NORADRENALINE IN THE RAT HEART IN VIVO. 184232 03-03

ACUTE EFFECTS OF ALCOHOL, DIAZEPAM, THIORIDAZINE, FLUPENTHIXOL AND ATROPINE ON PSYCHOMOTOR PERFORMANCE PROFILES. 184848 03-14

THE CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES IN THE PLASMA AFTER AN ACUTE AND CHRONIC ADMINISTRATION. 184978 03-13

DRUG DOSAGE IN ACUTE PHASE SCHIZOPHRENIA. 185898 03-17

PROPRANOLOL AND BEHAVIOR OF ALCOHOL ADDICTS AFTER ACUTE ALCOHOL INGESTION. 187257 04-14

MESORIDAZINE (TPS-23 SANDOZ) IN ACUTE PSYCHOTIC STATES. 187958 04-11

INTERACTIONS OF CHLORPHENIRAMINE ETHANOL COMBINATIONS: ACUTE TOXICITY AND ANTIHISTAMINIC ACTIVITY. 188875 04-05

INFLUENCE ON ACUTE PRETREATMENT WITH DELTA9-TETRAHYDROCANNABINOL OF THE LD50 OF VARIOUS SUBSTANCES THAT ALTER NEUROHUMORAL TRANSMISSION. 188876 04-05

THE ACUTE TOXICITY OF L-DOPA. 189587 04-05

THE LACK OF EFFECTS OF PRETREATMENT WITH PHENOBARBITAL AND CHLORPROMAZINE ON THE ACUTE TOXICITY OF BENZENE IN RATS. 189600 04-05

THE EFFECT OF CHLORPROMAZINE AND STELAZINE ON LYSOSOMES OF RAT LIVER DURING ACUTE INTOXICATION. 191121 04-03

EMERGENCY TREATMENT OF AN ACUTE STATE OF MENTAL ABERRATION. 191723 04-09

SUBCELLULAR LOCALIZATION OF H3-DELTA9-TETRAHYDROCANNABINOL IN DOG BRAIN AFTER ACUTE OR CHRONIC ADMINISTRATION. 191970 04-03

ADAPTATION

EFFECT OF 6-HYDROXYDOPAMINE ON DARK ADAPTATION IN THE RAT RETINA. 167358 01-03

REFLECTION OF SHORT-TERM LIGHT ADAPTATION EFFECT IN THE ELECTRORETINOGRAM. 180591 02-04

ADAPTATION TO NITROGEN NARCOSIS MANIFESTED BY TIMING BEHAVIOR IN THE RAT. 186630 03-04

ADDICT

FATAL INTOXICATION OF A YOUNG DRUG ADDICT WITH DIAZEPAM. 178619 02-05

ADDICTING

STATE-DEPENDENT LEARNING PRODUCED BY ADDICTING DRUGS. 169071 01-03

ADDICTION

AFFECTIVE DISORDERS AND CHEMICAL DEPENDENCE: LITHIUM FOR ALCOHOL AND DRUG ADDICTION 189775 04-09

ENHANCEMENT OF PENTOBARBITAL AFTER MORPHINE ADDICTION. 191898 04-03

ADDICTS

USE OF PSYCHOTHERAPEUTIC DRUGS IN THE ACUTE DETOXIFICATION OF HEROIN ADDICTS. 169746 01-11

TESTOSTERONE AND LUTEINIZING HORMONE (LH) IN UNTREATED AND METHADONE MAINTAINED NARCOTIC ADDICTS. 182166 02-13

PROPRANOLOL AND BEHAVIOR OF ALCOHOL ADDICTS AFTER ACUTE ALCOHOL INGESTION. 187257 04-14

ADDITIVE

THE ADDITIVE EFFECTS OF TRANQUILIZERS AND DOPAMINE ON SMOOTH MUSCLE. 187804 04-03

ADENINE

SUBSTITUTED PIPERAZINOQUINAZOLONES: RELATIONSHIP BETWEEN SELECTIVE INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND ANTICONVULSANT ACTIVITY. 183598 03-02

SUBSTITUTED BENZOXAZOLE/BENZTHIAZOLE-2-THIONES: INTERRELATIONSHIP BETWEEN ANTICONVULSANT ACTIVITY AND INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND MONOAMINE OXIDASE. 183601 03-03

ADENOSINE

THE ROLE OF CYCLIC 3,5 ADENOSINE MONOPHOSPHATE IN NEUROMUSCULAR TRANSMISSION. 170660 01-13

TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER). 170876 01-03

CYCLIC ADENOSINE MONOPHOSPHATE: SELECTIVE INCREASE IN CAUDATE NUCLEUS AFTER ADMINISTRATION OF L-DOPA. 176254 02-13

NEUROCHEMICAL ROLE OF ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AND GUANOSINE 3,5 CYCLIC MONOPHOSPHATE AND THEIR RELATION TO NEUROTRANSMITTERS; EFFECT OF TETRAHYDROCANNABINOLS. (PH.D. DISSERTATION). 185582 03-03

IN VIVO CHANGES OF CEREBRAL CYCLIC ADENOSINE 3,5 MONOPHOSPHATE INDUCED BY BIOGENIC AMINES: ASSOCIATION WITH PHOSPHORYLASE ACTIVATION. 188291 04-03

ADENOSINE ACTION ON SYNAPTIC TRANSMISSION IN BRAIN SLICES. 191945 04-03

ADENYL

EFFECTS OF CENTRALLY ACTING DRUGS ON ADENYL CYCLASE ACTIVITY AND CYCLIC AMP LEVELS OF MOUSE BRAIN. (PH.D. DISSERTATION). 172019 01-03

EFFECTS OF SELECTED CENTRALLY ACTING AGENTS ON ADENYL CYCLASE ACTIVITY IN MOUSE BRAIN. 182153 02-03

EFFECTS OF DOPAMINE-LIKE DRUGS ON RAT STRIATAL ADENYL CYCLASE HAVE IMPLICATIONS FOR CNS DOPAMINE RECEPTOR TOPOGRAPHY. 190545 04-03

ADENYLATE

DOPAMINE IN THE MESOLIMBIC SYSTEM OF THE RAT BRAIN: ENDOGENOUS LEVELS AND THE EFFECTS OF DRUGS ON THE UPTAKE MECHANISM AND STIMULATION OF ADENYLATE CYCLASE ACTIVITY. 177131 02-03

NOREPINEPHRINE SENSITIVE ADENYLATE CYCLASES IN RAT BRAIN: RELATION TO BEHAVIOR AND TYROSINE HYDROXYLASE. 177252 02-03

EFFECT OF CHLORPROMAZINE AND SOME OF ITS METABOLITES ON THE DOPAMINE SENSITIVE ADENYLATE CYCLASE OF RAT BRAIN STRIATUM. 180060 02-03

A ROLE FOR NICOTINIC RECEPTORS IN THE REGULATION OF THE ADENYLATE CYCLASE OF ADRENAL MEDULLA. 186675 03-03

THE EFFECT OF LITHIUM ON HORMONE SENSITIVE ADENYLATE CYCLASE FROM VARIOUS REGIONS OF THE RAT BRAIN. 187110 03-03

STIMULATION OF A DOPAMINE SENSITIVE ADENYLATE CYCLASE IN HOMOGENATES OF RAT STRIATUM BY A METABOLITE OF PIRIBEDIL (ET-495). 189616 04-03

EFFECT OF CHRONIC TREATMENT WITH DESIPRAMINE (DMI) AND IPRINDOLE (IP) ON THE NOREPINEPHRINE (NE) SENSITIVE ADENYLATE CYCLASE SYSTEM IN SLICES OF THE RAT LIMBIC FOREBRAIN.
192003 04-03

ADJUNCT

AMPHETAMINES: VALUABLE ADJUNCT IN TREATMENT OF PARKINSONISM.
169220 01-11

ADJUSTMENT

TREATMENT EFFECTS ON THE SOCIAL ADJUSTMENT OF DEPRESSED PATIENTS.
185322 03-10

ADMINISTERED

ANIMAL MODELS FOR AN ENZYMIC BLOOD-BRAIN BARRIER MECHANISM FOR THERAPEUTICALLY ADMINISTERED L-DOPA.
167359 01-03

THE EFFECTS OF MESCALINE ADMINISTERED BEFORE OR DURING EMBRYOGENESIS UPON THE HATCHABILITY AND BEHAVIOR OF THE CHICK. (PH.D. DISSERTATION).
173791 01-04

A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY IN MAN OF INTRAVENOUSLY ADMINISTERED DELTA9-TETRAHYDROCANNABINOL, CANNABINOL, AND CANNABIDIOL.
176747 02-03

BEHAVIOURAL EFFECTS OF YOHIMBINE ADMINISTERED INTRAVENTRICULARLY IN THE RAT.
177721 02-04

INTERACTION OF CENTRALLY ADMINISTERED OUABAIN WITH AGENTS AFFECTING SYMPATHETIC FUNCTION.
178640 02-03

THE EFFECTS OF INTRAVENTRICULARLY ADMINISTERED CATECHOLAMINES AND SEROTONIN ON THE RESERPINE INDUCED SPIKE WAVES RECORDED FROM THE MEDICAL NUCLEUS TRAPEZOIDES IN THE RABBIT.
182094 02-03

COMPARISON OF INTRAVENOUSLY ADMINISTERED METHADONE (ME), MORPHINE (MO), HEROIN (H) AND PLACEBO (P).
182163 02-03

EFFECTS OF CHRONICALLY ADMINISTERED DELTA1-TETRAHYDROCANNABINOL OF ADRENAL AND GONADAL ACTIVITY OF MALE RATS.
183358 03-03

THE EFFECT OF PAIN RELIEVING DRUGS ADMINISTERED DURING LABOR AND DELIVERY ON THE BEHAVIOR OF THE NEWBORN: A REVIEW.
183706 03-17

THE EFFECT OF ORALLY ADMINISTERED COCAINE ON SLEEP OF DEPRESSED PATIENTS.
187642 04-14

EFFECTS OF ALPHA-METHYLTYROSINE ON D-AMPHETAMINE INDUCED RELEASE OF ENDOGENOUSLY SYNTHESIZED AND EXOGENOUSLY ADMINISTERED CATECHOLAMINES FROM THE CAT BRAIN IN VIVO.
189397 04-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) ADMINISTERED SUBCUTANEOUSLY TO RABBITS FOR 28 DAYS.
191965 04-03

CHROMOSOME EXAMINATIONS AFTER MEDICALLY ADMINISTERED LYSERGIC ACID DIETHYLAMIDE AND DEXTROAMPHETAMINE.
192084 04-15

ADMINISTRATION

EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF CANNABIS-SATIVA EXTRACT ON THE MOUSE-KILLING BEHAVIOR OF RATS.
167362 01-04

EFFECT OF PRENATAL MATERNAL ADMINISTRATION OF D-AMPHETAMINE ON RAT OFFSPRING ACTIVITY AND PASSIVE AVOIDANCE LEARNING.
167415 01-03

A CONTROLLED STUDY OF SINGLE DOSE ADMINISTRATION OF IMIPRAMINE PAMOATE IN ENDOGENOUS DEPRESSION.
167775 01-09

GROWTH HORMONE RESPONSES TO ADMINISTRATION OF L-5-HYDROXYTRYPTOPHAN (L-5-HTP) IN MANIC-DEPRESSIVE PSYCHOSES.
167919 01-09

PSYCHOLOGICAL AND PHYSIOLOGICAL EFFECTS OF CHRONIC MARIJUANA ADMINISTRATION IN MAN.
169070 01-13

BLOOD LEVEL PROFILE IN MAN FOLLOWING CHRONIC ORAL ADMINISTRATION OF FLURAZEPAM HYDROCHLORIDE.
169817 01-13

PHARMACOKINETIC PROFILE OF DIAZEPAM IN MAN FOLLOWING SINGLE INTRAVENOUS AND ORAL AND CHRONIC ORAL ADMINISTRATION.
170838 01-13

INTERRESPONSE TIME CHANGES AS A FUNCTION OF DEPRIVATION AND AMPHETAMINE ADMINISTRATION.
171612 01-04

ALTERATION OF MATERNAL BEHAVIOR IN MICE FOLLOWING ADMINISTRATION OF CYPROTERONE ACETATE.
172374 01-04

QUANTITATIVE HISTOCHEMICAL STUDIES OF STRIATAL DOPAMINE DEPLETION FOLLOWING DL-ALPHA-METHYL-P-TYROSINE ADMINISTRATION.
172924 01-03

DMT ADMINISTRATION TO HUMAN SUBJECTS. (UNPUBLISHED PAPER).
173522 01-12

ELECTROENCEPHALOGRAPHIC MODIFICATIONS DURING ADMINISTRATION OF LITHIUM.
174566 01-09

DELIRIOUS SYNDROME AFTER THE ADMINISTRATION OF HALOPERIDOL.
174784 01-15

RELATIONSHIP BETWEEN RESPONSE TO LOW PENTAMETHYLENETETRAZOL ADMINISTRATION AND PERSONALITY OF JUVENILE OFFENDERS AND THEIR REPEATED CRIMES.
175072 02-17

SHORT-TERM AND LONG-TERM LITHIUM ADMINISTRATION: EFFECTS ON THE BRAINS SEROTONERGIC BIOSYNTHETIC SYSTEMS.
175149 02-13

EFFECTS OF INTRAPERITONEAL AND INTRAVENTRICULAR D-AMPHETAMINE ADMINISTRATION ON ACTIVE AVOIDANCE PERFORMANCE IN THE RAT.
175242 02-04

BLOCKADE OF THE PROESTROUS LH SURGE IN CYCLIC RATS BY BARBITURATE ADMINISTRATION ON DIESTRUS.
175650 02-03

EFFECTS OF STIMULUS ASSOCIATED WITH AMOBARBITAL ADMINISTRATION ON AVOIDANCE BEHAVIOR.
175877 02-04

CYCLIC ADENOSINE MONOPHOSPHATE: SELECTIVE INCREASE IN CAUDATE NUCLEUS AFTER ADMINISTRATION OF L-DOPA.
176254 02-13

EFFECT OF CHRONIC ADMINISTRATION OF L-DOPA ON CATECHOL-O-METHYLTRANSFERASE IN RAT TISSUES.
176936 02-03

SUBACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MALE AND FEMALE RATS: ORAL ADMINISTRATION FOR ONE MONTH.
177097 02-05

ADRENALINE, NORADRENALINE AND DOPAMINE LEVELS IN BRAIN AND HEART AFTER ADMINISTRATION OF 6-HYDROXYDOPAMINE AND GUANETHIDINE TO NEWBORN MICE.
177338 02-03

EFFECTS OF OVERTRAINING AND PRETRIAL ADMINISTRATION OF DEXTROAMPHETAMINE ON REVERSAL LEARNING IN RATS.
177533 02-04

EFFECT OF ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL ON MEMORY, SPEECH, AND PERCEPTION OF THERMAL STIMULATION: RESULTS WITH FOUR NORMAL HUMAN VOLUNTEER SUBJECTS. PRELIMINARY REPORT.
177674 02-14

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: IV. THE EFFECTS OF CHLORPROMAZINE.
177716 02-14

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: V. THE EFFECTS OF CHLORAL HYDRATE.
177717 02-14

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: VI. THE EFFECTS OF CHLORDIAZEPOXIDE.
177718 02-14

THE EFFECT OF PROBENECID AND LARGE DOSE AMPHETAMINE ADMINISTRATION ON CEREBROSPINAL FLUID HOMOVANILLIC ACID.
177826 02-13

ACUTE LETHALITY FOR MICE FOLLOWING ADMINISTRATION OF CYCLOPHOSPHAMIDE WITH BARBITURATES.
177834 02-05

DREAM REPORTS AFTER RESERPINE ADMINISTRATION IN CHRONIC LOBOTOMIZED SCHIZOPHRENIC PATIENTS.
178187 02-08

THE EFFECTS OF EARLY P-CHLOROPHENYLALANINE ADMINISTRATION AND POSTWEANING HOUSING CONDITIONS ON SEROTONIN AND BEHAVIOR IN RATS.
178638 02-04

PENTAZOCINE IN RHESUS MONKEY PLASMA AND BRAIN AFTER PARENTERAL AND ORAL ADMINISTRATION.
178641 02-03

DISSOCIATIVE CHANGE IN ANTIAGGRESSIVE AND MUSCLE RELAXANT ACTIONS OF S-TRIAZOLOBENZODIAZEPINE (D-40TA) BY REPEATED ADMINISTRATION AND PHENOBARBITAL PRETREATMENT, AND ITS RELATION TO METABOLISM.
181654 02-04

STUDIES ON CENTRAL REGULATING MECHANISM OF THE HYPOGLYCEMIA INDUCED BY INTRAVENTRICULAR ADMINISTRATION OF CHLORPROMAZINE.
182093 02-03

EFFECTS OF CONSECUTIVE ADMINISTRATION OF DIAZEPAM AND DOXEPIN ON BOTH APPROACH WITHDRAWAL AND APPROACH AVOIDANCE RESPONSES IN RATS.
182117 02-04

EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF WATER SOLUBLE 1oDELTA9-TETRAHYDROCANNABINOL (W THC) ON WEB-BUILDING OF SPIDERS.
182193 02-04

EEG CHANGES & MOTOR IMPAIRMENT AFTER DISULFIRAM ADMINISTRATION TO CATS.
182248 03-03

EFFECTS OF CHRONIC ADMINISTRATION OF AMPHETAMINE UPON THE CATECHOLAMINE CONTENT OF MOUSE BRAIN.
182255 03-03

A SMALL CONTROLLED STUDY TO DETERMINE THE TIME OF ONSET OF ACTION OF OXYPERTINE AFTER ORAL ADMINISTRATION IN NORMAL SUBJECTS.
182763 03-14

THE INFLUENCE OF CHRONIC ADMINISTRATION OF LITHIUM CARBONATE ON THE BRAIN NOREPINEPHRINE CONTENT IN RATS.
182872 03-03

BEHAVIORAL EFFECTS OF SEPARATE AND COMBINED ADMINISTRATION OF NALOXONE AND D-AMPHETAMINE.
183892 03-04

EFFECT OF CHRONIC METHADONE ADMINISTRATION ON PREGNANT RATS AND THEIR OFFSPRING.
183894 03-03

THE EFFECTS OF ACUTE ADMINISTRATION OF PROPRANOLOL AND PRACTOLOL ON THE UPTAKE, CONTENT, RELEASE AND TURNOVER OF NORADRENALINE IN THE RAT HEART IN VIVO.
184232 03-03

EFFECTS OF NEONATAL STRYCHNINE ADMINISTRATION ON ACTIVE AVOIDANCE IN RATS.
184242 03-04

THE CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES IN THE PLASMA AFTER AN ACUTE AND CHRONIC ADMINISTRATION.
184978 03-13

EFFECTS OF PROLONGED LSD-25 ADMINISTRATION UPON NEURONS OF SPINAL CORD GANGLIA TISSUE CULTURES.
185112 03-03

EFFECTS OF CONCURRENT BEHAVIOR MODIFICATION AND CHLORPROMAZINE ADMINISTRATION IN MENTALLY RETARDED WOMEN. (PH.D. DISSERTATION).
185604 03-14

A COMPARISON OF THE EFFECTS OF CHRONIC ADMINISTRATION OF ETHANOL AND ACETALDEHYDE TO MICE: EVIDENCE FOR A ROLE OF ACETALDEHYDE IN ETHANOL DEPENDENCE.
185992 03-03

PHARMACOLOGY OF NEUROLEPTICS UPON REPEATED ADMINISTRATION.
186368 03-04

ENHANCEMENT OF METHYLPHENIDATE INDUCED STEREOTYPIES BY REPEATED ADMINISTRATION OF NEUROLEPTICS.
186369 03-04

BIOCHEMICAL AND BEHAVIOURAL ALTERATIONS FOLLOWING 5,6 DIHYDROXYTRYPTAMINE ADMINISTRATION INTO BRAIN.
186634 03-04

EVIDENCE FOR A CRITICAL PERIOD FOR POSTNATAL ELEVATION OF BRAIN TYROSINE HYDROXYLASE ACTIVITY RESULTING FROM RESERPINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT.
186695 03-03

THE ADMINISTRATION OF METHIONINE TO CHRONIC SCHIZOPHRENIC PATIENTS: A REVIEW OF TEN STUDIES.
187113 03-08

EFFECTS OF SHORT-TERM ADMINISTRATION OF N-NITROSO COMPOUNDS ON LIVER HISTOLOGY AND PENTOBARBITAL INDUCED SLEEPING TIME IN MICE.
187575 04-04

PERPHENAZINE CONCENTRATIONS IN HUMAN WHOLE BLOOD: A PILOT STUDY DURING ANTIPSYCHOTIC THERAPY USING DIFFERENT ADMINISTRATION FORMS.
187639 04-16

DELTA9-TETRAHYDROCANNABINOL: EFFECTS OF ROUTE OF ADMINISTRATION ON ONSET AND DURATION OF ACTIVITY AND TOLERANCE DEVELOPMENT.
187928 04-03

EFFECT OF PROLONGED CHLORPROMAZINE ADMINISTRATION ON THE SLEEP OF CHRONIC SCHIZOPHRENICS.
188115 04-08

REPEAT ADMINISTRATION OF MARIHUANA SMOKE TO HUMANS.
188120 04-13

EFFECT OF ORAL ADMINISTRATION OF METHADONE ON HEPATIC MICROSOMAL MIXED FUNCTION OXIDASE ACTIVITY IN MICE.
188178 04-03

CLINICAL EXPERIENCES WITH MESORIDAZINE (TPS-23): ITS ADMINISTRATION TO HOSPITALIZED SCHIZOPHRENIC PATIENTS.
188934 04-08

SELECTIVE RESERPINE RESISTANT ACCUMULATION OF CATECHOLAMINES IN CENTRAL DOPAMINE NEURONES AFTER DOPA ADMINISTRATION.
189026 04-03

CRUDE MARIHUANA EXTRACT: EEG AND BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION IN RHESUS MONKEYS.
189516 04-04

EFFECTS OF CHRONIC NICOTINE ADMINISTRATION AND AGE ON VARIOUS NEUROTRANSMITTERS AND ASSOCIATED ENZYMES IN MALE FISCHER 344 RATS.
189597 04-03

CANNABINOIDS: NEUROCHEMICAL ASPECTS AFTER ORAL CHRONIC ADMINISTRATION TO RATS.
189599 04-03

PROPHYLACTIC EFFICACY OF LITHIUM CARBONATE IN MANIC-DEPRESSIVE ILLNESS: REPORT OF THE VETERANS ADMINISTRATION AND NATIONAL INSTITUTE OF MENTAL HEALTH (VA-NIMH) COLLABORATIVE STUDY GROUP.
189735 04-09

CHANGES IN ORIENTING AND HABITUATION IN THE RAT FOLLOWING ADMINISTRATION OF CHLORPROMAZINE.
191211 04-04

EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF CLOZAPINE ON THE METABOLISM OF DOPAMINE AND NORADRENALINE IN THE BRAIN OF THE RAT.
191418 04-03

PHARMACOKINETICS AND DISTRIBUTION PROPERTIES OF PENTOBARBITAL IN HUMANS FOLLOWING ORAL AND INTRAVENOUS ADMINISTRATION.
191444 04-13

RELATIONSHIP OF CATECHOLAMINE NEURAL SYSTEMS TO THE BEHAVIORAL ALTERATIONS PRODUCED BY 6-HYDROXYDOPAMINE ADMINISTRATION INTO BRAIN.
191518 04-03

EFFECT OF PREGESTATIONAL MORPHINE ADMINISTRATION TO MICE ON BEHAVIOR OF THEIR OFFSPRING.
191902 04-04

SUBCELLULAR LOCALIZATION OF H3-DELTA9-TETRAHYDROCANNABINOL IN DOG BRAIN AFTER ACUTE OR CHRONIC ADMINISTRATION.
191970 04-03

EFFECTS OF CHRONIC METHYLPHENIDATE ADMINISTRATION ON LEARNING AND OFFSPRING BEHAVIOR.
192116 04-04

ADMITTED

A DOUBLE-BLIND, COMPARATIVE CLINICAL TRIAL WITH LUDIOMIL (CIBA-34276-BA) AND AMITRIPTYLINE IN NEWLY ADMITTED DEPRESSED PATIENTS.
167774 01-09

SERUM PROLACTIN LEVELS IN NEWLY ADMITTED PSYCHIATRIC PATIENTS.
191506 04-13

ADOLESCENCE

HYPERKINETIC, HYPOSCHOLASTIC BEHAVIOUR AND CHARACTER DISORDERS OF CHILDHOOD AND ADOLESCENCE: DIAGNOSIS AND PHARMACOTHERAPY.
172800 01-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: II. PIMOZIDE IN THE TREATMENT OF BEHAVIOURAL DISORDERS IN CHILDHOOD AND ADOLESCENCE.
183192 03-11

ADOLESCENTS

PIMOZIDE IN THE TREATMENT OF BEHAVIORAL DISORDERS OF HOSPITALIZED ADOLESCENTS.
176109 02-14

ACTION OF OPIPRAMOL (G-33040) IN DEPRESSIVE SYNDROMES IN CHILDREN AND ADOLESCENTS.
182432 03-10

ANTIAGGRESSIVE EFFECT OF LITHIUM SALTS IN MENTALLY RETARDED ADOLESCENTS.
182435 03-11

THE EFFECT OF CHLORPROMAZINE AND AMYTAL SODIUM ON THE CONFORMITY OF ADOLESCENTS UNDER PSYCHIATRIC OBSERVATION.
191776 04-14

ADRENAL

ONTOGENESIS OF CIRCADIAN PITUITARY ADRENAL PERIODICITY IN RATS AFFECTED BY NEONATAL TREATMENT WITH ACTH.
181576 02-03

EFFECTS OF CHRONICALLY ADMINISTERED DELTA1-TETRAHYDROCANNABINOL OF ADRENAL AND GONADAL ACTIVITY OF MALE RATS.
183358 03-03

A ROLE FOR NICOTINIC RECEPTORS IN THE REGULATION OF THE ADENYLATE CYCLASE OF ADRENAL MEDULLA.
186675 03-03

MECHANISM OF ADRENAL CATECHOLAMINE RELEASE BY DIVALENT MERCURY.
189591 04-03

INFLUENCE OF DIFFERENT ANIONS ON TYRAMINE AND AMPHETAMINE UPTAKE BY COW ADRENAL MEDULLA CHROMAFFIN VESICLES.
190907 04-03

ADRENALINE

ADRENALINE, NORADRENALINE AND DOPAMINE LEVELS IN BRAIN AND HEART AFTER ADMINISTRATION OF 6-HYDROXYDOPAMINE AND GUANETHIDINE TO NEWBORN MICE.
177338 02-03

ADRENALS
COMPARISON OF PHARMACOLOGICAL RESPONSES TO NICOTINE AND RELEASE OF CATECHOLAMINES FROM THE ADRENALS IN DOGS AND MONKEYS.
188199 04-03

ADRENERGIC
ELECTROCARDIOGRAPHIC CHANGES IN HYPERTHYROIDISM AFTER ADRENERGIC BLOCKADE WITH RESERPINE AND PROPRANOLOL.
167460 01-13
EFFECT OF SUBSTITUTED TRYPTAMINES ON THE EFFLUX OF NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
168747 01-03
TEMPERATURE DEPENDENT TOXICITY OF ADRENERGIC AGONISTS IN MICE AS A BASIS FOR TREATING D-AMPHETAMINE POISONING.
169688 01-05
TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER).
170876 01-03
OSCILLATORY POTENTIALS OF THE CAT RETINA: EFFECTS OF ADRENERGIC DRUGS.
172916 01-03
EFFECTS OF CHRONIC PRETREATMENT WITH SMALL DOSES OF RESERPINE UPON ADRENERGIC NERVE FUNCTION.
177406 02-03
EFFECT OF ADRENERGIC SUBSTANCES ON OXYGEN CONSUMPTION OF RAT BRAIN TISSUE.
180058 02-03
EFFECTS OF CHOLINOMIMETICS ON ADRENERGIC TRANSMISSION.
182088 02-03
EVIDENCE FOR REDISTRIBUTION OF FILTRATE AMONG NEPHRONS AFTER BETA- ADRENERGIC STIMULATION AND BLOCKADE.
184222 03-03
POSSIBLE PERIPHERAL ADRENERGIC AND CHOLINERGIC MECHANISMS IN PSEUDOCONDITIONING.
186575 03-03
EFFECTS OF LITHIUM ON ADRENERGIC AMINE UPTAKE IN RAT BRAIN SYNAPTOSOMES.
186633 03-03
SPECIFICITY OF BLOCKADE OF THE NICOTINE INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ADRENERGIC NEURONS OF THE GUINEA-PIG HEART BY VARIOUS PHARMACOLOGICAL AGENTS.
186676 03-03
ABSENCE OF DEGENERATION OF ADRENERGIC NEURONS AFTER PROLONGED TREATMENT WITH DEBRISOQUIN.
186677 03-03
INFLUENCE OF ADRENERGIC BLOCKERS AND ANTILIPEMIC AGENTS ON PHARMACODYNAMIC ACTIONS OF MORPHINE IN CARBON TETRACHLORIDE TREATED RATS.
188873 04-03
THE EFFECT OF 5,7 DIHYDROXYTRYPTAMINE ON PERIPHERAL ADRENERGIC NERVES IN THE MOUSE.
188977 04-03
EFFECTS OF ADRENERGIC AGENTS, THEOPHYLLINE AND OTHER DRUGS ON DEXTRAN EDEMA AND HISTAMINE RELEASE IN RATS.
189895 04-03
CHOLINERGIC AND ADRENERGIC BALANCE IN MANIA AND SCHIZOPHRENIA.
191530 04-09
ADRENERGIC AND CHOLINERGIC FACTORS IN EXTRAPYRAMIDAL DISORDERS.
191533 04-11
NEUROPHARMACOLOGICAL ANALYSIS OF CENTRAL ADRENERGIC AND CHOLINERGIC ANTAGONISM OF DELTA9-TETRAHYDROCANNABINOL.
191992 04-03

ADRENOCORTICOL
THE RATE LIMITING CONTROL OF ENZYMES MONOAMINE OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN THE FETUS AND THE ADULT BY ADRENOCORTICOL HORMONES.
178815 02-03

ADRENOMEDULLARY
INCREASED SYNTHESIS OF ADRENOMEDULLARY CATECHOLAMINES INDUCED BY CAFFEINE AND THEOPHYLLINE.
184201 03-03

ADULT
SIMULTANEOUS MASS FRAGMENTOGRAPHIC ASSAY OF NOREPINEPHRINE (NE), EPINEPHRINE (E) AND DOPAMINE (DA) IN RAT SYMPATHETIC GANGLION: EFFECTS OF DEXAMETHASONE IN NEWBORN AND ADULT RATS. (UNPUBLISHED PAPER).
170747 01-03
THE RATE LIMITING CONTROL OF ENZYMES MONOAMINE OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN THE FETUS AND THE ADULT BY ADRENOCORTICOL HORMONES.
178815 02-03
SEIZURE SUSCEPTIBILITY AND AVOIDANCE CONDITIONING IN ADULT RATS TREATED PRENATALLY WITH CHLORPROMAZINE.
184371 03-04
PASSAGE OF TAURINE INTO ADULT MAMMALIAN BRAIN.
191331 04-03
THE EFFECTS OF EARLY SALINE INJECTIONS AND PENTYLENETETRAZOL ON HEBB-WILLIAMS MAZE PERFORMANCE IN THE ADULT RAT.
191378 04-04

ADULTS
THE USE OF PSYCHOACTIVE DRUGS BY ADULTS.
167585 01-17
CENTRAL NERVOUS STIMULANT INDUCED PHYSIOLOGICAL AND PERFORMANCE CHANGES IN ADULTS DURING SUSTAINED PSYCHOMOTOR TRACKING.
179023 02-13

ADVANCED
CLINICAL EXPERIENCE WITH DIAMORPHINE IN ADVANCED MALIGNANT DISEASE.
191606 04-17

ADVANTAGES
A CRITICAL EVALUATION OF THE PRINCIPLES GOVERNING THE ADVANTAGES OF INTRAARTERIAL INFUSIONS.
170112 01-06

ADVERSE
ACUTE ADVERSE REACTIONS TO PSYCHOACTIVE DRUGS, DRUG USAGE, AND PERSONALITY. (UNPUBLISHED PAPER).
167832 01-15
AVOIDANCE OF ADVERSE REACTIONS.
180247 02-15

AFFECTIONS
FEATURES OF THE EFFECT OF SYMPATHOMIMETIC AMINES IN RADIATION AFFECTIONS.
191123 04-05

AFFECTIVE
TRAZODONE IN THE TREATMENT OF AFFECTIVE DISORDERS.
168807 01-11
A COMPARISON OF LITHIUM CARBONATE IN THE PREVENTION OF MANIC AND DEPRESSIVE EPISODES IN RECURRENT AFFECTIVE DISORDER.
169090 01-09
CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS: RECENT STUDIES OF MHPG EXCRETION.
169091 01-13
CHANGES IN SOMATOSENSORY EVOKED POTENTIALS PRODUCED BY DRUGS USED IN THE TREATMENT OF AFFECTIVE DISORDERS.
169092 01-09
A COLLABORATIVE ASSESSMENT OF NOREPINEPHRINE METABOLISM IN AFFECTIVE DISORDERS.
169094 01-09
THE USE OF LITHIUM IN AFFECTIVE DISORDERS, III: A DOUBLE-BLIND STUDY OF PROPHYLAXIS IN BIPOLAR ILLNESS.
169495 01-09
INFLUENCE OF AFFECTIVE STATES AND PSYCHOACTIVE DRUGS ON VERBAL LEARNING AND MEMORY.
169504 01-09
DRUGS AND PSYCHODYNAMIC SHIFTS IN AFFECTIVE ILLNESS. (UNPUBLISHED PAPER).
170079 01-09
BRAIN SEROTONIN, AFFECTIVE ILLNESS AND ANTIDEPRESSANT DRUGS: CEREBROSPINAL FLUID STUDIES WITH PROBENECID. (UNPUBLISHED PAPER).
170084 01-09
L-TRYPTOPHAN IN MANIA: CONTRIBUTION TO A PERMISSIVE HYPOTHESIS OF AFFECTIVE DISORDERS.
171500 01-09
LITHIUM CARBONATE AND SLEEP IN AFFECTIVE DISORDERS: FURTHER CONSIDERATIONS.
171503 01-09
LITHIUM PROPHYLAXIS IN RECURRENT AFFECTIVE ILLNESS.
171926 01-09
LITHIUM PROPHYLAXIS IN AFFECTIVE DISORDERS: AN OPEN TRIAL WITH MATCHED CONTROLS.
172401 01-09
LONG-TERM USE OF LITHIUM CARBONATE IN AFFECTIVE DISORDERS: A CLINICAL EVALUATION.
174778 01-09
LITHIUM DISTRIBUTION BETWEEN CEREBROSPINAL FLUID AND SERUM OF AFFECTIVE PSYCHOTIC PATIENTS TREATED WITH LITHIUM CARBONATE AND ITS CLINICAL RESPONSE.
180301 02-11
CENTRAL DOPAMINE FUNCTION IN AFFECTIVE ILLNESS: EVIDENCE FROM PRECURSORS, ENZYME INHIBITORS AND STUDIES OF CENTRAL DOPAMINE TURNOVER. (UNPUBLISHED PAPER).
181358 02-09
A PSYCHOPHARMACOLOGICAL STUDY OF CATECHOLAMINES IN AFFECTIVE DISORDERS.
184653 03-09
L-TRYPTOPHAN IN AFFECTIVE DISORDERS: INDOLEAMINE CHANGES AND DIFFERENTIAL CLINICAL EFFECTS.
185928 03-09
THE EFFECT OF LITHIUM ON THYROID IODINE RELEASE IN PATIENTS WITH PRIMARY AFFECTIVE DISORDER.
186580 03-09

AFFECTIVE STATE AND THYROTROPIN AND PROLACTIN RESPONSES AFTER REPEATED INJECTIONS OF THYROTROPIN RELEASING HORMONE IN DEPRESSED PATIENTS.
189076 04-09

AFFECTIVE DISORDERS AND CHEMICAL DEPENDENCE: LITHIUM FOR ALCOHOL AND DRUG ADDICTION
189775 04-09

LITHIUM IN TREATMENT AND PREVENTION OF AFFECTIVE DISORDER: A VA-NIMH COLLABORATIVE STUDY.
190381 04-09

REBOUND PHENOMENON IN MANIC PATIENTS FOLLOWING PHYSOSTIGMINE: TOWARDS AN UNDERSTANDING OF AMINERGIC MECHANISMS UNDERLYING AFFECTIVE DISORDERS.
191531 04-09

AFFERENT

THE EFFECT OF DIAZEPAM ON SOME CARDIOVASCULAR AND RESPIRATORY REFLEXES ELICITED BY AFFERENT ABDOMINAL VAGUS STIMULATION.
178945 02-03

EFFECT OF ANTICONVULSANT DRUGS ON THE NUMBER OF AFFERENT STIMULI NEEDED TO CAUSE A HIPPOCAMPAL SEIZURE DISCHARGE.
189608 04-03

5-HYDROXYTRYPTAMINE AND NORADRENALINE IN THE HIPPOCAMPAL REGION: EFFECT OF TRANSECTION OF AFFERENT PATHWAYS ON ENDOGENOUS LEVELS, HIGH AFFINITY UPTAKE AND SOME TRANSMITTER RELATED ENZYMES.
191319 04-03

AFFINITY

STRIATAL TYROSINE HYDROXYLASES WITH HIGH AND LOW AFFINITY FOR TYROSINE: IMPLICATIONS FOR THE MULTIPLE POOL CONCEPT OF CATECHOLAMINES.
167325 01-03

DRUG-INDUCED ACTIVATION OF STRIATAL TYROSINE HYDROXYLASE: CHANGES IN THE AFFINITY FOR PTERIDINE COFACTORS. (UNPUBLISHED PAPER).
173381 01-03

ANTISCHIZOPHRENIC DRUGS AND BRAIN CHOLINERGIC RECEPTORS: AFFINITY FOR MUSCARINIC SITES PREDICTS EXTRAPYRAMIDAL EFFECTS.
188114 04-15

5-HYDROXYTRYPTAMINE AND NORADRENALINE IN THE HIPPOCAMPAL REGION: EFFECT OF TRANSECTION OF AFFERENT PATHWAYS ON ENDOGENOUS LEVELS, HIGH AFFINITY UPTAKE AND SOME TRANSMITTER RELATED ENZYMES.
191319 04-03

AFRODEX

AFRODEX VS. PLACEBO IN THE TREATMENT OF MALE IMPOTENCE: STATISTICAL ANALYSIS OF TWO DOUBLE-BLIND CROSSOVER STUDIES.
181959 02-14

AFTERDISCHARGE

THE ANTAGONISM OF HIPPOCAMPAL AND CORTICAL AFTERDISCHARGE BY SC-13504, A NEW ANTICONVULSANT.
186632 03-03

AFTEREFFECT

EFFECT AND AFTEREFFECT OF DRUGS: ETHICAL CONSIDERATIONS ON THE USE OF PSYCHOTROPIC AGENTS (1).
170847 01-17

THE SPIRAL AFTEREFFECT (SAE) AS A MEASURE OF MOTION SICKNESS SUSCEPTIBILITY AND THE EFFECT ON THE SAE OF AN ANTIMOTION SICKNESS DRUG AND A CENTRAL NERVOUS SYSTEM DEPRESSANT.
172780 01-03

AGE

L-DOPA IN 122 CASES OF PARKINSONS DISEASE AT AGE 70 OR OVER. A COMPARATIVE STUDY WITH A GROUP OF PATIENTS AGED 41 TO 69 YEARS.
168369 01-11

PSYCHOPHARMACOLOGY OF OLD AGE.
169945 01-17

POLYMYALGIA RHEUMATICA IN A GERIATRIC DEPARTMENT: NINE PATIENTS WITH AN AVERAGE AGE OF 83 YEARS.
187236 03-11

EFFECTS OF CHRONIC NICOTINE ADMINISTRATION AND AGE ON VARIOUS NEUROTRANSMITTERS AND ASSOCIATED ENZYMES IN MALE FISCHER 344 RATS.
189597 04-03

AGED

INFLUENCE OF TREATMENT ON SYMPTOMATOLOGY AND CORRELATED ELECTROENCEPHALOGRAPHIC (EEG) CHANGES IN THE AGED.
167336 01-13

L-DOPA IN 122 CASES OF PARKINSONS DISEASE AT AGE 70 OR OVER. A COMPARATIVE STUDY WITH A GROUP OF PATIENTS AGED 41 TO 69 YEARS.
168369 01-11

MEGAVITAMIN TREATMENT, CULTURE AND TRANQUILIZERS, DRUGS FOR THE AGED: PROJECTS OF A CANADIAN GRANT.
170293 01-11

AN ERGOT ALKALOID PREPARATION (HYDERGINE) VERSUS PAPAVERINE IN TREATING COMMON COMPLAINTS OF THE AGED: DOUBLE-BLIND STUDY.
173190 01-11

PSYCHIATRIC PHARMACOLOGY OF THE AGED.
191693 04-17

PHARMACOLOGY OF DEPRESSION IN THE AGED: EVALUATION OF GEROVITAL-H3 AS AN ANTIDEPRESSANT DRUG.
192229 04-09

AGGREGATED

EFFECTS OF PSYCHOTROPIC DRUGS ON METHAMPHETAMINE INDUCED EXCITATIONS IN THE AGGREGATED MICE.
182107 02-04

AGGREGATION

INFLUENCE OF VARIOUS SUBSTANCES WHICH INDUCE AND INHIBIT AGGREGATION ON THE UPTAKE OF DEOXYGLUCOSE BY HUMAN BLOOD PLATELETS.
191770 04-13

AGGRESSION

EFFECT OF LITHIUM ON AGGRESSION, MANIA AND PERMSELECTIVE MEMBRANES.
167448 01-09

EFFECT OF DOPAMINERGIC STIMULATION OR BLOCKADE ON MORPHINE WITHDRAWAL AGGRESSION.
171300 01-04

DELTA9-TETRAHYDROCANNABINOL INDUCED INHIBITION OF PREDATORY AGGRESSION IN THE RAT.
172745 01-04

SELECTIVE BLOCKADE OF APOMORPHINE INDUCED AGGRESSION AND GNAWING FOLLOWING FENFLURAMINE OR RAPHE LESIONS IN THE RAT.
182128 02-04

EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL IN SEVERAL ANIMAL MODELS OF AGGRESSION.
182188 02-04

INHIBITION OF ISOLATION INDUCED AGGRESSION IN THE MOUSE BY ANTICHOLINERGIC COMPOUNDS.
182239 03-04

INHIBITION OF ISOLATION INDUCED AGGRESSION IN MICE BY ANTISEROTONERGIC DRUGS.
182240 03-04

THE NEUROPHARMACOLOGY OF AGGRESSION: A CRITICAL REVIEW.
183615 03-14

DRUG-INDUCED AGGRESSION IN CHICKS: DIFFERENTIAL INVOLVEMENT OF BIOGENIC AMINES.
191977 04-04

AGGRESSIVE

STEREOTYPED AND AGGRESSIVE BEHAVIOR INDUCED BY SUSTAINED HIGH DOSE OF THEOPHYLLINE IN RATS.
177019 02-04

FURTHER ASPECTS OF AGGRESSIVE BEHAVIOR INDUCED BY SUSTAINED HIGH DOSE OF THEOPHYLLINE IN RATS.
177020 02-04

DEXTROAMPHETAMINE AND METHYLPHENIDATE IN THE TREATMENT OF HYPERACTIVE/AGGRESSIVE CHILDREN.
177771 02-14

PREDATION: SEPARATION OF AGGRESSIVE AND HUNGER MOTIVATION BY CONDITIONED AVERSION.
185463 03-04

BRAIN AMINES AND APOMORPHINE-INDUCED INTRASPECIFIC AGGRESSIVE BEHAVIOR IN THE RAT.
186374 03-04

DELTA9-TETRAHYDROCANNABINOL AND AGGRESSIVE BEHAVIOR IN RATS.
189525 04-04

NEUROCHEMICAL ANALYSIS OF AGGRESSIVE - DEFENSIVE BEHAVIOR ELICITED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS AND CENTRAL GRAY MATTER.
191784 04-02

AGGRESSIVENESS

THE EFFECT OF METHAMPHETAMINE ON BRAIN ACH CONSUMPTION AND AGGRESSIVENESS IN MICE STRESSED MILDLY BY LONG-TERM ISOLATION.
182108 02-04

INFLUENCE OF PSYCHOTROPIC DRUGS ON AGGRESSIVENESS EVOKED BY DESTRUCTION OF ISOLATED STRUCTURES OF THE FOREBRAIN.
191788 04-04

AGGRESSIVITY

BEHAVIORAL CHANGES AND AGGRESSIVITY EVOKED BY DRUGS IN MICE.
174604 01-04

AGING

PSYCHOPATHOLOGICAL IMPORTANCE AND THERAPEUTIC EFFECTS OF A COMBINATION OF HYDERGINE AND THIORIDAZINE IN PSYCHIATRIC SYNDROMES IN THE AGING.
168976 01-14

GEROVITAL-H3 IN THE TREATMENT OF THE DEPRESSED AGING PATIENT.
177373 02-11

AGONIST
PARKINSON DISEASE TREATED WITH A SUSPECTED DOPAMINE RECEPTOR AGONIST.
186029 03-11
METHODOLOGY FOR THE EVALUATION OF PENTAZOCINE, PROTOTYPE OF THE NEW MORPHINE AGONIST ANTAGONIST ANALGESICS.
191603 04-16
NALTREXONE AND NALOXONE: AGONIST AND ANTAGONIST EFFECTS ON KEY-PRESS RESPONDING OF PIGEONS MAINTAINED UNDER A MULTIPLE SCHEDULE OF FOOD PRESENTATION.
191926 04-04
DOPAMINE AGONIST INDUCED DISORIENTATION IN A RAT SWIMMING TASK.
192018 04-04

AGONISTIC
THE EFFECTS OF CHLORDIAZEPOXIDE (LIBRIUM) ON THE INTENSITY AND HABITUATION OF AGONISTIC BEHAVIOR IN MALE SIAMESE FIGHTING FISH.
177722 02-04
INHIBITORY EFFECT OF DOXEPIN ON AGONISTIC BEHAVIOUR ELICITED BY HYPOTHALAMIC STIMULATION IN THE CAT.
180044 02-04

AGONISTS
CENTRAL MONOAMINE METABOLISM IN MAN: EFFECT OF PUTATIVE DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS.
169377 01-13
TEMPERATURE DEPENDENT TOXICITY OF ADRENERGIC AGONISTS IN MICE AS A BASIS FOR TREATING D-AMPHETAMINE POISONING.
169688 01-05
PROGRESS REPORT ON THE USE OF THE DOG FOR ASSESSING MORPHINE-LIKE AND NALORPHINE-LIKE AGONISTS AS WELL AS DEPOT PREPARATIONS OF ANTAGONISTS. (UNPUBLISHED PAPER).
176312 02-03
A ROLE FOR THE AMYGDALA IN THE DEVELOPMENT OF THE CATALEPTIC AND STEREOTYPIC ACTIONS OF THE NARCOTIC AGONISTS AND ANTAGONISTS IN THE RAT.
186577 03-03
THE ANTAGONISM BETWEEN CHOLINOMIMETIC AGONISTS AND BETA-ADRENOCEPTOR STIMULANTS: THE DIFFERENTIATION BETWEEN BETWEEN FUNCTIONAL AND METAFFINOID ANTAGONISM.
191420 04-03
BEHAVIORAL EFFECTS OF DIRECT AND INDIRECT ACTING DOPAMINERGIC AGONISTS.
191521 04-04
SUPERSENSITIVITY TO DOPAMINERGIC AGONISTS FOLLOWING WITHDRAWAL OF A CHRONIC DIET CONTAINING HALOPERIDOL OR PIMOZIDE.
192012 04-04

AGRYPNIA
ONE CASE OF AGRYPNIA (4 MONTHS WITHOUT SLEEP) IN A MORVAN DISEASE: FAVORABLE ACTION OF 5-HYDROXYTRYPTOPHAN.
187237 03-14

AID
SERUM DOPAMINE-BETA-HYDROXYLASE: A POSSIBLE AID IN THE EVALUATION OF HYPERTENSION.
191512 04-13

AKATHISIA
IMIPRAMINE WITHDRAWAL: AN AKATHISIA LIKE SYNDROME.
177710 02-15

ALBINO
THE EFFECT OF PSYCHOTROPIC AGENTS ON THE FORMATION OF AVOIDANCE REACTION IN ALBINO RATS DURING ELECTROPAIN STIMULATION OF ANOTHER RAT.
183206 03-04
CONDITIONING OF AMPHETAMINE-INDUCED BEHAVIOUR IN THE ALBINO RAT.
185954 03-04
EFFECTS OF NEUROLEPTIC AGENT ON CENTRAL NERVOUS SYSTEM OF ALBINO RATS.
191613 04-03

ALBUMIN
BINDING OF DIAZOXIDE AND OTHER BENZOTHIADIAZINES TO HUMAN ALBUMIN.
179987 02-13
INFLUENCE OF VARIOUS DRUGS ON THE BINDING OF CHLORPROMAZINE TO ERYTHROCYTES AND ALBUMIN.
181470 02-03
INFLUENCE OF PH ON THE BENZODIAZEPINE HUMAN SERUM ALBUMIN COMPLEX: CIRCULAR DICHROISM STUDIES.
189595 04-13

ALCOHOL
MESORIDAZINE AND CHLORPROMAZINE IN THE TREATMENT OF ALCOHOL WITHDRAWAL SYNDROME.
168314 01-11
PREVENTION OF ALCOHOL WITHDRAWAL SEIZURES: THE ROLES OF DIPHENYLHYDANTOIN AND CHLORDIAZEPOXIDE.
172275 01-11
PSYCHOPHYSIOLOGICAL EFFECTS OF DIAZEPAM (VALIUM) COMBINED WITH A MODERATE DOSE OF ALCOHOL IN MAN.
180699 02-14
L-DOPA AND POTENTIATION OF ALCOHOL ANESTHESIA BY CHLORPROMAZINE.
182091 02-03
CHANGES IN THE NEUROEXCITABILITY OF ALCOHOL DEPENDENT RATS UNDERGOING WITHDRAWAL AS MEASURED BY THE PENTYLENETETRAZOL SEIZURE THRESHOLD.
182348 03-03
ACUTE EFFECTS OF ALCOHOL, DIAZEPAM, THIORIDAZINE, FLUPENTHIXOL AND ATROPINE ON PSYCHOMOTOR PERFORMANCE PROFILES.
184848 03-14
TEMPORAL DISORGANIZATION AND DELUSIONAL-LIKE IDEATION: PROCESSES INDUCED BY HASHISH AND ALCOHOL.
185330 03-14
PROPRANOLOL AND BEHAVIOR OF ALCOHOL ADDICTS AFTER ACUTE ALCOHOL INGESTION.
187257 04-14
THE EFFECT OF MEDAZEPAM AND ALCOHOL ON COGNITIVE AND MOTOR SKILLS USED IN CAR DRIVING.
189408 04-14
EFFECTS OF DIAZEPAM AND CODEINE, ALONE AND IN COMBINATION WITH ALCOHOL, ON SIMULATED DRIVING.
189619 04-14
AFFECTIVE DISORDERS AND CHEMICAL DEPENDENCE: LITHIUM FOR ALCOHOL AND DRUG ADDICTION
189775 04-09
INTERACTION BETWEEN ALCOHOL, MINOR TRANQUILIZERS AND MORPHINE.
191141 04-04
COMPARISON OF CODEINE AND ETHYL ALCOHOL SELF-ADMINISTRATION UNDER A VARIABLE INTERVAL (VI) SCHEDULE IN MONKEYS.
191983 04-04

ALCOHOLIC
EXCRETION OF NOREPINEPHRINE AND DOPAMINE ALCOHOLIC METABOLITES AFTER 6-HYDROXYDOPAMINE.
179986 02-03
DIURETIC ANTIDEPRESSANT COMBINATION IN ALCOHOLIC DEPRESSIVES.
187866 04-11

ALCOHOLICS
RESPONSE TO INCREMENTAL DOSES OF DITRAN IN ABSTINENT ALCOHOLICS AND DRUG USERS.
185875 03-11

ALCOHOLISM
PSYCHOTHERAPEUTICS OF ALCOHOLISM.
172834 01-11
PSYCHOTIC COMPLICATIONS AFTER TETRAETHYLTHIURAMDISULFIDE USED IN THE TREATMENT OF ALCOHOLISM.
175047 02-11
STUDY OF THE USE OF DISULFIRAM IMPLANT IN THE TREATMENT OF ALCOHOLISM.
183030 03-11
DOUBLE-BLIND COMPARISON OF THIOTHIXENE, TRIFLUOPERAZINE, AND PLACEBO IN CHRONIC ALCOHOLISM.
188584 04-11
DRUG MAINTENANCE IN THE OUTPATIENT TREATMENT OF CHRONIC ALCOHOLISM.
189926 04-11

ALCOHOLS
CALCIUM REVERSAL OF NERVE BLOCKADE BY ALCOHOLS, ANESTHETICS, TRANQUILIZERS, AND BARBITURATES.
187802 04-03
THE IMPULSE BLOCKING CONCENTRATIONS OF ANESTHETICS, ALCOHOLS, ANTICONVULSANTS, BARBITURATES, AND NARCOTICS ON PHRENIC AND SCIATIC NERVES.
187803 04-03

ALDEHYDE
PARTIAL PURIFICATION AND CHARACTERIZATION OF NADPH-LINKED ALDEHYDE REDUCTASE FROM MONKEY BRAIN.
175232 02-03

ALDOSTERONE
THE INFLUENCE OF ALDOSTERONE OR METHAMPHETAMINE ON LIVER GLYCOGEN DEPOSITION OF MICE STRESSED BY LONG-TERM ISOLATION.
182105 02-03

ALERTNESS
EFFECTS OF CAFFEINE ON ALERTNESS IN SIMULATED AUTOMOBILE DRIVING.
190743 04-14

ALGORITHMS
SIMPLE ALGORITHMS FOR PREDICTING PSYCHOTROPIC DRUGS ASSIGNED TO PSYCHIATRIC INPATIENTS.
176676 02-17

ALIMENTARY
NORADRENALINE IN THE GUINEA-PIG ALIMENTARY CANAL: REGIONAL DISTRIBUTION AND SENSITIVITY TO DENERVATION AND RESERPINE.
191326 04-03

ALKALI
EFFECTS OF ALKALI METALS ON SPONTANEOUS MOTOR ACTIVITIES OF MICE.
182637 03-02

ALKALOID
AN ERGOT ALKALOID PREPARATION (HYDERGINE) VERSUS PAPAVERINE IN TREATING COMMON COMPLAINTS OF THE AGED: DOUBLE-BLIND STUDY.
173190 01-11

HYPOTHERMIA EVOKED BY A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE ALKALOID.
182130 02-03

IN VIVO INHIBITION OF NEURONAL UPTAKE OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY COCAINE AND BY DESMETHYLIMIPRAMINE (DMI).
182150 02-03

UPTAKE, STORAGE AND RELEASE IN VIVO OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY SYMPATHETIC NERVES OF THE IRIS.
182204 02-03

ALKALOID STUDIES. 9. PREPARATION OF 18-ACYLYOHIMBAN-17-ONES AND THEIR CONVERSION TO NEW HETEROCYCLIC YOHIMBANS.
185033 03-04

FURTHER EVIDENCE FOR A DOPAMINE RECEPTOR STIMULATING ACTION OF AN ERGOT ALKALOID.
188739 04-03

ALKALOIDS
TETRAHYDROISOQUINOLINE ALKALOIDS: IN VIVO METABOLITES OF L-DOPA IN MAN.
168286 01-13

PEYOTE AND RELATED ALKALOIDS XVI: SYNTHESIS OF 3,4,5 TRIMETHOXYPHENYLALANINE, AN AMINO ANALOG OF MESCALINE.
170839 01-06

THE CHEMISTRY OF PEYOTE ALKALOIDS.
192875 04-12

BIOSYNTHESIS OF THE PEYOTE ALKALOIDS.
192876 04-12

CACTUS ALKALOIDS. XIX. CRYSTALLIZATION OF MESCALINE HCL AND 3-METHOXYTYRAMINE HCL FROM TRICHOCEREUS-PACHANOI.
192878 04-01

CACTUS ALKALOIDS. XXII. DOLICHOTHELE SURCULOSA AND OTHER DOLICHOTHELE SPECIES.
192879 04-01

CACTUS ALKALOIDS: XVIII. PHENOLIC BETA-PHENETHYLAMINES FROM MAMMILLARIA-ELONGATA.
192882 04-01

ALKYLAMINE
STIMULATION OF BRAIN AROMATIC ALKYLAMINE N-METHYLTRANSFERASE ACTIVITY BY FAD AND METHYLCOBALAMIN.
180020 02-03

ALLERGIC
OXAZEPAM IN ALLERGIC CONDITIONS.
168923 01-11

ALPHA
MASS FRAGMENTOGRAPHIC ANALYSIS OF HOMOVANILLIC ACID AND ITS HOMOISO ANALOGUE IN CEREBROSPINAL FLUID USING THE ALPHA DIDEUTERO ACID AS INTERNAL STANDARD.
186566 03-16

EVIDENCE FOR A NORADRENERGIC AND DOPAMINERGIC MECHANISM IN THE HYPERACTIVITY PRODUCED BY 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.
190309 04-04

ALPHA-ADRENERGIC
ALPHA-ADRENERGIC RECEPTORS MEDIATE SUPPRESSION OF DRINKING INDUCED BY HYPOTHALAMIC AMPHETAMINE INJECTION.
182216 03-03

ALPHA-ADRENERGIC BLOCKING AGENTS: ANTINOCICEPTIVE ACTIVITY AND ENHANCEMENT OF MORPHINE-INDUCED ANALGESIA.
183895 03-03

TREATMENT OF ANXIETY NEUROSIS BY ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKING AGENTS.
186780 03-10

CENTRAL HYPOTHERMIA BY 2-DEOXY-D-GLUCOSE: ANTAGONISM BY ALPHA-ADRENERGIC ACTIVATION.
188200 04-03

ALPHA-ADRENOCEPTOR
PARADOXICAL THERMOREGULATORY BEHAVIOUR IN RATS INDUCED BY (..) AMPHETAMINE: BLOCKADE BY ALPHA-ADRENOCEPTOR OR DOPAMINE RECEPTOR BLOCKING AGENTS.
183797 03-03

ALPHA-ADRENORECEPTOR
EFFECTS OF CLONIDINE AND SOME ALPHA-ADRENORECEPTOR BLOCKING AGENTS ON AVOIDANCE CONDITIONED REFLEXES IN RATS: THEIR INTERACTIONS AND ANTAGONISM BY ATROPINE.
186576 03-04

ALPHA-BLOCKERS
1-AMINOTETRALINES -- CNS AGENTS AND ALPHA-BLOCKERS.
175762 02-17

ALPHA-L-ACETYLMETHADOL
ALPHA-L-ACETYLMETHADOL AND ITS N-DEMTHYLATED METABOLITES HAVE POTENT OPIATE ACTION IN THE GUINEA-PIG ISOLATED ILEUM.
187130 03-03

ALPHA-METHYL-M-TYRAMINE
INTERACTION OF APOMORPHINE, NEUROLEPTICS AND STIMULANTS WITH ALPHA-METHYL-M-TYRAMINE, A FALSE DOPAMINERGIC TRANSMITTER.
181809 02-03

ALPHA-METHYL-P-TYROSINE
CATALEPSY INDUCED BY ALPHA-METHYL-P-TYROSINE AND D-AMPHETAMINE: THE ROLE OF CATECHOLAMINE METABOLISM.
185750 03-03

EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: I. EFFECT ON THE BEHAVIOURAL CHANGES INDUCED BY RESERPINE, ALPHA-METHYL-P-TYROSINE OR AMPHETAMINE.
186587 03-04

ALPHA-METHYL-P-TYROSINE INHIBITION OF SELF-ADMINISTERED INTRAVENOUS MORPHINE AND ORAL WATER IN RATS.
191940 04-04

ALPHA-METHYL-PARA-TYROSINE
INTERACTIONS IN MAN OF DELTA9-TETRAHYDROCANNABINOL: I. ALPHA-METHYL-PARA-TYROSINE.
174347 01-13

ALPHA-METHYLDOPA
POTENTIATION OF HALOPERIDOL BY ALPHA-METHYLDOPA IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
167343 01-08

EFFECT OF ALPHA-METHYLDOPA ON THE METABOLISM OF DOPAMINE IN THE STRIATUM OF THE RAT.
186694 03-03

THE ACTION OF ALPHA-METHYLDOPA IN THE CERVEAU ISOLE PREPARATION.
187075 03-03

ALPHA-METHYLDOPAMINE
ALPHA-METHYLDOPAMINE DERIVATIVES. SYNTHESIS AND PHARMACOLOGY.
189177 04-02

ALPHA-METHYLTRYPTAMINE
ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN DIMETHYLAMINOPROPYLTHIOCINNAMANILIDE HYDROCHLORIDE), A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN (5-HTP) AND ALPHA-METHYLTRYPTAMINE.
176861 02-04

ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN, A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN AND ALPHA-METHYLTRYPTAMINE.
176873 02-04

ALPHA-METHYLTYROSINE
INHIBITION OF ANTICHOLINERGIC DRUG-INDUCED LOCOMOTOR STIMULATION IN MICE BY ALPHA-METHYLTYROSINE.
177840 02-03

INFLUENCE OF ALPHA-METHYLTYROSINE ON ENHANCEMENT OF SHUTTLEBOX AVOIDANCE BY MARIJUANA AND PENTOBARBITAL.
187572 04-04

EFFECTS OF ALPHA-METHYLTYROSINE ON D-AMPHETAMINE INDUCED RELEASE OF ENDOGENOUSLY SYNTHESIZED AND EXOGENOUSLY ADMINISTERED CATECHOLAMINES FROM THE CAT BRAIN IN VIVO.
189397 04-03

THE EFFECT OF INCREASED GAMMA-AMINOBUTYRIC ACID ON ALPHA-METHYLTYROSINE INDUCED DECREASE IN CATECHOLAMINES IN RAT BRAIN.
191988 04-03

DIFFERENTIAL INCREASE OF BEHAVIORAL AND EXTRAPYRAMIDAL STIMULATING ACTIONS OF NEUROLEPTICS BY ALPHA-METHYLTYROSINE PRETREATMENT IN RATS.
192016 04-04

ALPHA-RECEPTORS
INVOLVEMENT OF ALPHA-RECEPTORS IN CLONIDINE INDUCED INHIBITION OF TRANSMITTER RELEASE FROM CENTRAL MONOAMINE NEURONES.
182345 03-03

ALTERATION
ALTERATION OF MATERNAL BEHAVIOR IN MICE FOLLOWING ADMINISTRATION OF CYPROTERONE ACETATE.
172374 01-04

ALTERATION OF 5-HYDROXYTRYPTAMINE-14C EFFLUX BY NICOTINE IN RAT BRAIN AREA SLICES.
172925 01-03

ALTERATION OF SENSORY AND MOTOR EVOKED RESPONSES BY DIELDRIN.
181818 02-03

AMPHETAMINE-INDUCED ALTERATION OF BIOGENIC AMINES AND SELF-STIMULATION.
182212 03-03

ALTERATION OF ETHANOL-INDUCED CNS DEPRESSION: INEFFECTIVENESS OF DRUGS THAT MODIFY CHOLINERGIC TRANSMISSION.
186375 03-03

ALTERATION OF EVOKED POTENTIALS IN CAUDATE NUCLEUS OF FREELY MOVING RATS BY L-DOPA, RESERPINE, AND PENTOBARBITAL.
187362 04-03

LONG-TERM ALTERATION OF SLEEP-WAKEFULNESS CYCLE DURING CHRONIC PENTOBARBITAL DOSING AND WITHDRAWAL IN CAT.
191952 04-04

ALTERATIONS

P-CHLOROPHENYLALANINE INDUCED ALTERATIONS IN THE BEHAVIORAL EFFECTS OF 5-HYDROXYTRYPTOPHAN.
174034 01-04

THE ONTOGENY OF AMPHETAMINE-INDUCED ALTERATIONS IN THERMAL REGULATION.
182246 03-03

BIOCHEMICAL AND BEHAVIOURAL ALTERATIONS FOLLOWING 5,6 DIHYDROXYTRYPTAMINE ADMINISTRATION INTO BRAIN.
186634 03-04

LIPIDOSIS-LIKE ALTERATIONS IN DORSAL ROOT GANGLION CELLS OF RATS TREATED WITH TRICYCLIC ANTIDEPRESSANTS.
189605 04-03

DOSE-RELATED ALTERATIONS IN METABOLISM OF LEVODOPA: POSSIBLE MECHANISM FOR HYPOTENSIVE EFFECT.
190194 04-11

PERMANENT ALTERATIONS IN 5-HYDROXYTRYPTAMINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN FOLLOWING EXPOSURE TO DRUGS DURING THE PERIOD OF DEVELOPMENT.
191383 04-03

RELATIONSHIP OF CATECHOLAMINE NEURAL SYSTEMS TO THE BEHAVIORAL ALTERATIONS PRODUCED BY 6-HYDROXYDOPAMINE ADMINISTRATION INTO BRAIN.
191518 04-03

EFFECTS OF ALTERATIONS IN IMPULSE FLOW ON TRANSMITTER METABOLISM IN CENTRAL DOPAMINERGIC NEURONS.
191519 04-03

PHARMACOLOGICAL ALTERATIONS IN THE STIMULUS INDUCED RELEASE OF NOREPINEPHRINE FROM THE RABBIT SUPERIOR CERVICAL GANGLION.
191896 04-03

ALTERED

ALTERED NOREPINEPHRINE SYNTHESIS OF SPLANCHNIC VESSELS IN NEUROGENIC HYPERTENSION.
188198 04-03

ALTERING

INTERACTIVE EFFECTS OF CYCLOHEXIMIDE AND PUROMYCIN IN ALTERING BRAIN POLYRIBOSOMES AND NEURAL AND BEHAVIOURAL RESPONSES TO ELECTROSHOCK IN MICE.
175230 02-03

ALTERNATION

EFFECTS OF DELTA9-THC, LSD-25 AND SCOPOLAMINE ON CONTINUOUS, SPONTANEOUS ALTERNATION IN THE Y-MAZE.
171306 01-04

THE EFFECT OF SOME CHOLINOLYTIC DRUGS ON A NUMBER OF BEHAVIOURAL PARAMETERS MEASURED IN THE T-MAZE ALTERNATION TEST: DOSE-RESPONSE RELATIONSHIPS.
187641 04-04

ALTERNATIONS

EKG ALTERNATIONS IN INFUSION TREATMENT WITH TRICYCLIC ANTIDEPRESSIVE DRUGS.
180063 02-15

ALTERNATIVE

A CHEMOTHERAPEUTIC ALTERNATIVE TO THE ANTIANXIETY AGENTS FOR THE EXTENDED TREATMENT OF PSYCHONEUROSIS.
192083 04-10

ALUMINUM

EFFECTS OF ALUMINUM SALTS ON CULTURED NEUROBLASTOMA CELLS.
191313 04-03

AMA

AMA DRUG EVALUATIONS.
191048 04-17

AMANTADINE

AMANTADINE HYDROCHLORIDE IN TREATMENT OF PARKINSONISM.
169461 01-11

HABITUATION OF BLINK REFLEXES IN PARKINSONIAN PATIENTS UNDER LEVODOPA AND AMANTADINE TREATMENT.
171794 01-13

THE EFFECT OF DOPAMINE ANTAGONISTS AND AMANTADINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
174829 01-04

INHIBITION OF THE APOMORPHINE GNAWING COMPULSION BY AMANTADINE.
176879 02-04

CENTRAL NERVOUS SYSTEM AND AUTONOMIC NERVOUS SYSTEM EFFECTS OF AMANTADINE AND OF SOME STANDARD ANTIPARKINSON DRUGS.
177729 02-13

ON THE SPECIFICITY OF DOPAMINE RELEASE BY AMANTADINE.
178557 02-03

AMANTADINE MAY STIMULATE DOPAMINE AND NORADRENALINE RECEPTORS.
183868 03-03

THE EFFECT OF AMANTADINE, L-DOPA, (_) AMPHETAMINE AND APOMORPHINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE.
186636 03-04

COMPARISON OF AMANTADINE, PLACEBO, AND LEVODOPA IN PARKINSONS DISEASE.
189502 04-11

CLINICAL EVALUATION OF AMANTADINE THERAPY FOR PARKINSONISM AND THE SIDE-EFFECTS -- IN CASES OF THALAMIC SURGERY AND L-DOPA THERAPY.
190095 04-11

AMBULANT

CLINICAL ASSAY OF LORAZEPAM WITH AMBULANT PATIENTS.
183201 03-11

AMBULATORY

TRIAL OF OXAZEPAM IN AMBULATORY PSYCHONEUROTICS.
170412 01-11

THE USE OF TIMED RELEASE NEUROLEPTICS IN AMBULATORY PSYCHIATRIC PRACTICE.
172977 01-11

PIPERACETAZINE IN AMBULATORY CHRONIC SCHIZOPHRENIC PATIENTS.
177748 02-08

HIGH DOSAGE PIPERACETAZINE (QUIDE-R) IN AMBULATORY SCHIZOPHRENIC PATIENTS: THERAPEUTIC EFFICACY AND TOXICITY.
187869 04-08

AMENORRHEA

FUNCTIONAL EVALUATION OF PITUITARY RESERVE IN PATIENTS WITH THE AMENORRHEA GALACTORRHEA SYNDROME UTILIZING LUTEINIZING HORMONE RELEASING HORMONE (LH-RH), L-DOPA AND CHLORPROMAZINE.
175245 02-13

AMENORRHOEA

THE EFFECTS OF PHENOTHIAZINES ON ENDOCRINE FUNCTION: I. PATIENTS WITH INAPPROPRIATE LACTATION AND AMENORRHOEA.
184436 03-15

AMINE

EFFECTS OF AMITRIPTYLINE AND IMIPRAMINE ON AMINE METABOLITES IN THE CEREBROSPINAL FLUID OF DEPRESSED PATIENTS.
174094 01-09

BRAIN BIOGENIC AMINE DEPLETION AND MOOD.
174994 02-14

STEREOCHEMICAL ASPECTS IN THE METABOLISM OF THE PSYCHOTOMIMETIC AMINE 1-(2,5 DIMETHOXY-4-METHYLPHENYL)-2 AMPHETAMINE.
175759 02-03

EVIDENCE FOR PERSISTENT RESERPINE BINDING TO AMINE STORAGE VESICLE MEMBRANES.
182234 03-03

PHARMACOLOGICAL ANALYSIS OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE REMOVAL FROM THE PULMONARY CIRCULATION: DIFFERENTIATION OF UPTAKE SITES FOR EACH AMINE.
182717 03-03

THE INHIBITION OF (3H) BIOGENIC AMINE ACCUMULATION INTO RAT BRAIN TISSUE SLICES BY VARIOUS TRYPTAMINE DERIVATIVES.
182723 03-03

EFFECT OF ANTIDEPRESSANT AND ANTIMANIC DRUGS ON AMINE UPTAKE IN MAN.
184654 03-13

PHARMACOLOGICAL DISTINCTIONS BETWEEN ACTIVE AND PASSIVE AVOIDANCE MEMORY FORMATION AS SHOWN BY MANIPULATION OF BIOGENIC AMINE ACTIVE COMPOUNDS.
185927 03-04

EFFECTS OF LITHIUM ON ADRENERGIC AMINE UPTAKE IN RAT BRAIN SYNAPTOSOMES.
186633 03-03

STUDIES OF CEREBROSPINAL FLUID AMINE METABOLITES IN DEPRESSED PATIENTS: CONCEPTUAL PROBLEMS AND THEORETICAL IMPLICATIONS. (UNPUBLISHED PAPER).
187398 04-13

PLASMA AND CEREBROSPINAL FLUID PROBENECID CONCENTRATIONS AS RELATED TO ACCUMULATION OF ACIDIC BIOGENIC AMINE METABOLITES IN MAN.
187933 04-13

CHEMICAL CONVERSION OF THE PSYCHOTOMIMETIC AMINE 1-(2,5 DIMETHOXY-4-METHYLPHENYL) 2-AMINOPROPANE TO 5-HYDROXYDIMETHYLINDOLE.
187941 04-01

THE EFFECT OF HYPOTHERMIC DOSES OF 1-DELTA9-TETRAHYDROCANNABINOL ON BIOGENIC AMINE METABOLISM IN SELECTED PARTS OF THE RAT BRAIN.
188231 04-03

A STUDY OF BIOGENIC AMINE METABOLITES IN THE CEREBROSPINAL FLUID AND URINE OF MONKEYS WITH CHLORPROMAZINE INDUCED DYSKINESIA.
189210 04-03

STEREOCHEMICAL ASPECTS AND METABOLITE FORMATION IN THE IN VIVO METABOLISM OF THE PSYCHOTOMIMETIC AMINE, 1-2,5-(DIMETHOXY-4-METHYLPHENYL) 2 AMINOPROPANE.
190718 04-03

THE USE OF SELECTIVE AND INHIBITOR DRUGS TO MODIFY AMINE METABOLISM IN BRAIN.
191500 04-03
CLINICAL INTIMATIONS OF AMINE BALANCE AND PERMISSION.
191534 04-09

AMINERGIC
REBOUND PHENOMENON IN MANIC PATIENTS FOLLOWING PHYSOSTIGMINE: TOWARDS AN UNDERSTANDING OF AMINERGIC MECHANISMS UNDERLYING AFFECTIVE DISORDERS.
191531 04-09
CHOLINERGIC AMINERGIC INTERACTIONS IN LEAD INDUCED HYPERACTIVITY.
191954 04-05

AMINES
L-DOPA: EFFECT ON ETHANOL NARCOSIS AND BRAIN BIOGENIC AMINES IN MICE.
169782 01-03
EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON ATTACK ELICITED BY HYPOTHALAMIC STIMULATION: RELATION TO BRAIN BIOGENIC AMINES.
170162 01-04
MEASUREMENT OF BIOGENIC AMINES AT THE PICOGRAM LEVEL. (UNPUBLISHED LEVEL).
173382 01-03
SIGNIFICANCE OF THE CENTRAL BIOGENIC AMINES FOR THE THRESHOLD IN ELECTRO AND PENTETRAZOLE SEIZURES.
181469 02-03
BRAIN AMINES IN PYRIDOXINE DEFICIENT RATS.
182171 02-03
AMPHETAMINE-INDUCED ALTERATION OF BIOGENIC AMINES AND SELF-STIMULATION.
182212 03-03
BRAIN AMINES AND APOMORPHINE-INDUCED INTRASPECIFIC AGGRESSIVE BEHAVIOR IN THE RAT.
186374 03-04
THE MONOAMINE OXIDASES OF BRAIN: SELECTIVE INHIBITION WITH DRUGS AND THE CONSEQUENCES FOR THE METABOLISM OF THE BIOGENIC AMINES.
186668 03-03
EFFECTS OF SOME METALLIC CATIONS ON CEREBRAL CORTICAL NEURONES AND THEIR INTERACTIONS WITH BIOGENIC AMINES.
187806 04-03
IN VIVO CHANGES OF CEREBRAL CYCLIC ADENOSINE 3,5 MONOPHOSPHATE INDUCED BY BIOGENIC AMINES: ASSOCIATION WITH PHOSPHORYLASE ACTIVATION.
188291 04-03
INTRACEREBRAL INJECTION OF 6-HYDROXYDOPAMINE AND HYDROGEN PEROXIDE IN CATS: SPECIFIC AND NONSPECIFIC EFFECTS ON STRIATAL BIOGENIC AMINES.
188426 04-03
EFFECT OF A BUTYROPHENONE DERIVATIVE, U-32802A, ON BRAIN BIOGENIC AMINES.
189584 04-02
FEATURES OF THE EFFECT OF SYMPATHOMIMETIC AMINES IN RADIATION AFFECTIONS.
191123 04-05
DRUG-INDUCED AGGRESSION IN CHICKS: DIFFERENTIAL INVOLVEMENT OF BIOGENIC AMINES.
191977 04-04

AMINO
PEYOTE AND RELATED ALKALOIDS XVI: SYNTHESIS OF 3,4,5 TRIMETHOXYPHENYLALANINE, AN AMINO ANALOG OF MESCALINE.
170839 01-06
BRAIN AMINO ACIDS DURING CONVULSIONS.
177135 02-03
ACTION OF CONVULSANTS ON ROOT POTENTIALS AND AMINO ACID RESPONSES IN ISOLATED FROG SPINAL CORD. (UNPUBLISHED PAPER).
177976 02-03
EFFECTS OF CHLORPROMAZINE AND ACTINOMYCIN D ON UPTAKE AND INCORPORATION OF CERTAIN AMINO ACIDS, HYPOXANTHINE AND THYMIDINE IN CULTURES OF HUMAN SKIN EPITHELIAL CELLS.
179989 02-13
THE EFFECTS OF CHRONIC RESERPINE AND NIALAMIDE TREATMENT ON THE FREE AMINO ACID LEVELS OF RAT BRAIN.
187645 04-03
POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES: 1. MODIFICATION OF THE AMINO ACID PORTION OF S-ADENOSYLHOMOCYSTEINE.
190716 04-01
STUDIES ON CONVULSANTS IN THE ISOLATED FROG SPINAL CORD. I. ANTAGONISM OF AMINO ACID RESPONSES. (UNPUBLISHED PAPER)
190727 04-03
DIAZEPAM, CYCLIC NUCLEOTIDES AND AMINO ACID NEUROTRANSMITTERS IN RAT CEREBELLUM. (UNPUBLISHED PAPER).
191764 04-03

AMINOACYL
MESCALINE INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON THE BINDING OF AMINOACYL TRANSFER RIBONUCLEIC ACID TO RIBOSOMES OF BRAIN TISSUE.
189582 04-05

AMINOINDANS
DISCRIMINANT ANALYSIS OF THE RELATIONSHIP BETWEEN PHYSICAL PROPERTIES AND THE INHIBITION OF MONOAMINE OXIDASE BY AMINOTETRALINS AND AMINOINDANS.
180096 02-03

AMINOPROPANE
STEREOCHEMICAL ASPECTS AND METABOLITE FORMATION IN THE IN VIVO METABOLISM OF THE PSYCHOTOMIMETIC AMINE, 1-2,5-(DIMETHOXY-4-METHYLPHENYL) 2 AMINOPROPANE.
190718 04-03

AMINOTETRALINS
DISCRIMINANT ANALYSIS OF THE RELATIONSHIP BETWEEN PHYSICAL PROPERTIES AND THE INHIBITION OF MONOAMINE OXIDASE BY AMINOTETRALINS AND AMINOINDANS.
180096 02-03

AMITRIPTYLINE
A DOUBLE-BLIND, COMPARATIVE CLINICAL TRIAL WITH LUDIOMIL (CIBA-34276-BA) AND AMITRIPTYLINE IN NEWLY ADMITTED DEPRESSED PATIENTS.
167774 01-09
CHLORDIAZEPOXIDE IN DEPRESSIVE NEUROSIS: AN OPEN LABEL CROSSOVER STUDY WITH AMITRIPTYLINE.
168316 01-10
AMITRIPTYLINE IN ANXIOUS DEPRESSED OUTPATIENTS: A CONTROLLED STUDY.
172993 01-10
EFFECTS OF AMITRIPTYLINE AND IMIPRAMINE ON AMINE METABOLITES IN THE CEREBROSPINAL FLUID OF DEPRESSED PATIENTS.
174094 01-09
GENERAL PRACTITIONER CLINICAL TRIALS. A LONG-ACTING AMITRIPTYLINE PREPARATION.
175583 02-09
QUALITATIVE AND QUANTITATIVE STUDIES ON THE DISPOSITION OF AMITRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANT DRUGS IN MAN AS IT RELATES TO THE MANAGEMENT OF THE OVERDOSED PATIENT.
177395 02-15
A DOUBLE-BLIND CONTROLLED STUDY COMPARING PROTRIPTYLINE AND AMITRIPTYLINE.
177567 02-09
AMITRIPTYLINE IN MAN: DECREASED FORMATION OF CENTRAL 5-HYDROXYINDOLEACETIC ACID.
177736 02-13
DOXEPIN AND AMITRIPTYLINE CHLORDIAZEPOXIDE COMBINATION IN NEUROTIC STATES: A COMPARATIVE DOUBLE-BLIND STUDY.
180048 02-10
CLOMIPRAMINE AND AMITRIPTYLINE IN DEPRESSED OUTPATIENTS: A CONTROLLED STUDY.
185747 03-09
TRYPTOPHAN AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIONS.
187536 04-09
AMITRIPTYLINE IN THE PSYCHOTIC STATES OF DOWNS SYNDROME: THE COMPARISON OF TWO CASES.
191192 04-11
A CONTROLLED TRIAL OF MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE IN GENERAL PRACTICE.
192510 04-09
TRIAL OF SUSTAINED RELEASE AMITRIPTYLINE ON ENURESIS.
192589 04-11

AMIZYL
CHANGES IN SHORT-TERM AND LONG-TERM MEMORY OF DOGS AND CATS UNDER THE EFFECTS OF AMIZYL (BENACTYZINE).
183517 03-04

AMNESIA
RETROGRADE AMNESIA FROM HYPOTHERMIA INDUCED BRAIN SEIZURES.
167398 01-04
RECOVERY FROM ELECTROCONVULSIVE SHOCK-INDUCED AMNESIA BY EXPOSURE TO THE TRAINING ENVIRONMENT: PHARMACOLOGICAL ENHANCEMENT BY PIRACETAM.
186704 03-04

AMOBARBITAL
EFFECTS OF STIMULUS ASSOCIATED WITH AMOBARBITAL ADMINISTRATION ON AVOIDANCE BEHAVIOR.
175877 02-04
GENERALIZED PENICILLIN EPILEPSY IN THE CAT: EFFECTS OF INTRACAROTID AND INTRAVERTEBRAL PENTYLENETETRAZOL AND AMOBARBITAL INJECTIONS.
188374 04-03

AMOXAPINE
AMOXAPINE AND IMIPRAMINE: A DOUBLE-BLIND STUDY IN DEPRESSED PATIENTS.
174138 01-09

AMP

EFFECT OF ETHANOL ON CYCLIC AMP LEVELS IN THE RAT BRAIN.
167326 01-03

EFFECTS OF CENTRALLY ACTING DRUGS ON ADENYL CYCLASE ACTIVITY AND CYCLIC AMP LEVELS OF MOUSE BRAIN. (PH.D. DISSERTATION).
172019 01-03

EFFECTS OF NEUROLEPTICS AND THYMOLEPTICS ON PHOSPHODIESTERASE ACTIVITY AND ON CYCLIC 3,5 AMP LEVELS IN RAT BRAIN.
181467 02-03

A CENTRAL EFFECT OF LOCAL ANESTHETICS: PREVENTION AGAINST THE ACCUMULATION OF CYCLIC AMP IN BRAIN SLICES.
182099 02-03

EFFECTS OF DECAPITATION, ETHER AND PENTOBARBITAL ON CYCLIC AMP AND CYCLIC GMP LEVELS IN RAT TISSUES.
182154 02-03

INTERACTION OF CYCLIC AMP WITH NEUROPHARMACOLOGIC DEPRESSANT AGENTS.
182155 02-03

THE EFFECT OF DOPAMINE RECEPTOR STIMULATING AGENTS AND OF N,O DIBUTYRYL CYCLIC AMP ON C14-DOPAMINE SYNTHESIS IN STRIATAL SLICES OF RATS.
182256 03-03

NOREPINEPHRINE -- AN ANTAGONIST OF DIBUTYRYL CYCLIC AMP IN THE REGULATION OF NARCOSIS IN THE RAT.
183789 03-03

BETA-ADRENERGIC EFFECTS ON RAT MYOMETRIUM: ROLE OF CYCLIC AMP.
188915 04-03

AMPHETAMINE

AVERAGE EVOKED RESPONSES IN NORMAL AND MINIMALLY BRAIN DYSFUNCTIONED CHILDREN TREATED WITH AMPHETAMINE: A PRELIMINARY REPORT.
169861 01-11

THE ACTIVITY OF SOME NEUROLEPTIC DRUGS AND AMPHETAMINE IN NORMAL AND ISOLATED RATS.
170126 01-04

TOLERANCE AND CROSS-TOLERANCE TO THE ANOREXIGENIC EFFECT OF SOME AMPHETAMINE DERIVATIVES IN RATS.
171602 01-03

STUDY INTO THE MECHANISM OF THE ANORECTIC ACTION OF AMPHETAMINE AND ITS P-CHLORO ANALOGUE.
171610 01-03

INTERRESPONSE TIME CHANGES AS A FUNCTION OF DEPRIVATION AND AMPHETAMINE ADMINISTRATION.
171612 01-04

A DIFFERENTIAL INHIBITORY ACTION OF LSD AND AMPHETAMINE ON COPULATORY BEHAVIOR IN THE FEMALE RAT.
171617 01-04

AMPHETAMINE USE AND MISUSE WITH RECOMMENDATIONS FOR STIMULANT CONTROL POLICY.
172109 01-17

ON THE MECHANISM OF CENTRAL ACTION OF AMPHETAMINE: THE ROLE OF CATECHOLAMINES.
172921 01-04

MODIFICATION OF STIMULATION BOUND BEHAVIOR BY TRIFLUOPERAZINE AND AMPHETAMINE IN RATS. (PH.D. DISSERTATION).
173158 01-04

AN ANALYSIS OF TOLERANCE TO THE ANOREXIGENIC EFFECTS OF AMPHETAMINE. (PH.D. DISSERTATION).
173775 01-03

DRINKING BEHAVIOUR AND BRAIN DOPAMINE: ANTAGONISTIC EFFECT OF TWO NEUROLEPTIC DRUGS (PIMOZIDE AND SPIRAMIDE) UPON AMPHETAMINE OR APOMORPHINE-INDUCED HYPODIPSIA.
174035 01-04

THE EFFECTS OF AMPHETAMINE, 2-AMINOINDANE AND 2-AMINOTETRALIN ON THE CONCENTRATIONS OF WHOLE BRAIN NORADRENALINE, DOPAMINE, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC ACID IN THE MOUSE.
174828 01-03

EFFECTS OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES ON CENTRAL NORADRENERGIC MECHANISMS. (PH.D. DISSERTATION).
174959 01-03

AMPHETAMINE TRICYCLIC INTERACTIONS: ROLE OF THE HYDROXYLATION OF AMPHETAMINE IN ITS CENTRAL AND PERIPHERAL MODE OF ACTION. (PH.D. DISSERTATION).
174963 01-03

STEREOCHEMICAL ASPECTS IN THE METABOLISM OF THE PSYCHOTOMIMETIC AMINE 1-(2,5 DIMETHOXY-4-METHYLPHENYL)-2 AMPHETAMINE.
175759 02-03

EFFECTS OF AMPHETAMINE (A), LSD, PSILOCYBIN (P), AND DOM ON SCHEDULE-CONTROLLED BEHAVIOR IN THE RAT.
176869 02-04

INABILITY OF RAT BRAIN HOMOGENATE TO OXIDIZE AMPHETAMINE.
177334 02-03

AMPHETAMINE IN HUMAN PLASMA: A SENSITIVE AND SPECIFIC ENZYMATIC ASSAY.
177403 02-16

THE THALAMIC RAT: GENERAL BEHAVIOR, OPERANT LEARNING WITH REWARDING HYPOTHALAMIC STIMULATION, AND EFFECTS OF AMPHETAMINE.
177477 02-04

THE EFFECT OF PROBENECID AND LARGE DOSE AMPHETAMINE ADMINISTRATION ON CEREBROSPINAL FLUID HOMOVANILLIC ACID.
177826 02-13

EFFECT OF CHRONIC INTOXICATION WITH (_) AMPHETAMINE ON ITS CONCENTRATION IN LIVER AND BRAIN AND ON (14C) LEUCINE INCORPORATION INTO MICROSOMAL AND CYTOPLASMIC PROTEINS OF RAT LIVER.
180056 02-05

STEREOTYPY WITH SELECTIVE STIMULATION OF CERTAIN ITEMS OF BEHAVIOUR OBSERVED IN AMPHETAMINE TREATED MONKEYS (CERCOPITHECUS).
180061 02-04

RELATIVE IMPORTANCE OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS FOR THE STIMULATION OF LOCOMOTOR ACTIVITY INDUCED BY AMPHETAMINE AND OTHER DRUGS.
182209 02-04

ALPHA-ADRENERGIC RECEPTORS MEDIATE SUPPRESSION OF DRINKING INDUCED BY HYPOTHALAMIC AMPHETAMINE INJECTION.
182216 03-03

EFFECTS OF AMPHETAMINE ISOMERS ON NEUROMUSCULAR TRANSMISSION IN RAT PHRENIC NERVE DIAPHRAGM PREPARATION.
182232 03-03

AMPHETAMINE AND PENTOBARBITAL EFFECTS ON THE DISCRIMINATIVE RESPONSE CONTROL BY DEPRIVATION OF RAPID EYE MOVEMENT SLEEP (REM).
182245 03-03

EFFECTS OF CHRONIC ADMINISTRATION OF AMPHETAMINE UPON THE CATECHOLAMINE CONTENT OF MOUSE BRAIN.
182255 03-03

PARADOXICAL THERMOREGULATORY BEHAVIOUR IN RATS INDUCED BY (_) AMPHETAMINE: BLOCKADE BY ALPHA-ADRENOCEPTOR OR DOPAMINE RECEPTOR BLOCKING AGENTS.
183797 03-03

AMPHETAMINE AND THERMOREGULATION: STUDIES IN THE UNRESTRAINED AND CURARIZED RAT.
184227 03-03

IN VIVO RELEASE OF NEWLY SYNTHESIZED CATECHOLAMINES FROM THE HYPOTHALAMUS BY AMPHETAMINE.
184230 03-03

EFFECTS OF AMPHETAMINE ON ELECTROSHOCK RESPONSES IN DEVELOPING RATS.
184372 03-03

BRAIN MECHANISMS UNDERLYING THE EFFECTS OF AMPHETAMINE ON FEEDING AND NONFEEDING BEHAVIORS: DISSOCIATION AND OVERLAP.
184839 03-03

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: IV. INFLUENCE OF AMPHETAMINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
185961 03-04

MODULATION OF REWARD AND AVERSION PROCESSES IN THE RAT DIENCEPHALON BY AMPHETAMINE.
186164 03-04

JOINT EFFECTS OF SODIUM AMYLOBARBITONE AND AMPHETAMINE SULPHATE ON RESISTANCE TO EXTINCTION OF A REWARDED RUNNING RESPONSE IN THE RAT.
186573 03-04

ROLE OF CATECHOLAMINES IN THE ANORECTIC EFFECTS OF AMPHETAMINE IN RATS.
186582 03-03

EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: I. EFFECT ON THE BEHAVIOURAL CHANGES INDUCED BY RESERPINE, ALPHA-METHYL-P-TYROSINE OR AMPHETAMINE.
186587 03-04

THE EFFECT OF AMANTADINE, L-DOPA, (_) AMPHETAMINE AND APOMORPHINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE.
186636 03-04

A COMPARISON OF THE EFFECTS OF AMPHETAMINE AND ITS METABOLITES, P-HYDROXYAMPHETAMINE AND P-HYDROXYNOREPHEDRINE, ON UPTAKE, RELEASE AND CATABOLISM OF 3H-NOREPINEPHRINE IN CEREBRAL CORTEX OF RAT BRAIN.
186669 03-03

COCAINE, PEMOLINE AND AMPHETAMINE ON LEARNING AND RETENTION OF A DISCRIMINATION TEST IN MICE.
186705 03-04

DOES LITHIUM BLOCK THE EFFECTS OF AMPHETAMINE? A REPORT OF THREE CASES.
186745 03-13

BEHAVIOR AND EEG ANALYSIS OF CHRONIC AMPHETAMINE EFFECT.
187116 03-13

CARDIOVASCULAR AND GROSS BEHAVIORAL EFFECTS OF AMPHETAMINE, 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPROPANE (DOM) AND 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPHENYL BUTANE (BL-3912A) IN THE CONSCIOUS DOG.
187573 04-03

BEHAVIORAL EFFECTS OF AMPHETAMINE IN RATS WITH LESIONS IN THE CORPUS-STRIATUM.
187698 04-04

AMPHETAMINE AND OPERANT BEHAVIOR IN RATS: RELATIONSHIP BETWEEN DRUG EFFECT AND CONTROL RESPONSE RATE.
187699 04-04

COMPARATIVE EFFECTS OF SCOPOLAMINE AND AMPHETAMINE UPON BEHAVIORAL REACTIVITY AND VISUAL EVOKED POTENTIALS TO FLASHES IN RATS.
187700 04-04

THE EFFECTS OF CHLORDIAZEPOXIDE, AMPHETAMINE AND COCAINE ON BAR-PRESS BEHAVIOR IN NORMAL AND GENETICALLY NERVOUS DOGS.
187868 04-04

AN INVESTIGATION OF THE BEHAVIOURAL NATURE OF THE PSYCHOMOTOR STIMULANT EFFECT OF AMPHETAMINE.
188620 04-04

INTERACTION OF LOW-DOSE AMPHETAMINE USE WITH SCHIZOPHRENIA IN OUTPATIENTS: THREE CASE REPORTS.
189099 04-15

ENHANCEMENT OF AMPHETAMINE ACTION AFTER INTERRUPTION OF ASCENDING SEROTONERGIC PATHWAYS.
189398 04-03

EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND AMPHETAMINE ON SELF-STIMULATION OF BRAIN FOLLOWING VARIOUS 6-HYDROXYDOPAMINE TREATMENTS.
189515 04-04

PSYCHOMOTOR TEST PERFORMANCE WITH A FENFLURAMINE AMPHETAMINE COMBINATION.
190146 04-07

INFLUENCE OF DIFFERENT ANIONS ON TYRAMINE AND AMPHETAMINE UPTAKE BY COW ADRENAL MEDULLA CHROMAFFIN VESICLES.
190907 04-03

BEHAVIORAL AND EEG CHANGES IN THE AMPHETAMINE MODEL OF PSYCHOSIS.
191505 04-04

AMPHETAMINE AND NA..,K.. - ATPASE IN THE BRAIN.
191789 04-03

AMPHETAMINE AND METHYLPHENIDATE INDUCED RELEASE OF STRIATAL DOPAMINE IN VIVO: DIFFERENTIAL EFFECTS ON NEWLY SYNTHESIZED AND STORED POOLS.
191897 04-03

THE EFFECTS OF AMPHETAMINE SULFATE ON THE DIURNAL RHYTHMS OF MIDBRAIN; CORTEX, NOREPINEPHRINE; SEROTONIN AND BLOOD GLUCOSE LEVELS IN THE MOUSE.
191918 04-03

PIMOZIDE, L-PROPRANOLOL AND PHENTOLAMINE EFFECTS ON AMPHETAMINE SELF-ADMINISTRATION BY THE RAT.
191919 04-04

THE 4-HYDROXYLATION OF AMPHETAMINE AND PHENTERMINE BY RAT LIVER MICROSOMES.
191921 04-03

A ROLE FOR DOPAMINE IN THE STIMULANT EFFECTS OF AMPHETAMINE ON LOCUS-COERULEUS SELF-STIMULATION.
191984 04-03

THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON THE COMPOSITION OF DIURNAL SLEEP OF NARCOLEPTICS.
192419 04-11

AMPHETAMINE-INDUCED

AMPHETAMINE-INDUCED ALTERATION OF BIOGENIC AMINES AND SELF-STIMULATION.
182212 03-03

THE ONTOGENY OF AMPHETAMINE-INDUCED ALTERATIONS IN THERMAL REGULATION.
182246 03-03

CONDITIONING OF AMPHETAMINE-INDUCED BEHAVIOUR IN THE ALBINO RAT.
185954 03-04

THE ANTAGONISM OF AMPHETAMINE-INDUCED SYMPTOMATOLOGY BY A NEUROLEPTIC.
186744 03-14

AMPHETAMINES

AMPHETAMINES: VALUABLE ADJUNCT IN TREATMENT OF PARKINSONISM.
169220 01-11

EFFECTS OF PSYCHOTOMIMETICS ON VASCULAR STRIPS: STUDIES OF METHOXYLATED AMPHETAMINES AND OPTICAL ISOMERS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE AND 2,5 DIMETHOXY-4-BROMOAMPHETAMINE.
177734 02-03

EFFECTS OF AMPHETAMINES ON REGIONAL TRYPTOPHAN HYDROXYLASE ACTIVITY AND SYNAPTOSOMAL CONVERSION OF TRYPTOPHAN TO 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
186674 03-03

AMPHETAMINES EFFECTS ON SELF-STIMULATION: DEVELOPMENT OF TOLERANCE AND POST-DRUG DEPRESSION.
191914 04-04

EFFECTS OF AMPHETAMINES ON MOLLUSCAN NEURONS.
191995 04-03

AMPLITUDE

THE EFFECTS OF METHAMPHETAMINE AND SECOBARBITAL ON THE CONTINGENT NEGATIVE VARIATION AMPLITUDE.
185932 03-13

AMSTERDAM

THE EFFECTS OF DALMANE (FLURAZEPAM HYDROCHLORIDE) ON THE CONTINGENT NEGATIVE VARIATION. (AMSTERDAM).
177645 02-16

AMYGDALA

POSSIBLE INVOLVEMENT OF A NORADRENERGIC AREA OF THE AMYGDALA WITH STEREOTYPED BEHAVIOUR.
176877 02-04

A ROLE FOR THE AMYGDALA IN THE DEVELOPMENT OF THE CATALEPTIC AND STEREOTYPIC ACTIONS OF THE NARCOTIC AGONISTS AND ANTAGONISTS IN THE RAT.
186577 03-03

AMYLOBARBITONE

INFLUENCE OF AMYLOBARBITONE ON OPERANT DEPRESSION AND ELATION EFFECTS IN THE RAT.
168834 01-04

SENSORY CONTINGENT BAR-PRESSING FOR FAMILIAR AND NOVEL CHANGE UNDER A DEXAMPHETAMINE AMYLOBARBITONE MIXTURE.
181605 02-04

SEDATIVE OR TRANQUILLIZER? A COMPARISON OF THE HYPNOTIC EFFECTS OF CHLORDIAZEPOXIDE AND AMYLOBARBITONE SODIUM.
184438 03-14

JOINT EFFECTS OF SODIUM AMYLOBARBITONE AND AMPHETAMINE SULPHATE ON RESISTANCE TO EXTINCTION OF A REWARDED RUNNING RESPONSE IN THE RAT.
186573 03-04

AMYOTROPHIC

LEVODOPA INDUCED DYSKINESIAS: COMPARISON IN PARKINSONISM DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS.
169376 01-15

AMYTAL

THE EFFECT OF CHLORPROMAZINE AND AMYTAL SODIUM ON THE CONFORMITY OF ADOLESCENTS UNDER PSYCHIATRIC OBSERVATION.
191776 04-14

ANAFRANIL

EXPERIENCE IN THE USE OF AN ANTIDEPRESSIVE, CLOMIPRAMINE (ANAFRANIL), IN PSYCHIATRIC OUTPATIENTS.
176475 02-09

ANALEPTICS

EFFECTS OF ANALEPTICS ON MAZE LEARNING IN MICE.
173078 01-04

ANALGESIA

CHROMATIN TEMPLATE ACTIVITY DURING MORPHINE-INDUCED ANALGESIA AND THE DEVELOPMENT OF ANALGESIC TOLERANCE.
182160 02-03

EFFECT OF GAMMA-AMINOBUTYRIC ACID (GABA) ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
182231 03-03

ALPHA-ADRENERGIC BLOCKING AGENTS: ANTINOCICEPTIVE ACTIVITY AND ENHANCEMENT OF MORPHINE-INDUCED ANALGESIA.
183895 03-03

THE EFFECTS OF P-CHLOROPHENYLALANINE ON MORPHINE ANALGESIA, TOLERANCE AND DEPENDENCE DEVELOPMENT IN TWO STRAINS OF RATS.
187930 04-04

ANALGESIA AND HYPERREACTIVITY PRODUCED BY INTRACRANIAL MICROINJECTIONS OF MORPHINE INTO THE PERIAQUEDUCTAL GRAY MATTER OF THE RAT.
191367 04-04

EFFECT OF L-PHENYL-3-2-THIAZOLYL 2-THIOUREA, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
191769 04-03

ANALGESIC

ANALGESIC POTENCY OF SODIUM SALICYLATE, INDOMETHACIN, AND CHLORDIAZEPOXIDE AS MEASURED BY THE SPATIAL PREFERENCE TECHNIQUE IN THE RAT.
171301 01-02

INFLUENCES OF RESERPINE AND CHLORPROMAZINE ON THE ANALGESIC AND METABOLIC EFFECTS OF MORPHINE.
180507 02-03

CHROMATIN TEMPLATE ACTIVITY DURING MORPHINE-INDUCED ANALGESIA AND THE DEVELOPMENT OF ANALGESIC TOLERANCE.
182160 02-03

ANTIPYRETIC, ANALGESIC AND ANTIINFLAMMATORY ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL IN THE RAT.
182221 03-03

COMPARISON OF PSYCHOEXPERIMENTAL PERFORMANCE UNDER THE INFLUENCE OF THE ANALGESIC PROPIRAM FUMARATE.
184618 03-14

ANALGESIC EFFECT OF DELTA9-TETRAHYDROCANNABINOL IN THE DOG.
186585 03-03

CONSIDERATIONS ON THE USE OF ANALGESIC DRUGS IN DIFFERENT STAGES OF NEOPLASTIC DISEASES.
191604 04-17

ANALGESICS

EFFECTS OF NARCOTIC ANALGESICS ON ENZYMES OF ACETYLCHOLINE METABOLISM IN CULTURED CHICK BRAIN CELLS.
182225 03-03

ANALGESICS. I. SELECTED 5-SUBSTITUTED 5-PROPIONOXYBARBITURIC ACIDS.
187939 04-01

PSYCHOTROPIC EFFECT OF ANALGESICS AND NEUROLEPTICS ON A MODEL OF INVESTIGATORY BEHAVIOR CHANGED BY PAIN.
191120 04-04

METHODOLOGY FOR THE EVALUATION OF PENTAZOCINE, PROTOTYPE OF THE NEW MORPHINE AGONIST ANTAGONIST ANALGESICS.
191603 04-16

ANALGETIC

3-ARYL-3-HYDROXYQUINOLIZIDINES WITH POTENTIAL HYPOTENSIVE, ANTIDEPRESSANT, AND ANALGETIC ACTIVITY.
187938 04-01

ANALOG

PEYOTE AND RELATED ALKALOIDS XVI: SYNTHESIS OF 3,4,5 TRIMETHOXYPHENYLALANINE, AN AMINO ANALOG OF MESCALINE.
170839 01-06

ANALOGS

THE ROLE OF HYDROPHOBICITY IN THE ANTISEROTONIN ACTIVITY OF LSD ANALOGS.
174606 01-12

QUINAZOLINES AND 1,4 BENZODIAZEPINES.64.COMPARISON OF THE STEREOCHEMISTRY OF DIAZEPAM WITH THAT OF CLOSE ANALOGS WITH MARGINAL BIOLOGICAL ACTIVITY.
185034 03-01

SALIGENIN ANALOGS OF L-DOPA AND DL-ALPHA-METHYL-DOPA.
187565 04-11

APPLICATION OF THE SEQUENTIAL SIMPLEX METHOD IN DESIGNING DRUG ANALOGS.
190714 04-01

ANALOGS OF CHOLINE: SYNAPTOSOMAL METABOLISM.
192000 04-03

MESCALINE: THE CHEMISTRY AND PHARMACOLOGY OF ITS ANALOGS.
192877 04-12

ANALOGUE

STUDY INTO THE MECHANISM OF THE ANORECTIC ACTION OF AMPHETAMINE AND ITS P-CHLORO ANALOGUE.
171610 01-03

MASS FRAGMENTOGRAPHIC ANALYSIS OF HOMOVANILLIC ACID AND ITS HOMOISO ANALOGUE IN CEREBROSPINAL FLUID USING THE ALPHA DIDEUTERO ACID AS INTERNAL STANDARD.
186566 03-16

ANALOGUES

STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF 5-HT UPTAKE INTO RAT HYPOTHALAMIC HOMOGENATES BY SEROTONIN AND TRYPTAMINE ANALOGUES.
175233 02-03

THE EFFECT OF PHENIRAMINE AND ITS STRUCTURAL ANALOGUES ON 5-HYDROXYTRYPTAMINE IN RAT AND MOUSE BRAIN.
175240 02-03

A FREQUENCY SHIFT IN THE HIPPOCAMPAL THETA ACTIVITY: AN ELECTRICAL CORRELATE OF CENTRAL ACTION OF ACTH ANALOGUES IN THE DOG
188166 04-04

INHIBITION OF CHOLINE UPTAKE INTO SYNAPTOSOMES BY CHOLINE ANALOGUES.
191999 04-03

ANALYSES

THE ROLE OF RESEARCH IN DRUG ABUSE INTERVENTION: STREET DRUG ANALYSES.
167382 01-17

ANALYSIS

NEUROPHARMACOLOGICAL ANALYSIS OF EFFECTS OF DOXEPIN IN RABBITS (PH.D. DISSERTATION).
168130 01-03

THE DESIGN OF THERAPEUTIC TRIALS: A CRITICAL ANALYSIS WITH ILLUSTRATIONS, PARTICULARLY FROM THE FIELD OF PSYCHOTROPIC DRUGS OR: WHY NO ONE CAN EVER DO A PROPER DRUG TRIAL.
173307 01-16

AN ANALYSIS OF TOLERANCE TO THE ANOREXIGENIC EFFECTS OF AMPHETAMINE. (PH.D. DISSERTATION).
173775 01-03

SEMI-QUANTITATIVE ANALYSIS OF BROMAZEPAM BY RING OVEN METHOD.
174853 01-16

SIMULTANEOUS ANALYSIS OF A 1,5 BENZODIAZEPINE AND ITS METABOLITE IN BLOOD AND URINE BY SPECTRODENSITOMETRY.
176871 02-16

MOTHER INFANT SEPARATION: BEHAVIORAL ANALYSIS OF AN ANIMAL MODEL OF DEPRESSION. (PH.D. DISSERTATION).
178867 02-04

GAS CHROMATOGRAPHIC ANALYSIS OF BENZODIAZEPINES. PART I: MEDAZEPAM AND ITS METABOLITES.
178948 02-06

AN ANALYSIS OF D-AMPHETAMINE PRODUCED FACILITATION OF AVOIDANCE ACQUISITION IN RATS AND PERFORMANCE CHANGES SUBSEQUENT TO DRUG TERMINATION.
179990 02-04

DISCRIMINANT ANALYSIS OF THE RELATIONSHIP BETWEEN PHYSICAL PROPERTIES AND THE INHIBITION OF MONOAMINE OXIDASE BY AMINOTETRALINS AND AMINOINDANS.
180096 02-03

AFRODEX VS. PLACEBO IN THE TREATMENT OF MALE IMPOTENCE: STATISTICAL ANALYSIS OF TWO DOUBLE-BLIND CROSSOVER STUDIES.
181959 02-14

AUTOMATIC RECORDING OF ANIMAL BEHAVIOR AND ITS ANALYSIS.
182106 02-17

PHARMACOLOGIC ANALYSIS OF THE CAUDATE SPINDLE IN CATS.
182124 02-03

ANALYSIS OF TREMORGENIC EFFECTS OF INTRACAUDATE D-AMPHETAMINE.
182129 02-03

ANALYSIS OF DRUG BLOCK OF LSD/5-HT/GABA BY MONITORING NEURONAL MEMBRANE CHANGES.
182143 02-03

PHARMACOLOGICAL ANALYSIS OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE REMOVAL FROM THE PULMONARY CIRCULATION: DIFFERENTIATION OF UPTAKE SITES FOR EACH AMINE.
182717 03-03

THE ANALYSIS OF THE POTENTIAL ACTION OF A MEDICATION.
184963 03-14

CHLORPROMAZINE AND AVOIDANCE: A GENETIC ANALYSIS.
185751 03-03

EFFECTS OF LSD ON AUDITORY PERCEPTION: A SIGNAL DETECTION ANALYSIS.
185752 03-04

MASS FRAGMENTOGRAPHIC ANALYSIS OF HOMOVANILLIC ACID AND ITS HOMOISO ANALOGUE IN CEREBROSPINAL FLUID USING THE ALPHA DIDEUTERO ACID AS INTERNAL STANDARD.
186566 03-16

A DETAILED ANALYSIS OF THE EFFECTS OF D-AMPHETAMINE ON BEHAVIOR UNDER FIXED-INTERVAL SCHEDULES.
187066 03-04

BEHAVIOR AND EEG ANALYSIS OF CHRONIC AMPHETAMINE EFFECT.
187116 03-13

DISAGGREGATION OF BRAIN POLYSOMES AFTER L-DOPA: AN ANALYSIS.
188433 04-03

VOLTAGE CLAMP ANALYSIS OF PENTYLENETETRAZOL EFFECTS ON APLYSIA NEURONS.
189032 04-03

AN ANALYSIS OF THE FACILITATION OF AVOIDANCE ACQUISITION BY D-AMPHETAMINE AND SCOPOLAMINE.
189521 04-04

CONFORMATIONAL ANALYSIS OF ACRIDAN DERIVATIVES BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY. A RELATIONSHIP BETWEEN CONFORMATION AND PHARMACOLOGICAL ACTIVITY.
190715 04-01

FLUORESCENCE AND ELECTRON MICROSCOPIC ANALYSIS OF CATECHOLAMINE CONTAINING FIBERS IN MUTANT MOUSE CEREBELLUM. (UNPUBLISHED PAPER).
191762 04-03

DIPSOGENIC ACTION OF DIAZOXIDE: A PHARMACOLOGIC ANALYSIS.
191768 04-03

NEUROCHEMICAL ANALYSIS OF AGGRESSIVE - DEFENSIVE BEHAVIOR ELICITED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS AND CENTRAL GRAY MATTER.
191784 04-02

NEUROPHARMACOLOGICAL ANALYSIS OF R(-)-2,5 DIMETHOXY-4-METHYLAMPHETAMINE (R-DOM).
191906 04-03

NEUROPHARMACOLOGICAL ANALYSIS OF CENTRAL ADRENERGIC AND CHOLINERGIC ANTAGONISM OF DELTA9-TETRAHYDROCANNABINOL.
191992 04-03

ANALYSIS OF HYPOTHERMIC ACTION OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) IN MICE.
191997 04-03

ANALYTICAL

CONSTITUENTS OF CANNABIS-SATIVA L. V.: STABILITY OF AN ANALYTICAL SAMPLE EXTRACTED WITH CHLOROFORM. (UNPUBLISHED PAPER).
180670 02-01

ANALYZED

COMPARISON OF THE CLINICAL AND COMPUTER ANALYZED EEG EFFECTS OF MESORIDAZINE AND CHLORPROMAZINE.
180064 02-10

ANALYZES
THE COMPUTER ANALYZES TWO PSYCHOTHERAPEUTIC AGENTS IN ANXIETY/DEPRESSED STATES.
167345 01-10

ANALYZING
A METHOD FOR ANALYZING CNS EFFECTS OF DRUGS AND BRAIN LESIONS ON PERMANENT GROUPS OF RATS.
176867 02-06

ANATENSOL
ASSESSMENT OF ANATENSOL (FLUPHENAZINE ENANTHATE) INJECTABLE IN THE TREATMENT OF SCHIZOPHRENIA.
172444 01-08

ANATOMIC
METHIOTHEPIN ELEVATION OF 5-HYDROXYINDOLEACETIC ACID LEVELS IN VARIOUS ANATOMIC REGIONS OF RAT BRAIN.
187831 04-03

ANDROGENIZATION
FURTHER EVIDENCE ON THE INTRAHYPOTHALAMIC LOCUS FOR ANDROGENIZATION OF FEMALE RATS.
187935 04-03

ANESTHESIA
SYNTHESIS OF ACETYLCHOLINE IN BRAIN NERVE TERMINALS DURING CONSCIOUSNESS AND BARBITURATE ANESTHESIA.
171600 01-03

L-DOPA AND POTENTIATION OF ALCOHOL ANESTHESIA BY CHLORPROMAZINE.
182091 02-03

MICROVASCULAR SMOOTH MUSCLE HYPERRESPONSIVENESS DURING HALOTHANE ANESTHESIA IN THE RAT.
182185 02-03

TURNOVER OF HISTAMINE IN RAT BRAIN AND ITS DECREASE UNDER BARBITURATE ANESTHESIA.
189396 04-03

ANESTHESIOLOGIC
THE PROBLEMS OF THE PSYCHOPHARMACOLOGICAL TREATMENT OF PSYCHOSOMATIC DISEASES -- THE ANESTHESIOLOGIC APPROACH.
177063 02-17

ANESTHETIC
OPERANT BEHAVIOR AND NEUROPHYSIOLOGICAL OBSERVATIONS OF NORMAL HUMAN VOLUNTEERS RECEIVING CL-1848C, A NEW DISSOCIATIVE ANESTHETIC.
167334 01-07

EFFECT OF ANESTHETIC AGENTS ON THE SYNTHESIS AND DISAPPEARANCE OF BRAIN DOPAMINE NORMALLY AND AFTER HALOPERIDOL, KCL OR AXOTOMY.
189571 04-03

EFFECT OF ANESTHETIC AGENTS ON PERIPHERAL SYMPATHETIC NERVOUS SYSTEM FUNCTION AS MONITORED BY ARTERIAL PLASMA CATECHOLAMINE LEVELS. (UNPUBLISHED PAPER
191495 04-03

ANESTHETICS
DECREASED HISTAMINE SYNTHESIS IN THE RAT BRAIN BY HYPNOTICS AND ANESTHETICS.
168750 01-03

EFFECT OF GENERAL ANESTHETICS ON SYSTEMIC CATECHOLAMINE CONCENTRATION I: HALOTHANE. (UNPUBLISHED PAPER).
168862 01-05

A CENTRAL EFFECT OF LOCAL ANESTHETICS: PREVENTION AGAINST THE ACCUMULATION OF CYCLIC AMP IN BRAIN SLICES.
182099 02-03

EFFECTS OF NON-HYDROGEN-BONDING ANESTHETICS ON MEMORY IN THE CHICK.
184380 03-04

CALCIUM REVERSAL OF NERVE BLOCKADE BY ALCOHOLS, ANESTHETICS, TRANQUILIZERS, AND BARBITURATES.
187802 04-03

THE IMPULSE BLOCKING CONCENTRATIONS OF ANESTHETICS, ALCOHOLS, ANTICONVULSANTS, BARBITURATES, AND NARCOTICS ON PHRENIC AND SCIATIC NERVES.
187803 04-03

ANESTHETIZED
CARDIOVASCULAR EFFECTS OF RESERPINE, YOHIMBINE, AND RESERPINE YOHIMBINE MIXTURES ON INTACT ANESTHETIZED DOG.
167328 01-03

CARDIOPULMONARY EFFECTS OF CANNABIDIOL IN ANESTHETIZED DOGS.
191993 04-05

ANHYDRIDE
STUDIES ON BENZODIAZEPINOOXAZOLES. V. REACTIONS OF BENZODIAZEPINOOXAZOLE DERIVATIVES WITH ACETIC ANHYDRIDE.
180489 02-01

ANIMAL
ANIMAL MODELS FOR AN ENZYMIC BLOOD-BRAIN BARRIER MECHANISM FOR THERAPEUTICALLY ADMINISTERED L-DOPA.
167359 01-03

MOTHER INFANT SEPARATION: BEHAVIORAL ANALYSIS OF AN ANIMAL MODEL OF DEPRESSION. (PH.D. DISSERTATION).
178867 02-04

EEG CHARACTERISTICS IN VARIOUS SPECIES OF ANIMAL AND THEIR RELATION TO THE CNS EFFECTS OF DRUGS.
182096 02-03

AUTOMATIC RECORDING OF ANIMAL BEHAVIOR AND ITS ANALYSIS.
182106 02-17

EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL IN SEVERAL ANIMAL MODELS OF AGGRESSION.
182188 02-04

RUBIDIUM SALTS -- ANIMAL TOXICITY STUDIES.
182442 03-05

LEAD INDUCED BEHAVIORAL DYSFUNCTION: AN ANIMAL MODEL OF HYPERACTIVITY.
184953 03-04

NEUROTOXICOLOGIC STUDIES OF TWO CARBAMATE PESTICIDES IN SUBACUTE ANIMAL EXPERIMENTS.
188874 04-05

ANIMALS
THE SAFETY TEST OF 10-CHLORO-11B-(2-CHLOROPHENYL) 2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE (CS-370): SECOND REPORT, EFFECT OF CS-370 UPON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
168498 01-05

THE PHARMACOLOGICAL EVALUATION IN LABORATORY ANIMALS OF KABI-1702 -- A NEW SEDATIVE HYPNOTIC DRUG.
171632 01-03

STUDIES ON METABOLISM OF BROMAZEPAM (II): COLORIMETRIC DETERMINATION AND METABOLIC FATE OF BROMAZEPAM IN ANIMALS.
181593 02-03

INHIBITION OF GROWTH IN ANIMALS TREATED WITH METHADONE.
182164 02-03

DISTRIBUTION OF 14C-PSILOCIN IN THE BRAINS OF VARIOUS ANIMALS.
192425 04-03

ANIONS
INFLUENCE OF DIFFERENT ANIONS ON TYRAMINE AND AMPHETAMINE UPTAKE BY COW ADRENAL MEDULLA CHROMAFFIN VESICLES.
190907 04-03

ANISOMYCIN
ANISOMYCIN, LIKE OTHER INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS, IMPAIRS LONG-TERM MEMORY OF A DISCRIMINATION TASK.
188605 04-04

ANORECTIC
STUDY INTO THE MECHANISM OF THE ANORECTIC ACTION OF AMPHETAMINE AND ITS P-CHLORO ANALOGUE.
171610 01-03

ROLE OF CATECHOLAMINES IN THE ANORECTIC EFFECTS OF AMPHETAMINE IN RATS.
186582 03-03

ANOREXIA
EFFECT OF A CARNITINE CYPROHEPTADINE COMBINATION ON ANOREXIA AND WEIGHT GAIN IN CHILDREN.
178811 02-10

DECREASED ANOREXIA, EXCITEMENT AND STEREOTYPY TO D-AMPHETAMINE AFTER LATERAL HYPOTHALAMIC 6-HYDROXYDOPAMINE (6-OHDA) INJECTIONS.
182136 02-04

EFFECTS OF 6-HYDROXYDOPAMINE ON ANOREXIA PRODUCED BY D-AMPHETAMINE AND RELATED PHENYLETHYLAMINES.
191905 04-03

ANOREXIA-NERVOSA
PLASMA LEVELS OF LUTEINIZING HORMONE AND OF IMMUNOREACTIVE ESTROGENS (ESTRADIOL) IN ANOREXIA-NERVOSA: RESPONSE TO CLOMIPHENE CITRATE.
183807 03-10

ANOREXIC
TIME SAMPLING OF RAT EXPLORATORY BEHAVIOUR: A RELIABLE SCREENING TEST FOR THE CNS EFFECTS OF ANOREXIC AGENTS.
187925 04-04

CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE DERIVATIVE SE-780 IN RATS.
187926 04-04

CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE METABOLITE, NORFENFLURAMINE: AN EVALUATION OF ITS ROLE IN THE ACTIONS OF FENFLURAMINE.
190335 04-04

ANOREXIGENIC
TOLERANCE AND CROSS-TOLERANCE TO THE ANOREXIGENIC EFFECT OF SOME AMPHETAMINE DERIVATIVES IN RATS.
171602 01-03

AN ANALYSIS OF TOLERANCE TO THE ANOREXIGENIC EFFECTS OF AMPHETAMINE. (PH.D. DISSERTATION).
173775 01-03

STUDIES ON THE ANOREXIGENIC ACTION OF PHENTERMINE.
182134 02-03

DIFFERENTIAL CIRCULATORY EFFECTS OF VARIOUS ANOREXIGENIC DRUGS.
182214 03-03

ANSWERS

THERAPEUTIC APPROACH TO THE APPROXIMATE ANSWERS OF A SCHIZOPHRENIC PATIENT.
170637 01-08

CEREBRAL STIMULANTS AND MINIMAL DYSFUNCTION: SOME QUESTIONS, SOME ANSWERS, AND SOME MORE QUESTIONS.
180992 02-11

ANTAGONISM

SELECTIVE ANTAGONISM OF CENTRAL NERVOUS SYSTEM DEPRESSANTS BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE.
171007 01-13

THE EFFECT OF PIPRADROL IN MICE AND ITS ANTAGONISM BY NEUROLEPTIC DRUGS.
171607 01-04

ANTAGONISM OF P-CHLOROAMPHETAMINE (PCA) INDUCED DEPLETION OF 5-HT FROM RAT BRAIN BY SOME THYMOLEPTICS AND OTHER PSYCHOTROPIC DRUGS.
171628 01-03

ANTAGONISM OF THE EFFECTS OF CHLORPROMAZINE AND MORPHINE ON DOPAMINE METABOLISM BY GABA.
176870 02-03

L-DOPA CHLORPROMAZINE ANTAGONISM ON RUNNING ACTIVITY IN MICE.
177785 02-04

METHYLPHENIDATE ANTAGONISM OF HALOPERIDOL, INTERACTION WITH CHOLINERGIC AND ANTICHOLINERGIC DRUGS.
186370 03-04

EFFECTS OF CLONIDINE AND SOME ALPHA-ADRENORECEPTOR BLOCKING AGENTS ON AVOIDANCE CONDITIONED REFLEXES IN RATS: THEIR INTERACTIONS AND ANTAGONISM BY ATROPINE.
186576 03-04

THE ANTAGONISM OF HIPPOCAMPAL AND CORTICAL AFTERDISCHARGE BY SC-13504, A NEW ANTICONVULSANT.
186632 03-03

THE ANTAGONISM OF AMPHETAMINE-INDUCED SYMPTOMATOLOGY BY A NEUROLEPTIC.
186744 03-14

NEUROLEPTIC ANTAGONISM OF CATECHOLAMINE INHIBITIONS IN RAT CEREBELLUM AND CAUDATE. (UNPUBLISHED PAPER).
187496 04-03

BIOCHEMICAL AND BEHAVIORAL ANTAGONISM BETWEEN FENFLURAMINE AND APOMORPHINE IN RATS.
188196 04-03

CENTRAL HYPOTHERMIA BY 2-DEOXY-D-GLUCOSE: ANTAGONISM BY ALPHA-ADRENERGIC ACTIVATION.
188200 04-03

PROPRANOLOL ANTAGONISM OF MORPHINE INFLUENCED BEHAVIOR.
188760 04-04

DIFFERENTIAL ANTAGONISM BY NALOXONE OF INHIBITORY EFFECTS OF HALOPERIDOL AND MORPHINE ON BRAIN SELF-STIMULATION.
190306 04-03

STUDIES ON CONVULSANTS IN THE ISOLATED FROG SPINAL CORD. I. ANTAGONISM OF AMINO ACID RESPONSES. (UNPUBLISHED PAPER)
190727 04-03

NEOMYCIN AND RUTHENIUM RED ANTAGONISM OF MONOAMINERGIC DEPRESSION OF CEREBRAL CORTICAL NEURONES.
191380 04-03

THE ANTAGONISM BETWEEN CHOLINOMIMETIC AGONISTS AND BETA-ADRENOCEPTOR STIMULANTS: THE DIFFERENTIATION BETWEEN BETWEEN FUNCTIONAL AND METAFFINOID ANTAGONISM.
191420 04-03

NEUROPHARMACOLOGICAL ANALYSIS OF CENTRAL ADRENERGIC AND CHOLINERGIC ANTAGONISM OF DELTA9-TETRAHYDROCANNABINOL.
191992 04-03

ANTAGONIST

DIURETIC ACTIVITY OF A NEW NARCOTIC ANTAGONIST IN MAN (BRISTOL-COMPOUND-2605). (UNPUBLISHED PAPER).
174473 01-13

THE EFFECTS OF PHENITRONE, A REPORTED HASHISH ANTAGONIST, ON THE OVERT BEHAVIOR OF CATS.
174607 01-04

ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN DIMETHYLAMINOPROPYLTHIOCINNAMANILIDE HYDROCHLORIDE), A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN (5-HTP) AND ALPHA-METHYLTRYPTAMINE.
176861 02-04

ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN, A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN AND ALPHA-METHYLTRYPTAMINE.
176873 02-04

INTERACTION OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A PURPORTED HASHISH AND LSD ANTAGONIST, WITH SEVERAL CENTRAL NEUROCHEMICAL SYSTEMS.
182217 03-04

NOREPINEPHRINE -- AN ANTAGONIST OF DIBUTYRYL CYCLIC AMP IN THE REGULATION OF NARCOSIS IN THE RAT.
183789 03-03

LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04

EFFECTS OF AN ESTROGEN ANTAGONIST, MER-25, ON MOUNTING BEHAVIOR AND LORDOSIS BEHAVIOR IN THE FEMALE RAT.
186691 03-04

STUDIES OF EN-1639A (NALTREXONE): A NEW NARCOTIC ANTAGONIST.
189059 04-07

METHODOLOGY FOR THE EVALUATION OF PENTAZOCINE, PROTOTYPE OF THE NEW MORPHINE AGONIST ANTAGONIST ANALGESICS.
191603 04-16

NALTREXONE AND NALOXONE: AGONIST AND ANTAGONIST EFFECTS ON KEY-PRESS RESPONDING OF PIGEONS MAINTAINED UNDER A MULTIPLE SCHEDULE OF FOOD PRESENTATION.
191926 04-04

ANTAGONISTIC

ANTAGONISTIC EFFECTS OF PHYSOSTIGMINE AND METHYLPHENIDATE IN MAN.
172272 01-11

DRINKING BEHAVIOUR AND BRAIN DOPAMINE: ANTAGONISTIC EFFECT OF TWO NEUROLEPTIC DRUGS (PIMOZIDE AND SPIRAMIDE) UPON AMPHETAMINE OR APOMORPHINE-INDUCED HYPODIPSIA.
174035 01-04

CHEMOTHERAPY AND PSYCHOTHERAPY, ARE THEY COMPLEMENTARY OR ANTAGONISTIC?: A PERSONAL STUDY.
184959 03-17

ANTAGONISTS

CENTRAL MONOAMINE METABOLISM IN MAN: EFFECT OF PUTATIVE DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS.
169377 01-13

THE EFFECT OF DOPAMINE ANTAGONISTS AND AMANTADINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
174829 01-04

PROGRESS REPORT ON THE USE OF THE DOG FOR ASSESSING MORPHINE-LIKE AND NALORPHINE-LIKE AGONISTS AS WELL AS DEPOT PREPARATIONS OF ANTAGONISTS. (UNPUBLISHED PAPER).
176312 02-03

NEGATIVE REINFORCING PROPERTIES OF MORPHINE ANTAGONISTS IN NAIVE RHESUS MONKEYS.
177719 02-04

BEHAVIORAL EFFECTS OF MORPHINE AND OPIOID ANTAGONISTS.
182859 03-04

A ROLE FOR THE AMYGDALA IN THE DEVELOPMENT OF THE CATALEPTIC AND STEREOTYPIC ACTIONS OF THE NARCOTIC AGONISTS AND ANTAGONISTS IN THE RAT.
186577 03-03

TRYPTAMINE ANTAGONISTS AND PUNISHED BEHAVIOR.
186692 03-04

NEW LONG LATENCY BULBOSPINAL EVOKED POTENTIALS BLOCKED BY SEROTONIN ANTAGONISTS.
188751 04-03

INTERACTION OF SEROTONIN ANTAGONISTS WITH 3,4-DICHLORO-2-(2-IMIDAZOLIN-2-YL-THIO) 2 ACETOPHENONE HYDROBROMIDE (DITA) AND D-AMPHETAMINE HYDROBROMIDE (DITA) AND D-AMPHETAMINE ON CERTAIN BEHAVIORAL PARAMETERS OF MALE MICE.
192014 04-04

ANTIAGGRESSION

TOWARD A MECHANISM OF THE ANTIAGGRESSION EFFECTS OF CHLORDIAZEPOXIDE IN RATS.
185934 03-04

ANTIAGGRESSIVE

DISSOCIATIVE CHANGE IN ANTIAGGRESSIVE AND MUSCLE RELAXANT ACTIONS OF S-TRIAZOLOBENZODIAZEPINE (D-40TA) BY REPEATED ADMINISTRATION AND PHENOBARBITAL PRETREATMENT, AND ITS RELATION TO METABOLISM.
181654 02-04

ANTIAGGRESSIVE EFFECT OF LITHIUM SALTS IN MENTALLY RETARDED ADOLESCENTS.
182435 03-11

ANTIANXIETY

ON THE ANTIANXIETY PROPERTIES OF A NEW BENZODIAZEPINE, ORF-8063.
172485 01-10

PERIPHERAL VERSUS CENTRAL MECHANISMS ACCOUNTING FOR ANTIANXIETY EFFECTS OF PROPRANOLOL.
181072 02-10

CROSS-NATIONAL STUDY OF THE EXTENT OF ANTIANXIETY SEDATIVE DRUG USE.
181713 02-17

ELECTROCLINICAL DISCREPANCIES IN ANTIANXIETY DRUGS.
181918 02-13

MANIFEST ANXIETY AND ANTIANXIETY DRUG EFFECTS IN NORMAL VOLUNTEERS.
182118 02-14

THE CONDITIONED EMOTIONAL RESPONSE (CER) AS A BASELINE FOR THE STUDY OF ANTIANXIETY DRUGS.
183862 03-04

CLASSIFICATION AND INDICATION OF ANTIANXIETY AGENTS IN CLINICAL PRACTICE.
184845 03-10

THE SHORT-TERM ANTIANXIETY EFFECTS OF PROPRANOLOL HCL.
185210 03-10

A STUDY OF ANTIANXIETY EFFECTS OF WY-4036.
185874 03-10

PYRAZAPON (CI-683): A NEW ANTIANXIETY AGENT.
186581 03-04

EFFECTS OF CNS AGENTS ON NICOTINE EXTENSOR CONVULSIONS AND LETHALITY IN MICE AND THEIR SEDATIVE ANTIANXIETY EFFECTS IN MAN.
191907 04-14

A CHEMOTHERAPEUTIC ALTERNATIVE TO THE ANTIANXIETY AGENTS FOR THE EXTENDED TREATMENT OF PSYCHONEUROSIS.
192083 04-10

ANTIAPOMORPHINE

THE PREDICTIVE VALUE OF THE ANTIAPOMORPHINE TEST IN DOGS FOR NEUROLEPTIC THERAPY IN MAN.
192421 04-04

ANTIBIOTICS

DRUG ABSORPTION IN RATS PRETREATED WITH ANTIBIOTICS.
182715 03-03

ANTIBODY

THE SPECIFICITY OF ANTIMESCALINE ANTIBODY PRODUCED IN RABBITS.
182186 02-03

ANTICHOLINERGIC

INHIBITION OF ANTICHOLINERGIC DRUG-INDUCED LOCOMOTOR STIMULATION IN MICE BY ALPHA-METHYLTYROSINE.
177840 02-03

INHIBITION OF ISOLATION INDUCED AGGRESSION IN THE MOUSE BY ANTICHOLINERGIC COMPOUNDS.
182239 03-04

METHYLPHENIDATE ANTAGONISM OF HALOPERIDOL, INTERACTION WITH CHOLINERGIC AND ANTICHOLINERGIC DRUGS.
186370 03-04

CORRELATION BETWEEN THE TRANQUILIZING AND SEDATIVE ACTION OF NEUROLEPTICS, ANTIDEPRESSANTS AND ANTICHOLINERGIC DRUGS.
191783 04-02

ANTICHOLINERGICS

ANTICHOLINERGICS: THEIR EFFECTS ON FEAR MOTIVATED BEHAVIOR, URINARY 11-HYDROXYCORTICOSTEROIDS, URINARY VOLUME, AND HEART RATE IN THE DOG.
178720 02-03

ANTICONVULSANT

SYNTHESIS OF SUBSTITUTED CINNAMIDES: RELATIONSHIP BETWEEN ANTICONVULSANT AND MONOAMINE OXIDASE INHIBITORY PROPERTIES.
169818 01-01

DEPENDENCE OF ANTICONVULSANT DRUG ACTION ON CENTRAL MONOAMINES.
172923 01-03

A STUDY OF THE RELATIVE ANTICONVULSANT AND TOXIC ACTIVITIES OF DELTA9-TETRAHYDROCANNABINOL AND ITS CONGENERS.
174608 01-05

THE ANTICONVULSANT ACTIVITY OF CANNABIDIOL AND CANNABINOL.
175238 02-03

COMPARISON OF ANTICONVULSANT EFFECTS OF CLORAZEPATE DIPOTASSIUM AND DIAZEPAM: FOUR WEEK ANTICONVULSANT STUDY IN RHESUS MONKEYS.
176677 02-03

ANTICONVULSANT ACTIVITY OF CLONAZEPAM AND RO-8-4192 AGAINST PENICILLIN AND LIDOCAINE INDUCED SEIZURES.
178947 02-03

INVESTIGATIONS ON THE FATE OF THE ANTICONVULSANT CLONAZEPAM IN THE ORGANISM OF MAN, RAT AND DOG.
179022 02-13

FIRST RESULTS OBTAINED WITH A NEW ANTICONVULSANT OF THE BENZODIAZEPINE SERIES (CLONAZEPAM).
180672 02-11

TREATMENT OF COMPULSIVE EATING DISTURBANCES WITH ANTICONVULSANT MEDICATION.
181270 02-14

SUBSTITUTED PIPERAZINOQUINAZOLONES: RELATIONSHIP BETWEEN SELECTIVE INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND ANTICONVULSANT ACTIVITY.
183598 03-02

SUBSTITUTED BENZOXAZOLE/BENZTHIAZOLE-2-THIONES: INTERRELATIONSHIP BETWEEN ANTICONVULSANT ACTIVITY AND INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND MONOAMINE OXIDASE.
183601 03-03

SERUM ANTICONVULSANT CONCENTRATIONS IN EPILEPTIC PATIENTS WITH MENTAL SYMPTOMS: A PRELIMINARY REPORT.
184439 03-15

ANTICONVULSANT ACTIVITY OF SUBSTITUTED INDOLEALKYLAMINES.
185035 03-01

CALCIUM METABOLISM IN ELDERLY EPILEPTIC PATIENTS DURING ANTICONVULSANT THERAPY.
185560 03-15

ANTICONVULSANT ACTIVITY AND INHIBITION OF RESPIRATION IN RAT BRAIN HOMOGENATES BY SUBSTITUTED OXADIAZOLES.
185980 03-01

THE ANTAGONISM OF HIPPOCAMPAL AND CORTICAL AFTERDISCHARGE BY SC-13504, A NEW ANTICONVULSANT.
186632 03-03

ANTICONVULSANT ACTION OF VITAMIN-D IN EPILEPTIC PATIENTS? A CONTROLLED PILOT STUDY.
188889 04-11

CARBAMAZEPINE SOLE ANTICONVULSANT FOR FOCAL EPILEPSY OF CHILDHOOD.
189174 04-11

ANTICONVULSANT EFFECTS OF CANNABINOLS IN MICE: DRUG INTERACTIONS WITH CANNABINOIDS AND CANNABINOID INTERACTIONS WITH PHENYTOIN.
189513 04-03

EFFECT OF ANTICONVULSANT DRUGS ON THE NUMBER OF AFFERENT STIMULI NEEDED TO CAUSE A HIPPOCAMPAL SEIZURE DISCHARGE.
189608 04-03

EFFECT OF SEIZURES AND ANTICONVULSANT AGENTS ON HIPPOCAMPAL RNA CONCENTRATION.
189609 04-03

ANTICONVULSANT DRUG SERUM LEVELS IN PSYCHIATRIC PATIENTS WITH SEIZURE DISORDERS: EFFECTS OF CERTAIN PSYCHOTROPIC DRUGS.
191096 04-13

ANTICONVULSANT PROPERTIES OF CANNABIDIOL.
191994 04-03

CARBAMAZEPINE AS AN ANTICONVULSANT: A PILOT STUDY.
192391 04-07

ANTICONVULSANTS

ANTICONVULSANTS AND POST-TETANIC POTENTIATION.
182249 03-03

THE IMPULSE BLOCKING CONCENTRATIONS OF ANESTHETICS, ALCOHOLS, ANTICONVULSANTS, BARBITURATES, AND NARCOTICS ON PHRENIC AND SCIATIC NERVES.
187803 04-03

ANTICONVULSIVE

ANTICONVULSIVE ACTIVITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) AND ITS EFFECT ON LIMBIC SYSTEM.
177099 02-02

ANTIDEPRESSANT

COMBINATIONS OF ANTIDEPRESSANT DRUGS IN THE TREATMENT OF DEPRESSIVE ILLNESS.
168317 01-09

CLOMIPRAMINE HCL -- A DOUBLE-BLIND STUDY OF A NEW ANTIDEPRESSANT DRUG.
168318 01-09

THE EFFECT OF LITHIUM AND OTHER ANTIDEPRESSANT MEDICATIONS ON THE AUTONOMIC NERVOUS SYSTEM.
169635 01-15

BRAIN SEROTONIN, AFFECTIVE ILLNESS AND ANTIDEPRESSANT DRUGS: CEREBROSPINAL FLUID STUDIES WITH PROBENECID. (UNPUBLISHED PAPER).
170084 01-09

MELANOCYTE STIMULATING HORMONE RELEASE INHIBITING HORMONE AS AN ANTIDEPRESSANT: A PILOT STUDY.
171501 01-09

EFFECTS OF ANTIDEPRESSANT AGENTS ON OPEN-FIELD BEHAVIOUR IN RATS.
174038 01-04

ANTIDEPRESSANT DRUGS.
174760 01-03

ANTIDEPRESSANT DRUGS.
174851 01-09

ANTIDEPRESSANT EFFECTS OF D-CHLORPHENIRAMINE -- CLINICAL EVALUATION (FIRST REPORT).
176889 02-09

QUALITATIVE AND QUANTITATIVE STUDIES ON THE DISPOSITION OF AMITRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANT DRUGS IN MAN AS IT RELATES TO THE MANAGEMENT OF THE OVERDOSED PATIENT.
177395 02-15

THE FIRST LONG-ACTING (RETARD) THYMOANALEPTIC OR ANTIDEPRESSANT: THE TIME-RELEASED DIBENZEPINE WITH PROLONGED ACTION.
178946 02-11

ANTIDEPRESSANT DRUGS.
180297 02-09

INDICATIONS FOR ANTIDEPRESSANT TREATMENT WITH SPECIAL REFERENCE TO DEPRESSED PRESCHOOL CHILDREN.
182428 03-10

RUBIDIUM SALTS -- TOXIC EFFECTS IN HUMANS AND CLINICAL EFFECTS AS AN ANTIDEPRESSANT DRUG.
182443 03-09

CLINICAL STUDY OF ANTIDEPRESSANT AGENT, NOVERIL.
182551 03-10

EXPERIMENTS IN ORAL AND INJECTABLE FORMS OF A NEW ANTIDEPRESSANT (DOXEPIN) ON FORTY PATIENTS.
182900 03-11

THE ABSORPTION AND DISTRIBUTION OF THE NEW ANTIDEPRESSANT AZAPHEN IN THE ORGANS.
183519 03-03

5-HYDROXYTRYPTOPHAN AS AN ANTIDEPRESSANT: THE PREDICTIVE VALUE OF THE PROBENECID TEST.
184652 03-09

EFFECT OF ANTIDEPRESSANT AND ANTIMANIC DRUGS ON AMINE UPTAKE IN MAN.
184654 03-13

A STUDY OF REFRACTORY CASES OF DEPRESSIVE ILLNESSES AND THEIR RESPONSE TO COMBINED ANTIDEPRESSANT TREATMENT.
185078 03-10

DIURETIC ANTIDEPRESSANT COMBINATION IN ALCOHOLIC DEPRESSIVES.
187866 04-11

3-ARYL-3-HYDROXYQUINOLIZIDINES WITH POTENTIAL HYPOTENSIVE, ANTIDEPRESSANT, AND ANALGETIC ACTIVITY.
187938 04-01

HEAT DYSCONTROL SYNDROME IN PATIENTS RECEIVING ANTIPSYCHOTIC, ANTIDEPRESSANT AND ANTIPARKINSON DRUG THERAPY.
188094 04-15

CLINICAL EXPERIENCES WITH A NEW ANTIDEPRESSANT, MAPROTILINE.
188893 04-09

ANTIDEPRESSANT EFFECT OF LITHIUM.
189793 04-09

THE USE OF A TRICYCLIC ANTIDEPRESSANT IN EPILEPSY.
190379 04-09

THE EFFICACY OF ANTIDEPRESSANT DRUGS: A REVIEW OF RESEARCH (1958 TO 1972).
191857 04-09

PHARMACOLOGY OF DEPRESSION IN THE AGED: EVALUATION OF GEROVITAL-H3 AS AN ANTIDEPRESSANT DRUG.
192229 04-09

CORRELATION OF PHARMACOLOGICAL INVESTIGATIONS WITH THE CLINICAL EFFICACY OF ANTIDEPRESSANT DRUGS.
192420 04-13

ANTIDEPRESSANTS

EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON ATTACK ELICITED BY HYPOTHALAMIC STIMULATION: RELATION TO BRAIN BIOGENIC AMINES.
170162 01-04

COMPARISON OF TRICYCLIC ANTIDEPRESSANTS AS TO THEIR CARDIOTOXIC ACTION IN CONSCIOUS RABBITS.
171629 01-03

AN ENZYME APPROACH IN APPRAISING THE MODE OF SOME TRANQUILIZERS AND ANTIDEPRESSANTS.
174318 01-03

A NEW MODIFICATION FOR STUDYING 5-HT UPTAKE BY BLOOD PLATELETS: A RE-EVALUATION OF TRICYCLIC ANTIDEPRESSANTS AS UPTAKE INHIBITORS.
180055 02-06

PRELIMINARY STUDIES OF CARPIPRAMINE: A COMPOUND SIMILAR TO BOTH ANTIDEPRESSANTS AND NEUROLEPTICS.
180725 02-07

BEHAVIORAL PHARMACOLOGICAL STUDIES ON TRICYCLIC ANTIDEPRESSANTS IN RATS.
182116 02-04

IMPORTANCE OF THE COOPERATION OF FAMILIES IN THE TREATMENT OF THE SICK: CONCERNING CHRONIC DELIRIUM TREATED WITH NEUROLEPTICS AND MELANCHOLY TREATED WITH ANTIDEPRESSANTS.
182899 03-17

SYNTHESIS AND SCREENING OF CYCLIC BENZYLHYDRAZINE CONGENERS AS ANTIDEPRESSANTS.
183600 03-01

COMPARISON OF TRICYCLIC ANTIDEPRESSANTS IN RABBITS: ANTINOCICEPTION AND POTENTIATION OF THE NORADRENALINE PRESSOR RESPONSES.
186579 03-03

LIPIDOSIS-LIKE ALTERATIONS IN DORSAL ROOT GANGLION CELLS OF RATS TREATED WITH TRICYCLIC ANTIDEPRESSANTS.
189605 04-03

SELF-EVALUATIONS OF ANTIDEPRESSANTS.
190305 04-17

EFFECT OF PHENOTHIAZINE NEUROLEPTIC DRUGS AND TRICYCLIC ANTIDEPRESSANTS ON PHOSPHODIESTERASE ACTIVITY IN RAT CEREBRAL CORTEX.
190311 04-03

INFLUENCE OF NEUROLEPTICS AND BENZODIAZEPINES ON METABOLISM OF TRICYCLIC ANTIDEPRESSANTS IN MAN.
191026 04-09

CORRELATION BETWEEN THE TRANQUILIZING AND SEDATIVE ACTION OF NEUROLEPTICS, ANTIDEPRESSANTS AND ANTICHOLINERGIC DRUGS.
191783 04-02

NORADRENERGIC NEURONS: EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON SINGLE UNIT ACTIVITY.
191931 04-03

PLASMA LEVELS AND TRICYCLIC ANTIDEPRESSANTS.
192872 04-10

ANTIDEPRESSIVE

EXPERIENCE IN THE USE OF AN ANTIDEPRESSIVE, CLOMIPRAMINE (ANAFRANIL), IN PSYCHIATRIC OUTPATIENTS.
176475 02-09

CLINICAL EXPERIENCES WITH AN ANTIDEPRESSIVE DRUG, NORITREN (NORTRIPTYLINE).
176565 02-09

EKG ALTERNATIONS IN INFUSION TREATMENT WITH TRICYCLIC ANTIDEPRESSIVE DRUGS.
180063 02-15

INFLUENCE OF ANTIDEPRESSIVE THERAPY ON THE DISTURBED TIME ESTIMATION OF DEPRESSIVES.
182591 03-14

LABORATORY ASSESSMENTS OF ANTIDEPRESSIVE ACTIVITY -- THEIR VALUE FOR CLINICAL PSYCHIATRY AND THE UNDERSTANDING OF DEPRESSION.
192422 04-09

ANTIDEPRESSIVES

COMBINED USE OF ECT AND PSYCHOTROPIC DRUGS: ANTIDEPRESSIVES AND ANTIPSYCHOTICS.
177670 02-11

ANTIEPILEPTIC

PHARMACOLOGY AND TOXICOLOGY OF THE ANTIEPILEPTIC DRUG CLONAZEPAM.
179021 02-05

ANTIHISTAMINES

EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON THE RHYTHMS OF WAKEFULNESS SLEEP CYCLE IN RATS.
182553 03-04

EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON ELECTROENCEPHALOGRAM AND FEEDING BEHAVIOR OF RATS.
182554 03-04

ANTIHISTAMINIC

INTERACTIONS OF CHLORPHENIRAMINE ETHANOL COMBINATIONS: ACUTE TOXICITY AND ANTIHISTAMINIC ACTIVITY.
188875 04-05

ANTIHYPERTENSIVE

ANTIHYPERTENSIVE AND CENTRAL NERVOUS SYSTEM DEPRESSANT PROPERTIES OF 3-(GAMMA-P-FLUOROBENZOYLPROPYL) 2,3,4,4A,5,6 HEXAHYDROPYRAZINOQUINOLINE HYDROCHLORIDE (COMPOUND-69-183, CENTPYRAQUIN).
176881 02-03

ANTIINFLAMMATORY

ANTIPYRETIC, ANALGESIC AND ANTIINFLAMMATORY ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL IN THE RAT.
182221 03-03

ANTILIPEMIC

INFLUENCE OF ADRENERGIC BLOCKERS AND ANTILIPEMIC AGENTS ON PHARMACODYNAMIC ACTIONS OF MORPHINE IN CARBON TETRACHLORIDE TREATED RATS.
188873 04-03

ANTIMANIC

EFFECT OF ANTIDEPRESSANT AND ANTIMANIC DRUGS ON AMINE UPTAKE IN MAN.
184654 03-13

ANTIMESCALINE

THE SPECIFICITY OF ANTIMESCALINE ANTIBODY PRODUCED IN RABBITS.
182186 02-03

ANTIMOTION

THE SPIRAL AFTEREFFECT (SAE) AS A MEASURE OF MOTION SICKNESS SUSCEPTIBILITY AND THE EFFECT ON THE SAE OF AN ANTIMOTION SICKNESS DRUG AND A CENTRAL NERVOUS SYSTEM DEPRESSANT.
172780 01-03

ANTINOCICEPTION

EFFECT OF CHEMICAL SYMPATHECTOMY ON MORPHINE ANTINOCICEPTION AND TOLERANCE IN RATS.
182159 02-03

COMPARISON OF TRICYCLIC ANTIDEPRESSANTS IN RABBITS: ANTINOCICEPTION AND POTENTIATION OF THE NORADRENALINE PRESSOR RESPONSES.
186579 03-03

ANTINOCICEPTIVE

ALPHA-ADRENERGIC BLOCKING AGENTS: ANTINOCICEPTIVE ACTIVITY AND ENHANCEMENT OF MORPHINE-INDUCED ANALGESIA.
183895 03-03

STUDIES ON THE POTENTIATION OF THE ANTINOCICEPTIVE EFFECT OF OXOTREMORINE BY TETRABENAZINE IN MICE.
185933 03-03

ANTIOVULATORY

A STUDY OF ANTIOVULATORY ACTIVITY OF HALOPERIDOL IN RABBITS.
177021 02-03

ANTIPARKINSON
ANTIPARKINSON DRUGS AS CAUSAL AGENTS IN TARDIVE DYSKINESIA.
169140 01-15
CENTRAL NERVOUS SYSTEM AND AUTONOMIC NERVOUS SYSTEM EFFECTS OF AMANTADINE AND OF SOME STANDARD ANTIPARKINSON DRUGS.
177729 02-13
HEAT DYSCONTROL SYNDROME IN PATIENTS RECEIVING ANTIPSYCHOTIC, ANTIDEPRESSANT AND ANTIPARKINSON DRUG THERAPY.
188094 04-15

ANTIPARKINSONIAN
ANTIPARKINSONIAN AGENTS AND DEPOT PHENOTHIAZINE.
173006 01-09
SYNTHESIS OF HYDROXYAPORPHINES AS POTENTIAL ANTIPARKINSONIAN AGENTS. (PH.D. DISSERTATION).
174967 02-01
EFFECTS OF ANTIPARKINSONIAN DRUGS ON NEUROLEPTIC INDUCED EXTRAPYRAMIDAL SIGNS IN MONKEYS.
183610 03-03
THE ABRUPT WITHDRAWAL OF ANTIPARKINSONIAN DRUGS IN SCHIZOPHRENIC PATIENTS.
185005 03-08

ANTIPSYCHOTIC
METIAPINE: THE EVALUATION OF THE ANTIPSYCHOTIC PROPERTIES OF A NEW NEUROLEPTIC. A PILOT STUDY.
167342 01-08
ANTIPSYCHOTIC AGENTS.
169152 01-11
CHANGES IN MENTAL FUNCTIONING ACCOMPANYING ANTIPSYCHOTIC DRUG THERAPY.
171124 01-10
IS THERE A RELATIONSHIP BETWEEN THE INVOLVEMENT OF EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS WITH THE CATALEPTIC ACTION OF NEUROLEPTIC AGENTS AND THEIR CLINICAL ANTIPSYCHOTIC EFFECT?
171305 01-03
PSYCHOLOGICAL EFFECTS OF SINGLE DOSE ANTIPSYCHOTIC MEDICATION.
173402 01-08
BASIC PRINCIPLES IN THE USE OF ANTIPSYCHOTIC AGENTS.
173433 01-11
SAFETY EVALUATION OF PENFLURIDOL, A NEW LONG-ACTING ORAL ANTIPSYCHOTIC AGENT.
177319 02-07
NEURONE BLOCKING ACTIONS OF ANTIPSYCHOTIC DRUGS.
182127 02-03
BEHAVIORAL EFFECTS OF EX-11-582A, A POTENTIAL ANTIPSYCHOTIC AGENT.
182242 03-04
ANTIPSYCHOTIC ACTION OF NEUROLEPTIC AGENTS AND THE FUNCTION OF BASAL GANGLIA (SURVEY OF LITERATURE).
183521 03-17
A COMPARATIVE STUDY OF THE ANTIPSYCHOTIC ACTION OF SOME NEUROLEPTICS BASED ON THE MODEL OF LSD PSYCHOSES.
183682 03-03
GUIDELINES FOR ANTIPSYCHOTIC DRUG USE.
186191 03-09
PERPHENAZINE CONCENTRATIONS IN HUMAN WHOLE BLOOD: A PILOT STUDY DURING ANTIPSYCHOTIC THERAPY USING DIFFERENT ADMINISTRATION FORMS.
187639 04-16
HEAT DYSCONTROL SYNDROME IN PATIENTS RECEIVING ANTIPSYCHOTIC, ANTIDEPRESSANT AND ANTIPARKINSON DRUG THERAPY.
188094 04-15
PENFLURIDOL: AN EFFICACIOUS LONG-ACTING ORAL ANTIPSYCHOTIC COMPOUND.
189072 04-08
RAPID DIGITALIZATION OF DECOMPENSATED SCHIZOPHRENIC PATIENTS WITH ANTIPSYCHOTIC AGENTS.
189095 04-08

ANTIPSYCHOTICS
COMBINED USE OF ECT AND PSYCHOTROPIC DRUGS: ANTIDEPRESSIVES AND ANTIPSYCHOTICS.
177670 02-11

ANTIPYRETIC
ANTIPYRETIC, ANALGESIC AND ANTIINFLAMMATORY ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL IN THE RAT.
182221 03-03

ANTIRESERPINE
EVALUATION OF CENTRAL ANTIRESERPINE EFFECT BY THE USE OF LIGHT BLINK REFLEX.
169469 01-04
SYNTHESIS AND ANTIRESERPINE ACTIVITY OF PEPTIDES OF L-DOPA.
180097 02-03

ANTISCHIZOPHRENIC
A POSSIBLE MECHANISM FOR THE ANTISCHIZOPHRENIC ACTION OF CHLORPROMAZINE: INHIBITION OF THE FORMATION OF DIMETHYLTRYPTAMINE BY CHLORPROMAZINE METABOLITES.
187576 04-03
ANTISCHIZOPHRENIC DRUGS AND BRAIN CHOLINERGIC RECEPTORS: AFFINITY FOR MUSCARINIC SITES PREDICTS EXTRAPYRAMIDAL EFFECTS.
188114 04-15

ANTISEROTONERGIC
INHIBITION OF ISOLATION INDUCED AGGRESSION IN MICE BY ANTISEROTONERGIC DRUGS.
182240 03-04

ANTISEROTONIN
QUANTUM CHEMICAL STUDIES ON DRUG ACTIONS: IV. CORRELATION OF SUBSTITUENT STRUCTURES AND ANTISEROTONIN ACTIVITY IN LYSERGAMIDE SERIES.
174605 01-12
THE ROLE OF HYDROPHOBICITY IN THE ANTISEROTONIN ACTIVITY OF LSD ANALOGS.
174606 01-12

ANTISUICIDAL
USE OF CHEMOTHERAPY AS ANTISUICIDAL PROPHYLAXIS.
191140 04-11

ANXIETY
CLORAZEPATE DIPOTASSIUM, DIAZEPAM AND PLACEBO IN CHRONIC ANXIETY.
167339 01-10
THE COMPUTER ANALYZES TWO PSYCHOTHERAPEUTIC AGENTS IN ANXIETY/DEPRESSED STATES.
167345 01-10
A MULTICENTER INVESTIGATION OF LORAZEPAM IN ANXIETY NEUROSIS.
167346 01-10
CHLORDIAZEPOXIDE AND DOTHIEPIN COMPARED IN ANXIETY/DEPRESSION IN GENERAL PRACTICE.
167575 01-10
BROMAZEPAM AND PHENOBARBITAL IN ANXIETY: A CONTROLLED STUDY.
167773 01-10
A STUDY OF THE CLINICAL EFFECTS OF PHENELZINE AND PLACEBO IN THE TREATMENT OF PHOBIC ANXIETY.
168832 01-10
LOW DOSAGE HALOPERIDOL AND INDUCED ANXIETY IN NORMAL VOLUNTEERS.
169745 01-14
THE PROBLEM OF ANXIETY IN A NON-WESTERN SOCIETY: A COMBINED CHEMOTHERAPEUTIC AND PSYCHOTHERAPEUTIC APPROACH.
171162 01-10
A DOUBLE-BLIND COMPARISON OF THIORIDAZINE (MELLARIL) VERSUS DIAZEPAM (VALIUM) IN PATIENTS WITH CHRONIC MIXED ANXIETY AND DEPRESSIVE SYMPTOMS.
172486 01-10
PILOT CLINICAL TRIAL OF PARENTERAL LORAZEPAM (TEMESTA) IN ANXIETY STATES.
174044 01-11
THE DIFFERENTIATION OF ANXIETY AND DEPRESSIVE DISORDERS: A PSYCHOPHARMACOLOGICAL APPROACH.
175286 02-10
LORAZEPAM IN THE TREATMENT OF ANXIETY.
176286 02-10
PREDICTING RELIEF FROM ANXIETY WITH PHENOBARBITAL.
177376 02-10
EFFECTS OF DIPHENYLHYDANTOIN ON ANXIETY AND HOSTILITY IN INSTITUTIONALIZED PRISONERS.
177671 02-11
TACITIN TREATMENT FOR THE PATIENT WITH ANXIETY.
178038 02-10
A DOUBLE-BLIND TRIAL OF TRIOXAZINE WITH PLACEBO IN ANXIETY STATES.
180249 02-10
MANIFEST ANXIETY AND ANTIANXIETY DRUG EFFECTS IN NORMAL VOLUNTEERS.
182118 02-14
SOME RECENT ADVANCES IN THE MANAGEMENT OF ANXIETY.
182764 03-10
A CONTROLLED TRIAL OF OXYPERTINE IN PATIENTS WITH ANXIETY.
182766 03-10
ANXIETY NEUROSIS IN GENERAL PRACTICE.
182767 03-10
MEASUREMENT OF ANXIETY IN GENERAL PRACTICE.
182768 03-10
A MULTICENTRE CLINICAL TRIAL OF OXYPERTINE IN ANXIETY NEUROSIS.
182769 03-10
CHLORMEZANONE IN ANXIETY: A DRUG REDISCOVERED?
184175 03-10
RELATIONSHIP OF PLASMA MEPERIDINE LEVELS TO CHANGES IN ANXIETY AND HOSTILITY.
185881 03-14

PLASMA LEVEL OF DIAZEPAM AS A THERAPEUTIC PREDICTOR IN ANXIETY STATES.
186584 03-10

TREATMENT OF ANXIETY NEUROSIS BY ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKING AGENTS.
186780 03-10

RESPONSE TO PROPRANOLOL AND DIAZEPAM IN SOMATIC AND PSYCHIC ANXIETY.
188887 04-10

MIXED ANXIETY DEPRESSION: FACT OR MYTH?
189919 04-10

THE TREATMENT OF MIXED ANXIETY AND DEPRESSION WITH LOXAPINE: A CONTROLLED COMPARATIVE STUDY.
190195 04-09

A DOUBLE-BLIND CONTROLLED STUDY OF LOXAPINE SUCCINATE IN THE TREATMENT OF ANXIETY NEUROSES.
190196 04-09

ANXIOLYTIC

A CLINICAL EVALUATION OF A NEW ANXIOLYTIC DRUG (THIENODIAZEPINE DERIVATIVE Y-6047) IN NEUROTICS AND PSYCHOSOMATIC DISORDERS -- A PRELIMINARY REPORT.
181771 02-07

PERCEPTUAL STYLE AND PAIN TOLERANCE -- II. THE INFLUENCE OF AN ANXIOLYTIC AGENT.
184291 03-14

CLINICAL EVALUATION OF ANXIOLYTIC DRUGS.
185350 03-17

PLASMA CONCENTRATIONS OF DIAZEPAM AND OF ITS METABOLITE N-DESMETHYLDIAZEPAM IN RELATION TO ANXIOLYTIC EFFECT.
186184 03-13

THE COMPARATIVE ANXIOLYTIC EFFECTS OF PLACEBO, IMIPRAMINE AND CHLORIMIPRAMINE USING PSYCHIATRIC AND PSYCHOPHYSIOLOGICAL MEASUREMENTS.
191137 04-14

ANXIOUS

ORTHOGONAL FACTORS VS. INTERDEPENDENT VARIABLES AS PREDICTORS OF DRUG TREATMENT RESPONSE IN ANXIOUS OUTPATIENTS.
171299 01-14

AMITRIPTYLINE IN ANXIOUS DEPRESSED OUTPATIENTS: A CONTROLLED STUDY.
172993 01-10

THE EFFECT OF LORAZEPAM ON ANXIOUS INSOMNIACS SLEEP AS RECORDED IN THE HOME ENVIRONMENT.
177318 02-14

CHLORDIAZEPOXIDE AND HOSTILITY IN ANXIOUS OUTPATIENTS.
181273 02-10

EFFECTS OF HYPNOTICS ON ANXIOUS PATIENTS.
184445 03-10

THIORIDAZINE IN NEUROTIC, ANXIOUS, AND DEPRESSED PATIENTS.
192227 04-10

APHRODISIAC

APHRODISIAC EFFECT OF L-DOPA AND APOMORPHINE IN MALE SEXUALLY SLUGGISH RATS.
188519 04-03

APLYSIA

VOLTAGE CLAMP ANALYSIS OF PENTYLENETETRAZOL EFFECTS ON APLYSIA NEURONS.
189032 04-03

APNEA

ECT, GLAUCOMA, AND PROLONGED APNEA.
187837 04-15

APOMORPHINE

PHARMACOLOGICALLY INDUCED BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE.
169120 01-03

DEVELOPMENT OF TOLERANCE IN RATS TO THE HYPOTHERMIC EFFECTS OF D-AMPHETAMINE AND APOMORPHINE.
174764 01-03

APOMORPHINE INDUCED BITING AND FIGHTING BEHAVIOUR IN RESERPINIZED RATS AND AN APPROACH TO THE MECHANISM OF ACTION.
174768 01-04

INHIBITION OF THE APOMORPHINE GNAWING COMPULSION BY AMANTADINE.
176879 02-04

DRUG-INDUCED CATALEPSY AS INFLUENCED BY PSYCHOSTIMULANTS, APOMORPHINE, L-DOPA, AND YOHIMBINE.
177730 02-13

FLAVOR AVERSIONS PRODUCED BY CONTINGENT DRUG INJECTION: RELATIVE EFFECTIVENESS OF APOMORPHINE, EMETINE, AND LITHIUM.
178502 02-04

EXPERIMENTAL DEPRESSION CAUSED BY APOMORPHINE AND PHENOHARMANE.
180062 02-10

INTERACTION OF APOMORPHINE, NEUROLEPTICS AND STIMULANTS WITH ALPHA-METHYL-M-TYRAMINE, A FALSE DOPAMINERGIC TRANSMITTER.
181809 02-03

SELECTIVE BLOCKADE OF APOMORPHINE INDUCED AGGRESSION AND GNAWING FOLLOWING FENFLURAMINE OR RAPHE LESIONS IN THE RAT.
182128 02-04

EFFECT OF MORPHINE, HALOPERIDOL, APOMORPHINE AND BENZTROPINE ON DOPAMINE TURNOVER IN RAT CORPUS-STRIATUM: EVIDENCE SHOWING MORPHINE-INDUCED REDUCTION IN CNS DOPAMINERGIC ACTIVITY.
182230 03-03

INVERSION BY APOMORPHINE OF THE TENDENCY OF FEMALE RATS TO BE DEFEATED BY MALES WHEN COMPETING FOR FOOD IN A STRAIGHT RUNWAY.
184212 03-04

INFLUENCE OF FLUPENTHIXOL AND FLUPENTHIXOL DECANOATE ON METHYLPHENIDATE AND APOMORPHINE INDUCED COMPULSIVE GNAWING IN MICE.
186371 03-04

A COMPARISON OF EFFECTS OF APOMORPHINE AND ET-495 ON LOCOMOTOR ACTIVITY AND CIRCLING BEHAVIOUR IN MICE.
186635 03-04

THE EFFECT OF AMANTADINE, L-DOPA, (_) AMPHETAMINE AND APOMORPHINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE.
186636 03-04

EFFECTS OF APOMORPHINE ON SELF-STIMULATION BEHAVIOR.
187666 04-04

BIOCHEMICAL AND BEHAVIORAL ANTAGONISM BETWEEN FENFLURAMINE AND APOMORPHINE IN RATS.
188196 04-03

APHRODISIAC EFFECT OF L-DOPA AND APOMORPHINE IN MALE SEXUALLY SLUGGISH RATS.
188519 04-03

EFFECTS OF NOMIFENSINE (HOE-984), D-AMPHETAMINE AND APOMORPHINE ON MOTOR ACTIVITY, CATECHOLAMINE TURNOVER AND CAMP CONCENTRATIONS IN RAT BRAIN. (UNPUBLISHED PAPER).
191766 04-03

POSITIVE REINFORCING EFFECTS OF APOMORPHINE, D-AMPHETAMINE AND MORPHINE: INTERACTION WITH HALOPERIDOL.
191899 04-04

APOMORPHINE-INDUCED

DRINKING BEHAVIOUR AND BRAIN DOPAMINE: ANTAGONISTIC EFFECT OF TWO NEUROLEPTIC DRUGS (PIMOZIDE AND SPIRAMIDE) UPON AMPHETAMINE OR APOMORPHINE-INDUCED HYPODIPSIA.
174035 01-04

EFFECTS OF MORPHINE AND CHLORPROMAZINE ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR.
185997 03-04

BRAIN AMINES AND APOMORPHINE-INDUCED INTRASPECIFIC AGGRESSIVE BEHAVIOR IN THE RAT.
186374 03-04

DOPAMINERGIC NATURE OF APOMORPHINE-INDUCED PECKING IN PIGEONS.
188204 04-03

APPARATUS

A NEW RECORDING APPARATUS FOR MEASUREMENT OF LOCOMOTOR ACTIVITY OF MICE. EXPERIMENTAL OBSERVATIONS ON ITS USE.
186377 03-06

APPETITE

DIFFERENTIAL SELF-INJECTION BEHAVIOR PRODUCED BY FENFLURAMINE VERSUS OTHER APPETITE INHIBITING DRUGS.
182215 03-04

APPRAISING

AN ENZYME APPROACH IN APPRAISING THE MODE OF SOME TRANQUILIZERS AND ANTIDEPRESSANTS.
174318 01-03

APPRECIATION

IN APPRECIATION OF BASIC BIOCHEMICAL RESEARCH IN MENTAL HEALTH. (UNPUBLISHED PAPER).
187488 04-17

APPROACH

THERAPEUTIC APPROACH TO THE APPROXIMATE ANSWERS OF A SCHIZOPHRENIC PATIENT.
170637 01-08

THE PROBLEM OF ANXIETY IN A NON-WESTERN SOCIETY: A COMBINED CHEMOTHERAPEUTIC AND PSYCHOTHERAPEUTIC APPROACH.
171162 01-10

THE NOOTROPIC APPROACH TO THE PHARMACOLOGY OF THE INTEGRATIVE ACTIVITY OF THE BRAIN.
173495 01-02

AN ENZYME APPROACH IN APPRAISING THE MODE OF SOME TRANQUILIZERS AND ANTIDEPRESSANTS.
174318 01-03

APOMORPHINE INDUCED BITING AND FIGHTING BEHAVIOUR IN RESERPINIZED RATS AND AN APPROACH TO THE MECHANISM OF ACTION.
174768 01-04

THE DIFFERENTIATION OF ANXIETY AND DEPRESSIVE DISORDERS: A PSYCHOPHARMACOLOGICAL APPROACH.
175286 02-10

THE PROBLEMS OF THE PSYCHOPHARMACOLOGICAL TREATMENT OF PSYCHOSOMATIC DISEASES -- THE ANESTHESIOLOGIC APPROACH.
177063 02-17
EFFECTS OF CONSECUTIVE ADMINISTRATION OF DIAZEPAM AND DOXEPIN ON BOTH APPROACH WITHDRAWAL AND APPROACH AVOIDANCE RESPONSES IN RATS.
182117 02-04
CLINICAL PHARMACOLOGY AS AN APPROACH TO THE STUDY OF BIOCHEMICAL SLEEP MECHANISMS: THE ACTION OF L-DOPA.
186643 03-14
INTERACTION BETWEEN NEUROLEPTIC THERAPY AND SOCIOTHERAPEUTIC APPROACH. AN INVESTIGATION WITH PENFLURIDOL AND HALOPERIDOL.
192431 04-08

APPROACHES
BIOCHEMICAL AND PHARMACOLOGICAL APPROACHES IN THE STUDY OF SYMPATHETIC NERVES. (UNPUBLISHED PAPER).
170082 01-03
NEW APPROACHES TO CONSCIOUSNESS.
178064 02-12

APPROXIMATE
THERAPEUTIC APPROACH TO THE APPROXIMATE ANSWERS OF A SCHIZOPHRENIC PATIENT.
170637 01-08

APY-606
EXPERIENCE IN THE APPLICATION OF DICEPLON (APY-606) -- COMPARED WITH FLOROPIPAMIDE.
176447 02-08
CLINICAL APPLICATION OF APY-606.
176541 02-08

ARCHITECTONICS
THE ACTION OF NEMBUTAL ON THE ULTRA ARCHITECTONICS OF THE NEUROHYPOPHYSIS.
183520 03-01

ARGENTINA
A COMPARISON OF CLINICALLY USED PSYCHOACTIVE DRUGS IN FOUR LATIN-AMERICAN COUNTRIES AND IN CANADA (ARGENTINA, COSTA-RICA, MEXICO AND PANAMA).
191139 04-17

AROMATIC
STIMULATION OF BRAIN AROMATIC ALKYLAMINE N-METHYLTRANSFERASE ACTIVITY BY FAD AND METHYLCOBALAMIN.
180020 02-03

AROUSAL
ONTOGENY OF SEROTONINERGIC INHIBITION OF BEHAVIORAL AROUSAL IN THE RAT.
174860 01-04

ARRHYTHMIAS
FAILURE OF BETA-ADRENERGIC RECEPTOR BLOCKADE TO PREVENT ARRHYTHMIAS INDUCED BY SYMPATHETIC NERVE STIMULATION.
187923 04-03

ARTERIAL
DIAZEPAM AND MEPERIDINE ON ARTERIAL BLOOD GASES IN HEALTHY VOLUNTEERS.
190147 04-13
EFFECT OF ANESTHETIC AGENTS ON PERIPHERAL SYMPATHETIC NERVOUS SYSTEM FUNCTION AS MONITORED BY ARTERIAL PLASMA CATECHOLAMINE LEVELS. (UNPUBLISHED PAPER
191495 04-03

ARTERIOSCLEROSIS
TREATMENT OF THE CEREBRAL MANIFESTATIONS OF ARTERIOSCLEROSIS WITH CYCLANDELATE.
185008 03-11

ARTISTIC
HALLUCINOGENIC DRUGS AND ARTISTIC CREATIVITY.
186026 03-12

ASAHIGAWA
CURRENT SITUATION OF THE USE OF DRUGS IN ASAHIGAWA JIDO-IN.
168302 01-17

ASCENDING
ENHANCEMENT OF AMPHETAMINE ACTION AFTER INTERRUPTION OF ASCENDING SEROTONERGIC PATHWAYS.
189398 04-03

ASCORBIC
INFLUENCE OF PHENOBARBITAL AND SEX HORMONES ON ENZYMES IN ASCORBIC ACID BIOSYNTHESIS IN MALE AND FEMALE RATS. (PH.D. DISSERTATION).
172017 01-03

ASPIRIN
RELIEF OF MUSCULOSKELETAL AND ASSOCIATED PSYCHOPATHOLOGICAL SYMPTOMS WITH MEPROBAMATE AND ASPIRIN: A CONTROLLED STUDY.
169632 01-10

ASSAY
SIMULTANEOUS MASS FRAGMENTOGRAPHIC ASSAY OF NOREPINEPHRINE (NE), EPINEPHRINE (E) AND DOPAMINE (DA) IN RAT SYMPATHETIC GANGLION: EFFECTS OF DEXAMETHASONE IN NEWBORN AND ADULT RATS. (UNPUBLISHED PAPER).
170747 01-03
STUDY ON THE PSYCHOPHARMACOLOGICAL ASSAY OF CENTRALLY ACTING DRUGS IN RATS.
171260 01-06
AMPHETAMINE IN HUMAN PLASMA: A SENSITIVE AND SPECIFIC ENZYMATIC ASSAY.
177403 02-16
CLINICAL ASSAY OF LORAZEPAM WITH AMBULANT PATIENTS.
183201 03-11
ASSAY PROCEDURES FOR THIORIDAZINE, TRIFLUOPERAZINE, AND THEIR SULFOXIDES AND DETERMINATION OF URINARY EXCRETION OF THESE COMPOUNDS IN MENTAL PATIENTS.
183602 03-01

ASSESSED
SOME RECENT HYPNOTICS ASSESSED.
189673 04-14

ASSESSING
PROGRESS REPORT ON THE USE OF THE DOG FOR ASSESSING MORPHINE-LIKE AND NALORPHINE-LIKE AGONISTS AS WELL AS DEPOT PREPARATIONS OF ANTAGONISTS. (UNPUBLISHED PAPER).
176312 02-03

ASSESSMENT
A COLLABORATIVE ASSESSMENT OF NOREPINEPHRINE METABOLISM IN AFFECTIVE DISORDERS.
169094 01-09
ASSESSMENT OF ANATENSOL (FLUPHENAZINE ENANTHATE) INJECTABLE IN THE TREATMENT OF SCHIZOPHRENIA.
172444 01-08
A CRITICAL ASSESSMENT OF METHODS FOR THE DETERMINATION OF MONOAMINE SYNTHESIS AND TURNOVER RATES IN VIVO.
191514 04-06
COMPREHENSIVE BEHAVIORAL ASSESSMENT OF THE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN RATS.
191966 04-04

ASSESSMENTS
LABORATORY ASSESSMENTS OF ANTIDEPRESSIVE ACTIVITY -- THEIR VALUE FOR CLINICAL PSYCHIATRY AND THE UNDERSTANDING OF DEPRESSION.
192422 04-09

ASSOCIATE
THE EFFECT OF TRANYLCYPROMINE (PARNATE) ON EYELID CONDITIONING AND PAIRED ASSOCIATE LEARNING IN DEPRESSED PATIENTS.
188107 04-09

ASSOCIATION
PARKINSONIAN SYNDROMES: TREATMENT BY ASSOCIATION OF L-DOPA PLUS DECARBOXYLASE INHIBITOR.
188093 04-11
IN VIVO CHANGES OF CEREBRAL CYCLIC ADENOSINE 3,5 MONOPHOSPHATE INDUCED BY BIOGENIC AMINES: ASSOCIATION WITH PHOSPHORYLASE ACTIVATION.
188291 04-03

ASSOCIATIVE
ROLE OF ASSOCIATIVE LEARNING IN FEEDING BEHAVIOR.
178044 02-17
THE EFFECTS OF PENTYLENETETRAZOL (METRAZOL) ON A LEARNED TASTE AVERSION PRODUCED BY LITHIUM CHLORIDE: THE ISSUE OF ASSOCIATIVE MEMORY VS. RETENTIVE MEMORY. (UNPUBLISHED PAPER).
188251 04-04

ATOMIC
DIRECT DETERMINATION OF LITHIUM IN SERUM BY ATOMIC ABSORPTION SPECTROSCOPY.
181653 02-06

ATP
(3H) OUABAIN BINDING TO NA_+-ATPASE AND K_+-ATPASE: INHIBITION BY BETA, GAMMA METHYLENE ATP.
182184 02-03
DDT EFFECT ON 32P INCORPORATION FROM GAMMA-LABELLED ATP INTO PROTEINS FROM LOBSTER NERVE.
191315 04-03

ATPASE
THE EFFECTS OF PSYCHIC STIMULANTS ON THE ACTIVITY OF POTASSIUM AND SODIUM ION STIMULATED ATPASE IN THE MICROSOMAL FRACTIONS OF THE BRAIN OF RATS.
183518 03-01
OUABAIN RECEPTOR INTERACTIONS IN (NA_+ , K_+) ATPASE PREPARATIONS.
189567 04-03
AMPHETAMINE AND NA_+,K_+ - ATPASE IN THE BRAIN.
191789 04-03

ATRIA
EFFECT OF SUBSTITUTED TRYPTAMINES ON THE EFFLUX OF NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
168747 01-03

ATROPINE
EFFECTS OF ATROPINE ON EXPLORATION, LEARNING AND ELECTROCORTICAL ACTIVITY IN THE DEVELOPING RAT.
169473 01-04

INTERACTION BETWEEN ATROPINE AND OXOTREMORINE ON CORTICAL ACETYLCHOLINE AND MOTOR ACTIVITY.
171606 01-03

TREATMENT OF HALLUCINATORY DISORDERS IN SCHIZOPHRENIA BY ATROPINE COMAS.
181778 02-08

ACUTE EFFECTS OF ALCOHOL, DIAZEPAM, THIORIDAZINE, FLUPENTHIXOL AND ATROPINE ON PSYCHOMOTOR PERFORMANCE PROFILES.
184848 03-14

EFFECTS OF CLONIDINE AND SOME ALPHA-ADRENORECEPTOR BLOCKING AGENTS ON AVOIDANCE CONDITIONED REFLEXES IN RATS: THEIR INTERACTIONS AND ANTAGONISM BY ATROPINE.
186576 03-04

ACTIONS OF ATROPINE, HEMICHOLINIUM-3, AND PHYSOSTIGMINE ON CHLORPROMAZINE INDUCED CHANGES IN RAT BRAIN MONOAMINES.
187800 04-03

EFFECT OF ATROPINE SULFATE ON THE SLEEP RELATED EEG SPIKE ACTIVITY OF THE TORTOISE, GEOCHELONE-CARBONARIA.
191389 04-03

ATTACHED

THE EFFECT OF CANNABINOIDS ON THE NUMBER OF NUCLEAR MEMBRANE ATTACHED RIBOSOMES IN INFANT RAT BRAIN.
183228 03-03

ATTACK

EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON ATTACK ELICITED BY HYPOTHALAMIC STIMULATION: RELATION TO BRAIN BIOGENIC AMINES.
170162 01-04

CENTRAL CHOLINERGIC (MUSCARINIC) LINK IN THE ATTACK REFLEXIVE BITING MECHANISM OF CATS.
182238 03-04

ATTACK ON THE GATE THEORY OF PAIN.
189610 04-17

ATTENTION

EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL (DELTA9-THC) ON MEMORY, ATTENTION AND SUBJECTIVE STATE: A DOUBLE-BLIND STUDY.
174043 01-14

ACQUISITION AND PERFORMANCE OF AN ATTENTION TASK BY RATS SUBJECTED TO CHRONIC NICOTINE TREATMENT.
176864 02-04

NEUROPSYCHOPHARMACOLOGICAL STUDIES OF ATTENTION.
181402 02-04

EFFECTS OF TWO LEVELS OF ATTENTION DEMAND ON VIGILANCE PERFORMANCE UNDER MARIHUANA.
189359 04-14

THE EFFECTS OF HOE-36801 ON MUSCLE ACTIVITY AND BLOOD PRESSURE, ON ATTENTION AND CONCENTRATION, ON TIME JUDGMENT AND SUBJECTIVE RESPONSES IN NEUROTICS AND NORMALS.
192429 04-14

ATTENUATED

KETAMINE INDUCED POSTANESTHETIC DELIRIUM ATTENUATED BY TETRAHYDROAMINOACRIDINE.
188689 04-05

ATTENUATION

ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN DIMETHYLAMINOPROPYLTHIOCINNAMANILIDE HYDROCHLORIDE), A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN (5-HTP) AND ALPHA-METHYLTRYPTAMINE.
176861 02-04

ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN, A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN AND ALPHA-METHYLTRYPTAMINE.
176873 02-04

HALLUCINOGENIC DRUG-INDUCED BEHAVIOR UNDER SENSORY ATTENUATION: PREDICTION OF RESPONSE TO PSILOCYBIN.
189744 04-12

ATTITUDES

PSYCHOLOGICAL STUDY ON ATTITUDES TOWARD TRANQUILIZERS.
173502 01-08

POPULAR ATTITUDES AND BELIEFS ABOUT TRANQUILIZERS.
177699 02-17

ATTRIBUTABLE

THE CORRECTIVE EFFECT OF PRAXINOR ON HYPOTENSION ATTRIBUTABLE TO PSYCHIATRIC THERAPY. SIDE-EFFECTS.
172980 01-11

AUDIOGENIC

EFFECT OF D-AMPHETAMINE SULFATE ON SUSCEPTIBILITY TO AUDIOGENIC SEIZURES IN DBA/2J MICE.
184235 03-03

AUDITORY

PHENOTHIAZINE DOSAGE LEVELS AND AUDITORY SIGNAL DETECTION IN SCHIZOPHRENIA.
167817 01-08

EFFECTS OF LSD ON AUDITORY PERCEPTION: A SIGNAL DETECTION ANALYSIS.
185752 03-04

AUTISM

ORAL 5-HTP IN PRIMARY AUTISM WITH 5-HT BINDING DEFECT.
181392 02-13

AUTOCRITICISM

AUTOCRITICISM AND REAL PLACE OF THE SAME MEDICATION (VESPRIN).
184964 03-11

AUTOMATIC

A RAPID AUTOMATIC METHOD FOR DETERMINING SHOCK SENSITIVITIES OF MICE.
171521 01-04

AUTOMATIC RECORDING OF ANIMAL BEHAVIOR AND ITS ANALYSIS.
182106 02-17

AUTOMATIC DETERMINATION OF THE PAIN THRESHOLD TO ELECTROSHOCK AND THE EFFECTS OF DELTA9-THC.
183363 03-03

AUTOMOBILE

EFFECTS OF CAFFEINE ON ALERTNESS IN SIMULATED AUTOMOBILE DRIVING.
190743 04-14

AUTONOMIC

THE EFFECT OF LITHIUM AND OTHER ANTIDEPRESSANT MEDICATIONS ON THE AUTONOMIC NERVOUS SYSTEM.
169635 01-15

CENTRAL NERVOUS SYSTEM AND AUTONOMIC NERVOUS SYSTEM EFFECTS OF AMANTADINE AND OF SOME STANDARD ANTIPARKINSON DRUGS.
177729 02-13

WORD RECOGNITION OF SCHIZOPHRENICS AS A FUNCTION OF PHENOTHIAZINE LEVEL AND AUTONOMIC RESPONSIVITY. (PH.D. DISSERTATION).
182524 03-08

ROLE OF THE CENTRAL AUTONOMIC NERVOUS SYSTEM IN THE HYPOTENSION AND BRADYCARDIA INDUCED BY (-) DELTA9-TETRAHYDROCANNABINOL.
183795 03-03

AUTOPSY

AN AUTOPSY CASE OF SCHIZOPHRENIA COMPLICATED WITH PARKINSONISM INDUCED BY PERPHENAZINE.
171275 01-15

DETERMINATION OF DOXEPIN IN AUTOPSY MATERIAL.
172398 01-16

AUTORADIOGRAPHIC

EVIDENCE FOR AN UNUSUAL DISTRIBUTION OF CHLORPHENTERMINE IN VIVO: AN AUTORADIOGRAPHIC STUDY IN MICE.
184226 03-03

AVERAGE

COMPARABLE THERAPEUTIC EFFICACY OF TRYPTOPHAN AND IMIPRAMINE: AVERAGE THERAPEUTIC RATINGS VERSUS TRUE EQUIVALENCE. AN IMPORTANT DIFFERENCE.
167344 01-09

AVERAGE EVOKED RESPONSES IN NORMAL AND MINIMALLY BRAIN DYSFUNCTIONED CHILDREN TREATED WITH AMPHETAMINE: A PRELIMINARY REPORT.
169861 01-11

POLYMYALGIA RHEUMATICA IN A GERIATRIC DEPARTMENT: NINE PATIENTS WITH AN AVERAGE AGE OF 83 YEARS.
187236 03-11

AVERSION

AN OBSESSIVE NEUROSIS FOLLOWING MORNING-GLORY SEED INGESTION TREATED BY AVERSION RELIEF.
184259 03-15

HIPPOCAMPAL LESIONS AND LEARNED TASTE AVERSION.
184834 03-04

PREDATION: SEPARATION OF AGGRESSIVE AND HUNGER MOTIVATION BY CONDITIONED AVERSION.
185463 03-04

MODULATION OF REWARD AND AVERSION PROCESSES IN THE RAT DIENCEPHALON BY AMPHETAMINE.
186164 03-04

THE EFFECTS OF PENTYLENETETRAZOL (METRAZOL) ON A LEARNED TASTE AVERSION PRODUCED BY LITHIUM CHLORIDE: THE ISSUE OF ASSOCIATIVE MEMORY VS. RETENTIVE MEMORY. (UNPUBLISHED PAPER).
188251 04-04

METRAZOL DISRUPTS CONDITIONED AVERSION PRODUCED BY LICL: A TIME DEPENDENT EFFECT.
188412 04-04

AVERSIONS

FLAVOR AVERSIONS PRODUCED BY CONTINGENT DRUG INJECTION: RELATIVE EFFECTIVENESS OF APOMORPHINE, EMETINE, AND LITHIUM.
178502 02-04

BACKWARD CONDITIONING OF TASTE AVERSIONS IN RATS USING CYCLOPHOSPHAMIDE AS THE US.
190265 04-04

AVERSIVE

NALORPHINE AS AN AVERSIVE AGENT. (PH.D. DISSERTATION).
185727 03-04

AVIAN

LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND GAMMA-AMINOBUTYRIC ACID (GABA) INTERACTION ON SPONTANEOUS POTENTIALS AND THE EVOKED RESPONSE IN THE AVIAN TECTUM.
169689 01-03

AVOIDANCE

ACQUISITION AND RETENTION OF AVOIDANCE BEHAVIORS FOLLOWING SEPTAL LESIONS OR SCOPOLAMINE INJECTIONS IN RATS.
167401 01-04

EFFECT OF PRENATAL MATERNAL ADMINISTRATION OF D-AMPHETAMINE ON RAT OFFSPRING ACTIVITY AND PASSIVE AVOIDANCE LEARNING.
167415 01-03

THE EFFECTS OF AGENTS THAT MODIFY MUSCARINIC TONE UPON BEHAVIOR CONTROLLED BY AN AVOIDANCE SCHEDULE THAT EMPLOYS SIGNALED UNAVOIDABLE SHOCK.
171302 01-04

MULTITRIAL PASSIVE AVOIDANCE IN RATS: MESCALINE, SHOCK, AND ITI EFFECTS. (PH.D. DISSERTATION).
173162 01-04

THE EFFECTS OF INTRACAUDATE INJECTIONS OF CHLORPROMAZINE ON CONDITIONED AVOIDANCE AND SELF-STIMULATION BEHAVIOR. (PH.D. DISSERTATION).
173749 01-04

THE EFFECT OF DOPAMINE ANTAGONISTS AND AMANTADINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
174829 01-04

THE EFFECT OF PHASE-SHIFT ON THE PASSIVE AVOIDANCE RESPONSE IN RATS, AND THE MODIFYING EFFECT OF CHLORDIAZEPOXIDE.
174830 01-04

EFFECTS OF INTRAPERITONEAL AND INTRAVENTRICULAR D-AMPHETAMINE ADMINISTRATION ON ACTIVE AVOIDANCE PERFORMANCE IN THE RAT.
175242 02-04

EFFECTS OF STIMULUS ASSOCIATED WITH AMOBARBITAL ADMINISTRATION ON AVOIDANCE BEHAVIOR.
175877 02-04

POSTTRIAL STRYCHNINE: LACK OF EFFECT ON CONDITIONED AVOIDANCE LEARNING.
176866 02-04

AN ANALYSIS OF D-AMPHETAMINE PRODUCED FACILITATION OF AVOIDANCE ACQUISITION IN RATS AND PERFORMANCE CHANGES SUBSEQUENT TO DRUG TERMINATION.
179990 02-04

AVOIDANCE OF ADVERSE REACTIONS.
180247 02-15

INCREASED GASTRIC ACID DURING SHOCK AVOIDANCE IN MAN.
181879 02-13

EFFECTS OF PSYCHOTROPIC DRUGS ON DISCRIMINATION AVOIDANCE CONDITIONING IN RATS WITH OLFACTORY BULB ABLATIONS.
182115 02-04

EFFECTS OF CONSECUTIVE ADMINISTRATION OF DIAZEPAM AND DOXEPIN ON BOTH APPROACH WITHDRAWAL AND APPROACH AVOIDANCE RESPONSES IN RATS.
182117 02-04

INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CAFFEINE, (C), NICOTINE (N), PHENOBARBITAL (P): EFFECTS ON CONDITIONED AVOIDANCE (CAR).
182192 02-04

THE EFFECT OF PSYCHOTROPIC AGENTS ON THE FORMATION OF AVOIDANCE REACTION IN ALBINO RATS DURING ELECTROPAIN STIMULATION OF ANOTHER RAT.
183206 03-04

FAILURE OF ACTH TO INFLUENCE AVOIDANCE EXTINCTION IN A ONE-WAY AVOIDANCE SITUATION.
183470 03-04

EFFECTS OF NEONATAL STRYCHNINE ADMINISTRATION ON ACTIVE AVOIDANCE IN RATS.
184242 03-04

SEIZURE SUSCEPTIBILITY AND AVOIDANCE CONDITIONING IN ADULT RATS TREATED PRENATALLY WITH CHLORPROMAZINE.
184371 03-04

THE EFFECTS OF CHLORPROMAZINE ON A REDEFINED PROCEDURE OF EXTINCTION OF SIDMAN AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
185715 03-14

CHLORPROMAZINE AND AVOIDANCE: A GENETIC ANALYSIS.
185751 03-03

PHARMACOLOGICAL DISTINCTIONS BETWEEN ACTIVE AND PASSIVE AVOIDANCE MEMORY FORMATION AS SHOWN BY MANIPULATION OF BIOGENIC AMINE ACTIVE COMPOUNDS.
185927 03-04

EFFECTS OF CLONIDINE AND SOME ALPHA-ADRENORECEPTOR BLOCKING AGENTS ON AVOIDANCE CONDITIONED REFLEXES IN RATS: THEIR INTERACTIONS AND ANTAGONISM BY ATROPINE.
186576 03-04

THE EFFECT OF IPRONIAZID AND TRANYLCYPROMINE STUDIED WITH A DARK AVOIDANCE CONDITIONED SCHEDULE.
186590 03-04

THE EFFECT OF AMANTADINE, L-DOPA, (..) AMPHETAMINE AND APOMORPHINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE.
186636 03-04

STRUCTURE-ACTIVITY RELATIONS OF SOME INDOLEALKYLAMINES IN COMPARISON TO PHENETHYLAMINES ON MOTOR ACTIVITY AND ACQUISITION OF AVOIDANCE BEHAVIOR.
186703 03-04

INFLUENCE OF ALPHA-METHYLTYROSINE ON ENHANCEMENT OF SHUTTLEBOX AVOIDANCE BY MARIJUANA AND PENTOBARBITAL.
187572 04-04

LOCALIZED BEHAVIORAL EFFECTS OF VASOPRESSIN ON MAINTENANCE OF AN ACTIVE AVOIDANCE RESPONSE IN RATS.
187697 04-04

INTERACTION AMONG GENOTYPE, UNCONDITIONED STIMULUS, D-AMPHETAMINE, AND ONE-WAY AVOIDANCE BEHAVIOR OF RATS.
187702 04-04

EFFECTS OF CYCLOHEXIMIDE ON ACQUISITION AND RETENTION OF AVOIDANCE LEARNING IN THE RAT: RECOVERY OF MEMORY.
189215 04-04

THE EFFECTS OF D-AMPHETAMINE ON THE INTERRESPONSE TIMES OF RATS AND GUINEA-PIGS ON A MODIFIED SIDMAN DISCRIMINATED AVOIDANCE SCHEDULE.
189519 04-04

AN ANALYSIS OF THE FACILITATION OF AVOIDANCE ACQUISITION BY D-AMPHETAMINE AND SCOPOLAMINE.
189521 04-04

MESCALINE FACILITATES RETENTION OF PASSIVE AVOIDANCE IN RATS.
190266 04-04

EFFECTS OF NICOTINE AND ITS WITHDRAWAL ON THE PERFORMANCE OF RATS ON SIGNALLED AND UNSIGNALLED AVOIDANCE SCHEDULES.
190331 04-04

EFFECTS OF NICOTINE ON THE OBSERVED BEHAVIOUR OF RATS DURING SIGNALLED AND UNSIGNALLED AVOIDANCE EXPERIMENTS.
190332 04-04

INTERACTION OF MESCALINE AND STRESS ON SHUTTLEBOX ESCAPE/AVOIDANCE IN RATS.
191934 04-04

INTERACTIONS BETWEEN RO-4-1284 AND D-AMPHETAMINE (DA) ON SHUTTLEBOX AVOIDANCE IN RATS.
192009 04-04

EFFECTS OF DELTA1-TETRAHYDROCANNABINOL ON SIDMAN DISCRIMINATED AVOIDANCE BEHAVIOR IN RATS.
192413 04-03

AXON

NONCHOLINERGIC MECHANISM OF ACTION OF CHOLINERGIC DRUGS ON SQUID AXON MEMBRANES.
186672 03-03

AXOPLASMIC

INCREASED AXOPLASMIC TRANSPORT OF H3-DOPAMINE IN NIGRO-NEOSTRIATAL NEURONS AFTER RESERPINE.
175241 02-03

EFFECT OF DRUGS UPON AXOPLASMIC TRANSPORT.
182772 03-17

AXOTOMY

INFLUENCES OF DRUGS ON THE INCREASES IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OF GAMMA-HYDROXYBUTYRIC ACID (GHBA).
171622 01-03

EFFECT OF ANESTHETIC AGENTS ON THE SYNTHESIS AND DISAPPEARANCE OF BRAIN DOPAMINE NORMALLY AND AFTER HALOPERIDOL, KCL OR AXOTOMY.
189571 04-03

AZAPHEN

THE ABSORPTION AND DISTRIBUTION OF THE NEW ANTIDEPRESSANT AZAPHEN IN THE ORGANS.
183519 03-03

BABOONS

THE COMPARATIVE EFFECTS OF PENTOBARBITAL AND D-AMPHETAMINE ON A SHORT-TERM MEMORY TASK IN BABOONS.
191917 04-04

BACKWARD

BACKWARD CONDITIONING OF TASTE AVERSIONS IN RATS USING CYCLOPHOSPHAMIDE AS THE US.
190265 04-04

BACTERIAL

A BACTERIAL MODEL FOR EVALUATION OF BARBITURATES.
191920 04-03

BALANCE

NEGATIVE SODIUM BALANCE IN LITHIUM CARBONATE TOXICITY: EVIDENCE OF MINERALOCORTICOID BLOCKADE.
169869 01-15

BALANCE BETWEEN ACETYLCHOLINE, SEROTONIN, NOREPINEPHRINE, AND DOPAMINE IN SELF-STIMULATION.
191528 04-04

CHOLINERGIC AND ADRENERGIC BALANCE IN MANIA AND SCHIZOPHRENIA.
191530 04-09

CLINICAL INTIMATIONS OF AMINE BALANCE AND PERMISSION.
191534 04-09

BALB
DIFFERENTIAL EFFECTS OF ETHANOL AND PENTOBARBITAL ON SLEEP TIME IN C57BL AND BALB MICE.
177733 02-03

BAMETHAN
TREATMENT OF CEREBROVASCULAR DISTURBANCES WITH 2-BUTYLAMINO-1-P-HYDROXYPHENYL ETHANOL SULFATE (BAMETHAN).
182790 03-11

BAR-PRESS
THE EFFECTS OF CHLORDIAZEPOXIDE, AMPHETAMINE AND COCAINE ON BAR-PRESS BEHAVIOR IN NORMAL AND GENETICALLY NERVOUS DOGS.
187868 04-04

BAR-PRESSING
SENSORY CONTINGENT BAR-PRESSING FOR FAMILIAR AND NOVEL CHANGE UNDER A DEXAMPHETAMINE AMYLOBARBITONE MIXTURE.
181605 02-04

BARBITAL
TOLERANCE TO HEXOBARBITAL AND SUPERSENSITIVITY TO PILOCARPINE INDUCED BY CHRONIC BARBITAL TREATMENT IN THE RAT.
171601 01-03
COMPARISON OF BARBITAL & PENTOBARBITAL PHYSICAL DEPENDENCE IN THE CAT.
191953 04-04

BARBITURATE
SYNTHESIS OF ACETYLCHOLINE IN BRAIN NERVE TERMINALS DURING CONSCIOUSNESS AND BARBITURATE ANESTHESIA.
171600 01-03
BLOCKADE OF THE PROESTROUS LH SURGE IN CYCLIC RATS BY BARBITURATE ADMINISTRATION ON DIESTRUS.
175650 02-03
BARBITURATE DEPENDENCE IN MICE INDUCED BY A SIMPLE SHORT-TERM ORAL PROCEDURE.
175895 02-03
THE ELECTROENCEPHALOGRAPHIC CHANGES IN ACUTE BARBITURATE POISONING.
180152 02-15
POTENTIATION OF BARBITURATE HYPNOSIS BY 5-DIAZOIMIDAZOLE-4-CARBOXAMIDE AND ITS DERIVATIVES.
182113 02-03
PHARMACOLOGIC ACTIVITY AND BIOTRANSFORMATION OF R.. AND S-BARBITURATE ENANTIOMERS IN MOUSE AND MAN.
182156 02-03
MECHANISMS UNDERLYING POTENTIATION OF BARBITURATE ACTION BY SODIUM NITRITE IN THE MOUSE: THE ROLE OF METHEMOGLOBIN INDUCED HYPOXIA.
182721 03-03
PGO WAVES IN THE LATERAL GENICULATE NUCLEUS TRIGGERED BY BARBITURATE.
187835 04-03
TURNOVER OF HISTAMINE IN RAT BRAIN AND ITS DECREASE UNDER BARBITURATE ANESTHESIA.
189396 04-03
ABSENCE OF REM REBOUND AFTER BARBITURATE WITHDRAWAL.
189884 04-14

BARBITURATES
TURNOVER CHANGES IN CENTRAL MONOAMINE NEURON SYSTEMS AFTER MINOR TRANQUILLIZERS AND BARBITURATES.
171604 01-03
ARE THERE SAFER HYPNOTICS THAN BARBITURATES?
174561 01-15
ACUTE LETHALITY FOR MICE FOLLOWING ADMINISTRATION OF CYCLOPHOSPHAMIDE WITH BARBITURATES.
177834 02-05
UPTAKE AND RELEASE OF NORADRENALINE IN RAT CEREBRAL CORTEX IN VITRO: NO EFFECT OF BENZODIAZEPINES AND BARBITURATES.
182347 03-03
CALCIUM REVERSAL OF NERVE BLOCKADE BY ALCOHOLS, ANESTHETICS, TRANQUILIZERS, AND BARBITURATES.
187802 04-03
THE IMPULSE BLOCKING CONCENTRATIONS OF ANESTHETICS, ALCOHOLS, ANTICONVULSANTS, BARBITURATES, AND NARCOTICS ON PHRENIC AND SCIATIC NERVES.
187803 04-03
BENZODIAZEPINES AND BARBITURATES: TURNOVER CHANGES IN CENTRAL 5-HYDROXYTRYPTAMINE PATHWAYS.
189611 04-03
A BACTERIAL MODEL FOR EVALUATION OF BARBITURATES.
191920 04-03

BARBITURIC
THE SITE OF ACTION ON THE OPTICAL ISOMERS OF 1-METHYL-5-PHENYL-5-PROPYL BARBITURIC ACID.
185901 03-03

BARRIER
ANIMAL MODELS FOR AN ENZYMIC BLOOD-BRAIN BARRIER MECHANISM FOR THERAPEUTICALLY ADMINISTERED L-DOPA.
167359 01-03
THE DEVELOPMENT OF A BLOOD-BRAIN BARRIER TO METHADONE IN THE NEWBORN RAT.
182165 02-03
TRUE AND APPARENT NON-PENETRATION OF THE BLOOD-BRAIN BARRIER BY PSYCHOTROPIC DRUGS.
192423 04-03

BASAL
ANTIPSYCHOTIC ACTION OF NEUROLEPTIC AGENTS AND THE FUNCTION OF BASAL GANGLIA (SURVEY OF LITERATURE).
183521 03-17

BASE
POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES. 2. MODIFICATION OF THE BASE PORTION OF S-ADENOSYLHOMOCYSTEINE.
190717 04-01

BASELINE
THE CONDITIONED EMOTIONAL RESPONSE (CER) AS A BASELINE FOR THE STUDY OF ANTIANXIETY DRUGS.
183862 03-04

BATRACHOTOXIN
THE INHIBITION OF 3H-DOPAMINE UPTAKE INTO RAT STRIATAL BY VERATRIDINE AND BATRACHOTOXIN. (UNPUBLISHED PAPER).
173380 01-03

BDP
PROTECTION PRODUCED BY BENZODIAZEPINES (BDP) AGAINST THE NEUROTOXIC AND CONFLICT BEHAVIOR EFFECTS OF HEXACHLOROPHENE (HCP) IN CATS.
176863 02-04

BED-WETTING
DRUGS FOR BED-WETTING.
189778 04-11

BEHAVIOR
OPERANT BEHAVIOR AND NEUROPHYSIOLOGICAL OBSERVATIONS OF NORMAL HUMAN VOLUNTEERS RECEIVING CL-1848C, A NEW DISSOCIATIVE ANESTHETIC.
167334 01-07
EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF CANNABIS-SATIVA EXTRACT ON THE MOUSE-KILLING BEHAVIOR OF RATS.
167362 01-04
THE EFFECTS OF D- AND L-AMPHETAMINE ON FIXED-INTERVAL AND FIXED-RATIO BEHAVIOR IN TOLERANT AND NONTOLERANT RATS.
168438 01-04
STIMULATION OF BEHAVIOR IN THE RAT BY CYCLAZOCINE: EFFECTS OF NALOXONE.
168439 01-04
EFFECTS OF IMIPRAMINE ON COPULATORY BEHAVIOR OF MALE RATS.
168718 01-04
THE SOCIAL PLAY BEHAVIOR OF CHIMPANZEES ACCORDING TO A PSYCHOPHARMACOLOGICAL TEST/.
168838 01-04
THE RELATIONSHIP OF MARIHUANA AND SOCIAL BEHAVIOR.
169084 01-13
THE EFFECTS OF AGENTS THAT MODIFY MUSCARINIC TONE UPON BEHAVIOR CONTROLLED BY AN AVOIDANCE SCHEDULE THAT EMPLOYS SIGNALED UNAVOIDABLE SHOCK.
171302 01-04
IMPORTANCE OF CATECHOLAMINE RELEASE BY NERVE IMPULSES FOR FREE OPERANT BEHAVIOR.
171611 01-04
CHANGE OF ESTROGEN ACTIVATED BEHAVIOR BY CYCLOHEXIMIDE IN THE FEMALE RAT.
171615 01-04
ACTIVATION OF COPULATORY BEHAVIOR BY PILOCARPINE AND OXOTREMORINE IN THE FEMALE RAT.
171616 01-04
A DIFFERENTIAL INHIBITORY ACTION OF LSD AND AMPHETAMINE ON COPULATORY BEHAVIOR IN THE FEMALE RAT.
171617 01-04
THE ROLE OF THE SEPTAL AREA OF THE BRAIN IN THE INHIBITORY MODULATION OF BEHAVIOR. (PH.D. DISSERTATION).
172021 01-03
ALTERATION OF MATERNAL BEHAVIOR IN MICE FOLLOWING ADMINISTRATION OF CYPROTERONE ACETATE.
172374 01-04
MODIFICATION OF STIMULATION BOUND BEHAVIOR BY TRIFLUOPERAZINE AND AMPHETAMINE IN RATS. (PH.D. DISSERTATION).
173158 01-04
BEHAVIOR AND SENSITIVITY TO EXPERIMENTAL HYPERTENSION: II. LACK OF CORRELATION BETWEEN CERTAIN BEHAVIOR PATTERNS AND HYPERTENSION IN TWO NEW STRAINS OF RATS.
173256 01-04
THE EFFECTS OF INTRACAUDATE INJECTIONS OF CHLORPROMAZINE ON CONDITIONED AVOIDANCE AND SELF-STIMULATION BEHAVIOR. (PH.D. DISSERTATION).
173749 01-04

THE EFFECTS OF MESCALINE ADMINISTERED BEFORE OR DURING EMBRYOGENESIS UPON THE HATCHABILITY AND BEHAVIOR OF THE CHICK. (PH.D. DISSERTATION).
173791 01-04

THE EFFECTS OF PHENITRONE, A REPORTED HASHISH ANTAGONIST, ON THE OVERT BEHAVIOR OF CATS.
174607 01-04

PHARMACOLOGICAL SUPPRESSION OF EATING BEHAVIOR IN RELATION TO DIENCEPHALIC NORADRENERGIC RECEPTORS.
174763 01-04

MARIHUANA AND SOCIAL BEHAVIOR.
175003 02-14

EFFECTS OF PSYCHOACTIVE DRUGS ON NONVERBAL COMMUNICATION AND GROUP SOCIAL BEHAVIOR OF MONKEYS.
175317 02-04

EFFECTS OF STIMULUS ASSOCIATED WITH AMOBARBITAL ADMINISTRATION ON AVOIDANCE BEHAVIOR.
175877 02-04

VOCALIZATION: A CHARACTERISTIC CANNABIS INDUCED BEHAVIOR IN THE RAT?
175884 02-04

ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN DIMETHYLAMINOPROPYLTHIOCINNAMANILIDE HYDROCHLORIDE), A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN (5-HTP) AND ALPHA-METHYLTRYPTAMINE.
176861 02-04

PROTECTION PRODUCED BY BENZODIAZEPINES (BDP) AGAINST THE NEUROTOXIC AND CONFLICT BEHAVIOR EFFECTS OF HEXACHLOROPHENE (HCP) IN CATS.
176863 02-04

EFFECTS OF AMPHETAMINE (A), LSD, PSILOCYBIN (P), AND DOM ON SCHEDULE-CONTROLLED BEHAVIOR IN THE RAT.
176869 02-04

ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN, A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN AND ALPHA-METHYLTRYPTAMINE.
176873 02-04

STEREOTYPED AND AGGRESSIVE BEHAVIOR INDUCED BY SUSTAINED HIGH DOSE OF THEOPHYLLINE IN RATS.
177019 02-04

FURTHER ASPECTS OF AGGRESSIVE BEHAVIOR INDUCED BY SUSTAINED HIGH DOSE OF THEOPHYLLINE IN RATS.
177020 02-04

NOREPINEPHRINE SENSITIVE ADENYLATE CYCLASES IN RAT BRAIN: RELATION TO BEHAVIOR AND TYROSINE HYDROXYLASE.
177252 02-03

THE THALAMIC RAT: GENERAL BEHAVIOR, OPERANT LEARNING WITH REWARDING HYPOTHALAMIC STIMULATION, AND EFFECTS OF AMPHETAMINE.
177477 02-04

THE EFFECTS OF CHLORDIAZEPOXIDE (LIBRIUM) ON THE INTENSITY AND HABITUATION OF AGONISTIC BEHAVIOR IN MALE SIAMESE FIGHTING FISH.
177722 02-04

EFFECTS OF CHLORPROMAZINE, CHLORDIAZEPOXIDE AND PENTOBARBITAL ON NEURONAL EXCITABILITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
177837 02-04

ROLE OF ASSOCIATIVE LEARNING IN FEEDING BEHAVIOR.
178044 02-17

THE EFFECTS OF EARLY P-CHLOROPHENYLALANINE ADMINISTRATION AND POSTWEANING HOUSING CONDITIONS ON SEROTONIN AND BEHAVIOR IN RATS.
178638 02-04

ANTICHOLINERGICS: THEIR EFFECTS ON FEAR MOTIVATED BEHAVIOR, URINARY 11-HYDROXYCORTICOSTEROIDS, URINARY VOLUME, AND HEART RATE IN THE DOG.
178720 02-03

OPEN-FIELD BEHAVIOR AND ACQUISITION OF DISCRIMINATIVE RESPONSE CONTROL IN DELTA9-THC TOLERANT RATS.
178813 02-04

COMPARISON OF CLOPENTHIXOL AND PERPHENAZINE IN BEHAVIOR AND EEG OF UNANESTHETIZED CATS.
181386 02-04

DRUGS ON EEG CORRELATES OF BEHAVIOR.
181396 02-04

BASIC TYPES OF EFFECTS OF DRUGS ON BEHAVIOR.
181399 02-04

EFFECTS OF PSYCHOPHARMACOLOGIC AGENTS ON BEHAVIOR.
181403 02-04

DETERMINANTS OF DRUG EFFECTS ON PUNISHED BEHAVIOR.
181405 02-04

AUTOMATIC RECORDING OF ANIMAL BEHAVIOR AND ITS ANALYSIS.
182106 02-17

EFFECTS OF CNS STIMULANTS ON OPERANT BEHAVIOR.
182110 02-04

EFFECTS OF CYPROHEPTADINE ON THE EATING BEHAVIOR OF RATS AND CATS.
182111 02-04

EFFECTS OF PSYCHOTROPIC DRUGS ON ABNORMAL BEHAVIOR INDUCED BY DELTA9-TETRAHYDROCANNABINOL.
182114 02-04

DISPOSITION OF NORAPOMORPHINE AND N,N PROPYLNORAPOMORPHINE IN MOUSE BRAIN AND ITS CORRELATION WITH STEREOTYPED GNAWING BEHAVIOR.
182131 02-04

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON THE DOMINANCE BEHAVIOR OF THE RAT.
182189 02-04

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND METHYSERGIDE ON DEFENSIVE BEHAVIOR IN RATS.
182190 02-04

DIFFERENTIAL SELF-INJECTION BEHAVIOR PRODUCED BY FENFLURAMINE VERSUS OTHER APPETITE INHIBITING DRUGS.
182215 03-04

DRUGS, BEHAVIOR AND CHOLINE ACETYLTRANSFERASE.
182237 03-04

THE USE OF BIOCHEMICAL CORRELATES FOR THE PREDICTION OF MURICIDAL BEHAVIOR IN THE WILD RAT.
182241 03-04

EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON ELECTROENCEPHALOGRAM AND FEEDING BEHAVIOR OF RATS.
182554 03-04

THE EFFECT OF PAIN RELIEVING DRUGS ADMINISTERED DURING LABOR AND DELIVERY ON THE BEHAVIOR OF THE NEWBORN: A REVIEW.
183706 03-17

REDUCTION IN COPULATORY BEHAVIOR OF MALE RATS FOLLOWING HASHISH INJECTIONS.
183790 03-04

MODIFICATION OF THE EFFECTS OF CHLORPROMAZINE ON BEHAVIOR IN THE CHIMPANZEE.
183889 03-04

BEHAVIOR AS A STIMULUS: JOINT EFFECTS OF D-AMPHETAMINE AND PENTOBARBITAL.
183890 03-04

DIAZEPAM-INDUCED PLAY BEHAVIOR IN CATS DURING PREY KILLING.
184979 03-04

AN INVESTIGATION OF INTERACTIONS AMONG LSD, DEXTROAMPHETAMINE, AND VERBAL BEHAVIOR IN MONOLOGUES AND DIALOGUES. (PH.D. DISSERTATION).
185600 03-14

EFFECTS OF CONCURRENT BEHAVIOR MODIFICATION AND CHLORPROMAZINE ADMINISTRATION IN MENTALLY RETARDED WOMEN. (PH.D. DISSERTATION).
185604 03-14

NEURAL AND CHEMICAL MECHANISMS OF FEMALE SEXUAL BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).
185705 03-04

THE EFFECTS OF CHLORPROMAZINE ON A REDEFINED PROCEDURE OF EXTINCTION OF SIDMAN AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
185715 03-14

TESTS OF EMOTIONAL BEHAVIOR IN RATS FOLLOWING DEPLETION OF NOREPINEPHRINE, OF SEROTONIN, OR OF BOTH.
185753 03-04

DOSE DEPENDENT SELECTIVE FACILITATION OF RESPONSE CONTINGENT LIGHT ONSET BEHAVIOR BY D-AMPHETAMINE.
185955 03-04

BRAIN AMINES AND APOMORPHINE-INDUCED INTRASPECIFIC AGGRESSIVE BEHAVIOR IN THE RAT.
186374 03-04

ADAPTATION TO NITROGEN NARCOSIS MANIFESTED BY TIMING BEHAVIOR IN THE RAT.
186630 03-04

LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04

EFFECTS OF AN ESTROGEN ANTAGONIST, MER-25, ON MOUNTING BEHAVIOR AND LORDOSIS BEHAVIOR IN THE FEMALE RAT.
186691 03-04

TRYPTAMINE ANTAGONISTS AND PUNISHED BEHAVIOR.
186692 03-04

STRUCTURE-ACTIVITY RELATIONS OF SOME INDOLEALKYLAMINES IN COMPARISON TO PHENETHYLAMINES ON MOTOR ACTIVITY AND ACQUISITION OF AVOIDANCE BEHAVIOR.
186703 03-04

A DETAILED ANALYSIS OF THE EFFECTS OF D-AMPHETAMINE ON BEHAVIOR UNDER FIXED-INTERVAL SCHEDULES.
187066 03-04

BEHAVIOR AND EEG ANALYSIS OF CHRONIC AMPHETAMINE EFFECT.
187116 03-13

PROPRANOLOL AND BEHAVIOR OF ALCOHOL ADDICTS AFTER ACUTE ALCOHOL INGESTION.
187257 04-14

EFFECTS OF LOCUS-COERULEUS STIMULATION ON HIPPOCAMPAL UNIT ACTIVITY AND ON BEHAVIOR IN UNRESTRAINED RATS. (UNPUBLISHED PAPER).
187499 04-04

EFFECTS OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL ON SOCIAL BEHAVIOR OF SQUIRREL MONKEY DYADS IN A WATER COMPETITION SITUATION.
187640 04-04

EFFECTS OF APOMORPHINE ON SELF-STIMULATION BEHAVIOR.
187666 04-04

AMPHETAMINE AND OPERANT BEHAVIOR IN RATS: RELATIONSHIP BETWEEN DRUG EFFECT AND CONTROL RESPONSE RATE.
187699 04-04

INTERACTION AMONG GENOTYPE, UNCONDITIONED STIMULUS, D-AMPHETAMINE, AND ONE-WAY AVOIDANCE BEHAVIOR OF RATS.
187702 04-04

THE EFFECTS OF CHLORDIAZEPOXIDE, AMPHETAMINE AND COCAINE ON BAR-PRESS BEHAVIOR IN NORMAL AND GENETICALLY NERVOUS DOGS.
187868 04-04

EFFECTS OF LSD AND MONOAMINE SYNTHESIS INHIBITORS ON HORMONE ACTIVATED COPULATORY BEHAVIOR IN THE FEMALE RAT.
188611 04-04

PROPRANOLOL ANTAGONISM OF MORPHINE INFLUENCED BEHAVIOR.
188760 04-04

DELTA9-TETRAHYDROCANNABINOL AND AGGRESSIVE BEHAVIOR IN RATS.
189525 04-04

HALLUCINOGENIC DRUG-INDUCED BEHAVIOR UNDER SENSORY ATTENUATION: PREDICTION OF RESPONSE TO PSILOCYBIN.
189744 04-12

DIAZEPAM ON DEMAND: DRUG SEEKING BEHAVIOR IN PSYCHIATRIC INPATIENTS.
189924 04-17

THE CONTROL OF DEVIANT SEXUAL BEHAVIOR BY DRUGS: A DOUBLE-BLIND CONTROLLED STUDY OF BENPERIDOL, CHLORPROMAZINE, AND PLACEBO.
190061 04-11

EFFECTS OF NICOTINE ON THE SHUTTLEBOX BEHAVIOR OF TRAINED GUINEA-PIGS.
190333 04-04

PSYCHOTROPIC EFFECT OF ANALGESICS AND NEUROLEPTICS ON A MODEL OF INVESTIGATORY BEHAVIOR CHANGED BY PAIN.
191120 04-04

PSYCHOENDOCRINE INVESTIGATION IN SCHIZOPHRENIA: RELATIONSHIP BETWEEN PITUITARY GONADAL FUNCTION AND BEHAVIOR.
191190 04-14

DRUG-INDUCED STEREOTYPED BEHAVIOR: SIMILARITIES AND DIFFERENCES.
191504 04-04

THE EFFECTS OF COMT INHIBITORS ON BEHAVIOR AND DOPAMINE METABOLISM.
191517 04-03

ROLE OF ACETYLCHOLINE AND DOPAMINE IN MANIC BEHAVIOR.
191532 04-09

NEUROCHEMICAL ANALYSIS OF AGGRESSIVE - DEFENSIVE BEHAVIOR ELICITED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS AND CENTRAL GRAY MATTER.
191784 04-02

EFFECT OF PREGESTATIONAL MORPHINE ADMINISTRATION TO MICE ON BEHAVIOR OF THEIR OFFSPRING.
191902 04-04

CORRELATION BETWEEN BRAIN N,N DIMETHYLTRYPTAMINE (DMT) LEVELS AND BAR PRESSING BEHAVIOR IN RATS: EFFECT OF MAO INHIBITION.
191935 04-04

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
191944 04-04

COMPARATIVE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CANNABIDIOL (CBD), AND CANNABINOL (CBN) ON TIMING BEHAVIOR IN RATS.
191967 04-04

EFFECTS OF PHENCYCLIDINE AND KETAMINE ON FOOD MAINTAINED BEHAVIOR IN THE PIGEON.
191973 04-04

EFFECTS OF CHLORPROMAZINE (CPZ) AND THIORIDAZINE PERFORMANCE AND STIMULUS CONTROL BEHAVIOR.
191974 04-04

EFFECTS OF MORPHINE SULFATE ON POSITIVELY AND NEGATIVELY REINFORCED BEHAVIOR IN TWO STRAINS OF RATS.
191975 04-04

COMPARATIVE EFFECTS OF SOME CNS ACTIVE DRUGS ON LEARNED AND UNLEARNED BEHAVIOR IN THE HAMSTER.
191976 04-04

EFFECTS OF CHRONIC METHYLPHENIDATE ADMINISTRATION ON LEARNING AND OFFSPRING BEHAVIOR.
192116 04-04

EFFECTS OF DELTA1-TETRAHYDROCANNABINOL ON SIDMAN DISCRIMINATED AVOIDANCE BEHAVIOR IN RATS.
192413 04-03

BEHAVIORAL

BEHAVIORAL PHARMACOLOGY.
168272 01-17

BEHAVIORAL EFFECT OF TRICYCLIC THYMOLEPTICS AND CHLORPHENIRAMINE IN MICE AFTER PRETREATMENT WITH 5 HYDROXYTRYPTOPHAN (5-HTP).
171609 01-04

HYDROXYLAMINE INTERFERES WITH THE BEHAVIORAL RESPONSE TO MORPHINE DEPENDENCE IN MICE.
171905 01-04

EFFECTS OF MOLINDONE ON CNS STRUCTURES: NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATIONS.
172749 01-03

EFFECTS OF SCOPOLAMINE UPON BEHAVIORAL REACTIVITY AND VISUALLY EVOKED POTENTIAL TO FLASHES IN RATS.
173032 01-04

BEHAVIORAL PARAMETERS OF DRUG ACTION: SIGNALED AND RESPONSE INDEPENDENT REINFORCEMENT.
174008 01-04

P-CHLOROPHENYLALANINE INDUCED ALTERATIONS IN THE BEHAVIORAL EFFECTS OF 5-HYDROXYTRYPTOPHAN.
174034 01-04

BEHAVIORAL EFFECTS OF A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR (FUSARIC ACID) IN MAN. (UNPUBLISHED PAPER
174329 01-09

BEHAVIORAL CHANGES AND AGGRESSIVITY EVOKED BY DRUGS IN MICE.
174604 01-04

BEHAVIORAL AND ELECTROENCEPHALOGRAPHIC STUDIES ON THIOSEMICARBAZIDE INDUCED SEIZURE IN RABBITS.
174855 01-05

ONTOGENY OF SEROTONINERGIC INHIBITION OF BEHAVIORAL AROUSAL IN THE RAT.
174860 01-04

PIMOZIDE IN THE TREATMENT OF BEHAVIORAL DISORDERS OF HOSPITALIZED ADOLESCENTS.
176109 02-14

REPEATED ACQUISITION OF BEHAVIORAL CHAINS UNDER CHRONIC DRUG CONDITIONS.
177408 02-04

EFFECTS OF LORAZEPAM ON CNS STRUCTURES: NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATIONS.
177749 02-03

MOTHER INFANT SEPARATION: BEHAVIORAL ANALYSIS OF AN ANIMAL MODEL OF DEPRESSION. (PH.D. DISSERTATION).
178867 02-04

BEHAVIORAL EVIDENCE FOR DOPAMINERGIC SUPERSENSITIVITY AFTER CHRONIC HALOPERIDOL.
180021 02-04

BEHAVIORAL PHARMACOLOGY OF BROMAZEPAM (RO-5-3350), A NEW BENZODIAZEPINE DERIVATIVE.
181384 02-04

PROGRAM IN BEHAVIORAL PHARMACOLOGY.
181394 02-14

BEHAVIORAL EFFECTS OF DRUGS IN MACACA-MULATTA.
181401 02-04

MECHANISMS OF DRUG-INDUCED BEHAVIORAL TOLERANCE.
181406 02-04

INFLUENCES OF LITHIUM ON THE BEHAVIORAL ACTION OF METHAMPHETAMINE AND TETRABENAZINE.
182109 02-04

BEHAVIORAL PHARMACOLOGICAL STUDIES ON TRICYCLIC ANTIDEPRESSANTS IN RATS.
182116 02-04

BEHAVIORAL EFFECTS OF SIMULTANEOUS DEPLETION OF BRAIN NOREPINEPHRINE AND SEROTONIN.
182211 03-04

BEHAVIORAL EFFECTS OF EX-11-582A, A POTENTIAL ANTIPSYCHOTIC AGENT.
182242 03-04

BEHAVIORAL AND PHYSIOLOGICAL ACTIVITY OF DEAMINATED METABOLITES OF MESCALINE.
182244 03-03

BEHAVIORAL EFFECTS OF MORPHINE AND OPIOID ANTAGONISTS.
182859 03-04

BEHAVIORAL EFFECTS OF SEPARATE AND COMBINED ADMINISTRATION OF NALOXONE AND D-AMPHETAMINE.
183892 03-04

DELTA9-TETRAHYDROCANNABINOL AND 11-HYDROXY-DELTA9-TETRAHYDROCANNABINOL: BEHAVIORAL EFFECTS AND TOLERANCE DEVELOPMENT.
183893 03-04

TOLERANCE TO THE BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF HALOPERIDOL AND MORPHINE IN RATS CHRONICALLY TREATED WITH MORPHINE OR HALOPERIDOL.
184225 03-03

LEAD INDUCED BEHAVIORAL DYSFUNCTION: AN ANIMAL MODEL OF HYPERACTIVITY.
184953 03-04

REDUCED BEHAVIORAL EFFECTS OF PILOCARPINE DURING CHRONIC TREATMENT WITH DFP.
185265 03-04

DOSE EFFECTS OF METHYLPHENIDATE ON BEHAVIORAL INHIBITION AND ACTIVATION IN HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
185676 03-14

EFFECTS OF CHLORPROMAZINE AND THREE METABOLITES ON BEHAVIORAL RESPONSES IN RATS.
185748 03-04

BEHAVIORAL EFFECTS OF PROFADOL IN THE RAT.
186373 03-04

BEHAVIORAL AND VISUAL EVOKED POTENTIAL INVESTIGATIONS DURING TRIHEXYPHENIDYL AND THIOTHIXENE TREATMENT IN PSYCHOTIC BOYS.
187115 03-09

A STUDY OF THE BEHAVIORAL DISRUPTION OF MICE INDUCED BY L-METHIONINE AND RELATED COMPOUNDS.
187260 04-04

ON THE BEHAVIORAL AND NEUROCHEMICAL ACTIONS OF 6-HYDROXYDOPA AND 5,6 DIHYDROXYTRYPTAMINE IN RATS.
187380 04-03

CARDIOVASCULAR AND GROSS BEHAVIORAL EFFECTS OF AMPHETAMINE, 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPROPANE (DOM) AND 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPHENYL BUTANE (BL-3912A) IN THE CONSCIOUS DOG.
187573 04-03

LOCALIZED BEHAVIORAL EFFECTS OF VASOPRESSIN ON MAINTENANCE OF AN ACTIVE AVOIDANCE RESPONSE IN RATS.
187697 04-04

BEHAVIORAL EFFECTS OF AMPHETAMINE IN RATS WITH LESIONS IN THE CORPUS-STRIATUM.
187698 04-04

COMPARATIVE EFFECTS OF SCOPOLAMINE AND AMPHETAMINE UPON BEHAVIORAL REACTIVITY AND VISUAL EVOKED POTENTIALS TO FLASHES IN RATS.
187700 04-04

A NEW PROLONGED ACTING TYPE OF CHLORPROMAZINE: BEHAVIORAL EFFECTS AND PROLONGED ACTIONS ON NERVE MEMBRANES.
187805 04-01

THE EFFECT OF PRETREATMENT WITH IPRONIAZID ON THE BEHAVIORAL ACTIVITIES OF BETA-PHENYLETHYLAMINE IN RATS.
187932 04-04

BIOCHEMICAL AND BEHAVIORAL ANTAGONISM BETWEEN FENFLURAMINE AND APOMORPHINE IN RATS.
188196 04-03

BEHAVIORAL AND ELECTROCORTICOGRAPHIC DOSE-RESPONSE RELATIONSHIPS WITH METRAZOL. (UNPUBLISHED PAPER).
188248 04-04

THE EFFECT OF BUTYLATED HYDROXYANISOLE AND BUTYLATED HYDROXYTOLUENE ON BEHAVIORAL DEVELOPMENT OF MICE.
188637 04-04

PARADOXICAL EFFECTS OF D-AMPHETAMINE ON BEHAVIORAL THERMOREGULATION: POSSIBLE MEDIATION BY BRAIN DOPAMINE.
189399 04-04

CRUDE MARIHUANA EXTRACT: EEG AND BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION IN RHESUS MONKEYS.
189516 04-04

BEHAVIORAL AND EEG CHANGES IN THE AMPHETAMINE MODEL OF PSYCHOSIS.
191505 04-04

RELATIONSHIP OF CATECHOLAMINE NEURAL SYSTEMS TO THE BEHAVIORAL ALTERATIONS PRODUCED BY 6-HYDROXYDOPAMINE ADMINISTRATION INTO BRAIN.
191518 04-03

BEHAVIORAL EFFECTS OF DIRECT AND INDIRECT ACTING DOPAMINERGIC AGONISTS.
191521 04-04

BEHAVIORAL EFFECTS OF COCAINE COMPARED UNDER TWO SCHEDULES OF FOOD PRESENTATION IN THE SQUIRREL MONKEY.
191916 04-04

COMPREHENSIVE BEHAVIORAL ASSESSMENT OF THE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN RATS.
191966 04-04

INTERACTION OF SEROTONIN ANTAGONISTS WITH 3,4-DICHLORO-2-(2-IMIDAZOLIN-2-YL-THIO) 2 ACETOPHENONE HYDROBROMIDE (DITA) AND D-AMPHETAMINE HYDROBROMIDE (DITA) AND D-AMPHETAMINE ON CERTAIN BEHAVIORAL PARAMETERS OF MALE MICE.
192014 04-04

DIFFERENTIAL INCREASE OF BEHAVIORAL AND EXTRAPYRAMIDAL STIMULATING ACTIONS OF NEUROLEPTICS BY ALPHA-METHYLTYROSINE PRETREATMENT IN RATS.
192016 04-04

BEHAVIORALLY

SAFETY AND EFFECTIVENESS OF HALOPERIDOL FOR MENTALLY RETARDED BEHAVIORALLY DISORDERED AND HYPERKINETIC PATIENTS.
169634 01-11

INTERACTION OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A PURPORTED HASHISH AND LSD ANTAGONIST, WITH SEVERAL CENTRAL NEUROCHEMICAL SYSTEMS.
182217 03-04

BEHAVIORS

ACQUISITION AND RETENTION OF AVOIDANCE BEHAVIORS FOLLOWING SEPTAL LESIONS OR SCOPOLAMINE INJECTIONS IN RATS.
167401 01-04

PSYCHOTROPIC DRUGS AND PHENOTYPICAL BEHAVIORS.
181407 02-05

BRAIN MECHANISMS UNDERLYING THE EFFECTS OF AMPHETAMINE ON FEEDING AND NONFEEDING BEHAVIORS: DISSOCIATION AND OVERLAP.
184839 03-03

THE EFFECTS ON INGESTIVE BEHAVIORS OF DAMAGE TO CENTRAL DOPAMINE CONTAINING NEURONS.
191520 04-04

BEHAVIOUR

THE EFFECTS OF SCOPOLAMINE ON FIXED-INTERVAL BEHAVIOUR IN THE RAT: A RATE-DEPENDENCY EFFECT.
168833 01-04

INHIBITION OF MOUSE-KILLING BEHAVIOUR IN RATS BY SOME THYMOLEPTIC DRUGS.
171608 01-04

EFFECTS OF TETRABENAZINE ON LORDOSIS BEHAVIOUR AND ON BRAIN MONOAMINES IN THE FEMALE RAT.
171614 01-04

HYPERKINETIC, HYPOSCHOLASTIC BEHAVIOUR AND CHARACTER DISORDERS OF CHILDHOOD AND ADOLESCENCE: DIAGNOSIS AND PHARMACOTHERAPY.
172800 01-11

DRINKING BEHAVIOUR AND BRAIN DOPAMINE: ANTAGONISTIC EFFECT OF TWO NEUROLEPTIC DRUGS (PIMOZIDE AND SPIRAMIDE) UPON AMPHETAMINE OR APOMORPHINE-INDUCED HYPODIPSIA.
174035 01-04

EFFECTS OF ANTIDEPRESSANT AGENTS ON OPEN-FIELD BEHAVIOUR IN RATS.
174038 01-04

APOMORPHINE INDUCED BITING AND FIGHTING BEHAVIOUR IN RESERPINIZED RATS AND AN APPROACH TO THE MECHANISM OF ACTION.
174768 01-04

POSSIBLE INVOLVEMENT OF A NORADRENERGIC AREA OF THE AMYGDALA WITH STEREOTYPED BEHAVIOUR.
176877 02-04

INHIBITORY EFFECT OF DOXEPIN ON AGONISTIC BEHAVIOUR ELICITED BY HYPOTHALAMIC STIMULATION IN THE CAT.
180044 02-04

STEREOTYPY WITH SELECTIVE STIMULATION OF CERTAIN ITEMS OF BEHAVIOUR OBSERVED IN AMPHETAMINE TREATED MONKEYS (CERCOPITHECUS).
180061 02-04

OXYPERTINE AND PRIMATE BEHAVIOUR.
182762 03-04

CATALEPSY AND STEREOTYPED BEHAVIOUR IN RATS TREATED CHRONICALLY WITH METHADONE: RELATION TO BRAIN HOMOVANILLIC ACID CONTENT.
183606 03-04

PARADOXICAL THERMOREGULATORY BEHAVIOUR IN RATS INDUCED BY (..) AMPHETAMINE: BLOCKADE BY ALPHA-ADRENOCEPTOR OR DOPAMINE RECEPTOR BLOCKING AGENTS.
183797 03-03

THE EFFECT OF SULTHIAME ON DISTURBED BEHAVIOUR IN MENTALLY SUBNORMAL PATIENTS.
185191 03-14

CONDITIONING OF AMPHETAMINE-INDUCED BEHAVIOUR IN THE ALBINO RAT.
185954 03-04

EFFECTS OF MORPHINE AND CHLORPROMAZINE ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR.
185997 03-04

A COMPARISON OF EFFECTS OF APOMORPHINE AND ET-495 ON LOCOMOTOR ACTIVITY AND CIRCLING BEHAVIOUR IN MICE.
186635 03-04

EFFECTS OF PHYSOSTIGMINE ON THE MAINTENANCE OF DISCRIMINATION BEHAVIOUR IN RATS.
186637 03-04

THE INFLUENCE OF 3-QUINUCLIDINYLBENZILATE ON THE BEHAVIOUR OF RATS IN A CIRCULAR RUNWAY.
187259 04-04

TIME SAMPLING OF RAT EXPLORATORY BEHAVIOUR: A RELIABLE SCREENING TEST FOR THE CNS EFFECTS OF ANOREXIC AGENTS.
187925 04-04

EFFECTS OF NICOTINE ON THE OBSERVED BEHAVIOUR OF RATS DURING SIGNALLED AND UNSIGNALLED AVOIDANCE EXPERIMENTS.
190332 04-04

THE EFFECTS OF PSILOCYBIN ON EEG AND BEHAVIOUR IN MONKEYS.
192415 04-04

THE EFFECT OF OCTOCLOTHEPIN AND PERPHENAZINE ON BEHAVIOUR IN RATS WITH DIFFERENT EXPLORATION AND DEFECATION RATES.
192430 04-04

BEHAVIOURAL

BEHAVIOURAL STATE CYCLES IN ABNORMAL INFANTS.
168523 01-14

PHARMACOLOGICALLY INDUCED BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE.
169120 01-03

INTERACTIVE EFFECTS OF CYCLOHEXIMIDE AND PUROMYCIN IN ALTERING BRAIN POLYRIBOSOMES AND NEURAL AND BEHAVIOURAL RESPONSES TO ELECTROSHOCK IN MICE.
175230 02-03

BEHAVIOURAL EFFECTS OF YOHIMBINE ADMINISTERED INTRAVENTRICULARLY IN THE RAT.
177721 02-04

BEHAVIOURAL EVALUATION OF PEPTIDES RELATED TO SCOTOPHOBIN.
177836 02-04

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: II. PIMOZIDE IN THE TREATMENT OF BEHAVIOURAL DISORDERS IN CHILDHOOD AND ADOLESCENCE.
183192 03-11

BEHAVIOURAL AND BIOCHEMICAL EFFECTS OF 6-HYDROXYDOPA IN RATS.
186571 03-04

EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: I. EFFECT ON THE BEHAVIOURAL CHANGES INDUCED BY RESERPINE, ALPHA-METHYL-P-TYROSINE OR AMPHETAMINE.
186587 03-04

BIOCHEMICAL AND BEHAVIOURAL ALTERATIONS FOLLOWING 5,6 DIHYDROXYTRYPTAMINE ADMINISTRATION INTO BRAIN.
186634 03-04

THE EFFECT OF SOME CHOLINOLYTIC DRUGS ON A NUMBER OF BEHAVIOURAL PARAMETERS MEASURED IN THE T-MAZE ALTERNATION TEST: DOSE-RESPONSE RELATIONSHIPS.
187641 04-04

CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE DERIVATIVE SE-780 IN RATS.
187926 04-04

AN INVESTIGATION OF THE BEHAVIOURAL NATURE OF THE PSYCHOMOTOR STIMULANT EFFECT OF AMPHETAMINE.
188620 04-04

EFFECTS OF CHLORDIAZEPOXIDE ON HEART RATE AND BEHAVIOURAL SUPPRESSION IN PIGS SUBJECTED TO OPERANT CONDITIONING PROCEDURES.
189409 04-04

CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE METABOLITE, NORFENFLURAMINE: AN EVALUATION OF ITS ROLE IN THE ACTIONS OF FENFLURAMINE.
190335 04-04

EFFECT OF CHRONIC TREATMENT WITH CENTRAL STIMULANTS ON BRAIN MONOAMINES AND SOME BEHAVIOURAL AND PHYSIOLOGICAL FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS.
191503 04-03

BELIEFS

POPULAR ATTITUDES AND BELIEFS ABOUT TRANQUILIZERS.
177699 02-17

BELLADONNA

CAUDATE NUCLEUS EFFECTS ON GERIATRIC SENILITY: EFFECT OF BELLADONNA ON LEARNING AND MEMORY OF GERIATRIC PATIENTS.
170744 01-11

BEMEGRIDE

SELECTIVE ANTAGONISM OF CENTRAL NERVOUS SYSTEM DEPRESSANTS BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE.
171007 01-13

BENACTYZINE

CHANGES IN SHORT-TERM AND LONG-TERM MEMORY OF DOGS AND CATS UNDER THE EFFECTS OF AMIZYL (BENACTYZINE).
183517 03-04

BENPERIDOL

THE CONTROL OF DEVIANT SEXUAL BEHAVIOR BY DRUGS: A DOUBLE-BLIND CONTROLLED STUDY OF BENPERIDOL, CHLORPROMAZINE, AND PLACEBO.
190061 04-11

BENZALIN

ISOLATION AND IDENTIFICATION OF HYPNOTICS (8): ISOLATION AND IDENTIFICATION OF BENZALIN AND CERCINE BY THIN-LAYER CHROMATOGRAPHY IN VITRO.
182626 03-01

BENZENE

THE LACK OF EFFECTS OF PRETREATMENT WITH PHENOBARBITAL AND CHLORPROMAZINE ON THE ACUTE TOXICITY OF BENZENE IN RATS.
189600 04-05

BENZOATE

LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04

SUPPRESSION OF LORDOSIS IN GUINEA-PIGS BY ETHAMOXY-TRIPHETOL (MER-25) GIVEN AT LONG INTERVALS (36-46 HR) AFTER ESTRADIOL BENZOATE TREATMENT.
186686 03-04

BENZOCTAMINE

BENZOCTAMINE IN PSYCHIATRY: A 30-CASE STUDY.
182901 03-11

BENZODIAZEPIN-2-ONES

3-ONIUM DERIVATIVES OF 1,4 BENZODIAZEPIN-2-ONES WITH TERTIARY ORGANIC BASES.
187942 04-01

BENZODIAZEPINE

CLINICAL EXPERIMENTATION WITH A NEW BENZODIAZEPINE IN THE MANAGEMENT OF PHOBIC AND OBSESSIVE SYMPTOMS.
167594 01-10

LORAZEPAM: CLINICAL TRIAL WITH A NEW BENZODIAZEPINE.
169297 01-07

METABOLITES OF BROMAZEPAM, A BENZODIAZEPINE, IN THE HUMAN, DOG, RAT, AND MOUSE.
170837 01-03

ON THE ANTIANXIETY PROPERTIES OF A NEW BENZODIAZEPINE, ORF-8063.
172485 01-10

SIMULTANEOUS ANALYSIS OF A 1,5 BENZODIAZEPINE AND ITS METABOLITE IN BLOOD AND URINE BY SPECTRODENSITOMETRY.
176871 02-16

TRIAZOLAM: A SLEEP LABORATORY STUDY OF A NEW BENZODIAZEPINE HYPNOTIC.
177747 02-07

CHARACTERISTICS OF BENZODIAZEPINE TRANQUILIZERS.
180307 02-17

FIRST RESULTS OBTAINED WITH A NEW ANTICONVULSANT OF THE BENZODIAZEPINE SERIES (CLONAZEPAM).
180672 02-11

BEHAVIORAL PHARMACOLOGY OF BROMAZEPAM (RO-5-3350), A NEW BENZODIAZEPINE DERIVATIVE.
181384 02-04

CENTRAL NERVOUS ACTION OF BROMAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.
181650 02-03

CENTRAL NERVOUS ACTION OF FLURAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.
182549 03-03

CONTROL OF INSOMNIA WITH A NEW BENZODIAZEPINE: THE FLUNITRAZEPAM OR RO-5-4200 (FIRST INVESTIGATIONS OF PHASE I AND CONTROLLED INVESTIGATIONS OF PHASE II).
183198 03-11

THE EFFECT OF A NEW BENZODIAZEPINE DERIVATIVE NIMETAZEPAM ON THE SLEEP CYCLE IN MAN.
188501 04-07

INVESTIGATION OF PHYSICAL DEPENDENCE ON A NEW BENZODIAZEPINE DERIVATIVE, BROMAZEPAM.
189209 04-05

INFLUENCE OF PH ON THE BENZODIAZEPINE HUMAN SERUM ALBUMIN COMPLEX: CIRCULAR DICHROISM STUDIES.
189595 04-13

BENZODIAZEPINES

SHOULD WE PUT BENZODIAZEPINES IN OUR DRINKING WATER
168361 01-17

PROTECTION PRODUCED BY BENZODIAZEPINES (BDP) AGAINST THE NEUROTOXIC AND CONFLICT BEHAVIOR EFFECTS OF HEXACHLOROPHENE (HCP) IN CATS.
176863 02-04

GAS CHROMATOGRAPHIC ANALYSIS OF BENZODIAZEPINES. PART I: MEDAZEPAM AND ITS METABOLITES.
178948 02-06

REGIONAL CYCLIC NUCLEOTIDES PHOSPHODIESTERASE ACTIVITY IN CAT CENTRAL NERVOUS SYSTEM: EFFECTS OF BENZODIAZEPINES.
181575 02-03

EFFECTS OF BENZODIAZEPINES ON SPINAL REFLEXES IN CATS.
182097 02-03

PENTYLENETETRAZOL CONVULSIONS AND BRAIN CATECHOLAMINE TURNOVER RATE IN RATS AND MICE RECEIVING DIPHENYLHYDANTOIN OR BENZODIAZEPINES.
182344 03-03

UPTAKE AND RELEASE OF NORADRENALINE IN RAT CEREBRAL CORTEX IN VITRO: NO EFFECT OF BENZODIAZEPINES AND BARBITURATES.
182347 03-03

EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON THE RHYTHMS OF WAKEFULNESS SLEEP CYCLE IN RATS.
182553 03-04

EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON ELECTROENCEPHALOGRAM AND FEEDING BEHAVIOR OF RATS.
182554 03-04

RECENT DEVELOPMENTS IN THE PHARMACOLOGY OF THE BENZODIAZEPINES.
182771 03-17

BENZODIAZEPINES. 4,2-OXYAMINO-5-PHENYLBENZODIAZEPINES.
185032 03-01
QUINAZOLINES AND 1,4 BENZODIAZEPINES.64.COMPARISON OF THE STEREOCHEMISTRY OF DIAZEPAM WITH THAT OF CLOSE ANALOGS WITH MARGINAL BIOLOGICAL ACTIVITY.
185034 03-01
BENZODIAZEPINES AND BARBITURATES: TURNOVER CHANGES IN CENTRAL 5-HYDROXYTRYPTAMINE PATHWAYS.
189611 04-03
INFLUENCE OF NEUROLEPTICS AND BENZODIAZEPINES ON METABOLISM OF TRICYCLIC ANTIDEPRESSANTS IN MAN.
191026 04-09

BENZODIAZEPINOOXAZOLE
STUDIES ON BENZODIAZEPINOOXAZOLES. III. REACTIONS AND REARRANGEMENTS OF BENZODIAZEPINOOXAZOLE DERIVATIVES.
180487 02-01
STUDIES ON BENZODIAZEPINOOXAZOLES. IV. THE FORMATION OF QUINOLONES BY THE RING CONTRACTION OF A BENZODIAZEPINOOXAZOLE DERIVATIVE.
180488 02-01
STUDIES ON BENZODIAZEPINOOXAZOLES. V. REACTIONS OF BENZODIAZEPINOOXAZOLE DERIVATIVES WITH ACETIC ANHYDRIDE.
180489 02-01

BENZODIAZEPINOOXAZOLES
STUDIES ON BENZODIAZEPINOOXAZOLES. III. REACTIONS AND REARRANGEMENTS OF BENZODIAZEPINOOXAZOLE DERIVATIVES.
180487 02-01
STUDIES ON BENZODIAZEPINOOXAZOLES. IV. THE FORMATION OF QUINOLONES BY THE RING CONTRACTION OF A BENZODIAZEPINOOXAZOLE DERIVATIVE.
180488 02-01
STUDIES ON BENZODIAZEPINOOXAZOLES. V. REACTIONS OF BENZODIAZEPINOOXAZOLE DERIVATIVES WITH ACETIC ANHYDRIDE.
180489 02-01
STUDIES ON BENZODIAZEPINOOXAZOLES. VI. SYNTHESIS AND PHARMACOLOGY OF 11B-PYRIDYL AND 11B-THIENYL DERIVATIVES OF BENZODIAZEPINOOXAZOLES.
180490 02-02

BENZOIC
A NOVEL SPASMOLYTIC AND CNS ACTIVE AGENT: 3-(2-BENZYLMETHYLAMINOETHYL) BENZOIC ACID METHYL ESTER HYDROCHLORIDE.
184581 03-02

BENZOQUINOLINES
SYNTHETIC STUDIES LEADING TOWARD THE PREPARATION OF LINEAR BENZOQUINOLINES. (PH.D. DISSERTATION).
180739 02-01

BENZOTHIADIAZINES
BINDING OF DIAZOXIDE AND OTHER BENZOTHIADIAZINES TO HUMAN ALBUMIN.
179987 02-13

BENZOXAZOLE
SUBSTITUTED BENZOXAZOLE/BENZTHIAZOLE-2-THIONES: INTERRELATIONSHIP BETWEEN ANTICONVULSANT ACTIVITY AND INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND MONOAMINE OXIDASE.
183601 03-03

BENZTHIAZOLE-2-THIONES
SUBSTITUTED BENZOXAZOLE/BENZTHIAZOLE-2-THIONES: INTERRELATIONSHIP BETWEEN ANTICONVULSANT ACTIVITY AND INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND MONOAMINE OXIDASE.
183601 03-03

BENZTROPINE
BENZTROPINE PSYCHOSIS.
168319 01-15
EFFECT OF MORPHINE, HALOPERIDOL, APOMORPHINE AND BENZTROPINE ON DOPAMINE TURNOVER IN RAT CORPUS-STRIATUM: EVIDENCE SHOWING MORPHINE-INDUCED REDUCTION IN CNS DOPAMINERGIC ACTIVITY.
182230 03-03

BENZYLHYDRAZINE
SYNTHESIS AND SCREENING OF CYCLIC BENZYLHYDRAZINE CONGENERS AS ANTIDEPRESSANTS.
183600 03-01

BEREAVED
PSYCHOPHARMACOLOGICAL AGENTS FOR THE TERMINALLY ILL AND BEREAVED.
188149 04-17

BETA-ADRENERGIC
TREATMENT OF ANXIETY NEUROSIS BY ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKING AGENTS.
186780 03-10
FAILURE OF BETA-ADRENERGIC RECEPTOR BLOCKADE TO PREVENT ARRHYTHMIAS INDUCED BY SYMPATHETIC NERVE STIMULATION.
187923 04-03
BETA-ADRENERGIC EFFECTS ON RAT MYOMETRIUM: ROLE OF CYCLIC AMP.
188915 04-03

BETA-ADRENOCEPTOR
THE INHIBITION BY BETA-ADRENOCEPTOR BLOCKING AGENTS OF CALCIUM UPTAKE INTO AND EFFLUX FROM ISOLATED SARCOPLASMIC VESICLES.
184223 03-03
THE ANTAGONISM BETWEEN CHOLINOMIMETIC AGONISTS AND BETA-ADRENOCEPTOR STIMULANTS: THE DIFFERENTIATION BETWEEN BETWEEN FUNCTIONAL AND METAFFINOID ANTAGONISM.
191420 04-03

BETA-BLOCKING
BETA-BLOCKING AGENTS IN THE TREATMENT OF CATECHOLAMINE INDUCED SYMPTOMS IN MUSICIANS.
192527 04-11

BETA-DIKETONES
EFFECT OF SELECTED BETA-DIKETONES ON LITHIUM FLUXES OF BOVINE RED BLOOD CELLS.
171792 01-05

BETA-HYDROXYMESCALINE
PHYSIOLOGICAL DISPOSITION OF BETA-PHENYLETHYLAMINE, 2,4,5 TRIMETHOXYPHENYLETHYLAMINE, 2,3,4,5,6 PENTAMETHOXYPHENYLETHYLAMINE AND BETA-HYDROXYMESCALINE IN RAT BRAIN, LIVER AND PLASMA.
186706 03-03

BETA-MELANOCYTE
INFLUENCE OF TETRACOSACTRIN (T) AND BETA-MELANOCYTE STIMULATING HORMONE (MSH) ON DEPRESSION OF THE SEGMENTAL REFLEX BY MORPHINE (MS). (UNPUBLISHED PAPER).
183324 03-03

BETA-PHENETHYLAMINES
CACTUS ALKALOIDS: XVIII. PHENOLIC BETA-PHENETHYLAMINES FROM MAMMILLARIA-ELONGATA.
192882 04-01

BETA-PHENYL-GABA
THE ACTION OF BETA-PHENYL-GABA DERIVATIVES ON NEURONES OF THE CAT CEREBRAL CORTEX.
189750 04-03

BETA-PHENYLETHYLAMINE
BETA-PHENYLETHYLAMINE: A SPECIFIC SUBSTRATE FOR TYPE B MONOAMINE OXIDASE OF BRAIN.
168437 01-03
PHYSIOLOGICAL DISPOSITION OF BETA-PHENYLETHYLAMINE, 2,4,5 TRIMETHOXYPHENYLETHYLAMINE, 2,3,4,5,6 PENTAMETHOXYPHENYLETHYLAMINE AND BETA-HYDROXYMESCALINE IN RAT BRAIN, LIVER AND PLASMA.
186706 03-03
THE EFFECT OF PRETREATMENT WITH IPRONIAZID ON THE BEHAVIORAL ACTIVITIES OF BETA-PHENYLETHYLAMINE IN RATS.
187932 04-04

BILIRUBIN
NONSEDATING DOSAGES OF DIAZEPAM AND PHENOBARBITAL IN THE REDUCTION OF NEONATAL BILIRUBIN LEVELS.
191607 04-17

BINDING
PLASMA BINDING OF IMIPRAMINE AND CLINICAL OUTCOME.
172271 01-13
BINDING OF DIAZOXIDE AND OTHER BENZOTHIADIAZINES TO HUMAN ALBUMIN.
179987 02-13
ORAL 5-HTP IN PRIMARY AUTISM WITH 5-HT BINDING DEFECT.
181392 02-13
INFLUENCE OF VARIOUS DRUGS ON THE BINDING OF CHLORPROMAZINE TO ERYTHROCYTES AND ALBUMIN.
181470 02-03
ON THE NATURE OF THE SEROTONIN BINDING AFTER LSD.
182168 02-03
(3H) OUABAIN BINDING TO NA.-ATPASE AND K.-ATPASE: INHIBITION BY BETA, GAMMA METHYLENE ATP.
182184 02-03
BINDING OF MORPHINE BY SERUM PROTEINS OF MORPHINE TREATED RABBITS.
182187 02-03
EVIDENCE FOR PERSISTENT RESERPINE BINDING TO AMINE STORAGE VESICLE MEMBRANES.
182234 03-03
ENHANCED BINDING OF CHLORPROMAZINE TO CHOLESTEROL DEPLETED SYNAPTOSOME FRACTIONS.
187801 04-03
PHYSIOCHEMICAL PROPERTIES, SOLUBILITY, AND PROTEIN BINDING OF DELTA9-TETRAHYDROCANNABINOL. (UNPUBLISHED PAPER).
188256 04-01
IN VITRO BINDING OF (4-14C) DIPHENYLHYDANTOIN TO RAT BRAIN MICROSOMES.
188404 04-03
THE NERVE IMPULSE BLOCKING ACTIONS OF TRANQUILIZERS AND THE BINDING OF NEUROLEPTICS TO SYNAPTOSOME MEMBRANES.
189400 04-03

MESCALINE INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON THE BINDING OF AMINOACYL TRANSFER RIBONUCLEIC ACID TO RIBOSOMES OF BRAIN TISSUE.
189582 04-05

PHYLOGENETIC DISTRIBUTION OF OPIATE RECEPTOR BINDING.
190476 04-03

SERUM TRYPTOPHAN BINDING IN CHLORPROMAZINE TREATED CHRONIC SCHIZOPHRENICS.
191320 04-08

BIOASSAY

THE ORAL HYPNOTIC BIOASSAY OF HYDROXYZINE AND PENTOBARBITAL FOR NIGHTTIME SEDATION.
177320 02-11

BIOAVAILABILITY

RELATIONSHIP BETWEEN BIOAVAILABILITY AND DISSOLUTION RATE OF OXAZEPAM.
171630 01-16

BIOCHEMICAL

TOWARDS A BIOCHEMICAL TYPOLOGY OF DEPRESSION.
169095 01-09

BIOCHEMICAL AND PHARMACOLOGICAL APPROACHES IN THE STUDY OF SYMPATHETIC NERVES. (UNPUBLISHED PAPER).
170082 01-03

THE USE OF BIOCHEMICAL CORRELATES FOR THE PREDICTION OF MURICIDAL BEHAVIOR IN THE WILD RAT.
182241 03-04

BEHAVIOURAL AND BIOCHEMICAL EFFECTS OF 6-HYDROXYDOPA IN RATS.
186571 03-04

BIOCHEMICAL AND BEHAVIOURAL ALTERATIONS FOLLOWING 5,6 DIHYDROXYTRYPTAMINE ADMINISTRATION INTO BRAIN.
186634 03-04

CLINICAL PHARMACOLOGY AS AN APPROACH TO THE STUDY OF BIOCHEMICAL SLEEP MECHANISMS: THE ACTION OF L-DOPA.
186643 03-14

IN APPRECIATION OF BASIC BIOCHEMICAL RESEARCH IN MENTAL HEALTH. (UNPUBLISHED PAPER).
187488 04-17

BIOCHEMICAL AND BEHAVIORAL ANTAGONISM BETWEEN FENFLURAMINE AND APOMORPHINE IN RATS.
188196 04-03

PHARMACOLOGICAL AND BIOCHEMICAL ACTIONS OF THE HEMOLYTIC AGENTS ACETYLPHENYLHYDRAZINE AND PHENYLHYDRAZINE ON MONOAMINE OXIDASE IN THE RAT.
188769 04-03

BIOCHEMISTRY

BIOCHEMISTRY AND PSYCHIATRY WITH SPECIAL REFERENCE TO PSYCHOPHARMACOLOGY.
189331 04-17

BIOELECTRICAL

CHANGES IN RHYTHMS OF BIOELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX IN HUMANS UNDER THE INFLUENCE OF ETHYMISOL.
191790 04-07

BIOEQUIVALENCY

BIOEQUIVALENCY OF GENERIC AND BRAND-NAMED CHLORPROMAZINE.
187255 03-08

BIOGENIC

L-DOPA: EFFECT ON ETHANOL NARCOSIS AND BRAIN BIOGENIC AMINES IN MICE.
169782 01-03

EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON ATTACK ELICITED BY HYPOTHALAMIC STIMULATION: RELATION TO BRAIN BIOGENIC AMINES.
170162 01-04

MEASUREMENT OF BIOGENIC AMINES AT THE PICOGRAM LEVEL. (UNPUBLISHED LEVEL).
173382 01-03

BRAIN BIOGENIC AMINE DEPLETION AND MOOD.
174994 02-14

SIGNIFICANCE OF THE CENTRAL BIOGENIC AMINES FOR THE THRESHOLD IN ELECTRO AND PENTETRAZOLE SEIZURES.
181469 02-03

AMPHETAMINE-INDUCED ALTERATION OF BIOGENIC AMINES AND SELF-STIMULATION.
182212 03-03

THE INHIBITION OF (3H) BIOGENIC AMINE ACCUMULATION INTO RAT BRAIN TISSUE SLICES BY VARIOUS TRYPTAMINE DERIVATIVES.
182723 03-03

PHARMACOLOGICAL DISTINCTIONS BETWEEN ACTIVE AND PASSIVE AVOIDANCE MEMORY FORMATION AS SHOWN BY MANIPULATION OF BIOGENIC AMINE ACTIVE COMPOUNDS.
185927 03-04

THE MONOAMINE OXIDASES OF BRAIN: SELECTIVE INHIBITION WITH DRUGS AND THE CONSEQUENCES FOR THE METABOLISM OF THE BIOGENIC AMINES.
186668 03-03

EFFECTS OF SOME METALLIC CATIONS ON CEREBRAL CORTICAL NEURONES AND THEIR INTERACTIONS WITH BIOGENIC AMINES.
187806 04-03

PLASMA AND CEREBROSPINAL FLUID PROBENECID CONCENTRATIONS AS RELATED TO ACCUMULATION OF ACIDIC BIOGENIC AMINE METABOLITES IN MAN.
187933 04-13

THE EFFECT OF HYPOTHERMIC DOSES OF 1-DELTA9-TETRAHYDROCANNABINOL ON BIOGENIC AMINE METABOLISM IN SELECTED PARTS OF THE RAT BRAIN.
188231 04-03

IN VIVO CHANGES OF CEREBRAL CYCLIC ADENOSINE 3,5 MONOPHOSPHATE INDUCED BY BIOGENIC AMINES: ASSOCIATION WITH PHOSPHORYLASE ACTIVATION.
188291 04-03

INTRACEREBRAL INJECTION OF 6-HYDROXYDOPAMINE AND HYDROGEN PEROXIDE IN CATS: SPECIFIC AND NONSPECIFIC EFFECTS ON STRIATAL BIOGENIC AMINES.
188426 04-03

A STUDY OF BIOGENIC AMINE METABOLITES IN THE CEREBROSPINAL FLUID AND URINE OF MONKEYS WITH CHLORPROMAZINE INDUCED DYSKINESIA.
189210 04-03

EFFECT OF A BUTYROPHENONE DERIVATIVE, U-32802A, ON BRAIN BIOGENIC AMINES.
189584 04-02

DRUG-INDUCED AGGRESSION IN CHICKS: DIFFERENTIAL INVOLVEMENT OF BIOGENIC AMINES.
191977 04-04

BIOLOGICAL

RADIOIMMUNOASSAY FOR LYSERGIDE (LSD) IN ILLICIT DRUGS AND BIOLOGICAL FLUIDS.
170840 01-06

DETERMINATION OF DRUG TRANSFER ACROSS BIOLOGICAL MEMBRANES: COMPARATIVE STUDY ON THE PASSAGE OF DRUGS INTO THE CENTRAL NERVOUS SYSTEM AND THEIR PLACENTAL TRANSFER AND FETAL LOCALIZATION IN THE PREGNANT RAT. (PH.D. DISSERTATION).
172018 01-03

THE BIOLOGICAL BASIS OF PSYCHOTICISM: A STUDY OF INDIVIDUAL DIFFERENCES IN RESPONSE TO DEXAMPHETAMINE.
175219 02-13

BIOLOGICAL INTERVENTIONS IN PSYCHOSES OF CHILDHOOD.
175872 02-17

QUINAZOLINES AND 1,4 BENZODIAZEPINES.64.COMPARISON OF THE STEREOCHEMISTRY OF DIAZEPAM WITH THAT OF CLOSE ANALOGS WITH MARGINAL BIOLOGICAL ACTIVITY.
185034 03-01

VALIDITY OF SCREENING METHODS FOR DRUGS OF ABUSE IN BIOLOGICAL FLUIDS. II. HEROIN IN PLASMA AND SALIVA.
187256 03-15

BIOPOTENTIALS

PREDICTION OF NEUROLEPTIC EFFECTS OF CI-686 BASED ON QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY: DRUG PROFILES AND DOSE RESPONSE CURVES BASED ON COMPUTERIZED CEREBRAL BIOPOTENTIALS.
181958 02-13

BIOSYNTHESIS

INFLUENCE OF PHENOBARBITAL AND SEX HORMONES ON ENZYMES IN ASCORBIC ACID BIOSYNTHESIS IN MALE AND FEMALE RATS. (PH.D. DISSERTATION).
172017 01-03

EFFECTS OF SOME TETRAHYDROCANNABINOLS ON THE BIOSYNTHESIS AND UTILIZATION OF CATECHOLAMINES IN THE RAT BRAIN.
172917 01-03

THE BIOSYNTHESIS OF THE CO-NEUROTRANSMITTER OCTOPAMINE IN COMPARISON WITH THE NEUROTRANSMITTER NORADRENALINE.
181468 02-03

DIMETHYLTRYPTAMINE: ITS BIOSYNTHESIS AND POSSIBLE ROLE IN MENTAL DISEASE.
191535 04-12

BIOSYNTHESIS OF THE PEYOTE ALKALOIDS.
192876 04-12

BIOSYNTHETIC

SHORT-TERM AND LONG-TERM LITHIUM ADMINISTRATION: EFFECTS ON THE BRAINS SEROTONERGIC BIOSYNTHETIC SYSTEMS.
175149 02-13

BIOTRANSFORMATION

PHARMACOLOGIC ACTIVITY AND BIOTRANSFORMATION OF R_ AND S-BARBITURATE ENANTIOMERS IN MOUSE AND MAN.
182156 02-03

BIPOLAR

THE USE OF LITHIUM IN AFFECTIVE DISORDERS, III: A DOUBLE-BLIND STUDY OF PROPHYLAXIS IN BIPOLAR ILLNESS.
169495 01-09

FACTORS ASSOCIATED WITH LITHIUM RESPONSE IN THE PROPHYLACTIC TREATMENT OF BIPOLAR MANIC-DEPRESSIVE ILLNESS.
186188 03-09

BISMUTH

MENTAL ILLNESS OR METAL ILLNESS? BISMUTH SUBGALLATE.
191215 04-15

BITING
APOMORPHINE INDUCED BITING AND FIGHTING BEHAVIOUR IN RESERPINIZED RATS AND AN APPROACH TO THE MECHANISM OF ACTION.
174768 01-04
CENTRAL CHOLINERGIC (MUSCARINIC) LINK IN THE ATTACK REFLEXIVE BITING MECHANISM OF CATS.
182238 03-04

BL-3912A
CARDIOVASCULAR AND GROSS BEHAVIORAL EFFECTS OF AMPHETAMINE, 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPROPANE (DOM) AND 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPHENYL BUTANE (BL-3912A) IN THE CONSCIOUS DOG.
187573 04-03

BLINK
EVALUATION OF CENTRAL ANTIRESERPINE EFFECT BY THE USE OF LIGHT BLINK REFLEX.
169469 01-04
HABITUATION OF BLINK REFLEXES IN PARKINSONIAN PATIENTS UNDER LEVODOPA AND AMANTADINE TREATMENT.
171794 01-13

BLOCK
ANALYSIS OF DRUG BLOCK OF LSD/5-HT/GABA BY MONITORING NEURONAL MEMBRANE CHANGES.
182143 02-03
DOES LITHIUM BLOCK THE EFFECTS OF AMPHETAMINE? A REPORT OF THREE CASES.
186745 03-13

BLOCKADE
EFFECTS OF DOPAMINE RECEPTOR STIMULATION AND BLOCKADE ON RO-4-1284 INDUCED ENHANCEMENT OF ELECTROSHOCK SEIZURE.
167287 01-03
ELECTROCARDIOGRAPHIC CHANGES IN HYPERTHYROIDISM AFTER ADRENERGIC BLOCKADE WITH RESERPINE AND PROPRANOLOL.
167460 01-13
PARADOXICAL BLOCKADE BY P-CHLOROPHENYLALANINE OF 5-HYDROXYTRYPTOPHAN FACILITATORY ACTIONS ON SPINAL REFLEXES.
168436 01-03
NEGATIVE SODIUM BALANCE IN LITHIUM CARBONATE TOXICITY: EVIDENCE OF MINERALOCORTICOID BLOCKADE.
169869 01-15
EFFECT OF DOPAMINERGIC STIMULATION OR BLOCKADE ON MORPHINE WITHDRAWAL AGGRESSION.
171300 01-04
BLOCKADE OF THE PROESTROUS LH SURGE IN CYCLIC RATS BY BARBITURATE ADMINISTRATION ON DIESTRUS.
175650 02-03
SELECTIVE BLOCKADE OF APOMORPHINE INDUCED AGGRESSION AND GNAWING FOLLOWING FENFLURAMINE OR RAPHE LESIONS IN THE RAT.
182128 02-04
PARADOXICAL THERMOREGULATORY BEHAVIOUR IN RATS INDUCED BY (..) AMPHETAMINE: BLOCKADE BY ALPHA-ADRENOCEPTOR OR DOPAMINE RECEPTOR BLOCKING AGENTS.
183797 03-03
EVIDENCE FOR REDISTRIBUTION OF FILTRATE AMONG NEPHRONS AFTER BETA- ADRENERGIC STIMULATION AND BLOCKADE.
184222 03-03
SPECIFICITY OF BLOCKADE OF THE NICOTINE INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ADRENERGIC NEURONS OF THE GUINEA-PIG HEART BY VARIOUS PHARMACOLOGICAL AGENTS.
186676 03-03
FEAR REDUCTION IN THE RAT FOLLOWING CENTRAL CHOLINERGIC BLOCKADE.
187703 04-04
CALCIUM REVERSAL OF NERVE BLOCKADE BY ALCOHOLS, ANESTHETICS, TRANQUILIZERS, AND BARBITURATES.
187802 04-03
FAILURE OF BETA-ADRENERGIC RECEPTOR BLOCKADE TO PREVENT ARRHYTHMIAS INDUCED BY SYMPATHETIC NERVE STIMULATION.
187923 04-03
BLOCKADE OF INSULIN RELEASE BY CERTAIN PHENOTHIAZINES.
189583 04-05
BLOCKADE OF EXCITATORY 5-HT SYNAPSE BY LSD.
191950 04-03

BLOCKED
NEW LONG LATENCY BULBOSPINAL EVOKED POTENTIALS BLOCKED BY SEROTONIN ANTAGONISTS.
188751 04-03

BLOCKERS
INFLUENCE OF ADRENERGIC BLOCKERS AND ANTILIPEMIC AGENTS ON PHARMACODYNAMIC ACTIONS OF MORPHINE IN CARBON TETRACHLORIDE TREATED RATS.
188873 04-03

BLOCKING
THE CURARIZED RAT AND HEART RATE CONDITIONING: A CONSIDERATION OF RESPIRATION PARAMETERS AND NEUROMUSCULAR BLOCKING AGENTS IN A CLASSICAL CONDITIONING PARADIGM. (PH.D. DISSERTATION).
173133 01-03
NEURONE BLOCKING ACTIONS OF ANTIPSYCHOTIC DRUGS.
182127 02-03
PARADOXICAL THERMOREGULATORY BEHAVIOUR IN RATS INDUCED BY (..) AMPHETAMINE: BLOCKADE BY ALPHA-ADRENOCEPTOR OR DOPAMINE RECEPTOR BLOCKING AGENTS.
183797 03-03
ALPHA-ADRENERGIC BLOCKING AGENTS: ANTINOCICEPTIVE ACTIVITY AND ENHANCEMENT OF MORPHINE-INDUCED ANALGESIA.
183895 03-03
THE INHIBITION BY BETA-ADRENOCEPTOR BLOCKING AGENTS OF CALCIUM UPTAKE INTO AND EFFLUX FROM ISOLATED SARCOPLASMIC VESICLES.
184223 03-03
EFFECTS OF CLONIDINE AND SOME ALPHA-ADRENORECEPTOR BLOCKING AGENTS ON AVOIDANCE CONDITIONED REFLEXES IN RATS: THEIR INTERACTIONS AND ANTAGONISM BY ATROPINE.
186576 03-04
TREATMENT OF ANXIETY NEUROSIS BY ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKING AGENTS.
186780 03-10
BLOCKING OF THE EFFECT OF A DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC) ON SPONTANEOUS MOTOR ACTIVITY IN THE RAT BY IMMUNIZATION WITH A PROTEIN CONJUGATE OF DELTA1-THC.
187129 03-04
THE IMPULSE BLOCKING CONCENTRATIONS OF ANESTHETICS, ALCOHOLS, ANTICONVULSANTS, BARBITURATES, AND NARCOTICS ON PHRENIC AND SCIATIC NERVES.
187803 04-03
THE NERVE IMPULSE BLOCKING ACTIONS OF TRANQUILIZERS AND THE BINDING OF NEUROLEPTICS TO SYNAPTOSOME MEMBRANES.
189400 04-03
DOPAMINERGIC INHIBITION OF STRIATAL CHOLINERGIC NEURONS: SYNERGISTIC BLOCKING ACTION OF GAMMA-BUTYROLACTONE AND NEUROLEPTIC DRUGS.
189602 04-03

BLOOD
BLOOD LEVEL PROFILE IN MAN FOLLOWING CHRONIC ORAL ADMINISTRATION OF FLURAZEPAM HYDROCHLORIDE.
169817 01-13
EFFECT OF SELECTED BETA-DIKETONES ON LITHIUM FLUXES OF BOVINE RED BLOOD CELLS.
171792 01-05
SIMULTANEOUS ANALYSIS OF A 1,5 BENZODIAZEPINE AND ITS METABOLITE IN BLOOD AND URINE BY SPECTRODENSITOMETRY.
176871 02-16
BLOOD AND BRAIN LEVELS OF DELTA1-TETRAHYDROCANNABINOL IN MICE -- THE EFFECT OF 7-HYDROXY-DELTA1-TETRAHYDROCANNABINOL.
177333 02-03
A NEW MODIFICATION FOR STUDYING 5-HT UPTAKE BY BLOOD PLATELETS: A RE-EVALUATION OF TRICYCLIC ANTIDEPRESSANTS AS UPTAKE INHIBITORS.
180055 02-06
EXPERIENCE IN THE TREATMENT OF CEREBRAL INSUFFICIENCY AND PERIPHERAL BLOOD CIRCULATION DISORDERS USING THE EP-50-100 EXPERIMENTAL DRUG.
180676 02-11
BLOOD LEVEL AND URINARY EXCRETION OF BROMAZEPAM IN MAN.
182556 03-13
QUANTITATIVE DETERMINATION OF IMIPRAMINE AND DESIPRAMINE IN HUMAN BLOOD PLASMA BY DIRECT DENSITOMETRY OF THIN-LAYER CHROMATOGRAMS.
183603 03-13
PERPHENAZINE CONCENTRATIONS IN HUMAN WHOLE BLOOD: A PILOT STUDY DURING ANTIPSYCHOTIC THERAPY USING DIFFERENT ADMINISTRATION FORMS.
187639 04-16
CONTROL OF NOREPINEPHRINE SYNTHESIS IN BLOOD VESSELS AND THE EFFECTS OF MONOAMINE OXIDASE INHIBITION.
189390 04-03
DIAZEPAM AND MEPERIDINE ON ARTERIAL BLOOD GASES IN HEALTHY VOLUNTEERS.
190147 04-13
COMPARATIVE PROPERTIES OF SOLUBLE AND PARTICULATE CATECHOL-O-METHYLTRANSFERASE FROM RAT RED BLOOD CELL: PRELIMINARY OBSERVATIONS.
191523 04-01
INFLUENCE OF VARIOUS SUBSTANCES WHICH INDUCE AND INHIBIT AGGREGATION ON THE UPTAKE OF DEOXYGLUCOSE BY HUMAN BLOOD PLATELETS.
191770 04-13
THE EFFECTS OF AMPHETAMINE SULFATE ON THE DIURNAL RHYTHMS OF MIDBRAIN, CORTEX, NOREPINEPHRINE, SEROTONIN AND BLOOD GLUCOSE LEVELS IN THE MOUSE.
191918 04-03

THE EFFECTS OF HOE-36801 ON MUSCLE ACTIVITY AND BLOOD PRESSURE, ON ATTENTION AND CONCENTRATION, ON TIME JUDGMENT AND SUBJECTIVE RESPONSES IN NEUROTICS AND NORMALS.
192429 04-14

BLOOD-BRAIN

ANIMAL MODELS FOR AN ENZYMIC BLOOD-BRAIN BARRIER MECHANISM FOR THERAPEUTICALLY ADMINISTERED L-DOPA.
167359 01-03

THE DEVELOPMENT OF A BLOOD-BRAIN BARRIER TO METHADONE IN THE NEWBORN RAT.
182165 02-03

TRUE AND APPARENT NON-PENETRATION OF THE BLOOD-BRAIN BARRIER BY PSYCHOTROPIC DRUGS.
192423 04-03

BODY

THE EFFECT OF LOWERED BODY TEMPERATURE ON LIFESPAN AND IMMUNE AND NONIMMUNE PROCESSES.
169675 01-03

METABOLIC CONTROL OF BODY TEMPERATURE IN MAN.
174134 01-08

POTENTIAL NEUROTRANSMITTERS AND RECEPTOR MECHANISMS INVOLVED IN THE CENTRAL CONTROL OF BODY TEMPERATURE IN HAMSTERS. (PH.D. DISSERTATION).
174962 01-03

DAILY RHYTHM IN BODY TEMPERATURE OF MENTAL PATIENTS: APPLICATION OF COSINOR METHOD -- FIRST REPORT.
191685 04-17

DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) IMIPRAMINE INTERACTION ON MOUSE BODY TEMPERATURE.
191996 04-03

BODYWEIGHT

INFLUENCE OF DIBENCYCLADINE AND IMIPRAMINE ON CALORIE INTAKE AND BODYWEIGHT.
183359 03-03

THE EFFECTS OF CHRONIC TREATMENT WITH D-AMPHETAMINE ON FOOD INTAKE, BODYWEIGHT, LOCOMOTOR ACTIVITY AND SUBCELLULAR DISTR'BUTION OF THE DRUG IN RAT BRAIN.
185931 03-03

INDEPENDENCE OF THE EFFECTS OF D-AMPHETAMINE AND FOOD DEPRIVATION OR BODYWEIGHT ON THE FOOD CONSUMPTION OF RATS.
186376 03-06

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON BODYWEIGHT AND BRAIN ELECTROLYTES IN THE CHICKEN.
186570 03-03

BONICA

JOHN J. BONICA ON PAIN MANAGEMENT.
189903 04-13

BOTANY

THE BOTANY AND CHEMISTRY OF HALLUCINOGENS.
189101 04-12

BOUND

MODIFICATION OF STIMULATION BOUND BEHAVIOR BY TRIFLUOPERAZINE AND AMPHETAMINE IN RATS. (PH.D. DISSERTATION).
173158 01-04

BOVINE

EFFECT OF SELECTED BETA-DIKETONES ON LITHIUM FLUXES OF BOVINE RED BLOOD CELLS.
171792 01-05

STUDIES OF MONOAMINE OXIDASES: PROPERTIES OF THE ENZYME IN BOVINE AND RABBIT BRAIN MITOCHONDRIA.
191300 04-03

THE PRESENCE OF MAO IN SYNAPTIC MEMBRANES OF BOVINE BRAIN.
191956 04-03

BOYS

IMIPRAMINE AND METHYLPHENIDATE TREATMENTS OF HYPERACTIVE BOYS: A DOUBLE-BLIND COMPARISON.
185324 03-14

BEHAVIORAL AND VISUAL EVOKED POTENTIAL INVESTIGATIONS DURING TRIHEXYPHENIDYL AND THIOTHIXENE TREATMENT IN PSYCHOTIC BOYS.
187115 03-09

ELECTRODERMAL ACTIVITY IN HYPERACTIVE BOYS WHO ARE METHYLPHENIDATE RESPONDERS.
191400 04-14

BRADYCARDIA

ROLE OF THE CENTRAL AUTONOMIC NERVOUS SYSTEM IN THE HYPOTENSION AND BRADYCARDIA INDUCED BY (-) DELTA9-TETRAHYDROCANNABINOL.
183795 03-03

BRAIN

EFFECT OF ETHANOL ON CYCLIC AMP LEVELS IN THE RAT BRAIN.
167326 01-03

RETROGRADE AMNESIA FROM HYPOTHERMIA INDUCED BRAIN SEIZURES.
167398 01-04

THE UPTAKE, RETENTION AND METABOLISM OF 3H-5-HYDROXYTRYPTAMINE IN BRAIN SLICES AND ILEUM FROM THE RAT: EFFECTS OF COCAINE, DESMETHYLIMIPRAMINE AND RESERPINE. (PH.D. DISSERTATION).
168131 01-03

BRAIN TO SERUM DISTRIBUTION OF RADIOACTIVITY OF INJECTED 3H-D-AMPHETAMINE IN DIFFERENTIALLY HOUSED MICE.
168418 01-03

BETA-PHENYLETHYLAMINE: A SPECIFIC SUBSTRATE FOR TYPE B MONOAMINE OXIDASE OF BRAIN.
168437 01-03

THE EFFECT OF D- AND L-P-CHLOROPHENYLALANINE ON THE METABOLISM OF 5-HYDROXYTRYPTAMINE IN BRAIN.
168748 01-03

DECREASED HISTAMINE SYNTHESIS IN THE RAT BRAIN BY HYPNOTICS AND ANESTHETICS.
168750 01-03

TRAZODONE IN THE TREATMENT OF ORGANIC BRAIN SYNDROMES, WITH SPECIAL REFERENCE TO PSYCHOGERIATRICS.
168805 01-11

EFFECT OF CHRONIC LITHIUM TREATMENT ON MONOAMINE METABOLISM IN RAT BRAIN.
168839 01-03

CHEMOTHERAPY IN CHRONIC ORGANIC BRAIN SYNDROME - A REVIEW OF THE LITERATURE.
169065 01-11

IMIPRAMINE IN THE TREATMENT OF MINIMAL BRAIN DYSFUNCTION IN CHILDREN.
169295 01-11

LITHIUM INDUCED DIABETES-INSIPIDUS: MANIC SYMPTOMS, BRAIN AND ELECTROLYTE CORRELATES, AND CHLOROTHIAZIDE TREATMENT.
169486 01-15

L-DOPA: EFFECT ON ETHANOL NARCOSIS AND BRAIN BIOGENIC AMINES IN MICE.
169782 01-03

AVERAGE EVOKED RESPONSES IN NORMAL AND MINIMALLY BRAIN DYSFUNCTIONED CHILDREN TREATED WITH AMPHETAMINE: A PRELIMINARY REPORT.
169861 01-11

BRAIN SEROTONIN, AFFECTIVE ILLNESS AND ANTIDEPRESSANT DRUGS: CEREBROSPINAL FLUID STUDIES WITH PROBENECID. (UNPUBLISHED PAPER).
170084 01-09

EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON ATTACK ELICITED BY HYPOTHALAMIC STIMULATION: RELATION TO BRAIN BIOGENIC AMINES.
170162 01-04

IS THERE A RELATIONSHIP BETWEEN THE INVOLVEMENT OF EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS WITH THE CATALEPTIC ACTION OF NEUROLEPTIC AGENTS AND THEIR CLINICAL ANTIPSYCHOTIC EFFECT?
171305 01-03

THE UPTAKE OF DOPAMINE AND SEROTONIN IN RAT BRAIN DURING PROGESTERONE DECLINE.
171307 01-03

SYNTHESIS OF ACETYLCHOLINE IN BRAIN NERVE TERMINALS DURING CONSCIOUSNESS AND BARBITURATE ANESTHESIA.
171600 01-03

EFFECTS OF TETRABENAZINE ON LORDOSIS BEHAVIOUR AND ON BRAIN MONOAMINES IN THE FEMALE RAT.
171614 01-04

INFLUENCES OF DRUGS ON THE INCREASES IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OF GAMMA-HYDROXYBUTYRIC ACID (GHBA).
171622 01-03

EFFECT OF IMIPRAMINE ON THE TURNOVER OF BRAIN 5-HT IN POSTNATAL RATS.
171624 01-03

LEVELS OF HVA IN MOUSE BRAIN FOLLOWING TREATMENT WITH METABOLITES OF CHLORPROMAZINE.
171626 01-03

THE EFFECT OF PROTRIPTYLINE ON THE METABOLISM OF LABELLED DOPAMINE AND NORADRENALINE IN THE RAT BRAIN.
171627 01-03

ANTAGONISM OF P-CHLOROAMPHETAMINE (PCA) INDUCED DEPLETION OF 5-HT FROM RAT BRAIN BY SOME THYMOLEPTICS AND OTHER PSYCHOTROPIC DRUGS.
171628 01-03

A SENSITIVE GAS CHROMATOGRAPHIC PROCEDURE FOR THE ESTIMATION OF NORADRENALINE, DOPAMINE AND 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
171971 01-01

EFFECTS OF CENTRALLY ACTING DRUGS ON ADENYL CYCLASE ACTIVITY AND CYCLIC AMP LEVELS OF MOUSE BRAIN. (PH.D. DISSERTATION).
172019 01-03

THE ROLE OF THE SEPTAL AREA OF THE BRAIN IN THE INHIBITORY MODULATION OF BEHAVIOR. (PH.D. DISSERTATION).
172021 01-03

THE DISTRIBUTION OF DELTA1-TETRAHYDROCANNABINOL AND 7-HYDROXY-DELTA1oTETRAHYDROCANNABINOL IN THE MOUSE BRAIN AFTER INTRAVENTRICULAR INJECTION.
172596 01-03

EFFECTS OF SOME TETRAHYDROCANNABINOLS ON THE BIOSYNTHESIS AND UTILIZATION OF CATECHOLAMINES IN THE RAT BRAIN.
172917 01-03

ALTERATION OF 5-HYDROXYTRYPTAMINE-14C EFFLUX BY NICOTINE IN RAT BRAIN AREA SLICES.
172925 01-03

THE NOOTROPIC APPROACH TO THE PHARMACOLOGY OF THE INTEGRATIVE ACTIVITY OF THE BRAIN.
173495 01-02

DRINKING BEHAVIOUR AND BRAIN DOPAMINE: ANTAGONISTIC EFFECT OF TWO NEUROLEPTIC DRUGS (PIMOZIDE AND SPIRAMIDE) UPON AMPHETAMINE OR APOMORPHINE-INDUCED HYPODIPSIA.
174035 01-04

EXCITANT AND DEPRESSANT DRUGS MODULATE EFFECTS OF ENVIRONMENT ON BRAIN WEIGHT AND CHOLINESTERASES.
174036 01-03

THE EFFECTS OF AMPHETAMINE, 2-AMINOINDANE AND 2-AMINOTETRALIN ON THE CONCENTRATIONS OF WHOLE BRAIN NORADRENALINE, DOPAMINE, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC ACID IN THE MOUSE.
174828 01-03

BRAIN BIOGENIC AMINE DEPLETION AND MOOD.
174994 02-14

INTERACTIVE EFFECTS OF CYCLOHEXIMIDE AND PUROMYCIN IN ALTERING BRAIN POLYRIBOSOMES AND NEURAL AND BEHAVIOURAL RESPONSES TO ELECTROSHOCK IN MICE.
175230 02-03

PARTIAL PURIFICATION AND CHARACTERIZATION OF NADPH-LINKED ALDEHYDE REDUCTASE FROM MONKEY BRAIN.
175232 02-03

THE EFFECT OF PHENIRAMINE AND ITS STRUCTURAL ANALOGUES ON 5-HYDROXYTRYPTAMINE IN RAT AND MOUSE BRAIN.
175240 02-03

A METHOD FOR ANALYZING CNS EFFECTS OF DRUGS AND BRAIN LESIONS ON PERMANENT GROUPS OF RATS.
176867 02-06

SPECIFIC FACILITATION OF MAZE LEARNING BY A PEPTIDE EXTRACTED FROM TRAINED MOUSE BRAIN.
176868 02-04

RELATIVE POTENCIES OF D- AND L-AMPHETAMINE ON THE RELEASE OF DOPAMINE FROM CAT BRAIN IN VIVO.
176874 02-03

STUDIES ON MONOAMINE OXIDASE -- REPORT 22: EFFECTS OF NANO2 AND NH2OH ON MITOCHONDRIAL MAO IN RAT BRAIN.
177022 02-03

DOPAMINE IN THE MESOLIMBIC SYSTEM OF THE RAT BRAIN: ENDOGENOUS LEVELS AND THE EFFECTS OF DRUGS ON THE UPTAKE MECHANISM AND STIMULATION OF ADENYLATE CYCLASE ACTIVITY.
177131 02-03

BRAIN AMINO ACIDS DURING CONVULSIONS.
177135 02-03

NOREPINEPHRINE SENSITIVE ADENYLATE CYCLASES IN RAT BRAIN: RELATION TO BEHAVIOR AND TYROSINE HYDROXYLASE.
177252 02-03

INHIBITION OF LUNG, LIVER AND BRAIN MONOAMINE OXIDASE BY IMIPRAMINE AND DESIPRAMINE.
177332 02-03

BLOOD AND BRAIN LEVELS OF DELTA1-TETRAHYDROCANNABINOL IN MICE -- THE EFFECT OF 7-HYDROXY-DELTA1-TETRAHYDROCANNABINOL.
177333 02-03

INABILITY OF RAT BRAIN HOMOGENATE TO OXIDIZE AMPHETAMINE.
177334 02-03

ADRENALINE, NORADRENALINE AND DOPAMINE LEVELS IN BRAIN AND HEART AFTER ADMINISTRATION OF 6-HYDROXYDOPAMINE AND GUANETHIDINE TO NEWBORN MICE.
177338 02-03

BRAIN RIBOSOMAL RNA SYNTHESIS INHIBITED BY CHLORPROMAZINE.
177835 02-03

PENTAZOCINE IN RHESUS MONKEY PLASMA AND BRAIN AFTER PARENTERAL AND ORAL ADMINISTRATION.
178641 02-03

STRUCTURAL FUNCTIONAL ORGANIZATION OF THE HUMAN BRAIN AND THE PATHOPHYSIOLOGY OF THE PARKINSONIAN TYPE HYPERKINESES.
178787 02-13

CHANGES IN BRAIN ACETYLCHOLINESTERASE ACTIVITY OF YOUNG RATS AFTER CHRONIC TREATMENT WITH TREMORINE.
178814 02-03

STIMULATION OF BRAIN AROMATIC ALKYLAMINE N-METHYLTRANSFERASE ACTIVITY BY FAD AND METHYLCOBALAMIN.
180020 02-03

LONG-TERM EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE ON BRAIN MONOAMINES.
180022 02-03

EFFECT OF CHRONIC INTOXICATION WITH (..) AMPHETAMINE ON ITS CONCENTRATION IN LIVER AND BRAIN AND ON (14C) LEUCINE INCORPORATION INTO MICROSOMAL AND CYTOPLASMIC PROTEINS OF RAT LIVER.
180056 02-05

EFFECT OF ADRENERGIC SUBSTANCES ON OXYGEN CONSUMPTION OF RAT BRAIN TISSUE.
180058 02-03

EFFECTS OF PHENOXYBENZAMINE, ACEPERONE AND CLONIDINE ON THE LEVEL OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL, (MOPEG) IN RAT BRAIN.
180059 02-03

EFFECT OF CHLORPROMAZINE AND SOME OF ITS METABOLITES ON THE DOPAMINE SENSITIVE ADENYLATE CYCLASE OF RAT BRAIN STRIATUM.
180060 02-03

SOLUBILIZATION AND PURIFICATION OF BRAIN RNA POLYMERASE.
180537 02-06

ACETYLCHOLINE TURNOVER IN BRAIN OF MICE AND RATS: EFFECTS OF VARIOUS DOSE REGIMENS OF MORPHINE. (UNPUBLISHED PAPER).
180582 02-03

EFFECTS OF NEUROLEPTICS AND THYMOLEPTICS ON PHOSPHODIESTERASE ACTIVITY AND ON CYCLIC 3,5 AMP LEVELS IN RAT BRAIN.
181467 02-03

CATECHOLAMINE TURNOVER IN THE RAT BRAIN: DIFFERENT RESULTS OBTAINED IN DIFFERENT EXPERIMENTAL CONDITIONS.
181471 02-03

SUBCELLULAR DISTRIBUTION OF DELTA9-TETRAHYDROCANNABINOL IN RAT BRAIN.
181810 02-03

EFFECTS OF L-DELTA9-TETRAHYDROCANNABINOL, DL-AMPHETAMINE AND PENTOBARBITAL ON OXYGEN CONSUMPTION BY MOUSE BRAIN AND HEART HOMOGENATES.
181813 02-03

CONVULSION PRODUCING PROPERTY OF THE DIALYZABLE GLYCOPEPTIDE PREPARATION FROM WHOLE RAT BRAIN.
181815 02-03

COMPARISON OF THE CHRONIC AND ACUTE EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) TREATMENT ON RAT BRAIN SEROTONIN AND NOREPINEPHRINE.
181945 02-03

A CENTRAL EFFECT OF LOCAL ANESTHETICS: PREVENTION AGAINST THE ACCUMULATION OF CYCLIC AMP IN BRAIN SLICES.
182099 02-03

THE EFFECT OF METHAMPHETAMINE ON BRAIN ACH CONSUMPTION AND AGGRESSIVENESS IN MICE STRESSED MILDLY BY LONG-TERM ISOLATION.
182108 02-04

DISPOSITION OF NORAPOMORPHINE AND N,N PROPYLNORAPOMORPHINE IN MOUSE BRAIN AND ITS CORRELATION WITH STEREOTYPED GNAWING BEHAVIOR.
182131 02-04

EFFECTS OF SELECTED CENTRALLY ACTING AGENTS ON ADENYL CYCLASE ACTIVITY IN MOUSE BRAIN.
182153 02-03

CONVERSION OF CHLORAL HYDRATE TO TRICHLOROETHANOL IN BRAIN AND LIVER.
182157 02-03

LSD TOLERANCE AND BRAIN SEROTONIN METABOLISM.
182167 02-03

INHIBITION OF C14-ACH UPTAKE IN RAT BRAIN SLICES BY DESMETHYLIMIPRAMINE.
182170 02-03

BRAIN AMINES IN PYRIDOXINE DEFICIENT RATS.
182171 02-03

BEHAVIORAL EFFECTS OF SIMULTANEOUS DEPLETION OF BRAIN NOREPINEPHRINE AND SEROTONIN.
182211 03-04

REGIONAL AND SUBCELLULAR DISTRIBUTION OF CHOLINE ACETYLTRANSFERASE IN THE BRAIN OF NORMAL AND MORPHINE TREATED RATS.
182224 03-03

EFFECTS OF NARCOTIC ANALGESICS ON ENZYMES OF ACETYLCHOLINE METABOLISM IN CULTURED CHICK BRAIN CELLS.
182225 03-03

EFFECT OF ACUTE AND CHRONIC MORPHINE ON SPECIFIC RADIOACTIVITIES OF CHOLINE AND ACETYLCHOLINE IN MOUSE BRAIN.
182226 03-03

EFFECTS OF MORPHINE, NALORPHINE AND NALOXONE ON RAT BRAIN RELEASE OF ACETYLCHOLINE.
182227 03-03

STUDIES ON THE EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT ON CATECHOLAMINE LEVELS AND TURNOVER IN DISCRETE BRAIN AREAS OF RATS.
182228 03-03

EFFECTS OF METHADONE ON ACTIVITY AND ON BRAIN MONOAMINES IN TWO MOUSE STRAINS.
182229 03-03

EFFECT OF 2-ARYLALANINES, 2-ARYLSERINES, TETRAPHENYLBORON AND 1,2 DL(2,4 DICHLOROPHENYL) ETHANOLAMINE ON LEVELS OF SEROTONIN (5-HT), NOREPINEPHRINE (NE) AND DOPAMINE (DM) IN WHOLE BRAIN OF MICE.
182254 03-03

EFFECTS OF CHRONIC ADMINISTRATION OF AMPHETAMINE UPON THE CATECHOLAMINE CONTENT OF MOUSE BRAIN.
182255 03-03

PENTYLENETETRAZOL CONVULSIONS AND BRAIN CATECHOLAMINE TURNOVER RATE IN RATS AND MICE RECEIVING DIPHENYLHYDANTOIN OR BENZODIAZEPINES.
182344 03-03

THE INHIBITION OF (3H) BIOGENIC AMINE ACCUMULATION INTO RAT BRAIN TISSUE SLICES BY VARIOUS TRYPTAMINE DERIVATIVES.
182723 03-03

NON-SPECIFICITY OF 5-HYDROXYTRYPTOPHAN IN REPLETING BRAIN SEROTONIN IN RATS WITH MFB LESIONS.
182725 03-03

THE INFLUENCE OF CHRONIC ADMINISTRATION OF LITHIUM CARBONATE ON THE BRAIN NOREPINEPHRINE CONTENT IN RATS.
182872 03-03

THE INFLUENCE OF NEUROTROPIC DRUGS ON MONOAMINE OXIDASE (MAO) AND 5-OXYTRYPTOPHANE DECARBOXYLASE (5-OTD) ACTIVITY IN THE BRAIN.
183142 03-13

THE EFFECT OF CANNABINOIDS ON THE NUMBER OF NUCLEAR MEMBRANE ATTACHED RIBOSOMES IN INFANT RAT BRAIN.
183228 03-03

EVALUATION OF EEG AND CLINICAL CHANGES ASSOCIATED WITH PAVABID THERAPY IN CHRONIC BRAIN SYNDROME.
183402 03-13

THE EFFECTS OF PSYCHIC STIMULANTS ON THE ACTIVITY OF POTASSIUM AND SODIUM ION STIMULATED ATPASE IN THE MICROSOMAL FRACTIONS OF THE BRAIN OF RATS.
183518 03-01

IMIPRAMINE AND ITS METABOLITES IN HUMAN BRAIN.
183604 03-13

CATALEPSY AND STEREOTYPED BEHAVIOUR IN RATS TREATED CHRONICALLY WITH METHADONE: RELATION TO BRAIN HOMOVANILLIC ACID CONTENT.
183606 03-04

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON THE METABOLISM OF 3H-5-HYDROXYTRYPTAMINE AND 3H-NOREPINEPHRINE IN THE RAT BRAIN.
183787 03-03

LONG-TERM EFFECTS OF 4-CHLOROAMPHETAMINE ON BRAIN 5-HYDROXYINDOLE METABOLISM IN RATS.
183869 03-03

A COMPARISON OF PSYCHOTOMIMETIC DRUG EFFECTS ON RAT BRAIN NOREPINEPHRINE METABOLISM.
183891 03-03

FORMATION OF NORADRENALINE IN THE RAT BRAIN FROM THE FOUR STEREOISOMERS OF 3,4 DIHYDROXYPHENYLSERINE.
184229 03-03

DOPAMINE IN BRAIN FUNCTION.
184329 03-03

EFFECTS OF VARIOUS MORPHINE TREATMENT SCHEDULES ON ACETYLCHOLINE TURNOVER RATE IN RAT BRAIN PARTS.
184553 03-03

BRAIN MECHANISMS UNDERLYING THE EFFECTS OF AMPHETAMINE ON FEEDING AND NONFEEDING BEHAVIORS: DISSOCIATION AND OVERLAP.
184839 03-03

EFFECT OF LSD-25 AND 1-METHYL-D-LYSERGIC ACID BUTANOLAMIDE ON RAT BRAIN AND PLATELET SEROTONIN LEVELS.
184975 03-03

HISTO-AUTORADIOGRAPHIC INVESTIGATIONS ON THE DISTRIBUTION OF INJECTED 5-HYDROXYTRYPTAMINE (SEROTONIN) IN THE BRAIN AND THE PITUITARY OF MICE.
185900 03-03

THE EFFECTS OF CHRONIC TREATMENT WITH D-AMPHETAMINE ON FOOD INTAKE, BODYWEIGHT, LOCOMOTOR ACTIVITY AND SUBCELLULAR DISTRIBUTION OF THE DRUG IN RAT BRAIN.
185931 03-03

ANTICONVULSANT ACTIVITY AND INHIBITION OF RESPIRATION IN RAT BRAIN HOMOGENATES BY SUBSTITUTED OXADIAZOLES.
185980 03-01

THE POSSIBLE ROLE OF TRYPTAMINE IN BRAIN FUNCTION AND ITS RELATIONSHIP TO THE ACTIONS OF LSD-LIKE HALLUCINOGENS.
186024 03-12

BRAIN AMINES AND APOMORPHINE-INDUCED INTRASPECIFIC AGGRESSIVE BEHAVIOR IN THE RAT.
186374 03-04

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON BODYWEIGHT AND BRAIN ELECTROLYTES IN THE CHICKEN.
186570 03-03

THE ISOLATED PERFUSED RAT BRAIN AS A MODEL FOR STUDYING DRUGS ACTING ON THE CNS.
186589 03-06

EFFECTS OF LITHIUM ON ADRENERGIC AMINE UPTAKE IN RAT BRAIN SYNAPTOSOMES.
186633 03-03

BIOCHEMICAL AND BEHAVIOURAL ALTERATIONS FOLLOWING 5,6 DIHYDROXYTRYPTAMINE ADMINISTRATION INTO BRAIN.
186634 03-04

THE MONOAMINE OXIDASES OF BRAIN: SELECTIVE INHIBITION WITH DRUGS AND THE CONSEQUENCES FOR THE METABOLISM OF THE BIOGENIC AMINES.
186668 03-03

A COMPARISON OF THE EFFECTS OF AMPHETAMINE AND ITS METABOLITES, P-HYDROXYAMPHETAMINE AND P-HYDROXYNOREPHEDRINE, ON UPTAKE, RELEASE AND CATABOLISM OF 3H-NOREPINEPHRINE IN CEREBRAL CORTEX OF RAT BRAIN.
186669 03-03

EFFECTS OF AMPHETAMINES ON REGIONAL TRYPTOPHAN HYDROXYLASE ACTIVITY AND SYNAPTOSOMAL CONVERSION OF TRYPTOPHAN TO 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
186674 03-03

EVIDENCE FOR A CRITICAL PERIOD FOR POSTNATAL ELEVATION OF BRAIN TYROSINE HYDROXYLASE ACTIVITY RESULTING FROM RESERPINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT.
186695 03-03

DIFFERENTIAL EFFECTS OF PILOCARPINE AND SCOPOLAMINE ON THE PERFORMANCE OF A LIGHT DARK DISCRIMINATION MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN.
186701 03-03

PHYSIOLOGICAL DISPOSITION OF BETA-PHENYLETHYLAMINE, 2,4,5 TRIMETHOXYPHENYLETHYLAMINE, 2,3,4,5,6 PENTAMETHOXYPHENYLETHYLAMINE AND BETA-HYDROXYMESCALINE IN RAT BRAIN, LIVER AND PLASMA.
186706 03-03

EFFECT OF MORPHINE ON REGIONAL LEVELS OF GAMMA-HYDROXYBUTYRATE IN MOUSE BRAIN.
187077 03-03

THE EFFECT OF LITHIUM ON HORMONE SENSITIVE ADENYLATE CYCLASE FROM VARIOUS REGIONS OF THE RAT BRAIN.
187110 03-03

THE INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LEVELS OF ENDOGENOUS 2-PHENYLETHYLAMINE IN RABBIT BRAIN.
187112 03-03

LEARNING IMPAIRMENT IN RATS AFTER 6-HYDROXYDOPAMINE INDUCED DEPLETION OF BRAIN CATECHOLAMINES.
187420 04-04

PENTOBARBITAL AND IN VIVO TURNOVER RATE OF ACETYLCHOLINE IN MOUSE BRAIN AND IN REGIONS OF RAT BRAIN. (UNPUBLISHED PAPER).
187526 04-03

REGULATION OF BRAIN DOPAMINE TURNOVER RATE: PHARMACOLOGICAL IMPLICATIONS. (UNPUBLISHED PAPER).
187527 04-03

DEVELOPMENT OF LOCOMOTION AND BRAIN CATECHOLAMINES.
187551 04-04

EFFECT OF SKF-525-A ON THE METABOLISM OF (-) DELTA9-TETRAHYDROCANNABINOL IN THE RAT BRAIN AND LIVER.
187578 04-03

THE EFFECTS OF CHRONIC RESERPINE AND NIALAMIDE TREATMENT ON THE FREE AMINO ACID LEVELS OF RAT BRAIN.
187645 04-03

ACTIONS OF ATROPINE, HEMICHOLINIUM-3, AND PHYSOSTIGMINE ON CHLORPROMAZINE INDUCED CHANGES IN RAT BRAIN MONOAMINES.
187800 04-03

METHIOTHEPIN ELEVATION OF 5-HYDROXYINDOLEACETIC ACID LEVELS IN VARIOUS ANATOMIC REGIONS OF RAT BRAIN.
187831 04-03

ANTISCHIZOPHRENIC DRUGS AND BRAIN CHOLINERGIC RECEPTORS: AFFINITY FOR MUSCARINIC SITES PREDICTS EXTRAPYRAMIDAL EFFECTS.
188114 04-15

EFFECTS OF LSD ON SYNTHESIS AND RELEASE OF 5-HT IN RAT BRAIN SLICES.
188164 04-03

EFFECT OF TETRAHYDROCANNABINOLS ON BRAIN ACETYLCHOLINE.
188167 04-03

THE EFFECT OF HYPOTHERMIC DOSES OF 1-DELTA9-TETRAHYDROCANNABINOL ON BIOGENIC AMINE METABOLISM IN SELECTED PARTS OF THE RAT BRAIN.
188231 04-03

DEPLETION OF TRYPTOPHAN HYDROXYLASE BY 5,6 DIHYDROXYTRYPTAMINE IN RAT BRAIN -- TIME COURSE AND REGIONAL DIFFERENCES.
188287 04-03

IN VITRO BINDING OF (4-14C) DIPHENYLHYDANTOIN TO RAT BRAIN MICROSOMES.
188404 04-03

DISAGGREGATION OF BRAIN POLYSOMES AFTER L-DOPA: AN ANALYSIS.
188433 04-03

INVOLVEMENT OF BRAIN CHOLINERGIC MECHANISMS IN THE ACTION OF CHLORPROMAZINE.
188891 04-03

ESTIMATION OF THE RATE OF 5-HT SYNTHESIS IN THE MOUSE BRAIN BY VARIOUS METHODS.
188976 04-03

EFFECT OF PENTOBARBITAL ON UPTAKE AND RELEASE OF (3H)GABA AND (14C)GLUTAMATE BY BRAIN SLICES.
189031 04-03

TURNOVER OF HISTAMINE IN RAT BRAIN AND ITS DECREASE UNDER BARBITURATE ANESTHESIA.
189396 04-03

EFFECTS OF ALPHA-METHYLTYROSINE ON D-AMPHETAMINE INDUCED RELEASE OF ENDOGENOUSLY SYNTHESIZED AND EXOGENOUSLY ADMINISTERED CATECHOLAMINES FROM THE CAT BRAIN IN VIVO.
189397 04-03

PARADOXICAL EFFECTS OF D-AMPHETAMINE ON BEHAVIORAL THERMOREGULATION: POSSIBLE MEDIATION BY BRAIN DOPAMINE.
189399 04-04

EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND AMPHETAMINE ON SELF-STIMULATION OF BRAIN FOLLOWING VARIOUS 6-HYDROXYDOPAMINE TREATMENTS.
189515 04-04

EFFECTS OF PERINATAL EXPOSURE TO METHYL MERCURY ON FUNCTIONAL BRAIN DEVELOPMENT AND NEUROCHEMISTRY.
189564 04-05

INFLUENCE OF MORPHINE AND NALOXONE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189568 04-03

INFLUENCE OF FENTANYL, LEVORPHANOL AND PETHIDINE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189569 04-03

EFFECT OF ANESTHETIC AGENTS ON THE SYNTHESIS AND DISAPPEARANCE OF BRAIN DOPAMINE NORMALLY AND AFTER HALOPERIDOL, KCL OR AXOTOMY.
189571 04-03

MESCALINE INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON THE BINDING OF AMINOACYL TRANSFER RIBONUCLEIC ACID TO RIBOSOMES OF BRAIN TISSUE.
189582 04-05

EFFECT OF A BUTYROPHENONE DERIVATIVE, U-32802A, ON BRAIN BIOGENIC AMINES.
189584 04-02

EFFECT OF MORPHINE ON THE TURNOVER AND SYNTHESIS OF (LEU-3H) PROTEIN AND (CH-14C) PHOSPHATIDYLCHOLINE IN DISCRETE REGIONS OF THE RAT BRAIN.
189586 04-03

DIHYDROPTERIDINE REDUCTASE IN RAT BRAIN: REGIONAL DISTRIBUTION AND THE EFFECT OF CATECHOLAMINE DEPLETING DRUGS.
189752 04-03

EFFECT OF OXOTREMORINE AND PHYSOSTIGMINE ON CHOLINE LEVELS IN MOUSE WHOLE BRAIN, SPLEEN AND CEREBELLUM.
189893 04-03

DIFFERENTIAL ANTAGONISM BY NALOXONE OF INHIBITORY EFFECTS OF HALOPERIDOL AND MORPHINE ON BRAIN SELF-STIMULATION.
190306 04-03

THE INFLUENCE OF PSYCHOSTIMULANTS ON K42 MEMBRANE PERMEABILITY IN VARIOUS PORTIONS OF RAT BRAIN.
191122 04-03

PHOTIC RESPONSES IN MINIMAL BRAIN DYSFUNCTION.
191188 04-15

STUDIES OF MONOAMINE OXIDASES: PROPERTIES OF THE ENZYME IN BOVINE AND RABBIT BRAIN MITOCHONDRIA.
191300 04-03

EFFECTS OF LIDOCAINE ON RABBIT BRAIN MICROTUBULAR PROTEIN.
191324 04-03

PASSAGE OF TAURINE INTO ADULT MAMMALIAN BRAIN.
191331 04-03

PERMANENT ALTERATIONS IN 5-HYDROXYTRYPTAMINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN FOLLOWING EXPOSURE TO DRUGS DURING THE PERIOD OF DEVELOPMENT.
191383 04-03

THE MODE OF MORPHINE UPTAKE INTO BRAIN SLICES.
191413 04-03

EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF CLOZAPINE ON THE METABOLISM OF DOPAMINE AND NORADRENALINE IN THE BRAIN OF THE RAT.
191418 04-03

EFFECT OF PIRIBEDIL AND ONE OF ITS METABOLITES ON THE CONCENTRATION OF HOMOVANILLIC ACID IN THE RAT BRAIN.
191422 04-03

EFFECT OF DIAZEPAM ON MOUSE WHOLE BRAIN AND BRAIN AREA ACETYLCHOLINE AND CHOLINE LEVELS.
191423 04-03

SOME INTERRELATED PROPERTIES OF BRAIN MONOAMINE OXIDASE.
191498 04-01

THE USE OF SELECTIVE AND INHIBITOR DRUGS TO MODIFY AMINE METABOLISM IN BRAIN.
191500 04-03

EFFECT OF CHRONIC TREATMENT WITH CENTRAL STIMULANTS ON BRAIN MONOAMINES AND SOME BEHAVIOURAL AND PHYSIOLOGICAL FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS.
191503 04-03

RELATIONSHIP OF CATECHOLAMINE NEURAL SYSTEMS TO THE BEHAVIORAL ALTERATIONS PRODUCED BY 6-HYDROXYDOPAMINE ADMINISTRATION INTO BRAIN.
191518 04-03

POST-MORTEM MEASUREMENT OF ENZYMES IN HUMAN BRAIN: EVIDENCE OF A CENTRAL NORADRENERGIC DEFICIT IN SCHIZOPHRENIA.
191529 04-13

EFFECTS OF NOMIFENSINE (HOE-984), D-AMPHETAMINE AND APOMORPHINE ON MOTOR ACTIVITY, CATECHOLAMINE TURNOVER AND CAMP CONCENTRATIONS IN RAT BRAIN. (UNPUBLISHED PAPER).
191766 04-03

ACTION OF HALOPERIDOL AND TRIFLUOPERAZINE ON THE MOTOR RESPONSES ELICITED BY ELECTRICAL STIMULATION OF THE BRAIN IN RABBITS.
191787 04-02

AMPHETAMINE AND NA..,K.. - ATPASE IN THE BRAIN.
191789 04-03

METABOLISM OF D-AMPHETAMINE BY RAT BRAIN IN VIVO AND IN VITRO.
191922 04-03

CORRELATION BETWEEN BRAIN N,N DIMETHYLTRYPTAMINE (DMT) LEVELS AND BAR PRESSING BEHAVIOR IN RATS: EFFECT OF MAO INHIBITION.
191935 04-04

ADENOSINE ACTION ON SYNAPTIC TRANSMISSION IN BRAIN SLICES.
191945 04-03

NORADRENERGIC REGULATION OF BRAIN SEROTONERGIC NEURONS: EVIDENCE FROM SINGLE UNIT STUDIES WITH CLONIDINE.
191948 04-03

EFFECT OF LILLY-110140, 3-(P-TRIFLUOROMETHYLPHENOXY) N METHYL-3-PHENYLPROPYLAMINE ON SYNTHESIS OF 3H-SEROTONIN FROM 3H-TRYPTOPHAN IN RAT BRAIN.
191951 04-03

THE PRESENCE OF MAO IN SYNAPTIC MEMBRANES OF BOVINE BRAIN.
191956 04-03

INCREASED BRAIN NOREPINEPHRINE TURNOVER IN LEAD EXPOSED HYPERACTIVE RATS.
191957 04-05

DISPOSITION OF H3-DELTA9-TETRAHYDROCANNABINOL IN BRAIN OF PREGNANT DOGS AND THEIR FETUSES.
191968 04-03

SUBCELLULAR LOCALIZATION OF H3-DELTA9-TETRAHYDROCANNABINOL IN DOG BRAIN AFTER ACUTE OR CHRONIC ADMINISTRATION.
191970 04-03

MORPHINE TOLERANCE, DEPENDENCE AND WITHDRAWAL AND BRAIN ACETYLCHOLINE.
191985 04-03

THE EFFECT OF INCREASED GAMMA-AMINOBUTYRIC ACID ON ALPHA-METHYLTYROSINE INDUCED DECREASE IN CATECHOLAMINES IN RAT BRAIN.
191988 04-03

TETRAHYDROCANNABINOLS: INHIBITION IN ACETYLCHOLINE SYNTHESIS IN REGIONAL RAT BRAIN SLICES.
191998 04-03

INHIBITION IN VIVO OF ACETYLCHOLINE SYNTHESIS IN MOUSE BRAIN BY INHIBITORS OF CHOLINE ACETYLTRANSFERASE.
192001 04-03

INCORPORATION OF 14C-DIHYDROPHENYLALANINE AND 14C-CHOLINE INTO RAT BRAIN SUBCELLULAR PARTICLES AND THE EFFECT OF PSYCHOACTIVE DRUGS.
192426 04-03

BRAINS

THE EFFECT OF PSYCHOTROPIC AGENTS ON SOME ASPECTS OF ACETYLCHOLINE METABOLISM IN CAT BRAINS.
174257 01-03

SHORT-TERM AND LONG-TERM LITHIUM ADMINISTRATION: EFFECTS ON THE BRAINS SEROTONERGIC BIOSYNTHETIC SYSTEMS.
175149 02-13

DISTRIBUTION OF 14C-PSILOCIN IN THE BRAINS OF VARIOUS ANIMALS.
192425 04-03

BRANCHING

MUSCLE ABNORMALITIES IN PSYCHOTIC PATIENTS: II. SERUM CPK ACTIVITY, FIBER ABNORMALITIES, AND BRANCHING AND SPROUTING OF SUBTERMINAL NERVES.
187114 03-09

BRAND-NAMED

BIOEQUIVALENCY OF GENERIC AND BRAND-NAMED CHLORPROMAZINE.
187255 03-08

BRETYLIUM

TREMOR INDUCTION BY INTRACAUDATE INJECTIONS OF BRETYLIUM, TETRABENAZINE, OR MESCALINE: FUNCTIONAL DEFICITS IN CAUDATE DOPAMINE.
167329 01-03

BRISTOL-COMPOUND-2605
DIURETIC ACTIVITY OF A NEW NARCOTIC ANTAGONIST IN MAN (BRISTOL-COMPOUND-2605). (UNPUBLISHED PAPER).
174473 01-13

BROMAZEPAM
BROMAZEPAM AND PHENOBARBITAL IN ANXIETY: A CONTROLLED STUDY.
167773 01-10
METABOLITES OF BROMAZEPAM, A BENZODIAZEPINE, IN THE HUMAN, DOG, RAT, AND MOUSE.
170837 01-03
A TRIAL ON BROMAZEPAM (LEXOTAN) AND PLACEBO IN THE TREATMENT OF PSYCHOPHYSIOLOGICAL DISORDERS.
171150 01-11
SEMI-QUANTITATIVE ANALYSIS OF BROMAZEPAM BY RING OVEN METHOD.
174853 01-16
CLINICAL PHARMACOLOGICAL STUDY OF BROMAZEPAM IN THE FIELD OF INTERNAL MEDICINE.
176473 02-10
PHARMACOLOGICAL STUDIES ON BROMAZEPAM.
178725 02-03
BEHAVIORAL PHARMACOLOGY OF BROMAZEPAM (RO-5-3350), A NEW BENZODIAZEPINE DERIVATIVE.
181384 02-04
STUDIES ON METABOLISM OF BROMAZEPAM (III): ABSORPTION, EXCRETION, AND METABOLISM OF BROMAZEPAM IN MAN.
181588 02-13
STUDIES ON METABOLISM OF BROMAZEPAM (II): COLORIMETRIC DETERMINATION AND METABOLIC FATE OF BROMAZEPAM IN ANIMALS.
181593 02-03
CENTRAL NERVOUS ACTION OF BROMAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.
181650 02-03
ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF BROMAZEPAM IN RABBIT.
182555 03-03
BLOOD LEVEL AND URINARY EXCRETION OF BROMAZEPAM IN MAN.
182556 03-13
DOUBLE-BLIND CROSSOVER COMPARISON OF BROMAZEPAM AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION.
182624 03-11
INVESTIGATION OF PHYSICAL DEPENDENCE ON A NEW BENZODIAZEPINE DERIVATIVE, BROMAZEPAM.
189209 04-05

BROMOMETHOXYAMPHETAMINES
POTENTIAL PSYCHOTOMIMETICS: BROMOMETHOXYAMPHETAMINES AND STRUCTURAL CONGENERS OF LYSERGIC ACID. (PH.D. DISSERTATION).
173588 01-03

BROTOPON
USE OF HALOPERIDOL (BROTOPON) IN THE TREATMENT OF SCHIZOPHRENIA.
191686 04-08

BUFOTENINE
EVIDENCE FOR THE ACTION OF D-LYSERGIC ACID DIETHYLAMIDE, MESCALINE AND BUFOTENINE ON 5-HYDROXYTRYPTAMINE RECEPTORS IN UMBILICAL VASCULATURE.
182716 03-03
EFFECTS OF BUFOTENINE AND P-CHLOROPHENYLALANINE ON REACTIVITY TO FOOTSHOCK.
184838 03-04

BULB
EFFECTS OF PSYCHOTROPIC DRUGS ON DISCRIMINATION AVOIDANCE CONDITIONING IN RATS WITH OLFACTORY BULB ABLATIONS.
182115 02-04

BULBOSPINAL
NEW LONG LATENCY BULBOSPINAL EVOKED POTENTIALS BLOCKED BY SEROTONIN ANTAGONISTS.
188751 04-03

BULLFROG
DIAZEPAM INHIBITION OF POST-TETANIC POTENTIATION IN BULLFROG SYMPATHETIC GANGLIA: POSSIBLE ROLE OF PROSTAGLANDINS.
186673 03-03

BUNDLE
EFFECTS OF CHLORPROMAZINE, CHLORDIAZEPOXIDE AND PENTOBARBITAL ON NEURONAL EXCITABILITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
177837 02-04
INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: IV. INFLUENCE OF AMPHETAMINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
185961 03-04

BURDEN
ROLE OF FLUPHENAZINE DECANOATE IN LESSENING THE BURDEN OF CHRONIC SCHIZOPHRENICS ON THE COMMUNITY.
169438 01-08

BUTANE
CARDIOVASCULAR AND GROSS BEHAVIORAL EFFECTS OF AMPHETAMINE, 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPROPANE (DOM) AND 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPHENYL BUTANE (BL-3912A) IN THE CONSCIOUS DOG.
187573 04-03

BUTANEDIOL
PHARMACOLOGICAL AND TOXICOLOGICAL STUDIES ON 1,4 BUTANEDIOL.
187381 04-03

BUTANOLAMIDE
EFFECT OF LSD-25 AND 1-METHYL-D-LYSERGIC ACID BUTANOLAMIDE ON RAT BRAIN AND PLATELET SEROTONIN LEVELS.
184975 03-03

BUTAPERAZINE
THE EFFECT OF CONJUGATED ESTROGENS ON PLASMA BUTAPERAZINE LEVELS IN WOMEN.
191959 04-15

BUTOBARBITONE
BUTOBARBITONE METABOLISM IN MAN: IDENTIFICATION OF 3-KETOBUTOBARBITONE.
183793 03-13

BUTYLATED
THE EFFECT OF BUTYLATED HYDROXYANISOLE AND BUTYLATED HYDROXYTOLUENE ON BEHAVIORAL DEVELOPMENT OF MICE.
188637 04-04

BUTYLBARBITAL
THE METABOLISM OF 1-N-BUTYL-5,5 DIETHYLBARBITURIC ACID (N-N BUTYLBARBITAL) IN THE RAT.
191057 04-03

BUTYROPHENONE
EFFECT OF A BUTYROPHENONE DERIVATIVE, U-32802A, ON BRAIN BIOGENIC AMINES.
189584 04-02

BUTYROPHENONES
HALOPERIDOL AND THE BUTYROPHENONES.
169296 01-09
EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON THE RHYTHMS OF WAKEFULNESS SLEEP CYCLE IN RATS.
182553 03-04
EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON ELECTROENCEPHALOGRAM AND FEEDING BEHAVIOR OF RATS.
182554 03-04

C-FIBER
THE EFFECT OF L-TRYPTOPHAN (TP) ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) REFLEXES IN ACUTE DECEREBRATE SPINAL CATS AND THE EFFECT OF PRETREATMENT WITH P-CHLOROPHENYLALANINE (PCPA) ON THE ACTION OF TP. (UNPUBLISHED PAPER).
170874 01-03
THE EFFECT IN THE CAT OF TRYPTAMINE (T) AND LSD ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) SPINAL REFLEXES. (UNPUBLISHED PAPER).
174480 01-12

C-NITROSO
METABOLISM OF CHLORPHENTERMINE AND PHENTERMINE IN MAN TO YIELD HYDROXYLAMINO, C-NITROSO AND NITRO COMPOUNDS.
183796 03-13

C-200
A CLINICAL STUDY OF L-TETRAHYDROPALMATINE (C-200) IN A NEUROPSYCHIATRIC CLINIC.
182902 03-09

CACTUS
CACTUS ALKALOIDS. XIX. CRYSTALLIZATION OF MESCALINE HCL AND 3-METHOXYTYRAMINE HCL FROM TRICHOCEREUS-PACHANOI.
192878 04-01
CACTUS ALKALOIDS. XXII. DOLICHOTHELE SURCULOSA AND OTHER DOLICHOTHELE SPECIES.
192879 04-01
CACTUS ALKALOIDS: XVIII. PHENOLIC BETA-PHENETHYLAMINES FROM MAMMILLARIA-ELONGATA.
192882 04-01

CAFFEINE
INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CAFFEINE, (C), NICOTINE (N), PHENOBARBITAL (P): EFFECTS ON CONDITIONED AVOIDANCE (CAR).
182192 02-04
INCREASED SYNTHESIS OF ADRENOMEDULLARY CATECHOLAMINES INDUCED BY CAFFEINE AND THEOPHYLLINE.
184201 03-03
THE EFFECT OF CAFFEINE, NITRAZEPAM AND CIGARETTE SMOKING ON THE CONTINGENT NEGATIVE VARIATION IN MAN.
187350 04-13
EFFECTS OF CAFFEINE ON ALERTNESS IN SIMULATED AUTOMOBILE DRIVING.
190743 04-14

CALCIUM
THE INHIBITION BY BETA-ADRENOCEPTOR BLOCKING AGENTS OF CALCIUM UPTAKE INTO AND EFFLUX FROM ISOLATED SARCOPLASMIC VESICLES.
184223 03-03
CALCIUM METABOLISM IN ELDERLY EPILEPTIC PATIENTS DURING ANTICONVULSANT THERAPY.
185560 03-15
EFFECT OF 5-METHOXYTRYPTAMINE ON SERUM CALCIUM AND PHOSPHATE IN RATS.
186678 03-03
CALCIUM REVERSAL OF NERVE BLOCKADE BY ALCOHOLS, ANESTHETICS, TRANQUILIZERS, AND BARBITURATES.
187802 04-03

CALIFORNIA
COMPARATIVE SURVEY OF PSYCHIATRISTS TREATMENT PREFERENCES: CALIFORNIA AND NEW-YORK.
185877 03-08

CALMPOSE
DIAZEPAM (CALMPOSE) IN ECLAMPSIA: A PRELIMINARY REPORT OF 16 CASES.
169633 01-11

CALORIE
INFLUENCE OF DIBENCYCLADINE AND IMIPRAMINE ON CALORIE INTAKE AND BODYWEIGHT.
183359 03-03

CAMBODIA
PSYCHOTROPIC DRUGS IN CAMBODIA.
178109 02-17

CAMP
TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER).
170876 01-03
EFFECTS OF NOMIFENSINE (HOE-984), D-AMPHETAMINE AND APOMORPHINE ON MOTOR ACTIVITY, CATECHOLAMINE TURNOVER AND CAMP CONCENTRATIONS IN RAT BRAIN. (UNPUBLISHED PAPER).
191766 04-03

CANADA
A COMPARISON OF CLINICALLY USED PSYCHOACTIVE DRUGS IN FOUR LATIN-AMERICAN COUNTRIES AND IN CANADA (ARGENTINA, COSTA-RICA, MEXICO AND PANAMA).
191139 04-17

CANADIAN
MEGAVITAMIN TREATMENT, CULTURE AND TRANQUILIZERS, DRUGS FOR THE AGED: PROJECTS OF A CANADIAN GRANT.
170293 01-11

CANAL
NORADRENALINE IN THE GUINEA-PIG ALIMENTARY CANAL: REGIONAL DISTRIBUTION AND SENSITIVITY TO DENERVATION AND RESERPINE.
191326 04-03

CANINE
EFFECTS OF PROSTAGLANDINS B1 AND B2 ON VASOCONSTRICTOR RESPONSES OF THE CANINE HINDPAW.
189395 04-03

CANNABIDIOL
THE EFFECT OF CANNABIDIOL ON MAXIMAL ELECTROSHOCK SEIZURES IN RATS.
168749 01-03
PHARMACOLOGICAL INTERACTION BETWEEN CANNABIDIOL AND DELTA9-TETRAHYDROCANNABINOL.
169472 01-03
THE ANTICONVULSANT ACTIVITY OF CANNABIDIOL AND CANNABINOL.
175238 02-03
A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY IN MAN OF INTRAVENOUSLY ADMINISTERED DELTA9-TETRAHYDROCANNABINOL, CANNABINOL, AND CANNABIDIOL.
176747 02-03
INTERACTION OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON INTESTINAL MOTILITY IN MICE.
180057 02-03
CANNABIDIOL AND CANNABIS-SATIVA EXTRACT PROTECT MICE AND RATS AGAINST CONVULSIVE AGENTS.
183609 03-03
CANNABIDIOL INTERACTION WITH DELTA9-TETRAHYDROCANNABINOL.
183788 03-03
COMPARATIVE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CANNABIDIOL (CBD), AND CANNABINOL (CBN) ON TIMING BEHAVIOR IN RATS.
191967 04-04
CARDIOPULMONARY EFFECTS OF CANNABIDIOL IN ANESTHETIZED DOGS.
191993 04-05
ANTICONVULSANT PROPERTIES OF CANNABIDIOL.
191994 04-03

CANNABINOID
ANTICONVULSANT EFFECTS OF CANNABINOLS IN MICE: DRUG INTERACTIONS WITH CANNABINOIDS AND CANNABINOID INTERACTIONS WITH PHENYTOIN.
189513 04-03
THE EFFECT OF CANNABINOID MIXTURES ON THE RESPONSE TO STIMULANT DRUGS IN MICE.
191991 04-04
COMMON CANNABINOID PHENOTYPES IN 350 STOCKS OF CANNABIS.
192787 04-17

CANNABINOIDS
PSYCHOPHARMACOLOGY OF THE CANNABINOIDS.
181152 02-14
THE EFFECT OF CANNABINOIDS ON THE NUMBER OF NUCLEAR MEMBRANE ATTACHED RIBOSOMES IN INFANT RAT BRAIN.
183228 03-03
ANTICONVULSANT EFFECTS OF CANNABINOLS IN MICE: DRUG INTERACTIONS WITH CANNABINOIDS AND CANNABINOID INTERACTIONS WITH PHENYTOIN.
189513 04-03
CANNABINOIDS AND HEXOBARBITAL INDUCED LOSS OF RIGHTING REFLEXES.
189573 04-04
CANNABINOIDS: NEUROCHEMICAL ASPECTS AFTER ORAL CHRONIC ADMINISTRATION TO RATS.
189599 04-03

CANNABINOL
THE ANTICONVULSANT ACTIVITY OF CANNABIDIOL AND CANNABINOL.
175238 02-03
A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY IN MAN OF INTRAVENOUSLY ADMINISTERED DELTA9-TETRAHYDROCANNABINOL, CANNABINOL, AND CANNABIDIOL.
176747 02-03
COMPARATIVE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CANNABIDIOL (CBD), AND CANNABINOL (CBN) ON TIMING BEHAVIOR IN RATS.
191967 04-04

CANNABINOLS
ANTICONVULSANT EFFECTS OF CANNABINOLS IN MICE: DRUG INTERACTIONS WITH CANNABINOIDS AND CANNABINOID INTERACTIONS WITH PHENYTOIN.
189513 04-03

CANNABIS
PROSTAGLANDINS AND CANNABIS: A POSSIBLE MODE OF ACTION FOR THC.
169067 01-03
EEG, HEART RATE, AND MOOD CHANGE (HIGH) AFTER CANNABIS.
169068 01-13
VOCALIZATION: A CHARACTERISTIC CANNABIS INDUCED BEHAVIOR IN THE RAT?
175884 02-04
EFFECT OF CANNABIS ON PENTOBARBITAL INDUCED SLEEPING TIME AND PENTOBARBITAL METABOLISM IN THE RAT.
179985 02-03
CANNABIS PSYCHOSIS.
180155 02-14
CLINICAL PHARMACOLOGY OF CANNABIS.
182741 03-14
COMMON CANNABINOID PHENOTYPES IN 350 STOCKS OF CANNABIS.
192787 04-17

CANNABIS-INDICA
CANNABIS-INDICA IN 19TH-CENTURY PSYCHIATRY.
192059 04-17

CANNABIS-SATIVA
EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF CANNABIS-SATIVA EXTRACT ON THE MOUSE-KILLING BEHAVIOR OF RATS.
167362 01-04
CONSTITUENTS OF CANNABIS-SATIVA L. V.: STABILITY OF AN ANALYTICAL SAMPLE EXTRACTED WITH CHLOROFORM. (UNPUBLISHED PAPER).
180670 02-01
CANNABIDIOL AND CANNABIS-SATIVA EXTRACT PROTECT MICE AND RATS AGAINST CONVULSIVE AGENTS.
183609 03-03

CAPABILITY
EVALUATION OF REINFORCING CAPABILITY OF DELTA9-TETRAHYDROCANNABINOL IN RHESUS MONKEYS.
187638 04-04

CAPSULE
MOLINDONE: A CROSSOVER EVALUATION OF CAPSULE AND TABLET FORMULATIONS IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
174137 01-08

CAR
INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CAFFEINE, (C), NICOTINE (N), PHENOBARBITAL (P): EFFECTS ON CONDITIONED AVOIDANCE (CAR).
182192 02-04

THE EFFECT OF MEDAZEPAM AND ALCOHOL ON COGNITIVE AND MOTOR SKILLS USED IN CAR DRIVING.
189408 04-14

CARBAMATE
NEUROTOXICOLOGIC STUDIES OF TWO CARBAMATE PESTICIDES IN SUBACUTE ANIMAL EXPERIMENTS.
188874 04-05

CENTRALLY ACTING MUSCLE RELAXANTS. ISOMERIC 9,10 DIHYDROXYOCTAHYDROPHENANTHRENES AND THEIR CARBAMATE ESTERS.
190719 04-02

CARBAMAZEPINE
CARBAMAZEPINE SOLE ANTICONVULSANT FOR FOCAL EPILEPSY OF CHILDHOOD.
189174 04-11

CARBAMAZEPINE AS AN ANTICONVULSANT: A PILOT STUDY.
192391 04-07

CARBIDOPA
LEVODOPA, CARBIDOPA, AND PYRIDOXINE IN PARKINSON DISEASE.
187877 04-13

CARBON
REDUCTION BY PRETREATMENT WITH DIBENAMINE OF HEPATOTOXICITY INDUCED BY CARBON TETRACHLORIDE, THIOACETAMINDE OR DIMETHYLNITROSAMINE.
188865 04-05

INFLUENCE OF ADRENERGIC BLOCKERS AND ANTILIPEMIC AGENTS ON PHARMACODYNAMIC ACTIONS OF MORPHINE IN CARBON TETRACHLORIDE TREATED RATS.
188873 04-03

CARBONATE
CLINICAL EFFECTS OF LITHIUM CARBONATE ON DEPRESSION.
167917 01-09

LITHIUM CARBONATE TREATMENT IN MANIC PSYCHOSIS.
167918 01-09

LITHIUM CARBONATE TOXICITY.
168505 01-15

A COMPARISON OF LITHIUM CARBONATE IN THE PREVENTION OF MANIC AND DEPRESSIVE EPISODES IN RECURRENT AFFECTIVE DISORDER.
169090 01-09

NEGATIVE SODIUM BALANCE IN LITHIUM CARBONATE TOXICITY: EVIDENCE OF MINERALOCORTICOID BLOCKADE.
169869 01-15

LITHIUM CARBONATE AND SLEEP IN AFFECTIVE DISORDERS: FURTHER CONSIDERATIONS.
171503 01-09

CLINICAL FACTORS IN LITHIUM CARBONATE PROPHYLAXIS FAILURE.
174093 01-09

LONG-TERM USE OF LITHIUM CARBONATE IN AFFECTIVE DISORDERS: A CLINICAL EVALUATION.
174778 01-09

DIFFERENTIAL EFFECTS OF D- AND L-AMPHETAMINE ON THE SLEEP OF DEPRESSED PSYCHIATRIC PATIENTS ON AND OFF LITHIUM CARBONATE TREATMENT. (UNPUBLISHED PAPER).
178432 02-09

LITHIUM DISTRIBUTION BETWEEN CEREBROSPINAL FLUID AND SERUM OF AFFECTIVE PSYCHOTIC PATIENTS TREATED WITH LITHIUM CARBONATE AND ITS CLINICAL RESPONSE.
180301 02-11

THE INFLUENCE OF CHRONIC ADMINISTRATION OF LITHIUM CARBONATE ON THE BRAIN NOREPINEPHRINE CONTENT IN RATS.
182872 03-03

LITHIUM CARBONATE IN MANIC-DEPRESSIVE PSYCHOSIS.
187477 04-09

LITHIUM CARBONATE: PSYCHIATRIC INDICATIONS AND MEDICAL COMPLICATIONS.
187786 04-15

HUNTINGTONS CHOREA TREATED WITH LITHIUM CARBONATE.
187985 04-11

PROPHYLACTIC EFFICACY OF LITHIUM CARBONATE IN MANIC-DEPRESSIVE ILLNESS: REPORT OF THE VETERANS ADMINISTRATION AND NATIONAL INSTITUTE OF MENTAL HEALTH (VA-NIMH) COLLABORATIVE STUDY GROUP.
189735 04-09

EXPERIMENT WITH LITHIUM CARBONATE ON THE TREATMENT OF MANIC STATE.
191670 04-09

CARDIOPULMONARY
CARDIOPULMONARY EFFECTS OF CANNABIDIOL IN ANESTHETIZED DOGS.
191993 04-05

CARDIOTOXIC
COMPARISON OF TRICYCLIC ANTIDEPRESSANTS AS TO THEIR CARDIOTOXIC ACTION IN CONSCIOUS RABBITS.
171629 01-03

CARDIOVASCULAR
CARDIOVASCULAR EFFECTS OF RESERPINE, YOHIMBINE, AND RESERPINE YOHIMBINE MIXTURES ON INTACT ANESTHETIZED DOG.
167328 01-03

EEG AND CARDIOVASCULAR EFFECTS OF TRYPTAMINE (T) AND LSD IN THE ENCEPHALE ISOLE CAT. (UNPUBLISHED PAPER)
174496 01-12

CARDIOVASCULAR PHARMACOLOGY OF DELTA9-TETRAHYDROCANNABINOL. (PH.D. DISSERTATION).
174964 01-03

THE EFFECT OF DIAZEPAM ON SOME CARDIOVASCULAR AND RESPIRATORY REFLEXES ELICITED BY AFFERENT ABDOMINAL VAGUS STIMULATION.
178945 02-03

THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (THC), PENTOBARBITAL AND SKF-525-A WITH THE CARDIOVASCULAR SYSTEM OF THE RAT.
182218 03-03

CARDIOVASCULAR AND GROSS BEHAVIORAL EFFECTS OF AMPHETAMINE, 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPROPANE (DOM) AND 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPHENYL BUTANE (BL-3912A) IN THE CONSCIOUS DOG.
187573 04-03

CARDIOVASCULAR REACTIVITY IN THE DOG AFTER CHEMICAL SYMPATHECTOMY WITH 6-HYDROXYDOPAMINE.
187807 04-03

CARDIOVASCULAR EFFECTS OF MARIHUANA IN MAN.
187812 04-13

CASE AGAINST THE USE OF D-TUBOCURARINE IN OPERANT STUDIES OF THE CARDIOVASCULAR SYSTEM.
189425 04-03

CARDIOVASCULAR EFFECTS OF DELTA8-THC AND DELTA9-TETRAHYDROCANNABINOL IN RATS.
191971 04-03

CARE
MESORIDAZINE IN THE CARE OF DISTURBED MENTALLY RETARDED PATIENTS.
168315 01-11

PSYCHIATRIC CARE: DRUGS, THERAPIST, COMMUNITY.
178189 02-17

MEDICATION GROUPS FOR CONTINUING CARE.
189640 04-17

CARNITINE
EFFECT OF A CARNITINE CYPROHEPTADINE COMBINATION ON ANOREXIA AND WEIGHT GAIN IN CHILDREN.
178811 02-10

CARPIPRAMINE
EXPERIENCE IN THE USE OF A LOW DOSAGE OF CARPIPRAMINE (DEFEKTON).
176472 02-08

COMPARISON OF THE EFFECTS OF Y-4153 AND CARPIPRAMINE ON SCHIZOPHRENIA BY A DOUBLE-BLIND METHOD.
178053 02-08

PRELIMINARY STUDIES OF CARPIPRAMINE: A COMPOUND SIMILAR TO BOTH ANTIDEPRESSANTS AND NEUROLEPTICS.
180725 02-07

A DOUBLE-BLIND COMPARISON OF PIMOZIDE WITH CARPIPRAMINE IN SCHIZOPHRENIC PATIENTS.
183195 03-08

CARRIER
LITHIUM THERAPY AND ERYTHROCYTE MEMBRANE CATION CARRIER.
187644 04-15

CASE
SLEEP STUDIES AND THERAPEUTIC TRIAL WITH L-DOPA IN A CASE OF STIFF-MAN SYNDROME.
171134 01-13

AN AUTOPSY CASE OF SCHIZOPHRENIA COMPLICATED WITH PARKINSONISM INDUCED BY PERPHENAZINE.
171275 01-15

A CASE OF ENCEPHALITIS WITH PSYCHOTIC COMPLICATIONS.
174783 01-11

A CASE OF WERNERS SYNDROME WITH SCHIZOPHRENIA-LIKE SYMPTOMS.
175120 02-09

ACUTE CEREBELLAR DISTURBANCE ASSOCIATED WITH DIAZEPAM THERAPY -- A CASE REPORT AND FURTHER INVESTIGATION.
177392 02-15

TIC DE GILLES-DE-LA-TOURETTE: CASE REPORT AND BRIEF DISCUSSION.
181158 02-09

SHORT-TERM PSYCHOTHERAPY WITH LSD: A CASE STUDY.
181461 02-12

A CASE OF KLEINE-LEVINE SYNDROME.
183418 03-14

LITHIUM IN THE TREATMENT OF PERIODIC CATATONIA: A CASE REPORT.
183648 03-09

A CASE OF TARDIVE DYSKINESIA APPEARING PRECOCIOUSLY UNDER NEUROLEPTICS.
184961 03-17

A CASE OF PERIODIC SOMNOLENCE IMPROVED BY THE CO-MEDICATION OF L-DOPA AND METHYLPHENIDATE.
185241 03-14

THYROTOXICOSIS DEVELOPING DURING LITHIUM TREATMENT: CASE REPORT.
186473 03-15

PSYCHEDELIC (LSD) PSYCHOTHERAPY: A CASE REPORT.
186994 03-08

ONE CASE OF AGRYPNIA (4 MONTHS WITHOUT SLEEP) IN A MORVAN DISEASE: FAVORABLE ACTION OF 5-HYDROXYTRYPTOPHAN.
187237 03-14

A CASE OF A NONSPECIFIC MENTAL ILLNESS WITH PSYCHOMOTOR VARIANT.
188517 04-09

STEROID PSYCHOSIS: A CASE REPORT.
189042 04-15

INTERACTION OF LOW-DOSE AMPHETAMINE USE WITH SCHIZOPHRENIA IN OUTPATIENTS: THREE CASE REPORTS.
189099 04-15

CASE AGAINST THE USE OF D-TUBOCURARINE IN OPERANT STUDIES OF THE CARDIOVASCULAR SYSTEM.
189425 04-03

CASTRATED

MONOAMINES AND COPULATORY ACTIVATION IN THE CASTRATED MALE RAT.
171618 01-04

LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04

CAT

OSCILLATORY POTENTIALS OF THE CAT RETINA: EFFECTS OF ADRENERGIC DRUGS.
172916 01-03

INHIBITION BY MORPHINE OF REPETITIVE ACTIVATION OF CAT SPINAL MOTONEURONES.
172926 01-03

THE EFFECT OF PSYCHOTROPIC AGENTS ON SOME ASPECTS OF ACETYLCHOLINE METABOLISM IN CAT BRAINS.
174257 01-03

THE EFFECT IN THE CAT OF TRYPTAMINE (T) AND LSD ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) SPINAL REFLEXES. (UNPUBLISHED PAPER).
174480 01-12

EEG AND CARDIOVASCULAR EFFECTS OF TRYPTAMINE (T) AND LSD IN THE ENCEPHALE ISOLE CAT. (UNPUBLISHED PAPER)
174496 01-12

RELATIVE POTENCIES OF D- AND L-AMPHETAMINE ON THE RELEASE OF DOPAMINE FROM CAT BRAIN IN VIVO.
176874 02-03

INHIBITORY EFFECT OF DOXEPIN ON AGONISTIC BEHAVIOUR ELICITED BY HYPOTHALAMIC STIMULATION IN THE CAT.
180044 02-04

REGIONAL CYCLIC NUCLEOTIDES PHOSPHODIESTERASE ACTIVITY IN CAT CENTRAL NERVOUS SYSTEM: EFFECTS OF BENZODIAZEPINES.
181575 02-03

A COMPARISON OF SOMATIC REFLEX EFFECTS OF THREE PSYCHOTROPIC AGENTS IN THE CHLORALOSE CAT.
182126 02-03

THE ACTIONS OF SEVERAL PSYCHOACTIVE AGENTS UPON THE MUSCARINIC MECHANISMS IN THE SUPERIOR CERVICAL GANGLION OF THE CAT.
183866 03-03

THE EFFECTS OF 5-HYDROXYTRYPTAMINE AND SOME RELATED COMPOUNDS ON THE CAT SUPERIOR CERVICAL GANGLION IN SITU.
184197 03-03

THE EFFECTS OF VARIOUS NICOTINE-LIKE AGENTS IN THE CAT SUPERIOR CERVICAL GANGLION IN SITU.
184202 03-03

GENERALIZED PENICILLIN EPILEPSY IN THE CAT: EFFECTS OF INTRACAROTID AND INTRAVERTEBRAL PENTYLENETETRAZOL AND AMOBARBITAL INJECTIONS.
188374 04-03

EFFECTS OF INTRACEREBRAL INJECTION OF 5,6-HYDROXYTRYPTAMINE ON CEREBRAL MONOAMINES AND SLEEP STATES IN THE CAT/.
189023 04-02

EFFECTS OF ALPHA-METHYLTYROSINE ON D-AMPHETAMINE INDUCED RELEASE OF ENDOGENOUSLY SYNTHESIZED AND EXOGENOUSLY ADMINISTERED CATECHOLAMINES FROM THE CAT BRAIN IN VIVO.
189397 04-03

THE ACTION OF BETA-PHENYL-GABA DERIVATIVES ON NEURONES OF THE CAT CEREBRAL CORTEX.
189750 04-03

EXCITABILITY CHANGES DURING THE GRADUAL DEVELOPMENT OF AND RECOVERY FROM PENTYLENETETRAZOL AND STRYCHNINE INDUCED CONVULSIONS IN THE CAT.
191927 04-03

LONG-TERM ALTERATION OF SLEEP-WAKEFULNESS CYCLE DURING CHRONIC PENTOBARBITAL DOSING AND WITHDRAWAL IN CAT.
191952 04-04

COMPARISON OF BARBITAL & PENTOBARBITAL PHYSICAL DEPENDENCE IN THE CAT.
191953 04-04

CATABOLISM

A COMPARISON OF THE EFFECTS OF AMPHETAMINE AND ITS METABOLITES, P-HYDROXYAMPHETAMINE AND P-HYDROXYNOREPHEDRINE, ON UPTAKE, RELEASE AND CATABOLISM OF 3H-NOREPINEPHRINE IN CEREBRAL CORTEX OF RAT BRAIN.
186669 03-03

CATAHOULA

PSYCHOPHARMACOLOGIC FACILITATION OF OPERANT CONDITIONING OF GENETICALLY NERVOUS CATAHOULA AND POINTER DOGS.
190696 04-04

CATALEPSY

DRUG-INDUCED CATALEPSY AS INFLUENCED BY PSYCHOSTIMULANTS, APOMORPHINE, L-DOPA, AND YOHIMBINE.
177730 02-13

CATALEPSY AND STEREOTYPED BEHAVIOUR IN RATS TREATED CHRONICALLY WITH METHADONE: RELATION TO BRAIN HOMOVANILLIC ACID CONTENT.
183606 03-04

CATALEPSY INDUCED BY ALPHA-METHYL-P-TYROSINE AND D-AMPHETAMINE: THE ROLE OF CATECHOLAMINE METABOLISM.
185750 03-03

ON CATALEPSY AND CATATONIA AND THE PREDICTABILITY OF THE CATALEPSY TEST FOR NEUROLEPTIC ACTIVITY.
185958 03-04

CATALEPSY AND STEREOTYPIES IN RATS TREATED WITH METHADONE; RELATION TO STRIATAL DOPAMINE.
191421 04-03

CATALEPTIC

IS THERE A RELATIONSHIP BETWEEN THE INVOLVEMENT OF EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS WITH THE CATALEPTIC ACTION OF NEUROLEPTIC AGENTS AND THEIR CLINICAL ANTIPSYCHOTIC EFFECT?
171305 01-03

A ROLE FOR THE AMYGDALA IN THE DEVELOPMENT OF THE CATALEPTIC AND STEREOTYPIC ACTIONS OF THE NARCOTIC AGONISTS AND ANTAGONISTS IN THE RAT.
186577 03-03

CATATONIA

EXPERIMENTAL CATATONIA AND PSYCHOPHARMACOLOGY.
180724 02-04

LITHIUM IN THE TREATMENT OF PERIODIC CATATONIA: A CASE REPORT.
183648 03-09

ON CATALEPSY AND CATATONIA AND THE PREDICTABILITY OF THE CATALEPSY TEST FOR NEUROLEPTIC ACTIVITY.
185958 03-04

CATECHOL-O-METHYLTRANSFERASE

EFFECT OF CHRONIC ADMINISTRATION OF L-DOPA ON CATECHOL-O-METHYLTRANSFERASE IN RAT TISSUES.
176936 02-03

THE RATE LIMITING CONTROL OF ENZYMES MONOAMINE OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN THE FETUS AND THE ADULT BY ADRENOCORTICOL HORMONES.
178815 02-03

NICOTINIC ACID AND CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN SCHIZOPHRENIA.
183360 03-13

COMPARATIVE PROPERTIES OF SOLUBLE AND PARTICULATE CATECHOL-O-METHYLTRANSFERASE FROM RAT RED BLOOD CELL: PRELIMINARY OBSERVATIONS.
191523 04-01

CATECHOLAMINE

EFFECT OF GENERAL ANESTHETICS ON SYSTEMIC CATECHOLAMINE CONCENTRATION I: HALOTHANE. (UNPUBLISHED PAPER).
168862 01-05

CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS: RECENT STUDIES OF MHPG EXCRETION.
169091 01-13

THE EFFECTS OF CHRONIC TREATMENT WITH DELTA9-TETRAHYDROCANNABINOL ON CATECHOLAMINE SYNTHESIS IN THE RAT.
169471 01-03

IMPORTANCE OF CATECHOLAMINE RELEASE BY NERVE IMPULSES FOR FREE OPERANT BEHAVIOR.
171611 01-04

CATECHOLAMINE TURNOVER IN THE RAT BRAIN: DIFFERENT RESULTS OBTAINED IN DIFFERENT EXPERIMENTAL CONDITIONS.
181471 02-03

THE EFFECTS OF DRUGS ON THE RELEASE OF CATECHOLAMINE.
182089 02-03

STUDIES ON THE EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT ON CATECHOLAMINE LEVELS AND TURNOVER IN DISCRETE BRAIN AREAS OF RATS.
182228 03-03

EFFECTS OF CHRONIC ADMINISTRATION OF AMPHETAMINE UPON THE CATECHOLAMINE CONTENT OF MOUSE BRAIN.
182255 03-03

PENTYLENETETRAZOL CONVULSIONS AND BRAIN CATECHOLAMINE TURNOVER RATE IN RATS AND MICE RECEIVING DIPHENYLHYDANTOIN OR BENZODIAZEPINES.
182344 03-03

CATALEPSY INDUCED BY ALPHA-METHYL-P-TYROSINE AND D-AMPHETAMINE: THE ROLE OF CATECHOLAMINE METABOLISM.
185750 03-03

COMPARATIVE EFFECTS OF DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE ON CATECHOLAMINE RELEASE AND REUPTAKE IN VITRO.
186671 03-03

NEUROLEPTIC ANTAGONISM OF CATECHOLAMINE INHIBITIONS IN RAT CEREBELLUM AND CAUDATE. (UNPUBLISHED PAPER).
187496 04-03

SELF-STIMULATION AND CATECHOLAMINES: DRUG-INDUCED MOBILIZATION OF THE RESERVE POOL RE-ESTABLISHES RESPONDING IN CATECHOLAMINE DEPLETED RATS.
189025 04-04

HYDROCORTISONE INDUCED INCREASE IN THE HISTOCHEMICALLY DEMONSTRABLE CATECHOLAMINE CONTENT OF SYMPATHETIC NEURONS OF THE NEWBORN RAT.
189027 04-03

EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND AMPHETAMINE ON SELF-STIMULATION OF BRAIN FOLLOWING VARIOUS 6-HYDROXYDOPAMINE TREATMENTS.
189515 04-04

MECHANISM OF ADRENAL CATECHOLAMINE RELEASE BY DIVALENT MERCURY.
189591 04-03

DIHYDROPTERIDINE REDUCTASE IN RAT BRAIN: REGIONAL DISTRIBUTION AND THE EFFECT OF CATECHOLAMINE DEPLETING DRUGS.
189752 04-03

EFFECT OF ANESTHETIC AGENTS ON PERIPHERAL SYMPATHETIC NERVOUS SYSTEM FUNCTION AS MONITORED BY ARTERIAL PLASMA CATECHOLAMINE LEVELS. (UNPUBLISHED PAPER
191495 04-03

RELATIONSHIP OF CATECHOLAMINE NEURAL SYSTEMS TO THE BEHAVIORAL ALTERATIONS PRODUCED BY 6-HYDROXYDOPAMINE ADMINISTRATION INTO BRAIN.
191518 04-03

FLUORESCENCE AND ELECTRON MICROSCOPIC ANALYSIS OF CATECHOLAMINE CONTAINING FIBERS IN MUTANT MOUSE CEREBELLUM. (UNPUBLISHED PAPER).
191762 04-03

EFFECTS OF NOMIFENSINE (HOE-984), D-AMPHETAMINE AND APOMORPHINE ON MOTOR ACTIVITY, CATECHOLAMINE TURNOVER AND CAMP CONCENTRATIONS IN RAT BRAIN. (UNPUBLISHED PAPER).
191766 04-03

NONSPONTANEOUS CONVULSIONS IN MICE ELICITED BY SOME CATECHOLAMINE RELEASERS AND 6,7 DIHYDROXYTETRAHYDROISOQUINOLINE (TIQ).
192013 04-05

THE EFFECTS OF HOE-36801 ON CATECHOLAMINE EXCRETION, HEART RATE AND PSYCHOMOTOR PERFORMANCE IN NEUROTICS AND NORMALS.
192428 04-13

BETA-BLOCKING AGENTS IN THE TREATMENT OF CATECHOLAMINE INDUCED SYMPTOMS IN MUSICIANS.
192527 04-11

CATECHOLAMINES

STRIATAL TYROSINE HYDROXYLASES WITH HIGH AND LOW AFFINITY FOR TYROSINE: IMPLICATIONS FOR THE MULTIPLE POOL CONCEPT OF CATECHOLAMINES.
167325 01-03

EFFECTS OF SOME TETRAHYDROCANNABINOLS ON THE BIOSYNTHESIS AND UTILIZATION OF CATECHOLAMINES IN THE RAT BRAIN.
172917 01-03

ON THE MECHANISM OF CENTRAL ACTION OF AMPHETAMINE: THE ROLE OF CATECHOLAMINES.
172921 01-04

TECHNICAL STRATEGIES FOR THE STUDY OF CATECHOLAMINES IN MAN. (UNPUBLISHED PAPER).
173387 01-03

STUDIES ON THE URINARY EXCRETION OF CATECHOLAMINES AND 17-KETOSTEROID IN MANIC-DEPRESSIVE PSYCHOSIS.
178623 02-09

THE EFFECTS OF INTRAVENTRICULARLY ADMINISTERED CATECHOLAMINES AND SEROTONIN ON THE RESERPINE INDUCED SPIKE WAVES RECORDED FROM THE MEDICAL NUCLEUS TRAPEZOIDES IN THE RABBIT.
182094 02-03

THE EFFECT OF CATECHOLAMINES, ACETYLCHOLINE AND SEROTONIN ON THE MORPHINE TOLERANT LONGITUDINAL MUSCLE STRIP OF THE GUINEA-PIG ILEUM.
182161 02-03

RECOVERY OF FEEDING AFTER 6-HYDROXYDOPAMINE (6-HDA) OR LATERAL HYPOTHALAMIC LESIONS: THE ROLE OF CATECHOLAMINES.
182213 03-03

COMPARATIVE EFFECTS OF DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE ON CENTRAL CATECHOLAMINES AND LOCOMOTOR ACTIVITY.
182253 03-04

INCREASED SYNTHESIS OF ADRENOMEDULLARY CATECHOLAMINES INDUCED BY CAFFEINE AND THEOPHYLLINE.
184201 03-03

IN VIVO RELEASE OF NEWLY SYNTHESIZED CATECHOLAMINES FROM THE HYPOTHALAMUS BY AMPHETAMINE.
184230 03-03

A PSYCHOPHARMACOLOGICAL STUDY OF CATECHOLAMINES IN AFFECTIVE DISORDERS.
184653 03-09

ROLE OF CATECHOLAMINES IN THE ANORECTIC EFFECTS OF AMPHETAMINE IN RATS.
186582 03-03

LEARNING IMPAIRMENT IN RATS AFTER 6-HYDROXYDOPAMINE INDUCED DEPLETION OF BRAIN CATECHOLAMINES.
187420 04-04

DEVELOPMENT OF LOCOMOTION AND BRAIN CATECHOLAMINES.
187551 04-04

EVIDENCE FOR AN INHIBITORY ROLE FOR ACETYLCHOLINE, CATECHOLAMINES, AND SEROTONIN ON THE CEREBRAL CORTEX.
187552 04-03

COMPARISON OF PHARMACOLOGICAL RESPONSES TO NICOTINE AND RELEASE OF CATECHOLAMINES FROM THE ADRENALS IN DOGS AND MONKEYS.
188199 04-03

SELF-STIMULATION AND CATECHOLAMINES: DRUG-INDUCED MOBILIZATION OF THE RESERVE POOL RE-ESTABLISHES RESPONDING IN CATECHOLAMINE DEPLETED RATS.
189025 04-04

SELECTIVE RESERPINE RESISTANT ACCUMULATION OF CATECHOLAMINES IN CENTRAL DOPAMINE NEURONES AFTER DOPA ADMINISTRATION.
189026 04-03

EFFECTS OF ALPHA-METHYLTYROSINE ON D-AMPHETAMINE INDUCED RELEASE OF ENDOGENOUSLY SYNTHESIZED AND EXOGENOUSLY ADMINISTERED CATECHOLAMINES FROM THE CAT BRAIN IN VIVO.
189397 04-03

THE EFFECT OF INCREASED GAMMA-AMINOBUTYRIC ACID ON ALPHA-METHYLTYROSINE INDUCED DECREASE IN CATECHOLAMINES IN RAT BRAIN.
191988 04-03

CATION

LITHIUM THERAPY AND ERYTHROCYTE MEMBRANE CATION CARRIER.
187644 04-15

CATIONS

EFFECTS OF SOME METALLIC CATIONS ON CEREBRAL CORTICAL NEURONES AND THEIR INTERACTIONS WITH BIOGENIC AMINES.
187806 04-03

EFFECT OF DIVALENT CATIONS ON ACH CONTRACTURES OF DEPOLARIZED DENERVATED RAT MUSCLES.
188914 04-03

CATS

THE EFFECT OF L-TRYPTOPHAN (TP) ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) REFLEXES IN ACUTE DECEREBRATE SPINAL CATS AND THE EFFECT OF PRETREATMENT WITH P-CHLOROPHENYLALANINE (PCPA) ON THE ACTION OF TP. (UNPUBLISHED PAPER).
170874 01-03

FAILURE OF N,N DIMETHYLTRYPTAMINE TO EVOKE TOLERANCE IN CATS.
173398 01-03

THE EFFECTS OF PHENITRONE, A REPORTED HASHISH ANTAGONIST, ON THE OVERT BEHAVIOR OF CATS.
174607 01-04

PROTECTION PRODUCED BY BENZODIAZEPINES (BDP) AGAINST THE NEUROTOXIC AND CONFLICT BEHAVIOR EFFECTS OF HEXACHLOROPHENE (HCP) IN CATS.
176863 02-04

COMPARISON OF CLOPENTHIXOL AND PERPHENAZINE IN BEHAVIOR AND EEG OF UNANESTHETIZED CATS.
181386 02-04

EFFECT OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) ON THE DAYTIME SLEEP-WAKEFULNESS PATTERNS IN NORMAL AND P-CHLOROPHENYLALANINE INSOMNIAC CATS.
181658 02-02

EFFECTS OF BENZODIAZEPINES ON SPINAL REFLEXES IN CATS.
182097 02-03

EFFECTS OF CYPROHEPTADINE ON THE EATING BEHAVIOR OF RATS AND CATS.
182111 02-04

PHARMACOLOGIC ANALYSIS OF THE CAUDATE SPINDLE IN CATS.
182124 02-03

CENTRAL CHOLINERGIC (MUSCARINIC) LINK IN THE ATTACK REFLEXIVE BITING MECHANISM OF CATS.
182238 03-04

EEG CHANGES & MOTOR IMPAIRMENT AFTER DISULFIRAM ADMINISTRATION TO CATS.
182248 03-03

CHANGES IN SHORT-TERM AND LONG-TERM MEMORY OF DOGS AND CATS UNDER THE EFFECTS OF AMIZYL (BENACTYZINE).
183517 03-04

DIAZEPAM-INDUCED PLAY BEHAVIOR IN CATS DURING PREY KILLING.
184979 03-04

NEUROLOGICAL CHANGES IN CATS FOLLOWING LONG-TERM DIET OF MERCURY CONTAMINATED TUNA.
186476 03-05

HYPERTHERMIC EFFECT OF PALMITATE SODIUM, STEARATE SODIUM AND OLEATE SODIUM INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS CATS.
186640 03-03

THE TRANSSYNAPTIC RELATIONSHIP BETWEEN DOPAMINE AND SEROTONIN IN THE CAUDATE NUCLEUS OF CATS.
186700 03-04

INTESTINAL EFFECTS OF 5-HYDROXYTRYPTAMINE AND MORPHINE IN GUINEA-PIGS, DOGS, CATS AND MONKEYS.
188202 04-03

INTRACEREBRAL INJECTION OF 6-HYDROXYDOPAMINE AND HYDROGEN PEROXIDE IN CATS: SPECIFIC AND NONSPECIFIC EFFECTS ON STRIATAL BIOGENIC AMINES.
188426 04-03

THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. I. NEURONAL RESPONSES TO STIMULATION OF THE RETICULAR FORMATION.
189855 04-03

THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. II. COMPARISON OF THE NEURONAL RESPONSES TO RETICULAR AND OTHER STIMULI.
189856 04-03

CAUDATE

TREMOR INDUCTION BY INTRACAUDATE INJECTIONS OF BRETYLIUM, TETRABENAZINE, OR MESCALINE: FUNCTIONAL DEFICITS IN CAUDATE DOPAMINE.
167329 01-03

CAUDATE NUCLEUS EFFECTS ON GERIATRIC SENILITY: EFFECT OF BELLADONNA ON LEARNING AND MEMORY OF GERIATRIC PATIENTS.
170744 01-11

CYCLIC ADENOSINE MONOPHOSPHATE: SELECTIVE INCREASE IN CAUDATE NUCLEUS AFTER ADMINISTRATION OF L-DOPA.
176254 02-13

PHARMACOLOGIC ANALYSIS OF THE CAUDATE SPINDLE IN CATS.
182124 02-03

EFFECTS OF DOPAMINERGIC STIMULANTS ON THE CAUDATE SPINDLE.
182125 02-03

THE ACTION OF D-AMPHETAMINE ON SPONTANEOUS ACTIVITY IN THE CAUDATE NUCLEUS AND RETICULAR FORMATION OF THE RAT.
185264 03-03

DIFFERENTIAL RECOVERY OF FUNCTION FOLLOWING CAUDATE, HIPPOCAMPAL, AND SEPTAL LESIONS IN MICE.
186620 03-04

THE TRANSSYNAPTIC RELATIONSHIP BETWEEN DOPAMINE AND SEROTONIN IN THE CAUDATE NUCLEUS OF CATS.
186700 03-04

ALTERATION OF EVOKED POTENTIALS IN CAUDATE NUCLEUS OF FREELY MOVING RATS BY L-DOPA, RESERPINE, AND PENTOBARBITAL.
187362 04-03

NEUROLEPTIC ANTAGONISM OF CATECHOLAMINE INHIBITIONS IN RAT CEREBELLUM AND CAUDATE. (UNPUBLISHED PAPER).
187496 04-03

CAUSAL

ANTIPARKINSON DRUGS AS CAUSAL AGENTS IN TARDIVE DYSKINESIA.
169140 01-15

CBD

COMPARATIVE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CANNABIDIOL (CBD), AND CANNABINOL (CBN) ON TIMING BEHAVIOR IN RATS.
191967 04-04

CBN

COMPARATIVE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CANNABIDIOL (CBD), AND CANNABINOL (CBN) ON TIMING BEHAVIOR IN RATS.
191967 04-04

CDP-CHOLINE

ELECTROPHYSIOLOGICAL STUDIES OF THE EFFECTS OF CDP-CHOLINE ON THE CENTRAL NERVOUS SYSTEM.
182547 03-03

CELL

SELF-STIMULATION OF NORADRENERGIC CELL GROUP (A6) IN LOCUS-COERULEUS OF RATS.
173029 01-03

COMPARATIVE PROPERTIES OF SOLUBLE AND PARTICULATE CATECHOL-O-METHYLTRANSFERASE FROM RAT RED BLOOD CELL: PRELIMINARY OBSERVATIONS.
191523 04-01

CELLS

EFFECTS OF P-CHLOROPHENYLALANINE ON DIFFERENTIATION OF SEROTONINERGIC RECEPTIVE CELLS DURING EMBRYOGENESIS. (UNPUBLISHED PAPER).
168817 01-03

EFFECT OF SELECTED BETA-DIKETONES ON LITHIUM FLUXES OF BOVINE RED BLOOD CELLS.
171792 01-05

EFFECTS OF CHLORPROMAZINE AND ACTINOMYCIN D ON UPTAKE AND INCORPORATION OF CERTAIN AMINO ACIDS, HYPOXANTHINE AND THYMIDINE IN CULTURES OF HUMAN SKIN EPITHELIAL CELLS.
179989 02-13

A COMPARISON OF EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) AND SEROTONIN ON PRE- AND POSTSYNAPTIC CELLS IN THE SEROTONIN SYSTEM.
182141 02-03

EFFECTS OF NARCOTIC ANALGESICS ON ENZYMES OF ACETYLCHOLINE METABOLISM IN CULTURED CHICK BRAIN CELLS.
182225 03-03

THE EFFECTS OF MORPHINE, ETORPHINE AND SINOMENINE ON THE CHEMICAL SENSITIVITY AND SYNAPTIC RESPONSES OF RENSHAW CELLS AND OTHER SPINAL NEURONES IN THE RAT.
188201 04-03

EFFECT OF IMIPRAMINE ON CULTURED RAT HEART CELLS.
188864 04-03

LIPIDOSIS-LIKE ALTERATIONS IN DORSAL ROOT GANGLION CELLS OF RATS TREATED WITH TRICYCLIC ANTIDEPRESSANTS.
189605 04-03

EFFECTS OF ALUMINUM SALTS ON CULTURED NEUROBLASTOMA CELLS.
191313 04-03

CELLULAR

KINETICS AND CELLULAR CONTROL MECHANISMS FOR IMIPRAMINE METABOLISM IN THE ISOLATED PERFUSED RAT LIVER. (PH.D. DISSERTATION).
173601 01-03

CELLULAR EFFECTS OF METHAQUALONE ON DRUG METABOLIZING ENZYMES.
191942 04-03

CENTERS

INTERNATIONAL REFERENCE CENTERS NETWORK FOR PSYCHOTROPIC DRUGS.
167706 01-17

THE ACTION OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTOR CENTERS OF EMOTIONS IN THE HYPOTHALAMUS.
191785 04-02

CENTPYRAQUIN

ANTIHYPERTENSIVE AND CENTRAL NERVOUS SYSTEM DEPRESSANT PROPERTIES OF 3-(GAMMA-P-FLUOROBENZOYLPROPYL) 2,3,4,4A,5,6 HEXAHYDROPYRAZINOQUINOLINE HYDROCHLORIDE (COMPOUND-69-183, CENTPYRAQUIN).
176881 02-03

CENTRAL

CENTRAL MONOAMINE METABOLISM IN MAN: EFFECT OF PUTATIVE DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS.
169377 01-13

EVALUATION OF CENTRAL ANTIRESERPINE EFFECT BY THE USE OF LIGHT BLINK REFLEX.
169469 01-04

SELECTIVE ANTAGONISM OF CENTRAL NERVOUS SYSTEM DEPRESSANTS BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE.
171007 01-13

THE EFFECT OF PANAX GINSENG SAPONIN ON THE CENTRAL NERVOUS SYSTEM IN RAT: THE PSYCHOPHARMACOLOGICAL EFFECT OF GINSENG.
171599 01-04

TURNOVER CHANGES IN CENTRAL MONOAMINE NEURON SYSTEMS AFTER MINOR TRANQUILLIZERS AND BARBITURATES.
171604 01-03

EFFECT OF TETRAHYDROCANNABINOLS ON CENTRAL MONOAMINE NEURONS.
171605 01-03

SEROTONINERGIC MECHANISMS IN THE CENTRAL ACTION OF PSYCHOTROPIC DRUGS. (PH.D. DISSERTATION).
172015 01-03

DETERMINATION OF DRUG TRANSFER ACROSS BIOLOGICAL MEMBRANES: COMPARATIVE STUDY ON THE PASSAGE OF DRUGS INTO THE CENTRAL NERVOUS SYSTEM AND THEIR PLACENTAL TRANSFER AND FETAL LOCALIZATION IN THE PREGNANT RAT. (PH.D. DISSERTATION).
172018 01-03

THE SPIRAL AFTEREFFECT (SAE) AS A MEASURE OF MOTION SICKNESS SUSCEPTIBILITY AND THE EFFECT ON THE SAE OF AN ANTIMOTION SICKNESS DRUG AND A CENTRAL NERVOUS SYSTEM DEPRESSANT.
172780 01-03

ON THE MECHANISM OF CENTRAL ACTION OF AMPHETAMINE: THE ROLE OF CATECHOLAMINES.
172921 01-04

DEPENDENCE OF ANTICONVULSANT DRUG ACTION ON CENTRAL MONOAMINES.
172923 01-03

CENTRAL MONOAMINES AND THE ACOUSTIC STARTLE REACTION IN RATS. (PH.D. DISSERTATION).
173136 01-04

EFFECT OF A NEW PSYCHOTROPIC DRUG, CS-370 (10-CHLORO-11B-(2-CHLOROPHENYL)-2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE) UPON THE CENTRAL NERVOUS SYSTEM.
174603 01-03

EFFECTS OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES ON CENTRAL NORADRENERGIC MECHANISMS. (PH.D. DISSERTATION).
174959 01-03

POTENTIAL NEUROTRANSMITTERS AND RECEPTOR MECHANISMS INVOLVED IN THE CENTRAL CONTROL OF BODY TEMPERATURE IN HAMSTERS. (PH.D. DISSERTATION).
174962 01-03

AMPHETAMINE TRICYCLIC INTERACTIONS: ROLE OF THE HYDROXYLATION OF AMPHETAMINE IN ITS CENTRAL AND PERIPHERAL MODE OF ACTION. (PH.D. DISSERTATION).
174963 01-03

ANTIHYPERTENSIVE AND CENTRAL NERVOUS SYSTEM DEPRESSANT PROPERTIES OF 3-(GAMMA-P-FLUOROBENZOYLPROPYL) 2,3,4,4A,5,6 HEXAHYDROPYRAZINOQUINOLINE HYDROCHLORIDE (COMPOUND-69-183, CENTPYRAQUIN).
176881 02-03

CENTRAL NERVOUS SYSTEM AND AUTONOMIC NERVOUS SYSTEM EFFECTS OF AMANTADINE AND OF SOME STANDARD ANTIPARKINSON DRUGS.
177729 02-13

AMITRIPTYLINE IN MAN: DECREASED FORMATION OF CENTRAL 5-HYDROXYINDOLEACETIC ACID.
177736 02-13

INFLUENCE OF N1-2-HYDROXYETHYL SUBSTITUTION ON CENTRAL ACTIVITY OF OXAZEPAM AND LORAZEPAM.
178756 02-04

CENTRAL NERVOUS STIMULANT INDUCED PHYSIOLOGICAL AND PERFORMANCE CHANGES IN ADULTS DURING SUSTAINED PSYCHOMOTOR TRACKING.
179023 02-13

PERIPHERAL VERSUS CENTRAL MECHANISMS ACCOUNTING FOR ANTIANXIETY EFFECTS OF PROPRANOLOL.
181072 02-10

CENTRAL DOPAMINE FUNCTION IN AFFECTIVE ILLNESS: EVIDENCE FROM PRECURSORS, ENZYME INHIBITORS AND STUDIES OF CENTRAL DOPAMINE TURNOVER. (UNPUBLISHED PAPER).
181358 02-09

SIGNIFICANCE OF THE CENTRAL BIOGENIC AMINES FOR THE THRESHOLD IN ELECTRO AND PENTETRAZOLE SEIZURES.
181469 02-03

REGIONAL CYCLIC NUCLEOTIDES PHOSPHODIESTERASE ACTIVITY IN CAT CENTRAL NERVOUS SYSTEM: EFFECTS OF BENZODIAZEPINES.
181575 02-03

CENTRAL NERVOUS ACTION OF BROMAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.
181650 02-03

OXIDATIVE METABOLISM OF MESCALINE IN THE CENTRAL NERVOUS SYSTEM -- IV: IN VIVO METABOLISM OF MESCALINE AND 2,3,4 TRIMETHOXY-BETA-PHENYLETHYLAMINE.
181944 02-03

STUDIES ON CENTRAL REGULATING MECHANISM OF THE HYPOGLYCEMIA INDUCED BY INTRAVENTRICULAR ADMINISTRATION OF CHLORPROMAZINE.
182093 02-03

A CENTRAL EFFECT OF LOCAL ANESTHETICS: PREVENTION AGAINST THE ACCUMULATION OF CYCLIC AMP IN BRAIN SLICES.
182099 02-03

EFFECTS OF LICL ON THE CENTRAL NERVOUS SYSTEM.
182112 02-04

INTERACTION OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A PURPORTED HASHISH AND LSD ANTAGONIST, WITH SEVERAL CENTRAL NEUROCHEMICAL SYSTEMS.
182217 03-04

THE EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC) AND ETHANOL ON MONOSYNAPTIC AND POLYSYNAPTIC TRANSMISSION IN THE CENTRAL NERVOUS SYSTEM.
182222 03-03

CENTRAL CHOLINERGIC (MUSCARINIC) LINK IN THE ATTACK REFLEXIVE BITING MECHANISM OF CATS.
182238 03-04

COMPARATIVE EFFECTS OF DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE ON CENTRAL CATECHOLAMINES AND LOCOMOTOR ACTIVITY.
182253 03-04

INVOLVEMENT OF ALPHA-RECEPTORS IN CLONIDINE INDUCED INHIBITION OF TRANSMITTER RELEASE FROM CENTRAL MONOAMINE NEURONES.
182345 03-03

ELECTROPHYSIOLOGICAL STUDIES OF THE EFFECTS OF CDP-CHOLINE ON THE CENTRAL NERVOUS SYSTEM.
182547 03-03

CENTRAL NERVOUS ACTION OF FLURAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.
182549 03-03

CENTRAL NERVOUS DEPRESSANT XV: SYNTHESIS AND PHARMACOLOGICAL SCREENING OF SOME TRIMETHOXYAZLACTONES.
182828 03-02

DRUGS ACTING ON THE CENTRAL NERVOUS SYSTEM.
182835 03-17

ROLE OF THE CENTRAL AUTONOMIC NERVOUS SYSTEM IN THE HYPOTENSION AND BRADYCARDIA INDUCED BY (-) DELTA9-TETRAHYDROCANNABINOL.
183795 03-03

L-DOPA EFFECTS ON MOTOR AND CENTRAL PROGRAMMING DEFICITS IN PARKINSONISM.
184976 03-14

FEAR REDUCTION IN THE RAT FOLLOWING CENTRAL CHOLINERGIC BLOCKADE.
187703 04-04

A FREQUENCY SHIFT IN THE HIPPOCAMPAL THETA ACTIVITY: AN ELECTRICAL CORRELATE OF CENTRAL ACTION OF ACTH ANALOGUES IN THE DOG
188166 04-04

CENTRAL HYPOTHERMIA BY 2-DEOXY-D-GLUCOSE: ANTAGONISM BY ALPHA-ADRENERGIC ACTIVATION.
188200 04-03

SELECTIVE RESERPINE RESISTANT ACCUMULATION OF CATECHOLAMINES IN CENTRAL DOPAMINE NEURONES AFTER DOPA ADMINISTRATION.
189026 04-03

SYNTHESIS AND CENTRAL NERVOUS SYSTEM ACTIVITY OF 1,2,3,4-TETRAHYDRO-1-AMINO-4-PHENYLNAPHTHALENES.
189178 04-02

BENZODIAZEPINES AND BARBITURATES: TURNOVER CHANGES IN CENTRAL 5-HYDROXYTRYPTAMINE PATHWAYS.
189611 04-03

INTERACTION OF D-AMPHETAMINE WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY OF MICE.
189613 04-04

EFFECT OF LITHIUM ON CENTRAL METABOLISM OF 5-HYDROXYTRYPTAMINE.
190337 04-03

PHYSICOCHEMICAL PROPERTIES, DEVELOPMENT, AND REGULATION OF CENTRAL AND PERIPHERAL MONOAMINE OXIDASE ACTIVITY.
191497 04-03

EFFECT OF CHRONIC TREATMENT WITH CENTRAL STIMULANTS ON BRAIN MONOAMINES AND SOME BEHAVIOURAL AND PHYSIOLOGICAL FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS.
191503 04-03

EFFECTS OF ALTERATIONS IN IMPULSE FLOW ON TRANSMITTER METABOLISM IN CENTRAL DOPAMINERGIC NEURONS.
191519 04-03

THE EFFECTS ON INGESTIVE BEHAVIORS OF DAMAGE TO CENTRAL DOPAMINE CONTAINING NEURONS.
191520 04-04

POST-MORTEM MEASUREMENT OF ENZYMES IN HUMAN BRAIN: EVIDENCE OF A CENTRAL NORADRENERGIC DEFICIT IN SCHIZOPHRENIA.
191529 04-13

EFFECTS OF NEUROLEPTIC AGENT ON CENTRAL NERVOUS SYSTEM OF ALBINO RATS.
191613 04-03

NEUROCHEMICAL ANALYSIS OF AGGRESSIVE - DEFENSIVE BEHAVIOR ELICITED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS AND CENTRAL GRAY MATTER.
191784 04-02

EVIDENCE FOR CHOLINERGICALLY MEDIATED EFFECT OF METHYLPHENIDATE HYDROCHLORIDE IN THE CENTRAL NERVOUS SYSTEM.
191946 04-03

NEUROPHARMACOLOGICAL ANALYSIS OF CENTRAL ADRENERGIC AND CHOLINERGIC ANTAGONISM OF DELTA9-TETRAHYDROCANNABINOL.
191992 04-03

ESTIMATION OF THE CONTRIBUTION OF PERIPHERAL AND CENTRAL NORADRENERGIC NEURONES TO URINARY 3-METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT.
192335 04-03

CENTRALLY

STUDY ON THE PSYCHOPHARMACOLOGICAL ASSAY OF CENTRALLY ACTING DRUGS IN RATS.
171260 01-06

EFFECTS OF CENTRALLY ACTING DRUGS ON ADENYL CYCLASE ACTIVITY AND CYCLIC AMP LEVELS OF MOUSE BRAIN. (PH.D. DISSERTATION).
172019 01-03

INTERACTION OF CENTRALLY ADMINISTERED OUABAIN WITH AGENTS AFFECTING SYMPATHETIC FUNCTION.
178640 02-03

EFFECTS OF SELECTED CENTRALLY ACTING AGENTS ON ADENYL CYCLASE ACTIVITY IN MOUSE BRAIN.
182153 02-03

EFFECTS OF CENTRALLY APPLIED DRUGS ON PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION.
185902 03-03

CENTRALLY ACTING MUSCLE RELAXANTS. ISOMERIC 9,10 DIHYDROXYOCTAHYDROPHENANTHRENES AND THEIR CARBAMATE ESTERS.
190719 04-02

CER

THE CONDITIONED EMOTIONAL RESPONSE (CER) AS A BASELINE FOR THE STUDY OF ANTIANXIETY DRUGS.
183862 03-04

CERCINE

ISOLATION AND IDENTIFICATION OF HYPNOTICS (8): ISOLATION AND IDENTIFICATION OF BENZALIN AND CERCINE BY THIN-LAYER CHROMATOGRAPHY IN VITRO.
182626 03-01

CERCOPITHECUS

STEREOTYPY WITH SELECTIVE STIMULATION OF CERTAIN ITEMS OF BEHAVIOUR OBSERVED IN AMPHETAMINE TREATED MONKEYS (CERCOPITHECUS).
180061 02-04

CEREBELLAR

ACUTE CEREBELLAR DISTURBANCE ASSOCIATED WITH DIAZEPAM THERAPY -- A CASE REPORT AND FURTHER INVESTIGATION.
177392 02-15

CEREBELLUM

NEUROLEPTIC ANTAGONISM OF CATECHOLAMINE INHIBITIONS IN RAT CEREBELLUM AND CAUDATE. (UNPUBLISHED PAPER).
187496 04-03

EFFECT OF OXOTREMORINE AND PHYSOSTIGMINE ON CHOLINE LEVELS IN MOUSE WHOLE BRAIN, SPLEEN AND CEREBELLUM.
189893 04-03

FLUORESCENCE AND ELECTRON MICROSCOPIC ANALYSIS OF CATECHOLAMINE CONTAINING FIBERS IN MUTANT MOUSE CEREBELLUM. (UNPUBLISHED PAPER).
191762 04-03

DIAZEPAM, CYCLIC NUCLEOTIDES AND AMINO ACID NEUROTRANSMITTERS IN RAT CEREBELLUM. (UNPUBLISHED PAPER).
191764 04-03

CEREBRAL

ONGOING INVESTIGATIONS OF CEREBRAL GLUTAMINE EXCRETION SCHIZOPHRENICS DURING TREATMENT WITH NEUROLEPTIC.
174101 01-08

TRANSPORT OF SYNAPTOSOMAL TRYPTOPHAN AND CEREBRAL TYROSINE: INCREASE IN THE SPEED OF UPTAKE OF RESERPINE OR THE INHIBITION OF MONOAMINE OXIDASE.
179988 02-13

EXPERIENCE IN THE TREATMENT OF CEREBRAL INSUFFICIENCY AND PERIPHERAL BLOOD CIRCULATION DISORDERS USING THE EP-50-100 EXPERIMENTAL DRUG.
180676 02-11

CEREBRAL STIMULANTS AND MINIMAL DYSFUNCTION: SOME QUESTIONS, SOME ANSWERS, AND SOME MORE QUESTIONS.
180992 02-11

EFFECTS OF LITHIUM ON CEREBRAL RNA METABOLISM IN VITRO AND IN VIVO.
181942 02-03

PREDICTION OF NEUROLEPTIC EFFECTS OF CI-686 BASED ON QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY: DRUG PROFILES AND DOSE RESPONSE CURVES BASED ON COMPUTERIZED CEREBRAL BIOPOTENTIALS.
181958 02-13

UPTAKE AND RELEASE OF NORADRENALINE IN RAT CEREBRAL CORTEX IN VITRO: NO EFFECT OF BENZODIAZEPINES AND BARBITURATES.
182347 03-03

TREATMENT OF THE CEREBRAL MANIFESTATIONS OF ARTERIOSCLEROSIS WITH CYCLANDELATE.
185008 03-11

HYPERTHERMIC EFFECT OF PALMITATE SODIUM, STEARATE SODIUM AND OLEATE SODIUM INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS CATS.
186640 03-03

A COMPARISON OF THE EFFECTS OF AMPHETAMINE AND ITS METABOLITES, P-HYDROXYAMPHETAMINE AND P-HYDROXYNOREPHEDRINE, ON UPTAKE, RELEASE AND CATABOLISM OF 3H-NOREPINEPHRINE IN CEREBRAL CORTEX OF RAT BRAIN.
186669 03-03

ON THE CEREBRAL ACCUMULATION OF KETAMINE AND THE RELATIONSHIP BETWEEN METABOLISM OF THE DRUG AND ITS PHARMACOLOGICAL EFFECTS.
186693 03-03

EVIDENCE FOR AN INHIBITORY ROLE FOR ACETYLCHOLINE, CATECHOLAMINES, AND SEROTONIN ON THE CEREBRAL CORTEX.
187552 04-03

EFFECTS OF SOME METALLIC CATIONS ON CEREBRAL CORTICAL NEURONES AND THEIR INTERACTIONS WITH BIOGENIC AMINES.
187806 04-03

IN VIVO CHANGES OF CEREBRAL CYCLIC ADENOSINE 3,5 MONOPHOSPHATE INDUCED BY BIOGENIC AMINES: ASSOCIATION WITH PHOSPHORYLASE ACTIVATION.
188291 04-03

ANISOMYCIN, LIKE OTHER INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS, IMPAIRS LONG-TERM MEMORY OF A DISCRIMINATION TASK.
188605 04-04

EVIDENCE FOR A SPECIFIC UPTAKE OF DOPAMINE BY DOPAMINERGIC TERMINALS OF THE RAT CEREBRAL CORTEX.
188978 04-03

EFFECTS OF INTRACEREBRAL INJECTION OF 5,6-HYDROXYTRYPTAMINE ON CEREBRAL MONOAMINES AND SLEEP STATES IN THE CAT/.
189023 04-02

THE ACTION OF BETA-PHENYL-GABA DERIVATIVES ON NEURONES OF THE CAT CEREBRAL CORTEX.
189750 04-03

EFFECT OF PHENOTHIAZINE NEUROLEPTIC DRUGS AND TRICYCLIC ANTIDEPRESSANTS ON PHOSPHODIESTERASE ACTIVITY IN RAT CEREBRAL CORTEX.
190311 04-03

NEOMYCIN AND RUTHENIUM RED ANTAGONISM OF MONOAMINERGIC DEPRESSION OF CEREBRAL CORTICAL NEURONES.
191380 04-03

THE EFFECT OF CHOLINOMIMETIC DRUGS ON POTASSIUM TRANSPORT IN RAT CEREBRAL CORTEX.
191411 04-03

CHANGES IN RHYTHMS OF BIOELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX IN HUMANS UNDER THE INFLUENCE OF ETHYMISOL.
191790 04-07

ENDURING LEARNING DEFICITS AND CEREBRAL SYNAPTIC MALFORMATION FROM EXPOSURE TO 10 PARTS OF HALOTHANE PER MILLION.
192565 04-04

CEREBROSPINAL

BRAIN SEROTONIN, AFFECTIVE ILLNESS AND ANTIDEPRESSANT DRUGS: CEREBROSPINAL FLUID STUDIES WITH PROBENECID. (UNPUBLISHED PAPER).
170084 01-09

ELECTROLYTES IN CEREBROSPINAL FLUID IN ENDOGENOUS DEPRESSION.
172402 01-09

EFFECTS OF AMITRIPTYLINE AND IMIPRAMINE ON AMINE METABOLITES IN THE CEREBROSPINAL FLUID OF DEPRESSED PATIENTS.
174094 01-09

THE EFFECT OF PROBENECID AND LARGE DOSE AMPHETAMINE ADMINISTRATION ON CEREBROSPINAL FLUID HOMOVANILLIC ACID.
177826 02-13

CHOLINE ACETYLTRANSFERASE ACTIVITY IN THE CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
180047 02-13

LITHIUM DISTRIBUTION BETWEEN CEREBROSPINAL FLUID AND SERUM OF AFFECTIVE PSYCHOTIC PATIENTS TREATED WITH LITHIUM CARBONATE AND ITS CLINICAL RESPONSE.
180301 02-11

THE ELIMINATION OF 5-HYDROXYINDOLEACETIC ACID FROM CEREBROSPINAL FLUID: CHARACTERISTICS OF THE ACID TRANSPORT SYSTEM OF THE CHOROID PLEXUS.
182718 03-03

THE EFFECT OF CHLORPROMAZINE ON HOMOVANILLIC ACID LEVELS IN CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS.
186565 03-08

MASS FRAGMENTOGRAPHIC ANALYSIS OF HOMOVANILLIC ACID AND ITS HOMOISO ANALOGUE IN CEREBROSPINAL FLUID USING THE ALPHA DIDEUTERO ACID AS INTERNAL STANDARD.
186566 03-16

STUDIES OF CEREBROSPINAL FLUID AMINE METABOLITES IN DEPRESSED PATIENTS: CONCEPTUAL PROBLEMS AND THEORETICAL IMPLICATIONS. (UNPUBLISHED PAPER).
187398 04-13

PLASMA AND CEREBROSPINAL FLUID PROBENECID CONCENTRATIONS AS RELATED TO ACCUMULATION OF ACIDIC BIOGENIC AMINE METABOLITES IN MAN.
187933 04-13

A STUDY OF BIOGENIC AMINE METABOLITES IN THE CEREBROSPINAL FLUID AND URINE OF MONKEYS WITH CHLORPROMAZINE INDUCED DYSKINESIA.
189210 04-03

CEREBROVASCULAR

TREATMENT OF CEREBROVASCULAR DISTURBANCES WITH 2-BUTYLAMINO-1-P-HYDROXYPHENYL ETHANOL SULFATE (BAMETHAN).
182790 03-11

CERULOPLASMIN

INTERACTION OF PHENOTHIAZINE DERIVATIVES WITH HUMAN CERULOPLASMIN.
177335 02-13

CERVEAU

THE ACTION OF ALPHA-METHYLDOPA IN THE CERVEAU ISOLE PREPARATION.
187075 03-03

CERVICAL

THE ACTIONS OF SEVERAL PSYCHOACTIVE AGENTS UPON THE MUSCARINIC MECHANISMS IN THE SUPERIOR CERVICAL GANGLION OF THE CAT.
183866 03-03

THE EFFECTS OF 5-HYDROXYTRYPTAMINE AND SOME RELATED COMPOUNDS ON THE CAT SUPERIOR CERVICAL GANGLION IN SITU.
184197 03-03

THE EFFECTS OF VARIOUS NICOTINE-LIKE AGENTS IN THE CAT SUPERIOR CERVICAL GANGLION IN SITU.
184202 03-03

THE EFFECTS OF LITHIUM ON HIGH ENERGY PHOSPHATE AND GLUCOSE LEVELS IN THE RAT SUPERIOR CERVICAL GANGLION.
187677 04-03

PHARMACOLOGICAL ALTERATIONS IN THE STIMULUS INDUCED RELEASE OF NOREPINEPHRINE FROM THE RABBIT SUPERIOR CERVICAL GANGLION.
191896 04-03

CFR

THE EFFECT OF L-TRYPTOPHAN (TP) ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) REFLEXES IN ACUTE DECEREBRATE SPINAL CATS AND THE EFFECT OF PRETREATMENT WITH P-CHLOROPHENYLALANINE (PCPA) ON THE ACTION OF TP. (UNPUBLISHED PAPER).
170874 01-03

THE EFFECT IN THE CAT OF TRYPTAMINE (T) AND LSD ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) SPINAL REFLEXES. (UNPUBLISHED PAPER).
174480 01-12

CHAINS

REPEATED ACQUISITION OF BEHAVIORAL CHAINS UNDER CHRONIC DRUG CONDITIONS.
177408 02-04

CHANGE

DRUG ENHANCED SENSORY CONTINGENT BAR PRESSING: COMPARING THE EFFECT OF CONTINGENT AND NONCONTINGENT SENSORY CHANGE.
168837 01-04

EEG, HEART RATE, AND MOOD CHANGE (HIGH) AFTER CANNABIS.
169068 01-13

CHANGE OF ESTROGEN ACTIVATED BEHAVIOR BY CYCLOHEXIMIDE IN THE FEMALE RAT.
171615 01-04

SENSORY CONTINGENT BAR-PRESSING FOR FAMILIAR AND NOVEL CHANGE UNDER A DEXAMPHETAMINE AMYLOBARBITONE MIXTURE.
181605 02-04

DISSOCIATIVE CHANGE IN ANTIAGGRESSIVE AND MUSCLE RELAXANT ACTIONS OF S-TRIAZOLOBENZODIAZEPINE (D-40TA) BY REPEATED ADMINISTRATION AND PHENOBARBITAL PRETREATMENT, AND ITS RELATION TO METABOLISM.
181654 02-04

CHANGED

PSYCHOTROPIC EFFECT OF ANALGESICS AND NEUROLEPTICS ON A MODEL OF INVESTIGATORY BEHAVIOR CHANGED BY PAIN.
191120 04-04

CHANGES

INFLUENCE OF TREATMENT ON SYMPTOMATOLOGY AND CORRELATED ELECTROENCEPHALOGRAPHIC (EEG) CHANGES IN THE AGED.
167336 01-13

ELECTROCARDIOGRAPHIC CHANGES IN HYPERTHYROIDISM AFTER ADRENERGIC BLOCKADE WITH RESERPINE AND PROPRANOLOL.
167460 01-13

CHANGES IN SOMATOSENSORY EVOKED POTENTIALS PRODUCED BY DRUGS USED IN THE TREATMENT OF AFFECTIVE DISORDERS.
169092 01-09

LIPID INDUCED CHANGES OF PENTOBARBITAL DISTRIBUTION AND METABOLISM.
170072 01-03

CHANGES IN MENTAL FUNCTIONING ACCOMPANYING ANTIPSYCHOTIC DRUG THERAPY.
171124 01-10

TURNOVER CHANGES IN CENTRAL MONOAMINE NEURON SYSTEMS AFTER MINOR TRANQUILLIZERS AND BARBITURATES.
171604 01-03

INTERRESPONSE TIME CHANGES AS A FUNCTION OF DEPRIVATION AND AMPHETAMINE ADMINISTRATION.
171612 01-04

DRUG-INDUCED ACTIVATION OF STRIATAL TYROSINE HYDROXYLASE: CHANGES IN THE AFFINITY FOR PTERIDINE COFACTORS. (UNPUBLISHED PAPER).
173381 01-03

BEHAVIORAL CHANGES AND AGGRESSIVITY EVOKED BY DRUGS IN MICE.
174604 01-04

SLEEP CHANGES IN CHRONIC SCHIZOPHRENICS: EFFECTS OF 5-HYDROXYTRYPTOPHAN (5-HTP). (UNPUBLISHED PAPER
178578 02-08

CHANGES IN BRAIN ACETYLCHOLINESTERASE ACTIVITY OF YOUNG RATS AFTER CHRONIC TREATMENT WITH TREMORINE.
178814 02-03

CENTRAL NERVOUS STIMULANT INDUCED PHYSIOLOGICAL AND PERFORMANCE CHANGES IN ADULTS DURING SUSTAINED PSYCHOMOTOR TRACKING.
179023 02-13

AN ANALYSIS OF D-AMPHETAMINE PRODUCED FACILITATION OF AVOIDANCE ACQUISITION IN RATS AND PERFORMANCE CHANGES SUBSEQUENT TO DRUG TERMINATION.
179990 02-04

ELECTROENCEPHALOGRAPHIC CHANGES IN ACUTE PHENOBARBITONE POISONING.
180149 02-15

THE ELECTROENCEPHALOGRAPHIC CHANGES IN ACUTE BARBITURATE POISONING.
180152 02-15

ANALYSIS OF DRUG BLOCK OF LSD/5-HT/GABA BY MONITORING NEURONAL MEMBRANE CHANGES.
182143 02-03

EEG CHANGES & MOTOR IMPAIRMENT AFTER DISULFIRAM ADMINISTRATION TO CATS.
182248 03-03

CHANGES IN THE NEUROEXCITABILITY OF ALCOHOL DEPENDENT RATS UNDERGOING WITHDRAWAL AS MEASURED BY THE PENTYLENETETRAZOL SEIZURE THRESHOLD.
182348 03-03

TREATMENT PROCESS OF DEPRESSION AND CHANGES IN MICROVIBRATION.
182620 03-09

EVALUATION OF EEG AND CLINICAL CHANGES ASSOCIATED WITH PAVABID THERAPY IN CHRONIC BRAIN SYNDROME.
183402 03-13

CHANGES IN SHORT-TERM AND LONG-TERM MEMORY OF DOGS AND CATS UNDER THE EFFECTS OF AMIZYL (BENACTYZINE).
183517 03-04

LONG-RANGE MOTOR PERFORMANCE CHANGES IN LEVODOPA TREATED PATIENTS WITH PARKINSONS DISEASE.
184195 03-11

RELATIONSHIP OF PLASMA MEPERIDINE LEVELS TO CHANGES IN ANXIETY AND HOSTILITY.
185881 03-14

REGIONAL CHANGES IN MONOAMINE LEVELS AND IN THE RATE OF TYROSINE AND TRYPTOPHAN HYDROXYLATION IN 4 WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
185899 03-03

L-TRYPTOPHAN IN AFFECTIVE DISORDERS: INDOLEAMINE CHANGES AND DIFFERENTIAL CLINICAL EFFECTS.
185928 03-09

NEUROLOGICAL CHANGES IN CATS FOLLOWING LONG-TERM DIET OF MERCURY CONTAMINATED TUNA.
186476 03-05

EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: I. EFFECT ON THE BEHAVIOURAL CHANGES INDUCED BY RESERPINE, ALPHA-METHYL-P-TYROSINE OR AMPHETAMINE.
186587 03-04

ACTIONS OF ATROPINE, HEMICHOLINIUM-3, AND PHYSOSTIGMINE ON CHLORPROMAZINE INDUCED CHANGES IN RAT BRAIN MONOAMINES.
187800 04-03

PERSISTENT ELECTROENCEPHALOGRAPHIC CHANGES IN RHESUS MONKEYS AFTER SINGLE DOSES OF PENTOBARBITAL, NITRAZEPAM AND IMIPRAMINE.
187931 04-03

IN VIVO CHANGES OF CEREBRAL CYCLIC ADENOSINE 3,5 MONOPHOSPHATE INDUCED BY BIOGENIC AMINES: ASSOCIATION WITH PHOSPHORYLASE ACTIVATION.
188291 04-03

MENTAL CHANGES IN PARKINSONISM.
188886 04-15

MESCALINE INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON THE BINDING OF AMINOACYL TRANSFER RIBONUCLEIC ACID TO RIBOSOMES OF BRAIN TISSUE.
189582 04-05

BENZODIAZEPINES AND BARBITURATES: TURNOVER CHANGES IN CENTRAL 5-HYDROXYTRYPTAMINE PATHWAYS.
189611 04-03

CHANGES IN ORIENTING AND HABITUATION IN THE RAT FOLLOWING ADMINISTRATION OF CHLORPROMAZINE.
191211 04-04

BEHAVIORAL AND EEG CHANGES IN THE AMPHETAMINE MODEL OF PSYCHOSIS.
191505 04-04

CHANGES IN RHYTHMS OF BIOELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX IN HUMANS UNDER THE INFLUENCE OF ETHYMISOL.
191790 04-07

EXCITABILITY CHANGES DURING THE GRADUAL DEVELOPMENT OF AND RECOVERY FROM PENTYLENETETRAZOL AND STRYCHNINE INDUCED CONVULSIONS IN THE CAT.
191927 04-03

CHANGING
CHANGING DEATHS PERSPECTIVE.
169138 01-11

CHARACTER
HYPERKINETIC, HYPOSCHOLASTIC BEHAVIOUR AND CHARACTER DISORDERS OF CHILDHOOD AND ADOLESCENCE: DIAGNOSIS AND PHARMACOTHERAPY.
172800 01-11

CHARACTERISTIC
VOCALIZATION: A CHARACTERISTIC CANNABIS INDUCED BEHAVIOR IN THE RAT?
175884 02-04

CHARACTERISTICS
CHARACTERISTICS OF BENZODIAZEPINE TRANQUILIZERS.
180307 02-17
EEG CHARACTERISTICS IN VARIOUS SPECIES OF ANIMAL AND THEIR RELATION TO THE CNS EFFECTS OF DRUGS.
182096 02-03
THE ELIMINATION OF 5-HYDROXYINDOLEACETIC ACID FROM CEREBROSPINAL FLUID: CHARACTERISTICS OF THE ACID TRANSPORT SYSTEM OF THE CHOROID PLEXUS.
182718 03-03
MONOAMINE OXIDASE IN MAN: ENZYME CHARACTERISTICS IN HUMAN PLATELETS, PLASMA, AND OTHER HUMAN TISSUES.
191502 04-13

CHARACTERIZATION
PARTIAL PURIFICATION AND CHARACTERIZATION OF NADPH-LINKED ALDEHYDE REDUCTASE FROM MONKEY BRAIN.
175232 02-03
THE LOCALIZATION AND CHARACTERIZATION OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE ACTIVITY IN SPECIFIC REGIONS OF THE CNS.
191932 04-03

CHELATION
METAL CHELATION OF CHLORPROMAZINES.
176763 02-06

CHEMICAL
QUANTUM CHEMICAL STUDIES ON DRUG ACTIONS: IV. CORRELATION OF SUBSTITUENT STRUCTURES AND ANTISEROTONIN ACTIVITY IN LYSERGAMIDE SERIES.
174605 01-12
EFFECT OF CHEMICAL SYMPATHECTOMY ON MORPHINE ANTINOCICEPTION AND TOLERANCE IN RATS.
182159 02-03
NIMH SPONSORED CHEMICAL SYNTHESIS PROGRAM.
182444 03-01
NEURAL AND CHEMICAL MECHANISMS OF FEMALE SEXUAL BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).
185705 03-04
CARDIOVASCULAR REACTIVITY IN THE DOG AFTER CHEMICAL SYMPATHECTOMY WITH 6-HYDROXYDOPAMINE.
187807 04-03
CHEMICAL CONVERSION OF THE PSYCHOTOMIMETIC AMINE 1-(2,5 DIMETHOXY-4-METHYLPHENYL) 2-AMINOPROPANE TO 5-HYDROXYDIMETHYLINDOLE.
187941 04-01
THE EFFECTS OF MORPHINE, ETORPHINE AND SINOMENINE ON THE CHEMICAL SENSITIVITY AND SYNAPTIC RESPONSES OF RENSHAW CELLS AND OTHER SPINAL NEURONES IN THE RAT.
188201 04-03
AFFECTIVE DISORDERS AND CHEMICAL DEPENDENCE: LITHIUM FOR ALCOHOL AND DRUG ADDICTION
189775 04-09

CHEMISTRY
CHEMISTRY OF TRAZODONE.
168801 01-01
THE BOTANY AND CHEMISTRY OF HALLUCINOGENS.
189101 04-12
THE CHEMISTRY OF PEYOTE ALKALOIDS.
192875 04-12
MESCALINE: THE CHEMISTRY AND PHARMACOLOGY OF ITS ANALOGS.
192877 04-12

CHEMOCONVULSIONS
THRESHOLDS FOR ELECTROCONVULSIONS AND CHEMOCONVULSIONS IN MICE AFTER TERMINATION OF TREATMENT WITH PHENOBARBITAL.
170073 01-03

CHEMOTHERAPEUTIC
THE PROBLEM OF ANXIETY IN A NON-WESTERN SOCIETY: A COMBINED CHEMOTHERAPEUTIC AND PSYCHOTHERAPEUTIC APPROACH.
171162 01-10
A CHEMOTHERAPEUTIC ALTERNATIVE TO THE ANTIANXIETY AGENTS FOR THE EXTENDED TREATMENT OF PSYCHONEUROSIS.
192083 04-10

CHEMOTHERAPY
CHEMOTHERAPY IN CHRONIC ORGANIC BRAIN SYNDROME - A REVIEW OF THE LITERATURE.
169065 01-11
A NEW AGENT FOR CHEMOTHERAPY OF MIGRAINE HEADACHES: A CONTROLLED STUDY.
169298 01-11
THE ROLE OF CHEMOTHERAPY IN MANAGING POTENTIALLY SUICIDAL PATIENTS.
178544 02-10
ADVANCES IN PHARMACOLOGY AND CHEMOTHERAPY.
179983 02-17
CHEMOTHERAPY IN CHILDHOOD DEPRESSION.
182430 03-09
CHEMOTHERAPY AND PSYCHOTHERAPY, ARE THEY COMPLEMENTARY OR ANTAGONISTIC?: A PERSONAL STUDY.
184959 03-17
USE OF CHEMOTHERAPY AS ANTISUICIDAL PROPHYLAXIS.
191140 04-11
CHEMOTHERAPY OF DELIRIUM-TREMENS: A SURVEY OF PHYSICIANS PREFERENCES.
192068 04-11

CHICK
THE EFFECTS OF MESCALINE ADMINISTERED BEFORE OR DURING EMBRYOGENESIS UPON THE HATCHABILITY AND BEHAVIOR OF THE CHICK. (PH.D. DISSERTATION).
173791 01-04
EFFECTS OF NARCOTIC ANALGESICS ON ENZYMES OF ACETYLCHOLINE METABOLISM IN CULTURED CHICK BRAIN CELLS.
182225 03-03
EFFECTS OF NON-HYDROGEN-BONDING ANESTHETICS ON MEMORY IN THE CHICK.
184380 03-04

CHICKEN
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON BODYWEIGHT AND BRAIN ELECTROLYTES IN THE CHICKEN.
186570 03-03

CHICKS
DRUG-INDUCED AGGRESSION IN CHICKS: DIFFERENTIAL INVOLVEMENT OF BIOGENIC AMINES.
191977 04-04

CHILD
CONTROL OF THE HYPERACTIVE CHILD VIA MEDICATION -- AT WHAT COST TO PERSONALITY DEVELOPMENT; SOME PSYCHOLOGICAL IMPLICATIONS AND CLINICAL INTERVENTIONS.
176810 02-11

CHILDHOOD
HYPERKINETIC, HYPOSCHOLASTIC BEHAVIOUR AND CHARACTER DISORDERS OF CHILDHOOD AND ADOLESCENCE: DIAGNOSIS AND PHARMACOTHERAPY.
172800 01-11
BIOLOGICAL INTERVENTIONS IN PSYCHOSES OF CHILDHOOD.
175872 02-17
CHEMOTHERAPY IN CHILDHOOD DEPRESSION.
182430 03-09
TREATMENT WITH PSYCHOPHARMACOLOGIC AGENTS IN CHILDHOOD DEPRESSIONS.
182431 03-11
PSYCHOTROPIC DRUGS IN CHILDHOOD DISTURBANCES.
182890 03-11
SOMATIC SIDE-EFFECTS OF PSYCHOTHERAPEUTIC DRUGS IN CHILDHOOD.
183183 03-15
A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: II. PIMOZIDE IN THE TREATMENT OF BEHAVIOURAL DISORDERS IN CHILDHOOD AND ADOLESCENCE.
183192 03-11
CARBAMAZEPINE SOLE ANTICONVULSANT FOR FOCAL EPILEPSY OF CHILDHOOD.
189174 04-11

CHILDREN
IMIPRAMINE IN THE TREATMENT OF MINIMAL BRAIN DYSFUNCTION IN CHILDREN.
169295 01-11
HALOPERIDOL FOR PSYCHIATRIC DISORDERS IN CHILDREN.
169457 01-14
AVERAGE EVOKED RESPONSES IN NORMAL AND MINIMALLY BRAIN DYSFUNCTIONED CHILDREN TREATED WITH AMPHETAMINE: A PRELIMINARY REPORT.
169861 01-11
EFFECTS OF MEDICATION ON LEARNING IN HYPERACTIVE FOUR-YEAR-OLD CHILDREN. (ED.D DISSERTATION).
172512 01-11
TANTU-PASHAN AND LUCIDRIL THERAPY IN MENTALLY RETARDED CHILDREN.
175628 02-11
SIDE-EFFECTS OF DEXTROAMPHETAMINE THERAPY OF HYPERACTIVE CHILDREN.
176238 02-15
A DOUBLE-BLIND COMPARISON OF FLUPHENAZINE AND HALOPERIDOL IN OUTPATIENT SCHIZOPHRENIC CHILDREN.
177754 02-08

DEXTROAMPHETAMINE AND METHYLPHENIDATE IN THE TREATMENT OF HYPERACTIVE/AGGRESSIVE CHILDREN.
177771 02-14
RESPONSE TO STIMULANT DRUG TREATMENT IN HYPERACTIVE CHILDREN: PREDICTION FROM EEG AND NEUROLOGICAL FINDINGS.
177778 02-11
RITALIN FOR SCHOOL CHILDREN: THE TEACHERS PERSPECTIVE.
178127 02-17
EFFECT OF A CARNITINE CYPROHEPTADINE COMBINATION ON ANOREXIA AND WEIGHT GAIN IN CHILDREN.
178811 02-10
INDICATIONS FOR ANTIDEPRESSANT TREATMENT WITH SPECIAL REFERENCE TO DEPRESSED PRESCHOOL CHILDREN.
182428 03-10
DRUG THERAPY FOR DEPRESSION IN CHILDREN. INDICATIONS AND METHODS.
182429 03-10
ACTION OF OPIPRAMOL (G-33040) IN DEPRESSIVE SYNDROMES IN CHILDREN AND ADOLESCENTS.
182432 03-10
LITHIUM IN PSYCHIATRIC THERAPY AND PROPHYLAXIS. A REVIEW WITH SPECIAL REGARD TO ITS USE IN CHILDREN.
182433 03-09
LITHIUM TREATMENT OF PSYCHOTIC CHILDREN. A CONTROLLED CLINICAL TRIAL.
182434 03-09
DIAZEPAM TREATMENT FOR ACUTE CONVULSIONS IN CHILDREN: A REPORT OF 41 PATIENTS, THREE WITH PLASMA LEVELS.
182595 03-11
SOMNAMBULISM IN CHILDREN -- CLINICAL COMMUNICATION.
182870 03-17
NEUROLOGICAL CONSEQUENCES OF PSYCHOTROPIC DRUG WITHDRAWAL IN SCHIZOPHRENIC CHILDREN.
183275 03-08
OUTPATIENT TREATMENT OF HYPERACTIVE SCHOOL CHILDREN WITH IMIPRAMINE.
184174 03-11
DOSE EFFECTS OF METHYLPHENIDATE ON BEHAVIORAL INHIBITION AND ACTIVATION IN HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
185676 03-14
A STUDY OF THE EFFECTS OF RITALIN INTERVENTION UPON THE PERCEPTUAL COMPETENCIES OF CHILDREN DIAGNOSED AS GIVING EVIDENCE OF PSYCHONEUROLOGICAL LEARNING DISABILITIES. (PH.D. DISSERTATION).
186833 03-14
METHYLPHENIDATE IN CHILDREN -- EFFECT OF DOSAGE.
187581 04-14
IMIPRAMINE SIDE-EFFECTS IN CHILDREN.
189512 04-15

CHILDRENS
EFFECTS OF METHYLPHENIDATE ON HYPERACTIVE CHILDRENS SLEEP.
190321 04-14

CHIMPANZEE
MODIFICATION OF THE EFFECTS OF CHLORPROMAZINE ON BEHAVIOR IN THE CHIMPANZEE.
183889 03-04

CHIMPANZEES
THE SOCIAL PLAY BEHAVIOR OF CHIMPANZEES ACCORDING TO A PSYCHOPHARMACOLOGICAL TEST/.
168838 01-04
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON DELAYED MATCHING-TO-SAMPLE CHOICE SPEEDS IN CHIMPANZEES.
171886 01-04
EFFECTS OF CHRONIC EXPOSURE TO DELTA9-TETRAHYDROCANNABINOL ON DELAYED MATCHING-TO-SAMPLE IN CHIMPANZEES.
189405 04-04

CHLORAL
THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: V. THE EFFECTS OF CHLORAL HYDRATE.
177717 02-14
CONVERSION OF CHLORAL HYDRATE TO TRICHLOROETHANOL IN BRAIN AND LIVER.
182157 02-03

CHLORALOSE
A COMPARISON OF SOMATIC REFLEX EFFECTS OF THREE PSYCHOTROPIC AGENTS IN THE CHLORALOSE CAT.
182126 02-03

CHLORAMPHENICOL
THE PRENATAL EFFECT OF CHLORAMPHENICOL ON THE POSTNATAL DEVELOPMENT OF MICE.
187076 03-05

CHLORDIAZEPOXIDE
CHLORDIAZEPOXIDE AND DOTHIEPIN COMPARED IN ANXIETY/DEPRESSION IN GENERAL PRACTICE.
167575 01-10
CHLORDIAZEPOXIDE IN DEPRESSIVE NEUROSIS: AN OPEN LABEL CROSSOVER STUDY WITH AMITRIPTYLINE.
168316 01-10
EFFECTS OF CHLORPROMAZINE, MEPROBAMATE AND CHLORDIAZEPOXIDE ON THE MAZE LEARNING IN MICE.
171259 01-04
ANALGESIC POTENCY OF SODIUM SALICYLATE, INDOMETHACIN, AND CHLORDIAZEPOXIDE AS MEASURED BY THE SPATIAL PREFERENCE TECHNIQUE IN THE RAT.
171301 01-02
PROPRANOLOL AND CHLORDIAZEPOXIDE ON EXPERIMENTAL ' INDUCED CONFLICT AND SHUTTLEBOX PERFORMANCE IN RODENTS.
171304 01-04
PREVENTION OF ALCOHOL WITHDRAWAL SEIZURES: THE ROLES OF DIPHENYLHYDANTOIN AND CHLORDIAZEPOXIDE.
172275 01-11
THE EFFECT OF PHASE-SHIFT ON THE PASSIVE AVOIDANCE RESPONSE IN RATS, AND THE MODIFYING EFFECT OF CHLORDIAZEPOXIDE.
174830 01-04
CHLORDIAZEPOXIDE OVERDOSE: INTERPRETATION OF SERUM DRUG CONCENTRATIONS.
177393 02-15
THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: VI. THE EFFECTS OF CHLORDIAZEPOXIDE.
177718 02-14
THE EFFECTS OF CHLORDIAZEPOXIDE (LIBRIUM) ON THE INTENSITY AND HABITUATION OF AGONISTIC BEHAVIOR IN MALE SIAMESE FIGHTING FISH.
177722 02-04
EFFECTS OF CHLORPROMAZINE, CHLORDIAZEPOXIDE AND PENTOBARBITAL ON NEURONAL EXCITABILITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
177837 02-04
DOXEPIN AND AMITRIPTYLINE CHLORDIAZEPOXIDE COMBINATION IN NEUROTIC STATES: A COMPARATIVE DOUBLE-BLIND STUDY.
180048 02-10
CHLORDIAZEPOXIDE AND HOSTILITY IN ANXIOUS OUTPATIENTS.
181273 02-10
SIMILARITY OF CHRONIC CHLORDIAZEPOXIDE TREATMENT AND REMOVAL OF CONFLICT SITUATION.
182258 03-04
SOCIAL HIERARCHY IN MONKEYS (MACACA-MULATTA) MODIFIED BY CHLORDIAZEPOXIDE HYDROCHLORIDE.
183863 03-04
SEDATIVE OR TRANQUILLIZER? A COMPARISON OF THE HYPNOTIC EFFECTS OF CHLORDIAZEPOXIDE AND AMYLOBARBITONE SODIUM.
184438 03-14
TOWARD A MECHANISM OF THE ANTIAGGRESSION EFFECTS OF CHLORDIAZEPOXIDE IN RATS.
185934 03-04
THE EFFECTS OF CHLORDIAZEPOXIDE, AMPHETAMINE AND COCAINE ON BAR-PRESS BEHAVIOR IN NORMAL AND GENETICALLY NERVOUS DOGS.
187868 04-04
EFFECTS OF CHLORDIAZEPOXIDE ON HEART RATE AND BEHAVIOURAL SUPPRESSION IN PIGS SUBJECTED TO OPERANT CONDITIONING PROCEDURES.
189409 04-04
CHLORDIAZEPOXIDE INDUCED BETA SPINDLE ACTIVITY IN RATS.
192416 04-03

CHLORIDE
THE EFFECTS OF PENTYLENETETRAZOL (METRAZOL) ON A LEARNED TASTE AVERSION PRODUCED BY LITHIUM CHLORIDE: THE ISSUE OF ASSOCIATIVE MEMORY VS. RETENTIVE MEMORY. (UNPUBLISHED PAPER).
188251 04-04

CHLORIMIPRAMINE
EFFECT OF CHLORIMIPRAMINE ON THE RATE OF TRYPTOPHAN HYDROXYLATION IN THE INTACT AND TRANSECTED SPINAL CORD.
168751 01-03
PHENOMENOLOGICAL - EXISTENTIAL STUDY OF PHOBIC - OBSESSIVE SYNDROMES TREATED WITH CHLORIMIPRAMINE.
182788 03-09
THE COMPARATIVE ANXIOLYTIC EFFECTS OF PLACEBO, IMIPRAMINE AND CHLORIMIPRAMINE USING PSYCHIATRIC AND PSYCHOPHYSIOLOGICAL MEASUREMENTS.
191137 04-14
CHLORIMIPRAMINE AND LSD: DIFFERENTIAL EFFECTS ON THE IN VIVO RELEASE OF 3H-5-HT.
191949 04-03

CHLORMEZANONE
CHLORMEZANONE IN ANXIETY: A DRUG REDISCOVERED?
184175 03-10

CHLOROFORM
CONSTITUENTS OF CANNABIS-SATIVA L. V.: STABILITY OF AN ANALYTICAL SAMPLE EXTRACTED WITH CHLOROFORM. (UNPUBLISHED PAPER).
180670 02-01
CHLOROFORM RESPONSES OF THE CHORDA TYMPANI NERVE IN THE RAT.
189219 04-03

CHLOROTHIAZIDE
LITHIUM INDUCED DIABETES-INSIPIDUS: MANIC SYMPTOMS, BRAIN AND ELECTROLYTE CORRELATES, AND CHLOROTHIAZIDE TREATMENT.
169486 01-15

CHLORPHENIRAMINE
BEHAVIORAL EFFECT OF TRICYCLIC THYMOLEPTICS AND CHLORPHENIRAMINE IN MICE AFTER PRETREATMENT WITH 5 HYDROXYTRYPTOPHAN (5-HTP).
171609 01-04

INTERACTIONS OF CHLORPHENIRAMINE ETHANOL COMBINATIONS: ACUTE TOXICITY AND ANTIHISTAMINIC ACTIVITY.
188875 04-05

CHLORPHENTERMINE
METABOLISM OF CHLORPHENTERMINE AND PHENTERMINE IN MAN TO YIELD HYDROXYLAMINO, C-NITROSO AND NITRO COMPOUNDS.
183796 03-13

EVIDENCE FOR AN UNUSUAL DISTRIBUTION OF CHLORPHENTERMINE IN VIVO: AN AUTORADIOGRAPHIC STUDY IN MICE.
184226 03-03

CHLORPROMAZINE
MESORIDAZINE AND CHLORPROMAZINE IN THE TREATMENT OF ALCOHOL WITHDRAWAL SYNDROME.
168314 01-11

EFFECT OF CHLORPROMAZINE (CPZ) ON INSULIN RELEASE IN VIVO AND IN VITRO IN THE RAT.
168440 01-03

THE POSSIBLE ROLE OF METABOLITES IN THERAPEUTIC RESPONSE TO CHLORPROMAZINE TREATMENT.
168836 01-08

EFFECTS OF CHLORPROMAZINE, MEPROBAMATE AND CHLORDIAZEPOXIDE ON THE MAZE LEARNING IN MICE.
171259 01-04

THE ELECTROCARDIOGRAPHIC ABNORMALITY INDUCED BY CHLORPROMAZINE.
171296 01-15

INTERACTION BETWEEN PRIOR EXPERIENCE AND THE EFFECTS OF CHLORPROMAZINE ON EXPLORATION IN THE RAT.
171308 01-04

LEVELS OF HVA IN MOUSE BRAIN FOLLOWING TREATMENT WITH METABOLITES OF CHLORPROMAZINE.
171626 01-03

THE EFFECTS OF INTRACAUDATE INJECTIONS OF CHLORPROMAZINE ON CONDITIONED AVOIDANCE AND SELF-STIMULATION BEHAVIOR. (PH.D. DISSERTATION).
173749 01-04

THE USE OF CHLORPROMAZINE IN SCHIZOPHRENIA.
174059 01-08

HIGH DOSES OF CHLORPROMAZINE AND TRIFLUOPERAZINE IN THE TREATMENT OF PATIENTS SUFFERING FROM SCHIZOPHRENIA.
174589 01-08

FUNCTIONAL EVALUATION OF PITUITARY RESERVE IN PATIENTS WITH THE AMENORRHEA GALACTORRHEA SYNDROME UTILIZING LUTEINIZING HORMONE RELEASING HORMONE (LH-RH), L-DOPA AND CHLORPROMAZINE.
175245 02-13

COMPARATIVE STUDIES OF SYNAPTIC MEMBRANE PROTEIN SOLUBILIZATION BY CHLORPROMAZINE AND SODIUM DODECYLSULFATE.
176703 02-03

ANTAGONISM OF THE EFFECTS OF CHLORPROMAZINE AND MORPHINE ON DOPAMINE METABOLISM BY GABA.
176870 02-03

EFFECTS OF LOW DOSES OF CHLORPROMAZINE ON A CONDITIONED EMOTIONAL RESPONSE IN THE RAT.
176963 02-04

RATE-DEPENDENT EFFECTS OF DRUGS. I. COMPARISONS OF D-AMPHETAMINE, PENTOBARBITAL, AND CHLORPROMAZINE ON MULTIPLE AND MIXED SCHEDULES.
177410 02-04

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: IV. THE EFFECTS OF CHLORPROMAZINE.
177716 02-14

L-DOPA CHLORPROMAZINE ANTAGONISM ON RUNNING ACTIVITY IN MICE.
177785 02-04

BRAIN RIBOSOMAL RNA SYNTHESIS INHIBITED BY CHLORPROMAZINE.
177835 02-03

EFFECTS OF CHLORPROMAZINE, CHLORDIAZEPOXIDE AND PENTOBARBITAL ON NEURONAL EXCITABILITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
177837 02-04

EFFECTS OF CHLORPROMAZINE AND ACTINOMYCIN D ON UPTAKE AND INCORPORATION OF CERTAIN AMINO ACIDS, HYPOXANTHINE AND THYMIDINE IN CULTURES OF HUMAN SKIN EPITHELIAL CELLS.
179989 02-13

EFFECT OF CHLORPROMAZINE AND SOME OF ITS METABOLITES ON THE DOPAMINE SENSITIVE ADENYLATE CYCLASE OF RAT BRAIN STRIATUM.
180060 02-03

COMPARISON OF THE CLINICAL AND COMPUTER ANALYZED EEG EFFECTS OF MESORIDAZINE AND CHLORPROMAZINE.
180064 02-10

INFLUENCES OF RESERPINE AND CHLORPROMAZINE ON THE ANALGESIC AND METABOLIC EFFECTS OF MORPHINE.
180507 02-03

INFLUENCE OF VARIOUS DRUGS ON THE BINDING OF CHLORPROMAZINE TO ERYTHROCYTES AND ALBUMIN.
181470 02-03

L-DOPA AND POTENTIATION OF ALCOHOL ANESTHESIA BY CHLORPROMAZINE.
182091 02-03

STUDIES ON CENTRAL REGULATING MECHANISM OF THE HYPOGLYCEMIA INDUCED BY INTRAVENTRICULAR ADMINISTRATION OF CHLORPROMAZINE.
182093 02-03

PHARMACOLOGY OF MONO AND DISUBSTITUTED CHLORPROMAZINE METABOLITES.
182243 03-03

MODIFICATION OF THE EFFECTS OF CHLORPROMAZINE ON BEHAVIOR IN THE CHIMPANZEE.
183889 03-04

SEIZURE SUSCEPTIBILITY AND AVOIDANCE CONDITIONING IN ADULT RATS TREATED PRENATALLY WITH CHLORPROMAZINE.
184371 03-04

EFFECTS OF CONCURRENT BEHAVIOR MODIFICATION AND CHLORPROMAZINE ADMINISTRATION IN MENTALLY RETARDED WOMEN. (PH.D. DISSERTATION).
185604 03-14

THE EFFECTS OF CHLORPROMAZINE ON A REDEFINED PROCEDURE OF EXTINCTION OF SIDMAN AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
185715 03-14

EFFECTS OF CHLORPROMAZINE AND THREE METABOLITES ON BEHAVIORAL RESPONSES IN RATS.
185748 03-04

CHLORPROMAZINE AND AVOIDANCE: A GENETIC ANALYSIS.
185751 03-03

EFFECTS OF MORPHINE AND CHLORPROMAZINE ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR.
185997 03-04

THE EFFECT OF CHLORPROMAZINE ON HOMOVANILLIC ACID LEVELS IN CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS.
186565 03-08

BIOEQUIVALENCY OF GENERIC AND BRAND-NAMED CHLORPROMAZINE.
187255 03-08

CHLORPROMAZINE INDUCED HYPERPHAGIA. (UNPUBLISHED PAPER).
187498 04-04

A POSSIBLE MECHANISM FOR THE ANTISCHIZOPHRENIC ACTION OF CHLORPROMAZINE: INHIBITION OF THE FORMATION OF DIMETHYLTRYPTAMINE BY CHLORPROMAZINE METABOLITES.
187576 04-03

CHLORPROMAZINE CAUSING EXTRAPYRAMIDAL DYSFUNCTION IN NEWBORN INFANT OF PSYCHOTIC MOTHER.
187787 04-15

ACTIONS OF ATROPINE, HEMICHOLINIUM-3, AND PHYSOSTIGMINE ON CHLORPROMAZINE INDUCED CHANGES IN RAT BRAIN MONOAMINES.
187800 04-03

ENHANCED BINDING OF CHLORPROMAZINE TO CHOLESTEROL DEPLETED SYNAPTOSOME FRACTIONS.
187801 04-03

A NEW PROLONGED ACTING TYPE OF CHLORPROMAZINE: BEHAVIORAL EFFECTS AND PROLONGED ACTIONS ON NERVE MEMBRANES.
187805 04-01

EFFECT OF PROLONGED CHLORPROMAZINE ADMINISTRATION ON THE SLEEP OF CHRONIC SCHIZOPHRENICS.
188115 04-08

EFFECTS OF CHLORPROMAZINE PLASMA LEVELS ON ELECTROCARDIOGRAM.
188838 04-13

INVOLVEMENT OF BRAIN CHOLINERGIC MECHANISMS IN THE ACTION OF CHLORPROMAZINE.
188891 04-03

A STUDY OF BIOGENIC AMINE METABOLITES IN THE CEREBROSPINAL FLUID AND URINE OF MONKEYS WITH CHLORPROMAZINE INDUCED DYSKINESIA.
189210 04-03

THE ACTION OF CHLORPROMAZINE ON EXPLORATION IN PAIRS OF RATS.
189514 04-04

THE LACK OF EFFECTS OF PRETREATMENT WITH PHENOBARBITAL AND CHLORPROMAZINE ON THE ACUTE TOXICITY OF BENZENE IN RATS.
189600 04-05

THE CONTROL OF DEVIANT SEXUAL BEHAVIOR BY DRUGS: A DOUBLE-BLIND CONTROLLED STUDY OF BENPERIDOL, CHLORPROMAZINE, AND PLACEBO.
190061 04-11

A POLAROGRAPHIC METHOD FOR THE DETERMINATION OF THE N-OXIDE, N-OXIDE-SULPHOXIDE AND SULPHOXIDE METABOLITES OF CHLORPROMAZINE.
190902 04-06

THE EFFECT OF CHLORPROMAZINE AND STELAZINE ON LYSOSOMES OF RAT LIVER DURING ACUTE INTOXICATION.
191121 04-03

CHANGES IN ORIENTING AND HABITUATION IN THE RAT FOLLOWING ADMINISTRATION OF CHLORPROMAZINE.
191211 04-04

SERUM TRYPTOPHAN BINDING IN CHLORPROMAZINE TREATED CHRONIC SCHIZOPHRENICS.
191320 04-08

EFFECTS OF D-AMPHETAMINE, MORPHINE AND CHLORPROMAZINE ON RESPONDING UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION OR ELECTRIC SHOCK PRESENTATION.
191767 04-03

THE EFFECT OF CHLORPROMAZINE AND AMYTAL SODIUM ON THE CONFORMITY OF ADOLESCENTS UNDER PSYCHIATRIC OBSERVATION.
191776 04-14

ACTIVATION OF STRIATAL HYDROXYLASE BY HYDROXYLATED METABOLITES OF CHLORPROMAZINE.
191908 04-03

EFFECTS OF CHLORPROMAZINE (CPZ) AND THIORIDAZINE PERFORMANCE AND STIMULUS CONTROL BEHAVIOR.
191974 04-04

CHLORPROMAZINES

SLEEP: A TOOL TO STUDY CHLORPROMAZINES ACTION. (UNPUBLISHED PAPER).
173521 01-14

METAL CHELATION OF CHLORPROMAZINES.
176763 02-06

CHOICE

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON DELAYED MATCHING-TO-SAMPLE CHOICE SPEEDS IN CHIMPANZEES.
171886 01-04

IMPROVING PSYCHIATRIC DRUG THERAPY: A MATTER OF DOSAGE AND CHOICE.
190144 04-17

CHOLESTEROL

ENHANCED BINDING OF CHLORPROMAZINE TO CHOLESTEROL DEPLETED SYNAPTOSOME FRACTIONS.
187801 04-03

CHOLINE

EFFECTS OF FOOD DEPRIVATION, DISCRIMINATION EXPERIENCE AND PHYSOSTIGMINE ON CHOLINE ACETYLASE AND ACETYLCHOLINE ESTERASE IN THE DORSAL HIPPOCAMPUS AND FRONTAL CORTEX OF RATS.
169467 01-03

CHOLINE ACTIVATION OF LITHIUM TRANSPORT.
178812 02-03

CHOLINE ACETYLTRANSFERASE ACTIVITY IN THE CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
180047 02-13

REGIONAL AND SUBCELLULAR DISTRIBUTION OF CHOLINE ACETYLTRANSFERASE IN THE BRAIN OF NORMAL AND MORPHINE TREATED RATS.
182224 03-03

EFFECT OF ACUTE AND CHRONIC MORPHINE ON SPECIFIC RADIOACTIVITIES OF CHOLINE AND ACETYLCHOLINE IN MOUSE BRAIN.
182226 03-03

DRUGS, BEHAVIOR AND CHOLINE ACETYLTRANSFERASE.
182237 03-04

TRANSSYNAPTIC INDUCTION OF CHOLINE ACETYLTRANSFERASE IN THE PREGANGLIONIC NEURON OF THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM.
182720 03-03

EFFECT OF OXOTREMORINE AND PHYSOSTIGMINE ON CHOLINE LEVELS IN MOUSE WHOLE BRAIN, SPLEEN AND CEREBELLUM.
189893 04-03

EFFECT OF DIAZEPAM ON MOUSE WHOLE BRAIN AND BRAIN AREA ACETYLCHOLINE AND CHOLINE LEVELS.
191423 04-03

INHIBITION OF CHOLINE UPTAKE INTO SYNAPTOSOMES BY CHOLINE ANALOGUES.
191999 04-03

ANALOGS OF CHOLINE: SYNAPTOSOMAL METABOLISM.
192000 04-03

INHIBITION IN VIVO OF ACETYLCHOLINE SYNTHESIS IN MOUSE BRAIN BY INHIBITORS OF CHOLINE ACETYLTRANSFERASE.
192001 04-03

CHOLINERGIC

TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER).
170876 01-03

CHOLINERGIC REVERSAL OF MANIC SYMPTOMS: A POSSIBLE EXPLANATION. (UNPUBLISHED PAPER).
173520 01-09

CENTRAL CHOLINERGIC (MUSCARINIC) LINK IN THE ATTACK REFLEXIVE BITING MECHANISM OF CATS.
182238 03-04

CHOLINERGIC MODIFICATION OF NALOXONE INDUCED JUMPING IN MORPHINE DEPENDENT MICE.
184179 03-03

ARE CHOLINERGIC MECHANISMS INVOLVED IN MORPHINE EFFECTS ON MOTILITY
184198 03-03

DOPAMINERGIC HYPERSENSITIVITY AND CHOLINERGIC HYPOFUNCTION IN THE PATHOPHYSIOLOGY OF TARDIVE DYSKINESIA.
185929 03-11

EFFECT OF SEVERAL DOPAMINERGIC DRUGS AND TRIHEXYPHENIDYL ON CHOLINERGIC PARAMETERS IN THE RAT STRIATUM.
185995 03-03

METHYLPHENIDATE ANTAGONISM OF HALOPERIDOL, INTERACTION WITH CHOLINERGIC AND ANTICHOLINERGIC DRUGS.
186370 03-04

ALTERATION OF ETHANOL-INDUCED CNS DEPRESSION: INEFFECTIVENESS OF DRUGS THAT MODIFY CHOLINERGIC TRANSMISSION.
186375 03-03

POSSIBLE PERIPHERAL ADRENERGIC AND CHOLINERGIC MECHANISMS IN PSEUDOCONDITIONING.
186575 03-03

NONCHOLINERGIC MECHANISM OF ACTION OF CHOLINERGIC DRUGS ON SQUID AXON MEMBRANES.
186672 03-03

FEAR REDUCTION IN THE RAT FOLLOWING CENTRAL CHOLINERGIC BLOCKADE.
187703 04-04

ANTISCHIZOPHRENIC DRUGS AND BRAIN CHOLINERGIC RECEPTORS: AFFINITY FOR MUSCARINIC SITES PREDICTS EXTRAPYRAMIDAL EFFECTS.
188114 04-15

INVOLVEMENT OF BRAIN CHOLINERGIC MECHANISMS IN THE ACTION OF CHLORPROMAZINE.
188891 04-03

CHOLINERGIC SUPPRESSION OF TARDIVE DYSKINESIA.
189403 04-11

DOPAMINERGIC INHIBITION OF STRIATAL CHOLINERGIC NEURONS: SYNERGISTIC BLOCKING ACTION OF GAMMA-BUTYROLACTONE AND NEUROLEPTIC DRUGS.
189602 04-03

THE MOTIVATIONAL CONSEQUENCES OF CHOLINERGIC STIMULATION OF THE MEDIAL SEPTAL AREA.
190260 04-04

CHOLINERGIC SUPPRESSION OF TARDIVE DYSKINESIA.
190314 04-13

CHOLINERGIC AND ADRENERGIC BALANCE IN MANIA AND SCHIZOPHRENIA.
191530 04-09

ADRENERGIC AND CHOLINERGIC FACTORS IN EXTRAPYRAMIDAL DISORDERS.
191533 04-11

CHOLINERGIC AMINERGIC INTERACTIONS IN LEAD INDUCED HYPERACTIVITY.
191954 04-05

NEUROPHARMACOLOGICAL ANALYSIS OF CENTRAL ADRENERGIC AND CHOLINERGIC ANTAGONISM OF DELTA9-TETRAHYDROCANNABINOL.
191992 04-03

CHOLINERGICALLY

EVIDENCE FOR CHOLINERGICALLY MEDIATED EFFECT OF METHYLPHENIDATE HYDROCHLORIDE IN THE CENTRAL NERVOUS SYSTEM.
191946 04-03

CHOLINESTERASES

EXCITANT AND DEPRESSANT DRUGS MODULATE EFFECTS OF ENVIRONMENT ON BRAIN WEIGHT AND CHOLINESTERASES.
174036 01-03

CHOLINOLYTIC

THE EFFECT OF SOME CHOLINOLYTIC DRUGS ON A NUMBER OF BEHAVIOURAL PARAMETERS MEASURED IN THE T-MAZE ALTERNATION TEST: DOSE-RESPONSE RELATIONSHIPS.
187641 04-04

CHOLINOMIMETIC

THE EFFECT OF CHOLINOMIMETIC DRUGS ON POTASSIUM TRANSPORT IN RAT CEREBRAL CORTEX.
191411 04-03

THE ANTAGONISM BETWEEN CHOLINOMIMETIC AGONISTS AND BETA-ADRENOCEPTOR STIMULANTS: THE DIFFERENTIATION BETWEEN BETWEEN FUNCTIONAL AND METAFFINOID ANTAGONISM.
191420 04-03

CHOLINOMIMETICS

EFFECTS OF CHOLINOMIMETICS ON ADRENERGIC TRANSMISSION.
182088 02-03

CHORDA
CHLOROFORM RESPONSES OF THE CHORDA TYMPANI NERVE IN THE RAT.
189219 04-03

CHOREA
HUNTINGTONS CHOREA: THE RIGID FORM (WESTPHAL VARIANT) TREATED WITH LEVODOPA.
187618 04-11
HUNTINGTONS CHOREA TREATED WITH LITHIUM CARBONATE.
187985 04-11

CHOROID
THE ELIMINATION OF 5-HYDROXYINDOLEACETIC ACID FROM CEREBROSPINAL FLUID: CHARACTERISTICS OF THE ACID TRANSPORT SYSTEM OF THE CHOROID PLEXUS.
182718 03-03

CHROMAFFIN
INFLUENCE OF DIFFERENT ANIONS ON TYRAMINE AND AMPHETAMINE UPTAKE BY COW ADRENAL MEDULLA CHROMAFFIN VESICLES.
190907 04-03

CHROMATIN
CHROMATIN TEMPLATE ACTIVITY DURING MORPHINE-INDUCED ANALGESIA AND THE DEVELOPMENT OF ANALGESIC TOLERANCE.
182160 02-03

CHROMATOGRAMS
QUANTITATIVE DETERMINATION OF IMIPRAMINE AND DESIPRAMINE IN HUMAN BLOOD PLASMA BY DIRECT DENSITOMETRY OF THIN-LAYER CHROMATOGRAMS.
183603 03-13

CHROMATOGRAPHIC
GAS CHROMATOGRAPHIC - MASS SPECTROMETRIC STUDIES ON TRICYCLIC PSYCHOTROPIC DRUGS.
169073 01-01
A SENSITIVE GAS CHROMATOGRAPHIC PROCEDURE FOR THE ESTIMATION OF NORADRENALINE, DOPAMINE AND 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
171971 01-01
GAS CHROMATOGRAPHIC DETERMINATION OF METHAQUALONE IN SMALL AMOUNTS OF SERUM AFTER INGESTION OF THERAPEUTIC DOSES.
172397 01-16
GAS CHROMATOGRAPHIC ANALYSIS OF BENZODIAZEPINES. PART I: MEDAZEPAM AND ITS METABOLITES.
178948 02-06
A GAS CHROMATOGRAPHIC METHOD FOR THE QUANTITATIVE ESTIMATION OF N-HYDROXYPHENTERMINE.
182203 02-06

CHROMATOGRAPHY
MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC) -- REPORT 1. THIN-LAYER CHROMATOGRAPHY OF HYPNOTICS AND TRANQUILIZERS.
181315 02-16
MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC): REPORT 2 -- ISOLATION AND IDENTIFICATION OF HYPNOTICS AND TRANQUILIZER IN VIVO.
182623 03-06
ISOLATION AND IDENTIFICATION OF HYPNOTICS (8): ISOLATION AND IDENTIFICATION OF BENZALIN AND CERCINE BY THIN-LAYER CHROMATOGRAPHY IN VITRO.
182626 03-01

CHROMOSOME
LSD...AN IN VIVO RETROSPECTIVE CHROMOSOME STUDY.
181811 02-13
CHROMOSOME EXAMINATIONS AFTER MEDICALLY ADMINISTERED LYSERGIC ACID DIETHYLAMIDE AND DEXTROAMPHETAMINE.
192084 04-15

CHROMOSOMES
MUTAGENICITY EXPERIMENTS WITH THE TRANQUILLIZER MEPROBAMATE IN DROSOPHILA-MELANOGASTER AND IN HUMAN LEUKOCYTE CHROMOSOMES IN VITRO.
184585 03-05

CHRONIC
CLORAZEPATE DIPOTASSIUM, DIAZEPAM AND PLACEBO IN CHRONIC ANXIETY.
167339 01-10
EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF CANNABIS-SATIVA EXTRACT ON THE MOUSE-KILLING BEHAVIOR OF RATS.
167362 01-04
EFFECT OF CHRONIC POSTTRIAL SALINE INJECTIONS ON MAZE PERFORMANCE.
167403 01-04
POTENTIATION OF THERAPEUTIC EFFECTS OF NICOTINIC ACID BY PYRIDOXINE IN CHRONIC SCHIZOPHRENICS.
168313 01-08
CLINICAL EVALUATION OF FLUSPIRILENE AS A MAINTENANCE THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS.
168320 01-08
EFFECT OF CHRONIC LITHIUM TREATMENT ON MONOAMINE METABOLISM IN RAT BRAIN.
168839 01-03
CHEMOTHERAPY IN CHRONIC ORGANIC BRAIN SYNDROME - A REVIEW OF THE LITERATURE.
169065 01-11
PSYCHOLOGICAL AND PHYSIOLOGICAL EFFECTS OF CHRONIC MARIJUANA ADMINISTRATION IN MAN.
169070 01-13
ROLE OF FLUPHENAZINE DECANOATE IN LESSENING THE BURDEN OF CHRONIC SCHIZOPHRENICS ON THE COMMUNITY.
169438 01-08
THE EFFECTS OF CHRONIC TREATMENT WITH DELTA9-TETRAHYDROCANNABINOL ON CATECHOLAMINE SYNTHESIS IN THE RAT.
169471 01-03
BLOOD LEVEL PROFILE IN MAN FOLLOWING CHRONIC ORAL ADMINISTRATION OF FLURAZEPAM HYDROCHLORIDE.
169817 01-13
PHARMACOKINETIC PROFILE OF DIAZEPAM IN MAN FOLLOWING SINGLE INTRAVENOUS AND ORAL AND CHRONIC ORAL ADMINISTRATION.
170838 01-13
DIPHENYLHYDANTOIN EFFECTIVENESS IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS: A DOUBLE-BLIND CONTROLLED STUDY WITH A PLACEBO.
171507 01-08
TOLERANCE TO HEXOBARBITAL AND SUPERSENSITIVITY TO PILOCARPINE INDUCED BY CHRONIC BARBITAL TREATMENT IN THE RAT.
171601 01-03
CHRONIC HYPNOTIC DRUG USE: INEFFECTIVENESS, DRUG WITHDRAWAL INSOMNIA, AND DEPENDENCE.
172114 01-15
A DOUBLE-BLIND COMPARISON OF THIORIDAZINE (MELLARIL) VERSUS DIAZEPAM (VALIUM) IN PATIENTS WITH CHRONIC MIXED ANXIETY AND DEPRESSIVE SYMPTOMS.
172486 01-10
A COMPARATIVE TRIAL OF HALOPERIDOL AND THIORIDAZINE: MANAGEMENT OF CHRONIC SCHIZOPHRENIA.
172741 01-08
PHARMACOTHERAPY IN CHRONIC SCHIZOPHRENIA.
172831 01-08
PRELIMINARY STUDY OF THE TREATMENT OF CHRONIC PSYCHOSES WITH FLUPENTHIXOL DECANOATE.
172978 01-09
HIGH AND LOW DOSE THIOTHIXENE TREATMENT IN CHRONIC SCHIZOPHRENIA.
176673 02-08
CLINICAL EXPERIENCES WITH NAVANE IN CHRONIC SCHIZOPHRENIA.
176726 02-08
CLINICAL EXPERIENCES WITH A PSYCHOTROPIC DRUG (OXYPERTINE) IN CHRONIC SCHIZOPHRENIA.
176727 02-08
ACQUISITION AND PERFORMANCE OF AN ATTENTION TASK BY RATS SUBJECTED TO CHRONIC NICOTINE TREATMENT.
176864 02-04
EFFECT OF CHRONIC ADMINISTRATION OF L-DOPA ON CATECHOL-O-METHYLTRANSFERASE IN RAT TISSUES.
176936 02-03
EFFECTS OF CHRONIC PRETREATMENT WITH SMALL DOSES OF RESERPINE UPON ADRENERGIC NERVE FUNCTION.
177406 02-03
REPEATED ACQUISITION OF BEHAVIORAL CHAINS UNDER CHRONIC DRUG CONDITIONS.
177408 02-04
THE EFFECTS OF PHYSOSTIGMINE IN PHENOTHIAZINE RESISTANT CHRONIC SCHIZOPHRENIC PATIENTS: PRELIMINARY OBSERVATIONS.
177669 02-08
PIPERACETAZINE IN AMBULATORY CHRONIC SCHIZOPHRENIC PATIENTS.
177748 02-08
EFFECTS OF AQUEOUS PINEAL EXTRACT IN CHRONIC SCHIZOPHRENIA.
177818 02-08
DREAM REPORTS AFTER RESERPINE ADMINISTRATION IN CHRONIC LOBOTOMIZED SCHIZOPHRENIC PATIENTS.
178187 02-08
PIMOZIDE (R-6238) IN CHRONIC SCHIZOPHRENIA: DOUBLE-BLIND TRIAL.
178255 02-08
SLEEP CHANGES IN CHRONIC SCHIZOPHRENICS: EFFECTS OF 5-HYDROXYTRYPTOPHAN (5-HTP). (UNPUBLISHED PAPER
178578 02-08
CHANGES IN BRAIN ACETYLCHOLINESTERASE ACTIVITY OF YOUNG RATS AFTER CHRONIC TREATMENT WITH TREMORINE.
178814 02-03
BEHAVIORAL EVIDENCE FOR DOPAMINERGIC SUPERSENSITIVITY AFTER CHRONIC HALOPERIDOL.
180021 02-04
EFFECT OF CHRONIC INTOXICATION WITH (..) AMPHETAMINE ON ITS CONCENTRATION IN LIVER AND BRAIN AND ON (14C) LEUCINE

INCORPORATION INTO MICROSOMAL AND CYTOPLASMIC PROTEINS OF RAT LIVER.
180056 02-05

EXPERIENCE GAINED IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PSYCHOSES WITH A THIORIDAZINE DERIVATIVE.
180675 02-08

CHRONIC MEPROBAMATE INTOXICATION AND PHOTOMYOCLONIC RESPONSE.
181377 02-15

COMPARISON OF THE CHRONIC AND ACUTE EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) TREATMENT ON RAT BRAIN SEROTONIN AND NOREPINEPHRINE.
181945 02-03

EFFECT OF ACUTE AND CHRONIC MORPHINE ON SPECIFIC RADIOACTIVITIES OF CHOLINE AND ACETYLCHOLINE IN MOUSE BRAIN.
182226 03-03

STUDIES ON THE EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT ON CATECHOLAMINE LEVELS AND TURNOVER IN DISCRETE BRAIN AREAS OF RATS.
182228 03-03

EFFECTS OF CHRONIC ADMINISTRATION OF AMPHETAMINE UPON THE CATECHOLAMINE CONTENT OF MOUSE BRAIN.
182255 03-03

SIMILARITY OF CHRONIC CHLORDIAZEPOXIDE TREATMENT AND REMOVAL OF CONFLICT SITUATION.
182258 03-04

CLINICAL STUDIES OF ACUTE PSYCHOSIS ON THE BASIS OF CHRONIC HYPNOTICA INTOXICATION -- AN ABSTRACT REPORT.
182755 03-15

THE INFLUENCE OF CHRONIC ADMINISTRATION OF LITHIUM CARBONATE ON THE BRAIN NOREPINEPHRINE CONTENT IN RATS.
182872 03-03

IMPORTANCE OF THE COOPERATION OF FAMILIES IN THE TREATMENT OF THE SICK: CONCERNING CHRONIC DELIRIUM TREATED WITH NEUROLEPTICS AND MELANCHOLY TREATED WITH ANTIDEPRESSANTS.
182899 03-17

CLINICAL OBSERVATIONS ON THE USE OF PIMOZIDE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS.
183196 03-08

EVALUATION OF EEG AND CLINICAL CHANGES ASSOCIATED WITH PAVABID THERAPY IN CHRONIC BRAIN SYNDROME.
183402 03-13

EFFECT OF CHRONIC METHADONE ADMINISTRATION ON PREGNANT RATS AND THEIR OFFSPRING.
183894 03-03

ON THE DYNAMICS AND TREATMENT OF THE TENDENCY OF SCHIZOPHRENIC PSYCHOSIS TO BECOME CHRONIC.
183957 03-08

THE CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES IN THE PLASMA AFTER AN ACUTE AND CHRONIC ADMINISTRATION.
184978 03-13

REDUCED BEHAVIORAL EFFECTS OF PILOCARPINE DURING CHRONIC TREATMENT WITH DFP.
185265 03-04

THE EFFECTS OF CHRONIC TREATMENT WITH D-AMPHETAMINE ON FOOD INTAKE, BODYWEIGHT, LOCOMOTOR ACTIVITY AND SUBCELLULAR DISTRIBUTION OF THE DRUG IN RAT BRAIN.
185931 03-03

A COMPARISON OF THE EFFECTS OF CHRONIC ADMINISTRATION OF ETHANOL AND ACETALDEHYDE TO MICE: EVIDENCE FOR A ROLE OF ACETALDEHYDE IN ETHANOL DEPENDENCE.
185992 03-03

THE ADMINISTRATION OF METHIONINE TO CHRONIC SCHIZOPHRENIC PATIENTS: A REVIEW OF TEN STUDIES.
187113 03-08

BEHAVIOR AND EEG ANALYSIS OF CHRONIC AMPHETAMINE EFFECT.
187116 03-13

THE EFFECTS OF CHRONIC RESERPINE AND NIALAMIDE TREATMENT ON THE FREE AMINO ACID LEVELS OF RAT BRAIN.
187645 04-03

CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE DERIVATIVE SE-780 IN RATS.
187926 04-04

EFFECT OF PROLONGED CHLORPROMAZINE ADMINISTRATION ON THE SLEEP OF CHRONIC SCHIZOPHRENICS.
188115 04-08

PLASMA DOPA AND FUNCTIONAL OSCILLATIONS AFTER CHRONIC TREATMENT OF PARKINSONS DISEASE.
188421 04-13

SENILITY AND CHRONIC MALNUTRITION.
188446 04-11

DOUBLE-BLIND COMPARISON OF THIOTHIXENE, TRIFLUOPERAZINE, AND PLACEBO IN CHRONIC ALCOHOLISM.
188584 04-11

EFFECTS OF CHRONIC EXPOSURE TO DELTA9-TETRAHYDROCANNABINOL ON DELAYED MATCHING-TO-SAMPLE IN CHIMPANZEES.
189405 04-04

CRUDE MARIHUANA EXTRACT: EEG AND BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION IN RHESUS MONKEYS.
189516 04-04

EFFECTS OF CHRONIC NICOTINE ADMINISTRATION AND AGE ON VARIOUS NEUROTRANSMITTERS AND ASSOCIATED ENZYMES IN MALE FISCHER 344 RATS.
189597 04-03

CANNABINOIDS: NEUROCHEMICAL ASPECTS AFTER ORAL CHRONIC ADMINISTRATION TO RATS.
189599 04-03

DRUG MAINTENANCE IN THE OUTPATIENT TREATMENT OF CHRONIC ALCOHOLISM.
189926 04-11

CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE METABOLITE, NORFENFLURAMINE: AN EVALUATION OF ITS ROLE IN THE ACTIONS OF FENFLURAMINE.
190335 04-04

DISSOCIATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN PARKINSONS DISEASE FOLLOWING CHRONIC L-DOPA THERAPY.
191233 04-13

SERUM TRYPTOPHAN BINDING IN CHLORPROMAZINE TREATED CHRONIC SCHIZOPHRENICS.
191320 04-08

EFFECT OF CHRONIC TREATMENT WITH CENTRAL STIMULANTS ON BRAIN MONOAMINES AND SOME BEHAVIOURAL AND PHYSIOLOGICAL FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS.
191503 04-03

EXPERIMENT WITH PENFLURIDOL (TLP-607) ON THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
191593 04-08

EFFECTS OF PHENETHYLAMINE (PEA) IN THE CHRONIC SPINAL DOG.
191904 04-03

LONG-TERM ALTERATION OF SLEEP-WAKEFULNESS CYCLE DURING CHRONIC PENTOBARBITAL DOSING AND WITHDRAWAL IN CAT.
191952 04-04

STUDIES OF THE IMMUNE RESPONSE IN CHRONIC MARIHUANA SMOKERS.
191961 04-13

SUBCELLULAR LOCALIZATION OF H3-DELTA9-TETRAHYDROCANNABINOL IN DOG BRAIN AFTER ACUTE OR CHRONIC ADMINISTRATION.
191970 04-03

EFFECT OF CHRONIC TREATMENT WITH DESIPRAMINE (DMI) AND IPRINDOLE (IP) ON THE NOREPINEPHRINE (NE) SENSITIVE ADENYLATE CYCLASE SYSTEM IN SLICES OF THE RAT LIMBIC FOREBRAIN.
192003 04-03

SUPERSENSITIVITY TO DOPAMINERGIC AGONISTS FOLLOWING WITHDRAWAL OF A CHRONIC DIET CONTAINING HALOPERIDOL OR PIMOZIDE.
192012 04-04

EFFECTS OF CHRONIC METHYLPHENIDATE ADMINISTRATION ON LEARNING AND OFFSPRING BEHAVIOR.
192116 04-04

CONDITIONING IN THE PREDICTION OF DRUG WITHDRAWAL EFFECTS IN CHRONIC SCHIZOPHRENIC PATIENTS.
192412 04-17

CHRONICALLY

END OF A BACK WARD: THE RAPID REHABILITATION AND RELEASE OF CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS.
181153 02-08

EFFECTS OF CHRONICALLY ADMINISTERED DELTA1-TETRAHYDROCANNABINOL OF ADRENAL AND GONADAL ACTIVITY OF MALE RATS.
183358 03-03

CATALEPSY AND STEREOTYPED BEHAVIOUR IN RATS TREATED CHRONICALLY WITH METHADONE: RELATION TO BRAIN HOMOVANILLIC ACID CONTENT.
183606 03-04

TOLERANCE TO THE BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF HALOPERIDOL AND MORPHINE IN RATS CHRONICALLY TREATED WITH MORPHINE OR HALOPERIDOL.
184225 03-03

CHRONOPHARMACOLOGY

CHRONOPHARMACOLOGY OF DELTA9-TETRAHYDROCANNABINOL HYPOTHERMIA IN MICE.
176880 02-03

CHRONOTROPIC

MECHANISM OF THE NEGATIVE CHRONOTROPIC AND INOTROPIC EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC).
182219 03-03

CI-683

PYRAZAPON (CI-683): A NEW ANTIANXIETY AGENT.
186581 03-04

CI-686

PREDICTION OF NEUROLEPTIC EFFECTS OF CI-686 BASED ON QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY: DRUG PROFILES AND DOSE RESPONSE CURVES BASED ON COMPUTERIZED CEREBRAL BIOPOTENTIALS.
181958 02-13

CIBA-34276-BA
A DOUBLE-BLIND, COMPARATIVE CLINICAL TRIAL WITH LUDIOMIL (CIBA-34276-BA) AND AMITRIPTYLINE IN NEWLY ADMITTED DEPRESSED PATIENTS.
167774 01-09

CIGARETTE
THE EFFECT OF CAFFEINE, NITRAZEPAM AND CIGARETTE SMOKING ON THE CONTINGENT NEGATIVE VARIATION IN MAN.
187350 04-13

CINANSERIN
ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN DIMETHYLAMINOPROPYLTHIOCINNAMANILIDE HYDROCHLORIDE), A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN (5-HTP) AND ALPHA-METHYLTRYPTAMINE.
176861 02-04
ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN, A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN AND ALPHA-METHYLTRYPTAMINE.
176873 02-04

CINNAMIDES
SYNTHESIS OF SUBSTITUTED CINNAMIDES: RELATIONSHIP BETWEEN ANTICONVULSANT AND MONOAMINE OXIDASE INHIBITORY PROPERTIES.
169818 01-01

CIRCADIAN
ONTOGENESIS OF CIRCADIAN PITUITARY ADRENAL PERIODICITY IN RATS AFFECTED BY NEONATAL TREATMENT WITH ACTH.
181576 02-03

CIRCLING
A COMPARISON OF EFFECTS OF APOMORPHINE AND ET-495 ON LOCOMOTOR ACTIVITY AND CIRCLING BEHAVIOUR IN MICE.
186635 03-04

CIRCULAR
THE INFLUENCE OF 3-QUINUCLIDINYLBENZILATE ON THE BEHAVIOUR OF RATS IN A CIRCULAR RUNWAY.
187259 04-04
INFLUENCE OF PH ON THE BENZODIAZEPINE HUMAN SERUM ALBUMIN COMPLEX: CIRCULAR DICHROISM STUDIES.
189595 04-13

CIRCULATION
EXPERIENCE IN THE TREATMENT OF CEREBRAL INSUFFICIENCY AND PERIPHERAL BLOOD CIRCULATION DISORDERS USING THE EP-50-100 EXPERIMENTAL DRUG.
180676 02-11
PHARMACOLOGICAL ANALYSIS OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE REMOVAL FROM THE PULMONARY CIRCULATION: DIFFERENTIATION OF UPTAKE SITES FOR EACH AMINE.
182717 03-03

CIRCULATORY
DIFFERENTIAL CIRCULATORY EFFECTS OF VARIOUS ANOREXIGENIC DRUGS.
182214 03-03

CITRATE
PLASMA LEVELS OF LUTEINIZING HORMONE AND OF IMMUNOREACTIVE ESTROGENS (ESTRADIOL) IN ANOREXIA-NERVOSA: RESPONSE TO CLOMIPHENE CITRATE.
183807 03-10

CL-1848C
OPERANT BEHAVIOR AND NEUROPHYSIOLOGICAL OBSERVATIONS OF NORMAL HUMAN VOLUNTEERS RECEIVING CL-1848C, A NEW DISSOCIATIVE ANESTHETIC.
167334 01-07

CLAMP
VOLTAGE CLAMP ANALYSIS OF PENTYLENETETRAZOL EFFECTS ON APLYSIA NEURONS.
189032 04-03

CLASS
REHABILITATION OF LEARNING IN A HOSPITAL CLASS USING PSYCHOACTIVE DRUGS.
174071 01-11

CLASSES
SPECIFIC INDICATIONS FOR DIFFERENT CLASSES OF PHENOTHIAZINES.
171505 01-08

CLASSICAL
THE CURARIZED RAT AND HEART RATE CONDITIONING: A CONSIDERATION OF RESPIRATION PARAMETERS AND NEUROMUSCULAR BLOCKING AGENTS IN A CLASSICAL CONDITIONING PARADIGM. (PH.D. DISSERTATION).
173133 01-03

CLASSIFICATION
CLASSIFICATION AND INDICATION OF ANTIANXIETY AGENTS IN CLINICAL PRACTICE.
184845 03-10
CLASSIFICATION OF DRUGS ACCORDING TO THEIR DISCRIMINABLE EFFECTS IN RATS.
188228 04-06

CLEARANCE
ABSORPTION AND CLEARANCE OF SECOBARBITAL, HEPTABARBITAL, METHAQUALONE, AND ETHINAMATE.
192575 04-13

CLINIC
A PSYCHIATRIC CLINIC FOR DEPOT PHENOTHIAZINES.
181192 02-08
A CLINICAL STUDY OF L-TETRAHYDROPALMATINE (C-200) IN A NEUROPSYCHIATRIC CLINIC.
182902 03-09

CLINICAL
DOUBLE-BLIND CLINICAL EVALUATION OF MAZINDOL, DEXTROAMPHETAMINE, AND PLACEBO IN TREATMENT OF EXOGENOUS OBESITY.
167335 01-11
CLINICAL EXPERIMENTATION WITH A NEW BENZODIAZEPINE IN THE MANAGEMENT OF PHOBIC AND OBSESSIVE SYMPTOMS.
167594 01-10
A DOUBLE-BLIND, COMPARATIVE CLINICAL TRIAL WITH LUDIOMIL (CIBA-34276-BA) AND AMITRIPTYLINE IN NEWLY ADMITTED DEPRESSED PATIENTS.
167774 01-09
CLINICAL EFFECTS OF LITHIUM CARBONATE ON DEPRESSION.
167917 01-09
CLINICAL EVALUATION OF FLUSPIRILENE AS A MAINTENANCE THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS.
168320 01-08
CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG, TRAZODONE: A REVIEW OF LITERATURE.
168803 01-11
SYSTEMATIC CLINICAL STUDIES WITH TRAZODONE: METHODOLOGICAL ASPECTS.
168804 01-16
A STUDY OF THE CLINICAL EFFECTS OF PHENELZINE AND PLACEBO IN THE TREATMENT OF PHOBIC ANXIETY.
168832 01-10
CLINICAL AND ELECTROMYOGRAPHIC RESEARCH CONCERNING TREATMENT OF PERIPHERAL NEUROPATHIES WITH NIVALASI.
168975 01-13
MASS FRAGMENTOGRAPHY IN CLINICAL PSYCHOPHARMACOLOGY.
169074 01-01
MARIHUANA USE IN MAN: AN EXPERIMENTAL INQUIRY -- CLINICAL PSYCHIATRIC IMPRESSIONS.
169085 01-14
LORAZEPAM: CLINICAL TRIAL WITH A NEW BENZODIAZEPINE.
169297 01-07
CLINICAL TRIAL WITH DARTALANR, DJAKARTA, INDONESIA.
170753 01-11
CLINICAL RESEARCH ASPECTS OF PSYCHOTROPIC MEDICATION.
170754 01-17
A CLINICAL EXPERIMENT WITH SULPIRIDE.
171122 01-11
CLINICAL TRIAL OF TRIFLUOPERAZINE (STELAZINE R) ON INDONESIAN PSYCHIATRIC PATIENTS.
171161 01-09
A DOUBLE-BLIND CLINICAL TRIAL OF DOXEPIN HYDROCHLORIDE AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION IN THE FIELD OF INTERNAL MEDICINE.
171282 01-11
IS THERE A RELATIONSHIP BETWEEN THE INVOLVEMENT OF EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS WITH THE CATALEPTIC ACTION OF NEUROLEPTIC AGENTS AND THEIR CLINICAL ANTIPSYCHOTIC EFFECT?
171305 01-03
DIAZEPAM IN LABOUR: ITS METABOLISM AND EFFECT ON THE CLINICAL CONDITION AND THERMOGENESIS OF THE NEWBORN.
171731 01-13
PLASMA BINDING OF IMIPRAMINE AND CLINICAL OUTCOME.
172271 01-13
ONE YEAR OF CLINICAL EXPERIENCE WITH LARGE DOSES OF 10 PERCENT FLUPENTHIXOL DECANOATE (LU-1705).
172735 01-07
CLINICAL EXPERIENCE WITH MELITHRACENE IN THE TREATMENT OF DEPRESSIVE STATES.
172979 01-09
CLINICAL STUDY OF THIOTHIXENE.
173563 01-08
PILOT CLINICAL TRIAL OF PARENTERAL LORAZEPAM (TEMESTA) IN ANXIETY STATES.
174044 01-11
CLINICAL FACTORS IN LITHIUM CARBONATE PROPHYLAXIS FAILURE.
174093 01-09
LONG-TERM CLINICAL AND QUANTITATIVE EEG EFFECTS OF CLOPENTHIXOL IN SCHIZOPHRENICS: CLINICAL NEUROPHYSIOLOGICAL CORRELATIONS.
174131 01-08
CLINICAL RESULTS WITH PIZOTYLINE IN DEPRESSION.
174299 01-09

TRIFLUPERIDOL -- A CONTROLLED CLINICAL TRIAL ON A GROUP OF SCHIZOPHRENIC PATIENTS.
174587 01-08

CLINICAL EXPERIENCES WITH FK-880 (SULPIRIDE).
174681 01-08

LONG-TERM USE OF LITHIUM CARBONATE IN AFFECTIVE DISORDERS: A CLINICAL EVALUATION.
174778 01-09

THE DOCUMENTATION OF CLINICAL PSYCHOTROPIC DRUG TRIALS.
175332 02-16

GENERAL PRACTITIONER CLINICAL TRIALS. A LONG-ACTING AMITRIPTYLINE PREPARATION.
175583 02-09

CLINICAL USE OF PSYCHOTHERAPEUTIC DRUGS.
175914 02-17

CLINICAL TRIAL OF PERAZINE (TAXILAN) IN TREATMENT OF SCHIZOPHRENIA.
176446 02-08

CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, ZISEPRON, IN TREATMENT OF PSYCHIATRIC DISEASES IN COMPARISON WITH THIORIDAZINE.
176467 02-08

CLINICAL EFFECTS OF DICEPLON, A PSYCHOTROPIC DRUG.
176470 02-08

CLINICAL PHARMACOLOGICAL STUDY OF BROMAZEPAM IN THE FIELD OF INTERNAL MEDICINE.
176473 02-10

CLINICAL APPLICATION OF APY-606.
176541 02-08

CLINICAL EXPERIENCES WITH A NEW PSYCHOTROPIC DRUG, R-6238 (PIMOZIDE).
176564 02-11

CLINICAL EXPERIENCES WITH AN ANTIDEPRESSIVE DRUG, NORITREN (NORTRIPTYLINE).
176565 02-09

CLINICAL TRIAL WITH NOZINAN-R. AT SEVERAL MENTAL HOSPITALS IN JAVA.
176582 02-11

CLINICAL STUDY OF DP-181 (OXYPERTINE).
176722 02-08

CLINICAL EXPERIENCES WITH NAVANE IN CHRONIC SCHIZOPHRENIA.
176726 02-08

CLINICAL EXPERIENCES WITH A PSYCHOTROPIC DRUG (OXYPERTINE) IN CHRONIC SCHIZOPHRENIA.
176727 02-08

CONTROL OF THE HYPERACTIVE CHILD VIA MEDICATION -- AT WHAT COST TO PERSONALITY DEVELOPMENT; SOME PSYCHOLOGICAL IMPLICATIONS AND CLINICAL INTERVENTIONS.
176810 02-11

ANTIDEPRESSANT EFFECTS OF D-CHLORPHENIRAMINE -- CLINICAL EVALUATION (FIRST REPORT).
176889 02-09

CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, DOXEPIN HYDROCHLORIDE, IN THE TREATMENT OF DEPRESSIVE STATES.
177569 02-11

CLINICAL EXPERIENCE WITH FLUPHENAZINE ENANTHATE.
178021 02-08

CLINICAL EXPERIENCES WITH FLUPENTHIXOL (FX-703).
178224 02-08

COMPARISON OF THE CLINICAL AND COMPUTER ANALYZED EEG EFFECTS OF MESORIDAZINE AND CHLORPROMAZINE.
180064 02-10

RESULTS OF CLINICAL RESEARCH IN PSYCHOTHERAPY WITH HALLUCINOGENS.
180145 02-12

THE DOCUMENTATION OF CLINICAL PSYCHOTROPIC DRUG TRIALS: SAMPLE OUTPUT PACKAGE.
180256 02-16

LITHIUM DISTRIBUTION BETWEEN CEREBROSPINAL FLUID AND SERUM OF AFFECTIVE PSYCHOTIC PATIENTS TREATED WITH LITHIUM CARBONATE AND ITS CLINICAL RESPONSE.
180301 02-11

A CLINICAL EVALUATION OF A NEW ANXIOLYTIC DRUG (THIENODIAZEPINE DERIVATIVE Y-6047) IN NEUROTICS AND PSYCHOSOMATIC DISORDERS -- A PRELIMINARY REPORT.
181771 02-07

LITHIUM TREATMENT OF PSYCHOTIC CHILDREN. A CONTROLLED CLINICAL TRIAL.
182434 03-09

RUBIDIUM SALTS -- TOXIC EFFECTS IN HUMANS AND CLINICAL EFFECTS AS AN ANTIDEPRESSANT DRUG.
182443 03-09

CLINICAL STUDY OF ANTIDEPRESSANT AGENT, NOVERIL.
182551 03-10

CLINICAL STUDY OF TRANQUILIZERS.
182574 03-17

CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG: FK-880 (SULPIRIDE), ITS EFFECT ON PATIENTS WITH PSYCHOSOMATIC DISEASES AND PSYCHONEUROSIS.
182731 03-10

CLINICAL PHARMACOLOGY OF CANNABIS.
182741 03-14

CLINICAL STUDIES OF ACUTE PSYCHOSIS ON THE BASIS OF CHRONIC HYPNOTICA INTOXICATION -- AN ABSTRACT REPORT.
182755 03-15

A MULTICENTRE CLINICAL TRIAL OF OXYPERTINE IN ANXIETY NEUROSIS.
182769 03-10

CLINICAL DATA AND SOCIOPSYCHIATRIC IMPLICATIONS OF OUTPATIENT TREATMENT WITH LONG-TERM PHENOTHIAZINES.
182791 03-09

SOMNAMBULISM IN CHILDREN -- CLINICAL COMMUNICATION.
182870 03-17

A CLINICAL STUDY OF L-TETRAHYDROPALMATINE (C-200) IN A NEUROPSYCHIATRIC CLINIC.
182902 03-09

DOUBLE-BLIND CLINICAL TRIAL OF NOVERIL AND OF NOVERIL-TR (NOVERIL 240MG).
183190 03-07

CLINICAL OBSERVATIONS ON THE USE OF PIMOZIDE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS.
183196 03-08

CLINICAL EXPERIMENT WITH A LONG-ACTING NEUROLEPTIC: FLUSPIRILENE (R6218).
183200 03-15

CLINICAL ASSAY OF LORAZEPAM WITH AMBULANT PATIENTS.
183201 03-11

EVALUATION OF EEG AND CLINICAL CHANGES ASSOCIATED WITH PAVABID THERAPY IN CHRONIC BRAIN SYNDROME.
183402 03-13

A SUMMARY OF THE CLINICAL DOSSIER ON DEPAMIDE.
183544 03-17

CLINICAL STUDY ON THE EFFECTS OF THIOTHIXENE IN HOSPITALIZED PSYCHOTIC PATIENTS.
183955 03-08

CLASSIFICATION AND INDICATION OF ANTIANXIETY AGENTS IN CLINICAL PRACTICE.
184845 03-10

ON THE CLINICAL EFFECT OF FLUPHENAZINE ENANTHATE IN OUTPATIENT SCHIZOPHRENICS.
185213 03-08

CLINICAL EVALUATION OF ANXIOLYTIC DRUGS.
185350 03-17

L-TRYPTOPHAN IN AFFECTIVE DISORDERS: INDOLEAMINE CHANGES AND DIFFERENTIAL CLINICAL EFFECTS.
185928 03-09

THE CLINICAL EFFECTIVENESS OF LITHIUM: COMPARISONS WITH OTHER DRUGS.
186189 03-09

CLINICAL PHARMACOLOGY AS AN APPROACH TO THE STUDY OF BIOCHEMICAL SLEEP MECHANISMS: THE ACTION OF L-DOPA.
186643 03-14

INSTITUTE OF PSYCHIATRY CLINICAL PSYCHOPHARMACOLOGY RESEARCH TEAM.
187022 03-17

THE PROBLEMS OF THE CLINICAL USAGE OF NITRAZEPAM: SUPPRESSIVE EFFECTS ON THE PHARYNGEAL REFLEX AND THE COMA, USING OTHER TRANQUILIZERS AT THE SAME TIME.
188450 04-15

ON-OFF PHENOMENON WITH LEVODOPA THERAPY IN PARKINSONISM: CLINICAL AND PHARMACOLOGIC CORRELATIONS AND THE EFFECT OF INTRAMUSCULAR PYRIDOXINE.
188560 04-11

CLINICAL EXPERIENCES WITH A NEW ANTIDEPRESSANT, MAPROTILINE.
188893 04-09

CLINICAL EXPERIENCES WITH MESORIDAZINE (TPS-23): ITS ADMINISTRATION TO HOSPITALIZED SCHIZOPHRENIC PATIENTS.
188934 04-08

CLINICAL EVALUATION OF AMANTADINE THERAPY FOR PARKINSONISM AND THE SIDE-EFFECTS -- IN CASES OF THALAMIC SURGERY AND L-DOPA THERAPY.
190095 04-11

CLINICAL STUDIES OF DOPAMINERGIC MECHANISMS.
191524 04-13

CLINICAL INTIMATIONS OF AMINE BALANCE AND PERMISSION.
191534 04-09

CLINICAL EXPERIENCE WITH DIAMORPHINE IN ADVANCED MALIGNANT DISEASE.
191606 04-17

CLINICAL EFFECTS OF IMIPRAMINE-N-OXIDE ON DEPRESSION.
191716 04-09

CLINICAL USE OF LUVATREN (METHYLPERIDOL) FOR THE TREATMENT OF SCHIZOPHRENIA.
191720 04-08

CLINICAL EFFECTS OF MARIHUANA SECOBARBITAL COMBINATION.
191989 04-14

CLINICAL EFFECTS OF MARIHUANA DEXTROAMPHETAMINE COMBINATION.
191990 04-14

THE TRANYLCYPROMINE ISOMERS: A CONTROLLED CLINICAL TRIAL.
192065 04-13

HALOPERIDOL VERSUS THIORIDAZINE FOR THE TREATMENT OF PSYCHOGERIATRIC PATIENTS: A DOUBLE-BLIND CLINICAL STUDY.
192231 04-09

CORRELATION OF PHARMACOLOGICAL INVESTIGATIONS WITH THE CLINICAL EFFICACY OF ANTIDEPRESSANT DRUGS.
192420 04-13

LABORATORY ASSESSMENTS OF ANTIDEPRESSIVE ACTIVITY -- THEIR VALUE FOR CLINICAL PSYCHIATRY AND THE UNDERSTANDING OF DEPRESSION.
192422 04-09

PLASMA NORTRIPTYLINE LEVELS -- RELATIONSHIP TO CLINICAL EFFECTS.
192873 04-09

CLINICALLY

A COMPARISON OF CLINICALLY USED PSYCHOACTIVE DRUGS IN FOUR LATIN-AMERICAN COUNTRIES AND IN CANADA (ARGENTINA, COSTA-RICA, MEXICO AND PANAMA).
191139 04-17

CLOMIPHENE

PLASMA LEVELS OF LUTEINIZING HORMONE AND OF IMMUNOREACTIVE ESTROGENS (ESTRADIOL) IN ANOREXIA-NERVOSA: RESPONSE TO CLOMIPHENE CITRATE.
183807 03-10

CLOMIPRAMINE

DEPRESSIVE FORMS OF SCHIZOPHRENIA AND EXPERIMENTAL TREATMENT BY CLOMIPRAMINE.
167676 01-08

CLOMIPRAMINE HCL -- A DOUBLE-BLIND STUDY OF A NEW ANTIDEPRESSANT DRUG.
168318 01-09

EXPERIENCE IN THE USE OF AN ANTIDEPRESSIVE, CLOMIPRAMINE (ANAFRANIL), IN PSYCHIATRIC OUTPATIENTS.
176475 02-09

CLOMIPRAMINE AND AMITRIPTYLINE IN DEPRESSED OUTPATIENTS: A CONTROLLED STUDY.
185747 03-09

CLONAZEPAM

ANTICONVULSANT ACTIVITY OF CLONAZEPAM AND RO-8-4192 AGAINST PENICILLIN AND LIDOCAINE INDUCED SEIZURES.
178947 02-03

PHARMACOLOGY AND TOXICOLOGY OF THE ANTIEPILEPTIC DRUG CLONAZEPAM.
179021 02-05

INVESTIGATIONS ON THE FATE OF THE ANTICONVULSANT CLONAZEPAM IN THE ORGANISM OF MAN, RAT AND DOG.
179022 02-13

FIRST RESULTS OBTAINED WITH A NEW ANTICONVULSANT OF THE BENZODIAZEPINE SERIES (CLONAZEPAM).
180672 02-11

CLONIDINE

EFFECTS OF PHENOXYBENZAMINE, ACEPERONE AND CLONIDINE ON THE LEVEL OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL, (MOPEG) IN RAT BRAIN.
180059 02-03

INVOLVEMENT OF ALPHA-RECEPTORS IN CLONIDINE INDUCED INHIBITION OF TRANSMITTER RELEASE FROM CENTRAL MONOAMINE NEURONES.
182345 03-03

EFFECTS OF CLONIDINE AND SOME ALPHA-ADRENORECEPTOR BLOCKING AGENTS ON AVOIDANCE CONDITIONED REFLEXES IN RATS: THEIR INTERACTIONS AND ANTAGONISM BY ATROPINE.
186576 03-04

NORADRENERGIC REGULATION OF BRAIN SEROTONERGIC NEURONS: EVIDENCE FROM SINGLE UNIT STUDIES WITH CLONIDINE.
191948 04-03

CLOPENTHIXOL

LONG-TERM CLINICAL AND QUANTITATIVE EEG EFFECTS OF CLOPENTHIXOL IN SCHIZOPHRENICS: CLINICAL NEUROPHYSIOLOGICAL CORRELATIONS.
174131 01-08

OBSERVATIONS ON THE THERAPEUTIC ACTIVITY OF CLOPENTHIXOL IN PSYCHIATRY.
175540 02-11

COMPARISON OF CLOPENTHIXOL AND PERPHENAZINE IN BEHAVIOR AND EEG OF UNANESTHETIZED CATS.
181386 02-04

CLORAZEPATE

CLORAZEPATE DIPOTASSIUM, DIAZEPAM AND PLACEBO IN CHRONIC ANXIETY.
167339 01-10

COMPARISON OF ANTICONVULSANT EFFECTS OF CLORAZEPATE DIPOTASSIUM AND DIAZEPAM: FOUR WEEK ANTICONVULSANT STUDY IN RHESUS MONKEYS.
176677 02-03

CLOZAPINE

LONG-TERM APPLICATION OF CLOZAPINE (W-801) IN SCHIZOPHRENIC PATIENTS.
174680 01-08

A DOUBLE-BLIND COMPARISON OF CLOZAPINE WITH THIORIDAZINE ON SCHIZOPHRENIA.
175119 02-08

EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF CLOZAPINE ON THE METABOLISM OF DOPAMINE AND NORADRENALINE IN THE BRAIN OF THE RAT.
191418 04-03

CNS

EFFECTS OF MOLINDONE ON CNS STRUCTURES: NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATIONS.
172749 01-03

CNS DEPRESSION IN THE ABSENCE OF PROLACTIN RELEASE FOLLOWING INTRAARTERIAL INJECTIONS OF SODIUM PENTOTHAL IN THE PROESTROUS RAT.
173257 01-03

1-AMINOTETRALINES -- CNS AGENTS AND ALPHA-BLOCKERS.
175762 02-17

ULTRASTRUCTURE OF CNS IN LITHIUM INTOXICATION.
176476 02-05

A METHOD FOR ANALYZING CNS EFFECTS OF DRUGS AND BRAIN LESIONS ON PERMANENT GROUPS OF RATS.
176867 02-06

EFFECTS OF LORAZEPAM ON CNS STRUCTURES: NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATIONS.
177749 02-03

EEG CHARACTERISTICS IN VARIOUS SPECIES OF ANIMAL AND THEIR RELATION TO THE CNS EFFECTS OF DRUGS.
182096 02-03

EFFECTS OF CNS STIMULANTS ON OPERANT BEHAVIOR.
182110 02-04

EFFECT OF MORPHINE, HALOPERIDOL, APOMORPHINE AND BENZTROPINE ON DOPAMINE TURNOVER IN RAT CORPUS-STRIATUM: EVIDENCE SHOWING MORPHINE-INDUCED REDUCTION IN CNS DOPAMINERGIC ACTIVITY.
182230 03-03

A NOVEL SPASMOLYTIC AND CNS ACTIVE AGENT: 3-(2-BENZYLMETHYLAMINOETHYL) BENZOIC ACID METHYL ESTER HYDROCHLORIDE.
184581 03-02

SYNTHESIS AND CNS ACTIVITY OF 3-SUBSTITUTED 7-CHLORO-5-PHENYLBENZOTRIAZEPIN-2-ONES.
185978 03-01

ALTERATION OF ETHANOL-INDUCED CNS DEPRESSION: INEFFECTIVENESS OF DRUGS THAT MODIFY CHOLINERGIC TRANSMISSION.
186375 03-03

THE ISOLATED PERFUSED RAT BRAIN AS A MODEL FOR STUDYING DRUGS ACTING ON THE CNS.
186589 03-06

TIME SAMPLING OF RAT EXPLORATORY BEHAVIOUR: A RELIABLE SCREENING TEST FOR THE CNS EFFECTS OF ANOREXIC AGENTS.
187925 04-04

EFFECTS OF DOPAMINE-LIKE DRUGS ON RAT STRIATAL ADENYL CYCLASE HAVE IMPLICATIONS FOR CNS DOPAMINE RECEPTOR TOPOGRAPHY.
190545 04-03

EFFECTS OF CNS AGENTS ON NICOTINE EXTENSOR CONVULSIONS AND LETHALITY IN MICE AND THEIR SEDATIVE ANTIANXIETY EFFECTS IN MAN.
191907 04-14

THE LOCALIZATION AND CHARACTERIZATION OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE ACTIVITY IN SPECIFIC REGIONS OF THE CNS.
191932 04-03

COMPARATIVE EFFECTS OF SOME CNS ACTIVE DRUGS ON LEARNED AND UNLEARNED BEHAVIOR IN THE HAMSTER.
191976 04-04

CO-MEDICATION

A CASE OF PERIODIC SOMNOLENCE IMPROVED BY THE CO-MEDICATION OF L-DOPA AND METHYLPHENIDATE.
185241 03-14

CO-NEUROTRANSMITTER

THE BIOSYNTHESIS OF THE CO-NEUROTRANSMITTER OCTOPAMINE IN COMPARISON WITH THE NEUROTRANSMITTER NORADRENALINE.
181468 02-03

COBALT

DIFFERENTIAL EFFECTS OF PENTYLENETETRAZOL ON REM SLEEP IN NAIVE AND COBALT EPILEPTIC RATS.
189407 04-03

COCAINE

THE UPTAKE, RETENTION AND METABOLISM OF 3H-5-HYDROXYTRYPTAMINE IN BRAIN SLICES AND ILEUM FROM THE RAT: EFFECTS OF COCAINE, DESMETHYLIMIPRAMINE AND RESERPINE. (PH.D. DISSERTATION).
168131 01-03

IN VIVO INHIBITION OF NEURONAL UPTAKE OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY COCAINE AND BY DESMETHYLIMIPRAMINE (DMI).
182150 02-03

THE EFFECTS OF COCAINE ON DEPRESSED PATIENTS.
184160 03-09

COCAINE, PEMOLINE AND AMPHETAMINE ON LEARNING AND RETENTION OF A DISCRIMINATION TEST IN MICE.
186705 03-04

THE EFFECT OF ORALLY ADMINISTERED COCAINE ON SLEEP OF DEPRESSED PATIENTS.
187642 04-14

THE EFFECTS OF CHLORDIAZEPOXIDE, AMPHETAMINE AND COCAINE ON BAR-PRESS BEHAVIOR IN NORMAL AND GENETICALLY NERVOUS DOGS.
187868 04-04

BEHAVIORAL EFFECTS OF COCAINE COMPARED UNDER TWO SCHEDULES OF FOOD PRESENTATION IN THE SQUIRREL MONKEY.
191916 04-04

CODEINE

EFFECTS OF MORPHINE, CODEINE AND NALOXONE ON FOOD AND CODEINE REINFORCED RESPONDING IN THE RHESUS MONKEY.
182195 02-04

EFFECTS OF DIAZEPAM AND CODEINE, ALONE AND IN COMBINATION WITH ALCOHOL, ON SIMULATED DRIVING.
189619 04-14

COMPARISON OF CODEINE AND ETHYL ALCOHOL SELF-ADMINISTRATION UNDER A VARIABLE INTERVAL (VI) SCHEDULE IN MONKEYS.
191983 04-04

COEXISTENCE

ON THE COEXISTENCE OF PARKINSONISM AND TARDIVE DYSKINESIA.
190380 04-11

COFACTORS

DRUG-INDUCED ACTIVATION OF STRIATAL TYROSINE HYDROXYLASE: CHANGES IN THE AFFINITY FOR PTERIDINE COFACTORS. (UNPUBLISHED PAPER).
173381 01-03

COGNITIVE

THE EFFECT OF MEDAZEPAM AND ALCOHOL ON COGNITIVE AND MOTOR SKILLS USED IN CAR DRIVING.
189408 04-14

COLLABORATIVE

A COLLABORATIVE ASSESSMENT OF NOREPINEPHRINE METABOLISM IN AFFECTIVE DISORDERS.
169094 01-09

DEPRESSION SUBTYPES AND RESPONSE TO PHENELZINE, DIAZEPAM, AND A PLACEBO: RESULTS OF A NINE HOSPITAL COLLABORATIVE STUDY.
171502 01-09

PROPHYLACTIC TREATMENT OF RECURRENT DEPRESSION: OBSERVATIONS FROM A MULTIHOSPITAL COLLABORATIVE STUDY.
186190 03-09

PROPHYLACTIC EFFICACY OF LITHIUM CARBONATE IN MANIC-DEPRESSIVE ILLNESS: REPORT OF THE VETERANS ADMINISTRATION AND NATIONAL INSTITUTE OF MENTAL HEALTH (VA-NIMH) COLLABORATIVE STUDY GROUP.
189735 04-09

LITHIUM IN TREATMENT AND PREVENTION OF AFFECTIVE DISORDER: A VA-NIMH COLLABORATIVE STUDY.
190381 04-09

COLORIMETRIC

STUDIES ON METABOLISM OF BROMAZEPAM (II): COLORIMETRIC DETERMINATION AND METABOLIC FATE OF BROMAZEPAM IN ANIMALS.
181593 02-03

COMA

THE PROBLEMS OF THE CLINICAL USAGE OF NITRAZEPAM: SUPPRESSIVE EFFECTS ON THE PHARYNGEAL REFLEX AND THE COMA, USING OTHER TRANQUILIZERS AT THE SAME TIME.
188450 04-15

COMAS

TREATMENT OF HALLUCINATORY DISORDERS IN SCHIZOPHRENIA BY ATROPINE COMAS.
181778 02-08

COMBINATION

PSYCHOPATHOLOGICAL IMPORTANCE AND THERAPEUTIC EFFECTS OF A COMBINATION OF HYDERGINE AND THIORIDAZINE IN PSYCHIATRIC SYNDROMES IN THE AGING.
168976 01-14

COMBINATION OF L-DOPA, DESIPRAMINE, AND A DECARBOXYLASE INHIBITOR IN THE TREATMENT OF DEPRESSION.
169468 01-09

POSSIBLE MUTUAL THERAPEUTIC COMBINATION OF PSYCHOPHARMACEUTICALS.
178029 02-17

EFFECT OF A CARNITINE CYPROHEPTADINE COMBINATION ON ANOREXIA AND WEIGHT GAIN IN CHILDREN.
178811 02-10

DOXEPIN AND AMITRIPTYLINE CHLORDIAZEPOXIDE COMBINATION IN NEUROTIC STATES: A COMPARATIVE DOUBLE-BLIND STUDY.
180048 02-10

PRELIMINARY EXPERIENCES WITH THE TREATMENT OF SOME MENTAL CASES UTILIZING AN ENZYME COMBINATION.
180298 02-17

LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04

DIURETIC ANTIDEPRESSANT COMBINATION IN ALCOHOLIC DEPRESSIVES.
187866 04-11

EFFECTS OF DIAZEPAM AND CODEINE, ALONE AND IN COMBINATION WITH ALCOHOL, ON SIMULATED DRIVING.
189619 04-14

PSYCHOMOTOR TEST PERFORMANCE WITH A FENFLURAMINE AMPHETAMINE COMBINATION.
190146 04-07

THE METHOHEXITAL METHYLPHENIDATE INTERVIEW: A PROPOSED NEW DRUG COMBINATION FOR NARCOTHERAPY.
190242 04-07

CLINICAL EFFECTS OF MARIHUANA SECOBARBITAL COMBINATION.
191989 04-14

CLINICAL EFFECTS OF MARIHUANA DEXTROAMPHETAMINE COMBINATION.
191990 04-14

COMBINATIONS

COMBINATIONS OF ANTIDEPRESSANT DRUGS IN THE TREATMENT OF DEPRESSIVE ILLNESS.
168317 01-09

POLYPHARMACY IN PSYCHIATRY: A MULTI-STATE COMPARISON OF PSYCHOTROPIC DRUG COMBINATIONS.
187840 04-17

INTERACTIONS OF CHLORPHENIRAMINE ETHANOL COMBINATIONS: ACUTE TOXICITY AND ANTIHISTAMINIC ACTIVITY.
188875 04-05

THE USE OF PROPRANOLOL WITH VARIOUS DRUG COMBINATIONS IN THE TREATMENT OF ESSENTIAL HYPERTENSION.
192511 04-13

COMBINED

THE PROBLEM OF ANXIETY IN A NON-WESTERN SOCIETY: A COMBINED CHEMOTHERAPEUTIC AND PSYCHOTHERAPEUTIC APPROACH.
171162 01-10

COMBINED USE OF ECT AND PSYCHOTROPIC DRUGS: ANTIDEPRESSIVES AND ANTIPSYCHOTICS.
177670 02-11

PSYCHOPHYSIOLOGICAL EFFECTS OF DIAZEPAM (VALIUM) COMBINED WITH A MODERATE DOSE OF ALCOHOL IN MAN.
180699 02-14

BEHAVIORAL EFFECTS OF SEPARATE AND COMBINED ADMINISTRATION OF NALOXONE AND D-AMPHETAMINE.
183892 03-04

A STUDY OF REFRACTORY CASES OF DEPRESSIVE ILLNESSES AND THEIR RESPONSE TO COMBINED ANTIDEPRESSANT TREATMENT.
185078 03-10

LEVODOPA COMBINED WITH MK-486 (L-ALPHA-METHYLDOPAHYDRAZINE) -- A PERIPHERAL DECARBOXYLASE INHIBITOR IN PARKINSONS DISEASE.
187615 04-11

COMMUNICATION

EFFECTS OF PSYCHOACTIVE DRUGS ON NONVERBAL COMMUNICATION AND GROUP SOCIAL BEHAVIOR OF MONKEYS.
175317 02-04

SOMNAMBULISM IN CHILDREN -- CLINICAL COMMUNICATION.
182870 03-17

COMMUNITY

ROLE OF FLUPHENAZINE DECANOATE IN LESSENING THE BURDEN OF CHRONIC SCHIZOPHRENICS ON THE COMMUNITY.
169438 01-08

PSYCHIATRIC CARE: DRUGS, THERAPIST, COMMUNITY.
178189 02-17

COMPARABLE

COMPARABLE THERAPEUTIC EFFICACY OF TRYPTOPHAN AND IMIPRAMINE: AVERAGE THERAPEUTIC RATINGS VERSUS TRUE EQUIVALENCE. AN IMPORTANT DIFFERENCE.
167344 01-09

COMPARED

CHLORDIAZEPOXIDE AND DOTHIEPIN COMPARED IN ANXIETY/DEPRESSION IN GENERAL PRACTICE.
167575 01-10

EXPERIENCE IN THE APPLICATION OF DICEPLON (APY-606) -- COMPARED WITH FLOROPIPAMIDE.
176447 02-08

DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) DOSE EFFECTS COMPARED ON THREE SCHEDULES OF FOOD REINFORCED OPERANT PERFORMANCE.
182191 02-04

SELECTIVE RESPIRATORY STIMULATING ACTION OF DOXAPRAM COMPARED TO PENTYLENETETRAZOL.
183887 03-03

BEHAVIORAL EFFECTS OF COCAINE COMPARED UNDER TWO SCHEDULES OF FOOD PRESENTATION IN THE SQUIRREL MONKEY.
191916 04-04

COMPARING

DRUG ENHANCED SENSORY CONTINGENT BAR PRESSING: COMPARING THE EFFECT OF CONTINGENT AND NONCONTINGENT SENSORY CHANGE.
168837 01-04

A DOUBLE-BLIND CONTROLLED STUDY COMPARING PROTRIPTYLINE AND AMITRIPTYLINE.
177567 02-09

SEQUENTIAL TRIAL COMPARING TWO PLASMA LEVELS OF NORTRIPTYLINE.
187582 04-10

COMPARISON

PREANESTHETIC MEDICATION IN ELECTIVE SURGERY: COMPARISON OF INTRAVENOUS DIAZEPAM WITH MEPERIDINE.
167338 01-11

A COMPARISON OF LITHIUM CARBONATE IN THE PREVENTION OF MANIC AND DEPRESSIVE EPISODES IN RECURRENT AFFECTIVE DISORDER.
169090 01-09

LEVODOPA INDUCED DYSKINESIAS: COMPARISON IN PARKINSONISM DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS.
169376 01-15

COMPARISON OF THIORIDAZINE AND DIAZEPAM IN THE CONTROL OF NONPSYCHOTIC SYMPTOMS ASSOCIATED WITH SENILITY: DOUBLE-BLIND STUDY.
170129 01-11

COMPARISON OF TRICYCLIC ANTIDEPRESSANTS AS TO THEIR CARDIOTOXIC ACTION IN CONSCIOUS RABBITS.
171629 01-03

A DOUBLE-BLIND COMPARISON OF THIORIDAZINE (MELLARIL) VERSUS DIAZEPAM (VALIUM) IN PATIENTS WITH CHRONIC MIXED ANXIETY AND DEPRESSIVE SYMPTOMS.
172486 01-10

A DOUBLE-BLIND COMPARISON OF CLOZAPINE WITH THIORIDAZINE ON SCHIZOPHRENIA.
175119 02-08

CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, ZISEPRON, IN TREATMENT OF PSYCHIATRIC DISEASES IN COMPARISON WITH THIORIDAZINE.
176467 02-08

COMPARISON OF ANTICONVULSANT EFFECTS OF CLORAZEPATE DIPOTASSIUM AND DIAZEPAM: FOUR WEEK ANTICONVULSANT STUDY IN RHESUS MONKEYS.
176677 02-03

A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY IN MAN OF INTRAVENOUSLY ADMINISTERED DELTA9-TETRAHYDROCANNABINOL, CANNABINOL, AND CANNABIDIOL.
176747 02-03

LYSERGIC ACID DIETHYLAMIDE AND SEROTONIN: A COMPARISON OF EFFECTS ON SEROTONERGIC NEURONS AND NEURONS RECEIVING A SEROTONERGIC INPUT.
177407 02-12

A DOUBLE-BLIND COMPARISON OF FLUPHENAZINE AND HALOPERIDOL IN OUTPATIENT SCHIZOPHRENIC CHILDREN.
177754 02-08

COMPARISON OF THE EFFECTS OF Y-4153 AND CARPIPRAMINE ON SCHIZOPHRENIA BY A DOUBLE-BLIND METHOD.
178053 02-08

COMPARISON OF THE CLINICAL AND COMPUTER ANALYZED EEG EFFECTS OF MESORIDAZINE AND CHLORPROMAZINE.
180064 02-10

STUDY WITH RADIOTRACERS OF THE DISTRIBUTION OF A NEW PSYCHOTROPE IN MICE: L-2-PYRROLIDONE-5-CARBOXYLATE DIMETHYLAMINOETHANOL. I. COMPARISON WITH L-GLUTAMIC AND L-2-PYRROLIDONE-5-CARBOXYLIC ACID.
180723 02-03

THE COMPARISON OF THERAPEUTIC EFFECTS OF FK-880 (SULPIRIDE) AND PERPHENAZINE IN SCHIZOPHRENIA BY A DOUBLE-BLIND CONTROLLED STUDY.
181378 02-08

COMPARISON OF CLOPENTHIXOL AND PERPHENAZINE IN BEHAVIOR AND EEG OF UNANESTHETIZED CATS.
181386 02-04

THE BIOSYNTHESIS OF THE CO-NEUROTRANSMITTER OCTOPAMINE IN COMPARISON WITH THE NEUROTRANSMITTER NORADRENALINE.
181468 02-03

COMPARISON OF THE CHRONIC AND ACUTE EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) TREATMENT ON RAT BRAIN SEROTONIN AND NOREPINEPHRINE.
181945 02-03

A COMPARISON OF SOMATIC REFLEX EFFECTS OF THREE PSYCHOTROPIC AGENTS IN THE CHLORALOSE CAT.
182126 02-03

A COMPARISON OF EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) AND SEROTONIN ON PRE- AND POSTSYNAPTIC CELLS IN THE SEROTONIN SYSTEM.
182141 02-03

COMPARISON OF INTRAVENOUSLY ADMINISTERED METHADONE (ME), MORPHINE (MO), HEROIN (H) AND PLACEBO (P).
182163 02-03

A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL AND ITS MONOHYDROXYLATED METABOLITES IN MAN.
182223 03-03

DOUBLE-BLIND CROSSOVER COMPARISON OF BROMAZEPAM AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION.
182624 03-11

A DOUBLE-BLIND COMPARISON OF PIMOZIDE WITH CARPIPRAMINE IN SCHIZOPHRENIC PATIENTS.
183195 03-08

A COMPARISON OF PSYCHOTOMIMETIC DRUG EFFECTS ON RAT BRAIN NOREPINEPHRINE METABOLISM.
183891 03-03

A CONTROLLED COMPARISON OF THE PSYCHOTROPIC EFFECTS OF PROPANIDID AND METHOHEXITONE.
184082 03-14

SEDATIVE OR TRANQUILLIZER? A COMPARISON OF THE HYPNOTIC EFFECTS OF CHLORDIAZEPOXIDE AND AMYLOBARBITONE SODIUM.
184438 03-14

COMPARISON OF PSYCHOEXPERIMENTAL PERFORMANCE UNDER THE INFLUENCE OF THE ANALGESIC PROPIRAM FUMARATE.
184618 03-14

TRIFLUOPERAZINE: A COMPARISON BETWEEN REGULAR AND HIGH DOSES.
184977 03-08

QUINAZOLINES AND 1,4 BENZODIAZEPINES.64.COMPARISON OF THE STEREOCHEMISTRY OF DIAZEPAM WITH THAT OF CLOSE ANALOGS WITH MARGINAL BIOLOGICAL ACTIVITY.
185034 03-01

IMIPRAMINE AND METHYLPHENIDATE TREATMENTS OF HYPERACTIVE BOYS: A DOUBLE-BLIND COMPARISON.
185324 03-14

AN IMPROVED METHOD FOR STUDYING THE PSYCHOGALVANIC REACTION IN MICE AND ITS INHIBITION BY PSYCHOLEPTIC DRUGS. COMPARISON WITH THE EFFECTS OF OTHER PHARMACOLOGICAL AGENTS.
185749 03-06

A COMPARISON OF THE EFFECTS OF CHRONIC ADMINISTRATION OF ETHANOL AND ACETALDEHYDE TO MICE: EVIDENCE FOR A ROLE OF ACETALDEHYDE IN ETHANOL DEPENDENCE.
185992 03-03

COMPARISON OF TRICYCLIC ANTIDEPRESSANTS IN RABBITS: ANTINOCICEPTION AND POTENTIATION OF THE NORADRENALINE PRESSOR RESPONSES.
186579 03-03

A COMPARISON OF EFFECTS OF APOMORPHINE AND ET-495 ON LOCOMOTOR ACTIVITY AND CIRCLING BEHAVIOUR IN MICE.
186635 03-04

A COMPARISON OF THE EFFECTS OF AMPHETAMINE AND ITS METABOLITES, P-HYDROXYAMPHETAMINE AND P-HYDROXYNOREPHEDRINE, ON UPTAKE, RELEASE AND CATABOLISM OF 3H-NOREPINEPHRINE IN CEREBRAL CORTEX OF RAT BRAIN.
186669 03-03

COMPARISON OF TYROSINE HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION WITH THE EFFECTS OF VARIOUS 6-HYDROXYDOPAMINE TREATMENTS ON D-AMPHETAMINE INDUCED MOTOR ACTIVITY.
186699 03-03

STRUCTURE-ACTIVITY RELATIONS OF SOME INDOLEALKYLAMINES IN COMPARISON TO PHENETHYLAMINES ON MOTOR ACTIVITY AND ACQUISITION OF AVOIDANCE BEHAVIOR.
186703 03-04

COMPARISON OF THE LOCOMOTOR STIMULANT MECHANISMS OF ACTION OF D-AMPHETAMINE AND D-AMPHETAMINE PLUS L-DOPA: POSSIBLE INVOLVEMENT OF SEROTONIN.
187119 03-04

COMPARISON OF GRADED SINGLE INTRAMUSCULAR DOSES OF MORPHINE AND PENTOBARBITAL IN MAN.
187254 03-15

POLYPHARMACY IN PSYCHIATRY: A MULTI-STATE COMPARISON OF PSYCHOTROPIC DRUG COMBINATIONS.
187840 04-17

ARE NEUROTIC PATIENTS IN PSYCHOTROPIC DRUG TRIALS REPRESENTATIVE? A COMPARISON OF STUDY AND NON-STUDY PATIENTS IN FOUR FAMILY PRACTICES.
188144 04-10

COMPARISON OF PHARMACOLOGICAL RESPONSES TO NICOTINE AND RELEASE OF CATECHOLAMINES FROM THE ADRENALS IN DOGS AND MONKEYS.
188199 04-03

DOUBLE-BLIND COMPARISON OF THIOTHIXENE, TRIFLUOPERAZINE, AND PLACEBO IN CHRONIC ALCOHOLISM.
188584 04-11

COMPARISON OF AMANTADINE, PLACEBO, AND LEVODOPA IN PARKINSONS DISEASE.
189502 04-11

THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. II. COMPARISON OF THE NEURONAL RESPONSES TO RETICULAR AND OTHER STIMULI.
189856 04-03

TREATMENT OF PHOBIAS BY SYSTEMATIC DESENSITIZATION: COMPARISON OF STANDARD VS METHOHEXITAL AIDED DESENSITIZATION.
189916 04-10

A COMPARISON OF CLINICALLY USED PSYCHOACTIVE DRUGS IN FOUR LATIN-AMERICAN COUNTRIES AND IN CANADA (ARGENTINA, COSTA-RICA, MEXICO AND PANAMA).
191139 04-17

AMITRIPTYLINE IN THE PSYCHOTIC STATES OF DOWNS SYNDROME: THE COMPARISON OF TWO CASES.
191192 04-11

COMPARISON OF BARBITAL & PENTOBARBITAL PHYSICAL DEPENDENCE IN THE CAT.
191953 04-04

COMPARISON OF CODEINE AND ETHYL ALCOHOL SELF-ADMINISTRATION UNDER A VARIABLE INTERVAL (VI) SCHEDULE IN MONKEYS.
191983 04-04

COMPARISONS

RATE-DEPENDENT EFFECTS OF DRUGS. I. COMPARISONS OF D-AMPHETAMINE, PENTOBARBITAL, AND CHLORPROMAZINE ON MULTIPLE AND MIXED SCHEDULES.
177410 02-04

THE CLINICAL EFFECTIVENESS OF LITHIUM: COMPARISONS WITH OTHER DRUGS.
186189 03-09

COMPETENCIES

A STUDY OF THE EFFECTS OF RITALIN INTERVENTION UPON THE PERCEPTUAL COMPETENCIES OF CHILDREN DIAGNOSED AS GIVING EVIDENCE OF PSYCHONEUROLOGICAL LEARNING DISABILITIES. (PH.D. DISSERTATION).
186833 03-14

COMPETING

INVERSION BY APOMORPHINE OF THE TENDENCY OF FEMALE RATS TO BE DEFEATED BY MALES WHEN COMPETING FOR FOOD IN A STRAIGHT RUNWAY.
184212 03-04

COMPETITION

EFFECTS OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL ON SOCIAL BEHAVIOR OF SQUIRREL MONKEY DYADS IN A WATER COMPETITION SITUATION.
187640 04-04

COMPLAINTS

AN ERGOT ALKALOID PREPARATION (HYDERGINE) VERSUS PAPAVERINE IN TREATING COMMON COMPLAINTS OF THE AGED: DOUBLE-BLIND STUDY.
173190 01-11

COMPLEMENTAL

COMPLEMENTAL PHARMACOLOGICAL STUDY OF DI-N-PROPYLACETAMIDE OR DEPAMIDE.
180722 02-07

COMPLEMENTARY

CHEMOTHERAPY AND PSYCHOTHERAPY, ARE THEY COMPLEMENTARY OR ANTAGONISTIC?: A PERSONAL STUDY.
184959 03-17

COMPLEX

INFLUENCE OF PH ON THE BENZODIAZEPINE HUMAN SERUM ALBUMIN COMPLEX: CIRCULAR DICHROISM STUDIES.
189595 04-13

COMPLICATED

AN AUTOPSY CASE OF SCHIZOPHRENIA COMPLICATED WITH PARKINSONISM INDUCED BY PERPHENAZINE.
171275 01-15

COMPLICATIONS

A CASE OF ENCEPHALITIS WITH PSYCHOTIC COMPLICATIONS.
174783 01-11

PSYCHOTIC COMPLICATIONS AFTER TETRAETHYLTHIURAMDISULFIDE USED IN THE TREATMENT OF ALCOHOLISM.
175047 02-11

COMPLICATIONS OF METHAQUALONE DIPHENHYDRAMINE (MANDRAX) ABUSE.
177452 02-15

THE OCULAR COMPLICATIONS BY MASSIVE DOSE OF PSYCHOTROPIC DRUGS.
182552 03-15

MYOCARDIOPATHIC COMPLICATIONS INDUCED BY IMIPRAMINE AND TRICYCLIC THYMOLEPTICS.
182898 03-15

PSYCHIATRIC COMPLICATIONS OF EVERYDAY DRUGS.
186092 03-15

LITHIUM CARBONATE: PSYCHIATRIC INDICATIONS AND MEDICAL COMPLICATIONS.
187786 04-15

COMPOSITION

THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON THE COMPOSITION OF DIURNAL SLEEP OF NARCOLEPTICS.
192419 04-11

COMPOUND-69-183

ANTIHYPERTENSIVE AND CENTRAL NERVOUS SYSTEM DEPRESSANT PROPERTIES OF 3-(GAMMA-P-FLUOROBENZOYLPROPYL) 2,3,4,4A,5,6 HEXAHYDROPYRAZINOQUINOLINE HYDROCHLORIDE (COMPOUND-69-183, CENTPYRAQUIN).
176881 02-03

COMPREHENSIVE

COMPREHENSIVE BEHAVIORAL ASSESSMENT OF THE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN RATS.
191966 04-04

COMPULSION

INHIBITION OF THE APOMORPHINE GNAWING COMPULSION BY AMANTADINE.
176879 02-04

COMPULSIVE

TREATMENT OF COMPULSIVE EATING DISTURBANCES WITH ANTICONVULSANT MEDICATION.
181270 02-14

INFLUENCE OF FLUPENTHIXOL AND FLUPENTHIXOL DECANOATE ON METHYLPHENIDATE AND APOMORPHINE INDUCED COMPULSIVE GNAWING IN MICE.
186371 03-04

COMPUTER

THE COMPUTER ANALYZES TWO PSYCHOTHERAPEUTIC AGENTS IN ANXIETY/DEPRESSED STATES.
167345 01-10

COMPARISON OF THE CLINICAL AND COMPUTER ANALYZED EEG EFFECTS OF MESORIDAZINE AND CHLORPROMAZINE.
180064 02-10

COMPUTERIZED

PREDICTION OF NEUROLEPTIC EFFECTS OF CI-686 BASED ON QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY: DRUG PROFILES AND DOSE RESPONSE CURVES BASED ON COMPUTERIZED CEREBRAL BIOPOTENTIALS.
181958 02-13

COMT

THE EFFECTS OF COMT INHIBITORS ON BEHAVIOR AND DOPAMINE METABOLISM.
191517 04-03

CONCENTRATION

INFLUENCE OF CONCENTRATION AND MOTOR PERFORMANCE ON TARDIVE DYSKINESIA AND RABBIT SYNDROME.
167587 01-15

EFFECT OF GENERAL ANESTHETICS ON SYSTEMIC CATECHOLAMINE CONCENTRATION I: HALOTHANE. (UNPUBLISHED PAPER).
168862 01-05

INCREASE IN THE PLASMA CONCENTRATION OF FREE TRYPTOPHAN CAUSED BY PROBENECID IN HUMANS.
169470 01-13

EFFECT OF CHRONIC INTOXICATION WITH (_) AMPHETAMINE ON ITS CONCENTRATION IN LIVER AND BRAIN AND ON (14C) LEUCINE INCORPORATION INTO MICROSOMAL AND CYTOPLASMIC PROTEINS OF RAT LIVER.
180056 02-05

EFFECT OF SEIZURES AND ANTICONVULSANT AGENTS ON HIPPOCAMPAL RNA CONCENTRATION.
189609 04-03

EFFECT OF PIRIBEDIL AND ONE OF ITS METABOLITES ON THE CONCENTRATION OF HOMOVANILLIC ACID IN THE RAT BRAIN.
191422 04-03

THE EFFECTS OF HOE-36801 ON MUSCLE ACTIVITY AND BLOOD PRESSURE, ON ATTENTION AND CONCENTRATION, ON TIME JUDGMENT AND SUBJECTIVE RESPONSES IN NEUROTICS AND NORMALS.
192429 04-14

CONCENTRATION EFFECT RELATIONSHIPS WITH MAJOR AND MINOR TRANQUILIZERS.
192871 04-14

CONCENTRATIONS

TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER).
170876 01-03

THE EFFECTS OF AMPHETAMINE, 2-AMINOINDANE AND 2-AMINOTETRALIN ON THE CONCENTRATIONS OF WHOLE BRAIN NORADRENALINE, DOPAMINE, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC ACID IN THE MOUSE.
174828 01-03

CHLORDIAZEPOXIDE OVERDOSE: INTERPRETATION OF SERUM DRUG CONCENTRATIONS.
177393 02-15

METHYPRYLON OVERDOSE: INTERPRETATION OF SERUM DRUG CONCENTRATIONS.
177394 02-15
SERUM ANTICONVULSANT CONCENTRATIONS IN EPILEPTIC PATIENTS WITH MENTAL SYMPTOMS: A PRELIMINARY REPORT.
184439 03-15
THE CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES IN THE PLASMA AFTER AN ACUTE AND CHRONIC ADMINISTRATION.
184978 03-13
PLASMA CONCENTRATIONS OF DIAZEPAM AND OF ITS METABOLITE N-DESMETHYLDIAZEPAM IN RELATION TO ANXIOLYTIC EFFECT.
186184 03-13
EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: II. EFFECT ON DOPAMINE AND NORADRENALINE CONCENTRATIONS AND TURNOVERS.
186588 03-04
PERPHENAZINE CONCENTRATIONS IN HUMAN WHOLE BLOOD: A PILOT STUDY DURING ANTIPSYCHOTIC THERAPY USING DIFFERENT ADMINISTRATION FORMS.
187639 04-16
THE IMPULSE BLOCKING CONCENTRATIONS OF ANESTHETICS, ALCOHOLS, ANTICONVULSANTS, BARBITURATES, AND NARCOTICS ON PHRENIC AND SCIATIC NERVES.
187803 04-03
PLASMA AND CEREBROSPINAL FLUID PROBENECID CONCENTRATIONS AS RELATED TO ACCUMULATION OF ACIDIC BIOGENIC AMINE METABOLITES IN MAN.
187933 04-13
EFFECTS OF NOMIFENSINE (HOE-984), D-AMPHETAMINE AND APOMORPHINE ON MOTOR ACTIVITY, CATECHOLAMINE TURNOVER AND CAMP CONCENTRATIONS IN RAT BRAIN. (UNPUBLISHED PAPER).
191766 04-03

CONCEPT
STRIATAL TYROSINE HYDROXYLASES WITH HIGH AND LOW AFFINITY FOR TYROSINE: IMPLICATIONS FOR THE MULTIPLE POOL CONCEPT OF CATECHOLAMINES.
167325 01-03

CONCEPTUAL
STUDIES OF CEREBROSPINAL FLUID AMINE METABOLITES IN DEPRESSED PATIENTS: CONCEPTUAL PROBLEMS AND THEORETICAL IMPLICATIONS. (UNPUBLISHED PAPER).
187398 04-13

CONDITION
DIAZEPAM IN LABOUR: ITS METABOLISM AND EFFECT ON THE CLINICAL CONDITION AND THERMOGENESIS OF THE NEWBORN.
171731 01-13
INABILITY TO CONDITION A PERIPHERAL ACTIVATING DRUG.
190698 04-04

CONDITIONED
THE EFFECTS OF INTRACAUDATE INJECTIONS OF CHLORPROMAZINE ON CONDITIONED AVOIDANCE AND SELF-STIMULATION BEHAVIOR. (PH.D. DISSERTATION).
173749 01-04
THE EFFECT OF DOPAMINE ANTAGONISTS AND AMANTADINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
174829 01-04
CONDITIONED HYPOGLYCEMIA: A MECHANISM FOR SACCHARIN INDUCED SENSITIVITY TO INSULIN IN THE RAT.
174877 01-03
POSTTRIAL STRYCHNINE: LACK OF EFFECT ON CONDITIONED AVOIDANCE LEARNING.
176866 02-04
EFFECTS OF LOW DOSES OF CHLORPROMAZINE ON A CONDITIONED EMOTIONAL RESPONSE IN THE RAT.
176963 02-04
INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CAFFEINE, (C), NICOTINE (N), PHENOBARBITAL (P): EFFECTS ON CONDITIONED AVOIDANCE (CAR).
182192 02-04
THE CONDITIONED EMOTIONAL RESPONSE (CER) AS A BASELINE FOR THE STUDY OF ANTIANXIETY DRUGS.
183862 03-04
PREDATION: SEPARATION OF AGGRESSIVE AND HUNGER MOTIVATION BY CONDITIONED AVERSION.
185463 03-04
EFFECTS OF CLONIDINE AND SOME ALPHA-ADRENORECEPTOR BLOCKING AGENTS ON AVOIDANCE CONDITIONED REFLEXES IN RATS: THEIR INTERACTIONS AND ANTAGONISM BY ATROPINE.
186576 03-04
THE EFFECT OF IPRONIAZID AND TRANYLCYPROMINE STUDIED WITH A DARK AVOIDANCE CONDITIONED SCHEDULE.
186590 03-04
THE EFFECT OF AMANTADINE, L-DOPA, (..) AMPHETAMINE AND APOMORPHINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE.
186636 03-04
METRAZOL DISRUPTS CONDITIONED AVERSION PRODUCED BY LICL: A TIME DEPENDENT EFFECT.
188412 04-04

CONDITIONING
THE CURARIZED RAT AND HEART RATE CONDITIONING: A CONSIDERATION OF RESPIRATION PARAMETERS AND NEUROMUSCULAR BLOCKING AGENTS IN A CLASSICAL CONDITIONING PARADIGM. (PH.D. DISSERTATION).
173133 01-03
EFFECTS OF PSYCHOTROPIC DRUGS ON DISCRIMINATION AVOIDANCE CONDITIONING IN RATS WITH OLFACTORY BULB ABLATIONS.
182115 02-04
SEIZURE SUSCEPTIBILITY AND AVOIDANCE CONDITIONING IN ADULT RATS TREATED PRENATALLY WITH CHLORPROMAZINE.
184371 03-04
CONDITIONING OF AMPHETAMINE-INDUCED BEHAVIOUR IN THE ALBINO RAT.
185954 03-04
EFFECTS OF METHAMPHETAMINE, PIPRADROL, AND METHYLPHENIDATE ON INSTRUMENTAL CONDITIONING AND SPONTANEOUS MOTOR ACTIVITY IN THE IMMATURE RAT.
186568 03-04
THE EFFECT OF TRANYLCYPROMINE (PARNATE) ON EYELID CONDITIONING AND PAIRED ASSOCIATE LEARNING IN DEPRESSED PATIENTS.
188107 04-09
EFFECTS OF CHLORDIAZEPOXIDE ON HEART RATE AND BEHAVIOURAL SUPPRESSION IN PIGS SUBJECTED TO OPERANT CONDITIONING PROCEDURES.
189409 04-04
DISSOCIATION BETWEEN SCOPOLAMINE AND MECAMYLAMINE DURING FEAR CONDITIONING IN RATS.
190264 04-04
BACKWARD CONDITIONING OF TASTE AVERSIONS IN RATS USING CYCLOPHOSPHAMIDE AS THE US.
190265 04-04
PSYCHOPHARMACOLOGIC FACILITATION OF OPERANT CONDITIONING OF GENETICALLY NERVOUS CATAHOULA AND POINTER DOGS.
190696 04-04
CONDITIONING IN THE PREDICTION OF DRUG WITHDRAWAL EFFECTS IN CHRONIC SCHIZOPHRENIC PATIENTS.
192412 04-17

CONDITIONS
THE EFFECTS OF L-DELTA9-TRANS-TETRAHYDROCANNABINOL ON LOW AND HIGH RESPONSE RATES GENERATED UNDER TWO SIMILAR CONDITIONS (PH.D. DISSERTATION).
168230 01-04
OXAZEPAM IN ALLERGIC CONDITIONS.
168923 01-11
DRUGS COMMONLY USED IN MENTAL CONDITIONS.
171257 01-17
REPEATED ACQUISITION OF BEHAVIORAL CHAINS UNDER CHRONIC DRUG CONDITIONS.
177408 02-04
THE EFFECTS OF EARLY P-CHLOROPHENYLALANINE ADMINISTRATION AND POSTWEANING HOUSING CONDITIONS ON SEROTONIN AND BEHAVIOR IN RATS.
178638 02-04
DOUBLE-BLIND PSYCHOMETRIC EVALUATION OF PIMOZIDE AND HALOPERIDOL VERSUS PLACEBO IN EMOTIONALLY LABILE VOLUNTEERS UNDER TWO DIFFERENT WORK LOAD CONDITIONS.
180065 02-14
CATECHOLAMINE TURNOVER IN THE RAT BRAIN: DIFFERENT RESULTS OBTAINED IN DIFFERENT EXPERIMENTAL CONDITIONS.
181471 02-03
PSYCHOLOGICAL EXPERIMENTATION ON THE EFFECTS OF PROPIRAM FUMARATE AND PROMETHAZINE UNDER NORMAL AND STRESS CONDITIONS.
184617 03-07

CONDUCTION
NERVE CONDUCTION VELOCITY IN PATIENTS ON LONG-TERM DIPHENYLHYDANTOIN THERAPY.
189173 04-15

CONFLICT
PROPRANOLOL AND CHLORDIAZEPOXIDE ON EXPERIMENTALLY INDUCED CONFLICT AND SHUTTLEBOX PERFORMANCE IN RODENTS.
171304 01-04
ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN DIMETHYLAMINOPROPYLTHIOCINNAMANILIDE HYDROCHLORIDE), A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN (5-HTP) AND ALPHA-METHYLTRYPTAMINE.
176861 02-04
PROTECTION PRODUCED BY BENZODIAZEPINES (BDP) AGAINST THE NEUROTOXIC AND CONFLICT BEHAVIOR EFFECTS OF HEXACHLOROPHENE (HCP) IN CATS.
176863 02-04
ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN, A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN AND ALPHA-METHYLTRYPTAMINE.
176873 02-04
SIMILARITY OF CHRONIC CHLORDIAZEPOXIDE TREATMENT AND REMOVAL OF CONFLICT SITUATION.
182258 03-04

CONFORMATION
MOLECULAR ORBITAL STUDIES ON THE CONFORMATION OF HALLUCINOGENIC INDOLEALKYLAMINES AND RELATED COMPOUNDS. THE ISOLATED MOLECULES AND THE SOLVENT EFFECT.
183406 03-01
CONFORMATIONAL ANALYSIS OF ACRIDAN DERIVATIVES BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY. A RELATIONSHIP BETWEEN CONFORMATION AND PHARMACOLOGICAL ACTIVITY.
190715 04-01

CONFORMATIONAL
CONFORMATIONAL ANALYSIS OF ACRIDAN DERIVATIVES BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY. A RELATIONSHIP BETWEEN CONFORMATION AND PHARMACOLOGICAL ACTIVITY.
190715 04-01

CONFORMITY
THE EFFECT OF CHLORPROMAZINE AND AMYTAL SODIUM ON THE CONFORMITY OF ADOLESCENTS UNDER PSYCHIATRIC OBSERVATION.
191776 04-14

CONGENERS
POTENTIAL PSYCHOTOMIMETICS: BROMOMETHOXYAMPHETAMINES AND STRUCTURAL CONGENERS OF LYSERGIC ACID. (PH.D. DISSERTATION).
173588 01-03
A STUDY OF THE RELATIVE ANTICONVULSANT AND TOXIC ACTIVITIES OF DELTA9-TETRAHYDROCANNABINOL AND ITS CONGENERS.
174608 01-05
SYNTHESIS AND SCREENING OF CYCLIC BENZYLHYDRAZINE CONGENERS AS ANTIDEPRESSANTS.
183600 03-01

CONJUGATE
BLOCKING OF THE EFFECT OF A DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC) ON SPONTANEOUS MOTOR ACTIVITY IN THE RAT BY IMMUNIZATION WITH A PROTEIN CONJUGATE OF DELTA1-THC.
187129 03-04

CONJUGATED
THE EFFECT OF CONJUGATED ESTROGENS ON PLASMA BUTAPERAZINE LEVELS IN WOMEN.
191959 04-15

CONSCIOUS
COMPARISON OF TRICYCLIC ANTIDEPRESSANTS AS TO THEIR CARDIOTOXIC ACTION IN CONSCIOUS RABBITS.
171629 01-03
HYPERTHERMIC EFFECT OF PALMITATE SODIUM, STEARATE SODIUM AND OLEATE SODIUM INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS CATS.
186640 03-03
CARDIOVASCULAR AND GROSS BEHAVIORAL EFFECTS OF AMPHETAMINE, 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPROPANE (DOM) AND 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPHENYL BUTANE (BL-3912A) IN THE CONSCIOUS DOG.
187573 04-03

CONSCIOUSNESS
SYNTHESIS OF ACETYLCHOLINE IN BRAIN NERVE TERMINALS DURING CONSCIOUSNESS AND BARBITURATE ANESTHESIA.
171600 01-03
NEW APPROACHES TO CONSCIOUSNESS.
178064 02-12
CREATIVITY AND THE STATE OF CONSCIOUSNESS.
186025 03-12
THE USE OF ETHYMISOL (ETHYLNORANTIPHEIN) IN PATIENTS WITH PROLONGED DISTURBANCES OF CONSCIOUSNESS.
191777 04-07

CONSECUTIVE
EFFECTS OF CONSECUTIVE ADMINISTRATION OF DIAZEPAM AND DOXEPIN ON BOTH APPROACH WITHDRAWAL AND APPROACH AVOIDANCE RESPONSES IN RATS.
182117 02-04

CONSTITUENTS
CONSTITUENTS OF CANNABIS-SATIVA L. V.: STABILITY OF AN ANALYTICAL SAMPLE EXTRACTED WITH CHLOROFORM. (UNPUBLISHED PAPER).
180670 02-01

CONSUMPTION
EFFECT OF ADRENERGIC SUBSTANCES ON OXYGEN CONSUMPTION OF RAT BRAIN TISSUE.
180058 02-03
EFFECTS OF L-DELTA9-TETRAHYDROCANNABINOL, DL-AMPHETAMINE AND PENTOBARBITAL ON OXYGEN CONSUMPTION BY MOUSE BRAIN AND HEART HOMOGENATES.
181813 02-03
THE EFFECT OF METHAMPHETAMINE ON BRAIN ACH CONSUMPTION AND AGGRESSIVENESS IN MICE STRESSED MILDLY BY LONG-TERM ISOLATION.
182108 02-04
INDEPENDENCE OF THE EFFECTS OF D-AMPHETAMINE AND FOOD DEPRIVATION OR BODYWEIGHT ON THE FOOD CONSUMPTION OF RATS.
186376 03-06
RELUCTANCE OF RATS TO DRINK HASHISH SUSPENSIONS: FREE-CHOICE AND FORCED CONSUMPTION, AND THE EFFECTS OF HYPOTHALAMIC STIMULATION.
186586 03-04

CONTAMINATED
NEUROLOGICAL CHANGES IN CATS FOLLOWING LONG-TERM DIET OF MERCURY CONTAMINATED TUNA.
186476 03-05

CONTINGENT
DRUG ENHANCED SENSORY CONTINGENT BAR PRESSING: COMPARING THE EFFECT OF CONTINGENT AND NONCONTINGENT SENSORY CHANGE.
168837 01-04
THE EFFECTS OF DALMANE (FLURAZEPAM HYDROCHLORIDE) ON THE CONTINGENT NEGATIVE VARIATION. (AMSTERDAM).
177645 02-16
FLAVOR AVERSIONS PRODUCED BY CONTINGENT DRUG INJECTION: RELATIVE EFFECTIVENESS OF APOMORPHINE, EMETINE, AND LITHIUM.
178502 02-04
SENSORY CONTINGENT BAR-PRESSING FOR FAMILIAR AND NOVEL CHANGE UNDER A DEXAMPHETAMINE AMYLOBARBITONE MIXTURE.
181605 02-04
THE EFFECTS OF METHAMPHETAMINE AND SECOBARBITAL ON THE CONTINGENT NEGATIVE VARIATION AMPLITUDE.
185932 03-13
DOSE DEPENDENT SELECTIVE FACILITATION OF RESPONSE CONTINGENT LIGHT ONSET BEHAVIOR BY D-AMPHETAMINE.
185955 03-04
THE EFFECT OF CAFFEINE, NITRAZEPAM AND CIGARETTE SMOKING ON THE CONTINGENT NEGATIVE VARIATION IN MAN.
187350 04-13

CONTINUING
MEDICATION GROUPS FOR CONTINUING CARE.
189640 04-17

CONTRACTION
STUDIES ON BENZODIAZEPINOOXAZOLES. IV. THE FORMATION OF QUINOLONES BY THE RING CONTRACTION OF A BENZODIAZEPINOOXAZOLE DERIVATIVE.
180488 02-01

CONTRACTURES
EFFECT OF DIVALENT CATIONS ON ACH CONTRACTURES OF DEPOLARIZED DENERVATED RAT MUSCLES.
188914 04-03

CONTRAINDICATED
PHENOTHIAZINES CONTRAINDICATED FOR THE UNDERFAT. (DR.P.H. DISSERTATION).
174966 01-15

CONTROL
COMPARISON OF THIORIDAZINE AND DIAZEPAM IN THE CONTROL OF NONPSYCHOTIC SYMPTOMS ASSOCIATED WITH SENILITY: DOUBLE-BLIND STUDY.
170129 01-11
RAPID CONTROL OF PSYCHOTIC EXCITEMENT STATES WITH INTRAMUSCULAR HALOPERIDOL.
170627 01-09
AMPHETAMINE USE AND MISUSE WITH RECOMMENDATIONS FOR STIMULANT CONTROL POLICY.
172109 01-17
SOME ASPECTS OF RESPIRATORY CONTROL IN NEUROLEPTOANALGESIA.
172835 01-03
KINETICS AND CELLULAR CONTROL MECHANISMS FOR IMIPRAMINE METABOLISM IN THE ISOLATED PERFUSED RAT LIVER. (PH.D. DISSERTATION).
173601 01-03
METABOLIC CONTROL OF BODY TEMPERATURE IN MAN.
174134 01-08
POTENTIAL NEUROTRANSMITTERS AND RECEPTOR MECHANISMS INVOLVED IN THE CENTRAL CONTROL OF BODY TEMPERATURE IN HAMSTERS. (PH.D. DISSERTATION).
174962 01-03
CONTROL OF THE HYPERACTIVE CHILD VIA MEDICATION -- AT WHAT COST TO PERSONALITY DEVELOPMENT; SOME PSYCHOLOGICAL IMPLICATIONS AND CLINICAL INTERVENTIONS.
176810 02-11
PARENTERAL HALOPERIDOL FOR RAPID CONTROL OF SEVERE, DISRUPTIVE SYMPTOMS OF ACUTE SCHIZOPHRENIA.
178545 02-08
OPEN-FIELD BEHAVIOR AND ACQUISITION OF DISCRIMINATIVE RESPONSE CONTROL IN DELTA9-THC TOLERANT RATS.
178813 02-04
THE RATE LIMITING CONTROL OF ENZYMES MONOAMINE OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN THE FETUS AND THE ADULT BY ADRENOCORTICOL HORMONES.
178815 02-03
PSYCHOACTIVE DRUG CONTROL: ISSUES AND RECOMMENDATIONS.
181638 02-17

AMPHETAMINE AND PENTOBARBITAL EFFECTS ON THE DISCRIMINATIVE RESPONSE CONTROL BY DEPRIVATION OF RAPID EYE MOVEMENT SLEEP (REM).
182245 03-03

CONTROL OF INSOMNIA WITH A NEW BENZODIAZEPINE: THE FLUNITRAZEPAM OR RO-5-4200 (FIRST INVESTIGATIONS OF PHASE I AND CONTROLLED INVESTIGATIONS OF PHASE II).
183198 03-11

CONTROL OF MENTAL ACTIVITIES.
185235 03-17

AMPHETAMINE AND OPERANT BEHAVIOR IN RATS: RELATIONSHIP BETWEEN DRUG EFFECT AND CONTROL RESPONSE RATE.
187699 04-04

LONG-TERM TREATMENT OF ENDOGENOUS DEPRESSION WITH NORTRIPTYLINE WITH CONTROL OF PLASMA LEVELS.
188832 04-09

CONTROL OF NOREPINEPHRINE SYNTHESIS IN BLOOD VESSELS AND THE EFFECTS OF MONOAMINE OXIDASE INHIBITION.
189390 04-03

THE CONTROL OF DEVIANT SEXUAL BEHAVIOR BY DRUGS: A DOUBLE-BLIND CONTROLLED STUDY OF BENPERIDOL, CHLORPROMAZINE, AND PLACEBO.
190061 04-11

SHORT-TERM CONTROL OF TYROSINE HYDROXYLASE.
191513 04-03

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
191944 04-04

EFFECTS OF CHLORPROMAZINE (CPZ) AND THIORIDAZINE PERFORMANCE AND STIMULUS CONTROL BEHAVIOR.
191974 04-04

CONTROLLED

BROMAZEPAM AND PHENOBARBITAL IN ANXIETY: A CONTROLLED STUDY.
167773 01-10

A CONTROLLED STUDY OF SINGLE DOSE ADMINISTRATION OF IMIPRAMINE PAMOATE IN ENDOGENOUS DEPRESSION.
167775 01-09

A NEW AGENT FOR CHEMOTHERAPY OF MIGRAINE HEADACHES: A CONTROLLED STUDY.
169298 01-11

RELIEF OF MUSCULOSKELETAL AND ASSOCIATED PSYCHOPATHOLOGICAL SYMPTOMS WITH MEPROBAMATE AND ASPIRIN: A CONTROLLED STUDY.
169632 01-10

THE EFFECTS OF AGENTS THAT MODIFY MUSCARINIC TONE UPON BEHAVIOR CONTROLLED BY AN AVOIDANCE SCHEDULE THAT EMPLOYS SIGNALED UNAVOIDABLE SHOCK.
171302 01-04

DIPHENYLHYDANTOIN EFFECTIVENESS IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS: A DOUBLE-BLIND CONTROLLED STUDY WITH A PLACEBO.
171507 01-08

AMITRIPTYLINE IN ANXIOUS DEPRESSED OUTPATIENTS: A CONTROLLED STUDY.
172993 01-10

TRIFLUPERIDOL -- A CONTROLLED CLINICAL TRIAL ON A GROUP OF SCHIZOPHRENIC PATIENTS.
174587 01-08

PIPRADROL IN MILD DEPRESSION: A CONTROLLED STUDY.
176107 02-10

A DOUBLE-BLIND CONTROLLED STUDY COMPARING PROTRIPTYLINE AND AMITRIPTYLINE.
177567 02-09

THE COMPARISON OF THERAPEUTIC EFFECTS OF FK-880 (SULPIRIDE) AND PERPHENAZINE IN SCHIZOPHRENIA BY A DOUBLE-BLIND CONTROLLED STUDY.
181378 02-08

LITHIUM TREATMENT OF PSYCHOTIC CHILDREN. A CONTROLLED CLINICAL TRIAL.
182434 03-09

A SMALL CONTROLLED STUDY TO DETERMINE THE TIME OF ONSET OF ACTION OF OXYPERTINE AFTER ORAL ADMINISTRATION IN NORMAL SUBJECTS.
182763 03-14

A CONTROLLED TRIAL OF OXYPERTINE IN PATIENTS WITH ANXIETY.
182766 03-10

CONTROL OF INSOMNIA WITH A NEW BENZODIAZEPINE: THE FLUNITRAZEPAM OR RO-5-4200 (FIRST INVESTIGATIONS OF PHASE I AND CONTROLLED INVESTIGATIONS OF PHASE II).
183198 03-11

A CONTROLLED COMPARISON OF THE PSYCHOTROPIC EFFECTS OF PROPANIDID AND METHOHEXITONE.
184082 03-14

DISULFIRAM IMPLANT: A CONTROLLED TRIAL.
185190 03-11

A CONTROLLED EVALUATION OF LITHIUM IN THE PREMENSTRUAL TENSION SYNDROME.
185192 03-11

CLOMIPRAMINE AND AMITRIPTYLINE IN DEPRESSED OUTPATIENTS: A CONTROLLED STUDY.
185747 03-09

A CONTROLLED TRIAL OF IMIPRAMINE HYDROCHLORIDE ON ENURESIS.
186553 03-11

EPISODIC DYSCONTROL: A CONTROLLED REPLICATION.
187839 04-09

ANTICONVULSANT ACTION OF VITAMIN-D IN EPILEPTIC PATIENTS? A CONTROLLED PILOT STUDY.
188889 04-11

THE USE OF DRUGS IN PSYCHIATRIC INTERVIEWS: SOME INTERPRETATIONS BASED ON CONTROLLED EXPERIMENTS.
189074 04-17

THE CONTROL OF DEVIANT SEXUAL BEHAVIOR BY DRUGS: A DOUBLE-BLIND CONTROLLED STUDY OF BENPERIDOL, CHLORPROMAZINE, AND PLACEBO.
190061 04-11

THE TREATMENT OF MIXED ANXIETY AND DEPRESSION WITH LOXAPINE: A CONTROLLED COMPARATIVE STUDY.
190195 04-09

A DOUBLE-BLIND CONTROLLED STUDY OF LOXAPINE SUCCINATE IN THE TREATMENT OF ANXIETY NEUROSES.
190196 04-09

THE TRANYLCYPROMINE ISOMERS: A CONTROLLED CLINICAL TRIAL.
192065 04-13

A CONTROLLED TRIAL OF MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE IN GENERAL PRACTICE.
192510 04-09

CONTROLS

LITHIUM PROPHYLAXIS IN AFFECTIVE DISORDERS: AN OPEN TRIAL WITH MATCHED CONTROLS.
172401 01-09

CONVERSION

METHYLTESTOSTERONE WITH IMIPRAMINE IN MEN: CONVERSION OF DEPRESSION TO PARANOID REACTION.
172992 01-15

CONVERSION OF CHLORAL HYDRATE TO TRICHLOROETHANOL IN BRAIN AND LIVER.
182157 02-03

ALKALOID STUDIES. 9. PREPARATION OF 18-ACYLYOHIMBAN-17-ONES AND THEIR CONVERSION TO NEW HETEROCYCLIC YOHIMBANS.
185033 03-04

EFFECTS OF AMPHETAMINES ON REGIONAL TRYPTOPHAN HYDROXYLASE ACTIVITY AND SYNAPTOSOMAL CONVERSION OF TRYPTOPHAN TO 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
186674 03-03

CHEMICAL CONVERSION OF THE PSYCHOTOMIMETIC AMINE 1-(2,5 DIMETHOXY-4-METHYLPHENYL) 2-AMINOPROPANE TO 5-HYDROXYDIMETHYLINDOLE.
187941 04-01

CONVULSANTS

ACTION OF CONVULSANTS ON ROOT POTENTIALS AND AMINO ACID RESPONSES IN ISOLATED FROG SPINAL CORD. (UNPUBLISHED PAPER).
177976 02-03

STUDIES ON CONVULSANTS IN THE ISOLATED FROG SPINAL CORD. I. ANTAGONISM OF AMINO ACID RESPONSES. (UNPUBLISHED PAPER)
190727 04-03

CONVULSION

CONVULSION PRODUCING PROPERTY OF THE DIALYZABLE GLYCOPEPTIDE PREPARATION FROM WHOLE RAT BRAIN.
181815 02-03

CONVULSIONS

CONTINUOUS INFUSION OF DIAZEPAM IN INFANTS WERE SEVERE RECURRENT CONVULSIONS.
174568 01-11

BRAIN AMINO ACIDS DURING CONVULSIONS.
177135 02-03

PENTYLENETETRAZOL CONVULSIONS AND BRAIN CATECHOLAMINE TURNOVER RATE IN RATS AND MICE RECEIVING DIPHENYLHYDANTOIN OR BENZODIAZEPINES.
182344 03-03

DIAZEPAM TREATMENT FOR ACUTE CONVULSIONS IN CHILDREN: A REPORT OF 41 PATIENTS, THREE WITH PLASMA LEVELS.
182595 03-11

EFFECTS OF CNS AGENTS ON NICOTINE EXTENSOR CONVULSIONS AND LETHALITY IN MICE AND THEIR SEDATIVE ANTIANXIETY EFFECTS IN MAN.
191907 04-14

EXCITABILITY CHANGES DURING THE GRADUAL DEVELOPMENT OF AND RECOVERY FROM PENTYLENETETRAZOL AND STRYCHNINE INDUCED CONVULSIONS IN THE CAT.
191927 04-03

NONSPONTANEOUS CONVULSIONS IN MICE ELICITED BY SOME CATECHOLAMINE RELEASERS AND 6,7 DIHYDROXYTETRAHYDROISOQUINOLINE (TIQ).
192013 04-05

CONVULSIVE
CANNABIDIOL AND CANNABIS-SATIVA EXTRACT PROTECT MICE AND RATS AGAINST CONVULSIVE AGENTS.
183609 03-03

COOPERATION
IMPORTANCE OF THE COOPERATION OF FAMILIES IN THE TREATMENT OF THE SICK: CONCERNING CHRONIC DELIRIUM TREATED WITH NEUROLEPTICS AND MELANCHOLY TREATED WITH ANTIDEPRESSANTS.
182899 03-17

COPULATORY
EFFECTS OF IMIPRAMINE ON COPULATORY BEHAVIOR OF MALE RATS.
168718 01-04
ACTIVATION OF COPULATORY BEHAVIOR BY PILOCARPINE AND OXOTREMORINE IN THE FEMALE RAT.
171616 01-04
A DIFFERENTIAL INHIBITORY ACTION OF LSD AND AMPHETAMINE ON COPULATORY BEHAVIOR IN THE FEMALE RAT.
171617 01-04
MONOAMINES AND COPULATORY ACTIVATION IN THE CASTRATED MALE RAT.
171618 01-04
REDUCTION IN COPULATORY BEHAVIOR OF MALE RATS FOLLOWING HASHISH INJECTIONS.
183790 03-04
EFFECTS OF LSD AND MONOAMINE SYNTHESIS INHIBITORS ON HORMONE ACTIVATED COPULATORY BEHAVIOR IN THE FEMALE RAT.
188611 04-04

CORD
EFFECT OF CHLORIMIPRAMINE ON THE RATE OF TRYPTOPHAN HYDROXYLATION IN THE INTACT AND TRANSECTED SPINAL CORD.
168751 01-03
EFFECTS OF P-CHLOROPHENYLALANINE (PCPA) AND NIALAMIDE ON 5-HYDROXYTRYPTAMINE (5-HT) IN THE TRANSECTED SPINAL CORD.
171623 01-03
ACTION OF CONVULSANTS ON ROOT POTENTIALS AND AMINO ACID RESPONSES IN ISOLATED FROG SPINAL CORD. (UNPUBLISHED PAPER).
177976 02-03
EFFECTS OF PROLONGED LSD-25 ADMINISTRATION UPON NEURONS OF SPINAL CORD GANGLIA TISSUE CULTURES.
185112 03-03
STUDIES ON CONVULSANTS IN THE ISOLATED FROG SPINAL CORD. I. ANTAGONISM OF AMINO ACID RESPONSES. (UNPUBLISHED PAPER)
190727 04-03

CORPORA-STRIATA
EVIDENCE THAT MORPHINE INCREASES DOPAMINE UTILIZATION IN CORPORA-STRIATA OF RATS.
176746 02-03

CORPUS-STRIATUM
EFFECT OF MORPHINE, HALOPERIDOL, APOMORPHINE AND BENZTROPINE ON DOPAMINE TURNOVER IN RAT CORPUS-STRIATUM: EVIDENCE SHOWING MORPHINE-INDUCED REDUCTION IN CNS DOPAMINERGIC ACTIVITY.
182230 03-03
BEHAVIORAL EFFECTS OF AMPHETAMINE IN RATS WITH LESIONS IN THE CORPUS-STRIATUM.
187698 04-04
THE EFFECTS OF DELTA9-THC AND A WATER SOLUBLE DERIVATIVE ON PGE1 SYNTHESIS IN THE CORPUS-STRIATUM.
191964 04-03

CORRECTIVE
THE CORRECTIVE EFFECT OF PRAXINOR ON HYPOTENSION ATTRIBUTABLE TO PSYCHIATRIC THERAPY. SIDE-EFFECTS.
172980 01-11

CORRELATE
A FREQUENCY SHIFT IN THE HIPPOCAMPAL THETA ACTIVITY: AN ELECTRICAL CORRELATE OF CENTRAL ACTION OF ACTH ANALOGUES IN THE DOG
188166 04-04

CORRELATED
INFLUENCE OF TREATMENT ON SYMPTOMATOLOGY AND CORRELATED ELECTROENCEPHALOGRAPHIC (EEG) CHANGES IN THE AGED.
167336 01-13

CORRELATES
LITHIUM INDUCED DIABETES-INSIPIDUS: MANIC SYMPTOMS, BRAIN AND ELECTROLYTE CORRELATES, AND CHLOROTHIAZIDE TREATMENT.
169486 01-15
DRUGS ON EEG CORRELATES OF BEHAVIOR.
181396 02-04
THE USE OF BIOCHEMICAL CORRELATES FOR THE PREDICTION OF MURICIDAL BEHAVIOR IN THE WILD RAT.
182241 03-04

CORRELATION
BEHAVIOR AND SENSITIVITY TO EXPERIMENTAL HYPERTENSION: II. LACK OF CORRELATION BETWEEN CERTAIN BEHAVIOR PATTERNS AND HYPERTENSION IN TWO NEW STRAINS OF RATS.
173256 01-04
QUANTUM CHEMICAL STUDIES ON DRUG ACTIONS: IV. CORRELATION OF SUBSTITUENT STRUCTURES AND ANTISEROTONIN ACTIVITY IN LYSERGAMIDE SERIES.
174605 01-12
DISPOSITION OF NORAPOMORPHINE AND N,N PROPYLNORAPOMORPHINE IN MOUSE BRAIN AND ITS CORRELATION WITH STEREOTYPED GNAWING BEHAVIOR.
182131 02-04
CORRELATION BETWEEN THE TRANQUILIZING AND SEDATIVE ACTION OF NEUROLEPTICS, ANTIDEPRESSANTS AND ANTICHOLINERGIC DRUGS.
191783 04-02
CORRELATION BETWEEN BRAIN N,N DIMETHYLTRYPTAMINE (DMT) LEVELS AND BAR PRESSING BEHAVIOR IN RATS: EFFECT OF MAO INHIBITION.
191935 04-04
CORRELATION OF PHARMACOLOGICAL INVESTIGATIONS WITH THE CLINICAL EFFICACY OF ANTIDEPRESSANT DRUGS.
192420 04-13

CORRELATIONS
EFFECTS OF MOLINDONE ON CNS STRUCTURES: NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATIONS.
172749 01-03
LONG-TERM CLINICAL AND QUANTITATIVE EEG EFFECTS OF CLOPENTHIXOL IN SCHIZOPHRENICS: CLINICAL NEUROPHYSIOLOGICAL CORRELATIONS.
174131 01-08
EFFECTS OF LORAZEPAM ON CNS STRUCTURES: NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATIONS.
177749 02-03
ON-OFF PHENOMENON WITH LEVODOPA THERAPY IN PARKINSONISM: CLINICAL AND PHARMACOLOGIC CORRELATIONS AND THE EFFECT OF INTRAMUSCULAR PYRIDOXINE.
188560 04-11
MULTIPLE FORMS OF MAO: SOME IN VIVO CORRELATIONS.
191496 04-03

CORTEX
LSD EFFECTS ON SIGNAL-TO-NOISE RATIO AND LATERALIZATION OF VISUAL CORTEX AND LATERAL GENICULATE DURING PHOTIC STIMULATION.
167449 01-03
EFFECTS OF FOOD DEPRIVATION, DISCRIMINATION EXPERIENCE AND PHYSOSTIGMINE ON CHOLINE ACETYLASE AND ACETYLCHOLINE ESTERASE IN THE DORSAL HIPPOCAMPUS AND FRONTAL CORTEX OF RATS.
169467 01-03
EFFECT OF PROCAINE, LIDOCAINE AND PENTOBARBITAL ON ELECTRICAL ACTIVITY OF GUINEA-PIG OLFACTORY CORTEX IN VITRO.
182092 02-03
UPTAKE AND RELEASE OF NORADRENALINE IN RAT CEREBRAL CORTEX IN VITRO: NO EFFECT OF BENZODIAZEPINES AND BARBITURATES.
182347 03-03
A COMPARISON OF THE EFFECTS OF AMPHETAMINE AND ITS METABOLITES, P-HYDROXYAMPHETAMINE AND P-HYDROXYNOREPHEDRINE, ON UPTAKE, RELEASE AND CATABOLISM OF 3H-NOREPINEPHRINE IN CEREBRAL CORTEX OF RAT BRAIN.
186669 03-03
EVIDENCE FOR AN INHIBITORY ROLE FOR ACETYLCHOLINE, CATECHOLAMINES, AND SEROTONIN ON THE CEREBRAL CORTEX.
187552 04-03
EVIDENCE FOR A SPECIFIC UPTAKE OF DOPAMINE BY DOPAMINERGIC TERMINALS OF THE RAT CEREBRAL CORTEX.
188978 04-03
INFLUENCE OF MORPHINE AND NALOXONE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189568 04-03
INFLUENCE OF FENTANYL, LEVORPHANOL AND PETHIDINE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189569 04-03
MESCALINE INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON THE BINDING OF AMINOACYL TRANSFER RIBONUCLEIC ACID TO RIBOSOMES OF BRAIN TISSUE.
189582 04-05
THE ACTION OF BETA-PHENYL-GABA DERIVATIVES ON NEURONES OF THE CAT CEREBRAL CORTEX.
189750 04-03
THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. I. NEURONAL RESPONSES TO STIMULATION OF THE RETICULAR FORMATION.
189855 04-03
THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. II. COMPARISON OF THE NEURONAL RESPONSES TO RETICULAR AND OTHER STIMULI.
189856 04-03
EFFECT OF DESIPRAMINE ON RAT CORTEX SLICES INCUBATED WITH 3H-DOPAMINE.
190310 04-03

EFFECT OF PHENOTHIAZINE NEUROLEPTIC DRUGS AND TRICYCLIC ANTIDEPRESSANTS ON PHOSPHODIESTERASE ACTIVITY IN RAT CEREBRAL CORTEX.
190311 04-03

THE EFFECT OF CHOLINOMIMETIC DRUGS ON POTASSIUM TRANSPORT IN RAT CEREBRAL CORTEX.
191411 04-03

CHANGES IN RHYTHMS OF BIOELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX IN HUMANS UNDER THE INFLUENCE OF ETHYMISOL.
191790 04-07

THE EFFECTS OF AMPHETAMINE SULFATE ON THE DIURNAL RHYTHMS OF MIDBRAIN; CORTEX, NOREPINEPHRINE; SEROTONIN AND BLOOD GLUCOSE LEVELS IN THE MOUSE.
191918 04-03

CORTICAL

INTERACTION BETWEEN ATROPINE AND OXOTREMORINE ON CORTICAL ACETYLCHOLINE AND MOTOR ACTIVITY.
171606 01-03

CORTICAL SYNAPTOSOMAL UPTAKE AND SUBSYNAPTOSOMAL DISTRIBUTION OF 3H-NOREPINEPHRINE AND 3H-AMPHETAMINE: MODIFICATION BY TRICYCLIC AND PSYCHOACTIVE AGENTS IN VITRO. (PH.D. DISSERTATION).
172020 01-03

THE ANTAGONISM OF HIPPOCAMPAL AND CORTICAL AFTERDISCHARGE BY SC-13504, A NEW ANTICONVULSANT.
186632 03-03

SHIFTING OF THE D-AMPHETAMINE DOSE-RESPONSE CURVE IN RATS WITH FRONTAL CORTICAL ABLATIONS.
187261 04-04

EFFECTS OF SOME METALLIC CATIONS ON CEREBRAL CORTICAL NEURONES AND THEIR INTERACTIONS WITH BIOGENIC AMINES.
187806 04-03

NEOMYCIN AND RUTHENIUM RED ANTAGONISM OF MONOAMINERGIC DEPRESSION OF CEREBRAL CORTICAL NEURONES.
191380 04-03

CORTICAL AND/OR SUBCORTICAL EFFECTS AS A FUNCTION OF HALLUCINOGENIC DRUG STRUCTURE
191936 04-03

CORTICOSTEROIDS

MODULATORY EFFECTS OF CORTICOSTEROIDS ON EVOKED ACTIVITY IN THE HIPPOCAMPUS AND THALAMUS OF THE RAT.
182119 02-03

THE EFFECT OF MINOR TRANQUILIZERS ON STRESS INDUCED INCREASES IN RAT PLASMA CORTICOSTEROIDS.
186578 03-03

CORTICOSTERONE

EFFECTS OF METHAMPHETAMINE ON DAILY RHYTHMS OF HYPOTHALAMIC NOREPINEPHRINE, SEROTONIN AND PLASMA CORTICOSTERONE LEVELS IN THE RAT.
184178 03-03

COSINOR

DAILY RHYTHM IN BODY TEMPERATURE OF MENTAL PATIENTS: APPLICATION OF COSINOR METHOD -- FIRST REPORT.
191685 04-17

COST

CONTROL OF THE HYPERACTIVE CHILD VIA MEDICATION -- AT WHAT COST TO PERSONALITY DEVELOPMENT; SOME PSYCHOLOGICAL IMPLICATIONS AND CLINICAL INTERVENTIONS.
176810 02-11

COSTA-RICA

A COMPARISON OF CLINICALLY USED PSYCHOACTIVE DRUGS IN FOUR LATIN-AMERICAN COUNTRIES AND IN CANADA (ARGENTINA, COSTA-RICA, MEXICO AND PANAMA).
191139 04-17

COUNTRIES

A COMPARISON OF CLINICALLY USED PSYCHOACTIVE DRUGS IN FOUR LATIN-AMERICAN COUNTRIES AND IN CANADA (ARGENTINA, COSTA-RICA, MEXICO AND PANAMA).
191139 04-17

COVERING

DOLICHOMEGACOLON INDUCED BY NEUROLEPTICS AMONG PSYCHIATRIC PATIENTS (MEMORANDUM COVERING 153 CASES).
176432 02-15

COW

INFLUENCE OF DIFFERENT ANIONS ON TYRAMINE AND AMPHETAMINE UPTAKE BY COW ADRENAL MEDULLA CHROMAFFIN VESICLES.
190907 04-03

CPK

MUSCLE ABNORMALITIES IN PSYCHOTIC PATIENTS: II. SERUM CPK ACTIVITY, FIBER ABNORMALITIES, AND BRANCHING AND SPROUTING OF SUBTERMINAL NERVES.
187114 03-09

CPZ

EFFECT OF CHLORPROMAZINE (CPZ) ON INSULIN RELEASE IN VIVO AND IN VITRO IN THE RAT.
168440 01-03

EFFECTS OF CHLORPROMAZINE (CPZ) AND THIORIDAZINE PERFORMANCE AND STIMULUS CONTROL BEHAVIOR.
191974 04-04

CREATIVITY

CREATIVITY AND THE STATE OF CONSCIOUSNESS.
186025 03-12

HALLUCINOGENIC DRUGS AND ARTISTIC CREATIVITY.
186026 03-12

CRIME

CRIME AND THE SEX DRIVE.
192410 04-17

CRIMES

RELATIONSHIP BETWEEN RESPONSE TO LOW PENTAMETHYLENETETRAZOL ADMINISTRATION AND PERSONALITY OF JUVENILE OFFENDERS AND THEIR REPEATED CRIMES.
175072 02-17

CRISIS

CRISIS PSYCHOPHARMACOLOGY TECHNIQUES.
174298 01-11

DRUG THERAPIES IN CRISIS MANAGEMENT.
189297 04-17

CROSS-NATIONAL

CROSS-NATIONAL STUDY OF THE EXTENT OF ANTIANXIETY SEDATIVE DRUG USE.
181713 02-17

CROSS-TOLERANCE

TOLERANCE AND CROSS-TOLERANCE TO THE ANOREXIGENIC EFFECT OF SOME AMPHETAMINE DERIVATIVES IN RATS.
171602 01-03

CROSSOVER

CHLORDIAZEPOXIDE IN DEPRESSIVE NEUROSIS: AN OPEN LABEL CROSSOVER STUDY WITH AMITRIPTYLINE.
168316 01-10

MOLINDONE: A CROSSOVER EVALUATION OF CAPSULE AND TABLET FORMULATIONS IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
174137 01-08

AFRODEX VS. PLACEBO IN THE TREATMENT OF MALE IMPOTENCE: STATISTICAL ANALYSIS OF TWO DOUBLE-BLIND CROSSOVER STUDIES.
181959 02-14

DOUBLE-BLIND CROSSOVER COMPARISON OF BROMAZEPAM AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION.
182624 03-11

A DOUBLE-BLIND CROSSOVER SEQUENTIAL TRIAL OF ORAL THYROTROPIN RELEASING HORMONE IN DEPRESSION.
188348 04-09

CRUDE

CRUDE MARIHUANA EXTRACT: EEG AND BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION IN RHESUS MONKEYS.
189516 04-04

CRYSTALLIZATION

CACTUS ALKALOIDS. XIX. CRYSTALLIZATION OF MESCALINE HCL AND 3-METHOXYTYRAMINE HCL FROM TRICHOCEREUS-PACHANOI.
192878 04-01

CS-370

THE SAFETY TEST OF 10-CHLORO-11B-(2-CHLOROPHENYL) 2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE (CS-370): SECOND REPORT, EFFECT OF CS-370 UPON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
168498 01-05

EFFECT OF A NEW PSYCHOTROPIC DRUG, CS-370 (10-CHLORO-11B-(2-CHLOROPHENYL)-2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE) UPON THE CENTRAL NERVOUS SYSTEM.
174603 01-03

CULTURE

MEGAVITAMIN TREATMENT, CULTURE AND TRANQUILIZERS, DRUGS FOR THE AGED: PROJECTS OF A CANADIAN GRANT.
170293 01-11

STIMULATION OF SEROTONIN N-ACETYLTRANSFERASE IN PINEAL ORGAN CULTURE BY DRUGS.
177128 02-03

CULTURED

EFFECTS OF NARCOTIC ANALGESICS ON ENZYMES OF ACETYLCHOLINE METABOLISM IN CULTURED CHICK BRAIN CELLS.
182225 03-03

EFFECT OF IMIPRAMINE ON CULTURED RAT HEART CELLS.
188864 04-03

EFFECTS OF ALUMINUM SALTS ON CULTURED NEUROBLASTOMA CELLS.
191313 04-03

CULTURES

EFFECTS OF CHLORPROMAZINE AND ACTINOMYCIN D ON UPTAKE AND INCORPORATION OF CERTAIN AMINO ACIDS, HYPOXANTHINE AND THYMIDINE IN CULTURES OF HUMAN SKIN EPITHELIAL CELLS.
179989 02-13

EFFECTS OF PROLONGED LSD-25 ADMINISTRATION UPON NEURONS OF SPINAL CORD GANGLIA TISSUE CULTURES.
185112 03-03

CURARIZED

THE CURARIZED RAT AND HEART RATE CONDITIONING: A CONSIDERATION OF RESPIRATION PARAMETERS AND NEUROMUSCULAR BLOCKING AGENTS IN A CLASSICAL CONDITIONING PARADIGM. (PH.D. DISSERTATION).
173133 01-03

AMPHETAMINE AND THERMOREGULATION: STUDIES IN THE UNRESTRAINED AND CURARIZED RAT.
184227 03-03

CURVE
SHIFTING OF THE D-AMPHETAMINE DOSE-RESPONSE CURVE IN RATS WITH FRONTAL CORTICAL ABLATIONS.
187261 04-04

CURVES
PREDICTION OF NEUROLEPTIC EFFECTS OF CI-686 BASED ON QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY: DRUG PROFILES AND DOSE RESPONSE CURVES BASED ON COMPUTERIZED CEREBRAL BIOPOTENTIALS.
181958 02-13

CUTANEOUS
THE EFFECT OF L-TRYPTOPHAN (TP) ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) REFLEXES IN ACUTE DECEREBRATE SPINAL CATS AND THE EFFECT OF PRETREATMENT WITH P-CHLOROPHENYLALANINE (PCPA) ON THE ACTION OF TP. (UNPUBLISHED PAPER).
170874 01-03

THE EFFECT IN THE CAT OF TRYPTAMINE (T) AND LSD ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) SPINAL REFLEXES. (UNPUBLISHED PAPER).
174480 01-12

CYCLANDELATE
TREATMENT OF THE CEREBRAL MANIFESTATIONS OF ARTERIOSCLEROSIS WITH CYCLANDELATE.
185008 03-11

CYCLASE
EFFECTS OF CENTRALLY ACTING DRUGS ON ADENYL CYCLASE ACTIVITY AND CYCLIC AMP LEVELS OF MOUSE BRAIN. (PH.D. DISSERTATION).
172019 01-03

DOPAMINE IN THE MESOLIMBIC SYSTEM OF THE RAT BRAIN: ENDOGENOUS LEVELS AND THE EFFECTS OF DRUGS ON THE UPTAKE MECHANISM AND STIMULATION OF ADENYLATE CYCLASE ACTIVITY.
177131 02-03

EFFECT OF CHLORPROMAZINE AND SOME OF ITS METABOLITES ON THE DOPAMINE SENSITIVE ADENYLATE CYCLASE OF RAT BRAIN STRIATUM.
180060 02-03

EFFECTS OF SELECTED CENTRALLY ACTING AGENTS ON ADENYL CYCLASE ACTIVITY IN MOUSE BRAIN.
182153 02-03

A ROLE FOR NICOTINIC RECEPTORS IN THE REGULATION OF THE ADENYLATE CYCLASE OF ADRENAL MEDULLA.
186675 03-03

THE EFFECT OF LITHIUM ON HORMONE SENSITIVE ADENYLATE CYCLASE FROM VARIOUS REGIONS OF THE RAT BRAIN.
187110 03-03

STIMULATION OF A DOPAMINE SENSITIVE ADENYLATE CYCLASE IN HOMOGENATES OF RAT STRIATUM BY A METABOLITE OF PIRIBEDIL (ET-495).
189616 04-03

EFFECTS OF DOPAMINE-LIKE DRUGS ON RAT STRIATAL ADENYL CYCLASE HAVE IMPLICATIONS FOR CNS DOPAMINE RECEPTOR TOPOGRAPHY.
190545 04-03

EFFECT OF CHRONIC TREATMENT WITH DESIPRAMINE (DMI) AND IPRINDOLE (IP) ON THE NOREPINEPHRINE (NE) SENSITIVE ADENYLATE CYCLASE SYSTEM IN SLICES OF THE RAT LIMBIC FOREBRAIN.
192003 04-03

CYCLASES
NOREPINEPHRINE SENSITIVE ADENYLATE CYCLASES IN RAT BRAIN: RELATION TO BEHAVIOR AND TYROSINE HYDROXYLASE.
177252 02-03

CYCLAZOCINE
STIMULATION OF BEHAVIOR IN THE RAT BY CYCLAZOCINE: EFFECTS OF NALOXONE.
168439 01-04

CYCLE
EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON THE RHYTHMS OF WAKEFULNESS SLEEP CYCLE IN RATS.
182553 03-04

FLUNITRAZEPAM (RO-5-4200) AND SLEEP CYCLE IN INSOMNIAC PATIENTS.
186574 03-11

THE EFFECT OF A NEW BENZODIAZEPINE DERIVATIVE NIMETAZEPAM ON THE SLEEP CYCLE IN MAN.
188501 04-07

LONG-TERM ALTERATION OF SLEEP-WAKEFULNESS CYCLE DURING CHRONIC PENTOBARBITAL DOSING AND WITHDRAWAL IN CAT.
191952 04-04

CYCLES
BEHAVIOURAL STATE CYCLES IN ABNORMAL INFANTS.
168523 01-14

CYCLIC
EFFECT OF ETHANOL ON CYCLIC AMP LEVELS IN THE RAT BRAIN.
167326 01-03

POSSIBLE INVOLVEMENT OF CYCLIC NUCLEOTIDES IN THE STIMULATION OF PITUITARY FUNCTION ELICITED BY RESERPINE. (UNPUBLISHED PAPER).
170086 01-03

THE ROLE OF CYCLIC 3,5 ADENOSINE MONOPHOSPHATE IN NEUROMUSCULAR TRANSMISSION.
170660 01-13

TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER).
170876 01-03

EFFECTS OF CENTRALLY ACTING DRUGS ON ADENYL CYCLASE ACTIVITY AND CYCLIC AMP LEVELS OF MOUSE BRAIN. (PH.D. DISSERTATION).
172019 01-03

BLOCKADE OF THE PROESTROUS LH SURGE IN CYCLIC RATS BY BARBITURATE ADMINISTRATION ON DIESTRUS.
175650 02-03

CYCLIC ADENOSINE MONOPHOSPHATE: SELECTIVE INCREASE IN CAUDATE NUCLEUS AFTER ADMINISTRATION OF L-DOPA.
176254 02-13

EFFECTS OF NEUROLEPTICS AND THYMOLEPTICS ON PHOSPHODIESTERASE ACTIVITY AND ON CYCLIC 3,5 AMP LEVELS IN RAT BRAIN.
181467 02-03

REGIONAL CYCLIC NUCLEOTIDES PHOSPHODIESTERASE ACTIVITY IN CAT CENTRAL NERVOUS SYSTEM: EFFECTS OF BENZODIAZEPINES.
181575 02-03

A CENTRAL EFFECT OF LOCAL ANESTHETICS: PREVENTION AGAINST THE ACCUMULATION OF CYCLIC AMP IN BRAIN SLICES.
182099 02-03

EFFECTS OF DECAPITATION, ETHER AND PENTOBARBITAL ON CYCLIC AMP AND CYCLIC GMP LEVELS IN RAT TISSUES.
182154 02-03

INTERACTION OF CYCLIC AMP WITH NEUROPHARMACOLOGIC DEPRESSANT AGENTS.
182155 02-03

THE EFFECT OF DOPAMINE RECEPTOR STIMULATING AGENTS AND OF N,O DIBUTYRYL CYCLIC AMP ON C14-DOPAMINE SYNTHESIS IN STRIATAL SLICES OF RATS.
182256 03-03

SYNTHESIS AND SCREENING OF CYCLIC BENZYLHYDRAZINE CONGENERS AS ANTIDEPRESSANTS.
183600 03-01

NOREPINEPHRINE -- AN ANTAGONIST OF DIBUTYRYL CYCLIC AMP IN THE REGULATION OF NARCOSIS IN THE RAT.
183789 03-03

NEUROCHEMICAL ROLE OF ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AND GUANOSINE 3,5 CYCLIC MONOPHOSPHATE AND THEIR RELATION TO NEUROTRANSMITTERS; EFFECT OF TETRAHYDROCANNABINOLS. (PH.D. DISSERTATION).
185582 03-03

IN VIVO CHANGES OF CEREBRAL CYCLIC ADENOSINE 3,5 MONOPHOSPHATE INDUCED BY BIOGENIC AMINES: ASSOCIATION WITH PHOSPHORYLASE ACTIVATION.
188291 04-03

BETA-ADRENERGIC EFFECTS ON RAT MYOMETRIUM: ROLE OF CYCLIC AMP.
188915 04-03

DIAZEPAM, CYCLIC NUCLEOTIDES AND AMINO ACID NEUROTRANSMITTERS IN RAT CEREBELLUM. (UNPUBLISHED PAPER).
191764 04-03

CYCLOHEXIMIDE
CHANGE OF ESTROGEN ACTIVATED BEHAVIOR BY CYCLOHEXIMIDE IN THE FEMALE RAT.
171615 01-04

INTERACTIVE EFFECTS OF CYCLOHEXIMIDE AND PUROMYCIN IN ALTERING BRAIN POLYRIBOSOMES AND NEURAL AND BEHAVIOURAL RESPONSES TO ELECTROSHOCK IN MICE.
175230 02-03

LACK OF EFFECTS OF CYCLOHEXIMIDE ON TOLERANCE DEVELOPMENT TO A STIMULATORY EFFECT OF MORPHINE ON MICE.
182158 02-03

EFFECTS OF CYCLOHEXIMIDE ON ACQUISITION AND RETENTION OF AVOIDANCE LEARNING IN THE RAT: RECOVERY OF MEMORY.
189215 04-04

CYCLOPHOSPHAMIDE
ACUTE LETHALITY FOR MICE FOLLOWING ADMINISTRATION OF CYCLOPHOSPHAMIDE WITH BARBITURATES.
177834 02-05

BACKWARD CONDITIONING OF TASTE AVERSIONS IN RATS USING CYCLOPHOSPHAMIDE AS THE US.
190265 04-04

CYPROHEPTADINE
EFFECT OF A CARNITINE CYPROHEPTADINE COMBINATION ON ANOREXIA AND WEIGHT GAIN IN CHILDREN.
178811 02-10

EFFECTS OF CYPROHEPTADINE ON THE EATING BEHAVIOR OF RATS AND CATS.
182111 02-04

CYPROTERONE
ALTERATION OF MATERNAL BEHAVIOR IN MICE FOLLOWING ADMINISTRATION OF CYPROTERONE ACETATE.
172374 01-04

EFFECTS OF CYPROTERONE ACETATE IN THE MALE JAPANESE QUAIL.
186681 03-03

CYTOGENETIC
CYTOGENETIC STUDIES IN THE OFFSPRING OF LSD USERS.
185083 03-12

CYTOGENIC
PSYCHOTROPIC DRUGS AND CYTOGENIC EFFECTS.
181395 02-15

CYTOMEGALOVIRUS
DEVELOPMENT OF A VACCINE AGAINST MENTAL RETARDATION CAUSED BY CYTOMEGALOVIRUS INFECTION IN UTERO.
178549 02-11

CYTOPLASMIC
EFFECT OF CHRONIC INTOXICATION WITH (_) AMPHETAMINE ON ITS CONCENTRATION IN LIVER AND BRAIN AND ON (14C) LEUCINE INCORPORATION INTO MICROSOMAL AND CYTOPLASMIC PROTEINS OF RAT LIVER.
180056 02-05

C14-ACH
INHIBITION OF C14-ACH UPTAKE IN RAT BRAIN SLICES BY DESMETHYLIMIPRAMINE.
182170 02-03

C14-DOPAMINE
THE EFFECT OF DOPAMINE RECEPTOR STIMULATING AGENTS AND OF N,O DIBUTYRYL CYCLIC AMP ON C14-DOPAMINE SYNTHESIS IN STRIATAL SLICES OF RATS.
182256 03-03

D-AMPHETAMINE
EFFECT OF PRENATAL MATERNAL ADMINISTRATION OF D-AMPHETAMINE ON RAT OFFSPRING ACTIVITY AND PASSIVE AVOIDANCE LEARNING.
167415 01-03

TEMPERATURE DEPENDENT TOXICITY OF ADRENERGIC AGONISTS IN MICE AS A BASIS FOR TREATING D-AMPHETAMINE POISONING.
169688 01-05

INTERACTION BY FENFLURAMINE WITH THE METABOLISM OF D-AMPHETAMINE IN THE RAT.
171634 01-03

INHIBITORY EFFECTS OF PRETEST AND POSTTEST D-AMPHETAMINE ON MOUSE-KILLING BY RATS. (PH.D. DISSERTATION).
173727 01-04

EFFECTS AND INTERACTIONS OF SCOPOLAMINE AND D-AMPHETAMINE ON SCHEDULE-CONTROLLED RESPONDING IN RATS. (PH.D. DISSERTATION).
173748 01-04

DEVELOPMENT OF TOLERANCE IN RATS TO THE HYPOTHERMIC EFFECTS OF D-AMPHETAMINE AND APOMORPHINE.
174764 01-03

EFFECTS OF INTRAPERITONEAL AND INTRAVENTRICULAR D-AMPHETAMINE ADMINISTRATION ON ACTIVE AVOIDANCE PERFORMANCE IN THE RAT.
175242 02-04

THE HYDROXYLATION OF D-AMPHETAMINE BY LIVER MICROSOMES OF THE MALE RAT.
177337 02-03

SPATIAL AND PAW PREFERENCES IN RATS: THEIR RELATIONSHIP TO RATE-DEPENDENT EFFECTS OF D-AMPHETAMINE.
177409 02-04

RATE-DEPENDENT EFFECTS OF DRUGS. I. COMPARISONS OF D-AMPHETAMINE, PENTOBARBITAL, AND CHLORPROMAZINE ON MULTIPLE AND MIXED SCHEDULES.
177410 02-04

AN ANALYSIS OF D-AMPHETAMINE PRODUCED FACILITATION OF AVOIDANCE ACQUISITION IN RATS AND PERFORMANCE CHANGES SUBSEQUENT TO DRUG TERMINATION.
179990 02-04

ANALYSIS OF TREMORGENIC EFFECTS OF INTRACAUDATE D-AMPHETAMINE.
182129 02-03

DECREASED ANOREXIA, EXCITEMENT AND STEREOTYPY TO D-AMPHETAMINE AFTER LATERAL HYPOTHALAMIC 6-HYDROXYDOPAMINE (6-OHDA) INJECTIONS.
182136 02-04

TOLERANCE TO THE ACTIVITY ENHANCING EFFECTS OF D-AMPHETAMINE.
182208 02-04

EFFECT OF D-AMPHETAMINE (D-A) AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) ON THE IN VIVO RELEASE OF 14C-NOREPINEPHRINE (NE) INTO THE LATERAL VENTRICLE OF RATS.
182251 03-03

COMPARATIVE EFFECTS OF DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE ON CENTRAL CATECHOLAMINES AND LOCOMOTOR ACTIVITY.
182253 03-04

BEHAVIOR AS A STIMULUS: JOINT EFFECTS OF D-AMPHETAMINE AND PENTOBARBITAL.
183890 03-04

BEHAVIORAL EFFECTS OF SEPARATE AND COMBINED ADMINISTRATION OF NALOXONE AND D-AMPHETAMINE.
183892 03-04

EFFECT OF D-AMPHETAMINE SULFATE ON SUSCEPTIBILITY TO AUDIOGENIC SEIZURES IN DBA/2J MICE.
184235 03-03

THE ACTION OF D-AMPHETAMINE ON SPONTANEOUS ACTIVITY IN THE CAUDATE NUCLEUS AND RETICULAR FORMATION OF THE RAT.
185264 03-03

CATALEPSY INDUCED BY ALPHA-METHYL-P-TYROSINE AND D-AMPHETAMINE: THE ROLE OF CATECHOLAMINE METABOLISM.
185750 03-03

THE EFFECTS OF CHRONIC TREATMENT WITH D-AMPHETAMINE ON FOOD INTAKE, BODYWEIGHT, LOCOMOTOR ACTIVITY AND SUBCELLULAR DISTRIBUTION OF THE DRUG IN RAT BRAIN.
185931 03-03

DOSE DEPENDENT SELECTIVE FACILITATION OF RESPONSE CONTINGENT LIGHT ONSET BEHAVIOR BY D-AMPHETAMINE.
185955 03-04

INDEPENDENCE OF THE EFFECTS OF D-AMPHETAMINE AND FOOD DEPRIVATION OR BODYWEIGHT ON THE FOOD CONSUMPTION OF RATS.
186376 03-06

COMPARATIVE EFFECTS OF DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE ON CATECHOLAMINE RELEASE AND REUPTAKE IN VITRO.
186671 03-03

COMPARISON OF TYROSINE HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION WITH THE EFFECTS OF VARIOUS 6-HYDROXYDOPAMINE TREATMENTS ON D-AMPHETAMINE INDUCED MOTOR ACTIVITY.
186699 03-03

A DETAILED ANALYSIS OF THE EFFECTS OF D-AMPHETAMINE ON BEHAVIOR UNDER FIXED-INTERVAL SCHEDULES.
187066 03-04

COMPARISON OF THE LOCOMOTOR STIMULANT MECHANISMS OF ACTION OF D-AMPHETAMINE AND D-AMPHETAMINE PLUS L-DOPA: POSSIBLE INVOLVEMENT OF SEROTONIN.
187119 03-04

SHIFTING OF THE D-AMPHETAMINE DOSE-RESPONSE CURVE IN RATS WITH FRONTAL CORTICAL ABLATIONS.
187261 04-04

INTERACTION AMONG GENOTYPE, UNCONDITIONED STIMULUS, D-AMPHETAMINE, AND ONE-WAY AVOIDANCE BEHAVIOR OF RATS.
187702 04-04

EFFECTS OF ALPHA-METHYLTYROSINE ON D-AMPHETAMINE INDUCED RELEASE OF ENDOGENOUSLY SYNTHESIZED AND EXOGENOUSLY ADMINISTERED CATECHOLAMINES FROM THE CAT BRAIN IN VIVO.
189397 04-03

PARADOXICAL EFFECTS OF D-AMPHETAMINE ON BEHAVIORAL THERMOREGULATION: POSSIBLE MEDIATION BY BRAIN DOPAMINE.
189399 04-04

THE EFFECTS OF D-AMPHETAMINE ON THE INTERRESPONSE TIMES OF RATS AND GUINEA-PIGS ON A MODIFIED SIDMAN DISCRIMINATED AVOIDANCE SCHEDULE.
189519 04-04

AN ANALYSIS OF THE FACILITATION OF AVOIDANCE ACQUISITION BY D-AMPHETAMINE AND SCOPOLAMINE.
189521 04-04

INTERACTION OF D-AMPHETAMINE WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY OF MICE.
189613 04-04

EFFECTS OF INTRAVENOUS D-AMPHETAMINE, L-AMPHETAMINE AND METHYLPHENIDATE IN SCHIZOPHRENICS.
191508 04-08

EFFECTS OF NOMIFENSINE (HOE-984), D-AMPHETAMINE AND APOMORPHINE ON MOTOR ACTIVITY, CATECHOLAMINE TURNOVER AND CAMP CONCENTRATIONS IN RAT BRAIN. (UNPUBLISHED PAPER).
191766 04-03

EFFECTS OF D-AMPHETAMINE, MORPHINE AND CHLORPROMAZINE ON RESPONDING UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION OR ELECTRIC SHOCK PRESENTATION.
191767 04-03

POSITIVE REINFORCING EFFECTS OF APOMORPHINE, D-AMPHETAMINE AND MORPHINE: INTERACTION WITH HALOPERIDOL.
191899 04-04

EFFECTS OF 6-HYDROXYDOPAMINE ON ANOREXIA PRODUCED BY D-AMPHETAMINE AND RELATED PHENYLETHYLAMINES.
191905 04-03

THE COMPARATIVE EFFECTS OF PENTOBARBITAL AND D-AMPHETAMINE ON A SHORT-TERM MEMORY TASK IN BABOONS.
191917 04-04

METABOLISM OF D-AMPHETAMINE BY RAT BRAIN IN VIVO AND IN VITRO.
191922 04-03

INTERACTIONS BETWEEN RO-4-1284 AND D-AMPHETAMINE (DA) ON SHUTTLEBOX AVOIDANCE IN RATS.
192009 04-04

INTERACTION OF SEROTONIN ANTAGONISTS WITH 3,4-DICHLORO-2-(2-IMIDAZOLIN-2-YL-THIO) 2 ACETOPHENONE HYDROBROMIDE (DITA) AND D-AMPHETAMINE HYDROBROMIDE (DITA) AND D-AMPHETAMINE ON CERTAIN BEHAVIORAL PARAMETERS OF MALE MICE.
192014 04-04

D-AMPHETAMINE-INDUCED
THE GENERAL LOCUS OF D-AMPHETAMINE-INDUCED DISCRIMINATIVE STIMULI. (PH.D. DISSERTATION).
185725 03-03

SIGNIFICANCE OF DOPAMINE RECEPTOR ACTIVITY IN DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY.
186670 03-04

D-CHLORPHENIRAMINE
ANTIDEPRESSANT EFFECTS OF D-CHLORPHENIRAMINE -- CLINICAL EVALUATION (FIRST REPORT).
176889 02-09

D-LYSERGIC
STUDIES ON ENZYMATIC DEALKYLATION OF D-LYSERGIC ACID DIETHYLAMIDE (LSD).
177336 02-03

COMPARISON OF THE CHRONIC AND ACUTE EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) TREATMENT ON RAT BRAIN SEROTONIN AND NOREPINEPHRINE.
181945 02-03

A COMPARISON OF EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) AND SEROTONIN ON PRE- AND POSTSYNAPTIC CELLS IN THE SEROTONIN SYSTEM.
182141 02-03

EVIDENCE FOR THE ACTION OF D-LYSERGIC ACID DIETHYLAMIDE, MESCALINE AND BUFOTENINE ON 5-HYDROXYTRYPTAMINE RECEPTORS IN UMBILICAL VASCULATURE.
182716 03-03

D-TUBOCURARINE
CASE AGAINST THE USE OF D-TUBOCURARINE IN OPERANT STUDIES OF THE CARDIOVASCULAR SYSTEM.
189425 04-03

D-40TA
ACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MICE, RATS, RABBITS AND DOGS.
173548 01-05

SUBACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MALE AND FEMALE RATS: ORAL ADMINISTRATION FOR ONE MONTH.
177097 02-05

ANTICONVULSIVE ACTIVITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) AND ITS EFFECT ON LIMBIC SYSTEM.
177099 02-02

DISSOCIATIVE CHANGE IN ANTIAGGRESSIVE AND MUSCLE RELAXANT ACTIONS OF S-TRIAZOLOBENZODIAZEPINE (D-40TA) BY REPEATED ADMINISTRATION AND PHENOBARBITAL PRETREATMENT, AND ITS RELATION TO METABOLISM.
181654 02-04

EFFECT OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) ON THE DAYTIME SLEEP-WAKEFULNESS PATTERNS IN MONKEYS.
181657 02-02

EFFECT OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) ON THE DAYTIME SLEEP-WAKEFULNESS PATTERNS IN NORMAL AND P-CHLOROPHENYLALANINE INSOMNIAC CATS.
181658 02-02

DAILY
THE TREATMENT OF DEPRESSION WITH A SINGLE DAILY DOSE OF IMIPRAMINE PAMOATE.
169491 01-09

SINGLE VERSUS DIVIDED DAILY DOSE OF TRIMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
170622 01-09

EFFECTS OF METHAMPHETAMINE ON DAILY RHYTHMS OF HYPOTHALAMIC NOREPINEPHRINE, SEROTONIN AND PLASMA CORTICOSTERONE LEVELS IN THE RAT.
184178 03-03

DAILY RHYTHM IN BODY TEMPERATURE OF MENTAL PATIENTS: APPLICATION OF COSINOR METHOD -- FIRST REPORT.
191685 04-17

DOXEPIN: IS A SINGLE DAILY DOSE ENOUGH?
192066 04-10

DALMANE
THE EFFECTS OF DALMANE (FLURAZEPAM HYDROCHLORIDE) ON THE CONTINGENT NEGATIVE VARIATION. (AMSTERDAM).
177645 02-16

DAMAGE
LACK OF EFFECT OF RIBAMINOL, TCAP, AND MAGNESIUM PEMOLINE ON RECOVERY FROM NEOCEREBELLAR DAMAGE.
171904 01-03

THE EFFECTS ON INGESTIVE BEHAVIORS OF DAMAGE TO CENTRAL DOPAMINE CONTAINING NEURONS.
191520 04-04

DANTROLENE
A COMPARATIVE STUDY OF DANTROLENE SODIUM AND OTHER SKELETAL MUSCLE RELAXANTS WITH THE STRAUB TAIL MOUSE.
186638 03-04

DARK
EFFECT OF 6-HYDROXYDOPAMINE ON DARK ADAPTATION IN THE RAT RETINA.
167358 01-03

THE EFFECT OF IPRONIAZID AND TRANYLCYPROMINE STUDIED WITH A DARK AVOIDANCE CONDITIONED SCHEDULE.
186590 03-04

DIFFERENTIAL EFFECTS OF PILOCARPINE AND SCOPOLAMINE ON THE PERFORMANCE OF A LIGHT DARK DISCRIMINATION MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN.
186701 03-03

DARKNESS
DETERMINANTS OF THE NORADRENERGIC SATIETY EFFECT: ENVIRONMENTAL DARKNESS VS. THE FEEDING PATTERN.
182133 02-04

DARTALANR
CLINICAL TRIAL WITH DARTALANR, DJAKARTA, INDONESIA.
170753 01-11

DATA
CLINICAL DATA AND SOCIOPSYCHIATRIC IMPLICATIONS OF OUTPATIENT TREATMENT WITH LONG-TERM PHENOTHIAZINES.
182791 03-09

DAWN
SCHIZOPHRENIA MANAGEMENT -- THE DAWN OF A NEW ERA.
172435 01-08

DAYS
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) ADMINISTERED SUBCUTANEOUSLY TO RABBITS FOR 28 DAYS.
191965 04-03

DAYTIME
EFFECT OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) ON THE DAYTIME SLEEP-WAKEFULNESS PATTERNS IN MONKEYS.
181657 02-02

EFFECT OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) ON THE DAYTIME SLEEP-WAKEFULNESS PATTERNS IN NORMAL AND P-CHLOROPHENYLALANINE INSOMNIAC CATS.
181658 02-02

DB-2182
EXPERIMENT WITH LOPRAMINE (DB-2182) ON THE TREATMENT OF DEPRESSION.
191665 04-09

DDT
DDT EFFECT ON 32P INCORPORATION FROM GAMMA-LABELLED ATP INTO PROTEINS FROM LOBSTER NERVE.
191315 04-03

DEALKYLATION
STUDIES ON ENZYMATIC DEALKYLATION OF D-LYSERGIC ACID DIETHYLAMIDE (LSD).
177336 02-03

DEAMINATED
BEHAVIORAL AND PHYSIOLOGICAL ACTIVITY OF DEAMINATED METABOLITES OF MESCALINE.
182244 03-03

DEANOL
DEANOL IN THE TREATMENT OF LEVODOPA INDUCED DYSKINESIAS.
184196 03-11

DEATH
A REVIEW OF THE USE OF LSD FOR THE PATIENT NEAR DEATH.
177681 02-12

DEATHS
CHANGING DEATHS PERSPECTIVE.
169138 01-11

DEBRISOQUIN
ABSENCE OF DEGENERATION OF ADRENERGIC NEURONS AFTER PROLONGED TREATMENT WITH DEBRISOQUIN.
186677 03-03

DECANOATE
ROLE OF FLUPHENAZINE DECANOATE IN LESSENING THE BURDEN OF CHRONIC SCHIZOPHRENICS ON THE COMMUNITY.
169438 01-08

ONE YEAR OF CLINICAL EXPERIENCE WITH LARGE DOSES OF 10 PERCENT FLUPENTHIXOL DECANOATE (LU-1705).
172735 01-07

PRELIMINARY STUDY OF THE TREATMENT OF CHRONIC PSYCHOSES WITH FLUPENTHIXOL DECANOATE.
172978 01-09

FEATURES OF THE THERAPEUTIC EFFECT OF FLUPHENAZINE DECANOATE IN SCHIZOPHRENIA.
183683 03-08

IMPLICATIONS OF SUSTAINED RELEASE PHENOTHIAZINES: A STUDY OF FLUPHENAZINE DECANOATE.
185007 03-09

FLUPENTHIXOL DECANOATE IN SCHIZOPHRENIA.
185194 03-08
INFLUENCE OF FLUPENTHIXOL AND FLUPENTHIXOL DECANOATE ON METHYLPHENIDATE AND APOMORPHINE INDUCED COMPULSIVE GNAWING IN MICE.
186371 03-04

DECAPITATION
EFFECTS OF DECAPITATION, ETHER AND PENTOBARBITAL ON CYCLIC AMP AND CYCLIC GMP LEVELS IN RAT TISSUES.
182154 02-03

DECARBOXYLASE
COMBINATION OF L-DOPA, DESIPRAMINE, AND A DECARBOXYLASE INHIBITOR IN THE TREATMENT OF DEPRESSION.
169468 01-09
THE INFLUENCE OF NEUROTROPIC DRUGS ON MONOAMINE OXIDASE (MAO) AND 5-OXYTRYPTOPHANE DECARBOXYLASE (5-OTD) ACTIVITY IN THE BRAIN.
183142 03-13
LEVODOPA COMBINED WITH MK-486 (L-ALPHA-METHYLDOPAHYDRAZINE) -- A PERIPHERAL DECARBOXYLASE INHIBITOR IN PARKINSONS DISEASE.
187615 04-11
PARKINSONIAN SYNDROMES: TREATMENT BY ASSOCIATION OF L-DOPA PLUS DECARBOXYLASE INHIBITOR.
188093 04-11

DECEREBRATE
THE EFFECT OF L-TRYPTOPHAN (TP) ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) REFLEXES IN ACUTE DECEREBRATE SPINAL CATS AND THE EFFECT OF PRETREATMENT WITH P-CHLOROPHENYLALANINE (PCPA) ON THE ACTION OF TP. (UNPUBLISHED PAPER).
170874 01-03

DECLINE
THE UPTAKE OF DOPAMINE AND SEROTONIN IN RAT BRAIN DURING PROGESTERONE DECLINE.
171307 01-03

DECOMPENSATED
RAPID DIGITALIZATION OF DECOMPENSATED SCHIZOPHRENIC PATIENTS WITH ANTIPSYCHOTIC AGENTS.
189095 04-08

DECOMPENSATION
PHENOTHIAZINE INDUCED DECOMPENSATION.
171506 01-15

DEFEATED
INVERSION BY APOMORPHINE OF THE TENDENCY OF FEMALE RATS TO BE DEFEATED BY MALES WHEN COMPETING FOR FOOD IN A STRAIGHT RUNWAY.
184212 03-04

DEFECATION
THE EFFECT OF OCTOCLOTHEPIN AND PERPHENAZINE ON BEHAVIOUR IN RATS WITH DIFFERENT EXPLORATION AND DEFECATION RATES.
192430 04-04

DEFECT
ORAL 5-HTP IN PRIMARY AUTISM WITH 5-HT BINDING DEFECT.
181392 02-13

DEFECTIVES
A DOUBLE-BLIND TRIAL OF LONG-TERM LITHIUM THERAPY IN MENTAL DEFECTIVES.
185193 03-11

DEFEKTON
EXPERIENCE IN THE USE OF A LOW DOSAGE OF CARPIPRAMINE (DEFEKTON).
176472 02-08

DEFENSIVE
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND METHYSERGIDE ON DEFENSIVE BEHAVIOR IN RATS.
182190 02-04
NEUROCHEMICAL ANALYSIS OF AGGRESSIVE - DEFENSIVE BEHAVIOR ELICITED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS AND CENTRAL GRAY MATTER.
191784 04-02

DEFICIENCY
POLLY: MENTAL DEFICIENCY AND SCHIZOPHRENIA.
174641 01-17

DEFICIENT
BRAIN AMINES IN PYRIDOXINE DEFICIENT RATS.
182171 02-03

DEFICIT
POST-MORTEM MEASUREMENT OF ENZYMES IN HUMAN BRAIN: EVIDENCE OF A CENTRAL NORADRENERGIC DEFICIT IN SCHIZOPHRENIA.
191529 04-13

DEFICITS
TREMOR INDUCTION BY INTRACAUDATE INJECTIONS OF BRETYLIUM, TETRABENAZINE, OR MESCALINE: FUNCTIONAL DEFICITS IN CAUDATE DOPAMINE.
167329 01-03
L-DOPA EFFECTS ON MOTOR AND CENTRAL PROGRAMMING DEFICITS IN PARKINSONISM.
184976 03-14
THE NATURE OF STORAGE DEFICITS AND STATE-DEPENDENT RETRIEVAL UNDER MARIHUANA.
189406 04-14
ENDURING LEARNING DEFICITS AND CEREBRAL SYNAPTIC MALFORMATION FROM EXPOSURE TO 10 PARTS OF HALOTHANE PER MILLION.
192565 04-04

DEGENERATION
ABSENCE OF DEGENERATION OF ADRENERGIC NEURONS AFTER PROLONGED TREATMENT WITH DEBRISOQUIN.
186677 03-03

DELAYED
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON DELAYED MATCHING-TO-SAMPLE CHOICE SPEEDS IN CHIMPANZEES.
171886 01-04
EFFECTS OF CHRONIC EXPOSURE TO DELTA9-TETRAHYDROCANNABINOL ON DELAYED MATCHING-TO-SAMPLE IN CHIMPANZEES.
189405 04-04

DELAYED-RESPONSE
SCOPOLAMINE EFFECTS ON TWO-TRIAL DELAYED-RESPONSE PERFORMANCE IN THE RAT.
186372 03-04

DELIRIOUS
DELIRIOUS SYNDROME AFTER THE ADMINISTRATION OF HALOPERIDOL.
174784 01-15

DELIRIUM
IMPORTANCE OF THE COOPERATION OF FAMILIES IN THE TREATMENT OF THE SICK: CONCERNING CHRONIC DELIRIUM TREATED WITH NEUROLEPTICS AND MELANCHOLY TREATED WITH ANTIDEPRESSANTS.
182899 03-17
KETAMINE INDUCED POSTANESTHETIC DELIRIUM ATTENUATED BY TETRAHYDROAMINOACRIDINE.
188689 04-05

DELIRIUM-TREMENS
CHEMOTHERAPY OF DELIRIUM-TREMENS: A SURVEY OF PHYSICIANS PREFERENCES.
192068 04-11

DELIVERY
THE EFFECT OF PAIN RELIEVING DRUGS ADMINISTERED DURING LABOR AND DELIVERY ON THE BEHAVIOR OF THE NEWBORN: A REVIEW.
183706 03-17
THE FUTURE OF PHARMACOTHERAPY: NEW DRUG DELIVERY SYSTEMS.
191044 04-08

DELTA1-TETRAHYDROCANNABINOL
THE DISTRIBUTION OF DELTA1-TETRAHYDROCANNABINOL AND 7-HYDROXY-DELTA1-TETRAHYDROCANNABINOL IN THE MOUSE BRAIN AFTER INTRAVENTRICULAR INJECTION.
172596 01-03
BLOOD AND BRAIN LEVELS OF DELTA1-TETRAHYDROCANNABINOL IN MICE -- THE EFFECT OF 7-HYDROXY-DELTA1-TETRAHYDROCANNABINOL.
177333 02-03
RELATIVE PHARMACOLOGICAL POTENCY IN MICE OF OPTICAL ISOMERS OF DELTA1-TETRAHYDROCANNABINOL.
181941 02-03
MECHANISM OF THE NEGATIVE CHRONOTROPIC AND INOTROPIC EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC).
182219 03-03
THE EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC) AND ETHANOL ON MONOSYNAPTIC AND POLYSYNAPTIC TRANSMISSION IN THE CENTRAL NERVOUS SYSTEM.
182222 03-03
EFFECTS OF CHRONICALLY ADMINISTERED DELTA1-TETRAHYDROCANNABINOL OF ADRENAL AND GONADAL ACTIVITY OF MALE RATS.
183358 03-03
BLOCKING OF THE EFFECT OF A DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC) ON SPONTANEOUS MOTOR ACTIVITY IN THE RAT BY IMMUNIZATION WITH A PROTEIN CONJUGATE OF DELTA1-THC.
187129 03-04
7-OXO-DELTA1-TETRAHYDROCANNABINOL: A NOVEL METABOLITE OF DELTA1-TETRAHYDROCANNABINOL.
187574 04-01
METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY RATS TOLERANT TO MARIHUANA.
192020 04-03
EFFECTS OF DELTA1-TETRAHYDROCANNABINOL ON SIDMAN DISCRIMINATED AVOIDANCE BEHAVIOR IN RATS.
192413 04-03

DELTA1-THC
MECHANISM OF THE NEGATIVE CHRONOTROPIC AND INOTROPIC EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC).
182219 03-03
THE EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC) AND ETHANOL ON MONOSYNAPTIC AND POLYSYNAPTIC TRANSMISSION IN THE CENTRAL NERVOUS SYSTEM.
182222 03-03

BLOCKING OF THE EFFECT OF A DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC) ON SPONTANEOUS MOTOR ACTIVITY IN THE RAT BY IMMUNIZATION WITH A PROTEIN CONJUGATE OF DELTA1-THC.
187129 03-04

DELTA8-THC

EFFECTS OF DELTA8-THC AND DELTA9-TETRAHYDROCANNABINOL ON THE IMMUNE RESPONSE IN MICE.
191960 04-03

CARDIOVASCULAR EFFECTS OF DELTA8-THC AND DELTA9-TETRAHYDROCANNABINOL IN RATS.
191971 04-03

DELTA9-TETRAHYDROCANNABINOL

THE EFFECTS OF CHRONIC TREATMENT WITH DELTA9-TETRAHYDROCANNABINOL ON CATECHOLAMINE SYNTHESIS IN THE RAT.
169471 01-03

PHARMACOLOGICAL INTERACTION BETWEEN CANNABIDIOL AND DELTA9-TETRAHYDROCANNABINOL.
169472 01-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON DELAYED MATCHING-TO-SAMPLE CHOICE SPEEDS IN CHIMPANZEES.
171886 01-04

DELTA9-TETRAHYDROCANNABINOL INDUCED INHIBITION OF PREDATORY AGGRESSION IN THE RAT.
172745 01-04

INTERACTIONS IN MAN OF DELTA9-TETRAHYDROCANNABINOL: I. ALPHA-METHYL-PARA-TYROSINE.
174347 01-13

A STUDY OF THE RELATIVE ANTICONVULSANT AND TOXIC ACTIVITIES OF DELTA9-TETRAHYDROCANNABINOL AND ITS CONGENERS.
174608 01-05

TOXICOLOGY OF DELTA9-TETRAHYDROCANNABINOL. (PH.D. DISSERTATION).
174961 01-05

CARDIOVASCULAR PHARMACOLOGY OF DELTA9-TETRAHYDROCANNABINOL. (PH.D. DISSERTATION).
174964 01-03

A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY IN MAN OF INTRAVENOUSLY ADMINISTERED DELTA9-TETRAHYDROCANNABINOL, CANNABINOL, AND CANNABIDIOL.
176747 02-03

CHRONOPHARMACOLOGY OF DELTA9-TETRAHYDROCANNABINOL HYPOTHERMIA IN MICE.
176880 02-03

EFFECT OF ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL ON MEMORY, SPEECH, AND PERCEPTION OF THERMAL STIMULATION: RESULTS WITH FOUR NORMAL HUMAN VOLUNTEER SUBJECTS. PRELIMINARY REPORT.
177674 02-14

FURTHER EVIDENCE FOR A ROLE OF 2-PHENYLETHYLAMINE IN THE MODE OF ACTION OF DELTA9-TETRAHYDROCANNABINOL.
179992 02-03

INTERACTION OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON INTESTINAL MOTILITY IN MICE.
180057 02-03

SUBCELLULAR DISTRIBUTION OF DELTA9-TETRAHYDROCANNABINOL IN RAT BRAIN.
181810 02-03

ELECTROENCEPHALOGRAPHIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL, LSD-25, MESCALINE AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE IN THE RABBITS.
182095 02-03

EFFECTS OF PSYCHOTROPIC DRUGS ON ABNORMAL BEHAVIOR INDUCED BY DELTA9-TETRAHYDROCANNABINOL.
182114 02-04

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON THE DOMINANCE BEHAVIOR OF THE RAT.
182189 02-04

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND METHYSERGIDE ON DEFENSIVE BEHAVIOR IN RATS.
182190 02-04

DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) DOSE EFFECTS COMPARED ON THREE SCHEDULES OF FOOD REINFORCED OPERANT PERFORMANCE.
182191 02-04

INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CAFFEINE, (C), NICOTINE (N), PHENOBARBITAL (P): EFFECTS ON CONDITIONED AVOIDANCE (CAR).
182192 02-04

THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (THC), PENTOBARBITAL AND SKF-525-A WITH THE CARDIOVASCULAR SYSTEM OF THE RAT.
182218 03-03

HYPOTHERMIC ACTION OF DELTA9-TETRAHYDROCANNABINOL, 11-OH-DELTA9-TETRAHYDROCANNABINOL AND 11-OH-DELTA8-TETRAHYDROCANNABINOL (DELTA9-THC, 11-OH-DELTA9-THC AND 11-OH-DELTA8-THC) IN MICE.
182220 03-03

ANTIPYRETIC, ANALGESIC AND ANTIINFLAMMATORY ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL IN THE RAT.
182221 03-03

A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL AND ITS MONOHYDROXYLATED METABOLITES IN MAN.
182223 03-03

DELTA9-TETRAHYDROCANNABINOL IN DEPRESSED PATIENTS.
183546 03-10

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON THE METABOLISM OF 3H-5-HYDROXYTRYPTAMINE AND 3H-NOREPINEPHRINE IN THE RAT BRAIN.
183787 03-03

CANNABIDIOL INTERACTION WITH DELTA9-TETRAHYDROCANNABINOL.
183788 03-03

ROLE OF THE CENTRAL AUTONOMIC NERVOUS SYSTEM IN THE HYPOTENSION AND BRADYCARDIA INDUCED BY (-) DELTA9-TETRAHYDROCANNABINOL.
183795 03-03

DELTA9-TETRAHYDROCANNABINOL AND 11-HYDROXY-DELTA9-TETRAHYDROCANNABINOL: BEHAVIORAL EFFECTS AND TOLERANCE DEVELOPMENT.
183893 03-04

TEMPORALLY RELATED STIMULUS PROPERTIES OF DELTA9-TETRAHYDROCANNABINOL IN MONKEYS.
186567 03-04

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON BODYWEIGHT AND BRAIN ELECTROLYTES IN THE CHICKEN.
186570 03-03

ANALGESIC EFFECT OF DELTA9-TETRAHYDROCANNABINOL IN THE DOG.
186585 03-03

EFFECTS OF ORAL DELTA9-TETRAHYDROCANNABINOL ON OPERANT REINFORCEMENT SCHEDULE PERFORMANCE IN RATS.
186645 03-04

EFFECT OF SKF-525-A ON THE METABOLISM OF (-) DELTA9-TETRAHYDROCANNABINOL IN THE RAT BRAIN AND LIVER.
187578 04-03

EVALUATION OF REINFORCING CAPABILITY OF DELTA9-TETRAHYDROCANNABINOL IN RHESUS MONKEYS.
187638 04-04

DELTA9-TETRAHYDROCANNABINOL: EFFECTS OF ROUTE OF ADMINISTRATION ON ONSET AND DURATION OF ACTIVITY AND TOLERANCE DEVELOPMENT.
187928 04-03

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON SLEEP.
187929 04-14

LONG-TERM USE OF MARIHUANA AND THE DEVELOPMENT OF TOLERANCE OR SENSITIVITY TO DELTA9-TETRAHYDROCANNABINOL.
188119 04-13

PHYSIOCHEMICAL PROPERTIES, SOLUBILITY, AND PROTEIN BINDING OF DELTA9-TETRAHYDROCANNABINOL. (UNPUBLISHED PAPER).
188256 04-01

ORAL AND INTRAVENOUS TOXICITY OF DELTA9-TETRAHYDROCANNABINOL IN RHESUS MONKEYS.
188872 04-05

INFLUENCE ON ACUTE PRETREATMENT WITH DELTA9-TETRAHYDROCANNABINOL OF THE LD50 OF VARIOUS SUBSTANCES THAT ALTER NEUROHUMORAL TRANSMISSION.
188876 04-05

EFFECTS OF CHRONIC EXPOSURE TO DELTA9-TETRAHYDROCANNABINOL ON DELAYED MATCHING-TO-SAMPLE IN CHIMPANZEES.
189405 04-04

DELTA9-TETRAHYDROCANNABINOL AND AGGRESSIVE BEHAVIOR IN RATS.
189525 04-04

INHALATION, PARENTERAL AND ORAL LD50 VALUES OF DELTA9-TETRAHYDROCANNABINOL IN FISCHER RATS.
189588 04-05

EFFECTS OF PHENOBARBITAL AND SKF-525-A PRETREATMENT, SEX, LIVER INJURY, AND VEHICLE ON DELTA9-TETRAHYDROCANNABINOL TOXICITY.
189598 04-05

EFFECTS OF DELTA8-THC AND DELTA9-TETRAHYDROCANNABINOL ON THE IMMUNE RESPONSE IN MICE.
191960 04-03

THE INFLUENCE OF DELTA9-TETRAHYDROCANNABINOL (THC) ON PILOCARPINE (PILO) INDUCED PAROTID SECRETIONS OF THE RAT.
191962 04-03

RETARDATION OF TUMOR GROWTH BY DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC).
191963 04-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) ADMINISTERED SUBCUTANEOUSLY TO RABBITS FOR 28 DAYS.
191965 04-03

COMPREHENSIVE BEHAVIORAL ASSESSMENT OF THE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN RATS.
191966 04-04

COMPARATIVE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CANNABIDIOL (CBD), AND CANNABINOL (CBN) ON TIMING BEHAVIOR IN RATS.
191967 04-04

CARDIOVASCULAR EFFECTS OF DELTA8-THC AND DELTA9-TETRAHYDROCANNABINOL IN RATS.
191971 04-03

NEUROPHARMACOLOGICAL ANALYSIS OF CENTRAL ADRENERGIC AND CHOLINERGIC ANTAGONISM OF DELTA9-TETRAHYDROCANNABINOL.
191992 04-03

DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) IMIPRAMINE INTERACTION ON MOUSE BODY TEMPERATURE.
191996 04-03

ANALYSIS OF HYPOTHERMIC ACTION OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) IN MICE.
191997 04-03

DELTA9-THC

EFFECTS OF DELTA9-THC, LSD-25 AND SCOPOLAMINE ON CONTINUOUS, SPONTANEOUS ALTERNATION IN THE Y-MAZE.
171306 01-04

(-)DELTA9-THC AS AN HYPNOT!C: AN EXPERIMENTAL STUDY OF THREE DOSE LEVELS.
174041 01-14

EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL (DELTA9-THC) ON MEMORY, ATTENTION AND SUBJECTIVE STATE: A DOUBLE-BLIND STUDY.
174043 01-14

OPEN-FIELD BEHAVIOR AND ACQUISITION OF DISCRIMINATIVE RESPONSE CONTROL IN DELTA9-THC TOLERANT RATS.
178813 02-04

DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) DOSE EFFECTS COMPARED ON THREE SCHEDULES OF FOOD REINFORCED OPERANT PERFORMANCE.
182191 02-04

INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CAFFEINE, (C), NICOTINE (N), PHENOBARBITAL (P): EFFECTS ON CONDITIONED AVOIDANCE (CAR).
182192 02-04

MECHANISM OF THE NEGATIVE CHRONOTROPIC AND INOTROPIC EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC).
182219 03-03

HYPOTHERMIC ACTION OF DELTA9-TETRAHYDROCANNABINOL, 11-OH-DELTA9-TETRAHYD?OCANNABINOL AND 11-OH-DELTA8-TETRAHYDROCANNABINOL (DELTA9-THC, 11-OH-DELTA9-THC AND 11-OH-DELTA8-THC) IN MICE.
182220 03-03

THE EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC) AND ETHANOL ON MONOSYNAPTIC AND POLYSYNAPTIC TRANSMISSION IN THE CENTRAL NERVOUS SYSTEM.
182222 03-03

AUTOMATIC DETERMINATION OF THE PAIN THRESHOLD TO ELECTROSHOCK AND THE EFFECTS OF DELTA9-THC.
183363 03-03

EFFECTS OF DELTA9-THC ON FOOD AND WATER INTAKE OF DEPRIVATION EXPERIENCED RATS.
191375 04-04

RETARDATION OF TUMOR GROWTH BY DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC).
191963 04-03

THE EFFECTS OF DELTA9-THC AND A WATER SOLUBLE DERIVATIVE ON PGE1 SYNTHESIS IN THE CORPUS-STRIATUM.
191964 04-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) ADMINISTERED SUBCUTANEOUSLY TO RABBITS FOR 28 DAYS.
191965 04-03

COMPARATIVE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CANNABIDIOL (CBD), AND CANNABINOL (CBN) ON TIMING BEHAVIOR IN RATS.
191967 04-04

DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) IMIPRAMINE INTERACTION ON MOUSE BODY TEMPERATURE.
191996 04-03

ANALYSIS OF HYPOTHERMIC ACTION OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) IN MICE.
191997 04-03

DELTA9-TRANS-TETRAHYDROCANNABINOL

EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL (DELTA9-THC) ON MEMORY, ATTENTION AND SUBJECTIVE STATE: A DOUBLE-BLIND STUDY.
174043 01-14

EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL IN SEVERAL ANIMAL MODELS OF AGGRESSION.
182188 02-04

EFFECTS OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL ON SOCIAL BEHAVIOR OF SQUIRREL MONKEY DYADS IN A WATER COMPETITION SITUATION.
187640 04-04

DELUSIONAL-LIKE

TEMPORAL DISORGANIZATION AND DELUSIONAL-LIKE IDEATION: PROCESSES INDUCED BY HASHISH AND ALCOHOL.
185330 03-14

DEMAND

EFFECTS OF TWO LEVELS OF ATTENTION DEMAND ON VIGILANCE PERFORMANCE UNDER MARIHUANA.
189359 04-14

DIAZEPAM ON DEMAND: DRUG SEEKING BEHAVIOR IN PSYCHIATRIC INPATIENTS.
189924 04-17

DEMENTIA

LEVODOPA INDUCED DYSKINESIAS: COMPARISON IN PARKINSONISM DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS.
169376 01-15

PARKINSONISM DEMENTIA OF GUAM: TREATMENT WITH LEVODOPA AND L-ALPHA-METHYLDOPAHYDRAZINE.
179996 02-13

DEMETHYLATION

DEMETHYLATION OF N,N DIMETHYLAMPHETAMINES - EVIDENCE FOR A MULTIENZYME SYSTEM.
191923 04-03

DEMONSTRABLE

HYDROCORTISONE INDUCED INCREASE IN THE HISTOCHEMICALLY DEMONSTRABLE CATECHOLAMINE CONTENT OF SYMPATHETIC NEURONS OF THE NEWBORN RAT.
189027 04-03

DENERVATED

EFFECT OF DIVALENT CATIONS ON ACH CONTRACTURES OF DEPOLARIZED DENERVATED RAT MUSCLES.
188914 04-03

DENERVATION

NORADRENALINE IN THE GUINEA-PIG ALIMENTARY CANAL: REGIONAL DISTRIBUTION AND SENSITIVITY TO DENERVATION AND RESERPINE.
191326 04-03

DENSITOMETRY

QUANTITATIVE DETERMINATION OF IMIPRAMINE AND DESIPRAMINE IN HUMAN BLOOD PLASMA BY DIRECT DENSITOMETRY OF THIN-LAYER CHROMATOGRAMS.
183603 03-13

DEOXYGLUCOSE

INFLUENCE OF VARIOUS SUBSTANCES WHICH INDUCE AND INHIBIT AGGREGATION ON THE UPTAKE OF DEOXYGLUCOSE BY HUMAN BLOOD PLATELETS.
191770 04-13

DEPAMIDE

COMPLEMENTAL PHARMACOLOGICAL STUDY OF DI-N-PROPYLACETAMIDE OR DEPAMIDE.
180722 02-07

A SUMMARY OF THE CLINICAL DOSSIER ON DEPAMIDE.
183544 03-17

DEPARTMENT

POLYMYALGIA RHEUMATICA IN A GERIATRIC DEPARTMENT: NINE PATIENTS WITH AN AVERAGE AGE OF 83 YEARS.
187236 03-11

DEPENDENCE

DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE IN RESPECT TO TIME AND DOSAGE AND QUANTIFICATION OF THE PRECIPITATED WITHDRAWAL SYNDROME IN RATS.
169474 01-03

ABUSE POTENTIAL OF ETORPHINE (M99) I. SUBJECTIVE EFFECTS AND PHYSICAL DEPENDENCE. (UNPUBLISHED PAPER).
171241 01-14

HYDROXYLAMINE INTERFERES WITH THE BEHAVIORAL RESPONSE TO MORPHINE DEPENDENCE IN MICE.
171905 01-04

CHRONIC HYPNOTIC DRUG USE: INEFFECTIVENESS, DRUG WITHDRAWAL INSOMNIA, AND DEPENDENCE.
172114 01-15

DEPENDENCE OF ANTICONVULSANT DRUG ACTION ON CENTRAL MONOAMINES.
172923 01-03

MORPHINE PHYSICAL DEPENDENCE UNALTERED BY PREVIOUS DEPENDENCE ON MORPHINE.
173872 01-03

DEPENDENCE LIABILITY OF SEVERAL SEDATIVE HYPNOTIC AGENTS EVALUATED IN MONKEYS.
174125 01-04

BARBITURATE DEPENDENCE IN MICE INDUCED BY A SIMPLE SHORT-TERM ORAL PROCEDURE.
175895 02-03

ATTEMPT TO EVALUATE THE PHYSICAL DEPENDENCE LIABILITY OF PSYCHOTROPIC DRUGS IN MICE.
182103 02-04

DRUG DEPENDENCE TEST OF PHENOBARBITAL AND MORPHINE IN RATS BY SPONTANEOUS INTAKE.
182104 02-04

SEPARATION OF THE DEPENDENCE PRODUCING ACTIONS FROM THE DIRECT ACTIONS OF NARCOTICS ON GUINEA-PIG ILEUM.
182162 02-03

EFFECT OF GAMMA-AMINOBUTYRIC ACID (GABA) ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
182231 03-03

A COMPARISON OF THE EFFECTS OF CHRONIC ADMINISTRATION OF ETHANOL AND ACETALDEHYDE TO MICE: EVIDENCE FOR A ROLE OF ACETALDEHYDE IN ETHANOL DEPENDENCE.
185992 03-03

AN EXPERIMENTAL INVESTIGATION OF DEPENDENCE LIABILITY OF METHAQUALONE IN RATS.
186569 03-03

MORPHINE PHYSICAL DEPENDENCE IN THE DOG.
186665 03-03

THE EFFECTS OF P-CHLOROPHENYLALANINE ON MORPHINE ANALGESIA, TOLERANCE AND DEPENDENCE DEVELOPMENT IN TWO STRAINS OF RATS.
187930 04-04

INVESTIGATION OF PHYSICAL DEPENDENCE ON A NEW BENZODIAZEPINE DERIVATIVE, BROMAZEPAM.
189209 04-05

AFFECTIVE DISORDERS AND CHEMICAL DEPENDENCE: LITHIUM FOR ALCOHOL AND DRUG ADDICTION
189775 04-09

EFFECT OF L-PHENYL-3-2-THIAZOLYL 2-THIOUREA, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
191769 04-03

COMPARISON OF BARBITAL & PENTOBARBITAL PHYSICAL DEPENDENCE IN THE CAT.
191953 04-04

MORPHINE TOLERANCE, DEPENDENCE AND WITHDRAWAL AND BRAIN ACETYLCHOLINE.
191985 04-03

DEPENDENT

TEMPERATURE DEPENDENT TOXICITY OF ADRENERGIC AGONISTS IN MICE AS A BASIS FOR TREATING D-AMPHETAMINE POISONING.
169688 01-05

CHANGES IN THE NEUROEXCITABILITY OF ALCOHOL DEPENDENT RATS UNDERGOING WITHDRAWAL AS MEASURED BY THE PENTYLENETETRAZOL SEIZURE THRESHOLD.
182348 03-03

SUBSTITUTED PIPERAZINOQUINAZOLONES: RELATIONSHIP BETWEEN SELECTIVE INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND ANTICONVULSANT ACTIVITY.
183598 03-02

SUBSTITUTED BENZOXAZOLE/BENZTHIAZOLE-2-THIONES: INTERRELATIONSHIP BETWEEN ANTICONVULSANT ACTIVITY AND INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND MONOAMINE OXIDASE.
183601 03-03

THE STANDARDIZED VIDEOTAPE INTERVIEW AS AN OBJECTIVE DEPENDENT VARIABLE IN PSYCHOTROPIC DRUG RESEARCH.
183635 03-17

CHOLINERGIC MODIFICATION OF NALOXONE INDUCED JUMPING IN MORPHINE DEPENDENT MICE.
184179 03-03

DOSE DEPENDENT SELECTIVE FACILITATION OF RESPONSE CONTINGENT LIGHT ONSET BEHAVIOR BY D-AMPHETAMINE.
185955 03-04

DOSE DEPENDENT POTENTIATION OR INHIBITION BY RO-4-4602 OF 5-HTP HYPERTHERMIA IN RABBITS.
185996 03-03

METRAZOL DISRUPTS CONDITIONED AVERSION PRODUCED BY LICL: A TIME DEPENDENT EFFECT.
188412 04-04

POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES: 1. MODIFICATION OF THE AMINO ACID PORTION OF S-ADENOSYLHOMOCYSTEINE.
190716 04-01

POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES. 2. MODIFICATION OF THE BASE PORTION OF S-ADENOSYLHOMOCYSTEINE.
190717 04-01

DEPLETED

EFFECT OF 3,4 DIMETHOXYPHENETHYLAMINE ON MONOAMINE DEPLETED RATS.
183608 03-03

ENHANCED BINDING OF CHLORPROMAZINE TO CHOLESTEROL DEPLETED SYNAPTOSOME FRACTIONS.
187801 04-03

SELF-STIMULATION AND CATECHOLAMINES: DRUG-INDUCED MOBILIZATION OF THE RESERVE POOL RE-ESTABLISHES RESPONDING IN CATECHOLAMINE DEPLETED RATS.
189025 04-04

DEPLETING

EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND AMPHETAMINE ON SELF-STIMULATION OF BRAIN FOLLOWING VARIOUS 6-HYDROXYDOPAMINE TREATMENTS.
189515 04-04

DIHYDROPTERIDINE REDUCTASE IN RAT BRAIN: REGIONAL DISTRIBUTION AND THE EFFECT OF CATECHOLAMINE DEPLETING DRUGS.
189752 04-03

DEPLETION

ANTAGONISM OF P-CHLOROAMPHETAMINE (PCA) INDUCED DEPLETION OF 5-HT FROM RAT BRAIN BY SOME THYMOLEPTICS AND OTHER PSYCHOTROPIC DRUGS.
171628 01-03

QUANTITATIVE HISTOCHEMICAL STUDIES OF STRIATAL DOPAMINE DEPLETION FOLLOWING DL-ALPHA-METHYL-P-TYROSINE ADMINISTRATION.
172924 01-03

BRAIN BIOGENIC AMINE DEPLETION AND MOOD.
174994 02-14

BEHAVIORAL EFFECTS OF SIMULTANEOUS DEPLETION OF BRAIN NOREPINEPHRINE AND SEROTONIN.
182211 03-04

TESTS OF EMOTIONAL BEHAVIOR IN RATS FOLLOWING DEPLETION OF NOREPINEPHRINE, OF SEROTONIN, OR OF BOTH.
185753 03-04

LEARNING IMPAIRMENT IN RATS AFTER 6-HYDROXYDOPAMINE INDUCED DEPLETION OF BRAIN CATECHOLAMINES.
187420 04-04

DEPLETION OF TRYPTOPHAN HYDROXYLASE BY 5,6 DIHYDROXYTRYPTAMINE IN RAT BRAIN -- TIME COURSE AND REGIONAL DIFFERENCES.
188287 04-03

DEPOLARIZED

EFFECT OF DIVALENT CATIONS ON ACH CONTRACTURES OF DEPOLARIZED DENERVATED RAT MUSCLES.
188914 04-03

DEPOLARIZING

ON THE MECHANISM OF RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVES INDUCED BY DEPOLARIZING AGENTS AND SYMPATHOMIMETIC DRUGS. (UNPUBLISHED PAPER).
187397 04-03

DEPOSITION

THE INFLUENCE OF ALDOSTERONE OR METHAMPHETAMINE ON LIVER GLYCOGEN DEPOSITION OF MICE STRESSED BY LONG-TERM ISOLATION.
182105 02-03

DEPOT

ANTIPARKINSONIAN AGENTS AND DEPOT PHENOTHIAZINE.
173006 01-09

PROGRESS REPORT ON THE USE OF THE DOG FOR ASSESSING MORPHINE-LIKE AND NALORPHINE-LIKE AGONISTS AS WELL AS DEPOT PREPARATIONS OF ANTAGONISTS. (UNPUBLISHED PAPER).
176312 02-03

A PSYCHIATRIC CLINIC FOR DEPOT PHENOTHIAZINES.
181192 02-08

SIDE-EFFECTS OF DEPOT FLUPHENAZINES.
188312 04-15

DEPRESSANT

THE SPIRAL AFTEREFFECT (SAE) AS A MEASURE OF MOTION SICKNESS SUSCEPTIBILITY AND THE EFFECT ON THE SAE OF AN ANTIMOTION SICKNESS DRUG AND A CENTRAL NERVOUS SYSTEM DEPRESSANT.
172780 01-03

EXCITANT AND DEPRESSANT DRUGS MODULATE EFFECTS OF ENVIRONMENT ON BRAIN WEIGHT AND CHOLINESTERASES.
174036 01-03

ANTIHYPERTENSIVE AND CENTRAL NERVOUS SYSTEM DEPRESSANT PROPERTIES OF 3-(GAMMA-P-FLUOROBENZOYLPROPYL) 2,3,4,4A,5,6 HEXAHYDROPYRAZINOQUINOLINE HYDROCHLORIDE (COMPOUND-69-183, CENTPYRAQUIN).
176881 02-03

INTERACTION OF CYCLIC AMP WITH NEUROPHARMACOLOGIC DEPRESSANT AGENTS.
182155 02-03

CENTRAL NERVOUS DEPRESSANT XV: SYNTHESIS AND PHARMACOLOGICAL SCREENING OF SOME TRIMETHOXYAZLACTONES.
182828 03-02

MODIFICATION OF LEARNING AND MEMORY IN GOLDFISH THROUGH THE USE OF STIMULANT AND DEPRESSANT DRUGS.
186583 03-04

DEPRESSANTS

SELECTIVE ANTAGONISM OF CENTRAL NERVOUS SYSTEM DEPRESSANTS BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE.
171007 01-13

INTERACTION OF D-AMPHETAMINE WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY OF MICE.
189613 04-04

DEPRESSED

THE COMPUTER ANALYZES TWO PSYCHOTHERAPEUTIC AGENTS IN ANXIETY/DEPRESSED STATES.
167345 01-10

A DOUBLE-BLIND, COMPARATIVE CLINICAL TRIAL WITH LUDIOMIL (CIBA-34276-BA) AND AMITRIPTYLINE IN NEWLY ADMITTED DEPRESSED PATIENTS.
167774 01-09

DRUG TREATMENT OF DEPRESSED PATIENTS REFERRED FOR HOSPITALIZATION.
170621 01-09

AMITRIPTYLINE IN ANXIOUS DEPRESSED OUTPATIENTS: A CONTROLLED STUDY.
172993 01-10

EFFECTS OF AMITRIPTYLINE AND IMIPRAMINE ON AMINE METABOLITES IN THE CEREBROSPINAL FLUID OF DEPRESSED PATIENTS.
174094 01-09

AMOXAPINE AND IMIPRAMINE: A DOUBLE-BLIND STUDY IN DEPRESSED PATIENTS.
174138 01-09

GEROVITAL-H3 IN THE TREATMENT OF THE DEPRESSED AGING PATIENT.
177373 02-11

DIFFERENTIAL EFFECTS OF D- AND L-AMPHETAMINE ON THE SLEEP OF DEPRESSED PSYCHIATRIC PATIENTS ON AND OFF LITHIUM CARBONATE TREATMENT. (UNPUBLISHED PAPER).
178432 02-09

HIGH FREQUENCY OF DYSPHORIC REACTIONS TO TETRAHYDROCANNABINOL AMONG DEPRESSED PATIENTS.
181274 02-09

INDICATIONS FOR ANTIDEPRESSANT TREATMENT WITH SPECIAL REFERENCE TO DEPRESSED PRESCHOOL CHILDREN.
182428 03-10

DELTA9-TETRAHYDROCANNABINOL IN DEPRESSED PATIENTS.
183546 03-10

THE EFFECTS OF COCAINE ON DEPRESSED PATIENTS.
184160 03-09

TREATMENT EFFECTS ON THE SOCIAL ADJUSTMENT OF DEPRESSED PATIENTS.
185322 03-10

CLOMIPRAMINE AND AMITRIPTYLINE IN DEPRESSED OUTPATIENTS: A CONTROLLED STUDY.
185747 03-09

STUDIES OF CEREBROSPINAL FLUID AMINE METABOLITES IN DEPRESSED PATIENTS; CONCEPTUAL PROBLEMS AND THEORETICAL IMPLICATIONS. (UNPUBLISHED PAPER).
187398 04-13

THE EFFECT OF ORALLY ADMINISTERED COCAINE ON SLEEP OF DEPRESSED PATIENTS.
187642 04-14

THE EFFECT OF TRANYLCYPROMINE (PARNATE) ON EYELID CONDITIONING AND PAIRED ASSOCIATE LEARNING IN DEPRESSED PATIENTS.
188107 04-09

AFFECTIVE STATE AND THYROTROPIN AND PROLACTIN RESPONSES AFTER REPEATED INJECTIONS OF THYROTROPIN RELEASING HORMONE IN DEPRESSED PATIENTS.
189076 04-09

DIFFERENTIAL EFFECTS OF TRAZODONE IN DEPRESSED, SCHIZOPHRENIC AND GERIATRIC PATIENTS.
191138 04-14

THIORIDAZINE IN NEUROTIC, ANXIOUS, AND DEPRESSED PATIENTS.
192227 04-10

DEPRESSION

CHLORDIAZEPOXIDE AND DOTHIEPIN COMPARED IN ANXIETY/DEPRESSION IN GENERAL PRACTICE.
167575 01-10

THE ROLE OF DOPAMINE IN DEPRESSION.
167584 01-13

A CONTROLLED STUDY OF SINGLE DOSE ADMINISTRATION OF IMIPRAMINE PAMOATE IN ENDOGENOUS DEPRESSION.
167775 01-09

CLINICAL EFFECTS OF LITHIUM CARBONATE ON DEPRESSION.
167917 01-09

PENTOBARBITAL: SELECTIVE DEPRESSION OF EXCITATORY POSTSYNAPTIC POTENTIALS.
168485 01-03

INFLUENCE OF AMYLOBARBITONE ON OPERANT DEPRESSION AND ELATION EFFECTS IN THE RAT.
168834 01-04

LONG-TERM TREATMENT OF DEPRESSION WITH DRUGS AND PSYCHOTHERAPY.
169087 01-09

THE HETEROGENEITY OF DEPRESSION.
169093 01-09

TOWARDS A BIOCHEMICAL TYPOLOGY OF DEPRESSION.
169095 01-09

COMBINATION OF L-DOPA, DESIPRAMINE, AND A DECARBOXYLASE INHIBITOR IN THE TREATMENT OF DEPRESSION.
169468 01-09

THE TREATMENT OF DEPRESSION WITH A SINGLE DAILY DOSE OF IMIPRAMINE PAMOATE.
169491 01-09

A DOUBLE-BLIND CLINICAL TRIAL OF DOXEPIN HYDROCHLORIDE AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION IN THE FIELD OF INTERNAL MEDICINE.
171282 01-11

DEPRESSION SUBTYPES AND RESPONSE TO PHENELZINE, DIAZEPAM, AND A PLACEBO: RESULTS OF A NINE HOSPITAL COLLABORATIVE STUDY.
171502 01-09

TREATMENT OF DEPRESSION BY DRUGS AND PSYCHOTHERAPY.
171924 01-10

DRUGS AND GROUP PSYCHOTHERAPY IN NEUROTIC DEPRESSION.
171925 01-10

ELECTROLYTES IN CEREBROSPINAL FLUID IN ENDOGENOUS DEPRESSION.
172402 01-09

METHYLTESTOSTERONE WITH IMIPRAMINE IN MEN: CONVERSION OF DEPRESSION TO PARANOID REACTION.
172992 01-15

CNS DEPRESSION IN THE ABSENCE OF PROLACTIN RELEASE FOLLOWING INTRAARTERIAL INJECTIONS OF SODIUM PENTOTHAL IN THE PROESTROUS RAT.
173257 01-03

CLINICAL RESULTS WITH PIZOTYLINE IN DEPRESSION.
174299 01-09

RAPID AND GENTLE PHARMACOTHERAPY OF DEPRESSION.
174495 01-10

PIPRADROL IN MILD DEPRESSION: A CONTROLLED STUDY.
176107 02-10

EXPERIENCE IN THE USE OF SINEQUAN (DOXEPIN HYDROCHLORIDE) IN TREATMENT OF NEUROSIS, DEPRESSION AND DEPRESSIVE STATES.
176471 02-11

INDUCTION OF SEVERE DEPRESSION BY PHYSOSTIGMINE IN MARIJUANA INTOXICATED INDIVIDUALS.
177450 02-14

MOTHER INFANT SEPARATION: BEHAVIORAL ANALYSIS OF AN ANIMAL MODEL OF DEPRESSION. (PH.D. DISSERTATION).
178867 02-04

EXPERIMENTAL DEPRESSION CAUSED BY APOMORPHINE AND PHENOHARMANE.
180062 02-10

DIAGNOSIS AND MANAGEMENT OF DEPRESSION IN GENERAL PRACTICE.
180406 02-09

DOUBLE-BLIND COMPARATIVE STUDY OF HF-1972/NOVERIL IN DEPRESSION.
180986 02-10

A TRIAL OF GEROVITAL-H3 IN DEPRESSION DURING SENILITY.
181957 02-10

DRUG THERAPY FOR DEPRESSION IN CHILDREN. INDICATIONS AND METHODS.
182429 03-10

CHEMOTHERAPY IN CHILDHOOD DEPRESSION.
182430 03-09

TREATMENT PROCESS OF DEPRESSION AND CHANGES IN MICROVIBRATION.
182620 03-09

DOUBLE-BLIND CROSSOVER COMPARISON OF BROMAZEPAM AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION.
182624 03-11

MASKED DEPRESSION.
182829 03-10

HYPERTENSION AND DEPRESSION AND THEIR TREATMENT.
183234 03-09

INFLUENCE OF TETRACOSACTRIN (T) AND BETA-MELANOCYTE STIMULATING HORMONE (MSH) ON DEPRESSION OF THE SEGMENTAL REFLEX BY MORPHINE (MS). (UNPUBLISHED PAPER).
183324 03-03

COMPARATIVE EVALUATION OF DIBENCYCLADINE (LUDIOMIL) AND IMIPRAMINE IN PSYCHOTIC DEPRESSION.
183361 03-09

SO-CALLED MASKED DEPRESSION AND ITS TREATMENT.
183369 03-10

LITHIUM TREATMENT OF DEPRESSION.
185873 03-09

PROPHYLACTIC TREATMENT OF RECURRENT DEPRESSION: OBSERVATIONS FROM A MULTIHOSPITAL COLLABORATIVE STUDY.
186190 03-09

ALTERATION OF ETHANOL-INDUCED CNS DEPRESSION: INEFFECTIVENESS OF DRUGS THAT MODIFY CHOLINERGIC TRANSMISSION.
186375 03-03

A DOUBLE-BLIND CROSSOVER SEQUENTIAL TRIAL OF ORAL THYROTROPIN RELEASING HORMONE IN DEPRESSION.
188348 04-09

ACETYLCHOLINE AND DEPRESSION.
188542 04-14

LONG-TERM TREATMENT OF ENDOGENOUS DEPRESSION WITH NORTRIPTYLINE WITH CONTROL OF PLASMA LEVELS.
188832 04-09

RECENT ADVANCES IN THE TREATMENT OF DEPRESSION.
189650 04-09

MIXED ANXIETY DEPRFSSION: FACT OR MYTH?
189919 04-10

THE TREATMENT OF MIXED ANXIETY AND DEPRESSION WITH LOXAPINE: A CONTROLLED COMPARATIVE STUDY.
190195 04-09

THIRTY-FIVE YEARS CONTINUOUS TREATMENT FOR RECURRENT DEPRESSION: FROM ECT TO DRUGS.
191119 04-09

NEOMYCIN AND RUTHENIUM RED ANTAGONISM OF MONOAMINERGIC DEPRESSION OF CEREBRAL CORTICAL NEURONES.
191380 04-03

EXPERIMENT WITH LOPRAMINE (DB-2182) ON THE TREATMENT OF DEPRESSION.
191665 04-09

CLINICAL EFFECTS OF IMIPRAMINE-N-OXIDE ON DEPRESSION.
191716 04-09

AMPHETAMINES EFFECTS ON SELF-STIMULATION: DEVELOPMENT OF TOLERANCE AND POST-DRUG DEPRESSION.
191914 04-04

WELLBATRIN IN THE TREATMENT OF DEPRESSION.
191978 04-10

PHARMACOLOGY OF DEPRESSION IN THE AGED: EVALUATION OF GEROVITAL-H3 AS AN ANTIDEPRESSANT DRUG.
192229 04-09

LABORATORY ASSESSMENTS OF ANTIDEPRESSIVE ACTIVITY -- THEIR VALUE FOR CLINICAL PSYCHIATRY AND THE UNDERSTANDING OF DEPRESSION.
192422 04-09

A PHARMACOLOGICAL MODEL WITH RHESUS MONKEYS FOR THE PREDICTION OF SELECTIVE DEPRESSION OF PSYCHIC FUNCTIONS.
192424 04-04

PHENYLALANINE FOR ENDOGENOUS DEPRESSION.
192521 04-09

THYROTROPHIN RELEASING HORMONE IN THE TREATMENT OF DEPRESSION.
192577 04-09

DEPRESSIONS

EXPERIENCES WITH LAROXYL (R) IN THE TREATMENT OF DEPRESSIONS IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
170413 01-11

MEASURING THE PHARMACOLOGICAL ACTION OF IMIPRAMINE IN THE TREATMENT OF DEPRESSIONS.
174995 02-09

TREATMENT WITH PSYCHOPHARMACOLOGIC AGENTS IN CHILDHOOD DEPRESSIONS.
182431 03-11

TRYPTOPHAN AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIONS.
187536 04-09

DEPRESSIVE

DEPRESSIVE FORMS OF SCHIZOPHRENIA AND EXPERIMENTAL TREATMENT BY CLOMIPRAMINE.
167676 01-08

CHLORDIAZEPOXIDE IN DEPRESSIVE NEUROSIS: AN OPEN LABEL CROSSOVER STUDY WITH AMITRIPTYLINE.
168316 01-10

COMBINATIONS OF ANTIDEPRESSANT DRUGS IN THE TREATMENT OF DEPRESSIVE ILLNESS.
168317 01-09

IMIPRAMINE, DIAZEPAM AND GROUP PSYCHOTHERAPY IN LONG-TERM TREATMENT OF DEPRESSIVE NEUROTICS.
169089 01-10

A COMPARISON OF LITHIUM CARBONATE IN THE PREVENTION OF MANIC AND DEPRESSIVE EPISODES IN RECURRENT AFFECTIVE DISORDER.
169090 01-09

SINGLE VERSUS DIVIDED DAILY DOSE OF TRIMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
170622 01-09

A DOUBLE-BLIND INVESTIGATION OF DIMETHACRINE VERSUS IMIPRAMINE IN HOSPITALIZED DEPRESSIVE STATES.
171695 01-09

A GUIDE FOR DRUG USE IN DEPRESSIVE DISORDERS.
171923 01-09

A DOUBLE-BLIND COMPARISON OF THIORIDAZINE (MELLARIL) VERSUS DIAZEPAM (VALIUM) IN PATIENTS WITH CHRONIC MIXED ANXIETY AND DEPRESSIVE SYMPTOMS.
172486 01-10

CLINICAL EXPERIENCE WITH MELITHRACENE IN THE TREATMENT OF DEPRESSIVE STATES.
172979 01-09

THE DIFFERENTIATION OF ANXIETY AND DEPRESSIVE DISORDERS: A PSYCHOPHARMACOLOGICAL APPROACH.
175286 02-10

EXPERIMENT WITH DOXEPIN (SINEQUAN) IN TREATMENT OF DEPRESSIVE STATES.
176454 02-11

EXPERIENCE IN THE USE OF SINEQUAN (DOXEPIN HYDROCHLORIDE) IN TREATMENT OF NEUROSIS, DEPRESSION AND DEPRESSIVE STATES.
176471 02-11

CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, DOXEPIN HYDROCHLORIDE, IN THE TREATMENT OF DEPRESSIVE STATES.
177569 02-11

ACTION OF OPIPRAMOL (G-33040) IN DEPRESSIVE SYNDROMES IN CHILDREN AND ADOLESCENTS.
182432 03-10

THE USE OF LOW DOSES OF MONOCHLORIMIPRAMINE IN THE THERAPY OF NEUROTIC DEPRESSIVE SYNDROMES.
182789 03-10

A PRELIMINARY STUDY ON THE ACTION OF THYROTROPINE RELEASING HORMONE OR TRH IN DEPRESSIVE STATES.
184962 03-09

A STUDY OF REFRACTORY CASES OF DEPRESSIVE ILLNESSES AND THEIR RESPONSE TO COMBINED ANTIDEPRESSANT TREATMENT.
185078 03-10

DEPRESSIVES

DRUG THERAPY AND MARITAL THERAPY IN OUTPATIENT DEPRESSIVES.
169088 01-09

A DOUBLE-BLIND TRIAL OF IPRINDOLE AND IMIPRAMINE IN DEPRESSIVES AND RESPONSE TO ECT IN REFRACTORY CASES.
174376 01-09

INFLUENCE OF ANTIDEPRESSIVE THERAPY ON THE DISTURBED TIME ESTIMATION OF DEPRESSIVES.
182591 03-14

DIURETIC ANTIDEPRESSANT COMBINATION IN ALCOHOLIC DEPRESSIVES.
187866 04-11

DEPRIVATION

EFFECTS OF FOOD DEPRIVATION, DISCRIMINATION EXPERIENCE AND PHYSOSTIGMINE ON CHOLINE ACETYLASE AND ACETYLCHOLINE ESTERASE IN THE DORSAL HIPPOCAMPUS AND FRONTAL CORTEX OF RATS.
169467 01-03

INTERRESPONSE TIME CHANGES AS A FUNCTION OF DEPRIVATION AND AMPHETAMINE ADMINISTRATION.
171612 01-04

AMPHETAMINE AND PENTOBARBITAL EFFECTS ON THE DISCRIMINATIVE RESPONSE CONTROL BY DEPRIVATION OF RAPID EYE MOVEMENT SLEEP (REM).
182245 03-03

INDEPENDENCE OF THE EFFECTS OF D-AMPHETAMINE AND FOOD DEPRIVATION OR BODYWEIGHT ON THE FOOD CONSUMPTION OF RATS.
186376 03-06

EFFECTS OF DELTA9-THC ON FOOD AND WATER INTAKE OF DEPRIVATION EXPERIENCED RATS.
191375 04-04

DEPRIVED

EFFECTS OF METHAMPHETAMINE ON FIXED-RATIO RESPONDING OF FOOD SATIATED AND FOOD DEPRIVED RATS.
185957 03-04

DERIVATIVE

STUDIES ON BENZODIAZEPINOOXAZOLES. IV. THE FORMATION OF QUINOLONES BY THE RING CONTRACTION OF A BENZODIAZEPINOOXAZOLE DERIVATIVE.
180488 02-01

EXPERIENCE GAINED IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PSYCHOSES WITH A THIORIDAZINE DERIVATIVE.
180675 02-08

BEHAVIORAL PHARMACOLOGY OF BROMAZEPAM (RO-5-3350), A NEW BENZODIAZEPINE DERIVATIVE.
181384 02-04

CENTRAL NERVOUS ACTION OF BROMAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.
181650 02-03

A CLINICAL EVALUATION OF A NEW ANXIOLYTIC DRUG (THIENODIAZEPINE DERIVATIVE Y-6047) IN NEUROTICS AND PSYCHOSOMATIC DISORDERS -- A PRELIMINARY REPORT.
181771 02-07

CENTRAL NERVOUS ACTION OF FLURAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.
182549 03-03

CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE DERIVATIVE SE-780 IN RATS.
187926 04-04

THE EFFECT OF A NEW BENZODIAZEPINE DERIVATIVE NIMETAZEPAM ON THE SLEEP CYCLE IN MAN.
188501 04-07

INVESTIGATION OF PHYSICAL DEPENDENCE ON A NEW BENZODIAZEPINE DERIVATIVE, BROMAZEPAM.
189209 04-05

EFFECT OF A BUTYROPHENONE DERIVATIVE, U-32802A, ON BRAIN BIOGENIC AMINES.
189584 04-02

THE EFFECTS OF DELTA9-THC AND A WATER SOLUBLE DERIVATIVE ON PGE1 SYNTHESIS IN THE CORPUS-STRIATUM.
191964 04-03

DERIVATIVES
TOLERANCE AND CROSS-TOLERANCE TO THE ANOREXIGENIC EFFECT OF SOME AMPHETAMINE DERIVATIVES IN RATS.
171602 01-03
STUDIES ON SIDE-EFFECTS AND WITHDRAWAL SYMPTOMS OF IMINODIBENZYL DERIVATIVES.
173080 01-15
THE SYNTHESES OF 2,3 DIHYDROBENZOTHIAZINE DERIVATIVES. (PH.D. DISSERTATION).
173589 01-01
PHARMACOKINETIC DISPOSITION OF NORAPOMORPHINE DERIVATIVES AND ITS INFLUENCE ON THE ELICITATION OF STEREOTYPICAL GNAWING. (PH.D. DISSERTATION).
174960 01-03
INTERACTION OF PHENOTHIAZINE DERIVATIVES WITH HUMAN CERULOPLASMIN.
177335 02-13
SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF OCTAHYDROBENZOCYCLOHEPTATHIAZINE DERIVATIVES.
180098 02-01
STUDIES ON BENZODIAZEPINOOXAZOLES. III. REACTIONS AND REARRANGEMENTS OF BENZODIAZEPINOOXAZOLE DERIVATIVES.
180487 02-01
STUDIES ON BENZODIAZEPINOOXAZOLES. V. REACTIONS OF BENZODIAZEPINOOXAZOLE DERIVATIVES WITH ACETIC ANHYDRIDE.
180489 02-01
STUDIES ON BENZODIAZEPINOOXAZOLES. VI. SYNTHESIS AND PHARMACOLOGY OF 11B-PYRIDYL AND 11B-THIENYL DERIVATIVES OF BENZODIAZEPINOOXAZOLES.
180490 02-02
POTENTIATION OF BARBITURATE HYPNOSIS BY 5-DIAZOIMIDAZOLE-4-CARBOXAMIDE AND ITS DERIVATIVES.
182113 02-03
INHIBITION OF THE SYNAPTOSOMAL UPTAKE MECHANISMS FOR L-NOREPINEPHRINE AND DOPAMINE BY N-ARYLALKYL DL-AMPHETAMINE DERIVATIVES.
182250 03-03
THE INHIBITION OF (3H) BIOGENIC AMINE ACCUMULATION INTO RAT BRAIN TISSUE SLICES BY VARIOUS TRYPTAMINE DERIVATIVES.
182723 03-03
3-ONIUM DERIVATIVES OF 1,4 BENZODIAZEPIN-2-ONES WITH TERTIARY ORGANIC BASES.
187942 04-01
ALPHA-METHYLDOPAMINE DERIVATIVES. SYNTHESIS AND PHARMACOLOGY.
189177 04-02
THE ACTION OF BETA-PHENYL-GABA DERIVATIVES ON NEURONES OF THE CAT CEREBRAL CORTEX.
189750 04-03
CONFORMATIONAL ANALYSIS OF ACRIDAN DERIVATIVES BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY. A RELATIONSHIP BETWEEN CONFORMATION AND PHARMACOLOGICAL ACTIVITY.
190715 04-01

DERIVED
HYPOTHERMIA EVOKED BY A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE ALKALOID.
182130 02-03
IN VIVO INHIBITION OF NEURONAL UPTAKE OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY COCAINE AND BY DESMETHYLIMIPRAMINE (DMI).
182150 02-03
UPTAKE, STORAGE AND RELEASE IN VIVO OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY SYMPATHETIC NERVES OF THE IRIS.
182204 02-03

DESENSITIZATION
TREATMENT OF PHOBIAS BY SYSTEMATIC DESENSITIZATION: COMPARISON OF STANDARD VS METHOHEXITAL AIDED DESENSITIZATION.
189916 04-10

DESIGN
THE DESIGN OF THERAPEUTIC TRIALS: A CRITICAL ANALYSIS WITH ILLUSTRATIONS, PARTICULARLY FROM THE FIELD OF PSYCHOTROPIC DRUGS OR: WHY NO ONE CAN EVER DO A PROPER DRUG TRIAL.
173307 01-16
SOME CONSIDERATIONS IN THE DESIGN OF SUBSTRATE AND TISSUE SPECIFIC INHIBITORS OF MAO.
191499 04-01

DESIPRAMINE
COMBINATION OF L-DOPA, DESIPRAMINE, AND A DECARBOXYLASE INHIBITOR IN THE TREATMENT OF DEPRESSION.
169468 01-09
INHIBITION OF LUNG, LIVER AND BRAIN MONOAMINE OXIDASE BY IMIPRAMINE AND DESIPRAMINE.
177332 02-03
QUANTITATIVE DETERMINATION OF IMIPRAMINE AND DESIPRAMINE IN HUMAN BLOOD PLASMA BY DIRECT DENSITOMETRY OF THIN-LAYER CHROMATOGRAMS.
183603 03-13
EFFECT OF DESIPRAMINE ON RAT CORTEX SLICES INCUBATED WITH 3H-DOPAMINE.
190310 04-03
EFFECT OF CHRONIC TREATMENT WITH DESIPRAMINE (DMI) AND IPRINDOLE (IP) ON THE NOREPINEPHRINE (NE) SENSITIVE ADENYLATE CYCLASE SYSTEM IN SLICES OF THE RAT LIMBIC FOREBRAIN.
192003 04-03

DESMETHYLIMIPRAMINE
THE UPTAKE, RETENTION AND METABOLISM OF 3H-5-HYDROXYTRYPTAMINE IN BRAIN SLICES AND ILEUM FROM THE RAT: EFFECTS OF COCAINE, DESMETHYLIMIPRAMINE AND RESERPINE. (PH.D. DISSERTATION).
168131 01-03
IN VIVO INHIBITION OF NEURONAL UPTAKE OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY COCAINE AND BY DESMETHYLIMIPRAMINE (DMI).
182150 02-03
INHIBITION OF C14-ACH UPTAKE IN RAT BRAIN SLICES BY DESMETHYLIMIPRAMINE.
182170 02-03

DESTRUCTION
INFLUENCE OF PSYCHOTROPIC DRUGS ON AGGRESSIVENESS EVOKED BY DESTRUCTION OF ISOLATED STRUCTURES OF THE FOREBRAIN.
191788 04-04

DETECTION
PHENOTHIAZINE DOSAGE LEVELS AND AUDITORY SIGNAL DETECTION IN SCHIZOPHRENIA.
167817 01-08
EFFECTS OF LSD ON AUDITORY PERCEPTION: A SIGNAL DETECTION ANALYSIS.
185752 03-04

DETERMINANTS
DETERMINANTS OF DRUG EFFECTS ON PUNISHED BEHAVIOR.
181405 02-04
DETERMINANTS OF THE NORADRENERGIC SATIETY EFFECT: ENVIRONMENTAL DARKNESS VS. THE FEEDING PATTERN.
182133 02-04

DETERMINATION
DETERMINATION OF DRUG TRANSFER ACROSS BIOLOGICAL MEMBRANES: COMPARATIVE STUDY ON THE PASSAGE OF DRUGS INTO THE CENTRAL NERVOUS SYSTEM AND THEIR PLACENTAL TRANSFER AND FETAL LOCALIZATION IN THE PREGNANT RAT. (PH.D. DISSERTATION).
172018 01-03
GAS CHROMATOGRAPHIC DETERMINATION OF METHAQUALONE IN SMALL AMOUNTS OF SERUM AFTER INGESTION OF THERAPEUTIC DOSES.
172397 01-16
DETERMINATION OF DOXEPIN IN AUTOPSY MATERIAL.
172398 01-16
STUDIES ON METABOLISM OF BROMAZEPAM (II): COLORIMETRIC DETERMINATION AND METABOLIC FATE OF BROMAZEPAM IN ANIMALS.
181593 02-03
DIRECT DETERMINATION OF LITHIUM IN SERUM BY ATOMIC ABSORPTION SPECTROSCOPY.
181653 02-06
AUTOMATIC DETERMINATION OF THE PAIN THRESHOLD TO ELECTROSHOCK AND THE EFFECTS OF DELTA9-THC.
183363 03-03
IDENTIFICATION AND QUANTITATIVE DETERMINATION OF PHENOTHIAZINE DRUGS IN URINE SAMPLES OF PSYCHIATRIC PATIENTS.
183599 03-02
ASSAY PROCEDURES FOR THIORIDAZINE, TRIFLUOPERAZINE, AND THEIR SULFOXIDES AND DETERMINATION OF URINARY EXCRETION OF THESE COMPOUNDS IN MENTAL PATIENTS.
183602 03-01
QUANTITATIVE DETERMINATION OF IMIPRAMINE AND DESIPRAMINE IN HUMAN BLOOD PLASMA BY DIRECT DENSITOMETRY OF THIN-LAYER CHROMATOGRAMS.
183603 03-13
GLC DETERMINATION OF MEPROBAMATE IN WATER, PLASMA AND URINE.
185977 03-16
A POLAROGRAPHIC METHOD FOR THE DETERMINATION OF THE N-OXIDE, N-OXIDE-SULPHOXIDE AND SULPHOXIDE METABOLITES OF CHLORPROMAZINE.
190902 04-06
A CRITICAL ASSESSMENT OF METHODS FOR THE DETERMINATION OF MONOAMINE SYNTHESIS AND TURNOVER RATES IN VIVO.
191514 04-06

DETERMINE
A SMALL CONTROLLED STUDY TO DETERMINE THE TIME OF ONSET OF ACTION OF OXYPERTINE AFTER ORAL ADMINISTRATION IN NORMAL SUBJECTS.
182763 03-14

DETOXIFICATION
USE OF PSYCHOTHERAPEUTIC DRUGS IN THE ACUTE DETOXIFICATION OF HEROIN ADDICTS.
169746 01-11
A ROLE OF THE DIETARY LIPID IN THE ABILITY OF PHENOBARBITAL TO STIMULATE DRUG DETOXIFICATION.
175859 02-03

DEVELOPING
EFFECTS OF ATROPINE ON EXPLORATION, LEARNING AND ELECTROCORTICAL ACTIVITY IN THE DEVELOPING RAT.
169473 01-04
EFFECTS OF AMPHETAMINE ON ELECTROSHOCK RESPONSES IN DEVELOPING RATS.
184372 03-03
THYROTOXICOSIS DEVELOPING DURING LITHIUM TREATMENT: CASE REPORT.
186473 03-15

DEVELOPMENT
THE SAFETY TEST OF 10-CHLORO-11B-(2-CHLOROPHENYL) 2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE (CS-370): SECOND REPORT, EFFECT OF CS-370 UPON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
168498 01-05
DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE IN RESPECT TO TIME AND DOSAGE AND QUANTIFICATION OF THE PRECIPITATED WITHDRAWAL SYNDROME IN RATS.
169474 01-03
DEVELOPMENT OF TOLERANCE IN RATS TO THE HYPOTHERMIC EFFECTS OF D-AMPHETAMINE AND APOMORPHINE.
174764 01-03
CONTROL OF THE HYPERACTIVE CHILD VIA MEDICATION -- AT WHAT COST TO PERSONALITY DEVELOPMENT; SOME PSYCHOLOGICAL IMPLICATIONS AND CLINICAL INTERVENTIONS.
176810 02-11
DEVELOPMENT OF A VACCINE AGAINST MENTAL RETARDATION CAUSED BY CYTOMEGALOVIRUS INFECTION IN UTERO.
178549 02-11
LACK OF EFFECTS OF CYCLOHEXIMIDE ON TOLERANCE DEVELOPMENT TO A STIMULATORY EFFECT OF MORPHINE ON MICE.
182158 02-03
CHROMATIN TEMPLATE ACTIVITY DURING MORPHINE-INDUCED ANALGESIA AND THE DEVELOPMENT OF ANALGESIC TOLERANCE.
182160 02-03
THE DEVELOPMENT OF A BLOOD-BRAIN BARRIER TO METHADONE IN THE NEWBORN RAT.
182165 02-03
DELTA9-TETRAHYDROCANNABINOL AND 11-HYDROXY-DELTA9-TETRAHYDROCANNABINOL: BEHAVIORAL EFFECTS AND TOLERANCE DEVELOPMENT.
183893 03-04
A ROLE FOR THE AMYGDALA IN THE DEVELOPMENT OF THE CATALEPTIC AND STEREOTYPIC ACTIONS OF THE NARCOTIC AGONISTS AND ANTAGONISTS IN THE RAT.
186577 03-03
EVIDENCE FOR A CRITICAL PERIOD FOR POSTNATAL ELEVATION OF BRAIN TYROSINE HYDROXYLASE ACTIVITY RESULTING FROM RESERPINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT.
186695 03-03
THE PRENATAL EFFECT OF CHLORAMPHENICOL ON THE POSTNATAL DEVELOPMENT OF MICE.
187076 03-05
DEVELOPMENT OF LOCOMOTION AND BRAIN CATECHOLAMINES.
187551 04-04
DELTA9-TETRAHYDROCANNABINOL: EFFECTS OF ROUTE OF ADMINISTRATION ON ONSET AND DURATION OF ACTIVITY AND TOLERANCE DEVELOPMENT.
187928 04-03
THE EFFECTS OF P-CHLOROPHENYLALANINE ON MORPHINE ANALGESIA, TOLERANCE AND DEPENDENCE DEVELOPMENT IN TWO STRAINS OF RATS.
187930 04-04
LONG-TERM USE OF MARIHUANA AND THE DEVELOPMENT OF TOLERANCE OR SENSITIVITY TO DELTA9-TETRAHYDROCANNABINOL.
188119 04-13
THE EFFECT OF BUTYLATED HYDROXYANISOLE AND BUTYLATED HYDROXYTOLUENE ON BEHAVIORAL DEVELOPMENT OF MICE.
188637 04-04
EFFECTS OF PERINATAL EXPOSURE TO METHYL MERCURY ON FUNCTIONAL BRAIN DEVELOPMENT AND NEUROCHEMISTRY.
189564 04-05
PERMANENT ALTERATIONS IN 5-HYDROXYTRYPTAMINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN FOLLOWING EXPOSURE TO DRUGS DURING THE PERIOD OF DEVELOPMENT.
191383 04-03
PHYSICOCHEMICAL PROPERTIES, DEVELOPMENT, AND REGULATION OF CENTRAL AND PERIPHERAL MONOAMINE OXIDASE ACTIVITY.
191497 04-03
AMPHETAMINES EFFECTS ON SELF-STIMULATION: DEVELOPMENT OF TOLERANCE AND POST-DRUG DEPRESSION.
191914 04-04
EXCITABILITY CHANGES DURING THE GRADUAL DEVELOPMENT OF AND RECOVERY FROM PENTYLENETETRAZOL AND STRYCHNINE INDUCED CONVULSIONS IN THE CAT.
191927 04-03

DEVELOPMENTS
RECENT DEVELOPMENTS IN THE PHARMACOLOGY OF THE BENZODIAZEPINES.
182771 03-17

DEVIANT
THE CONTROL OF DEVIANT SEXUAL BEHAVIOR BY DRUGS: A DOUBLE-BLIND CONTROLLED STUDY OF BENPERIDOL, CHLORPROMAZINE, AND PLACEBO.
190061 04-11

DEXAMETHASONE
SIMULTANEOUS MASS FRAGMENTOGRAPHIC ASSAY OF NOREPINEPHRINE (NE), EPINEPHRINE (E) AND DOPAMINE (DA) IN RAT SYMPATHETIC GANGLION: EFFECTS OF DEXAMETHASONE IN NEWBORN AND ADULT RATS. (UNPUBLISHED PAPER).
170747 01-03

DEXAMPHETAMINE
THE BIOLOGICAL BASIS OF PSYCHOTICISM: A STUDY OF INDIVIDUAL DIFFERENCES IN RESPONSE TO DEXAMPHETAMINE.
175219 02-13
SENSORY CONTINGENT BAR-PRESSING FOR FAMILIAR AND NOVEL CHANGE UNDER A DEXAMPHETAMINE AMYLOBARBITONE MIXTURE.
181605 02-04

DEXPHENMETRAZINE
THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON THE COMPOSITION OF DIURNAL SLEEP OF NARCOLEPTICS.
192419 04-11

DEXTRAN
EFFECTS OF ADRENERGIC AGENTS, THEOPHYLLINE AND OTHER DRUGS ON DEXTRAN EDEMA AND HISTAMINE RELEASE IN RATS.
189895 04-03

DEXTROAMPHETAMINE
DOUBLE-BLIND CLINICAL EVALUATION OF MAZINDOL, DEXTROAMPHETAMINE, AND PLACEBO IN TREATMENT OF EXOGENOUS OBESITY.
167335 01-11
EFFECTS OF LSD-25 AND DEXTROAMPHETAMINE ON SPEECH RHYTHMS IN PSYCHOTHERAPY DIALOGUES.
168420 01-12
SIDE-EFFECTS OF DEXTROAMPHETAMINE THERAPY OF HYPERACTIVE CHILDREN.
176238 02-15
EFFECTS OF OVERTRAINING AND PRETRIAL ADMINISTRATION OF DEXTROAMPHETAMINE ON REVERSAL LEARNING IN RATS.
177533 02-04
DEXTROAMPHETAMINE AND METHYLPHENIDATE IN THE TREATMENT OF HYPERACTIVE/AGGRESSIVE CHILDREN.
177771 02-14
AN INVESTIGATION OF INTERACTIONS AMONG LSD, DEXTROAMPHETAMINE, AND VERBAL BEHAVIOR IN MONOLOGUES AND DIALOGUES. (PH.D. DISSERTATION).
185600 03-14
THE STATE-DEPENDENT EFFECTS OF METHYLPHENIDATE AND DEXTROAMPHETAMINE.
185861 03-14
CLINICAL EFFECTS OF MARIHUANA DEXTROAMPHETAMINE COMBINATION.
191990 04-14
CHROMOSOME EXAMINATIONS AFTER MEDICALLY ADMINISTERED LYSERGIC ACID DIETHYLAMIDE AND DEXTROAMPHETAMINE.
192084 04-15

DFP
REDUCED BEHAVIORAL EFFECTS OF PILOCARPINE DURING CHRONIC TREATMENT WITH DFP.
185265 03-04

DH-524
SELECTIVE ANTAGONISM OF CENTRAL NERVOUS SYSTEM DEPRESSANTS BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE.
171007 01-13

DI-N-PROPYLACETAMIDE
COMPLEMENTAL PHARMACOLOGICAL STUDY OF DI-N-PROPYLACETAMIDE OR DEPAMIDE.
180722 02-07

DIABETES-INSIPIDUS
LITHIUM INDUCED DIABETES-INSIPIDUS: MANIC SYMPTOMS, BRAIN AND ELECTROLYTE CORRELATES, AND CHLOROTHIAZIDE TREATMENT.
169486 01-15

DIAGNOSED
A STUDY OF THE EFFECTS OF RITALIN INTERVENTION UPON THE PERCEPTUAL COMPETENCIES OF CHILDREN DIAGNOSED AS GIVING

EVIDENCE OF PSYCHONEUROLOGICAL LEARNING DISABILITIES. (PH.D. DISSERTATION).
186833 03-14

DIAGNOSIS
HYPERKINETIC, HYPOSCHOLASTIC BEHAVIOUR AND CHARACTER DISORDERS OF CHILDHOOD AND ADOLESCENCE: DIAGNOSIS AND PHARMACOTHERAPY
172800 01-11
DIAGNOSIS AND MANAGEMENT OF DEPRESSION IN GENERAL PRACTICE.
180406 02-09
MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN THE LIGHT OF PROGNOSIS ORIENTED DIAGNOSIS.
186081 03-08

DIALOGUES
EFFECTS OF LSD-25 AND DEXTROAMPHETAMINE ON SPEECH RHYTHMS IN PSYCHOTHERAPY DIALOGUES.
168420 01-12
AN INVESTIGATION OF INTERACTIONS AMONG LSD, DEXTROAMPHETAMINE, AND VERBAL BEHAVIOR IN MONOLOGUES AND DIALOGUES. (PH.D. DISSERTATION).
185600 03-14

DIALYZABLE
CONVULSION PRODUCING PROPERTY OF THE DIALYZABLE GLYCOPEPTIDE PREPARATION FROM WHOLE RAT BRAIN.
181815 02-03

DIAMORPHINE
CLINICAL EXPERIENCE WITH DIAMORPHINE IN ADVANCED MALIGNANT DISEASE.
191606 04-17

DIAPHRAGM
EFFECTS OF AMPHETAMINE ISOMERS ON NEUROMUSCULAR TRANSMISSION IN RAT PHRENIC NERVE DIAPHRAGM PREPARATION.
182232 03-03

DIAZEPAM
PREANESTHETIC MEDICATION IN ELECTIVE SURGERY: COMPARISON OF INTRAVENOUS DIAZEPAM WITH MEPERIDINE.
167338 01-11
CLORAZEPATE DIPOTASSIUM, DIAZEPAM AND PLACEBO IN CHRONIC ANXIETY.
167339 01-10
IMIPRAMINE, DIAZEPAM AND GROUP PSYCHOTHERAPY IN LONG-TERM TREATMENT OF DEPRESSIVE NEUROTICS.
169089 01-10
DIAZEPAM (CALMPOSE) IN ECLAMPSIA: A PRELIMINARY REPORT OF 16 CASES.
169633 01-11
COMPARISON OF THIORIDAZINE AND DIAZEPAM IN THE CONTROL OF NONPSYCHOTIC SYMPTOMS ASSOCIATED WITH SENILITY: DOUBLE-BLIND STUDY.
170129 01-11
DIAZEPAM AND POST-TETANIC POTENTIATION: POSSIBLE ROLE OF PROSTAGLANDINS. (UNPUBLISHED PAPER).
170748 01-03
PHARMACOKINETIC PROFILE OF DIAZEPAM IN MAN FOLLOWING SINGLE INTRAVENOUS AND ORAL AND CHRONIC ORAL ADMINISTRATION.
170838 01-13
A DOUBLE-BLIND CLINICAL TRIAL OF DOXEPIN HYDROCHLORIDE AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION IN THE FIELD OF INTERNAL MEDICINE.
171282 01-11
DEPRESSION SUBTYPES AND RESPONSE TO PHENELZINE, DIAZEPAM, AND A PLACEBO: RESULTS OF A NINE HOSPITAL COLLABORATIVE STUDY.
171502 01-09
INTERACTIONS OF DIAZEPAM AND HALOTHANE IN RATS.
171633 01-03
DIAZEPAM IN LABOUR: ITS METABOLISM AND EFFECT ON THE CLINICAL CONDITION AND THERMOGENESIS OF THE NEWBORN.
171731 01-13
A DOUBLE-BLIND COMPARISON OF THIORIDAZINE (MELLARIL) VERSUS DIAZEPAM (VALIUM) IN PATIENTS WITH CHRONIC MIXED ANXIETY AND DEPRESSIVE SYMPTOMS.
172486 01-10
CONTINUOUS INFUSION OF DIAZEPAM IN INFANTS WERE SEVERE RECURRENT CONVULSIONS.
174568 01-11
DIAZEPAM USED INTRAVENOUSLY DURING REDUCTION OF FRACTURES AND DISLOCATIONS.
174880 01-17
COMPARISON OF ANTICONVULSANT EFFECTS OF CLORAZEPATE DIPOTASSIUM AND DIAZEPAM: FOUR WEEK ANTICONVULSANT STUDY IN RHESUS MONKEYS.
176677 02-03
ACUTE CEREBELLAR DISTURBANCE ASSOCIATED WITH DIAZEPAM THERAPY -- A CASE REPORT AND FURTHER INVESTIGATION.
177392 02-15
FATAL INTOXICATION OF A YOUNG DRUG ADDICT WITH DIAZEPAM.
178619 02-05
THE EFFECT OF DIAZEPAM ON SOME CARDIOVASCULAR AND RESPIRATORY REFLEXES ELICITED BY AFFERENT ABDOMINAL VAGUS STIMULATION.
178945 02-03
A COMPARATIVE STUDY OF DIAZEPAM AND METHOCARBAMOL IN THE TREATMENT OF LOMBOSCIATALGIAS.
178950 02-11
PSYCHOPHYSIOLOGICAL EFFECTS OF DIAZEPAM (VALIUM) COMBINED WITH A MODERATE DOSE OF ALCOHOL IN MAN.
180699 02-14
EFFECTS OF CONSECUTIVE ADMINISTRATION OF DIAZEPAM AND DOXEPIN ON BOTH APPROACH WITHDRAWAL AND APPROACH AVOIDANCE RESPONSES IN RATS.
182117 02-04
DIAZEPAM TREATMENT FOR ACUTE CONVULSIONS IN CHILDREN: A REPORT OF 41 PATIENTS, THREE WITH PLASMA LEVELS.
182595 03-11
DOUBLE-BLIND CROSSOVER COMPARISON OF BROMAZEPAM AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION.
182624 03-11
THE EFFECT OF HYPOTHALAMIC STIMULATION ON ORAL INGESTION OF DIAZEPAM IN RATS.
184238 03-04
ACUTE EFFECTS OF ALCOHOL, DIAZEPAM, THIORIDAZINE, FLUPENTHIXOL AND ATROPINE ON PSYCHOMOTOR PERFORMANCE PROFILES.
184848 03-14
THE CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES IN THE PLASMA AFTER AN ACUTE AND CHRONIC ADMINISTRATION.
184978 03-13
QUINAZOLINES AND 1,4 BENZODIAZEPINES.64.COMPARISON OF THE STEREOCHEMISTRY OF DIAZEPAM WITH THAT OF CLOSE ANALOGS WITH MARGINAL BIOLOGICAL ACTIVITY.
185034 03-01
PLASMA CONCENTRATIONS OF DIAZEPAM AND OF ITS METABOLITE N-DESMETHYLDIAZEPAM IN RELATION TO ANXIOLYTIC EFFECT.
186184 03-13
PLASMA LEVEL OF DIAZEPAM AS A THERAPEUTIC PREDICTOR IN ANXIETY STATES.
186584 03-10
DIAZEPAM INHIBITION OF POST-TETANIC POTENTIATION IN BULLFROG SYMPATHETIC GANGLIA: POSSIBLE ROLE OF PROSTAGLANDINS.
186673 03-03
RESPONSE TO PROPRANOLOL AND DIAZEPAM IN SOMATIC AND PSYCHIC ANXIETY.
188887 04-10
EFFECTS OF DIAZEPAM AND CODEINE, ALONE AND IN COMBINATION WITH ALCOHOL, ON SIMULATED DRIVING.
189619 04-14
DIAZEPAM ON DEMAND: DRUG SEEKING BEHAVIOR IN PSYCHIATRIC INPATIENTS.
189924 04-17
DIAZEPAM AND MEPERIDINE ON ARTERIAL BLOOD GASES IN HEALTHY VOLUNTEERS.
190147 04-13
EFFECT OF DIAZEPAM ON MOUSE WHOLE BRAIN AND BRAIN AREA ACETYLCHOLINE AND CHOLINE LEVELS.
191423 04-03
NONSEDATING DOSAGES OF DIAZEPAM AND PHENOBARBITAL IN THE REDUCTION OF NEONATAL BILIRUBIN LEVELS.
191607 04-17
DIAZEPAM, CYCLIC NUCLEOTIDES AND AMINO ACID NEUROTRANSMITTERS IN RAT CEREBELLUM. (UNPUBLISHED PAPER).
191764 04-03
SOURCES OF VARIABILITY IN THE PHARMACODYNAMICS OF 14C-IMIPRAMINE INCLUDING INTERACTION WITH DIAZEPAM OR THIORIDAZINE.
191925 04-03

DIAZEPAM-INDUCED
DIAZEPAM-INDUCED PLAY BEHAVIOR IN CATS DURING PREY KILLING.
184979 03-04
DIAZEPAM-INDUCED EATING AND LEVER PRESSING FOR FOOD IN SATED RATS.
186613 03-04

DIAZOXIDE
BINDING OF DIAZOXIDE AND OTHER BENZOTHIADIAZINES TO HUMAN ALBUMIN.
179987 02-13
DIPSOGENIC ACTION OF DIAZOXIDE: A PHARMACOLOGIC ANALYSIS.
191768 04-03

DIBENAMINE
REDUCTION BY PRETREATMENT WITH DIBENAMINE OF HEPATOTOXICITY INDUCED BY CARBON TETRACHLORIDE, THIOACETAMINDE OR DIMETHYLNITROSAMINE.
188865 04-05

DIBENCYCLADINE
INFLUENCE OF DIBENCYCLADINE AND IMIPRAMINE ON CALORIE INTAKE AND BODYWEIGHT.
183359 03-03

COMPARATIVE EVALUATION OF DIBENCYCLADINE (LUDIOMIL) AND IMIPRAMINE IN PSYCHOTIC DEPRESSION.
183361 03-09

DIBENZEPINE
THE FIRST LONG-ACTING (RETARD) THYMOANALEPTIC OR ANTIDEPRESSANT: THE TIME-RELEASED DIBENZEPINE WITH PROLONGED ACTION.
178946 02-11

DIBUTYRYL
THE EFFECT OF DOPAMINE RECEPTOR STIMULATING AGENTS AND OF N,O DIBUTYRYL CYCLIC AMP ON C14-DOPAMINE SYNTHESIS IN STRIATAL SLICES OF RATS.
182256 03-03

NOREPINEPHRINE -- AN ANTAGONIST OF DIBUTYRYL CYCLIC AMP IN THE REGULATION OF NARCOSIS IN THE RAT.
183789 03-03

DICEPLON
EXPERIENCE IN THE APPLICATION OF DICEPLON (APY-606) -- COMPARED WITH FLOROPIPAMIDE.
176447 02-08

CLINICAL EFFECTS OF DICEPLON, A PSYCHOTROPIC DRUG.
176470 02-08

DICHLOROPHENYL
EFFECT OF 2-ARYLALANINES, 2-ARYLSERINES, TETRAPHENYLBORON AND 1,2 DL(2,4 DICHLOROPHENYL) ETHANOLAMINE ON LEVELS OF SEROTONIN (5-HT), NOREPINEPHRINE (NE) AND DOPAMINE (DM) IN WHOLE BRAIN OF MICE.
182254 03-03

DICHROISM
INFLUENCE OF PH ON THE BENZODIAZEPINE HUMAN SERUM ALBUMIN COMPLEX: CIRCULAR DICHROISM STUDIES.
189595 04-13

DIDEUTERO
MASS FRAGMENTOGRAPHIC ANALYSIS OF HOMOVANILLIC ACID AND ITS HOMOISO ANALOGUE IN CEREBROSPINAL FLUID USING THE ALPHA DIDEUTERO ACID AS INTERNAL STANDARD.
186566 03-16

DIELDRIN
ALTERATION OF SENSORY AND MOTOR EVOKED RESPONSES BY DIELDRIN.
181818 02-03

DIENCEPHALIC
PHARMACOLOGICAL SUPPRESSION OF EATING BEHAVIOR IN RELATION TO DIENCEPHALIC NORADRENERGIC RECEPTORS.
174763 01-04

DIENCEPHALON
MODULATION OF REWARD AND AVERSION PROCESSES IN THE RAT DIENCEPHALON BY AMPHETAMINE.
186164 03-04

DIESTRUS
BLOCKADE OF THE PROESTROUS LH SURGE IN CYCLIC RATS BY BARBITURATE ADMINISTRATION ON DIESTRUS.
175650 02-03

DIET
NEUROLOGICAL CHANGES IN CATS FOLLOWING LONG-TERM DIET OF MERCURY CONTAMINATED TUNA.
186476 03-05

SUPERSENSITIVITY TO DOPAMINERGIC AGONISTS FOLLOWING WITHDRAWAL OF A CHRONIC DIET CONTAINING HALOPERIDOL OR PIMOZIDE.
192012 04-04

DIETARY
A ROLE OF THE DIETARY LIPID IN THE ABILITY OF PHENOBARBITAL TO STIMULATE DRUG DETOXIFICATION.
175859 02-03

DIETHYLAMIDE
LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND GAMMA-AMINOBUTYRIC ACID (GABA) INTERACTION ON SPONTANEOUS POTENTIALS AND THE EVOKED RESPONSE IN THE AVIAN TECTUM.
169689 01-03

STUDIES ON ENZYMATIC DEALKYLATION OF D-LYSERGIC ACID DIETHYLAMIDE (LSD).
177336 02-03

LYSERGIC ACID DIETHYLAMIDE AND SEROTONIN: A COMPARISON OF EFFECTS ON SEROTONERGIC NEURONS AND NEURONS RECEIVING A SEROTONERGIC INPUT.
177407 02-12

COMPARISON OF THE CHRONIC AND ACUTE EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) TREATMENT ON RAT BRAIN SEROTONIN AND NOREPINEPHRINE.
181945 02-03

A COMPARISON OF EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) AND SEROTONIN ON PRE- AND POSTSYNAPTIC CELLS IN THE SEROTONIN SYSTEM.
182141 02-03

EVIDENCE FOR THE ACTION OF D-LYSERGIC ACID DIETHYLAMIDE, MESCALINE AND BUFOTENINE ON 5-HYDROXYTRYPTAMINE RECEPTORS IN UMBILICAL VASCULATURE.
182716 03-03

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
191944 04-04

CHROMOSOME EXAMINATIONS AFTER MEDICALLY ADMINISTERED LYSERGIC ACID DIETHYLAMIDE AND DEXTROAMPHETAMINE.
192084 04-15

DIETHYLBARBITURIC
THE METABOLISM OF 1-N-BUTYL-5,5 DIETHYLBARBITURIC ACID (N-N BUTYLBARBITAL) IN THE RAT.
191057 04-03

DIETHYLETHER
INDUCTION OF A DIETHYLETHER WITHDRAWAL SYNDROME IN MICE BY EXPOSURE TO ETHER VAPOR.
192006 04-03

DIFFERENCE
COMPARABLE THERAPEUTIC EFFICACY OF TRYPTOPHAN AND IMIPRAMINE: AVERAGE THERAPEUTIC RATINGS VERSUS TRUE EQUIVALENCE. AN IMPORTANT DIFFERENCE.
167344 01-09

DIFFERENTIALLY
BRAIN TO SERUM DISTRIBUTION OF RADIOACTIVITY OF INJECTED 3H-D-AMPHETAMINE IN DIFFERENTIALLY HOUSED MICE.
168418 01-03

DIFFERENTIATING
DIFFERENTIATING STIMULUS AND STORAGE HYPOTHESES OF STATE-DEPENDENT LEARNING.
188226 04-14

DIFFERENTIATION
EFFECTS OF P-CHLOROPHENYLALANINE ON DIFFERENTIATION OF SEROTONINERGIC RECEPTIVE CELLS DURING EMBRYOGENESIS. (UNPUBLISHED PAPER).
168817 01-03

THE DIFFERENTIATION OF ANXIETY AND DEPRESSIVE DISORDERS: A PSYCHOPHARMACOLOGICAL APPROACH.
175286 02-10

PHARMACOLOGICAL ANALYSIS OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE REMOVAL FROM THE PULMONARY CIRCULATION: DIFFERENTIATION OF UPTAKE SITES FOR EACH AMINE.
182717 03-03

THE ANTAGONISM BETWEEN CHOLINOMIMETIC AGONISTS AND BETA-ADRENOCEPTOR STIMULANTS: THE DIFFERENTIATION BETWEEN BETWEEN FUNCTIONAL AND METAFFINOID ANTAGONISM.
191420 04-03

DIGITALIZATION
RAPID DIGITALIZATION OF DECOMPENSATED SCHIZOPHRENIC PATIENTS WITH ANTIPSYCHOTIC AGENTS.
189095 04-08

DIHYDROBENZOTHIAZINE
THE SYNTHESES OF 2,3 DIHYDROBENZOTHIAZINE DERIVATIVES. (PH.D. DISSERTATION).
173589 01-01

DIHYDRODIBENZOTHIEPINS
D-(R)- AND L-(S) 3-ALKYLAMINOPYRROLIDINO-SUBSTITUTED DIHYDRODIBENZOTHIEPINS, XANTHENES, AND DIPHENYLMETHANES.
187937 04-01

DIHYDROPTERIDINE
DIHYDROPTERIDINE REDUCTASE IN RAT BRAIN: REGIONAL DISTRIBUTION AND THE EFFECT OF CATECHOLAMINE DEPLETING DRUGS.
189752 04-03

DIHYDROXYOCTAHYDROPHENANTHRENES
CENTRALLY ACTING MUSCLE RELAXANTS. ISOMERIC 9,10 DIHYDROXYOCTAHYDROPHENANTHRENES AND THEIR CARBAMATE ESTERS.
190719 04-02

DIHYDROXYPHENYLSERINE
THREO-3,4 DIHYDROXYPHENYLSERINE, A POOR SOURCE OF NORADRENALINE IN THE RAT.
167445 01-03

FORMATION OF NORADRENALINE IN THE RAT BRAIN FROM THE FOUR STEREOISOMERS OF 3,4 DIHYDROXYPHENYLSERINE.
184229 03-03

DIHYDROXYTETRAHYDROISOQUINOLINE
NONSPONTANEOUS CONVULSIONS IN MICE ELICITED BY SOME CATECHOLAMINE RELEASERS AND 6,7 DIHYDROXYTETRAHYDROISOQUINOLINE (TIQ).
192013 04-05

DIHYDROXYTRYPTAMINE
LONG-TERM EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE ON BRAIN MONOAMINES.
180022 02-03

BIOCHEMICAL AND BEHAVIOURAL ALTERATIONS FOLLOWING 5,6 DIHYDROXYTRYPTAMINE ADMINISTRATION INTO BRAIN.
186634 03-04

ON THE BEHAVIORAL AND NEUROCHEMICAL ACTIONS OF 6-HYDROXYDOPA AND 5,6 DIHYDROXYTRYPTAMINE IN RATS.
187380 04-03

DEPLETION OF TRYPTOPHAN HYDROXYLASE BY 5,6 DIHYDROXYTRYPTAMINE IN RAT BRAIN -- TIME COURSE AND REGIONAL DIFFERENCES.
188287 04-03

THE EFFECT OF 5,7 DIHYDROXYTRYPTAMINE ON PERIPHERAL ADRENERGIC NERVES IN THE MOUSE.
188977 04-03

EFFECTS OF VARIOUS DRUGS ON THE ACTIONS OF 5,7 DIHYDROXYTRYPTAMINE.
191955 04-03

DIMETHACRINE

A DOUBLE-BLIND INVESTIGATION OF DIMETHACRINE VERSUS IMIPRAMINE IN HOSPITALIZED DEPRESSIVE STATES.
171695 01-09

DIMETHOXY-4-BROMOAMPHETAMINE

EFFECTS OF PSYCHOTOMIMETICS ON VASCULAR STRIPS: STUDIES OF METHOXYLATED AMPHETAMINES AND OPTICAL ISOMERS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE AND 2,5 DIMETHOXY-4-BROMOAMPHETAMINE.
177734 02-03

DIMETHOXY-4-ETHYLAMPHETAMINE

STEREOSPECIFIC ACTIONS OF DOET (2,5 DIMETHOXY-4-ETHYLAMPHETAMINE) IN MAN.
188121 04-12

DIMETHOXY-4-METHYLAMPHETAMINE

EFFECTS OF PSYCHOTOMIMETICS ON VASCULAR STRIPS: STUDIES OF METHOXYLATED AMPHETAMINES AND OPTICAL ISOMERS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE AND 2,5 DIMETHOXY-4-BROMOAMPHETAMINE.
177734 02-03

ELECTROENCEPHALOGRAPHIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL, LSD-25, MESCALINE AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE IN THE RABBITS.
182095 02-03

EFFECT OF D-AMPHETAMINE (D-A) AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) ON THE IN VIVO RELEASE OF 14C-NOREPINEPHRINE (NE) INTO THE LATERAL VENTRICLE OF RATS.
182251 03-03

NEUROPHARMACOLOGICAL ANALYSIS OF R(-)-2,5 DIMETHOXY-4-METHYLAMPHETAMINE (R-DOM).
191906 04-03

DIMETHOXY-4-METHYLPHENYL

STEREOCHEMICAL ASPECTS IN THE METABOLISM OF THE PSYCHOTOMIMETIC AMINE 1-(2,5 DIMETHOXY-4-METHYLPHENYL)-2 AMPHETAMINE.
175759 02-03

CARDIOVASCULAR AND GROSS BEHAVIORAL EFFECTS OF AMPHETAMINE, 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPROPANE (DOM) AND 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPHENYL BUTANE (BL-3912A) IN THE CONSCIOUS DOG.
187573 04-03

CHEMICAL CONVERSION OF THE PSYCHOTOMIMETIC AMINE 1-(2,5 DIMETHOXY-4-METHYLPHENYL) 2-AMINOPROPANE TO 5-HYDROXYDIMETHYLINDOLE.
187941 04-01

STEREOCHEMICAL ASPECTS AND METABOLITE FORMATION IN THE IN VIVO METABOLISM OF THE PSYCHOTOMIMETIC AMINE, 1-2,5-(DIMETHOXY-4-METHYLPHENYL) 2 AMINOPROPANE.
190718 04-03

DIMETHOXY-4-METHYLPROPANE

CARDIOVASCULAR AND GROSS BEHAVIORAL EFFECTS OF AMPHETAMINE, 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPROPANE (DOM) AND 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPHENYL BUTANE (BL-3912A) IN THE CONSCIOUS DOG.
187573 04-03

DIMETHOXYMETHYL-PHENOBARBITAL

THE METABOLIC FATE OF N,N DIMETHOXYMETHYL-PHENOBARBITAL IN THE RAT.
177731 02-03

DIMETHOXYPHENETHYLAMINE

EFFECT OF 3,4 DIMETHOXYPHENETHYLAMINE ON MONOAMINE DEPLETED RATS.
183608 03-03

DIMETHOXYPHENYLETHYLAMINE

THE EFFECTS OF 3,4 DIMETHOXYPHENYLETHYLAMINE IN RATS TRAINED WITH MESCALINE AS A DISCRIMINATIVE STIMULUS.
186667 03-04

DIMETHYL-M-TYRAMINE

EVIDENCE FOR A NORADRENERGIC AND DOPAMINERGIC MECHANISM IN THE HYPERACTIVITY PRODUCED BY 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.
190309 04-04

DIMETHYLAMINOETHANOL

STUDY WITH RADIOTRACERS OF THE DISTRIBUTION OF A NEW PSYCHOTROPE IN MICE: L-2-PYRROLIDONE-5-CARBOXYLATE DIMETHYLAMINOETHANOL. I. COMPARISON WITH L-GLUTAMIC AND L-2-PYRROLIDONE-5-CARBOXYLIC ACID.
180723 02-03

DIMETHYLAMINOPROPYLTHIOCINNAMANILIDE

ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN DIMETHYLAMINOPROPYLTHIOCINNAMANILIDE HYDROCHLORIDE), A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN (5-HTP) AND ALPHA-METHYLTRYPTAMINE.
176861 02-04

DIMETHYLAMPHETAMINES

DEMETHYLATION OF N,N DIMETHYLAMPHETAMINES - EVIDENCE FOR A MULTIENZYME SYSTEM.
191923 04-03

DIMETHYLNITROSAMINE

REDUCTION BY PRETREATMENT WITH DIBENAMINE OF HEPATOTOXICITY INDUCED BY CARBON TETRACHLORIDE, THIOACETAMINDE OR DIMETHYLNITROSAMINE.
188865 04-05

DIMETHYLTRYPTAMINE

FAILURE OF N,N DIMETHYLTRYPTAMINE TO EVOKE TOLERANCE IN CATS.
173398 01-03

A POSSIBLE MECHANISM FOR THE ANTISCHIZOPHRENIC ACTION OF CHLORPROMAZINE: INHIBITION OF THE FORMATION OF DIMETHYLTRYPTAMINE BY CHLORPROMAZINE METABOLITES.
187576 04-03

DIMETHYLTRYPTAMINE: ITS BIOSYNTHESIS AND POSSIBLE ROLE IN MENTAL DISEASE.
191535 04-12

CORRELATION BETWEEN BRAIN N,N DIMETHYLTRYPTAMINE (DMT) LEVELS AND BAR PRESSING BEHAVIOR IN RATS: EFFECT OF MAO INHIBITION.
191935 04-04

DIMINISHES

MARIJUANA DIMINISHES GSR ACTIVATION PEAKING.
181887 02-13

DINUCLEOTIDE

SUBSTITUTED PIPERAZINOQUINAZOLONES: RELATIONSHIP BETWEEN SELECTIVE INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND ANTICONVULSANT ACTIVITY.
183598 03-02

SUBSTITUTED BENZOXAZOLE/BENZTHIAZOLE-2-THIONES: INTERRELATIONSHIP BETWEEN ANTICONVULSANT ACTIVITY AND INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND MONOAMINE OXIDASE.
183601 03-03

DIPHENHYDRAMINE

COMPLICATIONS OF METHAQUALONE DIPHENHYDRAMINE (MANDRAX) ABUSE.
177452 02-15

AN ELECTROENCEPHALOGRAPHIC STUDY ON THE TOLERANCE OF THE VARIOUS PSYCHIATRIC AND NEUROLOGICAL PATIENTS TO THE HYPNOTIC EFFECTS OF DIPHENHYDRAMINE -- MEASURED BY THE AMOUNTS OF SLEEP EEG AS AN INDICATOR.
182550 03-11

DIPHENYLHYDANTOIN

DIPHENYLHYDANTOIN EFFECTIVENESS IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS: A DOUBLE-BLIND CONTROLLED STUDY WITH A PLACEBO.
171507 01-08

PREVENTION OF ALCOHOL WITHDRAWAL SEIZURES: THE ROLES OF DIPHENYLHYDANTOIN AND CHLORDIAZEPOXIDE.
172275 01-11

EFFECTS OF DIPHENYLHYDANTOIN ON ANXIETY AND HOSTILITY IN INSTITUTIONALIZED PRISONERS.
177671 02-11

PENTYLENETETRAZOL CONVULSIONS AND BRAIN CATECHOLAMINE TURNOVER RATE IN RATS AND MICE RECEIVING DIPHENYLHYDANTOIN OR BENZODIAZEPINES.
182344 03-03

IN VITRO BINDING OF (4-14C) DIPHENYLHYDANTOIN TO RAT BRAIN MICROSOMES.
188404 04-03

NERVE CONDUCTION VELOCITY IN PATIENTS ON LONG-TERM DIPHENYLHYDANTOIN THERAPY.
189173 04-15

DIPHENYLMETHANES

D-(R)- AND L-(S) 3-ALKYLAMINOPYRROLIDINO-SUBSTITUTED DIHYDRODIBENZOTHIEPINS, XANTHENES, AND DIPHENYLMETHANES.
187937 04-01

DIPOTASSIUM

CLORAZEPATE DIPOTASSIUM, DIAZEPAM AND PLACEBO IN CHRONIC ANXIETY.
167339 01-10

COMPARISON OF ANTICONVULSANT EFFECTS OF CLORAZEPATE DIPOTASSIUM AND DIAZEPAM: FOUR WEEK ANTICONVULSANT STUDY IN RHESUS MONKEYS.
176677 02-03

DIPSOGENIC

DIPSOGENIC ACTION OF DIAZOXIDE: A PHARMACOLOGIC ANALYSIS.
191768 04-03

DIRECT
DIRECT DETERMINATION OF LITHIUM IN SERUM BY ATOMIC ABSORPTION SPECTROSCOPY.
181653 02-06
SEPARATION OF THE DEPENDENCE PRODUCING ACTIONS FROM THE DIRECT ACTIONS OF NARCOTICS ON GUINEA-PIG ILEUM.
182162 02-03
QUANTITATIVE DETERMINATION OF IMIPRAMINE AND DESIPRAMINE IN HUMAN BLOOD PLASMA BY DIRECT DENSITOMETRY OF THIN-LAYER CHROMATOGRAMS.
183603 03-13
BEHAVIORAL EFFECTS OF DIRECT AND INDIRECT ACTING DOPAMINERGIC AGONISTS.
191521 04-04

DISABILITIES
A STUDY OF THE EFFECTS OF RITALIN INTERVENTION UPON THE PERCEPTUAL COMPETENCIES OF CHILDREN DIAGNOSED AS GIVING EVIDENCE OF PSYCHONEUROLOGICAL LEARNING DISABILITIES. (PH.D. DISSERTATION).
186833 03-14

DISAGGREGATION
DISAGGREGATION OF BRAIN POLYSOMES AFTER L-DOPA: AN ANALYSIS.
188433 04-03

DISCHARGE
EFFECT OF ANTICONVULSANT DRUGS ON THE NUMBER OF AFFERENT STIMULI NEEDED TO CAUSE A HIPPOCAMPAL SEIZURE DISCHARGE.
189608 04-03

DISCHARGED
THE DISCHARGED PATIENTS DRUG TREATMENT.
185195 03-17

DISCIPLINE
AN ACCOUNT OF THE USE OF FLUPHENAZINE SINCE THE ESTABLISHMENT OF PSYCHIATRY AS A SEPARATE DISCIPLINE.
176431 02-11

DISCREPANCIES
ELECTROCLINICAL DISCREPANCIES IN ANTIANXIETY DRUGS.
181918 02-13

DISCRIMINABLE
CLASSIFICATION OF DRUGS ACCORDING TO THEIR DISCRIMINABLE EFFECTS IN RATS.
188228 04-06

DISCRIMINANT
DISCRIMINANT ANALYSIS OF THE RELATIONSHIP BETWEEN PHYSICAL PROPERTIES AND THE INHIBITION OF MONOAMINE OXIDASE BY AMINOTETRALINS AND AMINOINDANS.
180096 02-03

DISCRIMINATED
THE EFFECTS OF D-AMPHETAMINE ON THE INTERRESPONSE TIMES OF RATS AND GUINEA-PIGS ON A MODIFIED SIDMAN DISCRIMINATED AVOIDANCE SCHEDULE.
189519 04-04
EFFECTS OF DELTA1-TETRAHYDROCANNABINOL ON SIDMAN DISCRIMINATED AVOIDANCE BEHAVIOR IN RATS.
192413 04-03

DISCRIMINATION
EFFECTS OF FOOD DEPRIVATION, DISCRIMINATION EXPERIENCE AND PHYSOSTIGMINE ON CHOLINE ACETYLASE AND ACETYLCHOLINE ESTERASE IN THE DORSAL HIPPOCAMPUS AND FRONTAL CORTEX OF RATS.
169467 01-03
EFFECTS OF PSYCHOTROPIC DRUGS ON DISCRIMINATION AVOIDANCE CONDITIONING IN RATS WITH OLFACTORY BULB ABLATIONS.
182115 02-04
EFFECTS OF PHYSOSTIGMINE ON THE MAINTENANCE OF DISCRIMINATION BEHAVIOUR IN RATS.
186637 03-04
DIFFERENTIAL EFFECTS OF PILOCARPINE AND SCOPOLAMINE ON THE PERFORMANCE OF A LIGHT DARK DISCRIMINATION MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN.
186701 03-03
COCAINE, PEMOLINE AND AMPHETAMINE ON LEARNING AND RETENTION OF A DISCRIMINATION TEST IN MICE.
186705 03-04
ANISOMYCIN, LIKE OTHER INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS, IMPAIRS LONG-TERM MEMORY OF A DISCRIMINATION TASK.
188605 04-04

DISCRIMINATIVE
OPEN-FIELD BEHAVIOR AND ACQUISITION OF DISCRIMINATIVE RESPONSE CONTROL IN DELTA9-THC TOLERANT RATS.
178813 02-04
AMPHETAMINE AND PENTOBARBITAL EFFECTS ON THE DISCRIMINATIVE RESPONSE CONTROL BY DEPRIVATION OF RAPID EYE MOVEMENT SLEEP (REM).
182245 03-03
THE GENERAL LOCUS OF D-AMPHETAMINE-INDUCED DISCRIMINATIVE STIMULI. (PH.D. DISSERTATION).
185725 03-03
THE EFFECTS OF 3,4 DIMETHOXYPHENYLETHYLAMINE IN RATS TRAINED WITH MESCALINE AS A DISCRIMINATIVE STIMULUS.
186667 03-04
HALLUCINOGENS AS DISCRIMINATIVE STIMULI.
188229 04-12
DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
191944 04-04

DISEASE
L-DOPA IN 122 CASES OF PARKINSONS DISEASE AT AGE 70 OR OVER. A COMPARATIVE STUDY WITH A GROUP OF PATIENTS AGED 41 TO 69 YEARS.
168369 01-11
VESTA VARIANT OF TOURETTES DISEASE: TREATMENT WITH HALOPERIDOL.
169286 01-10
A DOUBLE-BLIND CLINICAL TRIAL OF DOXEPIN HYDROCHLORIDE AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION IN THE FIELD OF INTERNAL MEDICINE.
171282 01-11
SOME PROBLEMS IN THE PSYCHOPHARMACOLOGICAL TREATMENT OF PSYCHOSOMATIC DISEASE.
177066 02-17
L-DOPA AND THE TREATMENT OF EXTRAPYRAMIDAL DISEASE. (UNPUBLISHED PAPER).
177975 02-11
DOUBLE-BLIND CROSSOVER COMPARISON OF BROMAZEPAM AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION.
182624 03-11
LONG-RANGE MOTOR PERFORMANCE CHANGES IN LEVODOPA TREATED PATIENTS WITH PARKINSONS DISEASE.
184195 03-11
PARKINSON DISEASE TREATED WITH A SUSPECTED DOPAMINE RECEPTOR AGONIST.
186029 03-11
ONE CASE OF AGRYPNIA (4 MONTHS WITHOUT SLEEP) IN A MORVAN DISEASE: FAVORABLE ACTION OF 5-HYDROXYTRYPTOPHAM.
187237 03-14
LEVODOPA COMBINED WITH MK-486 (L-ALPHA-METHYLDOPAHYDRAZINE) -- A PERIPHERAL DECARBOXYLASE INHIBITOR IN PARKINSONS DISEASE.
187615 04-11
LEVODOPA, CARBIDOPA, AND PYRIDOXINE IN PARKINSON DISEASE.
187877 04-13
PLASMA DOPA AND FUNCTIONAL OSCILLATIONS AFTER CHRONIC TREATMENT OF PARKINSONS DISEASE.
188421 04-13
PHARMACOGENETICS AND MENTAL DISEASE.
188826 04-11
COMPARISON OF AMANTADINE, PLACEBO, AND LEVODOPA IN PARKINSONS DISEASE.
189502 04-11
DISSOCIATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN PARKINSONS DISEASE FOLLOWING CHRONIC L-DOPA THERAPY.
191233 04-13
EFFECTS OF PIRIBEDIL (ET-495) -- A DOPAMINERGIC RECEPTOR STIMULATING AGENT IN PARKINSONS DISEASE.
191522 04-13
DIMETHYLTRYPTAMINE: ITS BIOSYNTHESIS AND POSSIBLE ROLE IN MENTAL DISEASE.
191535 04-12
CLINICAL EXPERIENCE WITH DIAMORPHINE IN ADVANCED MALIGNANT DISEASE.
191606 04-17

DISEASES
CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, ZISEPRON, IN TREATMENT OF PSYCHIATRIC DISEASES IN COMPARISON WITH THIORIDAZINE.
176467 02-08
THE PROBLEMS OF THE PSYCHOPHARMACOLOGICAL TREATMENT OF PSYCHOSOMATIC DISEASES -- THE ANESTHESIOLOGIC APPROACH.
177063 02-17
CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG: FK-880 (SULPIRIDE), ITS EFFECT ON PATIENTS WITH PSYCHOSOMATIC DISEASES AND PSYCHONEUROSIS.
182731 03-10
CONSIDERATIONS ON THE USE OF ANALGESIC DRUGS IN DIFFERENT STAGES OF NEOPLASTIC DISEASES.
191604 04-17

DISLOCATIONS
DIAZEPAM USED INTRAVENOUSLY DURING REDUCTION OF FRACTURES AND DISLOCATIONS.
174880 01-17

DISORDER
A COMPARISON OF LITHIUM CARBONATE IN THE PREVENTION OF MANIC AND DEPRESSIVE EPISODES IN RECURRENT AFFECTIVE DISORDER.
169090 01-09

THE EFFECT OF LITHIUM ON THYROID IODINE RELEASE IN PATIENTS WITH PRIMARY AFFECTIVE DISORDER.
186580 03-09

LITHIUM IN TREATMENT AND PREVENTION OF AFFECTIVE DISORDER: A VA-NIMH COLLABORATIVE STUDY.
190381 04-09

DISORDERED

SAFETY AND EFFECTIVENESS OF HALOPERIDOL FOR MENTALLY RETARDED BEHAVIORALLY DISORDERED AND HYPERKINETIC PATIENTS.
169634 01-11

DISORDERS

TRAZODONE IN THE TREATMENT OF AFFECTIVE DISORDERS.
168807 01-11

CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS: RECENT STUDIES OF MHPG EXCRETION.
169091 01-13

CHANGES IN SOMATOSENSORY EVOKED POTENTIALS PRODUCED BY DRUGS USED IN THE TREATMENT OF AFFECTIVE DISORDERS.
169092 01-09

A COLLABORATIVE ASSESSMENT OF NOREPINEPHRINE METABOLISM IN AFFECTIVE DISORDERS.
169094 01-09

HALOPERIDOL FOR PSYCHIATRIC DISORDERS IN CHILDREN.
169457 01-14

THE USE OF LITHIUM IN AFFECTIVE DISORDERS, III: A DOUBLE-BLIND STUDY OF PROPHYLAXIS IN BIPOLAR ILLNESS.
169495 01-09

A TRIAL ON BROMAZEPAM (LEXOTAN) AND PLACEBO IN THE TREATMENT OF PSYCHOPHYSIOLOGICAL DISORDERS.
171150 01-11

L-TRYPTOPHAN IN MANIA: CONTRIBUTION TO A PERMISSIVE HYPOTHESIS OF AFFECTIVE DISORDERS.
171500 01-09

LITHIUM CARBONATE AND SLEEP IN AFFECTIVE DISORDERS: FURTHER CONSIDERATIONS.
171503 01-09

A GUIDE FOR DRUG USE IN DEPRESSIVE DISORDERS.
171923 01-09

LITHIUM PROPHYLAXIS IN AFFECTIVE DISORDERS: AN OPEN TRIAL WITH MATCHED CONTROLS.
172401 01-09

HYPERKINETIC, HYPOSCHOLASTIC BEHAVIOUR AND CHARACTER DISORDERS OF CHILDHOOD AND ADOLESCENCE: DIAGNOSIS AND PHARMACOTHERAPY.
172800 01-11

L-TRYPTOPHAN IN THE TREATMENT OF LEVODOPA INDUCED PSYCHIATRIC DISORDERS.
174297 01-15

LONG-TERM USE OF LITHIUM CARBONATE IN AFFECTIVE DISORDERS: A CLINICAL EVALUATION.
174778 01-09

THE DIFFERENTIATION OF ANXIETY AND DEPRESSIVE DISORDERS: A PSYCHOPHARMACOLOGICAL APPROACH.
175286 02-10

PIMOZIDE IN THE TREATMENT OF BEHAVIORAL DISORDERS OF HOSPITALIZED ADOLESCENTS.
176109 02-14

NEUROPHARMACOLOGICAL STUDIES OF MOOD DISORDERS.
178114 02-09

EXPERIENCE IN THE TREATMENT OF CEREBRAL INSUFFICIENCY AND PERIPHERAL BLOOD CIRCULATION DISORDERS USING THE EP-50-100 EXPERIMENTAL DRUG.
180676 02-11

A CLINICAL EVALUATION OF A NEW ANXIOLYTIC DRUG (THIENODIAZEPINE DERIVATIVE Y-6047) IN NEUROTICS AND PSYCHOSOMATIC DISORDERS -- A PRELIMINARY REPORT.
181771 02-07

TREATMENT OF HALLUCINATORY DISORDERS IN SCHIZOPHRENIA BY ATROPINE COMAS.
181778 02-08

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: I. PIMOZIDE IN THE TREATMENT OF PERSONALITY DISORDERS.
183191 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: II. PIMOZIDE IN THE TREATMENT OF BEHAVIOURAL DISORDERS IN CHILDHOOD AND ADOLESCENCE.
183192 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: III. PIMOZIDE IN THE TREATMENT OF STRESS INDUCED PSYCHIC AND FUNCTIONAL DISORDERS.
183193 03-11

A PSYCHOPHARMACOLOGICAL STUDY OF CATECHOLAMINES IN AFFECTIVE DISORDERS.
184653 03-09

TREATMENT OF MENTAL DISORDERS.
185182 03-17

L-TRYPTOPHAN IN AFFECTIVE DISORDERS: INDOLEAMINE CHANGES AND DIFFERENTIAL CLINICAL EFFECTS.
185928 03-09

AFFECTIVE DISORDERS AND CHEMICAL DEPENDENCE: LITHIUM FOR ALCOHOL AND DRUG ADDICTION
189775 04-09

A FEW REMARKS ON THE USE OF PSYCHOACTIVE AGENTS IN THE TREATMENT OF EMOTIONAL DISORDERS.
190241 04-09

ANTICONVULSANT DRUG SERUM LEVELS IN PSYCHIATRIC PATIENTS WITH SEIZURE DISORDERS: EFFECTS OF CERTAIN PSYCHOTROPIC DRUGS.
191096 04-13

REBOUND PHENOMENON IN MANIC PATIENTS FOLLOWING PHYSOSTIGMINE: TOWARDS AN UNDERSTANDING OF AMINERGIC MECHANISMS UNDERLYING AFFECTIVE DISORDERS.
191531 04-09

ADRENERGIC AND CHOLINERGIC FACTORS IN EXTRAPYRAMIDAL DISORDERS.
191533 04-11

DISORGANIZATION

TEMPORAL DISORGANIZATION AND DELUSIONAL-LIKE IDEATION: PROCESSES INDUCED BY HASHISH AND ALCOHOL.
185330 03-14

DISORIENTATION

PAROXYSMAL RIGHT LEFT DISORIENTATION IN AN EPILEPTIC PATIENT.
171246 01-11

DOPAMINE AGONIST INDUCED DISORIENTATION IN A RAT SWIMMING TASK.
192018 04-04

DISPOSITION

PHARMACOKINETIC DISPOSITION OF NORAPOMORPHINE DERIVATIVES AND ITS INFLUENCE ON THE ELICITATION OF STEREOTYPICAL GNAWING. (PH.D. DISSERTATION).
174960 01-03

QUALITATIVE AND QUANTITATIVE STUDIES ON THE DISPOSITION OF AMITRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANT DRUGS IN MAN AS IT RELATES TO THE MANAGEMENT OF THE OVERDOSED PATIENT.
177395 02-15

DISPOSITION OF NORAPOMORPHINE AND N,N PROPYLNORAPOMORPHINE IN MOUSE BRAIN AND ITS CORRELATION WITH STEREOTYPED GNAWING BEHAVIOR.
182131 02-04

PHYSIOLOGICAL DISPOSITION OF BETA-PHENYLETHYLAMINE, 2,4,5 TRIMETHOXYPHENYLETHYLAMINE, 2,3,4,5,6 PENTAMETHOXYPHENYLETHYLAMINE AND BETA-HYDROXYMESCALINE IN RAT BRAIN, LIVER AND PLASMA.
186706 03-03

DISPOSITION OF H3-DELTA9-TETRAHYDROCANNABINOL IN BRAIN OF PREGNANT DOGS AND THEIR FETUSES.
191968 04-03

DISRUPTION

A STUDY OF THE BEHAVIORAL DISRUPTION OF MICE INDUCED BY L-METHIONINE AND RELATED COMPOUNDS.
187260 04-04

DISRUPTIVE

PARENTERAL HALOPERIDOL FOR RAPID CONTROL OF SEVERE, DISRUPTIVE SYMPTOMS OF ACUTE SCHIZOPHRENIA.
178545 02-08

DISRUPTS

METRAZOL DISRUPTS CONDITIONED AVERSION PRODUCED BY LICL: A TIME DEPENDENT EFFECT.
188412 04-04

DISSOCIATION

DISSOCIATION OF STIMULATORY AND SYNTHETIC PHASES IN THE INDUCTION OF TYROSINE HYDROXYLASE.
171785 01-03

BRAIN MECHANISMS UNDERLYING THE EFFECTS OF AMPHETAMINE ON FEEDING AND NONFEEDING BEHAVIORS: DISSOCIATION AND OVERLAP.
184839 03-03

TEMPORAL ASPECTS OF SCOPOLAMINE INDUCED ONE-WAY MEMORY DISSOCIATION IN MICE.
187701 04-04

DISSOCIATION BETWEEN SCOPOLAMINE AND MECAMYLAMINE DURING FEAR CONDITIONING IN RATS.
190264 04-04

DISSOCIATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN PARKINSONS DISEASE FOLLOWING CHRONIC L-DOPA THERAPY.
191233 04-13

DISSOCIATIVE

OPERANT BEHAVIOR AND NEUROPHYSIOLOGICAL OBSERVATIONS OF NORMAL HUMAN VOLUNTEERS RECEIVING CL-1848C, A NEW DISSOCIATIVE ANESTHETIC.
167334 01-07

DISSOCIATIVE CHANGE IN ANTIAGGRESSIVE AND MUSCLE RELAXANT ACTIONS OF S-TRIAZOLOBENZODIAZEPINE (D-40TA) BY REPEATED

ADMINISTRATION AND PHENOBARBITAL PRETREATMENT, AND ITS RELATION TO METABOLISM.
181654 02-04

DISSOLUTION
RELATIONSHIP BETWEEN BIOAVAILABILITY AND DISSOLUTION RATE OF OXAZEPAM.
171630 01-16

DISTINCTIONS
PHARMACOLOGICAL DISTINCTIONS BETWEEN ACTIVE AND PASSIVE AVOIDANCE MEMORY FORMATION AS SHOWN BY MANIPULATION OF BIOGENIC AMINE ACTIVE COMPOUNDS.
185927 03-04

DISTRIBUTION
BRAIN TO SERUM DISTRIBUTION OF RADIOACTIVITY OF INJECTED 3H-D-AMPHETAMINE IN DIFFERENTIALLY HOUSED MICE.
168418 01-03

LIPID INDUCED CHANGES OF PENTOBARBITAL DISTRIBUTION AND METABOLISM.
170072 01-03

CORTICAL SYNAPTOSOMAL UPTAKE AND SUBSYNAPTOSOMAL DISTRIBUTION OF 3H-NOREPINEPHRINE AND 3H-AMPHETAMINE: MODIFICATION BY TRICYCLIC AND PSYCHOACTIVE AGENTS IN VITRO. (PH.D. DISSERTATION).
172020 01-03

THE DISTRIBUTION OF DELTA1-TETRAHYDROCANNABINOL AND 7-HYDROXY-DELTA1-TETRAHYDROCANNABINOL IN THE MOUSE BRAIN AFTER INTRAVENTRICULAR INJECTION.
172596 01-03

LITHIUM DISTRIBUTION BETWEEN CEREBROSPINAL FLUID AND SERUM OF AFFECTIVE PSYCHOTIC PATIENTS TREATED WITH LITHIUM CARBONATE AND ITS CLINICAL RESPONSE.
180301 02-11

STUDY WITH RADIOTRACERS OF THE DISTRIBUTION OF A NEW PSYCHOTROPE IN MICE: L-2-PYRROLIDONE-5-CARBOXYLATE DIMETHYLAMINOETHANOL. I. COMPARISON WITH L-GLUTAMIC AND L-2-PYRROLIDONE-5-CARBOXYLIC ACID.
180723 02-03

SUBCELLULAR DISTRIBUTION OF DELTA9-TETRAHYDROCANNABINOL IN RAT BRAIN.
181810 02-03

REGIONAL AND SUBCELLULAR DISTRIBUTION OF CHOLINE ACETYLTRANSFERASE IN THE BRAIN OF NORMAL AND MORPHINE TREATED RATS.
182224 03-03

ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF BROMAZEPAM IN RABBIT.
182555 03-03

THE ABSORPTION AND DISTRIBUTION OF THE NEW ANTIDEPRESSANT AZAPHEN IN THE ORGANS.
183519 03-03

EVIDENCE FOR AN UNUSUAL DISTRIBUTION OF CHLORPHENTERMINE IN VIVO: AN AUTORADIOGRAPHIC STUDY IN MICE.
184226 03-03

HISTO-AUTORADIOGRAPHIC INVESTIGATIONS ON THE DISTRIBUTION OF INJECTED 5-HYDROXYTRYPTAMINE (SEROTONIN) IN THE BRAIN AND THE PITUITARY OF MICE.
185900 03-03

THE EFFECTS OF CHRONIC TREATMENT WITH D-AMPHETAMINE ON FOOD INTAKE, BODYWEIGHT, LOCOMOTOR ACTIVITY AND SUBCELLULAR DISTRIBUTION OF THE DRUG IN RAT BRAIN.
185931 03-03

DIHYDROPTERIDINE REDUCTASE IN RAT BRAIN: REGIONAL DISTRIBUTION AND THE EFFECT OF CATECHOLAMINE DEPLETING DRUGS.
189752 04-03

PHYLOGENETIC DISTRIBUTION OF OPIATE RECEPTOR BINDING.
190476 04-03

NORADRENALINE IN THE GUINEA-PIG ALIMENTARY CANAL: REGIONAL DISTRIBUTION AND SENSITIVITY TO DENERVATION AND RESERPINE.
191326 04-03

PHARMACOKINETICS AND DISTRIBUTION PROPERTIES OF PENTOBARBITAL IN HUMANS FOLLOWING ORAL AND INTRAVENOUS ADMINISTRATION.
191444 04-13

DISTRIBUTION OF 14C-DELTA9-THC IN MALE AND FEMALE RATS.
191969 04-03

DISTRIBUTION OF 14C-PSILOCIN IN THE BRAINS OF VARIOUS ANIMALS.
192425 04-03

DISTURBANCE
ACUTE CEREBELLAR DISTURBANCE ASSOCIATED WITH DIAZEPAM THERAPY -- A CASE REPORT AND FURTHER INVESTIGATION.
177392 02-15

DISTURBANCES
EXTRAPYRAMIDAL DISTURBANCES BROUGHT ON BY NEUROLEPTICS.
180070 02-15

TREATMENT OF COMPULSIVE EATING DISTURBANCES WITH ANTICONVULSANT MEDICATION.
181270 02-14

TREATMENT OF CEREBROVASCULAR DISTURBANCES WITH 2-BUTYLAMINO-1-P-HYDROXYPHENYL ETHANOL SULFATE (BAMETHAN).
182790 03-11

PSYCHOTROPIC DRUGS IN CHILDHOOD DISTURBANCES.
182890 03-11

THE USE OF ETHYMISOL (ETHYLNORANTIPHEIN) IN PATIENTS WITH PROLONGED DISTURBANCES OF CONSCIOUSNESS.
191777 04-07

DISTURBED
MESORIDAZINE IN THE CARE OF DISTURBED MENTALLY RETARDED PATIENTS.
168315 01-11

INFLUENCE OF ANTIDEPRESSIVE THERAPY ON THE DISTURBED TIME ESTIMATION OF DEPRESSIVES.
182591 03-14

THE EFFECT OF SULTHIAME ON DISTURBED BEHAVIOUR IN MENTALLY SUBNORMAL PATIENTS.
185191 03-14

DISUBSTITUTED
PHARMACOLOGY OF MONO AND DISUBSTITUTED CHLORPROMAZINE METABOLITES.
182243 03-03

DISULFIRAM
EEG CHANGES & MOTOR IMPAIRMENT AFTER DISULFIRAM ADMINISTRATION TO CATS.
182248 03-03

STUDY OF THE USE OF DISULFIRAM IMPLANT IN THE TREATMENT OF ALCOHOLISM.
183030 03-11

DISULFIRAM IMPLANT: A CONTROLLED TRIAL.
185190 03-11

DITA
INTERACTION OF SEROTONIN ANTAGONISTS WITH 3,4-DICHLORO-2-(2-IMIDAZOLIN-2-YL-THIO) 2 ACETOPHENONE HYDROBROMIDE (DITA) AND D-AMPHETAMINE HYDROBROMIDE (DITA) AND D-AMPHETAMINE ON CERTAIN BEHAVIORAL PARAMETERS OF MALE MICE.
192014 04-04

DITRAN
RESPONSE TO INCREMENTAL DOSES OF DITRAN IN ABSTINENT ALCOHOLICS AND DRUG USERS.
185875 03-11

DIURESIS
ENHANCED RENAL TUBULAR SECRETION OF MEPROBAMATE: ROLE OF SALINE FUROSEMIDE DIURESIS.
184243 03-03

DIURETIC
DIURETIC ACTIVITY OF A NEW NARCOTIC ANTAGONIST IN MAN (BRISTOL-COMPOUND-2605). (UNPUBLISHED PAPER).
174473 01-13

DIURETIC ANTIDEPRESSANT COMBINATION IN ALCOHOLIC DEPRESSIVES.
187866 04-11

DIURNAL
THE EFFECTS OF AMPHETAMINE SULFATE ON THE DIURNAL RHYTHMS OF MIDBRAIN; CORTEX, NOREPINEPHRINE; SEROTONIN AND BLOOD GLUCOSE LEVELS IN THE MOUSE.
191918 04-03

THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON THE COMPOSITION OF DIURNAL SLEEP OF NARCOLEPTICS.
192419 04-11

DIVALENT
EFFECT OF DIVALENT CATIONS ON ACH CONTRACTURES OF DEPOLARIZED DENERVATED RAT MUSCLES.
188914 04-03

MECHANISM OF ADRENAL CATECHOLAMINE RELEASE BY DIVALENT MERCURY.
189591 04-03

DIVIDED
SINGLE VERSUS DIVIDED DAILY DOSE OF TRIMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
170622 01-09

DJAKARTA
EXPERIENCES WITH LAROXYL (R) IN THE TREATMENT OF DEPRESSIONS IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
170413 01-11

PRELIMINARY EXPERIENCES WITH NOBRIUM IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
170414 01-11

CLINICAL TRIAL WITH DARTALANR, DJAKARTA, INDONESIA.
170753 01-11

DL-ALPHA-METHYL-DOPA
SALIGENIN ANALOGS OF L-DOPA AND DL-ALPHA-METHYL-DOPA.
187565 04-11

DL-ALPHA-METHYL-P-TYROSINE
QUANTITATIVE HISTOCHEMICAL STUDIES OF STRIATAL DOPAMINE DEPLETION FOLLOWING DL-ALPHA-METHYL-P-TYROSINE ADMINISTRATION.
172924 01-03

DL-AMPHETAMINE

EFFECTS OF L-DELTA9-TETRAHYDROCANNABINOL, DL-AMPHETAMINE AND PENTOBARBITAL ON OXYGEN CONSUMPTION BY MOUSE BRAIN AND HEART HOMOGENATES.
181813 02-03

INHIBITION OF THE SYNAPTOSOMAL UPTAKE MECHANISMS FOR L-NOREPINEPHRINE AND DOPAMINE BY N-ARYLALKYL DL-AMPHETAMINE DERIVATIVES.
182250 03-03

DL-P-METHOXYAMPHETAMINE

COMPARATIVE EFFECTS OF DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE ON CENTRAL CATECHOLAMINES AND LOCOMOTOR ACTIVITY.
182253 03-04

SIGNIFICANCE OF DOPAMINE RECEPTOR ACTIVITY IN DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY.
186670 03-04

COMPARATIVE EFFECTS OF DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE ON CATECHOLAMINE RELEASE AND REUPTAKE IN VITRO.
186671 03-03

DMI

IN VIVO INHIBITION OF NEURONAL UPTAKE OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY COCAINE AND BY DESMETHYLIMIPRAMINE (DMI).
182150 02-03

EFFECT OF CHRONIC TREATMENT WITH DESIPRAMINE (DMI) AND IPRINDOLE (IP) ON THE NOREPINEPHRINE (NE) SENSITIVE ADENYLATE CYCLASE SYSTEM IN SLICES OF THE RAT LIMBIC FOREBRAIN.
192003 04-03

DMT

DMT ADMINISTRATION TO HUMAN SUBJECTS. (UNPUBLISHED PAPER).
173522 01-12

ATTEMPTS TO EVOKE TOLERANCE TO DMT IN MAN. (UNPUBLISHED PAPER).
176480 02-12

CORRELATION BETWEEN BRAIN N,N DIMETHYLTRYPTAMINE (DMT) LEVELS AND BAR PRESSING BEHAVIOR IN RATS: EFFECT OF MAO INHIBITION.
191935 04-04

DOCUMENTATION

THE DOCUMENTATION OF CLINICAL PSYCHOTROPIC DRUG TRIALS.
175332 02-16

THE DOCUMENTATION OF CLINICAL PSYCHOTROPIC DRUG TRIALS: SAMPLE OUTPUT PACKAGE.
180256 02-16

DODECYLSULFATE

COMPARATIVE STUDIES OF SYNAPTIC MEMBRANE PROTEIN SOLUBILIZATION BY CHLORPROMAZINE AND SODIUM DODECYLSULFATE.
176703 02-03

DOET

STEREOSPECIFIC ACTIONS OF DOET (2,5 DIMETHOXY-4-ETHYLAMPHETAMINE) IN MAN.
188121 04-12

DOG

CARDIOVASCULAR EFFECTS OF RESERPINE, YOHIMBINE, AND RESERPINE YOHIMBINE MIXTURES ON INTACT ANESTHETIZED DOG.
167328 01-03

METABOLITES OF BROMAZEPAM, A BENZODIAZEPINE, IN THE HUMAN, DOG, RAT, AND MOUSE.
170837 01-03

PROGRESS REPORT ON THE USE OF THE DOG FOR ASSESSING MORPHINE-LIKE AND NALORPHINE-LIKE AGONISTS AS WELL AS DEPOT PREPARATIONS OF ANTAGONISTS. (UNPUBLISHED PAPER).
176312 02-03

ANTICHOLINERGICS: THEIR EFFECTS ON FEAR MOTIVATED BEHAVIOR, URINARY 11-HYDROXYCORTICOSTEROIDS, URINARY VOLUME, AND HEART RATE IN THE DOG.
178720 02-03

INVESTIGATIONS ON THE FATE OF THE ANTICONVULSANT CLONAZEPAM IN THE ORGANISM OF MAN, RAT AND DOG.
179022 02-13

ANALGESIC EFFECT OF DELTA9-TETRAHYDROCANNABINOL IN THE DOG.
186585 03-03

MORPHINE PHYSICAL DEPENDENCE IN THE DOG.
186665 03-03

CARDIOVASCULAR AND GROSS BEHAVIORAL EFFECTS OF AMPHETAMINE, 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPROPANE (DOM) AND 2-AMINO-1-(2,5 DIMETHOXY-4-METHYLPHENYL BUTANE (BL-3912A) IN THE CONSCIOUS DOG.
187573 04-03

CARDIOVASCULAR REACTIVITY IN THE DOG AFTER CHEMICAL SYMPATHECTOMY WITH 6-HYDROXYDOPAMINE.
187807 04-03

A FREQUENCY SHIFT IN THE HIPPOCAMPAL THETA ACTIVITY: AN ELECTRICAL CORRELATE OF CENTRAL ACTION OF ACTH ANALOGUES IN THE DOG
188166 04-04

COMPARATIVE METABOLISM OF TRIAZOLAM, A NEW SEDATIVE HYPNOTIC, IN RAT, DOG AND MAN.
191900 04-02

EFFECTS OF PHENETHYLAMINE (PEA) IN THE CHRONIC SPINAL DOG.
191904 04-03

SUBCELLULAR LOCALIZATION OF H3-DELTA9-TETRAHYDROCANNABINOL IN DOG BRAIN AFTER ACUTE OR CHRONIC ADMINISTRATION.
191970 04-03

DOGS

ACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MICE, RATS, RABBITS AND DOGS.
173548 01-05

CHANGES IN SHORT-TERM AND LONG-TERM MEMORY OF DOGS AND CATS UNDER THE EFFECTS OF AMIZYL (BENACTYZINE).
183517 03-04

THE EFFECTS OF CHLORDIAZEPOXIDE, AMPHETAMINE AND COCAINE ON BAR-PRESS BEHAVIOR IN NORMAL AND GENETICALLY NERVOUS DOGS.
187868 04-04

COMPARISON OF PHARMACOLOGICAL RESPONSES TO NICOTINE AND RELEASE OF CATECHOLAMINES FROM THE ADRENALS IN DOGS AND MONKEYS.
188199 04-03

INTESTINAL EFFECTS OF 5-HYDROXYTRYPTAMINE AND MORPHINE IN GUINEA-PIGS, DOGS, CATS AND MONKEYS.
188202 04-03

PSYCHOPHARMACOLOGIC FACILITATION OF OPERANT CONDITIONING OF GENETICALLY NERVOUS CATAHOULA AND POINTER DOGS.
190696 04-04

DISPOSITION OF H3-DELTA9-TETRAHYDROCANNABINOL IN BRAIN OF PREGNANT DOGS AND THEIR FETUSES.
191968 04-03

CARDIOPULMONARY EFFECTS OF CANNABIDIOL IN ANESTHETIZED DOGS.
191993 04-05

THE PREDICTIVE VALUE OF THE ANTIAPOMORPHINE TEST IN DOGS FOR NEUROLEPTIC THERAPY IN MAN.
192421 04-04

DOLICHOMEGACOLON

DOLICHOMEGACOLON INDUCED BY NEUROLEPTICS AMONG PSYCHIATRIC PATIENTS (MEMORANDUM COVERING 153 CASES).
176432 02-15

DOLICHOTHELE

CACTUS ALKALOIDS. XXII. DOLICHOTHELE SURCULOSA AND OTHER DOLICHOTHELE SPECIES.
192879 04-01

DOMINANCE

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON THE DOMINANCE BEHAVIOR OF THE RAT.
182189 02-04

DOPA

PLASMA DOPA AND FUNCTIONAL OSCILLATIONS AFTER CHRONIC TREATMENT OF PARKINSONS DISEASE.
188421 04-13

SELECTIVE RESERPINE RESISTANT ACCUMULATION OF CATECHOLAMINES IN CENTRAL DOPAMINE NEURONES AFTER DOPA ADMINISTRATION.
189026 04-03

DOPAMINE

EFFECTS OF DOPAMINE RECEPTOR STIMULATION AND BLOCKADE ON RO-4-1284 INDUCED ENHANCEMENT OF ELECTROSHOCK SEIZURE.
167287 01-03

TREMOR INDUCTION BY INTRACAUDATE INJECTIONS OF BRETYLIUM, TETRABENAZINE, OR MESCALINE: FUNCTIONAL DEFICITS IN CAUDATE DOPAMINE.
167329 01-03

THE ROLE OF DOPAMINE IN DEPRESSION.
167584 01-13

CENTRAL MONOAMINE METABOLISM IN MAN: EFFECT OF PUTATIVE DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS.
169377 01-13

DOPAMINE AND 5-HYDROXYTRYPTAMINE INHIBIT FEEDING IN RATS.
170177 01-04

SIMULTANEOUS MASS FRAGMENTOGRAPHIC ASSAY OF NOREPINEPHRINE (NE), EPINEPHRINE (E) AND DOPAMINE (DA) IN RAT SYMPATHETIC GANGLION: EFFECTS OF DEXAMETHASONE IN NEWBORN AND ADULT RATS. (UNPUBLISHED PAPER).
170747 01-03

THE UPTAKE OF DOPAMINE AND SEROTONIN IN RAT BRAIN DURING PROGESTERONE DECLINE.
171307 01-03

INFLUENCES OF DRUGS ON THE INCREASES IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OF GAMMA-HYDROXYBUTYRIC ACID (GHBA).
171622 01-03

THE EFFECT OF PROTRIPTYLINE ON THE METABOLISM OF LABELLED DOPAMINE AND NORADRENALINE IN THE RAT BRAIN.
171627 01-03

A SENSITIVE GAS CHROMATOGRAPHIC PROCEDURE FOR THE ESTIMATION OF NORADRENALINE, DOPAMINE AND 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
171971 01-01

QUANTITATIVE HISTOCHEMICAL STUDIES OF STRIATAL DOPAMINE DEPLETION FOLLOWING DL-ALPHA-METHYL-P-TYROSINE ADMINISTRATION.
172924 01-03

DRINKING BEHAVIOUR AND BRAIN DOPAMINE: ANTAGONISTIC EFFECT OF TWO NEUROLEPTIC DRUGS (PIMOZIDE AND SPIRAMIDE) UPON AMPHETAMINE OR APOMORPHINE-INDUCED HYPODIPSIA.
174035 01-04

THE EFFECTS OF AMPHETAMINE, 2-AMINOINDANE AND 2-AMINOTETRALIN ON THE CONCENTRATIONS OF WHOLE BRAIN NORADRENALINE, DOPAMINE, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC ACID IN THE MOUSE.
174828 01-03

THE EFFECT OF DOPAMINE ANTAGONISTS AND AMANTADINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
174829 01-04

EVIDENCE THAT MORPHINE INCREASES DOPAMINE UTILIZATION IN CORPORA-STRIATA OF RATS.
176746 02-03

ANTAGONISM OF THE EFFECTS OF CHLORPROMAZINE AND MORPHINE ON DOPAMINE METABOLISM BY GABA.
176870 02-03

RELATIVE POTENCIES OF D- AND L-AMPHETAMINE ON THE RELEASE OF DOPAMINE FROM CAT BRAIN IN VIVO.
176874 02-03

DOPAMINE IN THE MESOLIMBIC SYSTEM OF THE RAT BRAIN: ENDOGENOUS LEVELS AND THE EFFECTS OF DRUGS ON THE UPTAKE MECHANISM AND STIMULATION OF ADENYLATE CYCLASE ACTIVITY.
177131 02-03

ADRENALINE, NORADRENALINE AND DOPAMINE LEVELS IN BRAIN AND HEART AFTER ADMINISTRATION OF 6-HYDROXYDOPAMINE AND GUANETHIDINE TO NEWBORN MICE.
177338 02-03

ON THE SPECIFICITY OF DOPAMINE RELEASE BY AMANTADINE.
178557 02-03

EXCRETION OF NOREPINEPHRINE AND DOPAMINE ALCOHOLIC METABOLITES AFTER 6-HYDROXYDOPAMINE.
179986 02-03

EFFECT OF CHLORPROMAZINE AND SOME OF ITS METABOLITES ON THE DOPAMINE SENSITIVE ADENYLATE CYCLASE OF RAT BRAIN STRIATUM.
180060 02-03

CENTRAL DOPAMINE FUNCTION IN AFFECTIVE ILLNESS: EVIDENCE FROM PRECURSORS, ENZYME INHIBITORS AND STUDIES OF CENTRAL DOPAMINE TURNOVER. (UNPUBLISHED PAPER).
181358 02-09

HYPOTHERMIA EVOKED BY A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE ALKALOID.
182130 02-03

IN VIVO INHIBITION OF NEURONAL UPTAKE OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY COCAINE AND BY DESMETHYLIMIPRAMINE (DMI).
182150 02-03

UPTAKE, STORAGE AND RELEASE IN VIVO OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY SYMPATHETIC NERVES OF THE IRIS.
182204 02-03

EFFECT OF MORPHINE, HALOPERIDOL, APOMORPHINE AND BENZTROPINE ON DOPAMINE TURNOVER IN RAT CORPUS-STRIATUM: EVIDENCE SHOWING MORPHINE-INDUCED REDUCTION IN CNS DOPAMINERGIC ACTIVITY.
182230 03-03

INHIBITION OF THE SYNAPTOSOMAL UPTAKE MECHANISMS FOR L-NOREPINEPHRINE AND DOPAMINE BY N-ARYLALKYL DL-AMPHETAMINE DERIVATIVES.
182250 03-03

EFFECT OF 2-ARYLALANINES, 2-ARYLSERINES, TETRAPHENYLBORON AND 1,2 DL(2,4 DICHLOROPHENYL) ETHANOLAMINE ON LEVELS OF SEROTONIN (5-HT), NOREPINEPHRINE (NE) AND DOPAMINE (DM) IN WHOLE BRAIN OF MICE.
182254 03-03

THE EFFECT OF DOPAMINE RECEPTOR STIMULATING AGENTS AND OF N,O DIBUTYRYL CYCLIC AMP ON C14-DOPAMINE SYNTHESIS IN STRIATAL SLICES OF RATS.
182256 03-03

PARADOXICAL THERMOREGULATORY BEHAVIOUR IN RATS INDUCED BY (..) AMPHETAMINE: BLOCKADE BY ALPHA-ADRENOCEPTOR OR DOPAMINE RECEPTOR BLOCKING AGENTS.
183797 03-03

AMANTADINE MAY STIMULATE DOPAMINE AND NORADRENALINE RECEPTORS.
183868 03-03

DOPAMINE IN BRAIN FUNCTION.
184329 03-03

PARKINSON DISEASE TREATED WITH A SUSPECTED DOPAMINE RECEPTOR AGONIST.
186029 03-11

EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: II. EFFECT ON DOPAMINE AND NORADRENALINE CONCENTRATIONS AND TURNOVERS.
186588 03-04

SIGNIFICANCE OF DOPAMINE RECEPTOR ACTIVITY IN DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY.
186670 03-04

EFFECT OF ALPHA-METHYLDOPA ON THE METABOLISM OF DOPAMINE IN THE STRIATUM OF THE RAT.
186694 03-03

THE TRANSSYNAPTIC RELATIONSHIP BETWEEN DOPAMINE AND SEROTONIN IN THE CAUDATE NUCLEUS OF CATS.
186700 03-04

REGULATION OF BRAIN DOPAMINE TURNOVER RATE: PHARMACOLOGICAL IMPLICATIONS. (UNPUBLISHED PAPER).
187527 04-03

THE ADDITIVE EFFECTS OF TRANQUILIZERS AND DOPAMINE ON SMOOTH MUSCLE.
187804 04-03

DOPAMINE AND GILLES-DE-LA-TOURETTES SYNDROME.
188431 04-11

FURTHER EVIDENCE FOR A DOPAMINE RECEPTOR STIMULATING ACTION OF AN ERGOT ALKALOID.
188739 04-03

EVIDENCE FOR A SPECIFIC UPTAKE OF DOPAMINE BY DOPAMINERGIC TERMINALS OF THE RAT CEREBRAL CORTEX.
188978 04-03

SELECTIVE RESERPINE RESISTANT ACCUMULATION OF CATECHOLAMINES IN CENTRAL DOPAMINE NEURONES AFTER DOPA ADMINISTRATION.
189026 04-03

PARADOXICAL EFFECTS OF D-AMPHETAMINE ON BEHAVIORAL THERMOREGULATION: POSSIBLE MEDIATION BY BRAIN DOPAMINE.
189399 04-04

THE DOPAMINE RELEASING ACTIONS OF NEUROLEPTICS AND ETHANOL.
189401 04-03

EFFECT OF ANESTHETIC AGENTS ON THE SYNTHESIS AND DISAPPEARANCE OF BRAIN DOPAMINE NORMALLY AND AFTER HALOPERIDOL, KCL OR AXOTOMY.
189571 04-03

STIMULATION OF A DOPAMINE SENSITIVE ADENYLATE CYCLASE IN HOMOGENATES OF RAT STRIATUM BY A METABOLITE OF PIRIBEDIL (ET-495).
189616 04-03

EFFECTS OF DOPAMINE-LIKE DRUGS ON RAT STRIATAL ADENYL CYCLASE HAVE IMPLICATIONS FOR CNS DOPAMINE RECEPTOR TOPOGRAPHY.
190545 04-03

EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF CLOZAPINE ON THE METABOLISM OF DOPAMINE AND NORADRENALINE IN THE BRAIN OF THE RAT.
191418 04-03

CATALEPSY AND STEREOTYPIES IN RATS TREATED WITH METHADONE; RELATION TO STRIATAL DOPAMINE.
191421 04-03

DOPAMINE AND PSYCHIATRIC STATES: PRELIMINARY REMARKS.
191507 04-13

THE EFFECTS OF COMT INHIBITORS ON BEHAVIOR AND DOPAMINE METABOLISM.
191517 04-03

THE EFFECTS ON INGESTIVE BEHAVIORS OF DAMAGE TO CENTRAL DOPAMINE CONTAINING NEURONS.
191520 04-04

ROLE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN IN INTRACRANIAL REWARD.
191527 04-04

BALANCE BETWEEN ACETYLCHOLINE, SEROTONIN, NOREPINEPHRINE, AND DOPAMINE IN SELF-STIMULATION.
191528 04-04

ROLE OF ACETYLCHOLINE AND DOPAMINE IN MANIC BEHAVIOR.
191532 04-09

AMPHETAMINE AND METHYLPHENIDATE INDUCED RELEASE OF STRIATAL DOPAMINE IN VIVO: DIFFERENTIAL EFFECTS ON NEWLY SYNTHESIZED AND STORED POOLS.
191897 04-03

A ROLE FOR DOPAMINE IN THE STIMULANT EFFECTS OF AMPHETAMINE ON LOCUS-COERULEUS SELF-STIMULATION.
191984 04-03

DOPAMINE AGONIST INDUCED DISORIENTATION IN A RAT SWIMMING TASK.
192018 04-04

DOPAMINE-BETA-HYDROXYLASE
SELECTIVE INHIBITION OF NOREPINEPHRINE SYNTHESIS IN MANIC-DEPRESSIVE PATIENTS WITH A DOPAMINE-BETA-HYDROXYLASE INHIBITOR. (UNPUBLISHED PAPER).
170083 01-03
BEHAVIORAL EFFECTS OF A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR (FUSARIC ACID) IN MAN. (UNPUBLISHED PAPER
174329 01-09
COMPARISON OF TYROSINE HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION WITH THE EFFECTS OF VARIOUS 6-HYDROXYDOPAMINE TREATMENTS ON D-AMPHETAMINE INDUCED MOTOR ACTIVITY.
186699 03-03
DOPAMINE-BETA-HYDROXYLASE AND THE REGULATION OF THE NORADRENERGIC NEURON.
191509 04-03
HUMAN SERUM DOPAMINE-BETA-HYDROXYLASE: RELATIONSHIP TO SYMPATHETIC ACTIVITY IN PHYSIOLOGICAL AND PATHOLOGICAL STATES.
191510 04-13
AN EVALUATION OF SERUM DOPAMINE-BETA-HYDROXYLASE AS AN INDEX OF SYMPATHETIC NERVE ACTIVITY IN MAN.
191511 04-13
SERUM DOPAMINE-BETA-HYDROXYLASE: A POSSIBLE AID IN THE EVALUATION OF HYPERTENSION.
191512 04-13
EFFECT OF L-PHENYL-3-2-THIAZOLYL 2-THIOUREA, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
191769 04-03

DOPAMINE-LIKE
EFFECTS OF DOPAMINE-LIKE DRUGS ON RAT STRIATAL ADENYL CYCLASE HAVE IMPLICATIONS FOR CNS DOPAMINE RECEPTOR TOPOGRAPHY.
190545 04-03

DOPAMINERGIC
EFFECT OF DOPAMINERGIC STIMULATION OR BLOCKADE ON MORPHINE WITHDRAWAL AGGRESSION.
171300 01-04
BEHAVIORAL EVIDENCE FOR DOPAMINERGIC SUPERSENSITIVITY AFTER CHRONIC HALOPERIDOL.
180021 02-04
INTERACTION OF APOMORPHINE, NEUROLEPTICS AND STIMULANTS WITH ALPHA-METHYL-M-TYRAMINE, A FALSE DOPAMINERGIC TRANSMITTER.
181809 02-03
EFFECTS OF DOPAMINERGIC STIMULANTS ON THE CAUDATE SPINDLE.
182125 02-03
RELATIVE IMPORTANCE OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS FOR THE STIMULATION OF LOCOMOTOR ACTIVITY INDUCED BY AMPHETAMINE AND OTHER DRUGS.
182209 02-04
EFFECT OF MORPHINE, HALOPERIDOL, APOMORPHINE AND BENZTROPINE ON DOPAMINE TURNOVER IN RAT CORPUS-STRIATUM: EVIDENCE SHOWING MORPHINE-INDUCED REDUCTION IN CNS DOPAMINERGIC ACTIVITY.
182230 03-03
IN VIVO ESTIMATION OF TYROSINE HYDROXYLATION IN THE DOPAMINERGIC TERMINALS OF THE RAT NEOSTRIATUM.
183794 03-03
DOPAMINERGIC HYPERSENSITIVITY AND CHOLINERGIC HYPOFUNCTION IN THE PATHOPHYSIOLOGY OF TARDIVE DYSKINESIA.
185929 03-11
EFFECT OF SEVERAL DOPAMINERGIC DRUGS AND TRIHEXYPHENIDYL ON CHOLINERGIC PARAMETERS IN THE RAT STRIATUM.
185995 03-03
EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: I. EFFECT ON THE BEHAVIOURAL CHANGES INDUCED BY RESERPINE, ALPHA-METHYL-P-TYROSINE OR AMPHETAMINE.
186587 03-04
EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: II. EFFECT ON DOPAMINE AND NORADRENALINE CONCENTRATIONS AND TURNOVERS.
186588 03-04
DOPAMINERGIC NATURE OF APOMORPHINE-INDUCED PECKING IN PIGEONS.
188204 04-03
INHIBITORY EFFECT OF DOPAMINERGIC STIMULATION ON GH RELEASE IN ACROMEGALY.
188350 04-13
ROLE OF DOPAMINERGIC MECHANISMS IN REGULATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN MAN.
188428 04-13
EVIDENCE FOR A SPECIFIC UPTAKE OF DOPAMINE BY DOPAMINERGIC TERMINALS OF THE RAT CEREBRAL CORTEX.
188978 04-03
DOPAMINERGIC INHIBITION OF STRIATAL CHOLINERGIC NEURONS: SYNERGISTIC BLOCKING ACTION OF GAMMA-BUTYROLACTONE AND NEUROLEPTIC DRUGS.
189602 04-03
EVIDENCE FOR A NORADRENERGIC AND DOPAMINERGIC MECHANISM IN THE HYPERACTIVITY PRODUCED BY 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.
190309 04-04
EFFECTS OF ALTERATIONS IN IMPULSE FLOW ON TRANSMITTER METABOLISM IN CENTRAL DOPAMINERGIC NEURONS.
191519 04-03
BEHAVIORAL EFFECTS OF DIRECT AND INDIRECT ACTING DOPAMINERGIC AGONISTS.
191521 04-04
EFFECTS OF PIRIBEDIL (ET-495) -- A DOPAMINERGIC RECEPTOR STIMULATING AGENT IN PARKINSONS DISEASE.
191522 04-13
CLINICAL STUDIES OF DOPAMINERGIC MECHANISMS.
191524 04-13
EVIDENCE FOR A DOPAMINERGIC INVOLVEMENT IN THE MAINTENANCE OF SELF-STIMULATION.
191526 04-03
SUPERSENSITIVITY TO DOPAMINERGIC AGONISTS FOLLOWING WITHDRAWAL OF A CHRONIC DIET CONTAINING HALOPERIDOL OR PIMOZIDE.
192012 04-04

DORSAL
EFFECTS OF FOOD DEPRIVATION, DISCRIMINATION EXPERIENCE AND PHYSOSTIGMINE ON CHOLINE ACETYLASE AND ACETYLCHOLINE ESTERASE IN THE DORSAL HIPPOCAMPUS AND FRONTAL CORTEX OF RATS.
169467 01-03
LIPIDOSIS-LIKE ALTERATIONS IN DORSAL ROOT GANGLION CELLS OF RATS TREATED WITH TRICYCLIC ANTIDEPRESSANTS.
189605 04-03
THE ROLE OF GAMMA-AMINOBUTYRIC ACID AS A MEDIATOR OF POSITIVE DORSAL ROOT POTENTIALS.
189832 04-03
DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
191944 04-04

DOSAGE
PHENOTHIAZINE DOSAGE LEVELS AND AUDITORY SIGNAL DETECTION IN SCHIZOPHRENIA.
167817 01-08
DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE IN RESPECT TO TIME AND DOSAGE AND QUANTIFICATION OF THE PRECIPITATED WITHDRAWAL SYNDROME IN RATS.
169474 01-03
LOW DOSAGE HALOPERIDOL AND INDUCED ANXIETY IN NORMAL VOLUNTEERS.
169745 01-14
EXPERIENCE IN THE USE OF A LOW DOSAGE OF CARPIPRAMINE (DEFEKTON).
176472 02-08
INDICATIONS AND DOSAGE FOR MAXIMAL ACTIVITY OF ORNITHINE-CARBAMYL-TRANSFERASE IN THE PSYCHIATRIC ENVIRONMENT.
184955 03-17
DRUG DOSAGE IN ACUTE PHASE SCHIZOPHRENIA.
185898 03-17
METHYLPHENIDATE IN CHILDREN -- EFFECT OF DOSAGE.
187581 04-14
HIGH DOSAGE PIPERACETAZINE (QUIDE-R) IN AMBULATORY SCHIZOPHRENIC PATIENTS: THERAPEUTIC EFFICACY AND TOXICITY.
187869 04-08
IMPROVING PSYCHIATRIC DRUG THERAPY: A MATTER OF DOSAGE AND CHOICE.
190144 04-17

DOSAGES
NONSEDATING DOSAGES OF DIAZEPAM AND PHENOBARBITAL IN THE REDUCTION OF NEONATAL BILIRUBIN LEVELS.
191607 04-17

DOSE
A CONTROLLED STUDY OF SINGLE DOSE ADMINISTRATION OF IMIPRAMINE PAMOATE IN ENDOGENOUS DEPRESSION.
167775 01-09
THE TREATMENT OF DEPRESSION WITH A SINGLE DAILY DOSE OF IMIPRAMINE PAMOATE.
169491 01-09
SINGLE VERSUS DIVIDED DAILY DOSE OF TRIMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
170622 01-09
PSYCHOLOGICAL EFFECTS OF SINGLE DOSE ANTIPSYCHOTIC MEDICATION.
173402 01-08
(-)DELTA9-THC AS AN HYPNOTIC: AN EXPERIMENTAL STUDY OF THREE DOSE LEVELS.
174041 01-14
HIGH AND LOW DOSE THIOTHIXENE TREATMENT IN CHRONIC SCHIZOPHRENIA.
176673 02-08

STEREOTYPED AND AGGRESSIVE BEHAVIOR INDUCED BY SUSTAINED HIGH DOSE OF THEOPHYLLINE IN RATS.
177019 02-04

FURTHER ASPECTS OF AGGRESSIVE BEHAVIOR INDUCED BY SUSTAINED HIGH DOSE OF THEOPHYLLINE IN RATS.
177020 02-04

THE EFFECT OF PROBENECID AND LARGE DOSE AMPHETAMINE ADMINISTRATION ON CEREBROSPINAL FLUID HOMOVANILLIC ACID.
177826 02-13

ACETYLCHOLINE TURNOVER IN BRAIN OF MICE AND RATS: EFFECTS OF VARIOUS DOSE REGIMENS OF MORPHINE. (UNPUBLISHED PAPER).
180582 02-03

PSYCHOPHYSIOLOGICAL EFFECTS OF DIAZEPAM (VALIUM) COMBINED WITH A MODERATE DOSE OF ALCOHOL IN MAN.
180699 02-14

PREDICTION OF NEUROLEPTIC EFFECTS OF CI-686 BASED ON QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY: DRUG PROFILES AND DOSE RESPONSE CURVES BASED ON COMPUTERIZED CEREBRAL BIOPOTENTIALS.
181958 02-13

DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) DOSE EFFECTS COMPARED ON THREE SCHEDULES OF FOOD REINFORCED OPERANT PERFORMANCE.
182191 02-04

THE OCULAR COMPLICATIONS BY MASSIVE DOSE OF PSYCHOTROPIC DRUGS.
182552 03-15

DOSE EFFECTS OF METHYLPHENIDATE ON BEHAVIORAL INHIBITION AND ACTIVATION IN HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
185676 03-14

DOSE DEPENDENT SELECTIVE FACILITATION OF RESPONSE CONTINGENT LIGHT ONSET BEHAVIOR BY D-AMPHETAMINE.
185955 03-04

DOSE DEPENDENT POTENTIATION OR INHIBITION BY RO-4-4602 OF 5-HTP HYPERTHERMIA IN RABBITS.
185996 03-03

DOXEPIN: IS A SINGLE DAILY DOSE ENOUGH?
192066 04-10

DOSE-RELATED

DOSE-RELATED ALTERATIONS IN METABOLISM OF LEVODOPA: POSSIBLE MECHANISM FOR HYPOTENSIVE EFFECT.
190194 04-11

DOSE-RESPONSE

SHIFTING OF THE D-AMPHETAMINE DOSE-RESPONSE CURVE IN RATS WITH FRONTAL CORTICAL ABLATIONS.
187261 04-04

THE EFFECT OF SOME CHOLINOLYTIC DRUGS ON A NUMBER OF BEHAVIOURAL PARAMETERS MEASURED IN THE T-MAZE ALTERNATION TEST: DOSE-RESPONSE RELATIONSHIPS.
187641 04-04

BEHAVIORAL AND ELECTROCORTICOGRAPHIC DOSE-RESPONSE RELATIONSHIPS WITH METRAZOL. (UNPUBLISHED PAPER).
188248 04-04

DOSES

GAS CHROMATOGRAPHIC DETERMINATION OF METHAQUALONE IN SMALL AMOUNTS OF SERUM AFTER INGESTION OF THERAPEUTIC DOSES.
172397 01-16

ONE YEAR OF CLINICAL EXPERIENCE WITH LARGE DOSES OF 10 PERCENT FLUPENTHIXOL DECANOATE (LU-1705).
172735 01-07

HIGH DOSES OF CHLORPROMAZINE AND TRIFLUOPERAZINE IN THE TREATMENT OF PATIENTS SUFFERING FROM SCHIZOPHRENIA.
174589 01-08

EFFECTS OF LOW DOSES OF CHLORPROMAZINE ON A CONDITIONED EMOTIONAL RESPONSE IN THE RAT.
176963 02-04

EFFECTS OF CHRONIC PRETREATMENT WITH SMALL DOSES OF RESERPINE UPON ADRENERGIC NERVE FUNCTION.
177406 02-03

THE USE OF LOW DOSES OF MONOCHLORIMIPRAMINE IN THE THERAPY OF NEUROTIC DEPRESSIVE SYNDROMES.
182789 03-10

TRIFLUOPERAZINE: A COMPARISON BETWEEN REGULAR AND HIGH DOSES.
184977 03-08

RESPONSE TO INCREMENTAL DOSES OF DITRAN IN ABSTINENT ALCOHOLICS AND DRUG USERS.
185875 03-11

COMPARISON OF GRADED SINGLE INTRAMUSCULAR DOSES OF MORPHINE AND PENTOBARBITAL IN MAN.
187254 03-15

PERSISTENT ELECTROENCEPHALOGRAPHIC CHANGES IN RHESUS MONKEYS AFTER SINGLE DOSES OF PENTOBARBITAL, NITRAZEPAM AND IMIPRAMINE.
187931 04-03

THE EFFECT OF HYPOTHERMIC DOSES OF 1-DELTA9-TETRAHYDROCANNABINOL ON BIOGENIC AMINE METABOLISM IN SELECTED PARTS OF THE RAT BRAIN.
188231 04-03

DOSING

LONG-TERM ALTERATION OF SLEEP-WAKEFULNESS CYCLE DURING CHRONIC PENTOBARBITAL DOSING AND WITHDRAWAL IN CAT.
191952 04-04

DOSSIER

A SUMMARY OF THE CLINICAL DOSSIER ON DEPAMIDE.
183544 03-17

DOTHIEPIN

CHLORDIAZEPOXIDE AND DOTHIEPIN COMPARED IN ANXIETY/DEPRESSION IN GENERAL PRACTICE.
167575 01-10

DOUBLE

EFFECTS OF INTRACISTERNAL 6-HYDROXYDOPAMINE TREATMENT ON ACQUISITION AND PERFORMANCE OF RATS IN A DOUBLE T-MAZE.
187696 04-04

DOUBLE-BLIND

DOUBLE-BLIND CLINICAL EVALUATION OF MAZINDOL, DEXTROAMPHETAMINE, AND PLACEBO IN TREATMENT OF EXOGENOUS OBESITY.
167335 01-11

A DOUBLE-BLIND, COMPARATIVE CLINICAL TRIAL WITH LUDIOMIL (CIBA-34276-BA) AND AMITRIPTYLINE IN NEWLY ADMITTED DEPRESSED PATIENTS.
167774 01-09

CLOMIPRAMINE HCL -- A DOUBLE-BLIND STUDY OF A NEW ANTIDEPRESSANT DRUG.
168318 01-09

TRAZODONE IN THE TREATMENT OF PSYCHONEUROSES: A DOUBLE-BLIND STUDY.
168809 01-11

THE USE OF LITHIUM IN AFFECTIVE DISORDERS, III: A DOUBLE-BLIND STUDY OF PROPHYLAXIS IN BIPOLAR ILLNESS.
169495 01-09

COMPARISON OF THIORIDAZINE AND DIAZEPAM IN THE CONTROL OF NONPSYCHOTIC SYMPTOMS ASSOCIATED WITH SENILITY: DOUBLE-BLIND STUDY.
170129 01-11

A DOUBLE-BLIND CLINICAL TRIAL OF DOXEPIN HYDROCHLORIDE AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION IN THE FIELD OF INTERNAL MEDICINE.
171282 01-11

DIPHENYLHYDANTOIN EFFECTIVENESS IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS: A DOUBLE-BLIND CONTROLLED STUDY WITH A PLACEBO.
171507 01-08

A DOUBLE-BLIND INVESTIGATION OF DIMETHACRINE VERSUS IMIPRAMINE IN HOSPITALIZED DEPRESSIVE STATES.
171695 01-09

A DOUBLE-BLIND COMPARISON OF THIORIDAZINE (MELLARIL) VERSUS DIAZEPAM (VALIUM) IN PATIENTS WITH CHRONIC MIXED ANXIETY AND DEPRESSIVE SYMPTOMS.
172486 01-10

AN ERGOT ALKALOID PREPARATION (HYDERGINE) VERSUS PAPAVERINE IN TREATING COMMON COMPLAINTS OF THE AGED: DOUBLE-BLIND STUDY.
173190 01-11

EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL (DELTA9-THC) ON MEMORY, ATTENTION AND SUBJECTIVE STATE: A DOUBLE-BLIND STUDY.
174043 01-14

AMOXAPINE AND IMIPRAMINE: A DOUBLE-BLIND STUDY IN DEPRESSED PATIENTS.
174138 01-09

A DOUBLE-BLIND TRIAL OF IPRINDOLE AND IMIPRAMINE IN DEPRESSIVES AND RESPONSE TO ECT IN REFRACTORY CASES.
174376 01-09

A DOUBLE-BLIND COMPARISON OF CLOZAPINE WITH THIORIDAZINE ON SCHIZOPHRENIA.
175119 02-08

A DOUBLE-BLIND CONTROLLED STUDY COMPARING PROTRIPTYLINE AND AMITRIPTYLINE.
177567 02-09

A DOUBLE-BLIND COMPARISON OF FLUPHENAZINE AND HALOPERIDOL IN OUTPATIENT SCHIZOPHRENIC CHILDREN.
177754 02-08

COMPARISON OF THE EFFECTS OF Y-4153 AND CARPIPRAMINE ON SCHIZOPHRENIA BY A DOUBLE-BLIND METHOD.
178053 02-08

PIMOZIDE (R-6238) IN CHRONIC SCHIZOPHRENIA: DOUBLE-BLIND TRIAL.
178255 02-08

DOXEPIN AND AMITRIPTYLINE CHLORDIAZEPOXIDE COMBINATION IN NEUROTIC STATES: A COMPARATIVE DOUBLE-BLIND STUDY.
180048 02-10

DOUBLE-BLIND PSYCHOMETRIC EVALUATION OF PIMOZIDE AND HALOPERIDOL VERSUS PLACEBO IN EMOTIONALLY LABILE VOLUNTEERS UNDER TWO DIFFERENT WORK LOAD CONDITIONS. 180065 02-14

A DOUBLE-BLIND TRIAL OF TRIOXAZINE WITH PLACEBO IN ANXIETY STATES. 180249 02-10

DOUBLE-BLIND COMPARATIVE STUDY OF HF-1972/NOVERIL IN DEPRESSION. 180986 02-10

THE COMPARISON OF THERAPEUTIC EFFECTS OF FK-880 (SULPIRIDE) AND PERPHENAZINE IN SCHIZOPHRENIA BY A DOUBLE-BLIND CONTROLLED STUDY. 181378 02-08

AFRODEX VS. PLACEBO IN THE TREATMENT OF MALE IMPOTENCE: STATISTICAL ANALYSIS OF TWO DOUBLE-BLIND CROSSOVER STUDIES. 181959 02-14

DOUBLE-BLIND CROSSOVER COMPARISON OF BROMAZEPAM AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION. 182624 03-11

DOUBLE-BLIND CLINICAL TRIAL OF NOVERIL AND OF NOVERIL-TR (NOVERIL 240MG). 183190 03-07

A DOUBLE-BLIND COMPARISON OF PIMOZIDE WITH CARPIPRAMINE IN SCHIZOPHRENIC PATIENTS. 183195 03-08

A DOUBLE-BLIND TRIAL OF LONG-TERM LITHIUM THERAPY IN MENTAL DEFECTIVES. 185193 03-11

IMIPRAMINE AND METHYLPHENIDATE TREATMENTS OF HYPERACTIVE BOYS: A DOUBLE-BLIND COMPARISON. 185324 03-14

A DOUBLE-BLIND CROSSOVER SEQUENTIAL TRIAL OF ORAL THYROTROPIN RELEASING HORMONE IN DEPRESSION. 188348 04-09

DOUBLE-BLIND COMPARISON OF THIOTHIXENE, TRIFLUOPERAZINE, AND PLACEBO IN CHRONIC ALCOHOLISM. 188584 04-11

THE CONTROL OF DEVIANT SEXUAL BEHAVIOR BY DRUGS: A DOUBLE-BLIND CONTROLLED STUDY OF BENPERIDOL, CHLORPROMAZINE, AND PLACEBO. 190061 04-11

A DOUBLE-BLIND CONTROLLED STUDY OF LOXAPINE SUCCINATE IN THE TREATMENT OF ANXIETY NEUROSES. 190196 04-09

HALOPERIDOL VERSUS THIORIDAZINE FOR THE TREATMENT OF PSYCHOGERIATRIC PATIENTS: A DOUBLE-BLIND CLINICAL STUDY. 192231 04-09

DOWNS

MYOCLONIC SEIZURES IN DOWNS SYNDROME. 173205 01-11

AMITRIPTYLINE IN THE PSYCHOTIC STATES OF DOWNS SYNDROME: THE COMPARISON OF TWO CASES. 191192 04-11

DOXAPRAM

SELECTIVE RESPIRATORY STIMULATING ACTION OF DOXAPRAM COMPARED TO PENTYLENETETRAZOL. 183887 03-03

DOXEPIN

NEUROPHARMACOLOGICAL ANALYSIS OF EFFECTS OF DOXEPIN IN RABBITS (PH.D. DISSERTATION). 168130 01-03

A DOUBLE-BLIND CLINICAL TRIAL OF DOXEPIN HYDROCHLORIDE AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION IN THE FIELD OF INTERNAL MEDICINE. 171282 01-11

DETERMINATION OF DOXEPIN IN AUTOPSY MATERIAL. 172398 01-16

EXPERIMENT WITH DOXEPIN (SINEQUAN) IN TREATMENT OF DEPRESSIVE STATES. 176454 02-11

EXPERIENCE IN THE USE OF SINEQUAN (DOXEPIN HYDROCHLORIDE) IN TREATMENT OF NEUROSIS, DEPRESSION AND DEPRESSIVE STATES. 176471 02-11

EXPERIENCE IN THE USE OF SINEQUAN (DOXEPIN HYDROCHLORIDE). 176474 02-10

CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, DOXEPIN HYDROCHLORIDE, IN THE TREATMENT OF DEPRESSIVE STATES. 177569 02-11

INHIBITORY EFFECT OF DOXEPIN ON AGONISTIC BEHAVIOUR ELICITED BY HYPOTHALAMIC STIMULATION IN THE CAT. 180044 02-04

DOXEPIN AND AMITRIPTYLINE CHLORDIAZEPOXIDE COMBINATION IN NEUROTIC STATES: A COMPARATIVE DOUBLE-BLIND STUDY. 180048 02-10

EFFECTS OF CONSECUTIVE ADMINISTRATION OF DIAZEPAM AND DOXEPIN ON BOTH APPROACH WITHDRAWAL AND APPROACH AVOIDANCE RESPONSES IN RATS. 182117 02-04

EXPERIMENTS IN ORAL AND INJECTABLE FORMS OF A NEW ANTIDEPRESSANT (DOXEPIN) ON FORTY PATIENTS. 182900 03-11

DOXEPIN: IS A SINGLE DAILY DOSE ENOUGH? 192066 04-10

DP-181

EXPERIENCE IN THE APPLICATION OF A NEW DRUG, DP-181 (OXYPERTINE), IN TREATMENT OF SCHIZOPHRENIA. 176468 02-08

CLINICAL STUDY OF DP-181 (OXYPERTINE). 176722 02-08

DREAM

DREAM REPORTS AFTER RESERPINE ADMINISTRATION IN CHRONIC LOBOTOMIZED SCHIZOPHRENIC PATIENTS. 178187 02-08

SLEEPING PILLS AND DREAM CONTENT. 189043 04-14

DRINK

RELUCTANCE OF RATS TO DRINK HASHISH SUSPENSIONS: FREE-CHOICE AND FORCED CONSUMPTION, AND THE EFFECTS OF HYPOTHALAMIC STIMULATION. 186586 03-04

DRINKING

SHOULD WE PUT BENZODIAZEPINES IN OUR DRINKING WATER 168361 01-17

RECOVERY OF FEEDING AND DRINKING BY RATS AFTER INTRAVENTRICULAR 6-HYDROXYDOPAMINE OR LATERAL HYPOTHALAMIC LESIONS. 168484 01-03

DRINKING BEHAVIOUR AND BRAIN DOPAMINE: ANTAGONISTIC EFFECT OF TWO NEUROLEPTIC DRUGS (PIMOZIDE AND SPIRAMIDE) UPON AMPHETAMINE OR APOMORPHINE-INDUCED HYPODIPSIA. 174035 01-04

ALPHA-ADRENERGIC RECEPTORS MEDIATE SUPPRESSION OF DRINKING INDUCED BY HYPOTHALAMIC AMPHETAMINE INJECTION. 182216 03-03

DRIVE

CRIME AND THE SEX DRIVE. 192410 04-17

DRIVES

THOUGHTS ON TREATMENT BY PRIVATE PHYSICIANS OF ABNORMAL SEX DRIVES. 180674 02-11

DRIVING

EEG DRIVING RESPONSES AS A FUNCTION OF MONOAMINE OXIDASE. 187149 03-13

THE EFFECT OF MEDAZEPAM AND ALCOHOL ON COGNITIVE AND MOTOR SKILLS USED IN CAR DRIVING. 189408 04-14

EFFECTS OF DIAZEPAM AND CODEINE, ALONE AND IN COMBINATION WITH ALCOHOL, ON SIMULATED DRIVING. 189619 04-14

EFFECTS OF CAFFEINE ON ALERTNESS IN SIMULATED AUTOMOBILE DRIVING. 190743 04-14

DROPERIDOL

DROPERIDOL -- A PREFERRED NEUROLEPTIC IN NARCOANALYSIS. 169462 01-14

THE USE OF ORAL DROPERIDOL IN PSYCHIATRIC THERAPY. 184965 03-07

DROSOPHILA-MELANOGASTER

MUTAGENICITY EXPERIMENTS WITH THE TRANQUILLIZER MEPROBAMATE IN DROSOPHILA-MELANOGASTER AND IN HUMAN LEUKOCYTE CHROMOSOMES IN VITRO. 184585 03-05

DRUG

THE ROLE OF RESEARCH IN DRUG ABUSE INTERVENTION: STREET DRUG ANALYSES. 167382 01-17

ACUTE ADVERSE REACTIONS TO PSYCHOACTIVE DRUGS, DRUG USAGE, AND PERSONALITY. (UNPUBLISHED PAPER). 167832 01-15

CLOMIPRAMINE HCL -- A DOUBLE-BLIND STUDY OF A NEW ANTIDEPRESSANT DRUG. 168318 01-09

CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG, TRAZODONE: A REVIEW OF LITERATURE. 168803 01-11

DRUG ENHANCED SENSORY CONTINGENT BAR PRESSING: COMPARING THE EFFECT OF CONTINGENT AND NONCONTINGENT SENSORY CHANGE. 168837 01-04

DRUG THERAPY AND MARITAL THERAPY IN OUTPATIENT DEPRESSIVES. 169088 01-09

PSYCHOTHERAPEUTIC DRUG TRIALS AMONG ENGLISH GENERAL PRACTITIONERS. 170292 01-11

DRUG TREATMENT OF DEPRESSED PATIENTS REFERRED FOR HOSPITALIZATION.
170621 01-09

CHANGES IN MENTAL FUNCTIONING ACCOMPANYING ANTIPSYCHOTIC DRUG THERAPY.
171124 01-10

ORTHOGONAL FACTORS VS. INTERDEPENDENT VARIABLES AS PREDICTORS OF DRUG TREATMENT RESPONSE IN ANXIOUS OUTPATIENTS.
171299 01-14

THE PHARMACOLOGICAL EVALUATION IN LABORATORY ANIMALS OF KABI-1702 -- A NEW SEDATIVE HYPNOTIC DRUG.
171632 01-03

A GUIDE FOR DRUG USE IN DEPRESSIVE DISORDERS.
171923 01-09

DETERMINATION OF DRUG TRANSFER ACROSS BIOLOGICAL MEMBRANES: COMPARATIVE STUDY ON THE PASSAGE OF DRUGS INTO THE CENTRAL NERVOUS SYSTEM AND THEIR PLACENTAL TRANSFER AND FETAL LOCALIZATION IN THE PREGNANT RAT. (PH.D. DISSERTATION).
172018 01-03

CHRONIC HYPNOTIC DRUG USE: INEFFECTIVENESS, DRUG WITHDRAWAL INSOMNIA, AND DEPENDENCE.
172114 01-15

THE SPIRAL AFTEREFFECT (SAE) AS A MEASURE OF MOTION SICKNESS SUSCEPTIBILITY AND THE EFFECT ON THE SAE OF AN ANTIMOTION SICKNESS DRUG AND A CENTRAL NERVOUS SYSTEM DEPRESSANT.
172780 01-03

DEPENDENCE OF ANTICONVULSANT DRUG ACTION ON CENTRAL MONOAMINES.
172923 01-03

THE DESIGN OF THERAPEUTIC TRIALS: A CRITICAL ANALYSIS WITH ILLUSTRATIONS, PARTICULARLY FROM THE FIELD OF PSYCHOTROPIC DRUGS OR: WHY NO ONE CAN EVER DO A PROPER DRUG TRIAL.
173307 01-16

BEHAVIORAL PARAMETERS OF DRUG ACTION: SIGNALED AND RESPONSE INDEPENDENT REINFORCEMENT.
174008 01-04

DRUGS AND PLACEBOS: DRUG GUESSING BY NORMAL VOLUNTEERS.
174210 01-14

EFFECT OF A NEW PSYCHOTROPIC DRUG, CS-370 (10-CHLORO-11B-(2-CHLOROPHENYL)-2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE) UPON THE CENTRAL NERVOUS SYSTEM.
174603 01-03

QUANTUM CHEMICAL STUDIES ON DRUG ACTIONS: IV. CORRELATION OF SUBSTITUENT STRUCTURES AND ANTISEROTONIN ACTIVITY IN LYSERGAMIDE SERIES.
174605 01-12

THE DOCUMENTATION OF CLINICAL PSYCHOTROPIC DRUG TRIALS.
175332 02-16

A ROLE OF THE DIETARY LIPID IN THE ABILITY OF PHENOBARBITAL TO STIMULATE DRUG DETOXIFICATION.
175859 02-03

DRUG EFFECTS ON GASTRIC ULCERATION RATE IN THE RAT. (UNPUBLISHED PAPER).
176307 02-03

CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, ZISEPRON, IN TREATMENT OF PSYCHIATRIC DISEASES IN COMPARISON WITH THIORIDAZINE.
176467 02-08

EXPERIENCE IN THE APPLICATION OF A NEW DRUG, DP-181 (OXYPERTINE), IN TREATMENT OF SCHIZOPHRENIA.
176468 02-08

CLINICAL EFFECTS OF DICEPLON, A PSYCHOTROPIC DRUG.
176470 02-08

EXPERIENCE IN THE DRUG HORIZON AND PSYCHIATRIC INTERVIEW.
176542 02-11

CLINICAL EXPERIENCES WITH A NEW PSYCHOTROPIC DRUG, R-6238 (PIMOZIDE).
176564 02-11

CLINICAL EXPERIENCES WITH AN ANTIDEPRESSIVE DRUG, NORITREN (NORTRIPTYLINE).
176565 02-09

CLINICAL EXPERIENCES WITH A PSYCHOTROPIC DRUG (OXYPERTINE) IN CHRONIC SCHIZOPHRENIA.
176727 02-08

CHLORDIAZEPOXIDE OVERDOSE: INTERPRETATION OF SERUM DRUG CONCENTRATIONS.
177393 02-15

METHYPRYLON OVERDOSE: INTERPRETATION OF SERUM DRUG CONCENTRATIONS.
177394 02-15

REPEATED ACQUISITION OF BEHAVIORAL CHAINS UNDER CHRONIC DRUG CONDITIONS.
177408 02-04

CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, DOXEPIN HYDROCHLORIDE, IN THE TREATMENT OF DEPRESSIVE STATES.
177569 02-11

RESPONSE TO STIMULANT DRUG TREATMENT IN HYPERACTIVE CHILDREN: PREDICTION FROM EEG AND NEUROLOGICAL FINDINGS.
177778 02-11

FLAVOR AVERSIONS PRODUCED BY CONTINGENT DRUG INJECTION: RELATIVE EFFECTIVENESS OF APOMORPHINE, EMETINE, AND LITHIUM.
178502 02-04

FATAL INTOXICATION OF A YOUNG DRUG ADDICT WITH DIAZEPAM.
178619 02-05

MARIHUANA -- A PSYCHEDELIC DRUG?
178695 02-17

PHARMACOLOGY AND TOXICOLOGY OF THE ANTIEPILEPTIC DRUG CLONAZEPAM.
179021 02-05

AN ANALYSIS OF D-AMPHETAMINE PRODUCED FACILITATION OF AVOIDANCE ACQUISITION IN RATS AND PERFORMANCE CHANGES SUBSEQUENT TO DRUG TERMINATION.
179990 02-04

DRUG ABUSE -- OVERDOSE AND RECOVERY.
180147 02-15

THE DOCUMENTATION OF CLINICAL PSYCHOTROPIC DRUG TRIALS: SAMPLE OUTPUT PACKAGE.
180256 02-16

EXPERIENCE IN THE TREATMENT OF CEREBRAL INSUFFICIENCY AND PERIPHERAL BLOOD CIRCULATION DISORDERS USING THE EP-50-100 EXPERIMENTAL DRUG.
180676 02-11

PSYCHOPHARMACOLOGIC AGENTS: EFFECT ON DRUG METABOLISM.
181398 02-13

DRUG EFFECTS ON LEARNING AND MEMORY.
181404 02-04

DETERMINANTS OF DRUG EFFECTS ON PUNISHED BEHAVIOR.
181405 02-04

PSYCHOACTIVE DRUG CONTROL: ISSUES AND RECOMMENDATIONS.
181638 02-17

CROSS-NATIONAL STUDY OF THE EXTENT OF ANTIANXIETY SEDATIVE DRUG USE.
181713 02-17

A CLINICAL EVALUATION OF A NEW ANXIOLYTIC DRUG (THIENODIAZEPINE DERIVATIVE Y-6047) IN NEUROTICS AND PSYCHOSOMATIC DISORDERS -- A PRELIMINARY REPORT.
181771 02-07

PREDICTION OF NEUROLEPTIC EFFECTS OF CI-686 BASED ON QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY: DRUG PROFILES AND DOSE RESPONSE CURVES BASED ON COMPUTERIZED CEREBRAL BIOPOTENTIALS.
181958 02-13

DRUG DEPENDENCE TEST OF PHENOBARBITAL AND MORPHINE IN RATS BY SPONTANEOUS INTAKE.
182104 02-04

MANIFEST ANXIETY AND ANTIANXIETY DRUG EFFECTS IN NORMAL VOLUNTEERS.
182118 02-14

ANALYSIS OF DRUG BLOCK OF LSD/5-HT/GABA BY MONITORING NEURONAL MEMBRANE CHANGES.
182143 02-03

INTERACTION OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A PURPORTED HASHISH AND LSD ANTAGONIST, WITH SEVERAL CENTRAL NEUROCHEMICAL SYSTEMS.
182217 03-04

DRUG THERAPY FOR DEPRESSION IN CHILDREN. INDICATIONS AND METHODS.
182429 03-10

RUBIDIUM SALTS -- TOXIC EFFECTS IN HUMANS AND CLINICAL EFFECTS AS AN ANTIDEPRESSANT DRUG.
182443 03-09

DRUG ABSORPTION IN RATS PRETREATED WITH ANTIBIOTICS.
182715 03-03

INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY LITHIUM TREATMENT.
182727 03-03

CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG: FK-880 (SULPIRIDE), ITS EFFECT ON PATIENTS WITH PSYCHOSOMATIC DISEASES AND PSYCHONEUROSIS.
182731 03-10

PSYCHIC FATIGABILITY, ITS FEATURES AND DRUG THERAPY.
183197 03-11

NEUROLOGICAL CONSEQUENCES OF PSYCHOTROPIC DRUG WITHDRAWAL IN SCHIZOPHRENIC CHILDREN.
183275 03-08

THE STANDARDIZED VIDEOTAPE INTERVIEW AS AN OBJECTIVE DEPENDENT VARIABLE IN PSYCHOTROPIC DRUG RESEARCH.
183635 03-17

A COMPARISON OF PSYCHOTOMIMETIC DRUG EFFECTS ON RAT BRAIN NOREPINEPHRINE METABOLISM.
183891 03-03

CHLORMEZANONE IN ANXIETY: A DRUG REDISCOVERED?
184175 03-10

DECREASED EFFECT OF PHENOBARBITAL TREATMENT ON MICROSOMAL DRUG METABOLIZING ENZYME ACTIVITY DURING GESTATION.
184228 03-03

THE DISCHARGED PATIENTS DRUG TREATMENT.
185195 03-17

FURTHER STUDIES ON THE INHIBITION OF DRUG METABOLISM BY PREGNANOLONE AND RELATED STEROIDS.
185866 03-03

RESPONSE TO INCREMENTAL DOSES OF DITRAN IN ABSTINENT ALCOHOLICS AND DRUG USERS.
185875 03-11

DRUG DOSAGE IN ACUTE PHASE SCHIZOPHRENIA.
185898 03-17

REGIONAL CHANGES IN MONOAMINE LEVELS AND IN THE RATE OF TYROSINE AND TRYPTOPHAN HYDROXYLATION IN 4 WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
185899 03-03

THE EFFECTS OF CHRONIC TREATMENT WITH D-AMPHETAMINE ON FOOD INTAKE, BODYWEIGHT, LOCOMOTOR ACTIVITY AND SUBCELLULAR DISTRIBUTION OF THE DRUG IN RAT BRAIN.
185931 03-03

DRUG LEVEL OF D- AND L-AMPHETAMINE DURING INTRAVENOUS SELF-ADMINISTRATION.
185960 03-04

GUIDELINES FOR ANTIPSYCHOTIC DRUG USE.
186191 03-09

SEXUAL DYSFUNCTION RESULTING FROM DRUG SIDE-EFFECTS.
186204 03-15

ON THE CEREBRAL ACCUMULATION OF KETAMINE AND THE RELATIONSHIP BETWEEN METABOLISM OF THE DRUG AND ITS PHARMACOLOGICAL EFFECTS.
186693 03-03

AMPHETAMINE AND OPERANT BEHAVIOR IN RATS: RELATIONSHIP BETWEEN DRUG EFFECT AND CONTROL RESPONSE RATE.
187699 04-04

POLYPHARMACY IN PSYCHIATRY: A MULTI-STATE COMPARISON OF PSYCHOTROPIC DRUG COMBINATIONS.
187840 04-17

HEAT DYSCONTROL SYNDROME IN PATIENTS RECEIVING ANTIPSYCHOTIC, ANTIDEPRESSANT AND ANTIPARKINSON DRUG THERAPY.
188094 04-15

ARE NEUROTIC PATIENTS IN PSYCHOTROPIC DRUG TRIALS REPRESENTATIVE? A COMPARISON OF STUDY AND NON-STUDY PATIENTS IN FOUR FAMILY PRACTICES.
188144 04-10

DRUG EFFECTS AND HYPOTHALAMIC ANTERIOR PITUITARY FUNCTION.
188393 04-03

DRUG THERAPIES IN CRISIS MANAGEMENT.
189297 04-17

ANTICONVULSANT EFFECTS OF CANNABINOLS IN MICE: DRUG INTERACTIONS WITH CANNABINOIDS AND CANNABINOID INTERACTIONS WITH PHENYTOIN.
189513 04-03

AFFECTIVE DISORDERS AND CHEMICAL DEPENDENCE: LITHIUM FOR ALCOHOL AND DRUG ADDICTION
189775 04-09

TARDIVE DYSKINESIA AND DRUG THERAPY IN GERIATRIC PATIENTS.
189923 04-13

DIAZEPAM ON DEMAND: DRUG SEEKING BEHAVIOR IN PSYCHIATRIC INPATIENTS.
189924 04-17

DRUG MAINTENANCE IN THE OUTPATIENT TREATMENT OF CHRONIC ALCOHOLISM.
189926 04-11

IMPROVING PSYCHIATRIC DRUG THERAPY: A MATTER OF DOSAGE AND CHOICE.
190144 04-17

THE METHOHEXITAL METHYLPHENIDATE INTERVIEW: A PROPOSED NEW DRUG COMBINATION FOR NARCOTHERAPY.
190242 04-07

DRUG INTERACTIONS.
190258 04-15

INABILITY TO CONDITION A PERIPHERAL ACTIVATING DRUG.
190698 04-04

APPLICATION OF THE SEQUENTIAL SIMPLEX METHOD IN DESIGNING DRUG ANALOGS.
190714 04-01

THE FUTURE OF PHARMACOTHERAPY: NEW DRUG DELIVERY SYSTEMS.
191044 04-08

AMA DRUG EVALUATIONS.
191048 04-17

ANTICONVULSANT DRUG SERUM LEVELS IN PSYCHIATRIC PATIENTS WITH SEIZURE DISORDERS: EFFECTS OF CERTAIN PSYCHOTROPIC DRUGS.
191096 04-13

CORTICAL AND/OR SUBCORTICAL EFFECTS AS A FUNCTION OF HALLUCINOGENIC DRUG STRUCTURE
191936 04-03

CELLULAR EFFECTS OF METHAQUALONE ON DRUG METABOLIZING ENZYMES.
191942 04-03

PHARMACOLOGY OF DEPRESSION IN THE AGED: EVALUATION OF GEROVITAL-H3 AS AN ANTIDEPRESSANT DRUG.
192229 04-09

CONDITIONING IN THE PREDICTION OF DRUG WITHDRAWAL EFFECTS IN CHRONIC SCHIZOPHRENIC PATIENTS.
192412 04-17

THE USE OF PROPRANOLOL WITH VARIOUS DRUG COMBINATIONS IN THE TREATMENT OF ESSENTIAL HYPERTENSION.
192511 04-13

DRUG NAME FAMILIARITY AND THE PLACEBO EFFECT.
192704 04-17

DRUG-INDUCED

ACUTE DRUG-INDUCED EXTRAPYRAMIDAL SYNDROMES.
167572 01-15

DRUG-INDUCED ACTIVATION OF STRIATAL TYROSINE HYDROXYLASE: CHANGES IN THE AFFINITY FOR PTERIDINE COFACTORS. (UNPUBLISHED PAPER).
173381 01-03

DRUG-INDUCED CATALEPSY AS INFLUENCED BY PSYCHOSTIMULANTS, APOMORPHINE, L-DOPA, AND YOHIMBINE.
177730 02-13

INHIBITION OF ANTICHOLINERGIC DRUG-INDUCED LOCOMOTOR STIMULATION IN MICE BY ALPHA-METHYLTYROSINE.
177840 02-03

MECHANISMS OF DRUG-INDUCED BEHAVIORAL TOLERANCE.
181406 02-04

SELF-STIMULATION AND CATECHOLAMINES: DRUG-INDUCED MOBILIZATION OF THE RESERVE POOL RE-ESTABLISHES RESPONDING IN CATECHOLAMINE DEPLETED RATS.
189025 04-04

HALLUCINOGENIC DRUG-INDUCED BEHAVIOR UNDER SENSORY ATTENUATION: PREDICTION OF RESPONSE TO PSILOCYBIN.
189744 04-12

DRUG-INDUCED STEREOTYPED BEHAVIOR: SIMILARITIES AND DIFFERENCES.
191504 04-04

DRUG-INDUCED AGGRESSION IN CHICKS: DIFFERENTIAL INVOLVEMENT OF BIOGENIC AMINES.
191977 04-04

A METHOD FOR TESTING DRUG-INDUCED PARKINSONIAN-LIKE EFFECT.
191982 04-15

DRUGS

THE USE OF PSYCHOACTIVE DRUGS BY ADULTS.
167585 01-17

INTERNATIONAL REFERENCE CENTERS NETWORK FOR PSYCHOTROPIC DRUGS.
167706 01-17

IN THE SEARCH FOR NEW TRANQUILIZING DRUGS.
167813 01-04

ACUTE ADVERSE REACTIONS TO PSYCHOACTIVE DRUGS, DRUG USAGE, AND PERSONALITY. (UNPUBLISHED PAPER).
167832 01-15

CURRENT SITUATION OF THE USE OF DRUGS IN ASAHIGAWA JIDO-IN.
168302 01-17

COMBINATIONS OF ANTIDEPRESSANT DRUGS IN THE TREATMENT OF DEPRESSIVE ILLNESS.
168317 01-09

THE EFFECT OF PLACEBO AND DRUGS ON HUMAN SLEEP.
168419 01-14

DYSTONIC REACTIONS TO DRUGS.
168526 01-15

STATE-DEPENDENT LEARNING PRODUCED BY ADDICTING DRUGS.
169071 01-03

GAS CHROMATOGRAPHIC - MASS SPECTROMETRIC STUDIES ON TRICYCLIC PSYCHOTROPIC DRUGS.
169073 01-01

LONG-TERM TREATMENT OF DEPRESSION WITH DRUGS AND PSYCHOTHERAPY.
169087 01-09

CHANGES IN SOMATOSENSORY EVOKED POTENTIALS PRODUCED BY DRUGS USED IN THE TREATMENT OF AFFECTIVE DISORDERS.
169092 01-09

ANTIPARKINSON DRUGS AS CAUSAL AGENTS IN TARDIVE DYSKINESIA.
169140 01-15

INFLUENCE OF AFFECTIVE STATES AND PSYCHOACTIVE DRUGS ON VERBAL LEARNING AND MEMORY.
169504 01-09

USE OF PSYCHOTHERAPEUTIC DRUGS IN THE ACUTE DETOXIFICATION OF HEROIN ADDICTS.
169746 01-11

PSYCHOTROPIC DRUGS AS THERAPEUTIC AGENTS.
169748 01-17

DRUGS AND PSYCHODYNAMIC SHIFTS IN AFFECTIVE ILLNESS. (UNPUBLISHED PAPER).
170079 01-09

BRAIN SEROTONIN, AFFECTIVE ILLNESS AND ANTIDEPRESSANT DRUGS: CEREBROSPINAL FLUID STUDIES WITH PROBENECID. (UNPUBLISHED PAPER).
170084 01-09

THE ACTIVITY OF SOME NEUROLEPTIC DRUGS AND AMPHETAMINE IN NORMAL AND ISOLATED RATS.
170126 01-04

MEGAVITAMIN TREATMENT, CULTURE AND TRANQUILIZERS, DRUGS FOR THE AGED: PROJECTS OF A CANADIAN GRANT.
170293 01-11

THE ELECTROCARDIOGRAPHIC ABNORMALITIES INDUCED BY PSYCHOTROPIC DRUGS.
170638 01-13

RADIOIMMUNOASSAY FOR LYSERGIDE (LSD) IN ILLICIT DRUGS AND BIOLOGICAL FLUIDS.
170840 01-06

EFFECT AND AFTEREFFECT OF DRUGS: ETHICAL CONSIDERATIONS ON THE USE OF PSYCHOTROPIC AGENTS (1).
170847 01-17

TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER).
170876 01-03

DRUGS AND PSYCHIATRIC READAPTATION.
171121 01-17

ABOUT THE PSYCHOTROPIC DRUGS.
171159 01-17

DRUGS COMMONLY USED IN MENTAL CONDITIONS.
171257 01-17

STUDY ON THE PSYCHOPHARMACOLOGICAL ASSAY OF CENTRALLY ACTING DRUGS IN RATS.
171260 01-06

PSYCHOTROPIC DRUGS IN MEDICAL PRACTICE.
171485 01-17

COMMON PSYCHOTROPIC DRUGS.
171568 01-17

THE EFFECT OF PIPRADROL IN MICE AND ITS ANTAGONISM BY NEUROLEPTIC DRUGS.
171607 01-04

INHIBITION OF MOUSE-KILLING BEHAVIOUR IN RATS BY SOME THYMOLEPTIC DRUGS.
171608 01-04

INFLUENCES OF DRUGS ON THE INCREASES IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OF GAMMA-HYDROXYBUTYRIC ACID (GHBA).
171622 01-03

ANTAGONISM OF P-CHLOROAMPHETAMINE (PCA) INDUCED DEPLETION OF 5-HT FROM RAT BRAIN BY SOME THYMOLEPTICS AND OTHER PSYCHOTROPIC DRUGS.
171628 01-03

TREATMENT OF DEPRESSION BY DRUGS AND PSYCHOTHERAPY.
171924 01-10

DRUGS AND GROUP PSYCHOTHERAPY IN NEUROTIC DEPRESSION.
171925 01-10

SEROTONINERGIC MECHANISMS IN THE CENTRAL ACTION OF PSYCHOTROPIC DRUGS. (PH.D. DISSERTATION).
172015 01-03

DETERMINATION OF DRUG TRANSFER ACROSS BIOLOGICAL MEMBRANES: COMPARATIVE STUDY ON THE PASSAGE OF DRUGS INTO THE CENTRAL NERVOUS SYSTEM AND THEIR PLACENTAL TRANSFER AND FETAL LOCALIZATION IN THE PREGNANT RAT. (PH.D. DISSERTATION).
172018 01-03

EFFECTS OF CENTRALLY ACTING DRUGS ON ADENYL CYCLASE ACTIVITY AND CYCLIC AMP LEVELS OF MOUSE BRAIN. (PH.D. DISSERTATION).
172019 01-03

SOME ASPECTS OF PSYCHOTOGENIC DRUGS.
172809 01-17

OSCILLATORY POTENTIALS OF THE CAT RETINA: EFFECTS OF ADRENERGIC DRUGS.
172916 01-03

THE EEG OF SLEEP AND PSYCHOTROPIC DRUGS.
172972 01-13

THE DESIGN OF THERAPEUTIC TRIALS: A CRITICAL ANALYSIS WITH ILLUSTRATIONS, PARTICULARLY FROM THE FIELD OF PSYCHOTROPIC DRUGS OR: WHY NO ONE CAN EVER DO A PROPER DRUG TRIAL.
173307 01-16

PSYCHOACTIVE DRUGS: IMMUNOASSAY AND LOCALIZATION.
173536 01-06

THE PSYCHIATRIC SIDE-EFFECTS OF DRUGS.
173866 01-15

DRINKING BEHAVIOUR AND BRAIN DOPAMINE: ANTAGONISTIC EFFECT OF TWO NEUROLEPTIC DRUGS (PIMOZIDE AND SPIRAMIDE) UPON AMPHETAMINE OR APOMORPHINE-INDUCED HYPODIPSIA.
174035 01-04

EXCITANT AND DEPRESSANT DRUGS MODULATE EFFECTS OF ENVIRONMENT ON BRAIN WEIGHT AND CHOLINESTERASES.
174036 01-03

REHABILITATION OF LEARNING IN A HOSPITAL CLASS USING PSYCHOACTIVE DRUGS.
174071 01-11

DRUGS AND PLACEBOS: DRUG GUESSING BY NORMAL VOLUNTEERS.
174210 01-14

BEHAVIORAL CHANGES AND AGGRESSIVITY EVOKED BY DRUGS IN MICE.
174604 01-04

ANTIDEPRESSANT DRUGS.
174760 01-03

ANTIDEPRESSANT DRUGS.
174851 01-09

PSYCHIATRISTS REACTIONS TO THEIR PATIENTS REFUSAL OF DRUGS.
175251 02-17

EFFECTS OF PSYCHOACTIVE DRUGS ON NONVERBAL COMMUNICATION AND GROUP SOCIAL BEHAVIOR OF MONKEYS.
175317 02-04

MANUAL OF INTOXICATING DRUGS.
175537 02-17

USE AND ABUSE OF DRUGS IN PSYCHIATRY.
175620 02-17

WITHDRAWAL OF MAINTENANCE DRUGS WITH LONG-TERM HOSPITALIZED MENTAL PATIENTS: A CRITICAL REVIEW.
175862 02-17

CLINICAL USE OF PSYCHOTHERAPEUTIC DRUGS.
175914 02-17

OVERDOSE OF PSYCHOTROPIC DRUGS.
175935 02-15

HYPOTENSION FROM DRUGS: INCIDENCE, PERIOD, PREVENTION.
176674 02-15

SIMPLE ALGORITHMS FOR PREDICTING PSYCHOTROPIC DRUGS ASSIGNED TO PSYCHIATRIC INPATIENTS.
176676 02-17

A METHOD FOR ANALYZING CNS EFFECTS OF DRUGS AND BRAIN LESIONS ON PERMANENT GROUPS OF RATS.
176867 02-06

STIMULATION OF SEROTONIN N-ACETYLTRANSFERASE IN PINEAL ORGAN CULTURE BY DRUGS.
177128 02-03

DOPAMINE IN THE MESOLIMBIC SYSTEM OF THE RAT BRAIN: ENDOGENOUS LEVELS AND THE EFFECTS OF DRUGS ON THE UPTAKE MECHANISM AND STIMULATION OF ADENYLATE CYCLASE ACTIVITY.
177131 02-03

QUALITATIVE AND QUANTITATIVE STUDIES ON THE DISPOSITION OF AMITRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANT DRUGS IN MAN AS IT RELATES TO THE MANAGEMENT OF THE OVERDOSED PATIENT.
177395 02-15

RATE-DEPENDENT EFFECTS OF DRUGS. I. COMPARISONS OF D-AMPHETAMINE, PENTOBARBITAL, AND CHLORPROMAZINE ON MULTIPLE AND MIXED SCHEDULES.
177410 02-04

COMBINED USE OF ECT AND PSYCHOTROPIC DRUGS: ANTIDEPRESSIVES AND ANTIPSYCHOTICS.
177670 02-11

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: IV. THE EFFECTS OF CHLORPROMAZINE.
177716 02-14

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: V. THE EFFECTS OF CHLORAL HYDRATE.
177717 02-14

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: VI. THE EFFECTS OF CHLORDIAZEPOXIDE.
177718 02-14

CENTRAL NERVOUS SYSTEM AND AUTONOMIC NERVOUS SYSTEM EFFECTS OF AMANTADINE AND OF SOME STANDARD ANTIPARKINSON DRUGS.
177729 02-13

PHARMACOLOGIC BASIS FOR USE OF PSYCHOTROPIC DRUGS: AN OVERVIEW.
177782 02-17

PSYCHOTROPIC DRUGS.
178002 02-17

PSYCHOTROPIC DRUGS IN CAMBODIA.
178109 02-17

PSYCHIATRIC CARE: DRUGS, THERAPIST, COMMUNITY.
178189 02-17

ROLE OF 5-HT IN THE ACTION OF SOME DRUGS AFFECTING EXTRAPYRAMIDAL SYSTEM.
178757 02-04

EKG ALTERNATIONS IN INFUSION TREATMENT WITH TRICYCLIC ANTIDEPRESSIVE DRUGS.
180063 02-15

ANTIDEPRESSANT DRUGS.
180297 02-09

EFFECTS OF DRUGS ON SLEEP.
181393 02-14

PSYCHOTROPIC DRUGS AND CYTOGENIC EFFECTS.
181395 02-15

DRUGS ON EEG CORRELATES OF BEHAVIOR.
181396 02-04

BASIC TYPES OF EFFECTS OF DRUGS ON BEHAVIOR.
181399 02-04

BEHAVIORAL EFFECTS OF DRUGS IN MACACA-MULATTA.
181401 02-04

PSYCHOTROPIC DRUGS AND PHENOTYPICAL BEHAVIORS.
181407 02-05

MODIFICATION OF THE FRUSTRATION EFFECT WITH DRUGS.
181408 02-04

INFLUENCE OF VARIOUS DRUGS ON THE BINDING OF CHLORPROMAZINE TO ERYTHROCYTES AND ALBUMIN.
181470 02-03

ELECTROCLINICAL DISCREPANCIES IN ANTIANXIETY DRUGS.
181918 02-13

THE EFFECTS OF DRUGS ON THE RELEASE OF CATECHOLAMINE.
182089 02-03

EEG CHARACTERISTICS IN VARIOUS SPECIES OF ANIMAL AND THEIR RELATION TO THE CNS EFFECTS OF DRUGS.
182096 02-03

ATTEMPT TO EVALUATE THE PHYSICAL DEPENDENCE LIABILITY OF PSYCHOTROPIC DRUGS IN MICE.
182103 02-04

EFFECTS OF PSYCHOTROPIC DRUGS ON METHAMPHETAMINE INDUCED EXCITATIONS IN THE AGGREGATED MICE.
182107 02-04

EFFECTS OF PSYCHOTROPIC DRUGS ON ABNORMAL BEHAVIOR INDUCED BY DELTA9-TETRAHYDROCANNABINOL.
182114 02-04

EFFECTS OF PSYCHOTROPIC DRUGS ON DISCRIMINATION AVOIDANCE CONDITIONING IN RATS WITH OLFACTORY BULB ABLATIONS.
182115 02-04

NEURONE BLOCKING ACTIONS OF ANTIPSYCHOTIC DRUGS.
182127 02-03

RELATIVE IMPORTANCE OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS FOR THE STIMULATION OF LOCOMOTOR ACTIVITY INDUCED BY AMPHETAMINE AND OTHER DRUGS.
182209 02-04

DIFFERENTIAL CIRCULATORY EFFECTS OF VARIOUS ANOREXIGENIC DRUGS.
182214 03-03

DIFFERENTIAL SELF-INJECTION BEHAVIOR PRODUCED BY FENFLURAMINE VERSUS OTHER APPETITE INHIBITING DRUGS.
182215 03-04

DRUGS, BEHAVIOR AND CHOLINE ACETYLTRANSFERASE.
182237 03-04

INHIBITION OF ISOLATION INDUCED AGGRESSION IN MICE BY ANTISEROTONERGIC DRUGS.
182240 03-04

THE OCULAR COMPLICATIONS BY MASSIVE DOSE OF PSYCHOTROPIC DRUGS.
182552 03-15

THE USE OF TRANQUILIZING DRUGS IN CASES OF SCHIZOPHRENIA.
182581 03-08

SOCIAL IMPLICATIONS OF PSYCHOTROPIC DRUGS.
182770 03-17

EFFECT OF DRUGS UPON AXOPLASMIC TRANSPORT.
182772 03-17

DRUGS ACTING ON THE CENTRAL NERVOUS SYSTEM.
182835 03-17

PSYCHOTROPIC DRUGS IN CHILDHOOD DISTURBANCES.
182890 03-11

THE INFLUENCE OF NEUROTROPIC DRUGS ON MONOAMINE OXIDASE (MAO) AND 5-OXYTRYPTOPHANE DECARBOXYLASE (5-OTD) ACTIVITY IN THE BRAIN.
183142 03-13

SOMATIC SIDE-EFFECTS OF PSYCHOTHERAPEUTIC DRUGS IN CHILDHOOD.
183183 03-15

IDENTIFICATION AND QUANTITATIVE DETERMINATION OF PHENOTHIAZINE DRUGS IN URINE SAMPLES OF PSYCHIATRIC PATIENTS.
183599 03-02

EFFECTS OF ANTIPARKINSONIAN DRUGS ON NEUROLEPTIC INDUCED EXTRAPYRAMIDAL SIGNS IN MONKEYS.
183610 03-03

THE EFFECT OF PAIN RELIEVING DRUGS ADMINISTERED DURING LABOR AND DELIVERY ON THE BEHAVIOR OF THE NEWBORN: A REVIEW.
183706 03-17

SIDE-EFFECTS OF NEUROLEPTIC DRUGS.
183749 03-15

SIDE-EFFECTS OF DRUGS.
183812 03-15

THE CONDITIONED EMOTIONAL RESPONSE (CER) AS A BASELINE FOR THE STUDY OF ANTIANXIETY DRUGS.
183862 03-04

IMPACT OF PSYCHOACTIVE DRUGS ON HYPNOTIZABILITY.
184021 03-12

INFLUENCE OF METHAMPHETAMINE AND NEUROLEPTIC DRUGS ON TYROSINE HYDROXYLASE ACTIVITY.
184180 03-03

EFFECT OF ANTIDEPRESSANT AND ANTIMANIC DRUGS ON AMINE UPTAKE IN MAN.
184654 03-13

THE ABRUPT WITHDRAWAL OF ANTIPARKINSONIAN DRUGS IN SCHIZOPHRENIC PATIENTS.
185005 03-08

CLINICAL EVALUATION OF ANXIOLYTIC DRUGS.
185350 03-17

AN IMPROVED METHOD FOR STUDYING THE PSYCHOGALVANIC REACTION IN MICE AND ITS INHIBITION BY PSYCHOLEPTIC DRUGS. COMPARISON WITH THE EFFECTS OF OTHER PHARMACOLOGICAL AGENTS.
185749 03-06

EFFECTS OF CENTRALLY APPLIED DRUGS ON PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION.
185902 03-03

EFFECT OF SEVERAL DOPAMINERGIC DRUGS AND TRIHEXYPHENIDYL ON CHOLINERGIC PARAMETERS IN THE RAT STRIATUM.
185995 03-03

HALLUCINOGENIC DRUGS AND ARTISTIC CREATIVITY.
186026 03-12

PSYCHIATRIC COMPLICATIONS OF EVERYDAY DRUGS.
186092 03-15

THE CLINICAL EFFECTIVENESS OF LITHIUM: COMPARISONS WITH OTHER DRUGS.
186189 03-09

METHYLPHENIDATE ANTAGONISM OF HALOPERIDOL, INTERACTION WITH CHOLINERGIC AND ANTICHOLINERGIC DRUGS.
186370 03-04

ALTERATION OF ETHANOL-INDUCED CNS DEPRESSION: INEFFECTIVENESS OF DRUGS THAT MODIFY CHOLINERGIC TRANSMISSION.
186375 03-03

DRUGS TO TREAT PAIN.
186395 03-14

MODIFICATION OF LEARNING AND MEMORY IN GOLDFISH THROUGH THE USE OF STIMULANT AND DEPRESSANT DRUGS.
186583 03-04

THE ISOLATED PERFUSED RAT BRAIN AS A MODEL FOR STUDYING DRUGS ACTING ON THE CNS.
186589 03-06

THE EFFECTS OF SOME DRUGS ON AN EVOKED RESPONSE SENSITIVE TO TETRAHYDROCANNABINOLS.
186666 03-03

THE MONOAMINE OXIDASES OF BRAIN: SELECTIVE INHIBITION WITH DRUGS AND THE CONSEQUENCES FOR THE METABOLISM OF THE BIOGENIC AMINES.
186668 03-03

NONCHOLINERGIC MECHANISM OF ACTION OF CHOLINERGIC DRUGS ON SQUID AXON MEMBRANES.
186672 03-03

THE INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LEVELS OF ENDOGENOUS 2-PHENYLETHYLAMINE IN RABBIT BRAIN.
187112 03-03

VALIDITY OF SCREENING METHODS FOR DRUGS OF ABUSE IN BIOLOGICAL FLUIDS. II. HEROIN IN PLASMA AND SALIVA.
187256 03-15

ON THE MECHANISM OF RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVES INDUCED BY DEPOLARIZING AGENTS AND SYMPATHOMIMETIC DRUGS. (UNPUBLISHED PAPER).
187397 04-03

THE EFFECT OF SOME CHOLINOLYTIC DRUGS ON A NUMBER OF BEHAVIOURAL PARAMETERS MEASURED IN THE T-MAZE ALTERNATION TEST: DOSE-RESPONSE RELATIONSHIPS.
187641 04-04

ANTISCHIZOPHRENIC DRUGS AND BRAIN CHOLINERGIC RECEPTORS: AFFINITY FOR MUSCARINIC SITES PREDICTS EXTRAPYRAMIDAL EFFECTS.
188114 04-15

CLASSIFICATION OF DRUGS ACCORDING TO THEIR DISCRIMINABLE EFFECTS IN RATS.
188228 04-06

A LOOK AT RESTRAINING PRACTICES AND THE USE OF PSYCHOTROPIC DRUGS.
188533 04-17

THE USE OF DRUGS IN PSYCHIATRIC INTERVIEWS: SOME INTERPRETATIONS BASED ON CONTROLLED EXPERIMENTS.
189074 04-17

EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND AMPHETAMINE ON SELF-STIMULATION OF BRAIN FOLLOWING VARIOUS 6-HYDROXYDOPAMINE TREATMENTS.
189515 04-04

DOPAMINERGIC INHIBITION OF STRIATAL CHOLINERGIC NEURONS: SYNERGISTIC BLOCKING ACTION OF GAMMA-BUTYROLACTONE AND NEUROLEPTIC DRUGS.
189602 04-03

EFFECT OF ANTICONVULSANT DRUGS ON THE NUMBER OF AFFERENT STIMULI NEEDED TO CAUSE A HIPPOCAMPAL SEIZURE DISCHARGE.
189608 04-03

DIHYDROPTERIDINE REDUCTASE IN RAT BRAIN: REGIONAL DISTRIBUTION AND THE EFFECT OF CATECHOLAMINE DEPLETING DRUGS.
189752 04-03

DRUGS FOR BED-WETTING.
189778 04-11

EFFECTS OF ADRENERGIC AGENTS, THEOPHYLLINE AND OTHER DRUGS ON DEXTRAN EDEMA AND HISTAMINE RELEASE IN RATS.
189895 04-03

THE CONTROL OF DEVIANT SEXUAL BEHAVIOR BY DRUGS: A DOUBLE-BLIND CONTROLLED STUDY OF BENPERIDOL, CHLORPROMAZINE, AND PLACEBO.
190061 04-11

PSYCHOTROPIC DRUGS -- HARM OR HELP.
190138 04-11

HOW TO PRESCRIBE PSYCHOACTIVE DRUGS.
190236 04-17

THE USES AND RELATIVE HAZARD POTENTIAL OF PSYCHOACTIVE DRUGS.
190237 04-17

EFFECT OF PHENOTHIAZINE NEUROLEPTIC DRUGS AND TRICYCLIC ANTIDEPRESSANTS ON PHOSPHODIESTERASE ACTIVITY IN RAT CEREBRAL CORTEX.
190311 04-03

EFFECTS OF DOPAMINE-LIKE DRUGS ON RAT STRIATAL ADENYL CYCLASE HAVE IMPLICATIONS FOR CNS DOPAMINE RECEPTOR TOPOGRAPHY.
190545 04-03

ANTICONVULSANT DRUG SERUM LEVELS IN PSYCHIATRIC PATIENTS WITH SEIZURE DISORDERS: EFFECTS OF CERTAIN PSYCHOTROPIC DRUGS.
191096 04-13

THIRTY-FIVE YEARS CONTINUOUS TREATMENT FOR RECURRENT DEPRESSION: FROM ECT TO DRUGS.
191119 04-09

A COMPARISON OF CLINICALLY USED PSYCHOACTIVE DRUGS IN FOUR LATIN-AMERICAN COUNTRIES AND IN CANADA (ARGENTINA, COSTA-RICA, MEXICO AND PANAMA).
191139 04-17

DRUGS, NEUROTRANSMITTERS, AND SCHIZOPHRENIA.
191290 04-08

PERMANENT ALTERATIONS IN 5-HYDROXYTRYPTAMINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN FOLLOWING EXPOSURE TO DRUGS DURING THE PERIOD OF DEVELOPMENT.
191383 04-03

THE EFFECT OF CHOLINOMIMETIC DRUGS ON POTASSIUM TRANSPORT IN RAT CEREBRAL CORTEX.
191411 04-03

THE USE OF SELECTIVE AND INHIBITOR DRUGS TO MODIFY AMINE METABOLISM IN BRAIN.
191500 04-03

CONSIDERATIONS ON THE USE OF ANALGESIC DRUGS IN DIFFERENT STAGES OF NEOPLASTIC DISEASES.
191604 04-17

PSYCHOTROPIC DRUGS AND ELECTROENCEPHALOGRAPHY -- FIRST REPORT.
191625 04-13

PSYCHOTROPIC DRUGS AND ELECTROENCEPHALOGRAPHY -- SECOND REPORT.
191667 04-13

INDICATION AND PROBLEMS OF PSYCHOTROPIC DRUGS IN GENERAL PRACTICE.
191677 04-17

CORRELATION BETWEEN THE TRANQUILIZING AND SEDATIVE ACTION OF NEUROLEPTICS, ANTIDEPRESSANTS AND ANTICHOLINERGIC DRUGS.
191783 04-02

INFLUENCE OF PSYCHOTROPIC DRUGS ON AGGRESSIVENESS EVOKED BY DESTRUCTION OF ISOLATED STRUCTURES OF THE FOREBRAIN.
191788 04-04

THE EFFICACY OF ANTIDEPRESSANT DRUGS: A REVIEW OF RESEARCH (1958 TO 1972).
191857 04-09

INTERACTIONS OF PSYCHOTROPIC DRUGS AND MESCALINE IN VITRO.
191933 04-03

INTRAGASTRIC SELF-ADMINISTRATION OF PSYCHOACTIVE DRUGS IN THE RHESUS MONKEY.
191939 04-04

EFFECTS OF VARIOUS DRUGS ON THE ACTIONS OF 5,7 DIHYDROXYTRYPTAMINE.
191955 04-03

COMPARATIVE EFFECTS OF SOME CNS ACTIVE DRUGS ON LEARNED AND UNLEARNED BEHAVIOR IN THE HAMSTER.
191976 04-04

THE EFFECT OF CANNABINOID MIXTURES ON THE RESPONSE TO STIMULANT DRUGS IN MICE.
191991 04-04

LSD AND THE INSANITY DRUGS, PART XXXI.
192092 04-17

RATIONAL USE OF PSYCHOTROPIC DRUGS: I. HYPNOTICS.
192190 04-14

CORRELATION OF PHARMACOLOGICAL INVESTIGATIONS WITH THE CLINICAL EFFICACY OF ANTIDEPRESSANT DRUGS.
192420 04-13

TRUE AND APPARENT NON-PENETRATION OF THE BLOOD-BRAIN BARRIER BY PSYCHOTROPIC DRUGS.
192423 04-03

INCORPORATION OF 14C-DIHYDROPHENYLALANINE AND 14C-CHOLINE INTO RAT BRAIN SUBCELLULAR PARTICLES AND THE EFFECT OF PSYCHOACTIVE DRUGS.
192426 04-03

PSYCHIATRIC SYMPTOMS PRODUCED BY DRUGS.
192513 04-15

DURATION

EFFECT OF 6-HYDROXYDOPAMINE ON THE DURATION OF HEXOBARBITAL SLEEP IN RATS.
178558 02-03

DELTA9-TETRAHYDROCANNABINOL: EFFECTS OF ROUTE OF ADMINISTRATION ON ONSET AND DURATION OF ACTIVITY AND TOLERANCE DEVELOPMENT.
187928 04-03

DYADIC

FIGHTING IN MICE: DYADIC ESCALATION AND WHAT IS LEARNED.
173039 01-04

DYADS

EFFECTS OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL ON SOCIAL BEHAVIOR OF SQUIRREL MONKEY DYADS IN A WATER COMPETITION SITUATION.
187640 04-04

DYNAMICS

THE DYNAMICS OF A GROUP IN PSYCHOTHERAPY.
180140 02-12

ON THE DYNAMICS AND TREATMENT OF THE TENDENCY OF SCHIZOPHRENIC PSYCHOSIS TO BECOME CHRONIC.
183957 03-08

DYSCONTROL

EPISODIC DYSCONTROL: A CONTROLLED REPLICATION.
187839 04-09

HEAT DYSCONTROL SYNDROME IN PATIENTS RECEIVING ANTIPSYCHOTIC, ANTIDEPRESSANT AND ANTIPARKINSON DRUG THERAPY.
188094 04-15

DYSFUNCTION

IMIPRAMINE IN THE TREATMENT OF MINIMAL BRAIN DYSFUNCTION IN CHILDREN.
169295 01-11

CEREBRAL STIMULANTS AND MINIMAL DYSFUNCTION: SOME QUESTIONS, SOME ANSWERS, AND SOME MORE QUESTIONS.
180992 02-11

LEAD INDUCED BEHAVIORAL DYSFUNCTION: AN ANIMAL MODEL OF HYPERACTIVITY.
184953 03-04

SEXUAL DYSFUNCTION RESULTING FROM DRUG SIDE-EFFECTS.
186204 03-15

CHLORPROMAZINE CAUSING EXTRAPYRAMIDAL DYSFUNCTION IN NEWBORN INFANT OF PSYCHOTIC MOTHER.
187787 04-15

PHOTIC RESPONSES IN MINIMAL BRAIN DYSFUNCTION.
191188 04-15

DYSFUNCTIONED

AVERAGE EVOKED RESPONSES IN NORMAL AND MINIMALLY BRAIN DYSFUNCTIONED CHILDREN TREATED WITH AMPHETAMINE: A PRELIMINARY REPORT.
169861 01-11

DYSKINESIA

INFLUENCE OF CONCENTRATION AND MOTOR PERFORMANCE ON TARDIVE DYSKINESIA AND RABBIT SYNDROME.
167587 01-15

ANTIPARKINSON DRUGS AS CAUSAL AGENTS IN TARDIVE DYSKINESIA.
169140 01-15

PSEUDOPARKINSONISM AND TARDIVE DYSKINESIA.
171974 01-15

STUDY OF THE EFFECT OF CERTAIN PHARMACOLOGICAL AGENTS ON TARDIVE DYSKINESIA AND THE RABBIT SYNDROME.
178193 02-11

A CASE OF TARDIVE DYSKINESIA APPEARING PRECOCIOUSLY UNDER NEUROLEPTICS.
184961 03-17

DOPAMINERGIC HYPERSENSITIVITY AND CHOLINERGIC HYPOFUNCTION IN THE PATHOPHYSIOLOGY OF TARDIVE DYSKINESIA.
185929 03-11

STUDIES ON THE ACTION OF CERTAIN PHARMACOLOGICAL AGENTS ON TARDIVE DYSKINESIA AND ON THE RABBIT SYNDROME.
188406 04-03

A STUDY OF BIOGENIC AMINE METABOLITES IN THE CEREBROSPINAL FLUID AND URINE OF MONKEYS WITH CHLORPROMAZINE INDUCED DYSKINESIA.
189210 04-03

CHOLINERGIC SUPPRESSION OF TARDIVE DYSKINESIA.
189403 04-11
IMPAIRMENT OF OPTOKINETIC NYSTAGMUS IN PATIENTS WITH TARDIVE DYSKINESIA.
189734 04-13
TARDIVE DYSKINESIA AND DRUG THERAPY IN GERIATRIC PATIENTS.
189923 04-13
CHOLINERGIC SUPPRESSION OF TARDIVE DYSKINESIA.
190314 04-13
ON THE COEXISTENCE OF PARKINSONISM AND TARDIVE DYSKINESIA.
190380 04-11
TARDIVE AND WITHDRAWAL DYSKINESIA ASSOCIATED WITH HALOPERIDOL.
191035 04-15

DYSKINESIAS
LEVODOPA INDUCED DYSKINESIAS: COMPARISON IN PARKINSONISM DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS.
169376 01-15
DEANOL IN THE TREATMENT OF LEVODOPA INDUCED DYSKINESIAS.
184196 03-11

DYSPHORIC
HIGH FREQUENCY OF DYSPHORIC REACTIONS TO TETRAHYDROCANNABINOL AMONG DEPRESSED PATIENTS.
181274 02-09

DYSTONIC
DYSTONIC REACTIONS TO DRUGS.
168526 01-15

EATING
PHARMACOLOGICAL SUPPRESSION OF EATING BEHAVIOR IN RELATION TO DIENCEPHALIC NORADRENERGIC RECEPTORS.
174763 01-04
TREATMENT OF COMPULSIVE EATING DISTURBANCES WITH ANTICONVULSANT MEDICATION.
181270 02-14
EFFECTS OF CYPROHEPTADINE ON THE EATING BEHAVIOR OF RATS AND CATS.
182111 02-04
DIAZEPAM-INDUCED EATING AND LEVER PRESSING FOR FOOD IN SATED RATS.
186613 03-04

ECLAMPSIA
DIAZEPAM (CALMPOSE) IN ECLAMPSIA: A PRELIMINARY REPORT OF 16 CASES.
169633 01-11

ECT
A DOUBLE-BLIND TRIAL OF IPRINDOLE AND IMIPRAMINE IN DEPRESSIVES AND RESPONSE TO ECT IN REFRACTORY CASES.
174376 01-09
COMBINED USE OF ECT AND PSYCHOTROPIC DRUGS: ANTIDEPRESSIVES AND ANTIPSYCHOTICS.
177670 02-11
EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: I. EFFECT ON THE BEHAVIOURAL CHANGES INDUCED BY RESERPINE, ALPHA-METHYL-P-TYROSINE OR AMPHETAMINE.
186587 03-04
EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: II. EFFECT ON DOPAMINE AND NORADRENALINE CONCENTRATIONS AND TURNOVERS.
186588 03-04
ECT, GLAUCOMA, AND PROLONGED APNEA.
187837 04-15
THIRTY-FIVE YEARS CONTINUOUS TREATMENT FOR RECURRENT DEPRESSION: FROM ECT TO DRUGS.
191119 04-09

EDEMA
EFFECTS OF ADRENERGIC AGENTS, THEOPHYLLINE AND OTHER DRUGS ON DEXTRAN EDEMA AND HISTAMINE RELEASE IN RATS.
189895 04-03

EEG
INFLUENCE OF TREATMENT ON SYMPTOMATOLOGY AND CORRELATED ELECTROENCEPHALOGRAPHIC (EEG) CHANGES IN THE AGED.
167336 01-13
EEG, HEART RATE, AND MOOD CHANGE (HIGH) AFTER CANNABIS.
169068 01-13
THE EEG OF SLEEP AND PSYCHOTROPIC DRUGS.
172972 01-13
LONG-TERM CLINICAL AND QUANTITATIVE EEG EFFECTS OF CLOPENTHIXOL IN SCHIZOPHRENICS: CLINICAL NEUROPHYSIOLOGICAL CORRELATIONS.
174131 01-08
A METHOD OF QUANTIFYING EEG FOR PSYCHOPHARMACOLOGICAL RESEARCH.
174135 01-16
EEG AND CARDIOVASCULAR EFFECTS OF TRYPTAMINE (T) AND LSD IN THE ENCEPHALE ISOLE CAT. (UNPUBLISHED PAPER)
174496 01-12
RESPONSE TO STIMULANT DRUG TREATMENT IN HYPERACTIVE CHILDREN: PREDICTION FROM EEG AND NEUROLOGICAL FINDINGS.
177778 02-11
COMPARISON OF THE CLINICAL AND COMPUTER ANALYZED EEG EFFECTS OF MESORIDAZINE AND CHLORPROMAZINE.
180064 02-10
COMPARISON OF CLOPENTHIXOL AND PERPHENAZINE IN BEHAVIOR AND EEG OF UNANESTHETIZED CATS.
181386 02-04
DRUGS ON EEG CORRELATES OF BEHAVIOR.
181396 02-04
EEG CHARACTERISTICS IN VARIOUS SPECIES OF ANIMAL AND THEIR RELATION TO THE CNS EFFECTS OF DRUGS.
182096 02-03
EEG CHANGES & MOTOR IMPAIRMENT AFTER DISULFIRAM ADMINISTRATION TO CATS.
182248 03-03
AN ELECTROENCEPHALOGRAPHIC STUDY ON THE TOLERANCE OF THE VARIOUS PSYCHIATRIC AND NEUROLOGICAL PATIENTS TO THE HYPNOTIC EFFECTS OF DIPHENHYDRAMINE -- MEASURED BY THE AMOUNTS OF SLEEP EEG AS AN INDICATOR.
182550 03-11
EVALUATION OF EEG AND CLINICAL CHANGES ASSOCIATED WITH PAVABID THERAPY IN CHRONIC BRAIN SYNDROME.
183402 03-13
BEHAVIOR AND EEG ANALYSIS OF CHRONIC AMPHETAMINE EFFECT.
187116 03-13
EEG DRIVING RESPONSES AS A FUNCTION OF MONOAMINE OXIDASE.
187149 03-13
CRUDE MARIHUANA EXTRACT: EEG AND BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION IN RHESUS MONKEYS.
189516 04-04
EFFECT OF ATROPINE SULFATE ON THE SLEEP RELATED EEG SPIKE ACTIVITY OF THE TORTOISE, GEOCHELONE-CARBONARIA.
191389 04-03
BEHAVIORAL AND EEG CHANGES IN THE AMPHETAMINE MODEL OF PSYCHOSIS.
191505 04-04
THE EFFECTS OF PSILOCYBIN ON EEG AND BEHAVIOUR IN MONKEYS.
192415 04-04

EFFECTIVENESS
RELATIONSHIP BETWEEN THE EFFECTIVENESS OF LITHIUM THERAPY AND FAMILY HISTORY.
169494 01-09
SAFETY AND EFFECTIVENESS OF HALOPERIDOL FOR MENTALLY RETARDED BEHAVIORALLY DISORDERED AND HYPERKINETIC PATIENTS.
169634 01-11
DIPHENYLHYDANTOIN EFFECTIVENESS IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS: A DOUBLE-BLIND CONTROLLED STUDY WITH A PLACEBO.
171507 01-08
FLAVOR AVERSIONS PRODUCED BY CONTINGENT DRUG INJECTION: RELATIVE EFFECTIVENESS OF APOMORPHINE, EMETINE, AND LITHIUM.
178502 02-04
THE CLINICAL EFFECTIVENESS OF LITHIUM: COMPARISONS WITH OTHER DRUGS.
186189 03-09

EFFECTOR
THE ACTION OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTOR CENTERS OF EMOTIONS IN THE HYPOTHALAMUS.
191785 04-02

EFFICACIOUS
PENFLURIDOL: AN EFFICACIOUS LONG-ACTING ORAL ANTIPSYCHOTIC COMPOUND.
189072 04-08

EFFLUX
EFFECT OF SUBSTITUTED TRYPTAMINES ON THE EFFLUX OF NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
168747 01-03
ALTERATION OF 5-HYDROXYTRYPTAMINE-14C EFFLUX BY NICOTINE IN RAT BRAIN AREA SLICES.
172925 01-03
THE INHIBITION BY BETA-ADRENOCEPTOR BLOCKING AGENTS OF CALCIUM UPTAKE INTO AND EFFLUX FROM ISOLATED SARCOPLASMIC VESICLES.
184223 03-03

EKG
EKG ALTERNATIONS IN INFUSION TREATMENT WITH TRICYCLIC ANTIDEPRESSIVE DRUGS.
180063 02-15

ELATION
INFLUENCE OF AMYLOBARBITONE ON OPERANT DEPRESSION AND ELATION EFFECTS IN THE RAT.
168834 01-04

ELDERLY
CALCIUM METABOLISM IN ELDERLY EPILEPTIC PATIENTS DURING ANTICONVULSANT THERAPY.
185560 03-15

ELECTIVE
PREANESTHETIC MEDICATION IN ELECTIVE SURGERY: COMPARISON OF INTRAVENOUS DIAZEPAM WITH MEPERIDINE.
167338 01-11

ELECTRIC
EFFECTS OF D-AMPHETAMINE, MORPHINE AND CHLORPROMAZINE ON RESPONDING UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION OR ELECTRIC SHOCK PRESENTATION.
191767 04-03

ELECTRICAL
EFFECT OF PROCAINE, LIDOCAINE AND PENTOBARBITAL ON ELECTRICAL ACTIVITY OF GUINEA-PIG OLFACTORY CORTEX IN VITRO.
182092 02-03
DIFFERENTIAL EFFECTS OF PILOCARPINE AND SCOPOLAMINE ON THE PERFORMANCE OF A LIGHT DARK DISCRIMINATION MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN.
186701 03-03
A FREQUENCY SHIFT IN THE HIPPOCAMPAL THETA ACTIVITY: AN ELECTRICAL CORRELATE OF CENTRAL ACTION OF ACTH ANALOGUES IN THE DOG
188166 04-04
NEUROCHEMICAL ANALYSIS OF AGGRESSIVE - DEFENSIVE BEHAVIOR ELICITED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS AND CENTRAL GRAY MATTER.
191784 04-02
INFLUENCE OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTS OF ELECTRICAL STIMULATION AND MICROINJECTION OF ACETYLCHOLINE, SEROTONIN AND NORADRENALINE INTO THE MESENCEPHALON.
191786 04-02
ACTION OF HALOPERIDOL AND TRIFLUOPERAZINE ON THE MOTOR RESPONSES ELICITED BY ELECTRICAL STIMULATION OF THE BRAIN IN RABBITS.
191787 04-02
DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
191944 04-04

ELECTRO
SIGNIFICANCE OF THE CENTRAL BIOGENIC AMINES FOR THE THRESHOLD IN ELECTRO AND PENTETRAZOLE SEIZURES.
181469 02-03

ELECTROCARDIOGRAM
EFFECTS OF CHLORPROMAZINE PLASMA LEVELS ON ELECTROCARDIOGRAM.
188838 04-13

ELECTROCARDIOGRAPHIC
ELECTROCARDIOGRAPHIC CHANGES IN HYPERTHYROIDISM AFTER ADRENERGIC BLOCKADE WITH RESERPINE AND PROPRANOLOL.
167460 01-13
THE ELECTROCARDIOGRAPHIC ABNORMALITIES INDUCED BY PSYCHOTROPIC DRUGS.
170638 01-13
THE ELECTROCARDIOGRAPHIC ABNORMALITY INDUCED BY CHLORPROMAZINE.
171296 01-15

ELECTROCLINICAL
ELECTROCLINICAL ASPECT OF INSIDON TREATMENT IN PATIENTS WITH NEUROTIC SYMPTOMS.
174777 01-10
ELECTROCLINICAL DISCREPANCIES IN ANTIANXIETY DRUGS.
181918 02-13

ELECTROCONVULSIONS
THRESHOLDS FOR ELECTROCONVULSIONS AND CHEMOCONVULSIONS IN MICE AFTER TERMINATION OF TREATMENT WITH PHENOBARBITAL.
170073 01-03

ELECTROCONVULSIVE
RECOVERY FROM ELECTROCONVULSIVE SHOCK-INDUCED AMNESIA BY EXPOSURE TO THE TRAINING ENVIRONMENT: PHARMACOLOGICAL ENHANCEMENT BY PIRACETAM.
186704 03-04

ELECTROCORTICAL
EFFECTS OF ATROPINE ON EXPLORATION, LEARNING AND ELECTROCORTICAL ACTIVITY IN THE DEVELOPING RAT.
169473 01-04

ELECTROCORTICOGRAPHIC
BEHAVIORAL AND ELECTROCORTICOGRAPHIC DOSE-RESPONSE RELATIONSHIPS WITH METRAZOL. (UNPUBLISHED PAPER).
188248 04-04

ELECTRODERMAL
ELECTRODERMAL ACTIVITY IN HYPERACTIVE BOYS WHO ARE METHYLPHENIDATE RESPONDERS.
191400 04-14

ELECTRODES
INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: IV. INFLUENCE OF AMPHETAMINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
185961 03-04

ELECTROENCEPHALOGRAM
ELECTROENCEPHALOGRAM OF HYSTERIC PATIENTS.
175069 02-09
ON THE STUPOROUS AND HYPOMANIC EPISODES ASSOCIATED WITH SPIKE AND WAVE IN ELECTROENCEPHALOGRAM.
181388 02-11
EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON ELECTROENCEPHALOGRAM AND FEEDING BEHAVIOR OF RATS.
182554 03-04

ELECTROENCEPHALOGRAPHIC
INFLUENCE OF TREATMENT ON SYMPTOMATOLOGY AND CORRELATED ELECTROENCEPHALOGRAPHIC (EEG) CHANGES IN THE AGED.
167336 01-13
ELECTROENCEPHALOGRAPHIC RESPONSES TO LITHIUM.
174132 01-14
EFFECTS OF MEBUTAMATE ON THE ELECTROENCEPHALOGRAPHIC SLEEP PROFILE.
174348 01-14
ELECTROENCEPHALOGRAPHIC MODIFICATIONS DURING ADMINISTRATION OF LITHIUM.
174566 01-09
BEHAVIORAL AND ELECTROENCEPHALOGRAPHIC STUDIES ON THIOSEMICARBAZIDE INDUCED SEIZURE IN RABBITS.
174855 01-05
ACUTE NITRAZEPAM (MOGADON) POISONING: AN ELECTROENCEPHALOGRAPHIC STUDY.
180148 02-15
ELECTROENCEPHALOGRAPHIC CHANGES IN ACUTE PHENOBARBITONE POISONING.
180149 02-15
THE ELECTROENCEPHALOGRAPHIC CHANGES IN ACUTE BARBITURATE POISONING.
180152 02-15
ELECTROENCEPHALOGRAPHIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL, LSD-25, MESCALINE AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE IN THE RABBITS.
182095 02-03
AN ELECTROENCEPHALOGRAPHIC STUDY ON THE TOLERANCE OF THE VARIOUS PSYCHIATRIC AND NEUROLOGICAL PATIENTS TO THE HYPNOTIC EFFECTS OF DIPHENHYDRAMINE -- MEASURED BY THE AMOUNTS OF SLEEP EEG AS AN INDICATOR.
182550 03-11
PERSISTENT ELECTROENCEPHALOGRAPHIC CHANGES IN RHESUS MONKEYS AFTER SINGLE DOSES OF PENTOBARBITAL, NITRAZEPAM AND IMIPRAMINE.
187931 04-03

ELECTROENCEPHALOGRAPHY
PSYCHOTROPIC DRUGS AND ELECTROENCEPHALOGRAPHY -- FIRST REPORT.
191625 04-13
PSYCHOTROPIC DRUGS AND ELECTROENCEPHALOGRAPHY -- SECOND REPORT.
191667 04-13

ELECTROLYTE
LITHIUM INDUCED DIABETES-INSIPIDUS: MANIC SYMPTOMS, BRAIN AND ELECTROLYTE CORRELATES, AND CHLOROTHIAZIDE TREATMENT.
169486 01-15

ELECTROLYTES
ELECTROLYTES IN CEREBROSPINAL FLUID IN ENDOGENOUS DEPRESSION.
172402 01-09
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON BODYWEIGHT AND BRAIN ELECTROLYTES IN THE CHICKEN.
186570 03-03

ELECTROMYOGRAPHIC
CLINICAL AND ELECTROMYOGRAPHIC RESEARCH CONCERNING TREATMENT OF PERIPHERAL NEUROPATHIES WITH NIVALASI.
168975 01-13

ELECTRON
FLUORESCENCE AND ELECTRON MICROSCOPIC ANALYSIS OF CATECHOLAMINE CONTAINING FIBERS IN MUTANT MOUSE CEREBELLUM. (UNPUBLISHED PAPER).
191762 04-03

ELECTROPAIN
THE EFFECT OF PSYCHOTROPIC AGENTS ON THE FORMATION OF AVOIDANCE REACTION IN ALBINO RATS DURING ELECTROPAIN STIMULATION OF ANOTHER RAT.
183206 03-04

ELECTROPHYSIOLOGICAL
ELECTROPHYSIOLOGICAL STUDIES OF THE EFFECTS OF CDP-CHOLINE ON THE CENTRAL NERVOUS SYSTEM.
182547 03-03

ELECTRORETINOGRAM
REFLECTION OF SHORT-TERM LIGHT ADAPTATION EFFECT IN THE ELECTRORETINOGRAM.
180591 02-04

ELECTROSHOCK
EFFECTS OF DOPAMINE RECEPTOR STIMULATION AND BLOCKADE ON RO-4-1284 INDUCED ENHANCEMENT OF ELECTROSHOCK SEIZURE.
167287 01-03

THE EFFECT OF CANNABIDIOL ON MAXIMAL ELECTROSHOCK SEIZURES IN RATS.
168749 01-03
INTERACTIVE EFFECTS OF CYCLOHEXIMIDE AND PUROMYCIN IN ALTERING BRAIN POLYRIBOSOMES AND NEURAL AND BEHAVIOURAL RESPONSES TO ELECTROSHOCK IN MICE.
175230 02-03
AUTOMATIC DETERMINATION OF THE PAIN THRESHOLD TO ELECTROSHOCK AND THE EFFECTS OF DELTA9-THC.
183363 03-03
EFFECTS OF AMPHETAMINE ON ELECTROSHOCK RESPONSES IN DEVELOPING RATS.
184372 03-03

ELEPHANT
MEDICATION AND/OR PSYCHOTHERAPY WITH SCHIZOPHRENICS: WHICH PART OF THE ELEPHANT HAVE YOU TOUCHED
173534 01-08

ELEVATION
EVIDENCE FOR A CRITICAL PERIOD FOR POSTNATAL ELEVATION OF BRAIN TYROSINE HYDROXYLASE ACTIVITY RESULTING FROM RESERPINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT.
186695 03-03
METHIOTHEPIN ELEVATION OF 5-HYDROXYINDOLEACETIC ACID LEVELS IN VARIOUS ANATOMIC REGIONS OF RAT BRAIN.
187831 04-03

ELICITATION
PHARMACOKINETIC DISPOSITION OF NORAPOMORPHINE DERIVATIVES AND ITS INFLUENCE ON THE ELICITATION OF STEREOTYPICAL GNAWING. (PH.D. DISSERTATION).
174960 01-03

ELIMINATION
THE ELIMINATION OF 5-HYDROXYINDOLEACETIC ACID FROM CEREBROSPINAL FLUID: CHARACTERISTICS OF THE ACID TRANSPORT SYSTEM OF THE CHOROID PLEXUS.
182718 03-03

EMBRYOGENESIS
EFFECTS OF P-CHLOROPHENYLALANINE ON DIFFERENTIATION OF SEROTONINERGIC RECEPTIVE CELLS DURING EMBRYOGENESIS. (UNPUBLISHED PAPER).
168817 01-03
THE EFFECTS OF MESCALINE ADMINISTERED BEFORE OR DURING EMBRYOGENESIS UPON THE HATCHABILITY AND BEHAVIOR OF THE CHICK. (PH.D. DISSERTATION).
173791 01-04

EMBRYONIC
EVIDENCE FOR A CRITICAL PERIOD FOR POSTNATAL ELEVATION OF BRAIN TYROSINE HYDROXYLASE ACTIVITY RESULTING FROM RESERPINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT.
186695 03-03

EMERGENCY
EMERGENCY TREATMENT OF AN ACUTE STATE OF MENTAL ABERRATION.
191723 04-09

EMETINE
FLAVOR AVERSIONS PRODUCED BY CONTINGENT DRUG INJECTION: RELATIVE EFFECTIVENESS OF APOMORPHINE, EMETINE, AND LITHIUM.
178502 02-04

EMOTION
PAIN AND EMOTION.
181590 02-11

EMOTIONAL
EMOTIONAL FUNCTIONS IN SHORT-TERM VS. LONG-TERM L-DOPA THERAPY IN PARKINSONISM.
168619 01-15
EFFECTS OF LOW DOSES OF CHLORPROMAZINE ON A CONDITIONED EMOTIONAL RESPONSE IN THE RAT.
176963 02-04
THE CONDITIONED EMOTIONAL RESPONSE (CER) AS A BASELINE FOR THE STUDY OF ANTIANXIETY DRUGS.
183862 03-04
TESTS OF EMOTIONAL BEHAVIOR IN RATS FOLLOWING DEPLETION OF NOREPINEPHRINE, OF SEROTONIN, OR OF BOTH.
185753 03-04
A FEW REMARKS ON THE USE OF PSYCHOACTIVE AGENTS IN THE TREATMENT OF EMOTIONAL DISORDERS.
190241 04-09

EMOTIONALLY
DOUBLE-BLIND PSYCHOMETRIC EVALUATION OF PIMOZIDE AND HALOPERIDOL VERSUS PLACEBO IN EMOTIONALLY LABILE VOLUNTEERS UNDER TWO DIFFERENT WORK LOAD CONDITIONS.
180065 02-14

EMOTIONS
CONTRIBUTION OF PSYCHOPHARMACOLOGY TO THE PSYCHOPHYSIOLOGICAL THEORY OF EMOTIONS.
178817 02-13
THE ACTION OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTOR CENTERS OF EMOTIONS IN THE HYPOTHALAMUS.
191785 04-02

EMPLOYS
THE EFFECTS OF AGENTS THAT MODIFY MUSCARINIC TONE UPON BEHAVIOR CONTROLLED BY AN AVOIDANCE SCHEDULE THAT EMPLOYS SIGNALED UNAVOIDABLE SHOCK.
171302 01-04

EN-1639A
STUDIES OF EN-1639A (NALTREXONE): A NEW NARCOTIC ANTAGONIST.
189059 04-07

ENANTHATE
EXPERIENCES WITH FLUPHENAZINE ENANTHATE IN LONG-STAY HOSPITALISED SCHIZOPHRENICS.
171985 01-08
ASSESSMENT OF ANATENSOL (FLUPHENAZINE ENANTHATE) INJECTABLE IN THE TREATMENT OF SCHIZOPHRENIA.
172444 01-08
EXAMINATION OF THE METHODS OF USING FLUPHENAZINE ENANTHATE.
176469 02-08
CLINICAL EXPERIENCE WITH FLUPHENAZINE ENANTHATE.
178021 02-08
FURTHER EXPERIENCE WITH FLUPHENAZINE ENANTHATE INJECTION.
180153 02-08
EXPERIENCES WITH FLUPHENAZINE ENANTHATE IN LONG-STAY HOSPITALIZED SCHIZOPHRENICS.
180154 02-08
PHARMACOLOGICAL DIFFERENCES BETWEEN FLUPHENAZINE ENANTHATE AND ITS HYDROCHLORIDE.
182634 03-02
ON THE CLINICAL EFFECT OF FLUPHENAZINE ENANTHATE IN OUTPATIENT SCHIZOPHRENICS.
185213 03-08

ENANTIOMERS
PHARMACOLOGIC ACTIVITY AND BIOTRANSFORMATION OF R- AND S-BARBITURATE ENANTIOMERS IN MOUSE AND MAN.
182156 02-03

ENCEPHALE
EEG AND CARDIOVASCULAR EFFECTS OF TRYPTAMINE (T) AND LSD IN THE ENCEPHALE ISOLE CAT. (UNPUBLISHED PAPER)
174496 01-12

ENCEPHALITIS
A CASE OF ENCEPHALITIS WITH PSYCHOTIC COMPLICATIONS.
174783 01-11

ENDOCRINE
THE EFFECTS OF PHENOTHIAZINES ON ENDOCRINE FUNCTION: I. PATIENTS WITH INAPPROPRIATE LACTATION AND AMENORRHOEA.
184436 03-15
THE EFFECTS OF PHENOTHIAZINES ON ENDOCRINE FUNCTION: II. EFFECTS IN MEN AND POST-MENOPAUSAL WOMEN.
184437 03-13

ENDOGENOUS
A CONTROLLED STUDY OF SINGLE DOSE ADMINISTRATION OF IMIPRAMINE PAMOATE IN ENDOGENOUS DEPRESSION.
167775 01-09
ELECTROLYTES IN CEREBROSPINAL FLUID IN ENDOGENOUS DEPRESSION.
172402 01-09
DOPAMINE IN THE MESOLIMBIC SYSTEM OF THE RAT BRAIN: ENDOGENOUS LEVELS AND THE EFFECTS OF DRUGS ON THE UPTAKE MECHANISM AND STIMULATION OF ADENYLATE CYCLASE ACTIVITY.
177131 02-03
THE INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LEVELS OF ENDOGENOUS 2-PHENYLETHYLAMINE IN RABBIT BRAIN.
187112 03-03
LONG-TERM TREATMENT OF ENDOGENOUS DEPRESSION WITH NORTRIPTYLINE WITH CONTROL OF PLASMA LEVELS.
188832 04-09
5-HYDROXYTRYPTAMINE AND NORADRENALINE IN THE HIPPOCAMPAL REGION: EFFECT OF TRANSECTION OF AFFERENT PATHWAYS ON ENDOGENOUS LEVELS, HIGH AFFINITY UPTAKE AND SOME TRANSMITTER RELATED ENZYMES.
191319 04-03
PHENYLALANINE FOR ENDOGENOUS DEPRESSION.
192521 04-09

ENDOGENOUSLY
EFFECTS OF ALPHA-METHYLTYROSINE ON D-AMPHETAMINE INDUCED RELEASE OF ENDOGENOUSLY SYNTHESIZED AND EXOGENOUSLY ADMINISTERED CATECHOLAMINES FROM THE CAT BRAIN IN VIVO.
189397 04-03

ENDURING
ENDURING LEARNING DEFICITS AND CEREBRAL SYNAPTIC MALFORMATION FROM EXPOSURE TO 10 PARTS OF HALOTHANE PER MILLION.
192565 04-04

ENERGY
THE EFFECTS OF LITHIUM ON HIGH ENERGY PHOSPHATE AND GLUCOSE LEVELS IN THE RAT SUPERIOR CERVICAL GANGLION.
187677 04-03

ENGLISH
PSYCHOTHERAPEUTIC DRUG TRIALS AMONG ENGLISH GENERAL PRACTITIONERS.
170292 01-11

ENHANCEMENT
EFFECTS OF DOPAMINE RECEPTOR STIMULATION AND BLOCKADE ON RO-4-1284 INDUCED ENHANCEMENT OF ELECTROSHOCK SEIZURE.
167287 01-03
ALPHA-ADRENERGIC BLOCKING AGENTS: ANTINOCICEPTIVE ACTIVITY AND ENHANCEMENT OF MORPHINE-INDUCED ANALGESIA.
183895 03-03
PROPRANOLOL ENHANCEMENT OF HYPOGLYCEMIC SWEATING.
186187 03-13
ENHANCEMENT OF METHYLPHENIDATE INDUCED STEREOTYPIES BY REPEATED ADMINISTRATION OF NEUROLEPTICS.
186369 03-04
RECOVERY FROM ELECTROCONVULSIVE SHOCK-INDUCED AMNESIA BY EXPOSURE TO THE TRAINING ENVIRONMENT: PHARMACOLOGICAL ENHANCEMENT BY PIRACETAM.
186704 03-04
INFLUENCE OF ALPHA-METHYLTYROSINE ON ENHANCEMENT OF SHUTTLEBOX AVOIDANCE BY MARIJUANA AND PENTOBARBITAL.
187572 04-04
ENHANCEMENT OF AMPHETAMINE ACTION AFTER INTERRUPTION OF ASCENDING SEROTONERGIC PATHWAYS.
189398 04-03
ENHANCEMENT OF NOCICEPTIVE REACTIONS BY NALOXONE IN MICE AND RATS.
189517 04-05
ENHANCEMENT OF PENTOBARBITAL AFTER MORPHINE ADDICTION.
191898 04-03

ENHANCING
TOLERANCE TO THE ACTIVITY ENHANCING EFFECTS OF D-AMPHETAMINE.
182208 02-04

ENURESIS
A CONTROLLED TRIAL OF IMIPRAMINE HYDROCHLORIDE ON ENURESIS.
186553 03-11
TRIAL OF SUSTAINED RELEASE AMITRIPTYLINE ON ENURESIS.
192589 04-11

ENVIRONMENT
EXCITANT AND DEPRESSANT DRUGS MODULATE EFFECTS OF ENVIRONMENT ON BRAIN WEIGHT AND CHOLINESTERASES.
174036 01-03
THE EFFECT OF LORAZEPAM ON ANXIOUS INSOMNIACS SLEEP AS RECORDED IN THE HOME ENVIRONMENT.
177318 02-14
INDICATIONS AND DOSAGE FOR MAXIMAL ACTIVITY OF ORNITHINE-CARBAMYL-TRANSFERASE IN THE PSYCHIATRIC ENVIRONMENT.
184955 03-17
RECOVERY FROM ELECTROCONVULSIVE SHOCK-INDUCED AMNESIA BY EXPOSURE TO THE TRAINING ENVIRONMENT: PHARMACOLOGICAL ENHANCEMENT BY PIRACETAM.
186704 03-04

ENVIRONMENTAL
DETERMINANTS OF THE NORADRENERGIC SATIETY EFFECT: ENVIRONMENTAL DARKNESS VS. THE FEEDING PATTERN.
182133 02-04
THE EFFECT OF LOW ENVIRONMENTAL TEMPERATURE ON THE TRANYLCYPROMINE MEPERIDINE INTERACTION IN MICE.
183897 03-03

ENZYMATIC
STUDIES ON ENZYMATIC DEALKYLATION OF D-LYSERGIC ACID DIETHYLAMIDE (LSD).
177336 02-03
AMPHETAMINE IN HUMAN PLASMA: A SENSITIVE AND SPECIFIC ENZYMATIC ASSAY.
177403 02-16

ENZYME
AN ENZYME APPROACH IN APPRAISING THE MODE OF SOME TRANQUILIZERS AND ANTIDEPRESSANTS.
174318 01-03
PRELIMINARY EXPERIENCES WITH THE TREATMENT OF SOME MENTAL CASES UTILIZING AN ENZYME COMBINATION.
180298 02-17
CENTRAL DOPAMINE FUNCTION IN AFFECTIVE ILLNESS: EVIDENCE FROM PRECURSORS, ENZYME INHIBITORS AND STUDIES OF CENTRAL DOPAMINE TURNOVER. (UNPUBLISHED PAPER).
181358 02-09
DECREASED EFFECT OF PHENOBARBITAL TREATMENT ON MICROSOMAL DRUG METABOLIZING ENZYME ACTIVITY DURING GESTATION.
184228 03-03
STUDIES OF MONOAMINE OXIDASES: PROPERTIES OF THE ENZYME IN BOVINE AND RABBIT BRAIN MITOCHONDRIA.
191300 04-03
MONOAMINE OXIDASE IN MAN: ENZYME CHARACTERISTICS IN HUMAN PLATELETS, PLASMA, AND OTHER HUMAN TISSUES.
191502 04-13

ENZYMES
INFLUENCE OF PHENOBARBITAL AND SEX HORMONES ON ENZYMES IN ASCORBIC ACID BIOSYNTHESIS IN MALE AND FEMALE RATS. (PH.D. DISSERTATION).
172017 01-03
THE RATE LIMITING CONTROL OF ENZYMES MONOAMINE OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN THE FETUS AND THE ADULT BY ADRENOCORTICOL HORMONES.
178815 02-03
EFFECTS OF NARCOTIC ANALGESICS ON ENZYMES OF ACETYLCHOLINE METABOLISM IN CULTURED CHICK BRAIN CELLS.
182225 03-03
INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY LITHIUM TREATMENT.
182727 03-03
EFFECTS OF CHRONIC NICOTINE ADMINISTRATION AND AGE ON VARIOUS NEUROTRANSMITTERS AND ASSOCIATED ENZYMES IN MALE FISCHER 344 RATS.
189597 04-03
5-HYDROXYTRYPTAMINE AND NORADRENALINE IN THE HIPPOCAMPAL REGION: EFFECT OF TRANSECTION OF AFFERENT PATHWAYS ON ENDOGENOUS LEVELS, HIGH AFFINITY UPTAKE AND SOME TRANSMITTER RELATED ENZYMES.
191319 04-03
POST-MORTEM MEASUREMENT OF ENZYMES IN HUMAN BRAIN: EVIDENCE OF A CENTRAL NORADRENERGIC DEFICIT IN SCHIZOPHRENIA.
191529 04-13
CELLULAR EFFECTS OF METHAQUALONE ON DRUG METABOLIZING ENZYMES.
191942 04-03

ENZYMIC
ANIMAL MODELS FOR AN ENZYMIC BLOOD-BRAIN BARRIER MECHANISM FOR THERAPEUTICALLY ADMINISTERED L-DOPA.
167359 01-03

EP-50-100
EXPERIENCE IN THE TREATMENT OF CEREBRAL INSUFFICIENCY AND PERIPHERAL BLOOD CIRCULATION DISORDERS USING THE EP-50-100 EXPERIMENTAL DRUG.
180676 02-11

EPILEPSY
STUDY OF THE PSYCHOTROPIC ACTION OF TEGRETOL IN PATIENTS WITH EPILEPSY.
172439 01-11
GENERALIZED PENICILLIN EPILEPSY IN THE CAT: EFFECTS OF INTRACAROTID AND INTRAVERTEBRAL PENTYLENETETRAZOL AND AMOBARBITAL INJECTIONS.
188374 04-03
IMIPRAMINE IN EXPERIMENTAL PETIT-MAL EPILEPSY.
188424 04-03
CARBAMAZEPINE SOLE ANTICONVULSANT FOR FOCAL EPILEPSY OF CHILDHOOD.
189174 04-11
THE USE OF A TRICYCLIC ANTIDEPRESSANT IN EPILEPSY.
190379 04-09

EPILEPTIC
PAROXYSMAL RIGHT LEFT DISORIENTATION IN AN EPILEPTIC PATIENT.
171246 01-11
SERUM ANTICONVULSANT CONCENTRATIONS IN EPILEPTIC PATIENTS WITH MENTAL SYMPTOMS: A PRELIMINARY REPORT.
184439 03-15
CALCIUM METABOLISM IN ELDERLY EPILEPTIC PATIENTS DURING ANTICONVULSANT THERAPY.
185560 03-15
ANTICONVULSANT ACTION OF VITAMIN-D IN EPILEPTIC PATIENTS? A CONTROLLED PILOT STUDY.
188889 04-11
DIFFERENTIAL EFFECTS OF PENTYLENETETRAZOL ON REM SLEEP IN NAIVE AND COBALT EPILEPTIC RATS.
189407 04-03

EPINEPHRINE
SIMULTANEOUS MASS FRAGMENTOGRAPHIC ASSAY OF NOREPINEPHRINE (NE), EPINEPHRINE (E) AND DOPAMINE (DA) IN RAT SYMPATHETIC GANGLION: EFFECTS OF DEXAMETHASONE IN NEWBORN AND ADULT RATS. (UNPUBLISHED PAPER).
170747 01-03

EPISODES
A COMPARISON OF LITHIUM CARBONATE IN THE PREVENTION OF MANIC AND DEPRESSIVE EPISODES IN RECURRENT AFFECTIVE DISORDER.
169090 01-09
ON THE STUPOROUS AND HYPOMANIC EPISODES ASSOCIATED WITH SPIKE AND WAVE IN ELECTROENCEPHALOGRAM.
181388 02-11

EPISODIC
EPISODIC DYSCONTROL: A CONTROLLED REPLICATION.
187839 04-09

EPISTEMIC
A NOTE ON EPISTEMIC ORGANIZATION AND HALLUCINOGENS.
190240 04-17

EPITHELIAL
EFFECTS OF CHLORPROMAZINE AND ACTINOMYCIN D ON UPTAKE AND INCORPORATION OF CERTAIN AMINO ACIDS, HYPOXANTHINE AND THYMIDINE IN CULTURES OF HUMAN SKIN EPITHELIAL CELLS.
179989 02-13

EQUIVALENCE
COMPARABLE THERAPEUTIC EFFICACY OF TRYPTOPHAN AND IMIPRAMINE: AVERAGE THERAPEUTIC RATINGS VERSUS TRUE EQUIVALENCE. AN IMPORTANT DIFFERENCE.
167344 01-09

ERGOT
AN ERGOT ALKALOID PREPARATION (HYDERGINE) VERSUS PAPAVERINE IN TREATING COMMON COMPLAINTS OF THE AGED: DOUBLE-BLIND STUDY.
173190 01-11
FURTHER EVIDENCE FOR A DOPAMINE RECEPTOR STIMULATING ACTION OF AN ERGOT ALKALOID.
188739 04-03

ERYTHROCYTE
LITHIUM THERAPY AND ERYTHROCYTE MEMBRANE CATION CARRIER.
187644 04-15

ERYTHROCYTES
INFLUENCE OF VARIOUS DRUGS ON THE BINDING OF CHLORPROMAZINE TO ERYTHROCYTES AND ALBUMIN.
181470 02-03

ESCALATION
FIGHTING IN MICE: DYADIC ESCALATION AND WHAT IS LEARNED.
173039 01-04

ESCAPE
INTERACTION OF MESCALINE AND STRESS ON SHUTTLEBOX ESCAPE/AVOIDANCE IN RATS.
191934 04-04

ESTABLISHMENT
AN ACCOUNT OF THE USE OF FLUPHENAZINE SINCE THE ESTABLISHMENT OF PSYCHIATRY AS A SEPARATE DISCIPLINE.
176431 02-11

ESTER
A NOVEL SPASMOLYTIC AND CNS ACTIVE AGENT: 3-(2-BENZYLMETHYLAMINOETHYL) BENZOIC ACID METHYL ESTER HYDROCHLORIDE.
184581 03-02

ESTERASE
EFFECTS OF FOOD DEPRIVATION, DISCRIMINATION EXPERIENCE AND PHYSOSTIGMINE ON CHOLINE ACETYLASE AND ACETYLCHOLINE ESTERASE IN THE DORSAL HIPPOCAMPUS AND FRONTAL CORTEX OF RATS.
169467 01-03

ESTERS
CENTRALLY ACTING MUSCLE RELAXANTS. ISOMERIC 9,10 DIHYDROXYOCTAHYDROPHENANTHRENES AND THEIR CARBAMATE ESTERS.
190719 04-02

ESTIMATION
A SENSITIVE GAS CHROMATOGRAPHIC PROCEDURE FOR THE ESTIMATION OF NORADRENALINE, DOPAMINE AND 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
171971 01-01
A GAS CHROMATOGRAPHIC METHOD FOR THE QUANTITATIVE ESTIMATION OF N-HYDROXYPHENTERMINE.
182203 02-06
INFLUENCE OF ANTIDEPRESSIVE THERAPY ON THE DISTURBED TIME ESTIMATION OF DEPRESSIVES.
182591 03-14
IN VIVO ESTIMATION OF TYROSINE HYDROXYLATION IN THE DOPAMINERGIC TERMINALS OF THE RAT NEOSTRIATUM.
183794 03-03
ESTIMATION OF THE RATE OF 5-HT SYNTHESIS IN THE MOUSE BRAIN BY VARIOUS METHODS.
188976 04-03
ESTIMATION OF THE CONTRIBUTION OF PERIPHERAL AND CENTRAL NORADRENERGIC NEURONES TO URINARY 3-METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT.
192335 04-03

ESTRADIOL
PLASMA LEVELS OF LUTEINIZING HORMONE AND OF IMMUNOREACTIVE ESTROGENS (ESTRADIOL) IN ANOREXIA-NERVOSA: RESPONSE TO CLOMIPHENE CITRATE.
183807 03-10
LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04
SUPPRESSION OF LORDOSIS IN GUINEA-PIGS BY ETHAMOXY-TRIPHETOL (MER-25) GIVEN AT LONG INTERVALS (36-46 HR) AFTER ESTRADIOL BENZOATE TREATMENT.
186686 03-04

ESTROGEN
CHANGE OF ESTROGEN ACTIVATED BEHAVIOR BY CYCLOHEXIMIDE IN THE FEMALE RAT.
171615 01-04
LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04
EFFECTS OF AN ESTROGEN ANTAGONIST, MER-25, ON MOUNTING BEHAVIOR AND LORDOSIS BEHAVIOR IN THE FEMALE RAT.
186691 03-04

ESTROGENS
PLASMA LEVELS OF LUTEINIZING HORMONE AND OF IMMUNOREACTIVE ESTROGENS (ESTRADIOL) IN ANOREXIA-NERVOSA: RESPONSE TO CLOMIPHENE CITRATE.
183807 03-10
THE EFFECT OF CONJUGATED ESTROGENS ON PLASMA BUTAPERAZINE LEVELS IN WOMEN.
191959 04-15

ET-495
A COMPARISON OF EFFECTS OF APOMORPHINE AND ET-495 ON LOCOMOTOR ACTIVITY AND CIRCLING BEHAVIOUR IN MICE.
186635 03-04
STIMULATION OF A DOPAMINE SENSITIVE ADENYLATE CYCLASE IN HOMOGENATES OF RAT STRIATUM BY A METABOLITE OF PIRIBEDIL (ET-495).
189616 04-03
EFFECTS OF PIRIBEDIL (ET-495) – A DOPAMINERGIC RECEPTOR STIMULATING AGENT IN PARKINSONS DISEASE.
191522 04-13

ETHAMOXY-TRIPHETOL
SUPPRESSION OF LORDOSIS IN GUINEA-PIGS BY ETHAMOXY-TRIPHETOL (MER-25) GIVEN AT LONG INTERVALS (36-46 HR) AFTER ESTRADIOL BENZOATE TREATMENT.
186686 03-04

ETHANOL
EFFECT OF ETHANOL ON CYCLIC AMP LEVELS IN THE RAT BRAIN.
167326 01-03
L-DOPA: EFFECT ON ETHANOL NARCOSIS AND BRAIN BIOGENIC AMINES IN MICE.
169782 01-03
DIFFERENTIAL EFFECTS OF ETHANOL AND PENTOBARBITAL ON SLEEP TIME IN C57BL AND BALB MICE.
177733 02-03
THE EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC) AND ETHANOL ON MONOSYNAPTIC AND POLYSYNAPTIC TRANSMISSION IN THE CENTRAL NERVOUS SYSTEM.
182222 03-03
TREATMENT OF CEREBROVASCULAR DISTURBANCES WITH 2-BUTYLAMINO-1-P-HYDROXYPHENYL ETHANOL SULFATE (BAMETHAN).
182790 03-11
A COMPARISON OF THE EFFECTS OF CHRONIC ADMINISTRATION OF ETHANOL AND ACETALDEHYDE TO MICE: EVIDENCE FOR A ROLE OF ACETALDEHYDE IN ETHANOL DEPENDENCE.
185992 03-03
INTERACTIONS OF CHLORPHENIRAMINE ETHANOL COMBINATIONS: ACUTE TOXICITY AND ANTIHISTAMINIC ACTIVITY.
188875 04-05
THE DOPAMINE RELEASING ACTIONS OF NEUROLEPTICS AND ETHANOL.
189401 04-03
LITHIUM TREATMENT DURING ETHANOL INGESTION AND WITHDRAWAL.
192005 04-11

ETHANOL-INDUCED
ALTERATION OF ETHANOL-INDUCED CNS DEPRESSION: INEFFECTIVENESS OF DRUGS THAT MODIFY CHOLINERGIC TRANSMISSION.
186375 03-03

ETHANOLAMINE
EFFECT OF 2-ARYLALANINES, 2-ARYLSERINES, TETRAPHENYLBORON AND 1,2 DL(2,4 DICHLOROPHENYL) ETHANOLAMINE ON LEVELS OF SEROTONIN (5-HT), NOREPINEPHRINE (NE) AND DOPAMINE (DM) IN WHOLE BRAIN OF MICE.
182254 03-03

ETHER
EFFECTS OF DECAPITATION, ETHER AND PENTOBARBITAL ON CYCLIC AMP AND CYCLIC GMP LEVELS IN RAT TISSUES.
182154 02-03
INDUCTION OF A DIETHYLETHER WITHDRAWAL SYNDROME IN MICE BY EXPOSURE TO ETHER VAPOR.
192006 04-03

ETHICAL
EFFECT AND AFTEREFFECT OF DRUGS: ETHICAL CONSIDERATIONS ON THE USE OF PSYCHOTROPIC AGENTS (1).
170847 01-17

ETHINAMATE
ABSORPTION AND CLEARANCE OF SECOBARBITAL, HEPTABARBITAL, METHAQUALONE, AND ETHINAMATE.
192575 04-13

ETHYL
COMPARISON OF CODEINE AND ETHYL ALCOHOL SELF-ADMINISTRATION UNDER A VARIABLE INTERVAL (VI) SCHEDULE IN MONKEYS.
191983 04-04

ETHYLNORANTIPHEIN
THE USE OF ETHYMISOL (ETHYLNORANTIPHEIN) IN PATIENTS WITH PROLONGED DISTURBANCES OF CONSCIOUSNESS.
191777 04-07

ETHYMISOL
THE USE OF ETHYMISOL (ETHYLNORANTIPHEIN) IN PATIENTS WITH PROLONGED DISTURBANCES OF CONSCIOUSNESS.
191777 04-07

CHANGES IN RHYTHMS OF BIOELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX IN HUMANS UNDER THE INFLUENCE OF ETHYMISOL.
191790 04-07

ETIOLOGY
EXACERBATION OF PSYCHOPATHOLOGY DURING TREATMENT: ETIOLOGY.
177676 02-17

ETORPHINE
ABUSE POTENTIAL OF ETORPHINE (M99) I. SUBJECTIVE EFFECTS AND PHYSICAL DEPENDENCE. (UNPUBLISHED PAPER).
171241 01-14

THE EFFECTS OF MORPHINE, ETORPHINE AND SINOMENINE ON THE CHEMICAL SENSITIVITY AND SYNAPTIC RESPONSES OF RENSHAW CELLS AND OTHER SPINAL NEURONES IN THE RAT.
188201 04-03

EUPHORIA
LITHIUM (LI): LACK OF EFFECT ON MORPHINE (MS) EUPHORIA. (UNPUBLISHED PAPER).
174479 01-14

EVALUATE
ATTEMPT TO EVALUATE THE PHYSICAL DEPENDENCE LIABILITY OF PSYCHOTROPIC DRUGS IN MICE.
182103 02-04

EVALUATED
DEPENDENCE LIABILITY OF SEVERAL SEDATIVE HYPNOTIC AGENTS EVALUATED IN MONKEYS.
174125 01-04

EVALUATION
DOUBLE-BLIND CLINICAL EVALUATION OF MAZINDOL, DEXTROAMPHETAMINE, AND PLACEBO IN TREATMENT OF EXOGENOUS OBESITY.
167335 01-11

METIAPINE: THE EVALUATION OF THE ANTIPSYCHOTIC PROPERTIES OF A NEW NEUROLEPTIC. A PILOT STUDY.
167342 01-08

CLINICAL EVALUATION OF FLUSPIRILENE AS A MAINTENANCE THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS.
168320 01-08

EVALUATION OF CENTRAL ANTIRESERPINE EFFECT BY THE USE OF LIGHT BLINK REFLEX.
169469 01-04

A CRITICAL EVALUATION OF THE PRINCIPLES GOVERNING THE ADVANTAGES OF INTRAARTERIAL INFUSIONS.
170112 01-06

EVALUATION OF THE HYPOTHERMIC ACTION OF TETRAHYDROCANNABINOLS IN MICE AND SQUIRREL MONKEYS.
170163 01-03

THE PHARMACOLOGICAL EVALUATION IN LABORATORY ANIMALS OF KABI-1702 -- A NEW SEDATIVE HYPNOTIC DRUG.
171632 01-03

MOLINDONE: A CROSSOVER EVALUATION OF CAPSULE AND TABLET FORMULATIONS IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
174137 01-08

LONG-TERM USE OF LITHIUM CARBONATE IN AFFECTIVE DISORDERS: A CLINICAL EVALUATION.
174778 01-09

FUNCTIONAL EVALUATION OF PITUITARY RESERVE IN PATIENTS WITH THE AMENORRHEA GALACTORRHEA SYNDROME UTILIZING LUTEINIZING HORMONE RELEASING HORMONE (LH-RH), L-DOPA AND CHLORPROMAZINE.
175245 02-13

EFFICACY AND RESIDUAL EFFECT EVALUATION OF A NEW HYPNOTIC, TRIAZOLAM.
176108 02-13

ANTIDEPRESSANT EFFECTS OF D-CHLORPHENIRAMINE -- CLINICAL EVALUATION (FIRST REPORT).
176889 02-09

SAFETY EVALUATION OF PENFLURIDOL, A NEW LONG-ACTING ORAL ANTIPSYCHOTIC AGENT.
177319 02-07

EVALUATION OF HYPNOTICS IN OUTPATIENTS WITH INSOMNIA USING A QUESTIONNAIRE AND A SELF-RATING TECHNIQUE.
177735 02-06

BEHAVIOURAL EVALUATION OF PEPTIDES RELATED TO SCOTOPHOBIN.
177836 02-04

DOUBLE-BLIND PSYCHOMETRIC EVALUATION OF PIMOZIDE AND HALOPERIDOL VERSUS PLACEBO IN EMOTIONALLY LABILE VOLUNTEERS UNDER TWO DIFFERENT WORK LOAD CONDITIONS.
180065 02-14

A CLINICAL EVALUATION OF A NEW ANXIOLYTIC DRUG (THIENODIAZEPINE DERIVATIVE Y-6047) IN NEUROTICS AND PSYCHOSOMATIC DISORDERS -- A PRELIMINARY REPORT.
181771 02-07

COMPARATIVE EVALUATION OF DIBENCYCLADINE (LUDIOMIL) AND IMIPRAMINE IN PSYCHOTIC DEPRESSION.
183361 03-09

EVALUATION OF EEG AND CLINICAL CHANGES ASSOCIATED WITH PAVABID THERAPY IN CHRONIC BRAIN SYNDROME.
183402 03-13

A CONTROLLED EVALUATION OF LITHIUM IN THE PREMENSTRUAL TENSION SYNDROME.
185192 03-11

CLINICAL EVALUATION OF ANXIOLYTIC DRUGS.
185350 03-17

EVALUATION OF REINFORCING CAPABILITY OF DELTA9-TETRAHYDROCANNABINOL IN RHESUS MONKEYS.
187638 04-04

CLINICAL EVALUATION OF AMANTADINE THERAPY FOR PARKINSONISM AND THE SIDE-EFFECTS -- IN CASES OF THALAMIC SURGERY AND L-DOPA THERAPY.
190095 04-11

CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE METABOLITE, NORFENFLURAMINE: AN EVALUATION OF ITS ROLE IN THE ACTIONS OF FENFLURAMINE.
190335 04-04

AN EVALUATION OF SERUM DOPAMINE-BETA-HYDROXYLASE AS AN INDEX OF SYMPATHETIC NERVE ACTIVITY IN MAN.
191511 04-13

SERUM DOPAMINE-BETA-HYDROXYLASE: A POSSIBLE AID IN THE EVALUATION OF HYPERTENSION.
191512 04-13

METHODOLOGY FOR THE EVALUATION OF PENTAZOCINE, PROTOTYPE OF THE NEW MORPHINE AGONIST ANTAGONIST ANALGESICS.
191603 04-16

A BACTERIAL MODEL FOR EVALUATION OF BARBITURATES.
191920 04-03

PHARMACOLOGY OF DEPRESSION IN THE AGED: EVALUATION OF GEROVITAL-H3 AS AN ANTIDEPRESSANT DRUG.
192229 04-09

EVALUATIONS
AMA DRUG EVALUATIONS.
191048 04-17

EVIDENCE
NEGATIVE SODIUM BALANCE IN LITHIUM CARBONATE TOXICITY: EVIDENCE OF MINERALOCORTICOID BLOCKADE.
169869 01-15

EVIDENCE THAT MORPHINE INCREASES DOPAMINE UTILIZATION IN CORPORA-STRIATA OF RATS.
176746 02-03

FURTHER EVIDENCE FOR A ROLE OF 2-PHENYLETHYLAMINE IN THE MODE OF ACTION OF DELTA9-TETRAHYDROCANNABINOL.
179992 02-03

BEHAVIORAL EVIDENCE FOR DOPAMINERGIC SUPERSENSITIVITY AFTER CHRONIC HALOPERIDOL.
180021 02-04

CENTRAL DOPAMINE FUNCTION IN AFFECTIVE ILLNESS: EVIDENCE FROM PRECURSORS, ENZYME INHIBITORS AND STUDIES OF CENTRAL DOPAMINE TURNOVER. (UNPUBLISHED PAPER).
181358 02-09

EFFECT OF MORPHINE, HALOPERIDOL, APOMORPHINE AND BENZTROPINE ON DOPAMINE TURNOVER IN RAT CORPUS-STRIATUM: EVIDENCE SHOWING MORPHINE-INDUCED REDUCTION IN CNS DOPAMINERGIC ACTIVITY.
182230 03-03

EVIDENCE FOR PERSISTENT RESERPINE BINDING TO AMINE STORAGE VESICLE MEMBRANES.
182234 03-03

EVIDENCE FOR THE ACTION OF D-LYSERGIC ACID DIETHYLAMIDE, MESCALINE AND BUFOTENINE ON 5-HYDROXYTRYPTAMINE RECEPTORS IN UMBILICAL VASCULATURE.
182716 03-03

EVIDENCE FOR REDISTRIBUTION OF FILTRATE AMONG NEPHRONS AFTER BETA- ADRENERGIC STIMULATION AND BLOCKADE.
184222 03-03

EVIDENCE FOR AN UNUSUAL DISTRIBUTION OF CHLORPHENTERMINE IN VIVO: AN AUTORADIOGRAPHIC STUDY IN MICE.
184226 03-03

A COMPARISON OF THE EFFECTS OF CHRONIC ADMINISTRATION OF ETHANOL AND ACETALDEHYDE TO MICE: EVIDENCE FOR A ROLE OF ACETALDEHYDE IN ETHANOL DEPENDENCE.
185992 03-03

EVIDENCE FOR A CRITICAL PERIOD FOR POSTNATAL ELEVATION OF BRAIN TYROSINE HYDROXYLASE ACTIVITY RESULTING FROM RESERPINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT.
186695 03-03

A STUDY OF THE EFFECTS OF RITALIN INTERVENTION UPON THE PERCEPTUAL COMPETENCIES OF CHILDREN DIAGNOSED AS GIVING

EVIDENCE OF PSYCHONEUROLOGICAL LEARNING DISABILITIES. (PH.D. DISSERTATION).
186833 03-14

EVIDENCE FOR AN INHIBITORY ROLE FOR ACETYLCHOLINE, CATECHOLAMINES, AND SEROTONIN ON THE CEREBRAL CORTEX.
187552 04-03

FURTHER EVIDENCE ON THE INTRAHYPOTHALAMIC LOCUS FOR ANDROGENIZATION OF FEMALE RATS.
187935 04-03

FURTHER EVIDENCE FOR A DOPAMINE RECEPTOR STIMULATING ACTION OF AN ERGOT ALKALOID.
188739 04-03

EVIDENCE FOR A SPECIFIC UPTAKE OF DOPAMINE BY DOPAMINERGIC TERMINALS OF THE RAT CEREBRAL CORTEX.
188978 04-03

EVIDENCE FOR A NORADRENERGIC AND DOPAMINERGIC MECHANISM IN THE HYPERACTIVITY PRODUCED BY 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.
190309 04-04

EVIDENCE FOR A DOPAMINERGIC INVOLVEMENT IN THE MAINTENANCE OF SELF-STIMULATION.
191526 04-03

POST-MORTEM MEASUREMENT OF ENZYMES IN HUMAN BRAIN: EVIDENCE OF A CENTRAL NORADRENERGIC DEFICIT IN SCHIZOPHRENIA.
191529 04-13

DEMETHYLATION OF N,N DIMETHYLAMPHETAMINES - EVIDENCE FOR A MULTIENZYME SYSTEM.
191923 04-03

EVIDENCE FOR CHOLINERGICALLY MEDIATED EFFECT OF METHYLPHENIDATE HYDROCHLORIDE IN THE CENTRAL NERVOUS SYSTEM.
191946 04-03

NORADRENERGIC REGULATION OF BRAIN SEROTONERGIC NEURONS: EVIDENCE FROM SINGLE UNIT STUDIES WITH CLONIDINE.
191948 04-03

EVOKE

FAILURE OF N,N DIMETHYLTRYPTAMINE TO EVOKE TOLERANCE IN CATS.
173398 01-03

ATTEMPTS TO EVOKE TOLERANCE TO DMT IN MAN. (UNPUBLISHED PAPER).
176480 02-12

EVOKED

CHANGES IN SOMATOSENSORY EVOKED POTENTIALS PRODUCED BY DRUGS USED IN THE TREATMENT OF AFFECTIVE DISORDERS.
169092 01-09

LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND GAMMA-AMINOBUTYRIC ACID (GABA) INTERACTION ON SPONTANEOUS POTENTIALS AND THE EVOKED RESPONSE IN THE AVIAN TECTUM.
169689 01-03

AVERAGE EVOKED RESPONSES IN NORMAL AND MINIMALLY BRAIN DYSFUNCTIONED CHILDREN TREATED WITH AMPHETAMINE: A PRELIMINARY REPORT.
169861 01-11

EFFECTS OF SCOPOLAMINE UPON BEHAVIORAL REACTIVITY AND VISUALLY EVOKED POTENTIAL TO FLASHES IN RATS.
173032 01-04

REINVESTIGATION ON THE EFFECTS OF THIOPENTAL ON THE HUMAN SOMATOSENSORY EVOKED RESPONSE.
174505 01-13

BEHAVIORAL CHANGES AND AGGRESSIVITY EVOKED BY DRUGS IN MICE.
174604 01-04

ALTERATION OF SENSORY AND MOTOR EVOKED RESPONSES BY DIELDRIN.
181818 02-03

MODULATORY EFFECTS OF CORTICOSTEROIDS ON EVOKED ACTIVITY IN THE HIPPOCAMPUS AND THALAMUS OF THE RAT.
182119 02-03

5-HYDROXYTRYPTAMINE AND HISTAMINE EFFECTS ON RETICULOCEREBELLAR EVOKED POTENTIALS.
182121 02-03

HYPOTHERMIA EVOKED BY A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE ALKALOID.
182130 02-03

THE EFFECTS OF SOME DRUGS ON AN EVOKED RESPONSE SENSITIVE TO TETRAHYDROCANNABINOLS.
186666 03-03

BEHAVIORAL AND VISUAL EVOKED POTENTIAL INVESTIGATIONS DURING TRIHEXYPHENIDYL AND THIOTHIXENE TREATMENT IN PSYCHOTIC BOYS.
187115 03-09

ALTERATION OF EVOKED POTENTIALS IN CAUDATE NUCLEUS OF FREELY MOVING RATS BY L-DOPA, RESERPINE, AND PENTOBARBITAL.
187362 04-03

COMPARATIVE EFFECTS OF SCOPOLAMINE AND AMPHETAMINE UPON BEHAVIORAL REACTIVITY AND VISUAL EVOKED POTENTIALS TO FLASHES IN RATS.
187700 04-04

NEW LONG LATENCY BULBOSPINAL EVOKED POTENTIALS BLOCKED BY SEROTONIN ANTAGONISTS.
188751 04-03

INFLUENCE OF PSYCHOTROPIC DRUGS ON AGGRESSIVENESS EVOKED BY DESTRUCTION OF ISOLATED STRUCTURES OF THE FOREBRAIN.
191788 04-04

EWES

EXCRETION OF THC AND ITS METABOLITES IN EWES MILK.
189590 04-03

EX-11-582A

BEHAVIORAL EFFECTS OF EX-11-582A, A POTENTIAL ANTIPSYCHOTIC AGENT.
182242 03-04

EXACERBATION

EXACERBATION OF PSYCHOPATHOLOGY DURING TREATMENT: ETIOLOGY.
177676 02-17

EXAMINATION

TRANQUILIZERS AND EXAMINATION STRESS.
168901 01-14

EXAMINATION OF THE METHODS OF USING FLUPHENAZINE ENANTHATE.
176469 02-08

EXAMINATIONS

CHROMOSOME EXAMINATIONS AFTER MEDICALLY ADMINISTERED LYSERGIC ACID DIETHYLAMIDE AND DEXTROAMPHETAMINE.
192084 04-15

EXCITABILITY

EFFECTS OF CHLORPROMAZINE, CHLORDIAZEPOXIDE AND PENTOBARBITAL ON NEURONAL EXCITABILITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
177837 02-04

EXCITABILITY CHANGES DURING THE GRADUAL DEVELOPMENT OF AND RECOVERY FROM PENTYLENETETRAZOL AND STRYCHNINE INDUCED CONVULSIONS IN THE CAT.
191927 04-03

EXCITANT

EXCITANT AND DEPRESSANT DRUGS MODULATE EFFECTS OF ENVIRONMENT ON BRAIN WEIGHT AND CHOLINESTERASES.
174036 01-03

EXCITATIONS

EFFECTS OF PSYCHOTROPIC DRUGS ON METHAMPHETAMINE INDUCED EXCITATIONS IN THE AGGREGATED MICE.
182107 02-04

EXCITATORY

PENTOBARBITAL: SELECTIVE DEPRESSION OF EXCITATORY POSTSYNAPTIC POTENTIALS.
168485 01-03

BLOCKADE OF EXCITATORY 5-HT SYNAPSE BY LSD.
191950 04-03

EXCITEMENT

RAPID CONTROL OF PSYCHOTIC EXCITEMENT STATES WITH INTRAMUSCULAR HALOPERIDOL.
170627 01-09

DECREASED ANOREXIA, EXCITEMENT AND STEREOTYPY TO D-AMPHETAMINE AFTER LATERAL HYPOTHALAMIC 6-HYDROXYDOPAMINE (6-OHDA) INJECTIONS.
182136 02-04

EXCRETION

CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS: RECENT STUDIES OF MHPG EXCRETION.
169091 01-13

ONGOING INVESTIGATIONS OF CEREBRAL GLUTAMINE EXCRETION SCHIZOPHRENICS DURING TREATMENT WITH NEUROLEPTIC.
174101 01-08

STUDIES ON THE URINARY EXCRETION OF CATECHOLAMINES AND 17-KETOSTEROID IN MANIC-DEPRESSIVE PSYCHOSIS.
178623 02-09

EXCRETION OF NOREPINEPHRINE AND DOPAMINE ALCOHOLIC METABOLITES AFTER 6-HYDROXYDOPAMINE.
179986 02-03

STUDIES ON METABOLISM OF BROMAZEPAM (III): ABSORPTION, EXCRETION, AND METABOLISM OF BROMAZEPAM IN MAN.
181588 02-13

ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF BROMAZEPAM IN RABBIT.
182555 03-03

BLOOD LEVEL AND URINARY EXCRETION OF BROMAZEPAM IN MAN.
182556 03-13

ASSAY PROCEDURES FOR THIORIDAZINE, TRIFLUOPERAZINE, AND THEIR SULFOXIDES AND DETERMINATION OF URINARY EXCRETION OF THESE COMPOUNDS IN MENTAL PATIENTS.
183602 03-01

EXCRETION OF THC AND ITS METABOLITES IN EWES MILK.
189590 04-03

THE EFFECTS OF HOE-36801 ON CATECHOLAMINE EXCRETION, HEART RATE AND PSYCHOMOTOR PERFORMANCE IN NEUROTICS AND NORMALS.
192428 04-13

EXISTENTIAL
PHENOMENOLOGICAL - EXISTENTIAL STUDY OF PHOBIC - OBSESSIVE SYNDROMES TREATED WITH CHLORIMIPRAMINE.
182788 03-09

EXOGENOUS
DOUBLE-BLIND CLINICAL EVALUATION OF MAZINDOL, DEXTROAMPHETAMINE, AND PLACEBO IN TREATMENT OF EXOGENOUS OBESITY.
167335 01-11

TREATMENT OF EXOGENOUS PSYCHOSIS BY THE USE OF FK-880 (SULPIRIDE).
191663 04-09

SKELETAL MUSCLE: RESERVOIR FOR EXOGENOUS L-DOPA.
191771 04-03

EXOGENOUSLY
EFFECTS OF ALPHA-METHYLTYROSINE ON D-AMPHETAMINE INDUCED RELEASE OF ENDOGENOUSLY SYNTHESIZED AND EXOGENOUSLY ADMINISTERED CATECHOLAMINES FROM THE CAT BRAIN IN VIVO.
189397 04-03

EXPERIENCE
CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG, TRAZODONE: A REVIEW OF LITERATURE.
168803 01-11

EFFECTS OF FOOD DEPRIVATION, DISCRIMINATION EXPERIENCE AND PHYSOSTIGMINE ON CHOLINE ACETYLASE AND ACETYLCHOLINE ESTERASE IN THE DORSAL HIPPOCAMPUS AND FRONTAL CORTEX OF RATS.
169467 01-03

INTERACTION BETWEEN PRIOR EXPERIENCE AND THE EFFECTS OF CHLORPROMAZINE ON EXPLORATION IN THE RAT.
171308 01-04

ONE YEAR OF CLINICAL EXPERIENCE WITH LARGE DOSES OF 10 PERCENT FLUPENTHIXOL DECANOATE (LU-1705).
172735 01-07

OUR EXPERIENCE WITH LITHIUM.
172976 01-09

CLINICAL EXPERIENCE WITH MELITHRACENE IN THE TREATMENT OF DEPRESSIVE STATES.
172979 01-09

EXPERIENCE IN THE APPLICATION OF DICEPLON (APY-606) -- COMPARED WITH FLOROPIPAMIDE.
176447 02-08

EXPERIENCE IN THE USE OF IMIPRAMINE.
176448 02-10

EXPERIENCE IN THE USE OF SERENAL (OXAZOLAM) IN THE FIELD OF PEDIATRICS.
176456 02-11

EXPERIENCE IN THE APPLICATION OF A NEW DRUG, DP-181 (OXYPERTINE), IN TREATMENT OF SCHIZOPHRENIA.
176468 02-08

EXPERIENCE IN THE USE OF SINEQUAN (DOXEPIN HYDROCHLORIDE) IN TREATMENT OF NEUROSIS, DEPRESSION AND DEPRESSIVE STATES.
176471 02-11

EXPERIENCE IN THE USE OF A LOW DOSAGE OF CARPIPRAMINE (DEFEKTON).
176472 02-08

EXPERIENCE IN THE USE OF SINEQUAN (DOXEPIN HYDROCHLORIDE).
176474 02-10

EXPERIENCE IN THE USE OF AN ANTIDEPRESSIVE, CLOMIPRAMINE (ANAFRANIL), IN PSYCHIATRIC OUTPATIENTS.
176475 02-09

EXPERIENCE IN THE DRUG HORIZON AND PSYCHIATRIC INTERVIEW.
176542 02-11

EXPERIENCE IN THE USE OF FK-880 (SULPIRIDE) IN THE FIELD OF PSYCHIATRY.
177568 02-08

CLINICAL EXPERIENCE WITH FLUPHENAZINE ENANTHATE.
178021 02-08

LONG-TERM CONSEQUENCES OF EXPERIENCE, MEDICATION, AND PSYCHOTHERAPY FOR SCHIZOPHRENIC PATIENTS. (UNPUBLISHED PAPER).
178677 02-17

FURTHER EXPERIENCE WITH FLUPHENAZINE ENANTHATE INJECTION.
180153 02-08

EXPERIENCE GAINED IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PSYCHOSES WITH A THIORIDAZINE DERIVATIVE.
180675 02-08

EXPERIENCE IN THE TREATMENT OF CEREBRAL INSUFFICIENCY AND PERIPHERAL BLOOD CIRCULATION DISORDERS USING THE EP-50-100 EXPERIMENTAL DRUG.
180676 02-11

CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG: FK-880 (SULPIRIDE), ITS EFFECT ON PATIENTS WITH PSYCHOSOMATIC DISEASES AND PSYCHONEUROSIS.
182731 03-10

CLINICAL EXPERIENCE WITH DIAMORPHINE IN ADVANCED MALIGNANT DISEASE.
191606 04-17

EXPERIENCED
EFFECTS OF DELTA9-THC ON FOOD AND WATER INTAKE OF DEPRIVATION EXPERIENCED RATS.
191375 04-04

EXPERIENCES
EXPERIENCES WITH LAROXYL (R) IN THE TREATMENT OF DEPRESSIONS IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
170413 01-11

PRELIMINARY EXPERIENCES WITH NOBRIUM IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
170414 01-11

EXPERIENCES WITH FLUPHENAZINE ENANTHATE IN LONG-STAY HOSPITALISED SCHIZOPHRENICS.
171985 01-08

CLINICAL EXPERIENCES WITH FK-880 (SULPIRIDE).
174681 01-08

CLINICAL EXPERIENCES WITH A NEW PSYCHOTROPIC DRUG, R-6238 (PIMOZIDE).
176564 02-11

CLINICAL EXPERIENCES WITH AN ANTIDEPRESSIVE DRUG, NORITREN (NORTRIPTYLINE).
176565 02-09

CLINICAL EXPERIENCES WITH NAVANE IN CHRONIC SCHIZOPHRENIA.
176726 02-08

CLINICAL EXPERIENCES WITH A PSYCHOTROPIC DRUG (OXYPERTINE) IN CHRONIC SCHIZOPHRENIA.
176727 02-08

CLINICAL EXPERIENCES WITH FLUPENTHIXOL (FX-703).
178224 02-08

EXPERIENCES WITH FLUPHENAZINE ENANTHATE IN LONG-STAY HOSPITALIZED SCHIZOPHRENICS.
180154 02-08

PRELIMINARY EXPERIENCES WITH THE TREATMENT OF SOME MENTAL CASES UTILIZING AN ENZYME COMBINATION.
180298 02-17

CLINICAL EXPERIENCES WITH A NEW ANTIDEPRESSANT, MAPROTILINE.
188893 04-09

CLINICAL EXPERIENCES WITH MESORIDAZINE (TPS-23): ITS ADMINISTRATION TO HOSPITALIZED SCHIZOPHRENIC PATIENTS.
188934 04-08

EXPERIMENT
A CLINICAL EXPERIMENT WITH SULPIRIDE.
171122 01-11

EXPERIMENT WITH DOXEPIN (SINEQUAN) IN TREATMENT OF DEPRESSIVE STATES.
176454 02-11

CLINICAL EXPERIMENT WITH A LONG-ACTING NEUROLEPTIC: FLUSPIRILENE (R6218).
183200 03-15

EXPERIMENT WITH PENFLURIDOL (TLP-607) ON THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
191593 04-08

EXPERIMENT WITH LOPRAMINE (DB-2182) ON THE TREATMENT OF DEPRESSION.
191665 04-09

EXPERIMENT WITH LITHIUM CARBONATE ON THE TREATMENT OF MANIC STATE.
191670 04-09

EXPERIMENTAL
DEPRESSIVE FORMS OF SCHIZOPHRENIA AND EXPERIMENTAL TREATMENT BY CLOMIPRAMINE.
167676 01-08

THE SAFETY TEST OF 10-CHLORO-11B-(2-CHLOROPHENYL) 2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE (CS-370): SECOND REPORT, EFFECT OF CS-370 UPON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
168498 01-05

MARIHUANA USE IN MAN: AN EXPERIMENTAL INQUIRY -- CLINICAL PSYCHIATRIC IMPRESSIONS.
169085 01-14

THE EFFECT OF MARIJUANA ON HOSTILITY IN AN EXPERIMENTAL GROUP SETTING: PRELIMINARY OBSERVATIONS.
169086 01-14

BEHAVIOR AND SENSITIVITY TO EXPERIMENTAL HYPERTENSION: II. LACK OF CORRELATION BETWEEN CERTAIN BEHAVIOR PATTERNS AND HYPERTENSION IN TWO NEW STRAINS OF RATS.
173256 01-04

(-)DELTA9-THC AS AN HYPNOTIC: AN EXPERIMENTAL STUDY OF THREE DOSE LEVELS.
174041 01-14

EXPERIMENTAL DEPRESSION CAUSED BY APOMORPHINE AND PHENOHARMANE.
180062 02-10

EXPERIENCE IN THE TREATMENT OF CEREBRAL INSUFFICIENCY AND PERIPHERAL BLOOD CIRCULATION DISORDERS USING THE EP-50-100 EXPERIMENTAL DRUG.
180676 02-11

EXPERIMENTAL CATATONIA AND PSYCHOPHARMACOLOGY.
180724 02-04

EXPERIMENTAL STUDIES IN COMPARATIVE PSYCHOPHARMACOLOGY.
181400 02-04
CATECHOLAMINE TURNOVER IN THE RAT BRAIN: DIFFERENT RESULTS OBTAINED IN DIFFERENT EXPERIMENTAL CONDITIONS.
181471 02-03
A NEW RECORDING APPARATUS FOR MEASUREMENT OF LOCOMOTOR ACTIVITY OF MICE. EXPERIMENTAL OBSERVATIONS ON ITS USE.
186377 03-06
AN EXPERIMENTAL INVESTIGATION OF DEPENDENCE LIABILITY OF METHAQUALONE IN RATS.
186569 03-03
IMIPRAMINE IN EXPERIMENTAL PETIT-MAL EPILEPSY.
188424 04-03
MYTHICIZING ELEMENTS IN EXPERIMENTAL PSYCHOLYSIS.
189754 04-12

EXPERIMENTALLY
PROPRANOLOL AND CHLORDIAZEPOXIDE ON EXPERIMENTALLY INDUCED CONFLICT AND SHUTTLEBOX PERFORMANCE IN RODENTS.
171304 01-04

EXPERIMENTATION
CLINICAL EXPERIMENTATION WITH A NEW BENZODIAZEPINE IN THE MANAGEMENT OF PHOBIC AND OBSESSIVE SYMPTOMS.
167594 01-10
PSYCHOLOGICAL EXPERIMENTATION ON THE EFFECTS OF PROPIRAM FUMARATE AND PROMETHAZINE UNDER NORMAL AND STRESS CONDITIONS.
184617 03-07

EXPERIMENTS
EXPERIMENTS IN ORAL AND INJECTABLE FORMS OF A NEW ANTIDEPRESSANT (DOXEPIN) ON FORTY PATIENTS.
182900 03-11
MUTAGENICITY EXPERIMENTS WITH THE TRANQUILLIZER MEPROBAMATE IN DROSOPHILA-MELANOGASTER AND IN HUMAN LEUKOCYTE CHROMOSOMES IN VITRO.
184585 03-05
NEUROTOXICOLOGIC STUDIES OF TWO CARBAMATE PESTICIDES IN SUBACUTE ANIMAL EXPERIMENTS.
188874 04-05
THE USE OF DRUGS IN PSYCHIATRIC INTERVIEWS: SOME INTERPRETATIONS BASED ON CONTROLLED EXPERIMENTS.
189074 04-17
EFFECTS OF NICOTINE ON THE OBSERVED BEHAVIOUR OF RATS DURING SIGNALLED AND UNSIGNALLED AVOIDANCE EXPERIMENTS.
190332 04-04

EXPLANATION
CHOLINERGIC REVERSAL OF MANIC SYMPTOMS: A POSSIBLE EXPLANATION. (UNPUBLISHED PAPER).
173520 01-09

EXPLORATION
EFFECTS OF ATROPINE ON EXPLORATION, LEARNING AND ELECTROCORTICAL ACTIVITY IN THE DEVELOPING RAT.
169473 01-04
INTERACTION BETWEEN PRIOR EXPERIENCE AND THE EFFECTS OF CHLORPROMAZINE ON EXPLORATION IN THE RAT.
171308 01-04
THE ACTION OF CHLORPROMAZINE ON EXPLORATION IN PAIRS OF RATS.
189514 04-04
THE EFFECT OF OCTOCLOTHEPIN AND PERPHENAZINE ON BEHAVIOUR IN RATS WITH DIFFERENT EXPLORATION AND DEFECATION RATES.
192430 04-04

EXPLORATORY
TIME SAMPLING OF RAT EXPLORATORY BEHAVIOUR: A RELIABLE SCREENING TEST FOR THE CNS EFFECTS OF ANOREXIC AGENTS.
187925 04-04

EXPOSED
INCREASED BRAIN NOREPINEPHRINE TURNOVER IN LEAD EXPOSED HYPERACTIVE RATS.
191957 04-05

EXPOSURE
RECOVERY FROM ELECTROCONVULSIVE SHOCK-INDUCED AMNESIA BY EXPOSURE TO THE TRAINING ENVIRONMENT: PHARMACOLOGICAL ENHANCEMENT BY PIRACETAM.
186704 03-04
EFFECTS OF CHRONIC EXPOSURE TO DELTA9-TETRAHYDROCANNABINOL ON DELAYED MATCHING-TO-SAMPLE IN CHIMPANZEES.
189405 04-04
EFFECTS OF PERINATAL EXPOSURE TO METHYL MERCURY ON FUNCTIONAL BRAIN DEVELOPMENT AND NEUROCHEMISTRY.
189564 04-05
PERMANENT ALTERATIONS IN 5-HYDROXYTRYPTAMINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN FOLLOWING EXPOSURE TO DRUGS DURING THE PERIOD OF DEVELOPMENT.
191383 04-03
INDUCTION OF A DIETHYLETHER WITHDRAWAL SYNDROME IN MICE BY EXPOSURE TO ETHER VAPOR.
192006 04-03
ENDURING LEARNING DEFICITS AND CEREBRAL SYNAPTIC MALFORMATION FROM EXPOSURE TO 10 PARTS OF HALOTHANE PER MILLION.
192565 04-04

EXTENSOR
EFFECTS OF CNS AGENTS ON NICOTINE EXTENSOR CONVULSIONS AND LETHALITY IN MICE AND THEIR SEDATIVE ANTIANXIETY EFFECTS IN MAN.
191907 04-14

EXTENT
CROSS-NATIONAL STUDY OF THE EXTENT OF ANTIANXIETY SEDATIVE DRUG USE.
181713 02-17

EXTINCTION
FAILURE OF ACTH TO INFLUENCE AVOIDANCE EXTINCTION IN A ONE-WAY AVOIDANCE SITUATION.
183470 03-04
THE EFFECTS OF CHLORPROMAZINE ON A REDEFINED PROCEDURE OF EXTINCTION OF SIDMAN AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
185715 03-14
JOINT EFFECTS OF SODIUM AMYLOBARBITONE AND AMPHETAMINE SULPHATE ON RESISTANCE TO EXTINCTION OF A REWARDED RUNNING RESPONSE IN THE RAT.
186573 03-04

EXTRACT
EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF CANNABIS-SATIVA EXTRACT ON THE MOUSE-KILLING BEHAVIOR OF RATS.
167362 01-04
EFFECTS OF AQUEOUS PINEAL EXTRACT IN CHRONIC SCHIZOPHRENIA.
177818 02-08
CANNABIDIOL AND CANNABIS-SATIVA EXTRACT PROTECT MICE AND RATS AGAINST CONVULSIVE AGENTS.
183609 03-03
CRUDE MARIHUANA EXTRACT: EEG AND BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION IN RHESUS MONKEYS.
189516 04-04

EXTRACTED
SPECIFIC FACILITATION OF MAZE LEARNING BY A PEPTIDE EXTRACTED FROM TRAINED MOUSE BRAIN.
176868 02-04
CONSTITUENTS OF CANNABIS-SATIVA L. V.: STABILITY OF AN ANALYTICAL SAMPLE EXTRACTED WITH CHLOROFORM. (UNPUBLISHED PAPER).
180670 02-01

EXTRANEURONAL
EXTRANEURONAL REMOVAL, ACCUMULATION AND O-METHYLATION OF ISOPRENALINE IN THE PERFUSED HEART.
189604 04-03

EXTRAPYRAMIDAL
ACUTE DRUG-INDUCED EXTRAPYRAMIDAL SYNDROMES.
167572 01-15
PHYSOSTIGMINE EFFECTS ON PHENOTHIAZINE INDUCED EXTRAPYRAMIDAL REACTIONS.
170662 01-13
IS THERE A RELATIONSHIP BETWEEN THE INVOLVEMENT OF EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS WITH THE CATALEPTIC ACTION OF NEUROLEPTIC AGENTS AND THEIR CLINICAL ANTIPSYCHOTIC EFFECT?
171305 01-03
L-DOPA AND THE TREATMENT OF EXTRAPYRAMIDAL DISEASE. (UNPUBLISHED PAPER).
177975 02-11
ROLE OF 5-HT IN THE ACTION OF SOME DRUGS AFFECTING EXTRAPYRAMIDAL SYSTEM.
178757 02-04
EXTRAPYRAMIDAL DISTURBANCES BROUGHT ON BY NEUROLEPTICS.
180070 02-15
TRIFLUPERIDOL -- THERAPEUTIC RESPONSE AND EXTRAPYRAMIDAL SYMPTOMS.
180248 02-15
EFFECTS OF ANTIPARKINSONIAN DRUGS ON NEUROLEPTIC INDUCED EXTRAPYRAMIDAL SIGNS IN MONKEYS.
183610 03-03
CHLORPROMAZINE CAUSING EXTRAPYRAMIDAL DYSFUNCTION IN NEWBORN INFANT OF PSYCHOTIC MOTHER.
187787 04-15
ANTISCHIZOPHRENIC DRUGS AND BRAIN CHOLINERGIC RECEPTORS: AFFINITY FOR MUSCARINIC SITES PREDICTS EXTRAPYRAMIDAL EFFECTS.
188114 04-15
ADRENERGIC AND CHOLINERGIC FACTORS IN EXTRAPYRAMIDAL DISORDERS.
191533 04-11
DIFFERENTIAL INCREASE OF BEHAVIORAL AND EXTRAPYRAMIDAL STIMULATING ACTIONS OF NEUROLEPTICS BY ALPHA-METHYLTYROSINE PRETREATMENT IN RATS.
192016 04-04

EYE
ON THE TREATMENT OF RAPID EYE MOVEMENT NARCOLEPSY.
171496 01-11
AMPHETAMINE AND PENTOBARBITAL EFFECTS ON THE DISCRIMINATIVE RESPONSE CONTROL BY DEPRIVATION OF RAPID EYE MOVEMENT SLEEP (REM).
182245 03-03

EYELID
THE EFFECT OF TRANYLCYPROMINE (PARNATE) ON EYELID CONDITIONING AND PAIRED ASSOCIATE LEARNING IN DEPRESSED PATIENTS.
188107 04-09

FACILITATES
MESCALINE FACILITATES RETENTION OF PASSIVE AVOIDANCE IN RATS.
190266 04-04

FACILITATION
SPECIFIC FACILITATION OF MAZE LEARNING BY A PEPTIDE EXTRACTED FROM TRAINED MOUSE BRAIN.
176868 02-04
AN ANALYSIS OF D-AMPHETAMINE PRODUCED FACILITATION OF AVOIDANCE ACQUISITION IN RATS AND PERFORMANCE CHANGES SUBSEQUENT TO DRUG TERMINATION.
179990 02-04
DOSE DEPENDENT SELECTIVE FACILITATION OF RESPONSE CONTINGENT LIGHT ONSET BEHAVIOR BY D-AMPHETAMINE.
185955 03-04
AN ANALYSIS OF THE FACILITATION OF AVOIDANCE ACQUISITION BY D-AMPHETAMINE AND SCOPOLAMINE.
189521 04-04
PSYCHOPHARMACOLOGIC FACILITATION OF OPERANT CONDITIONING OF GENETICALLY NERVOUS CATAHOULA AND POINTER DOGS.
190696 04-04

FACILITATORY
PARADOXICAL BLOCKADE BY P-CHLOROPHENYLALANINE OF 5-HYDROXYTRYPTOPHAN FACILITATORY ACTIONS ON SPINAL REFLEXES.
168436 01-03

FACT
MIXED ANXIETY DEPRESSION: FACT OR MYTH?
189919 04-10

FAD
STIMULATION OF BRAIN AROMATIC ALKYLAMINE N-METHYLTRANSFERASE ACTIVITY BY FAD AND METHYLCOBALAMIN.
180020 02-03

FAILURE
FAILURE OF N,N DIMETHYLTRYPTAMINE TO EVOKE TOLERANCE IN CATS.
173398 01-03
CLINICAL FACTORS IN LITHIUM CARBONATE PROPHYLAXIS FAILURE.
174093 01-09
FAILURE OF ACTH TO INFLUENCE AVOIDANCE EXTINCTION IN A ONE-WAY AVOIDANCE SITUATION.
183470 03-04
FAILURE OF BETA-ADRENERGIC RECEPTOR BLOCKADE TO PREVENT ARRHYTHMIAS INDUCED BY SYMPATHETIC NERVE STIMULATION.
187923 04-03

FAILURES
FAILURES OF L-DOPA.
168777 01-13

FAMILIAR
SENSORY CONTINGENT BAR-PRESSING FOR FAMILIAR AND NOVEL CHANGE UNDER A DEXAMPHETAMINE AMYLOBARBITONE MIXTURE.
181605 02-04

FAMILIARITY
DRUG NAME FAMILIARITY AND THE PLACEBO EFFECT.
192704 04-17

FAMILIES
IMPORTANCE OF THE COOPERATION OF FAMILIES IN THE TREATMENT OF THE SICK: CONCERNING CHRONIC DELIRIUM TREATED WITH NEUROLEPTICS AND MELANCHOLY TREATED WITH ANTIDEPRESSANTS.
182899 03-17

FAMILY
RELATIONSHIP BETWEEN THE EFFECTIVENESS OF LITHIUM THERAPY AND FAMILY HISTORY.
169494 01-09
ARE NEUROTIC PATIENTS IN PSYCHOTROPIC DRUG TRIALS REPRESENTATIVE? A COMPARISON OF STUDY AND NON-STUDY PATIENTS IN FOUR FAMILY PRACTICES.
188144 04-10
RESILIENCE OF FAMILY PROCESS: EFFECT OF SECOBARBITAL.
189743 04-14

FATAL
FATAL INTOXICATION OF A YOUNG DRUG ADDICT WITH DIAZEPAM.
178619 02-05
FATAL SUICIDAL INGESTION OF THIORIDAZINE.
189606 04-15

FATE
THE METABOLIC FATE OF N,N DIMETHOXYMETHYL-PHENOBARBITAL IN THE RAT.
177731 02-03
THE METABOLIC FATE OF HEXOBARBITAL IN THE RAT.
177732 02-03
INVESTIGATIONS ON THE FATE OF THE ANTICONVULSANT CLONAZEPAM IN THE ORGANISM OF MAN, RAT AND DOG.
179022 02-13
STUDIES ON METABOLISM OF BROMAZEPAM (II): COLORIMETRIC DETERMINATION AND METABOLIC FATE OF BROMAZEPAM IN ANIMALS.
181593 02-03

FATIGABILITY
PSYCHIC FATIGABILITY, ITS FEATURES AND DRUG THERAPY.
183197 03-11

FAVORABLE
ONE CASE OF AGRYPNIA (4 MONTHS WITHOUT SLEEP) IN A MORVAN DISEASE: FAVORABLE ACTION OF 5-HYDROXYTRYPTOPHAN.
187237 03-14

FEAR
ANTICHOLINERGICS: THEIR EFFECTS ON FEAR MOTIVATED BEHAVIOR, URINARY 11-HYDROXYCORTICOSTEROIDS, URINARY VOLUME, AND HEART RATE IN THE DOG.
178720 02-03
FEAR REDUCTION IN THE RAT FOLLOWING CENTRAL CHOLINERGIC BLOCKADE.
187703 04-04
DISSOCIATION BETWEEN SCOPOLAMINE AND MECAMYLAMINE DURING FEAR CONDITIONING IN RATS.
190264 04-04

FEEDING
RECOVERY OF FEEDING AND DRINKING BY RATS AFTER INTRAVENTRICULAR 6-HYDROXYDOPAMINE OR LATERAL HYPOTHALAMIC LESIONS.
168484 01-03
DOPAMINE AND 5-HYDROXYTRYPTAMINE INHIBIT FEEDING IN RATS.
170177 01-04
ROLE OF ASSOCIATIVE LEARNING IN FEEDING BEHAVIOR.
178044 02-17
DETERMINANTS OF THE NORADRENERGIC SATIETY EFFECT: ENVIRONMENTAL DARKNESS VS. THE FEEDING PATTERN.
182133 02-04
RECOVERY OF FEEDING AFTER 6-HYDROXYDOPAMINE (6-HDA) OR LATERAL HYPOTHALAMIC LESIONS: THE ROLE OF CATECHOLAMINES.
182213 03-03
EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON ELECTROENCEPHALOGRAM AND FEEDING BEHAVIOR OF RATS.
182554 03-04
BRAIN MECHANISMS UNDERLYING THE EFFECTS OF AMPHETAMINE ON FEEDING AND NONFEEDING BEHAVIORS: DISSOCIATION AND OVERLAP.
184839 03-03

FEMALE
EFFECTS OF TETRABENAZINE ON LORDOSIS BEHAVIOUR AND ON BRAIN MONOAMINES IN THE FEMALE RAT.
171614 01-04
CHANGE OF ESTROGEN ACTIVATED BEHAVIOR BY CYCLOHEXIMIDE IN THE FEMALE RAT.
171615 01-04
ACTIVATION OF COPULATORY BEHAVIOR BY PILOCARPINE AND OXOTREMORINE IN THE FEMALE RAT.
171616 01-04
A DIFFERENTIAL INHIBITORY ACTION OF LSD AND AMPHETAMINE ON COPULATORY BEHAVIOR IN THE FEMALE RAT.
171617 01-04
INFLUENCE OF PHENOBARBITAL AND SEX HORMONES ON ENZYMES IN ASCORBIC ACID BIOSYNTHESIS IN MALE AND FEMALE RATS. (PH.D. DISSERTATION).
172017 01-03
SUBACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MALE AND FEMALE RATS: ORAL ADMINISTRATION FOR ONE MONTH.
177097 02-05
INVERSION BY APOMORPHINE OF THE TENDENCY OF FEMALE RATS TO BE DEFEATED BY MALES WHEN COMPETING FOR FOOD IN A STRAIGHT RUNWAY.
184212 03-04
NEURAL AND CHEMICAL MECHANISMS OF FEMALE SEXUAL BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).
185705 03-04
EFFECTS OF AN ESTROGEN ANTAGONIST, MER-25, ON MOUNTING BEHAVIOR AND LORDOSIS BEHAVIOR IN THE FEMALE RAT.
186691 03-04
FURTHER EVIDENCE ON THE INTRAHYPOTHALAMIC LOCUS FOR ANDROGENIZATION OF FEMALE RATS.
187935 04-03
EFFECTS OF LSD AND MONOAMINE SYNTHESIS INHIBITORS ON HORMONE ACTIVATED COPULATORY BEHAVIOR IN THE FEMALE RAT.
188611 04-04
DISTRIBUTION OF 14C-DELTA9-THC IN MALE AND FEMALE RATS.
191969 04-03

FENFLURAMINE
INTERACTION BY FENFLURAMINE WITH THE METABOLISM OF D-AMPHETAMINE IN THE RAT.
171634 01-03
SELECTIVE BLOCKADE OF APOMORPHINE INDUCED AGGRESSION AND GNAWING FOLLOWING FENFLURAMINE OR RAPHE LESIONS IN THE RAT.
182128 02-04
DIFFERENTIAL SELF-INJECTION BEHAVIOR PRODUCED BY FENFLURAMINE VERSUS OTHER APPETITE INHIBITING DRUGS.
182215 03-04
CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE DERIVATIVE SE-780 IN RATS.
187926 04-04
BIOCHEMICAL AND BEHAVIORAL ANTAGONISM BETWEEN FENFLURAMINE AND APOMORPHINE IN RATS.
188196 04-03
PSYCHOMOTOR TEST PERFORMANCE WITH A FENFLURAMINE AMPHETAMINE COMBINATION.
190146 04-07
CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE METABOLITE, NORFENFLURAMINE: AN EVALUATION OF ITS ROLE IN THE ACTIONS OF FENFLURAMINE.
190335 04-04

FENTANYL
INFLUENCE OF FENTANYL, LEVORPHANOL AND PETHIDINE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189569 04-03

FETAL
DETERMINATION OF DRUG TRANSFER ACROSS BIOLOGICAL MEMBRANES: COMPARATIVE STUDY ON THE PASSAGE OF DRUGS INTO THE CENTRAL NERVOUS SYSTEM AND THEIR PLACENTAL TRANSFER AND FETAL LOCALIZATION IN THE PREGNANT RAT. (PH.D. DISSERTATION).
172018 01-03

FETUS
THE RATE LIMITING CONTROL OF ENZYMES MONOAMINE OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN THE FETUS AND THE ADULT BY ADRENOCORTICOL HORMONES.
178815 02-03

FETUSES
DISPOSITION OF H3-DELTA9-TETRAHYDROCANNABINOL IN BRAIN OF PREGNANT DOGS AND THEIR FETUSES.
191968 04-03

FIBER
MUSCLE ABNORMALITIES IN PSYCHOTIC PATIENTS: II. SERUM CPK ACTIVITY, FIBER ABNORMALITIES, AND BRANCHING AND SPROUTING OF SUBTERMINAL NERVES.
187114 03-09

FIBERS
FLUORESCENCE AND ELECTRON MICROSCOPIC ANALYSIS OF CATECHOLAMINE CONTAINING FIBERS IN MUTANT MOUSE CEREBELLUM. (UNPUBLISHED PAPER).
191762 04-03

FIGHTING
FIGHTING IN MICE: DYADIC ESCALATION AND WHAT IS LEARNED.
173039 01-04
APOMORPHINE INDUCED BITING AND FIGHTING BEHAVIOUR IN RESERPINIZED RATS AND AN APPROACH TO THE MECHANISM OF ACTION.
174768 01-04
THE EFFECTS OF CHLORDIAZEPOXIDE (LIBRIUM) ON THE INTENSITY AND HABITUATION OF AGONISTIC BEHAVIOR IN MALE SIAMESE FIGHTING FISH.
177722 02-04

FILTRATE
EVIDENCE FOR REDISTRIBUTION OF FILTRATE AMONG NEPHRONS AFTER BETA- ADRENERGIC STIMULATION AND BLOCKADE.
184222 03-03

FIRST-PASS
ON THE FIRST-PASS EFFECT IN THE LIVER OF NORTRIPTYLINE, LIDOCAINE AND PROPRANOLOL.
171631 01-03

FISCHER
INHALATION, PARENTERAL AND ORAL LD50 VALUES OF DELTA9-TETRAHYDROCANNABINOL IN FISCHER RATS.
189588 04-05
EFFECTS OF CHRONIC NICOTINE ADMINISTRATION AND AGE ON VARIOUS NEUROTRANSMITTERS AND ASSOCIATED ENZYMES IN MALE FISCHER 344 RATS.
189597 04-03

FISH
THE EFFECTS OF CHLORDIAZEPOXIDE (LIBRIUM) ON THE INTENSITY AND HABITUATION OF AGONISTIC BEHAVIOR IN MALE SIAMESE FIGHTING FISH.
177722 02-04

FIXED-INTERVAL
THE EFFECTS OF D- AND L-AMPHETAMINE ON FIXED-INTERVAL AND FIXED-RATIO BEHAVIOR IN TOLERANT AND NONTOLERANT RATS.
168438 01-04
THE EFFECTS OF SCOPOLAMINE ON FIXED-INTERVAL BEHAVIOUR IN THE RAT: A RATE-DEPENDENCY EFFECT.
168833 01-04
A DETAILED ANALYSIS OF THE EFFECTS OF D-AMPHETAMINE ON BEHAVIOR UNDER FIXED-INTERVAL SCHEDULES.
187066 03-04
EFFECTS OF D-AMPHETAMINE, MORPHINE AND CHLORPROMAZINE ON RESPONDING UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION OR ELECTRIC SHOCK PRESENTATION.
191767 04-03

FIXED-RATIO
THE EFFECTS OF D- AND L-AMPHETAMINE ON FIXED-INTERVAL AND FIXED-RATIO BEHAVIOR IN TOLERANT AND NONTOLERANT RATS.
168438 01-04
EFFECTS OF METHAMPHETAMINE ON FIXED-RATIO RESPONDING OF FOOD SATIATED AND FOOD DEPRIVED RATS.
185957 03-04

FK-880
CLINICAL EXPERIENCES WITH FK-880 (SULPIRIDE).
174681 01-08
EXPERIENCE IN THE USE OF FK-880 (SULPIRIDE) IN THE FIELD OF PSYCHIATRY.
177568 02-08
THE COMPARISON OF THERAPEUTIC EFFECTS OF FK-880 (SULPIRIDE) AND PERPHENAZINE IN SCHIZOPHRENIA BY A DOUBLE-BLIND CONTROLLED STUDY.
181378 02-08
CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG: FK-880 (SULPIRIDE), ITS EFFECT ON PATIENTS WITH PSYCHOSOMATIC DISEASES AND PSYCHONEUROSIS.
182731 03-10
TREATMENT OF EXOGENOUS PSYCHOSIS BY THE USE OF FK-880 (SULPIRIDE).
191663 04-09

FLASHES
EFFECTS OF SCOPOLAMINE UPON BEHAVIORAL REACTIVITY AND VISUALLY EVOKED POTENTIAL TO FLASHES IN RATS.
173032 01-04
COMPARATIVE EFFECTS OF SCOPOLAMINE AND AMPHETAMINE UPON BEHAVIORAL REACTIVITY AND VISUAL EVOKED POTENTIALS TO FLASHES IN RATS.
187700 04-04

FLAVOR
FLAVOR AVERSIONS PRODUCED BY CONTINGENT DRUG INJECTION: RELATIVE EFFECTIVENESS OF APOMORPHINE, EMETINE, AND LITHIUM.
178502 02-04

FLICKER
EFFECTS OF SHORT-TERM VERSUS LONG-TERM L-DOPA THERAPY IN PARKINSONISM ON CRITICAL FLICKER FREQUENCY.
177511 02-11

FLOROPIPAMIDE
EXPERIENCE IN THE APPLICATION OF DICEPLON (APY-606) -- COMPARED WITH FLOROPIPAMIDE.
176447 02-08

FLOW
EFFECTS OF ALTERATIONS IN IMPULSE FLOW ON TRANSMITTER METABOLISM IN CENTRAL DOPAMINERGIC NEURONS.
191519 04-03

FLUID
BRAIN SEROTONIN, AFFECTIVE ILLNESS AND ANTIDEPRESSANT DRUGS: CEREBROSPINAL FLUID STUDIES WITH PROBENECID. (UNPUBLISHED PAPER).
170084 01-09
ELECTROLYTES IN CEREBROSPINAL FLUID IN ENDOGENOUS DEPRESSION.
172402 01-09
EFFECTS OF AMITRIPTYLINE AND IMIPRAMINE ON AMINE METABOLITES IN THE CEREBROSPINAL FLUID OF DEPRESSED PATIENTS.
174094 01-09
THE EFFECT OF PROBENECID AND LARGE DOSE AMPHETAMINE ADMINISTRATION ON CEREBROSPINAL FLUID HOMOVANILLIC ACID.
177826 02-13
CHOLINE ACETYLTRANSFERASE ACTIVITY IN THE CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
180047 02-13
LITHIUM DISTRIBUTION BETWEEN CEREBROSPINAL FLUID AND SERUM OF AFFECTIVE PSYCHOTIC PATIENTS TREATED WITH LITHIUM CARBONATE AND ITS CLINICAL RESPONSE.
180301 02-11
THE ELIMINATION OF 5-HYDROXYINDOLEACETIC ACID FROM CEREBROSPINAL FLUID: CHARACTERISTICS OF THE ACID TRANSPORT SYSTEM OF THE CHOROID PLEXUS.
182718 03-03
THE EFFECT OF CHLORPROMAZINE ON HOMOVANILLIC ACID LEVELS IN CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS.
186565 03-08
MASS FRAGMENTOGRAPHIC ANALYSIS OF HOMOVANILLIC ACID AND ITS HOMOISO ANALOGUE IN CEREBROSPINAL FLUID USING THE ALPHA DIDEUTERO ACID AS INTERNAL STANDARD.
186566 03-16

STUDIES OF CEREBROSPINAL FLUID AMINE METABOLITES IN DEPRESSED PATIENTS: CONCEPTUAL PROBLEMS AND THEORETICAL IMPLICATIONS. (UNPUBLISHED PAPER).
187398 04-13

PLASMA AND CEREBROSPINAL FLUID PROBENECID CONCENTRATIONS AS RELATED TO ACCUMULATION OF ACIDIC BIOGENIC AMINE METABOLITES IN MAN.
187933 04-13

A STUDY OF BIOGENIC AMINE METABOLITES IN THE CEREBROSPINAL FLUID AND URINE OF MONKEYS WITH CHLORPROMAZINE INDUCED DYSKINESIA.
189210 04-03

FLUIDS

RADIOIMMUNOASSAY FOR LYSERGIDE (LSD) IN ILLICIT DRUGS AND BIOLOGICAL FLUIDS.
170840 01-06

VALIDITY OF SCREENING METHODS FOR DRUGS OF ABUSE IN BIOLOGICAL FLUIDS. II. HEROIN IN PLASMA AND SALIVA.
187256 03-15

FLUNITRAZEPAM

CONTROL OF INSOMNIA WITH A NEW BENZODIAZEPINE: THE FLUNITRAZEPAM OR RO-5-4200 (FIRST INVESTIGATIONS OF PHASE I AND CONTROLLED INVESTIGATIONS OF PHASE II).
183198 03-11

FLUNITRAZEPAM (RO-5-4200) AND SLEEP CYCLE IN INSOMNIAC PATIENTS.
186574 03-11

FLUORESCENCE

FLUORESCENCE AND ELECTRON MICROSCOPIC ANALYSIS OF CATECHOLAMINE CONTAINING FIBERS IN MUTANT MOUSE CEREBELLUM. (UNPUBLISHED PAPER).
191762 04-03

FLUPENTHIXOL

ONE YEAR OF CLINICAL EXPERIENCE WITH LARGE DOSES OF 10 PERCENT FLUPENTHIXOL DECANOATE (LU-1705).
172735 01-07

PRELIMINARY STUDY OF THE TREATMENT OF CHRONIC PSYCHOSES WITH FLUPENTHIXOL DECANOATE.
172978 01-09

FLUPENTHIXOL IN CERTAIN PSYCHIATRIC ILLNESSES.
175393 02-11

FLUPENTHIXOL IN SCHIZOPHRENIA.
175460 02-08

CLINICAL EXPERIENCES WITH FLUPENTHIXOL (FX-703).
178224 02-08

THE USE OF FLUPENTHIXOL IN THERAPY.
183124 03-11

ACUTE EFFECTS OF ALCOHOL, DIAZEPAM, THIORIDAZINE, FLUPENTHIXOL AND ATROPINE ON PSYCHOMOTOR PERFORMANCE PROFILES.
184848 03-14

FLUPENTHIXOL DECANOATE IN SCHIZOPHRENIA.
185194 03-08

INFLUENCE OF FLUPENTHIXOL AND FLUPENTHIXOL DECANOATE ON METHYLPHENIDATE AND APOMORPHINE INDUCED COMPULSIVE GNAWING IN MICE.
186371 03-04

FLUPHENAZINE

ROLE OF FLUPHENAZINE DECANOATE IN LESSENING THE BURDEN OF CHRONIC SCHIZOPHRENICS ON THE COMMUNITY.
169438 01-08

EXPERIENCES WITH FLUPHENAZINE ENANTHATE IN LONG-STAY HOSPITALISED SCHIZOPHRENICS.
171985 01-08

ASSESSMENT OF ANATENSOL (FLUPHENAZINE ENANTHATE) INJECTABLE IN THE TREATMENT OF SCHIZOPHRENIA.
172444 01-08

AN ACCOUNT OF THE USE OF FLUPHENAZINE SINCE THE ESTABLISHMENT OF PSYCHIATRY AS A SEPARATE DISCIPLINE.
176431 02-11

EXAMINATION OF THE METHODS OF USING FLUPHENAZINE ENANTHATE.
176469 02-08

A DOUBLE-BLIND COMPARISON OF FLUPHENAZINE AND HALOPERIDOL IN OUTPATIENT SCHIZOPHRENIC CHILDREN.
177754 02-08

CLINICAL EXPERIENCE WITH FLUPHENAZINE ENANTHATE.
178021 02-08

FURTHER EXPERIENCE WITH FLUPHENAZINE ENANTHATE INJECTION.
180153 02-08

EXPERIENCES WITH FLUPHENAZINE ENANTHATE IN LONG-STAY HOSPITALIZED SCHIZOPHRENICS.
180154 02-08

PHARMACOLOGICAL DIFFERENCES BETWEEN FLUPHENAZINE ENANTHATE AND ITS HYDROCHLORIDE.
182634 03-02

FEATURES OF THE THERAPEUTIC EFFECT OF FLUPHENAZINE DECANOATE IN SCHIZOPHRENIA.
183683 03-08

IMPLICATIONS OF SUSTAINED RELEASE PHENOTHIAZINES: A STUDY OF FLUPHENAZINE DECANOATE.
185007 03-09

ON THE CLINICAL EFFECT OF FLUPHENAZINE ENANTHATE IN OUTPATIENT SCHIZOPHRENICS.
185213 03-08

FLUPHENAZINES

SIDE-EFFECTS OF DEPOT FLUPHENAZINES.
188312 04-15

FLURAZEPAM

THE RESIDUAL EFFECTS OF FLURAZEPAM.
168831 01-14

BLOOD LEVEL PROFILE IN MAN FOLLOWING CHRONIC ORAL ADMINISTRATION OF FLURAZEPAM HYDROCHLORIDE.
169817 01-13

THE EFFECTS OF DALMANE (FLURAZEPAM HYDROCHLORIDE) ON THE CONTINGENT NEGATIVE VARIATION. (AMSTERDAM).
177645 02-16

CENTRAL NERVOUS ACTION OF FLURAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.
182549 03-03

THE EFFECT OF FLURAZEPAM ON THE PHOTOPALPEBRAL REFLEX.
184314 03-13

FLUSPIRILENE

CLINICAL EVALUATION OF FLUSPIRILENE AS A MAINTENANCE THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS.
168320 01-08

FLUSPIRILENE, A LONG-ACTING INJECTABLE NEUROLEPTIC.
183199 03-11

CLINICAL EXPERIMENT WITH A LONG-ACTING NEUROLEPTIC: FLUSPIRILENE (R6218).
183200 03-15

FLUXES

EFFECT OF SELECTED BETA-DIKETONES ON LITHIUM FLUXES OF BOVINE RED BLOOD CELLS.
171792 01-05

FOCAL

CARBAMAZEPINE SOLE ANTICONVULSANT FOR FOCAL EPILEPSY OF CHILDHOOD.
189174 04-11

FOLLICULITIS

LITHIUM INDUCED FOLLICULITIS.
169492 01-15

FOOD

EFFECTS OF FOOD DEPRIVATION, DISCRIMINATION EXPERIENCE AND PHYSOSTIGMINE ON CHOLINE ACETYLASE AND ACETYLCHOLINE ESTERASE IN THE DORSAL HIPPOCAMPUS AND FRONTAL CORTEX OF RATS.
169467 01-03

DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) DOSE EFFECTS COMPARED ON THREE SCHEDULES OF FOOD REINFORCED OPERANT PERFORMANCE.
182191 02-04

EFFECTS OF MORPHINE, CODEINE AND NALOXONE ON FOOD AND CODEINE REINFORCED RESPONDING IN THE RHESUS MONKEY.
182195 02-04

INVERSION BY APOMORPHINE OF THE TENDENCY OF FEMALE RATS TO BE DEFEATED BY MALES WHEN COMPETING FOR FOOD IN A STRAIGHT RUNWAY.
184212 03-04

THE EFFECTS OF CHRONIC TREATMENT WITH D-AMPHETAMINE ON FOOD INTAKE, BODYWEIGHT, LOCOMOTOR ACTIVITY AND SUBCELLULAR DISTRIBUTION OF THE DRUG IN RAT BRAIN.
185931 03-03

EFFECTS OF METHAMPHETAMINE ON FIXED-RATIO RESPONDING OF FOOD SATIATED AND FOOD DEPRIVED RATS.
185957 03-04

INDEPENDENCE OF THE EFFECTS OF D-AMPHETAMINE AND FOOD DEPRIVATION OR BODYWEIGHT ON THE FOOD CONSUMPTION OF RATS.
186376 03-06

DIAZEPAM-INDUCED EATING AND LEVER PRESSING FOR FOOD IN SATED RATS.
186613 03-04

INTERACTION OF D-AMPHETAMINE WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY OF MICE.
189613 04-04

EFFECTS OF DELTA9-THC ON FOOD AND WATER INTAKE OF DEPRIVATION EXPERIENCED RATS.
191375 04-04

EFFECTS OF D-AMPHETAMINE, MORPHINE AND CHLORPROMAZINE ON RESPONDING UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION OR ELECTRIC SHOCK PRESENTATION.
191767 04-03

BEHAVIORAL EFFECTS OF COCAINE COMPARED UNDER TWO SCHEDULES OF FOOD PRESENTATION IN THE SQUIRREL MONKEY.
191916 04-04

NALTREXONE AND NALOXONE: AGONIST AND ANTAGONIST EFFECTS ON KEY-PRESS RESPONDING OF PIGEONS MAINTAINED UNDER A MULTIPLE SCHEDULE OF FOOD PRESENTATION.
191926 04-04

EFFECTS OF PHENCYCLIDINE AND KETAMINE ON FOOD MAINTAINED BEHAVIOR IN THE PIGEON.
191973 04-04

FOOTSHOCK
EFFECTS OF BUFOTENINE AND P-CHLOROPHENYLALANINE ON REACTIVITY TO FOOTSHOCK.
184838 03-04

FORCED
RELUCTANCE OF RATS TO DRINK HASHISH SUSPENSIONS: FREE-CHOICE AND FORCED CONSUMPTION, AND THE EFFECTS OF HYPOTHALAMIC STIMULATION.
186586 03-04

FOREBRAIN
EFFECTS OF CHLORPROMAZINE, CHLORDIAZEPOXIDE AND PENTOBARBITAL ON NEURONAL EXCITABILITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
177837 02-04

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: IV. INFLUENCE OF AMPHETAMINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
185961 03-04

THE EFFECT OF P-CHLOROPHENYLALANINE ON FOREBRAIN TRYPTOPHAN HYDROXYLASE IN RATS WITH LESIONS IN THE RAPHE NUCLEUS.
188750 04-03

INFLUENCE OF PSYCHOTROPIC DRUGS ON AGGRESSIVENESS EVOKED BY DESTRUCTION OF ISOLATED STRUCTURES OF THE FOREBRAIN.
191788 04-04

EFFECT OF CHRONIC TREATMENT WITH DESIPRAMINE (DMI) AND IPRINDOLE (IP) ON THE NOREPINEPHRINE (NE) SENSITIVE ADENYLATE CYCLASE SYSTEM IN SLICES OF THE RAT LIMBIC FOREBRAIN.
192003 04-03

FORMATION
AMITRIPTYLINE IN MAN: DECREASED FORMATION OF CENTRAL 5-HYDROXYINDOLEACETIC ACID.
177736 02-13

STUDIES ON BENZODIAZEPINOOXAZOLES. IV. THE FORMATION OF QUINOLONES BY THE RING CONTRACTION OF A BENZODIAZEPINOOXAZOLE DERIVATIVE.
180488 02-01

THE EFFECT OF PSYCHOTROPIC AGENTS ON THE FORMATION OF AVOIDANCE REACTION IN ALBINO RATS DURING ELECTROPAIN STIMULATION OF ANOTHER RAT.
183206 03-04

FORMATION OF NORADRENALINE IN THE RAT BRAIN FROM THE FOUR STEREOISOMERS OF 3,4 DIHYDROXYPHENYLSERINE.
184229 03-03

THE ACTION OF D-AMPHETAMINE ON SPONTANEOUS ACTIVITY IN THE CAUDATE NUCLEUS AND RETICULAR FORMATION OF THE RAT.
185264 03-03

PHARMACOLOGICAL DISTINCTIONS BETWEEN ACTIVE AND PASSIVE AVOIDANCE MEMORY FORMATION AS SHOWN BY MANIPULATION OF BIOGENIC AMINE ACTIVE COMPOUNDS.
185927 03-04

A POSSIBLE MECHANISM FOR THE ANTISCHIZOPHRENIC ACTION OF CHLORPROMAZINE: INHIBITION OF THE FORMATION OF DIMETHYLTRYPTAMINE BY CHLORPROMAZINE METABOLITES.
187576 04-03

THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. I. NEURONAL RESPONSES TO STIMULATION OF THE RETICULAR FORMATION.
189855 04-03

STEREOCHEMICAL ASPECTS AND METABOLITE FORMATION IN THE IN VIVO METABOLISM OF THE PSYCHOTOMIMETIC AMINE, 1-2,5-(DIMETHOXY-4-METHYLPHENYL) 2 AMINOPROPANE.
190718 04-03

FORMULATIONS
MOLINDONE: A CROSSOVER EVALUATION OF CAPSULE AND TABLET FORMULATIONS IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
174137 01-08

FOUR-YEAR-OLD
EFFECTS OF MEDICATION ON LEARNING IN HYPERACTIVE FOUR-YEAR-OLD CHILDREN. (ED.D DISSERTATION).
172512 01-11

FRACTIONS
THE EFFECTS OF PSYCHIC STIMULANTS ON THE ACTIVITY OF POTASSIUM AND SODIUM ION STIMULATED ATPASE IN THE MICROSOMAL FRACTIONS OF THE BRAIN OF RATS.
183518 03-01

ENHANCED BINDING OF CHLORPROMAZINE TO CHOLESTEROL DEPLETED SYNAPTOSOME FRACTIONS.
187801 04-03

FRACTURES
DIAZEPAM USED INTRAVENOUSLY DURING REDUCTION OF FRACTURES AND DISLOCATIONS.
174880 01-17

FRAGMENTOGRAPHIC
SIMULTANEOUS MASS FRAGMENTOGRAPHIC ASSAY OF NOREPINEPHRINE (NE), EPINEPHRINE (E) AND DOPAMINE (DA) IN RAT SYMPATHETIC GANGLION: EFFECTS OF DEXAMETHASONE IN NEWBORN AND ADULT RATS. (UNPUBLISHED PAPER).
170747 01-03

MASS FRAGMENTOGRAPHIC ANALYSIS OF HOMOVANILLIC ACID AND ITS HOMOISO ANALOGUE IN CEREBROSPINAL FLUID USING THE ALPHA DIDEUTERO ACID AS INTERNAL STANDARD.
186566 03-16

FRAGMENTOGRAPHY
MASS FRAGMENTOGRAPHY IN CLINICAL PSYCHOPHARMACOLOGY.
169074 01-01

FREE
INCREASE IN THE PLASMA CONCENTRATION OF FREE TRYPTOPHAN CAUSED BY PROBENECID IN HUMANS.
169470 01-13

IMPORTANCE OF CATECHOLAMINE RELEASE BY NERVE IMPULSES FOR FREE OPERANT BEHAVIOR.
171611 01-04

THE EFFECTS OF CHRONIC RESERPINE AND NIALAMIDE TREATMENT ON THE FREE AMINO ACID LEVELS OF RAT BRAIN.
187645 04-03

FREE-CHOICE
RELUCTANCE OF RATS TO DRINK HASHISH SUSPENSIONS: FREE-CHOICE AND FORCED CONSUMPTION, AND THE EFFECTS OF HYPOTHALAMIC STIMULATION.
186586 03-04

FREQUENCY
EFFECTS OF SHORT-TERM VERSUS LONG-TERM L-DOPA THERAPY IN PARKINSONISM ON CRITICAL FLICKER FREQUENCY.
177511 02-11

HIGH FREQUENCY OF DYSPHORIC REACTIONS TO TETRAHYDROCANNABINOL AMONG DEPRESSED PATIENTS.
181274 02-09

A FREQUENCY SHIFT IN THE HIPPOCAMPAL THETA ACTIVITY: AN ELECTRICAL CORRELATE OF CENTRAL ACTION OF ACTH ANALOGUES IN THE DOG
188166 04-04

FROG
ACTION OF CONVULSANTS ON ROOT POTENTIALS AND AMINO ACID RESPONSES IN ISOLATED FROG SPINAL CORD. (UNPUBLISHED PAPER).
177976 02-03

STUDIES ON CONVULSANTS IN THE ISOLATED FROG SPINAL CORD. I. ANTAGONISM OF AMINO ACID RESPONSES. (UNPUBLISHED PAPER)
190727 04-03

FRONTAL
EFFECTS OF FOOD DEPRIVATION, DISCRIMINATION EXPERIENCE AND PHYSOSTIGMINE ON CHOLINE ACETYLASE AND ACETYLCHOLINE ESTERASE IN THE DORSAL HIPPOCAMPUS AND FRONTAL CORTEX OF RATS.
169467 01-03

SHIFTING OF THE D-AMPHETAMINE DOSE-RESPONSE CURVE IN RATS WITH FRONTAL CORTICAL ABLATIONS.
187261 04-04

FRUSTRATION
MODIFICATION OF THE FRUSTRATION EFFECT WITH DRUGS.
181408 02-04

FUMARATE
PSYCHOLOGICAL EXPERIMENTATION ON THE EFFECTS OF PROPIRAM FUMARATE AND PROMETHAZINE UNDER NORMAL AND STRESS CONDITIONS.
184617 03-07

COMPARISON OF PSYCHOEXPERIMENTAL PERFORMANCE UNDER THE INFLUENCE OF THE ANALGESIC PROPIRAM FUMARATE.
184618 03-14

FUNCTION
POSSIBLE INVOLVEMENT OF CYCLIC NUCLEOTIDES IN THE STIMULATION OF PITUITARY FUNCTION ELICITED BY RESERPINE. (UNPUBLISHED PAPER).
170086 01-03

INTERRESPONSE TIME CHANGES AS A FUNCTION OF DEPRIVATION AND AMPHETAMINE ADMINISTRATION.
171612 01-04

EFFECTS OF CHRONIC PRETREATMENT WITH SMALL DOSES OF RESERPINE UPON ADRENERGIC NERVE FUNCTION.
177406 02-03

INTERACTION OF CENTRALLY ADMINISTERED OUABAIN WITH AGENTS AFFECTING SYMPATHETIC FUNCTION.
178640 02-03

CENTRAL DOPAMINE FUNCTION IN AFFECTIVE ILLNESS: EVIDENCE FROM PRECURSORS, ENZYME INHIBITORS AND STUDIES OF CENTRAL DOPAMINE TURNOVER. (UNPUBLISHED PAPER).
181358 02-09

WORD RECOGNITION OF SCHIZOPHRENICS AS A FUNCTION OF PHENOTHIAZINE LEVEL AND AUTONOMIC RESPONSIVITY. (PH.D. DISSERTATION).
182524 03-08

ANTIPSYCHOTIC ACTION OF NEUROLEPTIC AGENTS AND THE FUNCTION OF BASAL GANGLIA (SURVEY OF LITERATURE).
183521 03-17

DOPAMINE IN BRAIN FUNCTION.
184329 03-03

THE EFFECTS OF PHENOTHIAZINES ON ENDOCRINE FUNCTION: I. PATIENTS WITH INAPPROPRIATE LACTATION AND AMENORRHOEA.
184436 03-15

THE EFFECTS OF PHENOTHIAZINES ON ENDOCRINE FUNCTION: II. EFFECTS IN MEN AND POST-MENOPAUSAL WOMEN.
184437 03-13

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: IV. INFLUENCE OF AMPHETAMINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
185961 03-04

THE POSSIBLE ROLE OF TRYPTAMINE IN BRAIN FUNCTION AND ITS RELATIONSHIP TO THE ACTIONS OF LSD-LIKE HALLUCINOGENS.
186024 03-12

DIFFERENTIAL RECOVERY OF FUNCTION FOLLOWING CAUDATE, HIPPOCAMPAL, AND SEPTAL LESIONS IN MICE.
186620 03-04

EEG DRIVING RESPONSES AS A FUNCTION OF MONOAMINE OXIDASE.
187149 03-13

EFFECT OF ORAL ADMINISTRATION OF METHADONE ON HEPATIC MICROSOMAL MIXED FUNCTION OXIDASE ACTIVITY IN MICE.
188178 04-03

DRUG EFFECTS AND HYPOTHALAMIC ANTERIOR PITUITARY FUNCTION.
188393 04-03

PSYCHOENDOCRINE INVESTIGATION IN SCHIZOPHRENIA: RELATIONSHIP BETWEEN PITUITARY GONADAL FUNCTION AND BEHAVIOR.
191190 04-14

EFFECT OF ANESTHETIC AGENTS ON PERIPHERAL SYMPATHETIC NERVOUS SYSTEM FUNCTION AS MONITORED BY ARTERIAL PLASMA CATECHOLAMINE LEVELS. (UNPUBLISHED PAPER
191495 04-03

REGULATION OF FUNCTION OF TRYPTOPHAN HYDROXYLASE.
191516 04-03

CORTICAL AND/OR SUBCORTICAL EFFECTS AS A FUNCTION OF HALLUCINOGENIC DRUG STRUCTURE
191936 04-03

FUNCTIONAL

TREMOR INDUCTION BY INTRACAUDATE INJECTIONS OF BRETYLIUM, TETRABENAZINE, OR MESCALINE: FUNCTIONAL DEFICITS IN CAUDATE DOPAMINE.
167329 01-03

FUNCTIONAL EVALUATION OF PITUITARY RESERVE IN PATIENTS WITH THE AMENORRHEA GALACTORRHEA SYNDROME UTILIZING LUTEINIZING HORMONE RELEASING HORMONE (LH-RH), L-DOPA AND CHLORPROMAZINE.
175245 02-13

STRUCTURAL FUNCTIONAL ORGANIZATION OF THE HUMAN BRAIN AND THE PATHOPHYSIOLOGY OF THE PARKINSONIAN TYPE HYPERKINESES.
178787 02-13

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: III. PIMOZIDE IN THE TREATMENT OF STRESS INDUCED PSYCHIC AND FUNCTIONAL DISORDERS.
183193 03-11

PLASMA DOPA AND FUNCTIONAL OSCILLATIONS AFTER CHRONIC TREATMENT OF PARKINSONS DISEASE.
188421 04-13

EFFECTS OF PERINATAL EXPOSURE TO METHYL MERCURY ON FUNCTIONAL BRAIN DEVELOPMENT AND NEUROCHEMISTRY.
189564 04-05

THE ANTAGONISM BETWEEN CHOLINOMIMETIC AGONISTS AND BETA-ADRENOCEPTOR STIMULANTS: THE DIFFERENTIATION BETWEEN BETWEEN FUNCTIONAL AND METAFFINOID ANTAGONISM.
191420 04-03

FUNCTIONING

CHANGES IN MENTAL FUNCTIONING ACCOMPANYING ANTIPSYCHOTIC DRUG THERAPY.
171124 01-10

FUNCTIONS

EMOTIONAL FUNCTIONS IN SHORT-TERM VS. LONG-TERM L-DOPA THERAPY IN PARKINSONISM.
168619 01-15

EFFECT OF CHRONIC TREATMENT WITH CENTRAL STIMULANTS ON BRAIN MONOAMINES AND SOME BEHAVIOURAL AND PHYSIOLOGICAL FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS.
191503 04-03

A PHARMACOLOGICAL MODEL WITH RHESUS MONKEYS FOR THE PREDICTION OF SELECTIVE DEPRESSION OF PSYCHIC FUNCTIONS.
192424 04-04

FUROSEMIDE

ENHANCED RENAL TUBULAR SECRETION OF MEPROBAMATE: ROLE OF SALINE FUROSEMIDE DIURESIS.
184243 03-03

FUROXANOBENZOFUROXAN

FUROXANOBENZOFUROXAN, A SELECTIVE MONOAMINE OXIDASE INHIBITOR.
188770 04-01

FUSARIC

BEHAVIORAL EFFECTS OF A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR (FUSARIC ACID) IN MAN. (UNPUBLISHED PAPER
174329 01-09

FX-703

CLINICAL EXPERIENCES WITH FLUPENTHIXOL (FX-703).
178224 02-08

G-33040

ACTION OF OPIPRAMOL (G-33040) IN DEPRESSIVE SYNDROMES IN CHILDREN AND ADOLESCENTS.
182432 03-10

GABA

LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND GAMMA-AMINOBUTYRIC ACID (GABA) INTERACTION ON SPONTANEOUS POTENTIALS AND THE EVOKED RESPONSE IN THE AVIAN TECTUM.
169689 01-03

ANTAGONISM OF THE EFFECTS OF CHLORPROMAZINE AND MORPHINE ON DOPAMINE METABOLISM BY GABA.
176870 02-03

ANALYSIS OF DRUG BLOCK OF LSD/5-HT/GABA BY MONITORING NEURONAL MEMBRANE CHANGES.
182143 02-03

EFFECT OF GAMMA-AMINOBUTYRIC ACID (GABA) ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
182231 03-03

EFFECT OF PENTOBARBITAL ON UPTAKE AND RELEASE OF (3H)GABA AND (14C)GLUTAMATE BY BRAIN SLICES.
189031 04-03

GAIN

WEIGHT GAIN IN LITHIUM TREATED RATS.
174133 01-04

EFFECT OF A CARNITINE CYPROHEPTADINE COMBINATION ON ANOREXIA AND WEIGHT GAIN IN CHILDREN.
178811 02-10

GALACTORRHEA

FUNCTIONAL EVALUATION OF PITUITARY RESERVE IN PATIENTS WITH THE AMENORRHEA GALACTORRHEA SYNDROME UTILIZING LUTEINIZING HORMONE RELEASING HORMONE (LH-RH), L-DOPA AND CHLORPROMAZINE.
175245 02-13

GALENIC

A FEW GALENIC METHOD TO PROLONG THE ACTION OF LITHIUM SULFATE.
180700 02-15

GAMMA

(3H) OUABAIN BINDING TO NA+-ATPASE AND K+-ATPASE: INHIBITION BY BETA, GAMMA METHYLENE ATP.
182184 02-03

GAMMA-AMINOBUTYRIC

LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND GAMMA-AMINOBUTYRIC ACID (GABA) INTERACTION ON SPONTANEOUS POTENTIALS AND THE EVOKED RESPONSE IN THE AVIAN TECTUM.
169689 01-03

EFFECT OF GAMMA-AMINOBUTYRIC ACID (GABA) ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
182231 03-03

THE ROLE OF GAMMA-AMINOBUTYRIC ACID AS A MEDIATOR OF POSITIVE DORSAL ROOT POTENTIALS.
189832 04-03

THE EFFECT OF INCREASED GAMMA-AMINOBUTYRIC ACID ON ALPHA-METHYLTYROSINE INDUCED DECREASE IN CATECHOLAMINES IN RAT BRAIN.
191988 04-03

GAMMA-BUTYROLACTONE

DOPAMINERGIC INHIBITION OF STRIATAL CHOLINERGIC NEURONS: SYNERGISTIC BLOCKING ACTION OF GAMMA-BUTYROLACTONE AND NEUROLEPTIC DRUGS.
189602 04-03

GAMMA-HYDROXYBUTYRATE

EFFECT OF MORPHINE ON REGIONAL LEVELS OF GAMMA-HYDROXYBUTYRATE IN MOUSE BRAIN.
187077 03-03

GAMMA-HYDROXYBUTYRIC

INFLUENCES OF DRUGS ON THE INCREASES IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OF GAMMA-HYDROXYBUTYRIC ACID (GHBA).
171622 01-03

GAMMA-LABELLED

DDT EFFECT ON 32P INCORPORATION FROM GAMMA-LABELLED ATP INTO PROTEINS FROM LOBSTER NERVE.
191315 04-03

GAMMA-P-FLUOROBENZOYLPROPYL
ANTIHYPERTENSIVE AND CENTRAL NERVOUS SYSTEM DEPRESSANT PROPERTIES OF 3-(GAMMA-P-FLUOROBENZOYLPROPYL) 2,3,4,4A,5,6 HEXAHYDROPYRAZINOQUINOLINE HYDROCHLORIDE (COMPOUND-69-183, CENTPYRAQUIN).
176881 02-03

GANGLIA
TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER).
170876 01-03
ANTIPSYCHOTIC ACTION OF NEUROLEPTIC AGENTS AND THE FUNCTION OF BASAL GANGLIA (SURVEY OF LITERATURE).
183521 03-17
EFFECTS OF PROLONGED LSD-25 ADMINISTRATION UPON NEURONS OF SPINAL CORD GANGLIA TISSUE CULTURES.
185112 03-03
DIAZEPAM INHIBITION OF POST-TETANIC POTENTIATION IN BULLFROG SYMPATHETIC GANGLIA: POSSIBLE ROLE OF PROSTAGLANDINS.
186673 03-03

GANGLION
SIMULTANEOUS MASS FRAGMENTOGRAPHIC ASSAY OF NOREPINEPHRINE (NE), EPINEPHRINE (E) AND DOPAMINE (DA) IN RAT SYMPATHETIC GANGLION: EFFECTS OF DEXAMETHASONE IN NEWBORN AND ADULT RATS. (UNPUBLISHED PAPER).
170747 01-03
THE ACTIONS OF SEVERAL PSYCHOACTIVE AGENTS UPON THE MUSCARINIC MECHANISMS IN THE SUPERIOR CERVICAL GANGLION OF THE CAT.
183866 03-03
THE EFFECTS OF 5-HYDROXYTRYPTAMINE AND SOME RELATED COMPOUNDS ON THE CAT SUPERIOR CERVICAL GANGLION IN SITU.
184197 03-03
THE EFFECTS OF VARIOUS NICOTINE-LIKE AGENTS IN THE CAT SUPERIOR CERVICAL GANGLION IN SITU.
184202 03-03
THE EFFECTS OF LITHIUM ON HIGH ENERGY PHOSPHATE AND GLUCOSE LEVELS IN THE RAT SUPERIOR CERVICAL GANGLION.
187677 04-03
LIPIDOSIS-LIKE ALTERATIONS IN DORSAL ROOT GANGLION CELLS OF RATS TREATED WITH TRICYCLIC ANTIDEPRESSANTS.
189605 04-03
PHARMACOLOGICAL ALTERATIONS IN THE STIMULUS INDUCED RELEASE OF NOREPINEPHRINE FROM THE RABBIT SUPERIOR CERVICAL GANGLION.
191896 04-03

GAS
GAS CHROMATOGRAPHIC - MASS SPECTROMETRIC STUDIES ON TRICYCLIC PSYCHOTROPIC DRUGS.
169073 01-01
A SENSITIVE GAS CHROMATOGRAPHIC PROCEDURE FOR THE ESTIMATION OF NORADRENALINE, DOPAMINE AND 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
171971 01-01
GAS CHROMATOGRAPHIC DETERMINATION OF METHAQUALONE IN SMALL AMOUNTS OF SERUM AFTER INGESTION OF THERAPEUTIC DOSES.
172397 01-16
GAS CHROMATOGRAPHIC ANALYSIS OF BENZODIAZEPINES. PART I: MEDAZEPAM AND ITS METABOLITES.
178948 02-06
A GAS CHROMATOGRAPHIC METHOD FOR THE QUANTITATIVE ESTIMATION OF N-HYDROXYPHENTERMINE.
182203 02-06

GASES
DIAZEPAM AND MEPERIDINE ON ARTERIAL BLOOD GASES IN HEALTHY VOLUNTEERS.
190147 04-13

GASTRIC
DRUG EFFECTS ON GASTRIC ULCERATION RATE IN THE RAT. (UNPUBLISHED PAPER).
176307 02-03
INCREASED GASTRIC ACID DURING SHOCK AVOIDANCE IN MAN.
181879 02-13
EFFECTS OF SCOPOLAMINE METHYLBROMIDE ON SHOCK-INDUCED GASTRIC LESIONS IN THE UNRESTRAINED RAT.
189381 04-03

GATE
ATTACK ON THE GATE THEORY OF PAIN.
189610 04-17

GENERALIZATION
DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
191944 04-04

GENERALIZED
GENERALIZED PENICILLIN EPILEPSY IN THE CAT: EFFECTS OF INTRACAROTID AND INTRAVERTEBRAL PENTYLENETETRAZOL AND AMOBARBITAL INJECTIONS.
188374 04-03

GENERATED
THE EFFECTS OF L-DELTA9-TRANS-TETRAHYDROCANNABINOL ON LOW AND HIGH RESPONSE RATES GENERATED UNDER TWO SIMILAR CONDITIONS (PH.D. DISSERTATION).
168230 01-04

GENERIC
BIOEQUIVALENCY OF GENERIC AND BRAND-NAMED CHLORPROMAZINE.
187255 03-08

GENETIC
GENETIC EFFECTS OF LSD.
175043 02-04
CHLORPROMAZINE AND AVOIDANCE: A GENETIC ANALYSIS.
185751 03-03

GENETICALLY
THE EFFECTS OF CHLORDIAZEPOXIDE, AMPHETAMINE AND COCAINE ON BAR-PRESS BEHAVIOR IN NORMAL AND GENETICALLY NERVOUS DOGS.
187868 04-04
PSYCHOPHARMACOLOGIC FACILITATION OF OPERANT CONDITIONING OF GENETICALLY NERVOUS CATAHOULA AND POINTER DOGS.
190696 04-04

GENICULATE
LSD EFFECTS ON SIGNAL-TO-NOISE RATIO AND LATERALIZATION OF VISUAL CORTEX AND LATERAL GENICULATE DURING PHOTIC STIMULATION.
167449 01-03
PGO WAVES IN THE LATERAL GENICULATE NUCLEUS TRIGGERED BY BARBITURATE.
187835 04-03

GENOTYPE
INTERACTION AMONG GENOTYPE, UNCONDITIONED STIMULUS, D-AMPHETAMINE, AND ONE-WAY AVOIDANCE BEHAVIOR OF RATS.
187702 04-04

GENTLE
RAPID AND GENTLE PHARMACOTHERAPY OF DEPRESSION.
174495 01-10

GEOCHELONE-CARBONARIA
EFFECT OF ATROPINE SULFATE ON THE SLEEP RELATED EEG SPIKE ACTIVITY OF THE TORTOISE, GEOCHELONE-CARBONARIA.
191389 04-03

GEOMETRIC
THE EFFECTS OF SCOPOLAMINE ON PERFORMANCE ON A GEOMETRIC PROGRESSIVE RATIO SCHEDULE.
190334 04-04

GERIATRIC
LORAZEPAM VERSUS GLUTETHIMIDE AS A SLEEP INDUCING AGENT FOR THE GERIATRIC PATIENT.
167496 01-11
CAUDATE NUCLEUS EFFECTS ON GERIATRIC SENILITY: EFFECT OF BELLADONNA ON LEARNING AND MEMORY OF GERIATRIC PATIENTS.
170744 01-11
SAFETY AND EFFICACY OF ZINC SULFATE IN GERIATRIC PATIENTS.
184177 03-11
POLYMYALGIA RHEUMATICA IN A GERIATRIC DEPARTMENT: NINE PATIENTS WITH AN AVERAGE AGE OF 83 YEARS.
187236 03-11
TARDIVE DYSKINESIA AND DRUG THERAPY IN GERIATRIC PATIENTS.
189923 04-13
DIFFERENTIAL EFFECTS OF TRAZODONE IN DEPRESSED, SCHIZOPHRENIC AND GERIATRIC PATIENTS.
191138 04-14

GERIATRICS
PSYCHOPHARMACOLOGY AND GERIATRICS.
176438 02-17

GEROVITAL-H3
GEROVITAL-H3 IN THE TREATMENT OF THE DEPRESSED AGING PATIENT.
177373 02-11
A TRIAL OF GEROVITAL-H3 IN DEPRESSION DURING SENILITY.
181957 02-10
PROCAINE (GEROVITAL-H3) THERAPY: MECHANISM OF INHIBITION OF MONOAMINE OXIDASE.
191281 04-03
PHARMACOLOGY OF DEPRESSION IN THE AGED: EVALUATION OF GEROVITAL-H3 AS AN ANTIDEPRESSANT DRUG.
192229 04-09

GESTATION
DECREASED EFFECT OF PHENOBARBITAL TREATMENT ON MICROSOMAL DRUG METABOLIZING ENZYME ACTIVITY DURING GESTATION.
184228 03-03

GHBA
INFLUENCES OF DRUGS ON THE INCREASES IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OF GAMMA-HYDROXYBUTYRIC ACID (GHBA).
171622 01-03

GILLES-DE-LA-TOURETTE
TIC DE GILLES-DE-LA-TOURETTE: CASE REPORT AND BRIEF DISCUSSION.
181158 02-09

GILLES-DE-LA-TOURETTES
DOPAMINE AND GILLES-DE-LA-TOURETTES SYNDROME.
188431 04-11

GINSENG
THE EFFECT OF PANAX GINSENG SAPONIN ON THE CENTRAL NERVOUS SYSTEM IN RAT: THE PSYCHOPHARMACOLOGICAL EFFECT OF GINSENG.
171599 01-04

GLAUCOMA
ECT, GLAUCOMA, AND PROLONGED APNEA.
187837 04-15

GLC
GLC DETERMINATION OF MEPROBAMATE IN WATER, PLASMA AND URINE.
185977 03-16

GLUCOSE
THE EFFECTS OF LITHIUM ON HIGH ENERGY PHOSPHATE AND GLUCOSE LEVELS IN THE RAT SUPERIOR CERVICAL GANGLION.
187677 04-03

THE EFFECTS OF AMPHETAMINE SULFATE ON THE DIURNAL RHYTHMS OF MIDBRAIN; CORTEX, NOREPINEPHRINE; SEROTONIN AND BLOOD GLUCOSE LEVELS IN THE MOUSE.
191918 04-03

GLUTAMATE
EFFECT OF PENTOBARBITAL ON UPTAKE AND RELEASE OF (3H)GABA AND (14C)GLUTAMATE BY BRAIN SLICES.
189031 04-03

GLUTAMINE
ONGOING INVESTIGATIONS OF CEREBRAL GLUTAMINE EXCRETION SCHIZOPHRENICS DURING TREATMENT WITH NEUROLEPTIC.
174101 01-08

GLUTETHIMIDE
LORAZEPAM VERSUS GLUTETHIMIDE AS A SLEEP INDUCING AGENT FOR THE GERIATRIC PATIENT.
167496 01-11

GLYCOGEN
THE INFLUENCE OF ALDOSTERONE OR METHAMPHETAMINE ON LIVER GLYCOGEN DEPOSITION OF MICE STRESSED BY LONG-TERM ISOLATION.
182105 02-03

GLYCOPEPTIDE
CONVULSION PRODUCING PROPERTY OF THE DIALYZABLE GLYCOPEPTIDE PREPARATION FROM WHOLE RAT BRAIN.
181815 02-03

GMP
EFFECTS OF DECAPITATION, ETHER AND PENTOBARBITAL ON CYCLIC AMP AND CYCLIC GMP LEVELS IN RAT TISSUES.
182154 02-03

GNAWING
PHARMACOKINETIC DISPOSITION OF NORAPOMORPHINE DERIVATIVES AND ITS INFLUENCE ON THE ELICITATION OF STEREOTYPICAL GNAWING. (PH.D. DISSERTATION).
174960 01-03

INHIBITION OF THE APOMORPHINE GNAWING COMPULSION BY AMANTADINE.
176879 02-04

SELECTIVE BLOCKADE OF APOMORPHINE INDUCED AGGRESSION AND GNAWING FOLLOWING FENFLURAMINE OR RAPHE LESIONS IN THE RAT.
182128 02-04

DISPOSITION OF NORAPOMORPHINE AND N,N PROPYLNORAPOMORPHINE IN MOUSE BRAIN AND ITS CORRELATION WITH STEREOTYPED GNAWING BEHAVIOR.
182131 02-04

INFLUENCE OF FLUPENTHIXOL AND FLUPENTHIXOL DECANOATE ON METHYLPHENIDATE AND APOMORPHINE INDUCED COMPULSIVE GNAWING IN MICE.
186371 03-04

GOLDFISH
MODIFICATION OF LEARNING AND MEMORY IN GOLDFISH THROUGH THE USE OF STIMULANT AND DEPRESSANT DRUGS.
186583 03-04

GONADAL
EFFECTS OF CHRONICALLY ADMINISTERED DELTA1-TETRAHYDROCANNABINOL OF ADRENAL AND GONADAL ACTIVITY OF MALE RATS.
183358 03-03

PSYCHOENDOCRINE INVESTIGATION IN SCHIZOPHRENIA: RELATIONSHIP BETWEEN PITUITARY GONADAL FUNCTION AND BEHAVIOR.
191190 04-14

GRADED
COMPARISON OF GRADED SINGLE INTRAMUSCULAR DOSES OF MORPHINE AND PENTOBARBITAL IN MAN.
187254 03-15

GRADUAL
EXCITABILITY CHANGES DURING THE GRADUAL DEVELOPMENT OF AND RECOVERY FROM PENTYLENETETRAZOL AND STRYCHNINE INDUCED CONVULSIONS IN THE CAT.
191927 04-03

GRAY
ANALGESIA AND HYPERREACTIVITY PRODUCED BY INTRACRANIAL MICROINJECTIONS OF MORPHINE INTO THE PERIAQUEDUCTAL GRAY MATTER OF THE RAT.
191367 04-04

NEUROCHEMICAL ANALYSIS OF AGGRESSIVE - DEFENSIVE BEHAVIOR ELICITED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS AND CENTRAL GRAY MATTER.
191784 04-02

GROUP
L-DOPA IN 122 CASES OF PARKINSONS DISEASE AT AGE 70 OR OVER. A COMPARATIVE STUDY WITH A GROUP OF PATIENTS AGED 41 TO 69 YEARS.
168369 01-11

THE EFFECT OF MARIJUANA ON HOSTILITY IN AN EXPERIMENTAL GROUP SETTING: PRELIMINARY OBSERVATIONS.
169086 01-14

IMIPRAMINE, DIAZEPAM AND GROUP PSYCHOTHERAPY IN LONG-TERM TREATMENT OF DEPRESSIVE NEUROTICS.
169089 01-10

DRUGS AND GROUP PSYCHOTHERAPY IN NEUROTIC DEPRESSION.
171925 01-10

SELF-STIMULATION OF NORADRENERGIC CELL GROUP (A6) IN LOCUS-COERULEUS OF RATS.
173029 01-03

TRIFLUPERIDOL -- A CONTROLLED CLINICAL TRIAL ON A GROUP OF SCHIZOPHRENIC PATIENTS.
174587 01-08

EFFECTS OF PSYCHOACTIVE DRUGS ON NONVERBAL COMMUNICATION AND GROUP SOCIAL BEHAVIOR OF MONKEYS.
175317 02-04

THE DYNAMICS OF A GROUP IN PSYCHOTHERAPY.
180140 02-12

THE USE OF HALLUCINOGENS IN GROUP PSYCHOTHERAPY.
180144 02-12

PROPHYLACTIC EFFICACY OF LITHIUM CARBONATE IN MANIC-DEPRESSIVE ILLNESS: REPORT OF THE VETERANS ADMINISTRATION AND NATIONAL INSTITUTE OF MENTAL HEALTH (VA-NIMH) COLLABORATIVE STUDY GROUP.
189735 04-09

GROUPS
A METHOD FOR ANALYZING CNS EFFECTS OF DRUGS AND BRAIN LESIONS ON PERMANENT GROUPS OF RATS.
176867 02-06

MEDICATION GROUPS FOR CONTINUING CARE.
189640 04-17

GROWTH
GROWTH HORMONE RESPONSES TO ADMINISTRATION OF L-5-HYDROXYTRYPTOPHAN (L-5-HTP) IN MANIC-DEPRESSIVE PSYCHOSES.
167919 01-09

INHIBITION OF GROWTH IN ANIMALS TREATED WITH METHADONE.
182164 02-03

THE EFFECT OF ZINC N TETRACOSACTRIN ON GROWTH HORMONE RELEASE DURING SLEEP.
183490 03-13

ROLE OF DOPAMINERGIC MECHANISMS IN REGULATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN MAN.
188428 04-13

INHIBITION OF THE SLEEP RELATED PEAK IN PHYSIOLOGIC HUMAN GROWTH HORMONE RELEASE BY SOMATOSTATIN.
190104 04-13

DISSOCIATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN PARKINSONS DISEASE FOLLOWING CHRONIC L-DOPA THERAPY.
191233 04-13

RETARDATION OF TUMOR GROWTH BY DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC).
191963 04-03

GSR
MARIJUANA DIMINISHES GSR ACTIVATION PEAKING.
181887 02-13

GUAM
PARKINSONISM DEMENTIA OF GUAM: TREATMENT WITH LEVODOPA AND L-ALPHA-METHYLDOPAHYDRAZINE.
179996 02-13

GUANETHIDINE
ADRENALINE, NORADRENALINE AND DOPAMINE LEVELS IN BRAIN AND HEART AFTER ADMINISTRATION OF 6-HYDROXYDOPAMINE AND GUANETHIDINE TO NEWBORN MICE.
177338 02-03

EFFECTS OF GUANETHIDINE AND IMIDAZOLE ON HISTAMINE RESPONSE.
187799 04-03

GUANOSINE
NEUROCHEMICAL ROLE OF ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AND GUANOSINE 3,5 CYCLIC MONOPHOSPHATE AND THEIR RELATION TO NEUROTRANSMITTERS; EFFECT OF TETRAHYDROCANNABINOLS. (PH.D. DISSERTATION).
185582 03-03

GUESSING
DRUGS AND PLACEBOS: DRUG GUESSING BY NORMAL VOLUNTEERS.
174210 01-14

GUIDE
A GUIDE FOR DRUG USE IN DEPRESSIVE DISORDERS.
171923 01-09

GUIDELINES
GUIDELINES FOR ANTIPSYCHOTIC DRUG USE.
186191 03-09

GUINEA-PIG
IN VIVO 3H-PROCHLORPERAZINE METABOLISM IN THE GUINEA-PIG AND RABBIT.
173875 01-03

EFFECT OF PROCAINE, LIDOCAINE AND PENTOBARBITAL ON ELECTRICAL ACTIVITY OF GUINEA-PIG OLFACTORY CORTEX IN VITRO.
182092 02-03

THE EFFECT OF CATECHOLAMINES, ACETYLCHOLINE AND SEROTONIN ON THE MORPHINE TOLERANT LONGITUDINAL MUSCLE STRIP OF THE GUINEA-PIG ILEUM.
182161 02-03

SEPARATION OF THE DEPENDENCE PRODUCING ACTIONS FROM THE DIRECT ACTIONS OF NARCOTICS ON GUINEA-PIG ILEUM.
182162 02-03

SPECIFICITY OF BLOCKADE OF THE NICOTINE INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ADRENERGIC NEURONS OF THE GUINEA-PIG HEART BY VARIOUS PHARMACOLOGICAL AGENTS.
186676 03-03

INTERACTION BETWEEN SEROTONIN AND MORPHINE IN THE GUINEA-PIG ILEUM.
186698 03-03

ALPHA-L-ACETYLMETHADOL AND ITS N-DEMTHYLATED METABOLITES HAVE POTENT OPIATE ACTION IN THE GUINEA-PIG ISOLATED ILEUM.
187130 03-03

NORADRENALINE IN THE GUINEA-PIG ALIMENTARY CANAL: REGIONAL DISTRIBUTION AND SENSITIVITY TO DENERVATION AND RESERPINE.
191326 04-03

GUINEA-PIGS
SUPPRESSION OF LORDOSIS IN GUINEA-PIGS BY ETHAMOXY-TRIPHETOL (MER-25) GIVEN AT LONG INTERVALS (36-46 HR) AFTER ESTRADIOL BENZOATE TREATMENT.
186686 03-04

INTESTINAL EFFECTS OF 5-HYDROXYTRYPTAMINE AND MORPHINE IN GUINEA-PIGS, DOGS, CATS AND MONKEYS.
188202 04-03

THE EFFECTS OF D-AMPHETAMINE ON THE INTERRESPONSE TIMES OF RATS AND GUINEA-PIGS ON A MODIFIED SIDMAN DISCRIMINATED AVOIDANCE SCHEDULE.
189519 04-04

EFFECTS OF NICOTINE ON THE SHUTTLEBOX BEHAVIOR OF TRAINED GUINEA-PIGS.
190333 04-04

EFFECT OF CHRONIC TREATMENT WITH CENTRAL STIMULANTS ON BRAIN MONOAMINES AND SOME BEHAVIOURAL AND PHYSIOLOGICAL FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS.
191503 04-03

GUNN
MORPHINE METABOLISM IN VIVO AND IN VITRO BY HOMOZYGOUS GUNN RATS.
183899 03-03

H-77-77
EVIDENCE FOR A NORADRENERGIC AND DOPAMINERGIC MECHANISM IN THE HYPERACTIVITY PRODUCED BY 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.
190309 04-04

HABITUATION
HABITUATION OF BLINK REFLEXES IN PARKINSONIAN PATIENTS UNDER LEVODOPA AND AMANTADINE TREATMENT.
171794 01-13

THE EFFECTS OF CHLORDIAZEPOXIDE (LIBRIUM) ON THE INTENSITY AND HABITUATION OF AGONISTIC BEHAVIOR IN MALE SIAMESE FIGHTING FISH.
177722 02-04

CHANGES IN ORIENTING AND HABITUATION IN THE RAT FOLLOWING ADMINISTRATION OF CHLORPROMAZINE.
191211 04-04

HALLUCINATIONS
MESCALINE HYPERREACTIVITY: HALLUCINATIONS IN RATS? (UNPUBLISHED PAPER).
178575 02-04

HALLUCINATORY
TREATMENT OF HALLUCINATORY DISORDERS IN SCHIZOPHRENIA BY ATROPINE COMAS.
181778 02-08

HALLUCINOGENIC
MOLECULAR ORBITAL STUDIES ON THE CONFORMATION OF HALLUCINOGENIC INDOLEALKYLAMINES AND RELATED COMPOUNDS. THE ISOLATED MOLECULES AND THE SOLVENT EFFECT.
183406 03-01

HALLUCINOGENIC DRUGS AND ARTISTIC CREATIVITY.
186026 03-12

HALLUCINOGENIC DRUG-INDUCED BEHAVIOR UNDER SENSORY ATTENUATION: PREDICTION OF RESPONSE TO PSILOCYBIN.
189744 04-12

CORTICAL AND/OR SUBCORTICAL EFFECTS AS A FUNCTION OF HALLUCINOGENIC DRUG STRUCTURE
191936 04-03

HALLUCINOGENS
PSYCHOPHARMACOLOGY OF HALLUCINOGENS.
180123 02-12

PSYCHOTHERAPY WITH HALLUCINOGENS.
180139 02-12

A HISTORY OF THE USE OF HALLUCINOGENS.
180141 02-12

THE MECHANISMS OF ACTION OF HALLUCINOGENS.
180142 02-12

INDIVIDUAL PSYCHOTHERAPY WITH HALLUCINOGENS.
180143 02-12

THE USE OF HALLUCINOGENS IN GROUP PSYCHOTHERAPY.
180144 02-12

RESULTS OF CLINICAL RESEARCH IN PSYCHOTHERAPY WITH HALLUCINOGENS.
180145 02-12

THE POSSIBLE ROLE OF TRYPTAMINE IN BRAIN FUNCTION AND ITS RELATIONSHIP TO THE ACTIONS OF LSD-LIKE HALLUCINOGENS.
186024 03-12

HALLUCINOGENS AS DISCRIMINATIVE STIMULI.
188229 04-12

THE BOTANY AND CHEMISTRY OF HALLUCINOGENS.
189101 04-12

A NOTE ON EPISTEMIC ORGANIZATION AND HALLUCINOGENS.
190240 04-17

HALLUCINOGENS, A RE-EVALUATION.
191938 04-03

HALOPERIDOL
POTENTIATION OF HALOPERIDOL BY ALPHA-METHYLDOPA IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
167343 01-08

VESTA VARIANT OF TOURETTES DISEASE: TREATMENT WITH HALOPERIDOL.
169286 01-10

HALOPERIDOL AND THE BUTYROPHENONES.
169296 01-09

HALOPERIDOL FOR PSYCHIATRIC DISORDERS IN CHILDREN.
169457 01-14

SAFETY AND EFFECTIVENESS OF HALOPERIDOL FOR MENTALLY RETARDED BEHAVIORALLY DISORDERED AND HYPERKINETIC PATIENTS.
169634 01-11

LOW DOSAGE HALOPERIDOL AND INDUCED ANXIETY IN NORMAL VOLUNTEERS.
169745 01-14

RAPID CONTROL OF PSYCHOTIC EXCITEMENT STATES WITH INTRAMUSCULAR HALOPERIDOL.
170627 01-09

HALOPERIDOL EFFECTS ON MORPHINE SELF-ADMINISTRATION: TESTING FOR PHARMACOLOGICAL MODIFICATION OF THE PRIMARY REINFORCEMENT MECHANISM.
172454 01-04

A COMPARATIVE TRIAL OF HALOPERIDOL AND THIORIDAZINE: MANAGEMENT OF CHRONIC SCHIZOPHRENIA.
172741 01-08

DELIRIOUS SYNDROME AFTER THE ADMINISTRATION OF HALOPERIDOL.
174784 01-15

MANAGEMENT OF HOSTILE, SUSPICIOUS PATIENTS. TRIFLUOPERAZINE VERSUS HALOPERIDOL.
176675 02-14

A STUDY OF ANTIOVULATORY ACTIVITY OF HALOPERIDOL IN RABBITS.
177021 02-03

A DOUBLE-BLIND COMPARISON OF FLUPHENAZINE AND HALOPERIDOL IN OUTPATIENT SCHIZOPHRENIC CHILDREN.
177754 02-08

PARENTERAL HALOPERIDOL FOR RAPID CONTROL OF SEVERE, DISRUPTIVE SYMPTOMS OF ACUTE SCHIZOPHRENIA.
178545 02-08

BEHAVIORAL EVIDENCE FOR DOPAMINERGIC SUPERSENSITIVITY AFTER CHRONIC HALOPERIDOL.
180021 02-04

DOUBLE-BLIND PSYCHOMETRIC EVALUATION OF PIMOZIDE AND HALOPERIDOL VERSUS PLACEBO IN EMOTIONALLY LABILE VOLUNTEERS UNDER TWO DIFFERENT WORK LOAD CONDITIONS.
180065 02-14

HALOPERIDOL (JANSSEN) IN THE TREATMENT OF UNSELECTED INSTITUTIONALIZED PSYCHIATRIC PATIENTS.
180299 02-11
EFFECT OF MORPHINE, HALOPERIDOL, APOMORPHINE AND BENZTROPINE ON DOPAMINE TURNOVER IN RAT CORPUS-STRIATUM: EVIDENCE SHOWING MORPHINE-INDUCED REDUCTION IN CNS DOPAMINERGIC ACTIVITY.
182230 03-03
TOLERANCE TO THE BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF HALOPERIDOL AND MORPHINE IN RATS CHRONICALLY TREATED WITH MORPHINE OR HALOPERIDOL.
184225 03-03
METHYLPHENIDATE ANTAGONISM OF HALOPERIDOL, INTERACTION WITH CHOLINERGIC AND ANTICHOLINERGIC DRUGS.
186370 03-04
EFFECT OF ANESTHETIC AGENTS ON THE SYNTHESIS AND DISAPPEARANCE OF BRAIN DOPAMINE NORMALLY AND AFTER HALOPERIDOL, KCL OR AXOTOMY.
189571 04-03
DIFFERENTIAL ANTAGONISM BY NALOXONE OF INHIBITORY EFFECTS OF HALOPERIDOL AND MORPHINE ON BRAIN SELF-STIMULATION.
190306 04-03
TARDIVE AND WITHDRAWAL DYSKINESIA ASSOCIATED WITH HALOPERIDOL.
191035 04-15
USE OF HALOPERIDOL (BROTOPON) IN THE TREATMENT OF SCHIZOPHRENIA.
191686 04-08
ACTION OF HALOPERIDOL AND TRIFLUOPERAZINE ON THE MOTOR RESPONSES ELICITED BY ELECTRICAL STIMULATION OF THE BRAIN IN RABBITS.
191787 04-02
POSITIVE REINFORCING EFFECTS OF APOMORPHINE, D-AMPHETAMINE AND MORPHINE: INTERACTION WITH HALOPERIDOL.
191899 04-04
SUPERSENSITIVITY TO DOPAMINERGIC AGONISTS FOLLOWING WITHDRAWAL OF A CHRONIC DIET CONTAINING HALOPERIDOL OR PIMOZIDE.
192012 04-04
HALOPERIDOL VERSUS THIORIDAZINE FOR THE TREATMENT OF PSYCHOGERIATRIC PATIENTS: A DOUBLE-BLIND CLINICAL STUDY.
192231 04-09
INTERACTION BETWEEN NEUROLEPTIC THERAPY AND SOCIOTHERAPEUTIC APPROACH. AN INVESTIGATION WITH PENFLURIDOL AND HALOPERIDOL.
192431 04-08

HALOTHANE
EFFECT OF GENERAL ANESTHETICS ON SYSTEMIC CATECHOLAMINE CONCENTRATION I: HALOTHANE. (UNPUBLISHED PAPER).
168862 01-05
INTERACTIONS OF DIAZEPAM AND HALOTHANE IN RATS.
171633 01-03
MICROVASCULAR SMOOTH MUSCLE HYPERRESPONSIVENESS DURING HALOTHANE ANESTHESIA IN THE RAT.
182185 02-03
ENDURING LEARNING DEFICITS AND CEREBRAL SYNAPTIC MALFORMATION FROM EXPOSURE TO 10 PARTS OF HALOTHANE PER MILLION.
192565 04-04

HAMSTER
COMPARATIVE EFFECTS OF SOME CNS ACTIVE DRUGS ON LEARNED AND UNLEARNED BEHAVIOR IN THE HAMSTER.
191976 04-04

HAMSTERS
POTENTIAL NEUROTRANSMITTERS AND RECEPTOR MECHANISMS INVOLVED IN THE CENTRAL CONTROL OF BODY TEMPERATURE IN HAMSTERS. (PH.D. DISSERTATION).
174962 01-03

HARM
PSYCHOTROPIC DRUGS -- HARM OR HELP.
190138 04-11

HASHISH
THE EFFECTS OF PHENITRONE, A REPORTED HASHISH ANTAGONIST, ON THE OVERT BEHAVIOR OF CATS.
174607 01-04
INTERACTION OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A PURPORTED HASHISH AND LSD ANTAGONIST, WITH SEVERAL CENTRAL NEUROCHEMICAL SYSTEMS.
182217 03-04
REDUCTION IN COPULATORY BEHAVIOR OF MALE RATS FOLLOWING HASHISH INJECTIONS.
183790 03-04
TEMPORAL DISORGANIZATION AND DELUSIONAL-LIKE IDEATION: PROCESSES INDUCED BY HASHISH AND ALCOHOL.
185330 03-14
RELUCTANCE OF RATS TO DRINK HASHISH SUSPENSIONS: FREE-CHOICE AND FORCED CONSUMPTION, AND THE EFFECTS OF HYPOTHALAMIC STIMULATION.
186586 03-04

HATCHABILITY
THE EFFECTS OF MESCALINE ADMINISTERED BEFORE OR DURING EMBRYOGENESIS UPON THE HATCHABILITY AND BEHAVIOR OF THE CHICK. (PH.D. DISSERTATION).
173791 01-04

HAZARD
THE USES AND RELATIVE HAZARD POTENTIAL OF PSYCHOACTIVE DRUGS.
190237 04-17

HAZARDS
HAZARDS OF LITHIUM PROPHYLAXIS.
191187 04-15

HCP
PROTECTION PRODUCED BY BENZODIAZEPINES (BDP) AGAINST THE NEUROTOXIC AND CONFLICT BEHAVIOR EFFECTS OF HEXACHLOROPHENE (HCP) IN CATS.
176863 02-04

HEADACHES
A NEW AGENT FOR CHEMOTHERAPY OF MIGRAINE HEADACHES: A CONTROLLED STUDY.
169298 01-11

HEALTH
LITHIUM AND MENTAL HEALTH.
178113 02-09
IN APPRECIATION OF BASIC BIOCHEMICAL RESEARCH IN MENTAL HEALTH. (UNPUBLISHED PAPER).
187488 04-17
FACTORS AFFECTING OUTCOME IN A SCHOOL MENTAL HEALTH SERVICE.
188567 04-11
PROPHYLACTIC EFFICACY OF LITHIUM CARBONATE IN MANIC-DEPRESSIVE ILLNESS: REPORT OF THE VETERANS ADMINISTRATION AND NATIONAL INSTITUTE OF MENTAL HEALTH (VA-NIMH) COLLABORATIVE STUDY GROUP.
189735 04-09

HEALTHY
DIAZEPAM AND MEPERIDINE ON ARTERIAL BLOOD GASES IN HEALTHY VOLUNTEERS.
190147 04-13

HEART
EEG, HEART RATE, AND MOOD CHANGE (HIGH) AFTER CANNABIS.
169068 01-13
THE CURARIZED RAT AND HEART RATE CONDITIONING: A CONSIDERATION OF RESPIRATION PARAMETERS AND NEUROMUSCULAR BLOCKING AGENTS IN A CLASSICAL CONDITIONING PARADIGM. (PH.D. DISSERTATION).
173133 01-03
ADRENALINE, NORADRENALINE AND DOPAMINE LEVELS IN BRAIN AND HEART AFTER ADMINISTRATION OF 6-HYDROXYDOPAMINE AND GUANETHIDINE TO NEWBORN MICE.
177338 02-03
ANTICHOLINERGICS: THEIR EFFECTS ON FEAR MOTIVATED BEHAVIOR, URINARY 11-HYDROXYCORTICOSTEROIDS, URINARY VOLUME, AND HEART RATE IN THE DOG.
178720 02-03
EFFECTS OF L-DELTA9-TETRAHYDROCANNABINOL, DL-AMPHETAMINE AND PENTOBARBITAL ON OXYGEN CONSUMPTION BY MOUSE BRAIN AND HEART HOMOGENATES.
181813 02-03
THE EFFECTS OF ACUTE ADMINISTRATION OF PROPRANOLOL AND PRACTOLOL ON THE UPTAKE, CONTENT, RELEASE AND TURNOVER OF NORADRENALINE IN THE RAT HEART IN VIVO.
184232 03-03
SPECIFICITY OF BLOCKADE OF THE NICOTINE INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ADRENERGIC NEURONS OF THE GUINEA-PIG HEART BY VARIOUS PHARMACOLOGICAL AGENTS.
186676 03-03
EFFECT OF IMIPRAMINE ON CULTURED RAT HEART CELLS.
188864 04-03
EFFECTS OF CHLORDIAZEPOXIDE ON HEART RATE AND BEHAVIOURAL SUPPRESSION IN PIGS SUBJECTED TO OPERANT CONDITIONING PROCEDURES.
189409 04-04
EXTRANEURONAL REMOVAL, ACCUMULATION AND O-METHYLATION OF ISOPRENALINE IN THE PERFUSED HEART.
189604 04-03
THE EFFECTS OF HOE-36801 ON CATECHOLAMINE EXCRETION, HEART RATE AND PSYCHOMOTOR PERFORMANCE IN NEUROTICS AND NORMALS.
192428 04-13

HEAT
HEAT DYSCONTROL SYNDROME IN PATIENTS RECEIVING ANTIPSYCHOTIC, ANTIDEPRESSANT AND ANTIPARKINSON DRUG THERAPY.
188094 04-15

HEBB-WILLIAMS
THE EFFECTS OF EARLY SALINE INJECTIONS AND PENTYLENETETRAZOL ON HEBB-WILLIAMS MAZE PERFORMANCE IN THE ADULT RAT.
191378 04-04

HEMICHOLINIUM-3
ACTIONS OF ATROPINE, HEMICHOLINIUM-3, AND PHYSOSTIGMINE ON CHLORPROMAZINE INDUCED CHANGES IN RAT BRAIN MONOAMINES.
187800 04-03

HEMOLYTIC
PHARMACOLOGICAL AND BIOCHEMICAL ACTIONS OF THE HEMOLYTIC AGENTS ACETYLPHENYLHYDRAZINE AND PHENYLHYDRAZINE ON MONOAMINE OXIDASE IN THE RAT.
188769 04-03

HEPATIC
INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY LITHIUM TREATMENT.
182727 03-03
EFFECT OF ORAL ADMINISTRATION OF METHADONE ON HEPATIC MICROSOMAL MIXED FUNCTION OXIDASE ACTIVITY IN MICE.
188178 04-03

HEPATOTOXICITY
EFFECT OF PHENOBARBITAL AND 3-METHYLCHOLANTHRENE PRETREATMENT ON THE HEPATOTOXICITY OF 1,1,1 TRICHLOROETHANE AND 1,1,2 TRICHLOROETHANE.
167361 01-05
REDUCTION BY PRETREATMENT WITH DIBENAMINE OF HEPATOTOXICITY INDUCED BY CARBON TETRACHLORIDE, THIOACETAMINDE OR DIMETHYLNITROSAMINE.
188865 04-05

HEPTABARBITAL
ABSORPTION AND CLEARANCE OF SECOBARBITAL, HEPTABARBITAL, METHAQUALONE, AND ETHINAMATE.
192575 04-13

HEROIN
USE OF PSYCHOTHERAPEUTIC DRUGS IN THE ACUTE DETOXIFICATION OF HEROIN ADDICTS.
169746 01-11
COMPARISON OF INTRAVENOUSLY ADMINISTERED METHADONE (ME), MORPHINE (MO), HEROIN (H) AND PLACEBO (P).
182163 02-03
VALIDITY OF SCREENING METHODS FOR DRUGS OF ABUSE IN BIOLOGICAL FLUIDS. II. HEROIN IN PLASMA AND SALIVA.
187256 03-15

HETEROCYCLIC
ALKALOID STUDIES. 9. PREPARATION OF 18-ACYLYOHIMBAN-17-ONES AND THEIR CONVERSION TO NEW HETEROCYCLIC YOHIMBANS.
185033 03-04

HETEROGENEITY
THE HETEROGENEITY OF DEPRESSION.
169093 01-09

HEXACHLOROPHENE
PROTECTION PRODUCED BY BENZODIAZEPINES (BDP) AGAINST THE NEUROTOXIC AND CONFLICT BEHAVIOR EFFECTS OF HEXACHLOROPHENE (HCP) IN CATS.
176863 02-04

HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE
THE SAFETY TEST OF 10-CHLORO-11B-(2-CHLOROPHENYL) 2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE (CS-370): SECOND REPORT, EFFECT OF CS-370 UPON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
168498 01-05
EFFECT OF A NEW PSYCHOTROPIC DRUG, CS-370 (10-CHLORO-11B-(2-CHLOROPHENYL)-2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE) UPON THE CENTRAL NERVOUS SYSTEM.
174603 01-03

HEXAHYDROPYRAZINOQUINOLINE
ANTIHYPERTENSIVE AND CENTRAL NERVOUS SYSTEM DEPRESSANT PROPERTIES OF 3-(GAMMA-P-FLUOROBENZOYLPROPYL) 2,3,4,4A,5,6 HEXAHYDROPYRAZINOQUINOLINE HYDROCHLORIDE (COMPOUND-69-183, CENTPYRAQUIN).
176881 02-03

HEXOBARBITAL
TOLERANCE TO HEXOBARBITAL AND SUPERSENSITIVITY TO PILOCARPINE INDUCED BY CHRONIC BARBITAL TREATMENT IN THE RAT.
171601 01-03
THE METABOLIC FATE OF HEXOBARBITAL IN THE RAT.
177732 02-03
EFFECT OF 6-HYDROXYDOPAMINE ON THE DURATION OF HEXOBARBITAL SLEEP IN RATS.
178558 02-03
ON THE MECHANISM OF THE SYNERGISTIC EFFECT OF PERAZINE AND HEXOBARBITAL.
184199 03-03
CANNABINOIDS AND HEXOBARBITAL INDUCED LOSS OF RIGHTING REFLEXES.
189573 04-04

HF-1972
DOUBLE-BLIND COMPARATIVE STUDY OF HF-1972/NOVERIL IN DEPRESSION.
180986 02-10

HIERARCHY
SOCIAL HIERARCHY IN MONKEYS (MACACA-MULATTA) MODIFIED BY CHLORDIAZEPOXIDE HYDROCHLORIDE.
183863 03-04

HINDPAW
EFFECTS OF PROSTAGLANDINS B1 AND B2 ON VASOCONSTRICTOR RESPONSES OF THE CANINE HINDPAW.
189395 04-03

HIPPOCAMPAL
HIPPOCAMPAL LESIONS AND LEARNED TASTE AVERSION.
184834 03-04
DIFFERENTIAL RECOVERY OF FUNCTION FOLLOWING CAUDATE, HIPPOCAMPAL, AND SEPTAL LESIONS IN MICE.
186620 03-04
THE ANTAGONISM OF HIPPOCAMPAL AND CORTICAL AFTERDISCHARGE BY SC-13504, A NEW ANTICONVULSANT.
186632 03-03
EFFECTS OF LOCUS-COERULEUS STIMULATION ON HIPPOCAMPAL UNIT ACTIVITY AND ON BEHAVIOR IN UNRESTRAINED RATS. (UNPUBLISHED PAPER).
187499 04-04
A FREQUENCY SHIFT IN THE HIPPOCAMPAL THETA ACTIVITY: AN ELECTRICAL CORRELATE OF CENTRAL ACTION OF ACTH ANALOGUES IN THE DOG
188166 04-04
EFFECT OF ANTICONVULSANT DRUGS ON THE NUMBER OF AFFERENT STIMULI NEEDED TO CAUSE A HIPPOCAMPAL SEIZURE DISCHARGE.
189608 04-03
EFFECT OF SEIZURES AND ANTICONVULSANT AGENTS ON HIPPOCAMPAL RNA CONCENTRATION.
189609 04-03
5-HYDROXYTRYPTAMINE AND NORADRENALINE IN THE HIPPOCAMPAL REGION: EFFECT OF TRANSECTION OF AFFERENT PATHWAYS ON ENDOGENOUS LEVELS, HIGH AFFINITY UPTAKE AND SOME TRANSMITTER RELATED ENZYMES.
191319 04-03

HIPPOCAMPUS
EFFECTS OF FOOD DEPRIVATION, DISCRIMINATION EXPERIENCE AND PHYSOSTIGMINE ON CHOLINE ACETYLASE AND ACETYLCHOLINE ESTERASE IN THE DORSAL HIPPOCAMPUS AND FRONTAL CORTEX OF RATS.
169467 01-03
MODULATORY EFFECTS OF CORTICOSTEROIDS ON EVOKED ACTIVITY IN THE HIPPOCAMPUS AND THALAMUS OF THE RAT.
182119 02-03
IN VIVO MEASUREMENT OF THE RELEASE OF 5-HYDROXYTRYPTAMINE (5-HT) FROM THE HIPPOCAMPUS OF THE RAT: EFFECT OF RO-4-1284, PARGYLINE AND P-CHLOROAMPHETAMINE (PCA).
182140 02-03
LITHIUM AND THE MONOAMINE NEUROTRANSMITTERS IN THE RAT HIPPOCAMPUS.
190829 04-03

HISTAMINE
DECREASED HISTAMINE SYNTHESIS IN THE RAT BRAIN BY HYPNOTICS AND ANESTHETICS.
168750 01-03
5-HYDROXYTRYPTAMINE AND HISTAMINE EFFECTS ON RETICULOCEREBELLAR EVOKED POTENTIALS.
182121 02-03
EFFECTS OF GUANETHIDINE AND IMIDAZOLE ON HISTAMINE RESPONSE.
187799 04-03
TURNOVER OF HISTAMINE IN RAT BRAIN AND ITS DECREASE UNDER BARBITURATE ANESTHESIA.
189396 04-03
EFFECTS OF ADRENERGIC AGENTS, THEOPHYLLINE AND OTHER DRUGS ON DEXTRAN EDEMA AND HISTAMINE RELEASE IN RATS.
189895 04-03

HISTO-AUTORADIOGRAPHIC
HISTO-AUTORADIOGRAPHIC INVESTIGATIONS ON THE DISTRIBUTION OF INJECTED 5-HYDROXYTRYPTAMINE (SEROTONIN) IN THE BRAIN AND THE PITUITARY OF MICE.
185900 03-03

HISTOCHEMICAL
QUANTITATIVE HISTOCHEMICAL STUDIES OF STRIATAL DOPAMINE DEPLETION FOLLOWING DL-ALPHA-METHYL-P-TYROSINE ADMINISTRATION.
172924 01-03

HISTOCHEMICALLY
HYDROCORTISONE INDUCED INCREASE IN THE HISTOCHEMICALLY DEMONSTRABLE CATECHOLAMINE CONTENT OF SYMPATHETIC NEURONS OF THE NEWBORN RAT.
189027 04-03

HISTOLOGY
EFFECTS OF SHORT-TERM ADMINISTRATION OF N-NITROSO COMPOUNDS ON LIVER HISTOLOGY AND PENTOBARBITAL INDUCED SLEEPING TIME IN MICE.
187575 04-04

HISTORY
RELATIONSHIP BETWEEN THE EFFECTIVENESS OF LITHIUM THERAPY AND FAMILY HISTORY.
169494 01-09
A HISTORY OF THE USE OF HALLUCINOGENS.
180141 02-12

HOE-36801
THE EFFECTS OF HOE-36801 ON CATECHOLAMINE EXCRETION, HEART RATE AND PSYCHOMOTOR PERFORMANCE IN NEUROTICS AND NORMALS.
192428 04-13
THE EFFECTS OF HOE-36801 ON MUSCLE ACTIVITY AND BLOOD PRESSURE, ON ATTENTION AND CONCENTRATION, ON TIME JUDGMENT AND SUBJECTIVE RESPONSES IN NEUROTICS AND NORMALS.
192429 04-14

HOE-984
EFFECTS OF NOMIFENSINE (HOE-984), D-AMPHETAMINE AND APOMORPHINE ON MOTOR ACTIVITY, CATECHOLAMINE TURNOVER AND CAMP CONCENTRATIONS IN RAT BRAIN. (UNPUBLISHED PAPER).
191766 04-03

HOME
THE EFFECT OF LORAZEPAM ON ANXIOUS INSOMNIACS SLEEP AS RECORDED IN THE HOME ENVIRONMENT.
177318 02-14

HOMEOSTASIS
EFFECTS ON HOMEOSTASIS OF INTRAVENTRICULAR INJECTIONS OF 6-HYDROXYDOPAMINE IN RATS.
187695 04-03

HOMOGENATE
INABILITY OF RAT BRAIN HOMOGENATE TO OXIDIZE AMPHETAMINE.
177334 02-03

HOMOGENATES
STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF 5-HT UPTAKE INTO RAT HYPOTHALAMIC HOMOGENATES BY SEROTONIN AND TRYPTAMINE ANALOGUES.
175233 02-03
EFFECTS OF L-DELTA9-TETRAHYDROCANNABINOL, DL-AMPHETAMINE AND PENTOBARBITAL ON OXYGEN CONSUMPTION BY MOUSE BRAIN AND HEART HOMOGENATES.
181813 02-03
ANTICONVULSANT ACTIVITY AND INHIBITION OF RESPIRATION IN RAT BRAIN HOMOGENATES BY SUBSTITUTED OXADIAZOLES.
185980 03-01
STIMULATION OF A DOPAMINE SENSITIVE ADENYLATE CYCLASE IN HOMOGENATES OF RAT STRIATUM BY A METABOLITE OF PIRIBEDIL (ET-495).
189616 04-03

HOMOISO
MASS FRAGMENTOGRAPHIC ANALYSIS OF HOMOVANILLIC ACID AND ITS HOMOISO ANALOGUE IN CEREBROSPINAL FLUID USING THE ALPHA DIDEUTERO ACID AS INTERNAL STANDARD.
186566 03-16

HOMOVANILLIC
THE EFFECT OF PROBENECID AND LARGE DOSE AMPHETAMINE ADMINISTRATION ON CEREBROSPINAL FLUID HOMOVANILLIC ACID.
177826 02-13
CATALEPSY AND STEREOTYPED BEHAVIOUR IN RATS TREATED CHRONICALLY WITH METHADONE: RELATION TO BRAIN HOMOVANILLIC ACID CONTENT.
183606 03-04
THE EFFECT OF CHLORPROMAZINE ON HOMOVANILLIC ACID LEVELS IN CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS.
186565 03-08
MASS FRAGMENTOGRAPHIC ANALYSIS OF HOMOVANILLIC ACID AND ITS HOMOISO ANALOGUE IN CEREBROSPINAL FLUID USING THE ALPHA DIDEUTERO ACID AS INTERNAL STANDARD.
186566 03-16
EFFECT OF PIRIBEDIL AND ONE OF ITS METABOLITES ON THE CONCENTRATION OF HOMOVANILLIC ACID IN THE RAT BRAIN.
191422 04-03

HOMOZYGOUS
MORPHINE METABOLISM IN VIVO AND IN VITRO BY HOMOZYGOUS GUNN RATS.
183899 03-03

HONG-KONG
PSYCHOTROPIC MEDICATION IN HONG-KONG.
180321 02-17

HORIZON
EXPERIENCE IN THE DRUG HORIZON AND PSYCHIATRIC INTERVIEW.
176542 02-11

HORIZONS
NEW HORIZONS IN PSYCHOPHARMACOLOGY.
176926 02-17

HORMONE
GROWTH HORMONE RESPONSES TO ADMINISTRATION OF L-5-HYDROXYTRYPTOPHAN (L-5-HTP) IN MANIC-DEPRESSIVE PSYCHOSES.
167919 01-09
MELANOCYTE STIMULATING HORMONE RELEASE INHIBITING HORMONE AS AN ANTIDEPRESSANT: A PILOT STUDY.
171501 01-09
FUNCTIONAL EVALUATION OF PITUITARY RESERVE IN PATIENTS WITH THE AMENORRHEA GALACTORRHEA SYNDROME UTILIZING LUTEINIZING HORMONE RELEASING HORMONE (LH-RH), L-DOPA AND CHLORPROMAZINE.
175245 02-13
TESTOSTERONE AND LUTEINIZING HORMONE (LH) IN UNTREATED AND METHADONE MAINTAINED NARCOTIC ADDICTS.
182166 02-13
INFLUENCE OF TETRACOSACTRIN (T) AND BETA-MELANOCYTE STIMULATING HORMONE (MSH) ON DEPRESSION OF THE SEGMENTAL REFLEX BY MORPHINE (MS). (UNPUBLISHED PAPER).
183324 03-03
THE EFFECT OF ZINC N TETRACOSACTRIN ON GROWTH HORMONE RELEASE DURING SLEEP.
183490 03-13
PLASMA LEVELS OF LUTEINIZING HORMONE AND OF IMMUNOREACTIVE ESTROGENS (ESTRADIOL) IN ANOREXIA-NERVOSA: RESPONSE TO CLOMIPHENE CITRATE.
183807 03-10
A PRELIMINARY STUDY ON THE ACTION OF THYROTROPINE RELEASING HORMONE OR TRH IN DEPRESSIVE STATES.
184962 03-09
THE EFFECT OF LITHIUM ON HORMONE SENSITIVE ADENYLATE CYCLASE FROM VARIOUS REGIONS OF THE RAT BRAIN.
187110 03-03
A DOUBLE-BLIND CROSSOVER SEQUENTIAL TRIAL OF ORAL THYROTROPIN RELEASING HORMONE IN DEPRESSION.
188348 04-09
ROLE OF DOPAMINERGIC MECHANISMS IN REGULATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN MAN.
188428 04-13
EFFECTS OF LSD AND MONOAMINE SYNTHESIS INHIBITORS ON HORMONE ACTIVATED COPULATORY BEHAVIOR IN THE FEMALE RAT.
188611 04-04
AFFECTIVE STATE AND THYROTROPIN AND PROLACTIN RESPONSES AFTER REPEATED INJECTIONS OF THYROTROPIN RELEASING HORMONE IN DEPRESSED PATIENTS.
189076 04-09
INHIBITION OF THE SLEEP RELATED PEAK IN PHYSIOLOGIC HUMAN GROWTH HORMONE RELEASE BY SOMATOSTATIN.
190104 04-13
DISSOCIATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN PARKINSONS DISEASE FOLLOWING CHRONIC L-DOPA THERAPY.
191233 04-13
THYROTROPHIN RELEASING HORMONE IN THE TREATMENT OF DEPRESSION.
192577 04-09

HORMONES
INFLUENCE OF PHENOBARBITAL AND SEX HORMONES ON ENZYMES IN ASCORBIC ACID BIOSYNTHESIS IN MALE AND FEMALE RATS. (PH.D. DISSERTATION).
172017 01-03
THE RATE LIMITING CONTROL OF ENZYMES MONOAMINE OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN THE FETUS AND THE ADULT BY ADRENOCORTICOL HORMONES.
178815 02-03

HOSPITAL
A PROGRAMME WHICH LED TO REDUCTION IN NIGHT SEDATION IN A MAJOR HOSPITAL.
170802 01-17
DEPRESSION SUBTYPES AND RESPONSE TO PHENELZINE, DIAZEPAM, AND A PLACEBO: RESULTS OF A NINE HOSPITAL COLLABORATIVE STUDY.
171502 01-09
REHABILITATION OF LEARNING IN A HOSPITAL CLASS USING PSYCHOACTIVE DRUGS.
174071 01-11

HOSPITALISED
EXPERIENCES WITH FLUPHENAZINE ENANTHATE IN LONG-STAY HOSPITALISED SCHIZOPHRENICS.
171985 01-08

HOSPITALIZATION
DRUG TREATMENT OF DEPRESSED PATIENTS REFERRED FOR HOSPITALIZATION.
170621 01-09

HOSPITALIZED
A DOUBLE-BLIND INVESTIGATION OF DIMETHACRINE VERSUS IMIPRAMINE IN HOSPITALIZED DEPRESSIVE STATES.
171695 01-09
WITHDRAWAL OF MAINTENANCE DRUGS WITH LONG-TERM HOSPITALIZED MENTAL PATIENTS: A CRITICAL REVIEW.
175862 02-17
PIMOZIDE IN THE TREATMENT OF BEHAVIORAL DISORDERS OF HOSPITALIZED ADOLESCENTS.
176109 02-14

EXPERIENCES WITH FLUPHENAZINE ENANTHATE IN LONG-STAY HOSPITALIZED SCHIZOPHRENICS.
180154 02-08

END OF A BACK WARD: THE RAPID REHABILITATION AND RELEASE OF CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS.
181153 02-08

CLINICAL STUDY ON THE EFFECTS OF THIOTHIXENE IN HOSPITALIZED PSYCHOTIC PATIENTS.
183955 03-08

CLINICAL EXPERIENCES WITH MESORIDAZINE (TPS-23): ITS ADMINISTRATION TO HOSPITALIZED SCHIZOPHRENIC PATIENTS.
188934 04-08

HOSPITALS

CLINICAL TRIAL WITH NOZINAN-R. AT SEVERAL MENTAL HOSPITALS IN JAVA.
176582 02-11

HOSTILE

MANAGEMENT OF HOSTILE, SUSPICIOUS PATIENTS. TRIFLUOPERAZINE VERSUS HALOPERIDOL.
176675 02-14

HOSTILITY

THE EFFECT OF MARIJUANA ON HOSTILITY IN AN EXPERIMENTAL GROUP SETTING: PRELIMINARY OBSERVATIONS.
169086 01-14

EFFECTS OF DIPHENYLHYDANTOIN ON ANXIETY AND HOSTILITY IN INSTITUTIONALIZED PRISONERS.
177671 02-11

CHLORDIAZEPOXIDE AND HOSTILITY IN ANXIOUS OUTPATIENTS.
181273 02-10

RELATIONSHIP OF PLASMA MEPERIDINE LEVELS TO CHANGES IN ANXIETY AND HOSTILITY.
185881 03-14

HOUSED

BRAIN TO SERUM DISTRIBUTION OF RADIOACTIVITY OF INJECTED 3H-D-AMPHETAMINE IN DIFFERENTIALLY HOUSED MICE.
168418 01-03

HOUSING

THE EFFECTS OF EARLY P-CHLOROPHENYLALANINE ADMINISTRATION AND POSTWEANING HOUSING CONDITIONS ON SEROTONIN AND BEHAVIOR IN RATS.
178638 02-04

HUMAN

OPERANT BEHAVIOR AND NEUROPHYSIOLOGICAL OBSERVATIONS OF NORMAL HUMAN VOLUNTEERS RECEIVING CL-1848C, A NEW DISSOCIATIVE ANESTHETIC.
167334 01-07

THE EFFECT OF PLACEBO AND DRUGS ON HUMAN SLEEP.
168419 01-14

METABOLITES OF BROMAZEPAM, A BENZODIAZEPINE, IN THE HUMAN, DOG, RAT, AND MOUSE.
170837 01-03

DMT ADMINISTRATION TO HUMAN SUBJECTS. (UNPUBLISHED PAPER).
173522 01-12

REINVESTIGATION ON THE EFFECTS OF THIOPENTAL ON THE HUMAN SOMATOSENSORY EVOKED RESPONSE.
174505 01-13

INTERACTION OF PHENOTHIAZINE DERIVATIVES WITH HUMAN CERULOPLASMIN.
177335 02-13

AMPHETAMINE IN HUMAN PLASMA: A SENSITIVE AND SPECIFIC ENZYMATIC ASSAY.
177403 02-16

EFFECT OF ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL ON MEMORY, SPEECH, AND PERCEPTION OF THERMAL STIMULATION: RESULTS WITH FOUR NORMAL HUMAN VOLUNTEER SUBJECTS. PRELIMINARY REPORT.
177674 02-14

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: IV. THE EFFECTS OF CHLORPROMAZINE.
177716 02-14

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: V. THE EFFECTS OF CHLORAL HYDRATE.
177717 02-14

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: VI. THE EFFECTS OF CHLORDIAZEPOXIDE.
177718 02-14

STRUCTURAL FUNCTIONAL ORGANIZATION OF THE HUMAN BRAIN AND THE PATHOPHYSIOLOGY OF THE PARKINSONIAN TYPE HYPERKINESES.
178787 02-13

BINDING OF DIAZOXIDE AND OTHER BENZOTHIADIAZINES TO HUMAN ALBUMIN.
179987 02-13

EFFECTS OF CHLORPROMAZINE AND ACTINOMYCIN D ON UPTAKE AND INCORPORATION OF CERTAIN AMINO ACIDS, HYPOXANTHINE AND THYMIDINE IN CULTURES OF HUMAN SKIN EPITHELIAL CELLS.
179989 02-13

ISOLATION OF A POSSIBLE NEW METABOLITE OF THIORIDAZINE AND MESORIDAZINE FROM HUMAN PLASMA.
182722 03-13

QUANTITATIVE DETERMINATION OF IMIPRAMINE AND DESIPRAMINE IN HUMAN BLOOD PLASMA BY DIRECT DENSITOMETRY OF THIN-LAYER CHROMATOGRAMS.
183603 03-13

IMIPRAMINE AND ITS METABOLITES IN HUMAN BRAIN.
183604 03-13

MUTAGENICITY EXPERIMENTS WITH THE TRANQUILLIZER MEPROBAMATE IN DROSOPHILA-MELANOGASTER AND IN HUMAN LEUKOCYTE CHROMOSOMES IN VITRO.
184585 03-05

PERPHENAZINE CONCENTRATIONS IN HUMAN WHOLE BLOOD: A PILOT STUDY DURING ANTIPSYCHOTIC THERAPY USING DIFFERENT ADMINISTRATION FORMS.
187639 04-16

INFLUENCE OF PH ON THE BENZODIAZEPINE HUMAN SERUM ALBUMIN COMPLEX: CIRCULAR DICHROISM STUDIES.
189595 04-13

INHIBITION OF THE SLEEP RELATED PEAK IN PHYSIOLOGIC HUMAN GROWTH HORMONE RELEASE BY SOMATOSTATIN.
190104 04-13

MONOAMINE OXIDASE IN MAN: ENZYME CHARACTERISTICS IN HUMAN PLATELETS, PLASMA, AND OTHER HUMAN TISSUES.
191502 04-13

HUMAN SERUM DOPAMINE-BETA-HYDROXYLASE: RELATIONSHIP TO SYMPATHETIC ACTIVITY IN PHYSIOLOGICAL AND PATHOLOGICAL STATES.
191510 04-13

POST-MORTEM MEASUREMENT OF ENZYMES IN HUMAN BRAIN: EVIDENCE OF A CENTRAL NORADRENERGIC DEFICIT IN SCHIZOPHRENIA.
191529 04-13

INFLUENCE OF VARIOUS SUBSTANCES WHICH INDUCE AND INHIBIT AGGREGATION ON THE UPTAKE OF DEOXYGLUCOSE BY HUMAN BLOOD PLATELETS.
191770 04-13

HUMANS

INCREASE IN THE PLASMA CONCENTRATION OF FREE TRYPTOPHAN CAUSED BY PROBENECID IN HUMANS.
169470 01-13

RUBIDIUM SALTS -- TOXIC EFFECTS IN HUMANS AND CLINICAL EFFECTS AS AN ANTIDEPRESSANT DRUG.
182443 03-09

REPEAT ADMINISTRATION OF MARIHUANA SMOKE TO HUMANS.
188120 04-13

PHARMACOKINETICS AND DISTRIBUTION PROPERTIES OF PENTOBARBITAL IN HUMANS FOLLOWING ORAL AND INTRAVENOUS ADMINISTRATION.
191444 04-13

CHANGES IN RHYTHMS OF BIOELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX IN HUMANS UNDER THE INFLUENCE OF ETHYMISOL.
191790 04-07

HUNGER

PREDATION: SEPARATION OF AGGRESSIVE AND HUNGER MOTIVATION BY CONDITIONED AVERSION.
185463 03-04

HUNTINGTONS

HUNTINGTONS CHOREA: THE RIGID FORM (WESTPHAL VARIANT) TREATED WITH LEVODOPA.
187618 04-11

HUNTINGTONS CHOREA TREATED WITH LITHIUM CARBONATE.
187985 04-11

HVA

LEVELS OF HVA IN MOUSE BRAIN FOLLOWING TREATMENT WITH METABOLITES OF CHLORPROMAZINE.
171626 01-03

HYDE

METHAQUALONE -- A DR. JEKYLL AND MR. HYDE?
177396 02-15

HYDERGINE

PSYCHOPATHOLOGICAL IMPORTANCE AND THERAPEUTIC EFFECTS OF A COMBINATION OF HYDERGINE AND THIORIDAZINE IN PSYCHIATRIC SYNDROMES IN THE AGING.
168976 01-14

AN ERGOT ALKALOID PREPARATION (HYDERGINE) VERSUS PAPAVERINE IN TREATING COMMON COMPLAINTS OF THE AGED: DOUBLE-BLIND STUDY.
173190 01-11

HYDRATE

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: V. THE EFFECTS OF CHLORAL HYDRATE.
177717 02-14

CONVERSION OF CHLORAL HYDRATE TO TRICHLOROETHANOL IN BRAIN AND LIVER.
182157 02-03

HYDROCORTISONE

HYDROCORTISONE INDUCED INCREASE IN THE HISTOCHEMICALLY DEMONSTRABLE CATECHOLAMINE CONTENT OF SYMPATHETIC NEURONS OF THE NEWBORN RAT.
189027 04-03

HYDROGEN
INTRACEREBRAL INJECTION OF 6-HYDROXYDOPAMINE AND HYDROGEN PEROXIDE IN CATS: SPECIFIC AND NONSPECIFIC EFFECTS ON STRIATAL BIOGENIC AMINES.
188426 04-03

HYDROPHOBICITY
THE ROLE OF HYDROPHOBICITY IN THE ANTISEROTONIN ACTIVITY OF LSD ANALOGS.
174606 01-12

HYDROXYANISOLE
THE EFFECT OF BUTYLATED HYDROXYANISOLE AND BUTYLATED HYDROXYTOLUENE ON BEHAVIORAL DEVELOPMENT OF MICE.
188637 04-04

HYDROXYAPORPHINES
SYNTHESIS OF HYDROXYAPORPHINES AS POTENTIAL ANTIPARKINSONIAN AGENTS. (PH.D. DISSERTATION).
174967 02-01

HYDROXYLAMINE
HYDROXYLAMINE INTERFERES WITH THE BEHAVIORAL RESPONSE TO MORPHINE DEPENDENCE IN MICE.
171905 01-04

HYDROXYLAMINO
METABOLISM OF CHLORPHENTERMINE AND PHENTERMINE IN MAN TO YIELD HYDROXYLAMINO, C-NITROSO AND NITRO COMPOUNDS.
183796 03-13

HYDROXYLASE
SPECIFIC ACTIVATION OF STRIATAL TYROSINE HYDROXYLASE (TH) BY NEUROLEPTICS. (UNPUBLISHED PAPER).
170755 01-03
TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER).
170876 01-03
DISSOCIATION OF STIMULATORY AND SYNTHETIC PHASES IN THE INDUCTION OF TYROSINE HYDROXYLASE.
171785 01-03
DRUG-INDUCED ACTIVATION OF STRIATAL TYROSINE HYDROXYLASE: CHANGES IN THE AFFINITY FOR PTERIDINE COFACTORS. (UNPUBLISHED PAPER).
173381 01-03
NOREPINEPHRINE SENSITIVE ADENYLATE CYCLASES IN RAT BRAIN: RELATION TO BEHAVIOR AND TYROSINE HYDROXYLASE.
177252 02-03
A SENSITIVE, SIMPLE METHOD FOR MEASUREMENT OF TYROSINE HYDROXYLASE AND TRYPTOPHAN-5-HYDROXYLASE ACTIVITIES.
182178 02-06
INFLUENCE OF METHAMPHETAMINE AND NEUROLEPTIC DRUGS ON TYROSINE HYDROXYLASE ACTIVITY.
184180 03-03
EFFECTS OF AMPHETAMINES ON REGIONAL TRYPTOPHAN HYDROXYLASE ACTIVITY AND SYNAPTOSOMAL CONVERSION OF TRYPTOPHAN TO 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
186674 03-03
EVIDENCE FOR A CRITICAL PERIOD FOR POSTNATAL ELEVATION OF BRAIN TYROSINE HYDROXYLASE ACTIVITY RESULTING FROM RESERPINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT.
186695 03-03
COMPARISON OF TYROSINE HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION WITH THE EFFECTS OF VARIOUS 6-HYDROXYDOPAMINE TREATMENTS ON D-AMPHETAMINE INDUCED MOTOR ACTIVITY.
186699 03-03
DEPLETION OF TRYPTOPHAN HYDROXYLASE BY 5,6 DIHYDROXYTRYPTAMINE IN RAT BRAIN -- TIME COURSE AND REGIONAL DIFFERENCES.
188287 04-03
THE EFFECT OF P-CHLOROPHENYLALANINE ON FOREBRAIN TRYPTOPHAN HYDROXYLASE IN RATS WITH LESIONS IN THE RAPHE NUCLEUS.
188750 04-03
SHORT-TERM CONTROL OF TYROSINE HYDROXYLASE.
191513 04-03
SHORT-TERM AND LONG-TERM REGULATION OF TYROSINE HYDROXYLASE.
191515 04-03
REGULATION OF FUNCTION OF TRYPTOPHAN HYDROXYLASE.
191516 04-03
ACTIVATION OF STRIATAL HYDROXYLASE BY HYDROXYLATED METABOLITES OF CHLORPROMAZINE.
191908 04-03

HYDROXYLASES
STRIATAL TYROSINE HYDROXYLASES WITH HIGH AND LOW AFFINITY FOR TYROSINE: IMPLICATIONS FOR THE MULTIPLE POOL CONCEPT OF CATECHOLAMINES.
167325 01-03

HYDROXYLATED
EFFECTS OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES ON CENTRAL NORADRENERGIC MECHANISMS. (PH.D. DISSERTATION).
174959 01-03
ACTIVATION OF STRIATAL HYDROXYLASE BY HYDROXYLATED METABOLITES OF CHLORPROMAZINE.
191908 04-03

HYDROXYLATION
EFFECT OF CHLORIMIPRAMINE ON THE RATE OF TRYPTOPHAN HYDROXYLATION IN THE INTACT AND TRANSECTED SPINAL CORD.
168751 01-03
AMPHETAMINE TRICYCLIC INTERACTIONS: ROLE OF THE HYDROXYLATION OF AMPHETAMINE IN ITS CENTRAL AND PERIPHERAL MODE OF ACTION. (PH.D. DISSERTATION).
174963 01-03
THE HYDROXYLATION OF D-AMPHETAMINE BY LIVER MICROSOMES OF THE MALE RAT.
177337 02-03
IN VIVO ESTIMATION OF TYROSINE HYDROXYLATION IN THE DOPAMINERGIC TERMINALS OF THE RAT NEOSTRIATUM.
183794 03-03
REGIONAL CHANGES IN MONOAMINE LEVELS AND IN THE RATE OF TYROSINE AND TRYPTOPHAN HYDROXYLATION IN 4 WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
185899 03-03

HYDROXYTOLUENE
THE EFFECT OF BUTYLATED HYDROXYANISOLE AND BUTYLATED HYDROXYTOLUENE ON BEHAVIORAL DEVELOPMENT OF MICE.
188637 04-04

HYDROXYTRYPTOPHAN
BEHAVIORAL EFFECT OF TRICYCLIC THYMOLEPTICS AND CHLORPHENIRAMINE IN MICE AFTER PRETREATMENT WITH 5 HYDROXYTRYPTOPHAN (5-HTP).
171609 01-04

HYDROXYZINE
THE ORAL HYPNOTIC BIOASSAY OF HYDROXYZINE AND PENTOBARBITAL FOR NIGHTTIME SEDATION.
177320 02-11

HYPERACTIVATING
TOLERANCE TO THE HYPERACTIVATING EFFECTS OF METHYLAMPHETAMINE.
186702 03-04

HYPERACTIVE
EFFECTS OF MEDICATION ON LEARNING IN HYPERACTIVE FOUR-YEAR-OLD CHILDREN. (ED.D DISSERTATION).
172512 01-11
SIDE-EFFECTS OF DEXTROAMPHETAMINE THERAPY OF HYPERACTIVE CHILDREN.
176238 02-15
CONTROL OF THE HYPERACTIVE CHILD VIA MEDICATION -- AT WHAT COST TO PERSONALITY DEVELOPMENT; SOME PSYCHOLOGICAL IMPLICATIONS AND CLINICAL INTERVENTIONS.
176810 02-11
DEXTROAMPHETAMINE AND METHYLPHENIDATE IN THE TREATMENT OF HYPERACTIVE/AGGRESSIVE CHILDREN.
177771 02-14
RESPONSE TO STIMULANT DRUG TREATMENT IN HYPERACTIVE CHILDREN: PREDICTION FROM EEG AND NEUROLOGICAL FINDINGS.
177778 02-11
OUTPATIENT TREATMENT OF HYPERACTIVE SCHOOL CHILDREN WITH IMIPRAMINE.
184174 03-11
IMIPRAMINE AND METHYLPHENIDATE TREATMENTS OF HYPERACTIVE BOYS: A DOUBLE-BLIND COMPARISON.
185324 03-14
DOSE EFFECTS OF METHYLPHENIDATE ON BEHAVIORAL INHIBITION AND ACTIVATION IN HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
185676 03-14
EFFECTS OF METHYLPHENIDATE ON HYPERACTIVE CHILDRENS SLEEP.
190321 04-14
ELECTRODERMAL ACTIVITY IN HYPERACTIVE BOYS WHO ARE METHYLPHENIDATE RESPONDERS.
191400 04-14
INCREASED BRAIN NOREPINEPHRINE TURNOVER IN LEAD EXPOSED HYPERACTIVE RATS.
191957 04-05

HYPERACTIVES
METHYLPHENIDATE AND THE ACTIVITY OF HYPERACTIVES IN THE INFORMAL SETTING.
181853 02-14

HYPERACTIVITY
LEAD INDUCED BEHAVIORAL DYSFUNCTION: AN ANIMAL MODEL OF HYPERACTIVITY.
184953 03-04
EVIDENCE FOR A NORADRENERGIC AND DOPAMINERGIC MECHANISM IN THE HYPERACTIVITY PRODUCED BY 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.
190309 04-04
CHOLINERGIC AMINERGIC INTERACTIONS IN LEAD INDUCED HYPERACTIVITY.
191954 04-05

HYPERKINESES
STRUCTURAL FUNCTIONAL ORGANIZATION OF THE HUMAN BRAIN AND THE PATHOPHYSIOLOGY OF THE PARKINSONIAN TYPE HYPERKINESES.
178787 02-13

HYPERKINETIC
SAFETY AND EFFECTIVENESS OF HALOPERIDOL FOR MENTALLY RETARDED BEHAVIORALLY DISORDERED AND HYPERKINETIC PATIENTS.
169634 01-11
HYPERKINETIC, HYPOSCHOLASTIC BEHAVIOUR AND CHARACTER DISORDERS OF CHILDHOOD AND ADOLESCENCE: DIAGNOSIS AND PHARMACOTHERAPY.
172800 01-11

HYPERPHAGIA
CHLORPROMAZINE INDUCED HYPERPHAGIA. (UNPUBLISHED PAPER).
187498 04-04

HYPERREACTIVITY
MESCALINE HYPERREACTIVITY: HALLUCINATIONS IN RATS? (UNPUBLISHED PAPER).
178575 02-04
ANALGESIA AND HYPERREACTIVITY PRODUCED BY INTRACRANIAL MICROINJECTIONS OF MORPHINE INTO THE PERIAQUEDUCTAL GRAY MATTER OF THE RAT.
191367 04-04

HYPERRESPONSIVENESS
MICROVASCULAR SMOOTH MUSCLE HYPERRESPONSIVENESS DURING HALOTHANE ANESTHESIA IN THE RAT.
182185 02-03

HYPERSENSITIVITY
DOPAMINERGIC HYPERSENSITIVITY AND CHOLINERGIC HYPOFUNCTION IN THE PATHOPHYSIOLOGY OF TARDIVE DYSKINESIA.
185929 03-11

HYPERTENSION
BEHAVIOR AND SENSITIVITY TO EXPERIMENTAL HYPERTENSION: II. LACK OF CORRELATION BETWEEN CERTAIN BEHAVIOR PATTERNS AND HYPERTENSION IN TWO NEW STRAINS OF RATS.
173256 01-04
HYPERTENSION AND DEPRESSION AND THEIR TREATMENT.
183234 03-09
ALTERED NOREPINEPHRINE SYNTHESIS OF SPLANCHNIC VESSELS IN NEUROGENIC HYPERTENSION.
188198 04-03
SERUM DOPAMINE-BETA-HYDROXYLASE: A POSSIBLE AID IN THE EVALUATION OF HYPERTENSION.
191512 04-13
THE USE OF PROPRANOLOL WITH VARIOUS DRUG COMBINATIONS IN THE TREATMENT OF ESSENTIAL HYPERTENSION.
192511 04-13

HYPERTHERMIA
DOSE DEPENDENT POTENTIATION OR INHIBITION BY RO-4-4602 OF 5-HTP HYPERTHERMIA IN RABBITS.
185996 03-03

HYPERTHERMIC
HYPERTHERMIC EFFECT OF PALMITATE SODIUM, STEARATE SODIUM AND OLEATE SODIUM INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS CATS.
186640 03-03

HYPERTHYROIDISM
ELECTROCARDIOGRAPHIC CHANGES IN HYPERTHYROIDISM AFTER ADRENERGIC BLOCKADE WITH RESERPINE AND PROPRANOLOL.
167460 01-13

HYPNOSIS
POTENTIATION OF BARBITURATE HYPNOSIS BY 5-DIAZOIMIDAZOLE-4-CARBOXAMIDE AND ITS DERIVATIVES.
182113 02-03

HYPNOTIC
THE PHARMACOLOGICAL EVALUATION IN LABORATORY ANIMALS OF KABI-1702 -- A NEW SEDATIVE HYPNOTIC DRUG.
171632 01-03
CHRONIC HYPNOTIC DRUG USE: INEFFECTIVENESS, DRUG WITHDRAWAL INSOMNIA, AND DEPENDENCE.
172114 01-15
ON THE RECENTLY REPORTED PHYSIOLOGICAL AND PHARMACOLOGICAL REALITY OF THE HYPNOTIC STATE.
173056 01-13
(-)DELTA9-THC AS AN HYPNOTIC: AN EXPERIMENTAL STUDY OF THREE DOSE LEVELS.
174041 01-14
DEPENDENCE LIABILITY OF SEVERAL SEDATIVE HYPNOTIC AGENTS EVALUATED IN MONKEYS.
174125 01-04
EFFICACY AND RESIDUAL EFFECT EVALUATION OF A NEW HYPNOTIC, TRIAZOLAM.
176109 02-13
THE ORAL HYPNOTIC BIOASSAY OF HYDROXYZINE AND PENTOBARBITAL FOR NIGHTTIME SEDATION.
177320 02-11
TRIAZOLAM: A SLEEP LABORATORY STUDY OF A NEW BENZODIAZEPINE HYPNOTIC.
177747 02-07
AN ELECTROENCEPHALOGRAPHIC STUDY ON THE TOLERANCE OF THE VARIOUS PSYCHIATRIC AND NEUROLOGICAL PATIENTS TO THE HYPNOTIC EFFECTS OF DIPHENHYDRAMINE -- MEASURED BY THE AMOUNTS OF SLEEP EEG AS AN INDICATOR.
182550 03-11
SEDATIVE OR TRANQUILLIZER? A COMPARISON OF THE HYPNOTIC EFFECTS OF CHLORDIAZEPOXIDE AND AMYLOBARBITONE SODIUM.
184438 03-14
METHAQUALONE: AN IRRATIONAL HYPNOTIC.
189902 04-15
COMPARATIVE METABOLISM OF TRIAZOLAM, A NEW SEDATIVE HYPNOTIC, IN RAT, DOG AND MAN.
191900 04-02
A PREDICTABLE LABORATORY MODEL FOR SEDATIVE/HYPNOTIC ACTIVITY IN MAN.
191943 04-14

HYPNOTICA
CLINICAL STUDIES OF ACUTE PSYCHOSIS ON THE BASIS OF CHRONIC HYPNOTICA INTOXICATION -- AN ABSTRACT REPORT.
182755 03-15

HYPNOTICS
DECREASED HISTAMINE SYNTHESIS IN THE RAT BRAIN BY HYPNOTICS AND ANESTHETICS.
168750 01-03
ARE THERE SAFER HYPNOTICS THAN BARBITURATES?
174561 01-15
EVALUATION OF HYPNOTICS IN OUTPATIENTS WITH INSOMNIA USING A QUESTIONNAIRE AND A SELF-RATING TECHNIQUE.
177735 02-06
MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC) -- REPORT 1. THIN-LAYER CHROMATOGRAPHY OF HYPNOTICS AND TRANQUILIZERS.
181315 02-16
MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC): REPORT 2 -- ISOLATION AND IDENTIFICATION OF HYPNOTICS AND TRANQUILIZER IN VIVO.
182623 03-06
ISOLATION AND IDENTIFICATION OF HYPNOTICS (8): ISOLATION AND IDENTIFICATION OF BENZALIN AND CERCINE BY THIN-LAYER CHROMATOGRAPHY IN VITRO.
182626 03-01
EFFECTS OF HYPNOTICS ON ANXIOUS PATIENTS.
184445 03-10
SOME RECENT HYPNOTICS ASSESSED.
189673 04-14
RATIONAL USE OF PSYCHOTROPIC DRUGS: I. HYPNOTICS.
192190 04-14

HYPNOTIZABILITY
IMPACT OF PSYCHOACTIVE DRUGS ON HYPNOTIZABILITY.
184021 03-12

HYPODIPSIA
DRINKING BEHAVIOUR AND BRAIN DOPAMINE: ANTAGONISTIC EFFECT OF TWO NEUROLEPTIC DRUGS (PIMOZIDE AND SPIRAMIDE) UPON AMPHETAMINE OR APOMORPHINE-INDUCED HYPODIPSIA.
174035 01-04

HYPOFUNCTION
DOPAMINERGIC HYPERSENSITIVITY AND CHOLINERGIC HYPOFUNCTION IN THE PATHOPHYSIOLOGY OF TARDIVE DYSKINESIA.
185929 03-11

HYPOGLYCEMIA
CONDITIONED HYPOGLYCEMIA: A MECHANISM FOR SACCHARIN INDUCED SENSITIVITY TO INSULIN IN THE RAT.
174877 01-03
STUDIES ON CENTRAL REGULATING MECHANISM OF THE HYPOGLYCEMIA INDUCED BY INTRAVENTRICULAR ADMINISTRATION OF CHLORPROMAZINE.
182093 02-03

HYPOGLYCEMIC
PROPRANOLOL ENHANCEMENT OF HYPOGLYCEMIC SWEATING.
186187 03-13

HYPOMANIC
ON THE STUPOROUS AND HYPOMANIC EPISODES ASSOCIATED WITH SPIKE AND WAVE IN ELECTROENCEPHALOGRAM.
181388 02-11

HYPOSCHOLASTIC
HYPERKINETIC, HYPOSCHOLASTIC BEHAVIOUR AND CHARACTER DISORDERS OF CHILDHOOD AND ADOLESCENCE: DIAGNOSIS AND PHARMACOTHERAPY.
172800 01-11

HYPOTENSION
THE CORRECTIVE EFFECT OF PRAXINOR ON HYPOTENSION ATTRIBUTABLE TO PSYCHIATRIC THERAPY. SIDE-EFFECTS.
172980 01-11
HYPOTENSION FROM DRUGS: INCIDENCE, PERIOD, PREVENTION.
176674 02-15

ROLE OF THE CENTRAL AUTONOMIC NERVOUS SYSTEM IN THE HYPOTENSION AND BRADYCARDIA INDUCED BY (-) DELTA9-TETRAHYDROCANNABINOL.
183795 03-03

HYPOTENSIVE
3-ARYL-3-HYDROXYQUINOLIZIDINES WITH POTENTIAL HYPOTENSIVE, ANTIDEPRESSANT, AND ANALGETIC ACTIVITY.
187938 04-01
DOSE-RELATED ALTERATIONS IN METABOLISM OF LEVODOPA: POSSIBLE MECHANISM FOR HYPOTENSIVE EFFECT.
190194 04-11

HYPOTHALAMIC
RECOVERY OF FEEDING AND DRINKING BY RATS AFTER INTRAVENTRICULAR 6-HYDROXYDOPAMINE OR LATERAL HYPOTHALAMIC LESIONS.
168484 01-03
INFLUENCE OF MORPHINE ON LATERAL HYPOTHALAMIC SELF-STIMULATION IN THE RAT.
168835 01-04
EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON ATTACK ELICITED BY HYPOTHALAMIC STIMULATION: RELATION TO BRAIN BIOGENIC AMINES.
170162 01-04
STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF 5-HT UPTAKE INTO RAT HYPOTHALAMIC HOMOGENATES BY SEROTONIN AND TRYPTAMINE ANALOGUES.
175233 02-03
THE THALAMIC RAT: GENERAL BEHAVIOR, OPERANT LEARNING WITH REWARDING HYPOTHALAMIC STIMULATION, AND EFFECTS OF AMPHETAMINE.
177477 02-04
INHIBITORY EFFECT OF DOXEPIN ON AGONISTIC BEHAVIOUR ELICITED BY HYPOTHALAMIC STIMULATION IN THE CAT.
180044 02-04
EFFECTS OF NEUROPHARMACOLOGICAL AGENTS ON HYPOTHALAMIC NEURONAL ACTIVITY: A MICROELECTROPHORETIC STUDY.
182123 02-03
DECREASED ANOREXIA, EXCITEMENT AND STEREOTYPY TO D-AMPHETAMINE AFTER LATERAL HYPOTHALAMIC 6-HYDROXYDOPAMINE (6-OHDA) INJECTIONS.
182136 02-04
RECOVERY OF FEEDING AFTER 6-HYDROXYDOPAMINE (6-HDA) OR LATERAL HYPOTHALAMIC LESIONS: THE ROLE OF CATECHOLAMINES.
182213 03-03
ALPHA-ADRENERGIC RECEPTORS MEDIATE SUPPRESSION OF DRINKING INDUCED BY HYPOTHALAMIC AMPHETAMINE INJECTION.
182216 03-03
EFFECTS OF METHAMPHETAMINE ON DAILY RHYTHMS OF HYPOTHALAMIC NOREPINEPHRINE, SEROTONIN AND PLASMA CORTICOSTERONE LEVELS IN THE RAT.
184178 03-03
THE EFFECT OF HYPOTHALAMIC STIMULATION ON ORAL INGESTION OF DIAZEPAM IN RATS.
184238 03-04
EFFECTS OF CENTRALLY APPLIED DRUGS ON PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION.
185902 03-03
RELUCTANCE OF RATS TO DRINK HASHISH SUSPENSIONS: FREE-CHOICE AND FORCED CONSUMPTION, AND THE EFFECTS OF HYPOTHALAMIC STIMULATION.
186586 03-04
DRUG EFFECTS AND HYPOTHALAMIC ANTERIOR PITUITARY FUNCTION.
188393 04-03

HYPOTHALAMUS
EFFECT OF MONOAMINE OXIDASE INHIBITORS ON METABOLISM AND IN VIVO RELEASE OF H3-NOREPINEPHRINE FROM THE HYPOTHALAMUS.
171973 01-03
IN VIVO RELEASE OF NEWLY SYNTHESIZED CATECHOLAMINES FROM THE HYPOTHALAMUS BY AMPHETAMINE.
184230 03-03
NEUROCHEMICAL ANALYSIS OF AGGRESSIVE - DEFENSIVE BEHAVIOR ELICITED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS AND CENTRAL GRAY MATTER.
191784 04-02
THE ACTION OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTOR CENTERS OF EMOTIONS IN THE HYPOTHALAMUS.
191785 04-02

HYPOTHERMIA
RETROGRADE AMNESIA FROM HYPOTHERMIA INDUCED BRAIN SEIZURES.
167398 01-04
CHRONOPHARMACOLOGY OF DELTA9-TETRAHYDROCANNABINOL HYPOTHERMIA IN MICE.
176880 02-03
HYPOTHERMIA EVOKED BY A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE ALKALOID.
182130 02-03
CENTRAL HYPOTHERMIA BY 2-DEOXY-D-GLUCOSE: ANTAGONISM BY ALPHA-ADRENERGIC ACTIVATION.
188200 04-03

HYPOTHERMIC
EVALUATION OF THE HYPOTHERMIC ACTION OF TETRAHYDROCANNABINOLS IN MICE AND SQUIRREL MONKEYS.
170163 01-03
DEVELOPMENT OF TOLERANCE IN RATS TO THE HYPOTHERMIC EFFECTS OF D-AMPHETAMINE AND APOMORPHINE.
174764 01-03
HYPOTHERMIC ACTION OF DELTA9-TETRAHYDROCANNABINOL, 11-OH-DELTA9-TETRAHYDROCANNABINOL AND 11-OH-DELTA8-TETRAHYDROCANNABINOL (DELTA9-THC, 11-OH-DELTA9-THC AND 11-OH-DELTA8-THC) IN MICE.
182220 03-03
THE EFFECT OF HYPOTHERMIC DOSES OF 1-DELTA9-TETRAHYDROCANNABINOL ON BIOGENIC AMINE METABOLISM IN SELECTED PARTS OF THE RAT BRAIN.
188231 04-03
ANALYSIS OF HYPOTHERMIC ACTION OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) IN MICE.
191997 04-03

HYPOTHESES
DIFFERENTIATING STIMULUS AND STORAGE HYPOTHESES OF STATE-DEPENDENT LEARNING.
188226 04-14

HYPOTHESIS
L-TRYPTOPHAN IN MANIA: CONTRIBUTION TO A PERMISSIVE HYPOTHESIS OF AFFECTIVE DISORDERS.
171500 01-09

HYPOXANTHINE
EFFECTS OF CHLORPROMAZINE AND ACTINOMYCIN D ON UPTAKE AND INCORPORATION OF CERTAIN AMINO ACIDS, HYPOXANTHINE AND THYMIDINE IN CULTURES OF HUMAN SKIN EPITHELIAL CELLS.
179989 02-13

HYPOXIA
MECHANISMS UNDERLYING POTENTIATION OF BARBITURATE ACTION BY SODIUM NITRITE IN THE MOUSE: THE ROLE OF METHEMOGLOBIN INDUCED HYPOXIA.
182721 03-03

HYSTERIC
ELECTROENCEPHALOGRAM OF HYSTERIC PATIENTS.
175069 02-09

H3-DELTA9-TETRAHYDROCANNABINOL
DISPOSITION OF H3-DELTA9-TETRAHYDROCANNABINOL IN BRAIN OF PREGNANT DOGS AND THEIR FETUSES.
191968 04-03
SUBCELLULAR LOCALIZATION OF H3-DELTA9-TETRAHYDROCANNABINOL IN DOG BRAIN AFTER ACUTE OR CHRONIC ADMINISTRATION.
191970 04-03

H3-DOPAMINE
INCREASED AXOPLASMIC TRANSPORT OF H3-DOPAMINE IN NIGRO-NEOSTRIATAL NEURONS AFTER RESERPINE.
175241 02-03

H3-NOREPINEPHRINE
EFFECT OF MONOAMINE OXIDASE INHIBITORS ON METABOLISM AND IN VIVO RELEASE OF H3-NOREPINEPHRINE FROM THE HYPOTHALAMUS.
171973 01-03

IDEATION
TEMPORAL DISORGANIZATION AND DELUSIONAL-LIKE IDEATION: PROCESSES INDUCED BY HASHISH AND ALCOHOL.
185330 03-14

IDENTIFICATION
MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC) -- REPORT 1. THIN-LAYER CHROMATOGRAPHY OF HYPNOTICS AND TRANQUILIZERS.
181315 02-16
MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC): REPORT 2 -- ISOLATION AND IDENTIFICATION OF HYPNOTICS AND TRANQUILIZER IN VIVO.
182623 03-06
ISOLATION AND IDENTIFICATION OF HYPNOTICS (8): ISOLATION AND IDENTIFICATION OF BENZALIN AND CERCINE BY THIN-LAYER CHROMATOGRAPHY IN VITRO.
182626 03-01
IDENTIFICATION AND QUANTITATIVE DETERMINATION OF PHENOTHIAZINE DRUGS IN URINE SAMPLES OF PSYCHIATRIC PATIENTS.
183599 03-02
BUTOBARBITONE METABOLISM IN MAN: IDENTIFICATION OF 3-KETOBUTOBARBITONE.
183793 03-13

ILEUM
THE UPTAKE, RETENTION AND METABOLISM OF 3H-5-HYDROXYTRYPTAMINE IN BRAIN SLICES AND ILEUM FROM THE RAT: EFFECTS OF COCAINE, DESMETHYLIMIPRAMINE AND RESERPINE. (PH.D. DISSERTATION).
168131 01-03

THE EFFECT OF CATECHOLAMINES, ACETYLCHOLINE AND SEROTONIN ON THE MORPHINE TOLERANT LONGITUDINAL MUSCLE STRIP OF THE GUINEA-PIG ILEUM.
182161 02-03

SEPARATION OF THE DEPENDENCE PRODUCING ACTIONS FROM THE DIRECT ACTIONS OF NARCOTICS ON GUINEA-PIG ILEUM.
182162 02-03

INTERACTION BETWEEN SEROTONIN AND MORPHINE IN THE GUINEA-PIG ILEUM.
186698 03-03

ALPHA-L-ACETYLMETHADOL AND ITS N-DEMTHYLATED METABOLITES HAVE POTENT OPIATE ACTION IN THE GUINEA-PIG ISOLATED ILEUM.
187130 03-03

ILL

MOLINDONE: A CROSSOVER EVALUATION OF CAPSULE AND TABLET FORMULATIONS IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
174137 01-08

PSYCHOPHARMACOLOGICAL AGENTS FOR THE TERMINALLY ILL AND BEREAVED.
188149 04-17

ILLICIT

RADIOIMMUNOASSAY FOR LYSERGIDE (LSD) IN ILLICIT DRUGS AND BIOLOGICAL FLUIDS.
170840 01-06

ILLNESS

COMBINATIONS OF ANTIDEPRESSANT DRUGS IN THE TREATMENT OF DEPRESSIVE ILLNESS.
168317 01-09

THE USE OF LITHIUM IN AFFECTIVE DISORDERS, III: A DOUBLE-BLIND STUDY OF PROPHYLAXIS IN BIPOLAR ILLNESS.
169495 01-09

DRUGS AND PSYCHODYNAMIC SHIFTS IN AFFECTIVE ILLNESS. (UNPUBLISHED PAPER).
170079 01-09

BRAIN SEROTONIN, AFFECTIVE ILLNESS AND ANTIDEPRESSANT DRUGS: CEREBROSPINAL FLUID STUDIES WITH PROBENECID. (UNPUBLISHED PAPER).
170084 01-09

SINGLE VERSUS DIVIDED DAILY DOSE OF TRIMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
170622 01-09

LITHIUM PROPHYLAXIS IN RECURRENT AFFECTIVE ILLNESS.
171926 01-09

CENTRAL DOPAMINE FUNCTION IN AFFECTIVE ILLNESS: EVIDENCE FROM PRECURSORS, ENZYME INHIBITORS AND STUDIES OF CENTRAL DOPAMINE TURNOVER. (UNPUBLISHED PAPER).
181358 02-09

FACTORS ASSOCIATED WITH LITHIUM RESPONSE IN THE PROPHYLACTIC TREATMENT OF BIPOLAR MANIC-DEPRESSIVE ILLNESS.
186188 03-09

A CASE OF A NONSPECIFIC MENTAL ILLNESS WITH PSYCHOMOTOR VARIANT.
188517 04-09

PROPHYLACTIC EFFICACY OF LITHIUM CARBONATE ''' MANIC-DEPRESSIVE ILLNESS: REPORT OF THE VETERANS ADMINISTRATION AND NATIONAL INSTITUTE OF MENTAL HEALTH (VA-NIMH) COLLABORATIVE STUDY GROUP.
189735 04-09

MENTAL ILLNESS OR METAL ILLNESS? BISMUTH SUBGALLATE.
191215 04-15

ILLNESSES

FLUPENTHIXOL IN CERTAIN PSYCHIATRIC ILLNESSES.
175393 02-11

A STUDY OF REFRACTORY CASES OF DEPRESSIVE ILLNESSES AND THEIR RESPONSE TO COMBINED ANTIDEPRESSANT TREATMENT.
185078 03-10

ILLUSTRATIONS

THE DESIGN OF THERAPEUTIC TRIALS: A CRITICAL ANALYSIS WITH ILLUSTRATIONS, PARTICULARLY FROM THE FIELD OF PSYCHOTROPIC DRUGS OR: WHY NO ONE CAN EVER DO A PROPER DRUG TRIAL.
173307 01-16

IMAO

ARE THE IMAO OUTDATED?
183202 03-09

IMIDAZOLE

EFFECTS OF GUANETHIDINE AND IMIDAZOLE ON HISTAMINE RESPONSE.
187799 04-03

IMINODIBENZYL

STUDIES ON SIDE-EFFECTS AND WITHDRAWAL SYMPTOMS OF IMINODIBENZYL DERIVATIVES.
173080 01-15

IMIPRAMINE

COMPARABLE THERAPEUTIC EFFICACY OF TRYPTOPHAN AND IMIPRAMINE: AVERAGE THERAPEUTIC RATINGS VERSUS TRUE EQUIVALENCE. AN IMPORTANT DIFFERENCE.
167344 01-09

CONTROLLED STUDY OF SINGLE DOSE ADMINISTRATION OF IMIPRAMINE PAMOATE IN ENDOGENOUS DEPRESSION.
167775 01-09

EFFECTS OF IMIPRAMINE ON COPULATORY BEHAVIOR OF MALE RATS.
168718 01-04

IMIPRAMINE, DIAZEPAM AND GROUP PSYCHOTHERAPY IN LONG-TERM TREATMENT OF DEPRESSIVE NEUROTICS.
169089 01-10

IMIPRAMINE IN THE TREATMENT OF MINIMAL BRAIN DYSFUNCTION IN CHILDREN.
169295 01-11

THE TREATMENT OF DEPRESSION WITH A SINGLE DAILY DOSE OF IMIPRAMINE PAMOATE.
169491 01-09

EFFECT OF IMIPRAMINE ON THE TURNOVER OF BRAIN 5-HT IN POSTNATAL RATS.
171624 01-03

A DOUBLE-BLIND INVESTIGATION OF DIMETHACRINE VERSUS IMIPRAMINE IN HOSPITALIZED DEPRESSIVE STATES.
171695 01-09

PLASMA BINDING OF IMIPRAMINE AND CLINICAL OUTCOME.
172271 01-13

METHYLTESTOSTERONE WITH IMIPRAMINE IN MEN: CONVERSION OF DEPRESSION TO PARANOID REACTION.
172992 01-15

KINETICS AND CELLULAR CONTROL MECHANISMS FOR IMIPRAMINE METABOLISM IN THE ISOLATED PERFUSED RAT LIVER. (PH.D. DISSERTATION).
173601 01-03

EFFECTS OF AMITRIPTYLINE AND IMIPRAMINE ON AMINE METABOLITES IN THE CEREBROSPINAL FLUID OF DEPRESSED PATIENTS.
174094 01-09

AMOXAPINE AND IMIPRAMINE: A DOUBLE-BLIND STUDY IN DEPRESSED PATIENTS.
174138 01-09

A DOUBLE-BLIND TRIAL OF IPRINDOLE AND IMIPRAMINE IN DEPRESSIVES AND RESPONSE TO ECT IN REFRACTORY CASES.
174376 01-09

MEASURING THE PHARMACOLOGICAL ACTION OF IMIPRAMINE IN THE TREATMENT OF DEPRESSIONS.
174995 02-09

EXPERIENCE IN THE USE OF IMIPRAMINE.
176448 02-10

INHIBITION OF LUNG, LIVER AND BRAIN MONOAMINE OXIDASE BY IMIPRAMINE AND DESIPRAMINE.
177332 02-03

IMIPRAMINE WITHDRAWAL: AN AKATHISIA LIKE SYNDROME.
177710 02-15

MYOCARDIOPATHIC COMPLICATIONS INDUCED BY IMIPRAMINE AND TRICYCLIC THYMOLEPTICS.
182898 03-15

INFLUENCE OF DIBENCYCLADINE AND IMIPRAMINE ON CALORIE INTAKE AND BODYWEIGHT.
183359 03-03

COMPARATIVE EVALUATION OF DIBENCYCLADINE (LUDIOMIL) AND IMIPRAMINE IN PSYCHOTIC DEPRESSION.
183361 03-09

QUANTITATIVE DETERMINATION OF IMIPRAMINE AND DESIPRAMINE IN HUMAN BLOOD PLASMA BY DIRECT DENSITOMETRY OF THIN-LAYER CHROMATOGRAMS.
183603 03-13

IMIPRAMINE AND ITS METABOLITES IN HUMAN BRAIN.
183604 03-13

OUTPATIENT TREATMENT OF HYPERACTIVE SCHOOL CHILDREN WITH IMIPRAMINE.
184174 03-11

IMIPRAMINE AND METHYLPHENIDATE TREATMENTS OF HYPERACTIVE BOYS: A DOUBLE-BLIND COMPARISON.
185324 03-14

IMIPRAMINE MEDIATED EFFECTS ON LEVODOPA METABOLISM IN MAN.
185998 03-13

A CONTROLLED TRIAL OF IMIPRAMINE HYDROCHLORIDE ON ENURESIS.
186553 03-11

PERSISTENT ELECTROENCEPHALOGRAPHIC CHANGES IN RHESUS MONKEYS AFTER SINGLE DOSES OF PENTOBARBITAL, NITRAZEPAM AND IMIPRAMINE.
187931 04-03

IMIPRAMINE IN EXPERIMENTAL PETIT-MAL EPILEPSY.
188424 04-03

EFFECT OF IMIPRAMINE ON CULTURED RAT HEART CELLS.
188864 04-03

IMIPRAMINE SIDE-EFFECTS IN CHILDREN.
189512 04-15

THE COMPARATIVE ANXIOLYTIC EFFECTS OF PLACEBO, IMIPRAMINE AND CHLORIMIPRAMINE USING PSYCHIATRIC AND PSYCHOPHYSIOLOGICAL MEASUREMENTS.
191137 04-14

DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) IMIPRAMINE INTERACTION ON MOUSE BODY TEMPERATURE.
191996 04-03

THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON THE COMPOSITION OF DIURNAL SLEEP OF NARCOLEPTICS.
192419 04-11

IMIPRAMINE-N-OXIDE
CLINICAL EFFECTS OF IMIPRAMINE-N-OXIDE ON DEPRESSION.
191716 04-09

IMMATURE
EFFECTS OF METHAMPHETAMINE, PIPRADROL, AND METHYLPHENIDATE ON INSTRUMENTAL CONDITIONING AND SPONTANEOUS MOTOR ACTIVITY IN THE IMMATURE RAT.
186568 03-04

IMMUNE
THE EFFECT OF LOWERED BODY TEMPERATURE ON LIFESPAN AND IMMUNE AND NONIMMUNE PROCESSES.
169675 01-03

EFFECTS OF DELTA8-THC AND DELTA9-TETRAHYDROCANNABINOL ON THE IMMUNE RESPONSE IN MICE.
191960 04-03

STUDIES OF THE IMMUNE RESPONSE IN CHRONIC MARIHUANA SMOKERS.
191961 04-13

IMMUNIZATION
BLOCKING OF THE EFFECT OF A DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC) ON SPONTANEOUS MOTOR ACTIVITY IN THE RAT BY IMMUNIZATION WITH A PROTEIN CONJUGATE OF DELTA1-THC.
187129 03-04

IMMUNOASSAY
PSYCHOACTIVE DRUGS: IMMUNOASSAY AND LOCALIZATION.
173536 01-06

IMMUNOREACTIVE
PLASMA LEVELS OF LUTEINIZING HORMONE AND OF IMMUNOREACTIVE ESTROGENS (ESTRADIOL) IN ANOREXIA-NERVOSA: RESPONSE TO CLOMIPHENE CITRATE.
183807 03-10

IMPACT
IMPACT OF PSYCHOACTIVE DRUGS ON HYPNOTIZABILITY.
184021 03-12

IMPAIRMENT
EEG CHANGES & MOTOR IMPAIRMENT AFTER DISULFIRAM ADMINISTRATION TO CATS.
182248 03-03

LEARNING IMPAIRMENT IN RATS AFTER 6-HYDROXYDOPAMINE INDUCED DEPLETION OF BRAIN CATECHOLAMINES.
187420 04-04

IMPAIRMENT OF OPTOKINETIC NYSTAGMUS IN PATIENTS WITH TARDIVE DYSKINESIA.
189734 04-13

IMPAIRS
ANISOMYCIN, LIKE OTHER INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS, IMPAIRS LONG-TERM MEMORY OF A DISCRIMINATION TASK.
188605 04-04

IMPLANT
STUDY OF THE USE OF DISULFIRAM IMPLANT IN THE TREATMENT OF ALCOHOLISM.
183030 03-11

DISULFIRAM IMPLANT: A CONTROLLED TRIAL.
185190 03-11

IMPORTANT
COMPARABLE THERAPEUTIC EFFICACY OF TRYPTOPHAN AND IMIPRAMINE: AVERAGE THERAPEUTIC RATINGS VERSUS TRUE EQUIVALENCE. AN IMPORTANT DIFFERENCE.
167344 01-09

IMPOTENCE
AFRODEX VS. PLACEBO IN THE TREATMENT OF MALE IMPOTENCE: STATISTICAL ANALYSIS OF TWO DOUBLE-BLIND CROSSOVER STUDIES.
181959 02-14

IMPRESSIONS
MARIHUANA USE IN MAN: AN EXPERIMENTAL INQUIRY -- CLINICAL PSYCHIATRIC IMPRESSIONS.
169085 01-14

IMPRESSIONS OF SCANDINAVIAN PSYCHIATRY -- 1973.
173452 01-17

IMPROVING
IMPROVING PSYCHIATRIC DRUG THERAPY: A MATTER OF DOSAGE AND CHOICE.
190144 04-17

IMPULSE
THE IMPULSE BLOCKING CONCENTRATIONS OF ANESTHETICS, ALCOHOLS, ANTICONVULSANTS, BARBITURATES, AND NARCOTICS ON PHRENIC AND SCIATIC NERVES.
187803 04-03

THE NERVE IMPULSE BLOCKING ACTIONS OF TRANQUILIZERS AND THE BINDING OF NEUROLEPTICS TO SYNAPTOSOME MEMBRANES.
189400 04-03

EFFECTS OF ALTERATIONS IN IMPULSE FLOW ON TRANSMITTER METABOLISM IN CENTRAL DOPAMINERGIC NEURONS.
191519 04-03

IMPULSES
IMPORTANCE OF CATECHOLAMINE RELEASE BY NERVE IMPULSES FOR FREE OPERANT BEHAVIOR.
171611 01-04

INABILITY
INABILITY OF RAT BRAIN HOMOGENATE TO OXIDIZE AMPHETAMINE.
177334 02-03

INABILITY TO CONDITION A PERIPHERAL ACTIVATING DRUG.
190698 04-04

INAPPROPRIATE
THE EFFECTS OF PHENOTHIAZINES ON ENDOCRINE FUNCTION: I. PATIENTS WITH INAPPROPRIATE LACTATION AND AMENORRHOEA.
184436 03-15

INCIDENCE
HYPOTENSION FROM DRUGS: INCIDENCE, PERIOD, PREVENTION.
176674 02-15

INCREASE
INCREASE IN THE PLASMA CONCENTRATION OF FREE TRYPTOPHAN CAUSED BY PROBENECID IN HUMANS.
169470 01-13

CYCLIC ADENOSINE MONOPHOSPHATE: SELECTIVE INCREASE IN CAUDATE NUCLEUS AFTER ADMINISTRATION OF L-DOPA.
176254 02-13

TRANSPORT OF SYNAPTOSOMAL TRYPTOPHAN AND CEREBRAL TYROSINE: INCREASE IN THE SPEED OF UPTAKE OF RESERPINE OR THE INHIBITION OF MONOAMINE OXIDASE.
179988 02-13

HYDROCORTISONE INDUCED INCREASE IN THE HISTOCHEMICALLY DEMONSTRABLE CATECHOLAMINE CONTENT OF SYMPATHETIC NEURONS OF THE NEWBORN RAT.
189027 04-03

DIFFERENTIAL INCREASE OF BEHAVIORAL AND EXTRAPYRAMIDAL STIMULATING ACTIONS OF NEUROLEPTICS BY ALPHA-METHYLTYROSINE PRETREATMENT IN RATS.
192016 04-04

INCREASES
INFLUENCES OF DRUGS ON THE INCREASES IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OF GAMMA-HYDROXYBUTYRIC ACID (GHBA).
171622 01-03

EVIDENCE THAT MORPHINE INCREASES DOPAMINE UTILIZATION IN CORPORA-STRIATA OF RATS.
176746 02-03

THE EFFECT OF MINOR TRANQUILIZERS ON STRESS INDUCED INCREASES IN RAT PLASMA CORTICOSTEROIDS.
186578 03-03

INCREMENTAL
RESPONSE TO INCREMENTAL DOSES OF DITRAN IN ABSTINENT ALCOHOLICS AND DRUG USERS.
185875 03-11

INCUBATED
EFFECT OF DESIPRAMINE ON RAT CORTEX SLICES INCUBATED WITH 3H-DOPAMINE.
190310 04-03

INDANETHYLAMINES
PREPARATION AND PHARMACOLOGICAL SCREENING OF INDANETHYLAMINES RELATED TO TRYPTAMINE.
185979 03-01

INDEPENDENCE
INDEPENDENCE OF THE EFFECTS OF D-AMPHETAMINE AND FOOD DEPRIVATION OR BODYWEIGHT ON THE FOOD CONSUMPTION OF RATS.
186376 03-06

INDEPENDENT
BEHAVIORAL PARAMETERS OF DRUG ACTION: SIGNALED AND RESPONSE INDEPENDENT REINFORCEMENT.
174008 01-04

INDICATION
CLASSIFICATION AND INDICATION OF ANTIANXIETY AGENTS IN CLINICAL PRACTICE.
184845 03-10

INDICATION AND PROBLEMS OF PSYCHOTROPIC DRUGS IN GENERAL PRACTICE.
191677 04-17

INDICATOR
AN ELECTROENCEPHALOGRAPHIC STUDY ON THE TOLERANCE OF THE VARIOUS PSYCHIATRIC AND NEUROLOGICAL PATIENTS TO THE HYPNOTIC EFFECTS OF DIPHENHYDRAMINE -- MEASURED BY THE AMOUNTS OF SLEEP EEG AS AN INDICATOR.
182550 03-11

INDIRECT
BEHAVIORAL EFFECTS OF DIRECT AND INDIRECT ACTING DOPAMINERGIC AGONISTS.
191521 04-04

INDIVIDUAL
THE BIOLOGICAL BASIS OF PSYCHOTICISM: A STUDY OF INDIVIDUAL DIFFERENCES IN RESPONSE TO DEXAMPHETAMINE.
175219 02-13

INDIVIDUAL PSYCHOTHERAPY WITH HALLUCINOGENS.
180143 02-12

INDIVIDUALS
INDUCTION OF SEVERE DEPRESSION BY PHYSOSTIGMINE IN MARIJUANA INTOXICATED INDIVIDUALS.
177450 02-14

INDOLEALKYLAMINES
MOLECULAR ORBITAL STUDIES ON THE CONFORMATION OF HALLUCINOGENIC INDOLEALKYLAMINES AND RELATED COMPOUNDS. THE ISOLATED MOLECULES AND THE SOLVENT EFFECT.
183406 03-01
ANTICONVULSANT ACTIVITY OF SUBSTITUTED INDOLEALKYLAMINES.
185035 03-01
STRUCTURE-ACTIVITY RELATIONS OF SOME INDOLEALKYLAMINES IN COMPARISON TO PHENETHYLAMINES ON MOTOR ACTIVITY AND ACQUISITION OF AVOIDANCE BEHAVIOR.
186703 03-04

INDOLEAMINE
L-TRYPTOPHAN IN AFFECTIVE DISORDERS: INDOLEAMINE CHANGES AND DIFFERENTIAL CLINICAL EFFECTS.
185928 03-09

INDOMETHACIN
ANALGESIC POTENCY OF SODIUM SALICYLATE, INDOMETHACIN, AND CHLORDIAZEPOXIDE AS MEASURED BY THE SPATIAL PREFERENCE TECHNIQUE IN THE RAT.
171301 01-02

INDONESIA
CLINICAL TRIAL WITH DARTALANR, DJAKARTA, INDONESIA.
170753 01-11
PSYCHOTROPIC MEDICATION IN INDONESIA (1970-1973).
174618 01-17

INDONESIAN
CLINICAL TRIAL OF TRIFLUOPERAZINE (STELAZINE R) ON INDONESIAN PSYCHIATRIC PATIENTS.
171161 01-09

INDUCE
INFLUENCE OF VARIOUS SUBSTANCES WHICH INDUCE AND INHIBIT AGGREGATION ON THE UPTAKE OF DEOXYGLUCOSE BY HUMAN BLOOD PLATELETS.
191770 04-13

INDUCED
EFFECTS OF DOPAMINE RECEPTOR STIMULATION AND BLOCKADE ON RO-4-1284 INDUCED ENHANCEMENT OF ELECTROSHOCK SEIZURE.
167287 01-03
RETROGRADE AMNESIA FROM HYPOTHERMIA INDUCED BRAIN SEIZURES.
167398 01-04
PHARMACOLOGICALLY INDUCED BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE.
169120 01-03
LEVODOPA INDUCED DYSKINESIAS: COMPARISON IN PARKINSONISM DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS.
169376 01-15
LITHIUM INDUCED DIABETES-INSIPIDUS: MANIC SYMPTOMS, BRAIN AND ELECTROLYTE CORRELATES, AND CHLOROTHIAZIDE TREATMENT.
169486 01-15
LITHIUM INDUCED FOLLICULITIS.
169492 01-15
LOW DOSAGE HALOPERIDOL AND INDUCED ANXIETY IN NORMAL VOLUNTEERS.
169745 01-14
LIPID INDUCED CHANGES OF PENTOBARBITAL DISTRIBUTION AND METABOLISM.
170072 01-03
THE ELECTROCARDIOGRAPHIC ABNORMALITIES INDUCED BY PSYCHOTROPIC DRUGS.
170638 01-13
PHYSOSTIGMINE EFFECTS ON PHENOTHIAZINE INDUCED EXTRAPYRAMIDAL REACTIONS.
170662 01-13
AN AUTOPSY CASE OF SCHIZOPHRENIA COMPLICATED WITH PARKINSONISM INDUCED BY PERPHENAZINE.
171275 01-15
THE ELECTROCARDIOGRAPHIC ABNORMALITY INDUCED BY CHLORPROMAZINE.
171296 01-15
PROPRANOLOL AND CHLORDIAZEPOXIDE ON EXPERIMENTALLY INDUCED CONFLICT AND SHUTTLEBOX PERFORMANCE IN RODENTS.
171304 01-04
PHENOTHIAZINE INDUCED DECOMPENSATION.
171506 01-15
TOLERANCE TO HEXOBARBITAL AND SUPERSENSITIVITY TO PILOCARPINE INDUCED BY CHRONIC BARBITAL TREATMENT IN THE RAT.
171601 01-03
ANTAGONISM OF P-CHLOROAMPHETAMINE (PCA) INDUCED DEPLETION OF 5-HT FROM RAT BRAIN BY SOME THYMOLEPTICS AND OTHER PSYCHOTROPIC DRUGS.
171628 01-03
DELTA9-TETRAHYDROCANNABINOL INDUCED INHIBITION OF PREDATORY AGGRESSION IN THE RAT.
172745 01-04
P-CHLOROPHENYLALANINE INDUCED ALTERATIONS IN THE BEHAVIORAL EFFECTS OF 5-HYDROXYTRYPTOPHAN.
174034 01-04
L-TRYPTOPHAN IN THE TREATMENT OF LEVODOPA INDUCED PSYCHIATRIC DISORDERS.
174297 01-15
APOMORPHINE INDUCED BITING AND FIGHTING BEHAVIOUR IN RESERPINIZED RATS AND AN APPROACH TO THE MECHANISM OF ACTION.
174768 01-04
BEHAVIORAL AND ELECTROENCEPHALOGRAPHIC STUDIES ON THIOSEMICARBAZIDE INDUCED SEIZURE IN RABBITS.
174855 01-05
CONDITIONED HYPOGLYCEMIA: A MECHANISM FOR SACCHARIN INDUCED SENSITIVITY TO INSULIN IN THE RAT.
174877 01-03
VOCALIZATION: A CHARACTERISTIC CANNABIS INDUCED BEHAVIOR IN THE RAT?
175884 02-04
BARBITURATE DEPENDENCE IN MICE INDUCED BY A SIMPLE SHORT-TERM ORAL PROCEDURE.
175895 02-03
DOLICHOMEGACOLON INDUCED BY NEUROLEPTICS AMONG PSYCHIATRIC PATIENTS (MEMORANDUM COVERING 153 CASES).
176432 02-15
STEREOTYPED AND AGGRESSIVE BEHAVIOR INDUCED BY SUSTAINED HIGH DOSE OF THEOPHYLLINE IN RATS.
177019 02-04
FURTHER ASPECTS OF AGGRESSIVE BEHAVIOR INDUCED BY SUSTAINED HIGH DOSE OF THEOPHYLLINE IN RATS.
177020 02-04
EFFECTS OF PG-501 ON PARAPYRAMIDAL SYSTEM SYNDROME INDUCED BY PSYCHOTROPICS.
178019 02-15
ANTICONVULSANT ACTIVITY OF CLONAZEPAM AND RO-8-4192 AGAINST PENICILLIN AND LIDOCAINE INDUCED SEIZURES.
178947 02-03
CENTRAL NERVOUS STIMULANT INDUCED PHYSIOLOGICAL AND PERFORMANCE CHANGES IN ADULTS DURING SUSTAINED PSYCHOMOTOR TRACKING.
179023 02-13
EFFECT OF CANNABIS ON PENTOBARBITAL INDUCED SLEEPING TIME AND PENTOBARBITAL METABOLISM IN THE RAT.
179985 02-03
NICOTINIC ACID INDUCED SYSTEMIC LUPUS-ERYTHEMATOSUS.
180243 02-15
STUDIES ON CENTRAL REGULATING MECHANISM OF THE HYPOGLYCEMIA INDUCED BY INTRAVENTRICULAR ADMINISTRATION OF CHLORPROMAZINE.
182093 02-03
THE EFFECTS OF INTRAVENTRICULARLY ADMINISTERED CATECHOLAMINES AND SEROTONIN ON THE RESERPINE INDUCED SPIKE WAVES RECORDED FROM THE MEDICAL NUCLEUS TRAPEZOIDES IN THE RABBIT.
182094 02-03
EFFECTS OF PSYCHOTROPIC DRUGS ON METHAMPHETAMINE INDUCED EXCITATIONS IN THE AGGREGATED MICE.
182107 02-04
EFFECTS OF PSYCHOTROPIC DRUGS ON ABNORMAL BEHAVIOR INDUCED BY DELTA9-TETRAHYDROCANNABINOL.
182114 02-04
SELECTIVE BLOCKADE OF APOMORPHINE INDUCED AGGRESSION AND GNAWING FOLLOWING FENFLURAMINE OR RAPHE LESIONS IN THE RAT.
182128 02-04
SUBSTANTIAL ORAL MORPHINE INTAKE BY THE RAT USING SCHEDULE INDUCED POLYDIPSIA.
182194 02-04
RELATIVE IMPORTANCE OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS FOR THE STIMULATION OF LOCOMOTOR ACTIVITY INDUCED BY AMPHETAMINE AND OTHER DRUGS.
182209 02-04
ALPHA-ADRENERGIC RECEPTORS MEDIATE SUPPRESSION OF DRINKING INDUCED BY HYPOTHALAMIC AMPHETAMINE INJECTION.
182216 03-03
INHIBITION OF ISOLATION INDUCED AGGRESSION IN THE MOUSE BY ANTICHOLINERGIC COMPOUNDS.
182239 03-04
INHIBITION OF ISOLATION INDUCED AGGRESSION IN MICE BY ANTISEROTONERGIC DRUGS.
182240 03-04
INVOLVEMENT OF ALPHA-RECEPTORS IN CLONIDINE INDUCED INHIBITION OF TRANSMITTER RELEASE FROM CENTRAL MONOAMINE NEURONES.
182345 03-03

MECHANISMS UNDERLYING POTENTIATION OF BARBITURATE ACTION BY SODIUM NITRITE IN THE MOUSE: THE ROLE OF METHEMOGLOBIN INDUCED HYPOXIA.
182721 03-03

MYOCARDIOPATHIC COMPLICATIONS INDUCED BY IMIPRAMINE AND TRICYCLIC THYMOLEPTICS.
182898 03-15

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: III. PIMOZIDE IN THE TREATMENT OF STRESS INDUCED PSYCHIC AND FUNCTIONAL DISORDERS.
183193 03-11

EFFECTS OF ANTIPARKINSONIAN DRUGS ON NEUROLEPTIC INDUCED EXTRAPYRAMIDAL SIGNS IN MONKEYS.
183610 03-03

ROLE OF THE CENTRAL AUTONOMIC NERVOUS SYSTEM IN THE HYPOTENSION AND BRADYCARDIA INDUCED BY (-) DELTA9-TETRAHYDROCANNABINOL.
183795 03-03

PARADOXICAL THERMOREGULATORY BEHAVIOUR IN RATS INDUCED BY (_) AMPHETAMINE: BLOCKADE BY ALPHA-ADRENOCEPTOR OR DOPAMINE RECEPTOR BLOCKING AGENTS.
183797 03-03

CHOLINERGIC MODIFICATION OF NALOXONE INDUCED JUMPING IN MORPHINE DEPENDENT MICE.
184179 03-03

DEANOL IN THE TREATMENT OF LEVODOPA INDUCED DYSKINESIAS.
184196 03-11

INCREASED SYNTHESIS OF ADRENOMEDULLARY CATECHOLAMINES INDUCED BY CAFFEINE AND THEOPHYLLINE.
184201 03-03

LEAD INDUCED BEHAVIORAL DYSFUNCTION: AN ANIMAL MODEL OF HYPERACTIVITY.
184953 03-04

TEMPORAL DISORGANIZATION AND DELUSIONAL-LIKE IDEATION: PROCESSES INDUCED BY HASHISH AND ALCOHOL.
185330 03-14

CATALEPSY INDUCED BY ALPHA-METHYL-P-TYROSINE AND D-AMPHETAMINE: THE ROLE OF CATECHOLAMINE METABOLISM.
185750 03-03

ENHANCEMENT OF METHYLPHENIDATE INDUCED STEREOTYPIES BY REPEATED ADMINISTRATION OF NEUROLEPTICS.
186369 03-04

INFLUENCE OF FLUPENTHIXOL AND FLUPENTHIXOL DECANOATE ON METHYLPHENIDATE AND APOMORPHINE INDUCED COMPULSIVE GNAWING IN MICE.
186371 03-04

THE EFFECT OF MINOR TRANQUILIZERS ON STRESS INDUCED INCREASES IN RAT PLASMA CORTICOSTEROIDS.
186578 03-03

EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: I. EFFECT ON THE BEHAVIOURAL CHANGES INDUCED BY RESERPINE, ALPHA-METHYL-P-TYROSINE OR AMPHETAMINE.
186587 03-04

SPECIFICITY OF BLOCKADE OF THE NICOTINE INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ADRENERGIC NEURONS OF THE GUINEA-PIG HEART BY VARIOUS PHARMACOLOGICAL AGENTS.
186676 03-03

COMPARISON OF TYROSINE HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION WITH THE EFFECTS OF VARIOUS 6-HYDROXYDOPAMINE TREATMENTS ON D-AMPHETAMINE INDUCED MOTOR ACTIVITY.
186699 03-03

A STUDY OF THE BEHAVIORAL DISRUPTION OF MICE INDUCED BY L-METHIONINE AND RELATED COMPOUNDS.
187260 04-04

ON THE MECHANISM OF RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVES INDUCED BY DEPOLARIZING AGENTS AND SYMPATHOMIMETIC DRUGS. (UNPUBLISHED PAPER).
187397 04-03

LEARNING IMPAIRMENT IN RATS AFTER 6-HYDROXYDOPAMINE INDUCED DEPLETION OF BRAIN CATECHOLAMINES.
187420 04-04

CHLORPROMAZINE INDUCED HYPERPHAGIA. (UNPUBLISHED PAPER).
187498 04-04

EFFECTS OF SHORT-TERM ADMINISTRATION OF N-NITROSO COMPOUNDS ON LIVER HISTOLOGY AND PENTOBARBITAL INDUCED SLEEPING TIME IN MICE.
187575 04-04

TEMPORAL ASPECTS OF SCOPOLAMINE INDUCED ONE-WAY MEMORY DISSOCIATION IN MICE.
187701 04-04

ACTIONS OF ATROPINE, HEMICHOLINIUM-3, AND PHYSOSTIGMINE ON CHLORPROMAZINE INDUCED CHANGES IN RAT BRAIN MONOAMINES.
187800 04-03

FAILURE OF BETA-ADRENERGIC RECEPTOR BLOCKADE TO PREVENT ARRHYTHMIAS INDUCED BY SYMPATHETIC NERVE STIMULATION.
187923 04-03

IN VIVO CHANGES OF CEREBRAL CYCLIC ADENOSINE 3,5 MONOPHOSPHATE INDUCED BY BIOGENIC AMINES: ASSOCIATION WITH PHOSPHORYLASE ACTIVATION.
188291 04-03

KETAMINE INDUCED POSTANESTHETIC DELIRIUM ATTENUATED BY TETRAHYDROAMINOACRIDINE.
188689 04-05

REDUCTION BY PRETREATMENT WITH DIBENAMINE OF HEPATOTOXICITY INDUCED BY CARBON TETRACHLORIDE, THIOACETAMINDE OR DIMETHYLNITROSAMINE.
188865 04-05

HYDROCORTISONE INDUCED INCREASE IN THE HISTOCHEMICALLY DEMONSTRABLE CATECHOLAMINE CONTENT OF SYMPATHETIC NEURONS OF THE NEWBORN RAT.
189027 04-03

A STUDY OF BIOGENIC AMINE METABOLITES IN THE CEREBROSPINAL FLUID AND URINE OF MONKEYS WITH CHLORPROMAZINE INDUCED DYSKINESIA.
189210 04-03

EFFECTS OF ALPHA-METHYLTYROSINE ON D-AMPHETAMINE INDUCED RELEASE OF ENDOGENOUSLY SYNTHESIZED AND EXOGENOUSLY ADMINISTERED CATECHOLAMINES FROM THE CAT BRAIN IN VIVO.
189397 04-03

CANNABINOIDS AND HEXOBARBITAL INDUCED LOSS OF RIGHTING REFLEXES.
189573 04-04

MESCALINE INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON THE BINDING OF AMINOACYL TRANSFER RIBONUCLEIC ACID TO RIBOSOMES OF BRAIN TISSUE.
189582 04-05

RATING OF PSYCHOLOGICAL EFFECTS INDUCED BY ORDINARY NOVERIL AND TIME-RELEASED NOVERIL.
190312 04-14

PHARMACOLOGICAL ALTERATIONS IN THE STIMULUS INDUCED RELEASE OF NOREPINEPHRINE FROM THE RABBIT SUPERIOR CERVICAL GANGLION.
191896 04-03

AMPHETAMINE AND METHYLPHENIDATE INDUCED RELEASE OF STRIATAL DOPAMINE IN VIVO: DIFFERENTIAL EFFECTS ON NEWLY SYNTHESIZED AND STORED POOLS.
191897 04-03

EXCITABILITY CHANGES DURING THE GRADUAL DEVELOPMENT OF AND RECOVERY FROM PENTYLENETETRAZOL AND STRYCHNINE INDUCED CONVULSIONS IN THE CAT.
191927 04-03

CHOLINERGIC AMINERGIC INTERACTIONS IN LEAD INDUCED HYPERACTIVITY.
191954 04-05

THE INFLUENCE OF DELTA9-TETRAHYDROCANNABINOL (THC) ON PILOCARPINE (PILO) INDUCED PAROTID SECRETIONS OF THE RAT.
191962 04-03

THE EFFECT OF INCREASED GAMMA-AMINOBUTYRIC ACID ON ALPHA-METHYLTYROSINE INDUCED DECREASE IN CATECHOLAMINES IN RAT BRAIN.
191988 04-03

DOPAMINE AGONIST INDUCED DISORIENTATION IN A RAT SWIMMING TASK.
192018 04-04

CHLORDIAZEPOXIDE INDUCED BETA SPINDLE ACTIVITY IN RATS.
192416 04-03

BETA-BLOCKING AGENTS IN THE TREATMENT OF CATECHOLAMINE INDUCED SYMPTOMS IN MUSICIANS.
192527 04-11

INDUCING

LORAZEPAM VERSUS GLUTETHIMIDE AS A SLEEP INDUCING AGENT FOR THE GERIATRIC PATIENT.
167496 01-11

INDUCTION

TREMOR INDUCTION BY INTRACAUDATE INJECTIONS OF BRETYLIUM, TETRABENAZINE, OR MESCALINE: FUNCTIONAL DEFICITS IN CAUDATE DOPAMINE.
167329 01-03

DISSOCIATION OF STIMULATORY AND SYNTHETIC PHASES IN THE INDUCTION OF TYROSINE HYDROXYLASE.
171785 01-03

INDUCTION OF SEVERE DEPRESSION BY PHYSOSTIGMINE IN MARIJUANA INTOXICATED INDIVIDUALS.
177450 02-14

TRANSSYNAPTIC INDUCTION OF CHOLINE ACETYLTRANSFERASE IN THE PREGANGLIONIC NEURON OF THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM.
182720 03-03

INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY LITHIUM TREATMENT.
182727 03-03

INDUCTION OF A DIETHYLETHER WITHDRAWAL SYNDROME IN MICE BY EXPOSURE TO ETHER VAPOR.
192006 04-03

INEFFECTIVENESS
CHRONIC HYPNOTIC DRUG USE: INEFFECTIVENESS, DRUG WITHDRAWAL INSOMNIA, AND DEPENDENCE.
172114 01-15
ALTERATION OF ETHANOL-INDUCED CNS DEPRESSION: INEFFECTIVENESS OF DRUGS THAT MODIFY CHOLINERGIC TRANSMISSION.
186375 03-03

INFANT
MOTHER INFANT SEPARATION: BEHAVIORAL ANALYSIS OF AN ANIMAL MODEL OF DEPRESSION. (PH.D. DISSERTATION).
178867 02-04
THE EFFECT OF CANNABINOIDS ON THE NUMBER OF NUCLEAR MEMBRANE ATTACHED RIBOSOMES IN INFANT RAT BRAIN.
183228 03-03
CHLORPROMAZINE CAUSING EXTRAPYRAMIDAL DYSFUNCTION IN NEWBORN INFANT OF PSYCHOTIC MOTHER.
187787 04-15

INFANTS
BEHAVIOURAL STATE CYCLES IN ABNORMAL INFANTS.
168523 01-14
CONTINUOUS INFUSION OF DIAZEPAM IN INFANTS WERE SEVERE RECURRENT CONVULSIONS.
174568 01-11

INFECTION
DEVELOPMENT OF A VACCINE AGAINST MENTAL RETARDATION CAUSED BY CYTOMEGALOVIRUS INFECTION IN UTERO.
178549 02-11

INFLUENCE
INFLUENCE OF TREATMENT ON SYMPTOMATOLOGY AND CORRELATED ELECTROENCEPHALOGRAPHIC (EEG) CHANGES IN THE AGED.
167336 01-13
INFLUENCE OF CONCENTRATION AND MOTOR PERFORMANCE ON TARDIVE DYSKINESIA AND RABBIT SYNDROME.
167587 01-15
INFLUENCE OF AMYLOBARBITONE ON OPERANT DEPRESSION AND ELATION EFFECTS IN THE RAT.
168834 01-04
INFLUENCE OF MORPHINE ON LATERAL HYPOTHALAMIC SELF-STIMULATION IN THE RAT.
168835 01-04
INFLUENCE OF AFFECTIVE STATES AND PSYCHOACTIVE DRUGS ON VERBAL LEARNING AND MEMORY.
169504 01-09
INFLUENCE OF PHENOBARBITAL AND SEX HORMONES ON ENZYMES IN ASCORBIC ACID BIOSYNTHESIS IN MALE AND FEMALE RATS. (PH.D. DISSERTATION).
172017 01-03
PHARMACOKINETIC DISPOSITION OF NORAPOMORPHINE DERIVATIVES AND ITS INFLUENCE ON THE ELICITATION OF STEREOTYPICAL GNAWING. (PH.D. DISSERTATION).
174960 01-03
INFLUENCE OF N1-2-HYDROXYETHYL SUBSTITUTION ON CENTRAL ACTIVITY OF OXAZEPAM AND LORAZEPAM.
178756 02-04
INFLUENCE OF VARIOUS DRUGS ON THE BINDING OF CHLORPROMAZINE TO ERYTHROCYTES AND ALBUMIN.
181470 02-03
THE INFLUENCE OF ALDOSTERONE OR METHAMPHETAMINE ON LIVER GLYCOGEN DEPOSITION OF MICE STRESSED BY LONG-TERM ISOLATION.
182105 02-03
INFLUENCE OF ANTIDEPRESSIVE THERAPY ON THE DISTURBED TIME ESTIMATION OF DEPRESSIVES.
182591 03-14
THE INFLUENCE OF CHRONIC ADMINISTRATION OF LITHIUM CARBONATE ON THE BRAIN NOREPINEPHRINE CONTENT IN RATS.
182872 03-03
THE INFLUENCE OF NEUROTROPIC DRUGS ON MONOAMINE OXIDASE (MAO) AND 5-OXYTRYPTOPHANE DECARBOXYLASE (5-OTD) ACTIVITY IN THE BRAIN.
183142 03-13
INFLUENCE OF TETRACOSACTRIN (T) AND BETA-MELANOCYTE STIMULATING HORMONE (MSH) ON DEPRESSION OF THE SEGMENTAL REFLEX BY MORPHINE (MS). (UNPUBLISHED PAPER).
183324 03-03
INFLUENCE OF DIBENCYCLADINE AND IMIPRAMINE ON CALORIE INTAKE AND BODYWEIGHT.
183359 03-03
FAILURE OF ACTH TO INFLUENCE AVOIDANCE EXTINCTION IN A ONE-WAY AVOIDANCE SITUATION.
183470 03-04
INFLUENCE OF METHAMPHETAMINE AND NEUROLEPTIC DRUGS ON TYROSINE HYDROXYLASE ACTIVITY.
184180 03-03
PERCEPTUAL STYLE AND PAIN TOLERANCE -- II. THE INFLUENCE OF AN ANXIOLYTIC AGENT.
184291 03-14
COMPARISON OF PSYCHOEXPERIMENTAL PERFORMANCE UNDER THE INFLUENCE OF THE ANALGESIC PROPIRAM FUMARATE.
184618 03-14
INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: IV. INFLUENCE OF AMPHETAMINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
185961 03-04
INFLUENCE OF FLUPENTHIXOL AND FLUPENTHIXOL DECANOATE ON METHYLPHENIDATE AND APOMORPHINE INDUCED COMPULSIVE GNAWING IN MICE.
186371 03-04
THE INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LEVELS OF ENDOGENOUS 2-PHENYLETHYLAMINE IN RABBIT BRAIN.
187112 03-03
THE INFLUENCE OF 3-QUINUCLIDINYLBENZILATE ON THE BEHAVIOUR OF RATS IN A CIRCULAR RUNWAY.
187259 04-04
INFLUENCE OF ALPHA-METHYLTYROSINE ON ENHANCEMENT OF SHUTTLEBOX AVOIDANCE BY MARIJUANA AND PENTOBARBITAL.
187572 04-04
INFLUENCE OF ADRENERGIC BLOCKERS AND ANTILIPEMIC AGENTS ON PHARMACODYNAMIC ACTIONS OF MORPHINE IN CARBON TETRACHLORIDE TREATED RATS.
188873 04-03
INFLUENCE ON ACUTE PRETREATMENT WITH DELTA9-TETRAHYDROCANNABINOL OF THE LD50 OF VARIOUS SUBSTANCES THAT ALTER NEUROHUMORAL TRANSMISSION.
188876 04-05
INFLUENCE OF MORPHINE AND NALOXONE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189568 04-03
INFLUENCE OF FENTANYL, LEVORPHANOL AND PETHIDINE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189569 04-03
INFLUENCE OF PH ON THE BENZODIAZEPINE HUMAN SERUM ALBUMIN COMPLEX: CIRCULAR DICHROISM STUDIES.
189595 04-13
INFLUENCE OF DIFFERENT ANIONS ON TYRAMINE AND AMPHETAMINE UPTAKE BY COW ADRENAL MEDULLA CHROMAFFIN VESICLES.
190907 04-03
INFLUENCE OF NEUROLEPTICS AND BENZODIAZEPINES ON METABOLISM OF TRICYCLIC ANTIDEPRESSANTS IN MAN.
191026 04-09
THE INFLUENCE OF PSYCHOSTIMULANTS ON K42 MEMBRANE PERMEABILITY IN VARIOUS PORTIONS OF RAT BRAIN.
191122 04-03
INFLUENCE OF VARIOUS SUBSTANCES WHICH INDUCE AND INHIBIT AGGREGATION ON THE UPTAKE OF DEOXYGLUCOSE BY HUMAN BLOOD PLATELETS.
191770 04-13
INFLUENCE OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTS OF ELECTRICAL STIMULATION AND MICROINJECTION OF ACETYLCHOLINE, SEROTONIN AND NORADRENALINE INTO THE MESENCEPHALON.
191786 04-02
INFLUENCE OF PSYCHOTROPIC DRUGS ON AGGRESSIVENESS EVOKED BY DESTRUCTION OF ISOLATED STRUCTURES OF THE FOREBRAIN.
191788 04-04
CHANGES IN RHYTHMS OF BIOELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX IN HUMANS UNDER THE INFLUENCE OF ETHYMISOL.
191790 04-07
THE INFLUENCE OF DELTA9-TETRAHYDROCANNABINOL (THC) ON PILOCARPINE (PILO) INDUCED PAROTID SECRETIONS OF THE RAT.
191962 04-03
THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON THE COMPOSITION OF DIURNAL SLEEP OF NARCOLEPTICS.
192419 04-11

INFLUENCED
DRUG-INDUCED CATALEPSY AS INFLUENCED BY PSYCHOSTIMULANTS, APOMORPHINE, L-DOPA, AND YOHIMBINE.
177730 02-13
PROPRANOLOL ANTAGONISM OF MORPHINE INFLUENCED BEHAVIOR.
188760 04-04

INFLUENCES
INFLUENCES OF DRUGS ON THE INCREASES IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OF GAMMA-HYDROXYBUTYRIC ACID (GHBA).
171622 01-03
INFLUENCES OF RESERPINE AND CHLORPROMAZINE ON THE ANALGESIC AND METABOLIC EFFECTS OF MORPHINE.
180507 02-03
INFLUENCES OF LITHIUM ON THE BEHAVIORAL ACTION OF METHAMPHETAMINE AND TETRABENAZINE.
182109 02-04

INFORMAL
METHYLPHENIDATE AND THE ACTIVITY OF HYPERACTIVES IN THE INFORMAL SETTING.
181853 02-14

INFUSION

CONTINUOUS INFUSION OF DIAZEPAM IN INFANTS WERE SEVERE RECURRENT CONVULSIONS.
174568 01-11

EKG ALTERNATIONS IN INFUSION TREATMENT WITH TRICYCLIC ANTIDEPRESSIVE DRUGS.
180063 02-15

INFUSIONS

A CRITICAL EVALUATION OF THE PRINCIPLES GOVERNING THE ADVANTAGES OF INTRAARTERIAL INFUSIONS.
170112 01-06

INGESTION

GAS CHROMATOGRAPHIC DETERMINATION OF METHAQUALONE IN SMALL AMOUNTS OF SERUM AFTER INGESTION OF THERAPEUTIC DOSES.
172397 01-16

THE EFFECT OF HYPOTHALAMIC STIMULATION ON ORAL INGESTION OF DIAZEPAM IN RATS.
184238 03-04

AN OBSESSIVE NEUROSIS FOLLOWING MORNING-GLORY SEED INGESTION TREATED BY AVERSION RELIEF.
184259 03-15

PROPRANOLOL AND BEHAVIOR OF ALCOHOL ADDICTS AFTER ACUTE ALCOHOL INGESTION.
187257 04-14

FATAL SUICIDAL INGESTION OF THIORIDAZINE.
189606 04-15

LITHIUM TREATMENT DURING ETHANOL INGESTION AND WITHDRAWAL.
192005 04-11

INGESTIVE

THE EFFECTS ON INGESTIVE BEHAVIORS OF DAMAGE TO CENTRAL DOPAMINE CONTAINING NEURONS.
191520 04-04

INHALATION

INHALATION, PARENTERAL AND ORAL LD50 VALUES OF DELTA9-TETRAHYDROCANNABINOL IN FISCHER RATS.
189588 04-05

INHIBIT

DOPAMINE AND 5-HYDROXYTRYPTAMINE INHIBIT FEEDING IN RATS.
170177 01-04

INFLUENCE OF VARIOUS SUBSTANCES WHICH INDUCE AND INHIBIT AGGREGATION ON THE UPTAKE OF DEOXYGLUCOSE BY HUMAN BLOOD PLATELETS.
191770 04-13

INHIBITED

BRAIN RIBOSOMAL RNA SYNTHESIS INHIBITED BY CHLORPROMAZINE.
177835 02-03

INHIBITING

MELANOCYTE STIMULATING HORMONE RELEASE INHIBITING HORMONE AS AN ANTIDEPRESSANT: A PILOT STUDY.
171501 01-09

DIFFERENTIAL SELF-INJECTION BEHAVIOR PRODUCED BY FENFLURAMINE VERSUS OTHER APPETITE INHIBITING DRUGS.
182215 03-04

INHIBITION

SELECTIVE INHIBITION OF NOREPINEPHRINE SYNTHESIS IN MANIC-DEPRESSIVE PATIENTS WITH A DOPAMINE-BETA-HYDROXYLASE INHIBITOR. (UNPUBLISHED PAPER).
170083 01-03

INHIBITION OF MOUSE-KILLING BEHAVIOUR IN RATS BY SOME THYMOLEPTIC DRUGS.
171608 01-04

DELTA9-TETRAHYDROCANNABINOL INDUCED INHIBITION OF PREDATORY AGGRESSION IN THE RAT.
172745 01-04

INHIBITION BY MORPHINE OF REPETITIVE ACTIVATION OF CAT SPINAL MOTONEURONES.
172926 01-03

THE INHIBITION OF 3H-DOPAMINE UPTAKE INTO RAT STRIATAL BY VERATRIDINE AND BATRACHOTOXIN. (UNPUBLISHED PAPER).
173380 01-03

ONTOGENY OF SEROTONINERGIC INHIBITION OF BEHAVIORAL AROUSAL IN THE RAT.
174860 01-04

STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF 5-HT UPTAKE INTO RAT HYPOTHALAMIC HOMOGENATES BY SEROTONIN AND TRYPTAMINE ANALOGUES.
175233 02-03

INHIBITION OF THE APOMORPHINE GNAWING COMPULSION BY AMANTADINE.
176879 02-04

INHIBITION OF LUNG, LIVER AND BRAIN MONOAMINE OXIDASE BY IMIPRAMINE AND DESIPRAMINE.
177332 02-03

INHIBITION OF ANTICHOLINERGIC DRUG-INDUCED LOCOMOTOR STIMULATION IN MICE BY ALPHA-METHYLTYROSINE.
177840 02-03

TRANSPORT OF SYNAPTOSOMAL TRYPTOPHAN AND CEREBRAL TYROSINE: INCREASE IN THE SPEED OF UPTAKE OF RESERPINE OR THE INHIBITION OF MONOAMINE OXIDASE.
179988 02-13

DISCRIMINANT ANALYSIS OF THE RELATIONSHIP BETWEEN PHYSICAL PROPERTIES AND THE INHIBITION OF MONOAMINE OXIDASE BY AMINOTETRALINS AND AMINOINDANS.
180096 02-03

IN VIVO INHIBITION OF NEURONAL UPTAKE OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY COCAINE AND BY DESMETHYLIMIPRAMINE (DMI).
182150 02-03

INHIBITION OF GROWTH IN ANIMALS TREATED WITH METHADONE.
182164 02-03

INHIBITION OF C14-ACH UPTAKE IN RAT BRAIN SLICES BY DESMETHYLIMIPRAMINE.
182170 02-03

(3H) OUABAIN BINDING TO NA$_{+}$-ATPASE AND K$_{+}$-ATPASE: INHIBITION BY BETA, GAMMA METHYLENE ATP.
182184 02-03

INHIBITION OF ISOLATION INDUCED AGGRESSION IN THE MOUSE BY ANTICHOLINERGIC COMPOUNDS.
182239 03-04

INHIBITION OF ISOLATION INDUCED AGGRESSION IN MICE BY ANTISEROTONERGIC DRUGS.
182240 03-04

INHIBITION OF THE SYNAPTOSOMAL UPTAKE MECHANISMS FOR L-NOREPINEPHRINE AND DOPAMINE BY N-ARYLALKYL DL-AMPHETAMINE DERIVATIVES.
182250 03-03

INVOLVEMENT OF ALPHA-RECEPTORS IN CLONIDINE INDUCED INHIBITION OF TRANSMITTER RELEASE FROM CENTRAL MONOAMINE NEURONES.
182345 03-03

THE INHIBITION OF (3H) BIOGENIC AMINE ACCUMULATION INTO RAT BRAIN TISSUE SLICES BY VARIOUS TRYPTAMINE DERIVATIVES.
182723 03-03

SUBSTITUTED PIPERAZINOQUINAZOLONES: RELATIONSHIP BETWEEN SELECTIVE INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND ANTICONVULSANT ACTIVITY.
183598 03-02

SUBSTITUTED BENZOXAZOLE/BENZTHIAZOLE-2-THIONES: INTERRELATIONSHIP BETWEEN ANTICONVULSANT ACTIVITY AND INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND MONOAMINE OXIDASE.
183601 03-03

METHADONE INHIBITION OF 3H-5-HYDROXYTRYPTAMINE UPTAKE BY SYNAPTOSOMES.
183896 03-03

THE INHIBITION BY BETA-ADRENOCEPTOR BLOCKING AGENTS OF CALCIUM UPTAKE INTO AND EFFLUX FROM ISOLATED SARCOPLASMIC VESICLES.
184223 03-03

DOSE EFFECTS OF METHYLPHENIDATE ON BEHAVIORAL INHIBITION AND ACTIVATION IN HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
185676 03-14

AN IMPROVED METHOD FOR STUDYING THE PSYCHOGALVANIC REACTION IN MICE AND ITS INHIBITION BY PSYCHOLEPTIC DRUGS. COMPARISON WITH THE EFFECTS OF OTHER PHARMACOLOGICAL AGENTS.
185749 03-06

FURTHER STUDIES ON THE INHIBITION OF DRUG METABOLISM BY PREGNANOLONE AND RELATED STEROIDS.
185866 03-03

THE EFFECT OF P-CHLOROAMPHETAMINE ON MOTILITY IN RATS AFTER INHIBITION OF MONOAMINE SYNTHESIS, STORAGE, UPTAKE AND RECEPTOR INTERACTION.
185959 03-04

ANTICONVULSANT ACTIVITY AND INHIBITION OF RESPIRATION IN RAT BRAIN HOMOGENATES BY SUBSTITUTED OXADIAZOLES.
185980 03-01

DOSE DEPENDENT POTENTIATION OR INHIBITION BY RO-4-4602 OF 5-HTP HYPERTHERMIA IN RABBITS.
185996 03-03

ACETYLCHOLINESTERASE INHIBITION AND MYELINOGENESIS IN VITRO.
186033 03-03

THE MONOAMINE OXIDASES OF BRAIN: SELECTIVE INHIBITION WITH DRUGS AND THE CONSEQUENCES FOR THE METABOLISM OF THE BIOGENIC AMINES.
186668 03-03

DIAZEPAM INHIBITION OF POST-TETANIC POTENTIATION IN BULLFROG SYMPATHETIC GANGLIA: POSSIBLE ROLE OF PROSTAGLANDINS.
186673 03-03

COMPARISON OF TYROSINE HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION WITH THE EFFECTS OF VARIOUS 6-HYDROXYDOPAMINE TREATMENTS ON D-AMPHETAMINE INDUCED MOTOR ACTIVITY.
186699 03-03

A POSSIBLE MECHANISM FOR THE ANTISCHIZOPHRENIC ACTION OF CHLORPROMAZINE: INHIBITION OF THE FORMATION OF DIMETHYLTRYPTAMINE BY CHLORPROMAZINE METABOLITES.
187576 04-03

CONTROL OF NOREPINEPHRINE SYNTHESIS IN BLOOD VESSELS AND THE EFFECTS OF MONOAMINE OXIDASE INHIBITION.
189390 04-03

DOPAMINERGIC INHIBITION OF STRIATAL CHOLINERGIC NEURONS: SYNERGISTIC BLOCKING ACTION OF GAMMA-BUTYROLACTONE AND NEUROLEPTIC DRUGS.
189602 04-03

INHIBITION OF THE SLEEP RELATED PEAK IN PHYSIOLOGIC HUMAN GROWTH HORMONE RELEASE BY SOMATOSTATIN.
190104 04-13

PROCAINE (GEROVITAL-H3) THERAPY: MECHANISM OF INHIBITION OF MONOAMINE OXIDASE.
191281 04-03

CORRELATION BETWEEN BRAIN N,N DIMETHYLTRYPTAMINE (DMT) LEVELS AND BAR PRESSING BEHAVIOR IN RATS: EFFECT OF MAO INHIBITION.
191935 04-04

ALPHA-METHYL-P-TYROSINE INHIBITION OF SELF-ADMINISTERED INTRAVENOUS MORPHINE AND ORAL WATER IN RATS.
191940 04-04

TETRAHYDROCANNABINOLS: INHIBITION IN ACETYLCHOLINE SYNTHESIS IN REGIONAL RAT BRAIN SLICES.
191998 04-03

INHIBITION OF CHOLINE UPTAKE INTO SYNAPTOSOMES BY CHOLINE ANALOGUES.
191999 04-03

INHIBITION IN VIVO OF ACETYLCHOLINE SYNTHESIS IN MOUSE BRAIN BY INHIBITORS OF CHOLINE ACETYLTRANSFERASE.
192001 04-03

INHIBITIONS

NEUROLEPTIC ANTAGONISM OF CATECHOLAMINE INHIBITIONS IN RAT CEREBELLUM AND CAUDATE. (UNPUBLISHED PAPER).
187496 04-03

INHIBITOR

COMBINATION OF L-DOPA, DESIPRAMINE, AND A DECARBOXYLASE INHIBITOR IN THE TREATMENT OF DEPRESSION.
169468 01-09

SELECTIVE INHIBITION OF NOREPINEPHRINE SYNTHESIS IN MANIC-DEPRESSIVE PATIENTS WITH A DOPAMINE-BETA-HYDROXYLASE INHIBITOR. (UNPUBLISHED PAPER).
170083 01-03

BEHAVIORAL EFFECTS OF A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR (FUSARIC ACID) IN MAN. (UNPUBLISHED PAPER
174329 01-09

THE MECHANISM OF ACTION OF THE MONOAMINE OXIDASE INHIBITOR PARGYLINE.
175239 02-03

LEVODOPA COMBINED WITH MK-486 (L-ALPHA-METHYLDOPAHYDRAZINE) -- A PERIPHERAL DECARBOXYLASE INHIBITOR IN PARKINSONS DISEASE.
187615 04-11

PARKINSONIAN SYNDROMES: TREATMENT BY ASSOCIATION OF L-DOPA PLUS DECARBOXYLASE INHIBITOR.
188093 04-11

FUROXANOBENZOFUROXAN, A SELECTIVE MONOAMINE OXIDASE INHIBITOR.
188770 04-01

THE USE OF SELECTIVE AND INHIBITOR DRUGS TO MODIFY AMINE METABOLISM IN BRAIN.
191500 04-03

EFFECT OF L-PHENYL-3-2-THIAZOLYL 2-THIOUREA, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
191769 04-03

INHIBITORS

EFFECT OF MONOAMINE OXIDASE INHIBITORS ON METABOLISM AND IN VIVO RELEASE OF H3-NOREPINEPHRINE FROM THE HYPOTHALAMUS.
171973 01-03

A NEW MODIFICATION FOR STUDYING 5-HT UPTAKE BY BLOOD PLATELETS: A RE-EVALUATION OF TRICYCLIC ANTIDEPRESSANTS AS UPTAKE INHIBITORS.
180055 02-06

CENTRAL DOPAMINE FUNCTION IN AFFECTIVE ILLNESS: EVIDENCE FROM PRECURSORS, ENZYME INHIBITORS AND STUDIES OF CENTRAL DOPAMINE TURNOVER. (UNPUBLISHED PAPER).
181358 02-09

ANISOMYCIN, LIKE OTHER INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS, IMPAIRS LONG-TERM MEMORY OF A DISCRIMINATION TASK.
188605 04-04

EFFECTS OF LSD AND MONOAMINE SYNTHESIS INHIBITORS ON HORMONE ACTIVATED COPULATORY BEHAVIOR IN THE FEMALE RAT.
188611 04-04

POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES: 1. MODIFICATION OF THE AMINO ACID PORTION OF S-ADENOSYLHOMOCYSTEINE.
190716 04-01

POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES. 2. MODIFICATION OF THE BASE PORTION OF S-ADENOSYLHOMOCYSTEINE.
190717 04-01

SOME CONSIDERATIONS IN THE DESIGN OF SUBSTRATE AND TISSUE SPECIFIC INHIBITORS OF MAO.
191499 04-01

THE EFFECTS OF COMT INHIBITORS ON BEHAVIOR AND DOPAMINE METABOLISM.
191517 04-03

INHIBITION IN VIVO OF ACETYLCHOLINE SYNTHESIS IN MOUSE BRAIN BY INHIBITORS OF CHOLINE ACETYLTRANSFERASE.
192001 04-03

INHIBITORY

SYNTHESIS OF SUBSTITUTED CINNAMIDES: RELATIONSHIP BETWEEN ANTICONVULSANT AND MONOAMINE OXIDASE INHIBITORY PROPERTIES.
169818 01-01

A DIFFERENTIAL INHIBITORY ACTION OF LSD AND AMPHETAMINE ON COPULATORY BEHAVIOR IN THE FEMALE RAT.
171617 01-04

THE ROLE OF THE SEPTAL AREA OF THE BRAIN IN THE INHIBITORY MODULATION OF BEHAVIOR. (PH.D. DISSERTATION).
172021 01-03

INHIBITORY EFFECTS OF PRETEST AND POSTTEST D-AMPHETAMINE ON MOUSE-KILLING BY RATS. (PH.D. DISSERTATION).
173727 01-04

INHIBITORY EFFECT OF DOXEPIN ON AGONISTIC BEHAVIOUR ELICITED BY HYPOTHALAMIC STIMULATION IN THE CAT.
180044 02-04

EVIDENCE FOR AN INHIBITORY ROLE FOR ACETYLCHOLINE, CATECHOLAMINES, AND SEROTONIN ON THE CEREBRAL CORTEX.
187552 04-03

INHIBITORY EFFECT OF DOPAMINERGIC STIMULATION ON GH RELEASE IN ACROMEGALY.
188350 04-13

EFFECTS OF SCOPOLAMINE ON INHIBITORY MECHANISMS.
190275 04-04

DIFFERENTIAL ANTAGONISM BY NALOXONE OF INHIBITORY EFFECTS OF HALOPERIDOL AND MORPHINE ON BRAIN SELF-STIMULATION.
190306 04-03

INJECTABLE

ASSESSMENT OF ANATENSOL (FLUPHENAZINE ENANTHATE) INJECTABLE IN THE TREATMENT OF SCHIZOPHRENIA.
172444 01-08

EXPERIMENTS IN ORAL AND INJECTABLE FORMS OF A NEW ANTIDEPRESSANT (DOXEPIN) ON FORTY PATIENTS.
182900 03-11

FLUSPIRILENE, A LONG-ACTING INJECTABLE NEUROLEPTIC.
183199 03-11

INJECTED

BRAIN TO SERUM DISTRIBUTION OF RADIOACTIVITY OF INJECTED 3H-D-AMPHETAMINE IN DIFFERENTIALLY HOUSED MICE.
168418 01-03

HISTO-AUTORADIOGRAPHIC INVESTIGATIONS ON THE DISTRIBUTION OF INJECTED 5-HYDROXYTRYPTAMINE (SEROTONIN) IN THE BRAIN AND THE PITUITARY OF MICE.
185900 03-03

HYPERTHERMIC EFFECT OF PALMITATE SODIUM, STEARATE SODIUM AND OLEATE SODIUM INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS CATS.
186640 03-03

INJECTION

THE DISTRIBUTION OF DELTA1-TETRAHYDROCANNABINOL AND 7-HYDROXY-DELTA1-TETRAHYDROCANNABINOL IN THE MOUSE BRAIN AFTER INTRAVENTRICULAR INJECTION.
172596 01-03

FLAVOR AVERSIONS PRODUCED BY CONTINGENT DRUG INJECTION: RELATIVE EFFECTIVENESS OF APOMORPHINE, EMETINE, AND LITHIUM.
178502 02-04

FURTHER EXPERIENCE WITH FLUPHENAZINE ENANTHATE INJECTION.
180153 02-08

ALPHA-ADRENERGIC RECEPTORS MEDIATE SUPPRESSION OF DRINKING INDUCED BY HYPOTHALAMIC AMPHETAMINE INJECTION.
182216 03-03

INTRACEREBRAL INJECTION OF 6-HYDROXYDOPAMINE AND HYDROGEN PEROXIDE IN CATS: SPECIFIC AND NONSPECIFIC EFFECTS ON STRIATAL BIOGENIC AMINES.
188426 04-03

EFFECTS OF INTRACEREBRAL INJECTION OF 5,6-HYDROXYTRYPTAMINE ON CEREBRAL MONOAMINES AND SLEEP STATES IN THE CAT/.
189023 04-02

INJECTIONS
TREMOR INDUCTION BY INTRACAUDATE INJECTIONS OF BRETYLIUM, TETRABENAZINE, OR MESCALINE: FUNCTIONAL DEFICITS IN CAUDATE DOPAMINE.
167329 01-03
ACQUISITION AND RETENTION OF AVOIDANCE BEHAVIORS FOLLOWING SEPTAL LESIONS OR SCOPOLAMINE INJECTIONS IN RATS.
167401 01-04
EFFECT OF CHRONIC POSTTRIAL SALINE INJECTIONS ON MAZE PERFORMANCE.
167403 01-04
CNS DEPRESSION IN THE ABSENCE OF PROLACTIN RELEASE FOLLOWING INTRAARTERIAL INJECTIONS OF SODIUM PENTOTHAL IN THE PROESTROUS RAT.
173257 01-03
THE EFFECTS OF INTRACAUDATE INJECTIONS OF CHLORPROMAZINE ON CONDITIONED AVOIDANCE AND SELF-STIMULATION BEHAVIOR. (PH.D. DISSERTATION).
173749 01-04
DECREASED ANOREXIA, EXCITEMENT AND STEREOTYPY TO D-AMPHETAMINE AFTER LATERAL HYPOTHALAMIC 6-HYDROXYDOPAMINE (6-OHDA) INJECTIONS.
182136 02-04
REDUCTION IN COPULATORY BEHAVIOR OF MALE RATS FOLLOWING HASHISH INJECTIONS.
183790 03-04
EFFECTS ON HOMEOSTASIS OF INTRAVENTRICULAR INJECTIONS OF 6-HYDROXYDOPAMINE IN RATS.
187695 04-03
GENERALIZED PENICILLIN EPILEPSY IN THE CAT: EFFECTS OF INTRACAROTID AND INTRAVERTEBRAL PENTYLENETETRAZOL AND AMOBARBITAL INJECTIONS.
188374 04-03
AFFECTIVE STATE AND THYROTROPIN AND PROLACTIN RESPONSES AFTER REPEATED INJECTIONS OF THYROTROPIN RELEASING HORMONE IN DEPRESSED PATIENTS.
189076 04-09
THE EFFECTS OF EARLY SALINE INJECTIONS AND PENTYLENETETRAZOL ON HEBB-WILLIAMS MAZE PERFORMANCE IN THE ADULT RAT.
191378 04-04

INJURY
EFFECTS OF PHENOBARBITAL AND SKF-525-A PRETREATMENT, SEX, LIVER INJURY, AND VEHICLE ON DELTA9-TETRAHYDROCANNABINOL TOXICITY.
189598 04-05

INOTROPIC
MECHANISM OF THE NEGATIVE CHRONOTROPIC AND INOTROPIC EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC).
182219 03-03

INPATIENTS
SIMPLE ALGORITHMS FOR PREDICTING PSYCHOTROPIC DRUGS ASSIGNED TO PSYCHIATRIC INPATIENTS.
176676 02-17
DIAZEPAM ON DEMAND: DRUG SEEKING BEHAVIOR IN PSYCHIATRIC INPATIENTS.
189924 04-17

INPUT
LYSERGIC ACID DIETHYLAMIDE AND SEROTONIN: A COMPARISON OF EFFECTS ON SEROTONERGIC NEURONS AND NEURONS RECEIVING A SEROTONERGIC INPUT.
177407 02-12

INQUIRY
MARIHUANA USE IN MAN: AN EXPERIMENTAL INQUIRY -- CLINICAL PSYCHIATRIC IMPRESSIONS.
169085 01-14

INSANITY
LSD AND THE INSANITY DRUGS, PART XXXI.
192092 04-17

INSIDON
ELECTROCLINICAL ASPECT OF INSIDON TREATMENT IN PATIENTS WITH NEUROTIC SYMPTOMS.
174777 01-10

INSOMNIA
THE USE OF N-DEMETHYLDIAZEPAM IN OUTPATIENTS SUFFERING FROM INSOMNIA.
167340 01-11
CHRONIC HYPNOTIC DRUG USE: INEFFECTIVENESS, DRUG WITHDRAWAL INSOMNIA, AND DEPENDENCE.
172114 01-15
EVALUATION OF HYPNOTICS IN OUTPATIENTS WITH INSOMNIA USING A QUESTIONNAIRE AND A SELF-RATING TECHNIQUE.
177735 02-06
CONTROL OF INSOMNIA WITH A NEW BENZODIAZEPINE: THE FLUNITRAZEPAM OR RO-5-4200 (FIRST INVESTIGATIONS OF PHASE I AND CONTROLLED INVESTIGATIONS OF PHASE II).
183198 03-11

INSOMNIAC
EFFECT OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) ON THE DAYTIME SLEEP-WAKEFULNESS PATTERNS IN NORMAL AND P-CHLOROPHENYLALANINE INSOMNIAC CATS.
181658 02-02
FLUNITRAZEPAM (RO-5-4200) AND SLEEP CYCLE IN INSOMNIAC PATIENTS.
186574 03-11

INSOMNIACS
THE EFFECT OF LORAZEPAM ON ANXIOUS INSOMNIACS SLEEP AS RECORDED IN THE HOME ENVIRONMENT.
177318 02-14

INSTITUTE
INSTITUTE OF PSYCHIATRY CLINICAL PSYCHOPHARMACOLOGY RESEARCH TEAM.
187022 03-17
PROPHYLACTIC EFFICACY OF LITHIUM CARBONATE IN MANIC-DEPRESSIVE ILLNESS: REPORT OF THE VETERANS ADMINISTRATION AND NATIONAL INSTITUTE OF MENTAL HEALTH (VA-NIMH) COLLABORATIVE STUDY GROUP.
189735 04-09

INSTITUTIONALIZED
EFFECTS OF DIPHENYLHYDANTOIN ON ANXIETY AND HOSTILITY IN INSTITUTIONALIZED PRISONERS.
177671 02-11
HALOPERIDOL (JANSSEN) IN THE TREATMENT OF UNSELECTED INSTITUTIONALIZED PSYCHIATRIC PATIENTS.
180299 02-11

INSTRUMENTAL
EFFECTS OF METHAMPHETAMINE, PIPRADROL, AND METHYLPHENIDATE ON INSTRUMENTAL CONDITIONING AND SPONTANEOUS MOTOR ACTIVITY IN THE IMMATURE RAT.
186568 03-04

INSUFFICIENCY
EXPERIENCE IN THE TREATMENT OF CEREBRAL INSUFFICIENCY AND PERIPHERAL BLOOD CIRCULATION DISORDERS USING THE EP-50-100 EXPERIMENTAL DRUG.
180676 02-11

INSULIN
EFFECT OF CHLORPROMAZINE (CPZ) ON INSULIN RELEASE IN VIVO AND IN VITRO IN THE RAT.
168440 01-03
CONDITIONED HYPOGLYCEMIA: A MECHANISM FOR SACCHARIN INDUCED SENSITIVITY TO INSULIN IN THE RAT.
174877 01-03
BLOCKADE OF INSULIN RELEASE BY CERTAIN PHENOTHIAZINES.
189583 04-05

INTACT
CARDIOVASCULAR EFFECTS OF RESERPINE, YOHIMBINE, AND RESERPINE YOHIMBINE MIXTURES ON INTACT ANESTHETIZED DOG.
167328 01-03
EFFECT OF CHLORIMIPRAMINE ON THE RATE OF TRYPTOPHAN HYDROXYLATION IN THE INTACT AND TRANSECTED SPINAL CORD.
168751 01-03
LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04

INTAKE
DRUG DEPENDENCE TEST OF PHENOBARBITAL AND MORPHINE IN RATS BY SPONTANEOUS INTAKE.
182104 02-04
SUBSTANTIAL ORAL MORPHINE INTAKE BY THE RAT USING SCHEDULE INDUCED POLYDIPSIA.
182194 02-04
INFLUENCE OF DIBENCYCLADINE AND IMIPRAMINE ON CALORIE INTAKE AND BODYWEIGHT.
183359 03-03
THE EFFECTS OF CHRONIC TREATMENT WITH D-AMPHETAMINE ON FOOD INTAKE, BODYWEIGHT, LOCOMOTOR ACTIVITY AND SUBCELLULAR DISTRIBUTION OF THE DRUG IN RAT BRAIN.
185931 03-03
INTERACTION OF D-AMPHETAMINE WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY OF MICE.
189613 04-04
EFFECTS OF DELTA9-THC ON FOOD AND WATER INTAKE OF DEPRIVATION EXPERIENCED RATS.
191375 04-04

INTEGRATIVE
THE NOOTROPIC APPROACH TO THE PHARMACOLOGY OF THE INTEGRATIVE ACTIVITY OF THE BRAIN.
173495 01-02

INTELLIGENCE
PARKINSONISM, L-DOPA, AND INTELLIGENCE.
175426 02-11

INTENSITY
THE EFFECTS OF CHLORDIAZEPOXIDE (LIBRIUM) ON THE INTENSITY AND HABITUATION OF AGONISTIC BEHAVIOR IN MALE SIAMESE FIGHTING FISH.
177722 02-04

INTERACTION
PHARMACOLOGICAL INTERACTION BETWEEN CANNABIDIOL AND DELTA9-TETRAHYDROCANNABINOL.
169472 01-03
LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND GAMMA-AMINOBUTYRIC ACID (GABA) INTERACTION ON SPONTANEOUS POTENTIALS AND THE EVOKED RESPONSE IN THE AVIAN TECTUM.
169689 01-03
INTERACTION BETWEEN PRIOR EXPERIENCE AND THE EFFECTS OF CHLORPROMAZINE ON EXPLORATION IN THE RAT.
171308 01-04
INTERACTION BETWEEN ATROPINE AND OXOTREMORINE ON CORTICAL ACETYLCHOLINE AND MOTOR ACTIVITY.
171606 01-03
INTERACTION BY FENFLURAMINE WITH THE METABOLISM OF D-AMPHETAMINE IN THE RAT.
171634 01-03
INTERACTION OF PHENOTHIAZINE DERIVATIVES WITH HUMAN CERULOPLASMIN.
177335 02-13
INTERACTION OF CENTRALLY ADMINISTERED OUABAIN WITH AGENTS AFFECTING SYMPATHETIC FUNCTION.
178640 02-03
INTERACTION OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON INTESTINAL MOTILITY IN MICE.
180057 02-03
INTERACTION OF APOMORPHINE, NEUROLEPTICS AND STIMULANTS WITH ALPHA-METHYL-M-TYRAMINE, A FALSE DOPAMINERGIC TRANSMITTER.
181809 02-03
INTERACTION OF CYCLIC AMP WITH NEUROPHARMACOLOGIC DEPRESSANT AGENTS.
182155 02-03
INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CAFFEINE, (C), NICOTINE (N), PHENOBARBITAL (P): EFFECTS ON CONDITIONED AVOIDANCE (CAR).
182192 02-04
INTERACTION OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A PURPORTED HASHISH AND LSD ANTAGONIST, WITH SEVERAL CENTRAL NEUROCHEMICAL SYSTEMS.
182217 03-04
THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (THC), PENTOBARBITAL AND SKF-525-A WITH THE CARDIOVASCULAR SYSTEM OF THE RAT.
182218 03-03
CANNABIDIOL INTERACTION WITH DELTA9-TETRAHYDROCANNABINOL.
183788 03-03
THE EFFECT OF LOW ENVIRONMENTAL TEMPERATURE ON THE TRANYLCYPROMINE MEPERIDINE INTERACTION IN MICE.
183897 03-03
THE EFFECT OF P-CHLOROAMPHETAMINE ON MOTILITY IN RATS AFTER INHIBITION OF MONOAMINE SYNTHESIS, STORAGE, UPTAKE AND RECEPTOR INTERACTION.
185959 03-04
METHYLPHENIDATE ANTAGONISM OF HALOPERIDOL, INTERACTION WITH CHOLINERGIC AND ANTICHOLINERGIC DRUGS.
186370 03-04
INTERACTION BETWEEN SEROTONIN AND MORPHINE IN THE GUINEA-PIG ILEUM.
186698 03-03
INTERACTION AMONG GENOTYPE, UNCONDITIONED STIMULUS, D-AMPHETAMINE, AND ONE-WAY AVOIDANCE BEHAVIOR OF RATS.
187702 04-04
INTERACTION OF LOW-DOSE AMPHETAMINE USE WITH SCHIZOPHRENIA IN OUTPATIENTS: THREE CASE REPORTS.
189099 04-15
INTERACTION OF D-AMPHETAMINE WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY OF MICE.
189613 04-04
INTERACTION BETWEEN ALCOHOL, MINOR TRANQUILIZERS AND MORPHINE.
191141 04-04
POSITIVE REINFORCING EFFECTS OF APOMORPHINE, D-AMPHETAMINE AND MORPHINE: INTERACTION WITH HALOPERIDOL.
191899 04-04
SOURCES OF VARIABILITY IN THE PHARMACODYNAMICS OF 14C-IMIPRAMINE INCLUDING INTERACTION WITH DIAZEPAM OR THIORIDAZINE.
191925 04-03
INTERACTION OF MESCALINE AND STRESS ON SHUTTLEBOX ESCAPE/AVOIDANCE IN RATS.
191934 04-04
DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) IMIPRAMINE INTERACTION ON MOUSE BODY TEMPERATURE.
191996 04-03
INTERACTION OF SEROTONIN ANTAGONISTS WITH 3,4-DICHLORO-2-(2-IMIDAZOLIN-2-YL-THIO) 2 ACETOPHENONE HYDROBROMIDE (DITA) AND D-AMPHETAMINE HYDROBROMIDE (DITA) AND D-AMPHETAMINE ON CERTAIN BEHAVIORAL PARAMETERS OF MALE MICE.
192014 04-04
INTERACTION BETWEEN NEUROLEPTIC THERAPY AND SOCIOTHERAPEUTIC APPROACH. AN INVESTIGATION WITH PENFLURIDOL AND HALOPERIDOL.
192431 04-08

INTERACTIONS
INTERACTIONS OF DIAZEPAM AND HALOTHANE IN RATS.
171633 01-03
EFFECTS AND INTERACTIONS OF SCOPOLAMINE AND D-AMPHETAMINE ON SCHEDULE-CONTROLLED RESPONDING IN RATS. (PH.D. DISSERTATION).
173748 01-04
INTERACTIONS IN MAN OF DELTA9-TETRAHYDROCANNABINOL: I. ALPHA-METHYL-PARA-TYROSINE.
174347 01-13
AMPHETAMINE TRICYCLIC INTERACTIONS: ROLE OF THE HYDROXYLATION OF AMPHETAMINE IN ITS CENTRAL AND PERIPHERAL MODE OF ACTION. (PH.D. DISSERTATION).
174963 01-03
AN INVESTIGATION OF INTERACTIONS AMONG LSD, DEXTROAMPHETAMINE, AND VERBAL BEHAVIOR IN MONOLOGUES AND DIALOGUES. (PH.D. DISSERTATION).
185600 03-14
EFFECTS OF CLONIDINE AND SOME ALPHA-ADRENORECEPTOR BLOCKING AGENTS ON AVOIDANCE CONDITIONED REFLEXES IN RATS: THEIR INTERACTIONS AND ANTAGONISM BY ATROPINE.
186576 03-04
EFFECTS OF SOME METALLIC CATIONS ON CEREBRAL CORTICAL NEURONES AND THEIR INTERACTIONS WITH BIOGENIC AMINES.
187806 04-03
INTERACTIONS OF CHLORPHENIRAMINE ETHANOL COMBINATIONS: ACUTE TOXICITY AND ANTIHISTAMINIC ACTIVITY.
188875 04-05
ANTICONVULSANT EFFECTS OF CANNABINOLS IN MICE: DRUG INTERACTIONS WITH CANNABINOIDS AND CANNABINOID INTERACTIONS WITH PHENYTOIN.
189513 04-03
OUABAIN RECEPTOR INTERACTIONS IN (NA$_{..}$ $_{..}$ K$_{..}$) ATPASE PREPARATIONS.
189567 04-03
DRUG INTERACTIONS.
190258 04-15
METABOLIC INTERACTIONS BETWEEN NORTRIPTYLINE AND THIORIDAZINE IN RATS.
190346 04-03
INTERACTIONS OF PSYCHOTROPIC DRUGS AND MESCALINE IN VITRO.
191933 04-03
CHOLINERGIC AMINERGIC INTERACTIONS IN LEAD INDUCED HYPERACTIVITY.
191954 04-05
INTERACTIONS BETWEEN RO-4-1284 AND D-AMPHETAMINE (DA) ON SHUTTLEBOX AVOIDANCE IN RATS.
192009 04-04

INTERACTIVE
INTERACTIVE EFFECTS OF CYCLOHEXIMIDE AND PUROMYCIN IN ALTERING BRAIN POLYRIBOSOMES AND NEURAL AND BEHAVIOURAL RESPONSES TO ELECTROSHOCK IN MICE.
175230 02-03

INTERDEPENDENT
ORTHOGONAL FACTORS VS. INTERDEPENDENT VARIABLES AS PREDICTORS OF DRUG TREATMENT RESPONSE IN ANXIOUS OUTPATIENTS.
171299 01-14

INTERFERES
HYDROXYLAMINE INTERFERES WITH THE BEHAVIORAL RESPONSE TO MORPHINE DEPENDENCE IN MICE.
171905 01-04

INTERNAL
A DOUBLE-BLIND CLINICAL TRIAL OF DOXEPIN HYDROCHLORIDE AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION IN THE FIELD OF INTERNAL MEDICINE.
171282 01-11
CLINICAL PHARMACOLOGICAL STUDY OF BROMAZEPAM IN THE FIELD OF INTERNAL MEDICINE.
176473 02-10
MASS FRAGMENTOGRAPHIC ANALYSIS OF HOMOVANILLIC ACID AND ITS HOMOISO ANALOGUE IN CEREBROSPINAL FLUID USING THE ALPHA DIDEUTERO ACID AS INTERNAL STANDARD.
186566 03-16

INTERNATIONAL
INTERNATIONAL REFERENCE CENTERS NETWORK FOR PSYCHOTROPIC DRUGS.
167706 01-17

INTERPRETATION
CHLORDIAZEPOXIDE OVERDOSE: INTERPRETATION OF SERUM DRUG CONCENTRATIONS.
177393 02-15
METHYPRYLON OVERDOSE: INTERPRETATION OF SERUM DRUG CONCENTRATIONS.
177394 02-15

INTERPRETATIONS
THE USE OF DRUGS IN PSYCHIATRIC INTERVIEWS: SOME INTERPRETATIONS BASED ON CONTROLLED EXPERIMENTS.
189074 04-17

INTERRELATED
SOME INTERRELATED PROPERTIES OF BRAIN MONOAMINE OXIDASE.
191498 04-01

INTERRELATIONSHIP
SUBSTITUTED BENZOXAZOLE/BENZTHIAZOLE-2-THIONES: INTERRELATIONSHIP BETWEEN ANTICONVULSANT ACTIVITY AND INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND MONOAMINE OXIDASE.
183601 03-03

INTERRESPONSE
INTERRESPONSE TIME CHANGES AS A FUNCTION OF DEPRIVATION AND AMPHETAMINE ADMINISTRATION.
171612 01-04
THE EFFECTS OF D-AMPHETAMINE ON THE INTERRESPONSE TIMES OF RATS AND GUINEA-PIGS ON A MODIFIED SIDMAN DISCRIMINATED AVOIDANCE SCHEDULE.
189519 04-04

INTERRUPTION
ENHANCEMENT OF AMPHETAMINE ACTION AFTER INTERRUPTION OF ASCENDING SEROTONERGIC PATHWAYS.
189398 04-03

INTERVAL
COMPARISON OF CODEINE AND ETHYL ALCOHOL SELF-ADMINISTRATION UNDER A VARIABLE INTERVAL (VI) SCHEDULE IN MONKEYS.
191983 04-04

INTERVALS
SUPPRESSION OF LORDOSIS IN GUINEA-PIGS BY ETHAMOXY-TRIPHETOL (MER-25) GIVEN AT LONG INTERVALS (36-46 HR) AFTER ESTRADIOL BENZOATE TREATMENT.
186686 03-04

INTERVENTION
THE ROLE OF RESEARCH IN DRUG ABUSE INTERVENTION: STREET DRUG ANALYSES.
167382 01-17
A STUDY OF THE EFFECTS OF RITALIN INTERVENTION UPON THE PERCEPTUAL COMPETENCIES OF CHILDREN DIAGNOSED AS GIVING EVIDENCE OF PSYCHONEUROLOGICAL LEARNING DISABILITIES. (PH.D. DISSERTATION).
186833 03-14

INTERVENTIONS
BIOLOGICAL INTERVENTIONS IN PSYCHOSES OF CHILDHOOD.
175872 02-17
CONTROL OF THE HYPERACTIVE CHILD VIA MEDICATION -- AT WHAT COST TO PERSONALITY DEVELOPMENT; SOME PSYCHOLOGICAL IMPLICATIONS AND CLINICAL INTERVENTIONS.
176810 02-11

INTERVIEW
EXPERIENCE IN THE DRUG HORIZON AND PSYCHIATRIC INTERVIEW.
176542 02-11
THE STANDARDIZED VIDEOTAPE INTERVIEW AS AN OBJECTIVE DEPENDENT VARIABLE IN PSYCHOTROPIC DRUG RESEARCH.
183635 03-17
THE METHOHEXITAL METHYLPHENIDATE INTERVIEW: A PROPOSED NEW DRUG COMBINATION FOR NARCOTHERAPY.
190242 04-07

INTERVIEWS
THE USE OF DRUGS IN PSYCHIATRIC INTERVIEWS: SOME INTERPRETATIONS BASED ON CONTROLLED EXPERIMENTS.
189074 04-17

INTESTINAL
INTERACTION OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON INTESTINAL MOTILITY IN MICE.
180057 02-03
INTESTINAL EFFECTS OF 5-HYDROXYTRYPTAMINE AND MORPHINE IN GUINEA-PIGS, DOGS, CATS AND MONKEYS.
188202 04-03

INTIMATIONS
CLINICAL INTIMATIONS OF AMINE BALANCE AND PERMISSION.
191534 04-09

INTOXICATED
INDUCTION OF SEVERE DEPRESSION BY PHYSOSTIGMINE IN MARIJUANA INTOXICATED INDIVIDUALS.
177450 02-14

INTOXICATING
MANUAL OF INTOXICATING DRUGS.
175537 02-17

INTOXICATION
ULTRASTRUCTURE OF CNS IN LITHIUM INTOXICATION.
176476 02-05
FATAL INTOXICATION OF A YOUNG DRUG ADDICT WITH DIAZEPAM.
178619 02-05
EFFECT OF CHRONIC INTOXICATION WITH (_) AMPHETAMINE ON ITS CONCENTRATION IN LIVER AND BRAIN AND ON (14C) LEUCINE INCORPORATION INTO MICROSOMAL AND CYTOPLASMIC PROTEINS OF RAT LIVER.
180056 02-05
CHRONIC MEPROBAMATE INTOXICATION AND PHOTOMYOCLONIC RESPONSE.
181377 02-15
CLINICAL STUDIES OF ACUTE PSYCHOSIS ON THE BASIS OF CHRONIC HYPNOTICA INTOXICATION -- AN ABSTRACT REPORT.
182755 03-15
THE EFFECT OF CHLORPROMAZINE AND STELAZINE ON LYSOSOMES OF RAT LIVER DURING ACUTE INTOXICATION.
191121 04-03

INTRAARTERIAL
A CRITICAL EVALUATION OF THE PRINCIPLES GOVERNING THE ADVANTAGES OF INTRAARTERIAL INFUSIONS.
170112 01-06
CNS DEPRESSION IN THE ABSENCE OF PROLACTIN RELEASE FOLLOWING INTRAARTERIAL INJECTIONS OF SODIUM PENTOTHAL IN THE PROESTROUS RAT.
173257 01-03

INTRACAROTID
GENERALIZED PENICILLIN EPILEPSY IN THE CAT: EFFECTS OF INTRACAROTID AND INTRAVERTEBRAL PENTYLENETETRAZOL AND AMOBARBITAL INJECTIONS.
188374 04-03

INTRACAUDATE
TREMOR INDUCTION BY INTRACAUDATE INJECTIONS OF BRETYLIUM, TETRABENAZINE, OR MESCALINE: FUNCTIONAL DEFICITS IN CAUDATE DOPAMINE.
167329 01-03
THE EFFECTS OF INTRACAUDATE INJECTIONS OF CHLORPROMAZINE ON CONDITIONED AVOIDANCE AND SELF-STIMULATION BEHAVIOR. (PH.D. DISSERTATION).
173749 01-04
ANALYSIS OF TREMORGENIC EFFECTS OF INTRACAUDATE D-AMPHETAMINE.
182129 02-03

INTRACEREBRAL
INTRACEREBRAL INJECTION OF 6-HYDROXYDOPAMINE AND HYDROGEN PEROXIDE IN CATS: SPECIFIC AND NONSPECIFIC EFFECTS ON STRIATAL BIOGENIC AMINES.
188426 04-03
EFFECTS OF INTRACEREBRAL INJECTION OF 5,6-HYDROXYTRYPTAMINE ON CEREBRAL MONOAMINES AND SLEEP STATES IN THE CAT/.
189023 04-02

INTRACISTERNAL
EFFECTS OF INTRACISTERNAL 6-HYDROXYDOPAMINE TREATMENT ON ACQUISITION AND PERFORMANCE OF RATS IN A DOUBLE T-MAZE.
187696 04-04

INTRACRANIAL
INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: IV. INFLUENCE OF AMPHETAMINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
185961 03-04
NEGATIVE AND POSITIVE INTRACRANIAL REINFORCEMENT THRESHOLDS: EFFECTS OF MORPHINE.
190330 04-04
ANALGESIA AND HYPERREACTIVITY PRODUCED BY INTRACRANIAL MICROINJECTIONS OF MORPHINE INTO THE PERIAQUEDUCTAL GRAY MATTER OF THE RAT.
191367 04-04
ROLE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN IN INTRACRANIAL REWARD.
191527 04-04

INTRAGASTRIC
INTRAGASTRIC SELF-ADMINISTRATION OF PSYCHOACTIVE DRUGS IN THE RHESUS MONKEY.
191939 04-04

INTRAHYPOTHALAMIC
FURTHER EVIDENCE ON THE INTRAHYPOTHALAMIC LOCUS FOR ANDROGENIZATION OF FEMALE RATS.
187935 04-03

INTRAMUSCULAR
RAPID CONTROL OF PSYCHOTIC EXCITEMENT STATES WITH INTRAMUSCULAR HALOPERIDOL.
170627 01-09

COMPARISON OF GRADED SINGLE INTRAMUSCULAR DOSES OF MORPHINE AND PENTOBARBITAL IN MAN.
187254 03-15

ON-OFF PHENOMENON WITH LEVODOPA THERAPY IN PARKINSONISM: CLINICAL AND PHARMACOLOGIC CORRELATIONS AND THE EFFECT OF INTRAMUSCULAR PYRIDOXINE.
188560 04-11

INTRAPERITONEAL

EFFECTS OF INTRAPERITONEAL AND INTRAVENTRICULAR D-AMPHETAMINE ADMINISTRATION ON ACTIVE AVOIDANCE PERFORMANCE IN THE RAT.
175242 02-04

INTRASPECIFIC

BRAIN AMINES AND APOMORPHINE-INDUCED INTRASPECIFIC AGGRESSIVE BEHAVIOR IN THE RAT.
186374 03-04

INTRAVENOUS

PREANESTHETIC MEDICATION IN ELECTIVE SURGERY: COMPARISON OF INTRAVENOUS DIAZEPAM WITH MEPERIDINE.
167338 01-11

PHARMACOKINETIC PROFILE OF DIAZEPAM IN MAN FOLLOWING SINGLE INTRAVENOUS AND ORAL AND CHRONIC ORAL ADMINISTRATION.
170838 01-13

DRUG LEVEL OF D- AND L-AMPHETAMINE DURING INTRAVENOUS SELF-ADMINISTRATION.
185960 03-04

ORAL AND INTRAVENOUS TOXICITY OF DELTA9-TETRAHYDROCANNABINOL IN RHESUS MONKEYS.
188872 04-05

PHARMACOKINETICS AND DISTRIBUTION PROPERTIES OF PENTOBARBITAL IN HUMANS FOLLOWING ORAL AND INTRAVENOUS ADMINISTRATION.
191444 04-13

EFFECTS OF INTRAVENOUS D-AMPHETAMINE, L-AMPHETAMINE AND METHYLPHENIDATE IN SCHIZOPHRENICS.
191508 04-08

ALPHA-METHYL-P-TYROSINE INHIBITION OF SELF-ADMINISTERED INTRAVENOUS MORPHINE AND ORAL WATER IN RATS.
191940 04-04

INTRAVENOUSLY

DIAZEPAM USED INTRAVENOUSLY DURING REDUCTION OF FRACTURES AND DISLOCATIONS.
174880 01-17

A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY IN MAN OF INTRAVENOUSLY ADMINISTERED DELTA9-TETRAHYDROCANNABINOL, CANNABINOL, AND CANNABIDIOL.
176747 02-03

COMPARISON OF INTRAVENOUSLY ADMINISTERED METHADONE (ME), MORPHINE (MO), HEROIN (H) AND PLACEBO (P).
182163 02-03

INTRAVENTRICULAR

RECOVERY OF FEEDING AND DRINKING BY RATS AFTER INTRAVENTRICULAR 6-HYDROXYDOPAMINE OR LATERAL HYPOTHALAMIC LESIONS.
168484 01-03

THE DISTRIBUTION OF DELTA1-TETRAHYDROCANNABINOL AND 7-HYDROXY-DELTA1-TETRAHYDROCANNABINOL IN THE MOUSE BRAIN AFTER INTRAVENTRICULAR INJECTION.
172596 01-03

EFFECTS OF INTRAPERITONEAL AND INTRAVENTRICULAR D-AMPHETAMINE ADMINISTRATION ON ACTIVE AVOIDANCE PERFORMANCE IN THE RAT.
175242 02-04

STUDIES ON CENTRAL REGULATING MECHANISM OF THE HYPOGLYCEMIA INDUCED BY INTRAVENTRICULAR ADMINISTRATION OF CHLORPROMAZINE.
182093 02-03

EFFECTS ON HOMEOSTASIS OF INTRAVENTRICULAR INJECTIONS OF 6-HYDROXYDOPAMINE IN RATS.
187695 04-03

INTRAVENTRICULARLY

BEHAVIOURAL EFFECTS OF YOHIMBINE ADMINISTERED INTRAVENTRICULARLY IN THE RAT.
177721 02-04

THE EFFECTS OF INTRAVENTRICULARLY ADMINISTERED CATECHOLAMINES AND SEROTONIN ON THE RESERPINE INDUCED SPIKE WAVES RECORDED FROM THE MEDICAL NUCLEUS TRAPEZOIDES IN THE RABBIT.
182094 02-03

INTRAVERTEBRAL

GENERALIZED PENICILLIN EPILEPSY IN THE CAT: EFFECTS OF INTRACAROTID AND INTRAVERTEBRAL PENTYLENETETRAZOL AND AMOBARBITAL INJECTIONS.
188374 04-03

INVERSION

INVERSION BY APOMORPHINE OF THE TENDENCY OF FEMALE RATS TO BE DEFEATED BY MALES WHEN COMPETING FOR FOOD IN A STRAIGHT RUNWAY.
184212 03-04

INVESTIGATION

A MULTICENTER INVESTIGATION OF LORAZEPAM IN ANXIETY NEUROSIS.
167346 01-10

A DOUBLE-BLIND INVESTIGATION OF DIMETHACRINE VERSUS IMIPRAMINE IN HOSPITALIZED DEPRESSIVE STATES.
171695 01-09

ACUTE CEREBELLAR DISTURBANCE ASSOCIATED WITH DIAZEPAM THERAPY -- A CASE REPORT AND FURTHER INVESTIGATION.
177392 02-15

AN INVESTIGATION OF INTERACTIONS AMONG LSD, DEXTROAMPHETAMINE, AND VERBAL BEHAVIOR IN MONOLOGUES AND DIALOGUES. (PH.D. DISSERTATION).
185600 03-14

AN EXPERIMENTAL INVESTIGATION OF DEPENDENCE LIABILITY OF METHAQUALONE IN RATS.
186569 03-03

AN INVESTIGATION OF THE BEHAVIOURAL NATURE OF THE PSYCHOMOTOR STIMULANT EFFECT OF AMPHETAMINE.
188620 04-04

INVESTIGATION OF PHYSICAL DEPENDENCE ON A NEW BENZODIAZEPINE DERIVATIVE, BROMAZEPAM.
189209 04-05

PSYCHOENDOCRINE INVESTIGATION IN SCHIZOPHRENIA: RELATIONSHIP BETWEEN PITUITARY GONADAL FUNCTION AND BEHAVIOR.
191190 04-14

INTERACTION BETWEEN NEUROLEPTIC THERAPY AND SOCIOTHERAPEUTIC APPROACH. AN INVESTIGATION WITH PENFLURIDOL AND HALOPERIDOL.
192431 04-08

INVESTIGATIONS

PSYCHOMETRIC INVESTIGATIONS IN PARKINSONS SYNDROME DURING TREATMENT WITH L-DOPA AND RELEVANCE OF SOME PSYCHOLOGICAL PHENOMENA.
168578 01-13

ONGOING INVESTIGATIONS OF CEREBRAL GLUTAMINE EXCRETION SCHIZOPHRENICS DURING TREATMENT WITH NEUROLEPTIC.
174101 01-08

INVESTIGATIONS ON THE FATE OF THE ANTICONVULSANT CLONAZEPAM IN THE ORGANISM OF MAN, RAT AND DOG.
179022 02-13

CONTROL OF INSOMNIA WITH A NEW BENZODIAZEPINE: THE FLUNITRAZEPAM OR RO-5-4200 (FIRST INVESTIGATIONS OF PHASE I AND CONTROLLED INVESTIGATIONS OF PHASE II).
183198 03-11

HISTO-AUTORADIOGRAPHIC INVESTIGATIONS ON THE DISTRIBUTION OF INJECTED 5-HYDROXYTRYPTAMINE (SEROTONIN) IN THE BRAIN AND THE PITUITARY OF MICE.
185900 03-03

BEHAVIORAL AND VISUAL EVOKED POTENTIAL INVESTIGATIONS DURING TRIHEXYPHENIDYL AND THIOTHIXENE TREATMENT IN PSYCHOTIC BOYS.
187115 03-09

CORRELATION OF PHARMACOLOGICAL INVESTIGATIONS WITH THE CLINICAL EFFICACY OF ANTIDEPRESSANT DRUGS.
192420 04-13

INVESTIGATORY

PSYCHOTROPIC EFFECT OF ANALGESICS AND NEUROLEPTICS ON A MODEL OF INVESTIGATORY BEHAVIOR CHANGED BY PAIN.
191120 04-04

INVOLUNTARY

THE SUPPRESSION OF INVOLUNTARY MOVEMENTS WITH TETRABENAZINE.
178618 02-11

INVOLVED

POTENTIAL NEUROTRANSMITTERS AND RECEPTOR MECHANISMS INVOLVED IN THE CENTRAL CONTROL OF BODY TEMPERATURE IN HAMSTERS. (PH.D. DISSERTATION).
174962 01-03

ARE CHOLINERGIC MECHANISMS INVOLVED IN MORPHINE EFFECTS ON MOTILITY
184198 03-03

INVOLVEMENT

POSSIBLE INVOLVEMENT OF CYCLIC NUCLEOTIDES IN THE STIMULATION OF PITUITARY FUNCTION ELICITED BY RESERPINE. (UNPUBLISHED PAPER).
170086 01-03

IS THERE A RELATIONSHIP BETWEEN THE INVOLVEMENT OF EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS WITH THE CATALEPTIC ACTION OF NEUROLEPTIC AGENTS AND THEIR CLINICAL ANTIPSYCHOTIC EFFECT?
171305 01-03

POSSIBLE INVOLVEMENT OF A NORADRENERGIC AREA OF THE AMYGDALA WITH STEREOTYPED BEHAVIOUR.
176877 02-04

INVOLVEMENT OF ALPHA-RECEPTORS IN CLONIDINE INDUCED INHIBITION OF TRANSMITTER RELEASE FROM CENTRAL MONOAMINE NEURONES.
182345 03-03

COMPARISON OF THE LOCOMOTOR STIMULANT MECHANISMS OF ACTION OF D-AMPHETAMINE AND D-AMPHETAMINE PLUS L-DOPA: POSSIBLE INVOLVEMENT OF SEROTONIN.
187119 03-04

INVOLVEMENT OF BRAIN CHOLINERGIC MECHANISMS IN THE ACTION OF CHLORPROMAZINE.
188891 04-03

EVIDENCE FOR A DOPAMINERGIC INVOLVEMENT IN THE MAINTENANCE OF SELF-STIMULATION.
191526 04-03

DRUG-INDUCED AGGRESSION IN CHICKS: DIFFERENTIAL INVOLVEMENT OF BIOGENIC AMINES.
191977 04-04

IODINE

THE EFFECT OF LITHIUM ON THYROID IODINE RELEASE IN PATIENTS WITH PRIMARY AFFECTIVE DISORDER.
186580 03-09

ION

THE EFFECTS OF PSYCHIC STIMULANTS ON THE ACTIVITY OF POTASSIUM AND SODIUM ION STIMULATED ATPASE IN THE MICROSOMAL FRACTIONS OF THE BRAIN OF RATS.
183518 03-01

IONTOPHORESIS

TO SPRITZ OR NOT TO SPRITZ: THE DOUBTFUL VALUE OF AIMLESS IONTOPHORESIS.
187132 03-06

IPRINDOLE

A DOUBLE-BLIND TRIAL OF IPRINDOLE AND IMIPRAMINE IN DEPRESSIVES AND RESPONSE TO ECT IN REFRACTORY CASES.
174376 01-09

EFFECT OF CHRONIC TREATMENT WITH DESIPRAMINE (DMI) AND IPRINDOLE (IP) ON THE NOREPINEPHRINE (NE) SENSITIVE ADENYLATE CYCLASE SYSTEM IN SLICES OF THE RAT LIMBIC FOREBRAIN.
192003 04-03

IPRONIAZID

THE EFFECT OF IPRONIAZID AND TRANYLCYPROMINE STUDIED WITH A DARK AVOIDANCE CONDITIONED SCHEDULE.
186590 03-04

THE EFFECT OF PRETREATMENT WITH IPRONIAZID ON THE BEHAVIORAL ACTIVITIES OF BETA-PHENYLETHYLAMINE IN RATS.
187932 04-04

IRIS

UPTAKE, STORAGE AND RELEASE IN VIVO OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY SYMPATHETIC NERVES OF THE IRIS.
182204 02-03

IRRATIONAL

METHAQUALONE: AN IRRATIONAL HYPNOTIC.
189902 04-15

ISOLATED

THE ACTIVITY OF SOME NEUROLEPTIC DRUGS AND AMPHETAMINE IN NORMAL AND ISOLATED RATS.
170126 01-04

KINETICS AND CELLULAR CONTROL MECHANISMS FOR IMIPRAMINE METABOLISM IN THE ISOLATED PERFUSED RAT LIVER. (PH.D. DISSERTATION).
173601 01-03

ACTION OF CONVULSANTS ON ROOT POTENTIALS AND AMINO ACID RESPONSES IN ISOLATED FROG SPINAL CORD. (UNPUBLISHED PAPER).
177976 02-03

MOLECULAR ORBITAL STUDIES ON THE CONFORMATION OF HALLUCINOGENIC INDOLEALKYLAMINES AND RELATED COMPOUNDS. THE ISOLATED MOLECULES AND THE SOLVENT EFFECT.
183406 03-01

THE INHIBITION BY BETA-ADRENOCEPTOR BLOCKING AGENTS OF CALCIUM UPTAKE INTO AND EFFLUX FROM ISOLATED SARCOPLASMIC VESICLES.
184223 03-03

THE ISOLATED PERFUSED RAT BRAIN AS A MODEL FOR STUDYING DRUGS ACTING ON THE CNS.
186589 03-06

ALPHA-L-ACETYLMETHADOL AND ITS N-DEMTHYLATED METABOLITES HAVE POTENT OPIATE ACTION IN THE GUINEA-PIG ISOLATED ILEUM.
187130 03-03

STUDIES ON CONVULSANTS IN THE ISOLATED FROG SPINAL CORD. I. ANTAGONISM OF AMINO ACID RESPONSES. (UNPUBLISHED PAPER)
190727 04-03

INFLUENCE OF PSYCHOTROPIC DRUGS ON AGGRESSIVENESS EVOKED BY DESTRUCTION OF ISOLATED STRUCTURES OF THE FOREBRAIN.
191788 04-04

ISOLATION

MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC) -- REPORT 1. THIN-LAYER CHROMATOGRAPHY OF HYPNOTICS AND TRANQUILIZERS.
181315 02-16

THE INFLUENCE OF ALDOSTERONE OR METHAMPHETAMINE ON LIVER GLYCOGEN DEPOSITION OF MICE STRESSED BY LONG-TERM ISOLATION.
182105 02-03

THE EFFECT OF METHAMPHETAMINE ON BRAIN ACH CONSUMPTION AND AGGRESSIVENESS IN MICE STRESSED MILDLY BY LONG-TERM ISOLATION.
182108 02-04

INHIBITION OF ISOLATION INDUCED AGGRESSION IN THE MOUSE BY ANTICHOLINERGIC COMPOUNDS.
182239 03-04

INHIBITION OF ISOLATION INDUCED AGGRESSION IN MICE BY ANTISEROTONERGIC DRUGS.
182240 03-04

MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC): REPORT 2 -- ISOLATION AND IDENTIFICATION OF HYPNOTICS AND TRANQUILIZER IN VIVO.
182623 03-06

ISOLATION AND IDENTIFICATION OF HYPNOTICS (8): ISOLATION AND IDENTIFICATION OF BENZALIN AND CERCINE BY THIN-LAYER CHROMATOGRAPHY IN VITRO.
182626 03-01

ISOLATION OF A POSSIBLE NEW METABOLITE OF THIORIDAZINE AND MESORIDAZINE FROM HUMAN PLASMA.
182722 03-13

ISOLE

EEG AND CARDIOVASCULAR EFFECTS OF TRYPTAMINE (T) AND LSD IN THE ENCEPHALE ISOLE CAT. (UNPUBLISHED PAPER)
174496 01-12

THE ACTION OF ALPHA-METHYLDOPA IN THE CERVEAU ISOLE PREPARATION.
187075 03-03

ISOMERIC

CENTRALLY ACTING MUSCLE RELAXANTS. ISOMERIC 9,10 DIHYDROXYOCTAHYDROPHENANTHRENES AND THEIR CARBAMATE ESTERS.
190719 04-02

ISOMERS

EFFECTS OF PSYCHOTOMIMETICS ON VASCULAR STRIPS: STUDIES OF METHOXYLATED AMPHETAMINES AND OPTICAL ISOMERS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE AND 2,5 DIMETHOXY-4-BROMOAMPHETAMINE.
177734 02-03

RELATIVE PHARMACOLOGICAL POTENCY IN MICE OF OPTICAL ISOMERS OF DELTA1-TETRAHYDROCANNABINOL.
181941 02-03

EFFECTS OF AMPHETAMINE ISOMERS ON NEUROMUSCULAR TRANSMISSION IN RAT PHRENIC NERVE DIAPHRAGM PREPARATION.
182232 03-03

THE SITE OF ACTION ON THE OPTICAL ISOMERS OF 1-METHYL-5-PHENYL-5-PROPYL BARBITURIC ACID.
185901 03-03

THE TRANYLCYPROMINE ISOMERS: A CONTROLLED CLINICAL TRIAL.
192065 04-13

ISOPRENALINE

EXTRANEURONAL REMOVAL, ACCUMULATION AND O-METHYLATION OF ISOPRENALINE IN THE PERFUSED HEART.
189604 04-03

ITEMS

STEREOTYPY WITH SELECTIVE STIMULATION OF CERTAIN ITEMS OF BEHAVIOUR OBSERVED IN AMPHETAMINE TREATED MONKEYS (CERCOPITHECUS).
180061 02-04

ITI

MULTITRIAL PASSIVE AVOIDANCE IN RATS: MESCALINE, SHOCK, AND ITI EFFECTS. (PH.D. DISSERTATION).
173162 01-04

JANSSEN

HALOPERIDOL (JANSSEN) IN THE TREATMENT OF UNSELECTED INSTITUTIONALIZED PSYCHIATRIC PATIENTS.
180299 02-11

JAPAN

PSYCHOTROPIC MEDICATION IN JAPAN.
180319 02-08

JAPANESE

EFFECTS OF CYPROTERONE ACETATE IN THE MALE JAPANESE QUAIL.
186681 03-03

JAVA

CLINICAL TRIAL WITH NOZINAN-R. AT SEVERAL MENTAL HOSPITALS IN JAVA.
176582 02-11

JEKYLL

METHAQUALONE -- A DR. JEKYLL AND MR. HYDE?
177396 02-15

JIDO-IN

CURRENT SITUATION OF THE USE OF DRUGS IN ASAHIGAWA JIDO-IN.
168302 01-17

JUDGMENT

THE EFFECTS OF HOE-36801 ON MUSCLE ACTIVITY AND BLOOD PRESSURE, ON ATTENTION AND CONCENTRATION, ON TIME

JUDGMENT AND SUBJECTIVE RESPONSES IN NEUROTICS AND NORMALS.
192429 04-14

JUMPING
CHOLINERGIC MODIFICATION OF NALOXONE INDUCED JUMPING IN MORPHINE DEPENDENT MICE.
184179 03-03

JUVENILE
RELATIONSHIP BETWEEN RESPONSE TO LOW PENTAMETHYLENETETRAZOL ADMINISTRATION AND PERSONALITY OF JUVENILE OFFENDERS AND THEIR REPEATED CRIMES.
175072 02-17

K.
OUABAIN RECEPTOR INTERACTIONS IN (NA. . K.) ATPASE PREPARATIONS.
189567 04-03

AMPHETAMINE AND NA.,K. - ATPASE IN THE BRAIN.
191789 04-03

K.-ATPASE
(3H) OUABAIN BINDING TO NA.-ATPASE AND K.-ATPASE: INHIBITION BY BETA, GAMMA METHYLENE ATP.
182184 02-03

KABI-1702
THE PHARMACOLOGICAL EVALUATION IN LABORATORY ANIMALS OF KABI-1702 -- A NEW SEDATIVE HYPNOTIC DRUG.
171632 01-03

KCL
EFFECT OF ANESTHETIC AGENTS ON THE SYNTHESIS AND DISAPPEARANCE OF BRAIN DOPAMINE NORMALLY AND AFTER HALOPERIDOL, KCL OR AXOTOMY.
189571 04-03

KETAMINE
THE USE OF KETAMINE IN PSYCHIATRY.
175282 02-07

ON THE CEREBRAL ACCUMULATION OF KETAMINE AND THE RELATIONSHIP BETWEEN METABOLISM OF THE DRUG AND ITS PHARMACOLOGICAL EFFECTS.
186693 03-03

KETAMINE INDUCED POSTANESTHETIC DELIRIUM ATTENUATED BY TETRAHYDROAMINOACRIDINE.
188689 04-05

EFFECTS OF PHENCYCLIDINE AND KETAMINE ON FOOD MAINTAINED BEHAVIOR IN THE PIGEON.
191973 04-04

KEY-PRESS
NALTREXONE AND NALOXONE: AGONIST AND ANTAGONIST EFFECTS ON KEY-PRESS RESPONDING OF PIGEONS MAINTAINED UNDER A MULTIPLE SCHEDULE OF FOOD PRESENTATION.
191926 04-04

KILLING
DIAZEPAM-INDUCED PLAY BEHAVIOR IN CATS DURING PREY KILLING.
184979 03-04

KINETICS
KINETICS AND CELLULAR CONTROL MECHANISMS FOR IMIPRAMINE METABOLISM IN THE ISOLATED PERFUSED RAT LIVER. (PH.D. DISSERTATION).
173601 01-03

KLEINE-LEVINE
A CASE OF KLEINE-LEVINE SYNDROME.
183418 03-14

K42
THE INFLUENCE OF PSYCHOSTIMULANTS ON K42 MEMBRANE PERMEABILITY IN VARIOUS PORTIONS OF RAT BRAIN.
191122 04-03

L-ALPHA-METHYLDOPAHYDRAZINE
PARKINSONISM DEMENTIA OF GUAM: TREATMENT WITH LEVODOPA AND L-ALPHA-METHYLDOPAHYDRAZINE.
179996 02-13

LEVODOPA COMBINED WITH MK-486 (L-ALPHA-METHYLDOPAHYDRAZINE) -- A PERIPHERAL DECARBOXYLASE INHIBITOR IN PARKINSONS DISEASE.
187615 04-11

L-AMPHETAMINE
THE EFFECTS OF D- AND L-AMPHETAMINE ON FIXED-INTERVAL AND FIXED-RATIO BEHAVIOR IN TOLERANT AND NONTOLERANT RATS.
168438 01-04

RELATIVE POTENCIES OF D- AND L-AMPHETAMINE ON THE RELEASE OF DOPAMINE FROM CAT BRAIN IN VIVO.
176874 02-03

DIFFERENTIAL EFFECTS OF D- AND L-AMPHETAMINE ON THE SLEEP OF DEPRESSED PSYCHIATRIC PATIENTS ON AND OFF LITHIUM CARBONATE TREATMENT. (UNPUBLISHED PAPER).
178432 02-09

DRUG LEVEL OF D- AND L-AMPHETAMINE DURING INTRAVENOUS SELF-ADMINISTRATION.
185960 03-04

EFFECTS OF INTRAVENOUS D-AMPHETAMINE, L-AMPHETAMINE AND METHYLPHENIDATE IN SCHIZOPHRENICS.
191508 04-08

L-ASPARAGINASE
EFFECT OF L-ASPARAGINASE ON RETENTION OF MAZE LEARNING IN MICE.
167324 01-04

L-DELTA9-TETRAHYDROCANNABINOL
EFFECTS OF L-DELTA9-TETRAHYDROCANNABINOL, DL-AMPHETAMINE AND PENTOBARBITAL ON OXYGEN CONSUMPTION BY MOUSE BRAIN AND HEART HOMOGENATES.
181813 02-03

L-DELTA9-TRANS-TETRAHYDROCANNABINOL
THE EFFECTS OF L-DELTA9-TRANS-TETRAHYDROCANNABINOL ON LOW AND HIGH RESPONSE RATES GENERATED UNDER TWO SIMILAR CONDITIONS (PH.D. DISSERTATION).
168230 01-04

L-DOPA
ANIMAL MODELS FOR AN ENZYMIC BLOOD-BRAIN BARRIER MECHANISM FOR THERAPEUTICALLY ADMINISTERED L-DOPA.
167359 01-03

EFFECTS OF L-DOPA ON NATURAL NIGHT SLEEP AND ON REBOUND OF REM SLEEP.
167921 01-14

TETRAHYDROISOQUINOLINE ALKALOIDS: IN VIVO METABOLITES OF L-DOPA IN MAN.
168286 01-13

L-DOPA IN 122 CASES OF PARKINSONS DISEASE AT AGE 70 OR OVER. A COMPARATIVE STUDY WITH A GROUP OF PATIENTS AGED 41 TO 69 YEARS.
168369 01-11

PSYCHOMETRIC INVESTIGATIONS IN PARKINSONS SYNDROME DURING TREATMENT WITH L-DOPA AND RELEVANCE OF SOME PSYCHOLOGICAL PHENOMENA.
168578 01-13

EMOTIONAL FUNCTIONS IN SHORT-TERM VS. LONG-TERM L-DOPA THERAPY IN PARKINSONISM.
168619 01-15

FAILURES OF L-DOPA.
168777 01-13

COMBINATION OF L-DOPA, DESIPRAMINE, AND A DECARBOXYLASE INHIBITOR IN THE TREATMENT OF DEPRESSION.
169468 01-09

L-DOPA: EFFECT ON ETHANOL NARCOSIS AND BRAIN BIOGENIC AMINES IN MICE.
169782 01-03

SLEEP STUDIES AND THERAPEUTIC TRIAL WITH L-DOPA IN A CASE OF STIFF-MAN SYNDROME.
171134 01-13

EFFECTS OF L-DOPA ON SCHIZOPHRENIA.
171245 01-08

FUNCTIONAL EVALUATION OF PITUITARY RESERVE IN PATIENTS WITH THE AMENORRHEA GALACTORRHEA SYNDROME UTILIZING LUTEINIZING HORMONE RELEASING HORMONE (LH-RH), L-DOPA AND CHLORPROMAZINE.
175245 02-13

PARKINSONISM, L-DOPA, AND INTELLIGENCE.
175426 02-11

THE PATIENTS VIEW OF L-DOPA AFTER ONE YEARS THERAPY.
175459 02-15

THREE CASES OF SCHIZOPHRENIA TREATED WITH L-DOPA.
175550 02-08

CYCLIC ADENOSINE MONOPHOSPHATE: SELECTIVE INCREASE IN CAUDATE NUCLEUS AFTER ADMINISTRATION OF L-DOPA.
176254 02-13

EFFECT OF CHRONIC ADMINISTRATION OF L-DOPA ON CATECHOL-O-METHYLTRANSFERASE IN RAT TISSUES.
176936 02-03

EFFECTS OF SHORT-TERM VERSUS LONG-TERM L-DOPA THERAPY IN PARKINSONISM ON CRITICAL FLICKER FREQUENCY.
177511 02-11

DRUG-INDUCED CATALEPSY AS INFLUENCED BY PSYCHOSTIMULANTS, APOMORPHINE, L-DOPA, AND YOHIMBINE.
177730 02-13

L-DOPA CHLORPROMAZINE ANTAGONISM ON RUNNING ACTIVITY IN MICE.
177785 02-04

L-DOPA AND THE TREATMENT OF EXTRAPYRAMIDAL DISEASE. (UNPUBLISHED PAPER).
177975 02-11

SYNTHESIS AND ANTIRESERPINE ACTIVITY OF PEPTIDES OF L-DOPA.
180097 02-03

L-DOPA AND POTENTIATION OF ALCOHOL ANESTHESIA BY CHLORPROMAZINE.
182091 02-03

L-DOPA EFFECTS ON MOTOR AND CENTRAL PROGRAMMING DEFICITS IN PARKINSONISM.
184976 03-14

A CASE OF PERIODIC SOMNOLENCE IMPROVED BY THE CO-MEDICATION OF L-DOPA AND METHYLPHENIDATE.
185241 03-14

EFFECT OF L-DOPA IN 54 MN INCORPORATION BY TISSUES.
185993 03-03

THE EFFECT OF AMANTADINE, L-DOPA, (..) AMPHETAMINE AND APOMORPHINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE.
186636 03-04

CLINICAL PHARMACOLOGY AS AN APPROACH TO THE STUDY OF BIOCHEMICAL SLEEP MECHANISMS: THE ACTION OF L-DOPA.
186643 03-14

COMPARISON OF THE LOCOMOTOR STIMULANT MECHANISMS OF ACTION OF D-AMPHETAMINE AND D-AMPHETAMINE PLUS L-DOPA: POSSIBLE INVOLVEMENT OF SEROTONIN.
187119 03-04

ALTERATION OF EVOKED POTENTIALS IN CAUDATE NUCLEUS OF FREELY MOVING RATS BY L-DOPA, RESERPINE, AND PENTOBARBITAL.
187362 04-03

SALIGENIN ANALOGS OF L-DOPA AND DL-ALPHA-METHYL-DOPA.
187565 04-11

PARKINSONIAN SYNDROMES: TREATMENT BY ASSOCIATION OF L-DOPA PLUS DECARBOXYLASE INHIBITOR.
188093 04-11

DISAGGREGATION OF BRAIN POLYSOMES AFTER L-DOPA: AN ANALYSIS.
188433 04-03

APHRODISIAC EFFECT OF L-DOPA AND APOMORPHINE IN MALE SEXUALLY SLUGGISH RATS.
188519 04-03

THE ACUTE TOXICITY OF L-DOPA.
189587 04-05

CLINICAL EVALUATION OF AMANTADINE THERAPY FOR PARKINSONISM AND THE SIDE-EFFECTS -- IN CASES OF THALAMIC SURGERY AND L-DOPA THERAPY.
190095 04-11

DISSOCIATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN PARKINSONS DISEASE FOLLOWING CHRONIC L-DOPA THERAPY.
191233 04-13

SKELETAL MUSCLE: RESERVOIR FOR EXOGENOUS L-DOPA.
191771 04-03

L-GLUTAMIC

STUDY WITH RADIOTRACERS OF THE DISTRIBUTION OF A NEW PSYCHOTROPE IN MICE: L-2-PYRROLIDONE-5-CARBOXYLATE DIMETHYLAMINOETHANOL. I. COMPARISON WITH L-GLUTAMIC AND L-2-PYRROLIDONE-5-CARBOXYLIC ACID.
180723 02-03

L-METHIONINE

A STUDY OF THE BEHAVIORAL DISRUPTION OF MICE INDUCED BY L-METHIONINE AND RELATED COMPOUNDS.
187260 04-04

L-NOREPINEPHRINE

INHIBITION OF THE SYNAPTOSOMAL UPTAKE MECHANISMS FOR L-NOREPINEPHRINE AND DOPAMINE BY N-ARYLALKYL DL-AMPHETAMINE DERIVATIVES.
182250 03-03

L-P-CHLOROPHENYLALANINE

THE EFFECT OF D- AND L-P-CHLOROPHENYLALANINE ON THE METABOLISM OF 5-HYDROXYTRYPTAMINE IN BRAIN.
168748 01-03

L-PHENYL-3-2-THIAZOLYL

EFFECT OF L-PHENYL-3-2-THIAZOLYL 2-THIOUREA, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
191769 04-03

L-PROPRANOLOL

PIMOZIDE, L-PROPRANOLOL AND PHENTOLAMINE EFFECTS ON AMPHETAMINE SELF-ADMINISTRATION BY THE RAT.
191919 04-04

L-TETRAHYDROPALMATINE

A CLINICAL STUDY OF L-TETRAHYDROPALMATINE (C-200) IN A NEUROPSYCHIATRIC CLINIC.
182902 03-09

L-TRYPTOPHAN

THE EFFECT OF L-TRYPTOPHAN (TP) ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) REFLEXES IN ACUTE DECEREBRATE SPINAL CATS AND THE EFFECT OF PRETREATMENT WITH P-CHLOROPHENYLALANINE (PCPA) ON THE ACTION OF TP. (UNPUBLISHED PAPER).
170874 01-03

L-TRYPTOPHAN IN MANIA: CONTRIBUTION TO A PERMISSIVE HYPOTHESIS OF AFFECTIVE DISORDERS.
171500 01-09

L-TRYPTOPHAN IN THE TREATMENT OF LEVODOPA INDUCED PSYCHIATRIC DISORDERS.
174297 01-15

L-TRYPTOPHAN IN AFFECTIVE DISORDERS: INDOLEAMINE CHANGES AND DIFFERENTIAL CLINICAL EFFECTS.
185928 03-09

L-2-PYRROLIDONE-5-CARBOXYLATE

STUDY WITH RADIOTRACERS OF THE DISTRIBUTION OF A NEW PSYCHOTROPE IN MICE: L-2-PYRROLIDONE-5-CARBOXYLATE DIMETHYLAMINOETHANOL. I. COMPARISON WITH L-GLUTAMIC AND L-2-PYRROLIDONE-5-CARBOXYLIC ACID.
180723 02-03

L-2-PYRROLIDONE-5-CARBOXYLIC

STUDY WITH RADIOTRACERS OF THE DISTRIBUTION OF A NEW PSYCHOTROPE IN MICE: L-2-PYRROLIDONE-5-CARBOXYLATE DIMETHYLAMINOETHANOL. I. COMPARISON WITH L-GLUTAMIC AND L-2-PYRROLIDONE-5-CARBOXYLIC ACID.
180723 02-03

L-5-HTP

GROWTH HORMONE RESPONSES TO ADMINISTRATION OF L-5-HYDROXYTRYPTOPHAN (L-5-HTP) IN MANIC-DEPRESSIVE PSYCHOSES.
167919 01-09

L-5-HYDROXYTRYPTOPHAN

GROWTH HORMONE RESPONSES TO ADMINISTRATION OF L-5-HYDROXYTRYPTOPHAN (L-5-HTP) IN MANIC-DEPRESSIVE PSYCHOSES.
167919 01-09

TREATMENT OF ACTION MYOCLONUS WITH L-5-HYDROXYTRYPTOPHAN.
188429 04-11

LABEL

CHLORDIAZEPOXIDE IN DEPRESSIVE NEUROSIS: AN OPEN LABEL CROSSOVER STUDY WITH AMITRIPTYLINE.
168316 01-10

LABELLED

THE EFFECT OF PROTRIPTYLINE ON THE METABOLISM OF LABELLED DOPAMINE AND NORADRENALINE IN THE RAT BRAIN.
171627 01-03

LABILE

DOUBLE-BLIND PSYCHOMETRIC EVALUATION OF PIMOZIDE AND HALOPERIDOL VERSUS PLACEBO IN EMOTIONALLY LABILE VOLUNTEERS UNDER TWO DIFFERENT WORK LOAD CONDITIONS.
180065 02-14

LABOR

THE EFFECT OF PAIN RELIEVING DRUGS ADMINISTERED DURING LABOR AND DELIVERY ON THE BEHAVIOR OF THE NEWBORN: A REVIEW.
183706 03-17

LABORATORY

RESEARCH ON SUPERSENSITIVE LABORATORY METHODS IN SWEDEN.
170302 01-06

THE PHARMACOLOGICAL EVALUATION IN LABORATORY ANIMALS OF KABI-1702 -- A NEW SEDATIVE HYPNOTIC DRUG.
171632 01-03

TRIAZOLAM: A SLEEP LABORATORY STUDY OF A NEW BENZODIAZEPINE HYPNOTIC.
177747 02-07

LABORATORY STUDIES FOR EVERY MEDICATED OUTPATIENT: ARE THEY REALLY NECESSARY?.
189075 04-13

A PREDICTABLE LABORATORY MODEL FOR SEDATIVE/HYPNOTIC ACTIVITY IN MAN.
191943 04-14

LABORATORY ASSESSMENTS OF ANTIDEPRESSIVE ACTIVITY -- THEIR VALUE FOR CLINICAL PSYCHIATRY AND THE UNDERSTANDING OF DEPRESSION.
192422 04-09

LABOUR

DIAZEPAM IN LABOUR: ITS METABOLISM AND EFFECT ON THE CLINICAL CONDITION AND THERMOGENESIS OF THE NEWBORN.
171731 01-13

LACTATION

THE EFFECTS OF PHENOTHIAZINES ON ENDOCRINE FUNCTION: I. PATIENTS WITH INAPPROPRIATE LACTATION AND AMENORRHOEA.
184436 03-15

LAROXYL

EXPERIENCES WITH LAROXYL (R) IN THE TREATMENT OF DEPRESSIONS IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
170413 01-11

LATENCY

NEW LONG LATENCY BULBOSPINAL EVOKED POTENTIALS BLOCKED BY SEROTONIN ANTAGONISTS.
188751 04-03

LATERAL

LSD EFFECTS ON SIGNAL-TO-NOISE RATIO AND LATERALIZATION OF VISUAL CORTEX AND LATERAL GENICULATE DURING PHOTIC STIMULATION.
167449 01-03

RECOVERY OF FEEDING AND DRINKING BY RATS AFTER INTRAVENTRICULAR 6-HYDROXYDOPAMINE OR LATERAL HYPOTHALAMIC LESIONS.
168484 01-03

INFLUENCE OF MORPHINE ON LATERAL HYPOTHALAMIC SELF-STIMULATION IN THE RAT.
168835 01-04

PRESENCE OF OSMORECEPTORS FOR THIRST IN THE LATERAL PREOPTIC NUCLEUS.
168859 01-03

LEVODOPA INDUCED DYSKINESIAS: COMPARISON IN PARKINSONISM DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS.
169376 01-15

DECREASED ANOREXIA, EXCITEMENT AND STEREOTYPY TO D-AMPHETAMINE AFTER LATERAL HYPOTHALAMIC 6-HYDROXYDOPAMINE (6-OHDA) INJECTIONS.
182136 02-04

RECOVERY OF FEEDING AFTER 6-HYDROXYDOPAMINE (6-HDA) OR LATERAL HYPOTHALAMIC LESIONS: THE ROLE OF CATECHOLAMINES.
182213 03-03

EFFECT OF D-AMPHETAMINE (D-A) AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) ON THE IN VIVO RELEASE OF 14C-NOREPINEPHRINE (NE) INTO THE LATERAL VENTRICLE OF RATS.
182251 03-03

PGO WAVES IN THE LATERAL GENICULATE NUCLEUS TRIGGERED BY BARBITURATE.
187835 04-03

LATERALIZATION

LSD EFFECTS ON SIGNAL-TO-NOISE RATIO AND LATERALIZATION OF VISUAL CORTEX AND LATERAL GENICULATE DURING PHOTIC STIMULATION.
167449 01-03

LATIN-AMERICAN

A COMPARISON OF CLINICALLY USED PSYCHOACTIVE DRUGS IN FOUR LATIN-AMERICAN COUNTRIES AND IN CANADA (ARGENTINA, COSTA-RICA, MEXICO AND PANAMA).
191139 04-17

LD50

INFLUENCE ON ACUTE PRETREATMENT WITH DELTA9-TETRAHYDROCANNABINOL OF THE LD50 OF VARIOUS SUBSTANCES THAT ALTER NEUROHUMORAL TRANSMISSION.
188876 04-05

INHALATION, PARENTERAL AND ORAL LD50 VALUES OF DELTA9-TETRAHYDROCANNABINOL IN FISCHER RATS.
189588 04-05

LEAD

LEAD INDUCED BEHAVIORAL DYSFUNCTION: AN ANIMAL MODEL OF HYPERACTIVITY.
184953 03-04

CHOLINERGIC AMINERGIC INTERACTIONS IN LEAD INDUCED HYPERACTIVITY.
191954 04-05

INCREASED BRAIN NOREPINEPHRINE TURNOVER IN LEAD EXPOSED HYPERACTIVE RATS.
191957 04-05

LEADING

SYNTHETIC STUDIES LEADING TOWARD THE PREPARATION OF LINEAR BENZOQUINOLINES. (PH.D. DISSERTATION).
180739 02-01

LEARNED

FIGHTING IN MICE: DYADIC ESCALATION AND WHAT IS LEARNED.
173039 01-04

HIPPOCAMPAL LESIONS AND LEARNED TASTE AVERSION.
184834 03-04

THE EFFECTS OF PENTYLENETETRAZOL (METRAZOL) ON A LEARNED TASTE AVERSION PRODUCED BY LITHIUM CHLORIDE: THE ISSUE OF ASSOCIATIVE MEMORY VS. RETENTIVE MEMORY. (UNPUBLISHED PAPER).
188251 04-04

COMPARATIVE EFFECTS OF SOME CNS ACTIVE DRUGS ON LEARNED AND UNLEARNED BEHAVIOR IN THE HAMSTER.
191976 04-04

LEARNING

EFFECT OF L-ASPARAGINASE ON RETENTION OF MAZE LEARNING IN MICE.
167324 01-04

EFFECT OF PRENATAL MATERNAL ADMINISTRATION OF D-AMPHETAMINE ON RAT OFFSPRING ACTIVITY AND PASSIVE AVOIDANCE LEARNING.
167415 01-03

STATE-DEPENDENT LEARNING PRODUCED BY ADDICTING DRUGS.
169071 01-03

EFFECTS OF ATROPINE ON EXPLORATION, LEARNING AND ELECTROCORTICAL ACTIVITY IN THE DEVELOPING RAT.
169473 01-04

INFLUENCE OF AFFECTIVE STATES AND PSYCHOACTIVE DRUGS ON VERBAL LEARNING AND MEMORY.
169504 01-09

CAUDATE NUCLEUS EFFECTS ON GERIATRIC SENILITY: EFFECT OF BELLADONNA ON LEARNING AND MEMORY OF GERIATRIC PATIENTS.
170744 01-11

EFFECTS OF CHLORPROMAZINE, MEPROBAMATE AND CHLORDIAZEPOXIDE ON THE MAZE LEARNING IN MICE.
171259 01-04

EFFECTS OF MEDICATION ON LEARNING IN HYPERACTIVE FOUR-YEAR-OLD CHILDREN. (ED.D DISSERTATION).
172512 01-11

EFFECTS OF ANALEPTICS ON MAZE LEARNING IN MICE.
173078 01-04

REHABILITATION OF LEARNING IN A HOSPITAL CLASS USING PSYCHOACTIVE DRUGS.
174071 01-11

POSTTRIAL STRYCHNINE: LACK OF EFFECT ON CONDITIONED AVOIDANCE LEARNING.
176866 02-04

SPECIFIC FACILITATION OF MAZE LEARNING BY A PEPTIDE EXTRACTED FROM TRAINED MOUSE BRAIN.
176868 02-04

THE THALAMIC RAT: GENERAL BEHAVIOR, OPERANT LEARNING WITH REWARDING HYPOTHALAMIC STIMULATION, AND EFFECTS OF AMPHETAMINE.
177477 02-04

EFFECTS OF OVERTRAINING AND PRETRIAL ADMINISTRATION OF DEXTROAMPHETAMINE ON REVERSAL LEARNING IN RATS.
177533 02-04

ROLE OF ASSOCIATIVE LEARNING IN FEEDING BEHAVIOR.
178044 02-17

DRUG EFFECTS ON LEARNING AND MEMORY.
181404 02-04

LEARNING AND MEMORY AFTER 6-HYDROXYDOPAMINE (6-OHDA).
182210 02-04

STRYCHNINE SULFATE AND PIRACETAM: LACK OF EFFECT ON LEARNING IN THE RAT.
184980 03-04

MODIFICATION OF LEARNING AND MEMORY IN GOLDFISH THROUGH THE USE OF STIMULANT AND DEPRESSANT DRUGS.
186583 03-04

COCAINE, PEMOLINE AND AMPHETAMINE ON LEARNING AND RETENTION OF A DISCRIMINATION TEST IN MICE.
186705 03-04

A STUDY OF THE EFFECTS OF RITALIN INTERVENTION UPON THE PERCEPTUAL COMPETENCIES OF CHILDREN DIAGNOSED AS GIVING EVIDENCE OF PSYCHONEUROLOGICAL LEARNING DISABILITIES. (PH.D. DISSERTATION).
186833 03-14

LEARNING IMPAIRMENT IN RATS AFTER 6-HYDROXYDOPAMINE INDUCED DEPLETION OF BRAIN CATECHOLAMINES.
187420 04-04

THE EFFECT OF TRANYLCYPROMINE (PARNATE) ON EYELID CONDITIONING AND PAIRED ASSOCIATE LEARNING IN DEPRESSED PATIENTS.
188107 04-09

DIFFERENTIATING STIMULUS AND STORAGE HYPOTHESES OF STATE-DEPENDENT LEARNING.
188226 04-14

EFFECTS OF CYCLOHEXIMIDE ON ACQUISITION AND RETENTION OF AVOIDANCE LEARNING IN THE RAT: RECOVERY OF MEMORY.
189215 04-04

PERFORMANCE ON A VERBAL LEARNING TASK BY SUBJECTS OF HEAVY PAST MARIJUANA USAGE.
190308 04-14

EFFECTS OF CHRONIC METHYLPHENIDATE ADMINISTRATION ON LEARNING AND OFFSPRING BEHAVIOR.
192116 04-04

ENDURING LEARNING DEFICITS AND CEREBRAL SYNAPTIC MALFORMATION FROM EXPOSURE TO 10 PARTS OF HALOTHANE PER MILLION.
192565 04-04

LEFT

PAROXYSMAL RIGHT LEFT DISORIENTATION IN AN EPILEPTIC PATIENT.
171246 01-11

LESIONS

ACQUISITION AND RETENTION OF AVOIDANCE BEHAVIORS FOLLOWING SEPTAL LESIONS OR SCOPOLAMINE INJECTIONS IN RATS.
167401 01-04

RECOVERY OF FEEDING AND DRINKING BY RATS AFTER INTRAVENTRICULAR 6-HYDROXYDOPAMINE OR LATERAL HYPOTHALAMIC LESIONS.
168484 01-03

A METHOD FOR ANALYZING CNS EFFECTS OF DRUGS AND BRAIN LESIONS ON PERMANENT GROUPS OF RATS.
176867 02-06

SELECTIVE BLOCKADE OF APOMORPHINE INDUCED AGGRESSION AND GNAWING FOLLOWING FENFLURAMINE OR RAPHE LESIONS IN THE RAT.
182128 02-04

RECOVERY OF FEEDING AFTER 6-HYDROXYDOPAMINE (6-HDA) OR LATERAL HYPOTHALAMIC LESIONS: THE ROLE OF CATECHOLAMINES.
182213 03-03

NON-SPECIFICITY OF 5-HYDROXYTRYPTOPHAN IN REPLETING BRAIN SEROTONIN IN RATS WITH MFB LESIONS.
182725 03-03

HIPPOCAMPAL LESIONS AND LEARNED TASTE AVERSION.
184834 03-04

DIFFERENTIAL RECOVERY OF FUNCTION FOLLOWING CAUDATE, HIPPOCAMPAL, AND SEPTAL LESIONS IN MICE.
186620 03-04

BEHAVIORAL EFFECTS OF AMPHETAMINE IN RATS WITH LESIONS IN THE CORPUS-STRIATUM.
187698 04-04

THE EFFECT OF P-CHLOROPHENYLALANINE ON FOREBRAIN TRYPTOPHAN HYDROXYLASE IN RATS WITH LESIONS IN THE RAPHE NUCLEUS.
188750 04-03

EFFECTS OF SCOPOLAMINE METHYLBROMIDE ON SHOCK-INDUCED GASTRIC LESIONS IN THE UNRESTRAINED RAT.
189381 04-03

LESSENING

ROLE OF FLUPHENAZINE DECANOATE IN LESSENING THE BURDEN OF CHRONIC SCHIZOPHRENICS ON THE COMMUNITY.
169438 01-08

LETHALITY

ACUTE LETHALITY FOR MICE FOLLOWING ADMINISTRATION OF CYCLOPHOSPHAMIDE WITH BARBITURATES.
177834 02-05

EFFECTS OF CNS AGENTS ON NICOTINE EXTENSOR CONVULSIONS AND LETHALITY IN MICE AND THEIR SEDATIVE ANTIANXIETY EFFECTS IN MAN.
191907 04-14

LEU-3H

EFFECT OF MORPHINE ON THE TURNOVER AND SYNTHESIS OF (LEU-3H) PROTEIN AND (CH-14C) PHOSPHATIDYLCHOLINE IN DISCRETE REGIONS OF THE RAT BRAIN.
189586 04-03

LEUCINE

EFFECT OF CHRONIC INTOXICATION WITH (_) AMPHETAMINE ON ITS CONCENTRATION IN LIVER AND BRAIN AND ON (14C) LEUCINE INCORPORATION INTO MICROSOMAL AND CYTOPLASMIC PROTEINS OF RAT LIVER.
180056 02-05

LEUKOCYTE

MUTAGENICITY EXPERIMENTS WITH THE TRANQUILLIZER MEPROBAMATE IN DROSOPHILA-MELANOGASTER AND IN HUMAN LEUKOCYTE CHROMOSOMES IN VITRO.
184585 03-05

LEVEL

BLOOD LEVEL PROFILE IN MAN FOLLOWING CHRONIC ORAL ADMINISTRATION OF FLURAZEPAM HYDROCHLORIDE.
169817 01-13

MEASUREMENT OF BIOGENIC AMINES AT THE PICOGRAM LEVEL. (UNPUBLISHED LEVEL).
173382 01-03

EFFECTS OF PHENOXYBENZAMINE, ACEPERONE AND CLONIDINE ON THE LEVEL OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL, (MOPEG) IN RAT BRAIN.
180059 02-03

WORD RECOGNITION OF SCHIZOPHRENICS AS A FUNCTION OF PHENOTHIAZINE LEVEL AND AUTONOMIC RESPONSIVITY. (PH.D. DISSERTATION).
182524 03-08

BLOOD LEVEL AND URINARY EXCRETION OF BROMAZEPAM IN MAN.
182556 03-13

DRUG LEVEL OF D- AND L-AMPHETAMINE DURING INTRAVENOUS SELF-ADMINISTRATION.
185960 03-04

PLASMA LEVEL OF DIAZEPAM AS A THERAPEUTIC PREDICTOR IN ANXIETY STATES.
186584 03-10

LEVELS

EFFECT OF ETHANOL ON CYCLIC AMP LEVELS IN THE RAT BRAIN.
167326 01-03

PHENOTHIAZINE DOSAGE LEVELS AND AUDITORY SIGNAL DETECTION IN SCHIZOPHRENIA.
167817 01-08

LEVELS OF HVA IN MOUSE BRAIN FOLLOWING TREATMENT WITH METABOLITES OF CHLORPROMAZINE.
171626 01-03

EFFECTS OF CENTRALLY ACTING DRUGS ON ADENYL CYCLASE ACTIVITY AND CYCLIC AMP LEVELS OF MOUSE BRAIN. (PH.D. DISSERTATION).
172019 01-03

(-)DELTA9-THC AS AN HYPNOTIC: AN EXPERIMENTAL STUDY OF THREE DOSE LEVELS.
174041 01-14

DOPAMINE IN THE MESOLIMBIC SYSTEM OF THE RAT BRAIN: ENDOGENOUS LEVELS AND THE EFFECTS OF DRUGS ON THE UPTAKE MECHANISM AND STIMULATION OF ADENYLATE CYCLASE ACTIVITY.
177131 02-03

BLOOD AND BRAIN LEVELS OF DELTA1-TETRAHYDROCANNABINOL IN MICE -- THE EFFECT OF 7-HYDROXY-DELTA1-TETRAHYDROCANNABINOL.
177333 02-03

ADRENALINE, NORADRENALINE AND DOPAMINE LEVELS IN BRAIN AND HEART AFTER ADMINISTRATION OF 6-HYDROXYDOPAMINE AND GUANETHIDINE TO NEWBORN MICE.
177338 02-03

EFFECTS OF NEUROLEPTICS AND THYMOLEPTICS ON PHOSPHODIESTERASE ACTIVITY AND ON CYCLIC 3,5 AMP LEVELS IN RAT BRAIN.
181467 02-03

EFFECTS OF DECAPITATION, ETHER AND PENTOBARBITAL ON CYCLIC AMP AND CYCLIC GMP LEVELS IN RAT TISSUES.
182154 02-03

STUDIES ON THE EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT ON CATECHOLAMINE LEVELS AND TURNOVER IN DISCRETE BRAIN AREAS OF RATS.
182228 03-03

EFFECT OF 2-ARYLALANINES, 2-ARYLSERINES, TETRAPHENYLBORON AND 1,2 DL(2,4 DICHLOROPHENYL) ETHANOLAMINE ON LEVELS OF SEROTONIN (5-HT), NOREPINEPHRINE (NE) AND DOPAMINE (DM) IN WHOLE BRAIN OF MICE.
182254 03-03

DIAZEPAM TREATMENT FOR ACUTE CONVULSIONS IN CHILDREN: A REPORT OF 41 PATIENTS, THREE WITH PLASMA LEVELS.
182595 03-11

EFFECT OF VARIOUS STEROIDS AND ACTH ON METHYPRYLON PLASMA LEVELS AND SLEEPING TIME IN RATS.
183611 03-03

PLASMA LEVELS OF LUTEINIZING HORMONE AND OF IMMUNOREACTIVE ESTROGENS (ESTRADIOL) IN ANOREXIA-NERVOSA: RESPONSE TO CLOMIPHENE CITRATE.
183807 03-10

EFFECTS OF METHAMPHETAMINE ON DAILY RHYTHMS OF HYPOTHALAMIC NOREPINEPHRINE, SEROTONIN AND PLASMA CORTICOSTERONE LEVELS IN THE RAT.
184178 03-03

EFFECT OF LSD-25 AND 1-METHYL-D-LYSERGIC ACID BUTANOLAMIDE ON RAT BRAIN AND PLATELET SEROTONIN LEVELS.
184975 03-03

RELATIONSHIP OF PLASMA MEPERIDINE LEVELS TO CHANGES IN ANXIETY AND HOSTILITY.
185881 03-14

REGIONAL CHANGES IN MONOAMINE LEVELS AND IN THE RATE OF TYROSINE AND TRYPTOPHAN HYDROXYLATION IN 4 WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
185899 03-03

THE EFFECT OF CHLORPROMAZINE ON HOMOVANILLIC ACID LEVELS IN CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS.
186565 03-08

EFFECT OF MORPHINE ON REGIONAL LEVELS OF GAMMA-HYDROXYBUTYRATE IN MOUSE BRAIN.
187077 03-03

THE INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LEVELS OF ENDOGENOUS 2-PHENYLETHYLAMINE IN RABBIT BRAIN.
187112 03-03

SEQUENTIAL TRIAL COMPARING TWO PLASMA LEVELS OF NORTRIPTYLINE.
187582 04-10

THE EFFECTS OF CHRONIC RESERPINE AND NIALAMIDE TREATMENT ON THE FREE AMINO ACID LEVELS OF RAT BRAIN.
187645 04-03

THE EFFECTS OF LITHIUM ON HIGH ENERGY PHOSPHATE AND GLUCOSE LEVELS IN THE RAT SUPERIOR CERVICAL GANGLION.
187677 04-03

METHIOTHEPIN ELEVATION OF 5-HYDROXYINDOLEACETIC ACID LEVELS IN VARIOUS ANATOMIC REGIONS OF RAT BRAIN.
187831 04-03

LONG-TERM TREATMENT OF ENDOGENOUS DEPRESSION WITH NORTRIPTYLINE WITH CONTROL OF PLASMA LEVELS.
188832 04-09

EFFECTS OF CHLORPROMAZINE PLASMA LEVELS ON ELECTROCARDIOGRAM.
188838 04-13

EFFECTS OF TWO LEVELS OF ATTENTION DEMAND ON VIGILANCE PERFORMANCE UNDER MARIHUANA.
189359 04-14

EFFECT OF OXOTREMORINE AND PHYSOSTIGMINE ON CHOLINE LEVELS IN MOUSE WHOLE BRAIN, SPLEEN AND CEREBELLUM.
189893 04-03

ANTICONVULSANT DRUG SERUM LEVELS IN PSYCHIATRIC PATIENTS WITH SEIZURE DISORDERS: EFFECTS OF CERTAIN PSYCHOTROPIC DRUGS.
191096 04-13

5-HYDROXYTRYPTAMINE AND NORADRENALINE IN THE HIPPOCAMPAL REGION: EFFECT OF TRANSECTION OF AFFERENT PATHWAYS ON ENDOGENOUS LEVELS, HIGH AFFINITY UPTAKE AND SOME TRANSMITTER RELATED ENZYMES.
191319 04-03

EFFECT OF DIAZEPAM ON MOUSE WHOLE BRAIN AND BRAIN AREA ACETYLCHOLINE AND CHOLINE LEVELS.
191423 04-03

EFFECT OF ANESTHETIC AGENTS ON PERIPHERAL SYMPATHETIC NERVOUS SYSTEM FUNCTION AS MONITORED BY ARTERIAL PLASMA CATECHOLAMINE LEVELS. (UNPUBLISHED PAPER
191495 04-03

SERUM PROLACTIN LEVELS IN NEWLY ADMITTED PSYCHIATRIC PATIENTS.
191506 04-13

NONSEDATING DOSAGES OF DIAZEPAM AND PHENOBARBITAL IN THE REDUCTION OF NEONATAL BILIRUBIN LEVELS.
191607 04-17

THE EFFECTS OF AMPHETAMINE SULFATE ON THE DIURNAL RHYTHMS OF MIDBRAIN, CORTEX, NOREPINEPHRINE, SEROTONIN AND BLOOD GLUCOSE LEVELS IN THE MOUSE.
191918 04-03

PROTRIPTYLINE STEADY-STATE PLASMA LEVELS IN MAN.
191924 04-13

CORRELATION BETWEEN BRAIN N,N DIMETHYLTRYPTAMINE (DMT) LEVELS AND BAR PRESSING BEHAVIOR IN RATS: EFFECT OF MAO INHIBITION.
191935 04-04

THE EFFECT OF CONJUGATED ESTROGENS ON PLASMA BUTAPERAZINE LEVELS IN WOMEN.
191959 04-15

PLASMA LEVELS AND TRICYCLIC ANTIDEPRESSANTS.
192872 04-10

PLASMA NORTRIPTYLINE LEVELS -- RELATIONSHIP TO CLINICAL EFFECTS.
192873 04-09

LEVER

DIAZEPAM-INDUCED EATING AND LEVER PRESSING FOR FOOD IN SATED RATS.
186613 03-04

LEVODOPA

LEVODOPA INDUCED DYSKINESIAS: COMPARISON IN PARKINSONISM DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS.
169376 01-15

HABITUATION OF BLINK REFLEXES IN PARKINSONIAN PATIENTS UNDER LEVODOPA AND AMANTADINE TREATMENT.
171794 01-13

L-TRYPTOPHAN IN THE TREATMENT OF LEVODOPA INDUCED PSYCHIATRIC DISORDERS.
174297 01-15

PARKINSONISM DEMENTIA OF GUAM: TREATMENT WITH LEVODOPA AND L-ALPHA-METHYLDOPAHYDRAZINE.
179996 02-13

LONG-RANGE MOTOR PERFORMANCE CHANGES IN LEVODOPA TREATED PATIENTS WITH PARKINSONS DISEASE.
184195 03-11

DEANOL IN THE TREATMENT OF LEVODOPA INDUCED DYSKINESIAS.
184196 03-11

IMIPRAMINE MEDIATED EFFECTS ON LEVODOPA METABOLISM IN MAN.
185998 03-13

LEVODOPA COMBINED WITH MK-486 (L-ALPHA-METHYLDOPAHYDRAZINE) -- A PERIPHERAL DECARBOXYLASE INHIBITOR IN PARKINSONS DISEASE.
187615 04-11

HUNTINGTONS CHOREA: THE RIGID FORM (WESTPHAL VARIANT) TREATED WITH LEVODOPA.
187618 04-11

LEVODOPA, CARBIDOPA, AND PYRIDOXINE IN PARKINSON DISEASE.
187877 04-13

LEVODOPA AND MELANOMA.
188414 04-15

ON-OFF PHENOMENON WITH LEVODOPA THERAPY IN PARKINSONISM: CLINICAL AND PHARMACOLOGIC CORRELATIONS AND THE EFFECT OF INTRAMUSCULAR PYRIDOXINE.
188560 04-11

RO-4-4602 AND LEVODOPA IN THE TREATMENT OF PARKINSONISM.
188561 04-11

COMPARISON OF AMANTADINE, PLACEBO, AND LEVODOPA IN PARKINSONS DISEASE.
189502 04-11

DOSE-RELATED ALTERATIONS IN METABOLISM OF LEVODOPA: POSSIBLE MECHANISM FOR HYPOTENSIVE EFFECT.
190194 04-11

LONG-TERM TREATMENT WITH LEVODOPA.
191614 04-11

LEVOMEPROMAZINE

THE ACTION OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTOR CENTERS OF EMOTIONS IN THE HYPOTHALAMUS.
191785 04-02

INFLUENCE OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTS OF ELECTRICAL STIMULATION AND MICROINJECTION OF ACETYLCHOLINE, SEROTONIN AND NORADRENALINE INTO THE MESENCEPHALON.
191786 04-02

LEVORPHANOL

INFLUENCE OF FENTANYL, LEVORPHANOL AND PETHIDINE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189569 04-03

LEXOTAN

A TRIAL ON BROMAZEPAM (LEXOTAN) AND PLACEBO IN THE TREATMENT OF PSYCHOPHYSIOLOGICAL DISORDERS.
171150 01-11

LH-RH

FUNCTIONAL EVALUATION OF PITUITARY RESERVE IN PATIENTS WITH THE AMENORRHEA GALACTORRHEA SYNDROME UTILIZING LUTEINIZING HORMONE RELEASING HORMONE (LH-RH), L-DOPA AND CHLORPROMAZINE.
175245 02-13

LIABILITY

DEPENDENCE LIABILITY OF SEVERAL SEDATIVE HYPNOTIC AGENTS EVALUATED IN MONKEYS.
174125 01-04

ATTEMPT TO EVALUATE THE PHYSICAL DEPENDENCE LIABILITY OF PSYCHOTROPIC DRUGS IN MICE.
182103 02-04

AN EXPERIMENTAL INVESTIGATION OF DEPENDENCE LIABILITY OF METHAQUALONE IN RATS.
186569 03-03

LIBRIUM

THE EFFECTS OF CHLORDIAZEPOXIDE (LIBRIUM) ON THE INTENSITY AND HABITUATION OF AGONISTIC BEHAVIOR IN MALE SIAMESE FIGHTING FISH.
177722 02-04

LICL

EFFECTS OF LICL ON THE CENTRAL NERVOUS SYSTEM.
182112 02-04

METRAZOL DISRUPTS CONDITIONED AVERSION PRODUCED BY LICL: A TIME DEPENDENT EFFECT.
188412 04-04

LIDOCAINE

ON THE FIRST-PASS EFFECT IN THE LIVER OF NORTRIPTYLINE, LIDOCAINE AND PROPRANOLOL.
171631 01-03

ANTICONVULSANT ACTIVITY OF CLONAZEPAM AND RO-8-4192 AGAINST PENICILLIN AND LIDOCAINE INDUCED SEIZURES.
178947 02-03

EFFECT OF PROCAINE, LIDOCAINE AND PENTOBARBITAL ON ELECTRICAL ACTIVITY OF GUINEA-PIG OLFACTORY CORTEX IN VITRO.
182092 02-03

EFFECTS OF LIDOCAINE ON RABBIT BRAIN MICROTUBULAR PROTEIN.
191324 04-03

LIFESPAN

THE EFFECT OF LOWERED BODY TEMPERATURE ON LIFESPAN AND IMMUNE AND NONIMMUNE PROCESSES.
169675 01-03

LIGHT

EVALUATION OF CENTRAL ANTIRESERPINE EFFECT BY THE USE OF LIGHT BLINK REFLEX.
169469 01-04

REFLECTION OF SHORT-TERM LIGHT ADAPTATION EFFECT IN THE ELECTRORETINOGRAM.
180591 02-04

DOSE DEPENDENT SELECTIVE FACILITATION OF RESPONSE CONTINGENT LIGHT ONSET BEHAVIOR BY D-AMPHETAMINE.
185955 03-04

MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN THE LIGHT OF PROGNOSIS ORIENTED DIAGNOSIS.
186081 03-08

DIFFERENTIAL EFFECTS OF PILOCARPINE AND SCOPOLAMINE ON THE PERFORMANCE OF A LIGHT DARK DISCRIMINATION MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN.
186701 03-03

LILLY-110140

EFFECT OF LILLY-110140, 3-(P-TRIFLUOROMETHYLPHENOXY) N METHYL-3-PHENYLPROPYLAMINE ON SYNTHESIS OF 3H-SEROTONIN FROM 3H-TRYPTOPHAN IN RAT BRAIN.
191951 04-03

LIMBIC

ANTICONVULSIVE ACTIVITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) AND ITS EFFECT ON LIMBIC SYSTEM.
177099 02-02

EFFECT OF CHRONIC TREATMENT WITH DESIPRAMINE (DMI) AND IPRINDOLE (IP) ON THE NOREPINEPHRINE (NE) SENSITIVE ADENYLATE CYCLASE SYSTEM IN SLICES OF THE RAT LIMBIC FOREBRAIN.
192003 04-03

LIMITING

THE RATE LIMITING CONTROL OF ENZYMES MONOAMINE OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN THE FETUS AND THE ADULT BY ADRENOCORTICOL HORMONES.
178815 02-03

LINEAR

SYNTHETIC STUDIES LEADING TOWARD THE PREPARATION OF LINEAR BENZOQUINOLINES. (PH.D. DISSERTATION).
180739 02-01

LINK

CENTRAL CHOLINERGIC (MUSCARINIC) LINK IN THE ATTACK REFLEXIVE BITING MECHANISM OF CATS.
182238 03-04

LIPID

LIPID INDUCED CHANGES OF PENTOBARBITAL DISTRIBUTION AND METABOLISM.
170072 01-03

A ROLE OF THE DIETARY LIPID IN THE ABILITY OF PHENOBARBITAL TO STIMULATE DRUG DETOXIFICATION.
175859 02-03

LIPIDOSIS-LIKE

LIPIDOSIS-LIKE ALTERATIONS IN DORSAL ROOT GANGLION CELLS OF RATS TREATED WITH TRICYCLIC ANTIDEPRESSANTS.
189605 04-03

LITERATURE

CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG, TRAZODONE: A REVIEW OF LITERATURE.
168803 01-11

CHEMOTHERAPY IN CHRONIC ORGANIC BRAIN SYNDROME - A REVIEW OF THE LITERATURE.
169065 01-11

THE PROPERTIES OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA). I. A REVIEW OF THE LITERATURE.
176597 02-17

ANTIPSYCHOTIC ACTION OF NEUROLEPTIC AGENTS AND THE FUNCTION OF BASAL GANGLIA (SURVEY OF LITERATURE).
183521 03-17

LITHIUM

EFFECT OF LITHIUM ON AGGRESSION, MANIA AND PERMSELECTIVE MEMBRANES.
167448 01-09

LITHIUM IN PSYCHIATRY.
167675 01-09

CLINICAL EFFECTS OF LITHIUM CARBONATE ON DEPRESSION.
167917 01-09

LITHIUM CARBONATE TREATMENT IN MANIC PSYCHOSIS.
167918 01-09

LITHIUM CARBONATE TOXICITY.
168505 01-15

EFFECT OF CHRONIC LITHIUM TREATMENT ON MONOAMINE METABOLISM IN RAT BRAIN.
168839 01-03

A COMPARISON OF LITHIUM CARBONATE IN THE PREVENTION OF MANIC AND DEPRESSIVE EPISODES IN RECURRENT AFFECTIVE DISORDER.
169090 01-09

LITHIUM INDUCED DIABETES-INSIPIDUS: MANIC SYMPTOMS, BRAIN AND ELECTROLYTE CORRELATES, AND CHLOROTHIAZIDE TREATMENT.
169486 01-15

LITHIUM INDUCED FOLLICULITIS.
169492 01-15

RELATIONSHIP BETWEEN THE EFFECTIVENESS OF LITHIUM THERAPY AND FAMILY HISTORY.
169494 01-09

THE USE OF LITHIUM IN AFFECTIVE DISORDERS, III: A DOUBLE-BLIND STUDY OF PROPHYLAXIS IN BIPOLAR ILLNESS.
169495 01-09

THE EFFECT OF LITHIUM AND OTHER ANTIDEPRESSANT MEDICATIONS ON THE AUTONOMIC NERVOUS SYSTEM.
169635 01-15

NEGATIVE SODIUM BALANCE IN LITHIUM CARBONATE TOXICITY: EVIDENCE OF MINERALOCORTICOID BLOCKADE.
169869 01-15

LITHIUM CARBONATE AND SLEEP IN AFFECTIVE DISORDERS: FURTHER CONSIDERATIONS.
171503 01-09

EFFECT OF SELECTED BETA-DIKETONES ON LITHIUM FLUXES OF BOVINE RED BLOOD CELLS.
171792 01-05

LITHIUM PROPHYLAXIS IN RECURRENT AFFECTIVE ILLNESS.
171926 01-09

LITHIUM PROPHYLAXIS IN AFFECTIVE DISORDERS: AN OPEN TRIAL WITH MATCHED CONTROLS.
172401 01-09

OUR EXPERIENCE WITH LITHIUM.
172976 01-09

CLINICAL FACTORS IN LITHIUM CARBONATE PROPHYLAXIS FAILURE.
174093 01-09

ELECTROENCEPHALOGRAPHIC RESPONSES TO LITHIUM.
174132 01-14

WEIGHT GAIN IN LITHIUM TREATED RATS.
174133 01-04

LITHIUM (LI): LACK OF EFFECT ON MORPHINE (MS) EUPHORIA. (UNPUBLISHED PAPER).
174479 01-14

ELECTROENCEPHALOGRAPHIC MODIFICATIONS DURING ADMINISTRATION OF LITHIUM.
174566 01-09

LONG-TERM USE OF LITHIUM CARBONATE IN AFFECTIVE DISORDERS: A CLINICAL EVALUATION.
174778 01-09

SHORT-TERM AND LONG-TERM LITHIUM ADMINISTRATION: EFFECTS ON THE BRAINS SEROTONERGIC BIOSYNTHETIC SYSTEMS.
175149 02-13

ULTRASTRUCTURE OF CNS IN LITHIUM INTOXICATION.
176476 02-05

LITHIUM AND MENTAL HEALTH.
178113 02-09

DIFFERENTIAL EFFECTS OF D- AND L-AMPHETAMINE ON THE SLEEP OF DEPRESSED PSYCHIATRIC PATIENTS ON AND OFF LITHIUM CARBONATE TREATMENT. (UNPUBLISHED PAPER).
178432 02-09

FLAVOR AVERSIONS PRODUCED BY CONTINGENT DRUG INJECTION: RELATIVE EFFECTIVENESS OF APOMORPHINE, EMETINE, AND LITHIUM.
178502 02-04

CHOLINE ACTIVATION OF LITHIUM TRANSPORT.
178812 02-03

LITHIUM IN THE TREATMENT OF SCHIZOPHRENIA.
180046 02-08

LITHIUM DISTRIBUTION BETWEEN CEREBROSPINAL FLUID AND SERUM OF AFFECTIVE PSYCHOTIC PATIENTS TREATED WITH LITHIUM CARBONATE AND ITS CLINICAL RESPONSE.
180301 02-11

A FEW GALENIC METHOD TO PROLONG THE ACTION OF LITHIUM SULFATE.
180700 02-15

DIRECT DETERMINATION OF LITHIUM IN SERUM BY ATOMIC ABSORPTION SPECTROSCOPY.
181653 02-06

EFFECTS OF LITHIUM ON CEREBRAL RNA METABOLISM IN VITRO AND IN VIVO.
181942 02-03

INFLUENCES OF LITHIUM ON THE BEHAVIORAL ACTION OF METHAMPHETAMINE AND TETRABENAZINE.
182109 02-04

LITHIUM IN PSYCHIATRIC THERAPY AND PROPHYLAXIS. A REVIEW WITH SPECIAL REGARD TO ITS USE IN CHILDREN.
182433 03-09

LITHIUM TREATMENT OF PSYCHOTIC CHILDREN. A CONTROLLED CLINICAL TRIAL.
182434 03-09

ANTIAGGRESSIVE EFFECT OF LITHIUM SALTS IN MENTALLY RETARDED ADOLESCENTS.
182435 03-11

INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY LITHIUM TREATMENT.
182727 03-03

THE INFLUENCE OF CHRONIC ADMINISTRATION OF LITHIUM CARBONATE ON THE BRAIN NOREPINEPHRINE CONTENT IN RATS.
182872 03-03

LITHIUM IN THE TREATMENT OF PERIODIC CATATONIA: A CASE REPORT.
183648 03-09

A CONTROLLED EVALUATION OF LITHIUM IN THE PREMENSTRUAL TENSION SYNDROME.
185192 03-11

A DOUBLE-BLIND TRIAL OF LONG-TERM LITHIUM THERAPY IN MENTAL DEFECTIVES.
185193 03-11

LITHIUM TREATMENT OF DEPRESSION.
185873 03-09

FACTORS ASSOCIATED WITH LITHIUM RESPONSE IN THE PROPHYLACTIC TREATMENT OF BIPOLAR MANIC-DEPRESSIVE ILLNESS.
186188 03-09

THE CLINICAL EFFECTIVENESS OF LITHIUM: COMPARISONS WITH OTHER DRUGS.
186189 03-09

THYROTOXICOSIS DEVELOPING DURING LITHIUM TREATMENT: CASE REPORT.
186473 03-15

THE EFFECT OF LITHIUM ON THYROID IODINE RELEASE IN PATIENTS WITH PRIMARY AFFECTIVE DISORDER.
186580 03-09

EFFECTS OF LITHIUM ON ADRENERGIC AMINE UPTAKE IN RAT BRAIN SYNAPTOSOMES.
186633 03-03

DOES LITHIUM BLOCK THE EFFECTS OF AMPHETAMINE? A REPORT OF THREE CASES.
186745 03-13

LITHIUM: ITS ROLE IN PSYCHIATRIC RESEARCH AND TREATMENT.
186920 03-09

THE EFFECT OF LITHIUM ON HORMONE SENSITIVE ADENYLATE CYCLASE FROM VARIOUS REGIONS OF THE RAT BRAIN.
187110 03-03

LITHIUM CARBONATE IN MANIC-DEPRESSIVE PSYCHOSIS.
187477 04-09

LITHIUM THERAPY AND ERYTHROCYTE MEMBRANE CATION CARRIER.
187644 04-15

THE EFFECTS OF LITHIUM ON HIGH ENERGY PHOSPHATE AND GLUCOSE LEVELS IN THE RAT SUPERIOR CERVICAL GANGLION.
187677 04-03

LITHIUM CARBONATE: PSYCHIATRIC INDICATIONS AND MEDICAL COMPLICATIONS.
187786 04-15

HUNTINGTONS CHOREA TREATED WITH LITHIUM CARBONATE.
187985 04-11

THE EFFECTS OF PENTYLENETETRAZOL (METRAZOL) ON A LEARNED TASTE AVERSION PRODUCED BY LITHIUM CHLORIDE: THE ISSUE OF ASSOCIATIVE MEMORY VS. RETENTIVE MEMORY. (UNPUBLISHED PAPER).
188251 04-04

PROPHYLACTIC EFFICACY OF LITHIUM CARBONATE IN MANIC-DEPRESSIVE ILLNESS: REPORT OF THE VETERANS ADMINISTRATION AND NATIONAL INSTITUTE OF MENTAL HEALTH (VA-NIMH) COLLABORATIVE STUDY GROUP.
189735 04-09

AFFECTIVE DISORDERS AND CHEMICAL DEPENDENCE: LITHIUM FOR ALCOHOL AND DRUG ADDICTION
189775 04-09

ANTIDEPRESSANT EFFECT OF LITHIUM.
189793 04-09

EFFECT OF LITHIUM ON CENTRAL METABOLISM OF 5-HYDROXYTRYPTAMINE.
190337 04-03

LITHIUM IN TREATMENT AND PREVENTION OF AFFECTIVE DISORDER: A VA-NIMH COLLABORATIVE STUDY.
190381 04-09

LITHIUM AND THE MONOAMINE NEUROTRANSMITTERS IN THE RAT HIPPOCAMPUS.
190829 04-03

THE EFFECT OF LITHIUM ON THYROID IN MAN.
191142 04-15

HAZARDS OF LITHIUM PROPHYLAXIS.
191187 04-15

EXPERIMENT WITH LITHIUM CARBONATE ON THE TREATMENT OF MANIC STATE.
191670 04-09

LITHIUM TREATMENT DURING ETHANOL INGESTION AND WITHDRAWAL.
192005 04-11

LIVER

ON THE FIRST-PASS EFFECT IN THE LIVER OF NORTRIPTYLINE, LIDOCAINE AND PROPRANOLOL.
171631 01-03

KINETICS AND CELLULAR CONTROL MECHANISMS FOR IMIPRAMINE METABOLISM IN THE ISOLATED PERFUSED RAT LIVER. (PH.D. DISSERTATION).
173601 01-03

INHIBITION OF LUNG, LIVER AND BRAIN MONOAMINE OXIDASE BY IMIPRAMINE AND DESIPRAMINE.
177332 02-03

THE HYDROXYLATION OF D-AMPHETAMINE BY LIVER MICROSOMES OF THE MALE RAT.
177337 02-03

EFFECT OF CHRONIC INTOXICATION WITH (_) AMPHETAMINE ON ITS CONCENTRATION IN LIVER AND BRAIN AND ON (14C) LEUCINE INCORPORATION INTO MICROSOMAL AND CYTOPLASMIC PROTEINS OF RAT LIVER.
180056 02-05

THE INFLUENCE OF ALDOSTERONE OR METHAMPHETAMINE ON LIVER GLYCOGEN DEPOSITION OF MICE STRESSED BY LONG-TERM ISOLATION.
182105 02-03

CONVERSION OF CHLORAL HYDRATE TO TRICHLOROETHANOL IN BRAIN AND LIVER.
182157 02-03

PHYSIOLOGICAL DISPOSITION OF BETA-PHENYLETHYLAMINE, 2,4,5 TRIMETHOXYPHENYLETHYLAMINE, 2,3,4,5,6 PENTAMETHOXYPHENYLETHYLAMINE AND BETA-HYDROXYMESCALINE IN RAT BRAIN, LIVER AND PLASMA.
186706 03-03

EFFECTS OF SHORT-TERM ADMINISTRATION OF N-NITROSO COMPOUNDS ON LIVER HISTOLOGY AND PENTOBARBITAL INDUCED SLEEPING TIME IN MICE.
187575 04-04

EFFECT OF SKF-525-A ON THE METABOLISM OF (-) DELTA9-TETRAHYDROCANNABINOL IN THE RAT BRAIN AND LIVER.
187578 04-03

EFFECTS OF PHENOBARBITAL AND SKF-525-A PRETREATMENT, SEX, LIVER INJURY, AND VEHICLE ON DELTA9-TETRAHYDROCANNABINOL TOXICITY.
189598 04-05

THE EFFECT OF CHLORPROMAZINE AND STELAZINE ON LYSOSOMES OF RAT LIVER DURING ACUTE INTOXICATION.
191121 04-03

THE 4-HYDROXYLATION OF AMPHETAMINE AND PHENTERMINE BY RAT LIVER MICROSOMES.
191921 04-03

LOAD

DOUBLE-BLIND PSYCHOMETRIC EVALUATION OF PIMOZIDE AND HALOPERIDOL VERSUS PLACEBO IN EMOTIONALLY LABILE VOLUNTEERS UNDER TWO DIFFERENT WORK LOAD CONDITIONS.
180065 02-14

LOBOTOMIZED

DREAM REPORTS AFTER RESERPINE ADMINISTRATION IN CHRONIC LOBOTOMIZED SCHIZOPHRENIC PATIENTS.
178187 02-08

LOBSTER

DDT EFFECT ON 32P INCORPORATION FROM GAMMA-LABELLED ATP INTO PROTEINS FROM LOBSTER NERVE.
191315 04-03

LOCAL

A CENTRAL EFFECT OF LOCAL ANESTHETICS: PREVENTION AGAINST THE ACCUMULATION OF CYCLIC AMP IN BRAIN SLICES.
182099 02-03

LOCALIZATION

DETERMINATION OF DRUG TRANSFER ACROSS BIOLOGICAL MEMBRANES: COMPARATIVE STUDY ON THE PASSAGE OF DRUGS INTO THE CENTRAL NERVOUS SYSTEM AND THEIR PLACENTAL TRANSFER AND FETAL LOCALIZATION IN THE PREGNANT RAT. (PH.D. DISSERTATION).
172018 01-03

PSYCHOACTIVE DRUGS: IMMUNOASSAY AND LOCALIZATION.
173536 01-06

TISSUE LOCALIZATION OF 7- AND 8-HYDROXYCHLORPROMAZINES.
189589 04-03

THE LOCALIZATION AND CHARACTERIZATION OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE ACTIVITY IN SPECIFIC REGIONS OF THE CNS.
191932 04-03

SUBCELLULAR LOCALIZATION OF H3-DELTA9-TETRAHYDROCANNABINOL IN DOG BRAIN AFTER ACUTE OR CHRONIC ADMINISTRATION.
191970 04-03

LOCALIZED

LOCALIZED BEHAVIORAL EFFECTS OF VASOPRESSIN ON MAINTENANCE OF AN ACTIVE AVOIDANCE RESPONSE IN RATS.
187697 04-04

LOCOMOTION

DEVELOPMENT OF LOCOMOTION AND BRAIN CATECHOLAMINES.
187551 04-04

LOCOMOTOR

INHIBITION OF ANTICHOLINERGIC DRUG-INDUCED LOCOMOTOR STIMULATION IN MICE BY ALPHA-METHYLTYROSINE.
177840 02-03

RELATIVE IMPORTANCE OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS FOR THE STIMULATION OF LOCOMOTOR ACTIVITY INDUCED BY AMPHETAMINE AND OTHER DRUGS.
182209 02-04

COMPARATIVE EFFECTS OF DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE ON CENTRAL CATECHOLAMINES AND LOCOMOTOR ACTIVITY.
182253 03-04

THE EFFECTS OF CHRONIC TREATMENT WITH D-AMPHETAMINE ON FOOD INTAKE, BODYWEIGHT, LOCOMOTOR ACTIVITY AND SUBCELLULAR DISTRIBUTION OF THE DRUG IN RAT BRAIN.
185931 03-03

A NEW RECORDING APPARATUS FOR MEASUREMENT OF LOCOMOTOR ACTIVITY OF MICE. EXPERIMENTAL OBSERVATIONS ON ITS USE.
186377 03-06

A COMPARISON OF EFFECTS OF APOMORPHINE AND ET-495 ON LOCOMOTOR ACTIVITY AND CIRCLING BEHAVIOUR IN MICE.
186635 03-04

SIGNIFICANCE OF DOPAMINE RECEPTOR ACTIVITY IN DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY.
186670 03-04

COMPARISON OF THE LOCOMOTOR STIMULANT MECHANISMS OF ACTION OF D-AMPHETAMINE AND D-AMPHETAMINE PLUS L-DOPA: POSSIBLE INVOLVEMENT OF SEROTONIN.
187119 03-04

LOCUS

THE GENERAL LOCUS OF D-AMPHETAMINE-INDUCED DISCRIMINATIVE STIMULI. (PH.D. DISSERTATION).
185725 03-03

FURTHER EVIDENCE ON THE INTRAHYPOTHALAMIC LOCUS FOR ANDROGENIZATION OF FEMALE RATS.
187935 04-03

LOCUS-COERULEUS

SELF-STIMULATION OF NORADRENERGIC CELL GROUP (A6) IN LOCUS-COERULEUS OF RATS.
173029 01-03

EFFECTS OF LOCUS-COERULEUS STIMULATION ON HIPPOCAMPAL UNIT ACTIVITY AND ON BEHAVIOR IN UNRESTRAINED RATS. (UNPUBLISHED PAPER).
187499 04-04

A ROLE FOR DOPAMINE IN THE STIMULANT EFFECTS OF AMPHETAMINE ON LOCUS-COERULEUS SELF-STIMULATION.
191984 04-03

LOMBOSCIATALGIAS

A COMPARATIVE STUDY OF DIAZEPAM AND METHOCARBAMOL IN THE TREATMENT OF LOMBOSCIATALGIAS.
178950 02-11

LONG

SUPPRESSION OF LORDOSIS IN GUINEA-PIGS BY ETHAMOXY-TRIPHETOL (MER-25) GIVEN AT LONG INTERVALS (36-46 HR) AFTER ESTRADIOL BENZOATE TREATMENT.
186686 03-04

NEW LONG LATENCY BULBOSPINAL EVOKED POTENTIALS BLOCKED BY SEROTONIN ANTAGONISTS.
188751 04-03

LONG-ACTING

GENERAL PRACTITIONER CLINICAL TRIALS. A LONG-ACTING AMITRIPTYLINE PREPARATION.
175583 02-09

SAFETY EVALUATION OF PENFLURIDOL, A NEW LONG-ACTING ORAL ANTIPSYCHOTIC AGENT.
177319 02-07

THE FIRST LONG-ACTING (RETARD) THYMOANALEPTIC OR ANTIDEPRESSANT: THE TIME-RELEASED DIBENZEPINE WITH PROLONGED ACTION.
178946 02-11

FLUSPIRILENE, A LONG-ACTING INJECTABLE NEUROLEPTIC.
183199 03-11

CLINICAL EXPERIMENT WITH A LONG-ACTING NEUROLEPTIC: FLUSPIRILENE (R6218).
183200 03-15

LONG-ACTING PHENOTHIAZINES AND SCHIZOPHRENIA.
186288 03-08

PENFLURIDOL: AN EFFICACIOUS LONG-ACTING ORAL ANTIPSYCHOTIC COMPOUND.
189072 04-08

LONG-RANGE

LONG-RANGE MOTOR PERFORMANCE CHANGES IN LEVODOPA TREATED PATIENTS WITH PARKINSONS DISEASE.
184195 03-11

LONG-STAY

EXPERIENCES WITH FLUPHENAZINE ENANTHATE IN LONG-STAY HOSPITALISED SCHIZOPHRENICS.
171985 01-08

EXPERIENCES WITH FLUPHENAZINE ENANTHATE IN LONG-STAY HOSPITALIZED SCHIZOPHRENICS.
180154 02-08

LONG-TERM

EMOTIONAL FUNCTIONS IN SHORT-TERM VS. LONG-TERM L-DOPA THERAPY IN PARKINSONISM.
168619 01-15

LONG-TERM TREATMENT OF DEPRESSION WITH DRUGS AND PSYCHOTHERAPY.
169087 01-09

IMIPRAMINE, DIAZEPAM AND GROUP PSYCHOTHERAPY IN LONG-TERM TREATMENT OF DEPRESSIVE NEUROTICS.
169089 01-10

LONG-TERM CLINICAL AND QUANTITATIVE EEG EFFECTS OF CLOPENTHIXOL IN SCHIZOPHRENICS: CLINICAL NEUROPHYSIOLOGICAL CORRELATIONS.
174131 01-08

LONG-TERM APPLICATION OF CLOZAPINE (W-801) IN SCHIZOPHRENIC PATIENTS.
174680 01-08

LONG-TERM USE OF LITHIUM CARBONATE IN AFFECTIVE DISORDERS: A CLINICAL EVALUATION.
174778 01-09

SHORT-TERM AND LONG-TERM LITHIUM ADMINISTRATION: EFFECTS ON THE BRAINS SEROTONERGIC BIOSYNTHETIC SYSTEMS.
175149 02-13

WITHDRAWAL OF MAINTENANCE DRUGS WITH LONG-TERM HOSPITALIZED MENTAL PATIENTS: A CRITICAL REVIEW.
175862 02-17

EFFECTS OF SHORT-TERM VERSUS LONG-TERM L-DOPA THERAPY IN PARKINSONISM ON CRITICAL FLICKER FREQUENCY.
177511 02-11

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: IV. THE EFFECTS OF CHLORPROMAZINE.
177716 02-14

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: V. THE EFFECTS OF CHLORAL HYDRATE.
177717 02-14

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: VI. THE EFFECTS OF CHLORDIAZEPOXIDE.
177718 02-14

LONG-TERM CONSEQUENCES OF EXPERIENCE, MEDICATION, AND PSYCHOTHERAPY FOR SCHIZOPHRENIC PATIENTS. (UNPUBLISHED PAPER).
178677 02-17

LONG-TERM EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE ON BRAIN MONOAMINES.
180022 02-03

THE INFLUENCE OF ALDOSTERONE OR METHAMPHETAMINE ON LIVER GLYCOGEN DEPOSITION OF MICE STRESSED BY LONG-TERM ISOLATION.
182105 02-03

THE EFFECT OF METHAMPHETAMINE ON BRAIN ACH CONSUMPTION AND AGGRESSIVENESS IN MICE STRESSED MILDLY BY LONG-TERM ISOLATION.
182108 02-04

CLINICAL DATA AND SOCIOPSYCHIATRIC IMPLICATIONS OF OUTPATIENT TREATMENT WITH LONG-TERM PHENOTHIAZINES.
182791 03-09

CHANGES IN SHORT-TERM AND LONG-TERM MEMORY OF DOGS AND CATS UNDER THE EFFECTS OF AMIZYL (BENACTYZINE).
183517 03-04

LONG-TERM EFFECTS OF 4-CHLOROAMPHETAMINE ON BRAIN 5-HYDROXYINDOLE METABOLISM IN RATS.
183869 03-03

A DOUBLE-BLIND TRIAL OF LONG-TERM LITHIUM THERAPY IN MENTAL DEFECTIVES.
185193 03-11

NEUROLOGICAL CHANGES IN CATS FOLLOWING LONG-TERM DIET OF MERCURY CONTAMINATED TUNA.
186476 03-05

LONG-TERM USE OF MARIHUANA AND THE DEVELOPMENT OF TOLERANCE OR SENSITIVITY TO DELTA9-TETRAHYDROCANNABINOL.
188119 04-13

ANISOMYCIN, LIKE OTHER INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS, IMPAIRS LONG-TERM MEMORY OF A DISCRIMINATION TASK.
188605 04-04

LONG-TERM TREATMENT OF ENDOGENOUS DEPRESSION WITH NORTRIPTYLINE WITH CONTROL OF PLASMA LEVELS.
188832 04-09

NERVE CONDUCTION VELOCITY IN PATIENTS ON LONG-TERM DIPHENYLHYDANTOIN THERAPY.
189173 04-15

SHORT-TERM AND LONG-TERM REGULATION OF TYROSINE HYDROXYLASE.
191515 04-03

LONG-TERM TREATMENT WITH LEVODOPA.
191614 04-11

LONG-TERM ALTERATION OF SLEEP-WAKEFULNESS CYCLE DURING CHRONIC PENTOBARBITAL DOSING AND WITHDRAWAL IN CAT.
191952 04-04

LONGITUDINAL

THE EFFECT OF CATECHOLAMINES, ACETYLCHOLINE AND SEROTONIN ON THE MORPHINE TOLERANT LONGITUDINAL MUSCLE STRIP OF THE GUINEA-PIG ILEUM.
182161 02-03

LOPRAMINE

EXPERIMENT WITH LOPRAMINE (DB-2182) ON THE TREATMENT OF DEPRESSION.
191665 04-09

LORAZEPAM

A MULTICENTER INVESTIGATION OF LORAZEPAM IN ANXIETY NEUROSIS.
167346 01-10

LORAZEPAM VERSUS GLUTETHIMIDE AS A SLEEP INDUCING AGENT FOR THE GERIATRIC PATIENT.
167496 01-11

LORAZEPAM: CLINICAL TRIAL WITH A NEW BENZODIAZEPINE.
169297 01-07

PILOT CLINICAL TRIAL OF PARENTERAL LORAZEPAM (TEMESTA) IN ANXIETY STATES.
174044 01-11

USE OF LORAZEPAM IN TREATING PATIENTS WITH NEUROTIC AND SOMATIZED PSYCHOVEGETATIVE SYMPTOMS.
174136 01-09

LORAZEPAM IN THE TREATMENT OF ANXIETY.
176286 02-10

THE EFFECT OF LORAZEPAM ON ANXIOUS INSOMNIACS SLEEP AS RECORDED IN THE HOME ENVIRONMENT.
177318 02-14

EFFECTS OF LORAZEPAM ON CNS STRUCTURES: NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATIONS.
177749 02-03

INFLUENCE OF N1-2-HYDROXYETHYL SUBSTITUTION ON CENTRAL ACTIVITY OF OXAZEPAM AND LORAZEPAM.
178756 02-04

WY-4036 (LORAZEPAM) – A NEW TRANQUILIZER.
180146 02-10

CLINICAL ASSAY OF LORAZEPAM WITH AMBULANT PATIENTS.
183201 03-11

LORDOSIS

EFFECTS OF TETRABENAZINE ON LORDOSIS BEHAVIOUR AND ON BRAIN MONOAMINES IN THE FEMALE RAT.
171614 01-04

LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04

SUPPRESSION OF LORDOSIS IN GUINEA-PIGS BY ETHAMOXY-TRIPHETOL (MER-25) GIVEN AT LONG INTERVALS (36-46 HR) AFTER ESTRADIOL BENZOATE TREATMENT.
186686 03-04

EFFECTS OF AN ESTROGEN ANTAGONIST, MER-25, ON MOUNTING BEHAVIOR AND LORDOSIS BEHAVIOR IN THE FEMALE RAT.
186691 03-04

LOSS

CANNABINOIDS AND HEXOBARBITAL INDUCED LOSS OF RIGHTING REFLEXES.
189573 04-04

LOW-DOSE

INTERACTION OF LOW-DOSE AMPHETAMINE USE WITH SCHIZOPHRENIA IN OUTPATIENTS: THREE CASE REPORTS.
189099 04-15

LOWERED

THE EFFECT OF LOWERED BODY TEMPERATURE ON LIFESPAN AND IMMUNE AND NONIMMUNE PROCESSES.
169675 01-03

LOXAPINE

THE TREATMENT OF MIXED ANXIETY AND DEPRESSION WITH LOXAPINE: A CONTROLLED COMPARATIVE STUDY.
190195 04-09

A DOUBLE-BLIND CONTROLLED STUDY OF LOXAPINE SUCCINATE IN THE TREATMENT OF ANXIETY NEUROSES.
190196 04-09

LSD

LSD EFFECTS ON SIGNAL-TO-NOISE RATIO AND LATERALIZATION OF VISUAL CORTEX AND LATERAL GENICULATE DURING PHOTIC STIMULATION.
167449 01-03

RADIOIMMUNOASSAY FOR LYSERGIDE (LSD) IN ILLICIT DRUGS AND BIOLOGICAL FLUIDS.
170840 01-06

A DIFFERENTIAL INHIBITORY ACTION OF LSD AND AMPHETAMINE ON COPULATORY BEHAVIOR IN THE FEMALE RAT.
171617 01-04

THE EFFECT IN THE CAT OF TRYPTAMINE (T) AND LSD ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) SPINAL REFLEXES. (UNPUBLISHED PAPER).
174480 01-12

EEG AND CARDIOVASCULAR EFFECTS OF TRYPTAMINE (T) AND LSD IN THE ENCEPHALE ISOLE CAT. (UNPUBLISHED PAPER)
174496 01-12

THE ROLE OF HYDROPHOBICITY IN THE ANTISEROTONIN ACTIVITY OF LSD ANALOGS.
174606 01-12

GENETIC EFFECTS OF LSD.
175043 02-04

EFFECTS OF AMPHETAMINE (A), LSD, PSILOCYBIN (P), AND DOM ON SCHEDULE-CONTROLLED BEHAVIOR IN THE RAT.
176869 02-04

STUDIES ON ENZYMATIC DEALKYLATION OF D-LYSERGIC ACID DIETHYLAMIDE (LSD).
177336 02-03

A REVIEW OF THE USE OF LSD FOR THE PATIENT NEAR DEATH.
177681 02-12

SHORT-TERM PSYCHOTHERAPY WITH LSD: A CASE STUDY.
181461 02-12

LSD...AN IN VIVO RETROSPECTIVE CHROMOSOME STUDY.
181811 02-13

COMPARISON OF THE CHRONIC AND ACUTE EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) TREATMENT ON RAT BRAIN SEROTONIN AND NOREPINEPHRINE.
181945 02-03

A COMPARISON OF EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) AND SEROTONIN ON PRE- AND POSTSYNAPTIC CELLS IN THE SEROTONIN SYSTEM.
182141 02-03

ANALYSIS OF DRUG BLOCK OF LSD/5-HT/GABA BY MONITORING NEURONAL MEMBRANE CHANGES.
182143 02-03

LSD TOLERANCE AND BRAIN SEROTONIN METABOLISM.
182167 02-03

ON THE NATURE OF THE SEROTONIN BINDING AFTER LSD.
182168 02-03

INTERACTION OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A PURPORTED HASHISH AND LSD ANTAGONIST, WITH SEVERAL CENTRAL NEUROCHEMICAL SYSTEMS.
182217 03-04

A COMPARATIVE STUDY OF THE ANTIPSYCHOTIC ACTION OF SOME NEUROLEPTICS BASED ON THE MODEL OF LSD PSYCHOSES.
183682 03-03

CYTOGENETIC STUDIES IN THE OFFSPRING OF LSD USERS.
185083 03-12

AN INVESTIGATION OF INTERACTIONS AMONG LSD, DEXTROAMPHETAMINE, AND VERBAL BEHAVIOR IN MONOLOGUES AND DIALOGUES. (PH.D. DISSERTATION).
185600 03-14

EFFECTS OF LSD ON AUDITORY PERCEPTION: A SIGNAL DETECTION ANALYSIS.
185752 03-04

PSYCHEDELIC (LSD) PSYCHOTHERAPY: A CASE REPORT.
186994 03-08

EFFECTS OF LSD ON SYNTHESIS AND RELEASE OF 5-HT IN RAT BRAIN SLICES.
188164 04-03

EFFECTS OF LSD AND MONOAMINE SYNTHESIS INHIBITORS ON HORMONE ACTIVATED COPULATORY BEHAVIOR IN THE FEMALE RAT.
188611 04-04

EFFECTS OF LSD, MESCALINE, AND PSILOCYBIN ON SYMPATHETIC PREGANGLIONIC NEURONS.
191937 04-03

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
191944 04-04

CHLORIMIPRAMINE AND LSD: DIFFERENTIAL EFFECTS ON THE IN VIVO RELEASE OF 3H-5-HT.
191949 04-03

BLOCKADE OF EXCITATORY 5-HT SYNAPSE BY LSD.
191950 04-03

LSD AND THE INSANITY DRUGS, PART XXXI.
192092 04-17

LSD-LIKE

THE POSSIBLE ROLE OF TRYPTAMINE IN BRAIN FUNCTION AND ITS RELATIONSHIP TO THE ACTIONS OF LSD-LIKE HALLUCINOGENS.
186024 03-12

LSD-25

EFFECTS OF LSD-25 AND DEXTROAMPHETAMINE ON SPEECH RHYTHMS IN PSYCHOTHERAPY DIALOGUES.
168420 01-12

LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND GAMMA-AMINOBUTYRIC ACID (GABA) INTERACTION ON SPONTANEOUS POTENTIALS AND THE EVOKED RESPONSE IN THE AVIAN TECTUM.
169689 01-03

EFFECTS OF DELTA9-THC, LSD-25 AND SCOPOLAMINE ON CONTINUOUS, SPONTANEOUS ALTERNATION IN THE Y-MAZE.
171306 01-04

ELECTROENCEPHALOGRAPHIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL, LSD-25, MESCALINE AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE IN THE RABBITS.
182095 02-03

EFFECT OF LSD-25 AND 1-METHYL-D-LYSERGIC ACID BUTANOLAMIDE ON RAT BRAIN AND PLATELET SEROTONIN LEVELS.
184975 03-03

EFFECTS OF PROLONGED LSD-25 ADMINISTRATION UPON NEURONS OF SPINAL CORD GANGLIA TISSUE CULTURES.
185112 03-03

LU-1705

ONE YEAR OF CLINICAL EXPERIENCE WITH LARGE DOSES OF 10 PERCENT FLUPENTHIXOL DECANOATE (LU-1705).
172735 01-07

LUCIDRIL

TANTU-PASHAN AND LUCIDRIL THERAPY IN MENTALLY RETARDED CHILDREN.
175628 02-11

LUDIOMIL

A DOUBLE-BLIND, COMPARATIVE CLINICAL TRIAL WITH LUDIOMIL (CIBA-34276-BA) AND AMITRIPTYLINE IN NEWLY ADMITTED DEPRESSED PATIENTS.
167774 01-09

COMPARATIVE EVALUATION OF DIBENCYCLADINE (LUDIOMIL) AND IMIPRAMINE IN PSYCHOTIC DEPRESSION.
183361 03-09

A CONTROLLED TRIAL OF MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE IN GENERAL PRACTICE.
192510 04-09

LUNG

INHIBITION OF LUNG, LIVER AND BRAIN MONOAMINE OXIDASE BY IMIPRAMINE AND DESIPRAMINE.
177332 02-03

LUPUS-ERYTHEMATOSUS

NICOTINIC ACID INDUCED SYSTEMIC LUPUS-ERYTHEMATOSUS.
180243 02-15

LUTEINIZING

FUNCTIONAL EVALUATION OF PITUITARY RESERVE IN PATIENTS WITH THE AMENORRHEA GALACTORRHEA SYNDROME UTILIZING LUTEINIZING HORMONE RELEASING HORMONE (LH-RH), L-DOPA AND CHLORPROMAZINE.
175245 02-13

TESTOSTERONE AND LUTEINIZING HORMONE (LH) IN UNTREATED AND METHADONE MAINTAINED NARCOTIC ADDICTS.
182166 02-13

PLASMA LEVELS OF LUTEINIZING HORMONE AND OF IMMUNOREACTIVE ESTROGENS (ESTRADIOL) IN ANOREXIA-NERVOSA: RESPONSE TO CLOMIPHENE CITRATE.
183807 03-10

LUVATREN
CLINICAL USE OF LUVATREN (METHYLPERIDOL) FOR THE TREATMENT OF SCHIZOPHRENIA.
191720 04-08

LYSERGAMIDE
QUANTUM CHEMICAL STUDIES ON DRUG ACTIONS: IV. CORRELATION OF SUBSTITUENT STRUCTURES AND ANTISEROTONIN ACTIVITY IN LYSERGAMIDE SERIES.
174605 01-12

LYSERGIC
LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND GAMMA-AMINOBUTYRIC ACID (GABA) INTERACTION ON SPONTANEOUS POTENTIALS AND THE EVOKED RESPONSE IN THE AVIAN TECTUM.
169689 01-03
POTENTIAL PSYCHOTOMIMETICS: BROMOMETHOXYAMPHETAMINES AND STRUCTURAL CONGENERS OF LYSERGIC ACID. (PH.D. DISSERTATION).
173588 01-03
LYSERGIC ACID DIETHYLAMIDE AND SEROTONIN: A COMPARISON OF EFFECTS ON SEROTONERGIC NEURONS AND NEURONS RECEIVING A SEROTONERGIC INPUT.
177407 02-12
SYNTHESIS OF COMPOUNDS RELATED TO LYSERGIC ACID.
182445 03-01
DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
191944 04-04
CHROMOSOME EXAMINATIONS AFTER MEDICALLY ADMINISTERED LYSERGIC ACID DIETHYLAMIDE AND DEXTROAMPHETAMINE.
192084 04-15

LYSERGIDE
RADIOIMMUNOASSAY FOR LYSERGIDE (LSD) IN ILLICIT DRUGS AND BIOLOGICAL FLUIDS.
170840 01-06

LYSOSOMES
THE EFFECT OF CHLORPROMAZINE AND STELAZINE ON LYSOSOMES OF RAT LIVER DURING ACUTE INTOXICATION.
191121 04-03

MACACA-MULATTA
BEHAVIORAL EFFECTS OF DRUGS IN MACACA-MULATTA.
181401 02-04
SOCIAL HIERARCHY IN MONKEYS (MACACA-MULATTA) MODIFIED BY CHLORDIAZEPOXIDE HYDROCHLORIDE.
183863 03-04

MAGNESIUM
LACK OF EFFECT OF RIBAMINOL, TCAP, AND MAGNESIUM PEMOLINE ON RECOVERY FROM NEOCEREBELLAR DAMAGE.
171904 01-03

MAGNETIC
CONFORMATIONAL ANALYSIS OF ACRIDAN DERIVATIVES BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY. A RELATIONSHIP BETWEEN CONFORMATION AND PHARMACOLOGICAL ACTIVITY.
190715 04-01

MAINTAINED
TESTOSTERONE AND LUTEINIZING HORMONE (LH) IN UNTREATED AND METHADONE MAINTAINED NARCOTIC ADDICTS.
182166 02-13
DIFFERENTIAL EFFECTS OF PILOCARPINE AND SCOPOLAMINE ON THE PERFORMANCE OF A LIGHT DARK DISCRIMINATION MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN.
186701 03-03
NALTREXONE AND NALOXONE: AGONIST AND ANTAGONIST EFFECTS ON KEY-PRESS RESPONDING OF PIGEONS MAINTAINED UNDER A MULTIPLE SCHEDULE OF FOOD PRESENTATION.
191926 04-04
EFFECTS OF PHENCYCLIDINE AND KETAMINE ON FOOD MAINTAINED BEHAVIOR IN THE PIGEON.
191973 04-04

MAINTENANCE
CLINICAL EVALUATION OF FLUSPIRILENE AS A MAINTENANCE THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS.
168320 01-08
THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA.
172963 01-08
WITHDRAWAL OF MAINTENANCE DRUGS WITH LONG-TERM HOSPITALIZED MENTAL PATIENTS: A CRITICAL REVIEW.
175862 02-17
MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN THE LIGHT OF PROGNOSIS ORIENTED DIAGNOSIS.
186081 03-08
EFFECTS OF PHYSOSTIGMINE ON THE MAINTENANCE OF DISCRIMINATION BEHAVIOUR IN RATS.
186637 03-04
LOCALIZED BEHAVIORAL EFFECTS OF VASOPRESSIN ON MAINTENANCE OF AN ACTIVE AVOIDANCE RESPONSE IN RATS.
187697 04-04
DRUG MAINTENANCE IN THE OUTPATIENT TREATMENT OF CHRONIC ALCOHOLISM.
189926 04-11
EVIDENCE FOR A DOPAMINERGIC INVOLVEMENT IN THE MAINTENANCE OF SELF-STIMULATION.
191526 04-03

MAJOR
A PROGRAMME WHICH LED TO REDUCTION IN NIGHT SEDATION IN A MAJOR HOSPITAL.
170802 01-17
CONCENTRATION EFFECT RELATIONSHIPS WITH MAJOR AND MINOR TRANQUILIZERS.
192871 04-14

MALE
EFFECTS OF IMIPRAMINE ON COPULATORY BEHAVIOR OF MALE RATS.
168718 01-04
MONOAMINES AND COPULATORY ACTIVATION IN THE CASTRATED MALE RAT.
171618 01-04
INFLUENCE OF PHENOBARBITAL AND SEX HORMONES ON ENZYMES IN ASCORBIC ACID BIOSYNTHESIS IN MALE AND FEMALE RATS. (PH.D. DISSERTATION).
172017 01-03
SUBACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MALE AND FEMALE RATS: ORAL ADMINISTRATION FOR ONE MONTH.
177097 02-05
THE HYDROXYLATION OF D-AMPHETAMINE BY LIVER MICROSOMES OF THE MALE RAT.
177337 02-03
THE EFFECTS OF CHLORDIAZEPOXIDE (LIBRIUM) ON THE INTENSITY AND HABITUATION OF AGONISTIC BEHAVIOR IN MALE SIAMESE FIGHTING FISH.
177722 02-04
AFRODEX VS. PLACEBO IN THE TREATMENT OF MALE IMPOTENCE: STATISTICAL ANALYSIS OF TWO DOUBLE-BLIND CROSSOVER STUDIES.
181959 02-14
EFFECTS OF CHRONICALLY ADMINISTERED DELTA1-TETRAHYDROCANNABINOL OF ADRENAL AND GONADAL ACTIVITY OF MALE RATS.
183358 03-03
REDUCTION IN COPULATORY BEHAVIOR OF MALE RATS FOLLOWING HASHISH INJECTIONS.
183790 03-04
EFFECTS OF CYPROTERONE ACETATE IN THE MALE JAPANESE QUAIL.
186681 03-03
LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04
APHRODISIAC EFFECT OF L-DOPA AND APOMORPHINE IN MALE SEXUALLY SLUGGISH RATS.
188519 04-03
EFFECTS OF CHRONIC NICOTINE ADMINISTRATION AND AGE ON VARIOUS NEUROTRANSMITTERS AND ASSOCIATED ENZYMES IN MALE FISCHER 344 RATS.
189597 04-03
DISTRIBUTION OF 14C-DELTA9-THC IN MALE AND FEMALE RATS.
191969 04-03
INTERACTION OF SEROTONIN ANTAGONISTS WITH 3,4-DICHLORO-2-(2-IMIDAZOLIN-2-YL-THIO) 2 ACETOPHENONE HYDROBROMIDE (DITA) AND D-AMPHETAMINE HYDROBROMIDE (DITA) AND D-AMPHETAMINE ON CERTAIN BEHAVIORAL PARAMETERS OF MALE MICE.
192014 04-04

MALES
INVERSION BY APOMORPHINE OF THE TENDENCY OF FEMALE RATS TO BE DEFEATED BY MALES WHEN COMPETING FOR FOOD IN A STRAIGHT RUNWAY.
184212 03-04

MALFORMATION
ENDURING LEARNING DEFICITS AND CEREBRAL SYNAPTIC MALFORMATION FROM EXPOSURE TO 10 PARTS OF HALOTHANE PER MILLION.
192565 04-04

MALIGNANT
CLINICAL EXPERIENCE WITH DIAMORPHINE IN ADVANCED MALIGNANT DISEASE.
191606 04-17

MALNUTRITION
SENILITY AND CHRONIC MALNUTRITION.
188446 04-11

MAMMALIAN
PASSAGE OF TAURINE INTO ADULT MAMMALIAN BRAIN.
191331 04-03

MAMMILLARIA-ELONGATA
CACTUS ALKALOIDS: XVIII. PHENOLIC BETA-PHENETHYLAMINES FROM MAMMILLARIA-ELONGATA.
192882 04-01

MAN

TETRAHYDROISOQUINOLINE ALKALOIDS: IN VIVO METABOLITES OF L-DOPA IN MAN.
168286 01-13

PSYCHOLOGICAL AND PHYSIOLOGICAL EFFECTS OF CHRONIC MARIJUANA ADMINISTRATION IN MAN.
169070 01-13

MARIHUANA USE IN MAN: AN EXPERIMENTAL INQUIRY -- CLINICAL PSYCHIATRIC IMPRESSIONS.
169085 01-14

CENTRAL MONOAMINE METABOLISM IN MAN: EFFECT OF PUTATIVE DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS.
169377 01-13

BLOOD LEVEL PROFILE IN MAN FOLLOWING CHRONIC ORAL ADMINISTRATION OF FLURAZEPAM HYDROCHLORIDE.
169817 01-13

PHARMACOKINETIC PROFILE OF DIAZEPAM IN MAN FOLLOWING SINGLE INTRAVENOUS AND ORAL AND CHRONIC ORAL ADMINISTRATION.
170838 01-13

ANTAGONISTIC EFFECTS OF PHYSOSTIGMINE AND METHYLPHENIDATE IN MAN.
172272 01-11

TECHNICAL STRATEGIES FOR THE STUDY OF CATECHOLAMINES IN MAN. (UNPUBLISHED PAPER).
173387 01-03

METABOLIC CONTROL OF BODY TEMPERATURE IN MAN.
174134 01-08

BEHAVIORAL EFFECTS OF A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR (FUSARIC ACID) IN MAN. (UNPUBLISHED PAPER
174329 01-09

INTERACTIONS IN MAN OF DELTA9-TETRAHYDROCANNABINOL: I. ALPHA-METHYL-PARA-TYROSINE.
174347 01-13

DIURETIC ACTIVITY OF A NEW NARCOTIC ANTAGONIST IN MAN (BRISTOL-COMPOUND-2605). (UNPUBLISHED PAPER).
174473 01-13

ATTEMPTS TO EVOKE TOLERANCE TO DMT IN MAN. (UNPUBLISHED PAPER).
176480 02-12

A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY IN MAN OF INTRAVENOUSLY ADMINISTERED DELTA9-TETRAHYDROCANNABINOL, CANNABINOL, AND CANNABIDIOL.
176747 02-03

QUALITATIVE AND QUANTITATIVE STUDIES ON THE DISPOSITION OF AMITRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANT DRUGS IN MAN AS IT RELATES TO THE MANAGEMENT OF THE OVERDOSED PATIENT.
177395 02-15

AMITRIPTYLINE IN MAN: DECREASED FORMATION OF CENTRAL 5-HYDROXYINDOLEACETIC ACID.
177736 02-13

INVESTIGATIONS ON THE FATE OF THE ANTICONVULSANT CLONAZEPAM IN THE ORGANISM OF MAN, RAT AND DOG.
179022 02-13

PSYCHOPHYSIOLOGICAL EFFECTS OF DIAZEPAM (VALIUM) COMBINED WITH A MODERATE DOSE OF ALCOHOL IN MAN.
180699 02-14

STUDIES ON METABOLISM OF BROMAZEPAM (III): ABSORPTION, EXCRETION, AND METABOLISM OF BROMAZEPAM IN MAN.
181588 02-13

INCREASED GASTRIC ACID DURING SHOCK AVOIDANCE IN MAN.
181879 02-13

PHARMACOLOGIC ACTIVITY AND BIOTRANSFORMATION OF R.. AND S-BARBITURATE ENANTIOMERS IN MOUSE AND MAN.
182156 02-03

A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL AND ITS MONOHYDROXYLATED METABOLITES IN MAN.
182223 03-03

BLOOD LEVEL AND URINARY EXCRETION OF BROMAZEPAM IN MAN.
182556 03-13

BUTOBARBITONE METABOLISM IN MAN: IDENTIFICATION OF 3-KETOBUTOBARBITONE.
183793 03-13

METABOLISM OF CHLORPHENTERMINE AND PHENTERMINE IN MAN TO YIELD HYDROXYLAMINO, C-NITROSO AND NITRO COMPOUNDS.
183796 03-13

EFFECT OF ANTIDEPRESSANT AND ANTIMANIC DRUGS ON AMINE UPTAKE IN MAN.
184654 03-13

IMIPRAMINE MEDIATED EFFECTS ON LEVODOPA METABOLISM IN MAN.
185998 03-13

MAN AND HIS MEDICINES.
186474 03-17

COMPARISON OF GRADED SINGLE INTRAMUSCULAR DOSES OF MORPHINE AND PENTOBARBITAL IN MAN.
187254 03-15

THE EFFECT OF CAFFEINE, NITRAZEPAM AND CIGARETTE SMOKING ON THE CONTINGENT NEGATIVE VARIATION IN MAN.
187350 04-13

N-(2-DIETHYLAMINOETHYL) 2 (P-HYDROXYPHENOXY) ACETAMIDE, A METABOLITE OF MEFEXAMIDE IN MAN.
187577 04-01

CARDIOVASCULAR EFFECTS OF MARIHUANA IN MAN.
187812 04-13

PLASMA AND CEREBROSPINAL FLUID PROBENECID CONCENTRATIONS AS RELATED TO ACCUMULATION OF ACIDIC BIOGENIC AMINE METABOLITES IN MAN.
187933 04-13

STEREOSPECIFIC ACTIONS OF DOET (2,5 DIMETHOXY-4-ETHYLAMPHETAMINE) IN MAN.
188121 04-12

ROLE OF DOPAMINERGIC MECHANISMS IN REGULATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN MAN.
188428 04-13

THE EFFECT OF A NEW BENZODIAZEPINE DERIVATIVE NIMETAZEPAM ON THE SLEEP CYCLE IN MAN.
188501 04-07

INFLUENCE OF NEUROLEPTICS AND BENZODIAZEPINES ON METABOLISM OF TRICYCLIC ANTIDEPRESSANTS IN MAN.
191026 04-09

THE EFFECT OF LITHIUM ON THYROID IN MAN.
191142 04-15

MONOAMINE OXIDASE IN MAN: ENZYME CHARACTERISTICS IN HUMAN PLATELETS, PLASMA, AND OTHER HUMAN TISSUES.
191502 04-13

AN EVALUATION OF SERUM DOPAMINE-BETA-HYDROXYLASE AS AN INDEX OF SYMPATHETIC NERVE ACTIVITY IN MAN.
191511 04-13

COMPARATIVE METABOLISM OF TRIAZOLAM, A NEW SEDATIVE HYPNOTIC, IN RAT, DOG AND MAN.
191900 04-02

EFFECTS OF CNS AGENTS ON NICOTINE EXTENSOR CONVULSIONS AND LETHALITY IN MICE AND THEIR SEDATIVE ANTIANXIETY EFFECTS IN MAN.
191907 04-14

PROTRIPTYLINE STEADY-STATE PLASMA LEVELS IN MAN.
191924 04-13

A PREDICTABLE LABORATORY MODEL FOR SEDATIVE/HYPNOTIC ACTIVITY IN MAN.
191943 04-14

THE PREDICTIVE VALUE OF THE ANTIAPOMORPHINE TEST IN DOGS FOR NEUROLEPTIC THERAPY IN MAN.
192421 04-04

MANAGEMENT

CLINICAL EXPERIMENTATION WITH A NEW BENZODIAZEPINE IN THE MANAGEMENT OF PHOBIC AND OBSESSIVE SYMPTOMS.
167594 01-10

SCHIZOPHRENIA MANAGEMENT -- THE DAWN OF A NEW ERA.
172435 01-08

A COMPARATIVE TRIAL OF HALOPERIDOL AND THIORIDAZINE: MANAGEMENT OF CHRONIC SCHIZOPHRENIA.
172741 01-08

MANAGEMENT OF HOSTILE, SUSPICIOUS PATIENTS. TRIFLUOPERAZINE VERSUS HALOPERIDOL.
176675 02-14

QUALITATIVE AND QUANTITATIVE STUDIES ON THE DISPOSITION OF AMITRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANT DRUGS IN MAN AS IT RELATES TO THE MANAGEMENT OF THE OVERDOSED PATIENT.
177395 02-15

DIAGNOSIS AND MANAGEMENT OF DEPRESSION IN GENERAL PRACTICE.
180406 02-09

SOME RECENT ADVANCES IN THE MANAGEMENT OF ANXIETY.
182764 03-10

DRUG THERAPIES IN CRISIS MANAGEMENT.
189297 04-17

JOHN J. BONICA ON PAIN MANAGEMENT.
189903 04-13

MANAGING

THE ROLE OF CHEMOTHERAPY IN MANAGING POTENTIALLY SUICIDAL PATIENTS.
178544 02-10

MANDRAX

COMPLICATIONS OF METHAQUALONE DIPHENHYDRAMINE (MANDRAX) ABUSE.
177452 02-15

MANIA

EFFECT OF LITHIUM ON AGGRESSION, MANIA AND PERMSELECTIVE MEMBRANES.
167448 01-09

L-TRYPTOPHAN IN MANIA: CONTRIBUTION TO A PERMISSIVE HYPOTHESIS OF AFFECTIVE DISORDERS.
171500 01-09

CHOLINERGIC AND ADRENERGIC BALANCE IN MANIA AND SCHIZOPHRENIA.
191530 04-09

MANIC
LITHIUM CARBONATE TREATMENT IN MANIC PSYCHOSIS.
167918 01-09
A COMPARISON OF LITHIUM CARBONATE IN THE PREVENTION OF MANIC AND DEPRESSIVE EPISODES IN RECURRENT AFFECTIVE DISORDER.
169090 01-09
LITHIUM INDUCED DIABETES-INSIPIDUS: MANIC SYMPTOMS, BRAIN AND ELECTROLYTE CORRELATES, AND CHLOROTHIAZIDE TREATMENT.
169486 01-15
CHOLINERGIC REVERSAL OF MANIC SYMPTOMS: A POSSIBLE EXPLANATION. (UNPUBLISHED PAPER).
173520 01-09
PRESENT TREATMENT OF MANIC STATES.
183189 03-09
REBOUND PHENOMENON IN MANIC PATIENTS FOLLOWING PHYSOSTIGMINE: TOWARDS AN UNDERSTANDING OF AMINERGIC MECHANISMS UNDERLYING AFFECTIVE DISORDERS.
191531 04-09
ROLE OF ACETYLCHOLINE AND DOPAMINE IN MANIC BEHAVIOR.
191532 04-09
EXPERIMENT WITH LITHIUM CARBONATE ON THE TREATMENT OF MANIC STATE.
191670 04-09

MANIC-DEPRESSIVE
GROWTH HORMONE RESPONSES TO ADMINISTRATION OF L-5-HYDROXYTRYPTOPHAN (L-5-HTP) IN MANIC-DEPRESSIVE PSYCHOSES.
167919 01-09
SELECTIVE INHIBITION OF NOREPINEPHRINE SYNTHESIS IN MANIC-DEPRESSIVE PATIENTS WITH A DOPAMINE-BETA-HYDROXYLASE INHIBITOR. (UNPUBLISHED PAPER).
170083 01-03
STUDIES ON THE URINARY EXCRETION OF CATECHOLAMINES AND 17-KETOSTEROID IN MANIC-DEPRESSIVE PSYCHOSIS.
178623 02-09
FACTORS ASSOCIATED WITH LITHIUM RESPONSE IN THE PROPHYLACTIC TREATMENT OF BIPOLAR MANIC-DEPRESSIVE ILLNESS.
186188 03-09
LITHIUM CARBONATE IN MANIC-DEPRESSIVE PSYCHOSIS.
187477 04-09
PROPHYLACTIC EFFICACY OF LITHIUM CARBONATE IN MANIC-DEPRESSIVE ILLNESS: REPORT OF THE VETERANS ADMINISTRATION AND NATIONAL INSTITUTE OF MENTAL HEALTH (VA-NIMH) COLLABORATIVE STUDY GROUP.
189735 04-09

MANIFESTATIONS
TREATMENT OF THE CEREBRAL MANIFESTATIONS OF ARTERIOSCLEROSIS WITH CYCLANDELATE.
185008 03-11

MANIFESTED
ADAPTATION TO NITROGEN NARCOSIS MANIFESTED BY TIMING BEHAVIOR IN THE RAT.
186630 03-04

MANIPULATION
PHARMACOLOGICAL DISTINCTIONS BETWEEN ACTIVE AND PASSIVE AVOIDANCE MEMORY FORMATION AS SHOWN BY MANIPULATION OF BIOGENIC AMINE ACTIVE COMPOUNDS.
185927 03-04

MANUAL
MANUAL OF INTOXICATING DRUGS.
175537 02-17

MAO
STUDIES ON MONOAMINE OXIDASE -- REPORT 22: EFFECTS OF NANO2 AND NH2OH ON MITOCHONDRIAL MAO IN RAT BRAIN.
177022 02-03
THE INFLUENCE OF NEUROTROPIC DRUGS ON MONOAMINE OXIDASE (MAO) AND 5-OXYTRYPTOPHANE DECARBOXYLASE (5-OTD) ACTIVITY IN THE BRAIN.
183142 03-13
MULTIPLE FORMS OF MAO: SOME IN VIVO CORRELATIONS.
191496 04-03
SOME CONSIDERATIONS IN THE DESIGN OF SUBSTRATE AND TISSUE SPECIFIC INHIBITORS OF MAO.
191499 04-01
CORRELATION BETWEEN BRAIN N,N DIMETHYLTRYPTAMINE (DMT) LEVELS AND BAR PRESSING BEHAVIOR IN RATS: EFFECT OF MAO INHIBITION.
191935 04-04
THE PRESENCE OF MAO IN SYNAPTIC MEMBRANES OF BOVINE BRAIN.
191956 04-03

MAPROTILINE
CLINICAL EXPERIENCES WITH A NEW ANTIDEPRESSANT, MAPROTILINE.
188893 04-09
A CONTROLLED TRIAL OF MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE IN GENERAL PRACTICE.
192510 04-09

MARGINAL
QUINAZOLINES AND 1,4 BENZODIAZEPINES.64.COMPARISON OF THE STEREOCHEMISTRY OF DIAZEPAM WITH THAT OF CLOSE ANALOGS WITH MARGINAL BIOLOGICAL ACTIVITY.
185034 03-01

MARIHUANA
THE RELATIONSHIP OF MARIHUANA AND SOCIAL BEHAVIOR.
169084 01-13
MARIHUANA USE IN MAN: AN EXPERIMENTAL INQUIRY -- CLINICAL PSYCHIATRIC IMPRESSIONS.
169085 01-14
TOXIC EFFECTS OF MARIHUANA TAR ON MOUSE SKIN.
170464 01-05
MARIHUANA AND SOCIAL BEHAVIOR.
175003 02-14
THE EFFECT OF MARIHUANA ON TRACKING TASK PERFORMANCE.
177720 02-14
MARIHUANA -- A PSYCHEDELIC DRUG?
178695 02-17
MARIHUANA AND PAIN.
182719 03-13
CARDIOVASCULAR EFFECTS OF MARIHUANA IN MAN.
187812 04-13
LONG-TERM USE OF MARIHUANA AND THE DEVELOPMENT OF TOLERANCE OR SENSITIVITY TO DELTA9-TETRAHYDROCANNABINOL.
188119 04-13
REPEAT ADMINISTRATION OF MARIHUANA SMOKE TO HUMANS.
188120 04-13
EFFECT OF MARIHUANA ON THE PSYCHOLOGICAL REFRACTORY PERIOD.
189358 04-14
EFFECTS OF TWO LEVELS OF ATTENTION DEMAND ON VIGILANCE PERFORMANCE UNDER MARIHUANA.
189359 04-14
THE NATURE OF STORAGE DEFICITS AND STATE-DEPENDENT RETRIEVAL UNDER MARIHUANA.
189406 04-14
CRUDE MARIHUANA EXTRACT: EEG AND BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION IN RHESUS MONKEYS.
189516 04-04
STUDIES OF THE IMMUNE RESPONSE IN CHRONIC MARIHUANA SMOKERS.
191961 04-13
CLINICAL EFFECTS OF MARIHUANA SECOBARBITAL COMBINATION.
191989 04-14
CLINICAL EFFECTS OF MARIHUANA DEXTROAMPHETAMINE COMBINATION.
191990 04-14
METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY RATS TOLERANT TO MARIHUANA.
192020 04-03

MARIJUANA
PSYCHOLOGICAL AND PHYSIOLOGICAL EFFECTS OF CHRONIC MARIJUANA ADMINISTRATION IN MAN.
169070 01-13
THE EFFECT OF MARIJUANA ON HOSTILITY IN AN EXPERIMENTAL GROUP SETTING: PRELIMINARY OBSERVATIONS.
169086 01-14
INDUCTION OF SEVERE DEPRESSION BY PHYSOSTIGMINE IN MARIJUANA INTOXICATED INDIVIDUALS.
177450 02-14
MARIJUANA DIMINISHES GSR ACTIVATION PEAKING.
181887 02-13
INFLUENCE OF ALPHA-METHYLTYROSINE ON ENHANCEMENT OF SHUTTLEBOX AVOIDANCE BY MARIJUANA AND PENTOBARBITAL.
187572 04-04
PERFORMANCE ON A VERBAL LEARNING TASK BY SUBJECTS OF HEAVY PAST MARIJUANA USAGE.
190308 04-14

MARITAL
DRUG THERAPY AND MARITAL THERAPY IN OUTPATIENT DEPRESSIVES.
169088 01-09

MASKED
MASKED DEPRESSION.
182829 03-10
SO-CALLED MASKED DEPRESSION AND ITS TREATMENT.
183369 03-10

MASSIVE
THE OCULAR COMPLICATIONS BY MASSIVE DOSE OF PSYCHOTROPIC DRUGS.
182552 03-15

MATCHED
LITHIUM PROPHYLAXIS IN AFFECTIVE DISORDERS: AN OPEN TRIAL WITH MATCHED CONTROLS.
172401 01-09

MATCHING-TO-SAMPLE
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON DELAYED MATCHING-TO-SAMPLE CHOICE SPEEDS IN CHIMPANZEES.
171886 01-04

EFFECTS OF CHRONIC EXPOSURE TO DELTA9-TETRAHYDROCANNABINOL ON DELAYED MATCHING-TO-SAMPLE IN CHIMPANZEES.
189405 04-04

MATERNAL
EFFECT OF PRENATAL MATERNAL ADMINISTRATION OF D-AMPHETAMINE ON RAT OFFSPRING ACTIVITY AND PASSIVE AVOIDANCE LEARNING.
167415 01-03
ALTERATION OF MATERNAL BEHAVIOR IN MICE FOLLOWING ADMINISTRATION OF CYPROTERONE ACETATE.
172374 01-04

MATTER
IMPROVING PSYCHIATRIC DRUG THERAPY: A MATTER OF DOSAGE AND CHOICE.
190144 04-17
ANALGESIA AND HYPERREACTIVITY PRODUCED BY INTRACRANIAL MICROINJECTIONS OF MORPHINE INTO THE PERIAQUEDUCTAL GRAY MATTER OF THE RAT.
191367 04-04
NEUROCHEMICAL ANALYSIS OF AGGRESSIVE - DEFENSIVE BEHAVIOR ELICITED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS AND CENTRAL GRAY MATTER.
191784 04-02

MAXIMAL
THE EFFECT OF CANNABIDIOL ON MAXIMAL ELECTROSHOCK SEIZURES IN RATS.
168749 01-03
INDICATIONS AND DOSAGE FOR MAXIMAL ACTIVITY OF ORNITHINE-CARBAMYL-TRANSFERASE IN THE PSYCHIATRIC ENVIRONMENT.
184955 03-17

MAZE
EFFECT OF L-ASPARAGINASE ON RETENTION OF MAZE LEARNING IN MICE.
167324 01-04
EFFECT OF CHRONIC POSTTRIAL SALINE INJECTIONS ON MAZE PERFORMANCE.
167403 01-04
EFFECTS OF CHLORPROMAZINE, MEPROBAMATE AND CHLORDIAZEPOXIDE ON THE MAZE LEARNING IN MICE.
171259 01-04
EFFECTS OF ANALEPTICS ON MAZE LEARNING IN MICE.
173078 01-04
SPECIFIC FACILITATION OF MAZE LEARNING BY A PEPTIDE EXTRACTED FROM TRAINED MOUSE BRAIN.
176868 02-04
THE EFFECTS OF EARLY SALINE INJECTIONS AND PENTYLENETETRAZOL ON HEBB-WILLIAMS MAZE PERFORMANCE IN THE ADULT RAT.
191378 04-04

MAZINDOL
DOUBLE-BLIND CLINICAL EVALUATION OF MAZINDOL, DEXTROAMPHETAMINE, AND PLACEBO IN TREATMENT OF EXOGENOUS OBESITY.
167335 01-11

MDA
THE PROPERTIES OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA). I. A REVIEW OF THE LITERATURE.
176597 02-17

MEASURE
THE SPIRAL AFTEREFFECT (SAE) AS A MEASURE OF MOTION SICKNESS SUSCEPTIBILITY AND THE EFFECT ON THE SAE OF AN ANTIMOTION SICKNESS DRUG AND A CENTRAL NERVOUS SYSTEM DEPRESSANT.
172780 01-03

MEASURED
ANALGESIC POTENCY OF SODIUM SALICYLATE, INDOMETHACIN, AND CHLORDIAZEPOXIDE AS MEASURED BY THE SPATIAL PREFERENCE TECHNIQUE IN THE RAT.
171301 01-02
CHANGES IN THE NEUROEXCITABILITY OF ALCOHOL DEPENDENT RATS UNDERGOING WITHDRAWAL AS MEASURED BY THE PENTYLENETETRAZOL SEIZURE THRESHOLD.
182348 03-03
AN ELECTROENCEPHALOGRAPHIC STUDY ON THE TOLERANCE OF THE VARIOUS PSYCHIATRIC AND NEUROLOGICAL PATIENTS TO THE HYPNOTIC EFFECTS OF DIPHENHYDRAMINE -- MEASURED BY THE AMOUNTS OF SLEEP EEG AS AN INDICATOR.
182550 03-11
THE EFFECT OF SOME CHOLINOLYTIC DRUGS ON A NUMBER OF BEHAVIOURAL PARAMETERS MEASURED IN THE T-MAZE ALTERNATION TEST: DOSE-RESPONSE RELATIONSHIPS.
187641 04-04

MEASUREMENT
MEASUREMENT OF BIOGENIC AMINES AT THE PICOGRAM LEVEL. (UNPUBLISHED LEVEL).
173382 01-03
IN VIVO MEASUREMENT OF THE RELEASE OF 5-HYDROXYTRYPTAMINE (5-HT) FROM THE HIPPOCAMPUS OF THE RAT: EFFECT OF RO-4-1284, PARGYLINE AND P-CHLOROAMPHETAMINE (PCA).
182140 02-03
A SENSITIVE, SIMPLE METHOD FOR MEASUREMENT OF TYROSINE HYDROXYLASE AND TRYPTOPHAN-5-HYDROXYLASE ACTIVITIES.
182178 02-06
MEASUREMENT OF ANXIETY IN GENERAL PRACTICE.
182768 03-10
A NEW RECORDING APPARATUS FOR MEASUREMENT OF LOCOMOTOR ACTIVITY OF MICE. EXPERIMENTAL OBSERVATIONS ON ITS USE.
186377 03-06
POST-MORTEM MEASUREMENT OF ENZYMES IN HUMAN BRAIN: EVIDENCE OF A CENTRAL NORADRENERGIC DEFICIT IN SCHIZOPHRENIA.
191529 04-13

MEASUREMENTS
THE COMPARATIVE ANXIOLYTIC EFFECTS OF PLACEBO, IMIPRAMINE AND CHLORIMIPRAMINE USING PSYCHIATRIC AND PSYCHOPHYSIOLOGICAL MEASUREMENTS.
191137 04-14

MEASURING
MEASURING THE PHARMACOLOGICAL ACTION OF IMIPRAMINE IN THE TREATMENT OF DEPRESSIONS.
174995 02-09

MEBUTAMATE
EFFECTS OF MEBUTAMATE ON THE ELECTROENCEPHALOGRAPHIC SLEEP PROFILE.
174348 01-14

MECAMYLAMINE
DISSOCIATION BETWEEN SCOPOLAMINE AND MECAMYLAMINE DURING FEAR CONDITIONING IN RATS.
190264 04-04

MECHANISM
ANIMAL MODELS FOR AN ENZYMIC BLOOD-BRAIN BARRIER MECHANISM FOR THERAPEUTICALLY ADMINISTERED L-DOPA.
167359 01-03
STUDY INTO THE MECHANISM OF THE ANORECTIC ACTION OF AMPHETAMINE AND ITS P-CHLORO ANALOGUE.
171610 01-03
HALOPERIDOL EFFECTS ON MORPHINE SELF-ADMINISTRATION: TESTING FOR PHARMACOLOGICAL MODIFICATION OF THE PRIMARY REINFORCEMENT MECHANISM.
172454 01-04
ON THE MECHANISM OF CENTRAL ACTION OF AMPHETAMINE: THE ROLE OF CATECHOLAMINES.
172921 01-04
APOMORPHINE INDUCED BITING AND FIGHTING BEHAVIOUR IN RESERPINIZED RATS AND AN APPROACH TO THE MECHANISM OF ACTION.
174768 01-04
CONDITIONED HYPOGLYCEMIA: A MECHANISM FOR SACCHARIN INDUCED SENSITIVITY TO INSULIN IN THE RAT.
174877 01-03
THE MECHANISM OF ACTION OF THE MONOAMINE OXIDASE INHIBITOR PARGYLINE.
175239 02-03
DOPAMINE IN THE MESOLIMBIC SYSTEM OF THE RAT BRAIN: ENDOGENOUS LEVELS AND THE EFFECTS OF DRUGS ON THE UPTAKE MECHANISM AND STIMULATION OF ADENYLATE CYCLASE ACTIVITY.
177131 02-03
MECHANISM OF RELEASE AT NORADRENERGIC NERVE TERMINALS BY RESERPINE AND SEVERAL SYMPATHOMIMETIC AGENTS. (UNPUBLISHED PAPER).
178747 02-03
STUDIES ON CENTRAL REGULATING MECHANISM OF THE HYPOGLYCEMIA INDUCED BY INTRAVENTRICULAR ADMINISTRATION OF CHLORPROMAZINE.
182093 02-03
MECHANISM OF THE NEGATIVE CHRONOTROPIC AND INOTROPIC EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC).
182219 03-03
CENTRAL CHOLINERGIC (MUSCARINIC) LINK IN THE ATTACK REFLEXIVE BITING MECHANISM OF CATS.
182238 03-04
ON THE MECHANISM OF THE SYNERGISTIC EFFECT OF PERAZINE AND HEXOBARBITAL.
184199 03-03
MECHANISM OF ACTION OF SUBSTANCE-P.
184200 03-04
TOWARD A MECHANISM OF THE ANTIAGGRESSION EFFECTS OF CHLORDIAZEPOXIDE IN RATS.
185934 03-04
NONCHOLINERGIC MECHANISM OF ACTION OF CHOLINERGIC DRUGS ON SQUID AXON MEMBRANES.
186672 03-03
ON THE MECHANISM OF RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVES INDUCED BY DEPOLARIZING AGENTS AND SYMPATHOMIMETIC DRUGS. (UNPUBLISHED PAPER).
187397 04-03

A POSSIBLE MECHANISM FOR THE ANTISCHIZOPHRENIC ACTION OF CHLORPROMAZINE: INHIBITION OF THE FORMATION OF DIMETHYLTRYPTAMINE BY CHLORPROMAZINE METABOLITES.
187576 04-03

MECHANISM OF THE VASOCONSTRICTOR ACTION OF PROSTAGLANDIN B.
189394 04-03

MECHANISM OF ADRENAL CATECHOLAMINE RELEASE BY DIVALENT MERCURY.
189591 04-03

DOSE-RELATED ALTERATIONS IN METABOLISM OF LEVODOPA: POSSIBLE MECHANISM FOR HYPOTENSIVE EFFECT.
190194 04-11

EVIDENCE FOR A NORADRENERGIC AND DOPAMINERGIC MECHANISM IN THE HYPERACTIVITY PRODUCED BY 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.
190309 04-04

PROCAINE (GEROVITAL-H3) THERAPY: MECHANISM OF INHIBITION OF MONOAMINE OXIDASE.
191281 04-03

MECHANISMS

SEROTONINERGIC MECHANISMS IN THE CENTRAL ACTION OF PSYCHOTROPIC DRUGS. (PH.D. DISSERTATION).
172015 01-03

KINETICS AND CELLULAR CONTROL MECHANISMS FOR IMIPRAMINE METABOLISM IN THE ISOLATED PERFUSED RAT LIVER. (PH.D. DISSERTATION).
173601 01-03

EFFECTS OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES ON CENTRAL NORADRENERGIC MECHANISMS. (PH.D. DISSERTATION).
174959 01-03

POTENTIAL NEUROTRANSMITTERS AND RECEPTOR MECHANISMS INVOLVED IN THE CENTRAL CONTROL OF BODY TEMPERATURE IN HAMSTERS. (PH.D. DISSERTATION).
174962 01-03

THE MECHANISMS OF ACTION OF HALLUCINOGENS.
180142 02-12

PERIPHERAL VERSUS CENTRAL MECHANISMS ACCOUNTING FOR ANTIANXIETY EFFECTS OF PROPRANOLOL.
181072 02-10

MECHANISMS OF DRUG-INDUCED BEHAVIORAL TOLERANCE.
181406 02-04

INHIBITION OF THE SYNAPTOSOMAL UPTAKE MECHANISMS FOR L-NOREPINEPHRINE AND DOPAMINE BY N-ARYLALKYL DL-AMPHETAMINE DERIVATIVES.
182250 03-03

RUBIDIUM SALTS: BASIC MECHANISMS OF ACTION.
182441 03-03

MECHANISMS UNDERLYING POTENTIATION OF BARBITURATE ACTION BY SODIUM NITRITE IN THE MOUSE: THE ROLE OF METHEMOGLOBIN INDUCED HYPOXIA.
182721 03-03

THE ACTIONS OF SEVERAL PSYCHOACTIVE AGENTS UPON THE MUSCARINIC MECHANISMS IN THE SUPERIOR CERVICAL GANGLION OF THE CAT.
183866 03-03

ARE CHOLINERGIC MECHANISMS INVOLVED IN MORPHINE EFFECTS ON MOTILITY
184198 03-03

BRAIN MECHANISMS UNDERLYING THE EFFECTS OF AMPHETAMINE ON FEEDING AND NONFEEDING BEHAVIORS: DISSOCIATION AND OVERLAP.
184839 03-03

NEURAL AND CHEMICAL MECHANISMS OF FEMALE SEXUAL BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).
185705 03-04

POSSIBLE PERIPHERAL ADRENERGIC AND CHOLINERGIC MECHANISMS IN PSEUDOCONDITIONING.
186575 03-03

EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: I. EFFECT ON THE BEHAVIOURAL CHANGES INDUCED BY RESERPINE, ALPHA-METHYL-P-TYROSINE OR AMPHETAMINE.
186587 03-04

EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: II. EFFECT ON DOPAMINE AND NORADRENALINE CONCENTRATIONS AND TURNOVERS.
186588 03-04

CLINICAL PHARMACOLOGY AS AN APPROACH TO THE STUDY OF BIOCHEMICAL SLEEP MECHANISMS: THE ACTION OF L-DOPA.
186643 03-14

COMPARISON OF THE LOCOMOTOR STIMULANT MECHANISMS OF ACTION OF D-AMPHETAMINE AND D-AMPHETAMINE PLUS L-DOPA: POSSIBLE INVOLVEMENT OF SEROTONIN.
187119 03-04

ROLE OF DOPAMINERGIC MECHANISMS IN REGULATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN MAN.
188428 04-13

INVOLVEMENT OF BRAIN CHOLINERGIC MECHANISMS IN THE ACTION OF CHLORPROMAZINE.
188891 04-03

EFFECTS OF SCOPOLAMINE ON INHIBITORY MECHANISMS.
190275 04-04

CLINICAL STUDIES OF DOPAMINERGIC MECHANISMS.
191524 04-13

REBOUND PHENOMENON IN MANIC PATIENTS FOLLOWING PHYSOSTIGMINE: TOWARDS AN UNDERSTANDING OF AMINERGIC MECHANISMS UNDERLYING AFFECTIVE DISORDERS.
191531 04-09

MEDAZEPAM

GAS CHROMATOGRAPHIC ANALYSIS OF BENZODIAZEPINES. PART I: MEDAZEPAM AND ITS METABOLITES.
178948 02-06

THE EFFECT OF MEDAZEPAM AND ALCOHOL ON COGNITIVE AND MOTOR SKILLS USED IN CAR DRIVING.
189408 04-14

MEDIAL

EFFECTS OF CHLORPROMAZINE, CHLORDIAZEPOXIDE AND PENTOBARBITAL ON NEURONAL EXCITABILITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
177837 02-04

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: IV. INFLUENCE OF AMPHETAMINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
185961 03-04

THE MOTIVATIONAL CONSEQUENCES OF CHOLINERGIC STIMULATION OF THE MEDIAL SEPTAL AREA.
190260 04-04

MEDIATE

ALPHA-ADRENERGIC RECEPTORS MEDIATE SUPPRESSION OF DRINKING INDUCED BY HYPOTHALAMIC AMPHETAMINE INJECTION.
182216 03-03

MEDIATED

IMIPRAMINE MEDIATED EFFECTS ON LEVODOPA METABOLISM IN MAN.
185998 03-13

EVIDENCE FOR CHOLINERGICALLY MEDIATED EFFECT OF METHYLPHENIDATE HYDROCHLORIDE IN THE CENTRAL NERVOUS SYSTEM.
191946 04-03

MEDIATION

PARADOXICAL EFFECTS OF D-AMPHETAMINE ON BEHAVIORAL THERMOREGULATION: POSSIBLE MEDIATION BY BRAIN DOPAMINE.
189399 04-04

MEDIATOR

THE ROLE OF GAMMA-AMINOBUTYRIC ACID AS A MEDIATOR OF POSITIVE DORSAL ROOT POTENTIALS.
189832 04-03

MEDICAL

PSYCHOTROPIC DRUGS IN MEDICAL PRACTICE.
171485 01-17

THE EFFECTS OF INTRAVENTRICULARLY ADMINISTERED CATECHOLAMINES AND SEROTONIN ON THE RESERPINE INDUCED SPIKE WAVES RECORDED FROM THE MEDICAL NUCLEUS TRAPEZOIDES IN THE RABBIT.
182094 02-03

LITHIUM CARBONATE: PSYCHIATRIC INDICATIONS AND MEDICAL COMPLICATIONS.
187786 04-15

MEDICALLY

CHROMOSOME EXAMINATIONS AFTER MEDICALLY ADMINISTERED LYSERGIC ACID DIETHYLAMIDE AND DEXTROAMPHETAMINE.
192084 04-15

MEDICATED

LABORATORY STUDIES FOR EVERY MEDICATED OUTPATIENT: ARE THEY REALLY NECESSARY?.
189075 04-13

MEDICATION

PREANESTHETIC MEDICATION IN ELECTIVE SURGERY: COMPARISON OF INTRAVENOUS DIAZEPAM WITH MEPERIDINE.
167338 01-11

ON PHARMACO-PSYCHOTHERAPY; THE ROLE OF THE PSYCHOTHERAPEUTIC SITUATION IN PSYCHOTROPIC MEDICATION.
170415 01-11

CLINICAL RESEARCH ASPECTS OF PSYCHOTROPIC MEDICATION.
170754 01-17

EFFECTS OF MEDICATION ON LEARNING IN HYPERACTIVE FOUR-YEAR-OLD CHILDREN. (ED.D DISSERTATION).
172512 01-11

PSYCHOLOGICAL EFFECTS OF SINGLE DOSE ANTIPSYCHOTIC MEDICATION.
173402 01-08

MEDICATION AND/OR PSYCHOTHERAPY WITH SCHIZOPHRENICS: WHICH PART OF THE ELEPHANT HAVE YOU TOUCHED
173534 01-08

PSYCHOTROPIC MEDICATION IN INDONESIA (1970-1973).
174618 01-17

CONTROL OF THE HYPERACTIVE CHILD VIA MEDICATION -- AT WHAT COST TO PERSONALITY DEVELOPMENT; SOME PSYCHOLOGICAL IMPLICATIONS AND CLINICAL INTERVENTIONS.
176810 02-11

LONG-TERM CONSEQUENCES OF EXPERIENCE, MEDICATION, AND PSYCHOTHERAPY FOR SCHIZOPHRENIC PATIENTS. (UNPUBLISHED PAPER).
178677 02-17

PSYCHOTROPIC MEDICATION IN JAPAN.
180319 02-08

STATUS OF PSYCHOTROPIC MEDICATION IN VIET-NAM.
180320 02-17

PSYCHOTROPIC MEDICATION IN HONG-KONG.
180321 02-17

TREATMENT OF COMPULSIVE EATING DISTURBANCES WITH ANTICONVULSANT MEDICATION.
181270 02-14

THE ANALYSIS OF THE POTENTIAL ACTION OF A MEDICATION.
184963 03-14

AUTOCRITICISM AND REAL PLACE OF THE SAME MEDICATION (VESPRIN).
184964 03-11

RECONSTRUCTIVE MEDICATION.
188447 04-11

MEDICATION GROUPS FOR CONTINUING CARE.
189640 04-17

MEDICATIONS

THE EFFECT OF LITHIUM AND OTHER ANTIDEPRESSANT MEDICATIONS ON THE AUTONOMIC NERVOUS SYSTEM.
169635 01-15

MEDICINE

TRAZODONE AND PSYCHOSOMATIC MEDICINE.
168808 01-11

A DOUBLE-BLIND CLINICAL TRIAL OF DOXEPIN HYDROCHLORIDE AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION IN THE FIELD OF INTERNAL MEDICINE.
171282 01-11

CLINICAL PHARMACOLOGICAL STUDY OF BROMAZEPAM IN THE FIELD OF INTERNAL MEDICINE.
176473 02-10

TOPICS IN PSYCHIATRY: PSYCHOTROPIC MEDICINE.
177190 02-17

MEDICINES

MAN AND HIS MEDICINES.
186474 03-17

MEDICOLEGAL

MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC) -- REPORT 1. THIN-LAYER CHROMATOGRAPHY OF HYPNOTICS AND TRANQUILIZERS.
181315 02-16

MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC): REPORT 2 -- ISOLATION AND IDENTIFICATION OF HYPNOTICS AND TRANQUILIZER IN VIVO.
182623 03-06

MEDULLA

A ROLE FOR NICOTINIC RECEPTORS IN THE REGULATION OF THE ADENYLATE CYCLASE OF ADRENAL MEDULLA.
186675 03-03

INFLUENCE OF DIFFERENT ANIONS ON TYRAMINE AND AMPHETAMINE UPTAKE BY COW ADRENAL MEDULLA CHROMAFFIN VESICLES.
190907 04-03

MEFEXAMIDE

N-(2-DIETHYLAMINOETHYL) 2 (P-HYDROXYPHENOXY) ACETAMIDE, A METABOLITE OF MEFEXAMIDE IN MAN.
187577 04-01

MEGAVITAMIN

MEGAVITAMIN TREATMENT, CULTURE AND TRANQUILIZERS, DRUGS FOR THE AGED: PROJECTS OF A CANADIAN GRANT.
170293 01-11

MELANCHOLY

IMPORTANCE OF THE COOPERATION OF FAMILIES IN THE TREATMENT OF THE SICK: CONCERNING CHRONIC DELIRIUM TREATED WITH NEUROLEPTICS AND MELANCHOLY TREATED WITH ANTIDEPRESSANTS.
182899 03-17

MELANOCYTE

MELANOCYTE STIMULATING HORMONE RELEASE INHIBITING HORMONE AS AN ANTIDEPRESSANT: A PILOT STUDY.
171501 01-09

MELANOMA

LEVODOPA AND MELANOMA.
188414 04-15

MELITHRACENE

CLINICAL EXPERIENCE WITH MELITHRACENE IN THE TREATMENT OF DEPRESSIVE STATES.
172979 01-09

MELLARIL

A DOUBLE-BLIND COMPARISON OF THIORIDAZINE (MELLARIL) VERSUS DIAZEPAM (VALIUM) IN PATIENTS WITH CHRONIC MIXED ANXIETY AND DEPRESSIVE SYMPTOMS.
172486 01-10

MEMBRANE

COMPARATIVE STUDIES OF SYNAPTIC MEMBRANE PROTEIN SOLUBILIZATION BY CHLORPROMAZINE AND SODIUM DODECYLSULFATE.
176703 02-03

ANALYSIS OF DRUG BLOCK OF LSD/5-HT/GABA BY MONITORING NEURONAL MEMBRANE CHANGES.
182143 02-03

THE EFFECT OF CANNABINOIDS ON THE NUMBER OF NUCLEAR MEMBRANE ATTACHED RIBOSOMES IN INFANT RAT BRAIN.
183228 03-03

LITHIUM THERAPY AND ERYTHROCYTE MEMBRANE CATION CARRIER.
187644 04-15

PHENOLS: EFFECTS ON MEMBRANE PERMEABILITY OF MOLLUSCAN NEURONS.
189033 04-03

THE INFLUENCE OF PSYCHOSTIMULANTS ON K42 MEMBRANE PERMEABILITY IN VARIOUS PORTIONS OF RAT BRAIN.
191122 04-03

MEMBRANES

EFFECT OF LITHIUM ON AGGRESSION, MANIA AND PERMSELECTIVE MEMBRANES.
167448 01-09

DETERMINATION OF DRUG TRANSFER ACROSS BIOLOGICAL MEMBRANES: COMPARATIVE STUDY ON THE PASSAGE OF DRUGS INTO THE CENTRAL NERVOUS SYSTEM AND THEIR PLACENTAL TRANSFER AND FETAL LOCALIZATION IN THE PREGNANT RAT. (PH.D. DISSERTATION).
172018 01-03

EVIDENCE FOR PERSISTENT RESERPINE BINDING TO AMINE STORAGE VESICLE MEMBRANES.
182234 03-03

NONCHOLINERGIC MECHANISM OF ACTION OF CHOLINERGIC DRUGS ON SQUID AXON MEMBRANES.
186672 03-03

A NEW PROLONGED ACTING TYPE OF CHLORPROMAZINE: BEHAVIORAL EFFECTS AND PROLONGED ACTIONS ON NERVE MEMBRANES.
187805 04-01

THE NERVE IMPULSE BLOCKING ACTIONS OF TRANQUILIZERS AND THE BINDING OF NEUROLEPTICS TO SYNAPTOSOME MEMBRANES.
189400 04-03

THE PRESENCE OF MAO IN SYNAPTIC MEMBRANES OF BOVINE BRAIN.
191956 04-03

MEMORY

INFLUENCE OF AFFECTIVE STATES AND PSYCHOACTIVE DRUGS ON VERBAL LEARNING AND MEMORY.
169504 01-09

CAUDATE NUCLEUS EFFECTS ON GERIATRIC SENILITY: EFFECT OF BELLADONNA ON LEARNING AND MEMORY OF GERIATRIC PATIENTS.
170744 01-11

EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL (DELTA9-THC) ON MEMORY, ATTENTION AND SUBJECTIVE STATE: A DOUBLE-BLIND STUDY.
174043 01-14

EFFECT OF ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL ON MEMORY, SPEECH, AND PERCEPTION OF THERMAL STIMULATION: RESULTS WITH FOUR NORMAL HUMAN VOLUNTEER SUBJECTS. PRELIMINARY REPORT.
177674 02-14

DRUG EFFECTS ON LEARNING AND MEMORY.
181404 02-04

LEARNING AND MEMORY AFTER 6-HYDROXYDOPAMINE (6-OHDA).
182210 02-04

CHANGES IN SHORT-TERM AND LONG-TERM MEMORY OF DOGS AND CATS UNDER THE EFFECTS OF AMIZYL (BENACTYZINE).
183517 03-04

EFFECTS OF NON-HYDROGEN-BONDING ANESTHETICS ON MEMORY IN THE CHICK.
184380 03-04

PHARMACOLOGICAL DISTINCTIONS BETWEEN ACTIVE AND PASSIVE AVOIDANCE MEMORY FORMATION AS SHOWN BY MANIPULATION OF BIOGENIC AMINE ACTIVE COMPOUNDS.
185927 03-04

MODIFICATION OF LEARNING AND MEMORY IN GOLDFISH THROUGH THE USE OF STIMULANT AND DEPRESSANT DRUGS.
186583 03-04

TEMPORAL ASPECTS OF SCOPOLAMINE INDUCED ONE-WAY MEMORY DISSOCIATION IN MICE.
187701 04-04

THE EFFECTS OF PENTYLENETETRAZOL (METRAZOL) ON A LEARNED TASTE AVERSION PRODUCED BY LITHIUM CHLORIDE: THE ISSUE OF ASSOCIATIVE MEMORY VS. RETENTIVE MEMORY. (UNPUBLISHED PAPER).
188251 04-04

ANISOMYCIN, LIKE OTHER INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS, IMPAIRS LONG-TERM MEMORY OF A DISCRIMINATION TASK.
188605 04-04

EFFECTS OF CYCLOHEXIMIDE ON ACQUISITION AND RETENTION OF AVOIDANCE LEARNING IN THE RAT: RECOVERY OF MEMORY.
189215 04-04

THE COMPARATIVE EFFECTS OF PENTOBARBITAL AND D-AMPHETAMINE ON A SHORT-TERM MEMORY TASK IN BABOONS.
191917 04-04

MEN

METHYLTESTOSTERONE WITH IMIPRAMINE IN MEN: CONVERSION OF DEPRESSION TO PARANOID REACTION.
172992 01-15

THE EFFECTS OF PHENOTHIAZINES ON ENDOCRINE FUNCTION: II. EFFECTS IN MEN AND POST-MENOPAUSAL WOMEN.
184437 03-13

MENTAL

CHANGES IN MENTAL FUNCTIONING ACCOMPANYING ANTIPSYCHOTIC DRUG THERAPY.
171124 01-10

DRUGS COMMONLY USED IN MENTAL CONDITIONS.
171257 01-17

POLLY: MENTAL DEFICIENCY AND SCHIZOPHRENIA.
174641 01-17

WITHDRAWAL OF MAINTENANCE DRUGS WITH LONG-TERM HOSPITALIZED MENTAL PATIENTS: A CRITICAL REVIEW.
175862 02-17

CLINICAL TRIAL WITH NOZINAN-R. AT SEVERAL MENTAL HOSPITALS IN JAVA.
176582 02-11

LITHIUM AND MENTAL HEALTH.
178113 02-09

DEVELOPMENT OF A VACCINE AGAINST MENTAL RETARDATION CAUSED BY CYTOMEGALOVIRUS INFECTION IN UTERO.
178549 02-11

PRELIMINARY EXPERIENCES WITH THE TREATMENT OF SOME MENTAL CASES UTILIZING AN ENZYME COMBINATION.
180298 02-17

ASSAY PROCEDURES FOR THIORIDAZINE, TRIFLUOPERAZINE, AND THEIR SULFOXIDES AND DETERMINATION OF URINARY EXCRETION OF THESE COMPOUNDS IN MENTAL PATIENTS.
183602 03-01

SERUM ANTICONVULSANT CONCENTRATIONS IN EPILEPTIC PATIENTS WITH MENTAL SYMPTOMS: A PRELIMINARY REPORT.
184439 03-15

TREATMENT OF MENTAL DISORDERS.
185182 03-17

A DOUBLE-BLIND TRIAL OF LONG-TERM LITHIUM THERAPY IN MENTAL DEFECTIVES.
185193 03-11

CONTROL OF MENTAL ACTIVITIES.
185235 03-17

IN APPRECIATION OF BASIC BIOCHEMICAL RESEARCH IN MENTAL HEALTH. (UNPUBLISHED PAPER).
187488 04-17

A CASE OF A NONSPECIFIC MENTAL ILLNESS WITH PSYCHOMOTOR VARIANT.
188517 04-09

FACTORS AFFECTING OUTCOME IN A SCHOOL MENTAL HEALTH SERVICE.
188567 04-11

PHARMACOGENETICS AND MENTAL DISEASE.
188826 04-11

MENTAL CHANGES IN PARKINSONISM.
188886 04-15

PROPHYLACTIC EFFICACY OF LITHIUM CARBONATE IN MANIC-DEPRESSIVE ILLNESS: REPORT OF THE VETERANS ADMINISTRATION AND NATIONAL INSTITUTE OF MENTAL HEALTH (VA-NIMH) COLLABORATIVE STUDY GROUP.
189735 04-09

MENTAL ILLNESS OR METAL ILLNESS? BISMUTH SUBGALLATE.
191215 04-15

DIMETHYLTRYPTAMINE: ITS BIOSYNTHESIS AND POSSIBLE ROLE IN MENTAL DISEASE.
191535 04-12

DAILY RHYTHM IN BODY TEMPERATURE OF MENTAL PATIENTS: APPLICATION OF COSINOR METHOD -- FIRST REPORT.
191685 04-17

EMERGENCY TREATMENT OF AN ACUTE STATE OF MENTAL ABERRATION.
191723 04-09

MENTALLY

MESORIDAZINE IN THE CARE OF DISTURBED MENTALLY RETARDED PATIENTS.
168315 01-11

SAFETY AND EFFECTIVENESS OF HALOPERIDOL FOR MENTALLY RETARDED BEHAVIORALLY DISORDERED AND HYPERKINETIC PATIENTS.
169634 01-11

TANTU-PASHAN AND LUCIDRIL THERAPY IN MENTALLY RETARDED CHILDREN.
175628 02-11

ANTIAGGRESSIVE EFFECT OF LITHIUM SALTS IN MENTALLY RETARDED ADOLESCENTS.
182435 03-11

THE EFFECT OF SULTHIAME ON DISTURBED BEHAVIOUR IN MENTALLY SUBNORMAL PATIENTS.
185191 03-14

EFFECTS OF CONCURRENT BEHAVIOR MODIFICATION AND CHLORPROMAZINE ADMINISTRATION IN MENTALLY RETARDED WOMEN. (PH.D. DISSERTATION).
185604 03-14

MEPERIDINE

PREANESTHETIC MEDICATION IN ELECTIVE SURGERY: COMPARISON OF INTRAVENOUS DIAZEPAM WITH MEPERIDINE.
167338 01-11

THE EFFECT OF LOW ENVIRONMENTAL TEMPERATURE ON THE TRANYLCYPROMINE MEPERIDINE INTERACTION IN MICE.
183897 03-03

RELATIONSHIP OF PLASMA MEPERIDINE LEVELS TO CHANGES IN ANXIETY AND HOSTILITY.
185881 03-14

DIAZEPAM AND MEPERIDINE ON ARTERIAL BLOOD GASES IN HEALTHY VOLUNTEERS.
190147 04-13

MEPROBAMATE

RELIEF OF MUSCULOSKELETAL AND ASSOCIATED PSYCHOPATHOLOGICAL SYMPTOMS WITH MEPROBAMATE AND ASPIRIN: A CONTROLLED STUDY.
169632 01-10

EFFECTS OF CHLORPROMAZINE, MEPROBAMATE AND CHLORDIAZEPOXIDE ON THE MAZE LEARNING IN MICE.
171259 01-04

CHRONIC MEPROBAMATE INTOXICATION AND PHOTOMYOCLONIC RESPONSE.
181377 02-15

ENHANCED RENAL TUBULAR SECRETION OF MEPROBAMATE: ROLE OF SALINE FUROSEMIDE DIURESIS.
184243 03-03

MUTAGENICITY EXPERIMENTS WITH THE TRANQUILLIZER MEPROBAMATE IN DROSOPHILA-MELANOGASTER AND IN HUMAN LEUKOCYTE CHROMOSOMES IN VITRO.
184585 03-05

GLC DETERMINATION OF MEPROBAMATE IN WATER, PLASMA AND URINE.
185977 03-16

MER-25

LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04

SUPPRESSION OF LORDOSIS IN GUINEA-PIGS BY ETHAMOXY-TRIPHETOL (MER-25) GIVEN AT LONG INTERVALS (36-46 HR) AFTER ESTRADIOL BENZOATE TREATMENT.
186686 03-04

EFFECTS OF AN ESTROGEN ANTAGONIST, MER-25, ON MOUNTING BEHAVIOR AND LORDOSIS BEHAVIOR IN THE FEMALE RAT.
186691 03-04

MERCURY

NEUROLOGICAL CHANGES IN CATS FOLLOWING LONG-TERM DIET OF MERCURY CONTAMINATED TUNA.
186476 03-05

EFFECTS OF PERINATAL EXPOSURE TO METHYL MERCURY ON FUNCTIONAL BRAIN DEVELOPMENT AND NEUROCHEMISTRY.
189564 04-05

MECHANISM OF ADRENAL CATECHOLAMINE RELEASE BY DIVALENT MERCURY.
189591 04-03

MESCALINE

TREMOR INDUCTION BY INTRACAUDATE INJECTIONS OF BRETYLIUM, TETRABENAZINE, OR MESCALINE: FUNCTIONAL DEFICITS IN CAUDATE DOPAMINE.
167329 01-03

PEYOTE AND RELATED ALKALOIDS XVI: SYNTHESIS OF 3,4,5 TRIMETHOXYPHENYLALANINE, AN AMINO ANALOG OF MESCALINE.
170839 01-06

MULTITRIAL PASSIVE AVOIDANCE IN RATS: MESCALINE, SHOCK, AND ITI EFFECTS. (PH.D. DISSERTATION).
173162 01-04

THE EFFECTS OF MESCALINE ADMINISTERED BEFORE OR DURING EMBRYOGENESIS UPON THE HATCHABILITY AND BEHAVIOR OF THE CHICK. (PH.D. DISSERTATION).
173791 01-04

MESCALINE HYPERREACTIVITY: HALLUCINATIONS IN RATS? (UNPUBLISHED PAPER).
178575 02-04

OXIDATIVE METABOLISM OF MESCALINE IN THE CENTRAL NERVOUS SYSTEM α- IV: IN VIVO METABOLISM OF MESCALINE AND 2,3,4 TRIMETHOXY-BETA-PHENYLETHYLAMINE.
181944 02-03

ELECTROENCEPHALOGRAPHIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL, LSD-25, MESCALINE AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE IN THE RABBITS.
182095 02-03

BEHAVIORAL AND PHYSIOLOGICAL ACTIVITY OF DEAMINATED METABOLITES OF MESCALINE.
182244 03-03

EVIDENCE FOR THE ACTION OF D-LYSERGIC ACID DIETHYLAMIDE, MESCALINE AND BUFOTENINE ON 5-HYDROXYTRYPTAMINE RECEPTORS IN UMBILICAL VASCULATURE.
182716 03-03

THE EFFECTS OF 3,4 DIMETHOXYPHENYLETHYLAMINE IN RATS TRAINED WITH MESCALINE AS A DISCRIMINATIVE STIMULUS.
186667 03-04

MESCALINE INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON THE BINDING OF AMINOACYL TRANSFER RIBONUCLEIC ACID TO RIBOSOMES OF BRAIN TISSUE.
189582 04-05

MESCALINE FACILITATES RETENTION OF PASSIVE AVOIDANCE IN RATS.
190266 04-04

INTERACTIONS OF PSYCHOTROPIC DRUGS AND MESCALINE IN VITRO.
191933 04-03

INTERACTION OF MESCALINE AND STRESS ON SHUTTLEBOX ESCAPE/AVOIDANCE IN RATS.
191934 04-04

EFFECTS OF LSD, MESCALINE, AND PSILOCYBIN ON SYMPATHETIC PREGANGLIONIC NEURONS.
191937 04-03

MESCALINE: THE CHEMISTRY AND PHARMACOLOGY OF ITS ANALOGS.
192877 04-12

CACTUS ALKALOIDS. XIX. CRYSTALLIZATION OF MESCALINE HCL AND 3-METHOXYTYRAMINE HCL FROM TRICHOCEREUS-PACHANOI.
192878 04-01

MESENCEPHALON

INFLUENCE OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTS OF ELECTRICAL STIMULATION AND MICROINJECTION OF ACETYLCHOLINE, SEROTONIN AND NORADRENALINE INTO THE MESENCEPHALON.
191786 04-02

MESOLIMBIC

IS THERE A RELATIONSHIP BETWEEN THE INVOLVEMENT OF EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS WITH THE CATALEPTIC ACTION OF NEUROLEPTIC AGENTS AND THEIR CLINICAL ANTIPSYCHOTIC EFFECT?
171305 01-03

DOPAMINE IN THE MESOLIMBIC SYSTEM OF THE RAT BRAIN: ENDOGENOUS LEVELS AND THE EFFECTS OF DRUGS ON THE UPTAKE MECHANISM AND STIMULATION OF ADENYLATE CYCLASE ACTIVITY.
177131 02-03

MESORIDAZINE

MESORIDAZINE AND CHLORPROMAZINE IN THE TREATMENT OF ALCOHOL WITHDRAWAL SYNDROME.
168314 01-11

MESORIDAZINE IN THE CARE OF DISTURBED MENTALLY RETARDED PATIENTS.
168315 01-11

COMPARISON OF THE CLINICAL AND COMPUTER ANALYZED EEG EFFECTS OF MESORIDAZINE AND CHLORPROMAZINE.
180064 02-10

ISOLATION OF A POSSIBLE NEW METABOLITE OF THIORIDAZINE AND MESORIDAZINE FROM HUMAN PLASMA.
182722 03-13

SIMULTANEOUS MESORIDAZINE AND PSYCHODRAMA IN NEUROTICS.
183362 03-10

MESORIDAZINE (TPS-23 SANDOZ) IN ACUTE PSYCHOTIC STATES.
187958 04-11

CLINICAL EXPERIENCES WITH MESORIDAZINE (TPS-23): ITS ADMINISTRATION TO HOSPITALIZED SCHIZOPHRENIC PATIENTS.
188934 04-08

META-SUBSITUTED

STRUCTURAL RELATIONSHIP BETWEEN META-SUBSITUTED N-ETHYLAMPHETAMINES AND SELF-ADMINISTRATION IN RHESUS MONKEYS.
191915 04-04

METABOLIC

METABOLIC CONTROL OF BODY TEMPERATURE IN MAN.
174134 01-08

THE METABOLIC FATE OF N,N DIMETHOXYMETHYL-PHENOBARBITAL IN THE RAT.
177731 02-03

THE METABOLIC FATE OF HEXOBARBITAL IN THE RAT.
177732 02-03

INFLUENCES OF RESERPINE AND CHLORPROMAZINE ON THE ANALGESIC AND METABOLIC EFFECTS OF MORPHINE.
180507 02-03

STUDIES ON METABOLISM OF BROMAZEPAM (II): COLORIMETRIC DETERMINATION AND METABOLIC FATE OF BROMAZEPAM IN ANIMALS.
181593 02-03

METABOLIC INTERACTIONS BETWEEN NORTRIPTYLINE AND THIORIDAZINE IN RATS.
190346 04-03

METABOLISM

THE UPTAKE, RETENTION AND METABOLISM OF 3H-5-HYDROXYTRYPTAMINE IN BRAIN SLICES AND ILEUM FROM THE RAT: EFFECTS OF COCAINE, DESMETHYLIMIPRAMINE AND RESERPINE. (PH.D. DISSERTATION).
168131 01-03

THE EFFECT OF D- AND L-P-CHLOROPHENYLALANINE ON THE METABOLISM OF 5-HYDROXYTRYPTAMINE IN BRAIN.
168748 01-03

EFFECT OF CHRONIC LITHIUM TREATMENT ON MONOAMINE METABOLISM IN RAT BRAIN.
168839 01-03

CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS: RECENT STUDIES OF MHPG EXCRETION.
169091 01-13

A COLLABORATIVE ASSESSMENT OF NOREPINEPHRINE METABOLISM IN AFFECTIVE DISORDERS.
169094 01-09

CENTRAL MONOAMINE METABOLISM IN MAN: EFFECT OF PUTATIVE DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS.
169377 01-13

LIPID INDUCED CHANGES OF PENTOBARBITAL DISTRIBUTION AND METABOLISM.
170072 01-03

THE EFFECT OF PROTRIPTYLINE ON THE METABOLISM OF LABELLED DOPAMINE AND NORADRENALINE IN THE RAT BRAIN.
171627 01-03

INTERACTION BY FENFLURAMINE WITH THE METABOLISM OF D-AMPHETAMINE IN THE RAT.
171634 01-03

DIAZEPAM IN LABOUR: ITS METABOLISM AND EFFECT ON THE CLINICAL CONDITION AND THERMOGENESIS OF THE NEWBORN.
171731 01-13

EFFECT OF MONOAMINE OXIDASE INHIBITORS ON METABOLISM AND IN VIVO RELEASE OF H3-NOREPINEPHRINE FROM THE HYPOTHALAMUS.
171973 01-03

THC: METABOLISM AND SUBJECTIVE EFFECTS OF STRESS. (UNPUBLISHED PAPER).
173516 01-14

KINETICS AND CELLULAR CONTROL MECHANISMS FOR IMIPRAMINE METABOLISM IN THE ISOLATED PERFUSED RAT LIVER. (PH.D. DISSERTATION).
173601 01-03

IN VIVO 3H-PROCHLORPERAZINE METABOLISM IN THE GUINEA-PIG AND RABBIT.
173875 01-03

THE EFFECT OF PSYCHOTROPIC AGENTS ON SOME ASPECTS OF ACETYLCHOLINE METABOLISM IN CAT BRAINS.
174257 01-03

3H-DELTA9-TETRAHYDROCANNABINOL (THC) METABOLISM IN RHESUS AND SQUIRREL MONKEYS.
175751 02-03

STEREOCHEMICAL ASPECTS IN THE METABOLISM OF THE PSYCHOTOMIMETIC AMINE 1-(2,5 DIMETHOXY-4-METHYLPHENYL)-2 AMPHETAMINE.
175759 02-03

ANTAGONISM OF THE EFFECTS OF CHLORPROMAZINE AND MORPHINE ON DOPAMINE METABOLISM BY GABA.
176870 02-03

EFFECT OF CANNABIS ON PENTOBARBITAL INDUCED SLEEPING TIME AND PENTOBARBITAL METABOLISM IN THE RAT.
179985 02-03

PSYCHOPHARMACOLOGIC AGENTS: EFFECT ON DRUG METABOLISM.
181398 02-13

STUDIES ON METABOLISM OF BROMAZEPAM (III): ABSORPTION, EXCRETION, AND METABOLISM OF BROMAZEPAM IN MAN.
181588 02-13

STUDIES ON METABOLISM OF BROMAZEPAM (II): COLORIMETRIC DETERMINATION AND METABOLIC FATE OF BROMAZEPAM IN ANIMALS.
181593 02-03

DISSOCIATIVE CHANGE IN ANTIAGGRESSIVE AND MUSCLE RELAXANT ACTIONS OF S-TRIAZOLOBENZODIAZEPINE (D-40TA) BY REPEATED ADMINISTRATION AND PHENOBARBITAL PRETREATMENT, AND ITS RELATION TO METABOLISM.
181654 02-04

EFFECTS OF LITHIUM ON CEREBRAL RNA METABOLISM IN VITRO AND IN VIVO.
181942 02-03

OXIDATIVE METABOLISM OF MESCALINE IN THE CENTRAL NERVOUS SYSTEM -- IV: IN VIVO METABOLISM OF MESCALINE AND 2,3,4 TRIMETHOXY-BETA-PHENYLETHYLAMINE.
181944 02-03

LSD TOLERANCE AND BRAIN SEROTONIN METABOLISM.
182167 02-03

EFFECTS OF NARCOTIC ANALGESICS ON ENZYMES OF ACETYLCHOLINE METABOLISM IN CULTURED CHICK BRAIN CELLS.
182225 03-03

ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF BROMAZEPAM IN RABBIT.
182555 03-03

THE METABOLISM OF THE TETRAHYDROCANNABINOLS.
182773 03-17

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON THE METABOLISM OF 3H-5-HYDROXYTRYPTAMINE AND 3H-NOREPINEPHRINE IN THE RAT BRAIN.
183787 03-03

BUTOBARBITONE METABOLISM IN MAN: IDENTIFICATION OF 3-KETOBUTOBARBITONE.
183793 03-13

METABOLISM OF CHLORPHENTERMINE AND PHENTERMINE IN MAN TO YIELD HYDROXYLAMINO, C-NITROSO AND NITRO COMPOUNDS.
183796 03-13

LONG-TERM EFFECTS OF 4-CHLOROAMPHETAMINE ON BRAIN 5-HYDROXYINDOLE METABOLISM IN RATS.
183869 03-03

A COMPARISON OF PSYCHOTOMIMETIC DRUG EFFECTS ON RAT BRAIN NOREPINEPHRINE METABOLISM.
183891 03-03

MORPHINE METABOLISM IN VIVO AND IN VITRO BY HOMOZYGOUS GUNN RATS.
183899 03-03

CALCIUM METABOLISM IN ELDERLY EPILEPTIC PATIENTS DURING ANTICONVULSANT THERAPY.
185560 03-15

CATALEPSY INDUCED BY ALPHA-METHYL-P-TYROSINE AND D-AMPHETAMINE: THE ROLE OF CATECHOLAMINE METABOLISM.
185750 03-03

FURTHER STUDIES ON THE INHIBITION OF DRUG METABOLISM BY PREGNANOLONE AND RELATED STEROIDS.
185866 03-03

IMIPRAMINE MEDIATED EFFECTS ON LEVODOPA METABOLISM IN MAN.
185998 03-13

THE MONOAMINE OXIDASES OF BRAIN: SELECTIVE INHIBITION WITH DRUGS AND THE CONSEQUENCES FOR THE METABOLISM OF THE BIOGENIC AMINES.
186668 03-03

ON THE CEREBRAL ACCUMULATION OF KETAMINE AND THE RELATIONSHIP BETWEEN METABOLISM OF THE DRUG AND ITS PHARMACOLOGICAL EFFECTS.
186693 03-03

EFFECT OF ALPHA-METHYLDOPA ON THE METABOLISM OF DOPAMINE IN THE STRIATUM OF THE RAT.
186694 03-03

EFFECT OF SKF-525-A ON THE METABOLISM OF (-) DELTA9-TETRAHYDROCANNABINOL IN THE RAT BRAIN AND LIVER.
187578 04-03

THE EFFECT OF HYPOTHERMIC DOSES OF 1-DELTA9-TETRAHYDROCANNABINOL ON BIOGENIC AMINE METABOLISM IN SELECTED PARTS OF THE RAT BRAIN.
188231 04-03

DOSE-RELATED ALTERATIONS IN METABOLISM OF LEVODOPA: POSSIBLE MECHANISM FOR HYPOTENSIVE EFFECT.
190194 04-11

EFFECT OF LITHIUM ON CENTRAL METABOLISM OF 5-HYDROXYTRYPTAMINE.
190337 04-03

STEREOCHEMICAL ASPECTS AND METABOLITE FORMATION IN THE IN VIVO METABOLISM OF THE PSYCHOTOMIMETIC AMINE, 1-2,5-(DIMETHOXY-4-METHYLPHENYL) 2 AMINOPROPANE.
190718 04-03

INFLUENCE OF NEUROLEPTICS AND BENZODIAZEPINES ON METABOLISM OF TRICYCLIC ANTIDEPRESSANTS IN MAN.
191026 04-09

THE METABOLISM OF 1-N-BUTYL-5,5 DIETHYLBARBITURIC ACID (N-N BUTYLBARBITAL) IN THE RAT.
191057 04-03

PERMANENT ALTERATIONS IN 5-HYDROXYTRYPTAMINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN FOLLOWING EXPOSURE TO DRUGS DURING THE PERIOD OF DEVELOPMENT.
191383 04-03

EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF CLOZAPINE ON THE METABOLISM OF DOPAMINE AND NORADRENALINE IN THE BRAIN OF THE RAT.
191418 04-03

THE USE OF SELECTIVE AND INHIBITOR DRUGS TO MODIFY AMINE METABOLISM IN BRAIN.
191500 04-03

THE EFFECTS OF COMT INHIBITORS ON BEHAVIOR AND DOPAMINE METABOLISM.
191517 04-03

EFFECTS OF ALTERATIONS IN IMPULSE FLOW ON TRANSMITTER METABOLISM IN CENTRAL DOPAMINERGIC NEURONS.
191519 04-03

COMPARATIVE METABOLISM OF TRIAZOLAM, A NEW SEDATIVE HYPNOTIC, IN RAT, DOG AND MAN.
191900 04-02

METABOLISM OF D-AMPHETAMINE BY RAT BRAIN IN VIVO AND IN VITRO.
191922 04-03

ANALOGS OF CHOLINE: SYNAPTOSOMAL METABOLISM.
192000 04-03

METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY RATS TOLERANT TO MARIHUANA.
192020 04-03

METABOLITE

SIMULTANEOUS ANALYSIS OF A 1,5 BENZODIAZEPINE AND ITS METABOLITE IN BLOOD AND URINE BY SPECTRODENSITOMETRY.
176871 02-16

ISOLATION OF A POSSIBLE NEW METABOLITE OF THIORIDAZINE AND MESORIDAZINE FROM HUMAN PLASMA.
182722 03-13

PLASMA CONCENTRATIONS OF DIAZEPAM AND OF ITS METABOLITE N-DESMETHYLDIAZEPAM IN RELATION TO ANXIOLYTIC EFFECT.
186184 03-13

7-OXO-DELTA1-TETRAHYDROCANNABINOL: A NOVEL METABOLITE OF DELTA1-TETRAHYDROCANNABINOL.
187574 04-01

N-(2-DIETHYLAMINOETHYL) 2 (P-HYDROXYPHENOXY) ACETAMIDE, A METABOLITE OF MEFEXAMIDE IN MAN.
187577 04-01

STIMULATION OF A DOPAMINE SENSITIVE ADENYLATE CYCLASE IN HOMOGENATES OF RAT STRIATUM BY A METABOLITE OF PIRIBEDIL (ET-495).
189616 04-03

CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE METABOLITE, NORFENFLURAMINE: AN EVALUATION OF ITS ROLE IN THE ACTIONS OF FENFLURAMINE.
190335 04-04

STEREOCHEMICAL ASPECTS AND METABOLITE FORMATION IN THE IN VIVO METABOLISM OF THE PSYCHOTOMIMETIC AMINE, 1-2,5-(DIMETHOXY-4-METHYLPHENYL) 2 AMINOPROPANE.
190718 04-03

METABOLITES

TETRAHYDROISOQUINOLINE ALKALOIDS: IN VIVO METABOLITES OF L-DOPA IN MAN.
168286 01-13

THE POSSIBLE ROLE OF METABOLITES IN THERAPEUTIC RESPONSE TO CHLORPROMAZINE TREATMENT.
168836 01-08

METABOLITES OF BROMAZEPAM, A BENZODIAZEPINE, IN THE HUMAN, DOG, RAT, AND MOUSE.
170837 01-03

LEVELS OF HVA IN MOUSE BRAIN FOLLOWING TREATMENT WITH METABOLITES OF CHLORPROMAZINE.
171626 01-03

EFFECTS OF AMITRIPTYLINE AND IMIPRAMINE ON AMINE METABOLITES IN THE CEREBROSPINAL FLUID OF DEPRESSED PATIENTS.
174094 01-09

EFFECTS OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES ON CENTRAL NORADRENERGIC MECHANISMS. (PH.D. DISSERTATION).
174959 01-03

GAS CHROMATOGRAPHIC ANALYSIS OF BENZODIAZEPINES. PART I: MEDAZEPAM AND ITS METABOLITES.
178948 02-06

EXCRETION OF NOREPINEPHRINE AND DOPAMINE ALCOHOLIC METABOLITES AFTER 6-HYDROXYDOPAMINE.
179986 02-03

EFFECT OF CHLORPROMAZINE AND SOME OF ITS METABOLITES ON THE DOPAMINE SENSITIVE ADENYLATE CYCLASE OF RAT BRAIN STRIATUM.
180060 02-03

A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL AND ITS MONOHYDROXYLATED METABOLITES IN MAN.
182223 03-03

PHARMACOLOGY OF MONO AND DISUBSTITUTED CHLORPROMAZINE METABOLITES.
182243 03-03

BEHAVIORAL AND PHYSIOLOGICAL ACTIVITY OF DEAMINATED METABOLITES OF MESCALINE.
182244 03-03

IMIPRAMINE AND ITS METABOLITES IN HUMAN BRAIN.
183604 03-13

THE CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES IN THE PLASMA AFTER AN ACUTE AND CHRONIC ADMINISTRATION.
184978 03-13

EFFECTS OF CHLORPROMAZINE AND THREE METABOLITES ON BEHAVIORAL RESPONSES IN RATS.
185748 03-04

A COMPARISON OF THE EFFECTS OF AMPHETAMINE AND ITS METABOLITES, P-HYDROXYAMPHETAMINE AND P-HYDROXYNOREPHEDRINE, ON UPTAKE, RELEASE AND CATABOLISM OF 3H-NOREPINEPHRINE IN CEREBRAL CORTEX OF RAT BRAIN.
186669 03-03

ALPHA-L-ACETYLMETHADOL AND ITS N-DEMTHYLATED METABOLITES HAVE POTENT OPIATE ACTION IN THE GUINEA-PIG ISOLATED ILEUM.
187130 03-03

STUDIES OF CEREBROSPINAL FLUID AMINE METABOLITES IN DEPRESSED PATIENTS: CONCEPTUAL PROBLEMS AND THEORETICAL IMPLICATIONS. (UNPUBLISHED PAPER).
187398 04-13

A POSSIBLE MECHANISM FOR THE ANTISCHIZOPHRENIC ACTION OF CHLORPROMAZINE: INHIBITION OF THE FORMATION OF DIMETHYLTRYPTAMINE BY CHLORPROMAZINE METABOLITES.
187576 04-03

PLASMA AND CEREBROSPINAL FLUID PROBENECID CONCENTRATIONS AS RELATED TO ACCUMULATION OF ACIDIC BIOGENIC AMINE METABOLITES IN MAN.
187933 04-13

A STUDY OF BIOGENIC AMINE METABOLITES IN THE CEREBROSPINAL FLUID AND URINE OF MONKEYS WITH CHLORPROMAZINE INDUCED DYSKINESIA.
189210 04-03

EXCRETION OF THC AND ITS METABOLITES IN EWES MILK.
189590 04-03

A POLAROGRAPHIC METHOD FOR THE DETERMINATION OF THE N-OXIDE, N-OXIDE-SULPHOXIDE AND SULPHOXIDE METABOLITES OF CHLORPROMAZINE.
190902 04-06

EFFECT OF PIRIBEDIL AND ONE OF ITS METABOLITES ON THE CONCENTRATION OF HOMOVANILLIC ACID IN THE RAT BRAIN.
191422 04-03

ABNORMALITIES IN TRYPTOPHAN METABOLITES IN SCHIZOPHRENIA.
191536 04-13

ACTIVATION OF STRIATAL HYDROXYLASE BY HYDROXYLATED METABOLITES OF CHLORPROMAZINE.
191908 04-03

METABOLIZING

INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY LITHIUM TREATMENT.
182727 03-03

DECREASED EFFECT OF PHENOBARBITAL TREATMENT ON MICROSOMAL DRUG METABOLIZING ENZYME ACTIVITY DURING GESTATION.
184228 03-03

CELLULAR EFFECTS OF METHAQUALONE ON DRUG METABOLIZING ENZYMES.
191942 04-03

METAFFINOID

THE ANTAGONISM BETWEEN CHOLINOMIMETIC AGONISTS AND BETA-ADRENOCEPTOR STIMULANTS: THE DIFFERENTIATION BETWEEN BETWEEN FUNCTIONAL AND METAFFINOID ANTAGONISM.
191420 04-03

METAL

METAL CHELATION OF CHLORPROMAZINES.
176763 02-06

MENTAL ILLNESS OR METAL ILLNESS? BISMUTH SUBGALLATE.
191215 04-15

METALLIC

EFFECTS OF SOME METALLIC CATIONS ON CEREBRAL CORTICAL NEURONES AND THEIR INTERACTIONS WITH BIOGENIC AMINES.
187806 04-03

METALS

EFFECTS OF ALKALI METALS ON SPONTANEOUS MOTOR ACTIVITIES OF MICE.
182637 03-02

METHADONE

COMPARISON OF INTRAVENOUSLY ADMINISTERED METHADONE (ME), MORPHINE (MO), HEROIN (H) AND PLACEBO (P).
182163 02-03

INHIBITION OF GROWTH IN ANIMALS TREATED WITH METHADONE.
182164 02-03

THE DEVELOPMENT OF A BLOOD-BRAIN BARRIER TO METHADONE IN THE NEWBORN RAT.
182165 02-03

TESTOSTERONE AND LUTEINIZING HORMONE (LH) IN UNTREATED AND METHADONE MAINTAINED NARCOTIC ADDICTS.
182166 02-13

EFFECTS OF METHADONE ON ACTIVITY AND ON BRAIN MONOAMINES IN TWO MOUSE STRAINS.
182229 03-03

CATALEPSY AND STEREOTYPED BEHAVIOUR IN RATS TREATED CHRONICALLY WITH METHADONE: RELATION TO BRAIN HOMOVANILLIC ACID CONTENT.
183606 03-04

EFFECT OF CHRONIC METHADONE ADMINISTRATION ON PREGNANT RATS AND THEIR OFFSPRING.
183894 03-03

METHADONE INHIBITION OF 3H-5-HYDROXYTRYPTAMINE UPTAKE BY SYNAPTOSOMES.
183896 03-03

EFFECT OF ORAL ADMINISTRATION OF METHADONE ON HEPATIC MICROSOMAL MIXED FUNCTION OXIDASE ACTIVITY IN MICE.
188178 04-03

CATALEPSY AND STEREOTYPIES IN RATS TREATED WITH METHADONE; RELATION TO STRIATAL DOPAMINE.
191421 04-03

METHAMPHETAMINE

THE INFLUENCE OF ALDOSTERONE OR METHAMPHETAMINE ON LIVER GLYCOGEN DEPOSITION OF MICE STRESSED BY LONG-TERM ISOLATION.
182105 02-03

EFFECTS OF PSYCHOTROPIC DRUGS ON METHAMPHETAMINE INDUCED EXCITATIONS IN THE AGGREGATED MICE.
182107 02-04

THE EFFECT OF METHAMPHETAMINE ON BRAIN ACH CONSUMPTION AND AGGRESSIVENESS IN MICE STRESSED MILDLY BY LONG-TERM ISOLATION.
182108 02-04

INFLUENCES OF LITHIUM ON THE BEHAVIORAL ACTION OF METHAMPHETAMINE AND TETRABENAZINE.
182109 02-04

EFFECTS OF METHAMPHETAMINE ON DAILY RHYTHMS OF HYPOTHALAMIC NOREPINEPHRINE, SEROTONIN AND PLASMA CORTICOSTERONE LEVELS IN THE RAT.
184178 03-03

INFLUENCE OF METHAMPHETAMINE AND NEUROLEPTIC DRUGS ON TYROSINE HYDROXYLASE ACTIVITY.
184180 03-03

THE EFFECTS OF METHAMPHETAMINE AND SECOBARBITAL ON THE CONTINGENT NEGATIVE VARIATION AMPLITUDE.
185932 03-13

EFFECTS OF METHAMPHETAMINE ON FIXED-RATIO RESPONDING OF FOOD SATIATED AND FOOD DEPRIVED RATS.
185957 03-04

EFFECTS OF METHAMPHETAMINE, PIPRADROL, AND METHYLPHENIDATE ON INSTRUMENTAL CONDITIONING AND SPONTANEOUS MOTOR ACTIVITY IN THE IMMATURE RAT.
186568 03-04

METHAQUALONE

GAS CHROMATOGRAPHIC DETERMINATION OF METHAQUALONE IN SMALL AMOUNTS OF SERUM AFTER INGESTION OF THERAPEUTIC DOSES.
172397 01-16

METHAQUALONE – A DR. JEKYLL AND MR. HYDE?
177396 02-15

COMPLICATIONS OF METHAQUALONE DIPHENHYDRAMINE (MANDRAX) ABUSE.
177452 02-15

AN EXPERIMENTAL INVESTIGATION OF DEPENDENCE LIABILITY OF METHAQUALONE IN RATS.
186569 03-03

METHAQUALONE: AN IRRATIONAL HYPNOTIC.
189902 04-15

CELLULAR EFFECTS OF METHAQUALONE ON DRUG METABOLIZING ENZYMES.
191942 04-03

ABSORPTION AND CLEARANCE OF SECOBARBITAL, HEPTABARBITAL, METHAQUALONE, AND ETHINAMATE.
192575 04-13

METHEMOGLOBIN

MECHANISMS UNDERLYING POTENTIATION OF BARBITURATE ACTION BY SODIUM NITRITE IN THE MOUSE: THE ROLE OF METHEMOGLOBIN INDUCED HYPOXIA.
182721 03-03

METHIONINE

THE ADMINISTRATION OF METHIONINE TO CHRONIC SCHIZOPHRENIC PATIENTS: A REVIEW OF TEN STUDIES.
187113 03-08

METHIOTHEPIN

METHIOTHEPIN ELEVATION OF 5-HYDROXYINDOLEACETIC ACID LEVELS IN VARIOUS ANATOMIC REGIONS OF RAT BRAIN.
187831 04-03

METHOCARBAMOL

A COMPARATIVE STUDY OF DIAZEPAM AND METHOCARBAMOL IN THE TREATMENT OF LOMBOSCIATALGIAS.
178950 02-11

METHOD

A RAPID AUTOMATIC METHOD FOR DETERMINING SHOCK SENSITIVITIES OF MICE.
171521 01-04

A METHOD OF QUANTIFYING EEG FOR PSYCHOPHARMACOLOGICAL RESEARCH.
174135 01-16

SEMI-QUANTITATIVE ANALYSIS OF BROMAZEPAM BY RING OVEN METHOD.
174853 01-16

A METHOD FOR ANALYZING CNS EFFECTS OF DRUGS AND BRAIN LESIONS ON PERMANENT GROUPS OF RATS.
176867 02-06

COMPARISON OF THE EFFECTS OF Y-4153 AND CARPIPRAMINE ON SCHIZOPHRENIA BY A DOUBLE-BLIND METHOD.
178053 02-08

A FEW GALENIC METHOD TO PROLONG THE ACTION OF LITHIUM SULFATE.
180700 02-15

A SENSITIVE, SIMPLE METHOD FOR MEASUREMENT OF TYROSINE HYDROXYLASE AND TRYPTOPHAN-5-HYDROXYLASE ACTIVITIES.
182178 02-06

A GAS CHROMATOGRAPHIC METHOD FOR THE QUANTITATIVE ESTIMATION OF N-HYDROXYPHENTERMINE.
182203 02-06

AN IMPROVED METHOD FOR STUDYING THE PSYCHOGALVANIC REACTION IN MICE AND ITS INHIBITION BY PSYCHOLEPTIC DRUGS. COMPARISON WITH THE EFFECTS OF OTHER PHARMACOLOGICAL AGENTS.
185749 03-06

APPLICATION OF THE SEQUENTIAL SIMPLEX METHOD IN DESIGNING DRUG ANALOGS.
190714 04-01

A POLAROGRAPHIC METHOD FOR THE DETERMINATION OF THE N-OXIDE, N-OXIDE-SULPHOXIDE AND SULPHOXIDE METABOLITES OF CHLORPROMAZINE.
190902 04-06

DAILY RHYTHM IN BODY TEMPERATURE OF MENTAL PATIENTS: APPLICATION OF COSINOR METHOD -- FIRST REPORT.
191685 04-17

A METHOD FOR TESTING DRUG-INDUCED PARKINSONIAN-LIKE EFFECT.
191982 04-15

METHODOLOGICAL

SYSTEMATIC CLINICAL STUDIES WITH TRAZODONE: METHODOLOGICAL ASPECTS.
168804 01-16

PSYCHOPHARMACOLOGICAL RESEARCH: SOME METHODOLOGICAL PROBLEMS.
169932 01-06

METHODOLOGY

METHODOLOGY FOR THE EVALUATION OF PENTAZOCINE, PROTOTYPE OF THE NEW MORPHINE AGONIST ANTAGONIST ANALGESICS.
191603 04-16

METHODS

RESEARCH ON SUPERSENSITIVE LABORATORY METHODS IN SWEDEN.
170302 01-06

EXAMINATION OF THE METHODS OF USING FLUPHENAZINE ENANTHATE.
176469 02-08

DRUG THERAPY FOR DEPRESSION IN CHILDREN. INDICATIONS AND METHODS.
182429 03-10

VALIDITY OF SCREENING METHODS FOR DRUGS OF ABUSE IN BIOLOGICAL FLUIDS. II. HEROIN IN PLASMA AND SALIVA.
187256 03-15

ESTIMATION OF THE RATE OF 5-HT SYNTHESIS IN THE MOUSE BRAIN BY VARIOUS METHODS.
188976 04-03

A CRITICAL ASSESSMENT OF METHODS FOR THE DETERMINATION OF MONOAMINE SYNTHESIS AND TURNOVER RATES IN VIVO.
191514 04-06

METHOHEXITAL

TREATMENT OF PHOBIAS BY SYSTEMATIC DESENSITIZATION: COMPARISON OF STANDARD VS METHOHEXITAL AIDED DESENSITIZATION.
189916 04-10

THE METHOHEXITAL METHYLPHENIDATE INTERVIEW: A PROPOSED NEW DRUG COMBINATION FOR NARCOTHERAPY.
190242 04-07

DIFFERENTIAL SENSITIVITY OF METHOHEXITAL SELF-ADMINISTRATION TO SHOCK PUNISHMENT EARLY VS. LATE IN SESSION.
191941 04-04

METHOHEXITONE

A CONTROLLED COMPARISON OF THE PSYCHOTROPIC EFFECTS OF PROPANIDID AND METHOHEXITONE.
184082 03-14

METHOXYLATED

EFFECTS OF PSYCHOTOMIMETICS ON VASCULAR STRIPS: STUDIES OF METHOXYLATED AMPHETAMINES AND OPTICAL ISOMERS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE AND 2,5 DIMETHOXY-4-BROMOAMPHETAMINE.
177734 02-03

METHYL

A NOVEL SPASMOLYTIC AND CNS ACTIVE AGENT: 3-(2-BENZYLMETHYLAMINOETHYL) BENZOIC ACID METHYL ESTER HYDROCHLORIDE.
184581 03-02

EFFECTS OF PERINATAL EXPOSURE TO METHYL MERCURY ON FUNCTIONAL BRAIN DEVELOPMENT AND NEUROCHEMISTRY.
189564 04-05

METHYL-3-PHENYLPROPYLAMINE

EFFECT OF LILLY-110140, 3-(P-TRIFLUOROMETHYLPHENOXY) N METHYL-3-PHENYLPROPYLAMINE ON SYNTHESIS OF 3H-SEROTONIN FROM 3H-TRYPTOPHAN IN RAT BRAIN.
191951 04-03

METHYLAMPHETAMINE

TOLERANCE TO THE HYPERACTIVATING EFFECTS OF METHYLAMPHETAMINE.
186702 03-04

METHYLBROMIDE

EFFECTS OF SCOPOLAMINE METHYLBROMIDE ON SHOCK-INDUCED GASTRIC LESIONS IN THE UNRESTRAINED RAT.
189381 04-03

METHYLCOBALAMIN

STIMULATION OF BRAIN AROMATIC ALKYLAMINE N-METHYLTRANSFERASE ACTIVITY BY FAD AND METHYLCOBALAMIN.
180020 02-03

METHYLENE

(3H) OUABAIN BINDING TO NA_-ATPASE AND K_-ATPASE: INHIBITION BY BETA, GAMMA METHYLENE ATP.
182184 02-03

METHYLENEDIOXYAMPHETAMINE

THE PROPERTIES OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA). I. A REVIEW OF THE LITERATURE.
176597 02-17

METHYLPERIDOL

CLINICAL USE OF LUVATREN (METHYLPERIDOL) FOR THE TREATMENT OF SCHIZOPHRENIA.
191720 04-08

METHYLPHENIDATE

ANTAGONISTIC EFFECTS OF PHYSOSTIGMINE AND METHYLPHENIDATE IN MAN.
172272 01-11

DEXTROAMPHETAMINE AND METHYLPHENIDATE IN THE TREATMENT OF HYPERACTIVE/AGGRESSIVE CHILDREN.
177771 02-14

METHYLPHENIDATE AND THE ACTIVITY OF HYPERACTIVES IN THE INFORMAL SETTING.
181853 02-14

A CASE OF PERIODIC SOMNOLENCE IMPROVED BY THE CO-MEDICATION OF L-DOPA AND METHYLPHENIDATE.
185241 03-14

IMIPRAMINE AND METHYLPHENIDATE TREATMENTS OF HYPERACTIVE BOYS: A DOUBLE-BLIND COMPARISON.
185324 03-14

DOSE EFFECTS OF METHYLPHENIDATE ON BEHAVIORAL INHIBITION AND ACTIVATION IN HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
185676 03-14

THE STATE-DEPENDENT EFFECTS OF METHYLPHENIDATE AND DEXTROAMPHETAMINE.
185861 03-14

ENHANCEMENT OF METHYLPHENIDATE INDUCED STEREOTYPIES BY REPEATED ADMINISTRATION OF NEUROLEPTICS.
186369 03-04

METHYLPHENIDATE ANTAGONISM OF HALOPERIDOL, INTERACTION WITH CHOLINERGIC AND ANTICHOLINERGIC DRUGS.
186370 03-04

INFLUENCE OF FLUPENTHIXOL AND FLUPENTHIXOL DECANOATE ON METHYLPHENIDATE AND APOMORPHINE INDUCED COMPULSIVE GNAWING IN MICE.
186371 03-04

EFFECTS OF METHAMPHETAMINE, PIPRADROL, AND METHYLPHENIDATE ON INSTRUMENTAL CONDITIONING AND SPONTANEOUS MOTOR ACTIVITY IN THE IMMATURE RAT.
186568 03-04

METHYLPHENIDATE IN CHILDREN -- EFFECT OF DOSAGE.
187581 04-14

THE METHOHEXITAL METHYLPHENIDATE INTERVIEW: A PROPOSED NEW DRUG COMBINATION FOR NARCOTHERAPY.
190242 04-07

EFFECTS OF METHYLPHENIDATE ON HYPERACTIVE CHILDRENS SLEEP.
190321 04-14

ELECTRODERMAL ACTIVITY IN HYPERACTIVE BOYS WHO ARE METHYLPHENIDATE RESPONDERS.
191400 04-14

EFFECTS OF INTRAVENOUS D-AMPHETAMINE, L-AMPHETAMINE AND METHYLPHENIDATE IN SCHIZOPHRENICS.
191508 04-08

AMPHETAMINE AND METHYLPHENIDATE INDUCED RELEASE OF STRIATAL DOPAMINE IN VIVO: DIFFERENTIAL EFFECTS ON NEWLY SYNTHESIZED AND STORED POOLS.
191897 04-03

EVIDENCE FOR CHOLINERGICALLY MEDIATED EFFECT OF METHYLPHENIDATE HYDROCHLORIDE IN THE CENTRAL NERVOUS SYSTEM.
191946 04-03

EFFECTS OF CHRONIC METHYLPHENIDATE ADMINISTRATION ON LEARNING AND OFFSPRING BEHAVIOR.
192116 04-04

METHYLTESTOSTERONE
METHYLTESTOSTERONE WITH IMIPRAMINE IN MEN: CONVERSION OF DEPRESSION TO PARANOID REACTION.
172992 01-15

METHYLTRANSFERASES
POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES: 1. MODIFICATION OF THE AMINO ACID PORTION OF S-ADENOSYLHOMOCYSTEINE.
190716 04-01

POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES. 2. MODIFICATION OF THE BASE PORTION OF S-ADENOSYLHOMOCYSTEINE.
190717 04-01

METHYPRYLON
METHYPRYLON OVERDOSE: INTERPRETATION OF SERUM DRUG CONCENTRATIONS.
177394 02-15

EFFECT OF VARIOUS STEROIDS AND ACTH ON METHYPRYLON PLASMA LEVELS AND SLEEPING TIME IN RATS.
183611 03-03

METHYSERGIDE
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND METHYSERGIDE ON DEFENSIVE BEHAVIOR IN RATS.
182190 02-04

METIAPINE
METIAPINE IN ACUTE SCHIZOPHRENIC PATIENTS.
167341 01-08

METIAPINE: THE EVALUATION OF THE ANTIPSYCHOTIC PROPERTIES OF A NEW NEUROLEPTIC. A PILOT STUDY.
167342 01-08

METRAZOL
BEHAVIORAL AND ELECTROCORTICOGRAPHIC DOSE-RESPONSE RELATIONSHIPS WITH METRAZOL. (UNPUBLISHED PAPER).
188248 04-04

THE EFFECTS OF PENTYLENETETRAZOL (METRAZOL) ON A LEARNED TASTE AVERSION PRODUCED BY LITHIUM CHLORIDE: THE ISSUE OF ASSOCIATIVE MEMORY VS. RETENTIVE MEMORY. (UNPUBLISHED PAPER).
188251 04-04

METRAZOL DISRUPTS CONDITIONED AVERSION PRODUCED BY LICL: A TIME DEPENDENT EFFECT.
188412 04-04

MEXICO
A COMPARISON OF CLINICALLY USED PSYCHOACTIVE DRUGS IN FOUR LATIN-AMERICAN COUNTRIES AND IN CANADA (ARGENTINA, COSTA-RICA, MEXICO AND PANAMA).
191139 04-17

MFB
NON-SPECIFICITY OF 5-HYDROXYTRYPTOPHAN IN REPLETING BRAIN SEROTONIN IN RATS WITH MFB LESIONS.
182725 03-03

MHPG
CATECHOLAMINE METABOLISM IN AFFECTIVE DISORDERS: RECENT STUDIES OF MHPG EXCRETION.
169091 01-13

MICE
EFFECT OF L-ASPARAGINASE ON RETENTION OF MAZE LEARNING IN MICE.
167324 01-04

BRAIN TO SERUM DISTRIBUTION OF RADIOACTIVITY OF INJECTED 3H-D-AMPHETAMINE IN DIFFERENTIALLY HOUSED MICE.
168418 01-03

TEMPERATURE DEPENDENT TOXICITY OF ADRENERGIC AGONISTS IN MICE AS A BASIS FOR TREATING D-AMPHETAMINE POISONING.
169688 01-05

L-DOPA: EFFECT ON ETHANOL NARCOSIS AND BRAIN BIOGENIC AMINES IN MICE.
169782 01-03

THRESHOLDS FOR ELECTROCONVULSIONS AND CHEMOCONVULSIONS IN MICE AFTER TERMINATION OF TREATMENT WITH PHENOBARBITAL.
170073 01-03

EVALUATION OF THE HYPOTHERMIC ACTION OF TETRAHYDROCANNABINOLS IN MICE AND SQUIRREL MONKEYS.
170163 01-03

EFFECTS OF CHLORPROMAZINE, MEPROBAMATE AND CHLORDIAZEPOXIDE ON THE MAZE LEARNING IN MICE.
171259 01-04

A RAPID AUTOMATIC METHOD FOR DETERMINING SHOCK SENSITIVITIES OF MICE.
171521 01-04

THE EFFECT OF PIPRADROL IN MICE AND ITS ANTAGONISM BY NEUROLEPTIC DRUGS.
171607 01-04

BEHAVIORAL EFFECT OF TRICYCLIC THYMOLEPTICS AND CHLORPHENIRAMINE IN MICE AFTER PRETREATMENT WITH 5 HYDROXYTRYPTOPHAN (5-HTP).
171609 01-04

THE EFFECTS OF 6-OH-DOPAMINE ON THE REPRODUCTION AND NA AND 5-HT CONTENTS OF SOME TISSUES IN MICE.
171613 01-03

HYDROXYLAMINE INTERFERES WITH THE BEHAVIORAL RESPONSE TO MORPHINE DEPENDENCE IN MICE.
171905 01-04

ALTERATION OF MATERNAL BEHAVIOR IN MICE FOLLOWING ADMINISTRATION OF CYPROTERONE ACETATE.
172374 01-04

FIGHTING IN MICE: DYADIC ESCALATION AND WHAT IS LEARNED.
173039 01-04

EFFECTS OF ANALEPTICS ON MAZE LEARNING IN MICE.
173078 01-04

ACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MICE, RATS, RABBITS AND DOGS.
173548 01-05

BEHAVIORAL CHANGES AND AGGRESSIVITY EVOKED BY DRUGS IN MICE.
174604 01-04

INTERACTIVE EFFECTS OF CYCLOHEXIMIDE AND PUROMYCIN IN ALTERING BRAIN POLYRIBOSOMES AND NEURAL AND BEHAVIOURAL RESPONSES TO ELECTROSHOCK IN MICE.
175230 02-03

BARBITURATE DEPENDENCE IN MICE INDUCED BY A SIMPLE SHORT-TERM ORAL PROCEDURE.
175895 02-03

CHRONOPHARMACOLOGY OF DELTA9-TETRAHYDROCANNABINOL HYPOTHERMIA IN MICE.
176880 02-03

BLOOD AND BRAIN LEVELS OF DELTA1-TETRAHYDROCANNABINOL IN MICE -- THE EFFECT OF 7-HYDROXY-DELTA1-TETRAHYDROCANNABINOL.
177333 02-03

ADRENALINE, NORADRENALINE AND DOPAMINE LEVELS IN BRAIN AND HEART AFTER ADMINISTRATION OF 6-HYDROXYDOPAMINE AND GUANETHIDINE TO NEWBORN MICE.
177338 02-03

DIFFERENTIAL EFFECTS OF ETHANOL AND PENTOBARBITAL ON SLEEP TIME IN C57BL AND BALB MICE.
177733 02-03

L-DOPA CHLORPROMAZINE ANTAGONISM ON RUNNING ACTIVITY IN MICE.
177785 02-04

ACUTE LETHALITY FOR MICE FOLLOWING ADMINISTRATION OF CYCLOPHOSPHAMIDE WITH BARBITURATES.
177834 02-05

INHIBITION OF ANTICHOLINERGIC DRUG-INDUCED LOCOMOTOR STIMULATION IN MICE BY ALPHA-METHYLTYROSINE.
177840 02-03

INTERACTION OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON INTESTINAL MOTILITY IN MICE.
180057 02-03

ACETYLCHOLINE TURNOVER IN BRAIN OF MICE AND RATS: EFFECTS OF VARIOUS DOSE REGIMENS OF MORPHINE. (UNPUBLISHED PAPER).
180582 02-03

STUDY WITH RADIOTRACERS OF THE DISTRIBUTION OF A NEW PSYCHOTROPE IN MICE: L-2-PYRROLIDONE-5-CARBOXYLATE DIMETHYLAMINOETHANOL. I. COMPARISON WITH L-GLUTAMIC AND L-2-PYRROLIDONE-5-CARBOXYLIC ACID.
180723 02-03

RELATIVE PHARMACOLOGICAL POTENCY IN MICE OF OPTICAL ISOMERS OF DELTA1-TETRAHYDROCANNABINOL.
181941 02-03

ATTEMPT TO EVALUATE THE PHYSICAL DEPENDENCE LIABILITY OF PSYCHOTROPIC DRUGS IN MICE.
182103 02-04

THE INFLUENCE OF ALDOSTERONE OR METHAMPHETAMINE ON LIVER GLYCOGEN DEPOSITION OF MICE STRESSED BY LONG-TERM ISOLATION.
182105 02-03

EFFECTS OF PSYCHOTROPIC DRUGS ON METHAMPHETAMINE INDUCED EXCITATIONS IN THE AGGREGATED MICE.
182107 02-04

THE EFFECT OF METHAMPHETAMINE ON BRAIN ACH CONSUMPTION AND AGGRESSIVENESS IN MICE STRESSED MILDLY BY LONG-TERM ISOLATION.
182108 02-04

LACK OF EFFECTS OF CYCLOHEXIMIDE ON TOLERANCE DEVELOPMENT TO A STIMULATORY EFFECT OF MORPHINE ON MICE.
182158 02-03

HYPOTHERMIC ACTION OF DELTA9-TETRAHYDROCANNABINOL, 11-OH-DELTA9-TETRAHYDROCANNABINOL AND 11-OH-DELTA8-TETRAHYDROCANNABINOL (DELTA9-THC, 11-OH-DELTA9-THC AND 11-OH-DELTA8-THC) IN MICE.
182220 03-03

INHIBITION OF ISOLATION INDUCED AGGRESSION IN MICE BY ANTISEROTONERGIC DRUGS.
182240 03-04

EFFECT OF 2-ARYLALANINES, 2-ARYLSERINES, TETRAPHENYLBORON AND 1,2 DL(2,4 DICHLOROPHENYL) ETHANOLAMINE ON LEVELS OF SEROTONIN (5-HT), NOREPINEPHRINE (NE) AND DOPAMINE (DM) IN WHOLE BRAIN OF MICE.
182254 03-03

PENTYLENETETRAZOL CONVULSIONS AND BRAIN CATECHOLAMINE TURNOVER RATE IN RATS AND MICE RECEIVING DIPHENYLHYDANTOIN OR BENZODIAZEPINES.
182344 03-03

EFFECTS OF ALKALI METALS ON SPONTANEOUS MOTOR ACTIVITIES OF MICE.
182637 03-02

CANNABIDIOL AND CANNABIS-SATIVA EXTRACT PROTECT MICE AND RATS AGAINST CONVULSIVE AGENTS.
183609 03-03

THE EFFECT OF LOW ENVIRONMENTAL TEMPERATURE ON THE TRANYLCYPROMINE MEPERIDINE INTERACTION IN MICE.
183897 03-03

CHOLINERGIC MODIFICATION OF NALOXONE INDUCED JUMPING IN MORPHINE DEPENDENT MICE.
184179 03-03

EVIDENCE FOR AN UNUSUAL DISTRIBUTION OF CHLORPHENTERMINE IN VIVO: AN AUTORADIOGRAPHIC STUDY IN MICE.
184226 03-03

EFFECT OF D-AMPHETAMINE SULFATE ON SUSCEPTIBILITY TO AUDIOGENIC SEIZURES IN DBA/2J MICE.
184235 03-03

AN IMPROVED METHOD FOR STUDYING THE PSYCHOGALVANIC REACTION IN MICE AND ITS INHIBITION BY PSYCHOLEPTIC DRUGS. COMPARISON WITH THE EFFECTS OF OTHER PHARMACOLOGICAL AGENTS.
185749 03-06

HISTO-AUTORADIOGRAPHIC INVESTIGATIONS ON THE DISTRIBUTION OF INJECTED 5-HYDROXYTRYPTAMINE (SEROTONIN) IN THE BRAIN AND THE PITUITARY OF MICE.
185900 03-03

STUDIES ON THE POTENTIATION OF THE ANTINOCICEPTIVE EFFECT OF OXOTREMORINE BY TETRABENAZINE IN MICE.
185933 03-03

A COMPARISON OF THE EFFECTS OF CHRONIC ADMINISTRATION OF ETHANOL AND ACETALDEHYDE TO MICE: EVIDENCE FOR A ROLE OF ACETALDEHYDE IN ETHANOL DEPENDENCE.
185992 03-03

INFLUENCE OF FLUPENTHIXOL AND FLUPENTHIXOL DECANOATE ON METHYLPHENIDATE AND APOMORPHINE INDUCED COMPULSIVE GNAWING IN MICE.
186371 03-04

A NEW RECORDING APPARATUS FOR MEASUREMENT OF LOCOMOTOR ACTIVITY OF MICE. EXPERIMENTAL OBSERVATIONS ON ITS USE.
186377 03-06

DIFFERENTIAL RECOVERY OF FUNCTION FOLLOWING CAUDATE, HIPPOCAMPAL, AND SEPTAL LESIONS IN MICE.
186620 03-04

A COMPARISON OF EFFECTS OF APOMORPHINE AND ET-495 ON LOCOMOTOR ACTIVITY AND CIRCLING BEHAVIOUR IN MICE.
186635 03-04

LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04

COCAINE, PEMOLINE AND AMPHETAMINE ON LEARNING AND RETENTION OF A DISCRIMINATION TEST IN MICE.
186705 03-04

THE PRENATAL EFFECT OF CHLORAMPHENICOL ON THE POSTNATAL DEVELOPMENT OF MICE.
187076 03-05

A STUDY OF THE BEHAVIORAL DISRUPTION OF MICE INDUCED BY L-METHIONINE AND RELATED COMPOUNDS.
187260 04-04

EFFECTS OF SHORT-TERM ADMINISTRATION OF N-NITROSO COMPOUNDS ON LIVER HISTOLOGY AND PENTOBARBITAL INDUCED SLEEPING TIME IN MICE.
187575 04-04

TEMPORAL ASPECTS OF SCOPOLAMINE INDUCED ONE-WAY MEMORY DISSOCIATION IN MICE.
187701 04-04

EFFECT OF ORAL ADMINISTRATION OF METHADONE ON HEPATIC MICROSOMAL MIXED FUNCTION OXIDASE ACTIVITY IN MICE.
188178 04-03

THE EFFECT OF BUTYLATED HYDROXYANISOLE AND BUTYLATED HYDROXYTOLUENE ON BEHAVIORAL DEVELOPMENT OF MICE.
188637 04-04

ANTICONVULSANT EFFECTS OF CANNABINOLS IN MICE: DRUG INTERACTIONS WITH CANNABINOIDS AND CANNABINOID INTERACTIONS WITH PHENYTOIN.
189513 04-03

ENHANCEMENT OF NOCICEPTIVE REACTIONS BY NALOXONE IN MICE AND RATS.
189517 04-05

INTERACTION OF D-AMPHETAMINE WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY OF MICE.
189613 04-04

EFFECT OF PREGESTATIONAL MORPHINE ADMINISTRATION TO MICE ON BEHAVIOR OF THEIR OFFSPRING.
191902 04-04

EFFECTS OF CNS AGENTS ON NICOTINE EXTENSOR CONVULSIONS AND LETHALITY IN MICE AND THEIR SEDATIVE ANTIANXIETY EFFECTS IN MAN.
191907 04-14

EFFECTS OF DELTA8-THC AND DELTA9-TETRAHYDROCANNABINOL ON THE IMMUNE RESPONSE IN MICE.
191960 04-03

THE EFFECT OF CANNABINOID MIXTURES ON THE RESPONSE TO STIMULANT DRUGS IN MICE.
191991 04-04

ANALYSIS OF HYPOTHERMIC ACTION OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) IN MICE.
191997 04-03

INDUCTION OF A DIETHYLETHER WITHDRAWAL SYNDROME IN MICE BY EXPOSURE TO ETHER VAPOR.
192006 04-03

NONSPONTANEOUS CONVULSIONS IN MICE ELICITED BY SOME CATECHOLAMINE RELEASERS AND 6,7 DIHYDROXYTETRAHYDROISOQUINOLINE (TIQ).
192013 04-05

INTERACTION OF SEROTONIN ANTAGONISTS WITH 3,4-DICHLORO-2-(2-IMIDAZOLIN-2-YL-THIO) 2 ACETOPHENONE HYDROBROMIDE (DITA) AND D-AMPHETAMINE HYDROBROMIDE (DITA) AND D-AMPHETAMINE ON CERTAIN BEHAVIORAL PARAMETERS OF MALE MICE.
192014 04-04

MICROANALYSIS

STABILITY AND MICROANALYSIS OF TETRAHYDROCANNABINOL.
169673 01-16

MICROELECTROPHORETIC

EFFECTS OF NEUROPHARMACOLOGICAL AGENTS ON HYPOTHALAMIC NEURONAL ACTIVITY: A MICROELECTROPHORETIC STUDY.
182123 02-03

MICROINJECTION

INFLUENCE OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTS OF ELECTRICAL STIMULATION AND MICROINJECTION OF ACETYLCHOLINE, SEROTONIN AND NORADRENALINE INTO THE MESENCEPHALON.
191786 04-02

MICROINJECTIONS

ANALGESIA AND HYPERREACTIVITY PRODUCED BY INTRACRANIAL MICROINJECTIONS OF MORPHINE INTO THE PERIAQUEDUCTAL GRAY MATTER OF THE RAT.
191367 04-04

MICROSCOPIC

FLUORESCENCE AND ELECTRON MICROSCOPIC ANALYSIS OF CATECHOLAMINE CONTAINING FIBERS IN MUTANT MOUSE CEREBELLUM. (UNPUBLISHED PAPER).
191762 04-03

MICROSOMAL

EFFECT OF CHRONIC INTOXICATION WITH (..) AMPHETAMINE ON ITS CONCENTRATION IN LIVER AND BRAIN AND ON (14C) LEUCINE INCORPORATION INTO MICROSOMAL AND CYTOPLASMIC PROTEINS OF RAT LIVER.
180056 02-05

THE EFFECTS OF PSYCHIC STIMULANTS ON THE ACTIVITY OF POTASSIUM AND SODIUM ION STIMULATED ATPASE IN THE MICROSOMAL FRACTIONS OF THE BRAIN OF RATS.
183518 03-01

DECREASED EFFECT OF PHENOBARBITAL TREATMENT ON MICROSOMAL DRUG METABOLIZING ENZYME ACTIVITY DURING GESTATION.
184228 03-03

EFFECT OF ORAL ADMINISTRATION OF METHADONE ON HEPATIC MICROSOMAL MIXED FUNCTION OXIDASE ACTIVITY IN MICE.
188178 04-03

MICROSOMES

THE HYDROXYLATION OF D-AMPHETAMINE BY LIVER MICROSOMES OF THE MALE RAT.
177337 02-03

IN VITRO BINDING OF (4-14C) DIPHENYLHYDANTOIN TO RAT BRAIN MICROSOMES.
188404 04-03

THE 4-HYDROXYLATION OF AMPHETAMINE AND PHENTERMINE BY RAT LIVER MICROSOMES.
191921 04-03

MICROTUBULAR
EFFECTS OF LIDOCAINE ON RABBIT BRAIN MICROTUBULAR PROTEIN.
191324 04-03

MICROVASCULAR
MICROVASCULAR SMOOTH MUSCLE HYPERRESPONSIVENESS DURING HALOTHANE ANESTHESIA IN THE RAT.
182185 02-03

MICROVIBRATION
TREATMENT PROCESS OF DEPRESSION AND CHANGES IN MICROVIBRATION.
182620 03-09

MIDBRAIN
THE EFFECTS OF AMPHETAMINE SULFATE ON THE DIURNAL RHYTHMS OF MIDBRAIN; CORTEX, NOREPINEPHRINE; SEROTONIN AND BLOOD GLUCOSE LEVELS IN THE MOUSE.
191918 04-03

MIGRAINE
A NEW AGENT FOR CHEMOTHERAPY OF MIGRAINE HEADACHES: A CONTROLLED STUDY.
169298 01-11

MILK
EXCRETION OF THC AND ITS METABOLITES IN EWES MILK.
189590 04-03

MINERALOCORTICOID
NEGATIVE SODIUM BALANCE IN LITHIUM CARBONATE TOXICITY: EVIDENCE OF MINERALOCORTICOID BLOCKADE.
169869 01-15

MINIMAL
IMIPRAMINE IN THE TREATMENT OF MINIMAL BRAIN DYSFUNCTION IN CHILDREN.
169295 01-11
CEREBRAL STIMULANTS AND MINIMAL DYSFUNCTION: SOME QUESTIONS, SOME ANSWERS, AND SOME MORE QUESTIONS.
180992 02-11
PHOTIC RESPONSES IN MINIMAL BRAIN DYSFUNCTION.
191188 04-15

MINIMALLY
AVERAGE EVOKED RESPONSES IN NORMAL AND MINIMALLY BRAIN DYSFUNCTIONED CHILDREN TREATED WITH AMPHETAMINE: A PRELIMINARY REPORT.
169861 01-11

MINOR
TURNOVER CHANGES IN CENTRAL MONOAMINE NEURON SYSTEMS AFTER MINOR TRANQUILLIZERS AND BARBITURATES.
171604 01-03
SECOND MINOR TRANQUILLISER ON PHARMACEUTICAL BENEFITS LIST.
184322 03-17
THE EFFECT OF MINOR TRANQUILIZERS ON STRESS INDUCED INCREASES IN RAT PLASMA CORTICOSTEROIDS.
186578 03-03
INTERACTION BETWEEN ALCOHOL, MINOR TRANQUILIZERS AND MORPHINE.
191141 04-04
CONCENTRATION EFFECT RELATIONSHIPS WITH MAJOR AND MINOR TRANQUILIZERS.
192871 04-14

MISUSE
AMPHETAMINE USE AND MISUSE WITH RECOMMENDATIONS FOR STIMULANT CONTROL POLICY.
172109 01-17

MITOCHONDRIA
STUDIES OF MONOAMINE OXIDASES: PROPERTIES OF THE ENZYME IN BOVINE AND RABBIT BRAIN MITOCHONDRIA.
191300 04-03

MITOCHONDRIAL
STUDIES ON MONOAMINE OXIDASE -- REPORT 22: EFFECTS OF NANO2 AND NH2OH ON MITOCHONDRIAL MAO IN RAT BRAIN.
177022 02-03

MIXED
A DOUBLE-BLIND COMPARISON OF THIORIDAZINE (MELLARIL) VERSUS DIAZEPAM (VALIUM) IN PATIENTS WITH CHRONIC MIXED ANXIETY AND DEPRESSIVE SYMPTOMS.
172486 01-10
RATE-DEPENDENT EFFECTS OF DRUGS. I. COMPARISONS OF D-AMPHETAMINE, PENTOBARBITAL, AND CHLORPROMAZINE ON MULTIPLE AND MIXED SCHEDULES.
177410 02-04
EFFECT OF ORAL ADMINISTRATION OF METHADONE ON HEPATIC MICROSOMAL MIXED FUNCTION OXIDASE ACTIVITY IN MICE.
188178 04-03
MIXED ANXIETY DEPRESSION: FACT OR MYTH?
189919 04-10
THE TREATMENT OF MIXED ANXIETY AND DEPRESSION WITH LOXAPINE: A CONTROLLED COMPARATIVE STUDY.
190195 04-09

MIXTURE
SENSORY CONTINGENT BAR-PRESSING FOR FAMILIAR AND NOVEL CHANGE UNDER A DEXAMPHETAMINE AMYLOBARBITONE MIXTURE.
181605 02-04

MIXTURES
CARDIOVASCULAR EFFECTS OF RESERPINE, YOHIMBINE, AND RESERPINE YOHIMBINE MIXTURES ON INTACT ANESTHETIZED DOG.
167328 01-03
THE EFFECT OF CANNABINOID MIXTURES ON THE RESPONSE TO STIMULANT DRUGS IN MICE.
191991 04-04

MK-486
LEVODOPA COMBINED WITH MK-486 (L-ALPHA-METHYLDOPAHYDRAZINE) -- A PERIPHERAL DECARBOXYLASE INHIBITOR IN PARKINSONS DISEASE.
187615 04-11

MOBILIZATION
SELF-STIMULATION AND CATECHOLAMINES: DRUG-INDUCED MOBILIZATION OF THE RESERVE POOL RE-ESTABLISHES RESPONDING IN CATECHOLAMINE DEPLETED RATS.
189025 04-04

MODE
PROSTAGLANDINS AND CANNABIS: A POSSIBLE MODE OF ACTION FOR THC.
169067 01-03
AN ENZYME APPROACH IN APPRAISING THE MODE OF SOME TRANQUILIZERS AND ANTIDEPRESSANTS.
174318 01-03
AMPHETAMINE TRICYCLIC INTERACTIONS: ROLE OF THE HYDROXYLATION OF AMPHETAMINE IN ITS CENTRAL AND PERIPHERAL MODE OF ACTION. (PH.D. DISSERTATION).
174963 01-03
FURTHER EVIDENCE FOR A ROLE OF 2-PHENYLETHYLAMINE IN THE MODE OF ACTION OF DELTA9-TETRAHYDROCANNABINOL.
179992 02-03
THE MODE OF MORPHINE UPTAKE INTO BRAIN SLICES.
191413 04-03

MODEL
MOTHER INFANT SEPARATION: BEHAVIORAL ANALYSIS OF AN ANIMAL MODEL OF DEPRESSION. (PH.D. DISSERTATION).
178867 02-04
A COMPARATIVE STUDY OF THE ANTIPSYCHOTIC ACTION OF SOME NEUROLEPTICS BASED ON THE MODEL OF LSD PSYCHOSES.
183682 03-03
LEAD INDUCED BEHAVIORAL DYSFUNCTION: AN ANIMAL MODEL OF HYPERACTIVITY.
184953 03-04
THE ISOLATED PERFUSED RAT BRAIN AS A MODEL FOR STUDYING DRUGS ACTING ON THE CNS.
186589 03-06
PSYCHOTROPIC EFFECT OF ANALGESICS AND NEUROLEPTICS ON A MODEL OF INVESTIGATORY BEHAVIOR CHANGED BY PAIN.
191120 04-04
BEHAVIORAL AND EEG CHANGES IN THE AMPHETAMINE MODEL OF PSYCHOSIS.
191505 04-04
A BACTERIAL MODEL FOR EVALUATION OF BARBITURATES.
191920 04-03
A PREDICTABLE LABORATORY MODEL FOR SEDATIVE/HYPNOTIC ACTIVITY IN MAN.
191943 04-14
A PHARMACOLOGICAL MODEL WITH RHESUS MONKEYS FOR THE PREDICTION OF SELECTIVE DEPRESSION OF PSYCHIC FUNCTIONS.
192424 04-04

MODELS
ANIMAL MODELS FOR AN ENZYMIC BLOOD-BRAIN BARRIER MECHANISM FOR THERAPEUTICALLY ADMINISTERED L-DOPA.
167359 01-03
EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL IN SEVERAL ANIMAL MODELS OF AGGRESSION.
182188 02-04

MODERATE
PSYCHOPHYSIOLOGICAL EFFECTS OF DIAZEPAM (VALIUM) COMBINED WITH A MODERATE DOSE OF ALCOHOL IN MAN.
180699 02-14

MODIFICATION
CORTICAL SYNAPTOSOMAL UPTAKE AND SUBSYNAPTOSOMAL DISTRIBUTION OF 3H-NOREPINEPHRINE AND 3H-AMPHETAMINE: MODIFICATION BY TRICYCLIC AND PSYCHOACTIVE AGENTS IN VITRO. (PH.D. DISSERTATION).
172020 01-03
HALOPERIDOL EFFECTS ON MORPHINE SELF-ADMINISTRATION: TESTING FOR PHARMACOLOGICAL MODIFICATION OF THE PRIMARY REINFORCEMENT MECHANISM.
172454 01-04
MODIFICATION OF STIMULATION BOUND BEHAVIOR BY TRIFLUOPERAZINE AND AMPHETAMINE IN RATS. (PH.D. DISSERTATION).
173158 01-04
A NEW MODIFICATION FOR STUDYING 5-HT UPTAKE BY BLOOD PLATELETS: A RE-EVALUATION OF TRICYCLIC ANTIDEPRESSANTS AS UPTAKE INHIBITORS.
180055 02-06

MODIFICATION OF THE FRUSTRATION EFFECT WITH DRUGS.
181408 02-04
MODIFICATION OF THE EFFECTS OF CHLORPROMAZINE ON BEHAVIOR IN THE CHIMPANZEE.
183889 03-04
CHOLINERGIC MODIFICATION OF NALOXONE INDUCED JUMPING IN MORPHINE DEPENDENT MICE.
184179 03-03
EFFECTS OF CONCURRENT BEHAVIOR MODIFICATION AND CHLORPROMAZINE ADMINISTRATION IN MENTALLY RETARDED WOMEN. (PH.D. DISSERTATION).
185604 03-14
MODIFICATION OF LEARNING AND MEMORY IN GOLDFISH THROUGH THE USE OF STIMULANT AND DEPRESSANT DRUGS.
186583 03-04
POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES: 1. MODIFICATION OF THE AMINO ACID PORTION OF S-ADENOSYLHOMOCYSTEINE.
190716 04-01
POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES. 2. MODIFICATION OF THE BASE PORTION OF S-ADENOSYLHOMOCYSTEINE.
190717 04-01

MODIFICATIONS
ELECTROENCEPHALOGRAPHIC MODIFICATIONS DURING ADMINISTRATION OF LITHIUM.
174566 01-09

MODIFIED
SOCIAL HIERARCHY IN MONKEYS (MACACA-MULATTA) MODIFIED BY CHLORDIAZEPOXIDE HYDROCHLORIDE.
183863 03-04
THE EFFECTS OF D-AMPHETAMINE ON THE INTERRESPONSE TIMES OF RATS AND GUINEA-PIGS ON A MODIFIED SIDMAN DISCRIMINATED AVOIDANCE SCHEDULE.
189519 04-04

MODIFY
THE EFFECTS OF AGENTS THAT MODIFY MUSCARINIC TONE UPON BEHAVIOR CONTROLLED BY AN AVOIDANCE SCHEDULE THAT EMPLOYS SIGNALED UNAVOIDABLE SHOCK.
171302 01-04
ALTERATION OF ETHANOL-INDUCED CNS DEPRESSION: INEFFECTIVENESS OF DRUGS THAT MODIFY CHOLINERGIC TRANSMISSION.
186375 03-03
THE USE OF SELECTIVE AND INHIBITOR DRUGS TO MODIFY AMINE METABOLISM IN BRAIN.
191500 04-03

MODIFYING
THE EFFECT OF PHASE-SHIFT ON THE PASSIVE AVOIDANCE RESPONSE IN RATS, AND THE MODIFYING EFFECT OF CHLORDIAZEPOXIDE.
174830 01-04

MODULATE
EXCITANT AND DEPRESSANT DRUGS MODULATE EFFECTS OF ENVIRONMENT ON BRAIN WEIGHT AND CHOLINESTERASES.
174036 01-03

MODULATION
THE ROLE OF THE SEPTAL AREA OF THE BRAIN IN THE INHIBITORY MODULATION OF BEHAVIOR. (PH.D. DISSERTATION).
172021 01-03
MODULATION OF REWARD AND AVERSION PROCESSES IN THE RAT DIENCEPHALON BY AMPHETAMINE.
186164 03-04

MODULATORY
MODULATORY EFFECTS OF CORTICOSTEROIDS ON EVOKED ACTIVITY IN THE HIPPOCAMPUS AND THALAMUS OF THE RAT.
182119 02-03

MOGADON
ACUTE NITRAZEPAM (MOGADON) POISONING: AN ELECTROENCEPHALOGRAPHIC STUDY.
180148 02-15
ACUTE POISONING BY NITRAZEPAM (MOGADON).
183786 03-15

MOLECULAR
MOLECULAR ORBITAL STUDIES ON THE CONFORMATION OF HALLUCINOGENIC INDOLEALKYLAMINES AND RELATED COMPOUNDS. THE ISOLATED MOLECULES AND THE SOLVENT EFFECT.
183406 03-01

MOLECULES
MOLECULAR ORBITAL STUDIES ON THE CONFORMATION OF HALLUCINOGENIC INDOLEALKYLAMINES AND RELATED COMPOUNDS. THE ISOLATED MOLECULES AND THE SOLVENT EFFECT.
183406 03-01

MOLINDONE
EFFECTS OF MOLINDONE ON CNS STRUCTURES: NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATIONS.
172749 01-03
MOLINDONE: A CROSSOVER EVALUATION OF CAPSULE AND TABLET FORMULATIONS IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
174137 01-08

MOLLUSCAN
PHENOLS: EFFECTS ON MEMBRANE PERMEABILITY OF MOLLUSCAN NEURONS.
189033 04-03
EFFECTS OF AMPHETAMINES ON MOLLUSCAN NEURONS.
191995 04-03

MONITORED
EFFECT OF ANESTHETIC AGENTS ON PERIPHERAL SYMPATHETIC NERVOUS SYSTEM FUNCTION AS MONITORED BY ARTERIAL PLASMA CATECHOLAMINE LEVELS. (UNPUBLISHED PAPER
191495 04-03

MONITORING
ANALYSIS OF DRUG BLOCK OF LSD/5-HT/GABA BY MONITORING NEURONAL MEMBRANE CHANGES.
182143 02-03

MONKEY
PARTIAL PURIFICATION AND CHARACTERIZATION OF NADPH-LINKED ALDEHYDE REDUCTASE FROM MONKEY BRAIN.
175232 02-03
PENTAZOCINE IN RHESUS MONKEY PLASMA AND BRAIN AFTER PARENTERAL AND ORAL ADMINISTRATION.
178641 02-03
EFFECTS OF MORPHINE, CODEINE AND NALOXONE ON FOOD AND CODEINE REINFORCED RESPONDING IN THE RHESUS MONKEY.
182195 02-04
EFFECTS OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL ON SOCIAL BEHAVIOR OF SQUIRREL MONKEY DYADS IN A WATER COMPETITION SITUATION.
187640 04-04
BEHAVIORAL EFFECTS OF COCAINE COMPARED UNDER TWO SCHEDULES OF FOOD PRESENTATION IN THE SQUIRREL MONKEY.
191916 04-04
INTRAGASTRIC SELF-ADMINISTRATION OF PSYCHOACTIVE DRUGS IN THE RHESUS MONKEY.
191939 04-04

MONKEYS
EVALUATION OF THE HYPOTHERMIC ACTION OF TETRAHYDROCANNABINOLS IN MICE AND SQUIRREL MONKEYS.
170163 01-03
DEPENDENCE LIABILITY OF SEVERAL SEDATIVE HYPNOTIC AGENTS EVALUATED IN MONKEYS.
174125 01-04
EFFECTS OF PSYCHOACTIVE DRUGS ON NONVERBAL COMMUNICATION AND GROUP SOCIAL BEHAVIOR OF MONKEYS.
175317 02-04
3H-DELTA9-TETRAHYDROCANNABINOL (THC) METABOLISM IN RHESUS AND SQUIRREL MONKEYS.
175751 02-03
COMPARISON OF ANTICONVULSANT EFFECTS OF CLORAZEPATE DIPOTASSIUM AND DIAZEPAM: FOUR WEEK ANTICONVULSANT STUDY IN RHESUS MONKEYS.
176677 02-03
NEGATIVE REINFORCING PROPERTIES OF MORPHINE ANTAGONISTS IN NAIVE RHESUS MONKEYS.
177719 02-04
STEREOTYPY WITH SELECTIVE STIMULATION OF CERTAIN ITEMS OF BEHAVIOUR OBSERVED IN AMPHETAMINE TREATED MONKEYS (CERCOPITHECUS).
180061 02-04
EFFECT OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) ON THE DAYTIME SLEEP-WAKEFULNESS PATTERNS IN MONKEYS.
181657 02-02
EFFECTS OF ANTIPARKINSONIAN DRUGS ON NEUROLEPTIC INDUCED EXTRAPYRAMIDAL SIGNS IN MONKEYS.
183610 03-03
SOCIAL HIERARCHY IN MONKEYS (MACACA-MULATTA) MODIFIED BY CHLORDIAZEPOXIDE HYDROCHLORIDE.
183863 03-04
TEMPORALLY RELATED STIMULUS PROPERTIES OF DELTA9-TETRAHYDROCANNABINOL IN MONKEYS.
186567 03-04
EVALUATION OF REINFORCING CAPABILITY OF DELTA9-TETRAHYDROCANNABINOL IN RHESUS MONKEYS.
187638 04-04
PERSISTENT ELECTROENCEPHALOGRAPHIC CHANGES IN RHESUS MONKEYS AFTER SINGLE DOSES OF PENTOBARBITAL, NITRAZEPAM AND IMIPRAMINE.
187931 04-03
COMPARISON OF PHARMACOLOGICAL RESPONSES TO NICOTINE AND RELEASE OF CATECHOLAMINES FROM THE ADRENALS IN DOGS AND MONKEYS.
188199 04-03
INTESTINAL EFFECTS OF 5-HYDROXYTRYPTAMINE AND MORPHINE IN GUINEA-PIGS, DOGS, CATS AND MONKEYS.
188202 04-03
ORAL AND INTRAVENOUS TOXICITY OF DELTA9-TETRAHYDROCANNABINOL IN RHESUS MONKEYS.
188872 04-05

A STUDY OF BIOGENIC AMINE METABOLITES IN THE CEREBROSPINAL FLUID AND URINE OF MONKEYS WITH CHLORPROMAZINE INDUCED DYSKINESIA.
189210 04-03

CRUDE MARIHUANA EXTRACT: EEG AND BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION IN RHESUS MONKEYS.
189516 04-04

STRUCTURAL RELATIONSHIP BETWEEN META-SUBSITUTED N-ETHYLAMPHETAMINES AND SELF-ADMINISTRATION IN RHESUS MONKEYS.
191915 04-04

EFFECTS OF MORPHINE, PENTAZOCINE, AND NALOXONE ON OPERANT RESPONDING IN MONKEYS AND PIGEONS.
191972 04-04

COMPARISON OF CODEINE AND ETHYL ALCOHOL SELF-ADMINISTRATION UNDER A VARIABLE INTERVAL (VI) SCHEDULE IN MONKEYS.
191983 04-04

THE EFFECTS OF PSILOCYBIN ON EEG AND BEHAVIOUR IN MONKEYS.
192415 04-04

A PHARMACOLOGICAL MODEL WITH RHESUS MONKEYS FOR THE PREDICTION OF SELECTIVE DEPRESSION OF PSYCHIC FUNCTIONS.
192424 04-04

MONOAMINE

BETA-PHENYLETHYLAMINE: A SPECIFIC SUBSTRATE FOR TYPE B MONOAMINE OXIDASE OF BRAIN.
168437 01-03

EFFECT OF CHRONIC LITHIUM TREATMENT ON MONOAMINE METABOLISM IN RAT BRAIN.
168839 01-03

CENTRAL MONOAMINE METABOLISM IN MAN: EFFECT OF PUTATIVE DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS.
169377 01-13

SYNTHESIS OF SUBSTITUTED CINNAMIDES: RELATIONSHIP BETWEEN ANTICONVULSANT AND MONOAMINE OXIDASE INHIBITORY PROPERTIES.
169818 01-01

TURNOVER CHANGES IN CENTRAL MONOAMINE NEURON SYSTEMS AFTER MINOR TRANQUILLIZERS AND BARBITURATES.
171604 01-03

EFFECT OF TETRAHYDROCANNABINOLS ON CENTRAL MONOAMINE NEURONS.
171605 01-03

EFFECT OF MONOAMINE OXIDASE INHIBITORS ON METABOLISM AND IN VIVO RELEASE OF H3-NOREPINEPHRINE FROM THE HYPOTHALAMUS.
171973 01-03

THE ROLE OF MONOAMINE OXIDASE IN TERMINATING THE REFLEX EFFECTS OF P-METHOXYPHENYLETHYLAMINE (PMPEA).
174319 01-03

PLATELET MONOAMINE OXIDASE ACTIVITY AND SUBSTRATE PREFERENCES IN SCHIZOPHRENIC PATIENTS.
174609 01-14

THE MECHANISM OF ACTION OF THE MONOAMINE OXIDASE INHIBITOR PARGYLINE.
175239 02-03

STUDIES ON MONOAMINE OXIDASE -- REPORT 22: EFFECTS OF NANO2 AND NH2OH ON MITOCHONDRIAL MAO IN RAT BRAIN.
177022 02-03

INHIBITION OF LUNG, LIVER AND BRAIN MONOAMINE OXIDASE BY IMIPRAMINE AND DESIPRAMINE.
177332 02-03

THE RATE LIMITING CONTROL OF ENZYMES MONOAMINE OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN THE FETUS AND THE ADULT BY ADRENOCORTICOL HORMONES.
178815 02-03

TRANSPORT OF SYNAPTOSOMAL TRYPTOPHAN AND CEREBRAL TYROSINE: INCREASE IN THE SPEED OF UPTAKE OF RESERPINE OR THE INHIBITION OF MONOAMINE OXIDASE.
179988 02-13

DISCRIMINANT ANALYSIS OF THE RELATIONSHIP BETWEEN PHYSICAL PROPERTIES AND THE INHIBITION OF MONOAMINE OXIDASE BY AMINOTETRALINS AND AMINOINDANS.
180096 02-03

INVOLVEMENT OF ALPHA-RECEPTORS IN CLONIDINE INDUCED INHIBITION OF TRANSMITTER RELEASE FROM CENTRAL MONOAMINE NEURONES.
182345 03-03

THE INFLUENCE OF NEUROTROPIC DRUGS ON MONOAMINE OXIDASE (MAO) AND 5-OXYTRYPTOPHANE DECARBOXYLASE (5-OTD) ACTIVITY IN THE BRAIN.
183142 03-13

SUBSTITUTED BENZOXAZOLE/BENZTHIAZOLE-2-THIONES: INTERRELATIONSHIP BETWEEN ANTICONVULSANT ACTIVITY AND INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND MONOAMINE OXIDASE.
183601 03-03

EFFECT OF 3,4 DIMETHOXYPHENETHYLAMINE ON MONOAMINE DEPLETED RATS.
183608 03-03

REGIONAL CHANGES IN MONOAMINE LEVELS AND IN THE RATE OF TYROSINE AND TRYPTOPHAN HYDROXYLATION IN 4 WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
185899 03-03

THE EFFECT OF P-CHLOROAMPHETAMINE ON MOTILITY IN RATS AFTER INHIBITION OF MONOAMINE SYNTHESIS, STORAGE, UPTAKE AND RECEPTOR INTERACTION.
185959 03-04

THE MONOAMINE OXIDASES OF BRAIN: SELECTIVE INHIBITION WITH DRUGS AND THE CONSEQUENCES FOR THE METABOLISM OF THE BIOGENIC AMINES.
186668 03-03

EEG DRIVING RESPONSES AS A FUNCTION OF MONOAMINE OXIDASE.
187149 03-13

EFFECTS OF LSD AND MONOAMINE SYNTHESIS INHIBITORS ON HORMONE ACTIVATED COPULATORY BEHAVIOR IN THE FEMALE RAT.
188611 04-04

PHARMACOLOGICAL AND BIOCHEMICAL ACTIONS OF THE HEMOLYTIC AGENTS ACETYLPHENYLHYDRAZINE AND PHENYLHYDRAZINE ON MONOAMINE OXIDASE IN THE RAT.
188769 04-03

FUROXANOBENZOFUROXAN, A SELECTIVE MONOAMINE OXIDASE INHIBITOR.
188770 04-01

CONTROL OF NOREPINEPHRINE SYNTHESIS IN BLOOD VESSELS AND THE EFFECTS OF MONOAMINE OXIDASE INHIBITION.
189390 04-03

LITHIUM AND THE MONOAMINE NEUROTRANSMITTERS IN THE RAT HIPPOCAMPUS.
190829 04-03

PROCAINE (GEROVITAL-H3) THERAPY: MECHANISM OF INHIBITION OF MONOAMINE OXIDASE.
191281 04-03

STUDIES OF MONOAMINE OXIDASES: PROPERTIES OF THE ENZYME IN BOVINE AND RABBIT BRAIN MITOCHONDRIA.
191300 04-03

PHYSICOCHEMICAL PROPERTIES, DEVELOPMENT, AND REGULATION OF CENTRAL AND PERIPHERAL MONOAMINE OXIDASE ACTIVITY.
191497 04-03

SOME INTERRELATED PROPERTIES OF BRAIN MONOAMINE OXIDASE.
191498 04-01

MONOAMINE OXIDASE IN MAN: ENZYME CHARACTERISTICS IN HUMAN PLATELETS, PLASMA, AND OTHER HUMAN TISSUES.
191502 04-13

A CRITICAL ASSESSMENT OF METHODS FOR THE DETERMINATION OF MONOAMINE SYNTHESIS AND TURNOVER RATES IN VIVO.
191514 04-06

MONOAMINERGIC

NEOMYCIN AND RUTHENIUM RED ANTAGONISM OF MONOAMINERGIC DEPRESSION OF CEREBRAL CORTICAL NEURONES.
191380 04-03

MONOAMINES

EFFECTS OF TETRABENAZINE ON LORDOSIS BEHAVIOUR AND ON BRAIN MONOAMINES IN THE FEMALE RAT.
171614 01-04

MONOAMINES AND COPULATORY ACTIVATION IN THE CASTRATED MALE RAT.
171618 01-04

DEPENDENCE OF ANTICONVULSANT DRUG ACTION ON CENTRAL MONOAMINES.
172923 01-03

CENTRAL MONOAMINES AND THE ACOUSTIC STARTLE REACTION IN RATS. (PH.D. DISSERTATION).
173136 01-04

LONG-TERM EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE ON BRAIN MONOAMINES.
180022 02-03

EFFECTS OF METHADONE ON ACTIVITY AND ON BRAIN MONOAMINES IN TWO MOUSE STRAINS.
182229 03-03

ACTIONS OF ATROPINE, HEMICHOLINIUM-3, AND PHYSOSTIGMINE ON CHLORPROMAZINE INDUCED CHANGES IN RAT BRAIN MONOAMINES.
187800 04-03

EFFECTS OF INTRACEREBRAL INJECTION OF 5,6-HYDROXYTRYPTAMINE ON CEREBRAL MONOAMINES AND SLEEP STATES IN THE CAT/.
189023 04-02

EFFECT OF CHRONIC TREATMENT WITH CENTRAL STIMULANTS ON BRAIN MONOAMINES AND SOME BEHAVIOURAL AND PHYSIOLOGICAL FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS.
191503 04-03

MONOCHLORIMIPRAMINE

THE USE OF LOW DOSES OF MONOCHLORIMIPRAMINE IN THE THERAPY OF NEUROTIC DEPRESSIVE SYNDROMES.
182789 03-10

MONOHYDROXYLATED
A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL AND ITS MONOHYDROXYLATED METABOLITES IN MAN.
182223 03-03

MONOLOGUES
AN INVESTIGATION OF INTERACTIONS AMONG LSD, DEXTROAMPHETAMINE, AND VERBAL BEHAVIOR IN MONOLOGUES AND DIALOGUES. (PH.D. DISSERTATION).
185600 03-14

MONOPHOSPHATE
THE ROLE OF CYCLIC 3,5 ADENOSINE MONOPHOSPHATE IN NEUROMUSCULAR TRANSMISSION.
170660 01-13
TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER).
170876 01-03
CYCLIC ADENOSINE MONOPHOSPHATE: SELECTIVE INCREASE IN CAUDATE NUCLEUS AFTER ADMINISTRATION OF L-DOPA.
176254 02-13
NEUROCHEMICAL ROLE OF ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AND GUANOSINE 3,5 CYCLIC MONOPHOSPHATE AND THEIR RELATION TO NEUROTRANSMITTERS; EFFECT OF TETRAHYDROCANNABINOLS. (PH.D. DISSERTATION).
185582 03-03
IN VIVO CHANGES OF CEREBRAL CYCLIC ADENOSINE 3,5 MONOPHOSPHATE INDUCED BY BIOGENIC AMINES: ASSOCIATION WITH PHOSPHORYLASE ACTIVATION.
188291 04-03

MONOPOLAR
INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: IV. INFLUENCE OF AMPHETAMINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
185961 03-04

MONOSYNAPTIC
THE EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC) AND ETHANOL ON MONOSYNAPTIC AND POLYSYNAPTIC TRANSMISSION IN THE CENTRAL NERVOUS SYSTEM.
182222 03-03

MOOD
EEG, HEART RATE, AND MOOD CHANGE (HIGH) AFTER CANNABIS.
169068 01-13
BRAIN BIOGENIC AMINE DEPLETION AND MOOD.
174994 02-14
NEUROPHARMACOLOGICAL STUDIES OF MOOD DISORDERS.
178114 02-09
PHENELZINE, MOOD RESPONSE, AND SLEEP.
183547 03-09

MOPEG
EFFECTS OF PHENOXYBENZAMINE, ACEPERONE AND CLONIDINE ON THE LEVEL OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL, (MOPEG) IN RAT BRAIN.
180059 02-03

MORNING-GLORY
AN OBSESSIVE NEUROSIS FOLLOWING MORNING-GLORY SEED INGESTION TREATED BY AVERSION RELIEF.
184259 03-15

MORPHINE
INFLUENCE OF MORPHINE ON LATERAL HYPOTHALAMIC SELF-STIMULATION IN THE RAT.
168835 01-04
DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE IN RESPECT TO TIME AND DOSAGE AND QUANTIFICATION OF THE PRECIPITATED WITHDRAWAL SYNDROME IN RATS.
169474 01-03
EFFECT OF DOPAMINERGIC STIMULATION OR BLOCKADE ON MORPHINE WITHDRAWAL AGGRESSION.
171300 01-04
HYDROXYLAMINE INTERFERES WITH THE BEHAVIORAL RESPONSE TO MORPHINE DEPENDENCE IN MICE.
171905 01-04
HALOPERIDOL EFFECTS ON MORPHINE SELF-ADMINISTRATION: TESTING FOR PHARMACOLOGICAL MODIFICATION OF THE PRIMARY REINFORCEMENT MECHANISM.
172454 01-04
INHIBITION BY MORPHINE OF REPETITIVE ACTIVATION OF CAT SPINAL MOTONEURONES.
172926 01-03
MORPHINE PHYSICAL DEPENDENCE UNALTERED BY PREVIOUS DEPENDENCE ON MORPHINE.
173872 01-03
LITHIUM (LI): LACK OF EFFECT ON MORPHINE (MS) EUPHORIA. (UNPUBLISHED PAPER).
174479 01-14
EVIDENCE THAT MORPHINE INCREASES DOPAMINE UTILIZATION IN CORPORA-STRIATA OF RATS.
176746 02-03
ANTAGONISM OF THE EFFECTS OF CHLORPROMAZINE AND MORPHINE ON DOPAMINE METABOLISM BY GABA.
176870 02-03
NEGATIVE REINFORCING PROPERTIES OF MORPHINE ANTAGONISTS IN NAIVE RHESUS MONKEYS.
177719 02-04
INFLUENCES OF RESERPINE AND CHLORPROMAZINE ON THE ANALGESIC AND METABOLIC EFFECTS OF MORPHINE.
180507 02-03
ACETYLCHOLINE TURNOVER IN BRAIN OF MICE AND RATS: EFFECTS OF VARIOUS DOSE REGIMENS OF MORPHINE. (UNPUBLISHED PAPER).
180582 02-03
DRUG DEPENDENCE TEST OF PHENOBARBITAL AND MORPHINE IN RATS BY SPONTANEOUS INTAKE.
182104 02-04
LACK OF EFFECTS OF CYCLOHEXIMIDE ON TOLERANCE DEVELOPMENT TO A STIMULATORY EFFECT OF MORPHINE ON MICE.
182158 02-03
EFFECT OF CHEMICAL SYMPATHECTOMY ON MORPHINE ANTINOCICEPTION AND TOLERANCE IN RATS.
182159 02-03
THE EFFECT OF CATECHOLAMINES, ACETYLCHOLINE AND SEROTONIN ON THE MORPHINE TOLERANT LONGITUDINAL MUSCLE STRIP OF THE GUINEA-PIG ILEUM.
182161 02-03
COMPARISON OF INTRAVENOUSLY ADMINISTERED METHADONE (ME), MORPHINE (MO), HEROIN (H) AND PLACEBO (P).
182163 02-03
BINDING OF MORPHINE BY SERUM PROTEINS OF MORPHINE TREATED RABBITS.
182187 02-03
SUBSTANTIAL ORAL MORPHINE INTAKE BY THE RAT USING SCHEDULE INDUCED POLYDIPSIA.
182194 02-04
EFFECTS OF MORPHINE, CODEINE AND NALOXONE ON FOOD AND CODEINE REINFORCED RESPONDING IN THE RHESUS MONKEY.
182195 02-04
REGIONAL AND SUBCELLULAR DISTRIBUTION OF CHOLINE ACETYLTRANSFERASE IN THE BRAIN OF NORMAL AND MORPHINE TREATED RATS.
182224 03-03
EFFECT OF ACUTE AND CHRONIC MORPHINE ON SPECIFIC RADIOACTIVITIES OF CHOLINE AND ACETYLCHOLINE IN MOUSE BRAIN.
182226 03-03
EFFECTS OF MORPHINE, NALORPHINE AND NALOXONE ON RAT BRAIN RELEASE OF ACETYLCHOLINE.
182227 03-03
STUDIES ON THE EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT ON CATECHOLAMINE LEVELS AND TURNOVER IN DISCRETE BRAIN AREAS OF RATS.
182228 03-03
EFFECT OF MORPHINE, HALOPERIDOL, APOMORPHINE AND BENZTROPINE ON DOPAMINE TURNOVER IN RAT CORPUS-STRIATUM: EVIDENCE SHOWING MORPHINE-INDUCED REDUCTION IN CNS DOPAMINERGIC ACTIVITY.
182230 03-03
EFFECT OF GAMMA-AMINOBUTYRIC ACID (GABA) ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
182231 03-03
BEHAVIORAL EFFECTS OF MORPHINE AND OPIOID ANTAGONISTS.
182859 03-04
INFLUENCE OF TETRACOSACTRIN (T) AND BETA-MELANOCYTE STIMULATING HORMONE (MSH) ON DEPRESSION OF THE SEGMENTAL REFLEX BY MORPHINE (MS). (UNPUBLISHED PAPER).
183324 03-03
MORPHINE METABOLISM IN VIVO AND IN VITRO BY HOMOZYGOUS GUNN RATS.
183899 03-03
CHOLINERGIC MODIFICATION OF NALOXONE INDUCED JUMPING IN MORPHINE DEPENDENT MICE.
184179 03-03
ARE CHOLINERGIC MECHANISMS INVOLVED IN MORPHINE EFFECTS ON MOTILITY
184198 03-03
TOLERANCE TO THE BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF HALOPERIDOL AND MORPHINE IN RATS CHRONICALLY TREATED WITH MORPHINE OR HALOPERIDOL.
184225 03-03
EFFECTS OF VARIOUS MORPHINE TREATMENT SCHEDULES ON ACETYLCHOLINE TURNOVER RATE IN RAT BRAIN PARTS.
184553 03-03
EFFECTS OF MORPHINE AND CHLORPROMAZINE ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR.
185997 03-04
MORPHINE PHYSICAL DEPENDENCE IN THE DOG.
186665 03-03

INTERACTION BETWEEN SEROTONIN AND MORPHINE IN THE GUINEA-PIG ILEUM.
186698 03-03

EFFECT OF MORPHINE ON REGIONAL LEVELS OF GAMMA-HYDROXYBUTYRATE IN MOUSE BRAIN.
187077 03-03

COMPARISON OF GRADED SINGLE INTRAMUSCULAR DOSES OF MORPHINE AND PENTOBARBITAL IN MAN.
187254 03-15

THE EFFECTS OF P-CHLOROPHENYLALANINE ON MORPHINE ANALGESIA, TOLERANCE AND DEPENDENCE DEVELOPMENT IN TWO STRAINS OF RATS.
187930 04-04

THE EFFECTS OF MORPHINE, ETORPHINE AND SINOMENINE ON THE CHEMICAL SENSITIVITY AND SYNAPTIC RESPONSES OF RENSHAW CELLS AND OTHER SPINAL NEURONES IN THE RAT.
188201 04-03

INTESTINAL EFFECTS OF 5-HYDROXYTRYPTAMINE AND MORPHINE IN GUINEA-PIGS, DOGS, CATS AND MONKEYS.
188202 04-03

PROPRANOLOL ANTAGONISM OF MORPHINE INFLUENCED BEHAVIOR.
188760 04-04

INFLUENCE OF ADRENERGIC BLOCKERS AND ANTILIPEMIC AGENTS ON PHARMACODYNAMIC ACTIONS OF MORPHINE IN CARBON TETRACHLORIDE TREATED RATS.
188873 04-03

INFLUENCE OF MORPHINE AND NALOXONE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189568 04-03

EFFECT OF MORPHINE ON THE TURNOVER AND SYNTHESIS OF (LEU-3H) PROTEIN AND (CH-14C) PHOSPHATIDYLCHOLINE IN DISCRETE REGIONS OF THE RAT BRAIN.
189586 04-03

DIFFERENTIAL ANTAGONISM BY NALOXONE OF INHIBITORY EFFECTS OF HALOPERIDOL AND MORPHINE ON BRAIN SELF-STIMULATION.
190306 04-03

NEGATIVE AND POSITIVE INTRACRANIAL REINFORCEMENT THRESHOLDS: EFFECTS OF MORPHINE.
190330 04-04

INTERACTION BETWEEN ALCOHOL, MINOR TRANQUILIZERS AND MORPHINE.
191141 04-04

ANALGESIA AND HYPERREACTIVITY PRODUCED BY INTRACRANIAL MICROINJECTIONS OF MORPHINE INTO THE PERIAQUEDUCTAL GRAY MATTER OF THE RAT.
191367 04-04

THE MODE OF MORPHINE UPTAKE INTO BRAIN SLICES.
191413 04-03

METHODOLOGY FOR THE EVALUATION OF PENTAZOCINE, PROTOTYPE OF THE NEW MORPHINE AGONIST ANTAGONIST ANALGESICS.
191603 04-16

EFFECTS OF D-AMPHETAMINE, MORPHINE AND CHLORPROMAZINE ON RESPONDING UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION OR ELECTRIC SHOCK PRESENTATION.
191767 04-03

EFFECT OF L-PHENYL-3-2-THIAZOLYL 2-THIOUREA, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
191769 04-03

ENHANCEMENT OF PENTOBARBITAL AFTER MORPHINE ADDICTION.
191898 04-03

POSITIVE REINFORCING EFFECTS OF APOMORPHINE, D-AMPHETAMINE AND MORPHINE: INTERACTION WITH HALOPERIDOL.
191899 04-04

EFFECT OF PREGESTATIONAL MORPHINE ADMINISTRATION TO MICE ON BEHAVIOR OF THEIR OFFSPRING.
191902 04-04

ALPHA-METHYL-P-TYROSINE INHIBITION OF SELF-ADMINISTERED INTRAVENOUS MORPHINE AND ORAL WATER IN RATS.
191940 04-04

EFFECTS OF MORPHINE, PENTAZOCINE, AND NALOXONE ON OPERANT RESPONDING IN MONKEYS AND PIGEONS.
191972 04-04

EFFECTS OF MORPHINE SULFATE ON POSITIVELY AND NEGATIVELY REINFORCED BEHAVIOR IN TWO STRAINS OF RATS.
191975 04-04

MORPHINE TOLERANCE, DEPENDENCE AND WITHDRAWAL AND BRAIN ACETYLCHOLINE.
191985 04-03

MORPHINE-INDUCED

CHROMATIN TEMPLATE ACTIVITY DURING MORPHINE-INDUCED ANALGESIA AND THE DEVELOPMENT OF ANALGESIC TOLERANCE.
182160 02-03

EFFECT OF MORPHINE, HALOPERIDOL, APOMORPHINE AND BENZTROPINE ON DOPAMINE TURNOVER IN RAT CORPUS-STRIATUM: EVIDENCE SHOWING MORPHINE-INDUCED REDUCTION IN CNS DOPAMINERGIC ACTIVITY.
182230 03-03

ALPHA-ADRENERGIC BLOCKING AGENTS: ANTINOCICEPTIVE ACTIVITY AND ENHANCEMENT OF MORPHINE-INDUCED ANALGESIA.
183895 03-03

MORPHINE-LIKE

PROGRESS REPORT ON THE USE OF THE DOG FOR ASSESSING MORPHINE-LIKE AND NALORPHINE-LIKE AGONISTS AS WELL AS DEPOT PREPARATIONS OF ANTAGONISTS. (UNPUBLISHED PAPER).
176312 02-03

MORVAN

ONE CASE OF AGRYPNIA (4 MONTHS WITHOUT SLEEP) IN A MORVAN DISEASE: FAVORABLE ACTION OF 5-HYDROXYTRYPTOPHAN.
187237 03-14

MOTHER

MOTHER INFANT SEPARATION: BEHAVIORAL ANALYSIS OF AN ANIMAL MODEL OF DEPRESSION. (PH.D. DISSERTATION).
178867 02-04

CHLORPROMAZINE CAUSING EXTRAPYRAMIDAL DYSFUNCTION IN NEWBORN INFANT OF PSYCHOTIC MOTHER.
187787 04-15

MOTHERS

REGIONAL CHANGES IN MONOAMINE LEVELS AND IN THE RATE OF TYROSINE AND TRYPTOPHAN HYDROXYLATION IN 4 WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
185899 03-03

MOTILITY

INTERACTION OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL ON INTESTINAL MOTILITY IN MICE.
180057 02-03

ARE CHOLINERGIC MECHANISMS INVOLVED IN MORPHINE EFFECTS ON MOTILITY
184198 03-03

THE EFFECT OF P-CHLOROAMPHETAMINE ON MOTILITY IN RATS AFTER INHIBITION OF MONOAMINE SYNTHESIS, STORAGE, UPTAKE AND RECEPTOR INTERACTION.
185959 03-04

MOTION

THE SPIRAL AFTEREFFECT (SAE) AS A MEASURE OF MOTION SICKNESS SUSCEPTIBILITY AND THE EFFECT ON THE SAE OF AN ANTIMOTION SICKNESS DRUG AND A CENTRAL NERVOUS SYSTEM DEPRESSANT.
172780 01-03

MOTIVATED

ANTICHOLINERGICS: THEIR EFFECTS ON FEAR MOTIVATED BEHAVIOR, URINARY 11-HYDROXYCORTICOSTEROIDS, URINARY VOLUME, AND HEART RATE IN THE DOG.
178720 02-03

MOTIVATION

PREDATION: SEPARATION OF AGGRESSIVE AND HUNGER MOTIVATION BY CONDITIONED AVERSION.
185463 03-04

MOTIVATIONAL

THE MOTIVATIONAL CONSEQUENCES OF CHOLINERGIC STIMULATION OF THE MEDIAL SEPTAL AREA.
190260 04-04

MOTONEURONES

INHIBITION BY MORPHINE OF REPETITIVE ACTIVATION OF CAT SPINAL MOTONEURONES.
172926 01-03

MOTOR

INFLUENCE OF CONCENTRATION AND MOTOR PERFORMANCE ON TARDIVE DYSKINESIA AND RABBIT SYNDROME.
167587 01-15

INTERACTION BETWEEN ATROPINE AND OXOTREMORINE ON CORTICAL ACETYLCHOLINE AND MOTOR ACTIVITY.
171606 01-03

ALTERATION OF SENSORY AND MOTOR EVOKED RESPONSES BY DIELDRIN.
181818 02-03

EEG CHANGES & MOTOR IMPAIRMENT AFTER DISULFIRAM ADMINISTRATION TO CATS.
182248 03-03

EFFECTS OF ALKALI METALS ON SPONTANEOUS MOTOR ACTIVITIES OF MICE.
182637 03-02

LONG-RANGE MOTOR PERFORMANCE CHANGES IN LEVODOPA TREATED PATIENTS WITH PARKINSONS DISEASE.
184195 03-11

L-DOPA EFFECTS ON MOTOR AND CENTRAL PROGRAMMING DEFICITS IN PARKINSONISM.
184976 03-14

EFFECTS OF METHAMPHETAMINE, PIPRADROL, AND METHYLPHENIDATE ON INSTRUMENTAL CONDITIONING AND SPONTANEOUS MOTOR ACTIVITY IN THE IMMATURE RAT.
186568 03-04

COMPARISON OF TYROSINE HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION WITH THE EFFECTS OF VARIOUS 6-HYDROXYDOPAMINE TREATMENTS ON D-AMPHETAMINE INDUCED MOTOR ACTIVITY.
186699 03-03

STRUCTURE-ACTIVITY RELATIONS OF SOME INDOLEALKYLAMINES IN COMPARISON TO PHENETHYLAMINES ON MOTOR ACTIVITY AND ACQUISITION OF AVOIDANCE BEHAVIOR.
186703 03-04

BLOCKING OF THE EFFECT OF A DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC) ON SPONTANEOUS MOTOR ACTIVITY IN THE RAT BY IMMUNIZATION WITH A PROTEIN CONJUGATE OF DELTA1-THC.
187129 03-04

THE EFFECT OF MEDAZEPAM AND ALCOHOL ON COGNITIVE AND MOTOR SKILLS USED IN CAR DRIVING.
189408 04-14

INTERACTION OF D-AMPHETAMINE WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY OF MICE.
189613 04-04

EFFECTS OF NOMIFENSINE (HOE-984), D-AMPHETAMINE AND APOMORPHINE ON MOTOR ACTIVITY, CATECHOLAMINE TURNOVER AND CAMP CONCENTRATIONS IN RAT BRAIN. (UNPUBLISHED PAPER).
191766 04-03

ACTION OF HALOPERIDOL AND TRIFLUOPERAZINE ON THE MOTOR RESPONSES ELICITED BY ELECTRICAL STIMULATION OF THE BRAIN IN RABBITS.
191787 04-02

MOUNTING

EFFECTS OF AN ESTROGEN ANTAGONIST, MER-25, ON MOUNTING BEHAVIOR AND LORDOSIS BEHAVIOR IN THE FEMALE RAT.
186691 03-04

MOUSE

TOXIC EFFECTS OF MARIHUANA TAR ON MOUSE SKIN.
170464 01-05

METABOLITES OF BROMAZEPAM, A BENZODIAZEPINE, IN THE HUMAN, DOG, RAT, AND MOUSE.
170837 01-03

LEVELS OF HVA IN MOUSE BRAIN FOLLOWING TREATMENT WITH METABOLITES OF CHLORPROMAZINE.
171626 01-03

EFFECTS OF CENTRALLY ACTING DRUGS ON ADENYL CYCLASE ACTIVITY AND CYCLIC AMP LEVELS OF MOUSE BRAIN. (PH.D. DISSERTATION).
172019 01-03

THE DISTRIBUTION OF DELTA1-TETRAHYDROCANNABINOL AND 7-HYDROXY-DELTA1-TETRAHYDROCANNABINOL IN THE MOUSE BRAIN AFTER INTRAVENTRICULAR INJECTION.
172596 01-03

THE EFFECTS OF AMPHETAMINE, 2-AMINOINDANE AND 2-AMINOTETRALIN ON THE CONCENTRATIONS OF WHOLE BRAIN NORADRENALINE, DOPAMINE, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC ACID IN THE MOUSE.
174828 01-03

THE EFFECT OF PHENIRAMINE AND ITS STRUCTURAL ANALOGUES ON 5-HYDROXYTRYPTAMINE IN RAT AND MOUSE BRAIN.
175240 02-03

SPECIFIC FACILITATION OF MAZE LEARNING BY A PEPTIDE EXTRACTED FROM TRAINED MOUSE BRAIN.
176868 02-04

EFFECTS OF L-DELTA9-TETRAHYDROCANNABINOL, DL-AMPHETAMINE AND PENTOBARBITAL ON OXYGEN CONSUMPTION BY MOUSE BRAIN AND HEART HOMOGENATES.
181813 02-03

DISPOSITION OF NORAPOMORPHINE AND N,N PROPYLNORAPOMORPHINE IN MOUSE BRAIN AND ITS CORRELATION WITH STEREOTYPED GNAWING BEHAVIOR.
182131 02-04

EFFECTS OF SELECTED CENTRALLY ACTING AGENTS ON ADENYL CYCLASE ACTIVITY IN MOUSE BRAIN.
182153 02-03

PHARMACOLOGIC ACTIVITY AND BIOTRANSFORMATION OF R_ AND S-BARBITURATE ENANTIOMERS IN MOUSE AND MAN.
182156 02-03

EFFECT OF ACUTE AND CHRONIC MORPHINE ON SPECIFIC RADIOACTIVITIES OF CHOLINE AND ACETYLCHOLINE IN MOUSE BRAIN.
182226 03-03

EFFECTS OF METHADONE ON ACTIVITY AND ON BRAIN MONOAMINES IN TWO MOUSE STRAINS.
182229 03-03

INHIBITION OF ISOLATION INDUCED AGGRESSION IN THE MOUSE BY ANTICHOLINERGIC COMPOUNDS.
182239 03-04

EFFECTS OF CHRONIC ADMINISTRATION OF AMPHETAMINE UPON THE CATECHOLAMINE CONTENT OF MOUSE BRAIN.
182255 03-03

MECHANISMS UNDERLYING POTENTIATION OF BARBITURATE ACTION BY SODIUM NITRITE IN THE MOUSE: THE ROLE OF METHEMOGLOBIN INDUCED HYPOXIA.
182721 03-03

A COMPARATIVE STUDY OF DANTROLENE SODIUM AND OTHER SKELETAL MUSCLE RELAXANTS WITH THE STRAUB TAIL MOUSE.
186638 03-04

EFFECT OF MORPHINE ON REGIONAL LEVELS OF GAMMA-HYDROXYBUTYRATE IN MOUSE BRAIN.
187077 03-03

PENTOBARBITAL AND IN VIVO TURNOVER RATE OF ACETYLCHOLINE IN MOUSE BRAIN AND IN REGIONS OF RAT BRAIN. (UNPUBLISHED PAPER).
187526 04-03

ESTIMATION OF THE RATE OF 5-HT SYNTHESIS IN THE MOUSE BRAIN BY VARIOUS METHODS.
188976 04-03

THE EFFECT OF 5,7 DIHYDROXYTRYPTAMINE ON PERIPHERAL ADRENERGIC NERVES IN THE MOUSE.
188977 04-03

EFFECT OF OXOTREMORINE AND PHYSOSTIGMINE ON CHOLINE LEVELS IN MOUSE WHOLE BRAIN, SPLEEN AND CEREBELLUM.
189893 04-03

EFFECT OF DIAZEPAM ON MOUSE WHOLE BRAIN AND BRAIN AREA ACETYLCHOLINE AND CHOLINE LEVELS.
191423 04-03

FLUORESCENCE AND ELECTRON MICROSCOPIC ANALYSIS OF CATECHOLAMINE CONTAINING FIBERS IN MUTANT MOUSE CEREBELLUM. (UNPUBLISHED PAPER).
191762 04-03

THE EFFECTS OF AMPHETAMINE SULFATE ON THE DIURNAL RHYTHMS OF MIDBRAIN; CORTEX, NOREPINEPHRINE; SEROTONIN AND BLOOD GLUCOSE LEVELS IN THE MOUSE.
191918 04-03

DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) IMIPRAMINE INTERACTION ON MOUSE BODY TEMPERATURE.
191996 04-03

INHIBITION IN VIVO OF ACETYLCHOLINE SYNTHESIS IN MOUSE BRAIN BY INHIBITORS OF CHOLINE ACETYLTRANSFERASE.
192001 04-03

MOUSE-KILLING

EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF CANNABIS-SATIVA EXTRACT ON THE MOUSE-KILLING BEHAVIOR OF RATS.
167362 01-04

INHIBITION OF MOUSE-KILLING BEHAVIOUR IN RATS BY SOME THYMOLEPTIC DRUGS.
171608 01-04

INHIBITORY EFFECTS OF PRETEST AND POSTTEST D-AMPHETAMINE ON MOUSE-KILLING BY RATS. (PH.D. DISSERTATION).
173727 01-04

MOVEMENT

ON THE TREATMENT OF RAPID EYE MOVEMENT NARCOLEPSY.
171496 01-11

AMPHETAMINE AND PENTOBARBITAL EFFECTS ON THE DISCRIMINATIVE RESPONSE CONTROL BY DEPRIVATION OF RAPID EYE MOVEMENT SLEEP (REM).
182245 03-03

MOVEMENTS

THE SUPPRESSION OF INVOLUNTARY MOVEMENTS WITH TETRABENAZINE.
178618 02-11

MOVING

ALTERATION OF EVOKED POTENTIALS IN CAUDATE NUCLEUS OF FREELY MOVING RATS BY L-DOPA, RESERPINE, AND PENTOBARBITAL.
187362 04-03

MSH

INFLUENCE OF TETRACOSACTRIN (T) AND BETA-MELANOCYTE STIMULATING HORMONE (MSH) ON DEPRESSION OF THE SEGMENTAL REFLEX BY MORPHINE (MS). (UNPUBLISHED PAPER).
183324 03-03

MULTI-STATE

POLYPHARMACY IN PSYCHIATRY: A MULTI-STATE COMPARISON OF PSYCHOTROPIC DRUG COMBINATIONS.
187840 04-17

MULTICENTER

A MULTICENTER INVESTIGATION OF LORAZEPAM IN ANXIETY NEUROSIS.
167346 01-10

MULTICENTRE

A MULTICENTRE CLINICAL TRIAL OF OXYPERTINE IN ANXIETY NEUROSIS.
182769 03-10

MULTICENTRIC

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: I. PIMOZIDE IN THE TREATMENT OF PERSONALITY DISORDERS.
183191 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: II. PIMOZIDE IN THE TREATMENT OF BEHAVIOURAL DISORDERS IN CHILDHOOD AND ADOLESCENCE.
183192 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: III. PIMOZIDE IN THE TREATMENT OF STRESS INDUCED PSYCHIC AND FUNCTIONAL DISORDERS.
183193 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: IV. PIMOZIDE IN THE TREATMENT OF PATIENTS WITH PARANOID SYMPTOMATOLOGY.
183194 03-09

MULTIENZYME
DEMETHYLATION OF N,N DIMETHYLAMPHETAMINES - EVIDENCE FOR A MULTIENZYME SYSTEM.
191923 04-03

MULTIHOSPITAL
PROPHYLACTIC TREATMENT OF RECURRENT DEPRESSION: OBSERVATIONS FROM A MULTIHOSPITAL COLLABORATIVE STUDY.
186190 03-09

MULTIPLE
STRIATAL TYROSINE HYDROXYLASES WITH HIGH AND LOW AFFINITY FOR TYROSINE: IMPLICATIONS FOR THE MULTIPLE POOL CONCEPT OF CATECHOLAMINES.
167325 01-03

RATE-DEPENDENT EFFECTS OF DRUGS. I. COMPARISONS OF D-AMPHETAMINE, PENTOBARBITAL, AND CHLORPROMAZINE ON MULTIPLE AND MIXED SCHEDULES.
177410 02-04

MULTIPLE FORMS OF MAO: SOME IN VIVO CORRELATIONS.
191496 04-03

NALTREXONE AND NALOXONE: AGONIST AND ANTAGONIST EFFECTS ON KEY-PRESS RESPONDING OF PIGEONS MAINTAINED UNDER A MULTIPLE SCHEDULE OF FOOD PRESENTATION.
191926 04-04

MULTITRIAL
MULTITRIAL PASSIVE AVOIDANCE IN RATS: MESCALINE, SHOCK, AND ITI EFFECTS. (PH.D. DISSERTATION).
173162 01-04

MURICIDAL
THE USE OF BIOCHEMICAL CORRELATES FOR THE PREDICTION OF MURICIDAL BEHAVIOR IN THE WILD RAT.
182241 03-04

MUSCARINIC
THE EFFECTS OF ^GENTS THAT MODIFY MUSCARINIC TONE UPON BEHAVIOR CONTROLLED BY AN AVOIDANCE SCHEDULE THAT EMPLOYS SIGNALED UNAVOIDABLE SHOCK.
171302 01-04

CENTRAL CHOLINERGIC (MUSCARINIC) LINK IN THE ATTACK REFLEXIVE BITING MECHANISM OF CATS.
182238 03-04

THE ACTIONS OF SEVERAL PSYCHOACTIVE AGENTS UPON THE MUSCARINIC MECHANISMS IN THE SUPERIOR CERVICAL GANGLION OF THE CAT.
183866 03-03

ANTISCHIZOPHRENIC DRUGS AND BRAIN CHOLINERGIC RECEPTORS: AFFINITY FOR MUSCARINIC SITES PREDICTS EXTRAPYRAMIDAL EFFECTS.
188114 04-15

MUSCLE
DISSOCIATIVE CHANGE IN ANTIAGGRESSIVE AND MUSCLE RELAXANT ACTIONS OF S-TRIAZOLOBENZODIAZEPINE (D-40TA) BY REPEATED ADMINISTRATION AND PHENOBARBITAL PRETREATMENT, AND ITS RELATION TO METABOLISM.
181654 02-04

THE EFFECT OF CATECHOLAMINES, ACETYLCHOLINE AND SEROTONIN ON THE MORPHINE TOLERANT LONGITUDINAL MUSCLE STRIP OF THE GUINEA-PIG ILEUM.
182161 02-03

MICROVASCULAR SMOOTH MUSCLE HYPERRESPONSIVENESS DURING HALOTHANE ANESTHESIA IN THE RAT.
182185 02-03

A COMPARATIVE STUDY OF DANTROLENE SODIUM AND OTHER SKELETAL MUSCLE RELAXANTS WITH THE STRAUB TAIL MOUSE.
186638 03-04

MUSCLE ABNORMALITIES IN PSYCHOTIC PATIENTS: II. SERUM CPK ACTIVITY, FIBER ABNORMALITIES, AND BRANCHING AND SPROUTING OF SUBTERMINAL NERVES.
187114 03-09

THE ADDITIVE EFFECTS OF TRANQUILIZERS AND DOPAMINE ON SMOOTH MUSCLE.
187804 04-03

CENTRALLY ACTING MUSCLE RELAXANTS. ISOMERIC 9,10 DIHYDROXYOCTAHYDROPHENANTHRENES AND THEIR CARBAMATE ESTERS.
190719 04-02

SKELETAL MUSCLE: RESERVOIR FOR EXOGENOUS L-DOPA.
191771 04-03

THE EFFECTS OF HOE-36801 ON MUSCLE ACTIVITY AND BLOOD PRESSURE, ON ATTENTION AND CONCENTRATION, ON TIME JUDGMENT AND SUBJECTIVE RESPONSES IN NEUROTICS AND NORMALS.
192429 04-14

MUSCLES
EFFECT OF DIVALENT CATIONS ON ACH CONTRACTURES OF DEPOLARIZED DENERVATED RAT MUSCLES.
188914 04-03

MUSCULOSKELETAL
RELIEF OF MUSCULOSKELETAL AND ASSOCIATED PSYCHOPATHOLOGICAL SYMPTOMS WITH MEPROBAMATE AND ASPIRIN: A CONTROLLED STUDY.
169632 01-10

MUSICIANS
BETA-BLOCKING AGENTS IN THE TREATMENT OF CATECHOLAMINE INDUCED SYMPTOMS IN MUSICIANS.
192527 04-11

MUTAGENICITY
MUTAGENICITY EXPERIMENTS WITH THE TRANQUILLIZER MEPROBAMATE IN DROSOPHILA-MELANOGASTER AND IN HUMAN LEUKOCYTE CHROMOSOMES IN VITRO.
184585 03-05

MUTANT
FLUORESCENCE AND ELECTRON MICROSCOPIC ANALYSIS OF CATECHOLAMINE CONTAINING FIBERS IN MUTANT MOUSE CEREBELLUM. (UNPUBLISHED PAPER).
191762 04-03

MUTUAL
POSSIBLE MUTUAL THERAPEUTIC COMBINATION OF PSYCHOPHARMACEUTICALS.
178029 02-17

MYELINOGENESIS
ACETYLCHOLINESTERASE INHIBITION AND MYELINOGENESIS IN VITRO.
186033 03-03

MYOCARDIOPATHIC
MYOCARDIOPATHIC COMPLICATIONS INDUCED BY IMIPRAMINE AND TRICYCLIC THYMOLEPTICS.
182898 03-15

MYOCLONIC
MYOCLONIC SEIZURES IN DOWNS SYNDROME.
173205 01-11

MYOCLONUS
TREATMENT OF ACTION MYOCLONUS WITH L-5-HYDROXYTRYPTOPHAN.
188429 04-11

MYOMETRIUM
BETA-ADRENERGIC EFFECTS ON RAT MYOMETRIUM: ROLE OF CYCLIC AMP.
188915 04-03

MYTH
MIXED ANXIETY DEPRESSION: FACT OR MYTH?
189919 04-10

MYTHICIZING
MYTHICIZING ELEMENTS IN EXPERIMENTAL PSYCHOLYSIS.
189754 04-12

M99
ABUSE POTENTIAL OF ETORPHINE (M99) I. SUBJECTIVE EFFECTS AND PHYSICAL DEPENDENCE. (UNPUBLISHED PAPER).
171241 01-14

N-ACETYLTRANSFERASE
STIMULATION OF SEROTONIN N-ACETYLTRANSFERASE IN PINEAL ORGAN CULTURE BY DRUGS.
177128 02-03

N-ARYLALKYL
INHIBITION OF THE SYNAPTOSOMAL UPTAKE MECHANISMS FOR L-NOREPINEPHRINE AND DOPAMINE BY N-ARYLALKYL DL-AMPHETAMINE DERIVATIVES.
182250 03-03

N-DEMETHYLDIAZEPAM
THE USE OF N-DEMETHYLDIAZEPAM IN OUTPATIENTS SUFFERING FROM INSOMNIA.
167340 01-11

N-DEMTHYLATED
ALPHA-L-ACETYLMETHADOL AND ITS N-DEMTHYLATED METABOLITES HAVE POTENT OPIATE ACTION IN THE GUINEA-PIG ISOLATED ILEUM.
187130 03-03

N-DESMETHYLDIAZEPAM
PLASMA CONCENTRATIONS OF DIAZEPAM AND OF ITS METABOLITE N-DESMETHYLDIAZEPAM IN RELATION TO ANXIOLYTIC EFFECT.
186184 03-13

THE RESIDUAL EFFECTS OF N-DESMETHYLDIAZEPAM IN PATIENTS.
190336 04-11

N-ETHYLAMPHETAMINES
STRUCTURAL RELATIONSHIP BETWEEN META-SUBSITUTED N-ETHYLAMPHETAMINES AND SELF-ADMINISTRATION IN RHESUS MONKEYS.
191915 04-04

N-HYDROXYPHENTERMINE
A GAS CHROMATOGRAPHIC METHOD FOR THE QUANTITATIVE ESTIMATION OF N-HYDROXYPHENTERMINE.
182203 02-06

N-METHYLTRANSFERASE
STIMULATION OF BRAIN AROMATIC ALKYLAMINE N-METHYLTRANSFERASE ACTIVITY BY FAD AND METHYLCOBALAMIN.
180020 02-03

N-N
THE METABOLISM OF 1-N-BUTYL-5,5 DIETHYLBARBITURIC ACID (N-N BUTYLBARBITAL) IN THE RAT.
191057 04-03

N-NITROSO
EFFECTS OF SHORT-TERM ADMINISTRATION OF N-NITROSO COMPOUNDS ON LIVER HISTOLOGY AND PENTOBARBITAL INDUCED SLEEPING TIME IN MICE.
187575 04-04

N-OXIDE
A POLAROGRAPHIC METHOD FOR THE DETERMINATION OF THE N-OXIDE, N-OXIDE-SULPHOXIDE AND SULPHOXIDE METABOLITES OF CHLORPROMAZINE.
190902 04-06

N-OXIDE-SULPHOXIDE
A POLAROGRAPHIC METHOD FOR THE DETERMINATION OF THE N-OXIDE, N-OXIDE-SULPHOXIDE AND SULPHOXIDE METABOLITES OF CHLORPROMAZINE.
190902 04-06

NA..
OUABAIN RECEPTOR INTERACTIONS IN (NA.. .. K..) ATPASE PREPARATIONS.
189567 04-03
AMPHETAMINE AND NA..,K.. - ATPASE IN THE BRAIN.
191789 04-03

NA..-ATPASE
(3H) OUABAIN BINDING TO NA..-ATPASE AND K..-ATPASE: INHIBITION BY BETA, GAMMA METHYLENE ATP.
182184 02-03

NADPH-LINKED
PARTIAL PURIFICATION AND CHARACTERIZATION OF NADPH-LINKED ALDEHYDE REDUCTASE FROM MONKEY BRAIN.
175232 02-03

NAIVE
NEGATIVE REINFORCING PROPERTIES OF MORPHINE ANTAGONISTS IN NAIVE RHESUS MONKEYS.
177719 02-04
DIFFERENTIAL EFFECTS OF PENTYLENETETRAZOL ON REM SLEEP IN NAIVE AND COBALT EPILEPTIC RATS.
189407 04-03

NALORPHINE
EFFECTS OF MORPHINE, NALORPHINE AND NALOXONE ON RAT BRAIN RELEASE OF ACETYLCHOLINE.
182227 03-03
NALORPHINE AS AN AVERSIVE AGENT. (PH.D. DISSERTATION).
185727 03-04

NALORPHINE-LIKE
PROGRESS REPORT ON THE USE OF THE DOG FOR ASSESSING MORPHINE-LIKE AND NALORPHINE-LIKE AGONISTS AS WELL AS DEPOT PREPARATIONS OF ANTAGONISTS. (UNPUBLISHED PAPER).
176312 02-03

NALOXONE
STIMULATION OF BEHAVIOR IN THE RAT BY CYCLAZOCINE: EFFECTS OF NALOXONE.
168439 01-04
EFFECTS OF MORPHINE, CODEINE AND NALOXONE ON FOOD AND CODEINE REINFORCED RESPONDING IN THE RHESUS MONKEY.
182195 02-04
EFFECTS OF MORPHINE, NALORPHINE AND NALOXONE ON RAT BRAIN RELEASE OF ACETYLCHOLINE.
182227 03-03
BEHAVIORAL EFFECTS OF SEPARATE AND COMBINED ADMINISTRATION OF NALOXONE AND D-AMPHETAMINE.
183892 03-04
CHOLINERGIC MODIFICATION OF NALOXONE INDUCED JUMPING IN MORPHINE DEPENDENT MICE.
184179 03-03
ENHANCEMENT OF NOCICEPTIVE REACTIONS BY NALOXONE IN MICE AND RATS.
189517 04-05
INFLUENCE OF MORPHINE AND NALOXONE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189568 04-03
DIFFERENTIAL ANTAGONISM BY NALOXONE OF INHIBITORY EFFECTS OF HALOPERIDOL AND MORPHINE ON BRAIN SELF-STIMULATION.
190306 04-03
NALTREXONE AND NALOXONE: AGONIST AND ANTAGONIST EFFECTS ON KEY-PRESS RESPONDING OF PIGEONS MAINTAINED UNDER A MULTIPLE SCHEDULE OF FOOD PRESENTATION.
191926 04-04
EFFECTS OF MORPHINE, PENTAZOCINE, AND NALOXONE ON OPERANT RESPONDING IN MONKEYS AND PIGEONS.
191972 04-04

NALTREXONE
STUDIES OF EN-1639A (NALTREXONE): A NEW NARCOTIC ANTAGONIST.
189059 04-07
NALTREXONE AND NALOXONE: AGONIST AND ANTAGONIST EFFECTS ON KEY-PRESS RESPONDING OF PIGEONS MAINTAINED UNDER A MULTIPLE SCHEDULE OF FOOD PRESENTATION.
191926 04-04

NAME
DRUG NAME FAMILIARITY AND THE PLACEBO EFFECT.
192704 04-17

NANO2
STUDIES ON MONOAMINE OXIDASE -- REPORT 22: EFFECTS OF NANO2 AND NH2OH ON MITOCHONDRIAL MAO IN RAT BRAIN.
177022 02-03

NARCOANALYSIS
DROPERIDOL -- A PREFERRED NEUROLEPTIC IN NARCOANALYSIS.
169462 01-14

NARCOLEPSY
ON THE TREATMENT OF RAPID EYE MOVEMENT NARCOLEPSY.
171496 01-11

NARCOLEPTICS
THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON THE COMPOSITION OF DIURNAL SLEEP OF NARCOLEPTICS.
192419 04-11

NARCOSIS
L-DOPA: EFFECT ON ETHANOL NARCOSIS AND BRAIN BIOGENIC AMINES IN MICE.
169782 01-03
NOREPINEPHRINE -- AN ANTAGONIST OF DIBUTYRYL CYCLIC AMP IN THE REGULATION OF NARCOSIS IN THE RAT.
183789 03-03
ADAPTATION TO NITROGEN NARCOSIS MANIFESTED BY TIMING BEHAVIOR IN THE RAT.
186630 03-04

NARCOTHERAPY
THE METHOHEXITAL METHYLPHENIDATE INTERVIEW: A PROPOSED NEW DRUG COMBINATION FOR NARCOTHERAPY.
190242 04-07

NARCOTIC
DIURETIC ACTIVITY OF A NEW NARCOTIC ANTAGONIST IN MAN (BRISTOL-COMPOUND-2605). (UNPUBLISHED PAPER).
174473 01-13
TESTOSTERONE AND LUTEINIZING HORMONE (LH) IN UNTREATED AND METHADONE MAINTAINED NARCOTIC ADDICTS.
182166 02-13
EFFECTS OF NARCOTIC ANALGESICS ON ENZYMES OF ACETYLCHOLINE METABOLISM IN CULTURED CHICK BRAIN CELLS.
182225 03-03
A ROLE FOR THE AMYGDALA IN THE DEVELOPMENT OF THE CATALEPTIC AND STEREOTYPIC ACTIONS OF THE NARCOTIC AGONISTS AND ANTAGONISTS IN THE RAT.
186577 03-03
STUDIES OF EN-1639A (NALTREXONE): A NEW NARCOTIC ANTAGONIST.
189059 04-07

NARCOTICS
SEPARATION OF THE DEPENDENCE PRODUCING ACTIONS FROM THE DIRECT ACTIONS OF NARCOTICS ON GUINEA-PIG ILEUM.
182162 02-03
THE IMPULSE BLOCKING CONCENTRATIONS OF ANESTHETICS, ALCOHOLS, ANTICONVULSANTS, BARBITURATES, AND NARCOTICS ON PHRENIC AND SCIATIC NERVES.
187803 04-03

NATIONAL
PROPHYLACTIC EFFICACY OF LITHIUM CARBONATE IN MANIC-DEPRESSIVE ILLNESS: REPORT OF THE VETERANS ADMINISTRATION AND NATIONAL INSTITUTE OF MENTAL HEALTH (VA-NIMH) COLLABORATIVE STUDY GROUP.
189735 04-09

NATURAL
EFFECTS OF L-DOPA ON NATURAL NIGHT SLEEP AND ON REBOUND OF REM SLEEP.
167921 01-14

NATURE
ON THE NATURE OF THE SEROTONIN BINDING AFTER LSD.
182168 02-03
DOPAMINERGIC NATURE OF APOMORPHINE-INDUCED PECKING IN PIGEONS.
188204 04-03
AN INVESTIGATION OF THE BEHAVIOURAL NATURE OF THE PSYCHOMOTOR STIMULANT EFFECT OF AMPHETAMINE.
188620 04-04
THE NATURE OF STORAGE DEFICITS AND STATE-DEPENDENT RETRIEVAL UNDER MARIHUANA.
189406 04-14

NAVANE
CLINICAL EXPERIENCES WITH NAVANE IN CHRONIC SCHIZOPHRENIA.
176726 02-08

NEEDED
EFFECT OF ANTICONVULSANT DRUGS ON THE NUMBER OF AFFERENT STIMULI NEEDED TO CAUSE A HIPPOCAMPAL SEIZURE DISCHARGE.
189608 04-03

NEGATIVE

NEGATIVE SODIUM BALANCE IN LITHIUM CARBONATE TOXICITY: EVIDENCE OF MINERALOCORTICOID BLOCKADE.
169869 01-15

THE EFFECTS OF DALMANE (FLURAZEPAM HYDROCHLORIDE) ON THE CONTINGENT NEGATIVE VARIATION. (AMSTERDAM).
177645 02-16

NEGATIVE REINFORCING PROPERTIES OF MORPHINE ANTAGONISTS IN NAIVE RHESUS MONKEYS.
177719 02-04

MECHANISM OF THE NEGATIVE CHRONOTROPIC AND INOTROPIC EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC).
182219 03-03

THE EFFECTS OF METHAMPHETAMINE AND SECOBARBITAL ON THE CONTINGENT NEGATIVE VARIATION AMPLITUDE.
185932 03-13

THE EFFECT OF CAFFEINE, NITRAZEPAM AND CIGARETTE SMOKING ON THE CONTINGENT NEGATIVE VARIATION IN MAN.
187350 04-13

NEGATIVE AND POSITIVE INTRACRANIAL REINFORCEMENT THRESHOLDS: EFFECTS OF MORPHINE.
190330 04-04

NEGATIVELY

EFFECTS OF MORPHINE SULFATE ON POSITIVELY AND NEGATIVELY REINFORCED BEHAVIOR IN TWO STRAINS OF RATS.
191975 04-04

NEMBUTAL

THE ACTION OF NEMBUTAL ON THE ULTRA ARCHITECTONICS OF THE NEUROHYPOPHYSIS.
183520 03-01

NEOCEREBELLAR

LACK OF EFFECT OF RIBAMINOL, TCAP, AND MAGNESIUM PEMOLINE ON RECOVERY FROM NEOCEREBELLAR DAMAGE.
171904 01-03

NEOMYCIN

NEOMYCIN AND RUTHENIUM RED ANTAGONISM OF MONOAMINERGIC DEPRESSION OF CEREBRAL CORTICAL NEURONES.
191380 04-03

NEONATAL

ONTOGENESIS OF CIRCADIAN PITUITARY ADRENAL PERIODICITY IN RATS AFFECTED BY NEONATAL TREATMENT WITH ACTH.
181576 02-03

EFFECTS OF NEONATAL STRYCHNINE ADMINISTRATION ON ACTIVE AVOIDANCE IN RATS.
184242 03-04

NONSEDATING DOSAGES OF DIAZEPAM AND PHENOBARBITAL IN THE REDUCTION OF NEONATAL BILIRUBIN LEVELS.
191607 04-17

NEOPLASTIC

CONSIDERATIONS ON THE USE OF ANALGESIC DRUGS IN DIFFERENT STAGES OF NEOPLASTIC DISEASES.
191604 04-17

NEOSTRIATUM

IN VIVO ESTIMATION OF TYROSINE HYDROXYLATION IN THE DOPAMINERGIC TERMINALS OF THE RAT NEOSTRIATUM.
183794 03-03

NEPHRONS

EVIDENCE FOR REDISTRIBUTION OF FILTRATE AMONG NEPHRONS AFTER BETA- ADRENERGIC STIMULATION AND BLOCKADE.
184222 03-03

NERVE

SYNTHESIS OF ACETYLCHOLINE IN BRAIN NERVE TERMINALS DURING CONSCIOUSNESS AND BARBITURATE ANESTHESIA.
171600 01-03

IMPORTANCE OF CATECHOLAMINE RELEASE BY NERVE IMPULSES FOR FREE OPERANT BEHAVIOR.
171611 01-04

EFFECTS OF CHRONIC PRETREATMENT WITH SMALL DOSES OF RESERPINE UPON ADRENERGIC NERVE FUNCTION.
177406 02-03

MECHANISM OF RELEASE AT NORADRENERGIC NERVE TERMINALS BY RESERPINE AND SEVERAL SYMPATHOMIMETIC AGENTS. (UNPUBLISHED PAPER).
178747 02-03

EFFECTS OF AMPHETAMINE ISOMERS ON NEUROMUSCULAR TRANSMISSION IN RAT PHRENIC NERVE DIAPHRAGM PREPARATION.
182232 03-03

CALCIUM REVERSAL OF NERVE BLOCKADE BY ALCOHOLS, ANESTHETICS, TRANQUILIZERS, AND BARBITURATES.
187802 04-03

A NEW PROLONGED ACTING TYPE OF CHLORPROMAZINE: BEHAVIORAL EFFECTS AND PROLONGED ACTIONS ON NERVE MEMBRANES.
187805 04-01

FAILURE OF BETA-ADRENERGIC RECEPTOR BLOCKADE TO PREVENT ARRHYTHMIAS INDUCED BY SYMPATHETIC NERVE STIMULATION.
187923 04-03

NERVE CONDUCTION VELOCITY IN PATIENTS ON LONG-TERM DIPHENYLHYDANTOIN THERAPY.
189173 04-15

CHLOROFORM RESPONSES OF THE CHORDA TYMPANI NERVE IN THE RAT.
189219 04-03

THE NERVE IMPULSE BLOCKING ACTIONS OF TRANQUILIZERS AND THE BINDING OF NEUROLEPTICS TO SYNAPTOSOME MEMBRANES.
189400 04-03

DDT EFFECT ON 32P INCORPORATION FROM GAMMA-LABELLED ATP INTO PROTEINS FROM LOBSTER NERVE.
191315 04-03

AN EVALUATION OF SERUM DOPAMINE-BETA-HYDROXYLASE AS AN INDEX OF SYMPATHETIC NERVE ACTIVITY IN MAN.
191511 04-13

NERVES

EFFECT OF SUBSTITUTED TRYPTAMINES ON THE EFFLUX OF NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
168747 01-03

BIOCHEMICAL AND PHARMACOLOGICAL APPROACHES IN THE STUDY OF SYMPATHETIC NERVES. (UNPUBLISHED PAPER).
170082 01-03

UPTAKE, STORAGE AND RELEASE IN VIVO OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY SYMPATHETIC NERVES OF THE IRIS.
182204 02-03

MUSCLE ABNORMALITIES IN PSYCHOTIC PATIENTS: II. SERUM CPK ACTIVITY, FIBER ABNORMALITIES, AND BRANCHING AND SPROUTING OF SUBTERMINAL NERVES.
187114 03-09

ON THE MECHANISM OF RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVES INDUCED BY DEPOLARIZING AGENTS AND SYMPATHOMIMETIC DRUGS. (UNPUBLISHED PAPER).
187397 04-03

THE IMPULSE BLOCKING CONCENTRATIONS OF ANESTHETICS, ALCOHOLS, ANTICONVULSANTS, BARBITURATES, AND NARCOTICS ON PHRENIC AND SCIATIC NERVES.
187803 04-03

THE EFFECT OF 5,7 DIHYDROXYTRYPTAMINE ON PERIPHERAL ADRENERGIC NERVES IN THE MOUSE.
188977 04-03

NERVOUS

THE EFFECT OF LITHIUM AND OTHER ANTIDEPRESSANT MEDICATIONS ON THE AUTONOMIC NERVOUS SYSTEM.
169635 01-15

SELECTIVE ANTAGONISM OF CENTRAL NERVOUS SYSTEM DEPRESSANTS BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE.
171007 01-13

THE EFFECT OF PANAX GINSENG SAPONIN ON THE CENTRAL NERVOUS SYSTEM IN RAT: THE PSYCHOPHARMACOLOGICAL EFFECT OF GINSENG.
171599 01-04

DETERMINATION OF DRUG TRANSFER ACROSS BIOLOGICAL MEMBRANES: COMPARATIVE STUDY ON THE PASSAGE OF DRUGS INTO THE CENTRAL NERVOUS SYSTEM AND THEIR PLACENTAL TRANSFER AND FETAL LOCALIZATION IN THE PREGNANT RAT. (PH.D. DISSERTATION).
172018 01-03

THE SPIRAL AFTEREFFECT (SAE) AS A MEASURE OF MOTION SICKNESS SUSCEPTIBILITY AND THE EFFECT ON THE SAE OF AN ANTIMOTION SICKNESS DRUG AND A CENTRAL NERVOUS SYSTEM DEPRESSANT.
172780 01-03

EFFECT OF A NEW PSYCHOTROPIC DRUG, CS-370 (10-CHLORO-11B-(2-CHLOROPHENYL)-2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE) UPON THE CENTRAL NERVOUS SYSTEM.
174603 01-03

ANTIHYPERTENSIVE AND CENTRAL NERVOUS SYSTEM DEPRESSANT PROPERTIES OF 3-(GAMMA-P-FLUOROBENZOYLPROPYL) 2,3,4,4A,5,6 HEXAHYDROPYRAZINOQUINOLINE HYDROCHLORIDE (COMPOUND-69-183, CENTPYRAQUIN).
176881 02-03

CENTRAL NERVOUS SYSTEM AND AUTONOMIC NERVOUS SYSTEM EFFECTS OF AMANTADINE AND OF SOME STANDARD ANTIPARKINSON DRUGS.
177729 02-13

CENTRAL NERVOUS STIMULANT INDUCED PHYSIOLOGICAL AND PERFORMANCE CHANGES IN ADULTS DURING SUSTAINED PSYCHOMOTOR TRACKING.
179023 02-13

REGIONAL CYCLIC NUCLEOTIDES PHOSPHODIESTERASE ACTIVITY IN CAT CENTRAL NERVOUS SYSTEM: EFFECTS OF BENZODIAZEPINES.
181575 02-03

CENTRAL NERVOUS ACTION OF BROMAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.
181650 02-03

OXIDATIVE METABOLISM OF MESCALINE IN THE CENTRAL NERVOUS SYSTEM -- IV: IN VIVO METABOLISM OF MESCALINE AND 2,3,4 TRIMETHOXY-BETA-PHENYLETHYLAMINE.
181944 02-03

EFFECTS OF LICL ON THE CENTRAL NERVOUS SYSTEM.
182112 02-04

THE EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC) AND ETHANOL ON MONOSYNAPTIC AND POLYSYNAPTIC TRANSMISSION IN THE CENTRAL NERVOUS SYSTEM.
182222 03-03

ELECTROPHYSIOLOGICAL STUDIES OF THE EFFECTS OF CDP-CHOLINE ON THE CENTRAL NERVOUS SYSTEM.
182547 03-03

CENTRAL NERVOUS ACTION OF FLURAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.
182549 03-03

TRANSSYNAPTIC INDUCTION OF CHOLINE ACETYLTRANSFERASE IN THE PREGANGLIONIC NEURON OF THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM.
182720 03-03

CENTRAL NERVOUS DEPRESSANT XV: SYNTHESIS AND PHARMACOLOGICAL SCREENING OF SOME TRIMETHOXYAZLACTONES.
182828 03-02

DRUGS ACTING ON THE CENTRAL NERVOUS SYSTEM.
182835 03-17

ROLE OF THE CENTRAL AUTONOMIC NERVOUS SYSTEM IN THE HYPOTENSION AND BRADYCARDIA INDUCED BY (-) DELTA9-TETRAHYDROCANNABINOL.
183795 03-03

THE EFFECTS OF CHLORDIAZEPOXIDE, AMPHETAMINE AND COCAINE ON BAR-PRESS BEHAVIOR IN NORMAL AND GENETICALLY NERVOUS DOGS.
187868 04-04

SYNTHESIS AND CENTRAL NERVOUS SYSTEM ACTIVITY OF 1,2,3,4-TETRAHYDRO-1-AMINO-4-PHENYLNAPHTHALENES.
189178 04-02

INTERACTION OF D-AMPHETAMINE WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY OF MICE.
189613 04-04

PSYCHOPHARMACOLOGIC FACILITATION OF OPERANT CONDITIONING OF GENETICALLY NERVOUS CATAHOULA AND POINTER DOGS.
190696 04-04

EFFECT OF ANESTHETIC AGENTS ON PERIPHERAL SYMPATHETIC NERVOUS SYSTEM FUNCTION AS MONITORED BY ARTERIAL PLASMA CATECHOLAMINE LEVELS. (UNPUBLISHED PAPER
191495 04-03

EFFECTS OF NEUROLEPTIC AGENT ON CENTRAL NERVOUS SYSTEM OF ALBINO RATS.
191613 04-03

EVIDENCE FOR CHOLINERGICALLY MEDIATED EFFECT OF METHYLPHENIDATE HYDROCHLORIDE IN THE CENTRAL NERVOUS SYSTEM.
191946 04-03

NETWORK

INTERNATIONAL REFERENCE CENTERS NETWORK FOR PSYCHOTROPIC DRUGS.
167706 01-17

NEURAL

INTERACTIVE EFFECTS OF CYCLOHEXIMIDE AND PUROMYCIN IN ALTERING BRAIN POLYRIBOSOMES AND NEURAL AND BEHAVIOURAL RESPONSES TO ELECTROSHOCK IN MICE.
175230 02-03

NEURAL AND CHEMICAL MECHANISMS OF FEMALE SEXUAL BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).
185705 03-04

RELATIONSHIP OF CATECHOLAMINE NEURAL SYSTEMS TO THE BEHAVIORAL ALTERATIONS PRODUCED BY 6-HYDROXYDOPAMINE ADMINISTRATION INTO BRAIN.
191518 04-03

NEUROBLASTOMA

EFFECTS OF ALUMINUM SALTS ON CULTURED NEUROBLASTOMA CELLS.
191313 04-03

NEUROCHEMICAL

INTERACTION OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A PURPORTED HASHISH AND LSD ANTAGONIST, WITH SEVERAL CENTRAL NEUROCHEMICAL SYSTEMS.
182217 03-04

TOLERANCE TO THE BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF HALOPERIDOL AND MORPHINE IN RATS CHRONICALLY TREATED WITH MORPHINE OR HALOPERIDOL.
184225 03-03

NEUROCHEMICAL ROLE OF ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AND GUANOSINE 3,5 CYCLIC MONOPHOSPHATE AND THEIR RELATION TO NEUROTRANSMITTERS; EFFECT OF TETRAHYDROCANNABINOLS. (PH.D. DISSERTATION).
185582 03-03

ON THE BEHAVIORAL AND NEUROCHEMICAL ACTIONS OF 6-HYDROXYDOPA AND 5,6 DIHYDROXYTRYPTAMINE IN RATS.
187380 04-03

CANNABINOIDS: NEUROCHEMICAL ASPECTS AFTER ORAL CHRONIC ADMINISTRATION TO RATS.
189599 04-03

NEUROCHEMICAL ANALYSIS OF AGGRESSIVE - DEFENSIVE BEHAVIOR ELICITED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS AND CENTRAL GRAY MATTER.
191784 04-02

NEUROCHEMISTRY

EFFECTS OF PERINATAL EXPOSURE TO METHYL MERCURY ON FUNCTIONAL BRAIN DEVELOPMENT AND NEUROCHEMISTRY.
189564 04-05

NEUROEXCITABILITY

CHANGES IN THE NEUROEXCITABILITY OF ALCOHOL DEPENDENT RATS UNDERGOING WITHDRAWAL AS MEASURED BY THE PENTYLENETETRAZOL SEIZURE THRESHOLD.
182348 03-03

NEUROGENIC

ALTERED NOREPINEPHRINE SYNTHESIS OF SPLANCHNIC VESSELS IN NEUROGENIC HYPERTENSION.
188198 04-03

NEUROHUMORAL

INFLUENCE ON ACUTE PRETREATMENT WITH DELTA9-TETRAHYDROCANNABINOL OF THE LD50 OF VARIOUS SUBSTANCES THAT ALTER NEUROHUMORAL TRANSMISSION.
188876 04-05

NEUROHYPOPHYSIS

THE ACTION OF NEMBUTAL ON THE ULTRA ARCHITECTONICS OF THE NEUROHYPOPHYSIS.
183520 03-01

NEUROLEPTIC

METIAPINE: THE EVALUATION OF THE ANTIPSYCHOTIC PROPERTIES OF A NEW NEUROLEPTIC. A PILOT STUDY.
167342 01-08

DROPERIDOL -- A PREFERRED NEUROLEPTIC IN NARCOANALYSIS.
169462 01-14

THE ACTIVITY OF SOME NEUROLEPTIC DRUGS AND AMPHETAMINE IN NORMAL AND ISOLATED RATS.
170126 01-04

IS THERE A RELATIONSHIP BETWEEN THE INVOLVEMENT OF EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS WITH THE CATALEPTIC ACTION OF NEUROLEPTIC AGENTS AND THEIR CLINICAL ANTIPSYCHOTIC EFFECT?
171305 01-03

THE EFFECT OF PIPRADROL IN MICE AND ITS ANTAGONISM BY NEUROLEPTIC DRUGS.
171607 01-04

DRINKING BEHAVIOUR AND BRAIN DOPAMINE: ANTAGONISTIC EFFECT OF TWO NEUROLEPTIC DRUGS (PIMOZIDE AND SPIRAMIDE) UPON AMPHETAMINE OR APOMORPHINE-INDUCED HYPODIPSIA.
174035 01-04

ONGOING INVESTIGATIONS OF CEREBRAL GLUTAMINE EXCRETION SCHIZOPHRENICS DURING TREATMENT WITH NEUROLEPTIC.
174101 01-08

PREDICTION OF NEUROLEPTIC EFFECTS OF CI-686 BASED ON QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY: DRUG PROFILES AND DOSE RESPONSE CURVES BASED ON COMPUTERIZED CEREBRAL BIOPOTENTIALS.
181958 02-13

FLUSPIRILENE, A LONG-ACTING INJECTABLE NEUROLEPTIC.
183199 03-11

CLINICAL EXPERIMENT WITH A LONG-ACTING NEUROLEPTIC: FLUSPIRILENE (R6218).
183200 03-15

ANTIPSYCHOTIC ACTION OF NEUROLEPTIC AGENTS AND THE FUNCTION OF BASAL GANGLIA (SURVEY OF LITERATURE).
183521 03-17

EFFECTS OF ANTIPARKINSONIAN DRUGS ON NEUROLEPTIC INDUCED EXTRAPYRAMIDAL SIGNS IN MONKEYS.
183610 03-03

SIDE-EFFECTS OF NEUROLEPTIC DRUGS.
183749 03-15

INFLUENCE OF METHAMPHETAMINE AND NEUROLEPTIC DRUGS ON TYROSINE HYDROXYLASE ACTIVITY.
184180 03-03

REGIONAL CHANGES IN MONOAMINE LEVELS AND IN THE RATE OF TYROSINE AND TRYPTOPHAN HYDROXYLATION IN 4 WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
185899 03-03

ON CATALEPSY AND CATATONIA AND THE PREDICTABILITY OF THE CATALEPSY TEST FOR NEUROLEPTIC ACTIVITY.
185958 03-04

THE ANTAGONISM OF AMPHETAMINE-INDUCED SYMPTOMATOLOGY BY A NEUROLEPTIC.
186744 03-14

NEUROLEPTIC ANTAGONISM OF CATECHOLAMINE INHIBITIONS IN RAT CEREBELLUM AND CAUDATE. (UNPUBLISHED PAPER).
187496 04-03

DOPAMINERGIC INHIBITION OF STRIATAL CHOLINERGIC NEURONS: SYNERGISTIC BLOCKING ACTION OF GAMMA-BUTYROLACTONE AND NEUROLEPTIC DRUGS.
189602 04-03

EFFECT OF PHENOTHIAZINE NEUROLEPTIC DRUGS AND TRICYCLIC ANTIDEPRESSANTS ON PHOSPHODIESTERASE ACTIVITY IN RAT CEREBRAL CORTEX.
190311 04-03

EFFECTS OF NEUROLEPTIC AGENT ON CENTRAL NERVOUS SYSTEM OF ALBINO RATS.
191613 04-03

THE PREDICTIVE VALUE OF THE ANTIAPOMORPHINE TEST IN DOGS FOR NEUROLEPTIC THERAPY IN MAN.
192421 04-04

INTERACTION BETWEEN NEUROLEPTIC THERAPY AND SOCIOTHERAPEUTIC APPROACH. AN INVESTIGATION WITH PENFLURIDOL AND HALOPERIDOL.
192431 04-08

NEUROLEPTICS

SPECIFIC ACTIVATION OF STRIATAL TYROSINE HYDROXYLASE (TH) BY NEUROLEPTICS. (UNPUBLISHED PAPER).
170755 01-03

THE USE OF TIMED RELEASE NEUROLEPTICS IN AMBULATORY PSYCHIATRIC PRACTICE.
172977 01-11

DOLICHOMEGACOLON INDUCED BY NEUROLEPTICS AMONG PSYCHIATRIC PATIENTS (MEMORANDUM COVERING 153 CASES).
176432 02-15

EXTRAPYRAMIDAL DISTURBANCES BROUGHT ON BY NEUROLEPTICS.
180070 02-15

PRELIMINARY STUDIES OF CARPIPRAMINE: A COMPOUND SIMILAR TO BOTH ANTIDEPRESSANTS AND NEUROLEPTICS.
180725 02-07

EFFECTS OF NEUROLEPTICS AND THYMOLEPTICS ON PHOSPHODIESTERASE ACTIVITY AND ON CYCLIC 3,5 AMP LEVELS IN RAT BRAIN.
181467 02-03

INTERACTION OF APOMORPHINE, NEUROLEPTICS AND STIMULANTS WITH ALPHA-METHYL-M-TYRAMINE, A FALSE DOPAMINERGIC TRANSMITTER.
181809 02-03

IMPORTANCE OF THE COOPERATION OF FAMILIES IN THE TREATMENT OF THE SICK: CONCERNING CHRONIC DELIRIUM TREATED WITH NEUROLEPTICS AND MELANCHOLY TREATED WITH ANTIDEPRESSANTS.
182899 03-17

A COMPARATIVE STUDY OF THE ANTIPSYCHOTIC ACTION OF SOME NEUROLEPTICS BASED ON THE MODEL OF LSD PSYCHOSES.
183682 03-03

A CASE OF TARDIVE DYSKINESIA APPEARING PRECOCIOUSLY UNDER NEUROLEPTICS.
184961 03-17

PHARMACOLOGY OF NEUROLEPTICS UPON REPEATED ADMINISTRATION.
186368 03-04

ENHANCEMENT OF METHYLPHENIDATE INDUCED STEREOTYPIES BY REPEATED ADMINISTRATION OF NEUROLEPTICS.
186369 03-04

THE NERVE IMPULSE BLOCKING ACTIONS OF TRANQUILIZERS AND THE BINDING OF NEUROLEPTICS TO SYNAPTOSOME MEMBRANES.
189400 04-03

THE DOPAMINE RELEASING ACTIONS OF NEUROLEPTICS AND ETHANOL.
189401 04-03

INFLUENCE OF NEUROLEPTICS AND BENZODIAZEPINES ON METABOLISM OF TRICYCLIC ANTIDEPRESSANTS IN MAN.
191026 04-09

PSYCHOTROPIC EFFECT OF ANALGESICS AND NEUROLEPTICS ON A MODEL OF INVESTIGATORY BEHAVIOR CHANGED BY PAIN.
191120 04-04

CORRELATION BETWEEN THE TRANQUILIZING AND SEDATIVE ACTION OF NEUROLEPTICS, ANTIDEPRESSANTS AND ANTICHOLINERGIC DRUGS.
191783 04-02

DIFFERENTIAL INCREASE OF BEHAVIORAL AND EXTRAPYRAMIDAL STIMULATING ACTIONS OF NEUROLEPTICS BY ALPHA-METHYLTYROSINE PRETREATMENT IN RATS.
192016 04-04

NEUROLEPTOANALGESIA

SOME ASPECTS OF RESPIRATORY CONTROL IN NEUROLEPTOANALGESIA.
172835 01-03

NEUROLOGICAL

RESPONSE TO STIMULANT DRUG TREATMENT IN HYPERACTIVE CHILDREN: PREDICTION FROM EEG AND NEUROLOGICAL FINDINGS.
177778 02-11

AN ELECTROENCEPHALOGRAPHIC STUDY ON THE TOLERANCE OF THE VARIOUS PSYCHIATRIC AND NEUROLOGICAL PATIENTS TO THE HYPNOTIC EFFECTS OF DIPHENHYDRAMINE -- MEASURED BY THE AMOUNTS OF SLEEP EEG AS AN INDICATOR.
182550 03-11

NEUROLOGICAL CONSEQUENCES OF PSYCHOTROPIC DRUG WITHDRAWAL IN SCHIZOPHRENIC CHILDREN.
183275 03-08

NEUROLOGICAL CHANGES IN CATS FOLLOWING LONG-TERM DIET OF MERCURY CONTAMINATED TUNA.
186476 03-05

NEUROMUSCULAR

THE ROLE OF CYCLIC 3,5 ADENOSINE MONOPHOSPHATE IN NEUROMUSCULAR TRANSMISSION.
170660 01-13

THE CURARIZED RAT AND HEART RATE CONDITIONING: A CONSIDERATION OF RESPIRATION PARAMETERS AND NEUROMUSCULAR BLOCKING AGENTS IN A CLASSICAL CONDITIONING PARADIGM. (PH.D. DISSERTATION).
173133 01-03

EFFECTS OF AMPHETAMINE ISOMERS ON NEUROMUSCULAR TRANSMISSION IN RAT PHRENIC NERVE DIAPHRAGM PREPARATION.
182232 03-03

NEURON

TURNOVER CHANGES IN CENTRAL MONOAMINE NEURON SYSTEMS AFTER MINOR TRANQUILLIZERS AND BARBITURATES.
171604 01-03

TRANSSYNAPTIC INDUCTION OF CHOLINE ACETYLTRANSFERASE IN THE PREGANGLIONIC NEURON OF THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM.
182720 03-03

DOPAMINE-BETA-HYDROXYLASE AND THE REGULATION OF THE NORADRENERGIC NEURON.
191509 04-03

NEURONAL

EFFECTS OF CHLORPROMAZINE, CHLORDIAZEPOXIDE AND PENTOBARBITAL ON NEURONAL EXCITABILITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
177837 02-04

EFFECTS OF NEUROPHARMACOLOGICAL AGENTS ON HYPOTHALAMIC NEURONAL ACTIVITY: A MICROELECTROPHORETIC STUDY.
182123 02-03

ANALYSIS OF DRUG BLOCK OF LSD/5-HT/GABA BY MONITORING NEURONAL MEMBRANE CHANGES.
182143 02-03

IN VIVO INHIBITION OF NEURONAL UPTAKE OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY COCAINE AND BY DESMETHYLIMIPRAMINE (DMI).
182150 02-03

RELATIVE IMPORTANCE OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS FOR THE STIMULATION OF LOCOMOTOR ACTIVITY INDUCED BY AMPHETAMINE AND OTHER DRUGS.
182209 02-04

THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. I. NEURONAL RESPONSES TO STIMULATION OF THE RETICULAR FORMATION.
189855 04-03

THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. II. COMPARISON OF THE NEURONAL RESPONSES TO RETICULAR AND OTHER STIMULI.
189856 04-03

NEURONE

NEURONE BLOCKING ACTIONS OF ANTIPSYCHOTIC DRUGS.
182127 02-03

NEURONES

INVOLVEMENT OF ALPHA-RECEPTORS IN CLONIDINE INDUCED INHIBITION OF TRANSMITTER RELEASE FROM CENTRAL MONOAMINE NEURONES.
182345 03-03

EFFECTS OF SOME METALLIC CATIONS ON CEREBRAL CORTICAL NEURONES AND THEIR INTERACTIONS WITH BIOGENIC AMINES.
187806 04-03

THE EFFECTS OF MORPHINE, ETORPHINE AND SINOMENINE ON THE CHEMICAL SENSITIVITY AND SYNAPTIC RESPONSES OF RENSHAW CELLS AND OTHER SPINAL NEURONES IN THE RAT.
188201 04-03

SELECTIVE RESERPINE RESISTANT ACCUMULATION OF CATECHOLAMINES IN CENTRAL DOPAMINE NEURONES AFTER DOPA ADMINISTRATION.
189026 04-03

THE ACTION OF BETA-PHENYL-GABA DERIVATIVES ON NEURONES OF THE CAT CEREBRAL CORTEX.
189750 04-03

NEOMYCIN AND RUTHENIUM RED ANTAGONISM OF MONOAMINERGIC DEPRESSION OF CEREBRAL CORTICAL NEURONES.
191380 04-03

ESTIMATION OF THE CONTRIBUTION OF PERIPHERAL AND CENTRAL NORADRENERGIC NEURONES TO URINARY 3-METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT.
192335 04-03

NEURONS

EFFECT OF TETRAHYDROCANNABINOLS ON CENTRAL MONOAMINE NEURONS.
171605 01-03

INCREASED AXOPLASMIC TRANSPORT OF H3-DOPAMINE IN NIGRO-NEOSTRIATAL NEURONS AFTER RESERPINE.
175241 02-03

LYSERGIC ACID DIETHYLAMIDE AND SEROTONIN: A COMPARISON OF EFFECTS ON SEROTONERGIC NEURONS AND NEURONS RECEIVING A SEROTONERGIC INPUT.
177407 02-12

EFFECTS OF PROLONGED LSD-25 ADMINISTRATION UPON NEURONS OF SPINAL CORD GANGLIA TISSUE CULTURES.
185112 03-03

SPECIFICITY OF BLOCKADE OF THE NICOTINE INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ADRENERGIC NEURONS OF THE GUINEA-PIG HEART BY VARIOUS PHARMACOLOGICAL AGENTS.
186676 03-03

ABSENCE OF DEGENERATION OF ADRENERGIC NEURONS AFTER PROLONGED TREATMENT WITH DEBRISOQUIN.
186677 03-03

HYDROCORTISONE INDUCED INCREASE IN THE HISTOCHEMICALLY DEMONSTRABLE CATECHOLAMINE CONTENT OF SYMPATHETIC NEURONS OF THE NEWBORN RAT.
189027 04-03

VOLTAGE CLAMP ANALYSIS OF PENTYLENETETRAZOL EFFECTS ON APLYSIA NEURONS.
189032 04-03

PHENOLS: EFFECTS ON MEMBRANE PERMEABILITY OF MOLLUSCAN NEURONS.
189033 04-03

DOPAMINERGIC INHIBITION OF STRIATAL CHOLINERGIC NEURONS: SYNERGISTIC BLOCKING ACTION OF GAMMA-BUTYROLACTONE AND NEUROLEPTIC DRUGS.
189602 04-03

EFFECTS OF ALTERATIONS IN IMPULSE FLOW ON TRANSMITTER METABOLISM IN CENTRAL DOPAMINERGIC NEURONS.
191519 04-03

THE EFFECTS ON INGESTIVE BEHAVIORS OF DAMAGE TO CENTRAL DOPAMINE CONTAINING NEURONS.
191520 04-04

NORADRENERGIC NEURONS: EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON SINGLE UNIT ACTIVITY.
191931 04-03

EFFECTS OF LSD, MESCALINE, AND PSILOCYBIN ON SYMPATHETIC PREGANGLIONIC NEURONS.
191937 04-03

NEUROTOXIC EFFECTS OF P-CHLOROAMPHETAMINE (P-CA) ON PERIKARYA OF RAPHE NEURONS.
191947 04-05

NORADRENERGIC REGULATION OF BRAIN SEROTONERGIC NEURONS: EVIDENCE FROM SINGLE UNIT STUDIES WITH CLONIDINE.
191948 04-03

EFFECTS OF AMPHETAMINES ON MOLLUSCAN NEURONS.
191995 04-03

NEUROPATHIES

CLINICAL AND ELECTROMYOGRAPHIC RESEARCH CONCERNING TREATMENT OF PERIPHERAL NEUROPATHIES WITH NIVALASI.
168975 01-13

NEUROPHARMACOLOGIC

INTERACTION OF CYCLIC AMP WITH NEUROPHARMACOLOGIC DEPRESSANT AGENTS.
182155 02-03

NEUROPHARMACOLOGICAL

NEUROPHARMACOLOGICAL ANALYSIS OF EFFECTS OF DOXEPIN IN RABBITS (PH.D. DISSERTATION).
168130 01-03

NEUROPHARMACOLOGICAL STUDIES OF MOOD DISORDERS.
178114 02-09

EFFECTS OF NEUROPHARMACOLOGICAL AGENTS ON HYPOTHALAMIC NEURONAL ACTIVITY: A MICROELECTROPHORETIC STUDY.
182123 02-03

NEUROPHARMACOLOGICAL ANALYSIS OF R(-)-2,5 DIMETHOXY-4-METHYLAMPHETAMINE (R-DOM).
191906 04-03

NEUROPHARMACOLOGICAL ANALYSIS OF CENTRAL ADRENERGIC AND CHOLINERGIC ANTAGONISM OF DELTA9-TETRAHYDROCANNABINOL.
191992 04-03

NEUROPHARMACOLOGY

NEUROPHARMACOLOGY OF PSYCHOPHARMACOLOGICAL AGENTS.
181397 02-04

THE NEUROPHARMACOLOGY OF AGGRESSION: A CRITICAL REVIEW.
183615 03-14

NEUROPHYSIOLOGICAL

OPERANT BEHAVIOR AND NEUROPHYSIOLOGICAL OBSERVATIONS OF NORMAL HUMAN VOLUNTEERS RECEIVING CL-1848C, A NEW DISSOCIATIVE ANESTHETIC.
167334 01-07

EFFECTS OF MOLINDONE ON CNS STRUCTURES: NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATIONS.
172749 01-03

LONG-TERM CLINICAL AND QUANTITATIVE EEG EFFECTS OF CLOPENTHIXOL IN SCHIZOPHRENICS: CLINICAL NEUROPHYSIOLOGICAL CORRELATIONS.
174131 01-08

EFFECTS OF LORAZEPAM ON CNS STRUCTURES: NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATIONS.
177749 02-03

NEUROPHYSIOLOGICAL RESEARCH IN PSYCHIATRY AND ITS RELATIONSHIP TO PSYCHOPHARMACOLOGY.
183693 03-17

NEUROPSYCHIATRIC

A CLINICAL STUDY OF L-TETRAHYDROPALMATINE (C-200) IN A NEUROPSYCHIATRIC CLINIC.
182902 03-09

NEUROPSYCHOPHARMACOLOGICAL

NEUROPSYCHOPHARMACOLOGICAL STUDIES OF ATTENTION.
181402 02-04

NEUROSES

A DOUBLE-BLIND CONTROLLED STUDY OF LOXAPINE SUCCINATE IN THE TREATMENT OF ANXIETY NEUROSES.
190196 04-09

NEUROSIS

A MULTICENTER INVESTIGATION OF LORAZEPAM IN ANXIETY NEUROSIS.
167346 01-10

CHLORDIAZEPOXIDE IN DEPRESSIVE NEUROSIS: AN OPEN LABEL CROSSOVER STUDY WITH AMITRIPTYLINE.
168316 01-10

A DOUBLE-BLIND CLINICAL TRIAL OF DOXEPIN HYDROCHLORIDE AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION IN THE FIELD OF INTERNAL MEDICINE.
171282 01-11

TRIOXAZINE IN THE TREATMENT OF NEUROSIS.
175967 02-10

EXPERIENCE IN THE USE OF SINEQUAN (DOXEPIN HYDROCHLORIDE) IN TREATMENT OF NEUROSIS, DEPRESSION AND DEPRESSIVE STATES.
176471 02-11

DOUBLE-BLIND CROSSOVER COMPARISON OF BROMAZEPAM AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION.
182624 03-11

ANXIETY NEUROSIS IN GENERAL PRACTICE.
182767 03-10

A MULTICENTRE CLINICAL TRIAL OF OXYPERTINE IN ANXIETY NEUROSIS.
182769 03-10

AN OBSESSIVE NEUROSIS FOLLOWING MORNING-GLORY SEED INGESTION TREATED BY AVERSION RELIEF.
184259 03-15

TREATMENT OF ANXIETY NEUROSIS BY ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKING AGENTS.
186780 03-10

NEUROTIC

DRUGS AND GROUP PSYCHOTHERAPY IN NEUROTIC DEPRESSION.
171925 01-10

USE OF LORAZEPAM IN TREATING PATIENTS WITH NEUROTIC AND SOMATIZED PSYCHOVEGETATIVE SYMPTOMS.
174136 01-09

ELECTROCLINICAL ASPECT OF INSIDON TREATMENT IN PATIENTS WITH NEUROTIC SYMPTOMS.
174777 01-10

DOXEPIN AND AMITRIPTYLINE CHLORDIAZEPOXIDE COMBINATION IN NEUROTIC STATES: A COMPARATIVE DOUBLE-BLIND STUDY.
180048 02-10

THE USE OF LOW DOSES OF MONOCHLORIMIPRAMINE IN THE THERAPY OF NEUROTIC DEPRESSIVE SYNDROMES.
182789 03-10

ARE NEUROTIC PATIENTS IN PSYCHOTROPIC DRUG TRIALS REPRESENTATIVE? A COMPARISON OF STUDY AND NON-STUDY PATIENTS IN FOUR FAMILY PRACTICES.
188144 04-10

THIORIDAZINE IN NEUROTIC, ANXIOUS, AND DEPRESSED PATIENTS.
192227 04-10

NEUROTICS

IMIPRAMINE, DIAZEPAM AND GROUP PSYCHOTHERAPY IN LONG-TERM TREATMENT OF DEPRESSIVE NEUROTICS.
169089 01-10

A CLINICAL EVALUATION OF A NEW ANXIOLYTIC DRUG (THIENODIAZEPINE DERIVATIVE Y-6047) IN NEUROTICS AND PSYCHOSOMATIC DISORDERS -- A PRELIMINARY REPORT.
181771 02-07

SIMULTANEOUS MESORIDAZINE AND PSYCHODRAMA IN NEUROTICS.
183362 03-10

THE EFFECTS OF HOE-36801 ON CATECHOLAMINE EXCRETION, HEART RATE AND PSYCHOMOTOR PERFORMANCE IN NEUROTICS AND NORMALS.
192428 04-13

THE EFFECTS OF HOE-36801 ON MUSCLE ACTIVITY AND BLOOD PRESSURE, ON ATTENTION AND CONCENTRATION, ON TIME JUDGMENT AND SUBJECTIVE RESPONSES IN NEUROTICS AND NORMALS.
192429 04-14

NEUROTOXIC

PROTECTION PRODUCED BY BENZODIAZEPINES (BDP) AGAINST THE NEUROTOXIC AND CONFLICT BEHAVIOR EFFECTS OF HEXACHLOROPHENE (HCP) IN CATS.
176863 02-04

NEUROTOXIC EFFECTS OF P-CHLOROAMPHETAMINE (P-CA) ON PERIKARYA OF RAPHE NEURONS.
191947 04-05

NEUROTOXICOLOGIC
NEUROTOXICOLOGIC STUDIES OF TWO CARBAMATE PESTICIDES IN SUBACUTE ANIMAL EXPERIMENTS.
188874 04-05

NEUROTRANSMITTER
THE BIOSYNTHESIS OF THE CO-NEUROTRANSMITTER OCTOPAMINE IN COMPARISON WITH THE NEUROTRANSMITTER NORADRENALINE.
181468 02-03

NEUROTRANSMITTERS
POTENTIAL NEUROTRANSMITTERS AND RECEPTOR MECHANISMS INVOLVED IN THE CENTRAL CONTROL OF BODY TEMPERATURE IN HAMSTERS. (PH.D. DISSERTATION).
174962 01-03

NEUROCHEMICAL ROLE OF ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AND GUANOSINE 3,5 CYCLIC MONOPHOSPHATE AND THEIR RELATION TO NEUROTRANSMITTERS; EFFECT OF TETRAHYDROCANNABINOLS. (PH.D. DISSERTATION).
185582 03-03

EFFECTS OF CHRONIC NICOTINE ADMINISTRATION AND AGE ON VARIOUS NEUROTRANSMITTERS AND ASSOCIATED ENZYMES IN MALE FISCHER 344 RATS.
189597 04-03

LITHIUM AND THE MONOAMINE NEUROTRANSMITTERS IN THE RAT HIPPOCAMPUS.
190829 04-03

DRUGS, NEUROTRANSMITTERS, AND SCHIZOPHRENIA.
191290 04-08

DIAZEPAM, CYCLIC NUCLEOTIDES AND AMINO ACID NEUROTRANSMITTERS IN RAT CEREBELLUM. (UNPUBLISHED PAPER).
191764 04-03

NEUROTROPIC
THE INFLUENCE OF NEUROTROPIC DRUGS ON MONOAMINE OXIDASE (MAO) AND 5-OXYTRYPTOPHANE DECARBOXYLASE (5-OTD) ACTIVITY IN THE BRAIN.
183142 03-13

NEW
OPERANT BEHAVIOR AND NEUROPHYSIOLOGICAL OBSERVATIONS OF NORMAL HUMAN VOLUNTEERS RECEIVING CL-1848C, A NEW DISSOCIATIVE ANESTHETIC.
167334 01-07

METIAPINE: THE EVALUATION OF THE ANTIPSYCHOTIC PROPERTIES OF A NEW NEUROLEPTIC. A PILOT STUDY.
167342 01-08

CLINICAL EXPERIMENTATION WITH A NEW BENZODIAZEPINE IN THE MANAGEMENT OF PHOBIC AND OBSESSIVE SYMPTOMS.
167594 01-10

IN THE SEARCH FOR NEW TRANQUILIZING DRUGS.
167813 01-04

CLOMIPRAMINE HCL -- A DOUBLE-BLIND STUDY OF A NEW ANTIDEPRESSANT DRUG.
168318 01-09

PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT (SECOND REPORT): GENERAL PHARMACOLOGY AND SUBACUTE TOXICITY.
168499 01-07

INTRODUCTORY REMARKS: NEW AGENTS IN PSYCHIATRY.
168800 01-17

CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG, TRAZODONE: A REVIEW OF LITERATURE.
168803 01-11

LORAZEPAM: CLINICAL TRIAL WITH A NEW BENZODIAZEPINE.
169297 01-07

A NEW AGENT FOR CHEMOTHERAPY OF MIGRAINE HEADACHES: A CONTROLLED STUDY.
169298 01-11

THE PHARMACOLOGICAL EVALUATION IN LABORATORY ANIMALS OF KABI-1702 -- A NEW SEDATIVE HYPNOTIC DRUG.
171632 01-03

SCHIZOPHRENIA MANAGEMENT -- THE DAWN OF A NEW ERA.
172435 01-08

ON THE ANTIANXIETY PROPERTIES OF A NEW BENZODIAZEPINE, ORF-8063.
172485 01-10

BEHAVIOR AND SENSITIVITY TO EXPERIMENTAL HYPERTENSION: II. LACK OF CORRELATION BETWEEN CERTAIN BEHAVIOR PATTERNS AND HYPERTENSION IN TWO NEW STRAINS OF RATS.
173256 01-04

BEHAVIORAL EFFECTS OF A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR (FUSARIC ACID) IN MAN. (UNPUBLISHED PAPER
174329 01-09

DIURETIC ACTIVITY OF A NEW NARCOTIC ANTAGONIST IN MAN (BRISTOL-COMPOUND-2605). (UNPUBLISHED PAPER).
174473 01-13

EFFECT OF A NEW PSYCHOTROPIC DRUG, CS-370 (10-CHLORO-11B-(2-CHLOROPHENYL)-2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE) UPON THE CENTRAL NERVOUS SYSTEM.
174603 01-03

EFFICACY AND RESIDUAL EFFECT EVALUATION OF A NEW HYPNOTIC, TRIAZOLAM.
176108 02-13

CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, ZISEPRON, IN TREATMENT OF PSYCHIATRIC DISEASES IN COMPARISON WITH THIORIDAZINE.
176467 02-08

EXPERIENCE IN THE APPLICATION OF A NEW DRUG, DP-181 (OXYPERTINE), IN TREATMENT OF SCHIZOPHRENIA.
176468 02-08

CLINICAL EXPERIENCES WITH A NEW PSYCHOTROPIC DRUG, R-6238 (PIMOZIDE).
176564 02-11

NEW HORIZONS IN PSYCHOPHARMACOLOGY.
176926 02-17

SAFETY EVALUATION OF PENFLURIDOL, A NEW LONG-ACTING ORAL ANTIPSYCHOTIC AGENT.
177319 02-07

CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, DOXEPIN HYDROCHLORIDE, IN THE TREATMENT OF DEPRESSIVE STATES.
177569 02-11

TRIAZOLAM: A SLEEP LABORATORY STUDY OF A NEW BENZODIAZEPINE HYPNOTIC.
177747 02-07

NEW APPROACHES TO CONSCIOUSNESS.
178064 02-12

A NEW MODIFICATION FOR STUDYING 5-HT UPTAKE BY BLOOD PLATELETS: A RE-EVALUATION OF TRICYCLIC ANTIDEPRESSANTS AS UPTAKE INHIBITORS.
180055 02-06

WY-4036 (LORAZEPAM) -- A NEW TRANQUILIZER.
180146 02-10

FIRST RESULTS OBTAINED WITH A NEW ANTICONVULSANT OF THE BENZODIAZEPINE SERIES (CLONAZEPAM).
180672 02-11

STUDY WITH RADIOTRACERS OF THE DISTRIBUTION OF A NEW PSYCHOTROPE IN MICE: L-2-PYRROLIDONE-5-CARBOXYLATE DIMETHYLAMINOETHANOL. I. COMPARISON WITH L-GLUTAMIC AND L-2-PYRROLIDONE-5-CARBOXYLIC ACID.
180723 02-03

BEHAVIORAL PHARMACOLOGY OF BROMAZEPAM (RO-5-3350), A NEW BENZODIAZEPINE DERIVATIVE.
181384 02-04

CENTRAL NERVOUS ACTION OF BROMAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.
181650 02-03

A CLINICAL EVALUATION OF A NEW ANXIOLYTIC DRUG (THIENODIAZEPINE DERIVATIVE Y-6047) IN NEUROTICS AND PSYCHOSOMATIC DISORDERS -- A PRELIMINARY REPORT.
181771 02-07

CENTRAL NERVOUS ACTION OF FLURAZEPAM, A NEW BENZODIAZEPINE DERIVATIVE.
182549 03-03

ISOLATION OF A POSSIBLE NEW METABOLITE OF THIORIDAZINE AND MESORIDAZINE FROM HUMAN PLASMA.
182722 03-13

CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG: FK-880 (SULPIRIDE), ITS EFFECT ON PATIENTS WITH PSYCHOSOMATIC DISEASES AND PSYCHONEUROSIS.
182731 03-10

EXPERIMENTS IN ORAL AND INJECTABLE FORMS OF A NEW ANTIDEPRESSANT (DOXEPIN) ON FORTY PATIENTS.
182900 03-11

CONTROL OF INSOMNIA WITH A NEW BENZODIAZEPINE: THE FLUNITRAZEPAM OR RO-5-4200 (FIRST INVESTIGATIONS OF PHASE I AND CONTROLLED INVESTIGATIONS OF PHASE II).
183198 03-11

THE ABSORPTION AND DISTRIBUTION OF THE NEW ANTIDEPRESSANT AZAPHEN IN THE ORGANS.
183519 03-03

ALKALOID STUDIES. 9. PREPARATION OF 18-ACYLYOHIMBAN-17-ONES AND THEIR CONVERSION TO NEW HETEROCYCLIC YOHIMBANS.
185033 03-04

A NEW RECORDING APPARATUS FOR MEASUREMENT OF LOCOMOTOR ACTIVITY OF MICE. EXPERIMENTAL OBSERVATIONS ON ITS USE.
186377 03-06

PYRAZAPON (CI-683): A NEW ANTIANXIETY AGENT.
186581 03-04

THE ANTAGONISM OF HIPPOCAMPAL AND CORTICAL AFTERDISCHARGE BY SC-13504, A NEW ANTICONVULSANT.
186632 03-03

A NEW PROLONGED ACTING TYPE OF CHLORPROMAZINE: BEHAVIORAL EFFECTS AND PROLONGED ACTIONS ON NERVE MEMBRANES.
187805 04-01

THE EFFECT OF A NEW BENZODIAZEPINE DERIVATIVE NIMETAZEPAM ON THE SLEEP CYCLE IN MAN.
188501 04-07
NEW LONG LATENCY BULBOSPINAL EVOKED POTENTIALS BLOCKED BY SEROTONIN ANTAGONISTS.
188751 04-03
CLINICAL EXPERIENCES WITH A NEW ANTIDEPRESSANT, MAPROTILINE.
188893 04-09
STUDIES OF EN-1639A (NALTREXONE): A NEW NARCOTIC ANTAGONIST.
189059 04-07
INVESTIGATION OF PHYSICAL DEPENDENCE ON A NEW BENZODIAZEPINE DERIVATIVE, BROMAZEPAM.
189209 04-05
THE METHOHEXITAL METHYLPHENIDATE INTERVIEW: A PROPOSED NEW DRUG COMBINATION FOR NARCOTHERAPY.
190242 04-07
THE FUTURE OF PHARMACOTHERAPY: NEW DRUG DELIVERY SYSTEMS.
191044 04-08
METHODOLOGY FOR THE EVALUATION OF PENTAZOCINE, PROTOTYPE OF THE NEW MORPHINE AGONIST ANTAGONIST ANALGESICS.
191603 04-16
COMPARATIVE METABOLISM OF TRIAZOLAM, A NEW SEDATIVE HYPNOTIC, IN RAT, DOG AND MAN.
191900 04-02

NEW-YORK
COMPARATIVE SURVEY OF PSYCHIATRISTS TREATMENT PREFERENCES: CALIFORNIA AND NEW-YORK.
185877 03-08

NEWBORN
SIMULTANEOUS MASS FRAGMENTOGRAPHIC ASSAY OF NOREPINEPHRINE (NE), EPINEPHRINE (E) AND DOPAMINE (DA) IN RAT SYMPATHETIC GANGLION: EFFECTS OF DEXAMETHASONE IN NEWBORN AND ADULT RATS. (UNPUBLISHED PAPER).
170747 01-03
DIAZEPAM IN LABOUR: ITS METABOLISM AND EFFECT ON THE CLINICAL CONDITION AND THERMOGENESIS OF THE NEWBORN.
171731 01-13
ADRENALINE, NORADRENALINE AND DOPAMINE LEVELS IN BRAIN AND HEART AFTER ADMINISTRATION OF 6-HYDROXYDOPAMINE AND GUANETHIDINE TO NEWBORN MICE.
177338 02-03
THE DEVELOPMENT OF A BLOOD-BRAIN BARRIER TO METHADONE IN THE NEWBORN RAT.
182165 02-03
THE EFFECT OF PAIN RELIEVING DRUGS ADMINISTERED DURING LABOR AND DELIVERY ON THE BEHAVIOR OF THE NEWBORN: A REVIEW.
183706 03-17
CHLORPROMAZINE CAUSING EXTRAPYRAMIDAL DYSFUNCTION IN NEWBORN INFANT OF PSYCHOTIC MOTHER.
187787 04-15
HYDROCORTISONE INDUCED INCREASE IN THE HISTOCHEMICALLY DEMONSTRABLE CATECHOLAMINE CONTENT OF SYMPATHETIC NEURONS OF THE NEWBORN RAT.
189027 04-03

NH2OH
STUDIES ON MONOAMINE OXIDASE -- REPORT 22: EFFECTS OF NANO2 AND NH2OH ON MITOCHONDRIAL MAO IN RAT BRAIN.
177022 02-03

NIALAMIDE
EFFECTS OF P-CHLOROPHENYLALANINE (PCPA) AND NIALAMIDE ON 5-HYDROXYTRYPTAMINE (5-HT) IN THE TRANSECTED SPINAL CORD.
171623 01-03
THE EFFECTS OF CHRONIC RESERPINE AND NIALAMIDE TREATMENT ON THE FREE AMINO ACID LEVELS OF RAT BRAIN.
187645 04-03

NICOTINAMIDE
SUBSTITUTED PIPERAZINOQUINAZOLONES: RELATIONSHIP BETWEEN SELECTIVE INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND ANTICONVULSANT ACTIVITY.
183598 03-02
SUBSTITUTED BENZOXAZOLE/BENZTHIAZOLE-2-THIONES: INTERRELATIONSHIP BETWEEN ANTICONVULSANT ACTIVITY AND INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND MONOAMINE OXIDASE.
183601 03-03

NICOTINE
ALTERATION OF 5-HYDROXYTRYPTAMINE-14C EFFLUX BY NICOTINE IN RAT BRAIN AREA SLICES.
172925 01-03
ACQUISITION AND PERFORMANCE OF AN ATTENTION TASK BY RATS SUBJECTED TO CHRONIC NICOTINE TREATMENT.
176864 02-04
INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CAFFEINE, (C), NICOTINE (N), PHENOBARBITAL (P): EFFECTS ON CONDITIONED AVOIDANCE (CAR).
182192 02-04
SPECIFICITY OF BLOCKADE OF THE NICOTINE INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ADRENERGIC NEURONS OF THE GUINEA-PIG HEART BY VARIOUS PHARMACOLOGICAL AGENTS.
186676 03-03
COMPARISON OF PHARMACOLOGICAL RESPONSES TO NICOTINE AND RELEASE OF CATECHOLAMINES FROM THE ADRENALS IN DOGS AND MONKEYS.
188199 04-03
EFFECTS OF CHRONIC NICOTINE ADMINISTRATION AND AGE ON VARIOUS NEUROTRANSMITTERS AND ASSOCIATED ENZYMES IN MALE FISCHER 344 RATS.
189597 04-03
EFFECTS OF NICOTINE AND ITS WITHDRAWAL ON THE PERFORMANCE OF RATS ON SIGNALLED AND UNSIGNALLED AVOIDANCE SCHEDULES.
190331 04-04
EFFECTS OF NICOTINE ON THE OBSERVED BEHAVIOUR OF RATS DURING SIGNALLED AND UNSIGNALLED AVOIDANCE EXPERIMENTS.
190332 04-04
EFFECTS OF NICOTINE ON THE SHUTTLEBOX BEHAVIOR OF TRAINED GUINEA-PIGS.
190333 04-04
EFFECTS OF CNS AGENTS ON NICOTINE EXTENSOR CONVULSIONS AND LETHALITY IN MICE AND THEIR SEDATIVE ANTIANXIETY EFFECTS IN MAN.
191907 04-14

NICOTINE-LIKE
THE EFFECTS OF VARIOUS NICOTINE-LIKE AGENTS IN THE CAT SUPERIOR CERVICAL GANGLION IN SITU.
184202 03-03

NICOTINIC
POTENTIATION OF THERAPEUTIC EFFECTS OF NICOTINIC ACID BY PYRIDOXINE IN CHRONIC SCHIZOPHRENICS.
168313 01-08
NICOTINIC ACID INDUCED SYSTEMIC LUPUS-ERYTHEMATOSUS.
180243 02-15
NICOTINIC ACID AND CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN SCHIZOPHRENIA.
183360 03-13
A ROLE FOR NICOTINIC RECEPTORS IN THE REGULATION OF THE ADENYLATE CYCLASE OF ADRENAL MEDULLA.
186675 03-03

NIGHT
EFFECTS OF L-DOPA ON NATURAL NIGHT SLEEP AND ON REBOUND OF REM SLEEP.
167921 01-14
A PROGRAMME WHICH LED TO REDUCTION IN NIGHT SEDATION IN A MAJOR HOSPITAL.
170802 01-17

NIGHTTIME
THE ORAL HYPNOTIC BIOASSAY OF HYDROXYZINE AND PENTOBARBITAL FOR NIGHTTIME SEDATION.
177320 02-11

NIGRO-NEOSTRIATAL
INCREASED AXOPLASMIC TRANSPORT OF H3-DOPAMINE IN NIGRO-NEOSTRIATAL NEURONS AFTER RESERPINE.
175241 02-03

NIMETAZEPAM
THE EFFECT OF A NEW BENZODIAZEPINE DERIVATIVE NIMETAZEPAM ON THE SLEEP CYCLE IN MAN.
188501 04-07

NIMH
NIMH SPONSORED CHEMICAL SYNTHESIS PROGRAM.
182444 03-01

NITRAZEPAM
ACUTE NITRAZEPAM (MOGADON) POISONING: AN ELECTROENCEPHALOGRAPHIC STUDY.
180148 02-15
ACUTE POISONING BY NITRAZEPAM (MOGADON).
183786 03-15
THE EFFECT OF CAFFEINE, NITRAZEPAM AND CIGARETTE SMOKING ON THE CONTINGENT NEGATIVE VARIATION IN MAN.
187350 04-13
PERSISTENT ELECTROENCEPHALOGRAPHIC CHANGES IN RHESUS MONKEYS AFTER SINGLE DOSES OF PENTOBARBITAL, NITRAZEPAM AND IMIPRAMINE.
187931 04-03
THE PROBLEMS OF THE CLINICAL USAGE OF NITRAZEPAM: SUPPRESSIVE EFFECTS ON THE PHARYNGEAL REFLEX AND THE COMA, USING OTHER TRANQUILIZERS AT THE SAME TIME.
188450 04-15

NITRITE
MECHANISMS UNDERLYING POTENTIATION OF BARBITURATE ACTION BY SODIUM NITRITE IN THE MOUSE: THE ROLE OF METHEMOGLOBIN INDUCED HYPOXIA.
182721 03-03

NITRO
METABOLISM OF CHLORPHENTERMINE AND PHENTERMINE IN MAN TO YIELD HYDROXYLAMINO, C-NITROSO AND NITRO COMPOUNDS.
183796 03-13

NITROGEN
ADAPTATION TO NITROGEN NARCOSIS MANIFESTED BY TIMING BEHAVIOR IN THE RAT.
186630 03-04

NIVALASI
CLINICAL AND ELECTROMYOGRAPHIC RESEARCH CONCERNING TREATMENT OF PERIPHERAL NEUROPATHIES WITH NIVALASI.
168975 01-13

NOBRIUM
PRELIMINARY EXPERIENCES WITH NOBRIUM IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
170414 01-11

NOCICEPTIVE
ENHANCEMENT OF NOCICEPTIVE REACTIONS BY NALOXONE IN MICE AND RATS.
189517 04-05

NOMIFENSINE
EFFECTS OF NOMIFENSINE (HOE-984), D-AMPHETAMINE AND APOMORPHINE ON MOTOR ACTIVITY, CATECHOLAMINE TURNOVER AND CAMP CONCENTRATIONS IN RAT BRAIN. (UNPUBLISHED PAPER).
191766 04-03

NON-HYDROGEN-BONDING
EFFECTS OF NON-HYDROGEN-BONDING ANESTHETICS ON MEMORY IN THE CHICK.
184380 03-04

NON-PENETRATION
TRUE AND APPARENT NON-PENETRATION OF THE BLOOD-BRAIN BARRIER BY PSYCHOTROPIC DRUGS.
192423 04-03

NON-SPECIFICITY
NON-SPECIFICITY OF 5-HYDROXYTRYPTOPHAN IN REPLETING BRAIN SEROTONIN IN RATS WITH MFB LESIONS.
182725 03-03

NON-STUDY
ARE NEUROTIC PATIENTS IN PSYCHOTROPIC DRUG TRIALS REPRESENTATIVE? A COMPARISON OF STUDY AND NON-STUDY PATIENTS IN FOUR FAMILY PRACTICES.
188144 04-10

NON-WESTERN
THE PROBLEM OF ANXIETY IN A NON-WESTERN SOCIETY: A COMBINED CHEMOTHERAPEUTIC AND PSYCHOTHERAPEUTIC APPROACH.
171162 01-10

NONCHOLINERGIC
NONCHOLINERGIC MECHANISM OF ACTION OF CHOLINERGIC DRUGS ON SQUID AXON MEMBRANES.
186672 03-03

NONCONTINGENT
DRUG ENHANCED SENSORY CONTINGENT BAR PRESSING: COMPARING THE EFFECT OF CONTINGENT AND NONCONTINGENT SENSORY CHANGE.
168837 01-04

NONFEEDING
BRAIN MECHANISMS UNDERLYING THE EFFECTS OF AMPHETAMINE ON FEEDING AND NONFEEDING BEHAVIORS: DISSOCIATION AND OVERLAP.
184839 03-03

NONIMMUNE
THE EFFECT OF LOWERED BODY TEMPERATURE ON LIFESPAN AND IMMUNE AND NONIMMUNE PROCESSES.
169675 01-03

NONPSYCHOTIC
COMPARISON OF THIORIDAZINE AND DIAZEPAM IN THE CONTROL OF NONPSYCHOTIC SYMPTOMS ASSOCIATED WITH SENILITY: DOUBLE-BLIND STUDY.
170129 01-11

NONSEDATING
NONSEDATING DOSAGES OF DIAZEPAM AND PHENOBARBITAL IN THE REDUCTION OF NEONATAL BILIRUBIN LEVELS.
191607 04-17

NONSPECIFIC
INTRACEREBRAL INJECTION OF 6-HYDROXYDOPAMINE AND HYDROGEN PEROXIDE IN CATS: SPECIFIC AND NONSPECIFIC EFFECTS ON STRIATAL BIOGENIC AMINES.
188426 04-03

A CASE OF A NONSPECIFIC MENTAL ILLNESS WITH PSYCHOMOTOR VARIANT.
188517 04-09

SUPPRESSION OF SEIZURES BY TAURINE -- SPECIFIC OR NONSPECIFIC?
189843 04-03

NONSPONTANEOUS
NONSPONTANEOUS CONVULSIONS IN MICE ELICITED BY SOME CATECHOLAMINE RELEASERS AND 6,7 DIHYDROXYTETRAHYDROISOQUINOLINE (TIQ).
192013 04-05

NONTOLERANT
THE EFFECTS OF D- AND L-AMPHETAMINE ON FIXED-INTERVAL AND FIXED-RATIO BEHAVIOR IN TOLERANT AND NONTOLERANT RATS.
168438 01-04

NONVERBAL
EFFECTS OF PSYCHOACTIVE DRUGS ON NONVERBAL COMMUNICATION AND GROUP SOCIAL BEHAVIOR OF MONKEYS.
175317 02-04

NOOTROPIC
THE NOOTROPIC APPROACH TO THE PHARMACOLOGY OF THE INTEGRATIVE ACTIVITY OF THE BRAIN.
173495 01-02

NORADRENALINE
THREO-3,4 DIHYDROXYPHENYLSERINE, A POOR SOURCE OF NORADRENALINE IN THE RAT.
167445 01-03

EFFECT OF SUBSTITUTED TRYPTAMINES ON THE EFFLUX OF NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
168747 01-03

THE EFFECT OF PROTRIPTYLINE ON THE METABOLISM OF LABELLED DOPAMINE AND NORADRENALINE IN THE RAT BRAIN.
171627 01-03

A SENSITIVE GAS CHROMATOGRAPHIC PROCEDURE FOR THE ESTIMATION OF NORADRENALINE, DOPAMINE AND 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
171971 01-01

THE EFFECTS OF AMPHETAMINE, 2-AMINOINDANE AND 2-AMINOTETRALIN ON THE CONCENTRATIONS OF WHOLE BRAIN NORADRENALINE, DOPAMINE, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC ACID IN THE MOUSE.
174828 01-03

ADRENALINE, NORADRENALINE AND DOPAMINE LEVELS IN BRAIN AND HEART AFTER ADMINISTRATION OF 6-HYDROXYDOPAMINE AND GUANETHIDINE TO NEWBORN MICE.
177338 02-03

THE BIOSYNTHESIS OF THE CO-NEUROTRANSMITTER OCTOPAMINE IN COMPARISON WITH THE NEUROTRANSMITTER NORADRENALINE.
181468 02-03

UPTAKE AND RELEASE OF NORADRENALINE IN RAT CEREBRAL CORTEX IN VITRO: NO EFFECT OF BENZODIAZEPINES AND BARBITURATES.
182347 03-03

AMANTADINE MAY STIMULATE DOPAMINE AND NORADRENALINE RECEPTORS.
183868 03-03

FORMATION OF NORADRENALINE IN THE RAT BRAIN FROM THE FOUR STEREOISOMERS OF 3,4 DIHYDROXYPHENYLSERINE.
184229 03-03

THE EFFECTS OF ACUTE ADMINISTRATION OF PROPRANOLOL AND PRACTOLOL ON THE UPTAKE, CONTENT, RELEASE AND TURNOVER OF NORADRENALINE IN THE RAT HEART IN VIVO.
184232 03-03

COMPARISON OF TRICYCLIC ANTIDEPRESSANTS IN RABBITS: ANTINOCICEPTION AND POTENTIATION OF THE NORADRENALINE PRESSOR RESPONSES.
186579 03-03

EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: II. EFFECT ON DOPAMINE AND NORADRENALINE CONCENTRATIONS AND TURNOVERS.
186588 03-04

INFLUENCE OF MORPHINE AND NALOXONE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189568 04-03

INFLUENCE OF FENTANYL, LEVORPHANOL AND PETHIDINE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189569 04-03

5-HYDROXYTRYPTAMINE AND NORADRENALINE IN THE HIPPOCAMPAL REGION: EFFECT OF TRANSECTION OF AFFERENT PATHWAYS ON ENDOGENOUS LEVELS, HIGH AFFINITY UPTAKE AND SOME TRANSMITTER RELATED ENZYMES.
191319 04-03

NORADRENALINE IN THE GUINEA-PIG ALIMENTARY CANAL: REGIONAL DISTRIBUTION AND SENSITIVITY TO DENERVATION AND RESERPINE.
191326 04-03

EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF CLOZAPINE ON THE METABOLISM OF DOPAMINE AND NORADRENALINE IN THE BRAIN OF THE RAT.
191418 04-03

INFLUENCE OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTS OF ELECTRICAL STIMULATION AND MICROINJECTION OF ACETYLCHOLINE, SEROTONIN AND NORADRENALINE INTO THE MESENCEPHALON.
191786 04-02

NORADRENERGIC
SELF-STIMULATION OF NORADRENERGIC CELL GROUP (A6) IN LOCUS-COERULEUS OF RATS.
173029 01-03

PHARMACOLOGICAL SUPPRESSION OF EATING BEHAVIOR IN RELATION TO DIENCEPHALIC NORADRENERGIC RECEPTORS.
174763 01-04

EFFECTS OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES ON CENTRAL NORADRENERGIC MECHANISMS. (PH.D. DISSERTATION).
174959 01-03

POSSIBLE INVOLVEMENT OF A NORADRENERGIC AREA OF THE AMYGDALA WITH STEREOTYPED BEHAVIOUR.
176877 02-04

MECHANISM OF RELEASE AT NORADRENERGIC NERVE TERMINALS BY RESERPINE AND SEVERAL SYMPATHOMIMETIC AGENTS. (UNPUBLISHED PAPER).
178747 02-03

DETERMINANTS OF THE NORADRENERGIC SATIETY EFFECT: ENVIRONMENTAL DARKNESS VS. THE FEEDING PATTERN.
182133 02-04

RELATIVE IMPORTANCE OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS FOR THE STIMULATION OF LOCOMOTOR ACTIVITY INDUCED BY AMPHETAMINE AND OTHER DRUGS.
182209 02-04

EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: I. EFFECT ON THE BEHAVIOURAL CHANGES INDUCED BY RESERPINE, ALPHA-METHYL-P-TYROSINE OR AMPHETAMINE.
186587 03-04

EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: II. EFFECT ON DOPAMINE AND NORADRENALINE CONCENTRATIONS AND TURNOVERS.
186588 03-04

EVIDENCE FOR A NORADRENERGIC AND DOPAMINERGIC MECHANISM IN THE HYPERACTIVITY PRODUCED BY 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.
190309 04-04

DOPAMINE-BETA-HYDROXYLASE AND THE REGULATION OF THE NORADRENERGIC NEURON.
191509 04-03

POST-MORTEM MEASUREMENT OF ENZYMES IN HUMAN BRAIN: EVIDENCE OF A CENTRAL NORADRENERGIC DEFICIT IN SCHIZOPHRENIA.
191529 04-13

NORADRENERGIC NEURONS: EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON SINGLE UNIT ACTIVITY.
191931 04-03

NORADRENERGIC REGULATION OF BRAIN SEROTONERGIC NEURONS: EVIDENCE FROM SINGLE UNIT STUDIES WITH CLONIDINE.
191948 04-03

ESTIMATION OF THE CONTRIBUTION OF PERIPHERAL AND CENTRAL NORADRENERGIC NEURONES TO URINARY 3-METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT.
192335 04-03

NORAPOMORPHINE

PHARMACOKINETIC DISPOSITION OF NORAPOMORPHINE DERIVATIVES AND ITS INFLUENCE ON THE ELICITATION OF STEREOTYPICAL GNAWING. (PH.D. DISSERTATION).
174960 01-03

DISPOSITION OF NORAPOMORPHINE AND N,N PROPYLNORAPOMORPHINE IN MOUSE BRAIN AND ITS CORRELATION WITH STEREOTYPED GNAWING BEHAVIOR.
182131 02-04

NOREPINEPHRINE

A COLLABORATIVE ASSESSMENT OF NOREPINEPHRINE METABOLISM IN AFFECTIVE DISORDERS.
169094 01-09

SELECTIVE INHIBITION OF NOREPINEPHRINE SYNTHESIS IN MANIC-DEPRESSIVE PATIENTS WITH A DOPAMINE-BETA-HYDROXYLASE INHIBITOR. (UNPUBLISHED PAPER).
170083 01-03

SIMULTANEOUS MASS FRAGMENTOGRAPHIC ASSAY OF NOREPINEPHRINE (NE), EPINEPHRINE (E) AND DOPAMINE (DA) IN RAT SYMPATHETIC GANGLION: EFFECTS OF DEXAMETHASONE IN NEWBORN AND ADULT RATS. (UNPUBLISHED PAPER).
170747 01-03

NOREPINEPHRINE SENSITIVE ADENYLATE CYCLASES IN RAT BRAIN: RELATION TO BEHAVIOR AND TYROSINE HYDROXYLASE.
177252 02-03

EXCRETION OF NOREPINEPHRINE AND DOPAMINE ALCOHOLIC METABOLITES AFTER 6-HYDROXYDOPAMINE.
179986 02-03

COMPARISON OF THE CHRONIC AND ACUTE EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) TREATMENT ON RAT BRAIN SEROTONIN AND NOREPINEPHRINE.
181945 02-03

BEHAVIORAL EFFECTS OF SIMULTANEOUS DEPLETION OF BRAIN NOREPINEPHRINE AND SEROTONIN.
182211 03-04

EFFECT OF 2-ARYLALANINES, 2-ARYLSERINES, TETRAPHENYLBORON AND 1,2 DL(2,4 DICHLOROPHENYL) ETHANOLAMINE ON LEVELS OF SEROTONIN (5-HT), NOREPINEPHRINE (NE) AND DOPAMINE (DM) IN WHOLE BRAIN OF MICE.
182254 03-03

PHARMACOLOGICAL ANALYSIS OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE REMOVAL FROM THE PULMONARY CIRCULATION: DIFFERENTIATION OF UPTAKE SITES FOR EACH AMINE.
182717 03-03

THE INFLUENCE OF CHRONIC ADMINISTRATION OF LITHIUM CARBONATE ON THE BRAIN NOREPINEPHRINE CONTENT IN RATS.
182872 03-03

NOREPINEPHRINE -- AN ANTAGONIST OF DIBUTYRYL CYCLIC AMP IN THE REGULATION OF NARCOSIS IN THE RAT.
183789 03-03

A COMPARISON OF PSYCHOTOMIMETIC DRUG EFFECTS ON RAT BRAIN NOREPINEPHRINE METABOLISM.
183891 03-03

EFFECTS OF METHAMPHETAMINE ON DAILY RHYTHMS OF HYPOTHALAMIC NOREPINEPHRINE, SEROTONIN AND PLASMA CORTICOSTERONE LEVELS IN THE RAT.
184178 03-03

TESTS OF EMOTIONAL BEHAVIOR IN RATS FOLLOWING DEPLETION OF NOREPINEPHRINE, OF SEROTONIN, OR OF BOTH.
185753 03-04

ON THE MECHANISM OF RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVES INDUCED BY DEPOLARIZING AGENTS AND SYMPATHOMIMETIC DRUGS. (UNPUBLISHED PAPER).
187397 04-03

ALTERED NOREPINEPHRINE SYNTHESIS OF SPLANCHNIC VESSELS IN NEUROGENIC HYPERTENSION.
188198 04-03

CONTROL OF NOREPINEPHRINE SYNTHESIS IN BLOOD VESSELS AND THE EFFECTS OF MONOAMINE OXIDASE INHIBITION.
189390 04-03

ROLE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN IN INTRACRANIAL REWARD.
191527 04-04

BALANCE BETWEEN ACETYLCHOLINE, SEROTONIN, NOREPINEPHRINE, AND DOPAMINE IN SELF-STIMULATION.
191528 04-04

PHARMACOLOGICAL ALTERATIONS IN THE STIMULUS INDUCED RELEASE OF NOREPINEPHRINE FROM THE RABBIT SUPERIOR CERVICAL GANGLION.
191896 04-03

THE EFFECTS OF AMPHETAMINE SULFATE ON THE DIURNAL RHYTHMS OF MIDBRAIN; CORTEX, NOREPINEPHRINE; SEROTONIN AND BLOOD GLUCOSE LEVELS IN THE MOUSE.
191918 04-03

INCREASED BRAIN NOREPINEPHRINE TURNOVER IN LEAD EXPOSED HYPERACTIVE RATS.
191957 04-05

EFFECT OF CHRONIC TREATMENT WITH DESIPRAMINE (DMI) AND IPRINDOLE (IP) ON THE NOREPINEPHRINE (NE) SENSITIVE ADENYLATE CYCLASE SYSTEM IN SLICES OF THE RAT LIMBIC FOREBRAIN.
192003 04-03

NORFENFLURAMINE

CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE METABOLITE, NORFENFLURAMINE: AN EVALUATION OF ITS ROLE IN THE ACTIONS OF FENFLURAMINE.
190335 04-04

NORITREN

CLINICAL EXPERIENCES WITH AN ANTIDEPRESSIVE DRUG, NORITREN (NORTRIPTYLINE).
176565 02-09

NORMAL

OPERANT BEHAVIOR AND NEUROPHYSIOLOGICAL OBSERVATIONS OF NORMAL HUMAN VOLUNTEERS RECEIVING CL-1848C, A NEW DISSOCIATIVE ANESTHETIC.
167334 01-07

LOW DOSAGE HALOPERIDOL AND INDUCED ANXIETY IN NORMAL VOLUNTEERS.
169745 01-14

AVERAGE EVOKED RESPONSES IN NORMAL AND MINIMALLY BRAIN DYSFUNCTIONED CHILDREN TREATED WITH AMPHETAMINE: A PRELIMINARY REPORT.
169861 01-11

THE ACTIVITY OF SOME NEUROLEPTIC DRUGS AND AMPHETAMINE IN NORMAL AND ISOLATED RATS.
170126 01-04

DRUGS AND PLACEBOS: DRUG GUESSING BY NORMAL VOLUNTEERS.
174210 01-14

EFFECT OF ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL ON MEMORY, SPEECH, AND PERCEPTION OF THERMAL STIMULATION: RESULTS WITH FOUR NORMAL HUMAN VOLUNTEER SUBJECTS. PRELIMINARY REPORT.
177674 02-14

EFFECT OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) ON THE DAYTIME SLEEP-WAKEFULNESS PATTERNS IN NORMAL AND P-CHLOROPHENYLALANINE INSOMNIAC CATS.
181658 02-02

MANIFEST ANXIETY AND ANTIANXIETY DRUG EFFECTS IN NORMAL VOLUNTEERS.
182118 02-14

REGIONAL AND SUBCELLULAR DISTRIBUTION OF CHOLINE ACETYLTRANSFERASE IN THE BRAIN OF NORMAL AND MORPHINE TREATED RATS.
182224 03-03

A SMALL CONTROLLED STUDY TO DETERMINE THE TIME OF ONSET OF ACTION OF OXYPERTINE AFTER ORAL ADMINISTRATION IN NORMAL SUBJECTS.
182763 03-14

PSYCHOLOGICAL EXPERIMENTATION ON THE EFFECTS OF PROPIRAM FUMARATE AND PROMETHAZINE UNDER NORMAL AND STRESS CONDITIONS.
184617 03-07

THE EFFECTS OF CHLORDIAZEPOXIDE, AMPHETAMINE AND COCAINE ON BAR-PRESS BEHAVIOR IN NORMAL AND GENETICALLY NERVOUS DOGS.
187868 04-04

NORMALS

THE EFFECTS OF HOE-36801 ON CATECHOLAMINE EXCRETION, HEART RATE AND PSYCHOMOTOR PERFORMANCE IN NEUROTICS AND NORMALS.
192428 04-13

THE EFFECTS OF HOE-36801 ON MUSCLE ACTIVITY AND BLOOD PRESSURE, ON ATTENTION AND CONCENTRATION, ON TIME JUDGMENT AND SUBJECTIVE RESPONSES IN NEUROTICS AND NORMALS.
192429 04-14

NORTRIPTYLINE

ON THE FIRST-PASS EFFECT IN THE LIVER OF NORTRIPTYLINE, LIDOCAINE AND PROPRANOLOL.
171631 01-03

CLINICAL EXPERIENCES WITH AN ANTIDEPRESSIVE DRUG, NORITREN (NORTRIPTYLINE).
176565 02-09

SEQUENTIAL TRIAL COMPARING TWO PLASMA LEVELS OF NORTRIPTYLINE.
187582 04-10

LONG-TERM TREATMENT OF ENDOGENOUS DEPRESSION WITH NORTRIPTYLINE WITH CONTROL OF PLASMA LEVELS.
188832 04-09

METABOLIC INTERACTIONS BETWEEN NORTRIPTYLINE AND THIORIDAZINE IN RATS.
190346 04-03

PLASMA NORTRIPTYLINE LEVELS – RELATIONSHIP TO CLINICAL EFFECTS.
192873 04-09

NOVERIL

DOUBLE-BLIND COMPARATIVE STUDY OF HF-1972/NOVERIL IN DEPRESSION.
180986 02-10

CLINICAL STUDY OF ANTIDEPRESSANT AGENT, NOVERIL.
182551 03-10

DOUBLE-BLIND CLINICAL TRIAL OF NOVERIL AND OF NOVERIL-TR (NOVERIL 240MG).
183190 03-07

RATING OF PSYCHOLOGICAL EFFECTS INDUCED BY ORDINARY NOVERIL AND TIME-RELEASED NOVERIL.
190312 04-14

NOVERIL-TR

DOUBLE-BLIND CLINICAL TRIAL OF NOVERIL AND OF NOVERIL-TR (NOVERIL 240MG).
183190 03-07

NOZINAN-R

CLINICAL TRIAL WITH NOZINAN-R. AT SEVERAL MENTAL HOSPITALS IN JAVA.
176582 02-11

NUCLEAR

THE EFFECT OF CANNABINOIDS ON THE NUMBER OF NUCLEAR MEMBRANE ATTACHED RIBOSOMES IN INFANT RAT BRAIN.
183228 03-03

CONFORMATIONAL ANALYSIS OF ACRIDAN DERIVATIVES BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY. A RELATIONSHIP BETWEEN CONFORMATION AND PHARMACOLOGICAL ACTIVITY.
190715 04-01

NUCLEOTIDES

POSSIBLE INVOLVEMENT OF CYCLIC NUCLEOTIDES IN THE STIMULATION OF PITUITARY FUNCTION ELICITED BY RESERPINE. (UNPUBLISHED PAPER).
170086 01-03

REGIONAL CYCLIC NUCLEOTIDES PHOSPHODIESTERASE ACTIVITY IN CAT CENTRAL NERVOUS SYSTEM: EFFECTS OF BENZODIAZEPINES.
181575 02-03

DIAZEPAM, CYCLIC NUCLEOTIDES AND AMINO ACID NEUROTRANSMITTERS IN RAT CEREBELLUM. (UNPUBLISHED PAPER).
191764 04-03

NUCLEUS

PRESENCE OF OSMORECEPTORS FOR THIRST IN THE LATERAL PREOPTIC NUCLEUS.
168859 01-03

CAUDATE NUCLEUS EFFECTS ON GERIATRIC SENILITY: EFFECT OF BELLADONNA ON LEARNING AND MEMORY OF GERIATRIC PATIENTS.
170744 01-11

CYCLIC ADENOSINE MONOPHOSPHATE: SELECTIVE INCREASE IN CAUDATE NUCLEUS AFTER ADMINISTRATION OF L-DOPA.
176254 02-13

THE EFFECTS OF INTRAVENTRICULARLY ADMINISTERED CATECHOLAMINES AND SEROTONIN ON THE RESERPINE INDUCED SPIKE WAVES RECORDED FROM THE MEDICAL NUCLEUS TRAPEZOIDES IN THE RABBIT.
182094 02-03

THE ACTION OF D-AMPHETAMINE ON SPONTANEOUS ACTIVITY IN THE CAUDATE NUCLEUS AND RETICULAR FORMATION OF THE RAT.
185264 03-03

THE TRANSSYNAPTIC RELATIONSHIP BETWEEN DOPAMINE AND SEROTONIN IN THE CAUDATE NUCLEUS OF CATS.
186700 03-04

ALTERATION OF EVOKED POTENTIALS IN CAUDATE NUCLEUS OF FREELY MOVING RATS BY L-DOPA, RESERPINE, AND PENTOBARBITAL.
187362 04-03

PGO WAVES IN THE LATERAL GENICULATE NUCLEUS TRIGGERED BY BARBITURATE.
187835 04-03

THE EFFECT OF P-CHLOROPHENYLALANINE ON FOREBRAIN TRYPTOPHAN HYDROXYLASE IN RATS WITH LESIONS IN THE RAPHE NUCLEUS.
188750 04-03

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
191944 04-04

NURSING

REGIONAL CHANGES IN MONOAMINE LEVELS AND IN THE RATE OF TYROSINE AND TRYPTOPHAN HYDROXYLATION IN 4 WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
185899 03-03

NYSTAGMUS

IMPAIRMENT OF OPTOKINETIC NYSTAGMUS IN PATIENTS WITH TARDIVE DYSKINESIA.
189734 04-13

N1-2-HYDROXYETHYL

INFLUENCE OF N1-2-HYDROXYETHYL SUBSTITUTION ON CENTRAL ACTIVITY OF OXAZEPAM AND LORAZEPAM.
178756 02-04

O-METHYLATION

EXTRANEURONAL REMOVAL, ACCUMULATION AND O-METHYLATION OF ISOPRENALINE IN THE PERFUSED HEART.
189604 04-03

OBESITY

DOUBLE-BLIND CLINICAL EVALUATION OF MAZINDOL, DEXTROAMPHETAMINE, AND PLACEBO IN TREATMENT OF EXOGENOUS OBESITY.
167335 01-11

OBJECTIVE

THE STANDARDIZED VIDEOTAPE INTERVIEW AS AN OBJECTIVE DEPENDENT VARIABLE IN PSYCHOTROPIC DRUG RESEARCH.
183635 03-17

OBSERVATION

THE EFFECT OF CHLORPROMAZINE AND AMYTAL SODIUM ON THE CONFORMITY OF ADOLESCENTS UNDER PSYCHIATRIC OBSERVATION.
191776 04-14

OBSERVATIONS

OPERANT BEHAVIOR AND NEUROPHYSIOLOGICAL OBSERVATIONS OF NORMAL HUMAN VOLUNTEERS RECEIVING CL-1848C, A NEW DISSOCIATIVE ANESTHETIC.
167334 01-07

THE EFFECT OF MARIJUANA ON HOSTILITY IN AN EXPERIMENTAL GROUP SETTING: PRELIMINARY OBSERVATIONS.
169086 01-14

OBSERVATIONS ON THE THERAPEUTIC ACTIVITY OF CLOPENTHIXOL IN PSYCHIATRY.
175540 02-11

THE EFFECTS OF PHYSOSTIGMINE IN PHENOTHIAZINE RESISTANT CHRONIC SCHIZOPHRENIC PATIENTS: PRELIMINARY OBSERVATIONS.
177669 02-08

CLINICAL OBSERVATIONS ON THE USE OF PIMOZIDE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS.
183196 03-08

PROPHYLACTIC TREATMENT OF RECURRENT DEPRESSION: OBSERVATIONS FROM A MULTIHOSPITAL COLLABORATIVE STUDY.
186190 03-09

A NEW RECORDING APPARATUS FOR MEASUREMENT OF LOCOMOTOR ACTIVITY OF MICE. EXPERIMENTAL OBSERVATIONS ON ITS USE.
186377 03-06

COMPARATIVE PROPERTIES OF SOLUBLE AND PARTICULATE CATECHOL-O-METHYLTRANSFERASE FROM RAT RED BLOOD CELL: PRELIMINARY OBSERVATIONS.
191523 04-01

OBSERVED

STEREOTYPY WITH SELECTIVE STIMULATION OF CERTAIN ITEMS OF BEHAVIOUR OBSERVED IN AMPHETAMINE TREATED MONKEYS (CERCOPITHECUS).
180061 02-04

EFFECTS OF NICOTINE ON THE OBSERVED BEHAVIOUR OF RATS DURING SIGNALLED AND UNSIGNALLED AVOIDANCE EXPERIMENTS.
190332 04-04

OBSESSIVE
CLINICAL EXPERIMENTATION WITH A NEW BENZODIAZEPINE IN THE MANAGEMENT OF PHOBIC AND OBSESSIVE SYMPTOMS.
167594 01-10

PHENOMENOLOGICAL - EXISTENTIAL STUDY OF PHOBIC - OBSESSIVE SYNDROMES TREATED WITH CHLORIMIPRAMINE.
182788 03-09

AN OBSESSIVE NEUROSIS FOLLOWING MORNING-GLORY SEED INGESTION TREATED BY AVERSION RELIEF.
184259 03-15

OCTAHYDROBENZOCYCLOHEPTATHIAZINE
SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF OCTAHYDROBENZOCYCLOHEPTATHIAZINE DERIVATIVES.
180098 02-01

OCTOCLOTHEPIN
THE EFFECT OF OCTOCLOTHEPIN AND PERPHENAZINE ON BEHAVIOUR IN RATS WITH DIFFERENT EXPLORATION AND DEFECATION RATES.
192430 04-04

OCTOPAMINE
THE BIOSYNTHESIS OF THE CO-NEUROTRANSMITTER OCTOPAMINE IN COMPARISON WITH THE NEUROTRANSMITTER NORADRENALINE.
181468 02-03

OCULAR
THE OCULAR COMPLICATIONS BY MASSIVE DOSE OF PSYCHOTROPIC DRUGS.
182552 03-15

OFFENDERS
RELATIONSHIP BETWEEN RESPONSE TO LOW PENTAMETHYLENETETRAZOL ADMINISTRATION AND PERSONALITY OF JUVENILE OFFENDERS AND THEIR REPEATED CRIMES.
175072 02-17

OFFSPRING
EFFECT OF PRENATAL MATERNAL ADMINISTRATION OF D-AMPHETAMINE ON RAT OFFSPRING ACTIVITY AND PASSIVE AVOIDANCE LEARNING.
167415 01-03

EFFECT OF CHRONIC METHADONE ADMINISTRATION ON PREGNANT RATS AND THEIR OFFSPRING.
183894 03-03

CYTOGENETIC STUDIES IN THE OFFSPRING OF LSD USERS.
185083 03-12

REGIONAL CHANGES IN MONOAMINE LEVELS AND IN THE RATE OF TYROSINE AND TRYPTOPHAN HYDROXYLATION IN 4 WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
185899 03-03

EFFECT OF PREGESTATIONAL MORPHINE ADMINISTRATION TO MICE ON BEHAVIOR OF THEIR OFFSPRING.
191902 04-04

EFFECTS OF CHRONIC METHYLPHENIDATE ADMINISTRATION ON LEARNING AND OFFSPRING BEHAVIOR.
192116 04-04

OFFSPRINGS
THE SAFETY TEST OF 10-CHLORO-11B-(2-CHLOROPHENYL) 2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE (CS-370): SECOND REPORT, EFFECT OF CS-370 UPON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
168498 01-05

OLEATE
HYPERTHERMIC EFFECT OF PALMITATE SODIUM, STEARATE SODIUM AND OLEATE SODIUM INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS CATS.
186640 03-03

OLFACTORY
EFFECT OF PROCAINE, LIDOCAINE AND PENTOBARBITAL ON ELECTRICAL ACTIVITY OF GUINEA-PIG OLFACTORY CORTEX IN VITRO.
182092 02-03

EFFECTS OF PSYCHOTROPIC DRUGS ON DISCRIMINATION AVOIDANCE CONDITIONING IN RATS WITH OLFACTORY BULB ABLATIONS.
182115 02-04

ON-OFF
ON-OFF PHENOMENON WITH LEVODOPA THERAPY IN PARKINSONISM: CLINICAL AND PHARMACOLOGIC CORRELATIONS AND THE EFFECT OF INTRAMUSCULAR PYRIDOXINE.
188560 04-11

ONE-WAY
FAILURE OF ACTH TO INFLUENCE AVOIDANCE EXTINCTION IN A ONE-WAY AVOIDANCE SITUATION.
183470 03-04

TEMPORAL ASPECTS OF SCOPOLAMINE INDUCED ONE-WAY MEMORY DISSOCIATION IN MICE.
187701 04-04

INTERACTION AMONG GENOTYPE, UNCONDITIONED STIMULUS, D-AMPHETAMINE, AND ONE-WAY AVOIDANCE BEHAVIOR OF RATS.
187702 04-04

ONGOING
ONGOING INVESTIGATIONS OF CEREBRAL GLUTAMINE EXCRETION SCHIZOPHRENICS DURING TREATMENT WITH NEUROLEPTIC.
174101 01-08

ONTOGENESIS
ONTOGENESIS OF CIRCADIAN PITUITARY ADRENAL PERIODICITY IN RATS AFFECTED BY NEONATAL TREATMENT WITH ACTH.
181576 02-03

ONTOGENY
ONTOGENY OF SEROTONINERGIC INHIBITION OF BEHAVIORAL AROUSAL IN THE RAT.
174860 01-04

THE ONTOGENY OF AMPHETAMINE-INDUCED ALTERATIONS IN THERMAL REGULATION.
182246 03-03

OPEN
CHLORDIAZEPOXIDE IN DEPRESSIVE NEUROSIS: AN OPEN LABEL CROSSOVER STUDY WITH AMITRIPTYLINE.
168316 01-10

LITHIUM PROPHYLAXIS IN AFFECTIVE DISORDERS: AN OPEN TRIAL WITH MATCHED CONTROLS.
172401 01-09

OPEN-FIELD
EFFECTS OF ANTIDEPRESSANT AGENTS ON OPEN-FIELD BEHAVIOUR IN RATS.
174038 01-04

OPEN-FIELD BEHAVIOR AND ACQUISITION OF DISCRIMINATIVE RESPONSE CONTROL IN DELTA9-THC TOLERANT RATS.
178813 02-04

OPERANT
OPERANT BEHAVIOR AND NEUROPHYSIOLOGICAL OBSERVATIONS OF NORMAL HUMAN VOLUNTEERS RECEIVING CL-1848C, A NEW DISSOCIATIVE ANESTHETIC.
167334 01-07

INFLUENCE OF AMYLOBARBITONE ON OPERANT DEPRESSION AND ELATION EFFECTS IN THE RAT.
168834 01-04

IMPORTANCE OF CATECHOLAMINE RELEASE BY NERVE IMPULSES FOR FREE OPERANT BEHAVIOR.
171611 01-04

THE THALAMIC RAT: GENERAL BEHAVIOR, OPERANT LEARNING WITH REWARDING HYPOTHALAMIC STIMULATION, AND EFFECTS OF AMPHETAMINE.
177477 02-04

EFFECTS OF CNS STIMULANTS ON OPERANT BEHAVIOR.
182110 02-04

DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) DOSE EFFECTS COMPARED ON THREE SCHEDULES OF FOOD REINFORCED OPERANT PERFORMANCE.
182191 02-04

EFFECTS OF ORAL DELTA9-TETRAHYDROCANNABINOL ON OPERANT REINFORCEMENT SCHEDULE PERFORMANCE IN RATS.
186645 03-04

AMPHETAMINE AND OPERANT BEHAVIOR IN RATS: RELATIONSHIP BETWEEN DRUG EFFECT AND CONTROL RESPONSE RATE.
187699 04-04

EFFECTS OF CHLORDIAZEPOXIDE ON HEART RATE AND BEHAVIOURAL SUPPRESSION IN PIGS SUBJECTED TO OPERANT CONDITIONING PROCEDURES.
189409 04-04

CASE AGAINST THE USE OF D-TUBOCURARINE IN OPERANT STUDIES OF THE CARDIOVASCULAR SYSTEM.
189425 04-03

PSYCHOPHARMACOLOGIC FACILITATION OF OPERANT CONDITIONING OF GENETICALLY NERVOUS CATAHOULA AND POINTER DOGS.
190696 04-04

EFFECTS OF MORPHINE, PENTAZOCINE, AND NALOXONE ON OPERANT RESPONDING IN MONKEYS AND PIGEONS.
191972 04-04

OPIATE
ALPHA-L-ACETYLMETHADOL AND ITS N-DEMTHYLATED METABOLITES HAVE POTENT OPIATE ACTION IN THE GUINEA-PIG ISOLATED ILEUM.
187130 03-03

PHYLOGENETIC DISTRIBUTION OF OPIATE RECEPTOR BINDING.
190476 04-03

OPIOID
BEHAVIORAL EFFECTS OF MORPHINE AND OPIOID ANTAGONISTS.
182859 03-04

OPIPRAMOL
ACTION OF OPIPRAMOL (G-33040) IN DEPRESSIVE SYNDROMES IN CHILDREN AND ADOLESCENTS.
182432 03-10

OPTICAL
EFFECTS OF PSYCHOTOMIMETICS ON VASCULAR STRIPS: STUDIES OF METHOXYLATED AMPHETAMINES AND OPTICAL ISOMERS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE AND 2,5 DIMETHOXY-4-BROMOAMPHETAMINE.
177734 02-03

RELATIVE PHARMACOLOGICAL POTENCY IN MICE OF OPTICAL ISOMERS OF DELTA1oTETRAHYDROCANNABINOL.
181941 02-03
THE SITE OF ACTION ON THE OPTICAL ISOMERS OF 1-METHYL-5-PHENYL-5-PROPYL BARBITURIC ACID.
185901 03-03

OPTOKINETIC
IMPAIRMENT OF OPTOKINETIC NYSTAGMUS IN PATIENTS WITH TARDIVE DYSKINESIA.
189734 04-13

ORAL
BLOOD LEVEL PROFILE IN MAN FOLLOWING CHRONIC ORAL ADMINISTRATION OF FLURAZEPAM HYDROCHLORIDE.
169817 01-13
PHARMACOKINETIC PROFILE OF DIAZEPAM IN MAN FOLLOWING SINGLE INTRAVENOUS AND ORAL AND CHRONIC ORAL ADMINISTRATION.
170838 01-13
BARBITURATE DEPENDENCE IN MICE INDUCED BY A SIMPLE SHORT-TERM ORAL PROCEDURE.
175895 02-03
SUBACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MALE AND FEMALE RATS: ORAL ADMINISTRATION FOR ONE MONTH.
177097 02-05
SAFETY EVALUATION OF PENFLURIDOL, A NEW LONG-ACTING ORAL ANTIPSYCHOTIC AGENT.
177319 02-07
THE ORAL HYPNOTIC BIOASSAY OF HYDROXYZINE AND PENTOBARBITAL FOR NIGHTTIME SEDATION.
177320 02-11
EFFECT OF ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL ON MEMORY, SPEECH, AND PERCEPTION OF THERMAL STIMULATION: RESULTS WITH FOUR NORMAL HUMAN VOLUNTEER SUBJECTS. PRELIMINARY REPORT.
177674 02-14
PENTAZOCINE IN RHESUS MONKEY PLASMA AND BRAIN AFTER PARENTERAL AND ORAL ADMINISTRATION.
178641 02-03
ORAL 5-HTP IN PRIMARY AUTISM WITH 5-HT BINDING DEFECT.
181392 02-13
SUBSTANTIAL ORAL MORPHINE INTAKE BY THE RAT USING SCHEDULE INDUCED POLYDIPSIA.
182194 02-04
A SMALL CONTROLLED STUDY TO DETERMINE THE TIME OF ONSET OF ACTION OF OXYPERTINE AFTER ORAL ADMINISTRATION IN NORMAL SUBJECTS.
182763 03-14
EXPERIMENTS IN ORAL AND INJECTABLE FORMS OF A NEW ANTIDEPRESSANT (DOXEPIN) ON FORTY PATIENTS.
182900 03-11
THE EFFECT OF HYPOTHALAMIC STIMULATION ON ORAL INGESTION OF DIAZEPAM IN RATS.
184238 03-04
THE USE OF ORAL DROPERIDOL IN PSYCHIATRIC THERAPY.
184965 03-07
EFFECTS OF ORAL DELTA9-TETRAHYDROCANNABINOL ON OPERANT REINFORCEMENT SCHEDULE PERFORMANCE IN RATS.
186645 03-04
EFFECT OF ORAL ADMINISTRATION OF METHADONE ON HEPATIC MICROSOMAL MIXED FUNCTION OXIDASE ACTIVITY IN MICE.
188178 04-03
A DOUBLE-BLIND CROSSOVER SEQUENTIAL TRIAL OF ORAL THYROTROPIN RELEASING HORMONE IN DEPRESSION.
188348 04-09
ORAL AND INTRAVENOUS TOXICITY OF DELTA9-TETRAHYDROCANNABINOL IN RHESUS MONKEYS.
188872 04-05
PENFLURIDOL: AN EFFICACIOUS LONG-ACTING ORAL ANTIPSYCHOTIC COMPOUND.
189072 04-08
CRUDE MARIHUANA EXTRACT: EEG AND BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION IN RHESUS MONKEYS.
189516 04-04
INHALATION, PARENTERAL AND ORAL LD50 VALUES OF DELTA9-TETRAHYDROCANNABINOL IN FISCHER RATS.
189588 04-05
CANNABINOIDS: NEUROCHEMICAL ASPECTS AFTER ORAL CHRONIC ADMINISTRATION TO RATS.
189599 04-03
PHARMACOKINETICS AND DISTRIBUTION PROPERTIES OF PENTOBARBITAL IN HUMANS FOLLOWING ORAL AND INTRAVENOUS ADMINISTRATION.
191444 04-13
ALPHA-METHYL-P-TYROSINE INHIBITION OF SELF-ADMINISTERED INTRAVENOUS MORPHINE AND ORAL WATER IN RATS.
191940 04-04

ORALLY
THE EFFECT OF ORALLY ADMINISTERED COCAINE ON SLEEP OF DEPRESSED PATIENTS.
187642 04-14

ORBITAL
MOLECULAR ORBITAL STUDIES ON THE CONFORMATION OF HALLUCINOGENIC INDOLEALKYLAMINES AND RELATED COMPOUNDS. THE ISOLATED MOLECULES AND THE SOLVENT EFFECT.
183406 03-01

ORDINARY
RATING OF PSYCHOLOGICAL EFFECTS INDUCED BY ORDINARY NOVERIL AND TIME-RELEASED NOVERIL.
190312 04-14

ORF-8063
ON THE ANTIANXIETY PROPERTIES OF A NEW BENZODIAZEPINE, ORF-8063.
172485 01-10

ORGAN
STIMULATION OF SEROTONIN N-ACETYLTRANSFERASE IN PINEAL ORGAN CULTURE BY DRUGS.
177128 02-03

ORGANIC
TRAZODONE IN THE TREATMENT OF ORGANIC BRAIN SYNDROMES, WITH SPECIAL REFERENCE TO PSYCHOGERIATRICS.
168805 01-11
CHEMOTHERAPY IN CHRONIC ORGANIC BRAIN SYNDROME - A REVIEW OF THE LITERATURE.
169065 01-11
3-ONIUM DERIVATIVES OF 1,4 BENZODIAZEPIN-2-ONES WITH TERTIARY ORGANIC BASES.
187942 04-01

ORGANISM
INVESTIGATIONS ON THE FATE OF THE ANTICONVULSANT CLONAZEPAM IN THE ORGANISM OF MAN, RAT AND DOG.
179022 02-13

ORGANIZATION
STRUCTURAL FUNCTIONAL ORGANIZATION OF THE HUMAN BRAIN AND THE PATHOPHYSIOLOGY OF THE PARKINSONIAN TYPE HYPERKINESES.
178787 02-13
A NOTE ON EPISTEMIC ORGANIZATION AND HALLUCINOGENS.
190240 04-17

ORGANS
THE ABSORPTION AND DISTRIBUTION OF THE NEW ANTIDEPRESSANT AZAPHEN IN THE ORGANS.
183519 03-03

ORIENTED
MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN THE LIGHT OF PROGNOSIS ORIENTED DIAGNOSIS.
186081 03-08

ORIENTING
CHANGES IN ORIENTING AND HABITUATION IN THE RAT FOLLOWING ADMINISTRATION OF CHLORPROMAZINE.
191211 04-04

ORNITHINE-CARBAMYL-TRANSFERASE
INDICATIONS AND DOSAGE FOR MAXIMAL ACTIVITY OF ORNITHINE-CARBAMYL-TRANSFERASE IN THE PSYCHIATRIC ENVIRONMENT.
184955 03-17

ORTHOGONAL
ORTHOGONAL FACTORS VS. INTERDEPENDENT VARIABLES AS PREDICTORS OF DRUG TREATMENT RESPONSE IN ANXIOUS OUTPATIENTS.
171299 01-14

OSCILLATIONS
PLASMA DOPA AND FUNCTIONAL OSCILLATIONS AFTER CHRONIC TREATMENT OF PARKINSONS DISEASE.
188421 04-13

OSCILLATORY
OSCILLATORY POTENTIALS OF THE CAT RETINA: EFFECTS OF ADRENERGIC DRUGS.
172916 01-03

OSMORECEPTORS
PRESENCE OF OSMORECEPTORS FOR THIRST IN THE LATERAL PREOPTIC NUCLEUS.
168859 01-03

OUABAIN
COMPARATIVE EFFECTS OF 6-HYDROXYDOPAMINE AND OF RESERPINE ON OUABAIN TOXICITY IN THE RAT.
172598 01-05
INTERACTION OF CENTRALLY ADMINISTERED OUABAIN WITH AGENTS AFFECTING SYMPATHETIC FUNCTION.
178640 02-03
(3H) OUABAIN BINDING TO NA_+-ATPASE AND K_+-ATPASE: INHIBITION BY BETA, GAMMA METHYLENE ATP.
182184 02-03
OUABAIN RECEPTOR INTERACTIONS IN (NA_+ - K_+) ATPASE PREPARATIONS.
189567 04-03

OUTCOME
PLASMA BINDING OF IMIPRAMINE AND CLINICAL OUTCOME.
172271 01-13
FACTORS AFFECTING OUTCOME IN A SCHOOL MENTAL HEALTH SERVICE.
188567 04-11

OUTPATIENT
DRUG THERAPY AND MARITAL THERAPY IN OUTPATIENT DEPRESSIVES.
169068 01-09
A DOUBLE-BLIND COMPARISON OF FLUPHENAZINE AND HALOPERIDOL IN OUTPATIENT SCHIZOPHRENIC CHILDREN.
177754 02-08
CLINICAL DATA AND SOCIOPSYCHIATRIC IMPLICATIONS OF OUTPATIENT TREATMENT WITH LONG-TERM PHENOTHIAZINES.
182791 03-09
OUTPATIENT TREATMENT OF HYPERACTIVE SCHOOL CHILDREN WITH IMIPRAMINE.
184174 03-11
ON THE CLINICAL EFFECT OF FLUPHENAZINE ENANTHATE IN OUTPATIENT SCHIZOPHRENICS.
185213 03-08
LABORATORY STUDIES FOR EVERY MEDICATED OUTPATIENT: ARE THEY REALLY NECESSARY?.
189075 04-13
DRUG MAINTENANCE IN THE OUTPATIENT TREATMENT OF CHRONIC ALCOHOLISM.
189926 04-11

OUTPATIENTS
THE USE OF N-DEMETHYLDIAZEPAM IN OUTPATIENTS SUFFERING FROM INSOMNIA.
167340 01-11
ORTHOGONAL FACTORS VS. INTERDEPENDENT VARIABLES AS PREDICTORS OF DRUG TREATMENT RESPONSE IN ANXIOUS OUTPATIENTS.
171299 01-14
AMITRIPTYLINE IN ANXIOUS DEPRESSED OUTPATIENTS: A CONTROLLED STUDY.
172993 01-10
EXPERIENCE IN THE USE OF AN ANTIDEPRESSIVE, CLOMIPRAMINE (ANAFRANIL), IN PSYCHIATRIC OUTPATIENTS.
176475 02-09
EVALUATION OF HYPNOTICS IN OUTPATIENTS WITH INSOMNIA USING A QUESTIONNAIRE AND A SELF-RATING TECHNIQUE.
177735 02-06
CHLORDIAZEPOXIDE AND HOSTILITY IN ANXIOUS OUTPATIENTS.
181273 02-10
CLOMIPRAMINE AND AMITRIPTYLINE IN DEPRESSED OUTPATIENTS: A CONTROLLED STUDY.
185747 03-09
INTERACTION OF LOW-DOSE AMPHETAMINE USE WITH SCHIZOPHRENIA IN OUTPATIENTS: THREE CASE REPORTS.
189099 04-15

OUTPUT
THE DOCUMENTATION OF CLINICAL PSYCHOTROPIC DRUG TRIALS: SAMPLE OUTPUT PACKAGE.
180256 02-16

OVEN
SEMI-QUANTITATIVE ANALYSIS OF BROMAZEPAM BY RING OVEN METHOD.
174853 01-16

OVERDOSE
OVERDOSE OF PSYCHOTROPIC DRUGS.
175935 02-15
CHLORDIAZEPOXIDE OVERDOSE: INTERPRETATION OF SERUM DRUG CONCENTRATIONS.
177393 02-15
METHYPRYLON OVERDOSE: INTERPRETATION OF SERUM DRUG CONCENTRATIONS.
177394 02-15
DRUG ABUSE -- OVERDOSE AND RECOVERY.
180147 02-15

OVERDOSED
QUALITATIVE AND QUANTITATIVE STUDIES ON THE DISPOSITION OF AMITRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANT DRUGS IN MAN AS IT RELATES TO THE MANAGEMENT OF THE OVERDOSED PATIENT.
177395 02-15

OVERLAP
BRAIN MECHANISMS UNDERLYING THE EFFECTS OF AMPHETAMINE ON FEEDING AND NONFEEDING BEHAVIORS: DISSOCIATION AND OVERLAP.
184839 03-03

OVERT
THE EFFECTS OF PHENITRONE, A REPORTED HASHISH ANTAGONIST, ON THE OVERT BEHAVIOR OF CATS.
174607 01-04

OVERTRAINING
EFFECTS OF OVERTRAINING AND PRETRIAL ADMINISTRATION OF DEXTROAMPHETAMINE ON REVERSAL LEARNING IN RATS.
177533 02-04

OVERVIEW
PHARMACOLOGIC BASIS FOR USE OF PSYCHOTROPIC DRUGS: AN OVERVIEW.
177782 02-17
AN OVERVIEW OF THE 6-HYDROXYDOPAMINE THEORY OF SCHIZOPHRENIA.
190239 04-08

OXADIAZOLES
ANTICONVULSANT ACTIVITY AND INHIBITION OF RESPIRATION IN RAT BRAIN HOMOGENATES BY SUBSTITUTED OXADIAZOLES.
185980 03-01

OXAZEPAM
OXAZEPAM IN ALLERGIC CONDITIONS.
168923 01-11
TRIAL OF OXAZEPAM IN AMBULATORY PSYCHONEUROTICS.
170412 01-11
RELATIONSHIP BETWEEN BIOAVAILABILITY AND DISSOLUTION RATE OF OXAZEPAM.
171630 01-16
INFLUENCE OF N1-2-HYDROXYETHYL SUBSTITUTION ON CENTRAL ACTIVITY OF OXAZEPAM AND LORAZEPAM.
178756 02-04

OXAZOLAM
EXPERIENCE IN THE USE OF SERENAL (OXAZOLAM) IN THE FIELD OF PEDIATRICS.
176456 02-11

OXAZOLAZEPAM
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT (SECOND REPORT): GENERAL PHARMACOLOGY AND SUBACUTE TOXICITY.
168499 01-07

OXIDASE
BETA-PHENYLETHYLAMINE: A SPECIFIC SUBSTRATE FOR TYPE B MONOAMINE OXIDASE OF BRAIN.
168437 01-03
SYNTHESIS OF SUBSTITUTED CINNAMIDES: RELATIONSHIP BETWEEN ANTICONVULSANT AND MONOAMINE OXIDASE INHIBITORY PROPERTIES.
169818 01-01
EFFECT OF MONOAMINE OXIDASE INHIBITORS ON METABOLISM AND IN VIVO RELEASE OF H3-NOREPINEPHRINE FROM THE HYPOTHALAMUS.
171973 01-03
THE ROLE OF MONOAMINE OXIDASE IN TERMINATING THE REFLEX EFFECTS OF P-METHOXYPHENYLETHYLAMINE (PMPEA).
174319 01-03
PLATELET MONOAMINE OXIDASE ACTIVITY AND SUBSTRATE PREFERENCES IN SCHIZOPHRENIC PATIENTS.
174609 01-14
THE MECHANISM OF ACTION OF THE MONOAMINE OXIDASE INHIBITOR PARGYLINE.
175239 02-03
STUDIES ON MONOAMINE OXIDASE -- REPORT 22: EFFECTS OF NANO2 AND NH2OH ON MITOCHONDRIAL MAO IN RAT BRAIN.
177022 02-03
INHIBITION OF LUNG, LIVER AND BRAIN MONOAMINE OXIDASE BY IMIPRAMINE AND DESIPRAMINE.
177332 02-03
THE RATE LIMITING CONTROL OF ENZYMES MONOAMINE OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN THE FETUS AND THE ADULT BY ADRENOCORTICOL HORMONES.
178815 02-03
TRANSPORT OF SYNAPTOSOMAL TRYPTOPHAN AND CEREBRAL TYROSINE: INCREASE IN THE SPEED OF UPTAKE OF RESERPINE OR THE INHIBITION OF MONOAMINE OXIDASE.
179988 02-13
DISCRIMINANT ANALYSIS OF THE RELATIONSHIP BETWEEN PHYSICAL PROPERTIES AND THE INHIBITION OF MONOAMINE OXIDASE BY AMINOTETRALINS AND AMINOINDANS.
180096 02-03
THE INFLUENCE OF NEUROTROPIC DRUGS ON MONOAMINE OXIDASE (MAO) AND 5-OXYTRYPTOPHANE DECARBOXYLASE (5-OTD) ACTIVITY IN THE BRAIN.
183142 03-13
SUBSTITUTED BENZOXAZOLE/BENZTHIAZOLE-2-THIONES: INTERRELATIONSHIP BETWEEN ANTICONVULSANT ACTIVITY AND INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND MONOAMINE OXIDASE.
183601 03-03
EEG DRIVING RESPONSES AS A FUNCTION OF MONOAMINE OXIDASE.
187149 03-13
EFFECT OF ORAL ADMINISTRATION OF METHADONE ON HEPATIC MICROSOMAL MIXED FUNCTION OXIDASE ACTIVITY IN MICE.
188178 04-03
PHARMACOLOGICAL AND BIOCHEMICAL ACTIONS OF THE HEMOLYTIC AGENTS ACETYLPHENYLHYDRAZINE AND PHENYLHYDRAZINE ON MONOAMINE OXIDASE IN THE RAT.
188769 04-03

FUROXANOBENZOFUROXAN, A SELECTIVE MONOAMINE OXIDASE INHIBITOR.
188770 04-01
CONTROL OF NOREPINEPHRINE SYNTHESIS IN BLOOD VESSELS AND THE EFFECTS OF MONOAMINE OXIDASE INHIBITION.
189390 04-03
PROCAINE (GEROVITAL-H3) THERAPY: MECHANISM OF INHIBITION OF MONOAMINE OXIDASE.
191281 04-03
PHYSICOCHEMICAL PROPERTIES, DEVELOPMENT, AND REGULATION OF CENTRAL AND PERIPHERAL MONOAMINE OXIDASE ACTIVITY.
191497 04-03
SOME INTERRELATED PROPERTIES OF BRAIN MONOAMINE OXIDASE.
191498 04-01
MONOAMINE OXIDASE IN MAN: ENZYME CHARACTERISTICS IN HUMAN PLATELETS, PLASMA, AND OTHER HUMAN TISSUES.
191502 04-13

OXIDASES
THE MONOAMINE OXIDASES OF BRAIN: SELECTIVE INHIBITION WITH DRUGS AND THE CONSEQUENCES FOR THE METABOLISM OF THE BIOGENIC AMINES.
186668 03-03
STUDIES OF MONOAMINE OXIDASES: PROPERTIES OF THE ENZYME IN BOVINE AND RABBIT BRAIN MITOCHONDRIA.
191300 04-03

OXIDATIONS
SUBSTITUTED PIPERAZINOQUINAZOLONES: RELATIONSHIP BETWEEN SELECTIVE INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND ANTICONVULSANT ACTIVITY.
183598 03-02
SUBSTITUTED BENZOXAZOLE/BENZTHIAZOLE-2-THIONES: INTERRELATIONSHIP BETWEEN ANTICONVULSANT ACTIVITY AND INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND MONOAMINE OXIDASE.
183601 03-03

OXIDATIVE
OXIDATIVE METABOLISM OF MESCALINE IN THE CENTRAL NERVOUS SYSTEM -- IV: IN VIVO METABOLISM OF MESCALINE AND 2,3,4 TRIMETHOXY-BETA-PHENYLETHYLAMINE.
181944 02-03

OXIDIZE
INABILITY OF RAT BRAIN HOMOGENATE TO OXIDIZE AMPHETAMINE.
177334 02-03

OXOTREMORINE
INTERACTION BETWEEN ATROPINE AND OXOTREMORINE ON CORTICAL ACETYLCHOLINE AND MOTOR ACTIVITY.
171606 01-03
ACTIVATION OF COPULATORY BEHAVIOR BY PILOCARPINE AND OXOTREMORINE IN THE FEMALE RAT.
171616 01-04
STUDIES ON THE POTENTIATION OF THE ANTINOCICEPTIVE EFFECT OF OXOTREMORINE BY TETRABENAZINE IN MICE.
185933 03-03
EFFECT OF OXOTREMORINE AND PHYSOSTIGMINE ON CHOLINE LEVELS IN MOUSE WHOLE BRAIN, SPLEEN AND CEREBELLUM.
189893 04-03

OXYGEN
EFFECT OF ADRENERGIC SUBSTANCES ON OXYGEN CONSUMPTION OF RAT BRAIN TISSUE.
180058 02-03
EFFECTS OF L-DELTA9-TETRAHYDROCANNABINOL, DL-AMPHETAMINE AND PENTOBARBITAL ON OXYGEN CONSUMPTION BY MOUSE BRAIN AND HEART HOMOGENATES.
181813 02-03

OXYPERTINE
EXPERIENCE IN THE APPLICATION OF A NEW DRUG, DP-181 (OXYPERTINE), IN TREATMENT OF SCHIZOPHRENIA.
176468 02-08
CLINICAL STUDY OF DP-181 (OXYPERTINE).
176722 02-08
CLINICAL EXPERIENCES WITH A PSYCHOTROPIC DRUG (OXYPERTINE) IN CHRONIC SCHIZOPHRENIA.
176727 02-08
THE BASIC PHARMACOLOGY OF OXYPERTINE.
182761 03-17
OXYPERTINE AND PRIMATE BEHAVIOUR.
182762 03-04
A SMALL CONTROLLED STUDY TO DETERMINE THE TIME OF ONSET OF ACTION OF OXYPERTINE AFTER ORAL ADMINISTRATION IN NORMAL SUBJECTS.
182763 03-14
IS OXYPERTINE AN ACTIVATING TRANQUILLIZER?
182765 03-09
A CONTROLLED TRIAL OF OXYPERTINE IN PATIENTS WITH ANXIETY.
182766 03-10
A MULTICENTRE CLINICAL TRIAL OF OXYPERTINE IN ANXIETY NEUROSIS.
182769 03-10

P-CA
NEUROTOXIC EFFECTS OF P-CHLOROAMPHETAMINE (P-CA) ON PERIKARYA OF RAPHE NEURONS.
191947 04-05

P-CHLORO
STUDY INTO THE MECHANISM OF THE ANORECTIC ACTION OF AMPHETAMINE AND ITS P-CHLORO ANALOGUE.
171610 01-03

P-CHLOROAMPHETAMINE
ANTAGONISM OF P-CHLOROAMPHETAMINE (PCA) INDUCED DEPLETION OF 5-HT FROM RAT BRAIN BY SOME THYMOLEPTICS AND OTHER PSYCHOTROPIC DRUGS.
171628 01-03
IN VIVO MEASUREMENT OF THE RELEASE OF 5-HYDROXYTRYPTAMINE (5-HT) FROM THE HIPPOCAMPUS OF THE RAT: EFFECT OF RO-4-1284, PARGYLINE AND P-CHLOROAMPHETAMINE (PCA).
182140 02-03
THE EFFECT OF P-CHLOROAMPHETAMINE ON MOTILITY IN RATS AFTER INHIBITION OF MONOAMINE SYNTHESIS, STORAGE, UPTAKE AND RECEPTOR INTERACTION.
185959 03-04
NEUROTOXIC EFFECTS OF P-CHLOROAMPHETAMINE (P-CA) ON PERIKARYA OF RAPHE NEURONS.
191947 04-05

P-CHLOROPHENYLALANINE
PARADOXICAL BLOCKADE BY P-CHLOROPHENYLALANINE OF 5-HYDROXYTRYPTOPHAN FACILITATORY ACTIONS ON SPINAL REFLEXES.
168436 01-03
EFFECTS OF P-CHLOROPHENYLALANINE ON DIFFERENTIATION OF SEROTONINERGIC RECEPTIVE CELLS DURING EMBRYOGENESIS. (UNPUBLISHED PAPER).
168817 01-03
THE EFFECT OF L-TRYPTOPHAN (TP) ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) REFLEXES IN ACUTE DECEREBRATE SPINAL CATS AND THE EFFECT OF PRETREATMENT WITH P-CHLOROPHENYLALANINE (PCPA) ON THE ACTION OF TP. (UNPUBLISHED PAPER).
170874 01-03
EFFECTS OF P-CHLOROPHENYLALANINE (PCPA) AND NIALAMIDE ON 5-HYDROXYTRYPTAMINE (5-HT) IN THE TRANSECTED SPINAL CORD.
171623 01-03
P-CHLOROPHENYLALANINE INDUCED ALTERATIONS IN THE BEHAVIORAL EFFECTS OF 5-HYDROXYTRYPTOPHAN.
174034 01-04
THE EFFECTS OF EARLY P-CHLOROPHENYLALANINE ADMINISTRATION AND POSTWEANING HOUSING CONDITIONS ON SEROTONIN AND BEHAVIOR IN RATS.
178638 02-04
EFFECT OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) ON THE DAYTIME SLEEP-WAKEFULNESS PATTERNS IN NORMAL AND P-CHLOROPHENYLALANINE INSOMNIAC CATS.
181658 02-02
EFFECTS OF BUFOTENINE AND P-CHLOROPHENYLALANINE ON REACTIVITY TO FOOTSHOCK.
184838 03-04
THE EFFECTS OF P-CHLOROPHENYLALANINE ON MORPHINE ANALGESIA, TOLERANCE AND DEPENDENCE DEVELOPMENT IN TWO STRAINS OF RATS.
187930 04-04
THE EFFECT OF P-CHLOROPHENYLALANINE ON FOREBRAIN TRYPTOPHAN HYDROXYLASE IN RATS WITH LESIONS IN THE RAPHE NUCLEUS.
188750 04-03
DIFFERENTIAL EFFECTS OF P-CHLOROPHENYLALANINE ON SLEEP IN TWO PRIMATES, PAPIO-PAPIO AND PAPIO-HAMADRYAS.
191629 04-04

P-HYDROXYAMPHETAMINE
A COMPARISON OF THE EFFECTS OF AMPHETAMINE AND ITS METABOLITES, P-HYDROXYAMPHETAMINE AND P-HYDROXYNOREPHEDRINE, ON UPTAKE, RELEASE AND CATABOLISM OF 3H-NOREPINEPHRINE IN CEREBRAL CORTEX OF RAT BRAIN.
186669 03-03

P-HYDROXYNOREPHEDRINE
A COMPARISON OF THE EFFECTS OF AMPHETAMINE AND ITS METABOLITES, P-HYDROXYAMPHETAMINE AND P-HYDROXYNOREPHEDRINE, ON UPTAKE, RELEASE AND CATABOLISM OF 3H-NOREPINEPHRINE IN CEREBRAL CORTEX OF RAT BRAIN.
186669 03-03

P-HYDROXYPHENOXY
N-(2-DIETHYLAMINOETHYL) 2 (P-HYDROXYPHENOXY) ACETAMIDE, A METABOLITE OF MEFEXAMIDE IN MAN.
187577 04-01

P-METHOXYPHENYLETHYLAMINE
THE ROLE OF MONOAMINE OXIDASE IN TERMINATING THE REFLEX EFFECTS OF P-METHOXYPHENYLETHYLAMINE (PMPEA).
174319 01-03

P-TRIFLUOROMETHYLPHENOXY
EFFECT OF LILLY-110140, 3-(P-TRIFLUOROMETHYLPHENOXY) N METHYL-3-PHENYLPROPYLAMINE ON SYNTHESIS OF 3H-SEROTONIN FROM 3H-TRYPTOPHAN IN RAT BRAIN.
191951 04-03

PACKAGE
THE DOCUMENTATION OF CLINICAL PSYCHOTROPIC DRUG TRIALS: SAMPLE OUTPUT PACKAGE.
180256 02-16

PAIN
PAIN AND EMOTION.
181590 02-11

MARIHUANA AND PAIN.
182719 03-13

AUTOMATIC DETERMINATION OF THE PAIN THRESHOLD TO ELECTROSHOCK AND THE EFFECTS OF DELTA9-THC.
183363 03-03

THE EFFECT OF PAIN RELIEVING DRUGS ADMINISTERED DURING LABOR AND DELIVERY ON THE BEHAVIOR OF THE NEWBORN: A REVIEW.
183706 03-17

PERCEPTUAL STYLE AND PAIN TOLERANCE -- II. THE INFLUENCE OF AN ANXIOLYTIC AGENT.
184291 03-14

DRUGS TO TREAT PAIN.
186395 03-14

PAIN AND PSYCHOPHARMACEUTICALS.
187959 04-17

ATTACK ON THE GATE THEORY OF PAIN.
189610 04-17

JOHN J. BONICA ON PAIN MANAGEMENT.
189903 04-13

PSYCHOTROPIC EFFECT OF ANALGESICS AND NEUROLEPTICS ON A MODEL OF INVESTIGATORY BEHAVIOR CHANGED BY PAIN.
191120 04-04

PAIRED
THE EFFECT OF TRANYLCYPROMINE (PARNATE) ON EYELID CONDITIONING AND PAIRED ASSOCIATE LEARNING IN DEPRESSED PATIENTS.
188107 04-09

PAIRS
THE ACTION OF CHLORPROMAZINE ON EXPLORATION IN PAIRS OF RATS.
189514 04-04

PALMITATE
HYPERTHERMIC EFFECT OF PALMITATE SODIUM, STEARATE SODIUM AND OLEATE SODIUM INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS CATS.
186640 03-03

PAMOATE
A CONTROLLED STUDY OF SINGLE DOSE ADMINISTRATION OF IMIPRAMINE PAMOATE IN ENDOGENOUS DEPRESSION.
167775 01-09

THE TREATMENT OF DEPRESSION WITH A SINGLE DAILY DOSE OF IMIPRAMINE PAMOATE.
169491 01-09

PANAMA
A COMPARISON OF CLINICALLY USED PSYCHOACTIVE DRUGS IN FOUR LATIN-AMERICAN COUNTRIES AND IN CANADA (ARGENTINA, COSTA-RICA, MEXICO AND PANAMA).
191139 04-17

PANAX
THE EFFECT OF PANAX GINSENG SAPONIN ON THE CENTRAL NERVOUS SYSTEM IN RAT: THE PSYCHOPHARMACOLOGICAL EFFECT OF GINSENG.
171599 01-04

PAPAVERINE
AN ERGOT ALKALOID PREPARATION (HYDERGINE) VERSUS PAPAVERINE IN TREATING COMMON COMPLAINTS OF THE AGED: DOUBLE-BLIND STUDY.
173190 01-11

PAPIO-HAMADRYAS
DIFFERENTIAL EFFECTS OF P-CHLOROPHENYLALANINE ON SLEEP IN TWO PRIMATES, PAPIO-PAPIO AND PAPIO-HAMADRYAS.
191629 04-04

PAPIO-PAPIO
DIFFERENTIAL EFFECTS OF P-CHLOROPHENYLALANINE ON SLEEP IN TWO PRIMATES, PAPIO-PAPIO AND PAPIO-HAMADRYAS.
191629 04-04

PARADIGM
THE CURARIZED RAT AND HEART RATE CONDITIONING: A CONSIDERATION OF RESPIRATION PARAMETERS AND NEUROMUSCULAR BLOCKING AGENTS IN A CLASSICAL CONDITIONING PARADIGM. (PH.D. DISSERTATION).
173133 01-03

PARADOXICAL
PARADOXICAL BLOCKADE BY P-CHLOROPHENYLALANINE OF 5-HYDROXYTRYPTOPHAN FACILITATORY ACTIONS ON SPINAL REFLEXES.
168436 01-03

PARADOXICAL THERMOREGULATORY BEHAVIOUR IN RATS INDUCED BY (_) AMPHETAMINE: BLOCKADE BY ALPHA-ADRENOCEPTOR OR DOPAMINE RECEPTOR BLOCKING AGENTS.
183797 03-03

PARADOXICAL EFFECTS OF D-AMPHETAMINE ON BEHAVIORAL THERMOREGULATION: POSSIBLE MEDIATION BY BRAIN DOPAMINE.
189399 04-04

PARAMETERS
THE CURARIZED RAT AND HEART RATE CONDITIONING: A CONSIDERATION OF RESPIRATION PARAMETERS AND NEUROMUSCULAR BLOCKING AGENTS IN A CLASSICAL CONDITIONING PARADIGM. (PH.D. DISSERTATION).
173133 01-03

BEHAVIORAL PARAMETERS OF DRUG ACTION: SIGNALED AND RESPONSE INDEPENDENT REINFORCEMENT.
174008 01-04

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: IV. INFLUENCE OF AMPHETAMINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
185961 03-04

EFFECT OF SEVERAL DOPAMINERGIC DRUGS AND TRIHEXYPHENIDYL ON CHOLINERGIC PARAMETERS IN THE RAT STRIATUM.
185995 03-03

THE EFFECT OF SOME CHOLINOLYTIC DRUGS ON A NUMBER OF BEHAVIOURAL PARAMETERS MEASURED IN THE T-MAZE ALTERNATION TEST: DOSE-RESPONSE RELATIONSHIPS.
187641 04-04

INTERACTION OF SEROTONIN ANTAGONISTS WITH 3,4-DICHLORO-2-(2-IMIDAZOLIN-2-YL-THIO) 2 ACETOPHENONE HYDROBROMIDE (DITA) AND D-AMPHETAMINE HYDROBROMIDE (DITA) AND D-AMPHETAMINE ON CERTAIN BEHAVIORAL PARAMETERS OF MALE MICE.
192014 04-04

PARANOID
METHYLTESTOSTERONE WITH IMIPRAMINE IN MEN: CONVERSION OF DEPRESSION TO PARANOID REACTION.
172992 01-15

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: IV. PIMOZIDE IN THE TREATMENT OF PATIENTS WITH PARANOID SYMPTOMATOLOGY.
183194 03-09

PARAPYRAMIDAL
EFFECTS OF PG-501 ON PARAPYRAMIDAL SYSTEM SYNDROME INDUCED BY PSYCHOTROPICS.
178019 02-15

PARENTERAL
PILOT CLINICAL TRIAL OF PARENTERAL LORAZEPAM (TEMESTA) IN ANXIETY STATES.
174044 01-11

PARENTERAL HALOPERIDOL FOR RAPID CONTROL OF SEVERE, DISRUPTIVE SYMPTOMS OF ACUTE SCHIZOPHRENIA.
178545 02-08

PENTAZOCINE IN RHESUS MONKEY PLASMA AND BRAIN AFTER PARENTERAL AND ORAL ADMINISTRATION.
178641 02-03

INHALATION, PARENTERAL AND ORAL LD50 VALUES OF DELTA9-TETRAHYDROCANNABINOL IN FISCHER RATS.
189588 04-05

PARGYLINE
THE MECHANISM OF ACTION OF THE MONOAMINE OXIDASE INHIBITOR PARGYLINE.
175239 02-03

IN VIVO MEASUREMENT OF THE RELEASE OF 5-HYDROXYTRYPTAMINE (5-HT) FROM THE HIPPOCAMPUS OF THE RAT: EFFECT OF RO-4-1284, PARGYLINE AND P-CHLOROAMPHETAMINE (PCA).
182140 02-03

PARKINSON
PARKINSON DISEASE TREATED WITH A SUSPECTED DOPAMINE RECEPTOR AGONIST.
186029 03-11

LEVODOPA, CARBIDOPA, AND PYRIDOXINE IN PARKINSON DISEASE.
187877 04-13

PARKINSONIAN
HABITUATION OF BLINK REFLEXES IN PARKINSONIAN PATIENTS UNDER LEVODOPA AND AMANTADINE TREATMENT.
171794 01-13

STRUCTURAL FUNCTIONAL ORGANIZATION OF THE HUMAN BRAIN AND THE PATHOPHYSIOLOGY OF THE PARKINSONIAN TYPE HYPERKINESES.
178787 02-13

PARKINSONIAN SYNDROMES: TREATMENT BY ASSOCIATION OF L-DOPA PLUS DECARBOXYLASE INHIBITOR.
188093 04-11

PARKINSONIAN-LIKE
A METHOD FOR TESTING DRUG-INDUCED PARKINSONIAN-LIKE EFFECT.
191982 04-15

PARKINSONISM
EMOTIONAL FUNCTIONS IN SHORT-TERM VS. LONG-TERM L-DOPA THERAPY IN PARKINSONISM.
168619 01-15

AMPHETAMINES: VALUABLE ADJUNCT IN TREATMENT OF PARKINSONISM.
169220 01-11

LEVODOPA INDUCED DYSKINESIAS: COMPARISON IN PARKINSONISM DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS.
169376 01-15

AMANTADINE HYDROCHLORIDE IN TREATMENT OF PARKINSONISM.
169461 01-11
AN AUTOPSY CASE OF SCHIZOPHRENIA COMPLICATED WITH PARKINSONISM INDUCED BY PERPHENAZINE.
171275 01-15
PARKINSONISM, L-DOPA, AND INTELLIGENCE.
175426 02-11
EFFECTS OF SHORT-TERM VERSUS LONG-TERM L-DOPA THERAPY IN PARKINSONISM ON CRITICAL FLICKER FREQUENCY.
177511 02-11
PARKINSONISM DEMENTIA OF GUAM: TREATMENT WITH LEVODOPA AND L-ALPHA-METHYLDOPAHYDRAZINE.
179996 02-13
L-DOPA EFFECTS ON MOTOR AND CENTRAL PROGRAMMING DEFICITS IN PARKINSONISM.
184976 03-14
ON-OFF PHENOMENON WITH LEVODOPA THERAPY IN PARKINSONISM: CLINICAL AND PHARMACOLOGIC CORRELATIONS AND THE EFFECT OF INTRAMUSCULAR PYRIDOXINE.
188560 04-11
RO-4-4602 AND LEVODOPA IN THE TREATMENT OF PARKINSONISM.
188561 04-11
MENTAL CHANGES IN PARKINSONISM.
188886 04-15
CLINICAL EVALUATION OF AMANTADINE THERAPY FOR PARKINSONISM AND THE SIDE-EFFECTS -- IN CASES OF THALAMIC SURGERY AND L-DOPA THERAPY.
190095 04-11
ON THE COEXISTENCE OF PARKINSONISM AND TARDIVE DYSKINESIA.
190380 04-11

PARKINSONS
L-DOPA IN 122 CASES OF PARKINSONS DISEASE AT AGE 70 OR OVER. A COMPARATIVE STUDY WITH A GROUP OF PATIENTS AGED 41 TO 69 YEARS.
168369 01-11
PSYCHOMETRIC INVESTIGATIONS IN PARKINSONS SYNDROME DURING TREATMENT WITH L-DOPA AND RELEVANCE OF SOME PSYCHOLOGICAL PHENOMENA.
168578 01-13
LONG-RANGE MOTOR PERFORMANCE CHANGES IN LEVODOPA TREATED PATIENTS WITH PARKINSONS DISEASE.
184195 03-11
LEVODOPA COMBINED WITH MK-486 (L-ALPHA-METHYLDOPAHYDRAZINE) -- A PERIPHERAL DECARBOXYLASE INHIBITOR IN PARKINSONS DISEASE.
187615 04-11
PLASMA DOPA AND FUNCTIONAL OSCILLATIONS AFTER CHRONIC TREATMENT OF PARKINSONS DISEASE.
188421 04-13
COMPARISON OF AMANTADINE, PLACEBO, AND LEVODOPA IN PARKINSONS DISEASE.
189502 04-11
DISSOCIATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN PARKINSONS DISEASE FOLLOWING CHRONIC L-DOPA THERAPY.
191233 04-13
EFFECTS OF PIRIBEDIL (ET-495) -- A DOPAMINERGIC RECEPTOR STIMULATING AGENT IN PARKINSONS DISEASE.
191522 04-13

PARNATE
THE EFFECT OF TRANYLCYPROMINE (PARNATE) ON EYELID CONDITIONING AND PAIRED ASSOCIATE LEARNING IN DEPRESSED PATIENTS.
188107 04-09

PAROTID
THE INFLUENCE OF DELTA9-TETRAHYDROCANNABINOL (THC) ON PILOCARPINE (PILO) INDUCED PAROTID SECRETIONS OF THE RAT.
191962 04-03

PAROXYSMAL
PAROXYSMAL RIGHT LEFT DISORIENTATION IN AN EPILEPTIC PATIENT.
171246 01-11

PARTIAL
PARTIAL PURIFICATION AND CHARACTERIZATION OF NADPH-LINKED ALDEHYDE REDUCTASE FROM MONKEY BRAIN.
175232 02-03

PARTICLES
INCORPORATION OF 14C-DIHYDROPHENYLALANINE AND 14C-CHOLINE INTO RAT BRAIN SUBCELLULAR PARTICLES AND THE EFFECT OF PSYCHOACTIVE DRUGS.
192426 04-03

PARTICULATE
COMPARATIVE PROPERTIES OF SOLUBLE AND PARTICULATE CATECHOL-O-METHYLTRANSFERASE FROM RAT RED BLOOD CELL: PRELIMINARY OBSERVATIONS.
191523 04-01

PASSAGE
DETERMINATION OF DRUG TRANSFER ACROSS BIOLOGICAL MEMBRANES: COMPARATIVE STUDY ON THE PASSAGE OF DRUGS INTO THE CENTRAL NERVOUS SYSTEM AND THEIR PLACENTAL TRANSFER AND FETAL LOCALIZATION IN THE PREGNANT RAT. (PH.D. DISSERTATION).
172018 01-03
PASSAGE OF TAURINE INTO ADULT MAMMALIAN BRAIN.
191331 04-03

PASSIVE
EFFECT OF PRENATAL MATERNAL ADMINISTRATION OF D-AMPHETAMINE ON RAT OFFSPRING ACTIVITY AND PASSIVE AVOIDANCE LEARNING.
167415 01-03
MULTITRIAL PASSIVE AVOIDANCE IN RATS: MESCALINE, SHOCK, AND ITI EFFECTS. (PH.D. DISSERTATION).
173162 01-04
THE EFFECT OF PHASE-SHIFT ON THE PASSIVE AVOIDANCE RESPONSE IN RATS, AND THE MODIFYING EFFECT OF CHLORDIAZEPOXIDE.
174830 01-04
PHARMACOLOGICAL DISTINCTIONS BETWEEN ACTIVE AND PASSIVE AVOIDANCE MEMORY FORMATION AS SHOWN BY MANIPULATION OF BIOGENIC AMINE ACTIVE COMPOUNDS.
185927 03-04
MESCALINE FACILITATES RETENTION OF PASSIVE AVOIDANCE IN RATS.
190266 04-04

PATHOLOGICAL
HUMAN SERUM DOPAMINE-BETA-HYDROXYLASE: RELATIONSHIP TO SYMPATHETIC ACTIVITY IN PHYSIOLOGICAL AND PATHOLOGICAL STATES.
191510 04-13

PATHOPHYSIOLOGY
STRUCTURAL FUNCTIONAL ORGANIZATION OF THE HUMAN BRAIN AND THE PATHOPHYSIOLOGY OF THE PARKINSONIAN TYPE HYPERKINESES.
178787 02-13
DOPAMINERGIC HYPERSENSITIVITY AND CHOLINERGIC HYPOFUNCTION IN THE PATHOPHYSIOLOGY OF TARDIVE DYSKINESIA.
185929 03-11

PATHWAYS
ENHANCEMENT OF AMPHETAMINE ACTION AFTER INTERRUPTION OF ASCENDING SEROTONERGIC PATHWAYS.
189398 04-03
BENZODIAZEPINES AND BARBITURATES: TURNOVER CHANGES IN CENTRAL 5-HYDROXYTRYPTAMINE PATHWAYS.
189611 04-03
5-HYDROXYTRYPTAMINE AND NORADRENALINE IN THE HIPPOCAMPAL REGION: EFFECT OF TRANSECTION OF AFFERENT PATHWAYS ON ENDOGENOUS LEVELS, HIGH AFFINITY UPTAKE AND SOME TRANSMITTER RELATED ENZYMES.
191319 04-03

PATIENT
LORAZEPAM VERSUS GLUTETHIMIDE AS A SLEEP INDUCING AGENT FOR THE GERIATRIC PATIENT.
167496 01-11
THERAPEUTIC APPROACH TO THE APPROXIMATE ANSWERS OF A SCHIZOPHRENIC PATIENT.
170637 01-08
PAROXYSMAL RIGHT LEFT DISORIENTATION IN AN EPILEPTIC PATIENT.
171246 01-11
GEROVITAL-H3 IN THE TREATMENT OF THE DEPRESSED AGING PATIENT.
177373 02-11
QUALITATIVE AND QUANTITATIVE STUDIES ON THE DISPOSITION OF AMITRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANT DRUGS IN MAN AS IT RELATES TO THE MANAGEMENT OF THE OVERDOSED PATIENT.
177395 02-15
A REVIEW OF THE USE OF LSD FOR THE PATIENT NEAR DEATH.
177681 02-12
TACITIN TREATMENT FOR THE PATIENT WITH ANXIETY.
178038 02-10

PATIENTS
METIAPINE IN ACUTE SCHIZOPHRENIC PATIENTS.
167341 01-08
POTENTIATION OF HALOPERIDOL BY ALPHA-METHYLDOPA IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
167343 01-08
A DOUBLE-BLIND, COMPARATIVE CLINICAL TRIAL WITH LUDIOMIL (CIBA-34276-BA) AND AMITRIPTYLINE IN NEWLY ADMITTED DEPRESSED PATIENTS.
167774 01-09
MESORIDAZINE IN THE CARE OF DISTURBED MENTALLY RETARDED PATIENTS.
168315 01-11
CLINICAL EVALUATION OF FLUSPIRILENE AS A MAINTENANCE THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS.
168320 01-08
L-DOPA IN 122 CASES OF PARKINSONS DISEASE AT AGE 70 OR OVER. A COMPARATIVE STUDY WITH A GROUP OF PATIENTS AGED 41 TO 69 YEARS.
168369 01-11
SAFETY AND EFFECTIVENESS OF HALOPERIDOL FOR MENTALLY RETARDED BEHAVIORALLY DISORDERED AND HYPERKINETIC PATIENTS.
169634 01-11
SELECTIVE INHIBITION OF NOREPINEPHRINE SYNTHESIS IN MANIC-DEPRESSIVE PATIENTS WITH A DOPAMINE-BETA-HYDROXYLASE INHIBITOR. (UNPUBLISHED PAPER).
170083 01-03

DRUG TREATMENT OF DEPRESSED PATIENTS REFERRED FOR HOSPITALIZATION.
170621 01-09

CAUDATE NUCLEUS EFFECTS ON GERIATRIC SENILITY: EFFECT OF BELLADONNA ON LEARNING AND MEMORY OF GERIATRIC PATIENTS.
170744 01-11

CLINICAL TRIAL OF TRIFLUOPERAZINE (STELAZINE R) ON INDONESIAN PSYCHIATRIC PATIENTS.
171161 01-09

HABITUATION OF BLINK REFLEXES IN PARKINSONIAN PATIENTS UNDER LEVODOPA AND AMANTADINE TREATMENT.
171794 01-13

STUDY OF THE PSYCHOTROPIC ACTION OF TEGRETOL IN PATIENTS WITH EPILEPSY.
172439 01-11

A DOUBLE-BLIND COMPARISON OF THIORIDAZINE (MELLARIL) VERSUS DIAZEPAM (VALIUM) IN PATIENTS WITH CHRONIC MIXED ANXIETY AND DEPRESSIVE SYMPTOMS.
172486 01-10

EFFECTS OF AMITRIPTYLINE AND IMIPRAMINE ON AMINE METABOLITES IN THE CEREBROSPINAL FLUID OF DEPRESSED PATIENTS.
174094 01-09

USE OF LORAZEPAM IN TREATING PATIENTS WITH NEUROTIC AND SOMATIZED PSYCHOVEGETATIVE SYMPTOMS.
174136 01-09

MOLINDONE: A CROSSOVER EVALUATION OF CAPSULE AND TABLET FORMULATIONS IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
174137 01-08

AMOXAPINE AND IMIPRAMINE: A DOUBLE-BLIND STUDY IN DEPRESSED PATIENTS.
174138 01-09

TRIFLUPERIDOL -- A CONTROLLED CLINICAL TRIAL ON A GROUP OF SCHIZOPHRENIC PATIENTS.
174587 01-08

HIGH DOSES OF CHLORPROMAZINE AND TRIFLUOPERAZINE IN THE TREATMENT OF PATIENTS SUFFERING FROM SCHIZOPHRENIA.
174589 01-08

PLATELET MONOAMINE OXIDASE ACTIVITY AND SUBSTRATE PREFERENCES IN SCHIZOPHRENIC PATIENTS.
174609 01-14

LONG-TERM APPLICATION OF CLOZAPINE (W-801) IN SCHIZOPHRENIC PATIENTS.
174680 01-08

ELECTROCLINICAL ASPECT OF INSIDON TREATMENT IN PATIENTS WITH NEUROTIC SYMPTOMS.
174777 01-10

ELECTROENCEPHALOGRAM OF HYSTERIC PATIENTS.
175069 02-09

FUNCTIONAL EVALUATION OF PITUITARY RESERVE IN PATIENTS WITH THE AMENORRHEA GALACTORRHEA SYNDROME UTILIZING LUTEINIZING HORMONE RELEASING HORMONE (LH-RH), L-DOPA AND CHLORPROMAZINE.
175245 02-13

PSYCHIATRISTS REACTIONS TO THEIR PATIENTS REFUSAL OF DRUGS.
175251 02-17

THE PATIENTS VIEW OF L-DOPA AFTER ONE YEARS THERAPY.
175459 02-15

WITHDRAWAL OF MAINTENANCE DRUGS WITH LONG-TERM HOSPITALIZED MENTAL PATIENTS: A CRITICAL REVIEW.
175862 02-17

DOLICHOMEGACOLON INDUCED BY NEUROLEPTICS AMONG PSYCHIATRIC PATIENTS (MEMORANDUM COVERING 153 CASES).
176432 02-15

MANAGEMENT OF HOSTILE, SUSPICIOUS PATIENTS. TRIFLUOPERAZINE VERSUS HALOPERIDOL.
176675 02-14

THE EFFECTS OF PHYSOSTIGMINE IN PHENOTHIAZINE RESISTANT CHRONIC SCHIZOPHRENIC PATIENTS: PRELIMINARY OBSERVATIONS.
177669 02-08

PIPERACETAZINE IN AMBULATORY CHRONIC SCHIZOPHRENIC PATIENTS.
177748 02-08

DREAM REPORTS AFTER RESERPINE ADMINISTRATION IN CHRONIC LOBOTOMIZED SCHIZOPHRENIC PATIENTS.
178187 02-08

DIFFERENTIAL EFFECTS OF D- AND L-AMPHETAMINE ON THE SLEEP OF DEPRESSED PSYCHIATRIC PATIENTS ON AND OFF LITHIUM CARBONATE TREATMENT. (UNPUBLISHED PAPER).
178432 02-09

THE ROLE OF CHEMOTHERAPY IN MANAGING POTENTIALLY SUICIDAL PATIENTS.
178544 02-10

LONG-TERM CONSEQUENCES OF EXPERIENCE, MEDICATION, AND PSYCHOTHERAPY FOR SCHIZOPHRENIC PATIENTS. (UNPUBLISHED PAPER).
178677 02-17

CHOLINE ACETYLTRANSFERASE ACTIVITY IN THE CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
180047 02-13

HALOPERIDOL (JANSSEN) IN THE TREATMENT OF UNSELECTED INSTITUTIONALIZED PSYCHIATRIC PATIENTS.
180299 02-11

LITHIUM DISTRIBUTION BETWEEN CEREBROSPINAL FLUID AND SERUM OF AFFECTIVE PSYCHOTIC PATIENTS TREATED WITH LITHIUM CARBONATE AND ITS CLINICAL RESPONSE.
180301 02-11

END OF A BACK WARD: THE RAPID REHABILITATION AND RELEASE OF CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS.
181153 02-08

HIGH FREQUENCY OF DYSPHORIC REACTIONS TO TETRAHYDROCANNABINOL AMONG DEPRESSED PATIENTS.
181274 02-09

AN ELECTROENCEPHALOGRAPHIC STUDY ON THE TOLERANCE OF THE VARIOUS PSYCHIATRIC AND NEUROLOGICAL PATIENTS TO THE HYPNOTIC EFFECTS OF DIPHENHYDRAMINE -- MEASURED BY THE AMOUNTS OF SLEEP EEG AS AN INDICATOR.
182550 03-11

DIAZEPAM TREATMENT FOR ACUTE CONVULSIONS IN CHILDREN: A REPORT OF 41 PATIENTS, THREE WITH PLASMA LEVELS.
182595 03-11

CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG: FK-880 (SULPIRIDE), ITS EFFECT ON PATIENTS WITH PSYCHOSOMATIC DISEASES AND PSYCHONEUROSIS.
182731 03-10

A CONTROLLED TRIAL OF OXYPERTINE IN PATIENTS WITH ANXIETY.
182766 03-10

EXPERIMENTS IN ORAL AND INJECTABLE FORMS OF A NEW ANTIDEPRESSANT (DOXEPIN) ON FORTY PATIENTS.
182900 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: IV. PIMOZIDE IN THE TREATMENT OF PATIENTS WITH PARANOID SYMPTOMATOLOGY.
183194 03-09

A DOUBLE-BLIND COMPARISON OF PIMOZIDE WITH CARPIPRAMINE IN SCHIZOPHRENIC PATIENTS.
183195 03-08

CLINICAL ASSAY OF LORAZEPAM WITH AMBULANT PATIENTS.
183201 03-11

DELTA9-TETRAHYDROCANNABINOL IN DEPRESSED PATIENTS.
183546 03-10

IDENTIFICATION AND QUANTITATIVE DETERMINATION OF PHENOTHIAZINE DRUGS IN URINE SAMPLES OF PSYCHIATRIC PATIENTS.
183599 03-02

ASSAY PROCEDURES FOR THIORIDAZINE, TRIFLUOPERAZINE, AND THEIR SULFOXIDES AND DETERMINATION OF URINARY EXCRETION OF THESE COMPOUNDS IN MENTAL PATIENTS.
183602 03-01

CLINICAL STUDY ON THE EFFECTS OF THIOTHIXENE IN HOSPITALIZED PSYCHOTIC PATIENTS.
183955 03-08

THE EFFECTS OF COCAINE ON DEPRESSED PATIENTS.
184160 03-09

SAFETY AND EFFICACY OF ZINC SULFATE IN GERIATRIC PATIENTS.
184177 03-11

LONG-RANGE MOTOR PERFORMANCE CHANGES IN LEVODOPA TREATED PATIENTS WITH PARKINSONS DISEASE.
184195 03-11

THE EFFECTS OF PHENOTHIAZINES ON ENDOCRINE FUNCTION: I. PATIENTS WITH INAPPROPRIATE LACTATION AND AMENORRHOEA.
184436 03-15

SERUM ANTICONVULSANT CONCENTRATIONS IN EPILEPTIC PATIENTS WITH MENTAL SYMPTOMS: A PRELIMINARY REPORT.
184439 03-15

EFFECTS OF HYPNOTICS ON ANXIOUS PATIENTS.
184445 03-10

THE ABRUPT WITHDRAWAL OF ANTIPARKINSONIAN DRUGS IN SCHIZOPHRENIC PATIENTS.
185005 03-08

THE EFFECT OF SULTHIAME ON DISTURBED BEHAVIOUR IN MENTALLY SUBNORMAL PATIENTS.
185191 03-14

THE DISCHARGED PATIENTS DRUG TREATMENT.
185195 03-17

TREATMENT EFFECTS ON THE SOCIAL ADJUSTMENT OF DEPRESSED PATIENTS.
185322 03-10

CALCIUM METABOLISM IN ELDERLY EPILEPTIC PATIENTS DURING ANTICONVULSANT THERAPY.
185560 03-15

THE EFFECT OF CHLORPROMAZINE ON HOMOVANILLIC ACID LEVELS IN CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS.
186565 03-08

FLUNITRAZEPAM (RO-5-4200) AND SLEEP CYCLE IN INSOMNIAC PATIENTS.
186574 03-11

THE EFFECT OF LITHIUM ON THYROID IODINE RELEASE IN PATIENTS WITH PRIMARY AFFECTIVE DISORDER.
186580 03-09
THE ADMINISTRATION OF METHIONINE TO CHRONIC SCHIZOPHRENIC PATIENTS: A REVIEW OF TEN STUDIES.
187113 03-08
MUSCLE ABNORMALITIES IN PSYCHOTIC PATIENTS: II. SERUM CPK ACTIVITY, FIBER ABNORMALITIES, AND BRANCHING AND SPROUTING OF SUBTERMINAL NERVES.
187114 03-09
POLYMYALGIA RHEUMATICA IN A GERIATRIC DEPARTMENT: NINE PATIENTS WITH AN AVERAGE AGE OF 83 YEARS.
187236 03-11
STUDIES OF CEREBROSPINAL FLUID AMINE METABOLITES IN DEPRESSED PATIENTS: CONCEPTUAL PROBLEMS AND THEORETICAL IMPLICATIONS. (UNPUBLISHED PAPER).
187398 04-13
THE EFFECT OF ORALLY ADMINISTERED COCAINE ON SLEEP OF DEPRESSED PATIENTS.
187642 04-14
HIGH DOSAGE PIPERACETAZINE (QUIDE-R) IN AMBULATORY SCHIZOPHRENIC PATIENTS: THERAPEUTIC EFFICACY AND TOXICITY.
187869 04-08
HEAT DYSCONTROL SYNDROME IN PATIENTS RECEIVING ANTIPSYCHOTIC, ANTIDEPRESSANT AND ANTIPARKINSON DRUG THERAPY.
188094 04-15
THE EFFECT OF TRANYLCYPROMINE (PARNATE) ON EYELID CONDITIONING AND PAIRED ASSOCIATE LEARNING IN DEPRESSED PATIENTS.
188107 04-09
ARE NEUROTIC PATIENTS IN PSYCHOTROPIC DRUG TRIALS REPRESENTATIVE? A COMPARISON OF STUDY AND NON-STUDY PATIENTS IN FOUR FAMILY PRACTICES.
188144 04-10
ANTICONVULSANT ACTION OF VITAMIN-D IN EPILEPTIC PATIENTS? A CONTROLLED PILOT STUDY.
188889 04-11
CLINICAL EXPERIENCES WITH MESORIDAZINE (TPS-23): ITS ADMINISTRATION TO HOSPITALIZED SCHIZOPHRENIC PATIENTS.
188934 04-08
AFFECTIVE STATE AND THYROTROPIN AND PROLACTIN RESPONSES AFTER REPEATED INJECTIONS OF THYROTROPIN RELEASING HORMONE IN DEPRESSED PATIENTS.
189076 04-09
RAPID DIGITALIZATION OF DECOMPENSATED SCHIZOPHRENIC PATIENTS WITH ANTIPSYCHOTIC AGENTS.
189095 04-08
NERVE CONDUCTION VELOCITY IN PATIENTS ON LONG-TERM DIPHENYLHYDANTOIN THERAPY.
189173 04-15
IMPAIRMENT OF OPTOKINETIC NYSTAGMUS IN PATIENTS WITH TARDIVE DYSKINESIA.
189734 04-13
TARDIVE DYSKINESIA AND DRUG THERAPY IN GERIATRIC PATIENTS.
189923 04-13
THE RESIDUAL EFFECTS OF N-DESMETHYLDIAZEPAM IN PATIENTS.
190336 04-11
ANTICONVULSANT DRUG SERUM LEVELS IN PSYCHIATRIC PATIENTS WITH SEIZURE DISORDERS: EFFECTS OF CERTAIN PSYCHOTROPIC DRUGS.
191096 04-13
DIFFERENTIAL EFFECTS OF TRAZODONE IN DEPRESSED, SCHIZOPHRENIC AND GERIATRIC PATIENTS.
191138 04-14
SERUM PROLACTIN LEVELS IN NEWLY ADMITTED PSYCHIATRIC PATIENTS.
191506 04-13
REBOUND PHENOMENON IN MANIC PATIENTS FOLLOWING PHYSOSTIGMINE: TOWARDS AN UNDERSTANDING OF AMINERGIC MECHANISMS UNDERLYING AFFECTIVE DISORDERS.
191531 04-09
DAILY RHYTHM IN BODY TEMPERATURE OF MENTAL PATIENTS: APPLICATION OF COSINOR METHOD -- FIRST REPORT.
191685 04-17
THE USE OF ETHYMISOL (ETHYLNORANTIPHEIN) IN PATIENTS WITH PROLONGED DISTURBANCES OF CONSCIOUSNESS.
191777 04-07
THIORIDAZINE IN NEUROTIC, ANXIOUS, AND DEPRESSED PATIENTS.
192227 04-10
HALOPERIDOL VERSUS THIORIDAZINE FOR THE TREATMENT OF PSYCHOGERIATRIC PATIENTS: A DOUBLE-BLIND CLINICAL STUDY.
192231 04-09
CONDITIONING IN THE PREDICTION OF DRUG WITHDRAWAL EFFECTS IN CHRONIC SCHIZOPHRENIC PATIENTS.
192412 04-17

PATTERN
DETERMINANTS OF THE NORADRENERGIC SATIETY EFFECT: ENVIRONMENTAL DARKNESS VS. THE FEEDING PATTERN.
182133 02-04

PATTERNS
BEHAVIOR AND SENSITIVITY TO EXPERIMENTAL HYPERTENSION: II. LACK OF CORRELATION BETWEEN CERTAIN BEHAVIOR PATTERNS AND HYPERTENSION IN TWO NEW STRAINS OF RATS.
173256 01-04
EFFECT OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) ON THE DAYTIME SLEEP-WAKEFULNESS PATTERNS IN MONKEYS.
181657 02-02
EFFECT OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) ON THE DAYTIME SLEEP-WAKEFULNESS PATTERNS IN NORMAL AND P-CHLOROPHENYLALANINE INSOMNIAC CATS.
181658 02-02
PSYCHOPHYSIOLOGICAL PATTERNS OF RESPONSE IN SCHIZOPHRENIA.
183629 03-08
COMMENTS ON PAPER, PSYCHOPHYSIOLOGICAL PATTERNS OF RESPONSE IN SCHIZOPHRENIA.
183630 03-17

PAVABID
EVALUATION OF EEG AND CLINICAL CHANGES ASSOCIATED WITH PAVABID THERAPY IN CHRONIC BRAIN SYNDROME.
183402 03-13

PAW
SPATIAL AND PAW PREFERENCES IN RATS: THEIR RELATIONSHIP TO RATE-DEPENDENT EFFECTS OF D-AMPHETAMINE.
177409 02-04

PCA
ANTAGONISM OF P-CHLOROAMPHETAMINE (PCA) INDUCED DEPLETION OF 5-HT FROM RAT BRAIN BY SOME THYMOLEPTICS AND OTHER PSYCHOTROPIC DRUGS.
171628 01-03
IN VIVO MEASUREMENT OF THE RELEASE OF 5-HYDROXYTRYPTAMINE (5-HT) FROM THE HIPPOCAMPUS OF THE RAT: EFFECT OF RO-4-1284, PARGYLINE AND P-CHLOROAMPHETAMINE (PCA).
182140 02-03

PCPA
THE EFFECT OF L-TRYPTOPHAN (TP) ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) REFLEXES IN ACUTE DECEREBRATE SPINAL CATS AND THE EFFECT OF PRETREATMENT WITH P-CHLOROPHENYLALANINE (PCPA) ON THE ACTION OF TP. (UNPUBLISHED PAPER).
170874 01-03
EFFECTS OF P-CHLOROPHENYLALANINE (PCPA) AND NIALAMIDE ON 5-HYDROXYTRYPTAMINE (5-HT) IN THE TRANSECTED SPINAL CORD.
171623 01-03

PEA
EFFECTS OF PHENETHYLAMINE (PEA) IN THE CHRONIC SPINAL DOG.
191904 04-03

PEAK
INHIBITION OF THE SLEEP RELATED PEAK IN PHYSIOLOGIC HUMAN GROWTH HORMONE RELEASE BY SOMATOSTATIN.
190104 04-13

PEAKING
MARIJUANA DIMINISHES GSR ACTIVATION PEAKING.
181887 02-13

PECKING
DOPAMINERGIC NATURE OF APOMORPHINE-INDUCED PECKING IN PIGEONS.
188204 04-03

PEDIATRICS
EXPERIENCE IN THE USE OF SERENAL (OXAZOLAM) IN THE FIELD OF PEDIATRICS.
176456 02-11

PEMOLINE
LACK OF EFFECT OF RIBAMINOL, TCAP, AND MAGNESIUM PEMOLINE ON RECOVERY FROM NEOCEREBELLAR DAMAGE.
171904 01-03
COCAINE, PEMOLINE AND AMPHETAMINE ON LEARNING AND RETENTION OF A DISCRIMINATION TEST IN MICE.
186705 03-04

PENFLURIDOL
SAFETY EVALUATION OF PENFLURIDOL, A NEW LONG-ACTING ORAL ANTIPSYCHOTIC AGENT.
177319 02-07
REGIONAL CHANGES IN MONOAMINE LEVELS AND IN THE RATE OF TYROSINE AND TRYPTOPHAN HYDROXYLATION IN 4 WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
185899 03-03
PENFLURIDOL: AN EFFICACIOUS LONG-ACTING ORAL ANTIPSYCHOTIC COMPOUND.
189072 04-08
EXPERIMENT WITH PENFLURIDOL (TLP-607) ON THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
191593 04-08
INTERACTION BETWEEN NEUROLEPTIC THERAPY AND SOCIOTHERAPEUTIC APPROACH. AN INVESTIGATION WITH PENFLURIDOL AND HALOPERIDOL.
192431 04-08

PENICILLIN
ANTICONVULSANT ACTIVITY OF CLONAZEPAM AND RO-8-4192 AGAINST PENICILLIN AND LIDOCAINE INDUCED SEIZURES.
178947 02-03
GENERALIZED PENICILLIN EPILEPSY IN THE CAT: EFFECTS OF INTRACAROTID AND INTRAVERTEBRAL PENTYLENETETRAZOL AND AMOBARBITAL INJECTIONS.
188374 04-03
COMMON SYNAPTIC EFFECTS OF PENTYLENETETRAZOL AND PENICILLIN.
188738 04-05

PENTAMETHOXYPHENYLETHYLAMINE
PHYSIOLOGICAL DISPOSITION OF BETA-PHENYLETHYLAMINE, 2,4,5 TRIMETHOXYPHENYLETHYLAMINE, 2,3,4,5,6 PENTAMETHOXYPHENYLETHYLAMINE AND BETA-HYDROXYMESCALINE IN RAT BRAIN, LIVER AND PLASMA.
186706 03-03

PENTAMETHYLENETETRAZOL
RELATIONSHIP BETWEEN RESPONSE TO LOW PENTAMETHYLENETETRAZOL ADMINISTRATION AND PERSONALITY OF JUVENILE OFFENDERS AND THEIR REPEATED CRIMES.
175072 02-17

PENTAZOCINE
PENTAZOCINE IN RHESUS MONKEY PLASMA AND BRAIN AFTER PARENTERAL AND ORAL ADMINISTRATION.
178641 02-03
METHODOLOGY FOR THE EVALUATION OF PENTAZOCINE, PROTOTYPE OF THE NEW MORPHINE AGONIST ANTAGONIST ANALGESICS.
191603 04-16
EFFECTS OF MORPHINE, PENTAZOCINE, AND NALOXONE ON OPERANT RESPONDING IN MONKEYS AND PIGEONS.
191972 04-04

PENTETRAZOLE
SIGNIFICANCE OF THE CENTRAL BIOGENIC AMINES FOR THE THRESHOLD IN ELECTRO AND PENTETRAZOLE SEIZURES.
181469 02-03

PENTOBARBITAL
PENTOBARBITAL: SELECTIVE DEPRESSION OF EXCITATORY POSTSYNAPTIC POTENTIALS.
168485 01-03
LIPID INDUCED CHANGES OF PENTOBARBITAL DISTRIBUTION AND METABOLISM.
170072 01-03
THE ORAL HYPNOTIC BIOASSAY OF HYDROXYZINE AND PENTOBARBITAL FOR NIGHTTIME SEDATION.
177320 02-11
RATE-DEPENDENT EFFECTS OF DRUGS. I. COMPARISONS OF D-AMPHETAMINE, PENTOBARBITAL, AND CHLORPROMAZINE ON MULTIPLE AND MIXED SCHEDULES.
177410 02-04
DIFFERENTIAL EFFECTS OF ETHANOL AND PENTOBARBITAL ON SLEEP TIME IN C57BL AND BALB MICE.
177733 02-03
EFFECTS OF CHLORPROMAZINE, CHLORDIAZEPOXIDE AND PENTOBARBITAL ON NEURONAL EXCITABILITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
177837 02-04
EFFECT OF CANNABIS ON PENTOBARBITAL INDUCED SLEEPING TIME AND PENTOBARBITAL METABOLISM IN THE RAT.
179985 02-03
EFFECTS OF L-DELTA9-TETRAHYDROCANNABINOL, DL-AMPHETAMINE AND PENTOBARBITAL ON OXYGEN CONSUMPTION BY MOUSE BRAIN AND HEART HOMOGENATES.
181813 02-03
EFFECT OF PROCAINE, LIDOCAINE AND PENTOBARBITAL ON ELECTRICAL ACTIVITY OF GUINEA-PIG OLFACTORY CORTEX IN VITRO.
182092 02-03
EFFECTS OF DECAPITATION, ETHER AND PENTOBARBITAL ON CYCLIC AMP AND CYCLIC GMP LEVELS IN RAT TISSUES.
182154 02-03
THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (THC), PENTOBARBITAL AND SKF-525-A WITH THE CARDIOVASCULAR SYSTEM OF THE RAT.
182218 03-03
AMPHETAMINE AND PENTOBARBITAL EFFECTS ON THE DISCRIMINATIVE RESPONSE CONTROL BY DEPRIVATION OF RAPID EYE MOVEMENT SLEEP (REM).
182245 03-03
BEHAVIOR AS A STIMULUS: JOINT EFFECTS OF D-AMPHETAMINE AND PENTOBARBITAL.
183890 03-04
COMPARISON OF GRADED SINGLE INTRAMUSCULAR DOSES OF MORPHINE AND PENTOBARBITAL IN MAN.
187254 03-15
ALTERATION OF EVOKED POTENTIALS IN CAUDATE NUCLEUS OF FREELY MOVING RATS BY L-DOPA, RESERPINE, AND PENTOBARBITAL.
187362 04-03
PENTOBARBITAL AND IN VIVO TURNOVER RATE OF ACETYLCHOLINE IN MOUSE BRAIN AND IN REGIONS OF RAT BRAIN. (UNPUBLISHED PAPER).
187526 04-03
INFLUENCE OF ALPHA-METHYLTYROSINE ON ENHANCEMENT OF SHUTTLEBOX AVOIDANCE BY MARIJUANA AND PENTOBARBITAL.
187572 04-04
EFFECTS OF SHORT-TERM ADMINISTRATION OF N-NITROSO COMPOUNDS ON LIVER HISTOLOGY AND PENTOBARBITAL INDUCED SLEEPING TIME IN MICE.
187575 04-04
PERSISTENT ELECTROENCEPHALOGRAPHIC CHANGES IN RHESUS MONKEYS AFTER SINGLE DOSES OF PENTOBARBITAL, NITRAZEPAM AND IMIPRAMINE.
187931 04-03
EFFECT OF PENTOBARBITAL ON UPTAKE AND RELEASE OF (3H)GABA AND (14C)GLUTAMATE BY BRAIN SLICES.
189031 04-03
PHARMACOKINETICS AND DISTRIBUTION PROPERTIES OF PENTOBARBITAL IN HUMANS FOLLOWING ORAL AND INTRAVENOUS ADMINISTRATION.
191444 04-13
ENHANCEMENT OF PENTOBARBITAL AFTER MORPHINE ADDICTION.
191898 04-03
THE COMPARATIVE EFFECTS OF PENTOBARBITAL AND D-AMPHETAMINE ON A SHORT-TERM MEMORY TASK IN BABOONS.
191917 04-04
LONG-TERM ALTERATION OF SLEEP-WAKEFULNESS CYCLE DURING CHRONIC PENTOBARBITAL DOSING AND WITHDRAWAL IN CAT.
191952 04-04
COMPARISON OF BARBITAL & PENTOBARBITAL PHYSICAL DEPENDENCE IN THE CAT.
191953 04-04

PENTOTHAL
CNS DEPRESSION IN THE ABSENCE OF PROLACTIN RELEASE FOLLOWING INTRAARTERIAL INJECTIONS OF SODIUM PENTOTHAL IN THE PROESTROUS RAT.
173257 01-03

PENTYLENETETRAZOL
PENTYLENETETRAZOL CONVULSIONS AND BRAIN CATECHOLAMINE TURNOVER RATE IN RATS AND MICE RECEIVING DIPHENYLHYDANTOIN OR BENZODIAZEPINES.
182344 03-03
CHANGES IN THE NEUROEXCITABILITY OF ALCOHOL DEPENDENT RATS UNDERGOING WITHDRAWAL AS MEASURED BY THE PENTYLENETETRAZOL SEIZURE THRESHOLD.
182348 03-03
SELECTIVE RESPIRATORY STIMULATING ACTION OF DOXAPRAM COMPARED TO PENTYLENETETRAZOL.
183887 03-03
THE EFFECTS OF PENTYLENETETRAZOL (METRAZOL) ON A LEARNED TASTE AVERSION PRODUCED BY LITHIUM CHLORIDE: THE ISSUE OF ASSOCIATIVE MEMORY VS. RETENTIVE MEMORY. (UNPUBLISHED PAPER).
188251 04-04
GENERALIZED PENICILLIN EPILEPSY IN THE CAT: EFFECTS OF INTRACAROTID AND INTRAVERTEBRAL PENTYLENETETRAZOL AND AMOBARBITAL INJECTIONS.
188374 04-03
COMMON SYNAPTIC EFFECTS OF PENTYLENETETRAZOL AND PENICILLIN.
188738 04-05
VOLTAGE CLAMP ANALYSIS OF PENTYLENETETRAZOL EFFECTS ON APLYSIA NEURONS.
189032 04-03
DIFFERENTIAL EFFECTS OF PENTYLENETETRAZOL ON REM SLEEP IN NAIVE AND COBALT EPILEPTIC RATS.
189407 04-03
THE EFFECTS OF EARLY SALINE INJECTIONS AND PENTYLENETETRAZOL ON HEBB-WILLIAMS MAZE PERFORMANCE IN THE ADULT RAT.
191378 04-04
EXCITABILITY CHANGES DURING THE GRADUAL DEVELOPMENT OF AND RECOVERY FROM PENTYLENETETRAZOL AND STRYCHNINE INDUCED CONVULSIONS IN THE CAT.
191927 04-03

PEPTIDE
SPECIFIC FACILITATION OF MAZE LEARNING BY A PEPTIDE EXTRACTED FROM TRAINED MOUSE BRAIN.
176868 02-04

PEPTIDES
BEHAVIOURAL EVALUATION OF PEPTIDES RELATED TO SCOTOPHOBIN.
177836 02-04
SYNTHESIS AND ANTIRESERPINE ACTIVITY OF PEPTIDES OF L-DOPA.
180097 02-03

PERAZINE
CLINICAL TRIAL OF PERAZINE (TAXILAN) IN TREATMENT OF SCHIZOPHRENIA.
176446 02-08

ON THE MECHANISM OF THE SYNERGISTIC EFFECT OF PERAZINE AND HEXOBARBITAL.
184199 03-03

PERCEPTION
EFFECT OF ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL ON MEMORY, SPEECH, AND PERCEPTION OF THERMAL STIMULATION: RESULTS WITH FOUR NORMAL HUMAN VOLUNTEER SUBJECTS. PRELIMINARY REPORT.
177674 02-14

EFFECTS OF LSD ON AUDITORY PERCEPTION: A SIGNAL DETECTION ANALYSIS.
185752 03-04

PERCEPTUAL
PERCEPTUAL STYLE AND PAIN TOLERANCE -- II. THE INFLUENCE OF AN ANXIOLYTIC AGENT.
184291 03-14

A STUDY OF THE EFFECTS OF RITALIN INTERVENTION UPON THE PERCEPTUAL COMPETENCIES OF CHILDREN DIAGNOSED AS GIVING EVIDENCE OF PSYCHONEUROLOGICAL LEARNING DISABILITIES. (PH.D. DISSERTATION).
186833 03-14

PERFORMANCE
EFFECT OF CHRONIC POSTTRIAL SALINE INJECTIONS ON MAZE PERFORMANCE.
167403 01-04

INFLUENCE OF CONCENTRATION AND MOTOR PERFORMANCE ON TARDIVE DYSKINESIA AND RABBIT SYNDROME.
167587 01-15

PROPRANOLOL AND CHLORDIAZEPOXIDE ON EXPERIMENTALLY INDUCED CONFLICT AND SHUTTLEBOX PERFORMANCE IN RODENTS.
171304 01-04

EFFECTS OF INTRAPERITONEAL AND INTRAVENTRICULAR D-AMPHETAMINE ADMINISTRATION ON ACTIVE AVOIDANCE PERFORMANCE IN THE RAT.
175242 02-04

ACQUISITION AND PERFORMANCE OF AN ATTENTION TASK BY RATS SUBJECTED TO CHRONIC NICOTINE TREATMENT.
176864 02-04

THE EFFECT OF MARIHUANA ON TRACKING TASK PERFORMANCE.
177720 02-14

CENTRAL NERVOUS STIMULANT INDUCED PHYSIOLOGICAL AND PERFORMANCE CHANGES IN ADULTS DURING SUSTAINED PSYCHOMOTOR TRACKING.
179023 02-13

AN ANALYSIS OF D-AMPHETAMINE PRODUCED FACILITATION OF AVOIDANCE ACQUISITION IN RATS AND PERFORMANCE CHANGES SUBSEQUENT TO DRUG TERMINATION.
179990 02-04

DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) DOSE EFFECTS COMPARED ON THREE SCHEDULES OF FOOD REINFORCED OPERANT PERFORMANCE.
182191 02-04

LONG-RANGE MOTOR PERFORMANCE CHANGES IN LEVODOPA TREATED PATIENTS WITH PARKINSONS DISEASE.
184195 03-11

COMPARISON OF PSYCHOEXPERIMENTAL PERFORMANCE UNDER THE INFLUENCE OF THE ANALGESIC PROPIRAM FUMARATE.
184618 03-14

ACUTE EFFECTS OF ALCOHOL, DIAZEPAM, THIORIDAZINE, FLUPENTHIXOL AND ATROPINE ON PSYCHOMOTOR PERFORMANCE PROFILES.
184848 03-14

SCOPOLAMINE EFFECTS ON TWO-TRIAL DELAYED-RESPONSE PERFORMANCE IN THE RAT.
186372 03-04

EFFECTS OF ORAL DELTA9-TETRAHYDROCANNABINOL ON OPERANT REINFORCEMENT SCHEDULE PERFORMANCE IN RATS.
186645 03-04

DIFFERENTIAL EFFECTS OF PILOCARPINE AND SCOPOLAMINE ON THE PERFORMANCE OF A LIGHT DARK DISCRIMINATION MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN.
186701 03-03

EFFECTS OF INTRACISTERNAL 6-HYDROXYDOPAMINE TREATMENT ON ACQUISITION AND PERFORMANCE OF RATS IN A DOUBLE T-MAZE.
187696 04-04

EFFECTS OF TWO LEVELS OF ATTENTION DEMAND ON VIGILANCE PERFORMANCE UNDER MARIHUANA.
189359 04-14

PSYCHOMOTOR TEST PERFORMANCE WITH A FENFLURAMINE AMPHETAMINE COMBINATION.
190146 04-07

PERFORMANCE ON A VERBAL LEARNING TASK BY SUBJECTS OF HEAVY PAST MARIJUANA USAGE.
190308 04-14

EFFECTS OF NICOTINE AND ITS WITHDRAWAL ON THE PERFORMANCE OF RATS ON SIGNALLED AND UNSIGNALLED AVOIDANCE SCHEDULES.
190331 04-04

THE EFFECTS OF SCOPOLAMINE ON PERFORMANCE ON A GEOMETRIC PROGRESSIVE RATIO SCHEDULE.
190334 04-04

THE EFFECTS OF EARLY SALINE INJECTIONS AND PENTYLENETETRAZOL ON HEBB-WILLIAMS MAZE PERFORMANCE IN THE ADULT RAT.
191378 04-04

EFFECTS OF CHLORPROMAZINE (CPZ) AND THIORIDAZINE PERFORMANCE AND STIMULUS CONTROL BEHAVIOR.
191974 04-04

THE EFFECTS OF HOE-36801 ON CATECHOLAMINE EXCRETION, HEART RATE AND PSYCHOMOTOR PERFORMANCE IN NEUROTICS AND NORMALS.
192428 04-13

PERFUSED
KINETICS AND CELLULAR CONTROL MECHANISMS FOR IMIPRAMINE METABOLISM IN THE ISOLATED PERFUSED RAT LIVER. (PH.D. DISSERTATION).
173601 01-03

THE ISOLATED PERFUSED RAT BRAIN AS A MODEL FOR STUDYING DRUGS ACTING ON THE CNS.
186589 03-06

EXTRANEURONAL REMOVAL, ACCUMULATION AND O-METHYLATION OF ISOPRENALINE IN THE PERFUSED HEART.
189604 04-03

PERIAQUEDUCTAL
ANALGESIA AND HYPERREACTIVITY PRODUCED BY INTRACRANIAL MICROINJECTIONS OF MORPHINE INTO THE PERIAQUEDUCTAL GRAY MATTER OF THE RAT.
191367 04-04

PERIKARYA
NEUROTOXIC EFFECTS OF P-CHLOROAMPHETAMINE (P-CA) ON PERIKARYA OF RAPHE NEURONS.
191947 04-05

PERINATAL
EFFECTS OF PERINATAL EXPOSURE TO METHYL MERCURY ON FUNCTIONAL BRAIN DEVELOPMENT AND NEUROCHEMISTRY.
189564 04-05

PERIODIC
LITHIUM IN THE TREATMENT OF PERIODIC CATATONIA: A CASE REPORT.
183648 03-09

A CASE OF PERIODIC SOMNOLENCE IMPROVED BY THE CO-MEDICATION OF L-DOPA AND METHYLPHENIDATE.
185241 03-14

PERIODICITY
ONTOGENESIS OF CIRCADIAN PITUITARY ADRENAL PERIODICITY IN RATS AFFECTED BY NEONATAL TREATMENT WITH ACTH.
181576 02-03

PERIPHERAL
CLINICAL AND ELECTROMYOGRAPHIC RESEARCH CONCERNING TREATMENT OF PERIPHERAL NEUROPATHIES WITH NIVALASI.
168975 01-13

AMPHETAMINE TRICYCLIC INTERACTIONS: ROLE OF THE HYDROXYLATION OF AMPHETAMINE IN ITS CENTRAL AND PERIPHERAL MODE OF ACTION. (PH.D. DISSERTATION).
174963 01-03

EXPERIENCE IN THE TREATMENT OF CEREBRAL INSUFFICIENCY AND PERIPHERAL BLOOD CIRCULATION DISORDERS USING THE EP-50-100 EXPERIMENTAL DRUG.
180676 02-11

PERIPHERAL VERSUS CENTRAL MECHANISMS ACCOUNTING FOR ANTIANXIETY EFFECTS OF PROPRANOLOL.
181072 02-10

TRANSSYNAPTIC INDUCTION OF CHOLINE ACETYLTRANSFERASE IN THE PREGANGLIONIC NEURON OF THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM.
182720 03-03

POSSIBLE PERIPHERAL ADRENERGIC AND CHOLINERGIC MECHANISMS IN PSEUDOCONDITIONING.
186575 03-03

LEVODOPA COMBINED WITH MK-486 (L-ALPHA-METHYLDOPAHYDRAZINE) -- A PERIPHERAL DECARBOXYLASE INHIBITOR IN PARKINSONS DISEASE.
187615 04-11

THE EFFECT OF 5,7 DIHYDROXYTRYPTAMINE ON PERIPHERAL ADRENERGIC NERVES IN THE MOUSE.
188977 04-03

INABILITY TO CONDITION A PERIPHERAL ACTIVATING DRUG.
190698 04-04

EFFECT OF ANESTHETIC AGENTS ON PERIPHERAL SYMPATHETIC NERVOUS SYSTEM FUNCTION AS MONITORED BY ARTERIAL PLASMA CATECHOLAMINE LEVELS. (UNPUBLISHED PAPER
191495 04-03

PHYSICOCHEMICAL PROPERTIES, DEVELOPMENT, AND REGULATION OF CENTRAL AND PERIPHERAL MONOAMINE OXIDASE ACTIVITY.
191497 04-03

ESTIMATION OF THE CONTRIBUTION OF PERIPHERAL AND CENTRAL NORADRENERGIC NEURONES TO URINARY 3-METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT.
192335 04-03

PERMANENT
A METHOD FOR ANALYZING CNS EFFECTS OF DRUGS AND BRAIN LESIONS ON PERMANENT GROUPS OF RATS.
176867 02-06
PERMANENT ALTERATIONS IN 5-HYDROXYTRYPTAMINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN FOLLOWING EXPOSURE TO DRUGS DURING THE PERIOD OF DEVELOPMENT.
191383 04-03

PERMEABILITY
PHENOLS: EFFECTS ON MEMBRANE PERMEABILITY OF MOLLUSCAN NEURONS.
189033 04-03
THE INFLUENCE OF PSYCHOSTIMULANTS ON K42 MEMBRANE PERMEABILITY IN VARIOUS PORTIONS OF RAT BRAIN.
191122 04-03

PERMISSION
CLINICAL INTIMATIONS OF AMINE BALANCE AND PERMISSION.
191534 04-09

PERMISSIVE
L-TRYPTOPHAN IN MANIA: CONTRIBUTION TO A PERMISSIVE HYPOTHESIS OF AFFECTIVE DISORDERS.
171500 01-09

PERMSELECTIVE
EFFECT OF LITHIUM ON AGGRESSION, MANIA AND PERMSELECTIVE MEMBRANES.
167448 01-09

PEROXIDE
INTRACEREBRAL INJECTION OF 6-HYDROXYDOPAMINE AND HYDROGEN PEROXIDE IN CATS: SPECIFIC AND NONSPECIFIC EFFECTS ON STRIATAL BIOGENIC AMINES.
188426 04-03

PERPHENAZINE
AN AUTOPSY CASE OF SCHIZOPHRENIA COMPLICATED WITH PARKINSONISM INDUCED BY PERPHENAZINE.
171275 01-15
THE COMPARISON OF THERAPEUTIC EFFECTS OF FK-880 (SULPIRIDE) AND PERPHENAZINE IN SCHIZOPHRENIA BY A DOUBLE-BLIND CONTROLLED STUDY.
181378 02-08
COMPARISON OF CLOPENTHIXOL AND PERPHENAZINE IN BEHAVIOR AND EEG OF UNANESTHETIZED CATS.
181386 02-04
PERPHENAZINE CONCENTRATIONS IN HUMAN WHOLE BLOOD: A PILOT STUDY DURING ANTIPSYCHOTIC THERAPY USING DIFFERENT ADMINISTRATION FORMS.
187639 04-16
THE EFFECT OF OCTOCLOTHEPIN AND PERPHENAZINE ON BEHAVIOUR IN RATS WITH DIFFERENT EXPLORATION AND DEFECATION RATES.
192430 04-04

PERSISTENT
EVIDENCE FOR PERSISTENT RESERPINE BINDING TO AMINE STORAGE VESICLE MEMBRANES.
182234 03-03
PERSISTENT ELECTROENCEPHALOGRAPHIC CHANGES IN RHESUS MONKEYS AFTER SINGLE DOSES OF PENTOBARBITAL, NITRAZEPAM AND IMIPRAMINE.
187931 04-03

PERSONAL
CHEMOTHERAPY AND PSYCHOTHERAPY, ARE THEY COMPLEMENTARY OR ANTAGONISTIC?: A PERSONAL STUDY.
184959 03-17

PERSONALITY
ACUTE ADVERSE REACTIONS TO PSYCHOACTIVE DRUGS, DRUG USAGE, AND PERSONALITY. (UNPUBLISHED PAPER).
167832 01-15
RELATIONSHIP BETWEEN RESPONSE TO LOW PENTAMETHYLENETETRAZOL ADMINISTRATION AND PERSONALITY OF JUVENILE OFFENDERS AND THEIR REPEATED CRIMES.
175072 02-17
CONTROL OF THE HYPERACTIVE CHILD VIA MEDICATION -- AT WHAT COST TO PERSONALITY DEVELOPMENT; SOME PSYCHOLOGICAL IMPLICATIONS AND CLINICAL INTERVENTIONS.
176810 02-11
A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: I. PIMOZIDE IN THE TREATMENT OF PERSONALITY DISORDERS.
183191 03-11

PERSPECTIVE
CHANGING DEATHS PERSPECTIVE.
169138 01-11
RITALIN FOR SCHOOL CHILDREN: THE TEACHERS PERSPECTIVE.
178127 02-17

PESTICIDES
NEUROTOXICOLOGIC STUDIES OF TWO CARBAMATE PESTICIDES IN SUBACUTE ANIMAL EXPERIMENTS.
188874 04-05

PETHIDINE
INFLUENCE OF FENTANYL, LEVORPHANOL AND PETHIDINE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189569 04-03

PETIT-MAL
IMIPRAMINE IN EXPERIMENTAL PETIT-MAL EPILEPSY.
188424 04-03

PEYOTE
PEYOTE AND RELATED ALKALOIDS XVI: SYNTHESIS OF 3,4,5 TRIMETHOXYPHENYLALANINE, AN AMINO ANALOG OF MESCALINE.
170839 01-06
PEYOTE: AN INTRODUCTION.
192874 04-12
THE CHEMISTRY OF PEYOTE ALKALOIDS.
192875 04-12
BIOSYNTHESIS OF THE PEYOTE ALKALOIDS.
192876 04-12

PG-501
EFFECTS OF PG-501 ON PARAPYRAMIDAL SYSTEM SYNDROME INDUCED BY PSYCHOTROPICS.
178019 02-15

PGE1
THE EFFECTS OF DELTA9-THC AND A WATER SOLUBLE DERIVATIVE ON PGE1 SYNTHESIS IN THE CORPUS-STRIATUM.
191964 04-03

PGO
PGO WAVES IN THE LATERAL GENICULATE NUCLEUS TRIGGERED BY BARBITURATE.
187835 04-03

PHARMACEUTICAL
SECOND MINOR TRANQUILLISER ON PHARMACEUTICAL BENEFITS LIST.
184322 03-17

PHARMACO-PSYCHOTHERAPY
ON PHARMACO-PSYCHOTHERAPY; THE ROLE OF THE PSYCHOTHERAPEUTIC SITUATION IN PSYCHOTROPIC MEDICATION.
170415 01-11

PHARMACODYNAMIC
INFLUENCE OF ADRENERGIC BLOCKERS AND ANTILIPEMIC AGENTS ON PHARMACODYNAMIC ACTIONS OF MORPHINE IN CARBON TETRACHLORIDE TREATED RATS.
188873 04-03

PHARMACODYNAMICS
SOURCES OF VARIABILITY IN THE PHARMACODYNAMICS OF 14C-IMIPRAMINE INCLUDING INTERACTION WITH DIAZEPAM OR THIORIDAZINE.
191925 04-03

PHARMACOELECTROENCEPHALOGRAPHY
PREDICTION OF NEUROLEPTIC EFFECTS OF CI-686 BASED ON QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY: DRUG PROFILES AND DOSE RESPONSE CURVES BASED ON COMPUTERIZED CEREBRAL BIOPOTENTIALS.
181958 02-13

PHARMACOGENETICS
PHARMACOGENETICS AND MENTAL DISEASE.
188826 04-11

PHARMACOKINETIC
PHARMACOKINETIC PROFILE OF DIAZEPAM IN MAN FOLLOWING SINGLE INTRAVENOUS AND ORAL AND CHRONIC ORAL ADMINISTRATION.
170838 01-13
PHARMACOKINETIC DISPOSITION OF NORAPOMORPHINE DERIVATIVES AND ITS INFLUENCE ON THE ELICITATION OF STEREOTYPICAL GNAWING. (PH.D. DISSERTATION).
174960 01-03

PHARMACOKINETICS
PHARMACOKINETICS AND DISTRIBUTION PROPERTIES OF PENTOBARBITAL IN HUMANS FOLLOWING ORAL AND INTRAVENOUS ADMINISTRATION.
191444 04-13

PHARMACOLOGIC
PHARMACOLOGIC BASIS FOR USE OF PSYCHOTROPIC DRUGS: AN OVERVIEW.
177782 02-17
PHARMACOLOGIC ANALYSIS OF THE CAUDATE SPINDLE IN CATS.
182124 02-03
PHARMACOLOGIC ACTIVITY AND BIOTRANSFORMATION OF R_ AND S-BARBITURATE ENANTIOMERS IN MOUSE AND MAN.
182156 02-03
ON-OFF PHENOMENON WITH LEVODOPA THERAPY IN PARKINSONISM: CLINICAL AND PHARMACOLOGIC CORRELATIONS AND THE EFFECT OF INTRAMUSCULAR PYRIDOXINE.
188560 04-11
DIPSOGENIC ACTION OF DIAZOXIDE: A PHARMACOLOGIC ANALYSIS.
191768 04-03

PHARMACOLOGICAL
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT (SECOND REPORT): GENERAL PHARMACOLOGY AND SUBACUTE TOXICITY.
168499 01-07

PHARMACOLOGICAL INTERACTION BETWEEN CANNABIDIOL AND DELTA9-TETRAHYDROCANNABINOL.
169472 01-03
BIOCHEMICAL AND PHARMACOLOGICAL APPROACHES IN THE STUDY OF SYMPATHETIC NERVES. (UNPUBLISHED PAPER).
170082 01-03
THE PHARMACOLOGICAL EVALUATION IN LABORATORY ANIMALS OF KABI-1702 -- A NEW SEDATIVE HYPNOTIC DRUG.
171632 01-03
HALOPERIDOL EFFECTS ON MORPHINE SELF-ADMINISTRATION: TESTING FOR PHARMACOLOGICAL MODIFICATION OF THE PRIMARY REINFORCEMENT MECHANISM.
172454 01-04
ON THE RECENTLY REPORTED PHYSIOLOGICAL AND PHARMACOLOGICAL REALITY OF THE HYPNOTIC STATE.
173056 01-13
PHARMACOLOGICAL SUPPRESSION OF EATING BEHAVIOR IN RELATION TO DIENCEPHALIC NORADRENERGIC RECEPTORS.
174763 01-04
MEASURING THE PHARMACOLOGICAL ACTION OF IMIPRAMINE IN THE TREATMENT OF DEPRESSIONS.
174995 02-09
CLINICAL PHARMACOLOGICAL STUDY OF BROMAZEPAM IN THE FIELD OF INTERNAL MEDICINE.
176473 02-10
A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY IN MAN OF INTRAVENOUSLY ADMINISTERED DELTA9-TETRAHYDROCANNABINOL, CANNABINOL, AND CANNABIDIOL.
176747 02-03
STUDY OF THE EFFECT OF CERTAIN PHARMACOLOGICAL AGENTS ON TARDIVE DYSKINESIA AND THE RABBIT SYNDROME.
178193 02-11
PSYCHIATRIC TREATMENT: WHAT COMES AFTER PHARMACOLOGICAL THERAPY
178655 02-17
PHARMACOLOGICAL STUDIES ON BROMAZEPAM.
178725 02-03
SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF OCTAHYDROBENZOCYCLOHEPTATHIAZINE DERIVATIVES.
180098 02-01
COMPLEMENTAL PHARMACOLOGICAL STUDY OF DI-N-PROPYLACETAMIDE OR DEPAMIDE.
180722 02-07
RELATIVE PHARMACOLOGICAL POTENCY IN MICE OF OPTICAL ISOMERS OF DELTA1-TETRAHYDROCANNABINOL.
181941 02-03
BEHAVIORAL PHARMACOLOGICAL STUDIES ON TRICYCLIC ANTIDEPRESSANTS IN RATS.
182116 02-04
A COMPARISON OF THE PHARMACOLOGICAL ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL AND ITS MONOHYDROXYLATED METABOLITES IN MAN.
182223 03-03
PHARMACOLOGICAL DIFFERENCES BETWEEN FLUPHENAZINE ENANTHATE AND ITS HYDROCHLORIDE.
182634 03-02
PHARMACOLOGICAL ANALYSIS OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE REMOVAL FROM THE PULMONARY CIRCULATION: DIFFERENTIATION OF UPTAKE SITES FOR EACH AMINE.
182717 03-03
CENTRAL NERVOUS DEPRESSANT XV: SYNTHESIS AND PHARMACOLOGICAL SCREENING OF SOME TRIMETHOXYAZLACTONES.
182828 03-02
AN IMPROVED METHOD FOR STUDYING THE PSYCHOGALVANIC REACTION IN MICE AND ITS INHIBITION BY PSYCHOLEPTIC DRUGS. COMPARISON WITH THE EFFECTS OF OTHER PHARMACOLOGICAL AGENTS.
185749 03-06
PHARMACOLOGICAL DISTINCTIONS BETWEEN ACTIVE AND PASSIVE AVOIDANCE MEMORY FORMATION AS SHOWN BY MANIPULATION OF BIOGENIC AMINE ACTIVE COMPOUNDS.
185927 03-04
PREPARATION AND PHARMACOLOGICAL SCREENING OF INDANETHYLAMINES RELATED TO TRYPTAMINE.
185979 03-01
SPECIFICITY OF BLOCKADE OF THE NICOTINE INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ADRENERGIC NEURONS OF THE GUINEA-PIG HEART BY VARIOUS PHARMACOLOGICAL AGENTS.
186676 03-03
ON THE CEREBRAL ACCUMULATION OF KETAMINE AND THE RELATIONSHIP BETWEEN METABOLISM OF THE DRUG AND ITS PHARMACOLOGICAL EFFECTS.
186693 03-03
RECOVERY FROM ELECTROCONVULSIVE SHOCK-INDUCED AMNESIA BY EXPOSURE TO THE TRAINING ENVIRONMENT: PHARMACOLOGICAL ENHANCEMENT BY PIRACETAM.
186704 03-04
PHARMACOLOGICAL AND TOXICOLOGICAL STUDIES ON 1,4 BUTANEDIOL.
187381 04-03
REGULATION OF BRAIN DOPAMINE TURNOVER RATE: PHARMACOLOGICAL IMPLICATIONS. (UNPUBLISHED PAPER).
187527 04-03
COMPARISON OF PHARMACOLOGICAL RESPONSES TO NICOTINE AND RELEASE OF CATECHOLAMINES FROM THE ADRENALS IN DOGS AND MONKEYS.
188199 04-03
STUDIES ON THE ACTION OF CERTAIN PHARMACOLOGICAL AGENTS ON TARDIVE DYSKINESIA AND ON THE RABBIT SYNDROME.
188406 04-03
PHARMACOLOGICAL AND BIOCHEMICAL ACTIONS OF THE HEMOLYTIC AGENTS ACETYLPHENYLHYDRAZINE AND PHENYLHYDRAZINE ON MONOAMINE OXIDASE IN THE RAT.
188769 04-03
CONFORMATIONAL ANALYSIS OF ACRIDAN DERIVATIVES BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY. A RELATIONSHIP BETWEEN CONFORMATION AND PHARMACOLOGICAL ACTIVITY.
190715 04-01
PHARMACOLOGICAL ALTERATIONS IN THE STIMULUS INDUCED RELEASE OF NOREPINEPHRINE FROM THE RABBIT SUPERIOR CERVICAL GANGLION.
191896 04-03
CORRELATION OF PHARMACOLOGICAL INVESTIGATIONS WITH THE CLINICAL EFFICACY OF ANTIDEPRESSANT DRUGS.
192420 04-13
A PHARMACOLOGICAL MODEL WITH RHESUS MONKEYS FOR THE PREDICTION OF SELECTIVE DEPRESSION OF PSYCHIC FUNCTIONS.
192424 04-04

PHARMACOLOGICALLY
PHARMACOLOGICALLY INDUCED BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE.
169120 01-03

PHARMACOLOGY
BEHAVIORAL PHARMACOLOGY.
168272 01-17
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT (SECOND REPORT): GENERAL PHARMACOLOGY AND SUBACUTE TOXICITY.
168499 01-07
PHARMACOLOGY OF TRAZODONE.
168802 01-13
THE NOOTROPIC APPROACH TO THE PHARMACOLOGY OF THE INTEGRATIVE ACTIVITY OF THE BRAIN.
173495 01-02
CARDIOVASCULAR PHARMACOLOGY OF DELTA9-TETRAHYDROCANNABINOL. (PH.D. DISSERTATION).
174964 01-03
PHARMACOLOGY AND TOXICOLOGY OF THE ANTIEPILEPTIC DRUG CLONAZEPAM.
179021 02-05
ADVANCES IN PHARMACOLOGY AND CHEMOTHERAPY.
179983 02-17
STUDIES ON BENZODIAZEPINOOXAZOLES. VI. SYNTHESIS AND PHARMACOLOGY OF 11B-PYRIDYL AND 11B-THIENYL DERIVATIVES OF BENZODIAZEPINOOXAZOLES.
180490 02-02
BEHAVIORAL PHARMACOLOGY OF BROMAZEPAM (RO-5-3350), A NEW BENZODIAZEPINE DERIVATIVE.
181384 02-04
PROGRAM IN BEHAVIORAL PHARMACOLOGY.
181394 02-14
PHARMACOLOGY OF MONO AND DISUBSTITUTED CHLORPROMAZINE METABOLITES.
182243 03-03
CLINICAL PHARMACOLOGY OF CANNABIS.
182741 03-14
THE BASIC PHARMACOLOGY OF OXYPERTINE.
182761 03-17
RECENT DEVELOPMENTS IN THE PHARMACOLOGY OF THE BENZODIAZEPINES.
182771 03-17
PHARMACOLOGY OF NEUROLEPTICS UPON REPEATED ADMINISTRATION.
186368 03-04
CLINICAL PHARMACOLOGY AS AN APPROACH TO THE STUDY OF BIOCHEMICAL SLEEP MECHANISMS: THE ACTION OF L-DOPA.
186643 03-14
ALPHA-METHYLDOPAMINE DERIVATIVES. SYNTHESIS AND PHARMACOLOGY.
189177 04-02
PSYCHIATRIC PHARMACOLOGY OF THE AGED.
191693 04-17
PHARMACOLOGY OF DEPRESSION IN THE AGED: EVALUATION OF GEROVITAL-H3 AS AN ANTIDEPRESSANT DRUG.
192229 04-09
MESCALINE: THE CHEMISTRY AND PHARMACOLOGY OF ITS ANALOGS.
192877 04-12

PHARMACOTHERAPY
HYPERKINETIC, HYPOSCHOLASTIC BEHAVIOUR AND CHARACTER DISORDERS OF CHILDHOOD AND ADOLESCENCE: DIAGNOSIS AND PHARMACOTHERAPY.
172800 01-11
PHARMACOTHERAPY IN CHRONIC SCHIZOPHRENIA.
172831 01-08
RAPID AND GENTLE PHARMACOTHERAPY OF DEPRESSION.
174495 01-10
THE FUTURE OF PHARMACOTHERAPY: NEW DRUG DELIVERY SYSTEMS.
191044 04-08

PHARYNGEAL
THE PROBLEMS OF THE CLINICAL USAGE OF NITRAZEPAM: SUPPRESSIVE EFFECTS ON THE PHARYNGEAL REFLEX AND THE COMA, USING OTHER TRANQUILIZERS AT THE SAME TIME.
188450 04-15

PHASE-SHIFT
THE EFFECT OF PHASE-SHIFT ON THE PASSIVE AVOIDANCE RESPONSE IN RATS, AND THE MODIFYING EFFECT OF CHLORDIAZEPOXIDE.
174830 01-04

PHASES
DISSOCIATION OF STIMULATORY AND SYNTHETIC PHASES IN THE INDUCTION OF TYROSINE HYDROXYLASE.
171785 01-03

PHENCYCLIDINE
EFFECTS OF PHENCYCLIDINE AND KETAMINE ON FOOD MAINTAINED BEHAVIOR IN THE PIGEON.
191973 04-04

PHENELZINE
A STUDY OF THE CLINICAL EFFECTS OF PHENELZINE AND PLACEBO IN THE TREATMENT OF PHOBIC ANXIETY.
168832 01-10
DEPRESSION SUBTYPES AND RESPONSE TO PHENELZINE, DIAZEPAM, AND A PLACEBO: RESULTS OF A NINE HOSPITAL COLLABORATIVE STUDY.
171502 01-09
PHENELZINE, MOOD RESPONSE, AND SLEEP.
183547 03-09

PHENETHYLAMINE
EFFECTS OF PHENETHYLAMINE (PEA) IN THE CHRONIC SPINAL DOG.
191904 04-03

PHENETHYLAMINES
STRUCTURE-ACTIVITY RELATIONS OF SOME INDOLEALKYLAMINES IN COMPARISON TO PHENETHYLAMINES ON MOTOR ACTIVITY AND ACQUISITION OF AVOIDANCE BEHAVIOR.
186703 03-04

PHENIRAMINE
THE EFFECT OF PHENIRAMINE AND ITS STRUCTURAL ANALOGUES ON 5-HYDROXYTRYPTAMINE IN RAT AND MOUSE BRAIN.
175240 02-03

PHENITRONE
THE EFFECTS OF PHENITRONE, A REPORTED HASHISH ANTAGONIST, ON THE OVERT BEHAVIOR OF CATS.
174607 01-04
INTERACTION OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A PURPORTED HASHISH AND LSD ANTAGONIST, WITH SEVERAL CENTRAL NEUROCHEMICAL SYSTEMS.
182217 03-04

PHENOBARBITAL
EFFECT OF PHENOBARBITAL AND 3-METHYLCHOLANTHRENE PRETREATMENT ON THE HEPATOTOXICITY OF 1,1,1 TRICHLOROETHANE AND 1,1,2 TRICHLOROETHANE.
167361 01-05
BROMAZEPAM AND PHENOBARBITAL IN ANXIETY: A CONTROLLED STUDY.
167773 01-10
THRESHOLDS FOR ELECTROCONVULSIONS AND CHEMOCONVULSIONS IN MICE AFTER TERMINATION OF TREATMENT WITH PHENOBARBITAL.
170073 01-03
INFLUENCE OF PHENOBARBITAL AND SEX HORMONES ON ENZYMES IN ASCORBIC ACID BIOSYNTHESIS IN MALE AND FEMALE RATS. (PH.D. DISSERTATION).
172017 01-03
A ROLE OF THE DIETARY LIPID IN THE ABILITY OF PHENOBARBITAL TO STIMULATE DRUG DETOXIFICATION.
175859 02-03
PREDICTING RELIEF FROM ANXIETY WITH PHENOBARBITAL.
177376 02-10
DISSOCIATIVE CHANGE IN ANTIAGGRESSIVE AND MUSCLE RELAXANT ACTIONS OF S-TRIAZOLOBENZODIAZEPINE (D-40TA) BY REPEATED ADMINISTRATION AND PHENOBARBITAL PRETREATMENT, AND ITS RELATION TO METABOLISM.
181654 02-04
DRUG DEPENDENCE TEST OF PHENOBARBITAL AND MORPHINE IN RATS BY SPONTANEOUS INTAKE.
182104 02-04
INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CAFFEINE, (C), NICOTINE (N), PHENOBARBITAL (P): EFFECTS ON CONDITIONED AVOIDANCE (CAR).
182192 02-04
DECREASED EFFECT OF PHENOBARBITAL TREATMENT ON MICROSOMAL DRUG METABOLIZING ENZYME ACTIVITY DURING GESTATION.
184228 03-03
EFFECTS OF PHENOBARBITAL AND SKF-525-A PRETREATMENT, SEX, LIVER INJURY, AND VEHICLE ON DELTA9-TETRAHYDROCANNABINOL TOXICITY.
189598 04-05
THE LACK OF EFFECTS OF PRETREATMENT WITH PHENOBARBITAL AND CHLORPROMAZINE ON THE ACUTE TOXICITY OF BENZENE IN RATS.
189600 04-05
NONSEDATING DOSAGES OF DIAZEPAM AND PHENOBARBITAL IN THE REDUCTION OF NEONATAL BILIRUBIN LEVELS.
191607 04-17

PHENOBARBITONE
ELECTROENCEPHALOGRAPHIC CHANGES IN ACUTE PHENOBARBITONE POISONING.
180149 02-15

PHENOHARMANE
EXPERIMENTAL DEPRESSION CAUSED BY APOMORPHINE AND PHENOHARMANE.
180062 02-10

PHENOLIC
CACTUS ALKALOIDS: XVIII. PHENOLIC BETA-PHENETHYLAMINES FROM MAMMILLARIA-ELONGATA.
192882 04-01

PHENOLS
PHENOLS: EFFECTS ON MEMBRANE PERMEABILITY OF MOLLUSCAN NEURONS.
189033 04-03

PHENOMENA
SLEEP PHENOMENA IN SCHIZOPHRENIA.
167954 01-08
PSYCHOMETRIC INVESTIGATIONS IN PARKINSONS SYNDROME DURING TREATMENT WITH L-DOPA AND RELEVANCE OF SOME PSYCHOLOGICAL PHENOMENA.
168578 01-13

PHENOMENOLOGICAL
PHENOMENOLOGICAL - EXISTENTIAL STUDY OF PHOBIC - OBSESSIVE SYNDROMES TREATED WITH CHLORIMIPRAMINE.
182788 03-09

PHENOTHIAZINE
PHENOTHIAZINE DOSAGE LEVELS AND AUDITORY SIGNAL DETECTION IN SCHIZOPHRENIA.
167817 01-08
PHYSOSTIGMINE EFFECTS ON PHENOTHIAZINE INDUCED EXTRAPYRAMIDAL REACTIONS.
170662 01-13
PHENOTHIAZINE INDUCED DECOMPENSATION.
171506 01-15
ANTIPARKINSONIAN AGENTS AND DEPOT PHENOTHIAZINE.
173006 01-09
INTERACTION OF PHENOTHIAZINE DERIVATIVES WITH HUMAN CERULOPLASMIN.
177335 02-13
THE EFFECTS OF PHYSOSTIGMINE IN PHENOTHIAZINE RESISTANT CHRONIC SCHIZOPHRENIC PATIENTS: PRELIMINARY OBSERVATIONS.
177669 02-08
WORD RECOGNITION OF SCHIZOPHRENICS AS A FUNCTION OF PHENOTHIAZINE LEVEL AND AUTONOMIC RESPONSIVITY. (PH.D. DISSERTATION).
182524 03-08
IDENTIFICATION AND QUANTITATIVE DETERMINATION OF PHENOTHIAZINE DRUGS IN URINE SAMPLES OF PSYCHIATRIC PATIENTS.
183599 03-02
EFFECT OF PHENOTHIAZINE NEUROLEPTIC DRUGS AND TRICYCLIC ANTIDEPRESSANTS ON PHOSPHODIESTERASE ACTIVITY IN RAT CEREBRAL CORTEX.
190311 04-03

PHENOTHIAZINES
SPECIFIC INDICATIONS FOR DIFFERENT CLASSES OF PHENOTHIAZINES.
171505 01-08
PHENOTHIAZINES CONTRAINDICATED FOR THE UNDERFAT. (DR.P.H. DISSERTATION).
174966 01-15
A PSYCHIATRIC CLINIC FOR DEPOT PHENOTHIAZINES.
181192 02-08
EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON THE RHYTHMS OF WAKEFULNESS SLEEP CYCLE IN RATS.
182553 03-04
EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON ELECTROENCEPHALOGRAM AND FEEDING BEHAVIOR OF RATS.
182554 03-04
CLINICAL DATA AND SOCIOPSYCHIATRIC IMPLICATIONS OF OUTPATIENT TREATMENT WITH LONG-TERM PHENOTHIAZINES.
182791 03-09

THE EFFECTS OF PHENOTHIAZINES ON ENDOCRINE FUNCTION: I. PATIENTS WITH INAPPROPRIATE LACTATION AND AMENORRHOEA.
184436 03-15
THE EFFECTS OF PHENOTHIAZINES ON ENDOCRINE FUNCTION: II. EFFECTS IN MEN AND POST-MENOPAUSAL WOMEN.
184437 03-13
IMPLICATIONS OF SUSTAINED RELEASE PHENOTHIAZINES: A STUDY OF FLUPHENAZINE DECANOATE.
185007 03-09
LONG-ACTING PHENOTHIAZINES AND SCHIZOPHRENIA.
186288 03-08
BLOCKADE OF INSULIN RELEASE BY CERTAIN PHENOTHIAZINES.
189583 04-05

PHENOTYPES
COMMON CANNABINOID PHENOTYPES IN 350 STOCKS OF CANNABIS.
192787 04-17

PHENOTYPICAL
PSYCHOTROPIC DRUGS AND PHENOTYPICAL BEHAVIORS.
181407 02-05

PHENOXYBENZAMINE
EFFECTS OF PHENOXYBENZAMINE, ACEPERONE AND CLONIDINE ON THE LEVEL OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL, (MOPEG) IN RAT BRAIN.
180059 02-03

PHENTERMINE
STUDIES ON THE ANOREXIGENIC ACTION OF PHENTERMINE.
182134 02-03
METABOLISM OF CHLORPHENTERMINE AND PHENTERMINE IN MAN TO YIELD HYDROXYLAMINO, C-NITROSO AND NITRO COMPOUNDS.
183796 03-13
THE 4-HYDROXYLATION OF AMPHETAMINE AND PHENTERMINE BY RAT LIVER MICROSOMES.
191921 04-03

PHENTOLAMINE
PIMOZIDE, L-PROPRANOLOL AND PHENTOLAMINE EFFECTS ON AMPHETAMINE SELF-ADMINISTRATION BY THE RAT.
191919 04-04

PHENYLALANINE
PHENYLALANINE FOR ENDOGENOUS DEPRESSION.
192521 04-09

PHENYLETHANOLAMINE-N-METHYLTRANSFERASE
THE LOCALIZATION AND CHARACTERIZATION OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE ACTIVITY IN SPECIFIC REGIONS OF THE CNS.
191932 04-03

PHENYLETHYLAMINES
EFFECTS OF 6-HYDROXYDOPAMINE ON ANOREXIA PRODUCED BY D-AMPHETAMINE AND RELATED PHENYLETHYLAMINES.
191905 04-03

PHENYLHYDRAZINE
PHARMACOLOGICAL AND BIOCHEMICAL ACTIONS OF THE HEMOLYTIC AGENTS ACETYLPHENYLHYDRAZINE AND PHENYLHYDRAZINE ON MONOAMINE OXIDASE IN THE RAT.
188769 04-03

PHENYLISOPROPYLAMINES
COMPARATIVE EFFECTS OF STEREOISOMERS OF PSYCHOTOMIMETIC PHENYLISOPROPYLAMINES.
172915 01-03

PHENYTOIN
ANTICONVULSANT EFFECTS OF CANNABINOLS IN MICE: DRUG INTERACTIONS WITH CANNABINOIDS AND CANNABINOID INTERACTIONS WITH PHENYTOIN.
189513 04-03

PHOBIAS
TREATMENT OF PHOBIAS BY SYSTEMATIC DESENSITIZATION: COMPARISON OF STANDARD VS METHOHEXITAL AIDED DESENSITIZATION.
189916 04-10

PHOBIC
CLINICAL EXPERIMENTATION WITH A NEW BENZODIAZEPINE IN THE MANAGEMENT OF PHOBIC AND OBSESSIVE SYMPTOMS.
167594 01-10
A STUDY OF THE CLINICAL EFFECTS OF PHENELZINE AND PLACEBO IN THE TREATMENT OF PHOBIC ANXIETY.
168832 01-10
PHENOMENOLOGICAL - EXISTENTIAL STUDY OF PHOBIC - OBSESSIVE SYNDROMES TREATED WITH CHLORIMIPRAMINE.
182788 03-09

PHOSPHATE
EFFECT OF 5-METHOXYTRYPTAMINE ON SERUM CALCIUM AND PHOSPHATE IN RATS.
186678 03-03
THE EFFECTS OF LITHIUM ON HIGH ENERGY PHOSPHATE AND GLUCOSE LEVELS IN THE RAT SUPERIOR CERVICAL GANGLION.
187677 04-03

PHOSPHATIDYLCHOLINE
EFFECT OF MORPHINE ON THE TURNOVER AND SYNTHESIS OF (LEU-3H) PROTEIN AND (CH-14C) PHOSPHATIDYLCHOLINE IN DISCRETE REGIONS OF THE RAT BRAIN.
189586 04-03

PHOSPHODIESTERASE
EFFECTS OF NEUROLEPTICS AND THYMOLEPTICS ON PHOSPHODIESTERASE ACTIVITY AND ON CYCLIC 3,5 AMP LEVELS IN RAT BRAIN.
181467 02-03
REGIONAL CYCLIC NUCLEOTIDES PHOSPHODIESTERASE ACTIVITY IN CAT CENTRAL NERVOUS SYSTEM: EFFECTS OF BENZODIAZEPINES.
181575 02-03
EFFECT OF PHENOTHIAZINE NEUROLEPTIC DRUGS AND TRICYCLIC ANTIDEPRESSANTS ON PHOSPHODIESTERASE ACTIVITY IN RAT CEREBRAL CORTEX.
190311 04-03

PHOSPHORYLASE
IN VIVO CHANGES OF CEREBRAL CYCLIC ADENOSINE 3,5 MONOPHOSPHATE INDUCED BY BIOGENIC AMINES: ASSOCIATION WITH PHOSPHORYLASE ACTIVATION.
188291 04-03

PHOTIC
LSD EFFECTS ON SIGNAL-TO-NOISE RATIO AND LATERALIZATION OF VISUAL CORTEX AND LATERAL GENICULATE DURING PHOTIC STIMULATION.
167449 01-03
PHOTIC RESPONSES IN MINIMAL BRAIN DYSFUNCTION.
191188 04-15

PHOTOMYOCLONIC
CHRONIC MEPROBAMATE INTOXICATION AND PHOTOMYOCLONIC RESPONSE.
181377 02-15

PHOTOPALPEBRAL
THE EFFECT OF FLURAZEPAM ON THE PHOTOPALPEBRAL REFLEX.
184314 03-13

PHRENIC
EFFECTS OF AMPHETAMINE ISOMERS ON NEUROMUSCULAR TRANSMISSION IN RAT PHRENIC NERVE DIAPHRAGM PREPARATION.
182232 03-03
THE IMPULSE BLOCKING CONCENTRATIONS OF ANESTHETICS, ALCOHOLS, ANTICONVULSANTS, BARBITURATES, AND NARCOTICS ON PHRENIC AND SCIATIC NERVES.
187803 04-03

PHYLOGENETIC
PHYLOGENETIC DISTRIBUTION OF OPIATE RECEPTOR BINDING.
190476 04-03

PHYSICAL
DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE IN RESPECT TO TIME AND DOSAGE AND QUANTIFICATION OF THE PRECIPITATED WITHDRAWAL SYNDROME IN RATS.
169474 01-03
ABUSE POTENTIAL OF ETORPHINE (M99) I. SUBJECTIVE EFFECTS AND PHYSICAL DEPENDENCE. (UNPUBLISHED PAPER).
171241 01-14
MORPHINE PHYSICAL DEPENDENCE UNALTERED BY PREVIOUS DEPENDENCE ON MORPHINE.
173872 01-03
DISCRIMINANT ANALYSIS OF THE RELATIONSHIP BETWEEN PHYSICAL PROPERTIES AND THE INHIBITION OF MONOAMINE OXIDASE BY AMINOTETRALINS AND AMINOINDANS.
180096 02-03
ATTEMPT TO EVALUATE THE PHYSICAL DEPENDENCE LIABILITY OF PSYCHOTROPIC DRUGS IN MICE.
182103 02-04
EFFECT OF GAMMA-AMINOBUTYRIC ACID (GABA) ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
182231 03-03
MORPHINE PHYSICAL DEPENDENCE IN THE DOG.
186665 03-03
INVESTIGATION OF PHYSICAL DEPENDENCE ON A NEW BENZODIAZEPINE DERIVATIVE, BROMAZEPAM.
189209 04-05
EFFECT OF L-PHENYL-3-2-THIAZOLYL 2-THIOUREA, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
191769 04-03
COMPARISON OF BARBITAL & PENTOBARBITAL PHYSICAL DEPENDENCE IN THE CAT.
191953 04-04

PHYSICIANS
THOUGHTS ON TREATMENT BY PRIVATE PHYSICIANS OF ABNORMAL SEX DRIVES.
180674 02-11
CHEMOTHERAPY OF DELIRIUM-TREMENS: A SURVEY OF PHYSICIANS PREFERENCES.
192068 04-11

PHYSICOCHEMICAL
PHYSICOCHEMICAL PROPERTIES, DEVELOPMENT, AND REGULATION OF CENTRAL AND PERIPHERAL MONOAMINE OXIDASE ACTIVITY.
191497 04-03

PHYSIOCHEMICAL
PHYSIOCHEMICAL PROPERTIES, SOLUBILITY, AND PROTEIN BINDING OF DELTA9-TETRAHYDROCANNABINOL. (UNPUBLISHED PAPER).
188256 04-01

PHYSIOLOGIC
INHIBITION OF THE SLEEP RELATED PEAK IN PHYSIOLOGIC HUMAN GROWTH HORMONE RELEASE BY SOMATOSTATIN.
190104 04-13

PHYSIOLOGICAL
PSYCHOLOGICAL AND PHYSIOLOGICAL EFFECTS OF CHRONIC MARIJUANA ADMINISTRATION IN MAN.
169070 01-13

ON THE RECENTLY REPORTED PHYSIOLOGICAL AND PHARMACOLOGICAL REALITY OF THE HYPNOTIC STATE.
173056 01-13

CENTRAL NERVOUS STIMULANT INDUCED PHYSIOLOGICAL AND PERFORMANCE CHANGES IN ADULTS DURING SUSTAINED PSYCHOMOTOR TRACKING.
179023 02-13

BEHAVIORAL AND PHYSIOLOGICAL ACTIVITY OF DEAMINATED METABOLITES OF MESCALINE.
182244 03-03

PHYSIOLOGICAL DISPOSITION OF BETA-PHENYLETHYLAMINE, 2,4,5 TRIMETHOXYPHENYLETHYLAMINE, 2,3,4,5,6 PENTAMETHOXYPHENYLETHYLAMINE AND BETA-HYDROXYMESCALINE IN RAT BRAIN, LIVER AND PLASMA.
186706 03-03

EFFECT OF CHRONIC TREATMENT WITH CENTRAL STIMULANTS ON BRAIN MONOAMINES AND SOME BEHAVIOURAL AND PHYSIOLOGICAL FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS.
191503 04-03

HUMAN SERUM DOPAMINE-BETA-HYDROXYLASE: RELATIONSHIP TO SYMPATHETIC ACTIVITY IN PHYSIOLOGICAL AND PATHOLOGICAL STATES.
191510 04-13

PHYSOSTIGMINE
EFFECTS OF FOOD DEPRIVATION, DISCRIMINATION EXPERIENCE AND PHYSOSTIGMINE ON CHOLINE ACETYLASE AND ACETYLCHOLINE ESTERASE IN THE DORSAL HIPPOCAMPUS AND FRONTAL CORTEX OF RATS.
169467 01-03

PHYSOSTIGMINE EFFECTS ON PHENOTHIAZINE INDUCED EXTRAPYRAMIDAL REACTIONS.
170662 01-13

ANTAGONISTIC EFFECTS OF PHYSOSTIGMINE AND METHYLPHENIDATE IN MAN.
172272 01-11

INDUCTION OF SEVERE DEPRESSION BY PHYSOSTIGMINE IN MARIJUANA INTOXICATED INDIVIDUALS.
177450 02-14

THE EFFECTS OF PHYSOSTIGMINE IN PHENOTHIAZINE RESISTANT CHRONIC SCHIZOPHRENIC PATIENTS: PRELIMINARY OBSERVATIONS.
177669 02-08

EFFECTS OF PHYSOSTIGMINE ON THE MAINTENANCE OF DISCRIMINATION BEHAVIOUR IN RATS.
186637 03-04

ACTIONS OF ATROPINE, HEMICHOLINIUM-3, AND PHYSOSTIGMINE ON CHLORPROMAZINE INDUCED CHANGES IN RAT BRAIN MONOAMINES.
187800 04-03

EFFECT OF OXOTREMORINE AND PHYSOSTIGMINE ON CHOLINE LEVELS IN MOUSE WHOLE BRAIN, SPLEEN AND CEREBELLUM.
189893 04-03

REBOUND PHENOMENON IN MANIC PATIENTS FOLLOWING PHYSOSTIGMINE: TOWARDS AN UNDERSTANDING OF AMINERGIC MECHANISMS UNDERLYING AFFECTIVE DISORDERS.
191531 04-09

PICOGRAM
MEASUREMENT OF BIOGENIC AMINES AT THE PICOGRAM LEVEL. (UNPUBLISHED LEVEL).
173382 01-03

PIGEON
EFFECTS OF PHENCYCLIDINE AND KETAMINE ON FOOD MAINTAINED BEHAVIOR IN THE PIGEON.
191973 04-04

PIGEONS
DOPAMINERGIC NATURE OF APOMORPHINE-INDUCED PECKING IN PIGEONS.
188204 04-03

NALTREXONE AND NALOXONE: AGONIST AND ANTAGONIST EFFECTS ON KEY-PRESS RESPONDING OF PIGEONS MAINTAINED UNDER A MULTIPLE SCHEDULE OF FOOD PRESENTATION.
191926 04-04

EFFECTS OF MORPHINE, PENTAZOCINE, AND NALOXONE ON OPERANT RESPONDING IN MONKEYS AND PIGEONS.
191972 04-04

PIGS
EFFECTS OF CHLORDIAZEPOXIDE ON HEART RATE AND BEHAVIOURAL SUPPRESSION IN PIGS SUBJECTED TO OPERANT CONDITIONING PROCEDURES.
189409 04-04

PILL
UPDATING THE SLEEPING PILL.
176011 02-11

PILLS
SLEEPING PILLS AND DREAM CONTENT.
189043 04-14

PILO
THE INFLUENCE OF DELTA9-TETRAHYDROCANNABINOL (THC) ON PILOCARPINE (PILO) INDUCED PAROTID SECRETIONS OF THE RAT.
191962 04-03

PILOCARPINE
TOLERANCE TO HEXOBARBITAL AND SUPERSENSITIVITY TO PILOCARPINE INDUCED BY CHRONIC BARBITAL TREATMENT IN THE RAT.
171601 01-03

ACTIVATION OF COPULATORY BEHAVIOR BY PILOCARPINE AND OXOTREMORINE IN THE FEMALE RAT.
171616 01-04

REDUCED BEHAVIORAL EFFECTS OF PILOCARPINE DURING CHRONIC TREATMENT WITH DFP.
185265 03-04

DIFFERENTIAL EFFECTS OF PILOCARPINE AND SCOPOLAMINE ON THE PERFORMANCE OF A LIGHT DARK DISCRIMINATION MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN.
186701 03-03

THE INFLUENCE OF DELTA9-TETRAHYDROCANNABINOL (THC) ON PILOCARPINE (PILO) INDUCED PAROTID SECRETIONS OF THE RAT.
191962 04-03

PILOT
METIAPINE: THE EVALUATION OF THE ANTIPSYCHOTIC PROPERTIES OF A NEW NEUROLEPTIC. A PILOT STUDY.
167342 01-08

MELANOCYTE STIMULATING HORMONE RELEASE INHIBITING HORMONE AS AN ANTIDEPRESSANT: A PILOT STUDY.
171501 01-09

PILOT CLINICAL TRIAL OF PARENTERAL LORAZEPAM (TEMESTA) IN ANXIETY STATES.
174044 01-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: I. PIMOZIDE IN THE TREATMENT OF PERSONALITY DISORDERS.
183191 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: II. PIMOZIDE IN THE TREATMENT OF BEHAVIOURAL DISORDERS IN CHILDHOOD AND ADOLESCENCE.
183192 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: III. PIMOZIDE IN THE TREATMENT OF STRESS INDUCED PSYCHIC AND FUNCTIONAL DISORDERS.
183193 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: IV. PIMOZIDE IN THE TREATMENT OF PATIENTS WITH PARANOID SYMPTOMATOLOGY.
183194 03-09

PERPHENAZINE CONCENTRATIONS IN HUMAN WHOLE BLOOD: A PILOT STUDY DURING ANTIPSYCHOTIC THERAPY USING DIFFERENT ADMINISTRATION FORMS.
187639 04-16

ANTICONVULSANT ACTION OF VITAMIN-D IN EPILEPTIC PATIENTS? A CONTROLLED PILOT STUDY.
188889 04-11

CARBAMAZEPINE AS AN ANTICONVULSANT: A PILOT STUDY.
192391 04-07

PIMOZIDE
DRINKING BEHAVIOUR AND BRAIN DOPAMINE: ANTAGONISTIC EFFECT OF TWO NEUROLEPTIC DRUGS (PIMOZIDE AND SPIRAMIDE) UPON AMPHETAMINE OR APOMORPHINE-INDUCED HYPODIPSIA.
174035 01-04

PIMOZIDE IN THE TREATMENT OF BEHAVIORAL DISORDERS OF HOSPITALIZED ADOLESCENTS.
176109 02-14

CLINICAL EXPERIENCES WITH A NEW PSYCHOTROPIC DRUG, R-6238 (PIMOZIDE).
176564 02-11

PIMOZIDE (R-6238) IN CHRONIC SCHIZOPHRENIA: DOUBLE-BLIND TRIAL.
178255 02-08

DOUBLE-BLIND PSYCHOMETRIC EVALUATION OF PIMOZIDE AND HALOPERIDOL VERSUS PLACEBO IN EMOTIONALLY LABILE VOLUNTEERS UNDER TWO DIFFERENT WORK LOAD CONDITIONS.
180065 02-14

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: I. PIMOZIDE IN THE TREATMENT OF PERSONALITY DISORDERS.
183191 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: II. PIMOZIDE IN THE TREATMENT OF BEHAVIOURAL DISORDERS IN CHILDHOOD AND ADOLESCENCE.
183192 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: III. PIMOZIDE IN THE TREATMENT OF STRESS INDUCED PSYCHIC AND FUNCTIONAL DISORDERS.
183193 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: IV. PIMOZIDE IN THE TREATMENT OF PATIENTS WITH PARANOID SYMPTOMATOLOGY.
183194 03-09

A DOUBLE-BLIND COMPARISON OF PIMOZIDE WITH CARPIPRAMINE IN SCHIZOPHRENIC PATIENTS.
183195 03-08

CLINICAL OBSERVATIONS ON THE USE OF PIMOZIDE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS.
183196 03-08

PIMOZIDE, L-PROPRANOLOL AND PHENTOLAMINE EFFECTS ON AMPHETAMINE SELF-ADMINISTRATION BY THE RAT.
191919 04-04

SUPERSENSITIVITY TO DOPAMINERGIC AGONISTS FOLLOWING WITHDRAWAL OF A CHRONIC DIET CONTAINING HALOPERIDOL OR PIMOZIDE.
192012 04-04

PINEAL

STIMULATION OF SEROTONIN N-ACETYLTRANSFERASE IN PINEAL ORGAN CULTURE BY DRUGS.
177128 02-03

EFFECTS OF AQUEOUS PINEAL EXTRACT IN CHRONIC SCHIZOPHRENIA.
177818 02-08

PIPERACETAZINE

PIPERACETAZINE IN AMBULATORY CHRONIC SCHIZOPHRENIC PATIENTS.
177748 02-08

HIGH DOSAGE PIPERACETAZINE (QUIDE-R) IN AMBULATORY SCHIZOPHRENIC PATIENTS: THERAPEUTIC EFFICACY AND TOXICITY.
187869 04-08

PIPERAZINES

1,4-BIS(2-INDOL-3-YLETHYL)PIPERAZINES.
187940 04-01

PIPERAZINOQUINAZOLONES

SUBSTITUTED PIPERAZINOQUINAZOLONES: RELATIONSHIP BETWEEN SELECTIVE INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND ANTICONVULSANT ACTIVITY.
183598 03-02

PIPRADROL

THE EFFECT OF PIPRADROL IN MICE AND ITS ANTAGONISM BY NEUROLEPTIC DRUGS.
171607 01-04

PIPRADROL IN MILD DEPRESSION: A CONTROLLED STUDY.
176107 02-10

EFFECTS OF METHAMPHETAMINE, PIPRADROL, AND METHYLPHENIDATE ON INSTRUMENTAL CONDITIONING AND SPONTANEOUS MOTOR ACTIVITY IN THE IMMATURE RAT.
186568 03-04

PIRACETAM

STRYCHNINE SULFATE AND PIRACETAM: LACK OF EFFECT ON LEARNING IN THE RAT.
184980 03-04

RECOVERY FROM ELECTROCONVULSIVE SHOCK-INDUCED AMNESIA BY EXPOSURE TO THE TRAINING ENVIRONMENT: PHARMACOLOGICAL ENHANCEMENT BY PIRACETAM.
186704 03-04

PIRIBEDIL

STIMULATION OF A DOPAMINE SENSITIVE ADENYLATE CYCLASE IN HOMOGENATES OF RAT STRIATUM BY A METABOLITE OF PIRIBEDIL (ET-495).
189616 04-03

EFFECT OF PIRIBEDIL AND ONE OF ITS METABOLITES ON THE CONCENTRATION OF HOMOVANILLIC ACID IN THE RAT BRAIN.
191422 04-03

EFFECTS OF PIRIBEDIL (ET-495) -- A DOPAMINERGIC RECEPTOR STIMULATING AGENT IN PARKINSONS DISEASE.
191522 04-13

PITUITARY

POSSIBLE INVOLVEMENT OF CYCLIC NUCLEOTIDES IN THE STIMULATION OF PITUITARY FUNCTION ELICITED BY RESERPINE. (UNPUBLISHED PAPER).
170086 01-03

FUNCTIONAL EVALUATION OF PITUITARY RESERVE IN PATIENTS WITH THE AMENORRHEA GALACTORRHEA SYNDROME UTILIZING LUTEINIZING HORMONE RELEASING HORMONE (LH-RH), L-DOPA AND CHLORPROMAZINE.
175245 02-13

ONTOGENESIS OF CIRCADIAN PITUITARY ADRENAL PERIODICITY IN RATS AFFECTED BY NEONATAL TREATMENT WITH ACTH.
181576 02-03

HISTO-AUTORADIOGRAPHIC INVESTIGATIONS ON THE DISTRIBUTION OF INJECTED 5-HYDROXYTRYPTAMINE (SEROTONIN) IN THE BRAIN AND THE PITUITARY OF MICE.
185900 03-03

DRUG EFFECTS AND HYPOTHALAMIC ANTERIOR PITUITARY FUNCTION.
188393 04-03

PSYCHOENDOCRINE INVESTIGATION IN SCHIZOPHRENIA: RELATIONSHIP BETWEEN PITUITARY GONADAL FUNCTION AND BEHAVIOR.
191190 04-14

PIZOTYLINE

CLINICAL RESULTS WITH PIZOTYLINE IN DEPRESSION.
174299 01-09

PLACEBO

DOUBLE-BLIND CLINICAL EVALUATION OF MAZINDOL, DEXTROAMPHETAMINE, AND PLACEBO IN TREATMENT OF EXOGENOUS OBESITY.
167335 01-11

CLORAZEPATE DIPOTASSIUM, DIAZEPAM AND PLACEBO IN CHRONIC ANXIETY.
167339 01-10

THE EFFECT OF PLACEBO AND DRUGS ON HUMAN SLEEP.
168419 01-14

A STUDY OF THE CLINICAL EFFECTS OF PHENELZINE AND PLACEBO IN THE TREATMENT OF PHOBIC ANXIETY.
168832 01-10

A TRIAL ON BROMAZEPAM (LEXOTAN) AND PLACEBO IN THE TREATMENT OF PSYCHOPHYSIOLOGICAL DISORDERS.
171150 01-11

DEPRESSION SUBTYPES AND RESPONSE TO PHENELZINE, DIAZEPAM, AND A PLACEBO: RESULTS OF A NINE HOSPITAL COLLABORATIVE STUDY.
171502 01-09

DIPHENYLHYDANTOIN EFFECTIVENESS IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS: A DOUBLE-BLIND CONTROLLED STUDY WITH A PLACEBO.
171507 01-08

DOUBLE-BLIND PSYCHOMETRIC EVALUATION OF PIMOZIDE AND HALOPERIDOL VERSUS PLACEBO IN EMOTIONALLY LABILE VOLUNTEERS UNDER TWO DIFFERENT WORK LOAD CONDITIONS.
180065 02-14

A DOUBLE-BLIND TRIAL OF TRIOXAZINE WITH PLACEBO IN ANXIETY STATES.
180249 02-10

AFRODEX VS. PLACEBO IN THE TREATMENT OF MALE IMPOTENCE: STATISTICAL ANALYSIS OF TWO DOUBLE-BLIND CROSSOVER STUDIES.
181959 02-14

COMPARISON OF INTRAVENOUSLY ADMINISTERED METHADONE (ME), MORPHINE (MO), HERCIN (H) AND PLACEBO (P).
182163 02-03

DOUBLE-BLIND COMPARISON OF THIOTHIXENE, TRIFLUOPERAZINE, AND PLACEBO IN CHRONIC ALCOHOLISM.
188584 04-11

COMPARISON OF AMANTADINE, PLACEBO, AND LEVODOPA IN PARKINSONS DISEASE.
189502 04-11

THE CONTROL OF DEVIANT SEXUAL BEHAVIOR BY DRUGS: A DOUBLE-BLIND CONTROLLED STUDY OF BENPERIDOL, CHLORPROMAZINE, AND PLACEBO.
190061 04-11

THE COMPARATIVE ANXIOLYTIC EFFECTS OF PLACEBO, IMIPRAMINE AND CHLORIMIPRAMINE USING PSYCHIATRIC AND PSYCHOPHYSIOLOGICAL MEASUREMENTS.
191137 04-14

DRUG NAME FAMILIARITY AND THE PLACEBO EFFECT.
192704 04-17

PLACEBOS

DRUGS AND PLACEBOS: DRUG GUESSING BY NORMAL VOLUNTEERS.
174210 01-14

PLACENTAL

DETERMINATION OF DRUG TRANSFER ACROSS BIOLOGICAL MEMBRANES: COMPARATIVE STUDY ON THE PASSAGE OF DRUGS INTO THE CENTRAL NERVOUS SYSTEM AND THEIR PLACENTAL TRANSFER AND FETAL LOCALIZATION IN THE PREGNANT RAT. (PH.D. DISSERTATION).
172018 01-03

PLASMA

INCREASE IN THE PLASMA CONCENTRATION OF FREE TRYPTOPHAN CAUSED BY PROBENECID IN HUMANS.
169470 01-13

PLASMA BINDING OF IMIPRAMINE AND CLINICAL OUTCOME.
172271 01-13

AMPHETAMINE IN HUMAN PLASMA: A SENSITIVE AND SPECIFIC ENZYMATIC ASSAY.
177403 02-16

PENTAZOCINE IN RHESUS MONKEY PLASMA AND BRAIN AFTER PARENTERAL AND ORAL ADMINISTRATION.
178641 02-03

DIAZEPAM TREATMENT FOR ACUTE CONVULSIONS IN CHILDREN: A REPORT OF 41 PATIENTS, THREE WITH PLASMA LEVELS.
182595 03-11

ISOLATION OF A POSSIBLE NEW METABOLITE OF THIORIDAZINE AND MESORIDAZINE FROM HUMAN PLASMA.
182722 03-13

QUANTITATIVE DETERMINATION OF IMIPRAMINE AND DESIPRAMINE IN HUMAN BLOOD PLASMA BY DIRECT DENSITOMETRY OF THIN-LAYER CHROMATOGRAMS.
183603 03-13

EFFECT OF VARIOUS STEROIDS AND ACTH ON METHYPRYLON PLASMA LEVELS AND SLEEPING TIME IN RATS.
183611 03-03

PLASMA LEVELS OF LUTEINIZING HORMONE AND OF IMMUNOREACTIVE ESTROGENS (ESTRADIOL) IN ANOREXIA-NERVOSA: RESPONSE TO CLOMIPHENE CITRATE.
183807 03-10

EFFECTS OF METHAMPHETAMINE ON DAILY RHYTHMS OF HYPOTHALAMIC NOREPINEPHRINE, SEROTONIN AND PLASMA CORTICOSTERONE LEVELS IN THE RAT.
184178 03-03

THE CONCENTRATIONS OF DIAZEPAM AND ITS METABOLITES IN THE PLASMA AFTER AN ACUTE AND CHRONIC ADMINISTRATION.
184978 03-13

RELATIONSHIP OF PLASMA MEPERIDINE LEVELS TO CHANGES IN ANXIETY AND HOSTILITY.
185881 03-14

GLC DETERMINATION OF MEPROBAMATE IN WATER, PLASMA AND URINE.
185977 03-16

PLASMA CONCENTRATIONS OF DIAZEPAM AND OF ITS METABOLITE N-DESMETHYLDIAZEPAM IN RELATION TO ANXIOLYTIC EFFECT.
186184 03-13

THE EFFECT OF MINOR TRANQUILIZERS ON STRESS INDUCED INCREASES IN RAT PLASMA CORTICOSTEROIDS.
186578 03-03

PLASMA LEVEL OF DIAZEPAM AS A THERAPEUTIC PREDICTOR IN ANXIETY STATES.
186584 03-10

PHYSIOLOGICAL DISPOSITION OF BETA-PHENYLETHYLAMINE, 2,4,5 TRIMETHOXYPHENYLETHYLAMINE, 2,3,4,5,6 PENTAMETHOXYPHENYLETHYLAMINE AND BETA-HYDROXYMESCALINE IN RAT BRAIN, LIVER AND PLASMA.
186706 03-03

VALIDITY OF SCREENING METHODS FOR DRUGS OF ABUSE IN BIOLOGICAL FLUIDS. II. HEROIN IN PLASMA AND SALIVA.
187256 03-15

SEQUENTIAL TRIAL COMPARING TWO PLASMA LEVELS OF NORTRIPTYLINE.
187582 04-10

PLASMA AND CEREBROSPINAL FLUID PROBENECID CONCENTRATIONS AS RELATED TO ACCUMULATION OF ACIDIC BIOGENIC AMINE METABOLITES IN MAN.
187933 04-13

PLASMA DOPA AND FUNCTIONAL OSCILLATIONS AFTER CHRONIC TREATMENT OF PARKINSONS DISEASE.
188421 04-13

LONG-TERM TREATMENT OF ENDOGENOUS DEPRESSION WITH NORTRIPTYLINE WITH CONTROL OF PLASMA LEVELS.
188832 04-09

EFFECTS OF CHLORPROMAZINE PLASMA LEVELS ON ELECTROCARDIOGRAM.
188838 04-13

EFFECT OF ANESTHETIC AGENTS ON PERIPHERAL SYMPATHETIC NERVOUS SYSTEM FUNCTION AS MONITORED BY ARTERIAL PLASMA CATECHOLAMINE LEVELS. (UNPUBLISHED PAPER
191495 04-03

MONOAMINE OXIDASE IN MAN: ENZYME CHARACTERISTICS IN HUMAN PLATELETS, PLASMA, AND OTHER HUMAN TISSUES.
191502 04-13

PROTRIPTYLINE STEADY-STATE PLASMA LEVELS IN MAN.
191924 04-13

THE EFFECT OF CONJUGATED ESTROGENS ON PLASMA BUTAPERAZINE LEVELS IN WOMEN.
191959 04-15

PLASMA LEVELS AND TRICYCLIC ANTIDEPRESSANTS.
192872 04-10

PLASMA NORTRIPTYLINE LEVELS – RELATIONSHIP TO CLINICAL EFFECTS.
192873 04-09

PLATELET

PLATELET MONOAMINE OXIDASE ACTIVITY AND SUBSTRATE PREFERENCES IN SCHIZOPHRENIC PATIENTS.
174609 01-14

EFFECT OF LSD-25 AND 1-METHYL-D-LYSERGIC ACID BUTANOLAMIDE ON RAT BRAIN AND PLATELET SEROTONIN LEVELS.
184975 03-03

PLATELETS

A NEW MODIFICATION FOR STUDYING 5-HT UPTAKE BY BLOOD PLATELETS: A RE-EVALUATION OF TRICYCLIC ANTIDEPRESSANTS AS UPTAKE INHIBITORS.
180055 02-06

MONOAMINE OXIDASE IN MAN: ENZYME CHARACTERISTICS IN HUMAN PLATELETS, PLASMA, AND OTHER HUMAN TISSUES.
191502 04-13

INFLUENCE OF VARIOUS SUBSTANCES WHICH INDUCE AND INHIBIT AGGREGATION ON THE UPTAKE OF DEOXYGLUCOSE BY HUMAN BLOOD PLATELETS.
191770 04-13

PLAY

THE SOCIAL PLAY BEHAVIOR OF CHIMPANZEES ACCORDING TO A PSYCHOPHARMACOLOGICAL TEST/.
168838 01-04

DIAZEPAM-INDUCED PLAY BEHAVIOR IN CATS DURING PREY KILLING.
184979 03-04

PLEXUS

THE ELIMINATION OF 5-HYDROXYINDOLEACETIC ACID FROM CEREBROSPINAL FLUID: CHARACTERISTICS OF THE ACID TRANSPORT SYSTEM OF THE CHOROID PLEXUS.
182718 03-03

PMPEA

THE ROLE OF MONOAMINE OXIDASE IN TERMINATING THE REFLEX EFFECTS OF P-METHOXYPHENYLETHYLAMINE (PMPEA).
174319 01-03

POINTER

PSYCHOPHARMACOLOGIC FACILITATION OF OPERANT CONDITIONING OF GENETICALLY NERVOUS CATAHOULA AND POINTER DOGS.
190696 04-04

POISONING

TEMPERATURE DEPENDENT TOXICITY OF ADRENERGIC AGONISTS IN MICE AS A BASIS FOR TREATING D-AMPHETAMINE POISONING.
169688 01-05

ACUTE NITRAZEPAM (MOGADON) POISONING: AN ELECTROENCEPHALOGRAPHIC STUDY.
180148 02-15

ELECTROENCEPHALOGRAPHIC CHANGES IN ACUTE PHENOBARBITONE POISONING.
180149 02-15

THE ELECTROENCEPHALOGRAPHIC CHANGES IN ACUTE BARBITURATE POISONING.
180152 02-15

ACUTE POISONING BY NITRAZEPAM (MOGADON).
183786 03-15

POLAROGRAPHIC

A POLAROGRAPHIC METHOD FOR THE DETERMINATION OF THE N-OXIDE, N-OXIDE-SULPHOXIDE AND SULPHOXIDE METABOLITES OF CHLORPROMAZINE.
190902 04-06

POLICY

AMPHETAMINE USE AND MISUSE WITH RECOMMENDATIONS FOR STIMULANT CONTROL POLICY.
172109 01-17

POLLY

POLLY: MENTAL DEFICIENCY AND SCHIZOPHRENIA.
174641 01-17

POLYDIPSIA

SUBSTANTIAL ORAL MORPHINE INTAKE BY THE RAT USING SCHEDULE INDUCED POLYDIPSIA.
182194 02-04

POLYMERASE

SOLUBILIZATION AND PURIFICATION OF BRAIN RNA POLYMERASE.
180537 02-06

POLYMYALGIA

POLYMYALGIA RHEUMATICA IN A GERIATRIC DEPARTMENT: NINE PATIENTS WITH AN AVERAGE AGE OF 83 YEARS.
187236 03-11

POLYPHARMACY

POLYPHARMACY IN PSYCHIATRY: A MULTI-STATE COMPARISON OF PSYCHOTROPIC DRUG COMBINATIONS.
187840 04-17

POLYRIBOSOMES

INTERACTIVE EFFECTS OF CYCLOHEXIMIDE AND PUROMYCIN IN ALTERING BRAIN POLYRIBOSOMES AND NEURAL AND BEHAVIOURAL RESPONSES TO ELECTROSHOCK IN MICE.
175230 02-03

POLYSOMES

DISAGGREGATION OF BRAIN POLYSOMES AFTER L-DOPA: AN ANALYSIS.
188433 04-03

POLYSYNAPTIC

THE EFFECT OF L-TRYPTOPHAN (TP) ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) REFLEXES IN ACUTE DECEREBRATE SPINAL CATS AND THE EFFECT OF PRETREATMENT WITH P-CHLOROPHENYLALANINE (PCPA) ON THE ACTION OF TP. (UNPUBLISHED PAPER).
170874 01-03

THE EFFECT IN THE CAT OF TRYPTAMINE (T) AND LSD ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) SPINAL REFLEXES. (UNPUBLISHED PAPER).
174480 01-12

THE EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC) AND ETHANOL ON MONOSYNAPTIC AND POLYSYNAPTIC TRANSMISSION IN THE CENTRAL NERVOUS SYSTEM.
182222 03-03

POOL
STRIATAL TYROSINE HYDROXYLASES WITH HIGH AND LOW AFFINITY FOR TYROSINE: IMPLICATIONS FOR THE MULTIPLE POOL CONCEPT OF CATECHOLAMINES.
167325 01-03
SELF-STIMULATION AND CATECHOLAMINES: DRUG-INDUCED MOBILIZATION OF THE RESERVE POOL RE-ESTABLISHES RESPONDING IN CATECHOLAMINE DEPLETED RATS.
189025 04-04

POOLS
AMPHETAMINE AND METHYLPHENIDATE INDUCED RELEASE OF STRIATAL DOPAMINE IN VIVO: DIFFERENTIAL EFFECTS ON NEWLY SYNTHESIZED AND STORED POOLS.
191897 04-03

POPULAR
POPULAR ATTITUDES AND BELIEFS ABOUT TRANQUILIZERS.
177699 02-17

PORTION
POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES: 1. MODIFICATION OF THE AMINO ACID PORTION OF S-ADENOSYLHOMOCYSTEINE.
190716 04-01
POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES. 2. MODIFICATION OF THE BASE PORTION OF S-ADENOSYLHOMOCYSTEINE.
190717 04-01

PORTIONS
THE INFLUENCE OF PSYCHOSTIMULANTS ON K42 MEMBRANE PERMEABILITY IN VARIOUS PORTIONS OF RAT BRAIN.
191122 04-03

POSITIVE
THE ROLE OF GAMMA-AMINOBUTYRIC ACID AS A MEDIATOR OF POSITIVE DORSAL ROOT POTENTIALS.
189832 04-03
NEGATIVE AND POSITIVE INTRACRANIAL REINFORCEMENT THRESHOLDS: EFFECTS OF MORPHINE.
190330 04-04
POSITIVE REINFORCING EFFECTS OF APOMORPHINE, D-AMPHETAMINE AND MORPHINE: INTERACTION WITH HALOPERIDOL.
191899 04-04

POSITIVELY
EFFECTS OF MORPHINE SULFATE ON POSITIVELY AND NEGATIVELY REINFORCED BEHAVIOR IN TWO STRAINS OF RATS.
191975 04-04

POST-DRUG
AMPHETAMINES EFFECTS ON SELF-STIMULATION: DEVELOPMENT OF TOLERANCE AND POST-DRUG DEPRESSION.
191914 04-04

POST-MENOPAUSAL
THE EFFECTS OF PHENOTHIAZINES ON ENDOCRINE FUNCTION: II. EFFECTS IN MEN AND POST-MENOPAUSAL WOMEN.
184437 03-13

POST-MORTEM
POST-MORTEM MEASUREMENT OF ENZYMES IN HUMAN BRAIN: EVIDENCE OF A CENTRAL NORADRENERGIC DEFICIT IN SCHIZOPHRENIA.
191529 04-13

POST-TETANIC
DIAZEPAM AND POST-TETANIC POTENTIATION: POSSIBLE ROLE OF PROSTAGLANDINS. (UNPUBLISHED PAPER).
170748 01-03
ANTICONVULSANTS AND POST-TETANIC POTENTIATION.
182249 03-03
DIAZEPAM INHIBITION OF POST-TETANIC POTENTIATION IN BULLFROG SYMPATHETIC GANGLIA: POSSIBLE ROLE OF PROSTAGLANDINS.
186673 03-03

POSTANESTHETIC
KETAMINE INDUCED POSTANESTHETIC DELIRIUM ATTENUATED BY TETRAHYDROAMINOACRIDINE.
188689 04-05

POSTNATAL
THE SAFETY TEST OF 10-CHLORO-11B-(2-CHLOROPHENYL) 2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE (CS-370): SECOND REPORT, EFFECT OF CS-370 UPON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
168498 01-05
EFFECT OF IMIPRAMINE ON THE TURNOVER OF BRAIN 5-HT IN POSTNATAL RATS.
171624 01-03
EVIDENCE FOR A CRITICAL PERIOD FOR POSTNATAL ELEVATION OF BRAIN TYROSINE HYDROXYLASE ACTIVITY RESULTING FROM RESERPINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT.
186695 03-03
THE PRENATAL EFFECT OF CHLORAMPHENICOL ON THE POSTNATAL DEVELOPMENT OF MICE.
187076 03-05

POSTSYNAPTIC
PENTOBARBITAL: SELECTIVE DEPRESSION OF EXCITATORY POSTSYNAPTIC POTENTIALS.
168485 01-03
A COMPARISON OF EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) AND SEROTONIN ON PRE- AND POSTSYNAPTIC CELLS IN THE SEROTONIN SYSTEM.
182141 02-03

POSTTEST
INHIBITORY EFFECTS OF PRETEST AND POSTTEST D-AMPHETAMINE ON MOUSE-KILLING BY RATS. (PH.D. DISSERTATION).
173727 01-04

POSTTRIAL
EFFECT OF CHRONIC POSTTRIAL SALINE INJECTIONS ON MAZE PERFORMANCE.
167403 01-04
POSTTRIAL STRYCHNINE: LACK OF EFFECT ON CONDITIONED AVOIDANCE LEARNING.
176866 02-04

POSTWEANING
THE EFFECTS OF EARLY P-CHLOROPHENYLALANINE ADMINISTRATION AND POSTWEANING HOUSING CONDITIONS ON SEROTONIN AND BEHAVIOR IN RATS.
178638 02-04

POTASSIUM
THE EFFECTS OF PSYCHIC STIMULANTS ON THE ACTIVITY OF POTASSIUM AND SODIUM ION STIMULATED ATPASE IN THE MICROSOMAL FRACTIONS OF THE BRAIN OF RATS.
183518 03-01
THE EFFECT OF CHOLINOMIMETIC DRUGS ON POTASSIUM TRANSPORT IN RAT CEREBRAL CORTEX.
191411 04-03

POTENCIES
RELATIVE POTENCIES OF D- AND L-AMPHETAMINE ON THE RELEASE OF DOPAMINE FROM CAT BRAIN IN VIVO.
176874 02-03

POTENCY
ANALGESIC POTENCY OF SODIUM SALICYLATE, INDOMETHACIN, AND CHLORDIAZEPOXIDE AS MEASURED BY THE SPATIAL PREFERENCE TECHNIQUE IN THE RAT.
171301 01-02
RELATIVE PHARMACOLOGICAL POTENCY IN MICE OF OPTICAL ISOMERS OF DELTA1-TETRAHYDROCANNABINOL.
181941 02-03

POTENT
ALPHA-L-ACETYLMETHADOL AND ITS N-DEMTHYLATED METABOLITES HAVE POTENT OPIATE ACTION IN THE GUINEA-PIG ISOLATED ILEUM.
187130 03-03

POTENTIAL
ABUSE POTENTIAL OF ETORPHINE (M99) I. SUBJECTIVE EFFECTS AND PHYSICAL DEPENDENCE. (UNPUBLISHED PAPER).
171241 01-14
EFFECTS OF SCOPOLAMINE UPON BEHAVIORAL REACTIVITY AND VISUALLY EVOKED POTENTIAL TO FLASHES IN RATS.
173032 01-04
POTENTIAL PSYCHOTOMIMETICS: BROMOMETHOXYAMPHETAMINES AND STRUCTURAL CONGENERS OF LYSERGIC ACID. (PH.D. DISSERTATION).
173588 01-03
POTENTIAL NEUROTRANSMITTERS AND RECEPTOR MECHANISMS INVOLVED IN THE CENTRAL CONTROL OF BODY TEMPERATURE IN HAMSTERS. (PH.D. DISSERTATION).
174962 01-03
SYNTHESIS OF HYDROXYAPORPHINES AS POTENTIAL ANTIPARKINSONIAN AGENTS. (PH.D. DISSERTATION).
174967 02-01
BEHAVIORAL EFFECTS OF EX-11-582A, A POTENTIAL ANTIPSYCHOTIC AGENT.
182242 03-04
POTENTIAL PSYCHOTROPIC QUINOLIZIDINES.
182446 03-01
THE ANALYSIS OF THE POTENTIAL ACTION OF A MEDICATION.
184963 03-14
BEHAVIORAL AND VISUAL EVOKED POTENTIAL INVESTIGATIONS DURING TRIHEXYPHENIDYL AND THIOTHIXENE TREATMENT IN PSYCHOTIC BOYS.
187115 03-09
3-ARYL-3-HYDROXYQUINOLIZIDINES WITH POTENTIAL HYPOTENSIVE, ANTIDEPRESSANT, AND ANALGETIC ACTIVITY.
187938 04-01
THE USES AND RELATIVE HAZARD POTENTIAL OF PSYCHOACTIVE DRUGS.
190237 04-17
POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES: 1. MODIFICATION OF THE AMINO ACID PORTION OF S-ADENOSYLHOMOCYSTEINE.
190716 04-01

POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES. 2. MODIFICATION OF THE BASE PORTION OF S-ADENOSYLHOMOCYSTEINE.
190717 04-01

POTENTIALLY
THE ROLE OF CHEMOTHERAPY IN MANAGING POTENTIALLY SUICIDAL PATIENTS.
178544 02-10

POTENTIALS
PENTOBARBITAL: SELECTIVE DEPRESSION OF EXCITATORY POSTSYNAPTIC POTENTIALS.
168485 01-03
CHANGES IN SOMATOSENSORY EVOKED POTENTIALS PRODUCED BY DRUGS USED IN THE TREATMENT OF AFFECTIVE DISORDERS.
169092 01-09
LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND GAMMA-AMINOBUTYRIC ACID (GABA) INTERACTION ON SPONTANEOUS POTENTIALS AND THE EVOKED RESPONSE IN THE AVIAN TECTUM.
169689 01-03
OSCILLATORY POTENTIALS OF THE CAT RETINA: EFFECTS OF ADRENERGIC DRUGS.
172916 01-03
ACTION OF CONVULSANTS ON ROOT POTENTIALS AND AMINO ACID RESPONSES IN ISOLATED FROG SPINAL CORD. (UNPUBLISHED PAPER).
177976 02-03
5-HYDROXYTRYPTAMINE AND HISTAMINE EFFECTS ON RETICULOCEREBELLAR EVOKED POTENTIALS.
182121 02-03
ALTERATION OF EVOKED POTENTIALS IN CAUDATE NUCLEUS OF FREELY MOVING RATS BY L-DOPA, RESERPINE, AND PENTOBARBITAL.
187362 04-03
COMPARATIVE EFFECTS OF SCOPOLAMINE AND AMPHETAMINE UPON BEHAVIORAL REACTIVITY AND VISUAL EVOKED POTENTIALS TO FLASHES IN RATS.
187700 04-04
NEW LONG LATENCY BULBOSPINAL EVOKED POTENTIALS BLOCKED BY SEROTONIN ANTAGONISTS.
188751 04-03
THE ROLE OF GAMMA-AMINOBUTYRIC ACID AS A MEDIATOR OF POSITIVE DORSAL ROOT POTENTIALS.
189832 04-03

POTENTIATION
POTENTIATION OF HALOPERIDOL BY ALPHA-METHYLDOPA IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
167343 01-08
POTENTIATION OF THERAPEUTIC EFFECTS OF NICOTINIC ACID BY PYRIDOXINE IN CHRONIC SCHIZOPHRENICS.
168313 01-08
DIAZEPAM AND POST-TETANIC POTENTIATION: POSSIBLE ROLE OF PROSTAGLANDINS. (UNPUBLISHED PAPER).
170748 01-03
L-DOPA AND POTENTIATION OF ALCOHOL ANESTHESIA BY CHLORPROMAZINE.
182091 02-03
POTENTIATION OF BARBITURATE HYPNOSIS BY 5-DIAZOIMIDAZOLE-4-CARBOXAMIDE AND ITS DERIVATIVES.
182113 02-03
ANTICONVULSANTS AND POST-TETANIC POTENTIATION.
182249 03-03
MECHANISMS UNDERLYING POTENTIATION OF BARBITURATE ACTION BY SODIUM NITRITE IN THE MOUSE: THE ROLE OF METHEMOGLOBIN INDUCED HYPOXIA.
182721 03-03
STUDIES ON THE POTENTIATION OF THE ANTINOCICEPTIVE EFFECT OF OXOTREMORINE BY TETRABENAZINE IN MICE.
185933 03-03
DOSE DEPENDENT POTENTIATION OR INHIBITION BY RO-4-4602 OF 5-HTP HYPERTHERMIA IN RABBITS.
185996 03-03
COMPARISON OF TRICYCLIC ANTIDEPRESSANTS IN RABBITS: ANTINOCICEPTION AND POTENTIATION OF THE NORADRENALINE PRESSOR RESPONSES.
186579 03-03
DIAZEPAM INHIBITION OF POST-TETANIC POTENTIATION IN BULLFROG SYMPATHETIC GANGLIA: POSSIBLE ROLE OF PROSTAGLANDINS.
186673 03-03

PRACTITIONER
GENERAL PRACTITIONER CLINICAL TRIALS. A LONG-ACTING AMITRIPTYLINE PREPARATION.
175583 02-09

PRACTITIONERS
PSYCHOTHERAPEUTIC DRUG TRIALS AMONG ENGLISH GENERAL PRACTITIONERS.
170292 01-11

PRACTOLOL
THE EFFECTS OF ACUTE ADMINISTRATION OF PROPRANOLOL AND PRACTOLOL ON THE UPTAKE, CONTENT, RELEASE AND TURNOVER OF NORADRENALINE IN THE RAT HEART IN VIVO.
184232 03-03

PRAXINOR
THE CORRECTIVE EFFECT OF PRAXINOR ON HYPOTENSION ATTRIBUTABLE TO PSYCHIATRIC THERAPY. SIDE-EFFECTS.
172980 01-11

PREANESTHETIC
PREANESTHETIC MEDICATION IN ELECTIVE SURGERY: COMPARISON OF INTRAVENOUS DIAZEPAM WITH MEPERIDINE.
167338 01-11

PRECIPITATED
DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE IN RESPECT TO TIME AND DOSAGE AND QUANTIFICATION OF THE PRECIPITATED WITHDRAWAL SYNDROME IN RATS.
169474 01-03

PRECOCIOUSLY
A CASE OF TARDIVE DYSKINESIA APPEARING PRECOCIOUSLY UNDER NEUROLEPTICS.
184961 03-17

PRECURSORS
CENTRAL DOPAMINE FUNCTION IN AFFECTIVE ILLNESS: EVIDENCE FROM PRECURSORS, ENZYME INHIBITORS AND STUDIES OF CENTRAL DOPAMINE TURNOVER. (UNPUBLISHED PAPER).
181358 02-09

PREDATION
PREDATION: SEPARATION OF AGGRESSIVE AND HUNGER MOTIVATION BY CONDITIONED AVERSION.
185463 03-04

PREDATORY
DELTA9-TETRAHYDROCANNABINOL INDUCED INHIBITION OF PREDATORY AGGRESSION IN THE RAT.
172745 01-04

PREDICTABILITY
ON CATALEPSY AND CATATONIA AND THE PREDICTABILITY OF THE CATALEPSY TEST FOR NEUROLEPTIC ACTIVITY.
185958 03-04

PREDICTABLE
A PREDICTABLE LABORATORY MODEL FOR SEDATIVE/HYPNOTIC ACTIVITY IN MAN.
191943 04-14

PREDICTING
SIMPLE ALGORITHMS FOR PREDICTING PSYCHOTROPIC DRUGS ASSIGNED TO PSYCHIATRIC INPATIENTS.
176676 02-17
PREDICTING RELIEF FROM ANXIETY WITH PHENOBARBITAL.
177376 02-10

PREDICTION
RESPONSE TO STIMULANT DRUG TREATMENT IN HYPERACTIVE CHILDREN: PREDICTION FROM EEG AND NEUROLOGICAL FINDINGS.
177778 02-11
PREDICTION OF NEUROLEPTIC EFFECTS OF CI-686 BASED ON QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY: DRUG PROFILES AND DOSE RESPONSE CURVES BASED ON COMPUTERIZED CEREBRAL BIOPOTENTIALS.
181958 02-13
THE USE OF BIOCHEMICAL CORRELATES FOR THE PREDICTION OF MURICIDAL BEHAVIOR IN THE WILD RAT.
182241 03-04
HALLUCINOGENIC DRUG-INDUCED BEHAVIOR UNDER SENSORY ATTENUATION: PREDICTION OF RESPONSE TO PSILOCYBIN.
189744 04-12
CONDITIONING IN THE PREDICTION OF DRUG WITHDRAWAL EFFECTS IN CHRONIC SCHIZOPHRENIC PATIENTS.
192412 04-17
A PHARMACOLOGICAL MODEL WITH RHESUS MONKEYS FOR THE PREDICTION OF SELECTIVE DEPRESSION OF PSYCHIC FUNCTIONS.
192424 04-04

PREDICTIVE
5-HYDROXYTRYPTOPHAN AS AN ANTIDEPRESSANT: THE PREDICTIVE VALUE OF THE PROBENECID TEST.
184652 03-09
THE PREDICTIVE VALUE OF THE ANTIAPOMORPHINE TEST IN DOGS FOR NEUROLEPTIC THERAPY IN MAN.
192421 04-04

PREDICTOR
PLASMA LEVEL OF DIAZEPAM AS A THERAPEUTIC PREDICTOR IN ANXIETY STATES.
186584 03-10

PREDICTORS
ORTHOGONAL FACTORS VS. INTERDEPENDENT VARIABLES AS PREDICTORS OF DRUG TREATMENT RESPONSE IN ANXIOUS OUTPATIENTS.
171299 01-14

PREDICTS
ANTISCHIZOPHRENIC DRUGS AND BRAIN CHOLINERGIC RECEPTORS: AFFINITY FOR MUSCARINIC SITES PREDICTS EXTRAPYRAMIDAL EFFECTS.
188114 04-15

PREFERENCE
ANALGESIC POTENCY OF SODIUM SALICYLATE, INDOMETHACIN, AND CHLORDIAZEPOXIDE AS MEASURED BY THE SPATIAL PREFERENCE TECHNIQUE IN THE RAT.
171301 01-02

PREFERENCES
PLATELET MONOAMINE OXIDASE ACTIVITY AND SUBSTRATE PREFERENCES IN SCHIZOPHRENIC PATIENTS.
174609 01-14
SPATIAL AND PAW PREFERENCES IN RATS: THEIR RELATIONSHIP TO RATE-DEPENDENT EFFECTS OF D-AMPHETAMINE.
177409 02-04
COMPARATIVE SURVEY OF PSYCHIATRISTS TREATMENT PREFERENCES: CALIFORNIA AND NEW-YORK.
185877 03-08
CHEMOTHERAPY OF DELIRIUM-TREMENS: A SURVEY OF PHYSICIANS PREFERENCES.
192068 04-11

PREGANGLIONIC
TRANSSYNAPTIC INDUCTION OF CHOLINE ACETYLTRANSFERASE IN THE PREGANGLIONIC NEURON OF THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM.
182720 03-03
EFFECTS OF LSD, MESCALINE, AND PSILOCYBIN ON SYMPATHETIC PREGANGLIONIC NEURONS.
191937 04-03

PREGESTATIONAL
EFFECT OF PREGESTATIONAL MORPHINE ADMINISTRATION TO MICE ON BEHAVIOR OF THEIR OFFSPRING.
191902 04-04

PREGNANOLONE
FURTHER STUDIES ON THE INHIBITION OF DRUG METABOLISM BY PREGNANOLONE AND RELATED STEROIDS.
185866 03-03

PREGNANT
DETERMINATION OF DRUG TRANSFER ACROSS BIOLOGICAL MEMBRANES: COMPARATIVE STUDY ON THE PASSAGE OF DRUGS INTO THE CENTRAL NERVOUS SYSTEM AND THEIR PLACENTAL TRANSFER AND FETAL LOCALIZATION IN THE PREGNANT RAT. (PH.D. DISSERTATION).
172018 01-03
EFFECT OF CHRONIC METHADONE ADMINISTRATION ON PREGNANT RATS AND THEIR OFFSPRING.
183894 03-03
DISPOSITION OF H3-DELTA9-TETRAHYDROCANNABINOL IN BRAIN OF PREGNANT DOGS AND THEIR FETUSES.
191968 04-03

PREMENSTRUAL
A CONTROLLED EVALUATION OF LITHIUM IN THE PREMENSTRUAL TENSION SYNDROME.
185192 03-11

PRENATAL
EFFECT OF PRENATAL MATERNAL ADMINISTRATION OF D-AMPHETAMINE ON RAT OFFSPRING ACTIVITY AND PASSIVE AVOIDANCE LEARNING.
167415 01-03
THE SAFETY TEST OF 10-CHLORO-11B-(2-CHLOROPHENYL) 2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE (CS-370): SECOND REPORT, EFFECT OF CS-370 UPON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
168498 01-05
THE PRENATAL EFFECT OF CHLORAMPHENICOL ON THE POSTNATAL DEVELOPMENT OF MICE.
187076 03-05

PRENATALLY
SEIZURE SUSCEPTIBILITY AND AVOIDANCE CONDITIONING IN ADULT RATS TREATED PRENATALLY WITH CHLORPROMAZINE.
184371 03-04

PREOPTIC
PRESENCE OF OSMORECEPTORS FOR THIRST IN THE LATERAL PREOPTIC NUCLEUS.
168859 01-03

PRESCHOOL
INDICATIONS FOR ANTIDEPRESSANT TREATMENT WITH SPECIAL REFERENCE TO DEPRESSED PRESCHOOL CHILDREN.
182428 03-10

PRESCRIBE
HOW TO PRESCRIBE PSYCHOACTIVE DRUGS.
190236 04-17

PRESSING
DRUG ENHANCED SENSORY CONTINGENT BAR PRESSING: COMPARING THE EFFECT OF CONTINGENT AND NONCONTINGENT SENSORY CHANGE.
168837 01-04
DIAZEPAM-INDUCED EATING AND LEVER PRESSING FOR FOOD IN SATED RATS.
186613 03-04
CORRELATION BETWEEN BRAIN N,N DIMETHYLTRYPTAMINE (DMT) LEVELS AND BAR PRESSING BEHAVIOR IN RATS: EFFECT OF MAO INHIBITION.
191935 04-04

PRESSOR
EFFECTS OF CENTRALLY APPLIED DRUGS ON PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION.
185902 03-03
COMPARISON OF TRICYCLIC ANTIDEPRESSANTS IN RABBITS: ANTINOCICEPTION AND POTENTIATION OF THE NORADRENALINE PRESSOR RESPONSES.
186579 03-03

PRESSURE
THE EFFECTS OF HOE-36801 ON MUSCLE ACTIVITY AND BLOOD PRESSURE, ON ATTENTION AND CONCENTRATION, ON TIME JUDGMENT AND SUBJECTIVE RESPONSES IN NEUROTICS AND NORMALS.
192429 04-14

PRETEST
INHIBITORY EFFECTS OF PRETEST AND POSTTEST D-AMPHETAMINE ON MOUSE-KILLING BY RATS. (PH.D. DISSERTATION).
173727 01-04

PRETREATED
DRUG ABSORPTION IN RATS PRETREATED WITH ANTIBIOTICS.
182715 03-03

PRETREATMENT
EFFECT OF PHENOBARBITAL AND 3-METHYLCHOLANTHRENE PRETREATMENT ON THE HEPATOTOXICITY OF 1,1,1 TRICHLOROETHANE AND 1,1,2 TRICHLOROETHANE.
167361 01-05
THE EFFECT OF L-TRYPTOPHAN (TP) ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) REFLEXES IN ACUTE DECEREBRATE SPINAL CATS AND THE EFFECT OF PRETREATMENT WITH P-CHLOROPHENYLALANINE (PCPA) ON THE ACTION OF TP. (UNPUBLISHED PAPER).
170874 01-03
BEHAVIORAL EFFECT OF TRICYCLIC THYMOLEPTICS AND CHLORPHENIRAMINE IN MICE AFTER PRETREATMENT WITH 5 HYDROXYTRYPTOPHAN (5-HTP).
171609 01-04
EFFECTS OF CHRONIC PRETREATMENT WITH SMALL DOSES OF RESERPINE UPON ADRENERGIC NERVE FUNCTION.
177406 02-03
DISSOCIATIVE CHANGE IN ANTIAGGRESSIVE AND MUSCLE RELAXANT ACTIONS OF S-TRIAZOLOBENZODIAZEPINE (D-40TA) BY REPEATED ADMINISTRATION AND PHENOBARBITAL PRETREATMENT, AND ITS RELATION TO METABOLISM.
181654 02-04
THE EFFECT OF PRETREATMENT WITH IPRONIAZID ON THE BEHAVIORAL ACTIVITIES OF BETA-PHENYLETHYLAMINE IN RATS.
187932 04-04
REDUCTION BY PRETREATMENT WITH DIBENAMINE OF HEPATOTOXICITY INDUCED BY CARBON TETRACHLORIDE, THIOACETAMINDE OR DIMETHYLNITROSAMINE.
188865 04-05
INFLUENCE ON ACUTE PRETREATMENT WITH DELTA9-TETRAHYDROCANNABINOL OF THE LD50 OF VARIOUS SUBSTANCES THAT ALTER NEUROHUMORAL TRANSMISSION.
188876 04-05
EFFECTS OF PHENOBARBITAL AND SKF-525-A PRETREATMENT, SEX, LIVER INJURY, AND VEHICLE ON DELTA9-TETRAHYDROCANNABINOL TOXICITY.
189598 04-05
THE LACK OF EFFECTS OF PRETREATMENT WITH PHENOBARBITAL AND CHLORPROMAZINE ON THE ACUTE TOXICITY OF BENZENE IN RATS.
189600 04-05
DIFFERENTIAL INCREASE OF BEHAVIORAL AND EXTRAPYRAMIDAL STIMULATING ACTIONS OF NEUROLEPTICS BY ALPHA-METHYLTYROSINE PRETREATMENT IN RATS.
192016 04-04

PRETRIAL
EFFECTS OF OVERTRAINING AND PRETRIAL ADMINISTRATION OF DEXTROAMPHETAMINE ON REVERSAL LEARNING IN RATS.
177533 02-04

PREVENT
FAILURE OF BETA-ADRENERGIC RECEPTOR BLOCKADE TO PREVENT ARRHYTHMIAS INDUCED BY SYMPATHETIC NERVE STIMULATION.
187923 04-03

PREVENTION
A COMPARISON OF LITHIUM CARBONATE IN THE PREVENTION OF MANIC AND DEPRESSIVE EPISODES IN RECURRENT AFFECTIVE DISORDER.
169090 01-09
PREVENTION OF ALCOHOL WITHDRAWAL SEIZURES: THE ROLES OF DIPHENYLHYDANTOIN AND CHLORDIAZEPOXIDE.
172275 01-11
HYPOTENSION FROM DRUGS: INCIDENCE, PERIOD, PREVENTION.
176674 02-15
A CENTRAL EFFECT OF LOCAL ANESTHETICS: PREVENTION AGAINST THE ACCUMULATION OF CYCLIC AMP IN BRAIN SLICES.
182099 02-03
LITHIUM IN TREATMENT AND PREVENTION OF AFFECTIVE DISORDER: A VA-NIMH COLLABORATIVE STUDY.
190381 04-09

PREY
DIAZEPAM-INDUCED PLAY BEHAVIOR IN CATS DURING PREY KILLING.
184979 03-04

PRIMARY
HALOPERIDOL EFFECTS ON MORPHINE SELF-ADMINISTRATION: TESTING FOR PHARMACOLOGICAL MODIFICATION OF THE PRIMARY REINFORCEMENT MECHANISM.
172454 01-04

ORAL 5-HTP IN PRIMARY AUTISM WITH 5-HT BINDING DEFECT.
181392 02-13

THE EFFECT OF LITHIUM ON THYROID IODINE RELEASE IN PATIENTS WITH PRIMARY AFFECTIVE DISORDER.
186580 03-09

PRIMATE
OXYPERTINE AND PRIMATE BEHAVIOUR.
182762 03-04

PRIMATES
DIFFERENTIAL EFFECTS OF P-CHLOROPHENYLALANINE ON SLEEP IN TWO PRIMATES, PAPIO-PAPIO AND PAPIO-HAMADRYAS.
191629 04-04

PRISONERS
EFFECTS OF DIPHENYLHYDANTOIN ON ANXIETY AND HOSTILITY IN INSTITUTIONALIZED PRISONERS.
177671 02-11

PRIVATE
EXPERIENCES WITH LAROXYL (R) IN THE TREATMENT OF DEPRESSIONS IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
170413 01-11

PRELIMINARY EXPERIENCES WITH NOBRIUM IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
170414 01-11

THOUGHTS ON TREATMENT BY PRIVATE PHYSICIANS OF ABNORMAL SEX DRIVES.
180674 02-11

PROBENECID
INCREASE IN THE PLASMA CONCENTRATION OF FREE TRYPTOPHAN CAUSED BY PROBENECID IN HUMANS.
169470 01-13

BRAIN SEROTONIN, AFFECTIVE ILLNESS AND ANTIDEPRESSANT DRUGS: CEREBROSPINAL FLUID STUDIES WITH PROBENECID. (UNPUBLISHED PAPER).
170084 01-09

THE EFFECT OF PROBENECID AND LARGE DOSE AMPHETAMINE ADMINISTRATION ON CEREBROSPINAL FLUID HOMOVANILLIC ACID.
177826 02-13

5-HYDROXYTRYPTOPHAN AS AN ANTIDEPRESSANT: THE PREDICTIVE VALUE OF THE PROBENECID TEST.
184652 03-09

PLASMA AND CEREBROSPINAL FLUID PROBENECID CONCENTRATIONS AS RELATED TO ACCUMULATION OF ACIDIC BIOGENIC AMINE METABOLITES IN MAN.
187933 04-13

PROBLEM
THE PROBLEM OF ANXIETY IN A NON-WESTERN SOCIETY: A COMBINED CHEMOTHERAPEUTIC AND PSYCHOTHERAPEUTIC APPROACH.
171162 01-10

PROBLEMS
PSYCHOPHARMACOLOGICAL RESEARCH: SOME METHODOLOGICAL PROBLEMS.
169932 01-06

THE PROBLEMS OF THE PSYCHOPHARMACOLOGICAL TREATMENT OF PSYCHOSOMATIC DISEASES -- THE ANESTHESIOLOGIC APPROACH.
177063 02-17

SOME PROBLEMS IN THE PSYCHOPHARMACOLOGICAL TREATMENT OF PSYCHOSOMATIC DISEASE.
177066 02-17

STUDIES OF CEREBROSPINAL FLUID AMINE METABOLITES IN DEPRESSED PATIENTS: CONCEPTUAL PROBLEMS AND THEORETICAL IMPLICATIONS. (UNPUBLISHED PAPER).
187398 04-13

THE PROBLEMS OF THE CLINICAL USAGE OF NITRAZEPAM: SUPPRESSIVE EFFECTS ON THE PHARYNGEAL REFLEX AND THE COMA, USING OTHER TRANQUILIZERS AT THE SAME TIME.
188450 04-15

INDICATION AND PROBLEMS OF PSYCHOTROPIC DRUGS IN GENERAL PRACTICE.
191677 04-17

PROCAINE
EFFECT OF PROCAINE, LIDOCAINE AND PENTOBARBITAL ON ELECTRICAL ACTIVITY OF GUINEA-PIG OLFACTORY CORTEX IN VITRO.
182092 02-03

PROCAINE (GEROVITAL-H3) THERAPY: MECHANISM OF INHIBITION OF MONOAMINE OXIDASE.
191281 04-03

PROCEDURE
A SENSITIVE GAS CHROMATOGRAPHIC PROCEDURE FOR THE ESTIMATION OF NORADRENALINE, DOPAMINE AND 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
171971 01-01

BARBITURATE DEPENDENCE IN MICE INDUCED BY A SIMPLE SHORT-TERM ORAL PROCEDURE.
175895 02-03

THE EFFECTS OF CHLORPROMAZINE ON A REDEFINED PROCEDURE OF EXTINCTION OF SIDMAN AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
185715 03-14

PROCEDURES
ASSAY PROCEDURES FOR THIORIDAZINE, TRIFLUOPERAZINE, AND THEIR SULFOXIDES AND DETERMINATION OF URINARY EXCRETION OF THESE COMPOUNDS IN MENTAL PATIENTS.
183602 03-01

EFFECTS OF CHLORDIAZEPOXIDE ON HEART RATE AND BEHAVIOURAL SUPPRESSION IN PIGS SUBJECTED TO OPERANT CONDITIONING PROCEDURES.
189409 04-04

PRODUCING
CONVULSION PRODUCING PROPERTY OF THE DIALYZABLE GLYCOPEPTIDE PREPARATION FROM WHOLE RAT BRAIN.
181815 02-03

SEPARATION OF THE DEPENDENCE PRODUCING ACTIONS FROM THE DIRECT ACTIONS OF NARCOTICS ON GUINEA-PIG ILEUM.
182162 02-03

PROESTROUS
CNS DEPRESSION IN THE ABSENCE OF PROLACTIN RELEASE FOLLOWING INTRAARTERIAL INJECTIONS OF SODIUM PENTOTHAL IN THE PROESTROUS RAT.
173257 01-03

BLOCKADE OF THE PROESTROUS LH SURGE IN CYCLIC RATS BY BARBITURATE ADMINISTRATION ON DIESTRUS.
175650 02-03

PROFADOL
BEHAVIORAL EFFECTS OF PROFADOL IN THE RAT.
186373 03-04

PROFILE
BLOOD LEVEL PROFILE IN MAN FOLLOWING CHRONIC ORAL ADMINISTRATION OF FLURAZEPAM HYDROCHLORIDE.
169817 01-13

PHARMACOKINETIC PROFILE OF DIAZEPAM IN MAN FOLLOWING SINGLE INTRAVENOUS AND ORAL AND CHRONIC ORAL ADMINISTRATION.
170838 01-13

EFFECTS OF MEBUTAMATE ON THE ELECTROENCEPHALOGRAPHIC SLEEP PROFILE.
174348 01-14

PROFILES
PREDICTION OF NEUROLEPTIC EFFECTS OF CI-686 BASED ON QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY: DRUG PROFILES AND DOSE RESPONSE CURVES BASED ON COMPUTERIZED CEREBRAL BIOPOTENTIALS.
181958 02-13

ACUTE EFFECTS OF ALCOHOL, DIAZEPAM, THIORIDAZINE, FLUPENTHIXOL AND ATROPINE ON PSYCHOMOTOR PERFORMANCE PROFILES.
184848 03-14

PROGESTERONE
THE UPTAKE OF DOPAMINE AND SEROTONIN IN RAT BRAIN DURING PROGESTERONE DECLINE.
171307 01-03

PROGNOSIS
MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN THE LIGHT OF PROGNOSIS ORIENTED DIAGNOSIS.
186081 03-08

PROGRAM
PROGRAM IN BEHAVIORAL PHARMACOLOGY.
181394 02-14

NIMH SPONSORED CHEMICAL SYNTHESIS PROGRAM.
182444 03-01

PROGRAMME
A PROGRAMME WHICH LED TO REDUCTION IN NIGHT SEDATION IN A MAJOR HOSPITAL.
170802 01-17

PROGRAMMING
L-DOPA EFFECTS ON MOTOR AND CENTRAL PROGRAMMING DEFICITS IN PARKINSONISM.
184976 03-14

PROGRESS
PROGRESS REPORT ON THE USE OF THE DOG FOR ASSESSING MORPHINE-LIKE AND NALORPHINE-LIKE AGONISTS AS WELL AS DEPOT PREPARATIONS OF ANTAGONISTS. (UNPUBLISHED PAPER).
176312 02-03

PROGRESSIVE
THE EFFECTS OF SCOPOLAMINE ON PERFORMANCE ON A GEOMETRIC PROGRESSIVE RATIO SCHEDULE.
190334 04-04

PROJECTS
MEGAVITAMIN TREATMENT, CULTURE AND TRANQUILIZERS, DRUGS FOR THE AGED: PROJECTS OF A CANADIAN GRANT.
170293 01-11

PROLACTIN
CNS DEPRESSION IN THE ABSENCE OF PROLACTIN RELEASE FOLLOWING INTRAARTERIAL INJECTIONS OF SODIUM PENTOTHAL IN THE PROESTROUS RAT.
173257 01-03
ROLE OF DOPAMINERGIC MECHANISMS IN REGULATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN MAN.
188428 04-13
AFFECTIVE STATE AND THYROTROPIN AND PROLACTIN RESPONSES AFTER REPEATED INJECTIONS OF THYROTROPIN RELEASING HORMONE IN DEPRESSED PATIENTS.
189076 04-09
DISSOCIATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN PARKINSONS DISEASE FOLLOWING CHRONIC L-DOPA THERAPY.
191233 04-13
SERUM PROLACTIN LEVELS IN NEWLY ADMITTED PSYCHIATRIC PATIENTS.
191506 04-13

PROLONG
A FEW GALENIC METHOD TO PROLONG THE ACTION OF LITHIUM SULFATE.
180700 02-15

PROLONGED
THE FIRST LONG-ACTING (RETARD) THYMOANALEPTIC OR ANTIDEPRESSANT: THE TIME-RELEASED DIBENZEPINE WITH PROLONGED ACTION.
178946 02-11
EFFECTS OF PROLONGED LSD-25 ADMINISTRATION UPON NEURONS OF SPINAL CORD GANGLIA TISSUE CULTURES.
185112 03-03
ABSENCE OF DEGENERATION OF ADRENERGIC NEURONS AFTER PROLONGED TREATMENT WITH DEBRISOQUIN.
186677 03-03
A NEW PROLONGED ACTING TYPE OF CHLORPROMAZINE: BEHAVIORAL EFFECTS AND PROLONGED ACTIONS ON NERVE MEMBRANES.
187805 04-01
ECT, GLAUCOMA, AND PROLONGED APNEA.
187837 04-15
EFFECT OF PROLONGED CHLORPROMAZINE ADMINISTRATION ON THE SLEEP OF CHRONIC SCHIZOPHRENICS.
188115 04-08
THE USE OF ETHYMISOL (ETHYLNORANTIPHEIN) IN PATIENTS WITH PROLONGED DISTURBANCES OF CONSCIOUSNESS.
191777 04-07

PROMETHAZINE
PSYCHOLOGICAL EXPERIMENTATION ON THE EFFECTS OF PROPIRAM FUMARATE AND PROMETHAZINE UNDER NORMAL AND STRESS CONDITIONS.
184617 03-07

PROPANIDID
A CONTROLLED COMPARISON OF THE PSYCHOTROPIC EFFECTS OF PROPANIDID AND METHOHEXITONE.
184082 03-14

PROPERTY
CONVULSION PRODUCING PROPERTY OF THE DIALYZABLE GLYCOPEPTIDE PREPARATION FROM WHOLE RAT BRAIN.
181815 02-03

PROPHYLACTIC
FACTORS ASSOCIATED WITH LITHIUM RESPONSE IN THE PROPHYLACTIC TREATMENT OF BIPOLAR MANIC-DEPRESSIVE ILLNESS.
186188 03-09
PROPHYLACTIC TREATMENT OF RECURRENT DEPRESSION: OBSERVATIONS FROM A MULTIHOSPITAL COLLABORATIVE STUDY.
186190 03-09
PROPHYLACTIC EFFICACY OF LITHIUM CARBONATE IN MANIC-DEPRESSIVE ILLNESS: REPORT OF THE VETERANS ADMINISTRATION AND NATIONAL INSTITUTE OF MENTAL HEALTH (VA-NIMH) COLLABORATIVE STUDY GROUP.
189735 04-09

PROPHYLAXIS
THE USE OF LITHIUM IN AFFECTIVE DISORDERS, III: A DOUBLE-BLIND STUDY OF PROPHYLAXIS IN BIPOLAR ILLNESS.
169495 01-09
LITHIUM PROPHYLAXIS IN RECURRENT AFFECTIVE ILLNESS.
171926 01-09
LITHIUM PROPHYLAXIS IN AFFECTIVE DISORDERS: AN OPEN TRIAL WITH MATCHED CONTROLS.
172401 01-09
CLINICAL FACTORS IN LITHIUM CARBONATE PROPHYLAXIS FAILURE.
174093 01-09
LITHIUM IN PSYCHIATRIC THERAPY AND PROPHYLAXIS. A REVIEW WITH SPECIAL REGARD TO ITS USE IN CHILDREN.
182433 03-09
USE OF CHEMOTHERAPY AS ANTISUICIDAL PROPHYLAXIS.
191140 04-11
HAZARDS OF LITHIUM PROPHYLAXIS.
191187 04-15

PROPIONATE
LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04

PROPIRAM
PSYCHOLOGICAL EXPERIMENTATION ON THE EFFECTS OF PROPIRAM FUMARATE AND PROMETHAZINE UNDER NORMAL AND STRESS CONDITIONS.
184617 03-07
COMPARISON OF PSYCHOEXPERIMENTAL PERFORMANCE UNDER THE INFLUENCE OF THE ANALGESIC PROPIRAM FUMARATE.
184618 03-14

PROPRANOLOL
ELECTROCARDIOGRAPHIC CHANGES IN HYPERTHYROIDISM AFTER ADRENERGIC BLOCKADE WITH RESERPINE AND PROPRANOLOL.
167460 01-13
PROPRANOLOL AND CHLORDIAZEPOXIDE ON EXPERIMENTALLY INDUCED CONFLICT AND SHUTTLEBOX PERFORMANCE IN RODENTS.
171304 01-04
ON THE FIRST-PASS EFFECT IN THE LIVER OF NORTRIPTYLINE, LIDOCAINE AND PROPRANOLOL.
171631 01-03
PERIPHERAL VERSUS CENTRAL MECHANISMS ACCOUNTING FOR ANTIANXIETY EFFECTS OF PROPRANOLOL.
181072 02-10
THE EFFECTS OF ACUTE ADMINISTRATION OF PROPRANOLOL AND PRACTOLOL ON THE UPTAKE, CONTENT, RELEASE AND TURNOVER OF NORADRENALINE IN THE RAT HEART IN VIVO.
184232 03-03
THE SHORT-TERM ANTIANXIETY EFFECTS OF PROPRANOLOL HCL.
185210 03-10
PROPRANOLOL ENHANCEMENT OF HYPOGLYCEMIC SWEATING.
186187 03-13
PROPRANOLOL AND BEHAVIOR OF ALCOHOL ADDICTS AFTER ACUTE ALCOHOL INGESTION.
187257 04-14
PROPRANOLOL ANTAGONISM OF MORPHINE INFLUENCED BEHAVIOR.
188760 04-04
RESPONSE TO PROPRANOLOL AND DIAZEPAM IN SOMATIC AND PSYCHIC ANXIETY.
188887 04-10
THE USE OF PROPRANOLOL WITH VARIOUS DRUG COMBINATIONS IN THE TREATMENT OF ESSENTIAL HYPERTENSION.
192511 04-13

PROPYLNORAPOMORPHINE
DISPOSITION OF NORAPOMORPHINE AND N,N PROPYLNORAPOMORPHINE IN MOUSE BRAIN AND ITS CORRELATION WITH STEREOTYPED GNAWING BEHAVIOR.
182131 02-04

PROSTAGLANDIN
MECHANISM OF THE VASOCONSTRICTOR ACTION OF PROSTAGLANDIN B.
189394 04-03

PROSTAGLANDINS
PROSTAGLANDINS AND CANNABIS: A POSSIBLE MODE OF ACTION FOR THC.
169067 01-03
DIAZEPAM AND POST-TETANIC POTENTIATION: POSSIBLE ROLE OF PROSTAGLANDINS. (UNPUBLISHED PAPER).
170748 01-03
DIAZEPAM INHIBITION OF POST-TETANIC POTENTIATION IN BULLFROG SYMPATHETIC GANGLIA: POSSIBLE ROLE OF PROSTAGLANDINS.
186673 03-03
EFFECTS OF PROSTAGLANDINS B1 AND B2 ON VASOCONSTRICTOR RESPONSES OF THE CANINE HINDPAW.
189395 04-03

PROTECT
CANNABIDIOL AND CANNABIS-SATIVA EXTRACT PROTECT MICE AND RATS AGAINST CONVULSIVE AGENTS.
183609 03-03

PROTECTION
PROTECTION PRODUCED BY BENZODIAZEPINES (BDP) AGAINST THE NEUROTOXIC AND CONFLICT BEHAVIOR EFFECTS OF HEXACHLOROPHENE (HCP) IN CATS.
176863 02-04

PROTEIN
COMPARATIVE STUDIES OF SYNAPTIC MEMBRANE PROTEIN SOLUBILIZATION BY CHLORPROMAZINE AND SODIUM DODECYLSULFATE.
176703 02-03
BLOCKING OF THE EFFECT OF A DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC) ON SPONTANEOUS MOTOR ACTIVITY IN THE RAT BY IMMUNIZATION WITH A PROTEIN CONJUGATE OF DELTA1-THC.
187129 03-04
PHYSIOCHEMICAL PROPERTIES, SOLUBILITY, AND PROTEIN BINDING OF DELTA9-TETRAHYDROCANNABINOL. (UNPUBLISHED PAPER).
188256 04-01

ANISOMYCIN, LIKE OTHER INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS, IMPAIRS LONG-TERM MEMORY OF A DISCRIMINATION TASK.
188605 04-04

EFFECT OF MORPHINE ON THE TURNOVER AND SYNTHESIS OF (LEU-3H) PROTEIN AND (CH-14C) PHOSPHATIDYLCHOLINE IN DISCRETE REGIONS OF THE RAT BRAIN.
189586 04-03

EFFECTS OF LIDOCAINE ON RABBIT BRAIN MICROTUBULAR PROTEIN.
191324 04-03

PROTEINS

EFFECT OF CHRONIC INTOXICATION WITH (_) AMPHETAMINE ON ITS CONCENTRATION IN LIVER AND BRAIN AND ON (14C) LEUCINE INCORPORATION INTO MICROSOMAL AND CYTOPLASMIC PROTEINS OF RAT LIVER.
180056 02-05

BINDING OF MORPHINE BY SERUM PROTEINS OF MORPHINE TREATED RABBITS.
182187 02-03

DDT EFFECT ON 32P INCORPORATION FROM GAMMA-LABELLED ATP INTO PROTEINS FROM LOBSTER NERVE.
191315 04-03

PROTOTYPE

METHODOLOGY FOR THE EVALUATION OF PENTAZOCINE, PROTOTYPE OF THE NEW MORPHINE AGONIST ANTAGONIST ANALGESICS.
191603 04-16

PROTRIPTYLINE

THE EFFECT OF PROTRIPTYLINE ON THE METABOLISM OF LABELLED DOPAMINE AND NORADRENALINE IN THE RAT BRAIN.
171627 01-03

A DOUBLE-BLIND CONTROLLED STUDY COMPARING PROTRIPTYLINE AND AMITRIPTYLINE.
177567 02-09

PROTRIPTYLINE STEADY-STATE PLASMA LEVELS IN MAN.
191924 04-13

PSEUDOCONDITIONING

POSSIBLE PERIPHERAL ADRENERGIC AND CHOLINERGIC MECHANISMS IN PSEUDOCONDITIONING.
186575 03-03

PSEUDOPARKINSONISM

PSEUDOPARKINSONISM AND TARDIVE DYSKINESIA.
171974 01-15

PSILOCYBIN

EFFECTS OF AMPHETAMINE (A), LSD, PSILOCYBIN (P), AND DOM ON SCHEDULE-CONTROLLED BEHAVIOR IN THE RAT.
176869 02-04

HALLUCINOGENIC DRUG-INDUCED BEHAVIOR UNDER SENSORY ATTENUATION: PREDICTION OF RESPONSE TO PSILOCYBIN.
189744 04-12

EFFECTS OF LSD, MESCALINE, AND PSILOCYBIN ON SYMPATHETIC PREGANGLIONIC NEURONS.
191937 04-03

THE EFFECTS OF PSILOCYBIN ON EEG AND BEHAVIOUR IN MONKEYS.
192415 04-04

PSR

THE EFFECT OF L-TRYPTOPHAN (TP) ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) REFLEXES IN ACUTE DECEREBRATE SPINAL CATS AND THE EFFECT OF PRETREATMENT WITH P-CHLOROPHENYLALANINE (PCPA) ON THE ACTION OF TP. (UNPUBLISHED PAPER).
170874 01-03

THE EFFECT IN THE CAT OF TRYPTAMINE (T) AND LSD ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) SPINAL REFLEXES. (UNPUBLISHED PAPER).
174480 01-12

PSYCHEDELIC

MARIHUANA -- A PSYCHEDELIC DRUG?
178695 02-17

PSYCHEDELIC (LSD) PSYCHOTHERAPY: A CASE REPORT.
186994 03-08

PSYCHIATRIC

PSYCHOPATHOLOGICAL IMPORTANCE AND THERAPEUTIC EFFECTS OF A COMBINATION OF HYDERGINE AND THIORIDAZINE IN PSYCHIATRIC SYNDROMES IN THE AGING.
168976 01-14

MARIHUANA USE IN MAN: AN EXPERIMENTAL INQUIRY -- CLINICAL PSYCHIATRIC IMPRESSIONS.
169085 01-14

HALOPERIDOL FOR PSYCHIATRIC DISORDERS IN CHILDREN.
169457 01-14

EXPERIENCES WITH LAROXYL (R) IN THE TREATMENT OF DEPRESSIONS IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
170413 01-11

PRELIMINARY EXPERIENCES WITH NOBRIUM IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
170414 01-11

DRUGS AND PSYCHIATRIC READAPTATION.
171121 01-17

CLINICAL TRIAL OF TRIFLUOPERAZINE (STELAZINE R) ON INDONESIAN PSYCHIATRIC PATIENTS.
171161 01-09

THE USE OF TIMED RELEASE NEUROLEPTICS IN AMBULATORY PSYCHIATRIC PRACTICE.
172977 01-11

THE CORRECTIVE EFFECT OF PRAXINOR ON HYPOTENSION ATTRIBUTABLE TO PSYCHIATRIC THERAPY. SIDE-EFFECTS.
172980 01-11

THE PSYCHIATRIC SIDE-EFFECTS OF DRUGS.
173866 01-15

L-TRYPTOPHAN IN THE TREATMENT OF LEVODOPA INDUCED PSYCHIATRIC DISORDERS.
174297 01-15

FLUPENTHIXOL IN CERTAIN PSYCHIATRIC ILLNESSES.
175393 02-11

DOLICHOMEGACOLON INDUCED BY NEUROLEPTICS AMONG PSYCHIATRIC PATIENTS (MEMORANDUM COVERING 153 CASES).
176432 02-15

CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, ZISEPRON, IN TREATMENT OF PSYCHIATRIC DISEASES IN COMPARISON WITH THIORIDAZINE.
176467 02-08

EXPERIENCE IN THE USE OF AN ANTIDEPRESSIVE, CLOMIPRAMINE (ANAFRANIL), IN PSYCHIATRIC OUTPATIENTS.
176475 02-09

EXPERIENCE IN THE DRUG HORIZON AND PSYCHIATRIC INTERVIEW.
176542 02-11

SIMPLE ALGORITHMS FOR PREDICTING PSYCHOTROPIC DRUGS ASSIGNED TO PSYCHIATRIC INPATIENTS.
176676 02-17

PSYCHIATRIC CARE: DRUGS, THERAPIST, COMMUNITY.
178189 02-17

DIFFERENTIAL EFFECTS OF D- AND L-AMPHETAMINE ON THE SLEEP OF DEPRESSED PSYCHIATRIC PATIENTS ON AND OFF LITHIUM CARBONATE TREATMENT. (UNPUBLISHED PAPER).
178432 02-09

PSYCHIATRIC TREATMENT: WHAT COMES AFTER PHARMACOLOGICAL THERAPY
178655 02-17

CHOLINE ACETYLTRANSFERASE ACTIVITY IN THE CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS.
180047 02-13

WHAT IS TECHNIQUE IN PSYCHIATRIC TREATMENT
180102 02-17

HALOPERIDOL (JANSSEN) IN THE TREATMENT OF UNSELECTED INSTITUTIONALIZED PSYCHIATRIC PATIENTS.
180299 02-11

END OF A BACK WARD: THE RAPID REHABILITATION AND RELEASE OF CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS.
181153 02-08

A PSYCHIATRIC CLINIC FOR DEPOT PHENOTHIAZINES.
181192 02-08

LITHIUM IN PSYCHIATRIC THERAPY AND PROPHYLAXIS. A REVIEW WITH SPECIAL REGARD TO ITS USE IN CHILDREN.
182433 03-09

AN ELECTROENCEPHALOGRAPHIC STUDY ON THE TOLERANCE OF THE VARIOUS PSYCHIATRIC AND NEUROLOGICAL PATIENTS TO THE HYPNOTIC EFFECTS OF DIPHENHYDRAMINE -- MEASURED BY THE AMOUNTS OF SLEEP EEG AS AN INDICATOR.
182550 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: I. PIMOZIDE IN THE TREATMENT OF PERSONALITY DISORDERS.
183191 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: II. PIMOZIDE IN THE TREATMENT OF BEHAVIOURAL DISORDERS IN CHILDHOOD AND ADOLESCENCE.
183192 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: III. PIMOZIDE IN THE TREATMENT OF STRESS INDUCED PSYCHIC AND FUNCTIONAL DISORDERS.
183193 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: IV. PIMOZIDE IN THE TREATMENT OF PATIENTS WITH PARANOID SYMPTOMATOLOGY.
183194 03-09

IDENTIFICATION AND QUANTITATIVE DETERMINATION OF PHENOTHIAZINE DRUGS IN URINE SAMPLES OF PSYCHIATRIC PATIENTS.
183599 03-02

INDICATIONS AND DOSAGE FOR MAXIMAL ACTIVITY OF ORNITHINE-CARBAMYL-TRANSFERASE IN THE PSYCHIATRIC ENVIRONMENT.
184955 03-17

THE USE OF ORAL DROPERIDOL IN PSYCHIATRIC THERAPY.
184965 03-07

PSYCHIATRIC COMPLICATIONS OF EVERYDAY DRUGS.
186092 03-15

LITHIUM: ITS ROLE IN PSYCHIATRIC RESEARCH AND TREATMENT.
186920 03-09

LITHIUM CARBONATE: PSYCHIATRIC INDICATIONS AND MEDICAL COMPLICATIONS.
187786 04-15

THE USE OF DRUGS IN PSYCHIATRIC INTERVIEWS: SOME INTERPRETATIONS BASED ON CONTROLLED EXPERIMENTS.
189074 04-17

DIAZEPAM ON DEMAND: DRUG SEEKING BEHAVIOR IN PSYCHIATRIC INPATIENTS.
189924 04-17

IMPROVING PSYCHIATRIC DRUG THERAPY: A MATTER OF DOSAGE AND CHOICE.
190144 04-17

ANTICONVULSANT DRUG SERUM LEVELS IN PSYCHIATRIC PATIENTS WITH SEIZURE DISORDERS: EFFECTS OF CERTAIN PSYCHOTROPIC DRUGS.
191096 04-13

THE COMPARATIVE ANXIOLYTIC EFFECTS OF PLACEBO, IMIPRAMINE AND CHLORIMIPRAMINE USING PSYCHIATRIC AND PSYCHOPHYSIOLOGICAL MEASUREMENTS.
191137 04-14

SERUM PROLACTIN LEVELS IN NEWLY ADMITTED PSYCHIATRIC PATIENTS.
191506 04-13

DOPAMINE AND PSYCHIATRIC STATES: PRELIMINARY REMARKS.
191507 04-13

PSYCHIATRIC PHARMACOLOGY OF THE AGED.
191693 04-17

THE EFFECT OF CHLORPROMAZINE AND AMYTAL SODIUM ON THE CONFORMITY OF ADOLESCENTS UNDER PSYCHIATRIC OBSERVATION.
191776 04-14

PSYCHIATRIC SYMPTOMS PRODUCED BY DRUGS.
192513 04-15

PSYCHIATRISTS

PSYCHIATRISTS REACTIONS TO THEIR PATIENTS REFUSAL OF DRUGS.
175251 02-17

COMPARATIVE SURVEY OF PSYCHIATRISTS TREATMENT PREFERENCES: CALIFORNIA AND NEW-YORK.
185877 03-08

PSYCHIATRY

LITHIUM IN PSYCHIATRY.
167675 01-09

INTRODUCTORY REMARKS: NEW AGENTS IN PSYCHIATRY.
168800 01-17

IMPRESSIONS OF SCANDINAVIAN PSYCHIATRY -- 1973.
173452 01-17

THE USE OF KETAMINE IN PSYCHIATRY.
175282 02-07

OBSERVATIONS ON THE THERAPEUTIC ACTIVITY OF CLOPENTHIXOL IN PSYCHIATRY.
175540 02-11

USE AND ABUSE OF DRUGS IN PSYCHIATRY.
175620 02-17

AN ACCOUNT OF THE USE OF FLUPHENAZINE SINCE THE ESTABLISHMENT OF PSYCHIATRY AS A SEPARATE DISCIPLINE.
176431 02-11

TOPICS IN PSYCHIATRY: PSYCHOTROPIC MEDICINE.
177190 02-17

EXPERIENCE IN THE USE OF FK-880 (SULPIRIDE) IN THE FIELD OF PSYCHIATRY.
177568 02-08

BENZOCTAMINE IN PSYCHIATRY: A 30-CASE STUDY.
182901 03-11

NEUROPHYSIOLOGICAL RESEARCH IN PSYCHIATRY AND ITS RELATIONSHIP TO PSYCHOPHARMACOLOGY.
183693 03-17

INSTITUTE OF PSYCHIATRY CLINICAL PSYCHOPHARMACOLOGY RESEARCH TEAM.
187022 03-17

POLYPHARMACY IN PSYCHIATRY: A MULTI-STATE COMPARISON OF PSYCHOTROPIC DRUG COMBINATIONS.
187840 04-17

BIOCHEMISTRY AND PSYCHIATRY WITH SPECIAL REFERENCE TO PSYCHOPHARMACOLOGY.
189331 04-17

CANNABIS-INDICA IN 19TH-CENTURY PSYCHIATRY.
192059 04-17

LABORATORY ASSESSMENTS OF ANTIDEPRESSIVE ACTIVITY -- THEIR VALUE FOR CLINICAL PSYCHIATRY AND THE UNDERSTANDING OF DEPRESSION.
192422 04-09

PSYCHIC

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: III. PIMOZIDE IN THE TREATMENT OF STRESS INDUCED PSYCHIC AND FUNCTIONAL DISORDERS.
183193 03-11

PSYCHIC FATIGABILITY, ITS FEATURES AND DRUG THERAPY.
183197 03-11

THE EFFECTS OF PSYCHIC STIMULANTS ON THE ACTIVITY OF POTASSIUM AND SODIUM ION STIMULATED ATPASE IN THE MICROSOMAL FRACTIONS OF THE BRAIN OF RATS.
183518 03-01

RESPONSE TO PROPRANOLOL AND DIAZEPAM IN SOMATIC AND PSYCHIC ANXIETY.
188887 04-10

A PHARMACOLOGICAL MODEL WITH RHESUS MONKEYS FOR THE PREDICTION OF SELECTIVE DEPRESSION OF PSYCHIC FUNCTIONS.
192424 04-04

PSYCHOACTIVE

THE USE OF PSYCHOACTIVE DRUGS BY ADULTS.
167585 01-17

ACUTE ADVERSE REACTIONS TO PSYCHOACTIVE DRUGS, DRUG USAGE, AND PERSONALITY. (UNPUBLISHED PAPER).
167832 01-15

INFLUENCE OF AFFECTIVE STATES AND PSYCHOACTIVE DRUGS ON VERBAL LEARNING AND MEMORY.
169504 01-09

CORTICAL SYNAPTOSOMAL UPTAKE AND SUBSYNAPTOSOMAL DISTRIBUTION OF 3H-NOREPINEPHRINE AND 3H-AMPHETAMINE: MODIFICATION BY TRICYCLIC AND PSYCHOACTIVE AGENTS IN VITRO. (PH.D. DISSERTATION).
172020 01-03

PSYCHOACTIVE DRUGS: IMMUNOASSAY AND LOCALIZATION.
173536 01-06

REHABILITATION OF LEARNING IN A HOSPITAL CLASS USING PSYCHOACTIVE DRUGS.
174071 01-11

EFFECTS OF PSYCHOACTIVE DRUGS ON NONVERBAL COMMUNICATION AND GROUP SOCIAL BEHAVIOR OF MONKEYS.
175317 02-04

PSYCHOACTIVE DRUG CONTROL: ISSUES AND RECOMMENDATIONS.
181638 02-17

THE ACTIONS OF SEVERAL PSYCHOACTIVE AGENTS UPON THE MUSCARINIC MECHANISMS IN THE SUPERIOR CERVICAL GANGLION OF THE CAT.
183866 03-03

IMPACT OF PSYCHOACTIVE DRUGS ON HYPNOTIZABILITY.
184021 03-12

HOW TO PRESCRIBE PSYCHOACTIVE DRUGS.
190236 04-17

THE USES AND RELATIVE HAZARD POTENTIAL OF PSYCHOACTIVE DRUGS.
190237 04-17

A FEW REMARKS ON THE USE OF PSYCHOACTIVE AGENTS IN THE TREATMENT OF EMOTIONAL DISORDERS.
190241 04-09

A COMPARISON OF CLINICALLY USED PSYCHOACTIVE DRUGS IN FOUR LATIN-AMERICAN COUNTRIES AND IN CANADA (ARGENTINA, COSTA-RICA, MEXICO AND PANAMA).
191139 04-17

INTRAGASTRIC SELF-ADMINISTRATION OF PSYCHOACTIVE DRUGS IN THE RHESUS MONKEY.
191939 04-04

INCORPORATION OF 14C-DIHYDROPHENYLALANINE AND 14C-CHOLINE INTO RAT BRAIN SUBCELLULAR PARTICLES AND THE EFFECT OF PSYCHOACTIVE DRUGS.
192426 04-03

PSYCHODRAMA

SIMULTANEOUS MESORIDAZINE AND PSYCHODRAMA IN NEUROTICS.
183362 03-10

PSYCHODYNAMIC

DRUGS AND PSYCHODYNAMIC SHIFTS IN AFFECTIVE ILLNESS. (UNPUBLISHED PAPER).
170079 01-09

PSYCHOENDOCRINE

PSYCHOENDOCRINE INVESTIGATION IN SCHIZOPHRENIA: RELATIONSHIP BETWEEN PITUITARY GONADAL FUNCTION AND BEHAVIOR.
191190 04-14

PSYCHOEXPERIMENTAL

COMPARISON OF PSYCHOEXPERIMENTAL PERFORMANCE UNDER THE INFLUENCE OF THE ANALGESIC PROPIRAM FUMARATE.
184618 03-14

PSYCHOGALVANIC

AN IMPROVED METHOD FOR STUDYING THE PSYCHOGALVANIC REACTION IN MICE AND ITS INHIBITION BY PSYCHOLEPTIC DRUGS. COMPARISON WITH THE EFFECTS OF OTHER PHARMACOLOGICAL AGENTS.
185749 03-06

PSYCHOGERIATRIC

HALOPERIDOL VERSUS THIORIDAZINE FOR THE TREATMENT OF PSYCHOGERIATRIC PATIENTS: A DOUBLE-BLIND CLINICAL STUDY.
192231 04-09

PSYCHOGERIATRICS

TRAZODONE IN THE TREATMENT OF ORGANIC BRAIN SYNDROMES, WITH SPECIAL REFERENCE TO PSYCHOGERIATRICS.
168805 01-11

PSYCHOLEPTIC
AN IMPROVED METHOD FOR STUDYING THE PSYCHOGALVANIC REACTION IN MICE AND ITS INHIBITION BY PSYCHOLEPTIC DRUGS. COMPARISON WITH THE EFFECTS OF OTHER PHARMACOLOGICAL AGENTS.
185749 03-06

PSYCHOLOGICAL
PSYCHOMETRIC INVESTIGATIONS IN PARKINSONS SYNDROME DURING TREATMENT WITH L-DOPA AND RELEVANCE OF SOME PSYCHOLOGICAL PHENOMENA.
168578 01-13
PSYCHOLOGICAL AND PHYSIOLOGICAL EFFECTS OF CHRONIC MARIJUANA ADMINISTRATION IN MAN.
169070 01-13
PSYCHOLOGICAL EFFECTS OF SINGLE DOSE ANTIPSYCHOTIC MEDICATION.
173402 01-08
PSYCHOLOGICAL STUDY ON ATTITUDES TOWARD TRANQUILIZERS.
173502 01-08
CONTROL OF THE HYPERACTIVE CHILD VIA MEDICATION -- AT WHAT COST TO PERSONALITY DEVELOPMENT; SOME PSYCHOLOGICAL IMPLICATIONS AND CLINICAL INTERVENTIONS.
176810 02-11
PSYCHOLOGICAL EXPERIMENTATION ON THE EFFECTS OF PROPIRAM FUMARATE AND PROMETHAZINE UNDER NORMAL AND STRESS CONDITIONS.
184617 03-07
EFFECT OF MARIHUANA ON THE PSYCHOLOGICAL REFRACTORY PERIOD.
189358 04-14
RATING OF PSYCHOLOGICAL EFFECTS INDUCED BY ORDINARY NOVERIL AND TIME-RELEASED NOVERIL.
190312 04-14

PSYCHOLYSIS
MYTHICIZING ELEMENTS IN EXPERIMENTAL PSYCHOLYSIS.
189754 04-12

PSYCHOMETRIC
PSYCHOMETRIC INVESTIGATIONS IN PARKINSONS SYNDROME DURING TREATMENT WITH L-DOPA AND RELEVANCE OF SOME PSYCHOLOGICAL PHENOMENA.
168578 01-13
DOUBLE-BLIND PSYCHOMETRIC EVALUATION OF PIMOZIDE AND HALOPERIDOL VERSUS PLACEBO IN EMOTIONALLY LABILE VOLUNTEERS UNDER TWO DIFFERENT WORK LOAD CONDITIONS.
180065 02-14

PSYCHOMOTOR
PSYCHOMOTOR STIMULANT SELF-ADMINISTRATION IN THE RAT.
169028 01-04
CENTRAL NERVOUS STIMULANT INDUCED PHYSIOLOGICAL AND PERFORMANCE CHANGES IN ADULTS DURING SUSTAINED PSYCHOMOTOR TRACKING.
179023 02-13
ACUTE EFFECTS OF ALCOHOL, DIAZEPAM, THIORIDAZINE, FLUPENTHIXOL AND ATROPINE ON PSYCHOMOTOR PERFORMANCE PROFILES.
184848 03-14
A CASE OF A NONSPECIFIC MENTAL ILLNESS WITH PSYCHOMOTOR VARIANT.
188517 04-09
AN INVESTIGATION OF THE BEHAVIOURAL NATURE OF THE PSYCHOMOTOR STIMULANT EFFECT OF AMPHETAMINE.
188620 04-04
PSYCHOMOTOR TEST PERFORMANCE WITH A FENFLURAMINE AMPHETAMINE COMBINATION.
190146 04-07
THE EFFECTS OF HOE-36801 ON CATECHOLAMINE EXCRETION, HEART RATE AND PSYCHOMOTOR PERFORMANCE IN NEUROTICS AND NORMALS.
192428 04-13

PSYCHONEUROLOGICAL
A STUDY OF THE EFFECTS OF RITALIN INTERVENTION UPON THE PERCEPTUAL COMPETENCIES OF CHILDREN DIAGNOSED AS GIVING EVIDENCE OF PSYCHONEUROLOGICAL LEARNING DISABILITIES. (PH.D. DISSERTATION).
186833 03-14

PSYCHONEUROSES
TRAZODONE IN THE TREATMENT OF PSYCHONEUROSES: A DOUBLE-BLIND STUDY.
168809 01-11

PSYCHONEUROSIS
CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG: FK-880 (SULPIRIDE), ITS EFFECT ON PATIENTS WITH PSYCHOSOMATIC DISEASES AND PSYCHONEUROSIS.
182731 03-10
A CHEMOTHERAPEUTIC ALTERNATIVE TO THE ANTIANXIETY AGENTS FOR THE EXTENDED TREATMENT OF PSYCHONEUROSIS.
192083 04-10

PSYCHONEUROTICS
TRIAL OF OXAZEPAM IN AMBULATORY PSYCHONEUROTICS.
170412 01-11

PSYCHOPATHOLOGICAL
PSYCHOPATHOLOGICAL IMPORTANCE AND THERAPEUTIC EFFECTS OF A COMBINATION OF HYDERGINE AND THIORIDAZINE IN PSYCHIATRIC SYNDROMES IN THE AGING.
168976 01-14
RELIEF OF MUSCULOSKELETAL AND ASSOCIATED PSYCHOPATHOLOGICAL SYMPTOMS WITH MEPROBAMATE AND ASPIRIN: A CONTROLLED STUDY.
169632 01-10

PSYCHOPATHOLOGY
EXACERBATION OF PSYCHOPATHOLOGY DURING TREATMENT: ETIOLOGY.
177676 02-17
PSYCHOPATHOLOGY AND PSYCHOPHARMACOLOGY.
184630 03-17

PSYCHOPHARMACEUTICALS
POSSIBLE MUTUAL THERAPEUTIC COMBINATION OF PSYCHOPHARMACEUTICALS.
178029 02-17
PAIN AND PSYCHOPHARMACEUTICALS.
187959 04-17

PSYCHOPHARMACOLOGIC
PSYCHOPHARMACOLOGIC AGENTS: EFFECT ON DRUG METABOLISM.
181398 02-13
EFFECTS OF PSYCHOPHARMACOLOGIC AGENTS ON BEHAVIOR.
181403 02-04
TREATMENT WITH PSYCHOPHARMACOLOGIC AGENTS IN CHILDHOOD DEPRESSIONS.
182431 03-11
PSYCHOPHARMACOLOGIC FACILITATION OF OPERANT CONDITIONING OF GENETICALLY NERVOUS CATAHOULA AND POINTER DOGS.
190696 04-04

PSYCHOPHARMACOLOGICAL
THE SOCIAL PLAY BEHAVIOR OF CHIMPANZEES ACCORDING TO A PSYCHOPHARMACOLOGICAL TEST/.
168838 01-04
PSYCHOPHARMACOLOGICAL RESEARCH: SOME METHODOLOGICAL PROBLEMS.
169932 01-06
STUDY ON THE PSYCHOPHARMACOLOGICAL ASSAY OF CENTRALLY ACTING DRUGS IN RATS.
171260 01-06
THE EFFECT OF PANAX GINSENG SAPONIN ON THE CENTRAL NERVOUS SYSTEM IN RAT: THE PSYCHOPHARMACOLOGICAL EFFECT OF GINSENG.
171599 01-04
A METHOD OF QUANTIFYING EEG FOR PSYCHOPHARMACOLOGICAL RESEARCH.
174135 01-16
THE DIFFERENTIATION OF ANXIETY AND DEPRESSIVE DISORDERS: A PSYCHOPHARMACOLOGICAL APPROACH.
175286 02-10
THE PROBLEMS OF THE PSYCHOPHARMACOLOGICAL TREATMENT OF PSYCHOSOMATIC DISEASES -- THE ANESTHESIOLOGIC APPROACH.
177063 02-17
SOME PROBLEMS IN THE PSYCHOPHARMACOLOGICAL TREATMENT OF PSYCHOSOMATIC DISEASE.
177066 02-17
PSYCHOPHARMACOLOGICAL AGENTS: STEREOCHEMICAL STUDIES.
181391 02-01
NEUROPHARMACOLOGY OF PSYCHOPHARMACOLOGICAL AGENTS.
181397 02-04
A PSYCHOPHARMACOLOGICAL STUDY OF CATECHOLAMINES IN AFFECTIVE DISORDERS.
184653 03-09
PSYCHOPHARMACOLOGICAL AGENTS FOR THE TERMINALLY ILL AND BEREAVED.
188149 04-17

PSYCHOPHARMACOLOGY
MASS FRAGMENTOGRAPHY IN CLINICAL PSYCHOPHARMACOLOGY.
169074 01-01
PSYCHOPHARMACOLOGY OF OLD AGE.
169945 01-17
CRISIS PSYCHOPHARMACOLOGY TECHNIQUES.
174298 01-11
PSYCHOPHARMACOLOGY AND GERIATRICS.
176438 02-17
NEW HORIZONS IN PSYCHOPHARMACOLOGY.
176926 02-17
CONTRIBUTION OF PSYCHOPHARMACOLOGY TO THE PSYCHOPHYSIOLOGICAL THEORY OF EMOTIONS.
178817 02-13
PSYCHOPHARMACOLOGY OF HALLUCINOGENS.
180123 02-12
EXPERIMENTAL CATATONIA AND PSYCHOPHARMACOLOGY.
180724 02-04
PSYCHOPHARMACOLOGY OF THE CANNABINOIDS.
181152 02-14
EXPERIMENTAL STUDIES IN COMPARATIVE PSYCHOPHARMACOLOGY.
181400 02-04

NEUROPHYSIOLOGICAL RESEARCH IN PSYCHIATRY AND ITS RELATIONSHIP TO PSYCHOPHARMACOLOGY.
183693 03-17

PSYCHOPATHOLOGY AND PSYCHOPHARMACOLOGY.
184630 03-17

INSTITUTE OF PSYCHIATRY CLINICAL PSYCHOPHARMACOLOGY RESEARCH TEAM.
187022 03-17

BIOCHEMISTRY AND PSYCHIATRY WITH SPECIAL REFERENCE TO PSYCHOPHARMACOLOGY.
189331 04-17

PSYCHOPHYSIOLOGICAL

A TRIAL ON BROMAZEPAM (LEXOTAN) AND PLACEBO IN THE TREATMENT OF PSYCHOPHYSIOLOGICAL DISORDERS.
171150 01-11

CONTRIBUTION OF PSYCHOPHARMACOLOGY TO THE PSYCHOPHYSIOLOGICAL THEORY OF EMOTIONS.
178817 02-13

PSYCHOPHYSIOLOGICAL EFFECTS OF DIAZEPAM (VALIUM) COMBINED WITH A MODERATE DOSE OF ALCOHOL IN MAN.
180699 02-14

PSYCHOPHYSIOLOGICAL PATTERNS OF RESPONSE IN SCHIZOPHRENIA.
183629 03-08

COMMENTS ON PAPER, PSYCHOPHYSIOLOGICAL PATTERNS OF RESPONSE IN SCHIZOPHRENIA.
183630 03-17

THE COMPARATIVE ANXIOLYTIC EFFECTS OF PLACEBO, IMIPRAMINE AND CHLORIMIPRAMINE USING PSYCHIATRIC AND PSYCHOPHYSIOLOGICAL MEASUREMENTS.
191137 04-14

PSYCHOSES

GROWTH HORMONE RESPONSES TO ADMINISTRATION OF L-5-HYDROXYTRYPTOPHAN (L-5-HTP) IN MANIC-DEPRESSIVE PSYCHOSES.
167919 01-09

PRELIMINARY STUDY OF THE TREATMENT OF CHRONIC PSYCHOSES WITH FLUPENTHIXOL DECANOATE.
172978 01-09

BIOLOGICAL INTERVENTIONS IN PSYCHOSES OF CHILDHOOD.
175872 02-17

EXPERIENCE GAINED IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PSYCHOSES WITH A THIORIDAZINE DERIVATIVE.
180675 02-08

A COMPARATIVE STUDY OF THE ANTIPSYCHOTIC ACTION OF SOME NEUROLEPTICS BASED ON THE MODEL OF LSD PSYCHOSES.
183682 03-03

PSYCHOSIS

LITHIUM CARBONATE TREATMENT IN MANIC PSYCHOSIS.
167918 01-09

BENZTROPINE PSYCHOSIS.
168319 01-15

STUDIES ON THE URINARY EXCRETION OF CATECHOLAMINES AND 17-KETOSTEROID IN MANIC-DEPRESSIVE PSYCHOSIS.
178623 02-09

CANNABIS PSYCHOSIS.
180155 02-14

CLINICAL STUDIES OF ACUTE PSYCHOSIS ON THE BASIS OF CHRONIC HYPNOTICA INTOXICATION -- AN ABSTRACT REPORT.
182755 03-15

ON THE DYNAMICS AND TREATMENT OF THE TENDENCY OF SCHIZOPHRENIC PSYCHOSIS TO BECOME CHRONIC.
183957 03-08

LITHIUM CARBONATE IN MANIC-DEPRESSIVE PSYCHOSIS.
187477 04-09

STEROID PSYCHOSIS: A CASE REPORT.
189042 04-15

BEHAVIORAL AND EEG CHANGES IN THE AMPHETAMINE MODEL OF PSYCHOSIS.
191505 04-04

TREATMENT OF EXOGENOUS PSYCHOSIS BY THE USE OF FK-880 (SULPIRIDE).
191663 04-09

PSYCHOSOMATIC

TRAZODONE AND PSYCHOSOMATIC MEDICINE.
168808 01-11

A DOUBLE-BLIND CLINICAL TRIAL OF DOXEPIN HYDROCHLORIDE AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION IN THE FIELD OF INTERNAL MEDICINE.
171282 01-11

THE PROBLEMS OF THE PSYCHOPHARMACOLOGICAL TREATMENT OF PSYCHOSOMATIC DISEASES -- THE ANESTHESIOLOGIC APPROACH.
177063 02-17

SOME PROBLEMS IN THE PSYCHOPHARMACOLOGICAL TREATMENT OF PSYCHOSOMATIC DISEASE.
177066 02-17

A CLINICAL EVALUATION OF A NEW ANXIOLYTIC DRUG (THIENODIAZEPINE DERIVATIVE Y-6047) IN NEUROTICS AND PSYCHOSOMATIC DISORDERS -- A PRELIMINARY REPORT.
181771 02-07

DOUBLE-BLIND CROSSOVER COMPARISON OF BROMAZEPAM AND DIAZEPAM IN PSYCHOSOMATIC DISEASE, NEUROSIS AND DEPRESSION.
182624 03-11

CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG: FK-880 (SULPIRIDE), ITS EFFECT ON PATIENTS WITH PSYCHOSOMATIC DISEASES AND PSYCHONEUROSIS.
182731 03-10

PSYCHOSTIMULANTS

DRUG-INDUCED CATALEPSY AS INFLUENCED BY PSYCHOSTIMULANTS, APOMORPHINE, L-DOPA, AND YOHIMBINE.
177730 02-13

THE INFLUENCE OF PSYCHOSTIMULANTS ON K42 MEMBRANE PERMEABILITY IN VARIOUS PORTIONS OF RAT BRAIN.
191122 04-03

PSYCHOTHERAPEUTIC

THE COMPUTER ANALYZES TWO PSYCHOTHERAPEUTIC AGENTS IN ANXIETY/DEPRESSED STATES.
167345 01-10

USE OF PSYCHOTHERAPEUTIC DRUGS IN THE ACUTE DETOXIFICATION OF HEROIN ADDICTS.
169746 01-11

PSYCHOTHERAPEUTIC DRUG TRIALS AMONG ENGLISH GENERAL PRACTITIONERS.
170292 01-11

ON PHARMACO-PSYCHOTHERAPY; THE ROLE OF THE PSYCHOTHERAPEUTIC SITUATION IN PSYCHOTROPIC MEDICATION.
170415 01-11

THE PROBLEM OF ANXIETY IN A NON-WESTERN SOCIETY: A COMBINED CHEMOTHERAPEUTIC AND PSYCHOTHERAPEUTIC APPROACH.
171162 01-10

CLINICAL USE OF PSYCHOTHERAPEUTIC DRUGS.
175914 02-17

SOMATIC SIDE-EFFECTS OF PSYCHOTHERAPEUTIC DRUGS IN CHILDHOOD.
183183 03-15

PSYCHOTHERAPEUTICS

PSYCHOTHERAPEUTICS OF ALCOHOLISM.
172834 01-11

PSYCHOTHERAPY

EFFECTS OF LSD-25 AND DEXTROAMPHETAMINE ON SPEECH RHYTHMS IN PSYCHOTHERAPY DIALOGUES.
168420 01-12

LONG-TERM TREATMENT OF DEPRESSION WITH DRUGS AND PSYCHOTHERAPY.
169087 01-09

IMIPRAMINE, DIAZEPAM AND GROUP PSYCHOTHERAPY IN LONG-TERM TREATMENT OF DEPRESSIVE NEUROTICS.
169089 01-10

TREATMENT OF DEPRESSION BY DRUGS AND PSYCHOTHERAPY.
171924 01-10

DRUGS AND GROUP PSYCHOTHERAPY IN NEUROTIC DEPRESSION.
171925 01-10

MEDICATION AND/OR PSYCHOTHERAPY WITH SCHIZOPHRENICS: WHICH PART OF THE ELEPHANT HAVE YOU TOUCHED
173534 01-08

LONG-TERM CONSEQUENCES OF EXPERIENCE, MEDICATION, AND PSYCHOTHERAPY FOR SCHIZOPHRENIC PATIENTS. (UNPUBLISHED PAPER).
178677 02-17

PSYCHOTHERAPY WITH HALLUCINOGENS.
180139 02-12

THE DYNAMICS OF A GROUP IN PSYCHOTHERAPY.
180140 02-12

INDIVIDUAL PSYCHOTHERAPY WITH HALLUCINOGENS.
180143 02-12

THE USE OF HALLUCINOGENS IN GROUP PSYCHOTHERAPY.
180144 02-12

RESULTS OF CLINICAL RESEARCH IN PSYCHOTHERAPY WITH HALLUCINOGENS.
180145 02-12

SHORT-TERM PSYCHOTHERAPY WITH LSD: A CASE STUDY.
181461 02-12

CHEMOTHERAPY AND PSYCHOTHERAPY, ARE THEY COMPLEMENTARY OR ANTAGONISTIC?: A PERSONAL STUDY.
184959 03-17

PSYCHEDELIC (LSD) PSYCHOTHERAPY: A CASE REPORT.
186994 03-08

PSYCHOTIC

RAPID CONTROL OF PSYCHOTIC EXCITEMENT STATES WITH INTRAMUSCULAR HALOPERIDOL.
170627 01-09

A CASE OF ENCEPHALITIS WITH PSYCHOTIC COMPLICATIONS.
174783 01-11

PSYCHOTIC COMPLICATIONS AFTER TETRAETHYLTHIURAMDISULFIDE USED IN THE TREATMENT OF ALCOHOLISM.
175047 02-11

LITHIUM DISTRIBUTION BETWEEN CEREBROSPINAL FLUID AND SERUM OF AFFECTIVE PSYCHOTIC PATIENTS TREATED WITH LITHIUM CARBONATE AND ITS CLINICAL RESPONSE.
180301 02-11

LITHIUM TREATMENT OF PSYCHOTIC CHILDREN. A CONTROLLED CLINICAL TRIAL.
182434 03-09

COMPARATIVE EVALUATION OF DIBENCYCLADINE (LUDIOMIL) AND IMIPRAMINE IN PSYCHOTIC DEPRESSION.
183361 03-09

CLINICAL STUDY ON THE EFFECTS OF THIOTHIXENE IN HOSPITALIZED PSYCHOTIC PATIENTS.
183955 03-08

MUSCLE ABNORMALITIES IN PSYCHOTIC PATIENTS: II. SERUM CPK ACTIVITY, FIBER ABNORMALITIES, AND BRANCHING AND SPROUTING OF SUBTERMINAL NERVES.
187114 03-09

BEHAVIORAL AND VISUAL EVOKED POTENTIAL INVESTIGATIONS DURING TRIHEXYPHENIDYL AND THIOTHIXENE TREATMENT IN PSYCHOTIC BOYS.
187115 03-09

CHLORPROMAZINE CAUSING EXTRAPYRAMIDAL DYSFUNCTION IN NEWBORN INFANT OF PSYCHOTIC MOTHER.
187787 04-15

MESORIDAZINE (TPS-23 SANDOZ) IN ACUTE PSYCHOTIC STATES.
187958 04-11

AMITRIPTYLINE IN THE PSYCHOTIC STATES OF DOWNS SYNDROME: THE COMPARISON OF TWO CASES.
191192 04-11

PSYCHOTICISM

THE BIOLOGICAL BASIS OF PSYCHOTICISM: A STUDY OF INDIVIDUAL DIFFERENCES IN RESPONSE TO DEXAMPHETAMINE.
175219 02-13

PSYCHOTOGENIC

SOME ASPECTS OF PSYCHOTOGENIC DRUGS.
172809 01-17

PSYCHOTOMIMETIC

COMPARATIVE EFFECTS OF STEREOISOMERS OF PSYCHOTOMIMETIC PHENYLISOPROPYLAMINES.
172915 01-03

STEREOCHEMICAL ASPECTS IN THE METABOLISM OF THE PSYCHOTOMIMETIC AMINE 1-(2,5 DIMETHOXY-4-METHYLPHENYL)-2 AMPHETAMINE.
175759 02-03

A COMPARISON OF PSYCHOTOMIMETIC DRUG EFFECTS ON RAT BRAIN NOREPINEPHRINE METABOLISM.
183891 03-03

CHEMICAL CONVERSION OF THE PSYCHOTOMIMETIC AMINE 1-(2,5 DIMETHOXY-4-METHYLPHENYL) 2-AMINOPROPANE TO 5-HYDROXYDIMETHYLINDOLE.
187941 04-01

STEREOCHEMICAL ASPECTS AND METABOLITE FORMATION IN THE IN VIVO METABOLISM OF THE PSYCHOTOMIMETIC AMINE, 1-2,5-(DIMETHOXY-4-METHYLPHENYL) 2 AMINOPROPANE.
190718 04-03

PSYCHOTOMIMETICS

POTENTIAL PSYCHOTOMIMETICS: BROMOMETHOXYAMPHETAMINES AND STRUCTURAL CONGENERS OF LYSERGIC ACID. (PH.D. DISSERTATION).
173588 01-03

EFFECTS OF PSYCHOTOMIMETICS ON VASCULAR STRIPS: STUDIES OF METHOXYLATED AMPHETAMINES AND OPTICAL ISOMERS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE AND 2,5 DIMETHOXY-4-BROMOAMPHETAMINE.
177734 02-03

PSYCHOTROPE

STUDY WITH RADIOTRACERS OF THE DISTRIBUTION OF A NEW PSYCHOTROPE IN MICE: L-2-PYRROLIDONE-5-CARBOXYLATE DIMETHYLAMINOETHANOL. I. COMPARISON WITH L-GLUTAMIC AND L-2-PYRROLIDONE-5-CARBOXYLIC ACID.
180723 02-03

PSYCHOTROPIC

INTERNATIONAL REFERENCE CENTERS NETWORK FOR PSYCHOTROPIC DRUGS.
167706 01-17

PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT (SECOND REPORT): GENERAL PHARMACOLOGY AND SUBACUTE TOXICITY.
168499 01-07

CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG, TRAZODONE: A REVIEW OF LITERATURE.
168803 01-11

GAS CHROMATOGRAPHIC - MASS SPECTROMETRIC STUDIES ON TRICYCLIC PSYCHOTROPIC DRUGS.
169073 01-01

PSYCHOTROPIC DRUGS AS THERAPEUTIC AGENTS.
169748 01-17

ON PHARMACO-PSYCHOTHERAPY; THE ROLE OF THE PSYCHOTHERAPEUTIC SITUATION IN PSYCHOTROPIC MEDICATION.
170415 01-11

THE ELECTROCARDIOGRAPHIC ABNORMALITIES INDUCED BY PSYCHOTROPIC DRUGS.
170638 01-13

CLINICAL RESEARCH ASPECTS OF PSYCHOTROPIC MEDICATION.
170754 01-17

EFFECT AND AFTEREFFECT OF DRUGS: ETHICAL CONSIDERATIONS ON THE USE OF PSYCHOTROPIC AGENTS (1).
170847 01-17

ABOUT THE PSYCHOTROPIC DRUGS.
171159 01-17

PSYCHOTROPIC DRUGS IN MEDICAL PRACTICE.
171485 01-17

COMMON PSYCHOTROPIC DRUGS.
171568 01-17

ANTAGONISM OF P-CHLOROAMPHETAMINE (PCA) INDUCED DEPLETION OF 5-HT FROM RAT BRAIN BY SOME THYMOLEPTICS AND OTHER PSYCHOTROPIC DRUGS.
171628 01-03

SEROTONINERGIC MECHANISMS IN THE CENTRAL ACTION OF PSYCHOTROPIC DRUGS. (PH.D. DISSERTATION).
172015 01-03

STUDY OF THE PSYCHOTROPIC ACTION OF TEGRETOL IN PATIENTS WITH EPILEPSY.
172439 01-11

THE EEG OF SLEEP AND PSYCHOTROPIC DRUGS.
172972 01-13

THE DESIGN OF THERAPEUTIC TRIALS: A CRITICAL ANALYSIS WITH ILLUSTRATIONS, PARTICULARLY FROM THE FIELD OF PSYCHOTROPIC DRUGS OR: WHY NO ONE CAN EVER DO A PROPER DRUG TRIAL.
173307 01-16

THE EFFECT OF PSYCHOTROPIC AGENTS ON SOME ASPECTS OF ACETYLCHOLINE METABOLISM IN CAT BRAINS.
174257 01-03

EFFECT OF A NEW PSYCHOTROPIC DRUG, CS-370 (10-CHLORO-11B-(2-CHLOROPHENYL)-2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE) UPON THE CENTRAL NERVOUS SYSTEM.
174603 01-03

PSYCHOTROPIC MEDICATION IN INDONESIA (1970-1973).
174618 01-17

THE DOCUMENTATION OF CLINICAL PSYCHOTROPIC DRUG TRIALS.
175332 02-16

OVERDOSE OF PSYCHOTROPIC DRUGS.
175935 02-15

CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, ZISEPRON, IN TREATMENT OF PSYCHIATRIC DISEASES IN COMPARISON WITH THIORIDAZINE.
176467 02-08

CLINICAL EFFECTS OF DICEPLON, A PSYCHOTROPIC DRUG.
176470 02-08

CLINICAL EXPERIENCES WITH A NEW PSYCHOTROPIC DRUG, R-6238 (PIMOZIDE).
176564 02-11

SIMPLE ALGORITHMS FOR PREDICTING PSYCHOTROPIC DRUGS ASSIGNED TO PSYCHIATRIC INPATIENTS.
176676 02-17

CLINICAL EXPERIENCES WITH A PSYCHOTROPIC DRUG (OXYPERTINE) IN CHRONIC SCHIZOPHRENIA.
176727 02-08

TOPICS IN PSYCHIATRY: PSYCHOTROPIC MEDICINE.
177190 02-17

CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, DOXEPIN HYDROCHLORIDE, IN THE TREATMENT OF DEPRESSIVE STATES.
177569 02-11

COMBINED USE OF ECT AND PSYCHOTROPIC DRUGS: ANTIDEPRESSIVES AND ANTIPSYCHOTICS.
177670 02-11

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: IV. THE EFFECTS OF CHLORPROMAZINE.
177716 02-14

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: V. THE EFFECTS OF CHLORAL HYDRATE.
177717 02-14

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: VI. THE EFFECTS OF CHLORDIAZEPOXIDE.
177718 02-14

PHARMACOLOGIC BASIS FOR USE OF PSYCHOTROPIC DRUGS: AN OVERVIEW.
177782 02-17

PSYCHOTROPIC DRUGS.
178002 02-17

PSYCHOTROPIC DRUGS IN CAMBODIA.
178109 02-17

THE DOCUMENTATION OF CLINICAL PSYCHOTROPIC DRUG TRIALS: SAMPLE OUTPUT PACKAGE.
180256 02-16

PSYCHOTROPIC MEDICATION IN JAPAN.
180319 02-08

STATUS OF PSYCHOTROPIC MEDICATION IN VIET-NAM.
180320 02-17

PSYCHOTROPIC MEDICATION IN HONG-KONG.
180321 02-17

PSYCHOTROPIC DRUGS AND CYTOGENIC EFFECTS.
181395 02-15
PSYCHOTROPIC DRUGS AND PHENOTYPICAL BEHAVIORS.
181407 02-05
ATTEMPT TO EVALUATE THE PHYSICAL DEPENDENCE LIABILITY OF PSYCHOTROPIC DRUGS IN MICE.
182103 02-04
EFFECTS OF PSYCHOTROPIC DRUGS ON METHAMPHETAMINE INDUCED EXCITATIONS IN THE AGGREGATED MICE.
182107 02-04
EFFECTS OF PSYCHOTROPIC DRUGS ON ABNORMAL BEHAVIOR INDUCED BY DELTA9-TETRAHYDROCANNABINOL.
182114 02-04
EFFECTS OF PSYCHOTROPIC DRUGS ON DISCRIMINATION AVOIDANCE CONDITIONING IN RATS WITH OLFACTORY BULB ABLATIONS.
182115 02-04
A COMPARISON OF SOMATIC REFLEX EFFECTS OF THREE PSYCHOTROPIC AGENTS IN THE CHLORALOSE CAT.
182126 02-03
POTENTIAL PSYCHOTROPIC QUINOLIZIDINES.
182446 03-01
THE OCULAR COMPLICATIONS BY MASSIVE DOSE OF PSYCHOTROPIC DRUGS.
182552 03-15
CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG: FK-880 (SULPIRIDE), ITS EFFECT ON PATIENTS WITH PSYCHOSOMATIC DISEASES AND PSYCHONEUROSIS.
182731 03-10
SOCIAL IMPLICATIONS OF PSYCHOTROPIC DRUGS.
182770 03-17
PSYCHOTROPIC DRUGS IN CHILDHOOD DISTURBANCES.
182890 03-11
THE EFFECT OF PSYCHOTROPIC AGENTS ON THE FORMATION OF AVOIDANCE REACTION IN ALBINO RATS DURING ELECTROPAIN STIMULATION OF ANOTHER RAT.
183206 03-04
NEUROLOGICAL CONSEQUENCES OF PSYCHOTROPIC DRUG WITHDRAWAL IN SCHIZOPHRENIC CHILDREN.
183275 03-08
THE STANDARDIZED VIDEOTAPE INTERVIEW AS AN OBJECTIVE DEPENDENT VARIABLE IN PSYCHOTROPIC DRUG RESEARCH.
183635 03-17
A CONTROLLED COMPARISON OF THE PSYCHOTROPIC EFFECTS OF PROPANIDID AND METHOHEXITONE.
184082 03-14
THE INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LEVELS OF ENDOGENOUS 2-PHENYLETHYLAMINE IN RABBIT BRAIN.
187112 03-03
POLYPHARMACY IN PSYCHIATRY: A MULTI-STATE COMPARISON OF PSYCHOTROPIC DRUG COMBINATIONS.
187840 04-17
ARE NEUROTIC PATIENTS IN PSYCHOTROPIC DRUG TRIALS REPRESENTATIVE? A COMPARISON OF STUDY AND NON-STUDY PATIENTS IN FOUR FAMILY PRACTICES.
188144 04-10
A LOOK AT RESTRAINING PRACTICES AND THE USE OF PSYCHOTROPIC DRUGS.
188533 04-17
PSYCHOTROPIC DRUGS -- HARM OR HELP.
190138 04-11
ANTICONVULSANT DRUG SERUM LEVELS IN PSYCHIATRIC PATIENTS WITH SEIZURE DISORDERS: EFFECTS OF CERTAIN PSYCHOTROPIC DRUGS.
191096 04-13
PSYCHOTROPIC EFFECT OF ANALGESICS AND NEUROLEPTICS ON A MODEL OF INVESTIGATORY BEHAVIOR CHANGED BY PAIN.
191120 04-04
PSYCHOTROPIC DRUGS AND ELECTROENCEPHALOGRAPHY -- FIRST REPORT.
191625 04-13
PSYCHOTROPIC DRUGS AND ELECTROENCEPHALOGRAPHY -- SECOND REPORT.
191667 04-13
INDICATION AND PROBLEMS OF PSYCHOTROPIC DRUGS IN GENERAL PRACTICE.
191677 04-17
INFLUENCE OF PSYCHOTROPIC DRUGS ON AGGRESSIVENESS EVOKED BY DESTRUCTION OF ISOLATED STRUCTURES OF THE FOREBRAIN.
191788 04-04
INTERACTIONS OF PSYCHOTROPIC DRUGS AND MESCALINE IN VITRO.
191933 04-03
RATIONAL USE OF PSYCHOTROPIC DRUGS: I. HYPNOTICS.
192190 04-14
TRUE AND APPARENT NON-PENETRATION OF THE BLOOD-BRAIN BARRIER BY PSYCHOTROPIC DRUGS.
192423 04-03

PSYCHOTROPICS
EFFECTS OF PG-501 ON PARAPYRAMIDAL SYSTEM SYNDROME INDUCED BY PSYCHOTROPICS.
178019 02-15

PSYCHOVEGETATIVE
USE OF LORAZEPAM IN TREATING PATIENTS WITH NEUROTIC AND SOMATIZED PSYCHOVEGETATIVE SYMPTOMS.
174136 01-09

PTERIDINE
DRUG-INDUCED ACTIVATION OF STRIATAL TYROSINE HYDROXYLASE: CHANGES IN THE AFFINITY FOR PTERIDINE COFACTORS. (UNPUBLISHED PAPER).
173381 01-03

PULMONARY
PHARMACOLOGICAL ANALYSIS OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE REMOVAL FROM THE PULMONARY CIRCULATION: DIFFERENTIATION OF UPTAKE SITES FOR EACH AMINE.
182717 03-03

PUNISHED
DETERMINANTS OF DRUG EFFECTS ON PUNISHED BEHAVIOR.
181405 02-04
TRYPTAMINE ANTAGONISTS AND PUNISHED BEHAVIOR.
186692 03-04

PUNISHMENT
DIFFERENTIAL SENSITIVITY OF METHOHEXITAL SELF-ADMINISTRATION TO SHOCK PUNISHMENT EARLY VS. LATE IN SESSION.
191941 04-04

PURIFICATION
PARTIAL PURIFICATION AND CHARACTERIZATION OF NADPH-LINKED ALDEHYDE REDUCTASE FROM MONKEY BRAIN.
175232 02-03
SOLUBILIZATION AND PURIFICATION OF BRAIN RNA POLYMERASE.
180537 02-06

PUROMYCIN
INTERACTIVE EFFECTS OF CYCLOHEXIMIDE AND PUROMYCIN IN ALTERING BRAIN POLYRIBOSOMES AND NEURAL AND BEHAVIOURAL RESPONSES TO ELECTROSHOCK IN MICE.
175230 02-03

PURPORTED
INTERACTION OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A PURPORTED HASHISH AND LSD ANTAGONIST, WITH SEVERAL CENTRAL NEUROCHEMICAL SYSTEMS.
182217 03-04

PUTATIVE
CENTRAL MONOAMINE METABOLISM IN MAN: EFFECT OF PUTATIVE DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS.
169377 01-13

PYRAZAPON
PYRAZAPON (CI-683): A NEW ANTIANXIETY AGENT.
186581 03-04

PYRIDOXINE
POTENTIATION OF THERAPEUTIC EFFECTS OF NICOTINIC ACID BY PYRIDOXINE IN CHRONIC SCHIZOPHRENICS.
168313 01-08
BRAIN AMINES IN PYRIDOXINE DEFICIENT RATS.
182171 02-03
LEVODOPA, CARBIDOPA, AND PYRIDOXINE IN PARKINSON DISEASE.
187877 04-13
ON-OFF PHENOMENON WITH LEVODOPA THERAPY IN PARKINSONISM: CLINICAL AND PHARMACOLOGIC CORRELATIONS AND THE EFFECT OF INTRAMUSCULAR PYRIDOXINE.
188560 04-11

QUAIL
EFFECTS OF CYPROTERONE ACETATE IN THE MALE JAPANESE QUAIL.
186681 03-03

QUALITATIVE
QUALITATIVE AND QUANTITATIVE STUDIES ON THE DISPOSITION OF AMITRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANT DRUGS IN MAN AS IT RELATES TO THE MANAGEMENT OF THE OVERDOSED PATIENT.
177395 02-15

QUANTIFICATION
DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE IN RESPECT TO TIME AND DOSAGE AND QUANTIFICATION OF THE PRECIPITATED WITHDRAWAL SYNDROME IN RATS.
169474 01-03

QUANTIFYING
A METHOD OF QUANTIFYING EEG FOR PSYCHOPHARMACOLOGICAL RESEARCH.
174135 01-16

QUANTITATIVE
QUANTITATIVE HISTOCHEMICAL STUDIES OF STRIATAL DOPAMINE DEPLETION FOLLOWING DL-ALPHA-METHYL-P-TYROSINE ADMINISTRATION.
172924 01-03
LONG-TERM CLINICAL AND QUANTITATIVE EEG EFFECTS OF CLOPENTHIXOL IN SCHIZOPHRENICS: CLINICAL NEUROPHYSIOLOGICAL CORRELATIONS.
174131 01-08

QUALITATIVE AND QUANTITATIVE STUDIES ON THE DISPOSITION OF AMITRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANT DRUGS IN MAN AS IT RELATES TO THE MANAGEMENT OF THE OVERDOSED PATIENT.
177395 02-15

PREDICTION OF NEUROLEPTIC EFFECTS OF CI-686 BASED ON QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY: DRUG PROFILES AND DOSE RESPONSE CURVES BASED ON COMPUTERIZED CEREBRAL BIOPOTENTIALS.
181958 02-13

A GAS CHROMATOGRAPHIC METHOD FOR THE QUANTITATIVE ESTIMATION OF N-HYDROXYPHENTERMINE.
182203 02-06

IDENTIFICATION AND QUANTITATIVE DETERMINATION OF PHENOTHIAZINE DRUGS IN URINE SAMPLES OF PSYCHIATRIC PATIENTS.
183599 03-02

QUANTITATIVE DETERMINATION OF IMIPRAMINE AND DESIPRAMINE IN HUMAN BLOOD PLASMA BY DIRECT DENSITOMETRY OF THIN-LAYER CHROMATOGRAMS.
183603 03-13

QUANTUM

QUANTUM CHEMICAL STUDIES ON DRUG ACTIONS: IV. CORRELATION OF SUBSTITUENT STRUCTURES AND ANTISEROTONIN ACTIVITY IN LYSERGAMIDE SERIES.
174605 01-12

QUESTIONNAIRE

EVALUATION OF HYPNOTICS IN OUTPATIENTS WITH INSOMNIA USING A QUESTIONNAIRE AND A SELF-RATING TECHNIQUE.
177735 02-06

QUIDE-R

HIGH DOSAGE PIPERACETAZINE (QUIDE-R) IN AMBULATORY SCHIZOPHRENIC PATIENTS: THERAPEUTIC EFFICACY AND TOXICITY.
187869 04-08

QUINAZOLINES

QUINAZOLINES AND 1,4 BENZODIAZEPINES.64.COMPARISON OF THE STEREOCHEMISTRY OF DIAZEPAM WITH THAT OF CLOSE ANALOGS WITH MARGINAL BIOLOGICAL ACTIVITY.
185034 03-01

QUINOLIZIDINES

POTENTIAL PSYCHOTROPIC QUINOLIZIDINES.
182446 03-01

QUINOLONES

STUDIES ON BENZODIAZEPINOOXAZOLES. IV. THE FORMATION OF QUINOLONES BY THE RING CONTRACTION OF A BENZODIAZEPINOOXAZOLE DERIVATIVE.
180488 02-01

R-DOM

NEUROPHARMACOLOGICAL ANALYSIS OF R(-)-2,5 DIMETHOXY-4-METHYLAMPHETAMINE (R-DOM).
191906 04-03

R-6238

CLINICAL EXPERIENCES WITH A NEW PSYCHOTROPIC DRUG, R-6238 (PIMOZIDE).
176564 02-11

PIMOZIDE (R-6238) IN CHRONIC SCHIZOPHRENIA: DOUBLE-BLIND TRIAL.
178255 02-08

RABBIT

INFLUENCE OF CONCENTRATION AND MOTOR PERFORMANCE ON TARDIVE DYSKINESIA AND RABBIT SYNDROME.
167587 01-15

EFFECT OF SUBSTITUTED TRYPTAMINES ON THE EFFLUX OF NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
168747 01-03

IN VIVO 3H-PROCHLORPERAZINE METABOLISM IN THE GUINEA-PIG AND RABBIT.
173875 01-03

STUDY OF THE EFFECT OF CERTAIN PHARMACOLOGICAL AGENTS ON TARDIVE DYSKINESIA AND THE RABBIT SYNDROME.
178193 02-11

THE EFFECTS OF INTRAVENTRICULARLY ADMINISTERED CATECHOLAMINES AND SEROTONIN ON THE RESERPINE INDUCED SPIKE WAVES RECORDED FROM THE MEDICAL NUCLEUS TRAPEZOIDES IN THE RABBIT.
182094 02-03

ABSORPTION, DISTRIBUTION, EXCRETION AND METABOLISM OF BROMAZEPAM IN RABBIT.
182555 03-03

THE INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LEVELS OF ENDOGENOUS 2-PHENYLETHYLAMINE IN RABBIT BRAIN.
187112 03-03

STUDIES ON THE ACTION OF CERTAIN PHARMACOLOGICAL AGENTS ON TARDIVE DYSKINESIA AND ON THE RABBIT SYNDROME.
188406 04-03

STUDIES OF MONOAMINE OXIDASES: PROPERTIES OF THE ENZYME IN BOVINE AND RABBIT BRAIN MITOCHONDRIA.
191300 04-03

EFFECTS OF LIDOCAINE ON RABBIT BRAIN MICROTUBULAR PROTEIN.
191324 04-03

PHARMACOLOGICAL ALTERATIONS IN THE STIMULUS INDUCED RELEASE OF NOREPINEPHRINE FROM THE RABBIT SUPERIOR CERVICAL GANGLION.
191896 04-03

RABBITS

NEUROPHARMACOLOGICAL ANALYSIS OF EFFECTS OF DOXEPIN IN RABBITS (PH.D. DISSERTATION).
168130 01-03

COMPARISON OF TRICYCLIC ANTIDEPRESSANTS AS TO THEIR CARDIOTOXIC ACTION IN CONSCIOUS RABBITS.
171629 01-03

ACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MICE, RATS, RABBITS AND DOGS.
173548 01-05

BEHAVIORAL AND ELECTROENCEPHALOGRAPHIC STUDIES ON THIOSEMICARBAZIDE INDUCED SEIZURE IN RABBITS.
174855 01-05

A STUDY OF ANTIOVULATORY ACTIVITY OF HALOPERIDOL IN RABBITS.
177021 02-03

ELECTROENCEPHALOGRAPHIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL, LSD-25, MESCALINE AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE IN THE RABBITS.
182095 02-03

THE SPECIFICITY OF ANTIMESCALINE ANTIBODY PRODUCED IN RABBITS.
182186 02-03

BINDING OF MORPHINE BY SERUM PROTEINS OF MORPHINE TREATED RABBITS.
182187 02-03

DOSE DEPENDENT POTENTIATION OR INHIBITION BY RO-4-4602 OF 5-HTP HYPERTHERMIA IN RABBITS.
185996 03-03

COMPARISON OF TRICYCLIC ANTIDEPRESSANTS IN RABBITS: ANTINOCICEPTION AND POTENTIATION OF THE NORADRENALINE PRESSOR RESPONSES.
186579 03-03

EFFECT OF CHRONIC TREATMENT WITH CENTRAL STIMULANTS ON BRAIN MONOAMINES AND SOME BEHAVIOURAL AND PHYSIOLOGICAL FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS.
191503 04-03

ACTION OF HALOPERIDOL AND TRIFLUOPERAZINE ON THE MOTOR RESPONSES ELICITED BY ELECTRICAL STIMULATION OF THE BRAIN IN RABBITS.
191787 04-02

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) ADMINISTERED SUBCUTANEOUSLY TO RABBITS FOR 28 DAYS.
191965 04-03

RADIATION

FEATURES OF THE EFFECT OF SYMPATHOMIMETIC AMINES IN RADIATION AFFECTIONS.
191123 04-05

RADIOACTIVITIES

EFFECT OF ACUTE AND CHRONIC MORPHINE ON SPECIFIC RADIOACTIVITIES OF CHOLINE AND ACETYLCHOLINE IN MOUSE BRAIN.
182226 03-03

RADIOACTIVITY

BRAIN TO SERUM DISTRIBUTION OF RADIOACTIVITY OF INJECTED 3H-D-AMPHETAMINE IN DIFFERENTIALLY HOUSED MICE.
168418 01-03

RADIOIMMUNOASSAY

RADIOIMMUNOASSAY FOR LYSERGIDE (LSD) IN ILLICIT DRUGS AND BIOLOGICAL FLUIDS.
170840 01-06

RADIOTRACERS

STUDY WITH RADIOTRACERS OF THE DISTRIBUTION OF A NEW PSYCHOTROPE IN MICE: L-2-PYRROLIDONE-5-CARBOXYLATE DIMETHYLAMINOETHANOL. I. COMPARISON WITH L-GLUTAMIC AND L-2-PYRROLIDONE-5-CARBOXYLIC ACID.
180723 02-03

RAPHE

SELECTIVE BLOCKADE OF APOMORPHINE INDUCED AGGRESSION AND GNAWING FOLLOWING FENFLURAMINE OR RAPHE LESIONS IN THE RAT.
182128 02-04

THE EFFECT OF P-CHLOROPHENYLALANINE ON FOREBRAIN TRYPTOPHAN HYDROXYLASE IN RATS WITH LESIONS IN THE RAPHE NUCLEUS.
188750 04-03

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
191944 04-04

NEUROTOXIC EFFECTS OF P-CHLOROAMPHETAMINE (P-CA) ON PERIKARYA OF RAPHE NEURONS.
191947 04-05

RAPID

RAPID CONTROL OF PSYCHOTIC EXCITEMENT STATES WITH INTRAMUSCULAR HALOPERIDOL.
170627 01-09

ON THE TREATMENT OF RAPID EYE MOVEMENT NARCOLEPSY.
171496 01-11
A RAPID AUTOMATIC METHOD FOR DETERMINING SHOCK SENSITIVITIES OF MICE.
171521 01-04
RAPID AND GENTLE PHARMACOTHERAPY OF DEPRESSION.
174495 01-10
PARENTERAL HALOPERIDOL FOR RAPID CONTROL OF SEVERE, DISRUPTIVE SYMPTOMS OF ACUTE SCHIZOPHRENIA.
178545 02-08
END OF A BACK WARD: THE RAPID REHABILITATION AND RELEASE OF CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS.
181153 02-08
AMPHETAMINE AND PENTOBARBITAL EFFECTS ON THE DISCRIMINATIVE RESPONSE CONTROL BY DEPRIVATION OF RAPID EYE MOVEMENT SLEEP (REM).
182245 03-03
RAPID DIGITALIZATION OF DECOMPENSATED SCHIZOPHRENIC PATIENTS WITH ANTIPSYCHOTIC AGENTS.
189095 04-08

RAT

EFFECT OF ETHANOL ON CYCLIC AMP LEVELS IN THE RAT BRAIN.
167326 01-03
EFFECT OF 6-HYDROXYDOPAMINE ON DARK ADAPTATION IN THE RAT RETINA.
167358 01-03
EFFECT OF PRENATAL MATERNAL ADMINISTRATION OF D-AMPHETAMINE ON RAT OFFSPRING ACTIVITY AND PASSIVE AVOIDANCE LEARNING.
167415 01-03
THREO-3,4 DIHYDROXYPHENYLSERINE, A POOR SOURCE OF NORADRENALINE IN THE RAT.
167445 01-03
THE UPTAKE, RETENTION AND METABOLISM OF 3H-5-HYDROXYTRYPTAMINE IN BRAIN SLICES AND ILEUM FROM THE RAT: EFFECTS OF COCAINE, DESMETHYLIMIPRAMINE AND RESERPINE. (PH.D. DISSERTATION).
168131 01-03
STIMULATION OF BEHAVIOR IN THE RAT BY CYCLAZOCINE: EFFECTS OF NALOXONE.
168439 01-04
EFFECT OF CHLORPROMAZINE (CPZ) ON INSULIN RELEASE IN VIVO AND IN VITRO IN THE RAT.
168440 01-03
DECREASED HISTAMINE SYNTHESIS IN THE RAT BRAIN BY HYPNOTICS AND ANESTHETICS.
168750 01-03
THE EFFECTS OF SCOPOLAMINE ON FIXED-INTERVAL BEHAVIOUR IN THE RAT: A RATE-DEPENDENCY EFFECT.
168833 01-04
INFLUENCE OF AMYLOBARBITONE ON OPERANT DEPRESSION AND ELATION EFFECTS IN THE RAT.
168834 01-04
INFLUENCE OF MORPHINE ON LATERAL HYPOTHALAMIC SELF-STIMULATION IN THE RAT.
168835 01-04
EFFECT OF CHRONIC LITHIUM TREATMENT ON MONOAMINE METABOLISM IN RAT BRAIN.
168839 01-03
PSYCHOMOTOR STIMULANT SELF-ADMINISTRATION IN THE RAT.
169028 01-04
THE EFFECTS OF CHRONIC TREATMENT WITH DELTA9-TETRAHYDROCANNABINOL ON CATECHOLAMINE SYNTHESIS IN THE RAT.
169471 01-03
EFFECTS OF ATROPINE ON EXPLORATION, LEARNING AND ELECTROCORTICAL ACTIVITY IN THE DEVELOPING RAT.
169473 01-04
SIMULTANEOUS MASS FRAGMENTOGRAPHIC ASSAY OF NOREPINEPHRINE (NE), EPINEPHRINE (E) AND DOPAMINE (DA) IN RAT SYMPATHETIC GANGLION: EFFECTS OF DEXAMETHASONE IN NEWBORN AND ADULT RATS. (UNPUBLISHED PAPER).
170747 01-03
METABOLITES OF BROMAZEPAM, A BENZODIAZEPINE, IN THE HUMAN, DOG, RAT, AND MOUSE.
170837 01-03
ANALGESIC POTENCY OF SODIUM SALICYLATE, INDOMETHACIN, AND CHLORDIAZEPOXIDE AS MEASURED BY THE SPATIAL PREFERENCE TECHNIQUE IN THE RAT.
171301 01-02
THE UPTAKE OF DOPAMINE AND SEROTONIN IN RAT BRAIN DURING PROGESTERONE DECLINE.
171307 01-03
INTERACTION BETWEEN PRIOR EXPERIENCE AND THE EFFECTS OF CHLORPROMAZINE ON EXPLORATION IN THE RAT.
171308 01-04
THE EFFECT OF PANAX GINSENG SAPONIN ON THE CENTRAL NERVOUS SYSTEM IN RAT: THE PSYCHOPHARMACOLOGICAL EFFECT OF GINSENG.
171599 01-04
TOLERANCE TO HEXOBARBITAL AND SUPERSENSITIVITY TO PILOCARPINE INDUCED BY CHRONIC BARBITAL TREATMENT IN THE RAT.
171601 01-03
EFFECTS OF TETRABENAZINE ON LORDOSIS BEHAVIOUR AND ON BRAIN MONOAMINES IN THE FEMALE RAT.
171614 01-04
CHANGE OF ESTROGEN ACTIVATED BEHAVIOR BY CYCLOHEXIMIDE IN THE FEMALE RAT.
171615 01-04
ACTIVATION OF COPULATORY BEHAVIOR BY PILOCARPINE AND OXOTREMORINE IN THE FEMALE RAT.
171616 01-04
A DIFFERENTIAL INHIBITORY ACTION OF LSD AND AMPHETAMINE ON COPULATORY BEHAVIOR IN THE FEMALE RAT.
171617 01-04
MONOAMINES AND COPULATORY ACTIVATION IN THE CASTRATED MALE RAT.
171618 01-04
THE EFFECT OF PROTRIPTYLINE ON THE METABOLISM OF LABELLED DOPAMINE AND NORADRENALINE IN THE RAT BRAIN.
171627 01-03
ANTAGONISM OF P-CHLOROAMPHETAMINE (PCA) INDUCED DEPLETION OF 5-HT FROM RAT BRAIN BY SOME THYMOLEPTICS AND OTHER PSYCHOTROPIC DRUGS.
171628 01-03
INTERACTION BY FENFLURAMINE WITH THE METABOLISM OF D-AMPHETAMINE IN THE RAT.
171634 01-03
A SENSITIVE GAS CHROMATOGRAPHIC PROCEDURE FOR THE ESTIMATION OF NORADRENALINE, DOPAMINE AND 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
171971 01-01
DETERMINATION OF DRUG TRANSFER ACROSS BIOLOGICAL MEMBRANES: COMPARATIVE STUDY ON THE PASSAGE OF DRUGS INTO THE CENTRAL NERVOUS SYSTEM AND THEIR PLACENTAL TRANSFER AND FETAL LOCALIZATION IN THE PREGNANT RAT. (PH.D. DISSERTATION).
172018 01-03
COMPARATIVE EFFECTS OF 6-HYDROXYDOPAMINE AND OF RESERPINE ON OUABAIN TOXICITY IN THE RAT.
172598 01-05
DELTA9-TETRAHYDROCANNABINOL INDUCED INHIBITION OF PREDATORY AGGRESSION IN THE RAT.
172745 01-04
EFFECTS OF SOME TETRAHYDROCANNABINOLS ON THE BIOSYNTHESIS AND UTILIZATION OF CATECHOLAMINES IN THE RAT BRAIN.
172917 01-03
ALTERATION OF 5-HYDROXYTRYPTAMINE-14C EFFLUX BY NICOTINE IN RAT BRAIN AREA SLICES.
172925 01-03
THE CURARIZED RAT AND HEART RATE CONDITIONING: A CONSIDERATION OF RESPIRATION PARAMETERS AND NEUROMUSCULAR BLOCKING AGENTS IN A CLASSICAL CONDITIONING PARADIGM. (PH.D. DISSERTATION).
173133 01-03
CNS DEPRESSION IN THE ABSENCE OF PROLACTIN RELEASE FOLLOWING INTRAARTERIAL INJECTIONS OF SODIUM PENTOTHAL IN THE PROESTROUS RAT.
173257 01-03
THE INHIBITION OF 3H-DOPAMINE UPTAKE INTO RAT STRIATAL BY VERATRIDINE AND BATRACHOTOXIN. (UNPUBLISHED PAPER).
173380 01-03
KINETICS AND CELLULAR CONTROL MECHANISMS FOR IMIPRAMINE METABOLISM IN THE ISOLATED PERFUSED RAT LIVER. (PH.D. DISSERTATION).
173601 01-03
ONTOGENY OF SEROTONINERGIC INHIBITION OF BEHAVIORAL AROUSAL IN THE RAT.
174860 01-04
CONDITIONED HYPOGLYCEMIA: A MECHANISM FOR SACCHARIN INDUCED SENSITIVITY TO INSULIN IN THE RAT.
174877 01-03
STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF 5-HT UPTAKE INTO RAT HYPOTHALAMIC HOMOGENATES BY SEROTONIN AND TRYPTAMINE ANALOGUES.
175233 02-03
THE EFFECT OF PHENIRAMINE AND ITS STRUCTURAL ANALOGUES ON 5-HYDROXYTRYPTAMINE IN RAT AND MOUSE BRAIN.
175240 02-03
EFFECTS OF INTRAPERITONEAL AND INTRAVENTRICULAR D-AMPHETAMINE ADMINISTRATION ON ACTIVE AVOIDANCE PERFORMANCE IN THE RAT.
175242 02-04
VOCALIZATION: A CHARACTERISTIC CANNABIS INDUCED BEHAVIOR IN THE RAT?
175884 02-04
DRUG EFFECTS ON GASTRIC ULCERATION RATE IN THE RAT. (UNPUBLISHED PAPER).
176307 02-03

EFFECTS OF AMPHETAMINE (A), LSD, PSILOCYBIN (P), AND DOM ON SCHEDULE-CONTROLLED BEHAVIOR IN THE RAT.
176869 02-04

EFFECT OF CHRONIC ADMINISTRATION OF L-DOPA ON CATECHOL-O-METHYLTRANSFERASE IN RAT TISSUES.
176936 02-03

EFFECTS OF LOW DOSES OF CHLORPROMAZINE ON A CONDITIONED EMOTIONAL RESPONSE IN THE RAT.
176963 02-04

STUDIES ON MONOAMINE OXIDASE -- REPORT 22: EFFECTS OF NANO2 AND NH2OH ON MITOCHONDRIAL MAO IN RAT BRAIN.
177022 02-03

DOPAMINE IN THE MESOLIMBIC SYSTEM OF THE RAT BRAIN: ENDOGENOUS LEVELS AND THE EFFECTS OF DRUGS ON THE UPTAKE MECHANISM AND STIMULATION OF ADENYLATE CYCLASE ACTIVITY.
177131 02-03

NOREPINEPHRINE SENSITIVE ADENYLATE CYCLASES IN RAT BRAIN: RELATION TO BEHAVIOR AND TYROSINE HYDROXYLASE.
177252 02-03

INABILITY OF RAT BRAIN HOMOGENATE TO OXIDIZE AMPHETAMINE.
177334 02-03

THE HYDROXYLATION OF D-AMPHETAMINE BY LIVER MICROSOMES OF THE MALE RAT.
177337 02-03

THE THALAMIC RAT: GENERAL BEHAVIOR, OPERANT LEARNING WITH REWARDING HYPOTHALAMIC STIMULATION, AND EFFECTS OF AMPHETAMINE.
177477 02-04

BEHAVIOURAL EFFECTS OF YOHIMBINE ADMINISTERED INTRAVENTRICULARLY IN THE RAT.
177721 02-04

THE METABOLIC FATE OF N,N DIMETHOXYMETHYL-PHENOBARBITAL IN THE RAT.
177731 02-03

THE METABOLIC FATE OF HEXOBARBITAL IN THE RAT.
177732 02-03

INVESTIGATIONS ON THE FATE OF THE ANTICONVULSANT CLONAZEPAM IN THE ORGANISM OF MAN, RAT AND DOG.
179022 02-13

EFFECT OF CANNABIS ON PENTOBARBITAL INDUCED SLEEPING TIME AND PENTOBARBITAL METABOLISM IN THE RAT.
179985 02-03

EFFECT OF CHRONIC INTOXICATION WITH (..) AMPHETAMINE ON ITS CONCENTRATION IN LIVER AND BRAIN AND ON (14C) LEUCINE INCORPORATION INTO MICROSOMAL AND CYTOPLASMIC PROTEINS OF RAT LIVER.
180056 02-05

EFFECT OF ADRENERGIC SUBSTANCES ON OXYGEN CONSUMPTION OF RAT BRAIN TISSUE.
180058 02-03

EFFECTS OF PHENOXYBENZAMINE, ACEPERONE AND CLONIDINE ON THE LEVEL OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL, (MOPEG) IN RAT BRAIN.
180059 02-03

EFFECT OF CHLORPROMAZINE AND SOME OF ITS METABOLITES ON THE DOPAMINE SENSITIVE ADENYLATE CYCLASE OF RAT BRAIN STRIATUM.
180060 02-03

EFFECTS OF NEUROLEPTICS AND THYMOLEPTICS ON PHOSPHODIESTERASE ACTIVITY AND ON CYCLIC 3,5 AMP LEVELS IN RAT BRAIN.
181467 02-03

CATECHOLAMINE TURNOVER IN THE RAT BRAIN: DIFFERENT RESULTS OBTAINED IN DIFFERENT EXPERIMENTAL CONDITIONS.
181471 02-03

SUBCELLULAR DISTRIBUTION OF DELTA9-TETRAHYDROCANNABINOL IN RAT BRAIN.
181810 02-03

CONVULSION PRODUCING PROPERTY OF THE DIALYZABLE GLYCOPEPTIDE PREPARATION FROM WHOLE RAT BRAIN.
181815 02-03

COMPARISON OF THE CHRONIC AND ACUTE EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) TREATMENT ON RAT BRAIN SEROTONIN AND NOREPINEPHRINE.
181945 02-03

MODULATORY EFFECTS OF CORTICOSTEROIDS ON EVOKED ACTIVITY IN THE HIPPOCAMPUS AND THALAMUS OF THE RAT.
182119 02-03

SELECTIVE BLOCKADE OF APOMORPHINE INDUCED AGGRESSION AND GNAWING FOLLOWING FENFLURAMINE OR RAPHE LESIONS IN THE RAT.
182128 02-04

IN VIVO MEASUREMENT OF THE RELEASE OF 5-HYDROXYTRYPTAMINE (5-HT) FROM THE HIPPOCAMPUS OF THE RAT: EFFECT OF RO-4-1284, PARGYLINE AND P-CHLOROAMPHETAMINE (PCA).
182140 02-03

EFFECTS OF DECAPITATION, ETHER AND PENTOBARBITAL ON CYCLIC AMP AND CYCLIC GMP LEVELS IN RAT TISSUES.
182154 02-03

THE DEVELOPMENT OF A BLOOD-BRAIN BARRIER TO METHADONE IN THE NEWBORN RAT.
182165 02-03

INHIBITION OF C14-ACH UPTAKE IN RAT BRAIN SLICES BY DESMETHYLIMIPRAMINE.
182170 02-03

MICROVASCULAR SMOOTH MUSCLE HYPERRESPONSIVENESS DURING HALOTHANE ANESTHESIA IN THE RAT.
182185 02-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON THE DOMINANCE BEHAVIOR OF THE RAT.
182189 02-04

SUBSTANTIAL ORAL MORPHINE INTAKE BY THE RAT USING SCHEDULE INDUCED POLYDIPSIA.
182194 02-04

THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (THC), PENTOBARBITAL AND SKF-525-A WITH THE CARDIOVASCULAR SYSTEM OF THE RAT.
182218 03-03

ANTIPYRETIC, ANALGESIC AND ANTIINFLAMMATORY ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL IN THE RAT.
182221 03-03

EFFECTS OF MORPHINE, NALORPHINE AND NALOXONE ON RAT BRAIN RELEASE OF ACETYLCHOLINE.
182227 03-03

EFFECT OF MORPHINE, HALOPERIDOL, APOMORPHINE AND BENZTROPINE ON DOPAMINE TURNOVER IN RAT CORPUS-STRIATUM: EVIDENCE SHOWING MORPHINE-INDUCED REDUCTION IN CNS DOPAMINERGIC ACTIVITY.
182230 03-03

EFFECTS OF AMPHETAMINE ISOMERS ON NEUROMUSCULAR TRANSMISSION IN RAT PHRENIC NERVE DIAPHRAGM PREPARATION.
182232 03-03

THE USE OF BIOCHEMICAL CORRELATES FOR THE PREDICTION OF MURICIDAL BEHAVIOR IN THE WILD RAT.
182241 03-04

UPTAKE AND RELEASE OF NORADRENALINE IN RAT CEREBRAL CORTEX IN VITRO: NO EFFECT OF BENZODIAZEPINES AND BARBITURATES.
182347 03-03

THE INHIBITION OF (3H) BIOGENIC AMINE ACCUMULATION INTO RAT BRAIN TISSUE SLICES BY VARIOUS TRYPTAMINE DERIVATIVES.
182723 03-03

THE EFFECT OF PSYCHOTROPIC AGENTS ON THE FORMATION OF AVOIDANCE REACTION IN ALBINO RATS DURING ELECTROPAIN STIMULATION OF ANOTHER RAT.
183206 03-04

THE EFFECT OF CANNABINOIDS ON THE NUMBER OF NUCLEAR MEMBRANE ATTACHED RIBOSOMES IN INFANT RAT BRAIN.
183228 03-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON THE METABOLISM OF 3H-5-HYDROXYTRYPTAMINE AND 3H-NOREPINEPHRINE IN THE RAT BRAIN.
183787 03-03

NOREPINEPHRINE -- AN ANTAGONIST OF DIBUTYRYL CYCLIC AMP IN THE REGULATION OF NARCOSIS IN THE RAT.
183789 03-03

IN VIVO ESTIMATION OF TYROSINE HYDROXYLATION IN THE DOPAMINERGIC TERMINALS OF THE RAT NEOSTRIATUM.
183794 03-03

A COMPARISON OF PSYCHOTOMIMETIC DRUG EFFECTS ON RAT BRAIN NOREPINEPHRINE METABOLISM.
183891 03-03

EFFECTS OF METHAMPHETAMINE ON DAILY RHYTHMS OF HYPOTHALAMIC NOREPINEPHRINE, SEROTONIN AND PLASMA CORTICOSTERONE LEVELS IN THE RAT.
184178 03-03

AMPHETAMINE AND THERMOREGULATION: STUDIES IN THE UNRESTRAINED AND CURARIZED RAT.
184227 03-03

FORMATION OF NORADRENALINE IN THE RAT BRAIN FROM THE FOUR STEREOISOMERS OF 3,4 DIHYDROXYPHENYLSERINE.
184229 03-03

THE EFFECTS OF ACUTE ADMINISTRATION OF PROPRANOLOL AND PRACTOLOL ON THE UPTAKE, CONTENT, RELEASE AND TURNOVER OF NORADRENALINE IN THE RAT HEART IN VIVO.
184232 03-03

EFFECTS OF VARIOUS MORPHINE TREATMENT SCHEDULES ON ACETYLCHOLINE TURNOVER RATE IN RAT BRAIN PARTS.
184553 03-03

EFFECT OF LSD-25 AND 1-METHYL-D-LYSERGIC ACID BUTANOLAMIDE ON RAT BRAIN AND PLATELET SEROTONIN LEVELS.
184975 03-03

STRYCHNINE SULFATE AND PIRACETAM: LACK OF EFFECT ON LEARNING IN THE RAT.
184980 03-04

THE ACTION OF D-AMPHETAMINE ON SPONTANEOUS ACTIVITY IN THE CAUDATE NUCLEUS AND RETICULAR FORMATION OF THE RAT.
185264 03-03

NEURAL AND CHEMICAL MECHANISMS OF FEMALE SEXUAL BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).
185705 03-04

THE EFFECTS OF CHRONIC TREATMENT WITH D-AMPHETAMINE ON FOOD INTAKE, BODYWEIGHT, LOCOMOTOR ACTIVITY AND SUBCELLULAR DISTRIBUTION OF THE DRUG IN RAT BRAIN.
185931 03-03

CONDITIONING OF AMPHETAMINE-INDUCED BEHAVIOUR IN THE ALBINO RAT.
185954 03-04

ANTICONVULSANT ACTIVITY AND INHIBITION OF RESPIRATION IN RAT BRAIN HOMOGENATES BY SUBSTITUTED OXADIAZOLES.
185980 03-01

EFFECT OF SEVERAL DOPAMINERGIC DRUGS AND TRIHEXYPHENIDYL ON CHOLINERGIC PARAMETERS IN THE RAT STRIATUM.
185995 03-03

MODULATION OF REWARD AND AVERSION PROCESSES IN THE RAT DIENCEPHALON BY AMPHETAMINE.
186164 03-04

SCOPOLAMINE EFFECTS ON TWO-TRIAL DELAYED-RESPONSE PERFORMANCE IN THE RAT.
186372 03-04

BEHAVIORAL EFFECTS OF PROFADOL IN THE RAT.
186373 03-04

BRAIN AMINES AND APOMORPHINE-INDUCED INTRASPECIFIC AGGRESSIVE BEHAVIOR IN THE RAT.
186374 03-04

EFFECTS OF METHAMPHETAMINE, PIPRADROL, AND METHYLPHENIDATE ON INSTRUMENTAL CONDITIONING AND SPONTANEOUS MOTOR ACTIVITY IN THE IMMATURE RAT.
186568 03-04

JOINT EFFECTS OF SODIUM AMYLOBARBITONE AND AMPHETAMINE SULPHATE ON RESISTANCE TO EXTINCTION OF A REWARDED RUNNING RESPONSE IN THE RAT.
186573 03-04

A ROLE FOR THE AMYGDALA IN THE DEVELOPMENT OF THE CATALEPTIC AND STEREOTYPIC ACTIONS OF THE NARCOTIC AGONISTS AND ANTAGONISTS IN THE RAT.
186577 03-03

THE EFFECT OF MINOR TRANQUILIZERS ON STRESS INDUCED INCREASES IN RAT PLASMA CORTICOSTEROIDS.
186578 03-03

THE ISOLATED PERFUSED RAT BRAIN AS A MODEL FOR STUDYING DRUGS ACTING ON THE CNS.
186589 03-06

ADAPTATION TO NITROGEN NARCOSIS MANIFESTED BY TIMING BEHAVIOR IN THE RAT.
186630 03-04

EFFECTS OF LITHIUM ON ADRENERGIC AMINE UPTAKE IN RAT BRAIN SYNAPTOSOMES.
186633 03-03

A COMPARISON OF THE EFFECTS OF AMPHETAMINE AND ITS METABOLITES, P-HYDROXYAMPHETAMINE AND P-HYDROXYNOREPHEDRINE, ON UPTAKE, RELEASE AND CATABOLISM OF 3H-NOREPINEPHRINE IN CEREBRAL CORTEX OF RAT BRAIN.
186669 03-03

EFFECTS OF AMPHETAMINES ON REGIONAL TRYPTOPHAN HYDROXYLASE ACTIVITY AND SYNAPTOSOMAL CONVERSION OF TRYPTOPHAN TO 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
186674 03-03

EFFECTS OF AN ESTROGEN ANTAGONIST, MER-25, ON MOUNTING BEHAVIOR AND LORDOSIS BEHAVIOR IN THE FEMALE RAT.
186691 03-04

EFFECT OF ALPHA-METHYLDOPA ON THE METABOLISM OF DOPAMINE IN THE STRIATUM OF THE RAT.
186694 03-03

PHYSIOLOGICAL DISPOSITION OF BETA-PHENYLETHYLAMINE, 2,4,5 TRIMETHOXYPHENYLETHYLAMINE, 2,3,4,5,6 PENTAMETHOXYPHENYLETHYLAMINE AND BETA-HYDROXYMESCALINE IN RAT BRAIN, LIVER AND PLASMA.
186706 03-03

THE EFFECT OF LITHIUM ON HORMONE SENSITIVE ADENYLATE CYCLASE FROM VARIOUS REGIONS OF THE RAT BRAIN.
187110 03-03

BLOCKING OF THE EFFECT OF A DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC) ON SPONTANEOUS MOTOR ACTIVITY IN THE RAT BY IMMUNIZATION WITH A PROTEIN CONJUGATE OF DELTA1-THC.
187129 03-04

NEUROLEPTIC ANTAGONISM OF CATECHOLAMINE INHIBITIONS IN RAT CEREBELLUM AND CAUDATE. (UNPUBLISHED PAPER).
187496 04-03

PENTOBARBITAL AND IN VIVO TURNOVER RATE OF ACETYLCHOLINE IN MOUSE BRAIN AND IN REGIONS OF RAT BRAIN. (UNPUBLISHED PAPER).
187526 04-03

EFFECT OF SKF-525-A ON THE METABOLISM OF (-) DELTA9-TETRAHYDROCANNABINOL IN THE RAT BRAIN AND LIVER.
187578 04-03

THE EFFECTS OF CHRONIC RESERPINE AND NIALAMIDE TREATMENT ON THE FREE AMINO ACID LEVELS OF RAT BRAIN.
187645 04-03

THE EFFECTS OF LITHIUM ON HIGH ENERGY PHOSPHATE AND GLUCOSE LEVELS IN THE RAT SUPERIOR CERVICAL GANGLION.
187677 04-03

FEAR REDUCTION IN THE RAT FOLLOWING CENTRAL CHOLINERGIC BLOCKADE.
187703 04-04

ACTIONS OF ATROPINE, HEMICHOLINIUM-3, AND PHYSOSTIGMINE ON CHLORPROMAZINE INDUCED CHANGES IN RAT BRAIN MONOAMINES.
187800 04-03

METHIOTHEPIN ELEVATION OF 5-HYDROXYINDOLEACETIC ACID LEVELS IN VARIOUS ANATOMIC REGIONS OF RAT BRAIN.
187831 04-03

TIME SAMPLING OF RAT EXPLORATORY BEHAVIOUR: A RELIABLE SCREENING TEST FOR THE CNS EFFECTS OF ANOREXIC AGENTS.
187925 04-04

EFFECTS OF LSD ON SYNTHESIS AND RELEASE OF 5-HT IN RAT BRAIN SLICES.
188164 04-03

THE EFFECTS OF MORPHINE, ETORPHINE AND SINOMENINE ON THE CHEMICAL SENSITIVITY AND SYNAPTIC RESPONSES OF RENSHAW CELLS AND OTHER SPINAL NEURONES IN THE RAT.
188201 04-03

THE EFFECT OF HYPOTHERMIC DOSES OF 1-DELTA9-TETRAHYDROCANNABINOL ON BIOGENIC AMINE METABOLISM IN SELECTED PARTS OF THE RAT BRAIN.
188231 04-03

DEPLETION OF TRYPTOPHAN HYDROXYLASE BY 5,6 DIHYDROXYTRYPTAMINE IN RAT BRAIN -- TIME COURSE AND REGIONAL DIFFERENCES.
188287 04-03

IN VITRO BINDING OF (4-14C) DIPHENYLHYDANTOIN TO RAT BRAIN MICROSOMES.
188404 04-03

EFFECTS OF LSD AND MONOAMINE SYNTHESIS INHIBITORS ON HORMONE ACTIVATED COPULATORY BEHAVIOR IN THE FEMALE RAT.
188611 04-04

PHARMACOLOGICAL AND BIOCHEMICAL ACTIONS OF THE HEMOLYTIC AGENTS ACETYLPHENYLHYDRAZINE AND PHENYLHYDRAZINE ON MONOAMINE OXIDASE IN THE RAT.
188769 04-03

EFFECT OF IMIPRAMINE ON CULTURED RAT HEART CELLS.
188864 04-03

EFFECT OF DIVALENT CATIONS ON ACH CONTRACTURES OF DEPOLARIZED DENERVATED RAT MUSCLES.
188914 04-03

BETA-ADRENERGIC EFFECTS ON RAT MYOMETRIUM: ROLE OF CYCLIC AMP.
188915 04-03

EVIDENCE FOR A SPECIFIC UPTAKE OF DOPAMINE BY DOPAMINERGIC TERMINALS OF THE RAT CEREBRAL CORTEX.
188978 04-03

HYDROCORTISONE INDUCED INCREASE IN THE HISTOCHEMICALLY DEMONSTRABLE CATECHOLAMINE CONTENT OF SYMPATHETIC NEURONS OF THE NEWBORN RAT.
189027 04-03

EFFECTS OF CYCLOHEXIMIDE ON ACQUISITION AND RETENTION OF AVOIDANCE LEARNING IN THE RAT: RECOVERY OF MEMORY.
189215 04-04

CHLOROFORM RESPONSES OF THE CHORDA TYMPANI NERVE IN THE RAT.
189219 04-03

EFFECTS OF SCOPOLAMINE METHYLBROMIDE ON SHOCK-INDUCED GASTRIC LESIONS IN THE UNRESTRAINED RAT.
189381 04-03

TURNOVER OF HISTAMINE IN RAT BRAIN AND ITS DECREASE UNDER BARBITURATE ANESTHESIA.
189396 04-03

INFLUENCE OF MORPHINE AND NALOXONE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189568 04-03

INFLUENCE OF FENTANYL, LEVORPHANOL AND PETHIDINE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189569 04-03

EFFECT OF MORPHINE ON THE TURNOVER AND SYNTHESIS OF (LEU-3H) PROTEIN AND (CH-14C) PHOSPHATIDYLCHOLINE IN DISCRETE REGIONS OF THE RAT BRAIN.
189586 04-03

STIMULATION OF A DOPAMINE SENSITIVE ADENYLATE CYCLASE IN HOMOGENATES OF RAT STRIATUM BY A METABOLITE OF PIRIBEDIL (ET-495).
189616 04-03

DIHYDROPTERIDINE REDUCTASE IN RAT BRAIN: REGIONAL DISTRIBUTION AND THE EFFECT OF CATECHOLAMINE DEPLETING DRUGS.
189752 04-03

EFFECT OF DESIPRAMINE ON RAT CORTEX SLICES INCUBATED WITH 3H-DOPAMINE.
190310 04-03

EFFECT OF PHENOTHIAZINE NEUROLEPTIC DRUGS AND TRICYCLIC ANTIDEPRESSANTS ON PHOSPHODIESTERASE ACTIVITY IN RAT CEREBRAL CORTEX.
190311 04-03

EFFECTS OF DOPAMINE-LIKE DRUGS ON RAT STRIATAL ADENYL CYCLASE HAVE IMPLICATIONS FOR CNS DOPAMINE RECEPTOR TOPOGRAPHY.
190545 04-03

LITHIUM AND THE MONOAMINE NEUROTRANSMITTERS IN THE RAT HIPPOCAMPUS.
190829 04-03

THE METABOLISM OF 1-N-BUTYL-5,5 DIETHYLBARBITURIC ACID (N-N BUTYLBARBITAL) IN THE RAT.
191057 04-03

THE EFFECT OF CHLORPROMAZINE AND STELAZINE ON LYSOSOMES OF RAT LIVER DURING ACUTE INTOXICATION.
191121 04-03

THE INFLUENCE OF PSYCHOSTIMULANTS ON K42 MEMBRANE PERMEABILITY IN VARIOUS PORTIONS OF RAT BRAIN.
191122 04-03

CHANGES IN ORIENTING AND HABITUATION IN THE RAT FOLLOWING ADMINISTRATION OF CHLORPROMAZINE.
191211 04-04

ANALGESIA AND HYPERREACTIVITY PRODUCED BY INTRACRANIAL MICROINJECTIONS OF MORPHINE INTO THE PERIAQUEDUCTAL GRAY MATTER OF THE RAT.
191367 04-04

THE EFFECTS OF EARLY SALINE INJECTIONS AND PENTYLENETETRAZOL ON HEBB-WILLIAMS MAZE PERFORMANCE IN THE ADULT RAT.
191378 04-04

PERMANENT ALTERATIONS IN 5-HYDROXYTRYPTAMINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN FOLLOWING EXPOSURE TO DRUGS DURING THE PERIOD OF DEVELOPMENT.
191383 04-03

THE EFFECT OF CHOLINOMIMETIC DRUGS ON POTASSIUM TRANSPORT IN RAT CEREBRAL CORTEX.
191411 04-03

EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF CLOZAPINE ON THE METABOLISM OF DOPAMINE AND NORADRENALINE IN THE BRAIN OF THE RAT.
191418 04-03

EFFECT OF PIRIBEDIL AND ONE OF ITS METABOLITES ON THE CONCENTRATION OF HOMOVANILLIC ACID IN THE RAT BRAIN.
191422 04-03

COMPARATIVE PROPERTIES OF SOLUBLE AND PARTICULATE CATECHOL-O-METHYLTRANSFERASE FROM RAT RED BLOOD CELL: PRELIMINARY OBSERVATIONS.
191523 04-01

DIAZEPAM, CYCLIC NUCLEOTIDES AND AMINO ACID NEUROTRANSMITTERS IN RAT CEREBELLUM. (UNPUBLISHED PAPER).
191764 04-03

EFFECTS OF NOMIFENSINE (HOE-984), D-AMPHETAMINE AND APOMORPHINE ON MOTOR ACTIVITY, CATECHOLAMINE TURNOVER AND CAMP CONCENTRATIONS IN RAT BRAIN. (UNPUBLISHED PAPER).
191766 04-03

COMPARATIVE METABOLISM OF TRIAZOLAM, A NEW SEDATIVE HYPNOTIC, IN RAT, DOG AND MAN.
191900 04-02

PIMOZIDE, L-PROPRANOLOL AND PHENTOLAMINE EFFECTS ON AMPHETAMINE SELF-ADMINISTRATION BY THE RAT.
191919 04-04

THE 4-HYDROXYLATION OF AMPHETAMINE AND PHENTERMINE BY RAT LIVER MICROSOMES.
191921 04-03

METABOLISM OF D-AMPHETAMINE BY RAT BRAIN IN VIVO AND IN VITRO.
191922 04-03

EFFECT OF LILLY-110140, 3-(P-TRIFLUOROMETHYLPHENOXY) N METHYL-3-PHENYLPROPYLAMINE ON SYNTHESIS OF 3H-SEROTONIN FROM 3H-TRYPTOPHAN IN RAT BRAIN.
191951 04-03

THE INFLUENCE OF DELTA9-TETRAHYDROCANNABINOL (THC) ON PILOCARPINE (PILO) INDUCED PAROTID SECRETIONS OF THE RAT.
191962 04-03

THE EFFECT OF INCREASED GAMMA-AMINOBUTYRIC ACID ON ALPHA-METHYLTYROSINE INDUCED DECREASE IN CATECHOLAMINES IN RAT BRAIN.
191988 04-03

TETRAHYDROCANNABINOLS: INHIBITION IN ACETYLCHOLINE SYNTHESIS IN REGIONAL RAT BRAIN SLICES.
191998 04-03

EFFECT OF CHRONIC TREATMENT WITH DESIPRAMINE (DMI) AND IPRINDOLE (IP) ON THE NOREPINEPHRINE (NE) SENSITIVE ADENYLATE CYCLASE SYSTEM IN SLICES OF THE RAT LIMBIC FOREBRAIN.
192003 04-03

DOPAMINE AGONIST INDUCED DISORIENTATION IN A RAT SWIMMING TASK.
192018 04-04

ESTIMATION OF THE CONTRIBUTION OF PERIPHERAL AND CENTRAL NORADRENERGIC NEURONES TO URINARY 3-METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT.
192335 04-03

INCORPORATION OF 14C-DIHYDROPHENYLALANINE AND 14C-CHOLINE INTO RAT BRAIN SUBCELLULAR PARTICLES AND THE EFFECT OF PSYCHOACTIVE DRUGS.
192426 04-03

RATE

EFFECT OF CHLORIMIPRAMINE ON THE RATE OF TRYPTOPHAN HYDROXYLATION IN THE INTACT AND TRANSECTED SPINAL CORD.
168751 01-03

EEG, HEART RATE, AND MOOD CHANGE (HIGH) AFTER CANNABIS.
169068 01-13

RELATIONSHIP BETWEEN BIOAVAILABILITY AND DISSOLUTION RATE OF OXAZEPAM.
171630 01-16

THE CURARIZED RAT AND HEART RATE CONDITIONING: A CONSIDERATION OF RESPIRATION PARAMETERS AND NEUROMUSCULAR BLOCKING AGENTS IN A CLASSICAL CONDITIONING PARADIGM. (PH.D. DISSERTATION).
173133 01-03

DRUG EFFECTS ON GASTRIC ULCERATION RATE IN THE RAT. (UNPUBLISHED PAPER).
176307 02-03

ANTICHOLINERGICS: THEIR EFFECTS ON FEAR MOTIVATED BEHAVIOR, URINARY 11-HYDROXYCORTICOSTEROIDS, URINARY VOLUME, AND HEART RATE IN THE DOG.
178720 02-03

THE RATE LIMITING CONTROL OF ENZYMES MONOAMINE OXIDASE AND CATECHOL-O-METHYLTRANSFERASE IN THE FETUS AND THE ADULT BY ADRENOCORTICOL HORMONES.
178815 02-03

PENTYLENETETRAZOL CONVULSIONS AND BRAIN CATECHOLAMINE TURNOVER RATE IN RATS AND MICE RECEIVING DIPHENYLHYDANTOIN OR BENZODIAZEPINES.
182344 03-03

EFFECTS OF VARIOUS MORPHINE TREATMENT SCHEDULES ON ACETYLCHOLINE TURNOVER RATE IN RAT BRAIN PARTS.
184553 03-03

REGIONAL CHANGES IN MONOAMINE LEVELS AND IN THE RATE OF TYROSINE AND TRYPTOPHAN HYDROXYLATION IN 4 WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
185899 03-03

PENTOBARBITAL AND IN VIVO TURNOVER RATE OF ACETYLCHOLINE IN MOUSE BRAIN AND IN REGIONS OF RAT BRAIN. (UNPUBLISHED PAPER).
187526 04-03

REGULATION OF BRAIN DOPAMINE TURNOVER RATE: PHARMACOLOGICAL IMPLICATIONS. (UNPUBLISHED PAPER).
187527 04-03

AMPHETAMINE AND OPERANT BEHAVIOR IN RATS: RELATIONSHIP BETWEEN DRUG EFFECT AND CONTROL RESPONSE RATE.
187699 04-04

ESTIMATION OF THE RATE OF 5-HT SYNTHESIS IN THE MOUSE BRAIN BY VARIOUS METHODS.
188976 04-03

EFFECTS OF CHLORDIAZEPOXIDE ON HEART RATE AND BEHAVIOURAL SUPPRESSION IN PIGS SUBJECTED TO OPERANT CONDITIONING PROCEDURES.
189409 04-04

THE EFFECTS OF HOE-36801 ON CATECHOLAMINE EXCRETION, HEART RATE AND PSYCHOMOTOR PERFORMANCE IN NEUROTICS AND NORMALS.
192428 04-13

RATE-DEPENDENCY

THE EFFECTS OF SCOPOLAMINE ON FIXED-INTERVAL BEHAVIOUR IN THE RAT: A RATE-DEPENDENCY EFFECT.
168833 01-04

RATE-DEPENDENT

SPATIAL AND PAW PREFERENCES IN RATS: THEIR RELATIONSHIP TO RATE-DEPENDENT EFFECTS OF D-AMPHETAMINE.
177409 02-04

RATE-DEPENDENT EFFECTS OF DRUGS. I. COMPARISONS OF D-AMPHETAMINE, PENTOBARBITAL, AND CHLORPROMAZINE ON MULTIPLE AND MIXED SCHEDULES.
177410 02-04

RATES

THE EFFECTS OF L-DELTA9-TRANS-TETRAHYDROCANNABINOL ON LOW AND HIGH RESPONSE RATES GENERATED UNDER TWO SIMILAR CONDITIONS (PH.D. DISSERTATION).
168230 01-04

A CRITICAL ASSESSMENT OF METHODS FOR THE DETERMINATION OF MONOAMINE SYNTHESIS AND TURNOVER RATES IN VIVO.
191514 04-06

THE EFFECT OF OCTOCLOTHEPIN AND PERPHENAZINE ON BEHAVIOUR IN RATS WITH DIFFERENT EXPLORATION AND DEFECATION RATES.
192430 04-04

RATING

RATING OF PSYCHOLOGICAL EFFECTS INDUCED BY ORDINARY NOVERIL AND TIME-RELEASED NOVERIL.
190312 04-14

RATINGS

COMPARABLE THERAPEUTIC EFFICACY OF TRYPTOPHAN AND IMIPRAMINE: AVERAGE THERAPEUTIC RATINGS VERSUS TRUE EQUIVALENCE. AN IMPORTANT DIFFERENCE.
167344 01-09

RATIO

LSD EFFECTS ON SIGNAL-TO-NOISE RATIO AND LATERALIZATION OF VISUAL CORTEX AND LATERAL GENICULATE DURING PHOTIC STIMULATION.
167449 01-03

THE EFFECTS OF SCOPOLAMINE ON PERFORMANCE ON A GEOMETRIC PROGRESSIVE RATIO SCHEDULE.
190334 04-04

RATIONAL

RATIONAL USE OF PSYCHOTROPIC DRUGS: I. HYPNOTICS.
192190 04-14

RATS

EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF CANNABIS-SATIVA EXTRACT ON THE MOUSE-KILLING BEHAVIOR OF RATS.
167362 01-04

ACQUISITION AND RETENTION OF AVOIDANCE BEHAVIORS FOLLOWING SEPTAL LESIONS OR SCOPOLAMINE INJECTIONS IN RATS.
167401 01-04

THE EFFECTS OF D- AND L-AMPHETAMINE ON FIXED-INTERVAL AND FIXED-RATIO BEHAVIOR IN TOLERANT AND NONTOLERANT RATS.
168438 01-04

RECOVERY OF FEEDING AND DRINKING BY RATS AFTER INTRAVENTRICULAR 6-HYDROXYDOPAMINE OR LATERAL HYPOTHALAMIC LESIONS.
168484 01-03

EFFECTS OF IMIPRAMINE ON COPULATORY BEHAVIOR OF MALE RATS.
168718 01-04

THE EFFECT OF CANNABIDIOL ON MAXIMAL ELECTROSHOCK SEIZURES IN RATS.
168749 01-03

EFFECTS OF FOOD DEPRIVATION, DISCRIMINATION EXPERIENCE AND PHYSOSTIGMINE ON CHOLINE ACETYLASE AND ACETYLCHOLINE ESTERASE IN THE DORSAL HIPPOCAMPUS AND FRONTAL CORTEX OF RATS.
169467 01-03

DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE IN RESPECT TO TIME AND DOSAGE AND QUANTIFICATION OF THE PRECIPITATED WITHDRAWAL SYNDROME IN RATS.
169474 01-03

THE ACTIVITY OF SOME NEUROLEPTIC DRUGS AND AMPHETAMINE IN NORMAL AND ISOLATED RATS.
170126 01-04

DOPAMINE AND 5-HYDROXYTRYPTAMINE INHIBIT FEEDING IN RATS.
170177 01-04

SIMULTANEOUS MASS FRAGMENTOGRAPHIC ASSAY OF NOREPINEPHRINE (NE), EPINEPHRINE (E) AND DOPAMINE (DA) IN RAT SYMPATHETIC GANGLION: EFFECTS OF DEXAMETHASONE IN NEWBORN AND ADULT RATS. (UNPUBLISHED PAPER).
170747 01-03

TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER).
170876 01-03

STUDY ON THE PSYCHOPHARMACOLOGICAL ASSAY OF CENTRALLY ACTING DRUGS IN RATS.
171260 01-06

TOLERANCE AND CROSS-TOLERANCE TO THE ANOREXIGENIC EFFECT OF SOME AMPHETAMINE DERIVATIVES IN RATS.
171602 01-03

INHIBITION OF MOUSE-KILLING BEHAVIOUR IN RATS BY SOME THYMOLEPTIC DRUGS.
171608 01-04

EFFECT OF IMIPRAMINE ON THE TURNOVER OF BRAIN 5-HT IN POSTNATAL RATS.
171624 01-03

INTERACTIONS OF DIAZEPAM AND HALOTHANE IN RATS.
171633 01-03

INFLUENCE OF PHENOBARBITAL AND SEX HORMONES ON ENZYMES IN ASCORBIC ACID BIOSYNTHESIS IN MALE AND FEMALE RATS. (PH.D. DISSERTATION).
172017 01-03

SELF-STIMULATION OF NORADRENERGIC CELL GROUP (A6) IN LOCUS-COERULEUS OF RATS.
173029 01-03

EFFECTS OF SCOPOLAMINE UPON BEHAVIORAL REACTIVITY AND VISUALLY EVOKED POTENTIAL TO FLASHES IN RATS.
173032 01-04

CENTRAL MONOAMINES AND THE ACOUSTIC STARTLE REACTION IN RATS. (PH.D. DISSERTATION).
173136 01-04

MODIFICATION OF STIMULATION BOUND BEHAVIOR BY TRIFLUOPERAZINE AND AMPHETAMINE IN RATS. (PH.D. DISSERTATION).
173158 01-04

MULTITRIAL PASSIVE AVOIDANCE IN RATS: MESCALINE, SHOCK, AND ITI EFFECTS. (PH.D. DISSERTATION).
173162 01-04

BEHAVIOR AND SENSITIVITY TO EXPERIMENTAL HYPERTENSION: II. LACK OF CORRELATION BETWEEN CERTAIN BEHAVIOR PATTERNS AND HYPERTENSION IN TWO NEW STRAINS OF RATS.
173256 01-04

ACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MICE, RATS, RABBITS AND DOGS.
173548 01-05

INHIBITORY EFFECTS OF PRETEST AND POSTTEST D-AMPHETAMINE ON MOUSE-KILLING BY RATS. (PH.D. DISSERTATION).
173727 01-04

EFFECTS AND INTERACTIONS OF SCOPOLAMINE AND D-AMPHETAMINE ON SCHEDULE-CONTROLLED RESPONDING IN RATS. (PH.D. DISSERTATION).
173748 01-04

EFFECTS OF ANTIDEPRESSANT AGENTS ON OPEN-FIELD BEHAVIOUR IN RATS.
174038 01-04

WEIGHT GAIN IN LITHIUM TREATED RATS.
174133 01-04

DEVELOPMENT OF TOLERANCE IN RATS TO THE HYPOTHERMIC EFFECTS OF D-AMPHETAMINE AND APOMORPHINE.
174764 01-03

APOMORPHINE INDUCED BITING AND FIGHTING BEHAVIOUR IN RESERPINIZED RATS AND AN APPROACH TO THE MECHANISM OF ACTION.
174768 01-04

THE EFFECT OF DOPAMINE ANTAGONISTS AND AMANTADINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
174829 01-04

THE EFFECT OF PHASE-SHIFT ON THE PASSIVE AVOIDANCE RESPONSE IN RATS, AND THE MODIFYING EFFECT OF CHLORDIAZEPOXIDE.
174830 01-04

BLOCKADE OF THE PROESTROUS LH SURGE IN CYCLIC RATS BY BARBITURATE ADMINISTRATION ON DIESTRUS.
175650 02-03

EVIDENCE THAT MORPHINE INCREASES DOPAMINE UTILIZATION IN CORPORA-STRIATA OF RATS.
176746 02-03

ACQUISITION AND PERFORMANCE OF AN ATTENTION TASK BY RATS SUBJECTED TO CHRONIC NICOTINE TREATMENT.
176864 02-04

A METHOD FOR ANALYZING CNS EFFECTS OF DRUGS AND BRAIN LESIONS ON PERMANENT GROUPS OF RATS.
176867 02-06

STEREOTYPED AND AGGRESSIVE BEHAVIOR INDUCED BY SUSTAINED HIGH DOSE OF THEOPHYLLINE IN RATS.
177019 02-04

FURTHER ASPECTS OF AGGRESSIVE BEHAVIOR INDUCED BY SUSTAINED HIGH DOSE OF THEOPHYLLINE IN RATS.
177020 02-04

SUBACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MALE AND FEMALE RATS: ORAL ADMINISTRATION FOR ONE MONTH.
177097 02-05

SPATIAL AND PAW PREFERENCES IN RATS: THEIR RELATIONSHIP TO RATE-DEPENDENT EFFECTS OF D-AMPHETAMINE.
177409 02-04

EFFECTS OF OVERTRAINING AND PRETRIAL ADMINISTRATION OF DEXTROAMPHETAMINE ON REVERSAL LEARNING IN RATS.
177533 02-04

EFFECT OF 6-HYDROXYDOPAMINE ON THE DURATION OF HEXOBARBITAL SLEEP IN RATS.
178558 02-03

MESCALINE HYPERREACTIVITY: HALLUCINATIONS IN RATS? (UNPUBLISHED PAPER).
178575 02-04

THE EFFECTS OF EARLY P-CHLOROPHENYLALANINE ADMINISTRATION AND POSTWEANING HOUSING CONDITIONS ON SEROTONIN AND BEHAVIOR IN RATS.
178638 02-04

OPEN-FIELD BEHAVIOR AND ACQUISITION OF DISCRIMINATIVE RESPONSE CONTROL IN DELTA9-THC TOLERANT RATS.
178813 02-04

CHANGES IN BRAIN ACETYLCHOLINESTERASE ACTIVITY OF YOUNG RATS AFTER CHRONIC TREATMENT WITH TREMORINE.
178814 02-03

AN ANALYSIS OF D-AMPHETAMINE PRODUCED FACILITATION OF AVOIDANCE ACQUISITION IN RATS AND PERFORMANCE CHANGES SUBSEQUENT TO DRUG TERMINATION.
179990 02-04

ACETYLCHOLINE TURNOVER IN BRAIN OF MICE AND RATS: EFFECTS OF VARIOUS DOSE REGIMENS OF MORPHINE. (UNPUBLISHED PAPER).
180582 02-03

ONTOGENESIS OF CIRCADIAN PITUITARY ADRENAL PERIODICITY IN RATS AFFECTED BY NEONATAL TREATMENT WITH ACTH.
181576 02-03

DRUG DEPENDENCE TEST OF PHENOBARBITAL AND MORPHINE IN RATS BY SPONTANEOUS INTAKE.
182104 02-04

EFFECTS OF CYPROHEPTADINE ON THE EATING BEHAVIOR OF RATS AND CATS.
182111 02-04

EFFECTS OF PSYCHOTROPIC DRUGS ON DISCRIMINATION AVOIDANCE CONDITIONING IN RATS WITH OLFACTORY BULB ABLATIONS.
182115 02-04

BEHAVIORAL PHARMACOLOGICAL STUDIES ON TRICYCLIC ANTIDEPRESSANTS IN RATS.
182116 02-04

EFFECTS OF CONSECUTIVE ADMINISTRATION OF DIAZEPAM AND DOXEPIN ON BOTH APPROACH WITHDRAWAL AND APPROACH AVOIDANCE RESPONSES IN RATS.
182117 02-04

EFFECT OF CHEMICAL SYMPATHECTOMY ON MORPHINE ANTINOCICEPTION AND TOLERANCE IN RATS.
182159 02-03

BRAIN AMINES IN PYRIDOXINE DEFICIENT RATS.
182171 02-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND METHYSERGIDE ON DEFENSIVE BEHAVIOR IN RATS.
182190 02-04

REGIONAL AND SUBCELLULAR DISTRIBUTION OF CHOLINE ACETYLTRANSFERASE IN THE BRAIN OF NORMAL AND MORPHINE TREATED RATS.
182224 03-03

STUDIES ON THE EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT ON CATECHOLAMINE LEVELS AND TURNOVER IN DISCRETE BRAIN AREAS OF RATS.
182228 03-03

EFFECT OF D-AMPHETAMINE (D-A) AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) ON THE IN VIVO RELEASE OF 14C-NOREPINEPHRINE (NE) INTO THE LATERAL VENTRICLE OF RATS.
182251 03-03

THE EFFECT OF DOPAMINE RECEPTOR STIMULATING AGENTS AND OF N,O DIBUTYRYL CYCLIC AMP ON C14-DOPAMINE SYNTHESIS IN STRIATAL SLICES OF RATS.
182256 03-03

PENTYLENETETRAZOL CONVULSIONS AND BRAIN CATECHOLAMINE TURNOVER RATE IN RATS AND MICE RECEIVING DIPHENYLHYDANTOIN OR BENZODIAZEPINES.
182344 03-03

CHANGES IN THE NEUROEXCITABILITY OF ALCOHOL DEPENDENT RATS UNDERGOING WITHDRAWAL AS MEASURED BY THE PENTYLENETETRAZOL SEIZURE THRESHOLD.
182348 03-03

EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON THE RHYTHMS OF WAKEFULNESS SLEEP CYCLE IN RATS.
182553 03-04

EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON ELECTROENCEPHALOGRAM AND FEEDING BEHAVIOR OF RATS.
182554 03-04

DRUG ABSORPTION IN RATS PRETREATED WITH ANTIBIOTICS.
182715 03-03

NON-SPECIFICITY OF 5-HYDROXYTRYPTOPHAN IN REPLETING BRAIN SEROTONIN IN RATS WITH MFB LESIONS.
182725 03-03

THE INFLUENCE OF CHRONIC ADMINISTRATION OF LITHIUM CARBONATE ON THE BRAIN NOREPINEPHRINE CONTENT IN RATS.
182872 03-03

THE EFFECT OF PSYCHOTROPIC AGENTS ON THE FORMATION OF AVOIDANCE REACTION IN ALBINO RATS DURING ELECTROPAIN STIMULATION OF ANOTHER RAT.
183206 03-04

EFFECTS OF CHRONICALLY ADMINISTERED DELTA1-TETRAHYDROCANNABINOL OF ADRENAL AND GONADAL ACTIVITY OF MALE RATS.
183358 03-03

THE EFFECTS OF PSYCHIC STIMULANTS ON THE ACTIVITY OF POTASSIUM AND SODIUM ION STIMULATED ATPASE IN THE MICROSOMAL FRACTIONS OF THE BRAIN OF RATS.
183518 03-01

CATALEPSY AND STEREOTYPED BEHAVIOUR IN RATS TREATED CHRONICALLY WITH METHADONE: RELATION TO BRAIN HOMOVANILLIC ACID CONTENT.
183606 03-04

EFFECT OF 3,4 DIMETHOXYPHENETHYLAMINE ON MONOAMINE DEPLETED RATS.
183608 03-03

CANNABIDIOL AND CANNABIS-SATIVA EXTRACT PROTECT MICE AND RATS AGAINST CONVULSIVE AGENTS.
183609 03-03

EFFECT OF VARIOUS STEROIDS AND ACTH ON METHYPRYLON PLASMA LEVELS AND SLEEPING TIME IN RATS.
183611 03-03

REDUCTION IN COPULATORY BEHAVIOR OF MALE RATS FOLLOWING HASHISH INJECTIONS.
183790 03-04

PARADOXICAL THERMOREGULATORY BEHAVIOUR IN RATS INDUCED BY (_) AMPHETAMINE: BLOCKADE BY ALPHA-ADRENOCEPTOR OR DOPAMINE RECEPTOR BLOCKING AGENTS.
183797 03-03

LONG-TERM EFFECTS OF 4-CHLOROAMPHETAMINE ON BRAIN 5-HYDROXYINDOLE METABOLISM IN RATS.
183869 03-03

EFFECT OF CHRONIC METHADONE ADMINISTRATION ON PREGNANT RATS AND THEIR OFFSPRING.
183894 03-03

MORPHINE METABOLISM IN VIVO AND IN VITRO BY HOMOZYGOUS GUNN RATS.
183899 03-03

INVERSION BY APOMORPHINE OF THE TENDENCY OF FEMALE RATS TO BE DEFEATED BY MALES WHEN COMPETING FOR FOOD IN A STRAIGHT RUNWAY.
184212 03-04

TOLERANCE TO THE BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF HALOPERIDOL AND MORPHINE IN RATS CHRONICALLY TREATED WITH MORPHINE OR HALOPERIDOL.
184225 03-03

THE EFFECT OF HYPOTHALAMIC STIMULATION ON ORAL INGESTION OF DIAZEPAM IN RATS.
184238 03-04

EFFECTS OF NEONATAL STRYCHNINE ADMINISTRATION ON ACTIVE AVOIDANCE IN RATS.
184242 03-04

SEIZURE SUSCEPTIBILITY AND AVOIDANCE CONDITIONING IN ADULT RATS TREATED PRENATALLY WITH CHLORPROMAZINE.
184371 03-04

EFFECTS OF AMPHETAMINE ON ELECTROSHOCK RESPONSES IN DEVELOPING RATS.
184372 03-03

EFFECTS OF CHLORPROMAZINE AND THREE METABOLITES ON BEHAVIORAL RESPONSES IN RATS.
185748 03-04

TESTS OF EMOTIONAL BEHAVIOR IN RATS FOLLOWING DEPLETION OF NOREPINEPHRINE, OF SEROTONIN, OR OF BOTH.
185753 03-04

TOWARD A MECHANISM OF THE ANTIAGGRESSION EFFECTS OF CHLORDIAZEPOXIDE IN RATS.
185934 03-04

EFFECTS OF METHAMPHETAMINE ON FIXED-RATIO RESPONDING OF FOOD SATIATED AND FOOD DEPRIVED RATS.
185957 03-04

THE EFFECT OF P-CHLOROAMPHETAMINE ON MOTILITY IN RATS AFTER INHIBITION OF MONOAMINE SYNTHESIS, STORAGE, UPTAKE AND RECEPTOR INTERACTION.
185959 03-04

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: IV. INFLUENCE OF AMPHETAMINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
185961 03-04

INDEPENDENCE OF THE EFFECTS OF D-AMPHETAMINE AND FOOD DEPRIVATION OR BODYWEIGHT ON THE FOOD CONSUMPTION OF RATS.
186376 03-06

AN EXPERIMENTAL INVESTIGATION OF DEPENDENCE LIABILITY OF METHAQUALONE IN RATS.
186569 03-03

BEHAVIOURAL AND BIOCHEMICAL EFFECTS OF 6-HYDROXYDOPA IN RATS.
186571 03-04

EFFECTS OF CLONIDINE AND SOME ALPHA-ADRENORECEPTOR BLOCKING AGENTS ON AVOIDANCE CONDITIONED REFLEXES IN RATS: THEIR INTERACTIONS AND ANTAGONISM BY ATROPINE.
186576 03-04

ROLE OF CATECHOLAMINES IN THE ANORECTIC EFFECTS OF AMPHETAMINE IN RATS.
186582 03-03

RELUCTANCE OF RATS TO DRINK HASHISH SUSPENSIONS: FREE-CHOICE AND FORCED CONSUMPTION, AND THE EFFECTS OF HYPOTHALAMIC STIMULATION.
186586 03-04

DIAZEPAM-INDUCED EATING AND LEVER PRESSING FOR FOOD IN SATED RATS.
186613 03-04

EFFECTS OF PHYSOSTIGMINE ON THE MAINTENANCE OF DISCRIMINATION BEHAVIOUR IN RATS.
186637 03-04

EFFECTS OF ORAL DELTA9-TETRAHYDROCANNABINOL ON OPERANT REINFORCEMENT SCHEDULE PERFORMANCE IN RATS.
186645 03-04

THE EFFECTS OF 3,4 DIMETHOXYPHENYLETHYLAMINE IN RATS TRAINED WITH MESCALINE AS A DISCRIMINATIVE STIMULUS.
186667 03-04

EFFECT OF 5-METHOXYTRYPTAMINE ON SERUM CALCIUM AND PHOSPHATE IN RATS.
186678 03-03

LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04

THE INFLUENCE OF 3-QUINUCLIDINYLBENZILATE ON THE BEHAVIOUR OF RATS IN A CIRCULAR RUNWAY.
187259 04-04

SHIFTING OF THE D-AMPHETAMINE DOSE-RESPONSE CURVE IN RATS WITH FRONTAL CORTICAL ABLATIONS.
187261 04-04

ALTERATION OF EVOKED POTENTIALS IN CAUDATE NUCLEUS OF FREELY MOVING RATS BY L-DOPA, RESERPINE, AND PENTOBARBITAL.
187362 04-03

ON THE BEHAVIORAL AND NEUROCHEMICAL ACTIONS OF 6-HYDROXYDOPA AND 5,6 DIHYDROXYTRYPTAMINE IN RATS.
187380 04-03

LEARNING IMPAIRMENT IN RATS AFTER 6-HYDROXYDOPAMINE INDUCED DEPLETION OF BRAIN CATECHOLAMINES.
187420 04-04

EFFECTS OF LOCUS-COERULEUS STIMULATION ON HIPPOCAMPAL UNIT ACTIVITY AND ON BEHAVIOR IN UNRESTRAINED RATS. (UNPUBLISHED PAPER).
187499 04-04

EFFECTS ON HOMEOSTASIS OF INTRAVENTRICULAR INJECTIONS OF 6-HYDROXYDOPAMINE IN RATS.
187695 04-03

EFFECTS OF INTRACISTERNAL 6-HYDROXYDOPAMINE TREATMENT ON ACQUISITION AND PERFORMANCE OF RATS IN A DOUBLE T-MAZE.
187696 04-04

LOCALIZED BEHAVIORAL EFFECTS OF VASOPRESSIN ON MAINTENANCE OF AN ACTIVE AVOIDANCE RESPONSE IN RATS.
187697 04-04

BEHAVIORAL EFFECTS OF AMPHETAMINE IN RATS WITH LESIONS IN THE CORPUS-STRIATUM.
187698 04-04

AMPHETAMINE AND OPERANT BEHAVIOR IN RATS: RELATIONSHIP BETWEEN DRUG EFFECT AND CONTROL RESPONSE RATE.
187699 04-04

COMPARATIVE EFFECTS OF SCOPOLAMINE AND AMPHETAMINE UPON BEHAVIORAL REACTIVITY AND VISUAL EVOKED POTENTIALS TO FLASHES IN RATS.
187700 04-04

INTERACTION AMONG GENOTYPE, UNCONDITIONED STIMULUS, D-AMPHETAMINE, AND ONE-WAY AVOIDANCE BEHAVIOR OF RATS.
187702 04-04

CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE DERIVATIVE SE-780 IN RATS.
187926 04-04

THE EFFECTS OF P-CHLOROPHENYLALANINE ON MORPHINE ANALGESIA, TOLERANCE AND DEPENDENCE DEVELOPMENT IN TWO STRAINS OF RATS.
187930 04-04

THE EFFECT OF PRETREATMENT WITH IPRONIAZID ON THE BEHAVIORAL ACTIVITIES OF BETA-PHENYLETHYLAMINE IN RATS.
187932 04-04

FURTHER EVIDENCE ON THE INTRAHYPOTHALAMIC LOCUS FOR ANDROGENIZATION OF FEMALE RATS.
187935 04-03

BIOCHEMICAL AND BEHAVIORAL ANTAGONISM BETWEEN FENFLURAMINE AND APOMORPHINE IN RATS.
188196 04-03

CLASSIFICATION OF DRUGS ACCORDING TO THEIR DISCRIMINABLE EFFECTS IN RATS.
188228 04-06

APHRODISIAC EFFECT OF L-DOPA AND APOMORPHINE IN MALE SEXUALLY SLUGGISH RATS.
188519 04-03

THE EFFECT OF P-CHLOROPHENYLALANINE ON FOREBRAIN TRYPTOPHAN HYDROXYLASE IN RATS WITH LESIONS IN THE RAPHE NUCLEUS.
188750 04-03

INFLUENCE OF ADRENERGIC BLOCKERS AND ANTILIPEMIC AGENTS ON PHARMACODYNAMIC ACTIONS OF MORPHINE IN CARBON TETRACHLORIDE TREATED RATS.
188873 04-03

SELF-STIMULATION AND CATECHOLAMINES: DRUG-INDUCED MOBILIZATION OF THE RESERVE POOL RE-ESTABLISHES RESPONDING IN CATECHOLAMINE DEPLETED RATS.
189025 04-04

DIFFERENTIAL EFFECTS OF PENTYLENETETRAZOL ON REM SLEEP IN NAIVE AND COBALT EPILEPTIC RATS.
189407 04-03

THE ACTION OF CHLORPROMAZINE ON EXPLORATION IN PAIRS OF RATS.
189514 04-04

ENHANCEMENT OF NOCICEPTIVE REACTIONS BY NALOXONE IN MICE AND RATS.
189517 04-05

THE EFFECTS OF D-AMPHETAMINE ON THE INTERRESPONSE TIMES OF RATS AND GUINEA-PIGS ON A MODIFIED SIDMAN DISCRIMINATED AVOIDANCE SCHEDULE.
189519 04-04

DELTA9-TETRAHYDROCANNABINOL AND AGGRESSIVE BEHAVIOR IN RATS.
189525 04-04

INHALATION, PARENTERAL AND ORAL LD50 VALUES OF DELTA9-TETRAHYDROCANNABINOL IN FISCHER RATS.
189588 04-05

EFFECTS OF CHRONIC NICOTINE ADMINISTRATION AND AGE ON VARIOUS NEUROTRANSMITTERS AND ASSOCIATED ENZYMES IN MALE FISCHER 344 RATS.
189597 04-03

CANNABINOIDS: NEUROCHEMICAL ASPECTS AFTER ORAL CHRONIC ADMINISTRATION TO RATS.
189599 04-03

THE LACK OF EFFECTS OF PRETREATMENT WITH PHENOBARBITAL AND CHLORPROMAZINE ON THE ACUTE TOXICITY OF BENZENE IN RATS.
189600 04-05

LIPIDOSIS-LIKE ALTERATIONS IN DORSAL ROOT GANGLION CELLS OF RATS TREATED WITH TRICYCLIC ANTIDEPRESSANTS.
189605 04-03

EFFECTS OF ADRENERGIC AGENTS, THEOPHYLLINE AND OTHER DRUGS ON DEXTRAN EDEMA AND HISTAMINE RELEASE IN RATS.
189895 04-03

DISSOCIATION BETWEEN SCOPOLAMINE AND MECAMYLAMINE DURING FEAR CONDITIONING IN RATS.
190264 04-04

BACKWARD CONDITIONING OF TASTE AVERSIONS IN RATS USING CYCLOPHOSPHAMIDE AS THE US.
190265 04-04

MESCALINE FACILITATES RETENTION OF PASSIVE AVOIDANCE IN RATS.
190266 04-04

EVIDENCE FOR A NORADRENERGIC AND DOPAMINERGIC MECHANISM IN THE HYPERACTIVITY PRODUCED BY 4,ALPHA DIMETHYL-M-TYRAMINE (H-77-77) IN RATS.
190309 04-04

EFFECTS OF NICOTINE AND ITS WITHDRAWAL ON THE PERFORMANCE OF RATS ON SIGNALLED AND UNSIGNALLED AVOIDANCE SCHEDULES.
190331 04-04

EFFECTS OF NICOTINE ON THE OBSERVED BEHAVIOUR OF RATS DURING SIGNALLED AND UNSIGNALLED AVOIDANCE EXPERIMENTS.
190332 04-04

METABOLIC INTERACTIONS BETWEEN NORTRIPTYLINE AND THIORIDAZINE IN RATS.
190346 04-03

EFFECTS OF DELTA9-THC ON FOOD AND WATER INTAKE OF DEPRIVATION EXPERIENCED RATS.
191375 04-04

CATALEPSY AND STEREOTYPIES IN RATS TREATED WITH METHADONE; RELATION TO STRIATAL DOPAMINE.
191421 04-03

EFFECT OF CHRONIC TREATMENT WITH CENTRAL STIMULANTS ON BRAIN MONOAMINES AND SOME BEHAVIOURAL AND PHYSIOLOGICAL FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS.
191503 04-03

EFFECTS OF NEUROLEPTIC AGENT ON CENTRAL NERVOUS SYSTEM OF ALBINO RATS.
191613 04-03

INTERACTION OF MESCALINE AND STRESS ON SHUTTLEBOX ESCAPE/AVOIDANCE IN RATS.
191934 04-04

CORRELATION BETWEEN BRAIN N,N DIMETHYLTRYPTAMINE (DMT) LEVELS AND BAR PRESSING BEHAVIOR IN RATS: EFFECT OF MAO INHIBITION.
191935 04-04

ALPHA-METHYL-P-TYROSINE INHIBITION OF SELF-ADMINISTERED INTRAVENOUS MORPHINE AND ORAL WATER IN RATS.
191940 04-04

INCREASED BRAIN NOREPINEPHRINE TURNOVER IN LEAD EXPOSED HYPERACTIVE RATS.
191957 04-05

COMPREHENSIVE BEHAVIORAL ASSESSMENT OF THE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN RATS.
191966 04-04

COMPARATIVE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CANNABIDIOL (CBD), AND CANNABINOL (CBN) ON TIMING BEHAVIOR IN RATS.
191967 04-04

DISTRIBUTION OF 14C-DELTA9-THC IN MALE AND FEMALE RATS.
191969 04-03

CARDIOVASCULAR EFFECTS OF DELTA8-THC AND DELTA9-TETRAHYDROCANNABINOL IN RATS.
191971 04-03

EFFECTS OF MORPHINE SULFATE ON POSITIVELY AND NEGATIVELY REINFORCED BEHAVIOR IN TWO STRAINS OF RATS.
191975 04-04

INTERACTIONS BETWEEN RO-4-1284 AND D-AMPHETAMINE (DA) ON SHUTTLEBOX AVOIDANCE IN RATS.
192009 04-04

DIFFERENTIAL INCREASE OF BEHAVIORAL AND EXTRAPYRAMIDAL STIMULATING ACTIONS OF NEUROLEPTICS BY ALPHA-METHYLTYROSINE PRETREATMENT IN RATS.
192016 04-04

METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY RATS TOLERANT TO MARIHUANA.
192020 04-03

EFFECTS OF DELTA1-TETRAHYDROCANNABINOL ON SIDMAN DISCRIMINATED AVOIDANCE BEHAVIOR IN RATS.
192413 04-03

CHLORDIAZEPOXIDE INDUCED BETA SPINDLE ACTIVITY IN RATS.
192416 04-03

THE EFFECT OF OCTOCLOTHEPIN AND PERPHENAZINE ON BEHAVIOUR IN RATS WITH DIFFERENT EXPLORATION AND DEFECATION RATES.
192430 04-04

RE-ESTABLISHES

SELF-STIMULATION AND CATECHOLAMINES: DRUG-INDUCED MOBILIZATION OF THE RESERVE POOL RE-ESTABLISHES RESPONDING IN CATECHOLAMINE DEPLETED RATS.
189025 04-04

RE-EVALUATION

A NEW MODIFICATION FOR STUDYING 5-HT UPTAKE BY BLOOD PLATELETS: A RE-EVALUATION OF TRICYCLIC ANTIDEPRESSANTS AS UPTAKE INHIBITORS.
180055 02-06

HALLUCINOGENS, A RE-EVALUATION.
191938 04-03

REACTION

METHYLTESTOSTERONE WITH IMIPRAMINE IN MEN: CONVERSION OF DEPRESSION TO PARANOID REACTION.
172992 01-15

CENTRAL MONOAMINES AND THE ACOUSTIC STARTLE REACTION IN RATS. (PH.D. DISSERTATION).
173136 01-04

THE EFFECT OF PSYCHOTROPIC AGENTS ON THE FORMATION OF AVOIDANCE REACTION IN ALBINO RATS DURING ELECTROPAIN STIMULATION OF ANOTHER RAT.
183206 03-04

AN IMPROVED METHOD FOR STUDYING THE PSYCHOGALVANIC REACTION IN MICE AND ITS INHIBITION BY PSYCHOLEPTIC DRUGS. COMPARISON WITH THE EFFECTS OF OTHER PHARMACOLOGICAL AGENTS.
185749 03-06

REACTIONS

ACUTE ADVERSE REACTIONS TO PSYCHOACTIVE DRUGS, DRUG USAGE, AND PERSONALITY. (UNPUBLISHED PAPER).
167832 01-15

DYSTONIC REACTIONS TO DRUGS.
168526 01-15

PHYSOSTIGMINE EFFECTS ON PHENOTHIAZINE INDUCED EXTRAPYRAMIDAL REACTIONS.
170662 01-13

PSYCHIATRISTS REACTIONS TO THEIR PATIENTS REFUSAL OF DRUGS.
175251 02-17

AVOIDANCE OF ADVERSE REACTIONS.
180247 02-15

STUDIES ON BENZODIAZEPINOOXAZOLES. III. REACTIONS AND REARRANGEMENTS OF BENZODIAZEPINOOXAZOLE DERIVATIVES.
180487 02-01

STUDIES ON BENZODIAZEPINOOXAZOLES. V. REACTIONS OF BENZODIAZEPINOOXAZOLE DERIVATIVES WITH ACETIC ANHYDRIDE.
180489 02-01

HIGH FREQUENCY OF DYSPHORIC REACTIONS TO TETRAHYDROCANNABINOL AMONG DEPRESSED PATIENTS.
181274 02-09

ENHANCEMENT OF NOCICEPTIVE REACTIONS BY NALOXONE IN MICE AND RATS.
189517 04-05

REACTIVITY

EFFECTS OF SCOPOLAMINE UPON BEHAVIORAL REACTIVITY AND VISUALLY EVOKED POTENTIAL TO FLASHES IN RATS.
173032 01-04

EFFECTS OF BUFOTENINE AND P-CHLOROPHENYLALANINE ON REACTIVITY TO FOOTSHOCK.
184838 03-04

COMPARATIVE EFFECTS OF SCOPOLAMINE AND AMPHETAMINE UPON BEHAVIORAL REACTIVITY AND VISUAL EVOKED POTENTIALS TO FLASHES IN RATS.
187700 04-04

CARDIOVASCULAR REACTIVITY IN THE DOG AFTER CHEMICAL SYMPATHECTOMY WITH 6-HYDROXYDOPAMINE.
187807 04-03

READAPTATION

DRUGS AND PSYCHIATRIC READAPTATION.
171121 01-17

REALITY

ON THE RECENTLY REPORTED PHYSIOLOGICAL AND PHARMACOLOGICAL REALITY OF THE HYPNOTIC STATE.
173056 01-13

REARRANGEMENTS

STUDIES ON BENZODIAZEPINOOXAZOLES. III. REACTIONS AND REARRANGEMENTS OF BENZODIAZEPINOOXAZOLE DERIVATIVES.
180487 02-01

REBOUND

EFFECTS OF L-DOPA ON NATURAL NIGHT SLEEP AND ON REBOUND OF REM SLEEP.
167921 01-14

ABSENCE OF REM REBOUND AFTER BARBITURATE WITHDRAWAL.
189884 04-14

REBOUND PHENOMENON IN MANIC PATIENTS FOLLOWING PHYSOSTIGMINE: TOWARDS AN UNDERSTANDING OF AMINERGIC MECHANISMS UNDERLYING AFFECTIVE DISORDERS.
191531 04-09

RECEIVING

OPERANT BEHAVIOR AND NEUROPHYSIOLOGICAL OBSERVATIONS OF NORMAL HUMAN VOLUNTEERS RECEIVING CL-1848C, A NEW DISSOCIATIVE ANESTHETIC.
167334 01-07

LYSERGIC ACID DIETHYLAMIDE AND SEROTONIN: A COMPARISON OF EFFECTS ON SEROTONERGIC NEURONS AND NEURONS RECEIVING A SEROTONERGIC INPUT.
177407 02-12

PENTYLENETETRAZOL CONVULSIONS AND BRAIN CATECHOLAMINE TURNOVER RATE IN RATS AND MICE RECEIVING DIPHENYLHYDANTOIN OR BENZODIAZEPINES.
182344 03-03

HEAT DYSCONTROL SYNDROME IN PATIENTS RECEIVING ANTIPSYCHOTIC, ANTIDEPRESSANT AND ANTIPARKINSON DRUG THERAPY.
188094 04-15

RECEPTIVE

EFFECTS OF P-CHLOROPHENYLALANINE ON DIFFERENTIATION OF SEROTONINERGIC RECEPTIVE CELLS DURING EMBRYOGENESIS. (UNPUBLISHED PAPER).
168817 01-03

RECEPTOR

EFFECTS OF DOPAMINE RECEPTOR STIMULATION AND BLOCKADE ON RO-4-1284 INDUCED ENHANCEMENT OF ELECTROSHOCK SEIZURE.
167287 01-03

CENTRAL MONOAMINE METABOLISM IN MAN: EFFECT OF PUTATIVE DOPAMINE RECEPTOR AGONISTS AND ANTAGONISTS.
169377 01-13

POTENTIAL NEUROTRANSMITTERS AND RECEPTOR MECHANISMS INVOLVED IN THE CENTRAL CONTROL OF BODY TEMPERATURE IN HAMSTERS. (PH.D. DISSERTATION).
174962 01-03

THE EFFECT OF DOPAMINE RECEPTOR STIMULATING AGENTS AND OF N,O DIBUTYRYL CYCLIC AMP ON C14-DOPAMINE SYNTHESIS IN STRIATAL SLICES OF RATS.
182256 03-03

PARADOXICAL THERMOREGULATORY BEHAVIOUR IN RATS INDUCED BY (-) AMPHETAMINE: BLOCKADE BY ALPHA-ADRENOCEPTOR OR DOPAMINE RECEPTOR BLOCKING AGENTS.
183797 03-03

THE EFFECT OF P-CHLOROAMPHETAMINE ON MOTILITY IN RATS AFTER INHIBITION OF MONOAMINE SYNTHESIS, STORAGE, UPTAKE AND RECEPTOR INTERACTION.
185959 03-04

PARKINSON DISEASE TREATED WITH A SUSPECTED DOPAMINE RECEPTOR AGONIST.
186029 03-11

SIGNIFICANCE OF DOPAMINE RECEPTOR ACTIVITY IN DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY.
186670 03-04

FAILURE OF BETA-ADRENERGIC RECEPTOR BLOCKADE TO PREVENT ARRHYTHMIAS INDUCED BY SYMPATHETIC NERVE STIMULATION.
187923 04-03

FURTHER EVIDENCE FOR A DOPAMINE RECEPTOR STIMULATING ACTION OF AN ERGOT ALKALOID.
188739 04-03

OUABAIN RECEPTOR INTERACTIONS IN (NA+ + K+) ATPASE PREPARATIONS.
189567 04-03

PHYLOGENETIC DISTRIBUTION OF OPIATE RECEPTOR BINDING.
190476 04-03

EFFECTS OF DOPAMINE-LIKE DRUGS ON RAT STRIATAL ADENYL CYCLASE HAVE IMPLICATIONS FOR CNS DOPAMINE RECEPTOR TOPOGRAPHY.
190545 04-03

EFFECTS OF PIRIBEDIL (ET-495) -- A DOPAMINERGIC RECEPTOR STIMULATING AGENT IN PARKINSONS DISEASE.
191522 04-13

RECEPTORS

PHARMACOLOGICAL SUPPRESSION OF EATING BEHAVIOR IN RELATION TO DIENCEPHALIC NORADRENERGIC RECEPTORS.
174763 01-04

ALPHA-ADRENERGIC RECEPTORS MEDIATE SUPPRESSION OF DRINKING INDUCED BY HYPOTHALAMIC AMPHETAMINE INJECTION.
182216 03-03

EVIDENCE FOR THE ACTION OF D-LYSERGIC ACID DIETHYLAMIDE, MESCALINE AND BUFOTENINE ON 5-HYDROXYTRYPTAMINE RECEPTORS IN UMBILICAL VASCULATURE.
182716 03-03

AMANTADINE MAY STIMULATE DOPAMINE AND NORADRENALINE RECEPTORS.
183868 03-03

A ROLE FOR NICOTINIC RECEPTORS IN THE REGULATION OF THE ADENYLATE CYCLASE OF ADRENAL MEDULLA.
186675 03-03

ANTISCHIZOPHRENIC DRUGS AND BRAIN CHOLINERGIC RECEPTORS: AFFINITY FOR MUSCARINIC SITES PREDICTS EXTRAPYRAMIDAL EFFECTS.
188114 04-15

RECOGNITION

WORD RECOGNITION OF SCHIZOPHRENICS AS A FUNCTION OF PHENOTHIAZINE LEVEL AND AUTONOMIC RESPONSIVITY. (PH.D. DISSERTATION).
182524 03-08

RECONSTRUCTIVE

RECONSTRUCTIVE MEDICATION.
188447 04-11

RECORDED

THE EFFECT OF LORAZEPAM ON ANXIOUS INSOMNIACS SLEEP AS RECORDED IN THE HOME ENVIRONMENT.
177318 02-14

THE EFFECTS OF INTRAVENTRICULARLY ADMINISTERED CATECHOLAMINES AND SEROTONIN ON THE RESERPINE INDUCED SPIKE WAVES RECORDED FROM THE MEDICAL NUCLEUS TRAPEZOIDES IN THE RABBIT.
182094 02-03

RECORDING

AUTOMATIC RECORDING OF ANIMAL BEHAVIOR AND ITS ANALYSIS.
182106 02-17

A NEW RECORDING APPARATUS FOR MEASUREMENT OF LOCOMOTOR ACTIVITY OF MICE. EXPERIMENTAL OBSERVATIONS ON ITS USE.
186377 03-06

RECOVERY

RECOVERY OF FEEDING AND DRINKING BY RATS AFTER INTRAVENTRICULAR 6-HYDROXYDOPAMINE OR LATERAL HYPOTHALAMIC LESIONS.
168484 01-03

LACK OF EFFECT OF RIBAMINOL, TCAP, AND MAGNESIUM PEMOLINE ON RECOVERY FROM NEOCEREBELLAR DAMAGE.
171904 01-03

DRUG ABUSE -- OVERDOSE AND RECOVERY.
180147 02-15

RECOVERY OF FEEDING AFTER 6-HYDROXYDOPAMINE (6-HDA) OR LATERAL HYPOTHALAMIC LESIONS: THE ROLE OF CATECHOLAMINES.
182213 03-03

DIFFERENTIAL RECOVERY OF FUNCTION FOLLOWING CAUDATE, HIPPOCAMPAL, AND SEPTAL LESIONS IN MICE.
186620 03-04

RECOVERY FROM ELECTROCONVULSIVE SHOCK-INDUCED AMNESIA BY EXPOSURE TO THE TRAINING ENVIRONMENT: PHARMACOLOGICAL ENHANCEMENT BY PIRACETAM.
186704 03-04

EFFECTS OF CYCLOHEXIMIDE ON ACQUISITION AND RETENTION OF AVOIDANCE LEARNING IN THE RAT: RECOVERY OF MEMORY.
189215 04-04

EXCITABILITY CHANGES DURING THE GRADUAL DEVELOPMENT OF AND RECOVERY FROM PENTYLENETETRAZOL AND STRYCHNINE INDUCED CONVULSIONS IN THE CAT.
191927 04-03

RECURRENT

A COMPARISON OF LITHIUM CARBONATE IN THE PREVENTION OF MANIC AND DEPRESSIVE EPISODES IN RECURRENT AFFECTIVE DISORDER.
169090 01-09

LITHIUM PROPHYLAXIS IN RECURRENT AFFECTIVE ILLNESS.
171926 01-09

CONTINUOUS INFUSION OF DIAZEPAM IN INFANTS WERE SEVERE RECURRENT CONVULSIONS.
174568 01-11

PROPHYLACTIC TREATMENT OF RECURRENT DEPRESSION: OBSERVATIONS FROM A MULTIHOSPITAL COLLABORATIVE STUDY.
186190 03-09

THIRTY-FIVE YEARS CONTINUOUS TREATMENT FOR RECURRENT DEPRESSION: FROM ECT TO DRUGS.
191119 04-09

RED

EFFECT OF SELECTED BETA-DIKETONES ON LITHIUM FLUXES OF BOVINE RED BLOOD CELLS.
171792 01-05

NEOMYCIN AND RUTHENIUM RED ANTAGONISM OF MONOAMINERGIC DEPRESSION OF CEREBRAL CORTICAL NEURONES.
191380 04-03

COMPARATIVE PROPERTIES OF SOLUBLE AND PARTICULATE CATECHOL-O-METHYLTRANSFERASE FROM RAT RED BLOOD CELL: PRELIMINARY OBSERVATIONS.
191523 04-01

REDEFINED

THE EFFECTS OF CHLORPROMAZINE ON A REDEFINED PROCEDURE OF EXTINCTION OF SIDMAN AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
185715 03-14

REDISCOVERED

CHLORMEZANONE IN ANXIETY: A DRUG REDISCOVERED?
184175 03-10

REDISTRIBUTION

EVIDENCE FOR REDISTRIBUTION OF FILTRATE AMONG NEPHRONS AFTER BETA- ADRENERGIC STIMULATION AND BLOCKADE.
184222 03-03

REDUCED

REDUCED BEHAVIORAL EFFECTS OF PILOCARPINE DURING CHRONIC TREATMENT WITH DFP.
185265 03-04

REDUCTASE

PARTIAL PURIFICATION AND CHARACTERIZATION OF NADPH-LINKED ALDEHYDE REDUCTASE FROM MONKEY BRAIN.
175232 02-03

DIHYDROPTERIDINE REDUCTASE IN RAT BRAIN: REGIONAL DISTRIBUTION AND THE EFFECT OF CATECHOLAMINE DEPLETING DRUGS.
189752 04-03

REDUCTION

A PROGRAMME WHICH LED TO REDUCTION IN NIGHT SEDATION IN A MAJOR HOSPITAL.
170802 01-17

DIAZEPAM USED INTRAVENOUSLY DURING REDUCTION OF FRACTURES AND DISLOCATIONS.
174880 01-17

EFFECT OF MORPHINE, HALOPERIDOL, APOMORPHINE AND BENZTROPINE ON DOPAMINE TURNOVER IN RAT CORPUS-STRIATUM: EVIDENCE SHOWING MORPHINE-INDUCED REDUCTION IN CNS DOPAMINERGIC ACTIVITY.
182230 03-03

REDUCTION IN COPULATORY BEHAVIOR OF MALE RATS FOLLOWING HASHISH INJECTIONS.
183790 03-04

FEAR REDUCTION IN THE RAT FOLLOWING CENTRAL CHOLINERGIC BLOCKADE.
187703 04-04

REDUCTION BY PRETREATMENT WITH DIBENAMINE OF HEPATOTOXICITY INDUCED BY CARBON TETRACHLORIDE, THIOACETAMINDE OR DIMETHYLNITROSAMINE.
188865 04-05

NONSEDATING DOSAGES OF DIAZEPAM AND PHENOBARBITAL IN THE REDUCTION OF NEONATAL BILIRUBIN LEVELS.
191607 04-17

REFERRED

DRUG TREATMENT OF DEPRESSED PATIENTS REFERRED FOR HOSPITALIZATION.
170621 01-09

REFLECTION

REFLECTION OF SHORT-TERM LIGHT ADAPTATION EFFECT IN THE ELECTRORETINOGRAM.
180591 02-04

REFLEX

EVALUATION OF CENTRAL ANTIRESERPINE EFFECT BY THE USE OF LIGHT BLINK REFLEX.
169469 01-04

THE ROLE OF MONOAMINE OXIDASE IN TERMINATING THE REFLEX EFFECTS OF P-METHOXYPHENYLETHYLAMINE (PMPEA).
174319 01-03

A COMPARISON OF SOMATIC REFLEX EFFECTS OF THREE PSYCHOTROPIC AGENTS IN THE CHLORALOSE CAT.
182126 02-03

INFLUENCE OF TETRACOSACTRIN (T) AND BETA-MELANOCYTE STIMULATING HORMONE (MSH) ON DEPRESSION OF THE SEGMENTAL REFLEX BY MORPHINE (MS). (UNPUBLISHED PAPER).
183324 03-03

THE EFFECT OF FLURAZEPAM ON THE PHOTOPALPEBRAL REFLEX.
184314 03-13

THE PROBLEMS OF THE CLINICAL USAGE OF NITRAZEPAM: SUPPRESSIVE EFFECTS ON THE PHARYNGEAL REFLEX AND THE COMA, USING OTHER TRANQUILIZERS AT THE SAME TIME.
188450 04-15

REFLEXES

PARADOXICAL BLOCKADE BY P-CHLOROPHENYLALANINE OF 5-HYDROXYTRYPTOPHAN FACILITATORY ACTIONS ON SPINAL REFLEXES.
168436 01-03

THE EFFECT OF L-TRYPTOPHAN (TP) ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) REFLEXES IN ACUTE DECEREBRATE SPINAL CATS AND THE EFFECT OF PRETREATMENT WITH P-CHLOROPHENYLALANINE (PCPA) ON THE ACTION OF TP. (UNPUBLISHED PAPER).
170874 01-03

HABITUATION OF BLINK REFLEXES IN PARKINSONIAN PATIENTS UNDER LEVODOPA AND AMANTADINE TREATMENT.
171794 01-13

THE EFFECT IN THE CAT OF TRYPTAMINE (T) AND LSD ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) SPINAL REFLEXES. (UNPUBLISHED PAPER).
174480 01-12

THE EFFECT OF DIAZEPAM ON SOME CARDIOVASCULAR AND RESPIRATORY REFLEXES ELICITED BY AFFERENT ABDOMINAL VAGUS STIMULATION.
178945 02-03

EFFECTS OF BENZODIAZEPINES ON SPINAL REFLEXES IN CATS.
182097 02-03

EFFECTS OF CLONIDINE AND SOME ALPHA-ADRENORECEPTOR BLOCKING AGENTS ON AVOIDANCE CONDITIONED REFLEXES IN RATS: THEIR INTERACTIONS AND ANTAGONISM BY ATROPINE.
186576 03-04

CANNABINOIDS AND HEXOBARBITAL INDUCED LOSS OF RIGHTING REFLEXES.
189573 04-04

REFLEXIVE

CENTRAL CHOLINERGIC (MUSCARINIC) LINK IN THE ATTACK REFLEXIVE BITING MECHANISM OF CATS.
182238 03-04

REFRACTORY

A DOUBLE-BLIND TRIAL OF IPRINDOLE AND IMIPRAMINE IN DEPRESSIVES AND RESPONSE TO ECT IN REFRACTORY CASES.
174376 01-09

A STUDY OF REFRACTORY CASES OF DEPRESSIVE ILLNESSES AND THEIR RESPONSE TO COMBINED ANTIDEPRESSANT TREATMENT.
185078 03-10

EFFECT OF MARIHUANA ON THE PSYCHOLOGICAL REFRACTORY PERIOD.
189358 04-14

REFUSAL

PSYCHIATRISTS REACTIONS TO THEIR PATIENTS REFUSAL OF DRUGS.
175251 02-17

REGIMENS

ACETYLCHOLINE TURNOVER IN BRAIN OF MICE AND RATS: EFFECTS OF VARIOUS DOSE REGIMENS OF MORPHINE. (UNPUBLISHED PAPER).
180582 02-03

REGION

5-HYDROXYTRYPTAMINE AND NORADRENALINE IN THE HIPPOCAMPAL REGION: EFFECT OF TRANSECTION OF AFFERENT PATHWAYS ON ENDOGENOUS LEVELS, HIGH AFFINITY UPTAKE AND SOME TRANSMITTER RELATED ENZYMES.
191319 04-03

REGULAR

TRIFLUOPERAZINE: A COMPARISON BETWEEN REGULAR AND HIGH DOSES.
184977 03-08

REGULATING

STUDIES ON CENTRAL REGULATING MECHANISM OF THE HYPOGLYCEMIA INDUCED BY INTRAVENTRICULAR ADMINISTRATION OF CHLORPROMAZINE.
182093 02-03

REGULATION

THE ONTOGENY OF AMPHETAMINE-INDUCED ALTERATIONS IN THERMAL REGULATION.
182246 03-03

NOREPINEPHRINE -- AN ANTAGONIST OF DIBUTYRYL CYCLIC AMP IN THE REGULATION OF NARCOSIS IN THE RAT.
183789 03-03

A ROLE FOR NICOTINIC RECEPTORS IN THE REGULATION OF THE ADENYLATE CYCLASE OF ADRENAL MEDULLA.
186675 03-03

REGULATION OF BRAIN DOPAMINE TURNOVER RATE: PHARMACOLOGICAL IMPLICATIONS. (UNPUBLISHED PAPER).
187527 04-03

ROLE OF DOPAMINERGIC MECHANISMS IN REGULATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN MAN.
188428 04-13

PHYSICOCHEMICAL PROPERTIES, DEVELOPMENT, AND REGULATION OF CENTRAL AND PERIPHERAL MONOAMINE OXIDASE ACTIVITY.
191497 04-03

DOPAMINE-BETA-HYDROXYLASE AND THE REGULATION OF THE NORADRENERGIC NEURON.
191509 04-03

SHORT-TERM AND LONG-TERM REGULATION OF TYROSINE HYDROXYLASE.
191515 04-03

REGULATION OF FUNCTION OF TRYPTOPHAN HYDROXYLASE.
191516 04-03

NORADRENERGIC REGULATION OF BRAIN SEROTONERGIC NEURONS: EVIDENCE FROM SINGLE UNIT STUDIES WITH CLONIDINE.
191948 04-03

REHABILITATION

REHABILITATION OF LEARNING IN A HOSPITAL CLASS USING PSYCHOACTIVE DRUGS.
174071 01-11

END OF A BACK WARD: THE RAPID REHABILITATION AND RELEASE OF CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS.
181153 02-08

REINFORCED

DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) DOSE EFFECTS COMPARED ON THREE SCHEDULES OF FOOD REINFORCED OPERANT PERFORMANCE.
182191 02-04

EFFECTS OF MORPHINE, CODEINE AND NALOXONE ON FOOD AND CODEINE REINFORCED RESPONDING IN THE RHESUS MONKEY.
182195 02-04

EFFECTS OF MORPHINE SULFATE ON POSITIVELY AND NEGATIVELY REINFORCED BEHAVIOR IN TWO STRAINS OF RATS.
191975 04-04

REINFORCEMENT

HALOPERIDOL EFFECTS ON MORPHINE SELF-ADMINISTRATION: TESTING FOR PHARMACOLOGICAL MODIFICATION OF THE PRIMARY REINFORCEMENT MECHANISM.
172454 01-04

BEHAVIORAL PARAMETERS OF DRUG ACTION: SIGNALED AND RESPONSE INDEPENDENT REINFORCEMENT.
174008 01-04

EFFECTS OF ORAL DELTA9-TETRAHYDROCANNABINOL ON OPERANT REINFORCEMENT SCHEDULE PERFORMANCE IN RATS.
186645 03-04

NEGATIVE AND POSITIVE INTRACRANIAL REINFORCEMENT THRESHOLDS: EFFECTS OF MORPHINE.
190330 04-04

REINFORCING

NEGATIVE REINFORCING PROPERTIES OF MORPHINE ANTAGONISTS IN NAIVE RHESUS MONKEYS.
177719 02-04

EVALUATION OF REINFORCING CAPABILITY OF DELTA9-TETRAHYDROCANNABINOL IN RHESUS MONKEYS.
187638 04-04

POSITIVE REINFORCING EFFECTS OF APOMORPHINE, D-AMPHETAMINE AND MORPHINE: INTERACTION WITH HALOPERIDOL.
191899 04-04

REINVESTIGATION

REINVESTIGATION ON THE EFFECTS OF THIOPENTAL ON THE HUMAN SOMATOSENSORY EVOKED RESPONSE.
174505 01-13

RELAXANT

DISSOCIATIVE CHANGE IN ANTIAGGRESSIVE AND MUSCLE RELAXANT ACTIONS OF S-TRIAZOLOBENZODIAZEPINE (D-40TA) BY REPEATED ADMINISTRATION AND PHENOBARBITAL PRETREATMENT, AND ITS RELATION TO METABOLISM.
181654 02-04

RELAXANTS

A COMPARATIVE STUDY OF DANTROLENE SODIUM AND OTHER SKELETAL MUSCLE RELAXANTS WITH THE STRAUB TAIL MOUSE.
186638 03-04

CENTRALLY ACTING MUSCLE RELAXANTS. ISOMERIC 9,10 DIHYDROXYOCTAHYDROPHENANTHRENES AND THEIR CARBAMATE ESTERS.
190719 04-02

RELEASE

EFFECT OF CHLORPROMAZINE (CPZ) ON INSULIN RELEASE IN VIVO AND IN VITRO IN THE RAT.
168440 01-03

MELANOCYTE STIMULATING HORMONE RELEASE INHIBITING HORMONE AS AN ANTIDEPRESSANT: A PILOT STUDY.
171501 01-09

IMPORTANCE OF CATECHOLAMINE RELEASE BY NERVE IMPULSES FOR FREE OPERANT BEHAVIOR.
171611 01-04
EFFECT OF MONOAMINE OXIDASE INHIBITORS ON METABOLISM AND IN VIVO RELEASE OF H3-NOREPINEPHRINE FROM THE HYPOTHALAMUS.
171973 01-03
THE USE OF TIMED RELEASE NEUROLEPTICS IN AMBULATORY PSYCHIATRIC PRACTICE.
172977 01-11
CNS DEPRESSION IN THE ABSENCE OF PROLACTIN RELEASE FOLLOWING INTRAARTERIAL INJECTIONS OF SODIUM PENTOTHAL IN THE PROESTROUS RAT.
173257 01-03
RELATIVE POTENCIES OF D- AND L-AMPHETAMINE ON THE RELEASE OF DOPAMINE FROM CAT BRAIN IN VIVO.
176874 02-03
ON THE SPECIFICITY OF DOPAMINE RELEASE BY AMANTADINE.
178557 02-03
MECHANISM OF RELEASE AT NORADRENERGIC NERVE TERMINALS BY RESERPINE AND SEVERAL SYMPATHOMIMETIC AGENTS. (UNPUBLISHED PAPER).
178747 02-03
END OF A BACK WARD: THE RAPID REHABILITATION AND RELEASE OF CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS.
181153 02-08
THE EFFECTS OF DRUGS ON THE RELEASE OF CATECHOLAMINE.
182089 02-03
IN VIVO MEASUREMENT OF THE RELEASE OF 5-HYDROXYTRYPTAMINE (5-HT) FROM THE HIPPOCAMPUS OF THE RAT: EFFECT OF RO-4-1284, PARGYLINE AND P-CHLOROAMPHETAMINE (PCA).
182140 02-03
UPTAKE, STORAGE AND RELEASE IN VIVO OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY SYMPATHETIC NERVES OF THE IRIS.
182204 02-03
EFFECTS OF MORPHINE, NALORPHINE AND NALOXONE ON RAT BRAIN RELEASE OF ACETYLCHOLINE.
182227 03-03
EFFECT OF D-AMPHETAMINE (D-A) AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) ON THE IN VIVO RELEASE OF 14C-NOREPINEPHRINE (NE) INTO THE LATERAL VENTRICLE OF RATS.
182251 03-03
INVOLVEMENT OF ALPHA-RECEPTORS IN CLONIDINE INDUCED INHIBITION OF TRANSMITTER RELEASE FROM CENTRAL MONOAMINE NEURONES.
182345 03-03
UPTAKE AND RELEASE OF NORADRENALINE IN RAT CEREBRAL CORTEX IN VITRO: NO EFFECT OF BENZODIAZEPINES AND BARBITURATES.
182347 03-03
THE EFFECT OF ZINC N TETRACOSACTRIN ON GROWTH HORMONE RELEASE DURING SLEEP.
183490 03-13
IN VIVO RELEASE OF NEWLY SYNTHESIZED CATECHOLAMINES FROM THE HYPOTHALAMUS BY AMPHETAMINE.
184230 03-03
THE EFFECTS OF ACUTE ADMINISTRATION OF PROPRANOLOL AND PRACTOLOL ON THE UPTAKE, CONTENT, RELEASE AND TURNOVER OF NORADRENALINE IN THE RAT HEART IN VIVO.
184232 03-03
IMPLICATIONS OF SUSTAINED RELEASE PHENOTHIAZINES: A STUDY OF FLUPHENAZINE DECANOATE.
185007 03-09
THE EFFECT OF LITHIUM ON THYROID IODINE RELEASE IN PATIENTS WITH PRIMARY AFFECTIVE DISORDER.
186580 03-09
A COMPARISON OF THE EFFECTS OF AMPHETAMINE AND ITS METABOLITES, P-HYDROXYAMPHETAMINE AND P-HYDROXYNOREPHEDRINE, ON UPTAKE, RELEASE AND CATABOLISM OF 3H-NOREPINEPHRINE IN CEREBRAL CORTEX OF RAT BRAIN.
186669 03-03
COMPARATIVE EFFECTS OF DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE ON CATECHOLAMINE RELEASE AND REUPTAKE IN VITRO.
186671 03-03
SPECIFICITY OF BLOCKADE OF THE NICOTINE INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ADRENERGIC NEURONS OF THE GUINEA-PIG HEART BY VARIOUS PHARMACOLOGICAL AGENTS.
186676 03-03
ON THE MECHANISM OF RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVES INDUCED BY DEPOLARIZING AGENTS AND SYMPATHOMIMETIC DRUGS. (UNPUBLISHED PAPER).
187397 04-03
EFFECTS OF LSD ON SYNTHESIS AND RELEASE OF 5-HT IN RAT BRAIN SLICES.
188164 04-03
COMPARISON OF PHARMACOLOGICAL RESPONSES TO NICOTINE AND RELEASE OF CATECHOLAMINES FROM THE ADRENALS IN DOGS AND MONKEYS.
188199 04-03
INHIBITORY EFFECT OF DOPAMINERGIC STIMULATION ON GH RELEASE IN ACROMEGALY.
188350 04-13
EFFECT OF PENTOBARBITAL ON UPTAKE AND RELEASE OF (3H)GABA AND (14C)GLUTAMATE BY BRAIN SLICES.
189031 04-03
EFFECTS OF ALPHA-METHYLTYROSINE ON D-AMPHETAMINE INDUCED RELEASE OF ENDOGENOUSLY SYNTHESIZED AND EXOGENOUSLY ADMINISTERED CATECHOLAMINES FROM THE CAT BRAIN IN VIVO.
189397 04-03
INFLUENCE OF MORPHINE AND NALOXONE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189568 04-03
INFLUENCE OF FENTANYL, LEVORPHANOL AND PETHIDINE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189569 04-03
BLOCKADE OF INSULIN RELEASE BY CERTAIN PHENOTHIAZINES.
189583 04-05
MECHANISM OF ADRENAL CATECHOLAMINE RELEASE BY DIVALENT MERCURY.
189591 04-03
EFFECTS OF ADRENERGIC AGENTS, THEOPHYLLINE AND OTHER DRUGS ON DEXTRAN EDEMA AND HISTAMINE RELEASE IN RATS.
189895 04-03
INHIBITION OF THE SLEEP RELATED PEAK IN PHYSIOLOGIC HUMAN GROWTH HORMONE RELEASE BY SOMATOSTATIN.
190104 04-13
PHARMACOLOGICAL ALTERATIONS IN THE STIMULUS INDUCED RELEASE OF NOREPINEPHRINE FROM THE RABBIT SUPERIOR CERVICAL GANGLION.
191896 04-03
AMPHETAMINE AND METHYLPHENIDATE INDUCED RELEASE OF STRIATAL DOPAMINE IN VIVO: DIFFERENTIAL EFFECTS ON NEWLY SYNTHESIZED AND STORED POOLS.
191897 04-03
CHLORIMIPRAMINE AND LSD: DIFFERENTIAL EFFECTS ON THE IN VIVO RELEASE OF 3H-5-HT.
191949 04-03
TRIAL OF SUSTAINED RELEASE AMITRIPTYLINE ON ENURESIS.
192589 04-11

RELEASERS
NONSPONTANEOUS CONVULSIONS IN MICE ELICITED BY SOME CATECHOLAMINE RELEASERS AND 6,7 DIHYDROXYTETRAHYDROISOQUINOLINE (TIQ).
192013 04-05

RELEASING
FUNCTIONAL EVALUATION OF PITUITARY RESERVE IN PATIENTS WITH THE AMENORRHEA GALACTORRHEA SYNDROME UTILIZING LUTEINIZING HORMONE RELEASING HORMONE (LH-RH), L-DOPA AND CHLORPROMAZINE.
175245 02-13
A PRELIMINARY STUDY ON THE ACTION OF THYROTROPINE RELEASING HORMONE OR TRH IN DEPRESSIVE STATES.
184962 03-09
A DOUBLE-BLIND CROSSOVER SEQUENTIAL TRIAL OF ORAL THYROTROPIN RELEASING HORMONE IN DEPRESSION.
188348 04-09
AFFECTIVE STATE AND THYROTROPIN AND PROLACTIN RESPONSES AFTER REPEATED INJECTIONS OF THYROTROPIN RELEASING HORMONE IN DEPRESSED PATIENTS.
189076 04-09
THE DOPAMINE RELEASING ACTIONS OF NEUROLEPTICS AND ETHANOL.
189401 04-03
THYROTROPHIN RELEASING HORMONE IN THE TREATMENT OF DEPRESSION.
192577 04-09

RELIABLE
TIME SAMPLING OF RAT EXPLORATORY BEHAVIOUR: A RELIABLE SCREENING TEST FOR THE CNS EFFECTS OF ANOREXIC AGENTS.
187925 04-04

RELIEF
RELIEF OF MUSCULOSKELETAL AND ASSOCIATED PSYCHOPATHOLOGICAL SYMPTOMS WITH MEPROBAMATE AND ASPIRIN: A CONTROLLED STUDY.
169632 01-10
PREDICTING RELIEF FROM ANXIETY WITH PHENOBARBITAL.
177376 02-10
AN OBSESSIVE NEUROSIS FOLLOWING MORNING-GLORY SEED INGESTION TREATED BY AVERSION RELIEF.
184259 03-15

RELIEVING
THE EFFECT OF PAIN RELIEVING DRUGS ADMINISTERED DURING LABOR AND DELIVERY ON THE BEHAVIOR OF THE NEWBORN: A REVIEW.
183706 03-17

RELUCTANCE
RELUCTANCE OF RATS TO DRINK HASHISH SUSPENSIONS: FREE-CHOICE AND FORCED CONSUMPTION, AND THE EFFECTS OF HYPOTHALAMIC STIMULATION.
186586 03-04

REM

EFFECTS OF L-DOPA ON NATURAL NIGHT SLEEP AND ON REBOUND OF REM SLEEP.
167921 01-14

AMPHETAMINE AND PENTOBARBITAL EFFECTS ON THE DISCRIMINATIVE RESPONSE CONTROL BY DEPRIVATION OF RAPID EYE MOVEMENT SLEEP (REM).
182245 03-03

DIFFERENTIAL EFFECTS OF PENTYLENETETRAZOL ON REM SLEEP IN NAIVE AND COBALT EPILEPTIC RATS.
189407 04-03

ABSENCE OF REM REBOUND AFTER BARBITURATE WITHDRAWAL.
189884 04-14

REMOVAL

SIMILARITY OF CHRONIC CHLORDIAZEPOXIDE TREATMENT AND REMOVAL OF CONFLICT SITUATION.
182258 03-04

PHARMACOLOGICAL ANALYSIS OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE REMOVAL FROM THE PULMONARY CIRCULATION: DIFFERENTIATION OF UPTAKE SITES FOR EACH AMINE.
182717 03-03

EXTRANEURONAL REMOVAL, ACCUMULATION AND O-METHYLATION OF ISOPRENALINE IN THE PERFUSED HEART.
189604 04-03

RENAL

ENHANCED RENAL TUBULAR SECRETION OF MEPROBAMATE: ROLE OF SALINE FUROSEMIDE DIURESIS.
184243 03-03

RENSHAW

THE EFFECTS OF MORPHINE, ETORPHINE AND SINOMENINE ON THE CHEMICAL SENSITIVITY AND SYNAPTIC RESPONSES OF RENSHAW CELLS AND OTHER SPINAL NEURONES IN THE RAT.
188201 04-03

REPEAT

REPEAT ADMINISTRATION OF MARIHUANA SMOKE TO HUMANS.
188120 04-13

REPEATED

RELATIONSHIP BETWEEN RESPONSE TO LOW PENTAMETHYLENETETRAZOL ADMINISTRATION AND PERSONALITY OF JUVENILE OFFENDERS AND THEIR REPEATED CRIMES.
175072 02-17

REPEATED ACQUISITION OF BEHAVIORAL CHAINS UNDER CHRONIC DRUG CONDITIONS.
177408 02-04

DISSOCIATIVE CHANGE IN ANTIAGGRESSIVE AND MUSCLE RELAXANT ACTIONS OF S-TRIAZOLOBENZODIAZEPINE (D-40TA) BY REPEATED ADMINISTRATION AND PHENOBARBITAL PRETREATMENT, AND ITS RELATION TO METABOLISM.
181654 02-04

EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF WATER SOLUBLE 1-DELTA9-TETRAHYDROCANNABINOL (W THC) ON WEB-BUILDING OF SPIDERS.
182193 02-04

PHARMACOLOGY OF NEUROLEPTICS UPON REPEATED ADMINISTRATION.
186368 03-04

ENHANCEMENT OF METHYLPHENIDATE INDUCED STEREOTYPIES BY REPEATED ADMINISTRATION OF NEUROLEPTICS.
186369 03-04

AFFECTIVE STATE AND THYROTROPIN AND PROLACTIN RESPONSES AFTER REPEATED INJECTIONS OF THYROTROPIN RELEASING HORMONE IN DEPRESSED PATIENTS.
189076 04-09

EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF CLOZAPINE ON THE METABOLISM OF DOPAMINE AND NORADRENALINE IN THE BRAIN OF THE RAT.
191418 04-03

REPETITIVE

INHIBITION BY MORPHINE OF REPETITIVE ACTIVATION OF CAT SPINAL MOTONEURONES.
172926 01-03

REPLETING

NON-SPECIFICITY OF 5-HYDROXYTRYPTOPHAN IN REPLETING BRAIN SEROTONIN IN RATS WITH MFB LESIONS.
182725 03-03

REPLICATION

EPISODIC DYSCONTROL: A CONTROLLED REPLICATION.
187839 04-09

REPRESENTATIVE

ARE NEUROTIC PATIENTS IN PSYCHOTROPIC DRUG TRIALS REPRESENTATIVE? A COMPARISON OF STUDY AND NON-STUDY PATIENTS IN FOUR FAMILY PRACTICES.
188144 04-10

REPRODUCTION

THE EFFECTS OF 6-OH-DOPAMINE ON THE REPRODUCTION AND NA AND 5-HT CONTENTS OF SOME TISSUES IN MICE.
171613 01-03

RESEARCH

THE ROLE OF RESEARCH IN DRUG ABUSE INTERVENTION: STREET DRUG ANALYSES.
167382 01-17

CLINICAL AND ELECTROMYOGRAPHIC RESEARCH CONCERNING TREATMENT OF PERIPHERAL NEUROPATHIES WITH NIVALASI.
168975 01-13

PSYCHOPHARMACOLOGICAL RESEARCH: SOME METHODOLOGICAL PROBLEMS.
169932 01-06

RESEARCH ON SUPERSENSITIVE LABORATORY METHODS IN SWEDEN.
170302 01-06

CLINICAL RESEARCH ASPECTS OF PSYCHOTROPIC MEDICATION.
170754 01-17

SLEEP RESEARCH. A CRITICAL REVIEW.
172615 01-11

A METHOD OF QUANTIFYING EEG FOR PSYCHOPHARMACOLOGICAL RESEARCH.
174135 01-16

RESULTS OF CLINICAL RESEARCH IN PSYCHOTHERAPY WITH HALLUCINOGENS.
180145 02-12

THE STANDARDIZED VIDEOTAPE INTERVIEW AS AN OBJECTIVE DEPENDENT VARIABLE IN PSYCHOTROPIC DRUG RESEARCH.
183635 03-17

NEUROPHYSIOLOGICAL RESEARCH IN PSYCHIATRY AND ITS RELATIONSHIP TO PSYCHOPHARMACOLOGY.
183693 03-17

LITHIUM: ITS ROLE IN PSYCHIATRIC RESEARCH AND TREATMENT.
186920 03-09

INSTITUTE OF PSYCHIATRY CLINICAL PSYCHOPHARMACOLOGY RESEARCH TEAM.
187022 03-17

IN APPRECIATION OF BASIC BIOCHEMICAL RESEARCH IN MENTAL HEALTH. (UNPUBLISHED PAPER).
187488 04-17

THE EFFICACY OF ANTIDEPRESSANT DRUGS: A REVIEW OF RESEARCH (1958 TO 1972).
191857 04-09

RESERPINE

CARDIOVASCULAR EFFECTS OF RESERPINE, YOHIMBINE, AND RESERPINE YOHIMBINE MIXTURES ON INTACT ANESTHETIZED DOG.
167328 01-03

ELECTROCARDIOGRAPHIC CHANGES IN HYPERTHYROIDISM AFTER ADRENERGIC BLOCKADE WITH RESERPINE AND PROPRANOLOL.
167460 01-13

THE UPTAKE, RETENTION AND METABOLISM OF 3H-5-HYDROXYTRYPTAMINE IN BRAIN SLICES AND ILEUM FROM THE RAT: EFFECTS OF COCAINE, DESMETHYLIMIPRAMINE AND RESERPINE. (PH.D. DISSERTATION).
168131 01-03

POSSIBLE INVOLVEMENT OF CYCLIC NUCLEOTIDES IN THE STIMULATION OF PITUITARY FUNCTION ELICITED BY RESERPINE. (UNPUBLISHED PAPER).
170086 01-03

COMPARATIVE EFFECTS OF 6-HYDROXYDOPAMINE AND OF RESERPINE ON OUABAIN TOXICITY IN THE RAT.
172598 01-05

INCREASED AXOPLASMIC TRANSPORT OF H3-DOPAMINE IN NIGRO-NEOSTRIATAL NEURONS AFTER RESERPINE.
175241 02-03

EFFECTS OF CHRONIC PRETREATMENT WITH SMALL DOSES OF RESERPINE UPON ADRENERGIC NERVE FUNCTION.
177406 02-03

DREAM REPORTS AFTER RESERPINE ADMINISTRATION IN CHRONIC LOBOTOMIZED SCHIZOPHRENIC PATIENTS.
178187 02-08

MECHANISM OF RELEASE AT NORADRENERGIC NERVE TERMINALS BY RESERPINE AND SEVERAL SYMPATHOMIMETIC AGENTS. (UNPUBLISHED PAPER).
178747 02-03

TRANSPORT OF SYNAPTOSOMAL TRYPTOPHAN AND CEREBRAL TYROSINE: INCREASE IN THE SPEED OF UPTAKE OF RESERPINE OR THE INHIBITION OF MONOAMINE OXIDASE.
179988 02-13

INFLUENCES OF RESERPINE AND CHLORPROMAZINE ON THE ANALGESIC AND METABOLIC EFFECTS OF MORPHINE.
180507 02-03

THE EFFECTS OF INTRAVENTRICULARLY ADMINISTERED CATECHOLAMINES AND SEROTONIN ON THE RESERPINE INDUCED SPIKE WAVES RECORDED FROM THE MEDICAL NUCLEUS TRAPEZOIDES IN THE RABBIT.
182094 02-03

EVIDENCE FOR PERSISTENT RESERPINE BINDING TO AMINE STORAGE VESICLE MEMBRANES.
182234 03-03

EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: I. EFFECT ON THE BEHAVIOURAL CHANGES INDUCED BY RESERPINE, ALPHA-METHYL-P-TYROSINE OR AMPHETAMINE.
186587 03-04
EVIDENCE FOR A CRITICAL PERIOD FOR POSTNATAL ELEVATION OF BRAIN TYROSINE HYDROXYLASE ACTIVITY RESULTING FROM RESERPINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT.
186695 03-03
ALTERATION OF EVOKED POTENTIALS IN CAUDATE NUCLEUS OF FREELY MOVING RATS BY L-DOPA, RESERPINE, AND PENTOBARBITAL.
187362 04-03
THE EFFECTS OF CHRONIC RESERPINE AND NIALAMIDE TREATMENT ON THE FREE AMINO ACID LEVELS OF RAT BRAIN.
187645 04-03
SELECTIVE RESERPINE RESISTANT ACCUMULATION OF CATECHOLAMINES IN CENTRAL DOPAMINE NEURONES AFTER DOPA ADMINISTRATION.
189026 04-03
NORADRENALINE IN THE GUINEA-PIG ALIMENTARY CANAL: REGIONAL DISTRIBUTION AND SENSITIVITY TO DENERVATION AND RESERPINE.
191326 04-03

RESERPINIZED
APOMORPHINE INDUCED BITING AND FIGHTING BEHAVIOUR IN RESERPINIZED RATS AND AN APPROACH TO THE MECHANISM OF ACTION.
174768 01-04

RESERVE
FUNCTIONAL EVALUATION OF PITUITARY RESERVE IN PATIENTS WITH THE AMENORRHEA GALACTORRHEA SYNDROME UTILIZING LUTEINIZING HORMONE RELEASING HORMONE (LH-RH), L-DOPA AND CHLORPROMAZINE.
175245 02-13
SELF-STIMULATION AND CATECHOLAMINES: DRUG-INDUCED MOBILIZATION OF THE RESERVE POOL RE-ESTABLISHES RESPONDING IN CATECHOLAMINE DEPLETED RATS.
189025 04-04

RESERVOIR
SKELETAL MUSCLE: RESERVOIR FOR EXOGENOUS L-DOPA.
191771 04-03

RESIDUAL
THE RESIDUAL EFFECTS OF FLURAZEPAM.
168831 01-14
EFFICACY AND RESIDUAL EFFECT EVALUATION OF A NEW HYPNOTIC, TRIAZOLAM.
176108 02-13
THE RESIDUAL EFFECTS OF N-DESMETHYLDIAZEPAM IN PATIENTS.
190336 04-11

RESILIENCE
RESILIENCE OF FAMILY PROCESS: EFFECT OF SECOBARBITAL.
189743 04-14

RESISTANCE
JOINT EFFECTS OF SODIUM AMYLOBARBITONE AND AMPHETAMINE SULPHATE ON RESISTANCE TO EXTINCTION OF A REWARDED RUNNING RESPONSE IN THE RAT.
186573 03-04

RESISTANT
THE EFFECTS OF PHYSOSTIGMINE IN PHENOTHIAZINE RESISTANT CHRONIC SCHIZOPHRENIC PATIENTS: PRELIMINARY OBSERVATIONS.
177669 02-08
SELECTIVE RESERPINE RESISTANT ACCUMULATION OF CATECHOLAMINES IN CENTRAL DOPAMINE NEURONES AFTER DOPA ADMINISTRATION.
189026 04-03

RESONANCE
CONFORMATIONAL ANALYSIS OF ACRIDAN DERIVATIVES BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY. A RELATIONSHIP BETWEEN CONFORMATION AND PHARMACOLOGICAL ACTIVITY.
190715 04-01

RESPIRATION
THE CURARIZED RAT AND HEART RATE CONDITIONING: A CONSIDERATION OF RESPIRATION PARAMETERS AND NEUROMUSCULAR BLOCKING AGENTS IN A CLASSICAL CONDITIONING PARADIGM. (PH.D. DISSERTATION).
173133 01-03
ANTICONVULSANT ACTIVITY AND INHIBITION OF RESPIRATION IN RAT BRAIN HOMOGENATES BY SUBSTITUTED OXADIAZOLES.
185980 03-01

RESPIRATORY
SOME ASPECTS OF RESPIRATORY CONTROL IN NEUROLEPTOANALGESIA.
172835 01-03
THE EFFECT OF DIAZEPAM ON SOME CARDIOVASCULAR AND RESPIRATORY REFLEXES ELICITED BY AFFERENT ABDOMINAL VAGUS STIMULATION.
178945 02-03
SELECTIVE RESPIRATORY STIMULATING ACTION OF DOXAPRAM COMPARED TO PENTYLENETETRAZOL.
183887 03-03

RESPONDERS
ELECTRODERMAL ACTIVITY IN HYPERACTIVE BOYS WHO ARE METHYLPHENIDATE RESPONDERS.
191400 04-14

RESPONSE
THE EFFECTS OF L-DELTA9-TRANS-TETRAHYDROCANNABINOL ON LOW AND HIGH RESPONSE RATES GENERATED UNDER TWO SIMILAR CONDITIONS (PH.D. DISSERTATION).
168230 01-04
THE POSSIBLE ROLE OF METABOLITES IN THERAPEUTIC RESPONSE TO CHLORPROMAZINE TREATMENT.
168836 01-08
LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND GAMMA-AMINOBUTYRIC ACID (GABA) INTERACTION ON SPONTANEOUS POTENTIALS AND THE EVOKED RESPONSE IN THE AVIAN TECTUM.
169689 01-03
ORTHOGONAL FACTORS VS. INTERDEPENDENT VARIABLES AS PREDICTORS OF DRUG TREATMENT RESPONSE IN ANXIOUS OUTPATIENTS.
171299 01-14
DEPRESSION SUBTYPES AND RESPONSE TO PHENELZINE, DIAZEPAM, AND A PLACEBO: RESULTS OF A NINE HOSPITAL COLLABORATIVE STUDY.
171502 01-09
HYDROXYLAMINE INTERFERES WITH THE BEHAVIORAL RESPONSE TO MORPHINE DEPENDENCE IN MICE.
171905 01-04
BEHAVIORAL PARAMETERS OF DRUG ACTION: SIGNALED AND RESPONSE INDEPENDENT REINFORCEMENT.
174008 01-04
A DOUBLE-BLIND TRIAL OF IPRINDOLE AND IMIPRAMINE IN DEPRESSIVES AND RESPONSE TO ECT IN REFRACTORY CASES.
174376 01-09
REINVESTIGATION ON THE EFFECTS OF THIOPENTAL ON THE HUMAN SOMATOSENSORY EVOKED RESPONSE.
174505 01-13
THE EFFECT OF DOPAMINE ANTAGONISTS AND AMANTADINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
174829 01-04
THE EFFECT OF PHASE-SHIFT ON THE PASSIVE AVOIDANCE RESPONSE IN RATS, AND THE MODIFYING EFFECT OF CHLORDIAZEPOXIDE.
174830 01-04
RELATIONSHIP BETWEEN RESPONSE TO LOW PENTAMETHYLENETETRAZOL ADMINISTRATION AND PERSONALITY OF JUVENILE OFFENDERS AND THEIR REPEATED CRIMES.
175072 02-17
THE BIOLOGICAL BASIS OF PSYCHOTICISM: A STUDY OF INDIVIDUAL DIFFERENCES IN RESPONSE TO DEXAMPHETAMINE.
175219 02-13
EFFECTS OF LOW DOSES OF CHLORPROMAZINE ON A CONDITIONED EMOTIONAL RESPONSE IN THE RAT.
176963 02-04
RESPONSE TO STIMULANT DRUG TREATMENT IN HYPERACTIVE CHILDREN: PREDICTION FROM EEG AND NEUROLOGICAL FINDINGS.
177778 02-11
OPEN-FIELD BEHAVIOR AND ACQUISITION OF DISCRIMINATIVE RESPONSE CONTROL IN DELTA9-THC TOLERANT RATS.
178813 02-04
TRIFLUPERIDOL -- THERAPEUTIC RESPONSE AND EXTRAPYRAMIDAL SYMPTOMS.
180248 02-15
LITHIUM DISTRIBUTION BETWEEN CEREBROSPINAL FLUID AND SERUM OF AFFECTIVE PSYCHOTIC PATIENTS TREATED WITH LITHIUM CARBONATE AND ITS CLINICAL RESPONSE.
180301 02-11
CHRONIC MEPROBAMATE INTOXICATION AND PHOTOMYOCLONIC RESPONSE.
181377 02-15
PREDICTION OF NEUROLEPTIC EFFECTS OF CI-686 BASED ON QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY: DRUG PROFILES AND DOSE RESPONSE CURVES BASED ON COMPUTERIZED CEREBRAL BIOPOTENTIALS.
181958 02-13
AMPHETAMINE AND PENTOBARBITAL EFFECTS ON THE DISCRIMINATIVE RESPONSE CONTROL BY DEPRIVATION OF RAPID EYE MOVEMENT SLEEP (REM).
182245 03-03
PHENELZINE, MOOD RESPONSE, AND SLEEP.
183547 03-09
PSYCHOPHYSIOLOGICAL PATTERNS OF RESPONSE IN SCHIZOPHRENIA.
183629 03-08
COMMENTS ON PAPER, PSYCHOPHYSIOLOGICAL PATTERNS OF RESPONSE IN SCHIZOPHRENIA.
183630 03-17
PLASMA LEVELS OF LUTEINIZING HORMONE AND OF IMMUNOREACTIVE ESTROGENS (ESTRADIOL) IN ANOREXIA-NERVOSA: RESPONSE TO CLOMIPHENE CITRATE.
183807 03-10
THE CONDITIONED EMOTIONAL RESPONSE (CER) AS A BASELINE FOR THE STUDY OF ANTIANXIETY DRUGS.
183862 03-04
A STUDY OF REFRACTORY CASES OF DEPRESSIVE ILLNESSES AND THEIR RESPONSE TO COMBINED ANTIDEPRESSANT TREATMENT.
185078 03-10

RESPONSE TO INCREMENTAL DOSES OF DITRAN IN ABSTINENT ALCOHOLICS AND DRUG USERS.
185875 03-11

DOSE DEPENDENT SELECTIVE FACILITATION OF RESPONSE CONTINGENT LIGHT ONSET BEHAVIOR BY D-AMPHETAMINE.
185955 03-04

FACTORS ASSOCIATED WITH LITHIUM RESPONSE IN THE PROPHYLACTIC TREATMENT OF BIPOLAR MANIC-DEPRESSIVE ILLNESS.
186188 03-09

JOINT EFFECTS OF SODIUM AMYLOBARBITONE AND AMPHETAMINE SULPHATE ON RESISTANCE TO EXTINCTION OF A REWARDED RUNNING RESPONSE IN THE RAT.
186573 03-04

THE EFFECT OF AMANTADINE, L-DOPA, (..) AMPHETAMINE AND APOMORPHINE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE.
186636 03-04

THE EFFECTS OF SOME DRUGS ON AN EVOKED RESPONSE SENSITIVE TO TETRAHYDROCANNABINOLS.
186666 03-03

LOCALIZED BEHAVIORAL EFFECTS OF VASOPRESSIN ON MAINTENANCE OF AN ACTIVE AVOIDANCE RESPONSE IN RATS.
187697 04-04

AMPHETAMINE AND OPERANT BEHAVIOR IN RATS: RELATIONSHIP BETWEEN DRUG EFFECT AND CONTROL RESPONSE RATE.
187699 04-04

EFFECTS OF GUANETHIDINE AND IMIDAZOLE ON HISTAMINE RESPONSE.
187799 04-03

RESPONSE TO PROPRANOLOL AND DIAZEPAM IN SOMATIC AND PSYCHIC ANXIETY.
188887 04-10

HALLUCINOGENIC DRUG-INDUCED BEHAVIOR UNDER SENSORY ATTENUATION: PREDICTION OF RESPONSE TO PSILOCYBIN.
189744 04-12

EFFECTS OF DELTA8-THC AND DELTA9-TETRAHYDROCANNABINOL ON THE IMMUNE RESPONSE IN MICE.
191960 04-03

STUDIES OF THE IMMUNE RESPONSE IN CHRONIC MARIHUANA SMOKERS.
191961 04-13

THE EFFECT OF CANNABINOID MIXTURES ON THE RESPONSE TO STIMULANT DRUGS IN MICE.
191991 04-04

RESPONSES

GROWTH HORMONE RESPONSES TO ADMINISTRATION OF L-5-HYDROXYTRYPTOPHAN (L-5-HTP) IN MANIC-DEPRESSIVE PSYCHOSES.
167919 01-09

AVERAGE EVOKED RESPONSES IN NORMAL AND MINIMALLY BRAIN DYSFUNCTIONED CHILDREN TREATED WITH AMPHETAMINE: A PRELIMINARY REPORT.
169861 01-11

ELECTROENCEPHALOGRAPHIC RESPONSES TO LITHIUM.
174132 01-14

INTERACTIVE EFFECTS OF CYCLOHEXIMIDE AND PUROMYCIN IN ALTERING BRAIN POLYRIBOSOMES AND NEURAL AND BEHAVIOURAL RESPONSES TO ELECTROSHOCK IN MICE.
175230 02-03

ACTION OF CONVULSANTS ON ROOT POTENTIALS AND AMINO ACID RESPONSES IN ISOLATED FROG SPINAL CORD. (UNPUBLISHED PAPER).
177976 02-03

ALTERATION OF SENSORY AND MOTOR EVOKED RESPONSES BY DIELDRIN.
181818 02-03

EFFECTS OF CONSECUTIVE ADMINISTRATION OF DIAZEPAM AND DOXEPIN ON BOTH APPROACH WITHDRAWAL AND APPROACH AVOIDANCE RESPONSES IN RATS.
182117 02-04

EFFECTS OF AMPHETAMINE ON ELECTROSHOCK RESPONSES IN DEVELOPING RATS.
184372 03-03

EFFECTS OF CHLORPROMAZINE AND THREE METABOLITES ON BEHAVIORAL RESPONSES IN RATS.
185748 03-04

EFFECTS OF CENTRALLY APPLIED DRUGS ON PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION.
185902 03-03

COMPARISON OF TRICYCLIC ANTIDEPRESSANTS IN RABBITS: ANTINOCICEPTION AND POTENTIATION OF THE NORADRENALINE PRESSOR RESPONSES.
186579 03-03

EEG DRIVING RESPONSES AS A FUNCTION OF MONOAMINE OXIDASE.
187149 03-13

COMPARISON OF PHARMACOLOGICAL RESPONSES TO NICOTINE AND RELEASE OF CATECHOLAMINES FROM THE ADRENALS IN DOGS AND MONKEYS.
188199 04-03

THE EFFECTS OF MORPHINE, ETORPHINE AND SINOMENINE ON THE CHEMICAL SENSITIVITY AND SYNAPTIC RESPONSES OF RENSHAW CELLS AND OTHER SPINAL NEURONES IN THE RAT.
188201 04-03

AFFECTIVE STATE AND THYROTROPIN AND PROLACTIN RESPONSES AFTER REPEATED INJECTIONS OF THYROTROPIN RELEASING HORMONE IN DEPRESSED PATIENTS.
189076 04-09

CHLOROFORM RESPONSES OF THE CHORDA TYMPANI NERVE IN THE RAT.
189219 04-03

EFFECTS OF PROSTAGLANDINS B1 AND B2 ON VASOCONSTRICTOR RESPONSES OF THE CANINE HINDPAW.
189395 04-03

THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. I. NEURONAL RESPONSES TO STIMULATION OF THE RETICULAR FORMATION.
189855 04-03

THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. II. COMPARISON OF THE NEURONAL RESPONSES TO RETICULAR AND OTHER STIMULI.
189856 04-03

STUDIES ON CONVULSANTS IN THE ISOLATED FROG SPINAL CORD. I. ANTAGONISM OF AMINO ACID RESPONSES. (UNPUBLISHED PAPER)
190727 04-03

PHOTIC RESPONSES IN MINIMAL BRAIN DYSFUNCTION.
191188 04-15

ACTION OF HALOPERIDOL AND TRIFLUOPERAZINE ON THE MOTOR RESPONSES ELICITED BY ELECTRICAL STIMULATION OF THE BRAIN IN RABBITS.
191787 04-02

THE EFFECTS OF HOE-36801 ON MUSCLE ACTIVITY AND BLOOD PRESSURE, ON ATTENTION AND CONCENTRATION, ON TIME JUDGMENT AND SUBJECTIVE RESPONSES IN NEUROTICS AND NORMALS.
192429 04-14

RESPONSIVITY

WORD RECOGNITION OF SCHIZOPHRENICS AS A FUNCTION OF PHENOTHIAZINE LEVEL AND AUTONOMIC RESPONSIVITY. (PH.D. DISSERTATION).
182524 03-08

RESTRAINING

A LOOK AT RESTRAINING PRACTICES AND THE USE OF PSYCHOTROPIC DRUGS.
188533 04-17

RETARD

THE FIRST LONG-ACTING (RETARD) THYMOANALEPTIC OR ANTIDEPRESSANT: THE TIME-RELEASED DIBENZEPINE WITH PROLONGED ACTION.
178946 02-11

RETARDATION

DEVELOPMENT OF A VACCINE AGAINST MENTAL RETARDATION CAUSED BY CYTOMEGALOVIRUS INFECTION IN UTERO.
178549 02-11

RETARDATION OF TUMOR GROWTH BY DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC).
191963 04-03

RETARDED

MESORIDAZINE IN THE CARE OF DISTURBED MENTALLY RETARDED PATIENTS.
168315 01-11

SAFETY AND EFFECTIVENESS OF HALOPERIDOL FOR MENTALLY RETARDED BEHAVIORALLY DISORDERED AND HYPERKINETIC PATIENTS.
169634 01-11

TANTU-PASHAN AND LUCIDRIL THERAPY IN MENTALLY RETARDED CHILDREN.
175628 02-11

ANTIAGGRESSIVE EFFECT OF LITHIUM SALTS IN MENTALLY RETARDED ADOLESCENTS.
182435 03-11

EFFECTS OF CONCURRENT BEHAVIOR MODIFICATION AND CHLORPROMAZINE ADMINISTRATION IN MENTALLY RETARDED WOMEN. (PH.D. DISSERTATION).
185604 03-14

RETENTION

EFFECT OF L-ASPARAGINASE ON RETENTION OF MAZE LEARNING IN MICE.
167324 01-04

ACQUISITION AND RETENTION OF AVOIDANCE BEHAVIORS FOLLOWING SEPTAL LESIONS OR SCOPOLAMINE INJECTIONS IN RATS.
167401 01-04

THE UPTAKE, RETENTION AND METABOLISM OF 3H-5-HYDROXYTRYPTAMINE IN BRAIN SLICES AND ILEUM FROM THE RAT: EFFECTS OF COCAINE, DESMETHYLIMIPRAMINE AND RESERPINE. (PH.D. DISSERTATION).
168131 01-03

COCAINE, PEMOLINE AND AMPHETAMINE ON LEARNING AND RETENTION OF A DISCRIMINATION TEST IN MICE.
186705 03-04

EFFECTS OF CYCLOHEXIMIDE ON ACQUISITION AND RETENTION OF AVOIDANCE LEARNING IN THE RAT: RECOVERY OF MEMORY.
189215 04-04
MESCALINE FACILITATES RETENTION OF PASSIVE AVOIDANCE IN RATS.
190266 04-04

RETENTIVE
THE EFFECTS OF PENTYLENETETRAZOL (METRAZOL) ON A LEARNED TASTE AVERSION PRODUCED BY LITHIUM CHLORIDE: THE ISSUE OF ASSOCIATIVE MEMORY VS. RETENTIVE MEMORY. (UNPUBLISHED PAPER).
188251 04-04

RETICULAR
THE ACTION OF D-AMPHETAMINE ON SPONTANEOUS ACTIVITY IN THE CAUDATE NUCLEUS AND RETICULAR FORMATION OF THE RAT.
185264 03-03
THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. I. NEURONAL RESPONSES TO STIMULATION OF THE RETICULAR FORMATION.
189855 04-03
THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. II. COMPARISON OF THE NEURONAL RESPONSES TO RETICULAR AND OTHER STIMULI.
189856 04-03

RETICULOCEREBELLAR
5-HYDROXYTRYPTAMINE AND HISTAMINE EFFECTS ON RETICULOCEREBELLAR EVOKED POTENTIALS.
182121 02-03

RETINA
EFFECT OF 6-HYDROXYDOPAMINE ON DARK ADAPTATION IN THE RAT RETINA.
167358 01-03
OSCILLATORY POTENTIALS OF THE CAT RETINA: EFFECTS OF ADRENERGIC DRUGS.
172916 01-03

RETRIEVAL
THE NATURE OF STORAGE DEFICITS AND STATE-DEPENDENT RETRIEVAL UNDER MARIHUANA.
189406 04-14

RETROGRADE
RETROGRADE AMNESIA FROM HYPOTHERMIA INDUCED BRAIN SEIZURES.
167398 01-04

RETROSPECTIVE
LSD...AN IN VIVO RETROSPECTIVE CHROMOSOME STUDY.
181811 02-13

REUPTAKE
COMPARATIVE EFFECTS OF DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE ON CATECHOLAMINE RELEASE AND REUPTAKE IN VITRO.
186671 03-03

REVERSAL
CHOLINERGIC REVERSAL OF MANIC SYMPTOMS: A POSSIBLE EXPLANATION. (UNPUBLISHED PAPER).
173520 01-09
ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN DIMETHYLAMINOPROPYLTHIOCINNAMANILIDE HYDROCHLORIDE), A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN (5-HTP) AND ALPHA-METHYLTRYPTAMINE.
176861 02-04
ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN, A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN AND ALPHA-METHYLTRYPTAMINE.
176873 02-04
EFFECTS OF OVERTRAINING AND PRETRIAL ADMINISTRATION OF DEXTROAMPHETAMINE ON REVERSAL LEARNING IN RATS.
177533 02-04
CALCIUM REVERSAL OF NERVE BLOCKADE BY ALCOHOLS, ANESTHETICS, TRANQUILIZERS, AND BARBITURATES.
187802 04-03

REVIEW
CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG, TRAZODONE: A REVIEW OF LITERATURE.
168803 01-11
CHEMOTHERAPY IN CHRONIC ORGANIC BRAIN SYNDROME - A REVIEW OF THE LITERATURE.
169065 01-11
SLEEP RESEARCH. A CRITICAL REVIEW.
172615 01-11
WITHDRAWAL OF MAINTENANCE DRUGS WITH LONG-TERM HOSPITALIZED MENTAL PATIENTS: A CRITICAL REVIEW.
175862 02-17
THE PROPERTIES OF 3,4 METHYLENEDIOXYAMPHETAMINE (MDA). I. A REVIEW OF THE LITERATURE.
176597 02-17
A REVIEW OF THE USE OF LSD FOR THE PATIENT NEAR DEATH.
177681 02-12
LITHIUM IN PSYCHIATRIC THERAPY AND PROPHYLAXIS. A REVIEW WITH SPECIAL REGARD TO ITS USE IN CHILDREN.
182433 03-09
THE NEUROPHARMACOLOGY OF AGGRESSION: A CRITICAL REVIEW.
183615 03-14
THE EFFECT OF PAIN RELIEVING DRUGS ADMINISTERED DURING LABOR AND DELIVERY ON THE BEHAVIOR OF THE NEWBORN: A REVIEW.
183706 03-17
THE ADMINISTRATION OF METHIONINE TO CHRONIC SCHIZOPHRENIC PATIENTS: A REVIEW OF TEN STUDIES.
187113 03-08
THE EFFICACY OF ANTIDEPRESSANT DRUGS: A REVIEW OF RESEARCH (1958 TO 1972).
191857 04-09

REWARD
MODULATION OF REWARD AND AVERSION PROCESSES IN THE RAT DIENCEPHALON BY AMPHETAMINE.
186164 03-04
ROLE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN IN INTRACRANIAL REWARD.
191527 04-04

REWARDED
JOINT EFFECTS OF SODIUM AMYLOBARBITONE AND AMPHETAMINE SULPHATE ON RESISTANCE TO EXTINCTION OF A REWARDED RUNNING RESPONSE IN THE RAT.
186573 03-04

REWARDING
THE THALAMIC RAT: GENERAL BEHAVIOR, OPERANT LEARNING WITH REWARDING HYPOTHALAMIC STIMULATION, AND EFFECTS OF AMPHETAMINE.
177477 02-04

RHESUS
3H-DELTA9-TETRAHYDROCANNABINOL (THC) METABOLISM IN RHESUS AND SQUIRREL MONKEYS.
175751 02-03
COMPARISON OF ANTICONVULSANT EFFECTS OF CLORAZEPATE DIPOTASSIUM AND DIAZEPAM: FOUR WEEK ANTICONVULSANT STUDY IN RHESUS MONKEYS.
176677 02-03
NEGATIVE REINFORCING PROPERTIES OF MORPHINE ANTAGONISTS IN NAIVE RHESUS MONKEYS.
177719 02-04
PENTAZOCINE IN RHESUS MONKEY PLASMA AND BRAIN AFTER PARENTERAL AND ORAL ADMINISTRATION.
178641 02-03
EFFECTS OF MORPHINE, CODEINE AND NALOXONE ON FOOD AND CODEINE REINFORCED RESPONDING IN THE RHESUS MONKEY.
182195 02-04
EVALUATION OF REINFORCING CAPABILITY OF DELTA9-TETRAHYDROCANNABINOL IN RHESUS MONKEYS.
187638 04-04
PERSISTENT ELECTROENCEPHALOGRAPHIC CHANGES IN RHESUS MONKEYS AFTER SINGLE DOSES OF PENTOBARBITAL, NITRAZEPAM AND IMIPRAMINE.
187931 04-03
ORAL AND INTRAVENOUS TOXICITY OF DELTA9-TETRAHYDROCANNABINOL IN RHESUS MONKEYS.
188872 04-05
CRUDE MARIHUANA EXTRACT: EEG AND BEHAVIORAL EFFECTS OF CHRONIC ORAL ADMINISTRATION IN RHESUS MONKEYS.
189516 04-04
STRUCTURAL RELATIONSHIP BETWEEN META-SUBSITUTED N-ETHYLAMPHETAMINES AND SELF-ADMINISTRATION IN RHESUS MONKEYS.
191915 04-04
INTRAGASTRIC SELF-ADMINISTRATION OF PSYCHOACTIVE DRUGS IN THE RHESUS MONKEY.
191939 04-04
A PHARMACOLOGICAL MODEL WITH RHESUS MONKEYS FOR THE PREDICTION OF SELECTIVE DEPRESSION OF PSYCHIC FUNCTIONS.
192424 04-04

RHEUMATICA
POLYMYALGIA RHEUMATICA IN A GERIATRIC DEPARTMENT: NINE PATIENTS WITH AN AVERAGE AGE OF 83 YEARS.
187236 03-11

RHYTHM
DAILY RHYTHM IN BODY TEMPERATURE OF MENTAL PATIENTS: APPLICATION OF COSINOR METHOD -- FIRST REPORT.
191685 04-17

RHYTHMS
EFFECTS OF LSD-25 AND DEXTROAMPHETAMINE ON SPEECH RHYTHMS IN PSYCHOTHERAPY DIALOGUES.
168420 01-12
EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON THE RHYTHMS OF WAKEFULNESS SLEEP CYCLE IN RATS.
182553 03-04
EFFECTS OF METHAMPHETAMINE ON DAILY RHYTHMS OF HYPOTHALAMIC NOREPINEPHRINE, SEROTONIN AND PLASMA CORTICOSTERONE LEVELS IN THE RAT.
184178 03-03

CHANGES IN RHYTHMS OF BIOELECTRICAL ACTIVITY OF THE CEREBRAL CORTEX IN HUMANS UNDER THE INFLUENCE OF ETHYMISOL.
191790 04-07
THE EFFECTS OF AMPHETAMINE SULFATE ON THE DIURNAL RHYTHMS OF MIDBRAIN; CORTEX, NOREPINEPHRINE; SEROTONIN AND BLOOD GLUCOSE LEVELS IN THE MOUSE.
191918 04-03

RIBAMINOL
LACK OF EFFECT OF RIBAMINOL, TCAP, AND MAGNESIUM PEMOLINE ON RECOVERY FROM NEOCEREBELLAR DAMAGE.
171904 01-03

RIBONUCLEIC
MESCALINE INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON THE BINDING OF AMINOACYL TRANSFER RIBONUCLEIC ACID TO RIBOSOMES OF BRAIN TISSUE.
189582 04-05

RIBOSOMAL
BRAIN RIBOSOMAL RNA SYNTHESIS INHIBITED BY CHLORPROMAZINE.
177835 02-03

RIBOSOMES
THE EFFECT OF CANNABINOIDS ON THE NUMBER OF NUCLEAR MEMBRANE ATTACHED RIBOSOMES IN INFANT RAT BRAIN.
183228 03-03
MESCALINE INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON THE BINDING OF AMINOACYL TRANSFER RIBONUCLEIC ACID TO RIBOSOMES OF BRAIN TISSUE.
189582 04-05

RIGHT
PAROXYSMAL RIGHT LEFT DISORIENTATION IN AN EPILEPTIC PATIENT.
171246 01-11

RIGHTING
CANNABINOIDS AND HEXOBARBITAL INDUCED LOSS OF RIGHTING REFLEXES.
189573 04-04

RIGID
HUNTINGTONS CHOREA: THE RIGID FORM (WESTPHAL VARIANT) TREATED WITH LEVODOPA.
187618 04-11

RITALIN
RITALIN FOR SCHOOL CHILDREN: THE TEACHERS PERSPECTIVE.
178127 02-17
A STUDY OF THE EFFECTS OF RITALIN INTERVENTION UPON THE PERCEPTUAL COMPETENCIES OF CHILDREN DIAGNOSED AS GIVING EVIDENCE OF PSYCHONEUROLOGICAL LEARNING DISABILITIES. (PH.D. DISSERTATION).
186833 03-14

RNA
BRAIN RIBOSOMAL RNA SYNTHESIS INHIBITED BY CHLORPROMAZINE.
177835 02-03
SOLUBILIZATION AND PURIFICATION OF BRAIN RNA POLYMERASE.
180537 02-06
EFFECTS OF LITHIUM ON CEREBRAL RNA METABOLISM IN VITRO AND IN VIVO.
181942 02-03
EFFECT OF SEIZURES AND ANTICONVULSANT AGENTS ON HIPPOCAMPAL RNA CONCENTRATION.
189609 04-03

RO-4-1284
EFFECTS OF DOPAMINE RECEPTOR STIMULATION AND BLOCKADE ON RO-4-1284 INDUCED ENHANCEMENT OF ELECTROSHOCK SEIZURE.
167287 01-03
IN VIVO MEASUREMENT OF THE RELEASE OF 5-HYDROXYTRYPTAMINE (5-HT) FROM THE HIPPOCAMPUS OF THE RAT: EFFECT OF RO-4-1284, PARGYLINE AND P-CHLOROAMPHETAMINE (PCA).
182140 02-03
INTERACTIONS BETWEEN RO-4-1284 AND D-AMPHETAMINE (DA) ON SHUTTLEBOX AVOIDANCE IN RATS.
192009 04-04

RO-4-4602
DOSE DEPENDENT POTENTIATION OR INHIBITION BY RO-4-4602 OF 5-HTP HYPERTHERMIA IN RABBITS.
185996 03-03
RO-4-4602 AND LEVODOPA IN THE TREATMENT OF PARKINSONISM.
188561 04-11

RO-5-3350
BEHAVIORAL PHARMACOLOGY OF BROMAZEPAM (RO-5-3350), A NEW BENZODIAZEPINE DERIVATIVE.
181384 02-04

RO-5-4200
CONTROL OF INSOMNIA WITH A NEW BENZODIAZEPINE: THE FLUNITRAZEPAM OR RO-5-4200 (FIRST INVESTIGATIONS OF PHASE I AND CONTROLLED INVESTIGATIONS OF PHASE II).
183198 03-11
FLUNITRAZEPAM (RO-5-4200) AND SLEEP CYCLE IN INSOMNIAC PATIENTS.
186574 03-11

RO-8-4192
ANTICONVULSANT ACTIVITY OF CLONAZEPAM AND RO-8-4192 AGAINST PENICILLIN AND LIDOCAINE INDUCED SEIZURES.
178947 02-03

RODENTS
PROPRANOLOL AND CHLORDIAZEPOXIDE ON EXPERIMENTALLY INDUCED CONFLICT AND SHUTTLEBOX PERFORMANCE IN RODENTS.
171304 01-04

ROLE
THE ROLE OF RESEARCH IN DRUG ABUSE INTERVENTION: STREET DRUG ANALYSES.
167382 01-17
THE ROLE OF DOPAMINE IN DEPRESSION.
167584 01-13
THE POSSIBLE ROLE OF METABOLITES IN THERAPEUTIC RESPONSE TO CHLORPROMAZINE TREATMENT.
168836 01-08
ROLE OF FLUPHENAZINE DECANOATE IN LESSENING THE BURDEN OF CHRONIC SCHIZOPHRENICS ON THE COMMUNITY.
169438 01-08
ON PHARMACO-PSYCHOTHERAPY; THE ROLE OF THE PSYCHOTHERAPEUTIC SITUATION IN PSYCHOTROPIC MEDICATION.
170415 01-11
THE ROLE OF CYCLIC 3,5 ADENOSINE MONOPHOSPHATE IN NEUROMUSCULAR TRANSMISSION.
170660 01-13
DIAZEPAM AND POST-TETANIC POTENTIATION: POSS!BLE ROLE OF PROSTAGLANDINS. (UNPUBLISHED PAPER).
170748 01-03
THE ROLE OF THE SEPTAL AREA OF THE BRAIN IN THE INHIBITORY MODULATION OF BEHAVIOR. (PH.D. DISSERTATION).
172021 01-03
ON THE MECHANISM OF CENTRAL ACTION OF AMPHETAMINE: THE ROLE OF CATECHOLAMINES.
172921 01-04
THE ROLE OF MONOAMINE OXIDASE IN TERMINATING THE REFLEX EFFECTS OF P-METHOXYPHENYLETHYLAMINE (PMPEA).
174319 01-03
THE ROLE OF HYDROPHOBICITY IN THE ANTISEROTONIN ACTIVITY OF LSD ANALOGS.
174606 01-12
AMPHETAMINE TRICYCLIC INTERACTIONS: ROLE OF THE HYDROXYLATION OF AMPHETAMINE IN ITS CENTRAL AND PERIPHERAL MODE OF ACTION. (PH.D. DISSERTATION).
174963 01-03
A ROLE OF THE DIETARY LIPID IN THE ABILITY OF PHENOBARBITAL TO STIMULATE DRUG DETOXIFICATION.
175859 02-03
ROLE OF ASSOCIATIVE LEARNING IN FEEDING BEHAVIOR.
178044 02-17
THE ROLE OF CHEMOTHERAPY IN MANAGING POTENTIALLY SUICIDAL PATIENTS.
178544 02-10
ROLE OF 5-HT IN THE ACTION OF SOME DRUGS AFFECTING EXTRAPYRAMIDAL SYSTEM.
178757 02-04
FURTHER EVIDENCE FOR A ROLE OF 2-PHENYLETHYLAMINE IN THE MODE OF ACTION OF DELTA9-TETRAHYDROCANNABINOL.
179992 02-03
RECOVERY OF FEEDING AFTER 6-HYDROXYDOPAMINE (6-HDA) OR LATERAL HYPOTHALAMIC LESIONS: THE ROLE OF CATECHOLAMINES.
182213 03-03
MECHANISMS UNDERLYING POTENTIATION OF BARBITURATE ACTION BY SODIUM NITRITE IN THE MOUSE: THE ROLE OF METHEMOGLOBIN INDUCED HYPOXIA.
182721 03-03
ROLE OF THE CENTRAL AUTONOMIC NERVOUS SYSTEM IN THE HYPOTENSION AND BRADYCARDIA INDUCED BY (-) DELTA9-TETRAHYDROCANNABINOL.
183795 03-03
ENHANCED RENAL TUBULAR SECRETION OF MEPROBAMATE: ROLE OF SALINE FUROSEMIDE DIURESIS.
184243 03-03
NEUROCHEMICAL ROLE OF ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AND GUANOSINE 3,5 CYCLIC MONOPHOSPHATE AND THEIR RELATION TO NEUROTRANSMITTERS; EFFECT OF TETRAHYDROCANNABINOLS. (PH.D. DISSERTATION).
185582 03-03
CATALEPSY INDUCED BY ALPHA-METHYL-P-TYROSINE AND D-AMPHETAMINE: THE ROLE OF CATECHOLAMINE METABOLISM.
185750 03-03
A COMPARISON OF THE EFFECTS OF CHRONIC ADMINISTRATION OF ETHANOL AND ACETALDEHYDE TO MICE: EVIDENCE FOR A ROLE OF ACETALDEHYDE IN ETHANOL DEPENDENCE.
185992 03-03
THE POSSIBLE ROLE OF TRYPTAMINE IN BRAIN FUNCTION AND ITS RELATIONSHIP TO THE ACTIONS OF LSD-LIKE HALLUCINOGENS.
186024 03-12

A ROLE FOR THE AMYGDALA IN THE DEVELOPMENT OF THE CATALEPTIC AND STEREOTYPIC ACTIONS OF THE NARCOTIC AGONISTS AND ANTAGONISTS IN THE RAT.
186577 03-03

ROLE OF CATECHOLAMINES IN THE ANORECTIC EFFECTS OF AMPHETAMINE IN RATS.
186582 03-03

DIAZEPAM INHIBITION OF POST-TETANIC POTENTIATION IN BULLFROG SYMPATHETIC GANGLIA: POSSIBLE ROLE OF PROSTAGLANDINS.
186673 03-03

A ROLE FOR NICOTINIC RECEPTORS IN THE REGULATION OF THE ADENYLATE CYCLASE OF ADRENAL MEDULLA.
186675 03-03

LITHIUM: ITS ROLE IN PSYCHIATRIC RESEARCH AND TREATMENT.
186920 03-09

EVIDENCE FOR AN INHIBITORY ROLE FOR ACETYLCHOLINE, CATECHOLAMINES, AND SEROTONIN ON THE CEREBRAL CORTEX.
187552 04-03

ROLE OF DOPAMINERGIC MECHANISMS IN REGULATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN MAN.
188428 04-13

BETA-ADRENERGIC EFFECTS ON RAT MYOMETRIUM: ROLE OF CYCLIC AMP.
188915 04-03

THE ROLE OF GAMMA-AMINOBUTYRIC ACID AS A MEDIATOR OF POSITIVE DORSAL ROOT POTENTIALS.
189832 04-03

CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE METABOLITE, NORFENFLURAMINE: AN EVALUATION OF ITS ROLE IN THE ACTIONS OF FENFLURAMINE.
190335 04-04

ROLE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN IN INTRACRANIAL REWARD.
191527 04-04

ROLE OF ACETYLCHOLINE AND DOPAMINE IN MANIC BEHAVIOR.
191532 04-09

DIMETHYLTRYPTAMINE: ITS BIOSYNTHESIS AND POSSIBLE ROLE IN MENTAL DISEASE.
191535 04-12

A ROLE FOR DOPAMINE IN THE STIMULANT EFFECTS OF AMPHETAMINE ON LOCUS-COERULEUS SELF-STIMULATION.
191984 04-03

ROLES
PREVENTION OF ALCOHOL WITHDRAWAL SEIZURES: THE ROLES OF DIPHENYLHYDANTOIN AND CHLORDIAZEPOXIDE.
172275 01-11

ROOT
ACTION OF CONVULSANTS ON ROOT POTENTIALS AND AMINO ACID RESPONSES IN ISOLATED FROG SPINAL CORD. (UNPUBLISHED PAPER).
177976 02-03

LIPIDOSIS-LIKE ALTERATIONS IN DORSAL ROOT GANGLION CELLS OF RATS TREATED WITH TRICYCLIC ANTIDEPRESSANTS.
189605 04-03

THE ROLE OF GAMMA-AMINOBUTYRIC ACID AS A MEDIATOR OF POSITIVE DORSAL ROOT POTENTIALS.
189832 04-03

ROUTE
DELTA9-TETRAHYDROCANNABINOL: EFFECTS OF ROUTE OF ADMINISTRATION ON ONSET AND DURATION OF ACTIVITY AND TOLERANCE DEVELOPMENT.
187928 04-03

RUBIDIUM
RUBIDIUM SALTS: BASIC MECHANISMS OF ACTION.
182441 03-03

RUBIDIUM SALTS -- ANIMAL TOXICITY STUDIES.
182442 03-05

RUBIDIUM SALTS -- TOXIC EFFECTS IN HUMANS AND CLINICAL EFFECTS AS AN ANTIDEPRESSANT DRUG.
182443 03-09

RUNWAY
INVERSION BY APOMORPHINE OF THE TENDENCY OF FEMALE RATS TO BE DEFEATED BY MALES WHEN COMPETING FOR FOOD IN A STRAIGHT RUNWAY.
184212 03-04

THE INFLUENCE OF 3-QUINUCLIDINYLBENZILATE ON THE BEHAVIOUR OF RATS IN A CIRCULAR RUNWAY.
187259 04-04

RUTHENIUM
NEOMYCIN AND RUTHENIUM RED ANTAGONISM OF MONOAMINERGIC DEPRESSION OF CEREBRAL CORTICAL NEURONES.
191380 04-03

R6218
CLINICAL EXPERIMENT WITH A LONG-ACTING NEUROLEPTIC: FLUSPIRILENE (R6218).
183200 03-15

S-ADENOSYLHOMOCYSTEINE
POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES: 1. MODIFICATION OF THE AMINO ACID PORTION OF S-ADENOSYLHOMOCYSTEINE.
190716 04-01

POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES. 2. MODIFICATION OF THE BASE PORTION OF S-ADENOSYLHOMOCYSTEINE.
190717 04-01

S-ADENOSYLMETHIONINE
POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES: 1. MODIFICATION OF THE AMINO ACID PORTION OF S-ADENOSYLHOMOCYSTEINE.
190716 04-01

POTENTIAL INHIBITORS OF S-ADENOSYLMETHIONINE DEPENDENT METHYLTRANSFERASES. 2. MODIFICATION OF THE BASE PORTION OF S-ADENOSYLHOMOCYSTEINE.
190717 04-01

S-TRIAZOLOBENZODIAZEPINE
DISSOCIATIVE CHANGE IN ANTIAGGRESSIVE AND MUSCLE RELAXANT ACTIONS OF S-TRIAZOLOBENZODIAZEPINE (D-40TA) BY REPEATED ADMINISTRATION AND PHENOBARBITAL PRETREATMENT, AND ITS RELATION TO METABOLISM.
181654 02-04

SACCHARIN
CONDITIONED HYPOGLYCEMIA: A MECHANISM FOR SACCHARIN INDUCED SENSITIVITY TO INSULIN IN THE RAT.
174877 01-03

SAE
THE SPIRAL AFTEREFFECT (SAE) AS A MEASURE OF MOTION SICKNESS SUSCEPTIBILITY AND THE EFFECT ON THE SAE OF AN ANTIMOTION SICKNESS DRUG AND A CENTRAL NERVOUS SYSTEM DEPRESSANT.
172780 01-03

SAFER
ARE THERE SAFER HYPNOTICS THAN BARBITURATES?
174561 01-15

SAFETY
THE SAFETY TEST OF 10-CHLORO-11B-(2-CHLOROPHENYL) 2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE (CS-370): SECOND REPORT, EFFECT OF CS-370 UPON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
168498 01-05

SAFETY AND EFFECTIVENESS OF HALOPERIDOL FOR MENTALLY RETARDED BEHAVIORALLY DISORDERED AND HYPERKINETIC PATIENTS.
169634 01-11

SAFETY EVALUATION OF PENFLURIDOL, A NEW LONG-ACTING ORAL ANTIPSYCHOTIC AGENT.
177319 02-07

SAFETY AND EFFICACY OF ZINC SULFATE IN GERIATRIC PATIENTS.
184177 03-11

SALICYLATE
ANALGESIC POTENCY OF SODIUM SALICYLATE, INDOMETHACIN, AND CHLORDIAZEPOXIDE AS MEASURED BY THE SPATIAL PREFERENCE TECHNIQUE IN THE RAT.
171301 01-02

SALIGENIN
SALIGENIN ANALOGS OF L-DOPA AND DL-ALPHA-METHYL-DOPA.
187565 04-11

SALINE
EFFECT OF CHRONIC POSTTRIAL SALINE INJECTIONS ON MAZE PERFORMANCE.
167403 01-04

ENHANCED RENAL TUBULAR SECRETION OF MEPROBAMATE: ROLE OF SALINE FUROSEMIDE DIURESIS.
184243 03-03

THE EFFECTS OF EARLY SALINE INJECTIONS AND PENTYLENETETRAZOL ON HEBB-WILLIAMS MAZE PERFORMANCE IN THE ADULT RAT.
191378 04-04

SALIVA
VALIDITY OF SCREENING METHODS FOR DRUGS OF ABUSE IN BIOLOGICAL FLUIDS. II. HEROIN IN PLASMA AND SALIVA.
187256 03-15

SALTS
ANTIAGGRESSIVE EFFECT OF LITHIUM SALTS IN MENTALLY RETARDED ADOLESCENTS.
182435 03-11

RUBIDIUM SALTS: BASIC MECHANISMS OF ACTION.
182441 03-03

RUBIDIUM SALTS -- ANIMAL TOXICITY STUDIES.
182442 03-05

RUBIDIUM SALTS -- TOXIC EFFECTS IN HUMANS AND CLINICAL EFFECTS AS AN ANTIDEPRESSANT DRUG.
182443 03-09

EFFECTS OF ALUMINUM SALTS ON CULTURED NEUROBLASTOMA CELLS.
191313 04-03

SAMPLE
THE DOCUMENTATION OF CLINICAL PSYCHOTROPIC DRUG TRIALS: SAMPLE OUTPUT PACKAGE.
180256 02-16

CONSTITUENTS OF CANNABIS-SATIVA L. V.: STABILITY OF AN ANALYTICAL SAMPLE EXTRACTED WITH CHLOROFORM. (UNPUBLISHED PAPER).
180670 02-01

SAMPLES
IDENTIFICATION AND QUANTITATIVE DETERMINATION OF PHENOTHIAZINE DRUGS IN URINE SAMPLES OF PSYCHIATRIC PATIENTS.
183599 03-02

SAMPLING
TIME SAMPLING OF RAT EXPLORATORY BEHAVIOUR: A RELIABLE SCREENING TEST FOR THE CNS EFFECTS OF ANOREXIC AGENTS.
187925 04-04

SAPONIN
THE EFFECT OF PANAX GINSENG SAPONIN ON THE CENTRAL NERVOUS SYSTEM IN RAT: THE PSYCHOPHARMACOLOGICAL EFFECT OF GINSENG.
171599 01-04

SARCOPLASMIC
THE INHIBITION BY BETA-ADRENOCEPTOR BLOCKING AGENTS OF CALCIUM UPTAKE INTO AND EFFLUX FROM ISOLATED SARCOPLASMIC VESICLES.
184223 03-03

SATED
DIAZEPAM-INDUCED EATING AND LEVER PRESSING FOR FOOD IN SATED RATS.
186613 03-04

SATIATED
EFFECTS OF METHAMPHETAMINE ON FIXED-RATIO RESPONDING OF FOOD SATIATED AND FOOD DEPRIVED RATS.
185957 03-04

SATIETY
DETERMINANTS OF THE NORADRENERGIC SATIETY EFFECT: ENVIRONMENTAL DARKNESS VS. THE FEEDING PATTERN.
182133 02-04

SC-13504
THE ANTAGONISM OF HIPPOCAMPAL AND CORTICAL AFTERDISCHARGE BY SC-13504, A NEW ANTICONVULSANT.
186632 03-03

SCANDINAVIAN
IMPRESSIONS OF SCANDINAVIAN PSYCHIATRY -- 1973.
173452 01-17

SCHEDULE
THE EFFECTS OF AGENTS THAT MODIFY MUSCARINIC TONE UPON BEHAVIOR CONTROLLED BY AN AVOIDANCE SCHEDULE THAT EMPLOYS SIGNALED UNAVOIDABLE SHOCK.
171302 01-04

SUBSTANTIAL ORAL MORPHINE INTAKE BY THE RAT USING SCHEDULE INDUCED POLYDIPSIA.
182194 02-04

THE EFFECT OF IPRONIAZID AND TRANYLCYPROMINE STUDIED WITH A DARK AVOIDANCE CONDITIONED SCHEDULE.
186590 03-04

EFFECTS OF ORAL DELTA9-TETRAHYDROCANNABINOL ON OPERANT REINFORCEMENT SCHEDULE PERFORMANCE IN RATS.
186645 03-04

THE EFFECTS OF D-AMPHETAMINE ON THE INTERRESPONSE TIMES OF RATS AND GUINEA-PIGS ON A MODIFIED SIDMAN DISCRIMINATED AVOIDANCE SCHEDULE.
189519 04-04

THE EFFECTS OF SCOPOLAMINE ON PERFORMANCE ON A GEOMETRIC PROGRESSIVE RATIO SCHEDULE.
190334 04-04

NALTREXONE AND NALOXONE: AGONIST AND ANTAGONIST EFFECTS ON KEY-PRESS RESPONDING OF PIGEONS MAINTAINED UNDER A MULTIPLE SCHEDULE OF FOOD PRESENTATION.
191926 04-04

COMPARISON OF CODEINE AND ETHYL ALCOHOL SELF-ADMINISTRATION UNDER A VARIABLE INTERVAL (VI) SCHEDULE IN MONKEYS.
191983 04-04

SCHEDULE-CONTROLLED
EFFECTS AND INTERACTIONS OF SCOPOLAMINE AND D-AMPHETAMINE ON SCHEDULE-CONTROLLED RESPONDING IN RATS. (PH.D. DISSERTATION).
173748 01-04

EFFECTS OF AMPHETAMINE (A), LSD, PSILOCYBIN (P), AND DOM ON SCHEDULE-CONTROLLED BEHAVIOR IN THE RAT.
176869 02-04

SCHEDULES
RATE-DEPENDENT EFFECTS OF DRUGS. I. COMPARISONS OF D-AMPHETAMINE, PENTOBARBITAL, AND CHLORPROMAZINE ON MULTIPLE AND MIXED SCHEDULES.
177410 02-04

DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) DOSE EFFECTS COMPARED ON THREE SCHEDULES OF FOOD REINFORCED OPERANT PERFORMANCE.
182191 02-04

EFFECTS OF VARIOUS MORPHINE TREATMENT SCHEDULES ON ACETYLCHOLINE TURNOVER RATE IN RAT BRAIN PARTS.
184553 03-03

A DETAILED ANALYSIS OF THE EFFECTS OF D-AMPHETAMINE ON BEHAVIOR UNDER FIXED-INTERVAL SCHEDULES.
187066 03-04

EFFECTS OF NICOTINE AND ITS WITHDRAWAL ON THE PERFORMANCE OF RATS ON SIGNALLED AND UNSIGNALLED AVOIDANCE SCHEDULES.
190331 04-04

EFFECTS OF D-AMPHETAMINE, MORPHINE AND CHLORPROMAZINE ON RESPONDING UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION OR ELECTRIC SHOCK PRESENTATION.
191767 04-03

BEHAVIORAL EFFECTS OF COCAINE COMPARED UNDER TWO SCHEDULES OF FOOD PRESENTATION IN THE SQUIRREL MONKEY.
191916 04-04

SCHIZOPHRENIA
DEPRESSIVE FORMS OF SCHIZOPHRENIA AND EXPERIMENTAL TREATMENT BY CLOMIPRAMINE.
167676 01-08

PHENOTHIAZINE DOSAGE LEVELS AND AUDITORY SIGNAL DETECTION IN SCHIZOPHRENIA.
167817 01-08

SLEEP PHENOMENA IN SCHIZOPHRENIA.
167954 01-08

EFFECTS OF L-DOPA ON SCHIZOPHRENIA.
171245 01-08

AN AUTOPSY CASE OF SCHIZOPHRENIA COMPLICATED WITH PARKINSONISM INDUCED BY PERPHENAZINE.
171275 01-15

SCHIZOPHRENIA MANAGEMENT -- THE DAWN OF A NEW ERA.
172435 01-08

ASSESSMENT OF ANATENSOL (FLUPHENAZINE ENANTHATE) INJECTABLE IN THE TREATMENT OF SCHIZOPHRENIA.
172444 01-08

A COMPARATIVE TRIAL OF HALOPERIDOL AND THIORIDAZINE: MANAGEMENT OF CHRONIC SCHIZOPHRENIA.
172741 01-08

PHARMACOTHERAPY IN CHRONIC SCHIZOPHRENIA.
172831 01-08

THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA.
172963 01-08

THE USE OF CHLORPROMAZINE IN SCHIZOPHRENIA.
174059 01-08

TRIFLUPERIDOL IN SCHIZOPHRENIA.
174588 01-08

HIGH DOSES OF CHLORPROMAZINE AND TRIFLUOPERAZINE IN THE TREATMENT OF PATIENTS SUFFERING FROM SCHIZOPHRENIA.
174589 01-08

POLLY: MENTAL DEFICIENCY AND SCHIZOPHRENIA.
174641 01-17

A DOUBLE-BLIND COMPARISON OF CLOZAPINE WITH THIORIDAZINE ON SCHIZOPHRENIA.
175119 02-08

FLUPENTHIXOL IN SCHIZOPHRENIA.
175460 02-08

THREE CASES OF SCHIZOPHRENIA TREATED WITH L-DOPA.
175550 02-08

ACUTE SCHIZOPHRENIA.
175725 02-08

CLINICAL TRIAL OF PERAZINE (TAXILAN) IN TREATMENT OF SCHIZOPHRENIA.
176446 02-08

EXPERIENCE IN THE APPLICATION OF A NEW DRUG, DP-181 (OXYPERTINE), IN TREATMENT OF SCHIZOPHRENIA.
176468 02-08

HIGH AND LOW DOSE THIOTHIXENE TREATMENT IN CHRONIC SCHIZOPHRENIA.
176673 02-08

CLINICAL EXPERIENCES WITH NAVANE IN CHRONIC SCHIZOPHRENIA.
176726 02-08

CLINICAL EXPERIENCES WITH A PSYCHOTROPIC DRUG (OXYPERTINE) IN CHRONIC SCHIZOPHRENIA.
176727 02-08

EFFECTS OF AQUEOUS PINEAL EXTRACT IN CHRONIC SCHIZOPHRENIA.
177818 02-08

SCHIZOPHRENIA.
177994 02-08

COMPARISON OF THE EFFECTS OF Y-4153 AND CARPIPRAMINE ON SCHIZOPHRENIA BY A DOUBLE-BLIND METHOD.
178053 02-08

PIMOZIDE (R-6238) IN CHRONIC SCHIZOPHRENIA: DOUBLE-BLIND TRIAL.
178255 02-08

PARENTERAL HALOPERIDOL FOR RAPID CONTROL OF SEVERE, DISRUPTIVE SYMPTOMS OF ACUTE SCHIZOPHRENIA.
178545 02-08

LITHIUM IN THE TREATMENT OF SCHIZOPHRENIA.
180046 02-08

THE COMPARISON OF THERAPEUTIC EFFECTS OF FK-880 (SULPIRIDE) AND PERPHENAZINE IN SCHIZOPHRENIA BY A DOUBLE-BLIND CONTROLLED STUDY.
181378 02-08

TREATMENT OF HALLUCINATORY DISORDERS IN SCHIZOPHRENIA BY ATROPINE COMAS.
181778 02-08

THE USE OF TRANQUILIZING DRUGS IN CASES OF SCHIZOPHRENIA.
182581 03-08

NICOTINIC ACID AND CATECHOL-O-METHYLTRANSFERASE ACTIVITY IN SCHIZOPHRENIA.
183360 03-13

PSYCHOPHYSIOLOGICAL PATTERNS OF RESPONSE IN SCHIZOPHRENIA.
183629 03-08

COMMENTS ON PAPER, PSYCHOPHYSIOLOGICAL PATTERNS OF RESPONSE IN SCHIZOPHRENIA.
183630 03-17

FEATURES OF THE THERAPEUTIC EFFECT OF FLUPHENAZINE DECANOATE IN SCHIZOPHRENIA.
183683 03-08

FLUPENTHIXOL DECANOATE IN SCHIZOPHRENIA.
185194 03-08

DRUG DOSAGE IN ACUTE PHASE SCHIZOPHRENIA.
185898 03-17

MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN THE LIGHT OF PROGNOSIS ORIENTED DIAGNOSIS.
186081 03-08

LONG-ACTING PHENOTHIAZINES AND SCHIZOPHRENIA.
186288 03-08

INTERACTION OF LOW-DOSE AMPHETAMINE USE WITH SCHIZOPHRENIA IN OUTPATIENTS: THREE CASE REPORTS.
189099 04-15

AN OVERVIEW OF THE 6-HYDROXYDOPAMINE THEORY OF SCHIZOPHRENIA.
190239 04-08

PSYCHOENDOCRINE INVESTIGATION IN SCHIZOPHRENIA: RELATIONSHIP BETWEEN PITUITARY GONADAL FUNCTION AND BEHAVIOR.
191190 04-14

DRUGS, NEUROTRANSMITTERS, AND SCHIZOPHRENIA.
191290 04-08

POST-MORTEM MEASUREMENT OF ENZYMES IN HUMAN BRAIN: EVIDENCE OF A CENTRAL NORADRENERGIC DEFICIT IN SCHIZOPHRENIA.
191529 04-13

CHOLINERGIC AND ADRENERGIC BALANCE IN MANIA AND SCHIZOPHRENIA.
191530 04-09

ABNORMALITIES IN TRYPTOPHAN METABOLITES IN SCHIZOPHRENIA.
191536 04-13

EXPERIMENT WITH PENFLURIDOL (TLP-607) ON THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
191593 04-08

USE OF HALOPERIDOL (BROTOPON) IN THE TREATMENT OF SCHIZOPHRENIA.
191686 04-08

CLINICAL USE OF LUVATREN (METHYLPERIDOL) FOR THE TREATMENT OF SCHIZOPHRENIA.
191720 04-08

SCHIZOPHRENIA-LIKE

A CASE OF WERNERS SYNDROME WITH SCHIZOPHRENIA-LIKE SYMPTOMS.
175120 02-09

SCHIZOPHRENIAS

TRAZODONE IN THE TREATMENT OF SCHIZOPHRENIAS.
168806 01-11

SCHIZOPHRENIC

METIAPINE IN ACUTE SCHIZOPHRENIC PATIENTS.
167341 01-08

POTENTIATION OF HALOPERIDOL BY ALPHA-METHYLDOPA IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
167343 01-08

CLINICAL EVALUATION OF FLUSPIRILENE AS A MAINTENANCE THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS.
168320 01-08

THERAPEUTIC APPROACH TO THE APPROXIMATE ANSWERS OF A SCHIZOPHRENIC PATIENT.
170637 01-08

MOLINDONE: A CROSSOVER EVALUATION OF CAPSULE AND TABLET FORMULATIONS IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
174137 01-08

TRIFLUPERIDOL -- A CONTROLLED CLINICAL TRIAL ON A GROUP OF SCHIZOPHRENIC PATIENTS.
174587 01-08

PLATELET MONOAMINE OXIDASE ACTIVITY AND SUBSTRATE PREFERENCES IN SCHIZOPHRENIC PATIENTS.
174609 01-14

LONG-TERM APPLICATION OF CLOZAPINE (W-801) IN SCHIZOPHRENIC PATIENTS.
174680 01-08

THE EFFECTS OF PHYSOSTIGMINE IN PHENOTHIAZINE RESISTANT CHRONIC SCHIZOPHRENIC PATIENTS: PRELIMINARY OBSERVATIONS.
177669 02-08

PIPERACETAZINE IN AMBULATORY CHRONIC SCHIZOPHRENIC PATIENTS.
177748 02-08

A DOUBLE-BLIND COMPARISON OF FLUPHENAZINE AND HALOPERIDOL IN OUTPATIENT SCHIZOPHRENIC CHILDREN.
177754 02-08

DREAM REPORTS AFTER RESERPINE ADMINISTRATION IN CHRONIC LOBOTOMIZED SCHIZOPHRENIC PATIENTS.
178187 02-08

LONG-TERM CONSEQUENCES OF EXPERIENCE, MEDICATION, AND PSYCHOTHERAPY FOR SCHIZOPHRENIC PATIENTS. (UNPUBLISHED PAPER).
178677 02-17

EXPERIENCE GAINED IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PSYCHOSES WITH A THIORIDAZINE DERIVATIVE.
180675 02-08

A DOUBLE-BLIND COMPARISON OF PIMOZIDE WITH CARPIPRAMINE IN SCHIZOPHRENIC PATIENTS.
183195 03-08

NEUROLOGICAL CONSEQUENCES OF PSYCHOTROPIC DRUG WITHDRAWAL IN SCHIZOPHRENIC CHILDREN.
183275 03-08

ON THE DYNAMICS AND TREATMENT OF THE TENDENCY OF SCHIZOPHRENIC PSYCHOSIS TO BECOME CHRONIC.
183957 03-08

THE ABRUPT WITHDRAWAL OF ANTIPARKINSONIAN DRUGS IN SCHIZOPHRENIC PATIENTS.
185005 03-08

THE EFFECT OF CHLORPROMAZINE ON HOMOVANILLIC ACID LEVELS IN CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS.
186565 03-08

THE ADMINISTRATION OF METHIONINE TO CHRONIC SCHIZOPHRENIC PATIENTS: A REVIEW OF TEN STUDIES.
187113 03-08

HIGH DOSAGE PIPERACETAZINE (QUIDE-R) IN AMBULATORY SCHIZOPHRENIC PATIENTS: THERAPEUTIC EFFICACY AND TOXICITY.
187869 04-08

CLINICAL EXPERIENCES WITH MESORIDAZINE (TPS-23): ITS ADMINISTRATION TO HOSPITALIZED SCHIZOPHRENIC PATIENTS.
188934 04-08

RAPID DIGITALIZATION OF DECOMPENSATED SCHIZOPHRENIC PATIENTS WITH ANTIPSYCHOTIC AGENTS.
189095 04-08

DIFFERENTIAL EFFECTS OF TRAZODONE IN DEPRESSED, SCHIZOPHRENIC AND GERIATRIC PATIENTS.
191138 04-14

CONDITIONING IN THE PREDICTION OF DRUG WITHDRAWAL EFFECTS IN CHRONIC SCHIZOPHRENIC PATIENTS.
192412 04-17

SCHIZOPHRENICS

POTENTIATION OF THERAPEUTIC EFFECTS OF NICOTINIC ACID BY PYRIDOXINE IN CHRONIC SCHIZOPHRENICS.
168313 01-08

ROLE OF FLUPHENAZINE DECANOATE IN LESSENING THE BURDEN OF CHRONIC SCHIZOPHRENICS ON THE COMMUNITY.
169438 01-08

DIPHENYLHYDANTOIN EFFECTIVENESS IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS: A DOUBLE-BLIND CONTROLLED STUDY WITH A PLACEBO.
171507 01-08

EXPERIENCES WITH FLUPHENAZINE ENANTHATE IN LONG-STAY HOSPITALISED SCHIZOPHRENICS.
171985 01-08

MEDICATION AND/OR PSYCHOTHERAPY WITH SCHIZOPHRENICS: WHICH PART OF THE ELEPHANT HAVE YOU TOUCHED
173534 01-08

ONGOING INVESTIGATIONS OF CEREBRAL GLUTAMINE EXCRETION SCHIZOPHRENICS DURING TREATMENT WITH NEUROLEPTIC.
174101 01-08

LONG-TERM CLINICAL AND QUANTITATIVE EEG EFFECTS OF CLOPENTHIXOL IN SCHIZOPHRENICS: CLINICAL NEUROPHYSIOLOGICAL CORRELATIONS.
174131 01-08

SLEEP CHANGES IN CHRONIC SCHIZOPHRENICS: EFFECTS OF 5-HYDROXYTRYPTOPHAN (5-HTP). (UNPUBLISHED PAPER
178578 02-08

EXPERIENCES WITH FLUPHENAZINE ENANTHATE IN LONG-STAY HOSPITALIZED SCHIZOPHRENICS.
180154 02-08

WORD RECOGNITION OF SCHIZOPHRENICS AS A FUNCTION OF PHENOTHIAZINE LEVEL AND AUTONOMIC RESPONSIVITY. (PH.D. DISSERTATION).
182524 03-08

CLINICAL OBSERVATIONS ON THE USE OF PIMOZIDE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS.
183196 03-08

ON THE CLINICAL EFFECT OF FLUPHENAZINE ENANTHATE IN OUTPATIENT SCHIZOPHRENICS.
185213 03-08
EFFECT OF PROLONGED CHLORPROMAZINE ADMINISTRATION ON THE SLEEP OF CHRONIC SCHIZOPHRENICS.
188115 04-08
SERUM TRYPTOPHAN BINDING IN CHLORPROMAZINE TREATED CHRONIC SCHIZOPHRENICS.
191320 04-08
EFFECTS OF INTRAVENOUS D-AMPHETAMINE, L-AMPHETAMINE AND METHYLPHENIDATE IN SCHIZOPHRENICS.
191508 04-08

SCHOOL
RITALIN FOR SCHOOL CHILDREN: THE TEACHERS PERSPECTIVE.
178127 02-17
OUTPATIENT TREATMENT OF HYPERACTIVE SCHOOL CHILDREN WITH IMIPRAMINE.
184174 03-11
FACTORS AFFECTING OUTCOME IN A SCHOOL MENTAL HEALTH SERVICE.
188567 04-11

SCIATIC
THE IMPULSE BLOCKING CONCENTRATIONS OF ANESTHETICS, ALCOHOLS, ANTICONVULSANTS, BARBITURATES, AND NARCOTICS ON PHRENIC AND SCIATIC NERVES.
187803 04-03

SCLEROSIS
LEVODOPA INDUCED DYSKINESIAS: COMPARISON IN PARKINSONISM DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS.
169376 01-15

SCOPOLAMINE
ACQUISITION AND RETENTION OF AVOIDANCE BEHAVIORS FOLLOWING SEPTAL LESIONS OR SCOPOLAMINE INJECTIONS IN RATS.
167401 01-04
THE EFFECTS OF SCOPOLAMINE ON FIXED-INTERVAL BEHAVIOUR IN THE RAT: A RATE-DEPENDENCY EFFECT.
168833 01-04
EFFECTS OF DELTA9-THC, LSD-25 AND SCOPOLAMINE ON CONTINUOUS, SPONTANEOUS ALTERNATION IN THE Y-MAZE.
171306 01-04
EFFECTS OF SCOPOLAMINE UPON BEHAVIORAL REACTIVITY AND VISUALLY EVOKED POTENTIAL TO FLASHES IN RATS.
173032 01-04
EFFECTS AND INTERACTIONS OF SCOPOLAMINE AND D-AMPHETAMINE ON SCHEDULE-CONTROLLED RESPONDING IN RATS. (PH.D. DISSERTATION).
173748 01-04
SCOPOLAMINE EFFECTS ON TWO-TRIAL DELAYED-RESPONSE PERFORMANCE IN THE RAT.
186372 03-04
DIFFERENTIAL EFFECTS OF PILOCARPINE AND SCOPOLAMINE ON THE PERFORMANCE OF A LIGHT DARK DISCRIMINATION MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN.
186701 03-03
COMPARATIVE EFFECTS OF SCOPOLAMINE AND AMPHETAMINE UPON BEHAVIORAL REACTIVITY AND VISUAL EVOKED POTENTIALS TO FLASHES IN RATS.
187700 04-04
TEMPORAL ASPECTS OF SCOPOLAMINE INDUCED ONE-WAY MEMORY DISSOCIATION IN MICE.
187701 04-04
EFFECTS OF SCOPOLAMINE METHYLBROMIDE ON SHOCK-INDUCED GASTRIC LESIONS IN THE UNRESTRAINED RAT.
189381 04-03
AN ANALYSIS OF THE FACILITATION OF AVOIDANCE ACQUISITION BY D-AMPHETAMINE AND SCOPOLAMINE.
189521 04-04
DISSOCIATION BETWEEN SCOPOLAMINE AND MECAMYLAMINE DURING FEAR CONDITIONING IN RATS.
190264 04-04
EFFECTS OF SCOPOLAMINE ON INHIBITORY MECHANISMS.
190275 04-04
THE EFFECTS OF SCOPOLAMINE ON PERFORMANCE ON A GEOMETRIC PROGRESSIVE RATIO SCHEDULE.
190334 04-04

SCOTOPHOBIN
BEHAVIOURAL EVALUATION OF PEPTIDES RELATED TO SCOTOPHOBIN.
177836 02-04

SCREENING
CENTRAL NERVOUS DEPRESSANT XV: SYNTHESIS AND PHARMACOLOGICAL SCREENING OF SOME TRIMETHOXYAZLACTONES.
182828 03-02
SYNTHESIS AND SCREENING OF CYCLIC BENZYLHYDRAZINE CONGENERS AS ANTIDEPRESSANTS.
183600 03-01
PREPARATION AND PHARMACOLOGICAL SCREENING OF INDANETHYLAMINES RELATED TO TRYPTAMINE.
185979 03-01
VALIDITY OF SCREENING METHODS FOR DRUGS OF ABUSE IN BIOLOGICAL FLUIDS. II. HEROIN IN PLASMA AND SALIVA.
187256 03-15
TIME SAMPLING OF RAT EXPLORATORY BEHAVIOUR: A RELIABLE SCREENING TEST FOR THE CNS EFFECTS OF ANOREXIC AGENTS.
187925 04-04

SE-780
CHRONIC ANOREXIC AND BEHAVIOURAL EFFECTS OF THE FENFLURAMINE DERIVATIVE SE-780 IN RATS.
187926 04-04

SEARCH
IN THE SEARCH FOR NEW TRANQUILIZING DRUGS.
167813 01-04

SECOBARBITAL
THE EFFECTS OF METHAMPHETAMINE AND SECOBARBITAL ON THE CONTINGENT NEGATIVE VARIATION AMPLITUDE.
185932 03-13
RESILIENCE OF FAMILY PROCESS: EFFECT OF SECOBARBITAL.
189743 04-14
CLINICAL EFFECTS OF MARIHUANA SECOBARBITAL COMBINATION.
191989 04-14
ABSORPTION AND CLEARANCE OF SECOBARBITAL, HEPTABARBITAL, METHAQUALONE, AND ETHINAMATE.
192575 04-13

SECRETION
ENHANCED RENAL TUBULAR SECRETION OF MEPROBAMATE: ROLE OF SALINE FUROSEMIDE DIURESIS.
184243 03-03
ROLE OF DOPAMINERGIC MECHANISMS IN REGULATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN MAN.
188428 04-13
DISSOCIATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN PARKINSONS DISEASE FOLLOWING CHRONIC L-DOPA THERAPY.
191233 04-13

SECRETIONS
THE INFLUENCE OF DELTA9-TETRAHYDROCANNABINOL (THC) ON PILOCARPINE (PILO) INDUCED PAROTID SECRETIONS OF THE RAT.
191962 04-03

SEDATION
A PROGRAMME WHICH LED TO REDUCTION IN NIGHT SEDATION IN A MAJOR HOSPITAL.
170802 01-17
THE ORAL HYPNOTIC BIOASSAY OF HYDROXYZINE AND PENTOBARBITAL FOR NIGHTTIME SEDATION.
177320 02-11

SEDATIVE
THE PHARMACOLOGICAL EVALUATION IN LABORATORY ANIMALS OF KABI-1702 -- A NEW SEDATIVE HYPNOTIC DRUG.
171632 01-03
DEPENDENCE LIABILITY OF SEVERAL SEDATIVE HYPNOTIC AGENTS EVALUATED IN MONKEYS.
174125 01-04
CROSS-NATIONAL STUDY OF THE EXTENT OF ANTIANXIETY SEDATIVE DRUG USE.
181713 02-17
SEDATIVE OR TRANQUILLIZER? A COMPARISON OF THE HYPNOTIC EFFECTS OF CHLORDIAZEPOXIDE AND AMYLOBARBITONE SODIUM.
184438 03-14
CORRELATION BETWEEN THE TRANQUILIZING AND SEDATIVE ACTION OF NEUROLEPTICS, ANTIDEPRESSANTS AND ANTICHOLINERGIC DRUGS.
191783 04-02
COMPARATIVE METABOLISM OF TRIAZOLAM, A NEW SEDATIVE HYPNOTIC, IN RAT, DOG AND MAN.
191900 04-02
EFFECTS OF CNS AGENTS ON NICOTINE EXTENSOR CONVULSIONS AND LETHALITY IN MICE AND THEIR SEDATIVE ANTIANXIETY EFFECTS IN MAN.
191907 04-14
A PREDICTABLE LABORATORY MODEL FOR SEDATIVE/HYPNOTIC ACTIVITY IN MAN.
191943 04-14

SEED
AN OBSESSIVE NEUROSIS FOLLOWING MORNING-GLORY SEED INGESTION TREATED BY AVERSION RELIEF.
184259 03-15

SEGMENTAL
INFLUENCE OF TETRACOSACTRIN (T) AND BETA-MELANOCYTE STIMULATING HORMONE (MSH) ON DEPRESSION OF THE SEGMENTAL REFLEX BY MORPHINE (MS). (UNPUBLISHED PAPER).
183324 03-03

SEIZURE
EFFECTS OF DOPAMINE RECEPTOR STIMULATION AND BLOCKADE ON RO-4-1284 INDUCED ENHANCEMENT OF ELECTROSHOCK SEIZURE.
167287 01-03
BEHAVIORAL AND ELECTROENCEPHALOGRAPHIC STUDIES ON THIOSEMICARBAZIDE INDUCED SEIZURE IN RABBITS.
174855 01-05

CHANGES IN THE NEUROEXCITABILITY OF ALCOHOL DEPENDENT RATS UNDERGOING WITHDRAWAL AS MEASURED BY THE PENTYLENETETRAZOL SEIZURE THRESHOLD.
182348 03-03

SEIZURE SUSCEPTIBILITY AND AVOIDANCE CONDITIONING IN ADULT RATS TREATED PRENATALLY WITH CHLORPROMAZINE.
184371 03-04

EFFECT OF ANTICONVULSANT DRUGS ON THE NUMBER OF AFFERENT STIMULI NEEDED TO CAUSE A HIPPOCAMPAL SEIZURE DISCHARGE.
189608 04-03

ANTICONVULSANT DRUG SERUM LEVELS IN PSYCHIATRIC PATIENTS WITH SEIZURE DISORDERS: EFFECTS OF CERTAIN PSYCHOTROPIC DRUGS.
191096 04-13

SEIZURES

RETROGRADE AMNESIA FROM HYPOTHERMIA INDUCED BRAIN SEIZURES.
167398 01-04

THE EFFECT OF CANNABIDIOL ON MAXIMAL ELECTROSHOCK SEIZURES IN RATS.
168749 01-03

PREVENTION OF ALCOHOL WITHDRAWAL SEIZURES: THE ROLES OF DIPHENYLHYDANTOIN AND CHLORDIAZEPOXIDE.
172275 01-11

MYOCLONIC SEIZURES IN DOWNS SYNDROME.
173205 01-11

ANTICONVULSANT ACTIVITY OF CLONAZEPAM AND RO-8-4192 AGAINST PENICILLIN AND LIDOCAINE INDUCED SEIZURES.
178947 02-03

SIGNIFICANCE OF THE CENTRAL BIOGENIC AMINES FOR THE THRESHOLD IN ELECTRO AND PENTETRAZOLE SEIZURES.
181469 02-03

EFFECT OF D-AMPHETAMINE SULFATE ON SUSCEPTIBILITY TO AUDIOGENIC SEIZURES IN DBA/2J MICE.
184235 03-03

EFFECT OF SEIZURES AND ANTICONVULSANT AGENTS ON HIPPOCAMPAL RNA CONCENTRATION.
189609 04-03

SUPPRESSION OF SEIZURES BY TAURINE -- SPECIFIC OR NONSPECIFIC?
189843 04-03

SELECTIVE

PENTOBARBITAL: SELECTIVE DEPRESSION OF EXCITATORY POSTSYNAPTIC POTENTIALS.
168485 01-03

SELECTIVE INHIBITION OF NOREPINEPHRINE SYNTHESIS IN MANIC-DEPRESSIVE PATIENTS WITH A DOPAMINE-BETA-HYDROXYLASE INHIBITOR. (UNPUBLISHED PAPER).
170083 01-03

SELECTIVE ANTAGONISM OF CENTRAL NERVOUS SYSTEM DEPRESSANTS BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE.
171007 01-13

CYCLIC ADENOSINE MONOPHOSPHATE: SELECTIVE INCREASE IN CAUDATE NUCLEUS AFTER ADMINISTRATION OF L-DOPA.
176254 02-13

STEREOTYPY WITH SELECTIVE STIMULATION OF CERTAIN ITEMS OF BEHAVIOUR OBSERVED IN AMPHETAMINE TREATED MONKEYS (CERCOPITHECUS).
180061 02-04

SELECTIVE BLOCKADE OF APOMORPHINE INDUCED AGGRESSION AND GNAWING FOLLOWING FENFLURAMINE OR RAPHE LESIONS IN THE RAT.
182128 02-04

SUBSTITUTED PIPERAZINOQUINAZOLONES: RELATIONSHIP BETWEEN SELECTIVE INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND ANTICONVULSANT ACTIVITY.
183598 03-02

SELECTIVE RESPIRATORY STIMULATING ACTION OF DOXAPRAM COMPARED TO PENTYLENETETRAZOL.
183887 03-03

DOSE DEPENDENT SELECTIVE FACILITATION OF RESPONSE CONTINGENT LIGHT ONSET BEHAVIOR BY D-AMPHETAMINE.
185955 03-04

THE MONOAMINE OXIDASES OF BRAIN: SELECTIVE INHIBITION WITH DRUGS AND THE CONSEQUENCES FOR THE METABOLISM OF THE BIOGENIC AMINES.
186668 03-03

FUROXANOBENZOFUROXAN, A SELECTIVE MONOAMINE OXIDASE INHIBITOR.
188770 04-01

SELECTIVE RESERPINE RESISTANT ACCUMULATION OF CATECHOLAMINES IN CENTRAL DOPAMINE NEURONES AFTER DOPA ADMINISTRATION.
189026 04-03

THE USE OF SELECTIVE AND INHIBITOR DRUGS TO MODIFY AMINE METABOLISM IN BRAIN.
191500 04-03

A PHARMACOLOGICAL MODEL WITH RHESUS MONKEYS FOR THE PREDICTION OF SELECTIVE DEPRESSION OF PSYCHIC FUNCTIONS.
192424 04-04

SELF-ADMINISTERED

ALPHA-METHYL-P-TYROSINE INHIBITION OF SELF-ADMINISTERED INTRAVENOUS MORPHINE AND ORAL WATER IN RATS.
191940 04-04

SELF-ADMINISTRATION

PSYCHOMOTOR STIMULANT SELF-ADMINISTRATION IN THE RAT.
169028 01-04

HALOPERIDOL EFFECTS ON MORPHINE SELF-ADMINISTRATION: TESTING FOR PHARMACOLOGICAL MODIFICATION OF THE PRIMARY REINFORCEMENT MECHANISM.
172454 01-04

DRUG LEVEL OF D- AND L-AMPHETAMINE DURING INTRAVENOUS SELF-ADMINISTRATION.
185960 03-04

STRUCTURAL RELATIONSHIP BETWEEN META-SUBSITUTED N-ETHYLAMPHETAMINES AND SELF-ADMINISTRATION IN RHESUS MONKEYS.
191915 04-04

PIMOZIDE, L-PROPRANOLOL AND PHENTOLAMINE EFFECTS ON AMPHETAMINE SELF-ADMINISTRATION BY THE RAT.
191919 04-04

INTRAGASTRIC SELF-ADMINISTRATION OF PSYCHOACTIVE DRUGS IN THE RHESUS MONKEY.
191939 04-04

DIFFERENTIAL SENSITIVITY OF METHOHEXITAL SELF-ADMINISTRATION TO SHOCK PUNISHMENT EARLY VS. LATE IN SESSION.
191941 04-04

COMPARISON OF CODEINE AND ETHYL ALCOHOL SELF-ADMINISTRATION UNDER A VARIABLE INTERVAL (VI) SCHEDULE IN MONKEYS.
191983 04-04

SELF-EVALUATIONS

SELF-EVALUATIONS OF ANTIDEPRESSANTS.
190305 04-17

SELF-INJECTION

DIFFERENTIAL SELF-INJECTION BEHAVIOR PRODUCED BY FENFLURAMINE VERSUS OTHER APPETITE INHIBITING DRUGS.
182215 03-04

SELF-RATING

EVALUATION OF HYPNOTICS IN OUTPATIENTS WITH INSOMNIA USING A QUESTIONNAIRE AND A SELF-RATING TECHNIQUE.
177735 02-06

SELF-STIMULATION

INFLUENCE OF MORPHINE ON LATERAL HYPOTHALAMIC SELF-STIMULATION IN THE RAT.
168835 01-04

SELF-STIMULATION OF NORADRENERGIC CELL GROUP (A6) IN LOCUS-COERULEUS OF RATS.
173029 01-03

THE EFFECTS OF INTRACAUDATE INJECTIONS OF CHLORPROMAZINE ON CONDITIONED AVOIDANCE AND SELF-STIMULATION BEHAVIOR. (PH.D. DISSERTATION).
173749 01-04

EFFECTS OF CHLORPROMAZINE, CHLORDIAZEPOXIDE AND PENTOBARBITAL ON NEURONAL EXCITABILITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
177837 02-04

AMPHETAMINE-INDUCED ALTERATION OF BIOGENIC AMINES AND SELF-STIMULATION.
182212 03-03

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: IV. INFLUENCE OF AMPHETAMINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
185961 03-04

EFFECTS OF APOMORPHINE ON SELF-STIMULATION BEHAVIOR.
187666 04-04

SELF-STIMULATION AND CATECHOLAMINES: DRUG-INDUCED MOBILIZATION OF THE RESERVE POOL RE-ESTABLISHES RESPONDING IN CATECHOLAMINE DEPLETED RATS.
189025 04-04

EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND AMPHETAMINE ON SELF-STIMULATION OF BRAIN FOLLOWING VARIOUS 6-HYDROXYDOPAMINE TREATMENTS.
189515 04-04

DIFFERENTIAL ANTAGONISM BY NALOXONE OF INHIBITORY EFFECTS OF HALOPERIDOL AND MORPHINE ON BRAIN SELF-STIMULATION.
190306 04-03

EVIDENCE FOR A DOPAMINERGIC INVOLVEMENT IN THE MAINTENANCE OF SELF-STIMULATION.
191526 04-03

BALANCE BETWEEN ACETYLCHOLINE, SEROTONIN, NOREPINEPHRINE, AND DOPAMINE IN SELF-STIMULATION.
191528 04-04

AMPHETAMINES EFFECTS ON SELF-STIMULATION: DEVELOPMENT OF TOLERANCE AND POST-DRUG DEPRESSION.
191914 04-04

A ROLE FOR DOPAMINE IN THE STIMULANT EFFECTS OF AMPHETAMINE ON LOCUS-COERULEUS SELF-STIMULATION.
191984 04-03

SEMI-QUANTITATIVE
SEMI-QUANTITATIVE ANALYSIS OF BROMAZEPAM BY RING OVEN METHOD.
174853 01-16

SENILITY
COMPARISON OF THIORIDAZINE AND DIAZEPAM IN THE CONTROL OF NONPSYCHOTIC SYMPTOMS ASSOCIATED WITH SENILITY: DOUBLE-BLIND STUDY.
170129 01-11
CAUDATE NUCLEUS EFFECTS ON GERIATRIC SENILITY: EFFECT OF BELLADONNA ON LEARNING AND MEMORY OF GERIATRIC PATIENTS.
170744 01-11
A TRIAL OF GEROVITAL-H3 IN DEPRESSION DURING SENILITY.
181957 02-10
SENILITY AND CHRONIC MALNUTRITION.
188446 04-11

SENSITIVE
A SENSITIVE GAS CHROMATOGRAPHIC PROCEDURE FOR THE ESTIMATION OF NORADRENALINE, DOPAMINE AND 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
171971 01-01
NOREPINEPHRINE SENSITIVE ADENYLATE CYCLASES IN RAT BRAIN: RELATION TO BEHAVIOR AND TYROSINE HYDROXYLASE.
177252 02-03
AMPHETAMINE IN HUMAN PLASMA: A SENSITIVE AND SPECIFIC ENZYMATIC ASSAY.
177403 02-16
EFFECT OF CHLORPROMAZINE AND SOME OF ITS METABOLITES ON THE DOPAMINE SENSITIVE ADENYLATE CYCLASE OF RAT BRAIN STRIATUM.
180060 02-03
A SENSITIVE, SIMPLE METHOD FOR MEASUREMENT OF TYROSINE HYDROXYLASE AND TRYPTOPHAN-5-HYDROXYLASE ACTIVITIES.
182178 02-06
THE EFFECTS OF SOME DRUGS ON AN EVOKED RESPONSE SENSITIVE TO TETRAHYDROCANNABINOLS.
186666 03-03
THE EFFECT OF LITHIUM ON HORMONE SENSITIVE ADENYLATE CYCLASE FROM VARIOUS REGIONS OF THE RAT BRAIN.
187110 03-03
STIMULATION OF A DOPAMINE SENSITIVE ADENYLATE CYCLASE IN HOMOGENATES OF RAT STRIATUM BY A METABOLITE OF PIRIBEDIL (ET-495).
189616 04-03
EFFECT OF CHRONIC TREATMENT WITH DESIPRAMINE (DMI) AND IPRINDOLE (IP) ON THE NOREPINEPHRINE (NE) SENSITIVE ADENYLATE CYCLASE SYSTEM IN SLICES OF THE RAT LIMBIC FOREBRAIN.
192003 04-03

SENSITIVITIES
A RAPID AUTOMATIC METHOD FOR DETERMINING SHOCK SENSITIVITIES OF MICE.
171521 01-04

SENSITIVITY
BEHAVIOR AND SENSITIVITY TO EXPERIMENTAL HYPERTENSION: II. LACK OF CORRELATION BETWEEN CERTAIN BEHAVIOR PATTERNS AND HYPERTENSION IN TWO NEW STRAINS OF RATS.
173256 01-04
CONDITIONED HYPOGLYCEMIA: A MECHANISM FOR SACCHARIN INDUCED SENSITIVITY TO INSULIN IN THE RAT.
174877 01-03
LONG-TERM USE OF MARIHUANA AND THE DEVELOPMENT OF TOLERANCE OR SENSITIVITY TO DELTA9-TETRAHYDROCANNABINOL.
188119 04-13
THE EFFECTS OF MORPHINE, ETORPHINE AND SINOMENINE ON THE CHEMICAL SENSITIVITY AND SYNAPTIC RESPONSES OF RENSHAW CELLS AND OTHER SPINAL NEURONES IN THE RAT.
188201 04-03
NORADRENALINE IN THE GUINEA-PIG ALIMENTARY CANAL: REGIONAL DISTRIBUTION AND SENSITIVITY TO DENERVATION AND RESERPINE.
191326 04-03
DIFFERENTIAL SENSITIVITY OF METHOHEXITAL SELF-ADMINISTRATION TO SHOCK PUNISHMENT EARLY VS. LATE IN SESSION.
191941 04-04

SENSORIMOTOR
THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. I. NEURONAL RESPONSES TO STIMULATION OF THE RETICULAR FORMATION.
189855 04-03
THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. II. COMPARISON OF THE NEURONAL RESPONSES TO RETICULAR AND OTHER STIMULI.
189856 04-03

SENSORY
DRUG ENHANCED SENSORY CONTINGENT BAR PRESSING: COMPARING THE EFFECT OF CONTINGENT AND NONCONTINGENT SENSORY CHANGE.
168837 01-04
SENSORY CONTINGENT BAR-PRESSING FOR FAMILIAR AND NOVEL CHANGE UNDER A DEXAMPHETAMINE AMYLOBARBITONE MIXTURE.
181605 02-04
ALTERATION OF SENSORY AND MOTOR EVOKED RESPONSES BY DIELDRIN.
181818 02-03
HALLUCINOGENIC DRUG-INDUCED BEHAVIOR UNDER SENSORY ATTENUATION: PREDICTION OF RESPONSE TO PSILOCYBIN.
189744 04-12

SEPARATION
MOTHER INFANT SEPARATION: BEHAVIORAL ANALYSIS OF AN ANIMAL MODEL OF DEPRESSION. (PH.D. DISSERTATION).
178867 02-04
SEPARATION OF THE DEPENDENCE PRODUCING ACTIONS FROM THE DIRECT ACTIONS OF NARCOTICS ON GUINEA-PIG ILEUM.
182162 02-03
PREDATION: SEPARATION OF AGGRESSIVE AND HUNGER MOTIVATION BY CONDITIONED AVERSION.
185463 03-04

SEPTAL
ACQUISITION AND RETENTION OF AVOIDANCE BEHAVIORS FOLLOWING SEPTAL LESIONS OR SCOPOLAMINE INJECTIONS IN RATS.
167401 01-04
THE ROLE OF THE SEPTAL AREA OF THE BRAIN IN THE INHIBITORY MODULATION OF BEHAVIOR. (PH.D. DISSERTATION).
172021 01-03
DIFFERENTIAL RECOVERY OF FUNCTION FOLLOWING CAUDATE, HIPPOCAMPAL, AND SEPTAL LESIONS IN MICE.
186620 03-04
THE MOTIVATIONAL CONSEQUENCES OF CHOLINERGIC STIMULATION OF THE MEDIAL SEPTAL AREA.
190260 04-04

SEQUENTIAL
SEQUENTIAL TRIAL COMPARING TWO PLASMA LEVELS OF NORTRIPTYLINE.
187582 04-10
A DOUBLE-BLIND CROSSOVER SEQUENTIAL TRIAL OF ORAL THYROTROPIN RELEASING HORMONE IN DEPRESSION.
188348 04-09
APPLICATION OF THE SEQUENTIAL SIMPLEX METHOD IN DESIGNING DRUG ANALOGS.
190714 04-01

SERENAL
EXPERIENCE IN THE USE OF SERENAL (OXAZOLAM) IN THE FIELD OF PEDIATRICS.
176456 02-11

SEROTONERGIC
SHORT-TERM AND LONG-TERM LITHIUM ADMINISTRATION: EFFECTS ON THE BRAINS SEROTONERGIC BIOSYNTHETIC SYSTEMS.
175149 02-13
LYSERGIC ACID DIETHYLAMIDE AND SEROTONIN: A COMPARISON OF EFFECTS ON SEROTONERGIC NEURONS AND NEURONS RECEIVING A SEROTONERGIC INPUT.
177407 02-12
ENHANCEMENT OF AMPHETAMINE ACTION AFTER INTERRUPTION OF ASCENDING SEROTONERGIC PATHWAYS.
189398 04-03
NORADRENERGIC REGULATION OF BRAIN SEROTONERGIC NEURONS: EVIDENCE FROM SINGLE UNIT STUDIES WITH CLONIDINE.
191948 04-03

SEROTONIN
BRAIN SEROTONIN, AFFECTIVE ILLNESS AND ANTIDEPRESSANT DRUGS: CEREBROSPINAL FLUID STUDIES WITH PROBENECID. (UNPUBLISHED PAPER).
170084 01-09
THE UPTAKE OF DOPAMINE AND SEROTONIN IN RAT BRAIN DURING PROGESTERONE DECLINE.
171307 01-03
STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF 5-HT UPTAKE INTO RAT HYPOTHALAMIC HOMOGENATES BY SEROTONIN AND TRYPTAMINE ANALOGUES.
175233 02-03
ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN DIMETHYLAMINOPROPYLTHIOCINNAMANILIDE HYDROCHLORIDE), A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN (5-HTP) AND ALPHA-METHYLTRYPTAMINE.
176861 02-04
ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN, A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN AND ALPHA-METHYLTRYPTAMINE.
176873 02-04
STIMULATION OF SEROTONIN N-ACETYLTRANSFERASE IN PINEAL ORGAN CULTURE BY DRUGS.
177128 02-03
LYSERGIC ACID DIETHYLAMIDE AND SEROTONIN: A COMPARISON OF EFFECTS ON SEROTONERGIC NEURONS AND NEURONS RECEIVING A SEROTONERGIC INPUT.
177407 02-12
THE EFFECTS OF EARLY P-CHLOROPHENYLALANINE ADMINISTRATION AND POSTWEANING HOUSING CONDITIONS ON SEROTONIN AND BEHAVIOR IN RATS.
178638 02-04

COMPARISON OF THE CHRONIC AND ACUTE EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) TREATMENT ON RAT BRAIN SEROTONIN AND NOREPINEPHRINE.
181945 02-03

THE EFFECTS OF INTRAVENTRICULARLY ADMINISTERED CATECHOLAMINES AND SEROTONIN ON THE RESERPINE INDUCED SPIKE WAVES RECORDED FROM THE MEDICAL NUCLEUS TRAPEZOIDES IN THE RABBIT.
182094 02-03

A COMPARISON OF EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) AND SEROTONIN ON PRE- AND POSTSYNAPTIC CELLS IN THE SEROTONIN SYSTEM.
182141 02-03

THE EFFECT OF CATECHOLAMINES, ACETYLCHOLINE AND SEROTONIN ON THE MORPHINE TOLERANT LONGITUDINAL MUSCLE STRIP OF THE GUINEA-PIG ILEUM.
182161 02-03

LSD TOLERANCE AND BRAIN SEROTONIN METABOLISM.
182167 02-03

ON THE NATURE OF THE SEROTONIN BINDING AFTER LSD.
182168 02-03

BEHAVIORAL EFFECTS OF SIMULTANEOUS DEPLETION OF BRAIN NOREPINEPHRINE AND SEROTONIN.
182211 03-04

EFFECT OF 2-ARYLALANINES, 2-ARYLSERINES, TETRAPHENYLBORON AND 1,2 DL(2,4 DICHLOROPHENYL) ETHANOLAMINE ON LEVELS OF SEROTONIN (5-HT), NOREPINEPHRINE (NE) AND DOPAMINE (DM) IN WHOLE BRAIN OF MICE.
182254 03-03

NON-SPECIFICITY OF 5-HYDROXYTRYPTOPHAN IN REPLETING BRAIN SEROTONIN IN RATS WITH MFB LESIONS.
182725 03-03

EFFECTS OF METHAMPHETAMINE ON DAILY RHYTHMS OF HYPOTHALAMIC NOREPINEPHRINE, SEROTONIN AND PLASMA CORTICOSTERONE LEVELS IN THE RAT.
184178 03-03

EFFECT OF LSD-25 AND 1-METHYL-D-LYSERGIC ACID BUTANOLAMIDE ON RAT BRAIN AND PLATELET SEROTONIN LEVELS.
184975 03-03

TESTS OF EMOTIONAL BEHAVIOR IN RATS FOLLOWING DEPLETION OF NOREPINEPHRINE, OF SEROTONIN, OR OF BOTH.
185753 03-04

HISTO-AUTORADIOGRAPHIC INVESTIGATIONS ON THE DISTRIBUTION OF INJECTED 5-HYDROXYTRYPTAMINE (SEROTONIN) IN THE BRAIN AND THE PITUITARY OF MICE.
185900 03-03

INTERACTION BETWEEN SEROTONIN AND MORPHINE IN THE GUINEA-PIG ILEUM.
186698 03-03

THE TRANSSYNAPTIC RELATIONSHIP BETWEEN DOPAMINE AND SEROTONIN IN THE CAUDATE NUCLEUS OF CATS.
186700 03-04

COMPARISON OF THE LOCOMOTOR STIMULANT MECHANISMS OF ACTION OF D-AMPHETAMINE AND D-AMPHETAMINE PLUS L-DOPA: POSSIBLE INVOLVEMENT OF SEROTONIN.
187119 03-04

EVIDENCE FOR AN INHIBITORY ROLE FOR ACETYLCHOLINE, CATECHOLAMINES, AND SEROTONIN ON THE CEREBRAL CORTEX.
187552 04-03

NEW LONG LATENCY BULBOSPINAL EVOKED POTENTIALS BLOCKED BY SEROTONIN ANTAGONISTS.
188751 04-03

ROLE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN IN INTRACRANIAL REWARD.
191527 04-04

BALANCE BETWEEN ACETYLCHOLINE, SEROTONIN, NOREPINEPHRINE, AND DOPAMINE IN SELF-STIMULATION.
191528 04-04

INFLUENCE OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTS OF ELECTRICAL STIMULATION AND MICROINJECTION OF ACETYLCHOLINE, SEROTONIN AND NORADRENALINE INTO THE MESENCEPHALON.
191786 04-02

THE EFFECTS OF AMPHETAMINE SULFATE ON THE DIURNAL RHYTHMS OF MIDBRAIN; CORTEX, NOREPINEPHRINE; SEROTONIN AND BLOOD GLUCOSE LEVELS IN THE MOUSE.
191918 04-03

INTERACTION OF SEROTONIN ANTAGONISTS WITH 3,4-DICHLORO-2-(2-IMIDAZOLIN-2-YL-THIO) 2 ACETOPHENONE HYDROBROMIDE (DITA) AND D-AMPHETAMINE HYDROBROMIDE (DITA) AND D-AMPHETAMINE ON CERTAIN BEHAVIORAL PARAMETERS OF MALE MICE.
192014 04-04

SEROTONINERGIC

EFFECTS OF P-CHLOROPHENYLALANINE ON DIFFERENTIATION OF SEROTONINERGIC RECEPTIVE CELLS DURING EMBRYOGENESIS. (UNPUBLISHED PAPER).
168817 01-03

SEROTONINERGIC MECHANISMS IN THE CENTRAL ACTION OF PSYCHOTROPIC DRUGS. (PH.D. DISSERTATION).
172015 01-03

ONTOGENY OF SEROTONINERGIC INHIBITION OF BEHAVIORAL AROUSAL IN THE RAT.
174860 01-04

SERUM

BRAIN TO SERUM DISTRIBUTION OF RADIOACTIVITY OF INJECTED 3H-D-AMPHETAMINE IN DIFFERENTIALLY HOUSED MICE.
168418 01-03

GAS CHROMATOGRAPHIC DETERMINATION OF METHAQUALONE IN SMALL AMOUNTS OF SERUM AFTER INGESTION OF THERAPEUTIC DOSES.
172397 01-16

CHLORDIAZEPOXIDE OVERDOSE: INTERPRETATION OF SERUM DRUG CONCENTRATIONS.
177393 02-15

METHYPRYLON OVERDOSE: INTERPRETATION OF SERUM DRUG CONCENTRATIONS.
177394 02-15

LITHIUM DISTRIBUTION BETWEEN CEREBROSPINAL FLUID AND SERUM OF AFFECTIVE PSYCHOTIC PATIENTS TREATED WITH LITHIUM CARBONATE AND ITS CLINICAL RESPONSE.
180301 02-11

DIRECT DETERMINATION OF LITHIUM IN SERUM BY ATOMIC ABSORPTION SPECTROSCOPY.
181653 02-06

BINDING OF MORPHINE BY SERUM PROTEINS OF MORPHINE TREATED RABBITS.
182187 02-03

SERUM ANTICONVULSANT CONCENTRATIONS IN EPILEPTIC PATIENTS WITH MENTAL SYMPTOMS: A PRELIMINARY REPORT.
184439 03-15

EFFECT OF 5-METHOXYTRYPTAMINE ON SERUM CALCIUM AND PHOSPHATE IN RATS.
186678 03-03

MUSCLE ABNORMALITIES IN PSYCHOTIC PATIENTS: II. SERUM CPK ACTIVITY, FIBER ABNORMALITIES, AND BRANCHING AND SPROUTING OF SUBTERMINAL NERVES.
187114 03-09

INFLUENCE OF PH ON THE BENZODIAZEPINE HUMAN SERUM ALBUMIN COMPLEX: CIRCULAR DICHROISM STUDIES.
189595 04-13

ANTICONVULSANT DRUG SERUM LEVELS IN PSYCHIATRIC PATIENTS WITH SEIZURE DISORDERS: EFFECTS OF CERTAIN PSYCHOTROPIC DRUGS.
191096 04-13

SERUM TRYPTOPHAN BINDING IN CHLORPROMAZINE TREATED CHRONIC SCHIZOPHRENICS.
191320 04-08

SERUM PROLACTIN LEVELS IN NEWLY ADMITTED PSYCHIATRIC PATIENTS.
191506 04-13

HUMAN SERUM DOPAMINE-BETA-HYDROXYLASE: RELATIONSHIP TO SYMPATHETIC ACTIVITY IN PHYSIOLOGICAL AND PATHOLOGICAL STATES.
191510 04-13

AN EVALUATION OF SERUM DOPAMINE-BETA-HYDROXYLASE AS AN INDEX OF SYMPATHETIC NERVE ACTIVITY IN MAN.
191511 04-13

SERUM DOPAMINE-BETA-HYDROXYLASE: A POSSIBLE AID IN THE EVALUATION OF HYPERTENSION.
191512 04-13

SEX

INFLUENCE OF PHENOBARBITAL AND SEX HORMONES ON ENZYMES IN ASCORBIC ACID BIOSYNTHESIS IN MALE AND FEMALE RATS. (PH.D. DISSERTATION).
172017 01-03

THOUGHTS ON TREATMENT BY PRIVATE PHYSICIANS OF ABNORMAL SEX DRIVES.
180674 02-11

EFFECTS OF PHENOBARBITAL AND SKF-525-A PRETREATMENT, SEX, LIVER INJURY, AND VEHICLE ON DELTA9-TETRAHYDROCANNABINOL TOXICITY.
189598 04-05

CRIME AND THE SEX DRIVE.
192410 04-17

SEXUAL

NEURAL AND CHEMICAL MECHANISMS OF FEMALE SEXUAL BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).
185705 03-04

SEXUAL DYSFUNCTION RESULTING FROM DRUG SIDE-EFFECTS.
186204 03-15

THE CONTROL OF DEVIANT SEXUAL BEHAVIOR BY DRUGS: A DOUBLE-BLIND CONTROLLED STUDY OF BENPERIDOL, CHLORPROMAZINE, AND PLACEBO.
190061 04-11

SEXUALLY

APHRODISIAC EFFECT OF L-DOPA AND APOMORPHINE IN MALE SEXUALLY SLUGGISH RATS.
188519 04-03

SHIFT
A FREQUENCY SHIFT IN THE HIPPOCAMPAL THETA ACTIVITY: AN ELECTRICAL CORRELATE OF CENTRAL ACTION OF ACTH ANALOGUES IN THE DOG
188166 04-04

SHIFTING
SHIFTING OF THE D-AMPHETAMINE DOSE-RESPONSE CURVE IN RATS WITH FRONTAL CORTICAL ABLATIONS.
187261 04-04

SHIFTS
DRUGS AND PSYCHODYNAMIC SHIFTS IN AFFECTIVE ILLNESS. (UNPUBLISHED PAPER).
170079 01-09

SHOCK
THE EFFECTS OF AGENTS THAT MODIFY MUSCARINIC TONE UPON BEHAVIOR CONTROLLED BY AN AVOIDANCE SCHEDULE THAT EMPLOYS SIGNALED UNAVOIDABLE SHOCK.
171302 01-04
A RAPID AUTOMATIC METHOD FOR DETERMINING SHOCK SENSITIVITIES OF MICE.
171521 01-04
MULTITRIAL PASSIVE AVOIDANCE IN RATS: MESCALINE, SHOCK, AND ITI EFFECTS. (PH.D. DISSERTATION).
173162 01-04
INCREASED GASTRIC ACID DURING SHOCK AVOIDANCE IN MAN.
181879 02-13
EFFECTS OF D-AMPHETAMINE, MORPHINE AND CHLORPROMAZINE ON RESPONDING UNDER FIXED-INTERVAL SCHEDULES OF FOOD PRESENTATION OR ELECTRIC SHOCK PRESENTATION.
191767 04-03
DIFFERENTIAL SENSITIVITY OF METHOHEXITAL SELF-ADMINISTRATION TO SHOCK PUNISHMENT EARLY VS. LATE IN SESSION.
191941 04-04

SHOCK-INDUCED
RECOVERY FROM ELECTROCONVULSIVE SHOCK-INDUCED AMNESIA BY EXPOSURE TO THE TRAINING ENVIRONMENT: PHARMACOLOGICAL ENHANCEMENT BY PIRACETAM.
186704 03-04
EFFECTS OF SCOPOLAMINE METHYLBROMIDE ON SHOCK-INDUCED GASTRIC LESIONS IN THE UNRESTRAINED RAT.
189381 04-03

SHORT-TERM
EMOTIONAL FUNCTIONS IN SHORT-TERM VS. LONG-TERM L-DOPA THERAPY IN PARKINSONISM.
168619 01-15
SHORT-TERM AND LONG-TERM LITHIUM ADMINISTRATION: EFFECTS ON THE BRAINS SEROTONERGIC BIOSYNTHETIC SYSTEMS.
175149 02-13
BARBITURATE DEPENDENCE IN MICE INDUCED BY A SIMPLE SHORT-TERM ORAL PROCEDURE.
175895 02-03
EFFECTS OF SHORT-TERM VERSUS LONG-TERM L-DOPA THERAPY IN PARKINSONISM ON CRITICAL FLICKER FREQUENCY.
177511 02-11
REFLECTION OF SHORT-TERM LIGHT ADAPTATION EFFECT IN THE ELECTRORETINOGRAM.
180591 02-04
SHORT-TERM PSYCHOTHERAPY WITH LSD: A CASE STUDY.
181461 02-12
CHANGES IN SHORT-TERM AND LONG-TERM MEMORY OF DOGS AND CATS UNDER THE EFFECTS OF AMIZYL (BENACTYZINE).
183517 03-04
THE SHORT-TERM ANTIANXIETY EFFECTS OF PROPRANOLOL HCL.
185210 03-10
EFFECTS OF SHORT-TERM ADMINISTRATION OF N-NITROSO COMPOUNDS ON LIVER HISTOLOGY AND PENTOBARBITAL INDUCED SLEEPING TIME IN MICE.
187575 04-04
SHORT-TERM CONTROL OF TYROSINE HYDROXYLASE.
191513 04-03
SHORT-TERM AND LONG-TERM REGULATION OF TYROSINE HYDROXYLASE.
191515 04-03
THE COMPARATIVE EFFECTS OF PENTOBARBITAL AND D-AMPHETAMINE ON A SHORT-TERM MEMORY TASK IN BABOONS.
191917 04-04

SHOWING
EFFECT OF MORPHINE, HALOPERIDOL, APOMORPHINE AND BENZTROPINE ON DOPAMINE TURNOVER IN RAT CORPUS-STRIATUM: EVIDENCE SHOWING MORPHINE-INDUCED REDUCTION IN CNS DOPAMINERGIC ACTIVITY.
182230 03-03

SHUTTLEBOX
PROPRANOLOL AND CHLORDIAZEPOXIDE ON EXPERIMENTALLY INDUCED CONFLICT AND SHUTTLEBOX PERFORMANCE IN RODENTS.
171304 01-04
INFLUENCE OF ALPHA-METHYLTYROSINE ON ENHANCEMENT OF SHUTTLEBOX AVOIDANCE BY MARIJUANA AND PENTOBARBITAL.
187572 04-04
EFFECTS OF NICOTINE ON THE SHUTTLEBOX BEHAVIOR OF TRAINED GUINEA-PIGS.
190333 04-04
INTERACTION OF MESCALINE AND STRESS ON SHUTTLEBOX ESCAPE/AVOIDANCE IN RATS.
191934 04-04
INTERACTIONS BETWEEN RO-4-1284 AND D-AMPHETAMINE (DA) ON SHUTTLEBOX AVOIDANCE IN RATS.
192009 04-04

SIAMESE
THE EFFECTS OF CHLORDIAZEPOXIDE (LIBRIUM) ON THE INTENSITY AND HABITUATION OF AGONISTIC BEHAVIOR IN MALE SIAMESE FIGHTING FISH.
177722 02-04

SICK
IMPORTANCE OF THE COOPERATION OF FAMILIES IN THE TREATMENT OF THE SICK: CONCERNING CHRONIC DELIRIUM TREATED WITH NEUROLEPTICS AND MELANCHOLY TREATED WITH ANTIDEPRESSANTS.
182899 03-17

SICKNESS
THE SPIRAL AFTEREFFECT (SAE) AS A MEASURE OF MOTION SICKNESS SUSCEPTIBILITY AND THE EFFECT ON THE SAE OF AN ANTIMOTION SICKNESS DRUG AND A CENTRAL NERVOUS SYSTEM DEPRESSANT.
172780 01-03

SIDE-EFFECTS
THE CORRECTIVE EFFECT OF PRAXINOR ON HYPOTENSION ATTRIBUTABLE TO PSYCHIATRIC THERAPY. SIDE-EFFECTS.
172980 01-11
STUDIES ON SIDE-EFFECTS AND WITHDRAWAL SYMPTOMS OF IMINODIBENZYL DERIVATIVES.
173080 01-15
THE PSYCHIATRIC SIDE-EFFECTS OF DRUGS.
173866 01-15
SIDE-EFFECTS OF DEXTROAMPHETAMINE THERAPY OF HYPERACTIVE CHILDREN.
176238 02-15
SOMATIC SIDE-EFFECTS OF PSYCHOTHERAPEUTIC DRUGS IN CHILDHOOD.
183183 03-15
SIDE-EFFECTS OF NEUROLEPTIC DRUGS.
183749 03-15
SIDE-EFFECTS OF DRUGS.
183812 03-15
SEXUAL DYSFUNCTION RESULTING FROM DRUG SIDE-EFFECTS.
186204 03-15
SIDE-EFFECTS OF DEPOT FLUPHENAZINES.
188312 04-15
IMIPRAMINE SIDE-EFFECTS IN CHILDREN.
189512 04-15
CLINICAL EVALUATION OF AMANTADINE THERAPY FOR PARKINSONISM AND THE SIDE-EFFECTS -- IN CASES OF THALAMIC SURGERY AND L-DOPA THERAPY.
190095 04-11

SIDMAN
THE EFFECTS OF CHLORPROMAZINE ON A REDEFINED PROCEDURE OF EXTINCTION OF SIDMAN AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
185715 03-14
THE EFFECTS OF D-AMPHETAMINE ON THE INTERRESPONSE TIMES OF RATS AND GUINEA-PIGS ON A MODIFIED SIDMAN DISCRIMINATED AVOIDANCE SCHEDULE.
189519 04-04
EFFECTS OF DELTA1-TETRAHYDROCANNABINOL ON SIDMAN DISCRIMINATED AVOIDANCE BEHAVIOR IN RATS.
192413 04-03

SIGNAL
PHENOTHIAZINE DOSAGE LEVELS AND AUDITORY SIGNAL DETECTION IN SCHIZOPHRENIA.
167817 01-08
EFFECTS OF LSD ON AUDITORY PERCEPTION: A SIGNAL DETECTION ANALYSIS.
185752 03-04

SIGNAL-TO-NOISE
LSD EFFECTS ON SIGNAL-TO-NOISE RATIO AND LATERALIZATION OF VISUAL CORTEX AND LATERAL GENICULATE DURING PHOTIC STIMULATION.
167449 01-03

SIGNALED
THE EFFECTS OF AGENTS THAT MODIFY MUSCARINIC TONE UPON BEHAVIOR CONTROLLED BY AN AVOIDANCE SCHEDULE THAT EMPLOYS SIGNALED UNAVOIDABLE SHOCK.
171302 01-04
BEHAVIORAL PARAMETERS OF DRUG ACTION: SIGNALED AND RESPONSE INDEPENDENT REINFORCEMENT.
174008 01-04

SIGNALLED
EFFECTS OF NICOTINE AND ITS WITHDRAWAL ON THE PERFORMANCE OF RATS ON SIGNALLED AND UNSIGNALLED AVOIDANCE SCHEDULES.
190331 04-04

EFFECTS OF NICOTINE ON THE OBSERVED BEHAVIOUR OF RATS DURING SIGNALLED AND UNSIGNALLED AVOIDANCE EXPERIMENTS.
190332 04-04

SIGNIFICANCE
SIGNIFICANCE OF THE CENTRAL BIOGENIC AMINES FOR THE THRESHOLD IN ELECTRO AND PENTETRAZOLE SEIZURES.
181469 02-03

SIGNIFICANCE OF DOPAMINE RECEPTOR ACTIVITY IN DL-P-METHOXYAMPHETAMINE AND D-AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY.
186670 03-04

SIGNS
EFFECTS OF ANTIPARKINSONIAN DRUGS ON NEUROLEPTIC INDUCED EXTRAPYRAMIDAL SIGNS IN MONKEYS.
183610 03-03

SIMILARITIES
DRUG-INDUCED STEREOTYPED BEHAVIOR: SIMILARITIES AND DIFFERENCES.
191504 04-04

SIMPLE
BARBITURATE DEPENDENCE IN MICE INDUCED BY A SIMPLE SHORT-TERM ORAL PROCEDURE.
175895 02-03

SIMPLE ALGORITHMS FOR PREDICTING PSYCHOTROPIC DRUGS ASSIGNED TO PSYCHIATRIC INPATIENTS.
176676 02-17

A SENSITIVE, SIMPLE METHOD FOR MEASUREMENT OF TYROSINE HYDROXYLASE AND TRYPTOPHAN-5-HYDROXYLASE ACTIVITIES.
182178 02-06

SIMULATED
EFFECTS OF DIAZEPAM AND CODEINE, ALONE AND IN COMBINATION WITH ALCOHOL, ON SIMULATED DRIVING.
189619 04-14

EFFECTS OF CAFFEINE ON ALERTNESS IN SIMULATED AUTOMOBILE DRIVING.
190743 04-14

SINEQUAN
EXPERIMENT WITH DOXEPIN (SINEQUAN) IN TREATMENT OF DEPRESSIVE STATES.
176454 02-11

EXPERIENCE IN THE USE OF SINEQUAN (DOXEPIN HYDROCHLORIDE) IN TREATMENT OF NEUROSIS, DEPRESSION AND DEPRESSIVE STATES.
176471 02-11

EXPERIENCE IN THE USE OF SINEQUAN (DOXEPIN HYDROCHLORIDE).
176474 02-10

SINGLE
A CONTROLLED STUDY OF SINGLE DOSE ADMINISTRATION OF IMIPRAMINE PAMOATE IN ENDOGENOUS DEPRESSION.
167775 01-09

THE TREATMENT OF DEPRESSION WITH A SINGLE DAILY DOSE OF IMIPRAMINE PAMOATE.
169491 01-09

SINGLE VERSUS DIVIDED DAILY DOSE OF TRIMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
170622 01-09

PHARMACOKINETIC PROFILE OF DIAZEPAM IN MAN FOLLOWING SINGLE INTRAVENOUS AND ORAL AND CHRONIC ORAL ADMINISTRATION.
170838 01-13

PSYCHOLOGICAL EFFECTS OF SINGLE DOSE ANTIPSYCHOTIC MEDICATION.
173402 01-08

EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF WATER SOLUBLE 1-DELTA9-TETRAHYDROCANNABINOL (W THC) ON WEB-BUILDING OF SPIDERS.
182193 02-04

COMPARISON OF GRADED SINGLE INTRAMUSCULAR DOSES OF MORPHINE AND PENTOBARBITAL IN MAN.
187254 03-15

PERSISTENT ELECTROENCEPHALOGRAPHIC CHANGES IN RHESUS MONKEYS AFTER SINGLE DOSES OF PENTOBARBITAL, NITRAZEPAM AND IMIPRAMINE.
187931 04-03

EFFECT OF SINGLE AND REPEATED ADMINISTRATION OF CLOZAPINE ON THE METABOLISM OF DOPAMINE AND NORADRENALINE IN THE BRAIN OF THE RAT.
191418 04-03

NORADRENERGIC NEURONS: EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON SINGLE UNIT ACTIVITY.
191931 04-03

NORADRENERGIC REGULATION OF BRAIN SEROTONERGIC NEURONS: EVIDENCE FROM SINGLE UNIT STUDIES WITH CLONIDINE.
191948 04-03

DOXEPIN: IS A SINGLE DAILY DOSE ENOUGH?
192066 04-10

SINOMENINE
THE EFFECTS OF MORPHINE, ETORPHINE AND SINOMENINE ON THE CHEMICAL SENSITIVITY AND SYNAPTIC RESPONSES OF RENSHAW CELLS AND OTHER SPINAL NEURONES IN THE RAT.
188201 04-03

SITES
PHARMACOLOGICAL ANALYSIS OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE REMOVAL FROM THE PULMONARY CIRCULATION: DIFFERENTIATION OF UPTAKE SITES FOR EACH AMINE.
182717 03-03

ANTISCHIZOPHRENIC DRUGS AND BRAIN CHOLINERGIC RECEPTORS: AFFINITY FOR MUSCARINIC SITES PREDICTS EXTRAPYRAMIDAL EFFECTS.
188114 04-15

SITUATION
CURRENT SITUATION OF THE USE OF DRUGS IN ASAHIGAWA JIDO-IN.
168302 01-17

ON PHARMACO-PSYCHOTHERAPY; THE ROLE OF THE PSYCHOTHERAPEUTIC SITUATION IN PSYCHOTROPIC MEDICATION.
170415 01-11

SIMILARITY OF CHRONIC CHLORDIAZEPOXIDE TREATMENT AND REMOVAL OF CONFLICT SITUATION.
182258 03-04

FAILURE OF ACTH TO INFLUENCE AVOIDANCE EXTINCTION IN A ONE-WAY AVOIDANCE SITUATION.
183470 03-04

EFFECTS OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL ON SOCIAL BEHAVIOR OF SQUIRREL MONKEY DYADS IN A WATER COMPETITION SITUATION.
187640 04-04

SKELETAL
A COMPARATIVE STUDY OF DANTROLENE SODIUM AND OTHER SKELETAL MUSCLE RELAXANTS WITH THE STRAUB TAIL MOUSE.
186638 03-04

SKELETAL MUSCLE: RESERVOIR FOR EXOGENOUS L-DOPA.
191771 04-03

SKF-525-A
THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (THC), PENTOBARBITAL AND SKF-525-A WITH THE CARDIOVASCULAR SYSTEM OF THE RAT.
182218 03-03

EFFECT OF SKF-525-A ON THE METABOLISM OF (-) DELTA9-TETRAHYDROCANNABINOL IN THE RAT BRAIN AND LIVER.
187578 04-03

EFFECTS OF PHENOBARBITAL AND SKF-525-A PRETREATMENT, SEX, LIVER INJURY, AND VEHICLE ON DELTA9-TETRAHYDROCANNABINOL TOXICITY.
189598 04-05

SKILLS
THE EFFECT OF MEDAZEPAM AND ALCOHOL ON COGNITIVE AND MOTOR SKILLS USED IN CAR DRIVING.
189408 04-14

SKIN
TOXIC EFFECTS OF MARIHUANA TAR ON MOUSE SKIN.
170464 01-05

EFFECTS OF CHLORPROMAZINE AND ACTINOMYCIN D ON UPTAKE AND INCORPORATION OF CERTAIN AMINO ACIDS, HYPOXANTHINE AND THYMIDINE IN CULTURES OF HUMAN SKIN EPITHELIAL CELLS.
179989 02-13

SLEEP
LORAZEPAM VERSUS GLUTETHIMIDE AS A SLEEP INDUCING AGENT FOR THE GERIATRIC PATIENT.
167496 01-11

EFFECTS OF L-DOPA ON NATURAL NIGHT SLEEP AND ON REBOUND OF REM SLEEP.
167921 01-14

SLEEP PHENOMENA IN SCHIZOPHRENIA.
167954 01-08

THE EFFECT OF PLACEBO AND DRUGS ON HUMAN SLEEP.
168419 01-14

SLEEP STUDIES AND THERAPEUTIC TRIAL WITH L-DOPA IN A CASE OF STIFF-MAN SYNDROME.
171134 01-13

LITHIUM CARBONATE AND SLEEP IN AFFECTIVE DISORDERS: FURTHER CONSIDERATIONS.
171503 01-09

SLEEP RESEARCH. A CRITICAL REVIEW.
172615 01-11

THE EEG OF SLEEP AND PSYCHOTROPIC DRUGS.
172972 01-13

SLEEP: A TOOL TO STUDY CHLORPROMAZINES ACTION. (UNPUBLISHED PAPER).
173521 01-14

EFFECTS OF MEBUTAMATE ON THE ELECTROENCEPHALOGRAPHIC SLEEP PROFILE.
174348 01-14

THE EFFECT OF LORAZEPAM ON ANXIOUS INSOMNIACS SLEEP AS RECORDED IN THE HOME ENVIRONMENT.
177318 02-14

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: IV. THE EFFECTS OF CHLORPROMAZINE.
177716 02-14

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: V. THE EFFECTS OF CHLORAL HYDRATE.
177717 02-14

THE EFFECTS OF LONG-TERM ADMINISTRATION OF PSYCHOTROPIC DRUGS ON HUMAN SLEEP: VI. THE EFFECTS OF CHLORDIAZEPOXIDE.
177718 02-14

DIFFERENTIAL EFFECTS OF ETHANOL AND PENTOBARBITAL ON SLEEP TIME IN C57BL AND BALB MICE.
177733 02-03

TRIAZOLAM: A SLEEP LABORATORY STUDY OF A NEW BENZODIAZEPINE HYPNOTIC.
177747 02-07

DIFFERENTIAL EFFECTS OF D- AND L-AMPHETAMINE ON THE SLEEP OF DEPRESSED PSYCHIATRIC PATIENTS ON AND OFF LITHIUM CARBONATE TREATMENT. (UNPUBLISHED PAPER).
178432 02-09

EFFECT OF 6-HYDROXYDOPAMINE ON THE DURATION OF HEXOBARBITAL SLEEP IN RATS.
178558 02-03

SLEEP CHANGES IN CHRONIC SCHIZOPHRENICS: EFFECTS OF 5-HYDROXYTRYPTOPHAN (5-HTP). (UNPUBLISHED PAPER
178578 02-08

EFFECTS OF DRUGS ON SLEEP.
181393 02-14

AMPHETAMINE AND PENTOBARBITAL EFFECTS ON THE DISCRIMINATIVE RESPONSE CONTROL BY DEPRIVATION OF RAPID EYE MOVEMENT SLEEP (REM).
182245 03-03

AN ELECTROENCEPHALOGRAPHIC STUDY ON THE TOLERANCE OF THE VARIOUS PSYCHIATRIC AND NEUROLOGICAL PATIENTS TO THE HYPNOTIC EFFECTS OF DIPHENHYDRAMINE -- MEASURED BY THE AMOUNTS OF SLEEP EEG AS AN INDICATOR.
182550 03-11

EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON THE RHYTHMS OF WAKEFULNESS SLEEP CYCLE IN RATS.
182553 03-04

THE EFFECT OF ZINC N TETRACOSACTRIN ON GROWTH HORMONE RELEASE DURING SLEEP.
183490 03-13

PHENELZINE, MOOD RESPONSE, AND SLEEP.
183547 03-09

FLUNITRAZEPAM (RO-5-4200) AND SLEEP CYCLE IN INSOMNIAC PATIENTS.
186574 03-11

CLINICAL PHARMACOLOGY AS AN APPROACH TO THE STUDY OF BIOCHEMICAL SLEEP MECHANISMS: THE ACTION OF L-DOPA.
186643 03-14

ONE CASE OF AGRYPNIA (4 MONTHS WITHOUT SLEEP) IN A MORVAN DISEASE: FAVORABLE ACTION OF 5-HYDROXYTRYPTOPHAN.
187237 03-14

THE EFFECT OF ORALLY ADMINISTERED COCAINE ON SLEEP OF DEPRESSED PATIENTS.
187642 04-14

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON SLEEP.
187929 04-14

EFFECT OF PROLONGED CHLORPROMAZINE ADMINISTRATION ON THE SLEEP OF CHRONIC SCHIZOPHRENICS.
188115 04-08

THE EFFECT OF A NEW BENZODIAZEPINE DERIVATIVE NIMETAZEPAM ON THE SLEEP CYCLE IN MAN.
188501 04-07

EFFECTS OF INTRACEREBRAL INJECTION OF 5,6-HYDROXYTRYPTAMINE ON CEREBRAL MONOAMINES AND SLEEP STATES IN THE CAT/.
189023 04-02

DIFFERENTIAL EFFECTS OF PENTYLENETETRAZOL ON REM SLEEP IN NAIVE AND COBALT EPILEPTIC RATS.
189407 04-03

INHIBITION OF THE SLEEP RELATED PEAK IN PHYSIOLOGIC HUMAN GROWTH HORMONE RELEASE BY SOMATOSTATIN.
190104 04-13

EFFECTS OF METHYLPHENIDATE ON HYPERACTIVE CHILDRENS SLEEP.
190321 04-14

EFFECT OF ATROPINE SULFATE ON THE SLEEP RELATED EEG SPIKE ACTIVITY OF THE TORTOISE, GEOCHELONE-CARBONARIA.
191389 04-03

DIFFERENTIAL EFFECTS OF P-CHLOROPHENYLALANINE ON SLEEP IN TWO PRIMATES, PAPIO-PAPIO AND PAPIO-HAMADRYAS.
191629 04-04

THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON THE COMPOSITION OF DIURNAL SLEEP OF NARCOLEPTICS.
192419 04-11

SLEEP-WAKEFULNESS

EFFECT OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) ON THE DAYTIME SLEEP-WAKEFULNESS PATTERNS IN MONKEYS.
181657 02-02

EFFECT OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) ON THE DAYTIME SLEEP-WAKEFULNESS PATTERNS IN NORMAL AND P-CHLOROPHENYLALANINE INSOMNIAC CATS.
181658 02-02

LONG-TERM ALTERATION OF SLEEP-WAKEFULNESS CYCLE DURING CHRONIC PENTOBARBITAL DOSING AND WITHDRAWAL IN CAT.
191952 04-04

SLEEPING

UPDATING THE SLEEPING PILL.
176011 02-11

EFFECT OF CANNABIS ON PENTOBARBITAL INDUCED SLEEPING TIME AND PENTOBARBITAL METABOLISM IN THE RAT.
179985 02-03

EFFECT OF VARIOUS STEROIDS AND ACTH ON METHYPRYLON PLASMA LEVELS AND SLEEPING TIME IN RATS.
183611 03-03

EFFECTS OF SHORT-TERM ADMINISTRATION OF N-NITROSO COMPOUNDS ON LIVER HISTOLOGY AND PENTOBARBITAL INDUCED SLEEPING TIME IN MICE.
187575 04-04

SLEEPING PILLS AND DREAM CONTENT.
189043 04-14

SLICES

THE UPTAKE, RETENTION AND METABOLISM OF 3H-5-HYDROXYTRYPTAMINE IN BRAIN SLICES AND ILEUM FROM THE RAT: EFFECTS OF COCAINE, DESMETHYLIMIPRAMINE AND RESERPINE. (PH.D. DISSERTATION).
168131 01-03

ALTERATION OF 5-HYDROXYTRYPTAMINE-14C EFFLUX BY NICOTINE IN RAT BRAIN AREA SLICES.
172925 01-03

A CENTRAL EFFECT OF LOCAL ANESTHETICS: PREVENTION AGAINST THE ACCUMULATION OF CYCLIC AMP IN BRAIN SLICES.
182099 02-03

INHIBITION OF C14-ACH UPTAKE IN RAT BRAIN SLICES BY DESMETHYLIMIPRAMINE.
182170 02-03

THE EFFECT OF DOPAMINE RECEPTOR STIMULATING AGENTS AND OF N,O DIBUTYRYL CYCLIC AMP ON C14-DOPAMINE SYNTHESIS IN STRIATAL SLICES OF RATS.
182256 03-03

THE INHIBITION OF (3H) BIOGENIC AMINE ACCUMULATION INTO RAT BRAIN TISSUE SLICES BY VARIOUS TRYPTAMINE DERIVATIVES.
182723 03-03

EFFECTS OF LSD ON SYNTHESIS AND RELEASE OF 5-HT IN RAT BRAIN SLICES.
188164 04-03

EFFECT OF PENTOBARBITAL ON UPTAKE AND RELEASE OF (3H)GABA AND (14C)GLUTAMATE BY BRAIN SLICES.
189031 04-03

INFLUENCE OF MORPHINE AND NALOXONE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189568 04-03

INFLUENCE OF FENTANYL, LEVORPHANOL AND PETHIDINE ON THE RELEASE OF NORADRENALINE FROM RAT BRAIN CORTEX SLICES.
189569 04-03

EFFECT OF DESIPRAMINE ON RAT CORTEX SLICES INCUBATED WITH 3H-DOPAMINE.
190310 04-03

THE MODE OF MORPHINE UPTAKE INTO BRAIN SLICES.
191413 04-03

ADENOSINE ACTION ON SYNAPTIC TRANSMISSION IN BRAIN SLICES.
191945 04-03

TETRAHYDROCANNABINOLS: INHIBITION IN ACETYLCHOLINE SYNTHESIS IN REGIONAL RAT BRAIN SLICES.
191998 04-03

EFFECT OF CHRONIC TREATMENT WITH DESIPRAMINE (DMI) AND IPRINDOLE (IP) ON THE NOREPINEPHRINE (NE) SENSITIVE ADENYLATE CYCLASE SYSTEM IN SLICES OF THE RAT LIMBIC FOREBRAIN.
192003 04-03

SLUGGISH

APHRODISIAC EFFECT OF L-DOPA AND APOMORPHINE IN MALE SEXUALLY SLUGGISH RATS.
188519 04-03

SMOKE

REPEAT ADMINISTRATION OF MARIHUANA SMOKE TO HUMANS.
188120 04-13

SMOKERS

STUDIES OF THE IMMUNE RESPONSE IN CHRONIC MARIHUANA SMOKERS.
191961 04-13

SMOKING

THE EFFECT OF CAFFEINE, NITRAZEPAM AND CIGARETTE SMOKING ON THE CONTINGENT NEGATIVE VARIATION IN MAN.
187350 04-13

SMOOTH

MICROVASCULAR SMOOTH MUSCLE HYPERRESPONSIVENESS DURING HALOTHANE ANESTHESIA IN THE RAT.
182185 02-03

THE ADDITIVE EFFECTS OF TRANQUILIZERS AND DOPAMINE ON SMOOTH MUSCLE.
187804 04-03

SOCIAL
THE SOCIAL PLAY BEHAVIOR OF CHIMPANZEES ACCORDING TO A PSYCHOPHARMACOLOGICAL TEST/.
168838 01-04
THE RELATIONSHIP OF MARIHUANA AND SOCIAL BEHAVIOR.
169084 01-13
MARIHUANA AND SOCIAL BEHAVIOR.
175003 02-14
EFFECTS OF PSYCHOACTIVE DRUGS ON NONVERBAL COMMUNICATION AND GROUP SOCIAL BEHAVIOR OF MONKEYS.
175317 02-04
SOCIAL IMPLICATIONS OF PSYCHOTROPIC DRUGS.
182770 03-17
SOCIAL HIERARCHY IN MONKEYS (MACACA-MULATTA) MODIFIED BY CHLORDIAZEPOXIDE HYDROCHLORIDE.
183863 03-04
TREATMENT EFFECTS ON THE SOCIAL ADJUSTMENT OF DEPRESSED PATIENTS.
185322 03-10
EFFECTS OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL ON SOCIAL BEHAVIOR OF SQUIRREL MONKEY DYADS IN A WATER COMPETITION SITUATION.
187640 04-04

SOCIETY
THE PROBLEM OF ANXIETY IN A NON-WESTERN SOCIETY: A COMBINED CHEMOTHERAPEUTIC AND PSYCHOTHERAPEUTIC APPROACH.
171162 01-10

SOCIOPSYCHIATRIC
CLINICAL DATA AND SOCIOPSYCHIATRIC IMPLICATIONS OF OUTPATIENT TREATMENT WITH LONG-TERM PHENOTHIAZINES.
182791 03-09

SOCIOTHERAPEUTIC
INTERACTION BETWEEN NEUROLEPTIC THERAPY AND SOCIOTHERAPEUTIC APPROACH. AN INVESTIGATION WITH PENFLURIDOL AND HALOPERIDOL.
192431 04-08

SODIUM
NEGATIVE SODIUM BALANCE IN LITHIUM CARBONATE TOXICITY: EVIDENCE OF MINERALOCORTICOID BLOCKADE.
169869 01-15
ANALGESIC POTENCY OF SODIUM SALICYLATE, INDOMETHACIN, AND CHLORDIAZEPOXIDE AS MEASURED BY THE SPATIAL PREFERENCE TECHNIQUE IN THE RAT.
171301 01-02
CNS DEPRESSION IN THE ABSENCE OF PROLACTIN RELEASE FOLLOWING INTRAARTERIAL INJECTIONS OF SODIUM PENTOTHAL IN THE PROESTROUS RAT.
173257 01-03
COMPARATIVE STUDIES OF SYNAPTIC MEMBRANE PROTEIN SOLUBILIZATION BY CHLORPROMAZINE AND SODIUM DODECYLSULFATE.
176703 02-03
MECHANISMS UNDERLYING POTENTIATION OF BARBITURATE ACTION BY SODIUM NITRITE IN THE MOUSE: THE ROLE OF METHEMOGLOBIN INDUCED HYPOXIA.
182721 03-03
THE EFFECTS OF PSYCHIC STIMULANTS ON THE ACTIVITY OF POTASSIUM AND SODIUM ION STIMULATED ATPASE IN THE MICROSOMAL FRACTIONS OF THE BRAIN OF RATS.
183518 03-01
SEDATIVE OR TRANQUILLIZER? A COMPARISON OF THE HYPNOTIC EFFECTS OF CHLORDIAZEPOXIDE AND AMYLOBARBITONE SODIUM.
184438 03-14
JOINT EFFECTS OF SODIUM AMYLOBARBITONE AND AMPHETAMINE SULPHATE ON RESISTANCE TO EXTINCTION OF A REWARDED RUNNING RESPONSE IN THE RAT.
186573 03-04
A COMPARATIVE STUDY OF DANTROLENE SODIUM AND OTHER SKELETAL MUSCLE RELAXANTS WITH THE STRAUB TAIL MOUSE.
186638 03-04
HYPERTHERMIC EFFECT OF PALMITATE SODIUM, STEARATE SODIUM AND OLEATE SODIUM INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS CATS.
186640 03-03
THE EFFECT OF CHLORPROMAZINE AND AMYTAL SODIUM ON THE CONFORMITY OF ADOLESCENTS UNDER PSYCHIATRIC OBSERVATION.
191776 04-14

SOLE
CARBAMAZEPINE SOLE ANTICONVULSANT FOR FOCAL EPILEPSY OF CHILDHOOD.
189174 04-11

SOLUBILITY
PHYSIOCHEMICAL PROPERTIES, SOLUBILITY, AND PROTEIN BINDING OF DELTA9-TETRAHYDROCANNABINOL. (UNPUBLISHED PAPER).
188256 04-01

SOLUBILIZATION
COMPARATIVE STUDIES OF SYNAPTIC MEMBRANE PROTEIN SOLUBILIZATION BY CHLORPROMAZINE AND SODIUM DODECYLSULFATE.
176703 02-03
SOLUBILIZATION AND PURIFICATION OF BRAIN RNA POLYMERASE.
180537 02-06

SOLUBLE
EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF WATER SOLUBLE 1-DELTA9-TETRAHYDROCANNABINOL (W THC) ON WEB-BUILDING OF SPIDERS.
182193 02-04
COMPARATIVE PROPERTIES OF SOLUBLE AND PARTICULATE CATECHOL-O-METHYLTRANSFERASE FROM RAT RED BLOOD CELL: PRELIMINARY OBSERVATIONS.
191523 04-01
THE EFFECTS OF DELTA9-THC AND A WATER SOLUBLE DERIVATIVE ON PGE1 SYNTHESIS IN THE CORPUS-STRIATUM.
191964 04-03

SOLVENT
MOLECULAR ORBITAL STUDIES ON THE CONFORMATION OF HALLUCINOGENIC INDOLEALKYLAMINES AND RELATED COMPOUNDS. THE ISOLATED MOLECULES AND THE SOLVENT EFFECT.
183406 03-01

SOMATIC
A COMPARISON OF SOMATIC REFLEX EFFECTS OF THREE PSYCHOTROPIC AGENTS IN THE CHLORALOSE CAT.
182126 02-03
SOMATIC SIDE-EFFECTS OF PSYCHOTHERAPEUTIC DRUGS IN CHILDHOOD.
183183 03-15
RESPONSE TO PROPRANOLOL AND DIAZEPAM IN SOMATIC AND PSYCHIC ANXIETY.
188887 04-10

SOMATIZED
USE OF LORAZEPAM IN TREATING PATIENTS WITH NEUROTIC AND SOMATIZED PSYCHOVEGETATIVE SYMPTOMS.
174136 01-09

SOMATOSENSORY
CHANGES IN SOMATOSENSORY EVOKED POTENTIALS PRODUCED BY DRUGS USED IN THE TREATMENT OF AFFECTIVE DISORDERS.
169092 01-09
REINVESTIGATION ON THE EFFECTS OF THIOPENTAL ON THE HUMAN SOMATOSENSORY EVOKED RESPONSE.
174505 01-13

SOMATOSTATIN
INHIBITION OF THE SLEEP RELATED PEAK IN PHYSIOLOGIC HUMAN GROWTH HORMONE RELEASE BY SOMATOSTATIN.
190104 04-13

SOMNAMBULISM
SOMNAMBULISM IN CHILDREN -- CLINICAL COMMUNICATION.
182870 03-17

SOMNOLENCE
A CASE OF PERIODIC SOMNOLENCE IMPROVED BY THE CO-MEDICATION OF L-DOPA AND METHYLPHENIDATE.
185241 03-14

SOURCE
THREO-3,4 DIHYDROXYPHENYLSERINE, A POOR SOURCE OF NORADRENALINE IN THE RAT.
167445 01-03

SPASMOLYTIC
A NOVEL SPASMOLYTIC AND CNS ACTIVE AGENT: 3-(2-BENZYLMETHYLAMINOETHYL) BENZOIC ACID METHYL ESTER HYDROCHLORIDE.
184581 03-02

SPATIAL
ANALGESIC POTENCY OF SODIUM SALICYLATE, INDOMETHACIN, AND CHLORDIAZEPOXIDE AS MEASURED BY THE SPATIAL PREFERENCE TECHNIQUE IN THE RAT.
171301 01-02
SPATIAL AND PAW PREFERENCES IN RATS: THEIR RELATIONSHIP TO RATE-DEPENDENT EFFECTS OF D-AMPHETAMINE.
177409 02-04

SPECIES
EEG CHARACTERISTICS IN VARIOUS SPECIES OF ANIMAL AND THEIR RELATION TO THE CNS EFFECTS OF DRUGS.
182096 02-03
CACTUS ALKALOIDS. XXII. DOLICHOTHELE SURCULOSA AND OTHER DOLICHOTHELE SPECIES.
192879 04-01

SPECIFIC
BETA-PHENYLETHYLAMINE: A SPECIFIC SUBSTRATE FOR TYPE B MONOAMINE OXIDASE OF BRAIN.
168437 01-03
SPECIFIC ACTIVATION OF STRIATAL TYROSINE HYDROXYLASE (TH) BY NEUROLEPTICS. (UNPUBLISHED PAPER).
170755 01-03
SPECIFIC INDICATIONS FOR DIFFERENT CLASSES OF PHENOTHIAZINES.
171505 01-08

SPECIFIC FACILITATION OF MAZE LEARNING BY A PEPTIDE EXTRACTED FROM TRAINED MOUSE BRAIN.
176868 02-04

AMPHETAMINE IN HUMAN PLASMA: A SENSITIVE AND SPECIFIC ENZYMATIC ASSAY.
177403 02-16

EFFECT OF ACUTE AND CHRONIC MORPHINE ON SPECIFIC RADIOACTIVITIES OF CHOLINE AND ACETYLCHOLINE IN MOUSE BRAIN.
182226 03-03

INTRACEREBRAL INJECTION OF 6-HYDROXYDOPAMINE AND HYDROGEN PEROXIDE IN CATS: SPECIFIC AND NONSPECIFIC EFFECTS ON STRIATAL BIOGENIC AMINES.
188426 04-03

EVIDENCE FOR A SPECIFIC UPTAKE OF DOPAMINE BY DOPAMINERGIC TERMINALS OF THE RAT CEREBRAL CORTEX.
188978 04-03

SUPPRESSION OF SEIZURES BY TAURINE -- SPECIFIC OR NONSPECIFIC?
189843 04-03

SOME CONSIDERATIONS IN THE DESIGN OF SUBSTRATE AND TISSUE SPECIFIC INHIBITORS OF MAO.
191499 04-01

THE LOCALIZATION AND CHARACTERIZATION OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE ACTIVITY IN SPECIFIC REGIONS OF THE CNS.
191932 04-03

SPECIFICITY

ON THE SPECIFICITY OF DOPAMINE RELEASE BY AMANTADINE.
178557 02-03

THE SPECIFICITY OF ANTIMESCALINE ANTIBODY PRODUCED IN RABBITS.
182186 02-03

SPECIFICITY OF BLOCKADE OF THE NICOTINE INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ADRENERGIC NEURONS OF THE GUINEA-PIG HEART BY VARIOUS PHARMACOLOGICAL AGENTS.
186676 03-03

SPECTRODENSITOMETRY

SIMULTANEOUS ANALYSIS OF A 1,5 BENZODIAZEPINE AND ITS METABOLITE IN BLOOD AND URINE BY SPECTRODENSITOMETRY.
176871 02-16

SPECTROMETRIC

GAS CHROMATOGRAPHIC - MASS SPECTROMETRIC STUDIES ON TRICYCLIC PSYCHOTROPIC DRUGS.
169073 01-01

SPECTROSCOPY

DIRECT DETERMINATION OF LITHIUM IN SERUM BY ATOMIC ABSORPTION SPECTROSCOPY.
181653 02-06

CONFORMATIONAL ANALYSIS OF ACRIDAN DERIVATIVES BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY. A RELATIONSHIP BETWEEN CONFORMATION AND PHARMACOLOGICAL ACTIVITY.
190715 04-01

SPEECH

EFFECTS OF LSD-25 AND DEXTROAMPHETAMINE ON SPEECH RHYTHMS IN PSYCHOTHERAPY DIALOGUES.
168420 01-12

EFFECT OF ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL ON MEMORY, SPEECH, AND PERCEPTION OF THERMAL STIMULATION: RESULTS WITH FOUR NORMAL HUMAN VOLUNTEER SUBJECTS. PRELIMINARY REPORT.
177674 02-14

SPEED

TRANSPORT OF SYNAPTOSOMAL TRYPTOPHAN AND CEREBRAL TYROSINE: INCREASE IN THE SPEED OF UPTAKE OF RESERPINE OR THE INHIBITION OF MONOAMINE OXIDASE.
179988 02-13

SPEEDS

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON DELAYED MATCHING-TO-SAMPLE CHOICE SPEEDS IN CHIMPANZEES.
171886 01-04

SPIDERS

EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF WATER SOLUBLE 1-DELTA9-TETRAHYDROCANNABINOL (W THC) ON WEB-BUILDING OF SPIDERS.
182193 02-04

SPIKE

ON THE STUPOROUS AND HYPOMANIC EPISODES ASSOCIATED WITH SPIKE AND WAVE IN ELECTROENCEPHALOGRAM.
181388 02-11

THE EFFECTS OF INTRAVENTRICULARLY ADMINISTERED CATECHOLAMINES AND SEROTONIN ON THE RESERPINE INDUCED SPIKE WAVES RECORDED FROM THE MEDICAL NUCLEUS TRAPEZOIDES IN THE RABBIT.
182094 02-03

EFFECT OF ATROPINE SULFATE ON THE SLEEP RELATED EEG SPIKE ACTIVITY OF THE TORTOISE, GEOCHELONE-CARBONARIA.
191389 04-03

SPINAL

PARADOXICAL BLOCKADE BY P-CHLOROPHENYLALANINE OF 5-HYDROXYTRYPTOPHAN FACILITATORY ACTIONS ON SPINAL REFLEXES.
168436 01-03

EFFECT OF CHLORIMIPRAMINE ON THE RATE OF TRYPTOPHAN HYDROXYLATION IN THE INTACT AND TRANSECTED SPINAL CORD.
168751 01-03

THE EFFECT OF L-TRYPTOPHAN (TP) ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) REFLEXES IN ACUTE DECEREBRATE SPINAL CATS AND THE EFFECT OF PRETREATMENT WITH P-CHLOROPHENYLALANINE (PCPA) ON THE ACTION OF TP. (UNPUBLISHED PAPER).
170874 01-03

EFFECTS OF P-CHLOROPHENYLALANINE (PCPA) AND NIALAMIDE ON 5-HYDROXYTRYPTAMINE (5-HT) IN THE TRANSECTED SPINAL CORD.
171623 01-03

INHIBITION BY MORPHINE OF REPETITIVE ACTIVATION OF CAT SPINAL MOTONEURONES.
172926 01-03

THE EFFECT IN THE CAT OF TRYPTAMINE (T) AND LSD ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) SPINAL REFLEXES. (UNPUBLISHED PAPER).
174480 01-12

ACTION OF CONVULSANTS ON ROOT POTENTIALS AND AMINO ACID RESPONSES IN ISOLATED FROG SPINAL CORD. (UNPUBLISHED PAPER).
177976 02-03

EFFECTS OF BENZODIAZEPINES ON SPINAL REFLEXES IN CATS.
182097 02-03

EFFECTS OF PROLONGED LSD-25 ADMINISTRATION UPON NEURONS OF SPINAL CORD GANGLIA TISSUE CULTURES.
185112 03-03

THE EFFECTS OF MORPHINE, ETORPHINE AND SINOMENINE ON THE CHEMICAL SENSITIVITY AND SYNAPTIC RESPONSES OF RENSHAW CELLS AND OTHER SPINAL NEURONES IN THE RAT.
188201 04-03

STUDIES ON CONVULSANTS IN THE ISOLATED FROG SPINAL CORD. I. ANTAGONISM OF AMINO ACID RESPONSES. (UNPUBLISHED PAPER)
190727 04-03

EFFECTS OF PHENETHYLAMINE (PEA) IN THE CHRONIC SPINAL DOG.
191904 04-03

SPINDLE

PHARMACOLOGIC ANALYSIS OF THE CAUDATE SPINDLE IN CATS.
182124 02-03

EFFECTS OF DOPAMINERGIC STIMULANTS ON THE CAUDATE SPINDLE.
182125 02-03

CHLORDIAZEPOXIDE INDUCED BETA SPINDLE ACTIVITY IN RATS.
192416 04-03

SPIRAL

THE SPIRAL AFTEREFFECT (SAE) AS A MEASURE OF MOTION SICKNESS SUSCEPTIBILITY AND THE EFFECT ON THE SAE OF AN ANTIMOTION SICKNESS DRUG AND A CENTRAL NERVOUS SYSTEM DEPRESSANT.
172780 01-03

SPIRAMIDE

DRINKING BEHAVIOUR AND BRAIN DOPAMINE: ANTAGONISTIC EFFECT OF TWO NEUROLEPTIC DRUGS (PIMOZIDE AND SPIRAMIDE) UPON AMPHETAMINE OR APOMORPHINE-INDUCED HYPODIPSIA.
174035 01-04

SPLANCHNIC

ALTERED NOREPINEPHRINE SYNTHESIS OF SPLANCHNIC VESSELS IN NEUROGENIC HYPERTENSION.
188198 04-03

SPLEEN

EFFECT OF OXOTREMORINE AND PHYSOSTIGMINE ON CHOLINE LEVELS IN MOUSE WHOLE BRAIN, SPLEEN AND CEREBELLUM.
189893 04-03

SPONSORED

NIMH SPONSORED CHEMICAL SYNTHESIS PROGRAM.
182444 03-01

SPONTANEOUS

LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND GAMMA-AMINOBUTYRIC ACID (GABA) INTERACTION ON SPONTANEOUS POTENTIALS AND THE EVOKED RESPONSE IN THE AVIAN TECTUM.
169689 01-03

EFFECTS OF DELTA9-THC, LSD-25 AND SCOPOLAMINE ON CONTINUOUS, SPONTANEOUS ALTERNATION IN THE Y-MAZE.
171306 01-04

DRUG DEPENDENCE TEST OF PHENOBARBITAL AND MORPHINE IN RATS BY SPONTANEOUS INTAKE.
182104 02-04

EFFECTS OF ALKALI METALS ON SPONTANEOUS MOTOR ACTIVITIES OF MICE.
182637 03-02

THE ACTION OF D-AMPHETAMINE ON SPONTANEOUS ACTIVITY IN THE CAUDATE NUCLEUS AND RETICULAR FORMATION OF THE RAT.
185264 03-03

EFFECTS OF METHAMPHETAMINE, PIPRADROL, AND METHYLPHENIDATE ON INSTRUMENTAL CONDITIONING AND SPONTANEOUS MOTOR ACTIVITY IN THE IMMATURE RAT.
186568 03-04

BLOCKING OF THE EFFECT OF A DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC) ON SPONTANEOUS MOTOR ACTIVITY IN THE RAT BY IMMUNIZATION WITH A PROTEIN CONJUGATE OF DELTA1-THC.
187129 03-04

INTERACTION OF D-AMPHETAMINE WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS ON FOOD INTAKE AND SPONTANEOUS MOTOR ACTIVITY OF MICE.
189613 04-04

SPRITZ
TO SPRITZ OR NOT TO SPRITZ: THE DOUBTFUL VALUE OF AIMLESS IONTOPHORESIS.
187132 03-06

SPROUTING
MUSCLE ABNORMALITIES IN PSYCHOTIC PATIENTS: II. SERUM CPK ACTIVITY, FIBER ABNORMALITIES, AND BRANCHING AND SPROUTING OF SUBTERMINAL NERVES.
187114 03-09

SQUID
NONCHOLINERGIC MECHANISM OF ACTION OF CHOLINERGIC DRUGS ON SQUID AXON MEMBRANES.
186672 03-03

SQUIRREL
EVALUATION OF THE HYPOTHERMIC ACTION OF TETRAHYDROCANNABINOLS IN MICE AND SQUIRREL MONKEYS.
170163 01-03
3H-DELTA9-TETRAHYDROCANNABINOL (THC) METABOLISM IN RHESUS AND SQUIRREL MONKEYS.
175751 02-03
EFFECTS OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL ON SOCIAL BEHAVIOR OF SQUIRREL MONKEY DYADS IN A WATER COMPETITION SITUATION.
187640 04-04
BEHAVIORAL EFFECTS OF COCAINE COMPARED UNDER TWO SCHEDULES OF FOOD PRESENTATION IN THE SQUIRREL MONKEY.
191916 04-04

STABILITY
STABILITY AND MICROANALYSIS OF TETRAHYDROCANNABINOL.
169673 01-16
CONSTITUENTS OF CANNABIS-SATIVA L. V.: STABILITY OF AN ANALYTICAL SAMPLE EXTRACTED WITH CHLOROFORM. (UNPUBLISHED PAPER).
180670 02-01

STAGES
CONSIDERATIONS ON THE USE OF ANALGESIC DRUGS IN DIFFERENT STAGES OF NEOPLASTIC DISEASES.
191604 04-17

STANDARD
CENTRAL NERVOUS SYSTEM AND AUTONOMIC NERVOUS SYSTEM EFFECTS OF AMANTADINE AND OF SOME STANDARD ANTIPARKINSON DRUGS.
177729 02-13
MASS FRAGMENTOGRAPHIC ANALYSIS OF HOMOVANILLIC ACID AND ITS HOMOISO ANALOGUE IN CEREBROSPINAL FLUID USING THE ALPHA DIDEUTERO ACID AS INTERNAL STANDARD.
186566 03-16
TREATMENT OF PHOBIAS BY SYSTEMATIC DESENSITIZATION: COMPARISON OF STANDARD VS METHOHEXITAL AIDED DESENSITIZATION.
189916 04-10

STANDARDIZED
THE STANDARDIZED VIDEOTAPE INTERVIEW AS AN OBJECTIVE DEPENDENT VARIABLE IN PSYCHOTROPIC DRUG RESEARCH.
183635 03-17

STARTLE
CENTRAL MONOAMINES AND THE ACOUSTIC STARTLE REACTION IN RATS. (PH.D. DISSERTATION).
173136 01-04

STATE
BEHAVIOURAL STATE CYCLES IN ABNORMAL INFANTS.
168523 01-14
ON THE RECENTLY REPORTED PHYSIOLOGICAL AND PHARMACOLOGICAL REALITY OF THE HYPNOTIC STATE.
173056 01-13
EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL (DELTA9-THC) ON MEMORY, ATTENTION AND SUBJECTIVE STATE: A DOUBLE-BLIND STUDY.
174043 01-14
CREATIVITY AND THE STATE OF CONSCIOUSNESS.
186025 03-12
AFFECTIVE STATE AND THYROTROPIN AND PROLACTIN RESPONSES AFTER REPEATED INJECTIONS OF THYROTROPIN RELEASING HORMONE IN DEPRESSED PATIENTS.
189076 04-09
EXPERIMENT WITH LITHIUM CARBONATE ON THE TREATMENT OF MANIC STATE.
191670 04-09
EMERGENCY TREATMENT OF AN ACUTE STATE OF MENTAL ABERRATION.
191723 04-09

STATE-DEPENDENT
STATE-DEPENDENT LEARNING PRODUCED BY ADDICTING DRUGS.
169071 01-03
THE STATE-DEPENDENT EFFECTS OF METHYLPHENIDATE AND DEXTROAMPHETAMINE.
185861 03-14
DIFFERENTIATING STIMULUS AND STORAGE HYPOTHESES OF STATE-DEPENDENT LEARNING.
188226 04-14
THE NATURE OF STORAGE DEFICITS AND STATE-DEPENDENT RETRIEVAL UNDER MARIHUANA.
189406 04-14

STATISTICAL
AFRODEX VS. PLACEBO IN THE TREATMENT OF MALE IMPOTENCE: STATISTICAL ANALYSIS OF TWO DOUBLE-BLIND CROSSOVER STUDIES.
181959 02-14

STEADY-STATE
PROTRIPTYLINE STEADY-STATE PLASMA LEVELS IN MAN.
191924 04-13

STEARATE
HYPERTHERMIC EFFECT OF PALMITATE SODIUM, STEARATE SODIUM AND OLEATE SODIUM INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS CATS.
186640 03-03

STELAZINE
CLINICAL TRIAL OF TRIFLUOPERAZINE (STELAZINE R) ON INDONESIAN PSYCHIATRIC PATIENTS.
171161 01-09
THE EFFECT OF CHLORPROMAZINE AND STELAZINE ON LYSOSOMES OF RAT LIVER DURING ACUTE INTOXICATION.
191121 04-03

STEREOCHEMICAL
STEREOCHEMICAL ASPECTS IN THE METABOLISM OF THE PSYCHOTOMIMETIC AMINE 1-(2,5 DIMETHOXY-4-METHYLPHENYL)-2 AMPHETAMINE.
175759 02-03
PSYCHOPHARMACOLOGICAL AGENTS: STEREOCHEMICAL STUDIES.
181391 02-01
STEREOCHEMICAL ASPECTS AND METABOLITE FORMATION IN THE IN VIVO METABOLISM OF THE PSYCHOTOMIMETIC AMINE, 1-2,5-(DIMETHOXY-4-METHYLPHENYL) 2 AMINOPROPANE.
190718 04-03

STEREOCHEMISTRY
QUINAZOLINES AND 1,4 BENZODIAZEPINES.64.COMPARISON OF THE STEREOCHEMISTRY OF DIAZEPAM WITH THAT OF CLOSE ANALOGS WITH MARGINAL BIOLOGICAL ACTIVITY.
185034 03-01

STEREOISOMERS
COMPARATIVE EFFECTS OF STEREOISOMERS OF PSYCHOTOMIMETIC PHENYLISOPROPYLAMINES.
172915 01-03
FORMATION OF NORADRENALINE IN THE RAT BRAIN FROM THE FOUR STEREOISOMERS OF 3,4 DIHYDROXYPHENYLSERINE.
184229 03-03

STEREOSPECIFIC
STEREOSPECIFIC ACTIONS OF DOET (2,5 DIMETHOXY-4-ETHYLAMPHETAMINE) IN MAN.
188121 04-12

STEREOTYPED
POSSIBLE INVOLVEMENT OF A NORADRENERGIC AREA OF THE AMYGDALA WITH STEREOTYPED BEHAVIOUR.
176877 02-04
STEREOTYPED AND AGGRESSIVE BEHAVIOR INDUCED BY SUSTAINED HIGH DOSE OF THEOPHYLLINE IN RATS.
177019 02-04
DISPOSITION OF NORAPOMORPHINE AND N,N PROPYLNORAPOMORPHINE IN MOUSE BRAIN AND ITS CORRELATION WITH STEREOTYPED GNAWING BEHAVIOR.
182131 02-04
CATALEPSY AND STEREOTYPED BEHAVIOUR IN RATS TREATED CHRONICALLY WITH METHADONE: RELATION TO BRAIN HOMOVANILLIC ACID CONTENT.
183606 03-04
EFFECTS OF MORPHINE AND CHLORPROMAZINE ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOUR.
185997 03-04
DRUG-INDUCED STEREOTYPED BEHAVIOR: SIMILARITIES AND DIFFERENCES.
191504 04-04

STEREOTYPIC
A ROLE FOR THE AMYGDALA IN THE DEVELOPMENT OF THE CATALEPTIC AND STEREOTYPIC ACTIONS OF THE NARCOTIC AGONISTS AND ANTAGONISTS IN THE RAT.
186577 03-03

STEREOTYPICAL
PHARMACOKINETIC DISPOSITION OF NORAPOMORPHINE DERIVATIVES AND ITS INFLUENCE ON THE ELICITATION OF STEREOTYPICAL GNAWING. (PH.D. DISSERTATION).
174960 01-03

STEREOTYPIES
ENHANCEMENT OF METHYLPHENIDATE INDUCED STEREOTYPIES BY REPEATED ADMINISTRATION OF NEUROLEPTICS.
186369 03-04
CATALEPSY AND STEREOTYPIES IN RATS TREATED WITH METHADONE; RELATION TO STRIATAL DOPAMINE.
191421 04-03

STEREOTYPY
STEREOTYPY WITH SELECTIVE STIMULATION OF CERTAIN ITEMS OF BEHAVIOUR OBSERVED IN AMPHETAMINE TREATED MONKEYS (CERCOPITHECUS).
180061 02-04
DECREASED ANOREXIA, EXCITEMENT AND STEREOTYPY TO D-AMPHETAMINE AFTER LATERAL HYPOTHALAMIC 6-HYDROXYDOPAMINE (6-OHDA) INJECTIONS.
182136 02-04

STEROID
STEROID PSYCHOSIS: A CASE REPORT.
189042 04-15

STEROIDS
EFFECT OF VARIOUS STEROIDS AND ACTH ON METHYPRYLON PLASMA LEVELS AND SLEEPING TIME IN RATS.
183611 03-03
FURTHER STUDIES ON THE INHIBITION OF DRUG METABOLISM BY PREGNANOLONE AND RELATED STEROIDS.
185866 03-03

STIFF-MAN
SLEEP STUDIES AND THERAPEUTIC TRIAL WITH L-DOPA IN A CASE OF STIFF-MAN SYNDROME.
171134 01-13
THE STIFF-MAN SYNDROME.
190670 04-11

STIMULANT
PSYCHOMOTOR STIMULANT SELF-ADMINISTRATION IN THE RAT.
169028 01-04
AMPHETAMINE USE AND MISUSE WITH RECOMMENDATIONS FOR STIMULANT CONTROL POLICY.
172109 01-17
RESPONSE TO STIMULANT DRUG TREATMENT IN HYPERACTIVE CHILDREN: PREDICTION FROM EEG AND NEUROLOGICAL FINDINGS.
177778 02-11
CENTRAL NERVOUS STIMULANT INDUCED PHYSIOLOGICAL AND PERFORMANCE CHANGES IN ADULTS DURING SUSTAINED PSYCHOMOTOR TRACKING.
179023 02-13
MODIFICATION OF LEARNING AND MEMORY IN GOLDFISH THROUGH THE USE OF STIMULANT AND DEPRESSANT DRUGS.
186583 03-04
COMPARISON OF THE LOCOMOTOR STIMULANT MECHANISMS OF ACTION OF D-AMPHETAMINE AND D-AMPHETAMINE PLUS L-DOPA: POSSIBLE INVOLVEMENT OF SEROTONIN.
187119 03-04
AN INVESTIGATION OF THE BEHAVIOURAL NATURE OF THE PSYCHOMOTOR STIMULANT EFFECT OF AMPHETAMINE.
188620 04-04
A ROLE FOR DOPAMINE IN THE STIMULANT EFFECTS OF AMPHETAMINE ON LOCUS-COERULEUS SELF-STIMULATION.
191984 04-03
THE EFFECT OF CANNABINOID MIXTURES ON THE RESPONSE TO STIMULANT DRUGS IN MICE.
191991 04-04

STIMULANTS
CEREBRAL STIMULANTS AND MINIMAL DYSFUNCTION: SOME QUESTIONS, SOME ANSWERS, AND SOME MORE QUESTIONS.
180992 02-11
INTERACTION OF APOMORPHINE, NEUROLEPTICS AND STIMULANTS WITH ALPHA-METHYL-M-TYRAMINE, A FALSE DOPAMINERGIC TRANSMITTER.
181809 02-03
EFFECTS OF CNS STIMULANTS ON OPERANT BEHAVIOR.
182110 02-04
EFFECTS OF DOPAMINERGIC STIMULANTS ON THE CAUDATE SPINDLE.
182125 02-03
THE EFFECTS OF PSYCHIC STIMULANTS ON THE ACTIVITY OF POTASSIUM AND SODIUM ION STIMULATED ATPASE IN THE MICROSOMAL FRACTIONS OF THE BRAIN OF RATS.
183518 03-01
THE ANTAGONISM BETWEEN CHOLINOMIMETIC AGONISTS AND BETA-ADRENOCEPTOR STIMULANTS: THE DIFFERENTIATION BETWEEN BETWEEN FUNCTIONAL AND METAFFINOID ANTAGONISM.
191420 04-03
EFFECT OF CHRONIC TREATMENT WITH CENTRAL STIMULANTS ON BRAIN MONOAMINES AND SOME BEHAVIOURAL AND PHYSIOLOGICAL FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS.
191503 04-03

STIMULATE
A ROLE OF THE DIETARY LIPID IN THE ABILITY OF PHENOBARBITAL TO STIMULATE DRUG DETOXIFICATION.
175859 02-03
AMANTADINE MAY STIMULATE DOPAMINE AND NORADRENALINE RECEPTORS.
183868 03-03

STIMULATED
THE EFFECTS OF PSYCHIC STIMULANTS ON THE ACTIVITY OF POTASSIUM AND SODIUM ION STIMULATED ATPASE IN THE MICROSOMAL FRACTIONS OF THE BRAIN OF RATS.
183518 03-01

STIMULATING
MELANOCYTE STIMULATING HORMONE RELEASE INHIBITING HORMONE AS AN ANTIDEPRESSANT: A PILOT STUDY.
171501 01-09
THE EFFECT OF DOPAMINE RECEPTOR STIMULATING AGENTS AND OF N,O DIBUTYRYL CYCLIC AMP ON C14-DOPAMINE SYNTHESIS IN STRIATAL SLICES OF RATS.
182256 03-03
INFLUENCE OF TETRACOSACTRIN (T) AND BETA-MELANOCYTE STIMULATING HORMONE (MSH) ON DEPRESSION OF THE SEGMENTAL REFLEX BY MORPHINE (MS). (UNPUBLISHED PAPER).
183324 03-03
SELECTIVE RESPIRATORY STIMULATING ACTION OF DOXAPRAM COMPARED TO PENTYLENETETRAZOL.
183887 03-03
FURTHER EVIDENCE FOR A DOPAMINE RECEPTOR STIMULATING ACTION OF AN ERGOT ALKALOID.
188739 04-03
EFFECTS OF PIRIBEDIL (ET-495) -- A DOPAMINERGIC RECEPTOR STIMULATING AGENT IN PARKINSONS DISEASE.
191522 04-13
DIFFERENTIAL INCREASE OF BEHAVIORAL AND EXTRAPYRAMIDAL STIMULATING ACTIONS OF NEUROLEPTICS BY ALPHA-METHYLTYROSINE PRETREATMENT IN RATS.
192016 04-04

STIMULATION
EFFECTS OF DOPAMINE RECEPTOR STIMULATION AND BLOCKADE ON RO-4-1284 INDUCED ENHANCEMENT OF ELECTROSHOCK SEIZURE.
167287 01-03
LSD EFFECTS ON SIGNAL-TO-NOISE RATIO AND LATERALIZATION OF VISUAL CORTEX AND LATERAL GENICULATE DURING PHOTIC STIMULATION.
167449 01-03
STIMULATION OF BEHAVIOR IN THE RAT BY CYCLAZOCINE: EFFECTS OF NALOXONE.
168439 01-04
POSSIBLE INVOLVEMENT OF CYCLIC NUCLEOTIDES IN THE STIMULATION OF PITUITARY FUNCTION ELICITED BY RESERPINE. (UNPUBLISHED PAPER).
170086 01-03
EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON ATTACK ELICITED BY HYPOTHALAMIC STIMULATION: RELATION TO BRAIN BIOGENIC AMINES.
170162 01-04
EFFECT OF DOPAMINERGIC STIMULATION OR BLOCKADE ON MORPHINE WITHDRAWAL AGGRESSION.
171300 01-04
MODIFICATION OF STIMULATION BOUND BEHAVIOR BY TRIFLUOPERAZINE AND AMPHETAMINE IN RATS. (PH.D. DISSERTATION).
173158 01-04
STIMULATION OF SEROTONIN N-ACETYLTRANSFERASE IN PINEAL ORGAN CULTURE BY DRUGS.
177128 02-03
DOPAMINE IN THE MESOLIMBIC SYSTEM OF THE RAT BRAIN: ENDOGENOUS LEVELS AND THE EFFECTS OF DRUGS ON THE UPTAKE MECHANISM AND STIMULATION OF ADENYLATE CYCLASE ACTIVITY.
177131 02-03
THE THALAMIC RAT: GENERAL BEHAVIOR, OPERANT LEARNING WITH REWARDING HYPOTHALAMIC STIMULATION, AND EFFECTS OF AMPHETAMINE.
177477 02-04
EFFECT OF ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL ON MEMORY, SPEECH, AND PERCEPTION OF THERMAL STIMULATION: RESULTS WITH FOUR NORMAL HUMAN VOLUNTEER SUBJECTS. PRELIMINARY REPORT.
177674 02-14
INHIBITION OF ANTICHOLINERGIC DRUG-INDUCED LOCOMOTOR STIMULATION IN MICE BY ALPHA-METHYLTYROSINE.
177840 02-03
THE EFFECT OF DIAZEPAM ON SOME CARDIOVASCULAR AND RESPIRATORY REFLEXES ELICITED BY AFFERENT ABDOMINAL VAGUS STIMULATION.
178945 02-03
STIMULATION OF BRAIN AROMATIC ALKYLAMINE N-METHYLTRANSFERASE ACTIVITY BY FAD AND METHYLCOBALAMIN.
180020 02-03
INHIBITORY EFFECT OF DOXEPIN ON AGONISTIC BEHAVIOUR ELICITED BY HYPOTHALAMIC STIMULATION IN THE CAT.
180044 02-04

STEREOTYPY WITH SELECTIVE STIMULATION OF CERTAIN ITEMS OF BEHAVIOUR OBSERVED IN AMPHETAMINE TREATED MONKEYS (CERCOPITHECUS).
180061 02-04

RELATIVE IMPORTANCE OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS FOR THE STIMULATION OF LOCOMOTOR ACTIVITY INDUCED BY AMPHETAMINE AND OTHER DRUGS.
182209 02-04

THE EFFECT OF PSYCHOTROPIC AGENTS ON THE FORMATION OF AVOIDANCE REACTION IN ALBINO RATS DURING ELECTROPAIN STIMULATION OF ANOTHER RAT.
183206 03-04

EVIDENCE FOR REDISTRIBUTION OF FILTRATE AMONG NEPHRONS AFTER BETA- ADRENERGIC STIMULATION AND BLOCKADE.
184222 03-03

THE EFFECT OF HYPOTHALAMIC STIMULATION ON ORAL INGESTION OF DIAZEPAM IN RATS.
184238 03-04

EFFECTS OF CENTRALLY APPLIED DRUGS ON PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION.
185902 03-03

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: IV. INFLUENCE OF AMPHETAMINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
185961 03-04

RELUCTANCE OF RATS TO DRINK HASHISH SUSPENSIONS: FREE-CHOICE AND FORCED CONSUMPTION, AND THE EFFECTS OF HYPOTHALAMIC STIMULATION.
186586 03-04

DIFFERENTIAL EFFECTS OF PILOCARPINE AND SCOPOLAMINE ON THE PERFORMANCE OF A LIGHT DARK DISCRIMINATION MAINTAINED BY ELECTRICAL STIMULATION OF THE BRAIN.
186701 03-03

EFFECTS OF LOCUS-COERULEUS STIMULATION ON HIPPOCAMPAL UNIT ACTIVITY AND ON BEHAVIOR IN UNRESTRAINED RATS. (UNPUBLISHED PAPER).
187499 04-04

FAILURE OF BETA-ADRENERGIC RECEPTOR BLOCKADE TO PREVENT ARRHYTHMIAS INDUCED BY SYMPATHETIC NERVE STIMULATION.
187923 04-03

INHIBITORY EFFECT OF DOPAMINERGIC STIMULATION ON GH RELEASE IN ACROMEGALY.
188350 04-13

STIMULATION OF A DOPAMINE SENSITIVE ADENYLATE CYCLASE IN HOMOGENATES OF RAT STRIATUM BY A METABOLITE OF PIRIBEDIL (ET-495).
189616 04-03

THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. I. NEURONAL RESPONSES TO STIMULATION OF THE RETICULAR FORMATION.
189855 04-03

THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. II. COMPARISON OF THE NEURONAL RESPONSES TO RETICULAR AND OTHER STIMULI.
189856 04-03

THE MOTIVATIONAL CONSEQUENCES OF CHOLINERGIC STIMULATION OF THE MEDIAL SEPTAL AREA.
190260 04-04

NEUROCHEMICAL ANALYSIS OF AGGRESSIVE - DEFENSIVE BEHAVIOR ELICITED BY ELECTRICAL STIMULATION OF THE HYPOTHALAMUS AND CENTRAL GRAY MATTER.
191784 04-02

INFLUENCE OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTS OF ELECTRICAL STIMULATION AND MICROINJECTION OF ACETYLCHOLINE, SEROTONIN AND NORADRENALINE INTO THE MESENCEPHALON.
191786 04-02

ACTION OF HALOPERIDOL AND TRIFLUOPERAZINE ON THE MOTOR RESPONSES ELICITED BY ELECTRICAL STIMULATION OF THE BRAIN IN RABBITS.
191787 04-02

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
191944 04-04

STIMULATORY

DISSOCIATION OF STIMULATORY AND SYNTHETIC PHASES IN THE INDUCTION OF TYROSINE HYDROXYLASE.
171785 01-03

LACK OF EFFECTS OF CYCLOHEXIMIDE ON TOLERANCE DEVELOPMENT TO A STIMULATORY EFFECT OF MORPHINE ON MICE.
182158 02-03

STIMULI

THE GENERAL LOCUS OF D-AMPHETAMINE-INDUCED DISCRIMINATIVE STIMULI. (PH.D. DISSERTATION).
185725 03-03

HALLUCINOGENS AS DISCRIMINATIVE STIMULI.
188229 04-12

EFFECT OF ANTICONVULSANT DRUGS ON THE NUMBER OF AFFERENT STIMULI NEEDED TO CAUSE A HIPPOCAMPAL SEIZURE DISCHARGE.
189608 04-03

THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. II. COMPARISON OF THE NEURONAL RESPONSES TO RETICULAR AND OTHER STIMULI.
189856 04-03

STIMULUS

EFFECTS OF STIMULUS ASSOCIATED WITH AMOBARBITAL ADMINISTRATION ON AVOIDANCE BEHAVIOR.
175877 02-04

BEHAVIOR AS A STIMULUS: JOINT EFFECTS OF D-AMPHETAMINE AND PENTOBARBITAL.
183890 03-04

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: IV. INFLUENCE OF AMPHETAMINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
185961 03-04

TEMPORALLY RELATED STIMULUS PROPERTIES OF DELTA9-TETRAHYDROCANNABINOL IN MONKEYS.
186567 03-04

THE EFFECTS OF 3,4 DIMETHOXYPHENYLETHYLAMINE IN RATS TRAINED WITH MESCALINE AS A DISCRIMINATIVE STIMULUS.
186667 03-04

INTERACTION AMONG GENOTYPE, UNCONDITIONED STIMULUS, D-AMPHETAMINE, AND ONE-WAY AVOIDANCE BEHAVIOR OF RATS.
187702 04-04

DIFFERENTIATING STIMULUS AND STORAGE HYPOTHESES OF STATE-DEPENDENT LEARNING.
188226 04-14

PHARMACOLOGICAL ALTERATIONS IN THE STIMULUS INDUCED RELEASE OF NOREPINEPHRINE FROM THE RABBIT SUPERIOR CERVICAL GANGLION.
191896 04-03

EFFECTS OF CHLORPROMAZINE (CPZ) AND THIORIDAZINE PERFORMANCE AND STIMULUS CONTROL BEHAVIOR.
191974 04-04

STOCKS

COMMON CANNABINOID PHENOTYPES IN 350 STOCKS OF CANNABIS.
192787 04-17

STORAGE

UPTAKE, STORAGE AND RELEASE IN VIVO OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY SYMPATHETIC NERVES OF THE IRIS.
182204 02-03

EVIDENCE FOR PERSISTENT RESERPINE BINDING TO AMINE STORAGE VESICLE MEMBRANES.
182234 03-03

THE EFFECT OF P-CHLOROAMPHETAMINE ON MOTILITY IN RATS AFTER INHIBITION OF MONOAMINE SYNTHESIS, STORAGE, UPTAKE AND RECEPTOR INTERACTION.
185959 03-04

DIFFERENTIATING STIMULUS AND STORAGE HYPOTHESES OF STATE-DEPENDENT LEARNING.
188226 04-14

THE NATURE OF STORAGE DEFICITS AND STATE-DEPENDENT RETRIEVAL UNDER MARIHUANA.
189406 04-14

STORED

AMPHETAMINE AND METHYLPHENIDATE INDUCED RELEASE OF STRIATAL DOPAMINE IN VIVO: DIFFERENTIAL EFFECTS ON NEWLY SYNTHESIZED AND STORED POOLS.
191897 04-03

STRAIGHT

INVERSION BY APOMORPHINE OF THE TENDENCY OF FEMALE RATS TO BE DEFEATED BY MALES WHEN COMPETING FOR FOOD IN A STRAIGHT RUNWAY.
184212 03-04

STRAINS

BEHAVIOR AND SENSITIVITY TO EXPERIMENTAL HYPERTENSION: II. LACK OF CORRELATION BETWEEN CERTAIN BEHAVIOR PATTERNS AND HYPERTENSION IN TWO NEW STRAINS OF RATS.
173256 01-04

EFFECTS OF METHADONE ON ACTIVITY AND ON BRAIN MONOAMINES IN TWO MOUSE STRAINS.
182229 03-03

THE EFFECTS OF P-CHLOROPHENYLALANINE ON MORPHINE ANALGESIA, TOLERANCE AND DEPENDENCE DEVELOPMENT IN TWO STRAINS OF RATS.
187930 04-04

EFFECTS OF MORPHINE SULFATE ON POSITIVELY AND NEGATIVELY REINFORCED BEHAVIOR IN TWO STRAINS OF RATS.
191975 04-04

STRATEGIES

TECHNICAL STRATEGIES FOR THE STUDY OF CATECHOLAMINES IN MAN. (UNPUBLISHED PAPER).
173387 01-03

STRAUB
A COMPARATIVE STUDY OF DANTROLENE SODIUM AND OTHER SKELETAL MUSCLE RELAXANTS WITH THE STRAUB TAIL MOUSE.
186638 03-04

STREET
THE ROLE OF RESEARCH IN DRUG ABUSE INTERVENTION: STREET DRUG ANALYSES.
167382 01-17

STRESS
TRANQUILIZERS AND EXAMINATION STRESS.
168901 01-14
THC: METABOLISM AND SUBJECTIVE EFFECTS OF STRESS. (UNPUBLISHED PAPER).
173516 01-14
A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: III. PIMOZIDE IN THE TREATMENT OF STRESS INDUCED PSYCHIC AND FUNCTIONAL DISORDERS.
183193 03-11
PSYCHOLOGICAL EXPERIMENTATION ON THE EFFECTS OF PROPIRAM FUMARATE AND PROMETHAZINE UNDER NORMAL AND STRESS CONDITIONS.
184617 03-07
THE EFFECT OF MINOR TRANQUILIZERS ON STRESS INDUCED INCREASES IN RAT PLASMA CORTICOSTEROIDS.
186578 03-03
INTERACTION OF MESCALINE AND STRESS ON SHUTTLEBOX ESCAPE/AVOIDANCE IN RATS.
191934 04-04

STRESSED
THE INFLUENCE OF ALDOSTERONE OR METHAMPHETAMINE ON LIVER GLYCOGEN DEPOSITION OF MICE STRESSED BY LONG-TERM ISOLATION.
182105 02-03
THE EFFECT OF METHAMPHETAMINE ON BRAIN ACH CONSUMPTION AND AGGRESSIVENESS IN MICE STRESSED MILDLY BY LONG-TERM ISOLATION.
182108 02-04

STRIATAL
STRIATAL TYROSINE HYDROXYLASES WITH HIGH AND LOW AFFINITY FOR TYROSINE: IMPLICATIONS FOR THE MULTIPLE POOL CONCEPT OF CATECHOLAMINES.
167325 01-03
SPECIFIC ACTIVATION OF STRIATAL TYROSINE HYDROXYLASE (TH) BY NEUROLEPTICS. (UNPUBLISHED PAPER).
170755 01-03
QUANTITATIVE HISTOCHEMICAL STUDIES OF STRIATAL DOPAMINE DEPLETION FOLLOWING DL-ALPHA-METHYL-P-TYROSINE ADMINISTRATION.
172924 01-03
THE INHIBITION OF 3H-DOPAMINE UPTAKE INTO RAT STRIATAL BY VERATRIDINE AND BATRACHOTOXIN. (UNPUBLISHED PAPER).
173380 01-03
DRUG-INDUCED ACTIVATION OF STRIATAL TYROSINE HYDROXYLASE: CHANGES IN THE AFFINITY FOR PTERIDINE COFACTORS. (UNPUBLISHED PAPER).
173381 01-03
THE EFFECT OF DOPAMINE RECEPTOR STIMULATING AGENTS AND OF N,O DIBUTYRYL CYCLIC AMP ON C14-DOPAMINE SYNTHESIS IN STRIATAL SLICES OF RATS.
182256 03-03
INTRACEREBRAL INJECTION OF 6-HYDROXYDOPAMINE AND HYDROGEN PEROXIDE IN CATS: SPECIFIC AND NONSPECIFIC EFFECTS ON STRIATAL BIOGENIC AMINES.
188426 04-03
DOPAMINERGIC INHIBITION OF STRIATAL CHOLINERGIC NEURONS: SYNERGISTIC BLOCKING ACTION OF GAMMA-BUTYROLACTONE AND NEUROLEPTIC DRUGS.
189602 04-03
EFFECTS OF DOPAMINE-LIKE DRUGS ON RAT STRIATAL ADENYL CYCLASE HAVE IMPLICATIONS FOR CNS DOPAMINE RECEPTOR TOPOGRAPHY.
190545 04-03
CATALEPSY AND STEREOTYPIES IN RATS TREATED WITH METHADONE; RELATION TO STRIATAL DOPAMINE.
191421 04-03
AMPHETAMINE AND METHYLPHENIDATE INDUCED RELEASE OF STRIATAL DOPAMINE IN VIVO: DIFFERENTIAL EFFECTS ON NEWLY SYNTHESIZED AND STORED POOLS.
191897 04-03
ACTIVATION OF STRIATAL HYDROXYLASE BY HYDROXYLATED METABOLITES OF CHLORPROMAZINE.
191908 04-03

STRIATUM
EFFECT OF CHLORPROMAZINE AND SOME OF ITS METABOLITES ON THE DOPAMINE SENSITIVE ADENYLATE CYCLASE OF RAT BRAIN STRIATUM.
180060 02-03
EFFECT OF SEVERAL DOPAMINERGIC DRUGS AND TRIHEXYPHENIDYL ON CHOLINERGIC PARAMETERS IN THE RAT STRIATUM.
185995 03-03
EFFECT OF ALPHA-METHYLDOPA ON THE METABOLISM OF DOPAMINE IN THE STRIATUM OF THE RAT.
186694 03-03
STIMULATION OF A DOPAMINE SENSITIVE ADENYLATE CYCLASE IN HOMOGENATES OF RAT STRIATUM BY A METABOLITE OF PIRIBEDIL (ET-495).
189616 04-03

STRIP
THE EFFECT OF CATECHOLAMINES, ACETYLCHOLINE AND SEROTONIN ON THE MORPHINE TOLERANT LONGITUDINAL MUSCLE STRIP OF THE GUINEA-PIG ILEUM.
182161 02-03

STRIPS
EFFECTS OF PSYCHOTOMIMETICS ON VASCULAR STRIPS: STUDIES OF METHOXYLATED AMPHETAMINES AND OPTICAL ISOMERS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE AND 2,5 DIMETHOXY-4-BROMOAMPHETAMINE.
177734 02-03

STRUCTURAL
POTENTIAL PSYCHOTOMIMETICS: BROMOMETHOXYAMPHETAMINES AND STRUCTURAL CONGENERS OF LYSERGIC ACID. (PH.D. DISSERTATION).
173588 01-03
THE EFFECT OF PHENIRAMINE AND ITS STRUCTURAL ANALOGUES ON 5-HYDROXYTRYPTAMINE IN RAT AND MOUSE BRAIN.
175240 02-03
STRUCTURAL FUNCTIONAL ORGANIZATION OF THE HUMAN BRAIN AND THE PATHOPHYSIOLOGY OF THE PARKINSONIAN TYPE HYPERKINESES.
178787 02-13
STRUCTURAL RELATIONSHIP BETWEEN META-SUBSITUTED N-ETHYLAMPHETAMINES AND SELF-ADMINISTRATION IN RHESUS MONKEYS.
191915 04-04

STRUCTURE
CORTICAL AND/OR SUBCORTICAL EFFECTS AS A FUNCTION OF HALLUCINOGENIC DRUG STRUCTURE
191936 04-03

STRUCTURE-ACTIVITY
STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF 5-HT UPTAKE INTO RAT HYPOTHALAMIC HOMOGENATES BY SEROTONIN AND TRYPTAMINE ANALOGUES.
175233 02-03
STRUCTURE-ACTIVITY RELATIONS OF SOME INDOLEALKYLAMINES IN COMPARISON TO PHENETHYLAMINES ON MOTOR ACTIVITY AND ACQUISITION OF AVOIDANCE BEHAVIOR.
186703 03-04

STRUCTURES
EFFECTS OF MOLINDONE ON CNS STRUCTURES: NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATIONS.
172749 01-03
QUANTUM CHEMICAL STUDIES ON DRUG ACTIONS: IV. CORRELATION OF SUBSTITUENT STRUCTURES AND ANTISEROTONIN ACTIVITY IN LYSERGAMIDE SERIES.
174605 01-12
EFFECTS OF LORAZEPAM ON CNS STRUCTURES: NEUROPHYSIOLOGICAL AND BEHAVIORAL CORRELATIONS.
177749 02-03
INFLUENCE OF PSYCHOTROPIC DRUGS ON AGGRESSIVENESS EVOKED BY DESTRUCTION OF ISOLATED STRUCTURES OF THE FOREBRAIN.
191788 04-04

STRYCHNINE
POSTTRIAL STRYCHNINE: LACK OF EFFECT ON CONDITIONED AVOIDANCE LEARNING.
176866 02-04
EFFECTS OF NEONATAL STRYCHNINE ADMINISTRATION ON ACTIVE AVOIDANCE IN RATS.
184242 03-04
STRYCHNINE SULFATE AND PIRACETAM: LACK OF EFFECT ON LEARNING IN THE RAT.
184980 03-04
EXCITABILITY CHANGES DURING THE GRADUAL DEVELOPMENT OF AND RECOVERY FROM PENTYLENETETRAZOL AND STRYCHNINE INDUCED CONVULSIONS IN THE CAT.
191927 04-03

STUDYING
A NEW MODIFICATION FOR STUDYING 5-HT UPTAKE BY BLOOD PLATELETS: A RE-EVALUATION OF TRICYCLIC ANTIDEPRESSANTS AS UPTAKE INHIBITORS.
180055 02-06
AN IMPROVED METHOD FOR STUDYING THE PSYCHOGALVANIC REACTION IN MICE AND ITS INHIBITION BY PSYCHOLEPTIC DRUGS. COMPARISON WITH THE EFFECTS OF OTHER PHARMACOLOGICAL AGENTS.
185749 03-06
THE ISOLATED PERFUSED RAT BRAIN AS A MODEL FOR STUDYING DRUGS ACTING ON THE CNS.
186589 03-06

STUPOROUS
ON THE STUPOROUS AND HYPOMANIC EPISODES ASSOCIATED WITH SPIKE AND WAVE IN ELECTROENCEPHALOGRAM.
181388 02-11

STYLE
PERCEPTUAL STYLE AND PAIN TOLERANCE – II. THE INFLUENCE OF AN ANXIOLYTIC AGENT.
184291 03-14

SUBACUTE
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT (SECOND REPORT): GENERAL PHARMACOLOGY AND SUBACUTE TOXICITY.
168499 01-07

SUBACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MALE AND FEMALE RATS: ORAL ADMINISTRATION FOR ONE MONTH.
177097 02-05

NEUROTOXICOLOGIC STUDIES OF TWO CARBAMATE PESTICIDES IN SUBACUTE ANIMAL EXPERIMENTS.
188874 04-05

SUBCELLULAR
SUBCELLULAR DISTRIBUTION OF DELTA9-TETRAHYDROCANNABINOL IN RAT BRAIN.
181810 02-03

REGIONAL AND SUBCELLULAR DISTRIBUTION OF CHOLINE ACETYLTRANSFERASE IN THE BRAIN OF NORMAL AND MORPHINE TREATED RATS.
182224 03-03

THE EFFECTS OF CHRONIC TREATMENT WITH D-AMPHETAMINE ON FOOD INTAKE, BODYWEIGHT, LOCOMOTOR ACTIVITY AND SUBCELLULAR DISTRIBUTION OF THE DRUG IN RAT BRAIN.
185931 03-03

SUBCELLULAR LOCALIZATION OF H3-DELTA9-TETRAHYDROCANNABINOL IN DOG BRAIN AFTER ACUTE OR CHRONIC ADMINISTRATION.
191970 04-03

INCORPORATION OF 14C-DIHYDROPHENYLALANINE AND 14C-CHOLINE INTO RAT BRAIN SUBCELLULAR PARTICLES AND THE EFFECT OF PSYCHOACTIVE DRUGS.
192426 04-03

SUBCORTICAL
CORTICAL AND/OR SUBCORTICAL EFFECTS AS A FUNCTION OF HALLUCINOGENIC DRUG STRUCTURE
191936 04-03

SUBCUTANEOUSLY
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) ADMINISTERED SUBCUTANEOUSLY TO RABBITS FOR 28 DAYS.
191965 04-03

SUBGALLATE
MENTAL ILLNESS OR METAL ILLNESS? BISMUTH SUBGALLATE.
191215 04-15

SUBJECTED
ACQUISITION AND PERFORMANCE OF AN ATTENTION TASK BY RATS SUBJECTED TO CHRONIC NICOTINE TREATMENT.
176864 02-04

EFFECTS OF CHLORDIAZEPOXIDE ON HEART RATE AND BEHAVIOURAL SUPPRESSION IN PIGS SUBJECTED TO OPERANT CONDITIONING PROCEDURES.
189409 04-04

SUBJECTIVE
ABUSE POTENTIAL OF ETORPHINE (M99) I. SUBJECTIVE EFFECTS AND PHYSICAL DEPENDENCE. (UNPUBLISHED PAPER).
171241 01-14

THC: METABOLISM AND SUBJECTIVE EFFECTS OF STRESS. (UNPUBLISHED PAPER).
173516 01-14

EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL (DELTA9-THC) ON MEMORY, ATTENTION AND SUBJECTIVE STATE: A DOUBLE-BLIND STUDY.
174043 01-14

THE EFFECTS OF HOE-36801 ON MUSCLE ACTIVITY AND BLOOD PRESSURE, ON ATTENTION AND CONCENTRATION, ON TIME JUDGMENT AND SUBJECTIVE RESPONSES IN NEUROTICS AND NORMALS.
192429 04-14

SUBJECTS
DMT ADMINISTRATION TO HUMAN SUBJECTS. (UNPUBLISHED PAPER).
173522 01-12

EFFECT OF ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL ON MEMORY, SPEECH, AND PERCEPTION OF THERMAL STIMULATION: RESULTS WITH FOUR NORMAL HUMAN VOLUNTEER SUBJECTS. PRELIMINARY REPORT.
177674 02-14

A SMALL CONTROLLED STUDY TO DETERMINE THE TIME OF ONSET OF ACTION OF OXYPERTINE AFTER ORAL ADMINISTRATION IN NORMAL SUBJECTS.
182763 03-14

PERFORMANCE ON A VERBAL LEARNING TASK BY SUBJECTS OF HEAVY PAST MARIJUANA USAGE.
190308 04-14

SUBNORMAL
THE EFFECT OF SULTHIAME ON DISTURBED BEHAVIOUR IN MENTALLY SUBNORMAL PATIENTS.
185191 03-14

SUBSEQUENT
AN ANALYSIS OF D-AMPHETAMINE PRODUCED FACILITATION OF AVOIDANCE ACQUISITION IN RATS AND PERFORMANCE CHANGES SUBSEQUENT TO DRUG TERMINATION.
179990 02-04

SUBSTANCE-P
MECHANISM OF ACTION OF SUBSTANCE-P.
184200 03-04

SUBSTANTIAL
SUBSTANTIAL ORAL MORPHINE INTAKE BY THE RAT USING SCHEDULE INDUCED POLYDIPSIA.
182194 02-04

SUBSTITUENT
QUANTUM CHEMICAL STUDIES ON DRUG ACTIONS: IV. CORRELATION OF SUBSTITUENT STRUCTURES AND ANTISEROTONIN ACTIVITY IN LYSERGAMIDE SERIES.
174605 01-12

SUBSTITUTED
EFFECT OF SUBSTITUTED TRYPTAMINES ON THE EFFLUX OF NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
168747 01-03

SYNTHESIS OF SUBSTITUTED CINNAMIDES: RELATIONSHIP BETWEEN ANTICONVULSANT AND MONOAMINE OXIDASE INHIBITORY PROPERTIES.
169818 01-01

SUBSTITUTED PIPERAZINOQUINAZOLONES: RELATIONSHIP BETWEEN SELECTIVE INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND ANTICONVULSANT ACTIVITY.
183598 03-02

SUBSTITUTED BENZOXAZOLE/BENZTHIAZOLE-2-THIONES: INTERRELATIONSHIP BETWEEN ANTICONVULSANT ACTIVITY AND INHIBITION OF NICOTINAMIDE ADENINE DINUCLEOTIDE DEPENDENT OXIDATIONS AND MONOAMINE OXIDASE.
183601 03-03

ANTICONVULSANT ACTIVITY OF SUBSTITUTED INDOLEALKYLAMINES.
185035 03-01

ANTICONVULSANT ACTIVITY AND INHIBITION OF RESPIRATION IN RAT BRAIN HOMOGENATES BY SUBSTITUTED OXADIAZOLES.
185980 03-01

SUBSTITUTION
INFLUENCE OF N1-2-HYDROXYETHYL SUBSTITUTION ON CENTRAL ACTIVITY OF OXAZEPAM AND LORAZEPAM.
178756 02-04

SUBSTRATE
BETA-PHENYLETHYLAMINE: A SPECIFIC SUBSTRATE FOR TYPE B MONOAMINE OXIDASE OF BRAIN.
168437 01-03

PLATELET MONOAMINE OXIDASE ACTIVITY AND SUBSTRATE PREFERENCES IN SCHIZOPHRENIC PATIENTS.
174609 01-14

SOME CONSIDERATIONS IN THE DESIGN OF SUBSTRATE AND TISSUE SPECIFIC INHIBITORS OF MAO.
191499 04-01

SUBSYNAPTOSOMAL
CORTICAL SYNAPTOSOMAL UPTAKE AND SUBSYNAPTOSOMAL DISTRIBUTION OF 3H-NOREPINEPHRINE AND 3H-AMPHETAMINE: MODIFICATION BY TRICYCLIC AND PSYCHOACTIVE AGENTS IN VITRO. (PH.D. DISSERTATION).
172020 01-03

SUBTERMINAL
MUSCLE ABNORMALITIES IN PSYCHOTIC PATIENTS: II. SERUM CPK ACTIVITY, FIBER ABNORMALITIES, AND BRANCHING AND SPROUTING OF SUBTERMINAL NERVES.
187114 03-09

SUBTYPES
DEPRESSION SUBTYPES AND RESPONSE TO PHENELZINE, DIAZEPAM, AND A PLACEBO: RESULTS OF A NINE HOSPITAL COLLABORATIVE STUDY.
171502 01-09

SUCCINATE
A DOUBLE-BLIND CONTROLLED STUDY OF LOXAPINE SUCCINATE IN THE TREATMENT OF ANXIETY NEUROSES.
190196 04-09

SUFFERING
THE USE OF N-DEMETHYLDIAZEPAM IN OUTPATIENTS SUFFERING FROM INSOMNIA.
167340 01-11

HIGH DOSES OF CHLORPROMAZINE AND TRIFLUOPERAZINE IN THE TREATMENT OF PATIENTS SUFFERING FROM SCHIZOPHRENIA.
174589 01-08

SUICIDAL
THE ROLE OF CHEMOTHERAPY IN MANAGING POTENTIALLY SUICIDAL PATIENTS.
178544 02-10

FATAL SUICIDAL INGESTION OF THIORIDAZINE.
189606 04-15

SULFATE
A FEW GALENIC METHOD TO PROLONG THE ACTION OF LITHIUM SULFATE.
180700 02-15
TREATMENT OF CEREBROVASCULAR DISTURBANCES WITH 2-BUTYLAMINO-1-P-HYDROXYPHENYL ETHANOL SULFATE (BAMETHAN).
182790 03-11
SAFETY AND EFFICACY OF ZINC SULFATE IN GERIATRIC PATIENTS.
184177 03-11
EFFECT OF D-AMPHETAMINE SULFATE ON SUSCEPTIBILITY TO AUDIOGENIC SEIZURES IN DBA/2J MICE.
184235 03-03
STRYCHNINE SULFATE AND PIRACETAM: LACK OF EFFECT ON LEARNING IN THE RAT.
184980 03-04
EFFECT OF ATROPINE SULFATE ON THE SLEEP RELATED EEG SPIKE ACTIVITY OF THE TORTOISE, GEOCHELONE-CARBONARIA.
191389 04-03
THE EFFECTS OF AMPHETAMINE SULFATE ON THE DIURNAL RHYTHMS OF MIDBRAIN; CORTEX, NOREPINEPHRINE; SEROTONIN AND BLOOD GLUCOSE LEVELS IN THE MOUSE.
191918 04-03
EFFECTS OF MORPHINE SULFATE ON POSITIVELY AND NEGATIVELY REINFORCED BEHAVIOR IN TWO STRAINS OF RATS.
191975 04-04

SULFOXIDES
ASSAY PROCEDURES FOR THIORIDAZINE, TRIFLUOPERAZINE, AND THEIR SULFOXIDES AND DETERMINATION OF URINARY EXCRETION OF THESE COMPOUNDS IN MENTAL PATIENTS.
183602 03-01

SULPHATE
JOINT EFFECTS OF SODIUM AMYLOBARBITONE AND AMPHETAMINE SULPHATE ON RESISTANCE TO EXTINCTION OF A REWARDED RUNNING RESPONSE IN THE RAT.
186573 03-04
THE INFLUENCE OF IMIPRAMINE, DEXPHENMETRAZINE AND AMPHETAMINE SULPHATE ON THE COMPOSITION OF DIURNAL SLEEP OF NARCOLEPTICS.
192419 04-11

SULPHOXIDE
A POLAROGRAPHIC METHOD FOR THE DETERMINATION OF THE N-OXIDE, N-OXIDE-SULPHOXIDE AND SULPHOXIDE METABOLITES OF CHLORPROMAZINE.
190902 04-06

SULPIRIDE
A CLINICAL EXPERIMENT WITH SULPIRIDE.
171122 01-11
CLINICAL EXPERIENCES WITH FK-880 (SULPIRIDE).
174681 01-08
EXPERIENCE IN THE USE OF FK-880 (SULPIRIDE) IN THE FIELD OF PSYCHIATRY.
177568 02-08
THE COMPARISON OF THERAPEUTIC EFFECTS OF FK-880 (SULPIRIDE) AND PERPHENAZINE IN SCHIZOPHRENIA BY A DOUBLE-BLIND CONTROLLED STUDY.
181378 02-08
CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG: FK-880 (SULPIRIDE), ITS EFFECT ON PATIENTS WITH PSYCHOSOMATIC DISEASES AND PSYCHONEUROSIS.
182731 03-10
TREATMENT OF EXOGENOUS PSYCHOSIS BY THE USE OF FK-880 (SULPIRIDE).
191663 04-09

SULTHIAME
THE EFFECT OF SULTHIAME ON DISTURBED BEHAVIOUR IN MENTALLY SUBNORMAL PATIENTS.
185191 03-14

SUPERIOR
THE ACTIONS OF SEVERAL PSYCHOACTIVE AGENTS UPON THE MUSCARINIC MECHANISMS IN THE SUPERIOR CERVICAL GANGLION OF THE CAT.
183866 03-03
THE EFFECTS OF 5-HYDROXYTRYPTAMINE AND SOME RELATED COMPOUNDS ON THE CAT SUPERIOR CERVICAL GANGLION IN SITU.
184197 03-03
THE EFFECTS OF VARIOUS NICOTINE-LIKE AGENTS IN THE CAT SUPERIOR CERVICAL GANGLION IN SITU.
184202 03-03
THE EFFECTS OF LITHIUM ON HIGH ENERGY PHOSPHATE AND GLUCOSE LEVELS IN THE RAT SUPERIOR CERVICAL GANGLION.
187677 04-03
PHARMACOLOGICAL ALTERATIONS IN THE STIMULUS INDUCED RELEASE OF NOREPINEPHRINE FROM THE RABBIT SUPERIOR CERVICAL GANGLION.
191896 04-03

SUPERSENSITIVE
RESEARCH ON SUPERSENSITIVE LABORATORY METHODS IN SWEDEN.
170302 01-06

SUPERSENSITIVITY
PHARMACOLOGICALLY INDUCED BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE.
169120 01-03
TOLERANCE TO HEXOBARBITAL AND SUPERSENSITIVITY TO PILOCARPINE INDUCED BY CHRONIC BARBITAL TREATMENT IN THE RAT.
171601 01-03
BEHAVIORAL EVIDENCE FOR DOPAMINERGIC SUPERSENSITIVITY AFTER CHRONIC HALOPERIDOL.
180021 02-04
SUPERSENSITIVITY TO DOPAMINERGIC AGONISTS FOLLOWING WITHDRAWAL OF A CHRONIC DIET CONTAINING HALOPERIDOL OR PIMOZIDE.
192012 04-04

SUPPRESSION
PHARMACOLOGICAL SUPPRESSION OF EATING BEHAVIOR IN RELATION TO DIENCEPHALIC NORADRENERGIC RECEPTORS.
174763 01-04
THE SUPPRESSION OF INVOLUNTARY MOVEMENTS WITH TETRABENAZINE.
178618 02-11
ALPHA-ADRENERGIC RECEPTORS MEDIATE SUPPRESSION OF DRINKING INDUCED BY HYPOTHALAMIC AMPHETAMINE INJECTION.
182216 03-03
SUPPRESSION OF LORDOSIS IN GUINEA-PIGS BY ETHAMOXY-TRIPHETOL (MER-25) GIVEN AT LONG INTERVALS (36-46 HR) AFTER ESTRADIOL BENZOATE TREATMENT.
186686 03-04
CHOLINERGIC SUPPRESSION OF TARDIVE DYSKINESIA.
189403 04-11
EFFECTS OF CHLORDIAZEPOXIDE ON HEART RATE AND BEHAVIOURAL SUPPRESSION IN PIGS SUBJECTED TO OPERANT CONDITIONING PROCEDURES.
189409 04-04
SUPPRESSION OF SEIZURES BY TAURINE – SPECIFIC OR NONSPECIFIC?
189843 04-03
CHOLINERGIC SUPPRESSION OF TARDIVE DYSKINESIA.
190314 04-13

SUPPRESSIVE
THE PROBLEMS OF THE CLINICAL USAGE OF NITRAZEPAM: SUPPRESSIVE EFFECTS ON THE PHARYNGEAL REFLEX AND THE COMA, USING OTHER TRANQUILIZERS AT THE SAME TIME.
188450 04-15

SURGE
BLOCKADE OF THE PROESTROUS LH SURGE IN CYCLIC RATS BY BARBITURATE ADMINISTRATION ON DIESTRUS.
175650 02-03

SURGERY
PREANESTHETIC MEDICATION IN ELECTIVE SURGERY: COMPARISON OF INTRAVENOUS DIAZEPAM WITH MEPERIDINE.
167338 01-11
CLINICAL EVALUATION OF AMANTADINE THERAPY FOR PARKINSONISM AND THE SIDE-EFFECTS – IN CASES OF THALAMIC SURGERY AND L-DOPA THERAPY.
190095 04-11

SURVEY
ANTIPSYCHOTIC ACTION OF NEUROLEPTIC AGENTS AND THE FUNCTION OF BASAL GANGLIA (SURVEY OF LITERATURE).
183521 03-17
COMPARATIVE SURVEY OF PSYCHIATRISTS TREATMENT PREFERENCES: CALIFORNIA AND NEW-YORK.
185877 03-08
CHEMOTHERAPY OF DELIRIUM-TREMENS: A SURVEY OF PHYSICIANS PREFERENCES.
192068 04-11

SUSCEPTIBILITY
THE SPIRAL AFTEREFFECT (SAE) AS A MEASURE OF MOTION SICKNESS SUSCEPTIBILITY AND THE EFFECT ON THE SAE OF AN ANTIMOTION SICKNESS DRUG AND A CENTRAL NERVOUS SYSTEM DEPRESSANT.
172780 01-03
EFFECT OF D-AMPHETAMINE SULFATE ON SUSCEPTIBILITY TO AUDIOGENIC SEIZURES IN DBA/2J MICE.
184235 03-03
SEIZURE SUSCEPTIBILITY AND AVOIDANCE CONDITIONING IN ADULT RATS TREATED PRENATALLY WITH CHLORPROMAZINE.
184371 03-04

SUSPECTED
PARKINSON DISEASE TREATED WITH A SUSPECTED DOPAMINE RECEPTOR AGONIST.
186029 03-11

SUSPENSIONS
RELUCTANCE OF RATS TO DRINK HASHISH SUSPENSIONS: FREE-CHOICE AND FORCED CONSUMPTION, AND THE EFFECTS OF HYPOTHALAMIC STIMULATION.
186586 03-04

SUSPICIOUS
MANAGEMENT OF HOSTILE, SUSPICIOUS PATIENTS. TRIFLUOPERAZINE VERSUS HALOPERIDOL.
176675 02-14

SUSTAINED
STEREOTYPED AND AGGRESSIVE BEHAVIOR INDUCED BY SUSTAINED HIGH DOSE OF THEOPHYLLINE IN RATS.
177019 02-04
FURTHER ASPECTS OF AGGRESSIVE BEHAVIOR INDUCED BY SUSTAINED HIGH DOSE OF THEOPHYLLINE IN RATS.
177020 02-04
CENTRAL NERVOUS STIMULANT INDUCED PHYSIOLOGICAL AND PERFORMANCE CHANGES IN ADULTS DURING SUSTAINED PSYCHOMOTOR TRACKING.
179023 02-13
IMPLICATIONS OF SUSTAINED RELEASE PHENOTHIAZINES: A STUDY OF FLUPHENAZINE DECANOATE.
185007 03-09
TRIAL OF SUSTAINED RELEASE AMITRIPTYLINE ON ENURESIS.
192589 04-11

SWEATING
PROPRANOLOL ENHANCEMENT OF HYPOGLYCEMIC SWEATING.
186187 03-13

SWEDEN
RESEARCH ON SUPERSENSITIVE LABORATORY METHODS IN SWEDEN.
170302 01-06

SWIMMING
DOPAMINE AGONIST INDUCED DISORIENTATION IN A RAT SWIMMING TASK.
192018 04-04

SYMPATHECTOMY
EFFECT OF CHEMICAL SYMPATHECTOMY ON MORPHINE ANTINOCICEPTION AND TOLERANCE IN RATS.
182159 02-03
CARDIOVASCULAR REACTIVITY IN THE DOG AFTER CHEMICAL SYMPATHECTOMY WITH 6-HYDROXYDOPAMINE.
187807 04-03

SYMPATHETIC
BIOCHEMICAL AND PHARMACOLOGICAL APPROACHES IN THE STUDY OF SYMPATHETIC NERVES. (UNPUBLISHED PAPER).
170082 01-03
SIMULTANEOUS MASS FRAGMENTOGRAPHIC ASSAY OF NOREPINEPHRINE (NE), EPINEPHRINE (E) AND DOPAMINE (DA) IN RAT SYMPATHETIC GANGLION: EFFECTS OF DEXAMETHASONE IN NEWBORN AND ADULT RATS. (UNPUBLISHED PAPER).
170747 01-03
TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER).
170876 01-03
INTERACTION OF CENTRALLY ADMINISTERED OUABAIN WITH AGENTS AFFECTING SYMPATHETIC FUNCTION.
178640 02-03
UPTAKE, STORAGE AND RELEASE IN VIVO OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY SYMPATHETIC NERVES OF THE IRIS.
182204 02-03
TRANSSYNAPTIC INDUCTION OF CHOLINE ACETYLTRANSFERASE IN THE PREGANGLIONIC NEURON OF THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM.
182720 03-03
DIAZEPAM INHIBITION OF POST-TETANIC POTENTIATION IN BULLFROG SYMPATHETIC GANGLIA: POSSIBLE ROLE OF PROSTAGLANDINS.
186673 03-03
ON THE MECHANISM OF RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVES INDUCED BY DEPOLARIZING AGENTS AND SYMPATHOMIMETIC DRUGS. (UNPUBLISHED PAPER).
187397 04-03
FAILURE OF BETA-ADRENERGIC RECEPTOR BLOCKADE TO PREVENT ARRHYTHMIAS INDUCED BY SYMPATHETIC NERVE STIMULATION.
187923 04-03
HYDROCORTISONE INDUCED INCREASE IN THE HISTOCHEMICALLY DEMONSTRABLE CATECHOLAMINE CONTENT OF SYMPATHETIC NEURONS OF THE NEWBORN RAT.
189027 04-03
EFFECT OF ANESTHETIC AGENTS ON PERIPHERAL SYMPATHETIC NERVOUS SYSTEM FUNCTION AS MONITORED BY ARTERIAL PLASMA CATECHOLAMINE LEVELS. (UNPUBLISHED PAPER
191495 04-03
HUMAN SERUM DOPAMINE-BETA-HYDROXYLASE: RELATIONSHIP TO SYMPATHETIC ACTIVITY IN PHYSIOLOGICAL AND PATHOLOGICAL STATES.
191510 04-13
AN EVALUATION OF SERUM DOPAMINE-BETA-HYDROXYLASE AS AN INDEX OF SYMPATHETIC NERVE ACTIVITY IN MAN.
191511 04-13
EFFECTS OF LSD, MESCALINE, AND PSILOCYBIN ON SYMPATHETIC PREGANGLIONIC NEURONS.
191937 04-03

SYMPATHOMIMETIC
MECHANISM OF RELEASE AT NORADRENERGIC NERVE TERMINALS BY RESERPINE AND SEVERAL SYMPATHOMIMETIC AGENTS. (UNPUBLISHED PAPER).
178747 02-03
ON THE MECHANISM OF RELEASE OF NOREPINEPHRINE FROM SYMPATHETIC NERVES INDUCED BY DEPOLARIZING AGENTS AND SYMPATHOMIMETIC DRUGS. (UNPUBLISHED PAPER).
187397 04-03
FEATURES OF THE EFFECT OF SYMPATHOMIMETIC AMINES IN RADIATION AFFECTIONS.
191123 04-05

SYMPTOMATOLOGY
INFLUENCE OF TREATMENT ON SYMPTOMATOLOGY AND CORRELATED ELECTROENCEPHALOGRAPHIC (EEG) CHANGES IN THE AGED.
167336 01-13
A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: IV. PIMOZIDE IN THE TREATMENT OF PATIENTS WITH PARANOID SYMPTOMATOLOGY.
183194 03-09
THE ANTAGONISM OF AMPHETAMINE-INDUCED SYMPTOMATOLOGY BY A NEUROLEPTIC.
186744 03-14

SYMPTOMS
CLINICAL EXPERIMENTATION WITH A NEW BENZODIAZEPINE IN THE MANAGEMENT OF PHOBIC AND OBSESSIVE SYMPTOMS.
167594 01-10
LITHIUM INDUCED DIABETES-INSIPIDUS: MANIC SYMPTOMS, BRAIN AND ELECTROLYTE CORRELATES, AND CHLOROTHIAZIDE TREATMENT.
169486 01-15
RELIEF OF MUSCULOSKELETAL AND ASSOCIATED PSYCHOPATHOLOGICAL SYMPTOMS WITH MEPROBAMATE AND ASPIRIN: A CONTROLLED STUDY.
169632 01-10
COMPARISON OF THIORIDAZINE AND DIAZEPAM IN THE CONTROL OF NONPSYCHOTIC SYMPTOMS ASSOCIATED WITH SENILITY: DOUBLE-BLIND STUDY.
170129 01-11
A DOUBLE-BLIND COMPARISON OF THIORIDAZINE (MELLARIL) VERSUS DIAZEPAM (VALIUM) IN PATIENTS WITH CHRONIC MIXED ANXIETY AND DEPRESSIVE SYMPTOMS.
172486 01-10
STUDIES ON SIDE-EFFECTS AND WITHDRAWAL SYMPTOMS OF IMINODIBENZYL DERIVATIVES.
173080 01-15
CHOLINERGIC REVERSAL OF MANIC SYMPTOMS: A POSSIBLE EXPLANATION. (UNPUBLISHED PAPER).
173520 01-09
USE OF LORAZEPAM IN TREATING PATIENTS WITH NEUROTIC AND SOMATIZED PSYCHOVEGETATIVE SYMPTOMS.
174136 01-09
ELECTROCLINICAL ASPECT OF INSIDON TREATMENT IN PATIENTS WITH NEUROTIC SYMPTOMS.
174777 01-10
A CASE OF WERNERS SYNDROME WITH SCHIZOPHRENIA-LIKE SYMPTOMS.
175120 02-09
PARENTERAL HALOPERIDOL FOR RAPID CONTROL OF SEVERE, DISRUPTIVE SYMPTOMS OF ACUTE SCHIZOPHRENIA.
178545 02-08
TRIFLUPERIDOL -- THERAPEUTIC RESPONSE AND EXTRAPYRAMIDAL SYMPTOMS.
180248 02-15
SERUM ANTICONVULSANT CONCENTRATIONS IN EPILEPTIC PATIENTS WITH MENTAL SYMPTOMS: A PRELIMINARY REPORT.
184439 03-15
PSYCHIATRIC SYMPTOMS PRODUCED BY DRUGS.
192513 04-15
BETA-BLOCKING AGENTS IN THE TREATMENT OF CATECHOLAMINE INDUCED SYMPTOMS IN MUSICIANS.
192527 04-11

SYNAPSE
BLOCKADE OF EXCITATORY 5-HT SYNAPSE BY LSD.
191950 04-03

SYNAPSES
TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER).
170876 01-03

SYNAPTIC
COMPARATIVE STUDIES OF SYNAPTIC MEMBRANE PROTEIN SOLUBILIZATION BY CHLORPROMAZINE AND SODIUM DODECYLSULFATE.
176703 02-03
THE EFFECTS OF MORPHINE, ETORPHINE AND SINOMENINE ON THE CHEMICAL SENSITIVITY AND SYNAPTIC RESPONSES OF RENSHAW CELLS AND OTHER SPINAL NEURONES IN THE RAT.
188201 04-03

COMMON SYNAPTIC EFFECTS OF PENTYLENETETRAZOL AND PENICILLIN.
188738 04-05
THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. I. NEURONAL RESPONSES TO STIMULATION OF THE RETICULAR FORMATION.
189855 04-03
THE EFFECTS OF ACETYLCHOLINE AND OF SYNAPTIC STIMULATION ON THE SENSORIMOTOR CORTEX OF CATS. II. COMPARISON OF THE NEURONAL RESPONSES TO RETICULAR AND OTHER STIMULI.
189856 04-03
ADENOSINE ACTION ON SYNAPTIC TRANSMISSION IN BRAIN SLICES.
191945 04-03
THE PRESENCE OF MAO IN SYNAPTIC MEMBRANES OF BOVINE BRAIN.
191956 04-03
ENDURING LEARNING DEFICITS AND CEREBRAL SYNAPTIC MALFORMATION FROM EXPOSURE TO 10 PARTS OF HALOTHANE PER MILLION.
192565 04-04

SYNAPTOSOMAL
CORTICAL SYNAPTOSOMAL UPTAKE AND SUBSYNAPTOSOMAL DISTRIBUTION OF 3H-NOREPINEPHRINE AND 3H-AMPHETAMINE: MODIFICATION BY TRICYCLIC AND PSYCHOACTIVE AGENTS IN VITRO. (PH.D. DISSERTATION).
172020 01-03
TRANSPORT OF SYNAPTOSOMAL TRYPTOPHAN AND CEREBRAL TYROSINE: INCREASE IN THE SPEED OF UPTAKE OF RESERPINE OR THE INHIBITION OF MONOAMINE OXIDASE.
179988 02-13
INHIBITION OF THE SYNAPTOSOMAL UPTAKE MECHANISMS FOR L-NOREPINEPHRINE AND DOPAMINE BY N-ARYLALKYL DL-AMPHETAMINE DERIVATIVES.
182250 03-03
EFFECTS OF AMPHETAMINES ON REGIONAL TRYPTOPHAN HYDROXYLASE ACTIVITY AND SYNAPTOSOMAL CONVERSION OF TRYPTOPHAN TO 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
186674 03-03
ANALOGS OF CHOLINE: SYNAPTOSOMAL METABOLISM.
192000 04-03

SYNAPTOSOME
ENHANCED BINDING OF CHLORPROMAZINE TO CHOLESTEROL DEPLETED SYNAPTOSOME FRACTIONS.
187801 04-03
THE NERVE IMPULSE BLOCKING ACTIONS OF TRANQUILIZERS AND THE BINDING OF NEUROLEPTICS TO SYNAPTOSOME MEMBRANES.
189400 04-03

SYNAPTOSOMES
METHADONE INHIBITION OF 3H-5-HYDROXYTRYPTAMINE UPTAKE BY SYNAPTOSOMES.
183896 03-03
EFFECTS OF LITHIUM ON ADRENERGIC AMINE UPTAKE IN RAT BRAIN SYNAPTOSOMES.
186633 03-03
INHIBITION OF CHOLINE UPTAKE INTO SYNAPTOSOMES BY CHOLINE ANALOGUES.
191999 04-03

SYNDROME
INFLUENCE OF CONCENTRATION AND MOTOR PERFORMANCE ON TARDIVE DYSKINESIA AND RABBIT SYNDROME.
167587 01-15
MESORIDAZINE AND CHLORPROMAZINE IN THE TREATMENT OF ALCOHOL WITHDRAWAL SYNDROME.
168314 01-11
PSYCHOMETRIC INVESTIGATIONS IN PARKINSONS SYNDROME DURING TREATMENT WITH L-DOPA AND RELEVANCE OF SOME PSYCHOLOGICAL PHENOMENA.
168578 01-13
CHEMOTHERAPY IN CHRONIC ORGANIC BRAIN SYNDROME - A REVIEW OF THE LITERATURE.
169065 01-11
DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE IN RESPECT TO TIME AND DOSAGE AND QUANTIFICATION OF THE PRECIPITATED WITHDRAWAL SYNDROME IN RATS.
169474 01-03
SLEEP STUDIES AND THERAPEUTIC TRIAL WITH L-DOPA IN A CASE OF STIFF-MAN SYNDROME.
171134 01-13
MYOCLONIC SEIZURES IN DOWNS SYNDROME.
173205 01-11
DELIRIOUS SYNDROME AFTER THE ADMINISTRATION OF HALOPERIDOL.
174784 01-15
A CASE OF WERNERS SYNDROME WITH SCHIZOPHRENIA-LIKE SYMPTOMS.
175120 02-09
FUNCTIONAL EVALUATION OF PITUITARY RESERVE IN PATIENTS WITH THE AMENORRHEA GALACTORRHEA SYNDROME UTILIZING LUTEINIZING HORMONE RELEASING HORMONE (LH-RH), L-DOPA AND CHLORPROMAZINE.
175245 02-13
IMIPRAMINE WITHDRAWAL: AN AKATHISIA LIKE SYNDROME.
177710 02-15
EFFECTS OF PG-501 ON PARAPYRAMIDAL SYSTEM SYNDROME INDUCED BY PSYCHOTROPICS.
178019 02-15
STUDY OF THE EFFECT OF CERTAIN PHARMACOLOGICAL AGENTS ON TARDIVE DYSKINESIA AND THE RABBIT SYNDROME.
178193 02-11
EVALUATION OF EEG AND CLINICAL CHANGES ASSOCIATED WITH PAVABID THERAPY IN CHRONIC BRAIN SYNDROME.
183402 03-13
A CASE OF KLEINE-LEVINE SYNDROME.
183418 03-14
A CONTROLLED EVALUATION OF LITHIUM IN THE PREMENSTRUAL TENSION SYNDROME.
185192 03-11
HEAT DYSCONTROL SYNDROME IN PATIENTS RECEIVING ANTIPSYCHOTIC, ANTIDEPRESSANT AND ANTIPARKINSON DRUG THERAPY.
188094 04-15
STUDIES ON THE ACTION OF CERTAIN PHARMACOLOGICAL AGENTS ON TARDIVE DYSKINESIA AND ON THE RABBIT SYNDROME.
188406 04-03
DOPAMINE AND GILLES-DE-LA-TOURETTES SYNDROME.
188431 04-11
THE STIFF-MAN SYNDROME.
190670 04-11
AMITRIPTYLINE IN THE PSYCHOTIC STATES OF DOWNS SYNDROME: THE COMPARISON OF TWO CASES.
191192 04-11
INDUCTION OF A DIETHYLETHER WITHDRAWAL SYNDROME IN MICE BY EXPOSURE TO ETHER VAPOR.
192006 04-03

SYNDROMES
ACUTE DRUG-INDUCED EXTRAPYRAMIDAL SYNDROMES.
167572 01-15
TRAZODONE IN THE TREATMENT OF ORGANIC BRAIN SYNDROMES, WITH SPECIAL REFERENCE TO PSYCHOGERIATRICS.
168805 01-11
PSYCHOPATHOLOGICAL IMPORTANCE AND THERAPEUTIC EFFECTS OF A COMBINATION OF HYDERGINE AND THIORIDAZINE IN PSYCHIATRIC SYNDROMES IN THE AGING.
168976 01-14
ACTION OF OPIPRAMOL (G-33040) IN DEPRESSIVE SYNDROMES IN CHILDREN AND ADOLESCENTS.
182432 03-10
PHENOMENOLOGICAL - EXISTENTIAL STUDY OF PHOBIC - OBSESSIVE SYNDROMES TREATED WITH CHLORIMIPRAMINE.
182788 03-09
THE USE OF LOW DOSES OF MONOCHLORIMIPRAMINE IN THE THERAPY OF NEUROTIC DEPRESSIVE SYNDROMES.
182789 03-10
PARKINSONIAN SYNDROMES: TREATMENT BY ASSOCIATION OF L-DOPA PLUS DECARBOXYLASE INHIBITOR.
188093 04-11

SYNERGISTIC
ON THE MECHANISM OF THE SYNERGISTIC EFFECT OF PERAZINE AND HEXOBARBITAL.
184199 03-03
DOPAMINERGIC INHIBITION OF STRIATAL CHOLINERGIC NEURONS: SYNERGISTIC BLOCKING ACTION OF GAMMA-BUTYROLACTONE AND NEUROLEPTIC DRUGS.
189602 04-03

SYNTHESES
THE SYNTHESES OF 2,3 DIHYDROBENZOTHIAZINE DERIVATIVES. (PH.D. DISSERTATION).
173589 01-01

SYNTHESIS
DECREASED HISTAMINE SYNTHESIS IN THE RAT BRAIN BY HYPNOTICS AND ANESTHETICS.
168750 01-03
THE EFFECTS OF CHRONIC TREATMENT WITH DELTA9-TETRAHYDROCANNABINOL ON CATECHOLAMINE SYNTHESIS IN THE RAT.
169471 01-03
SYNTHESIS OF SUBSTITUTED CINNAMIDES: RELATIONSHIP BETWEEN ANTICONVULSANT AND MONOAMINE OXIDASE INHIBITORY PROPERTIES.
169818 01-01
SELECTIVE INHIBITION OF NOREPINEPHRINE SYNTHESIS IN MANIC-DEPRESSIVE PATIENTS WITH A DOPAMINE-BETA-HYDROXYLASE INHIBITOR. (UNPUBLISHED PAPER).
170083 01-03
PEYOTE AND RELATED ALKALOIDS XVI: SYNTHESIS OF 3,4,5 TRIMETHOXYPHENYLALANINE, AN AMINO ANALOG OF MESCALINE.
170839 01-06
SYNTHESIS OF ACETYLCHOLINE IN BRAIN NERVE TERMINALS DURING CONSCIOUSNESS AND BARBITURATE ANESTHESIA.
171600 01-03

SYNTHESIS OF HYDROXYAPORPHINES AS POTENTIAL ANTIPARKINSONIAN AGENTS. (PH.D. DISSERTATION).
174967 02-01
BRAIN RIBOSOMAL RNA SYNTHESIS INHIBITED BY CHLORPROMAZINE.
177835 02-03
SYNTHESIS AND ANTIRESERPINE ACTIVITY OF PEPTIDES OF L-DOPA.
180097 02-03
SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF OCTAHYDROBENZOCYCLOHEPTATHIAZINE DERIVATIVES.
180098 02-01
STUDIES ON BENZODIAZEPINOOXAZOLES. VI. SYNTHESIS AND PHARMACOLOGY OF 11B-PYRIDYL AND 11B-THIENYL DERIVATIVES OF BENZODIAZEPINOOXAZOLES.
180490 02-02
THE EFFECT OF DOPAMINE RECEPTOR STIMULATING AGENTS AND OF N,O DIBUTYRYL CYCLIC AMP ON C14-DOPAMINE SYNTHESIS IN STRIATAL SLICES OF RATS.
182256 03-03
NIMH SPONSORED CHEMICAL SYNTHESIS PROGRAM.
182444 03-01
SYNTHESIS OF COMPOUNDS RELATED TO LYSERGIC ACID.
182445 03-01
CENTRAL NERVOUS DEPRESSANT XV: SYNTHESIS AND PHARMACOLOGICAL SCREENING OF SOME TRIMETHOXYAZLACTONES.
182828 03-02
SYNTHESIS AND SCREENING OF CYCLIC BENZYLHYDRAZINE CONGENERS AS ANTIDEPRESSANTS.
183600 03-01
INCREASED SYNTHESIS OF ADRENOMEDULLARY CATECHOLAMINES INDUCED BY CAFFEINE AND THEOPHYLLINE.
184201 03-03
THE EFFECT OF P-CHLOROAMPHETAMINE ON MOTILITY IN RATS AFTER INHIBITION OF MONOAMINE SYNTHESIS, STORAGE, UPTAKE AND RECEPTOR INTERACTION.
185959 03-04
SYNTHESIS AND CNS ACTIVITY OF 3-SUBSTITUTED 7-CHLORO-5-PHENYLBENZOTRIAZEPIN-2-ONES.
185978 03-01
EFFECTS OF LSD ON SYNTHESIS AND RELEASE OF 5-HT IN RAT BRAIN SLICES.
188164 04-03
ALTERED NOREPINEPHRINE SYNTHESIS OF SPLANCHNIC VESSELS IN NEUROGENIC HYPERTENSION.
188198 04-03
ANISOMYCIN, LIKE OTHER INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS, IMPAIRS LONG-TERM MEMORY OF A DISCRIMINATION TASK.
188605 04-04
EFFECTS OF LSD AND MONOAMINE SYNTHESIS INHIBITORS ON HORMONE ACTIVATED COPULATORY BEHAVIOR IN THE FEMALE RAT.
188611 04-04
ESTIMATION OF THE RATE OF 5-HT SYNTHESIS IN THE MOUSE BRAIN BY VARIOUS METHODS.
188976 04-03
ALPHA-METHYLDOPAMINE DERIVATIVES. SYNTHESIS AND PHARMACOLOGY.
189177 04-02
SYNTHESIS AND CENTRAL NERVOUS SYSTEM ACTIVITY OF 1,2,3,4-TETRAHYDRO-1-AMINO-4-PHENYLNAPHTHALENES.
189178 04-02
CONTROL OF NOREPINEPHRINE SYNTHESIS IN BLOOD VESSELS AND THE EFFECTS OF MONOAMINE OXIDASE INHIBITION.
189390 04-03
EFFECT OF ANESTHETIC AGENTS ON THE SYNTHESIS AND DISAPPEARANCE OF BRAIN DOPAMINE NORMALLY AND AFTER HALOPERIDOL, KCL OR AXOTOMY.
189571 04-03
EFFECT OF MORPHINE ON THE TURNOVER AND SYNTHESIS OF (LEU-3H) PROTEIN AND (CH-14C) PHOSPHATIDYLCHOLINE IN DISCRETE REGIONS OF THE RAT BRAIN.
189586 04-03
A CRITICAL ASSESSMENT OF METHODS FOR THE DETERMINATION OF MONOAMINE SYNTHESIS AND TURNOVER RATES IN VIVO.
191514 04-06
EFFECT OF LILLY-110140, 3-(P-TRIFLUOROMETHYLPHENOXY) N METHYL-3-PHENYLPROPYLAMINE ON SYNTHESIS OF 3H-SEROTONIN FROM 3H-TRYPTOPHAN IN RAT BRAIN.
191951 04-03
THE EFFECTS OF DELTA9-THC AND A WATER SOLUBLE DERIVATIVE ON PGE1 SYNTHESIS IN THE CORPUS-STRIATUM.
191964 04-03
TETRAHYDROCANNABINOLS: INHIBITION IN ACETYLCHOLINE SYNTHESIS IN REGIONAL RAT BRAIN SLICES.
191998 04-03
INHIBITION IN VIVO OF ACETYLCHOLINE SYNTHESIS IN MOUSE BRAIN BY INHIBITORS OF CHOLINE ACETYLTRANSFERASE.
192001 04-03

SYNTHESIZED
IN VIVO RELEASE OF NEWLY SYNTHESIZED CATECHOLAMINES FROM THE HYPOTHALAMUS BY AMPHETAMINE.
184230 03-03
EFFECTS OF ALPHA-METHYLTYROSINE ON D-AMPHETAMINE INDUCED RELEASE OF ENDOGENOUSLY SYNTHESIZED AND EXOGENOUSLY ADMINISTERED CATECHOLAMINES FROM THE CAT BRAIN IN VIVO.
189397 04-03
AMPHETAMINE AND METHYLPHENIDATE INDUCED RELEASE OF STRIATAL DOPAMINE IN VIVO: DIFFERENTIAL EFFECTS ON NEWLY SYNTHESIZED AND STORED POOLS.
191897 04-03

SYNTHETIC
DISSOCIATION OF STIMULATORY AND SYNTHETIC PHASES IN THE INDUCTION OF TYROSINE HYDROXYLASE.
171785 01-03
SYNTHETIC STUDIES LEADING TOWARD THE PREPARATION OF LINEAR BENZOQUINOLINES. (PH.D. DISSERTATION).
180739 02-01

SYSTEMATIC
SYSTEMATIC CLINICAL STUDIES WITH TRAZODONE: METHODOLOGICAL ASPECTS.
168804 01-16
TREATMENT OF PHOBIAS BY SYSTEMATIC DESENSITIZATION: COMPARISON OF STANDARD VS METHOHEXITAL AIDED DESENSITIZATION.
189916 04-10

SYSTEMIC
EFFECT OF GENERAL ANESTHETICS ON SYSTEMIC CATECHOLAMINE CONCENTRATION I: HALOTHANE. (UNPUBLISHED PAPER).
168862 01-05
NICOTINIC ACID INDUCED SYSTEMIC LUPUS-ERYTHEMATOSUS.
180243 02-15

SYSTEMS
TURNOVER CHANGES IN CENTRAL MONOAMINE NEURON SYSTEMS AFTER MINOR TRANQUILLIZERS AND BARBITURATES.
171604 01-03
SHORT-TERM AND LONG-TERM LITHIUM ADMINISTRATION: EFFECTS ON THE BRAINS SEROTONERGIC BIOSYNTHETIC SYSTEMS.
175149 02-13
RELATIVE IMPORTANCE OF DOPAMINERGIC AND NORADRENERGIC NEURONAL SYSTEMS FOR THE STIMULATION OF LOCOMOTOR ACTIVITY INDUCED BY AMPHETAMINE AND OTHER DRUGS.
182209 02-04
INTERACTION OF THE BEHAVIORALLY ACTIVE DRUG, PHENITRONE, A PURPORTED HASHISH AND LSD ANTAGONIST, WITH SEVERAL CENTRAL NEUROCHEMICAL SYSTEMS.
182217 03-04
THE FUTURE OF PHARMACOTHERAPY: NEW DRUG DELIVERY SYSTEMS.
191044 04-08
RELATIONSHIP OF CATECHOLAMINE NEURAL SYSTEMS TO THE BEHAVIORAL ALTERATIONS PRODUCED BY 6-HYDROXYDOPAMINE ADMINISTRATION INTO BRAIN.
191518 04-03

T-MAZE
THE EFFECT OF SOME CHOLINOLYTIC DRUGS ON A NUMBER OF BEHAVIOURAL PARAMETERS MEASURED IN THE T-MAZE ALTERNATION TEST: DOSE-RESPONSE RELATIONSHIPS.
187641 04-04
EFFECTS OF INTRACISTERNAL 6-HYDROXYDOPAMINE TREATMENT ON ACQUISITION AND PERFORMANCE OF RATS IN A DOUBLE T-MAZE.
187696 04-04

TABLET
MOLINDONE: A CROSSOVER EVALUATION OF CAPSULE AND TABLET FORMULATIONS IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
174137 01-08

TACITIN
TACITIN TREATMENT FOR THE PATIENT WITH ANXIETY.
178038 02-10

TAIL
A COMPARATIVE STUDY OF DANTROLENE SODIUM AND OTHER SKELETAL MUSCLE RELAXANTS WITH THE STRAUB TAIL MOUSE.
186638 03-04

TANTU-PASHAN
TANTU-PASHAN AND LUCIDRIL THERAPY IN MENTALLY RETARDED CHILDREN.
175628 02-11

TAR
TOXIC EFFECTS OF MARIHUANA TAR ON MOUSE SKIN.
170464 01-05

TARDIVE
INFLUENCE OF CONCENTRATION AND MOTOR PERFORMANCE ON TARDIVE DYSKINESIA AND RABBIT SYNDROME.
167587 01-15
ANTIPARKINSON DRUGS AS CAUSAL AGENTS IN TARDIVE DYSKINESIA.
169140 01-15
PSEUDOPARKINSONISM AND TARDIVE DYSKINESIA.
171974 01-15

STUDY OF THE EFFECT OF CERTAIN PHARMACOLOGICAL AGENTS ON TARDIVE DYSKINESIA AND THE RABBIT SYNDROME.
178193 02-11

A CASE OF TARDIVE DYSKINESIA APPEARING PRECOCIOUSLY UNDER NEUROLEPTICS.
184961 03-17

DOPAMINERGIC HYPERSENSITIVITY AND CHOLINERGIC HYPOFUNCTION IN THE PATHOPHYSIOLOGY OF TARDIVE DYSKINESIA.
185929 03-11

STUDIES ON THE ACTION OF CERTAIN PHARMACOLOGICAL AGENTS ON TARDIVE DYSKINESIA AND ON THE RABBIT SYNDROME.
188406 04-03

CHOLINERGIC SUPPRESSION OF TARDIVE DYSKINESIA.
189403 04-11

IMPAIRMENT OF OPTOKINETIC NYSTAGMUS IN PATIENTS WITH TARDIVE DYSKINESIA.
189734 04-13

TARDIVE DYSKINESIA AND DRUG THERAPY IN GERIATRIC PATIENTS.
189923 04-13

CHOLINERGIC SUPPRESSION OF TARDIVE DYSKINESIA.
190314 04-13

ON THE COEXISTENCE OF PARKINSONISM AND TARDIVE DYSKINESIA.
190380 04-11

TARDIVE AND WITHDRAWAL DYSKINESIA ASSOCIATED WITH HALOPERIDOL.
191035 04-15

TASK

ACQUISITION AND PERFORMANCE OF AN ATTENTION TASK BY RATS SUBJECTED TO CHRONIC NICOTINE TREATMENT.
176864 02-04

THE EFFECT OF MARIHUANA ON TRACKING TASK PERFORMANCE.
177720 02-14

ANISOMYCIN, LIKE OTHER INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS, IMPAIRS LONG-TERM MEMORY OF A DISCRIMINATION TASK.
188605 04-04

PERFORMANCE ON A VERBAL LEARNING TASK BY SUBJECTS OF HEAVY PAST MARIJUANA USAGE.
190308 04-14

THE COMPARATIVE EFFECTS OF PENTOBARBITAL AND D-AMPHETAMINE ON A SHORT-TERM MEMORY TASK IN BABOONS.
191917 04-04

DOPAMINE AGONIST INDUCED DISORIENTATION IN A RAT SWIMMING TASK.
192018 04-04

TASTE

HIPPOCAMPAL LESIONS AND LEARNED TASTE AVERSION.
184834 03-04

THE EFFECTS OF PENTYLENETETRAZOL (METRAZOL) ON A LEARNED TASTE AVERSION PRODUCED BY LITHIUM CHLORIDE: THE ISSUE OF ASSOCIATIVE MEMORY VS. RETENTIVE MEMORY. (UNPUBLISHED PAPER).
188251 04-04

BACKWARD CONDITIONING OF TASTE AVERSIONS IN RATS USING CYCLOPHOSPHAMIDE AS THE US.
190265 04-04

TAURINE

SUPPRESSION OF SEIZURES BY TAURINE -- SPECIFIC OR NONSPECIFIC?
189843 04-03

PASSAGE OF TAURINE INTO ADULT MAMMALIAN BRAIN.
191331 04-03

TAXILAN

CLINICAL TRIAL OF PERAZINE (TAXILAN) IN TREATMENT OF SCHIZOPHRENIA.
176446 02-08

TCAP

LACK OF EFFECT OF RIBAMINOL, TCAP, AND MAGNESIUM PEMOLINE ON RECOVERY FROM NEOCEREBELLAR DAMAGE.
171904 01-03

TEACHERS

RITALIN FOR SCHOOL CHILDREN: THE TEACHERS PERSPECTIVE.
178127 02-17

TEAM

INSTITUTE OF PSYCHIATRY CLINICAL PSYCHOPHARMACOLOGY RESEARCH TEAM.
187022 03-17

TECHNICAL

TECHNICAL STRATEGIES FOR THE STUDY OF CATECHOLAMINES IN MAN. (UNPUBLISHED PAPER).
173387 01-03

TECHNIQUE

ANALGESIC POTENCY OF SODIUM SALICYLATE, INDOMETHACIN, AND CHLORDIAZEPOXIDE AS MEASURED BY THE SPATIAL PREFERENCE TECHNIQUE IN THE RAT.
171301 01-02

EVALUATION OF HYPNOTICS IN OUTPATIENTS WITH INSOMNIA USING A QUESTIONNAIRE AND A SELF-RATING TECHNIQUE.
177735 02-06

WHAT IS TECHNIQUE IN PSYCHIATRIC TREATMENT
180102 02-17

TECHNIQUES

CRISIS PSYCHOPHARMACOLOGY TECHNIQUES.
174298 01-11

TECTUM

LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND GAMMA-AMINOBUTYRIC ACID (GABA) INTERACTION ON SPONTANEOUS POTENTIALS AND THE EVOKED RESPONSE IN THE AVIAN TECTUM.
169689 01-03

TEGRETOL

STUDY OF THE PSYCHOTROPIC ACTION OF TEGRETOL IN PATIENTS WITH EPILEPSY.
172439 01-11

TEMESTA

PILOT CLINICAL TRIAL OF PARENTERAL LORAZEPAM (TEMESTA) IN ANXIETY STATES.
174044 01-11

TEMPERATURE

THE EFFECT OF LOWERED BODY TEMPERATURE ON LIFESPAN AND IMMUNE AND NONIMMUNE PROCESSES.
169675 01-03

TEMPERATURE DEPENDENT TOXICITY OF ADRENERGIC AGONISTS IN MICE AS A BASIS FOR TREATING D-AMPHETAMINE POISONING.
169688 01-05

METABOLIC CONTROL OF BODY TEMPERATURE IN MAN.
174134 01-08

POTENTIAL NEUROTRANSMITTERS AND RECEPTOR MECHANISMS INVOLVED IN THE CENTRAL CONTROL OF BODY TEMPERATURE IN HAMSTERS. (PH.D. DISSERTATION).
174962 01-03

THE EFFECT OF LOW ENVIRONMENTAL TEMPERATURE ON THE TRANYLCYPROMINE MEPERIDINE INTERACTION IN MICE.
183897 03-03

DAILY RHYTHM IN BODY TEMPERATURE OF MENTAL PATIENTS: APPLICATION OF COSINOR METHOD -- FIRST REPORT.
191685 04-17

DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) IMIPRAMINE INTERACTION ON MOUSE BODY TEMPERATURE.
191996 04-03

TEMPLATE

CHROMATIN TEMPLATE ACTIVITY DURING MORPHINE-INDUCED ANALGESIA AND THE DEVELOPMENT OF ANALGESIC TOLERANCE.
182160 02-03

TEMPORAL

TEMPORAL DISORGANIZATION AND DELUSIONAL-LIKE IDEATION: PROCESSES INDUCED BY HASHISH AND ALCOHOL.
185330 03-14

TEMPORAL ASPECTS OF SCOPOLAMINE INDUCED ONE-WAY MEMORY DISSOCIATION IN MICE.
187701 04-04

TENDENCY

ON THE DYNAMICS AND TREATMENT OF THE TENDENCY OF SCHIZOPHRENIC PSYCHOSIS TO BECOME CHRONIC.
183957 03-08

INVERSION BY APOMORPHINE OF THE TENDENCY OF FEMALE RATS TO BE DEFEATED BY MALES WHEN COMPETING FOR FOOD IN A STRAIGHT RUNWAY.
184212 03-04

TENSION

A CONTROLLED EVALUATION OF LITHIUM IN THE PREMENSTRUAL TENSION SYNDROME.
185192 03-11

TERMINALLY

PSYCHOPHARMACOLOGICAL AGENTS FOR THE TERMINALLY ILL AND BEREAVED.
188149 04-17

TERMINALS

SYNTHESIS OF ACETYLCHOLINE IN BRAIN NERVE TERMINALS DURING CONSCIOUSNESS AND BARBITURATE ANESTHESIA.
171600 01-03

MECHANISM OF RELEASE AT NORADRENERGIC NERVE TERMINALS BY RESERPINE AND SEVERAL SYMPATHOMIMETIC AGENTS. (UNPUBLISHED PAPER).
178747 02-03

IN VIVO ESTIMATION OF TYROSINE HYDROXYLATION IN THE DOPAMINERGIC TERMINALS OF THE RAT NEOSTRIATUM.
183794 03-03

EVIDENCE FOR A SPECIFIC UPTAKE OF DOPAMINE BY DOPAMINERGIC TERMINALS OF THE RAT CEREBRAL CORTEX.
188978 04-03

TERMINATING

THE ROLE OF MONOAMINE OXIDASE IN TERMINATING THE REFLEX EFFECTS OF P-METHOXYPHENYLETHYLAMINE (PMPEA).
174319 01-03

TERMINATION

THRESHOLDS FOR ELECTROCONVULSIONS AND CHEMOCONVULSIONS IN MICE AFTER TERMINATION OF TREATMENT WITH PHENOBARBITAL.
170073 01-03

AN ANALYSIS OF D-AMPHETAMINE PRODUCED FACILITATION OF AVOIDANCE ACQUISITION IN RATS AND PERFORMANCE CHANGES SUBSEQUENT TO DRUG TERMINATION.
179990 02-04

TERTIARY
3-ONIUM DERIVATIVES OF 1,4 BENZODIAZEPIN-2-ONES WITH TERTIARY ORGANIC BASES.
187942 04-01

TEST
THE SAFETY TEST OF 10-CHLORO-11B-(2-CHLOROPHENYL) 2,3,5,6,7,11B HEXAHYDROBENZODIAZEPINOOXAZOL-6-ONE (CS-370): SECOND REPORT, EFFECT OF CS-370 UPON THE DEVELOPMENT OF PRENATAL AND POSTNATAL OFFSPRINGS OF EXPERIMENTAL ANIMALS.
168498 01-05
THE SOCIAL PLAY BEHAVIOR OF CHIMPANZEES ACCORDING TO A PSYCHOPHARMACOLOGICAL TEST/.
168838 01-04
DRUG DEPENDENCE TEST OF PHENOBARBITAL AND MORPHINE IN RATS BY SPONTANEOUS INTAKE.
182104 02-04
5-HYDROXYTRYPTOPHAN AS AN ANTIDEPRESSANT: THE PREDICTIVE VALUE OF THE PROBENECID TEST.
184652 03-09
ON CATALEPSY AND CATATONIA AND THE PREDICTABILITY OF THE CATALEPSY TEST FOR NEUROLEPTIC ACTIVITY.
185958 03-04
COCAINE, PEMOLINE AND AMPHETAMINE ON LEARNING AND RETENTION OF A DISCRIMINATION TEST IN MICE.
186705 03-04
THE EFFECT OF SOME CHOLINOLYTIC DRUGS ON A NUMBER OF BEHAVIOURAL PARAMETERS MEASURED IN THE T-MAZE ALTERNATION TEST: DOSE-RESPONSE RELATIONSHIPS.
187641 04-04
TIME SAMPLING OF RAT EXPLORATORY BEHAVIOUR: A RELIABLE SCREENING TEST FOR THE CNS EFFECTS OF ANOREXIC AGENTS.
187925 04-04
PSYCHOMOTOR TEST PERFORMANCE WITH A FENFLURAMINE AMPHETAMINE COMBINATION.
190146 04-07
THE PREDICTIVE VALUE OF THE ANTIAPOMORPHINE TEST IN DOGS FOR NEUROLEPTIC THERAPY IN MAN.
192421 04-04

TESTING
HALOPERIDOL EFFECTS ON MORPHINE SELF-ADMINISTRATION: TESTING FOR PHARMACOLOGICAL MODIFICATION OF THE PRIMARY REINFORCEMENT MECHANISM.
172454 01-04
A METHOD FOR TESTING DRUG-INDUCED PARKINSONIAN-LIKE EFFECT.
191982 04-15

TESTOSTERONE
TESTOSTERONE AND LUTEINIZING HORMONE (LH) IN UNTREATED AND METHADONE MAINTAINED NARCOTIC ADDICTS.
182166 02-13
LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04

TESTS
TESTS OF EMOTIONAL BEHAVIOR IN RATS FOLLOWING DEPLETION OF NOREPINEPHRINE, OF SEROTONIN, OR OF BOTH.
185753 03-04

TETRABENAZINE
TREMOR INDUCTION BY INTRACAUDATE INJECTIONS OF BRETYLIUM, TETRABENAZINE, OR MESCALINE: FUNCTIONAL DEFICITS IN CAUDATE DOPAMINE.
167329 01-03
EFFECTS OF TETRABENAZINE ON LORDOSIS BEHAVIOUR AND ON BRAIN MONOAMINES IN THE FEMALE RAT.
171614 01-04
THE SUPPRESSION OF INVOLUNTARY MOVEMENTS WITH TETRABENAZINE.
178618 02-11
INFLUENCES OF LITHIUM ON THE BEHAVIORAL ACTION OF METHAMPHETAMINE AND TETRABENAZINE.
182109 02-04
STUDIES ON THE POTENTIATION OF THE ANTINOCICEPTIVE EFFECT OF OXOTREMORINE BY TETRABENAZINE IN MICE.
185933 03-03

TETRACHLORIDE
REDUCTION BY PRETREATMENT WITH DIBENAMINE OF HEPATOTOXICITY INDUCED BY CARBON TETRACHLORIDE, THIOACETAMINDE OR DIMETHYLNITROSAMINE.
188865 04-05
INFLUENCE OF ADRENERGIC BLOCKERS AND ANTILIPEMIC AGENTS ON PHARMACODYNAMIC ACTIONS OF MORPHINE IN CARBON TETRACHLORIDE TREATED RATS.
188873 04-03

TETRACOSACTRIN
INFLUENCE OF TETRACOSACTRIN (T) AND BETA-MELANOCYTE STIMULATING HORMONE (MSH) ON DEPRESSION OF THE SEGMENTAL REFLEX BY MORPHINE (MS). (UNPUBLISHED PAPER).
183324 03-03
THE EFFECT OF ZINC N TETRACOSACTRIN ON GROWTH HORMONE RELEASE DURING SLEEP.
183490 03-13

TETRAETHYLTHIURAMDISULFIDE
PSYCHOTIC COMPLICATIONS AFTER TETRAETHYLTHIURAMDISULFIDE USED IN THE TREATMENT OF ALCOHOLISM.
175047 02-11

TETRAHYDRO-1-AMINO-4-PHENYLNAPHTHALENES
SYNTHESIS AND CENTRAL NERVOUS SYSTEM ACTIVITY OF 1,2,3,4-TETRAHYDRO-1-AMINO-4-PHENYLNAPHTHALENES.
189178 04-02

TETRAHYDROAMINOACRIDINE
KETAMINE INDUCED POSTANESTHETIC DELIRIUM ATTENUATED BY TETRAHYDROAMINOACRIDINE.
188689 04-05

TETRAHYDROCANNABINOL
STABILITY AND MICROANALYSIS OF TETRAHYDROCANNABINOL.
169673 01-16
HIGH FREQUENCY OF DYSPHORIC REACTIONS TO TETRAHYDROCANNABINOL AMONG DEPRESSED PATIENTS.
181274 02-09

TETRAHYDROCANNABINOLS
EVALUATION OF THE HYPOTHERMIC ACTION OF TETRAHYDROCANNABINOLS IN MICE AND SQUIRREL MONKEYS.
170163 01-03
EFFECT OF TETRAHYDROCANNABINOLS ON CENTRAL MONOAMINE NEURONS.
171605 01-03
EFFECTS OF SOME TETRAHYDROCANNABINOLS ON THE BIOSYNTHESIS AND UTILIZATION OF CATECHOLAMINES IN THE RAT BRAIN.
172917 01-03
THE METABOLISM OF THE TETRAHYDROCANNABINOLS.
182773 03-17
NEUROCHEMICAL ROLE OF ADENOSINE 3,5 CYCLIC MONOPHOSPHATE AND GUANOSINE 3,5 CYCLIC MONOPHOSPHATE AND THEIR RELATION TO NEUROTRANSMITTERS; EFFECT OF TETRAHYDROCANNABINOLS. (PH.D. DISSERTATION).
185582 03-03
THE EFFECTS OF SOME DRUGS ON AN EVOKED RESPONSE SENSITIVE TO TETRAHYDROCANNABINOLS.
186666 03-03
EFFECT OF TETRAHYDROCANNABINOLS ON BRAIN ACETYLCHOLINE.
188167 04-03
TETRAHYDROCANNABINOLS: INHIBITION IN ACETYLCHOLINE SYNTHESIS IN REGIONAL RAT BRAIN SLICES.
191998 04-03

TETRAHYDROISOQUINOLINE
TETRAHYDROISOQUINOLINE ALKALOIDS: IN VIVO METABOLITES OF L-DOPA IN MAN.
168286 01-13
HYPOTHERMIA EVOKED BY A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE ALKALOID.
182130 02-03
IN VIVO INHIBITION OF NEURONAL UPTAKE OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY COCAINE AND BY DESMETHYLIMIPRAMINE (DMI).
182150 02-03
UPTAKE, STORAGE AND RELEASE IN VIVO OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY SYMPATHETIC NERVES OF THE IRIS.
182204 02-03

TETRAPHENYLBORON
EFFECT OF 2-ARYLALANINES, 2-ARYLSERINES, TETRAPHENYLBORON AND 1,2 DL(2,4 DICHLOROPHENYL) ETHANOLAMINE ON LEVELS OF SEROTONIN (5-HT), NOREPINEPHRINE (NE) AND DOPAMINE (DM) IN WHOLE BRAIN OF MICE.
182254 03-03

THALAMIC
THE THALAMIC RAT: GENERAL BEHAVIOR, OPERANT LEARNING WITH REWARDING HYPOTHALAMIC STIMULATION, AND EFFECTS OF AMPHETAMINE.
177477 02-04
CLINICAL EVALUATION OF AMANTADINE THERAPY FOR PARKINSONISM AND THE SIDE-EFFECTS -- IN CASES OF THALAMIC SURGERY AND L-DOPA THERAPY.
190095 04-11

THALAMUS
MODULATORY EFFECTS OF CORTICOSTEROIDS ON EVOKED ACTIVITY IN THE HIPPOCAMPUS AND THALAMUS OF THE RAT.
182119 02-03

THC
PROSTAGLANDINS AND CANNABIS: A POSSIBLE MODE OF ACTION FOR THC.
169067 01-03

THC: METABOLISM AND SUBJECTIVE EFFECTS OF STRESS. (UNPUBLISHED PAPER).
173516 01-14

3H-DELTA9-TETRAHYDROCANNABINOL (THC) METABOLISM IN RHESUS AND SQUIRREL MONKEYS.
175751 02-03

EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF WATER SOLUBLE 1-DELTA9-TETRAHYDROCANNABINOL (W THC) ON WEB-BUILDING OF SPIDERS.
182193 02-04

THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL (THC), PENTOBARBITAL AND SKF-525-A WITH THE CARDIOVASCULAR SYSTEM OF THE RAT.
182218 03-03

EXCRETION OF THC AND ITS METABOLITES IN EWES MILK.
189590 04-03

THE INFLUENCE OF DELTA9-TETRAHYDROCANNABINOL (THC) ON PILOCARPINE (PILO) INDUCED PAROTID SECRETIONS OF THE RAT.
191962 04-03

THEOPHYLLINE

STEREOTYPED AND AGGRESSIVE BEHAVIOR INDUCED BY SUSTAINED HIGH DOSE OF THEOPHYLLINE IN RATS.
177019 02-04

FURTHER ASPECTS OF AGGRESSIVE BEHAVIOR INDUCED BY SUSTAINED HIGH DOSE OF THEOPHYLLINE IN RATS.
177020 02-04

INCREASED SYNTHESIS OF ADRENOMEDULLARY CATECHOLAMINES INDUCED BY CAFFEINE AND THEOPHYLLINE.
184201 03-03

EFFECTS OF ADRENERGIC AGENTS, THEOPHYLLINE AND OTHER DRUGS ON DEXTRAN EDEMA AND HISTAMINE RELEASE IN RATS.
189895 04-03

THEORETICAL

STUDIES OF CEREBROSPINAL FLUID AMINE METABOLITES IN DEPRESSED PATIENTS: CONCEPTUAL PROBLEMS AND THEORETICAL IMPLICATIONS. (UNPUBLISHED PAPER).
187398 04-13

THEORY

CONTRIBUTION OF PSYCHOPHARMACOLOGY TO THE PSYCHOPHYSIOLOGICAL THEORY OF EMOTIONS.
178817 02-13

ATTACK ON THE GATE THEORY OF PAIN.
189610 04-17

AN OVERVIEW OF THE 6-HYDROXYDOPAMINE THEORY OF SCHIZOPHRENIA.
190239 04-08

THERAPEUTIC

COMPARABLE THERAPEUTIC EFFICACY OF TRYPTOPHAN AND IMIPRAMINE: AVERAGE THERAPEUTIC RATINGS VERSUS TRUE EQUIVALENCE. AN IMPORTANT DIFFERENCE.
167344 01-09

POTENTIATION OF THERAPEUTIC EFFECTS OF NICOTINIC ACID BY PYRIDOXINE IN CHRONIC SCHIZOPHRENICS.
168313 01-08

THE POSSIBLE ROLE OF METABOLITES IN THERAPEUTIC RESPONSE TO CHLORPROMAZINE TREATMENT.
168836 01-08

PSYCHOPATHOLOGICAL IMPORTANCE AND THERAPEUTIC EFFECTS OF A COMBINATION OF HYDERGINE AND THIORIDAZINE IN PSYCHIATRIC SYNDROMES IN THE AGING.
168976 01-14

PSYCHOTROPIC DRUGS AS THERAPEUTIC AGENTS.
169748 01-17

THERAPEUTIC APPROACH TO THE APPROXIMATE ANSWERS OF A SCHIZOPHRENIC PATIENT.
170637 01-08

SLEEP STUDIES AND THERAPEUTIC TRIAL WITH L-DOPA IN A CASE OF STIFF-MAN SYNDROME.
171134 01-13

GAS CHROMATOGRAPHIC DETERMINATION OF METHAQUALONE IN SMALL AMOUNTS OF SERUM AFTER INGESTION OF THERAPEUTIC DOSES.
172397 01-16

THE DESIGN OF THERAPEUTIC TRIALS: A CRITICAL ANALYSIS WITH ILLUSTRATIONS, PARTICULARLY FROM THE FIELD OF PSYCHOTROPIC DRUGS OR: WHY NO ONE CAN EVER DO A PROPER DRUG TRIAL.
173307 01-16

OBSERVATIONS ON THE THERAPEUTIC ACTIVITY OF CLOPENTHIXOL IN PSYCHIATRY.
175540 02-11

POSSIBLE MUTUAL THERAPEUTIC COMBINATION OF PSYCHOPHARMACEUTICALS.
178029 02-17

TRIFLUPERIDOL -- THERAPEUTIC RESPONSE AND EXTRAPYRAMIDAL SYMPTOMS.
180248 02-15

THE COMPARISON OF THERAPEUTIC EFFECTS OF FK-880 (SULPIRIDE) AND PERPHENAZINE IN SCHIZOPHRENIA BY A DOUBLE-BLIND CONTROLLED STUDY.
181378 02-08

FEATURES OF THE THERAPEUTIC EFFECT OF FLUPHENAZINE DECANOATE IN SCHIZOPHRENIA.
183683 03-08

PLASMA LEVEL OF DIAZEPAM AS A THERAPEUTIC PREDICTOR IN ANXIETY STATES.
186584 03-10

HIGH DOSAGE PIPERACETAZINE (QUIDE-R) IN AMBULATORY SCHIZOPHRENIC PATIENTS: THERAPEUTIC EFFICACY AND TOXICITY.
187869 04-08

THERAPEUTICALLY

ANIMAL MODELS FOR AN ENZYMIC BLOOD-BRAIN BARRIER MECHANISM FOR THERAPEUTICALLY ADMINISTERED L-DOPA.
167359 01-03

THERAPIES

DRUG THERAPIES IN CRISIS MANAGEMENT.
189297 04-17

THERAPIST

PSYCHIATRIC CARE: DRUGS, THERAPIST, COMMUNITY.
178189 02-17

THERAPY

CLINICAL EVALUATION OF FLUSPIRILENE AS A MAINTENANCE THERAPY IN CHRONIC SCHIZOPHRENIC PATIENTS.
168320 01-08

EMOTIONAL FUNCTIONS IN SHORT-TERM VS. LONG-TERM L-DOPA THERAPY IN PARKINSONISM.
168619 01-15

DRUG THERAPY AND MARITAL THERAPY IN OUTPATIENT DEPRESSIVES.
169088 01-09

RELATIONSHIP BETWEEN THE EFFECTIVENESS OF LITHIUM THERAPY AND FAMILY HISTORY.
169494 01-09

CHANGES IN MENTAL FUNCTIONING ACCOMPANYING ANTIPSYCHOTIC DRUG THERAPY.
171124 01-10

THE CORRECTIVE EFFECT OF PRAXINOR ON HYPOTENSION ATTRIBUTABLE TO PSYCHIATRIC THERAPY. SIDE-EFFECTS.
172980 01-11

THE PATIENTS VIEW OF L-DOPA AFTER ONE YEARS THERAPY.
175459 02-15

TANTU-PASHAN AND LUCIDRIL THERAPY IN MENTALLY RETARDED CHILDREN.
175628 02-11

SIDE-EFFECTS OF DEXTROAMPHETAMINE THERAPY OF HYPERACTIVE CHILDREN.
176238 02-15

ACUTE CEREBELLAR DISTURBANCE ASSOCIATED WITH DIAZEPAM THERAPY -- A CASE REPORT AND FURTHER INVESTIGATION.
177392 02-15

EFFECTS OF SHORT-TERM VERSUS LONG-TERM L-DOPA THERAPY IN PARKINSONISM ON CRITICAL FLICKER FREQUENCY.
177511 02-11

PSYCHIATRIC TREATMENT: WHAT COMES AFTER PHARMACOLOGICAL THERAPY
178655 02-17

DRUG THERAPY FOR DEPRESSION IN CHILDREN. INDICATIONS AND METHODS.
182429 03-10

LITHIUM IN PSYCHIATRIC THERAPY AND PROPHYLAXIS. A REVIEW WITH SPECIAL REGARD TO ITS USE IN CHILDREN.
182433 03-09

INFLUENCE OF ANTIDEPRESSIVE THERAPY ON THE DISTURBED TIME ESTIMATION OF DEPRESSIVES.
182591 03-14

THE USE OF LOW DOSES OF MONOCHLORIMIPRAMINE IN THE THERAPY OF NEUROTIC DEPRESSIVE SYNDROMES.
182789 03-10

THE USE OF FLUPENTHIXOL IN THERAPY.
183124 03-11

PSYCHIC FATIGABILITY, ITS FEATURES AND DRUG THERAPY.
183197 03-11

EVALUATION OF EEG AND CLINICAL CHANGES ASSOCIATED WITH PAVABID THERAPY IN CHRONIC BRAIN SYNDROME.
183402 03-13

THE USE OF ORAL DROPERIDOL IN PSYCHIATRIC THERAPY.
184965 03-07

A DOUBLE-BLIND TRIAL OF LONG-TERM LITHIUM THERAPY IN MENTAL DEFECTIVES.
185193 03-11

CALCIUM METABOLISM IN ELDERLY EPILEPTIC PATIENTS DURING ANTICONVULSANT THERAPY.
185560 03-15

PERPHENAZINE CONCENTRATIONS IN HUMAN WHOLE BLOOD: A PILOT STUDY DURING ANTIPSYCHOTIC THERAPY USING DIFFERENT ADMINISTRATION FORMS.
187639 04-16

LITHIUM THERAPY AND ERYTHROCYTE MEMBRANE CATION CARRIER.
187644 04-15

HEAT DYSCONTROL SYNDROME IN PATIENTS RECEIVING ANTIPSYCHOTIC, ANTIDEPRESSANT AND ANTIPARKINSON DRUG THERAPY.
188094 04-15

ON-OFF PHENOMENON WITH LEVODOPA THERAPY IN PARKINSONISM: CLINICAL AND PHARMACOLOGIC CORRELATIONS AND THE EFFECT OF INTRAMUSCULAR PYRIDOXINE.
188560 04-11

NERVE CONDUCTION VELOCITY IN PATIENTS ON LONG-TERM DIPHENYLHYDANTOIN THERAPY.
189173 04-15

TARDIVE DYSKINESIA AND DRUG THERAPY IN GERIATRIC PATIENTS.
189923 04-13

CLINICAL EVALUATION OF AMANTADINE THERAPY FOR PARKINSONISM AND THE SIDE-EFFECTS -- IN CASES OF THALAMIC SURGERY AND L-DOPA THERAPY.
190095 04-11

IMPROVING PSYCHIATRIC DRUG THERAPY: A MATTER OF DOSAGE AND CHOICE.
190144 04-17

DISSOCIATION OF GROWTH HORMONE AND PROLACTIN SECRETION IN PARKINSONS DISEASE FOLLOWING CHRONIC L-DOPA THERAPY.
191233 04-13

PROCAINE (GEROVITAL-H3) THERAPY: MECHANISM OF INHIBITION OF MONOAMINE OXIDASE.
191281 04-03

THE PREDICTIVE VALUE OF THE ANTIAPOMORPHINE TEST IN DOGS FOR NEUROLEPTIC THERAPY IN MAN.
192421 04-04

INTERACTION BETWEEN NEUROLEPTIC THERAPY AND SOCIOTHERAPEUTIC APPROACH. AN INVESTIGATION WITH PENFLURIDOL AND HALOPERIDOL.
192431 04-08

THERMAL

EFFECT OF ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL ON MEMORY, SPEECH, AND PERCEPTION OF THERMAL STIMULATION: RESULTS WITH FOUR NORMAL HUMAN VOLUNTEER SUBJECTS. PRELIMINARY REPORT.
177674 02-14

THE ONTOGENY OF AMPHETAMINE-INDUCED ALTERATIONS IN THERMAL REGULATION.
182246 03-03

THERMOGENESIS

DIAZEPAM IN LABOUR: ITS METABOLISM AND EFFECT ON THE CLINICAL CONDITION AND THERMOGENESIS OF THE NEWBORN.
171731 01-13

THERMOREGULATION

AMPHETAMINE AND THERMOREGULATION: STUDIES IN THE UNRESTRAINED AND CURARIZED RAT.
184227 03-03

PARADOXICAL EFFECTS OF D-AMPHETAMINE ON BEHAVIORAL THERMOREGULATION: POSSIBLE MEDIATION BY BRAIN DOPAMINE.
189399 04-04

THERMOREGULATORY

PARADOXICAL THERMOREGULATORY BEHAVIOUR IN RATS INDUCED BY (..) AMPHETAMINE: BLOCKADE BY ALPHA-ADRENOCEPTOR OR DOPAMINE RECEPTOR BLOCKING AGENTS.
183797 03-03

THETA

A FREQUENCY SHIFT IN THE HIPPOCAMPAL THETA ACTIVITY: AN ELECTRICAL CORRELATE OF CENTRAL ACTION OF ACTH ANALOGUES IN THE DOG
188166 04-04

THIENODIAZEPINE

A CLINICAL EVALUATION OF A NEW ANXIOLYTIC DRUG (THIENODIAZEPINE DERIVATIVE Y-6047) IN NEUROTICS AND PSYCHOSOMATIC DISORDERS -- A PRELIMINARY REPORT.
181771 02-07

THIN-LAYER

MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC) -- REPORT 1. THIN-LAYER CHROMATOGRAPHY OF HYPNOTICS AND TRANQUILIZERS.
181315 02-16

MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC): REPORT 2 -- ISOLATION AND IDENTIFICATION OF HYPNOTICS AND TRANQUILIZER IN VIVO.
182623 03-06

ISOLATION AND IDENTIFICATION OF HYPNOTICS (B): ISOLATION AND IDENTIFICATION OF BENZALIN AND CERCINE BY THIN-LAYER CHROMATOGRAPHY IN VITRO.
182626 03-01

QUANTITATIVE DETERMINATION OF IMIPRAMINE AND DESIPRAMINE IN HUMAN BLOOD PLASMA BY DIRECT DENSITOMETRY OF THIN-LAYER CHROMATOGRAMS.
183603 03-13

THIOACETAMINDE

REDUCTION BY PRETREATMENT WITH DIBENAMINE OF HEPATOTOXICITY INDUCED BY CARBON TETRACHLORIDE, THIOACETAMINDE OR DIMETHYLNITROSAMINE.
188865 04-05

THIOPENTAL

REINVESTIGATION ON THE EFFECTS OF THIOPENTAL ON THE HUMAN SOMATOSENSORY EVOKED RESPONSE.
174505 01-13

THIORIDAZINE

PSYCHOPATHOLOGICAL IMPORTANCE AND THERAPEUTIC EFFECTS OF A COMBINATION OF HYDERGINE AND THIORIDAZINE IN PSYCHIATRIC SYNDROMES IN THE AGING.
168976 01-14

COMPARISON OF THIORIDAZINE AND DIAZEPAM IN THE CONTROL OF NONPSYCHOTIC SYMPTOMS ASSOCIATED WITH SENILITY: DOUBLE-BLIND STUDY.
170129 01-11

A DOUBLE-BLIND COMPARISON OF THIORIDAZINE (MELLARIL) VERSUS DIAZEPAM (VALIUM) IN PATIENTS WITH CHRONIC MIXED ANXIETY AND DEPRESSIVE SYMPTOMS.
172486 01-10

A COMPARATIVE TRIAL OF HALOPERIDOL AND THIORIDAZINE: MANAGEMENT OF CHRONIC SCHIZOPHRENIA.
172741 01-08

A DOUBLE-BLIND COMPARISON OF CLOZAPINE WITH THIORIDAZINE ON SCHIZOPHRENIA.
175119 02-08

CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, ZISEPRON, IN TREATMENT OF PSYCHIATRIC DISEASES IN COMPARISON WITH THIORIDAZINE.
176467 02-08

EXPERIENCE GAINED IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PSYCHOSES WITH A THIORIDAZINE DERIVATIVE.
180675 02-08

ISOLATION OF A POSSIBLE NEW METABOLITE OF THIORIDAZINE AND MESORIDAZINE FROM HUMAN PLASMA.
182722 03-13

ASSAY PROCEDURES FOR THIORIDAZINE, TRIFLUOPERAZINE, AND THEIR SULFOXIDES AND DETERMINATION OF URINARY EXCRETION OF THESE COMPOUNDS IN MENTAL PATIENTS.
183602 03-01

ACUTE EFFECTS OF ALCOHOL, DIAZEPAM, THIORIDAZINE, FLUPENTHIXOL AND ATROPINE ON PSYCHOMOTOR PERFORMANCE PROFILES.
184848 03-14

FATAL SUICIDAL INGESTION OF THIORIDAZINE.
189606 04-15

METABOLIC INTERACTIONS BETWEEN NORTRIPTYLINE AND THIORIDAZINE IN RATS.
190346 04-03

SOURCES OF VARIABILITY IN THE PHARMACODYNAMICS OF 14C-IMIPRAMINE INCLUDING INTERACTION WITH DIAZEPAM OR THIORIDAZINE.
191925 04-03

EFFECTS OF CHLORPROMAZINE (CPZ) AND THIORIDAZINE PERFORMANCE AND STIMULUS CONTROL BEHAVIOR.
191974 04-04

THIORIDAZINE IN NEUROTIC, ANXIOUS, AND DEPRESSED PATIENTS.
192227 04-10

HALOPERIDOL VERSUS THIORIDAZINE FOR THE TREATMENT OF PSYCHOGERIATRIC PATIENTS: A DOUBLE-BLIND CLINICAL STUDY.
192231 04-09

THIOSEMICARBAZIDE

BEHAVIORAL AND ELECTROENCEPHALOGRAPHIC STUDIES ON THIOSEMICARBAZIDE INDUCED SEIZURE IN RABBITS.
174855 01-05

THIOTHIXENE

CLINICAL STUDY OF THIOTHIXENE.
173563 01-08

HIGH AND LOW DOSE THIOTHIXENE TREATMENT IN CHRONIC SCHIZOPHRENIA.
176673 02-08

CLINICAL STUDY ON THE EFFECTS OF THIOTHIXENE IN HOSPITALIZED PSYCHOTIC PATIENTS.
183955 03-08

BEHAVIORAL AND VISUAL EVOKED POTENTIAL INVESTIGATIONS DURING TRIHEXYPHENIDYL AND THIOTHIXENE TREATMENT IN PSYCHOTIC BOYS.
187115 03-09

DOUBLE-BLIND COMPARISON OF THIOTHIXENE, TRIFLUOPERAZINE, AND PLACEBO IN CHRONIC ALCOHOLISM.
188584 04-11

THIRST

PRESENCE OF OSMORECEPTORS FOR THIRST IN THE LATERAL PREOPTIC NUCLEUS.
168859 01-03

THOUGHTS
THOUGHTS ON TREATMENT BY PRIVATE PHYSICIANS OF ABNORMAL SEX DRIVES.
180674 02-11

THRESHOLD
SIGNIFICANCE OF THE CENTRAL BIOGENIC AMINES FOR THE THRESHOLD IN ELECTRO AND PENTETRAZOLE SEIZURES.
181469 02-03
CHANGES IN THE NEUROEXCITABILITY OF ALCOHOL DEPENDENT RATS UNDERGOING WITHDRAWAL AS MEASURED BY THE PENTYLENETETRAZOL SEIZURE THRESHOLD.
182348 03-03
AUTOMATIC DETERMINATION OF THE PAIN THRESHOLD TO ELECTROSHOCK AND THE EFFECTS OF DELTA9-THC.
183363 03-03

THRESHOLDS
THRESHOLDS FOR ELECTROCONVULSIONS AND CHEMOCONVULSIONS IN MICE AFTER TERMINATION OF TREATMENT WITH PHENOBARBITAL.
170073 01-03
NEGATIVE AND POSITIVE INTRACRANIAL REINFORCEMENT THRESHOLDS: EFFECTS OF MORPHINE.
190330 04-04

THYMIDINE
EFFECTS OF CHLORPROMAZINE AND ACTINOMYCIN D ON UPTAKE AND INCORPORATION OF CERTAIN AMINO ACIDS, HYPOXANTHINE AND THYMIDINE IN CULTURES OF HUMAN SKIN EPITHELIAL CELLS.
179989 02-13

THYMOANALEPTIC
THE FIRST LONG-ACTING (RETARD) THYMOANALEPTIC OR ANTIDEPRESSANT: THE TIME-RELEASED DIBENZEPINE WITH PROLONGED ACTION.
178946 02-11

THYMOLEPTIC
INHIBITION OF MOUSE-KILLING BEHAVIOUR IN RATS BY SOME THYMOLEPTIC DRUGS.
171608 01-04

THYMOLEPTICS
BEHAVIORAL EFFECT OF TRICYCLIC THYMOLEPTICS AND CHLORPHENIRAMINE IN MICE AFTER PRETREATMENT WITH 5 HYDROXYTRYPTOPHAN (5-HTP).
171609 01-04
ANTAGONISM OF P-CHLOROAMPHETAMINE (PCA) INDUCED DEPLETION OF 5-HT FROM RAT BRAIN BY SOME THYMOLEPTICS AND OTHER PSYCHOTROPIC DRUGS.
171628 01-03
EFFECTS OF NEUROLEPTICS AND THYMOLEPTICS ON PHOSPHODIESTERASE ACTIVITY AND ON CYCLIC 3,5 AMP LEVELS IN RAT BRAIN.
181467 02-03
MYOCARDIOPATHIC COMPLICATIONS INDUCED BY IMIPRAMINE AND TRICYCLIC THYMOLEPTICS.
182898 03-15

THYROID
THE EFFECT OF LITHIUM ON THYROID IODINE RELEASE IN PATIENTS WITH PRIMARY AFFECTIVE DISORDER.
186580 03-09
THE EFFECT OF LITHIUM ON THYROID IN MAN.
191142 04-15

THYROTOXICOSIS
THYROTOXICOSIS DEVELOPING DURING LITHIUM TREATMENT: CASE REPORT.
186473 03-15

THYROTROPHIN
THYROTROPHIN RELEASING HORMONE IN THE TREATMENT OF DEPRESSION.
192577 04-09

THYROTROPIN
A DOUBLE-BLIND CROSSOVER SEQUENTIAL TRIAL OF ORAL THYROTROPIN RELEASING HORMONE IN DEPRESSION.
188348 04-09
AFFECTIVE STATE AND THYROTROPIN AND PROLACTIN RESPONSES AFTER REPEATED INJECTIONS OF THYROTROPIN RELEASING HORMONE IN DEPRESSED PATIENTS.
189076 04-09

THYROTROPINE
A PRELIMINARY STUDY ON THE ACTION OF THYROTROPINE RELEASING HORMONE OR TRH IN DEPRESSIVE STATES.
184962 03-09

TIC
TIC DE GILLES-DE-LA-TOURETTE: CASE REPORT AND BRIEF DISCUSSION.
181158 02-09

TIME
DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE IN RESPECT TO TIME AND DOSAGE AND QUANTIFICATION OF THE PRECIPITATED WITHDRAWAL SYNDROME IN RATS.
169474 01-03
INTERRESPONSE TIME CHANGES AS A FUNCTION OF DEPRIVATION AND AMPHETAMINE ADMINISTRATION.
171612 01-04
DIFFERENTIAL EFFECTS OF ETHANOL AND PENTOBARBITAL ON SLEEP TIME IN C57BL AND BALB MICE.
177733 02-03
EFFECT OF CANNABIS ON PENTOBARBITAL INDUCED SLEEPING TIME AND PENTOBARBITAL METABOLISM IN THE RAT.
179985 02-03
INFLUENCE OF ANTIDEPRESSIVE THERAPY ON THE DISTURBED TIME ESTIMATION OF DEPRESSIVES.
182591 03-14
A SMALL CONTROLLED STUDY TO DETERMINE THE TIME OF ONSET OF ACTION OF OXYPERTINE AFTER ORAL ADMINISTRATION IN NORMAL SUBJECTS.
182763 03-14
EFFECT OF VARIOUS STEROIDS AND ACTH ON METHYPRYLON PLASMA LEVELS AND SLEEPING TIME IN RATS.
183611 03-03
EFFECTS OF SHORT-TERM ADMINISTRATION OF N-NITROSO COMPOUNDS ON LIVER HISTOLOGY AND PENTOBARBITAL INDUCED SLEEPING TIME IN MICE.
187575 04-04
TIME SAMPLING OF RAT EXPLORATORY BEHAVIOUR: A RELIABLE SCREENING TEST FOR THE CNS EFFECTS OF ANOREXIC AGENTS.
187925 04-04
DEPLETION OF TRYPTOPHAN HYDROXYLASE BY 5,6 DIHYDROXYTRYPTAMINE IN RAT BRAIN -- TIME COURSE AND REGIONAL DIFFERENCES.
188287 04-03
METRAZOL DISRUPTS CONDITIONED AVERSION PRODUCED BY LICL: A TIME DEPENDENT EFFECT.
188412 04-04
THE PROBLEMS OF THE CLINICAL USAGE OF NITRAZEPAM: SUPPRESSIVE EFFECTS ON THE PHARYNGEAL REFLEX AND THE COMA, USING OTHER TRANQUILIZERS AT THE SAME TIME.
188450 04-15
THE EFFECTS OF HOE-36801 ON MUSCLE ACTIVITY AND BLOOD PRESSURE, ON ATTENTION AND CONCENTRATION, ON TIME JUDGMENT AND SUBJECTIVE RESPONSES IN NEUROTICS AND NORMALS.
192429 04-14

TIME-RELEASED
THE FIRST LONG-ACTING (RETARD) THYMOANALEPTIC OR ANTIDEPRESSANT: THE TIME-RELEASED DIBENZEPINE WITH PROLONGED ACTION.
178946 02-11
RATING OF PSYCHOLOGICAL EFFECTS INDUCED BY ORDINARY NOVERIL AND TIME-RELEASED NOVERIL.
190312 04-14

TIMED
THE USE OF TIMED RELEASE NEUROLEPTICS IN AMBULATORY PSYCHIATRIC PRACTICE.
172977 01-11

TIMES
THE EFFECTS OF D-AMPHETAMINE ON THE INTERRESPONSE TIMES OF RATS AND GUINEA-PIGS ON A MODIFIED SIDMAN DISCRIMINATED AVOIDANCE SCHEDULE.
189519 04-04

TIMING
ADAPTATION TO NITROGEN NARCOSIS MANIFESTED BY TIMING BEHAVIOR IN THE RAT.
186630 03-04
COMPARATIVE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC), CANNABIDIOL (CBD), AND CANNABINOL (CBN) ON TIMING BEHAVIOR IN RATS.
191967 04-04

TIQ
IN VIVO INHIBITION OF NEURONAL UPTAKE OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY COCAINE AND BY DESMETHYLIMIPRAMINE (DMI).
182150 02-03
UPTAKE, STORAGE AND RELEASE IN VIVO OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY SYMPATHETIC NERVES OF THE IRIS.
182204 02-03
NONSPONTANEOUS CONVULSIONS IN MICE ELICITED BY SOME CATECHOLAMINE RELEASERS AND 6,7 DIHYDROXYTETRAHYDROISOQUINOLINE (TIQ).
192013 04-05

TISSUE
EFFECT OF ADRENERGIC SUBSTANCES ON OXYGEN CONSUMPTION OF RAT BRAIN TISSUE.
180058 02-03
THE INHIBITION OF (3H) BIOGENIC AMINE ACCUMULATION INTO RAT BRAIN TISSUE SLICES BY VARIOUS TRYPTAMINE DERIVATIVES.
182723 03-03
EFFECTS OF PROLONGED LSD-25 ADMINISTRATION UPON NEURONS OF SPINAL CORD GANGLIA TISSUE CULTURES.
185112 03-03

MESCALINE INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON THE BINDING OF AMINOACYL TRANSFER RIBONUCLEIC ACID TO RIBOSOMES OF BRAIN TISSUE.
189582 04-05
TISSUE LOCALIZATION OF 7- AND 8-HYDROXYCHLORPROMAZINES.
189589 04-03
SOME CONSIDERATIONS IN THE DESIGN OF SUBSTRATE AND TISSUE SPECIFIC INHIBITORS OF MAO.
191499 04-01

TISSUES
THE EFFECTS OF 6-OH-DOPAMINE ON THE REPRODUCTION AND NA AND 5-HT CONTENTS OF SOME TISSUES IN MICE.
171613 01-03
EFFECT OF CHRONIC ADMINISTRATION OF L-DOPA ON CATECHOL-O-METHYLTRANSFERASE IN RAT TISSUES.
176936 02-03
EFFECTS OF DECAPITATION, ETHER AND PENTOBARBITAL ON CYCLIC AMP AND CYCLIC GMP LEVELS IN RAT TISSUES.
182154 02-03
EFFECT OF L-DOPA IN 54 MN INCORPORATION BY TISSUES.
185993 03-03
MONOAMINE OXIDASE IN MAN: ENZYME CHARACTERISTICS IN HUMAN PLATELETS, PLASMA, AND OTHER HUMAN TISSUES.
191502 04-13

TLC
MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC) -- REPORT 1. THIN-LAYER CHROMATOGRAPHY OF HYPNOTICS AND TRANQUILIZERS.
181315 02-16
MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC): REPORT 2 -- ISOLATION AND IDENTIFICATION OF HYPNOTICS AND TRANQUILIZER IN VIVO.
182623 03-06

TLP-607
EXPERIMENT WITH PENFLURIDOL (TLP-607) ON THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
191593 04-08

TOLERANCE
TOLERANCE TO HEXOBARBITAL AND SUPERSENSITIVITY TO PILOCARPINE INDUCED BY CHRONIC BARBITAL TREATMENT IN THE RAT.
171601 01-03
TOLERANCE AND CROSS-TOLERANCE TO THE ANOREXIGENIC EFFECT OF SOME AMPHETAMINE DERIVATIVES IN RATS.
171602 01-03
FAILURE OF N,N DIMETHYLTRYPTAMINE TO EVOKE TOLERANCE IN CATS.
173398 01-03
AN ANALYSIS OF TOLERANCE TO THE ANOREXIGENIC EFFECTS OF AMPHETAMINE. (PH.D. DISSERTATION).
173775 01-03
DEVELOPMENT OF TOLERANCE IN RATS TO THE HYPOTHERMIC EFFECTS OF D-AMPHETAMINE AND APOMORPHINE.
174764 01-03
ATTEMPTS TO EVOKE TOLERANCE TO DMT IN MAN. (UNPUBLISHED PAPER).
176480 02-12
MECHANISMS OF DRUG-INDUCED BEHAVIORAL TOLERANCE.
181406 02-04
LACK OF EFFECTS OF CYCLOHEXIMIDE ON TOLERANCE DEVELOPMENT TO A STIMULATORY EFFECT OF MORPHINE ON MICE.
182158 02-03
EFFECT OF CHEMICAL SYMPATHECTOMY ON MORPHINE ANTINOCICEPTION AND TOLERANCE IN RATS.
182159 02-03
CHROMATIN TEMPLATE ACTIVITY DURING MORPHINE-INDUCED ANALGESIA AND THE DEVELOPMENT OF ANALGESIC TOLERANCE.
182160 02-03
LSD TOLERANCE AND BRAIN SEROTONIN METABOLISM.
182167 02-03
TOLERANCE TO THE ACTIVITY ENHANCING EFFECTS OF D-AMPHETAMINE.
182208 02-04
EFFECT OF GAMMA-AMINOBUTYRIC ACID (GABA) ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
182231 03-03
AN ELECTROENCEPHALOGRAPHIC STUDY ON THE TOLERANCE OF THE VARIOUS PSYCHIATRIC AND NEUROLOGICAL PATIENTS TO THE HYPNOTIC EFFECTS OF DIPHENHYDRAMINE -- MEASURED BY THE AMOUNTS OF SLEEP EEG AS AN INDICATOR.
182550 03-11
DELTA9-TETRAHYDROCANNABINOL AND 11-HYDROXY-DELTA9-TETRAHYDROCANNABINOL: BEHAVIORAL EFFECTS AND TOLERANCE DEVELOPMENT.
183893 03-04
TOLERANCE TO THE BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF HALOPERIDOL AND MORPHINE IN RATS CHRONICALLY TREATED WITH MORPHINE OR HALOPERIDOL.
184225 03-03
PERCEPTUAL STYLE AND PAIN TOLERANCE -- II. THE INFLUENCE OF AN ANXIOLYTIC AGENT.
184291 03-14
TOLERANCE TO THE HYPERACTIVATING EFFECTS OF METHYLAMPHETAMINE.
186702 03-04
DELTA9-TETRAHYDROCANNABINOL: EFFECTS OF ROUTE OF ADMINISTRATION ON ONSET AND DURATION OF ACTIVITY AND TOLERANCE DEVELOPMENT.
187928 04-03
THE EFFECTS OF P-CHLOROPHENYLALANINE ON MORPHINE ANALGESIA, TOLERANCE AND DEPENDENCE DEVELOPMENT IN TWO STRAINS OF RATS.
187930 04-04
LONG-TERM USE OF MARIHUANA AND THE DEVELOPMENT OF TOLERANCE OR SENSITIVITY TO DELTA9-TETRAHYDROCANNABINOL.
188119 04-13
EFFECT OF L-PHENYL-3-2-THIAZOLYL 2-THIOUREA, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
191769 04-03
AMPHETAMINES EFFECTS ON SELF-STIMULATION: DEVELOPMENT OF TOLERANCE AND POST-DRUG DEPRESSION.
191914 04-04
MORPHINE TOLERANCE, DEPENDENCE AND WITHDRAWAL AND BRAIN ACETYLCHOLINE.
191985 04-03

TOLERANT
THE EFFECTS OF D- AND L-AMPHETAMINE ON FIXED-INTERVAL AND FIXED-RATIO BEHAVIOR IN TOLERANT AND NONTOLERANT RATS.
168438 01-04
OPEN-FIELD BEHAVIOR AND ACQUISITION OF DISCRIMINATIVE RESPONSE CONTROL IN DELTA9-THC TOLERANT RATS.
178813 02-04
THE EFFECT OF CATECHOLAMINES, ACETYLCHOLINE AND SEROTONIN ON THE MORPHINE TOLERANT LONGITUDINAL MUSCLE STRIP OF THE GUINEA-PIG ILEUM.
182161 02-03
METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY RATS TOLERANT TO MARIHUANA.
192020 04-03

TOMORROW
YESTERDAY, TODAY AND TOMORROW: A POINT OF VIEW.
168312 01-17

TONE
THE EFFECTS OF AGENTS THAT MODIFY MUSCARINIC TONE UPON BEHAVIOR CONTROLLED BY AN AVOIDANCE SCHEDULE THAT EMPLOYS SIGNALED UNAVOIDABLE SHOCK.
171302 01-04

TOOL
SLEEP: A TOOL TO STUDY CHLORPROMAZINES ACTION. (UNPUBLISHED PAPER).
173521 01-14

TOPICS
TOPICS IN PSYCHIATRY: PSYCHOTROPIC MEDICINE.
177190 02-17

TOPOGRAPHY
EFFECTS OF DOPAMINE-LIKE DRUGS ON RAT STRIATAL ADENYL CYCLASE HAVE IMPLICATIONS FOR CNS DOPAMINE RECEPTOR TOPOGRAPHY.
190545 04-03

TORTOISE
EFFECT OF ATROPINE SULFATE ON THE SLEEP RELATED EEG SPIKE ACTIVITY OF THE TORTOISE, GEOCHELONE-CARBONARIA.
191389 04-03

TOUCHED
MEDICATION AND/OR PSYCHOTHERAPY WITH SCHIZOPHRENICS: WHICH PART OF THE ELEPHANT HAVE YOU TOUCHED
173534 01-08

TOURETTES
VESTA VARIANT OF TOURETTES DISEASE: TREATMENT WITH HALOPERIDOL.
169286 01-10

TOXIC
TOXIC EFFECTS OF MARIHUANA TAR ON MOUSE SKIN.
170464 01-05
A STUDY OF THE RELATIVE ANTICONVULSANT AND TOXIC ACTIVITIES OF DELTA9-TETRAHYDROCANNABINOL AND ITS CONGENERS.
174608 01-05
RUBIDIUM SALTS -- TOXIC EFFECTS IN HUMANS AND CLINICAL EFFECTS AS AN ANTIDEPRESSANT DRUG.
182443 03-09

TOXICITY
PHARMACOLOGICAL STUDIES OF OXAZOLAZEPAM, A NEW PSYCHOTROPIC AGENT (SECOND REPORT): GENERAL PHARMACOLOGY AND SUBACUTE TOXICITY.
168499 01-07
LITHIUM CARBONATE TOXICITY.
168505 01-15

TEMPERATURE DEPENDENT TOXICITY OF ADRENERGIC AGONISTS IN MICE AS A BASIS FOR TREATING D-AMPHETAMINE POISONING.
169688 01-05

NEGATIVE SODIUM BALANCE IN LITHIUM CARBONATE TOXICITY: EVIDENCE OF MINERALOCORTICOID BLOCKADE.
169869 01-15

COMPARATIVE EFFECTS OF 6-HYDROXYDOPAMINE AND OF RESERPINE ON OUABAIN TOXICITY IN THE RAT.
172598 01-05

ACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MICE, RATS, RABBITS AND DOGS.
173548 01-05

SUBACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MALE AND FEMALE RATS: ORAL ADMINISTRATION FOR ONE MONTH.
177097 02-05

RUBIDIUM SALTS -- ANIMAL TOXICITY STUDIES.
182442 03-05

HIGH DOSAGE PIPERACETAZINE (QUIDE-R) IN AMBULATORY SCHIZOPHRENIC PATIENTS: THERAPEUTIC EFFICACY AND TOXICITY.
187869 04-08

ORAL AND INTRAVENOUS TOXICITY OF DELTA9-TETRAHYDROCANNABINOL IN RHESUS MONKEYS.
188872 04-05

INTERACTIONS OF CHLORPHENIRAMINE ETHANOL COMBINATIONS: ACUTE TOXICITY AND ANTIHISTAMINIC ACTIVITY.
188875 04-05

THE ACUTE TOXICITY OF L-DOPA.
189587 04-05

EFFECTS OF PHENOBARBITAL AND SKF-525-A PRETREATMENT, SEX, LIVER INJURY, AND VEHICLE ON DELTA9-TETRAHYDROCANNABINOL TOXICITY.
189598 04-05

THE LACK OF EFFECTS OF PRETREATMENT WITH PHENOBARBITAL AND CHLORPROMAZINE ON THE ACUTE TOXICITY OF BENZENE IN RATS.
189600 04-05

TOXICOLOGICAL
PHARMACOLOGICAL AND TOXICOLOGICAL STUDIES ON 1,4 BUTANEDIOL.
187381 04-03

TOXICOLOGY
TOXICOLOGY OF DELTA9-TETRAHYDROCANNABINOL. (PH.D. DISSERTATION).
174961 01-05

PHARMACOLOGY AND TOXICOLOGY OF THE ANTIEPILEPTIC DRUG CLONAZEPAM.
179021 02-05

TPS-23
MESORIDAZINE (TPS-23 SANDOZ) IN ACUTE PSYCHOTIC STATES.
187958 04-11

CLINICAL EXPERIENCES WITH MESORIDAZINE (TPS-23): ITS ADMINISTRATION TO HOSPITALIZED SCHIZOPHRENIC PATIENTS.
188934 04-08

TRACKING
THE EFFECT OF MARIHUANA ON TRACKING TASK PERFORMANCE.
177720 02-14

CENTRAL NERVOUS STIMULANT INDUCED PHYSIOLOGICAL AND PERFORMANCE CHANGES IN ADULTS DURING SUSTAINED PSYCHOMOTOR TRACKING.
179023 02-13

TRAINED
SPECIFIC FACILITATION OF MAZE LEARNING BY A PEPTIDE EXTRACTED FROM TRAINED MOUSE BRAIN.
176868 02-04

THE EFFECTS OF 3,4 DIMETHOXYPHENYLETHYLAMINE IN RATS TRAINED WITH MESCALINE AS A DISCRIMINATIVE STIMULUS.
186667 03-04

EFFECTS OF NICOTINE ON THE SHUTTLEBOX BEHAVIOR OF TRAINED GUINEA-PIGS.
190333 04-04

TRAINING
RECOVERY FROM ELECTROCONVULSIVE SHOCK-INDUCED AMNESIA BY EXPOSURE TO THE TRAINING ENVIRONMENT: PHARMACOLOGICAL ENHANCEMENT BY PIRACETAM.
186704 03-04

TRANQUILIZER
WY-4036 (LORAZEPAM) -- A NEW TRANQUILIZER.
180146 02-10

MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC): REPORT 2 -- ISOLATION AND IDENTIFICATION OF HYPNOTICS AND TRANQUILIZER IN VIVO.
182623 03-06

TRANQUILIZERS
TRANQUILIZERS AND EXAMINATION STRESS.
168901 01-14

MEGAVITAMIN TREATMENT, CULTURE AND TRANQUILIZERS, DRUGS FOR THE AGED: PROJECTS OF A CANADIAN GRANT.
170293 01-11

PSYCHOLOGICAL STUDY ON ATTITUDES TOWARD TRANQUILIZERS.
173502 01-08

AN ENZYME APPROACH IN APPRAISING THE MODE OF SOME TRANQUILIZERS AND ANTIDEPRESSANTS.
174318 01-03

POPULAR ATTITUDES AND BELIEFS ABOUT TRANQUILIZERS.
177699 02-17

CHARACTERISTICS OF BENZODIAZEPINE TRANQUILIZERS.
180307 02-17

MEDICOLEGAL STUDIES ON ISOLATION AND IDENTIFICATION OF HYPNOTICS BY THIN-LAYER CHROMATOGRAPHY (TLC) -- REPORT 1. THIN-LAYER CHROMATOGRAPHY OF HYPNOTICS AND TRANQUILIZERS.
181315 02-16

CLINICAL STUDY OF TRANQUILIZERS.
182574 03-17

THE EFFECT OF MINOR TRANQUILIZERS ON STRESS INDUCED INCREASES IN RAT PLASMA CORTICOSTEROIDS.
186578 03-03

CALCIUM REVERSAL OF NERVE BLOCKADE BY ALCOHOLS, ANESTHETICS, TRANQUILIZERS, AND BARBITURATES.
187802 04-03

THE ADDITIVE EFFECTS OF TRANQUILIZERS AND DOPAMINE ON SMOOTH MUSCLE.
187804 04-03

THE PROBLEMS OF THE CLINICAL USAGE OF NITRAZEPAM: SUPPRESSIVE EFFECTS ON THE PHARYNGEAL REFLEX AND THE COMA, USING OTHER TRANQUILIZERS AT THE SAME TIME.
188450 04-15

THE NERVE IMPULSE BLOCKING ACTIONS OF TRANQUILIZERS AND THE BINDING OF NEUROLEPTICS TO SYNAPTOSOME MEMBRANES.
189400 04-03

INTERACTION BETWEEN ALCOHOL, MINOR TRANQUILIZERS AND MORPHINE.
191141 04-04

CONCENTRATION EFFECT RELATIONSHIPS WITH MAJOR AND MINOR TRANQUILIZERS.
192871 04-14

TRANQUILIZING
IN THE SEARCH FOR NEW TRANQUILIZING DRUGS.
167813 01-04

THE USE OF TRANQUILIZING DRUGS IN CASES OF SCHIZOPHRENIA.
182581 03-08

CORRELATION BETWEEN THE TRANQUILIZING AND SEDATIVE ACTION OF NEUROLEPTICS, ANTIDEPRESSANTS AND ANTICHOLINERGIC DRUGS.
191783 04-02

TRANQUILLISER
SECOND MINOR TRANQUILLISER ON PHARMACEUTICAL BENEFITS LIST.
184322 03-17

TRANQUILLIZER
IS OXYPERTINE AN ACTIVATING TRANQUILLIZER?
182765 03-09

SEDATIVE OR TRANQUILLIZER? A COMPARISON OF THE HYPNOTIC EFFECTS OF CHLORDIAZEPOXIDE AND AMYLOBARBITONE SODIUM.
184438 03-14

MUTAGENICITY EXPERIMENTS WITH THE TRANQUILLIZER MEPROBAMATE IN DROSOPHILA-MELANOGASTER AND IN HUMAN LEUKOCYTE CHROMOSOMES IN VITRO.
184585 03-05

TRANQUILLIZERS
TURNOVER CHANGES IN CENTRAL MONOAMINE NEURON SYSTEMS AFTER MINOR TRANQUILLIZERS AND BARBITURATES.
171604 01-03

TRANSECTED
EFFECT OF CHLORIMIPRAMINE ON THE RATE OF TRYPTOPHAN HYDROXYLATION IN THE INTACT AND TRANSECTED SPINAL CORD.
168751 01-03

EFFECTS OF P-CHLOROPHENYLALANINE (PCPA) AND NIALAMIDE ON 5-HYDROXYTRYPTAMINE (5-HT) IN THE TRANSECTED SPINAL CORD.
171623 01-03

TRANSECTION
5-HYDROXYTRYPTAMINE AND NORADRENALINE IN THE HIPPOCAMPAL REGION: EFFECT OF TRANSECTION OF AFFERENT PATHWAYS ON ENDOGENOUS LEVELS, HIGH AFFINITY UPTAKE AND SOME TRANSMITTER RELATED ENZYMES.
191319 04-03

TRANSFER
DETERMINATION OF DRUG TRANSFER ACROSS BIOLOGICAL MEMBRANES: COMPARATIVE STUDY ON THE PASSAGE OF DRUGS INTO THE CENTRAL NERVOUS SYSTEM AND THEIR PLACENTAL TRANSFER AND FETAL LOCALIZATION IN THE PREGNANT RAT. (PH.D. DISSERTATION).
172018 01-03

MESCALINE INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON THE BINDING OF AMINOACYL TRANSFER RIBONUCLEIC ACID TO RIBOSOMES OF BRAIN TISSUE.
189582 04-05

TRANSMISSION
THE ROLE OF CYCLIC 3,5 ADENOSINE MONOPHOSPHATE IN NEUROMUSCULAR TRANSMISSION.
170660 01-13

EFFECTS OF CHOLINOMIMETICS ON ADRENERGIC TRANSMISSION.
182088 02-03
THE EFFECTS OF DELTA1-TETRAHYDROCANNABINOL (DELTA1-THC OR DELTA9-THC) AND ETHANOL ON MONOSYNAPTIC AND POLYSYNAPTIC TRANSMISSION IN THE CENTRAL NERVOUS SYSTEM.
182222 03-03
EFFECTS OF AMPHETAMINE ISOMERS ON NEUROMUSCULAR TRANSMISSION IN RAT PHRENIC NERVE DIAPHRAGM PREPARATION.
182232 03-03
ALTERATION OF ETHANOL-INDUCED CNS DEPRESSION: INEFFECTIVENESS OF DRUGS THAT MODIFY CHOLINERGIC TRANSMISSION.
186375 03-03
INFLUENCE ON ACUTE PRETREATMENT WITH DELTA9-TETRAHYDROCANNABINOL OF THE LD50 OF VARIOUS SUBSTANCES THAT ALTER NEUROHUMORAL TRANSMISSION.
188876 04-05
ADENOSINE ACTION ON SYNAPTIC TRANSMISSION IN BRAIN SLICES.
191945 04-03

TRANSMITTER
INTERACTION OF APOMORPHINE, NEUROLEPTICS AND STIMULANTS WITH ALPHA-METHYL-M-TYRAMINE, A FALSE DOPAMINERGIC TRANSMITTER.
181809 02-03
INVOLVEMENT OF ALPHA-RECEPTORS IN CLONIDINE INDUCED INHIBITION OF TRANSMITTER RELEASE FROM CENTRAL MONOAMINE NEURONES.
182345 03-03
5-HYDROXYTRYPTAMINE AND NORADRENALINE IN THE HIPPOCAMPAL REGION: EFFECT OF TRANSECTION OF AFFERENT PATHWAYS ON ENDOGENOUS LEVELS, HIGH AFFINITY UPTAKE AND SOME TRANSMITTER RELATED ENZYMES.
191319 04-03
EFFECTS OF ALTERATIONS IN IMPULSE FLOW ON TRANSMITTER METABOLISM IN CENTRAL DOPAMINERGIC NEURONS.
191519 04-03

TRANSPORT
INCREASED AXOPLASMIC TRANSPORT OF H3-DOPAMINE IN NIGRO-NEOSTRIATAL NEURONS AFTER RESERPINE.
175241 02-03
CHOLINE ACTIVATION OF LITHIUM TRANSPORT.
178812 02-03
TRANSPORT OF SYNAPTOSOMAL TRYPTOPHAN AND CEREBRAL TYROSINE: INCREASE IN THE SPEED OF UPTAKE OF RESERPINE OR THE INHIBITION OF MONOAMINE OXIDASE.
179988 02-13
THE ELIMINATION OF 5-HYDROXYINDOLEACETIC ACID FROM CEREBROSPINAL FLUID: CHARACTERISTICS OF THE ACID TRANSPORT SYSTEM OF THE CHOROID PLEXUS.
182718 03-03
EFFECT OF DRUGS UPON AXOPLASMIC TRANSPORT.
182772 03-17
THE EFFECT OF CHOLINOMIMETIC DRUGS ON POTASSIUM TRANSPORT IN RAT CEREBRAL CORTEX.
191411 04-03

TRANSSYNAPTIC
TRANSSYNAPTIC INDUCTION OF CHOLINE ACETYLTRANSFERASE IN THE PREGANGLIONIC NEURON OF THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM.
182720 03-03
THE TRANSSYNAPTIC RELATIONSHIP BETWEEN DOPAMINE AND SEROTONIN IN THE CAUDATE NUCLEUS OF CATS.
186700 03-04

TRANYLCYPROMINE
THE EFFECT OF LOW ENVIRONMENTAL TEMPERATURE ON THE TRANYLCYPROMINE MEPERIDINE INTERACTION IN MICE.
183897 03-03
THE EFFECT OF IPRONIAZID AND TRANYLCYPROMINE STUDIED WITH A DARK AVOIDANCE CONDITIONED SCHEDULE.
186590 03-04
THE EFFECT OF TRANYLCYPROMINE (PARNATE) ON EYELID CONDITIONING AND PAIRED ASSOCIATE LEARNING IN DEPRESSED PATIENTS.
188107 04-09
THE TRANYLCYPROMINE ISOMERS: A CONTROLLED CLINICAL TRIAL.
192065 04-13

TRAPEZOIDES
THE EFFECTS OF INTRAVENTRICULARLY ADMINISTERED CATECHOLAMINES AND SEROTONIN ON THE RESERPINE INDUCED SPIKE WAVES RECORDED FROM THE MEDICAL NUCLEUS TRAPEZOIDES IN THE RABBIT.
182094 02-03

TRAZODONE
CHEMISTRY OF TRAZODONE.
168801 01-01
PHARMACOLOGY OF TRAZODONE.
168802 01-13
CLINICAL EXPERIENCE WITH A NEW PSYCHOTROPIC DRUG, TRAZODONE: A REVIEW OF LITERATURE.
168803 01-11
SYSTEMATIC CLINICAL STUDIES WITH TRAZODONE: METHODOLOGICAL ASPECTS.
168804 01-16
TRAZODONE IN THE TREATMENT OF ORGANIC BRAIN SYNDROMES, WITH SPECIAL REFERENCE TO PSYCHOGERIATRICS.
168805 01-11
TRAZODONE IN THE TREATMENT OF SCHIZOPHRENIAS.
168806 01-11
TRAZODONE IN THE TREATMENT OF AFFECTIVE DISORDERS.
168807 01-11
TRAZODONE AND PSYCHOSOMATIC MEDICINE.
168808 01-11
TRAZODONE IN THE TREATMENT OF PSYCHONEUROSES: A DOUBLE-BLIND STUDY.
168809 01-11
DIFFERENTIAL EFFECTS OF TRAZODONE IN DEPRESSED, SCHIZOPHRENIC AND GERIATRIC PATIENTS.
191138 04-14

TREAT
DRUGS TO TREAT PAIN.
186395 03-14

TREATED
AVERAGE EVOKED RESPONSES IN NORMAL AND MINIMALLY BRAIN DYSFUNCTIONED CHILDREN TREATED WITH AMPHETAMINE: A PRELIMINARY REPORT.
169861 01-11
WEIGHT GAIN IN LITHIUM TREATED RATS.
174133 01-04
THREE CASES OF SCHIZOPHRENIA TREATED WITH L-DOPA.
175550 02-08
STEREOTYPY WITH SELECTIVE STIMULATION OF CERTAIN ITEMS OF BEHAVIOUR OBSERVED IN AMPHETAMINE TREATED MONKEYS (CERCOPITHECUS).
180061 02-04
LITHIUM DISTRIBUTION BETWEEN CEREBROSPINAL FLUID AND SERUM OF AFFECTIVE PSYCHOTIC PATIENTS TREATED WITH LITHIUM CARBONATE AND ITS CLINICAL RESPONSE.
180301 02-11
INHIBITION OF GROWTH IN ANIMALS TREATED WITH METHADONE.
182164 02-03
BINDING OF MORPHINE BY SERUM PROTEINS OF MORPHINE TREATED RABBITS.
182187 02-03
REGIONAL AND SUBCELLULAR DISTRIBUTION OF CHOLINE ACETYLTRANSFERASE IN THE BRAIN OF NORMAL AND MORPHINE TREATED RATS.
182224 03-03
PHENOMENOLOGICAL - EXISTENTIAL STUDY OF PHOBIC - OBSESSIVE SYNDROMES TREATED WITH CHLORIMIPRAMINE.
182788 03-09
IMPORTANCE OF THE COOPERATION OF FAMILIES IN THE TREATMENT OF THE SICK: CONCERNING CHRONIC DELIRIUM TREATED WITH NEUROLEPTICS AND MELANCHOLY TREATED WITH ANTIDEPRESSANTS.
182899 03-17
CATALEPSY AND STEREOTYPED BEHAVIOUR IN RATS TREATED CHRONICALLY WITH METHADONE: RELATION TO BRAIN HOMOVANILLIC ACID CONTENT.
183606 03-04
LONG-RANGE MOTOR PERFORMANCE CHANGES IN LEVODOPA TREATED PATIENTS WITH PARKINSONS DISEASE.
184195 03-11
TOLERANCE TO THE BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF HALOPERIDOL AND MORPHINE IN RATS CHRONICALLY TREATED WITH MORPHINE OR HALOPERIDOL.
184225 03-03
AN OBSESSIVE NEUROSIS FOLLOWING MORNING-GLORY SEED INGESTION TREATED BY AVERSION RELIEF.
184259 03-15
SEIZURE SUSCEPTIBILITY AND AVOIDANCE CONDITIONING IN ADULT RATS TREATED PRENATALLY WITH CHLORPROMAZINE.
184371 03-04
REGIONAL CHANGES IN MONOAMINE LEVELS AND IN THE RATE OF TYROSINE AND TRYPTOPHAN HYDROXYLATION IN 4 WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
185899 03-03
PARKINSON DISEASE TREATED WITH A SUSPECTED DOPAMINE RECEPTOR AGONIST.
186029 03-11
LORDOSIS BEHAVIOR IN CASTRATED MALE MICE TREATED WITH ESTRADIOL BENZOATE OR TESTOSTERONE PROPIONATE IN COMBINATION WITH AN ESTROGEN ANTAGONIST, MER-25, AN IN INTACT MALE RATS.
186683 03-04
HUNTINGTONS CHOREA: THE RIGID FORM (WESTPHAL VARIANT) TREATED WITH LEVODOPA.
187618 04-11
HUNTINGTONS CHOREA TREATED WITH LITHIUM CARBONATE.
187985 04-11

INFLUENCE OF ADRENERGIC BLOCKERS AND ANTILIPEMIC AGENTS ON PHARMACODYNAMIC ACTIONS OF MORPHINE IN CARBON TETRACHLORIDE TREATED RATS.
188873 04-03

LIPIDOSIS-LIKE ALTERATIONS IN DORSAL ROOT GANGLION CELLS OF RATS TREATED WITH TRICYCLIC ANTIDEPRESSANTS.
189605 04-03

SERUM TRYPTOPHAN BINDING IN CHLORPROMAZINE TREATED CHRONIC SCHIZOPHRENICS.
191320 04-08

CATALEPSY AND STEREOTYPIES IN RATS TREATED WITH METHADONE; RELATION TO STRIATAL DOPAMINE.
191421 04-03

TREATING

TEMPERATURE DEPENDENT TOXICITY OF ADRENERGIC AGONISTS IN MICE AS A BASIS FOR TREATING D-AMPHETAMINE POISONING.
169688 01-05

AN ERGOT ALKALOID PREPARATION (HYDERGINE) VERSUS PAPAVERINE IN TREATING COMMON COMPLAINTS OF THE AGED: DOUBLE-BLIND STUDY.
173190 01-11

USE OF LORAZEPAM IN TREATING PATIENTS WITH NEUROTIC AND SOMATIZED PSYCHOVEGETATIVE SYMPTOMS.
174136 01-09

TREATMENT

DOUBLE-BLIND CLINICAL EVALUATION OF MAZINDOL, DEXTROAMPHETAMINE, AND PLACEBO IN TREATMENT OF EXOGENOUS OBESITY.
167335 01-11

INFLUENCE OF TREATMENT ON SYMPTOMATOLOGY AND CORRELATED ELECTROENCEPHALOGRAPHIC (EEG) CHANGES IN THE AGED.
167336 01-13

POTENTIATION OF HALOPERIDOL BY ALPHA-METHYLDOPA IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
167343 01-08

DEPRESSIVE FORMS OF SCHIZOPHRENIA AND EXPERIMENTAL TREATMENT BY CLOMIPRAMINE.
167676 01-08

LITHIUM CARBONATE TREATMENT IN MANIC PSYCHOSIS.
167918 01-09

MESORIDAZINE AND CHLORPROMAZINE IN THE TREATMENT OF ALCOHOL WITHDRAWAL SYNDROME.
168314 01-11

COMBINATIONS OF ANTIDEPRESSANT DRUGS IN THE TREATMENT OF DEPRESSIVE ILLNESS.
168317 01-09

PSYCHOMETRIC INVESTIGATIONS IN PARKINSONS SYNDROME DURING TREATMENT WITH L-DOPA AND RELEVANCE OF SOME PSYCHOLOGICAL PHENOMENA.
168578 01-13

TRAZODONE IN THE TREATMENT OF ORGANIC BRAIN SYNDROMES, WITH SPECIAL REFERENCE TO PSYCHOGERIATRICS.
168805 01-11

TRAZODONE IN THE TREATMENT OF SCHIZOPHRENIAS.
168806 01-11

TRAZODONE IN THE TREATMENT OF AFFECTIVE DISORDERS.
168807 01-11

TRAZODONE IN THE TREATMENT OF PSYCHONEUROSES: A DOUBLE-BLIND STUDY.
168809 01-11

A STUDY OF THE CLINICAL EFFECTS OF PHENELZINE AND PLACEBO IN THE TREATMENT OF PHOBIC ANXIETY.
168832 01-10

THE POSSIBLE ROLE OF METABOLITES IN THERAPEUTIC RESPONSE TO CHLORPROMAZINE TREATMENT.
168836 01-08

EFFECT OF CHRONIC LITHIUM TREATMENT ON MONOAMINE METABOLISM IN RAT BRAIN.
168839 01-03

CLINICAL AND ELECTROMYOGRAPHIC RESEARCH CONCERNING TREATMENT OF PERIPHERAL NEUROPATHIES WITH NIVALASI.
168975 01-13

LONG-TERM TREATMENT OF DEPRESSION WITH DRUGS AND PSYCHOTHERAPY.
169087 01-09

IMIPRAMINE, DIAZEPAM AND GROUP PSYCHOTHERAPY IN LONG-TERM TREATMENT OF DEPRESSIVE NEUROTICS.
169089 01-10

CHANGES IN SOMATOSENSORY EVOKED POTENTIALS PRODUCED BY DRUGS USED IN THE TREATMENT OF AFFECTIVE DISORDERS.
169092 01-09

AMPHETAMINES: VALUABLE ADJUNCT IN TREATMENT OF PARKINSONISM.
169220 01-11

VESTA VARIANT OF TOURETTES DISEASE: TREATMENT WITH HALOPERIDOL.
169286 01-10

IMIPRAMINE IN THE TREATMENT OF MINIMAL BRAIN DYSFUNCTION IN CHILDREN.
169295 01-11

AMANTADINE HYDROCHLORIDE IN TREATMENT OF PARKINSONISM.
169461 01-11

COMBINATION OF L-DOPA, DESIPRAMINE, AND A DECARBOXYLASE INHIBITOR IN THE TREATMENT OF DEPRESSION.
169468 01-09

THE EFFECTS OF CHRONIC TREATMENT WITH DELTA9-TETRAHYDROCANNABINOL ON CATECHOLAMINE SYNTHESIS IN THE RAT.
169471 01-03

LITHIUM INDUCED DIABETES-INSIPIDUS: MANIC SYMPTOMS, BRAIN AND ELECTROLYTE CORRELATES, AND CHLOROTHIAZIDE TREATMENT.
169486 01-15

THE TREATMENT OF DEPRESSION WITH A SINGLE DAILY DOSE OF IMIPRAMINE PAMOATE.
169491 01-09

THRESHOLDS FOR ELECTROCONVULSIONS AND CHEMOCONVULSIONS IN MICE AFTER TERMINATION OF TREATMENT WITH PHENOBARBITAL.
170073 01-03

MEGAVITAMIN TREATMENT, CULTURE AND TRANQUILIZERS, DRUGS FOR THE AGED: PROJECTS OF A CANADIAN GRANT.
170293 01-11

EXPERIENCES WITH LAROXYL (R) IN THE TREATMENT OF DEPRESSIONS IN PRIVATE PSYCHIATRIC PRACTICE IN DJAKARTA.
170413 01-11

DRUG TREATMENT OF DEPRESSED PATIENTS REFERRED FOR HOSPITALIZATION.
170621 01-09

SINGLE VERSUS DIVIDED DAILY DOSE OF TRIMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
170622 01-09

A TRIAL ON BROMAZEPAM (LEXOTAN) AND PLACEBO IN THE TREATMENT OF PSYCHOPHYSIOLOGICAL DISORDERS.
171150 01-11

ORTHOGONAL FACTORS VS. INTERDEPENDENT VARIABLES AS PREDICTORS OF DRUG TREATMENT RESPONSE IN ANXIOUS OUTPATIENTS.
171299 01-14

ON THE TREATMENT OF RAPID EYE MOVEMENT NARCOLEPSY.
171496 01-11

DIPHENYLHYDANTOIN EFFECTIVENESS IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS: A DOUBLE-BLIND CONTROLLED STUDY WITH A PLACEBO.
171507 01-08

TOLERANCE TO HEXOBARBITAL AND SUPERSENSITIVITY TO PILOCARPINE INDUCED BY CHRONIC BARBITAL TREATMENT IN THE RAT.
171601 01-03

LEVELS OF HVA IN MOUSE BRAIN FOLLOWING TREATMENT WITH METABOLITES OF CHLORPROMAZINE.
171626 01-03

HABITUATION OF BLINK REFLEXES IN PARKINSONIAN PATIENTS UNDER LEVODOPA AND AMANTADINE TREATMENT.
171794 01-13

TREATMENT OF DEPRESSION BY DRUGS AND PSYCHOTHERAPY.
171924 01-10

ASSESSMENT OF ANATENSOL (FLUPHENAZINE ENANTHATE) INJECTABLE IN THE TREATMENT OF SCHIZOPHRENIA.
172444 01-08

THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA.
172963 01-08

PRELIMINARY STUDY OF THE TREATMENT OF CHRONIC PSYCHOSES WITH FLUPENTHIXOL DECANOATE.
172978 01-09

CLINICAL EXPERIENCE WITH MELITHRACENE IN THE TREATMENT OF DEPRESSIVE STATES.
172979 01-09

ONGOING INVESTIGATIONS OF CEREBRAL GLUTAMINE EXCRETION SCHIZOPHRENICS DURING TREATMENT WITH NEUROLEPTIC.
174101 01-08

L-TRYPTOPHAN IN THE TREATMENT OF LEVODOPA INDUCED PSYCHIATRIC DISORDERS.
174297 01-15

HIGH DOSES OF CHLORPROMAZINE AND TRIFLUOPERAZINE IN THE TREATMENT OF PATIENTS SUFFERING FROM SCHIZOPHRENIA.
174589 01-08

ELECTROCLINICAL ASPECT OF INSIDON TREATMENT IN PATIENTS WITH NEUROTIC SYMPTOMS.
174777 01-10

MEASURING THE PHARMACOLOGICAL ACTION OF IMIPRAMINE IN THE TREATMENT OF DEPRESSIONS.
174995 02-09

PSYCHOTIC COMPLICATIONS AFTER TETRAETHYLTHIURAMDISULFIDE USED IN THE TREATMENT OF ALCOHOLISM.
175047 02-11

TRIOXAZINE IN THE TREATMENT OF NEUROSIS.
175967 02-10

PIMOZIDE IN THE TREATMENT OF BEHAVIORAL DISORDERS OF HOSPITALIZED ADOLESCENTS.
176109 02-14

LORAZEPAM IN THE TREATMENT OF ANXIETY.
176286 02-10

CLINICAL TRIAL OF PERAZINE (TAXILAN) IN TREATMENT OF SCHIZOPHRENIA.
176446 02-08

EXPERIMENT WITH DOXEPIN (SINEQUAN) IN TREATMENT OF DEPRESSIVE STATES.
176454 02-11

CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, ZISEPRON, IN TREATMENT OF PSYCHIATRIC DISEASES IN COMPARISON WITH THIORIDAZINE.
176467 02-08

EXPERIENCE IN THE APPLICATION OF A NEW DRUG, DP-181 (OXYPERTINE), IN TREATMENT OF SCHIZOPHRENIA.
176468 02-08

EXPERIENCE IN THE USE OF SINEQUAN (DOXEPIN HYDROCHLORIDE) IN TREATMENT OF NEUROSIS, DEPRESSION AND DEPRESSIVE STATES.
176471 02-11

HIGH AND LOW DOSE THIOTHIXENE TREATMENT IN CHRONIC SCHIZOPHRENIA.
176673 02-08

ACQUISITION AND PERFORMANCE OF AN ATTENTION TASK BY RATS SUBJECTED TO CHRONIC NICOTINE TREATMENT.
176864 02-04

THE PROBLEMS OF THE PSYCHOPHARMACOLOGICAL TREATMENT OF PSYCHOSOMATIC DISEASES -- THE ANESTHESIOLOGIC APPROACH.
177063 02-17

SOME PROBLEMS IN THE PSYCHOPHARMACOLOGICAL TREATMENT OF PSYCHOSOMATIC DISEASE.
177066 02-17

GEROVITAL-H3 IN THE TREATMENT OF THE DEPRESSED AGING PATIENT.
177373 02-11

CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, DOXEPIN HYDROCHLORIDE, IN THE TREATMENT OF DEPRESSIVE STATES.
177569 02-11

EXACERBATION OF PSYCHOPATHOLOGY DURING TREATMENT: ETIOLOGY.
177676 02-17

DEXTROAMPHETAMINE AND METHYLPHENIDATE IN THE TREATMENT OF HYPERACTIVE/AGGRESSIVE CHILDREN.
177771 02-14

RESPONSE TO STIMULANT DRUG TREATMENT IN HYPERACTIVE CHILDREN: PREDICTION FROM EEG AND NEUROLOGICAL FINDINGS.
177778 02-11

L-DOPA AND THE TREATMENT OF EXTRAPYRAMIDAL DISEASE. (UNPUBLISHED PAPER).
177975 02-11

TACITIN TREATMENT FOR THE PATIENT WITH ANXIETY.
178038 02-10

DIFFERENTIAL EFFECTS OF D- AND L-AMPHETAMINE ON THE SLEEP OF DEPRESSED PSYCHIATRIC PATIENTS ON AND OFF LITHIUM CARBONATE TREATMENT. (UNPUBLISHED PAPER).
178432 02-09

PSYCHIATRIC TREATMENT: WHAT COMES AFTER PHARMACOLOGICAL THERAPY
178655 02-17

CHANGES IN BRAIN ACETYLCHOLINESTERASE ACTIVITY OF YOUNG RATS AFTER CHRONIC TREATMENT WITH TREMORINE.
178814 02-03

A COMPARATIVE STUDY OF DIAZEPAM AND METHOCARBAMOL IN THE TREATMENT OF LOMBOSCIATALGIAS.
178950 02-11

PARKINSONISM DEMENTIA OF GUAM: TREATMENT WITH LEVODOPA AND L-ALPHA-METHYLDOPAHYDRAZINE.
179996 02-13

LITHIUM IN THE TREATMENT OF SCHIZOPHRENIA.
180046 02-08

EKG ALTERNATIONS IN INFUSION TREATMENT WITH TRICYCLIC ANTIDEPRESSIVE DRUGS.
180063 02-15

WHAT IS TECHNIQUE IN PSYCHIATRIC TREATMENT
180102 02-17

PRELIMINARY EXPERIENCES WITH THE TREATMENT OF SOME MENTAL CASES UTILIZING AN ENZYME COMBINATION.
180298 02-17

HALOPERIDOL (JANSSEN) IN THE TREATMENT OF UNSELECTED INSTITUTIONALIZED PSYCHIATRIC PATIENTS.
180299 02-11

THOUGHTS ON TREATMENT BY PRIVATE PHYSICIANS OF ABNORMAL SEX DRIVES.
180674 02-11

EXPERIENCE GAINED IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PSYCHOSES WITH A THIORIDAZINE DERIVATIVE.
180675 02-08

EXPERIENCE IN THE TREATMENT OF CEREBRAL INSUFFICIENCY AND PERIPHERAL BLOOD CIRCULATION DISORDERS USING THE EP-50-100 EXPERIMENTAL DRUG.
180676 02-11

TREATMENT OF COMPULSIVE EATING DISTURBANCES WITH ANTICONVULSANT MEDICATION.
181270 02-14

ONTOGENESIS OF CIRCADIAN PITUITARY ADRENAL PERIODICITY IN RATS AFFECTED BY NEONATAL TREATMENT WITH ACTH.
181576 02-03

TREATMENT OF HALLUCINATORY DISORDERS IN SCHIZOPHRENIA BY ATROPINE COMAS.
181778 02-08

COMPARISON OF THE CHRONIC AND ACUTE EFFECTS OF D-LYSERGIC ACID DIETHYLAMIDE (LSD) TREATMENT ON RAT BRAIN SEROTONIN AND NOREPINEPHRINE.
181945 02-03

AFRODEX VS. PLACEBO IN THE TREATMENT OF MALE IMPOTENCE: STATISTICAL ANALYSIS OF TWO DOUBLE-BLIND CROSSOVER STUDIES.
181959 02-14

STUDIES ON THE EFFECT OF ACUTE AND CHRONIC MORPHINE TREATMENT ON CATECHOLAMINE LEVELS AND TURNOVER IN DISCRETE BRAIN AREAS OF RATS.
182228 03-03

SIMILARITY OF CHRONIC CHLORDIAZEPOXIDE TREATMENT AND REMOVAL OF CONFLICT SITUATION.
182258 03-04

INDICATIONS FOR ANTIDEPRESSANT TREATMENT WITH SPECIAL REFERENCE TO DEPRESSED PRESCHOOL CHILDREN.
182428 03-10

TREATMENT WITH PSYCHOPHARMACOLOGIC AGENTS IN CHILDHOOD DEPRESSIONS.
182431 03-11

LITHIUM TREATMENT OF PSYCHOTIC CHILDREN. A CONTROLLED CLINICAL TRIAL.
182434 03-09

DIAZEPAM TREATMENT FOR ACUTE CONVULSIONS IN CHILDREN: A REPORT OF 41 PATIENTS, THREE WITH PLASMA LEVELS.
182595 03-11

TREATMENT PROCESS OF DEPRESSION AND CHANGES IN MICROVIBRATION.
182620 03-09

INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY LITHIUM TREATMENT.
182727 03-03

TREATMENT OF CEREBROVASCULAR DISTURBANCES WITH 2-BUTYLAMINO-1-P-HYDROXYPHENYL ETHANOL SULFATE (BAMETHAN).
182790 03-11

CLINICAL DATA AND SOCIOPSYCHIATRIC IMPLICATIONS OF OUTPATIENT TREATMENT WITH LONG-TERM PHENOTHIAZINES.
182791 03-09

IMPORTANCE OF THE COOPERATION OF FAMILIES IN THE TREATMENT OF THE SICK: CONCERNING CHRONIC DELIRIUM TREATED WITH NEUROLEPTICS AND MELANCHOLY TREATED WITH ANTIDEPRESSANTS.
182899 03-17

STUDY OF THE USE OF DISULFIRAM IMPLANT IN THE TREATMENT OF ALCOHOLISM.
183030 03-11

PRESENT TREATMENT OF MANIC STATES.
183189 03-09

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: I. PIMOZIDE IN THE TREATMENT OF PERSONALITY DISORDERS.
183191 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: II. PIMOZIDE IN THE TREATMENT OF BEHAVIOURAL DISORDERS IN CHILDHOOD AND ADOLESCENCE.
183192 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: III. PIMOZIDE IN THE TREATMENT OF STRESS INDUCED PSYCHIC AND FUNCTIONAL DISORDERS.
183193 03-11

A SERIES OF MULTICENTRIC PILOT TRIALS WITH PIMOZIDE IN PSYCHIATRIC PRACTICE: IV. PIMOZIDE IN THE TREATMENT OF PATIENTS WITH PARANOID SYMPTOMATOLOGY.
183194 03-09

CLINICAL OBSERVATIONS ON THE USE OF PIMOZIDE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS.
183196 03-08

HYPERTENSION AND DEPRESSION AND THEIR TREATMENT.
183234 03-09

SO-CALLED MASKED DEPRESSION AND ITS TREATMENT.
183369 03-10

LITHIUM IN THE TREATMENT OF PERIODIC CATATONIA: A CASE REPORT.
183648 03-09

ON THE DYNAMICS AND TREATMENT OF THE TENDENCY OF SCHIZOPHRENIC PSYCHOSIS TO BECOME CHRONIC.
183957 03-08

OUTPATIENT TREATMENT OF HYPERACTIVE SCHOOL CHILDREN WITH IMIPRAMINE.
184174 03-11

DEANOL IN THE TREATMENT OF LEVODOPA INDUCED DYSKINESIAS.
184196 03-11

DECREASED EFFECT OF PHENOBARBITAL TREATMENT ON MICROSOMAL DRUG METABOLIZING ENZYME ACTIVITY DURING GESTATION.
184228 03-03

EFFECTS OF VARIOUS MORPHINE TREATMENT SCHEDULES ON ACETYLCHOLINE TURNOVER RATE IN RAT BRAIN PARTS.
184553 03-03

TREATMENT OF THE CEREBRAL MANIFESTATIONS OF ARTERIOSCLEROSIS WITH CYCLANDELATE.
185008 03-11

A STUDY OF REFRACTORY CASES OF DEPRESSIVE ILLNESSES AND THEIR RESPONSE TO COMBINED ANTIDEPRESSANT TREATMENT.
185078 03-10

TREATMENT OF MENTAL DISORDERS.
185182 03-17

THE DISCHARGED PATIENTS DRUG TREATMENT.
185195 03-17

REDUCED BEHAVIORAL EFFECTS OF PILOCARPINE DURING CHRONIC TREATMENT WITH DFP.
185265 03-04

TREATMENT EFFECTS ON THE SOCIAL ADJUSTMENT OF DEPRESSED PATIENTS.
185322 03-10

LITHIUM TREATMENT OF DEPRESSION.
185873 03-09

COMPARATIVE SURVEY OF PSYCHIATRISTS TREATMENT PREFERENCES: CALIFORNIA AND NEW-YORK.
185877 03-08

THE EFFECTS OF CHRONIC TREATMENT WITH D-AMPHETAMINE ON FOOD INTAKE, BODYWEIGHT, LOCOMOTOR ACTIVITY AND SUBCELLULAR DISTRIBUTION OF THE DRUG IN RAT BRAIN.
185931 03-03

MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN THE LIGHT OF PROGNOSIS ORIENTED DIAGNOSIS.
186081 03-08

FACTORS ASSOCIATED WITH LITHIUM RESPONSE IN THE PROPHYLACTIC TREATMENT OF BIPOLAR MANIC-DEPRESSIVE ILLNESS.
186188 03-09

PROPHYLACTIC TREATMENT OF RECURRENT DEPRESSION: OBSERVATIONS FROM A MULTIHOSPITAL COLLABORATIVE STUDY.
186190 03-09

THYROTOXICOSIS DEVELOPING DURING LITHIUM TREATMENT: CASE REPORT.
186473 03-15

ABSENCE OF DEGENERATION OF ADRENERGIC NEURONS AFTER PROLONGED TREATMENT WITH DEBRISOQUIN.
186677 03-03

SUPPRESSION OF LORDOSIS IN GUINEA-PIGS BY ETHAMOXY-TRIPHETOL (MER-25) GIVEN AT LONG INTERVALS (36-46 HR) AFTER ESTRADIOL BENZOATE TREATMENT.
186686 03-04

TREATMENT OF ANXIETY NEUROSIS BY ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKING AGENTS.
186780 03-10

LITHIUM: ITS ROLE IN PSYCHIATRIC RESEARCH AND TREATMENT.
186920 03-09

BEHAVIORAL AND VISUAL EVOKED POTENTIAL INVESTIGATIONS DURING TRIHEXYPHENIDYL AND THIOTHIXENE TREATMENT IN PSYCHOTIC BOYS.
187115 03-09

TRYPTOPHAN AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIONS.
187536 04-09

THE EFFECTS OF CHRONIC RESERPINE AND NIALAMIDE TREATMENT ON THE FREE AMINO ACID LEVELS OF RAT BRAIN.
187645 04-03

EFFECTS OF INTRACISTERNAL 6-HYDROXYDOPAMINE TREATMENT ON ACQUISITION AND PERFORMANCE OF RATS IN A DOUBLE T-MAZE.
187696 04-04

PARKINSONIAN SYNDROMES: TREATMENT BY ASSOCIATION OF L-DOPA PLUS DECARBOXYLASE INHIBITOR.
188093 04-11

PLASMA DOPA AND FUNCTIONAL OSCILLATIONS AFTER CHRONIC TREATMENT OF PARKINSONS DISEASE.
188421 04-13

TREATMENT OF ACTION MYOCLONUS WITH L-5-HYDROXYTRYPTOPHAN.
188429 04-11

RO-4-4602 AND LEVODOPA IN THE TREATMENT OF PARKINSONISM.
188561 04-11

LONG-TERM TREATMENT OF ENDOGENOUS DEPRESSION WITH NORTRIPTYLINE WITH CONTROL OF PLASMA LEVELS.
188832 04-09

RECENT ADVANCES IN THE TREATMENT OF DEPRESSION.
189650 04-09

TREATMENT OF PHOBIAS BY SYSTEMATIC DESENSITIZATION: COMPARISON OF STANDARD VS METHOHEXITAL AIDED DESENSITIZATION.
189916 04-10

DRUG MAINTENANCE IN THE OUTPATIENT TREATMENT OF CHRONIC ALCOHOLISM.
189926 04-11

THE TREATMENT OF MIXED ANXIETY AND DEPRESSION WITH LOXAPINE: A CONTROLLED COMPARATIVE STUDY.
190195 04-09

A DOUBLE-BLIND CONTROLLED STUDY OF LOXAPINE SUCCINATE IN THE TREATMENT OF ANXIETY NEUROSES.
190196 04-09

A FEW REMARKS ON THE USE OF PSYCHOACTIVE AGENTS IN THE TREATMENT OF EMOTIONAL DISORDERS.
190241 04-09

LITHIUM IN TREATMENT AND PREVENTION OF AFFECTIVE DISORDER: A VA-NIMH COLLABORATIVE STUDY.
190381 04-09

THIRTY-FIVE YEARS CONTINUOUS TREATMENT FOR RECURRENT DEPRESSION: FROM ECT TO DRUGS.
191119 04-09

EFFECT OF CHRONIC TREATMENT WITH CENTRAL STIMULANTS ON BRAIN MONOAMINES AND SOME BEHAVIOURAL AND PHYSIOLOGICAL FUNCTIONS IN RATS, GUINEA-PIGS, AND RABBITS.
191503 04-03

EXPERIMENT WITH PENFLURIDOL (TLP-607) ON THE TREATMENT OF CHRONIC SCHIZOPHRENIA.
191593 04-08

LONG-TERM TREATMENT WITH LEVODOPA.
191614 04-11

TREATMENT OF EXOGENOUS PSYCHOSIS BY THE USE OF FK-880 (SULPIRIDE).
191663 04-09

EXPERIMENT WITH LOPRAMINE (DB-2182) ON THE TREATMENT OF DEPRESSION.
191665 04-09

EXPERIMENT WITH LITHIUM CARBONATE ON THE TREATMENT OF MANIC STATE.
191670 04-09

USE OF HALOPERIDOL (BROTOPON) IN THE TREATMENT OF SCHIZOPHRENIA.
191686 04-08

CLINICAL USE OF LUVATREN (METHYLPERIDOL) FOR THE TREATMENT OF SCHIZOPHRENIA.
191720 04-08

EMERGENCY TREATMENT OF AN ACUTE STATE OF MENTAL ABERRATION.
191723 04-09

WELLBATRIN IN THE TREATMENT OF DEPRESSION.
191978 04-10

EFFECT OF CHRONIC TREATMENT WITH DESIPRAMINE (DMI) AND IPRINDOLE (IP) ON THE NOREPINEPHRINE (NE) SENSITIVE ADENYLATE CYCLASE SYSTEM IN SLICES OF THE RAT LIMBIC FOREBRAIN.
192003 04-03

LITHIUM TREATMENT DURING ETHANOL INGESTION AND WITHDRAWAL.
192005 04-11

A CHEMOTHERAPEUTIC ALTERNATIVE TO THE ANTIANXIETY AGENTS FOR THE EXTENDED TREATMENT OF PSYCHONEUROSIS.
192083 04-10

HALOPERIDOL VERSUS THIORIDAZINE FOR THE TREATMENT OF PSYCHOGERIATRIC PATIENTS: A DOUBLE-BLIND CLINICAL STUDY.
192231 04-09

THE USE OF PROPRANOLOL WITH VARIOUS DRUG COMBINATIONS IN THE TREATMENT OF ESSENTIAL HYPERTENSION.
192511 04-13

BETA-BLOCKING AGENTS IN THE TREATMENT OF CATECHOLAMINE INDUCED SYMPTOMS IN MUSICIANS.
192527 04-11

THYROTROPHIN RELEASING HORMONE IN THE TREATMENT OF DEPRESSION.
192577 04-09

TREATMENTS

IMIPRAMINE AND METHYLPHENIDATE TREATMENTS OF HYPERACTIVE BOYS: A DOUBLE-BLIND COMPARISON.
185324 03-14

COMPARISON OF TYROSINE HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION WITH THE EFFECTS OF VARIOUS 6-HYDROXYDOPAMINE TREATMENTS ON D-AMPHETAMINE INDUCED MOTOR ACTIVITY.
186699 03-03

EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND AMPHETAMINE ON SELF-STIMULATION OF BRAIN FOLLOWING VARIOUS 6-HYDROXYDOPAMINE TREATMENTS.
189515 04-04

TREMOR

TREMOR INDUCTION BY INTRACAUDATE INJECTIONS OF BRETYLIUM, TETRABENAZINE, OR MESCALINE: FUNCTIONAL DEFICITS IN CAUDATE DOPAMINE.
167329 01-03

TREMORGENIC
ANALYSIS OF TREMORGENIC EFFECTS OF INTRACAUDATE D-AMPHETAMINE.
182129 02-03

TREMORINE
CHANGES IN BRAIN ACETYLCHOLINESTERASE ACTIVITY OF YOUNG RATS AFTER CHRONIC TREATMENT WITH TREMORINE.
178814 02-03

TRH
A PRELIMINARY STUDY ON THE ACTION OF THYROTROPINE RELEASING HORMONE OR TRH IN DEPRESSIVE STATES.
184962 03-09

TRIAZOLAM
EFFICACY AND RESIDUAL EFFECT EVALUATION OF A NEW HYPNOTIC, TRIAZOLAM.
176108 02-13
TRIAZOLAM: A SLEEP LABORATORY STUDY OF A NEW BENZODIAZEPINE HYPNOTIC.
177747 02-07
COMPARATIVE METABOLISM OF TRIAZOLAM, A NEW SEDATIVE HYPNOTIC, IN RAT, DOG AND MAN.
191900 04-02

TRICHLOROETHANE
EFFECT OF PHENOBARBITAL AND 3-METHYLCHOLANTHRENE PRETREATMENT ON THE HEPATOTOXICITY OF 1,1,1 TRICHLOROETHANE AND 1,1,2 TRICHLOROETHANE.
167361 01-05

TRICHLOROETHANOL
CONVERSION OF CHLORAL HYDRATE TO TRICHLOROETHANOL IN BRAIN AND LIVER.
182157 02-03

TRICHOCEREUS-PACHANOI
CACTUS ALKALOIDS. XIX. CRYSTALLIZATION OF MESCALINE HCL AND 3-METHOXYTYRAMINE HCL FROM TRICHOCEREUS-PACHANOI.
192878 04-01

TRICYCLIC
GAS CHROMATOGRAPHIC - MASS SPECTROMETRIC STUDIES ON TRICYCLIC PSYCHOTROPIC DRUGS.
169073 01-01
EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON ATTACK ELICITED BY HYPOTHALAMIC STIMULATION: RELATION TO BRAIN BIOGENIC AMINES.
170162 01-04
BEHAVIORAL EFFECT OF TRICYCLIC THYMOLEPTICS AND CHLORPHENIRAMINE IN MICE AFTER PRETREATMENT WITH 5 HYDROXYTRYPTOPHAN (5-HTP).
171609 01-04
COMPARISON OF TRICYCLIC ANTIDEPRESSANTS AS TO THEIR CARDIOTOXIC ACTION IN CONSCIOUS RABBITS.
171629 01-03
CORTICAL SYNAPTOSOMAL UPTAKE AND SUBSYNAPTOSOMAL DISTRIBUTION OF 3H-NOREPINEPHRINE AND 3H-AMPHETAMINE: MODIFICATION BY TRICYCLIC AND PSYCHOACTIVE AGENTS IN VITRO. (PH.D. DISSERTATION).
172020 01-03
AMPHETAMINE TRICYCLIC INTERACTIONS: ROLE OF THE HYDROXYLATION OF AMPHETAMINE IN ITS CENTRAL AND PERIPHERAL MODE OF ACTION. (PH.D. DISSERTATION).
174963 01-03
QUALITATIVE AND QUANTITATIVE STUDIES ON THE DISPOSITION OF AMITRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANT DRUGS IN MAN AS IT RELATES TO THE MANAGEMENT OF THE OVERDOSED PATIENT.
177395 02-15
A NEW MODIFICATION FOR STUDYING 5-HT UPTAKE BY BLOOD PLATELETS: A RE-EVALUATION OF TRICYCLIC ANTIDEPRESSANTS AS UPTAKE INHIBITORS.
180055 02-06
EKG ALTERNATIONS IN INFUSION TREATMENT WITH TRICYCLIC ANTIDEPRESSIVE DRUGS.
180063 02-15
BEHAVIORAL PHARMACOLOGICAL STUDIES ON TRICYCLIC ANTIDEPRESSANTS IN RATS.
182116 02-04
MYOCARDIOPATHIC COMPLICATIONS INDUCED BY IMIPRAMINE AND TRICYCLIC THYMOLEPTICS.
182898 03-15
COMPARISON OF TRICYCLIC ANTIDEPRESSANTS IN RABBITS: ANTINOCICEPTION AND POTENTIATION OF THE NORADRENALINE PRESSOR RESPONSES.
186579 03-03
LIPIDOSIS-LIKE ALTERATIONS IN DORSAL ROOT GANGLION CELLS OF RATS TREATED WITH TRICYCLIC ANTIDEPRESSANTS.
189605 04-03
EFFECT OF PHENOTHIAZINE NEUROLEPTIC DRUGS AND TRICYCLIC ANTIDEPRESSANTS ON PHOSPHODIESTERASE ACTIVITY IN RAT CEREBRAL CORTEX.
190311 04-03
THE USE OF A TRICYCLIC ANTIDEPRESSANT IN EPILEPSY.
190379 04-09
INFLUENCE OF NEUROLEPTICS AND BENZODIAZEPINES ON METABOLISM OF TRICYCLIC ANTIDEPRESSANTS IN MAN.
191026 04-09
NORADRENERGIC NEURONS: EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON SINGLE UNIT ACTIVITY.
191931 04-03
PLASMA LEVELS AND TRICYCLIC ANTIDEPRESSANTS.
192872 04-10

TRIFLUOPERAZINE
CLINICAL TRIAL OF TRIFLUOPERAZINE (STELAZINE R) ON INDONESIAN PSYCHIATRIC PATIENTS.
171161 01-09
MODIFICATION OF STIMULATION BOUND BEHAVIOR BY TRIFLUOPERAZINE AND AMPHETAMINE IN RATS. (PH.D. DISSERTATION).
173158 01-04
HIGH DOSES OF CHLORPROMAZINE AND TRIFLUOPERAZINE IN THE TREATMENT OF PATIENTS SUFFERING FROM SCHIZOPHRENIA.
174589 01-08
MANAGEMENT OF HOSTILE, SUSPICIOUS PATIENTS. TRIFLUOPERAZINE VERSUS HALOPERIDOL.
176675 02-14
ASSAY PROCEDURES FOR THIORIDAZINE, TRIFLUOPERAZINE, AND THEIR SULFOXIDES AND DETERMINATION OF URINARY EXCRETION OF THESE COMPOUNDS IN MENTAL PATIENTS.
183602 03-01
TRIFLUOPERAZINE: A COMPARISON BETWEEN REGULAR AND HIGH DOSES.
184977 03-08
DOUBLE-BLIND COMPARISON OF THIOTHIXENE, TRIFLUOPERAZINE, AND PLACEBO IN CHRONIC ALCOHOLISM.
188584 04-11
ACTION OF HALOPERIDOL AND TRIFLUOPERAZINE ON THE MOTOR RESPONSES ELICITED BY ELECTRICAL STIMULATION OF THE BRAIN IN RABBITS.
191787 04-02

TRIFLUPERIDOL
TRIFLUPERIDOL -- A CONTROLLED CLINICAL TRIAL ON A GROUP OF SCHIZOPHRENIC PATIENTS.
174587 01-08
TRIFLUPERIDOL IN SCHIZOPHRENIA.
174588 01-08
TRIFLUPERIDOL -- THERAPEUTIC RESPONSE AND EXTRAPYRAMIDAL SYMPTOMS.
180248 02-15

TRIGGERED
PGO WAVES IN THE LATERAL GENICULATE NUCLEUS TRIGGERED BY BARBITURATE.
187835 04-03

TRIHEXYPHENIDYL
EFFECT OF SEVERAL DOPAMINERGIC DRUGS AND TRIHEXYPHENIDYL ON CHOLINERGIC PARAMETERS IN THE RAT STRIATUM.
185995 03-03
BEHAVIORAL AND VISUAL EVOKED POTENTIAL INVESTIGATIONS DURING TRIHEXYPHENIDYL AND THIOTHIXENE TREATMENT IN PSYCHOTIC BOYS.
187115 03-09

TRIMEPRIMINE
THE ACTION OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTOR CENTERS OF EMOTIONS IN THE HYPOTHALAMUS.
191785 04-02
INFLUENCE OF LEVOMEPROMAZINE AND TRIMEPRIMINE ON EFFECTS OF ELECTRICAL STIMULATION AND MICROINJECTION OF ACETYLCHOLINE, SEROTONIN AND NORADRENALINE INTO THE MESENCEPHALON.
191786 04-02

TRIMETHOXY-BETA-PHENYLETHYLAMINE
OXIDATIVE METABOLISM OF MESCALINE IN THE CENTRAL NERVOUS SYSTEM -- IV: IN VIVO METABOLISM OF MESCALINE AND 2,3,4 TRIMETHOXY-BETA-PHENYLETHYLAMINE.
181944 02-03

TRIMETHOXYAZLACTONES
CENTRAL NERVOUS DEPRESSANT XV: SYNTHESIS AND PHARMACOLOGICAL SCREENING OF SOME TRIMETHOXYAZLACTONES.
182828 03-02

TRIMETHOXYPHENYLALANINE
PEYOTE AND RELATED ALKALOIDS XVI: SYNTHESIS OF 3,4,5 TRIMETHOXYPHENYLALANINE, AN AMINO ANALOG OF MESCALINE.
170839 01-06

TRIMETHOXYPHENYLETHYLAMINE
PHYSIOLOGICAL DISPOSITION OF BETA-PHENYLETHYLAMINE, 2,4,5 TRIMETHOXYPHENYLETHYLAMINE, 2,3,4,5,6 PENTAMETHOXYPHENYLETHYLAMINE AND BETA-HYDROXYMESCALINE IN RAT BRAIN, LIVER AND PLASMA.
186706 03-03

TRIMIPRAMINE
SINGLE VERSUS DIVIDED DAILY DOSE OF TRIMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
170622 01-09
A TRIAL OF TRIMIPRAMINE.
175410 02-09

TRIOXAZINE
TRIOXAZINE IN THE TREATMENT OF NEUROSIS.
175967 02-10
A DOUBLE-BLIND TRIAL OF TRIOXAZINE WITH PLACEBO IN ANXIETY STATES.
180249 02-10

TRYPTAMINE
THE EFFECT IN THE CAT OF TRYPTAMINE (T) AND LSD ON CUTANEOUS C-FIBER (CFR) AND POLYSYNAPTIC (PSR) SPINAL REFLEXES. (UNPUBLISHED PAPER).
174480 01-12
EEG AND CARDIOVASCULAR EFFECTS OF TRYPTAMINE (T) AND LSD IN THE ENCEPHALE ISOLE CAT. (UNPUBLISHED PAPER)
174496 01-12
STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF 5-HT UPTAKE INTO RAT HYPOTHALAMIC HOMOGENATES BY SEROTONIN AND TRYPTAMINE ANALOGUES.
175233 02-03
THE INHIBITION OF (3H) BIOGENIC AMINE ACCUMULATION INTO RAT BRAIN TISSUE SLICES BY VARIOUS TRYPTAMINE DERIVATIVES.
182723 03-03
PREPARATION AND PHARMACOLOGICAL SCREENING OF INDANETHYLAMINES RELATED TO TRYPTAMINE.
185979 03-01
THE POSSIBLE ROLE OF TRYPTAMINE IN BRAIN FUNCTION AND ITS RELATIONSHIP TO THE ACTIONS OF LSD-LIKE HALLUCINOGENS.
186024 03-12
TRYPTAMINE ANTAGONISTS AND PUNISHED BEHAVIOR.
186692 03-04

TRYPTAMINES
EFFECT OF SUBSTITUTED TRYPTAMINES ON THE EFFLUX OF NORADRENALINE FROM ADRENERGIC NERVES IN RABBIT ATRIA.
168747 01-03

TRYPTOPHAN
COMPARABLE THERAPEUTIC EFFICACY OF TRYPTOPHAN AND IMIPRAMINE: AVERAGE THERAPEUTIC RATINGS VERSUS TRUE EQUIVALENCE. AN IMPORTANT DIFFERENCE.
167344 01-09
EFFECT OF CHLORIMIPRAMINE ON THE RATE OF TRYPTOPHAN HYDROXYLATION IN THE INTACT AND TRANSECTED SPINAL CORD.
168751 01-03
INCREASE IN THE PLASMA CONCENTRATION OF FREE TRYPTOPHAN CAUSED BY PROBENECID IN HUMANS.
169470 01-13
TRANSPORT OF SYNAPTOSOMAL TRYPTOPHAN AND CEREBRAL TYROSINE: INCREASE IN THE SPEED OF UPTAKE OF RESERPINE OR THE INHIBITION OF MONOAMINE OXIDASE.
179988 02-13
REGIONAL CHANGES IN MONOAMINE LEVELS AND IN THE RATE OF TYROSINE AND TRYPTOPHAN HYDROXYLATION IN 4 WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
185899 03-03
EFFECTS OF AMPHETAMINES ON REGIONAL TRYPTOPHAN HYDROXYLASE ACTIVITY AND SYNAPTOSOMAL CONVERSION OF TRYPTOPHAN TO 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
186674 03-03
TRYPTOPHAN AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIONS.
187536 04-09
DEPLETION OF TRYPTOPHAN HYDROXYLASE BY 5,6 DIHYDROXYTRYPTAMINE IN RAT BRAIN -- TIME COURSE AND REGIONAL DIFFERENCES.
188287 04-03
THE EFFECT OF P-CHLOROPHENYLALANINE ON FOREBRAIN TRYPTOPHAN HYDROXYLASE IN RATS WITH LESIONS IN THE RAPHE NUCLEUS.
188750 04-03
SERUM TRYPTOPHAN BINDING IN CHLORPROMAZINE TREATED CHRONIC SCHIZOPHRENICS.
191320 04-08
REGULATION OF FUNCTION OF TRYPTOPHAN HYDROXYLASE.
191516 04-03
ABNORMALITIES IN TRYPTOPHAN METABOLITES IN SCHIZOPHRENIA.
191536 04-13

TRYPTOPHAN-5-HYDROXYLASE
A SENSITIVE, SIMPLE METHOD FOR MEASUREMENT OF TYROSINE HYDROXYLASE AND TRYPTOPHAN-5-HYDROXYLASE ACTIVITIES.
182178 02-06

TUBULAR
ENHANCED RENAL TUBULAR SECRETION OF MEPROBAMATE: ROLE OF SALINE FUROSEMIDE DIURESIS.
184243 03-03

TUMOR
RETARDATION OF TUMOR GROWTH BY DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC).
191963 04-03

TUNA
NEUROLOGICAL CHANGES IN CATS FOLLOWING LONG-TERM DIET OF MERCURY CONTAMINATED TUNA.
186476 03-05

TURNOVERS
EFFECT OF ECT ON DOPAMINERGIC AND NORADRENERGIC MECHANISMS: II. EFFECT ON DOPAMINE AND NORADRENALINE CONCENTRATIONS AND TURNOVERS.
186588 03-04

TWO-TRIAL
SCOPOLAMINE EFFECTS ON TWO-TRIAL DELAYED-RESPONSE PERFORMANCE IN THE RAT.
186372 03-04

TYMPANI
CHLOROFORM RESPONSES OF THE CHORDA TYMPANI NERVE IN THE RAT.
189219 04-03

TYPOLOGY
TOWARDS A BIOCHEMICAL TYPOLOGY OF DEPRESSION.
169095 01-09

TYRAMINE
INFLUENCE OF DIFFERENT ANIONS ON TYRAMINE AND AMPHETAMINE UPTAKE BY COW ADRENAL MEDULLA CHROMAFFIN VESICLES.
190907 04-03

TYROSINE
STRIATAL TYROSINE HYDROXYLASES WITH HIGH AND LOW AFFINITY FOR TYROSINE: IMPLICATIONS FOR THE MULTIPLE POOL CONCEPT OF CATECHOLAMINES.
167325 01-03
SPECIFIC ACTIVATION OF STRIATAL TYROSINE HYDROXYLASE (TH) BY NEUROLEPTICS. (UNPUBLISHED PAPER).
170755 01-03
TYROSINE HYDROXYLASE (TH) ACTIVITY AND CYCLIC 3,5 ADENOSINE MONOPHOSPHATE (CAMP) CONCENTRATIONS IN SYMPATHETIC GANGLIA OF RATS: EFFECTS OF DRUGS ACTING AT CHOLINERGIC AND ADRENERGIC SYNAPSES. (UNPUBLISHED PAPER).
170876 01-03
DISSOCIATION OF STIMULATORY AND SYNTHETIC PHASES IN THE INDUCTION OF TYROSINE HYDROXYLASE.
171785 01-03
DRUG-INDUCED ACTIVATION OF STRIATAL TYROSINE HYDROXYLASE: CHANGES IN THE AFFINITY FOR PTERIDINE COFACTORS. (UNPUBLISHED PAPER).
173381 01-03
NOREPINEPHRINE SENSITIVE ADENYLATE CYCLASES IN RAT BRAIN: RELATION TO BEHAVIOR AND TYROSINE HYDROXYLASE.
177252 02-03
TRANSPORT OF SYNAPTOSOMAL TRYPTOPHAN AND CEREBRAL TYROSINE: INCREASE IN THE SPEED OF UPTAKE OF RESERPINE OR THE INHIBITION OF MONOAMINE OXIDASE.
179988 02-13
A SENSITIVE, SIMPLE METHOD FOR MEASUREMENT OF TYROSINE HYDROXYLASE AND TRYPTOPHAN-5-HYDROXYLASE ACTIVITIES.
182178 02-06
IN VIVO ESTIMATION OF TYROSINE HYDROXYLATION IN THE DOPAMINERGIC TERMINALS OF THE RAT NEOSTRIATUM.
183794 03-03
INFLUENCE OF METHAMPHETAMINE AND NEUROLEPTIC DRUGS ON TYROSINE HYDROXYLASE ACTIVITY.
184180 03-03
REGIONAL CHANGES IN MONOAMINE LEVELS AND IN THE RATE OF TYROSINE AND TRYPTOPHAN HYDROXYLATION IN 4 WEEK OLD OFFSPRING OF NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
185899 03-03
EVIDENCE FOR A CRITICAL PERIOD FOR POSTNATAL ELEVATION OF BRAIN TYROSINE HYDROXYLASE ACTIVITY RESULTING FROM RESERPINE ADMINISTRATION DURING EMBRYONIC DEVELOPMENT.
186695 03-03
COMPARISON OF TYROSINE HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION WITH THE EFFECTS OF VARIOUS 6-HYDROXYDOPAMINE TREATMENTS ON D-AMPHETAMINE INDUCED MOTOR ACTIVITY.
186699 03-03
SHORT-TERM CONTROL OF TYROSINE HYDROXYLASE.
191513 04-03
SHORT-TERM AND LONG-TERM REGULATION OF TYROSINE HYDROXYLASE.
191515 04-03

U-32802A
EFFECT OF A BUTYROPHENONE DERIVATIVE, U-32802A, ON BRAIN BIOGENIC AMINES.
189584 04-02

ULCERATION
DRUG EFFECTS ON GASTRIC ULCERATION RATE IN THE RAT. (UNPUBLISHED PAPER).
176307 02-03

ULTRA
THE ACTION OF NEMBUTAL ON THE ULTRA ARCHITECTONICS OF THE NEUROHYPOPHYSIS.
183520 03-01

ULTRASTRUCTURE
ULTRASTRUCTURE OF CNS IN LITHIUM INTOXICATION.
176476 02-05

UMBILICAL
EVIDENCE FOR THE ACTION OF D-LYSERGIC ACID DIETHYLAMIDE, MESCALINE AND BUFOTENINE ON 5-HYDROXYTRYPTAMINE RECEPTORS IN UMBILICAL VASCULATURE.
182716 03-03

UNALTERED
MORPHINE PHYSICAL DEPENDENCE UNALTERED BY PREVIOUS DEPENDENCE ON MORPHINE.
173872 01-03

UNANESTHETIZED
COMPARISON OF CLOPENTHIXOL AND PERPHENAZINE IN BEHAVIOR AND EEG OF UNANESTHETIZED CATS.
181386 02-04

UNAVOIDABLE
THE EFFECTS OF AGENTS THAT MODIFY MUSCARINIC TONE UPON BEHAVIOR CONTROLLED BY AN AVOIDANCE SCHEDULE THAT EMPLOYS SIGNALED UNAVOIDABLE SHOCK.
171302 01-04

UNCONDITIONED
INTERACTION AMONG GENOTYPE, UNCONDITIONED STIMULUS, D-AMPHETAMINE, AND ONE-WAY AVOIDANCE BEHAVIOR OF RATS.
187702 04-04

UNDERFAT
PHENOTHIAZINES CONTRAINDICATED FOR THE UNDERFAT. (DR.P.H. DISSERTATION).
174966 01-15

UNDERSTANDING
REBOUND PHENOMENON IN MANIC PATIENTS FOLLOWING PHYSOSTIGMINE: TOWARDS AN UNDERSTANDING OF AMINERGIC MECHANISMS UNDERLYING AFFECTIVE DISORDERS.
191531 04-09
LABORATORY ASSESSMENTS OF ANTIDEPRESSIVE ACTIVITY -- THEIR VALUE FOR CLINICAL PSYCHIATRY AND THE UNDERSTANDING OF DEPRESSION.
192422 04-09

UNIT
EFFECTS OF LOCUS-COERULEUS STIMULATION ON HIPPOCAMPAL UNIT ACTIVITY AND ON BEHAVIOR IN UNRESTRAINED RATS. (UNPUBLISHED PAPER).
187499 04-04
NORADRENERGIC NEURONS: EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON SINGLE UNIT ACTIVITY.
191931 04-03
NORADRENERGIC REGULATION OF BRAIN SEROTONERGIC NEURONS: EVIDENCE FROM SINGLE UNIT STUDIES WITH CLONIDINE.
191948 04-03

UNLEARNED
COMPARATIVE EFFECTS OF SOME CNS ACTIVE DRUGS ON LEARNED AND UNLEARNED BEHAVIOR IN THE HAMSTER.
191976 04-04

UNRESTRAINED
AMPHETAMINE AND THERMOREGULATION: STUDIES IN THE UNRESTRAINED AND CURARIZED RAT.
184227 03-03
EFFECTS OF LOCUS-COERULEUS STIMULATION ON HIPPOCAMPAL UNIT ACTIVITY AND ON BEHAVIOR IN UNRESTRAINED RATS. (UNPUBLISHED PAPER).
187499 04-04
EFFECTS OF SCOPOLAMINE METHYLBROMIDE ON SHOCK-INDUCED GASTRIC LESIONS IN THE UNRESTRAINED RAT.
189381 04-03

UNSIGNALLED
EFFECTS OF NICOTINE AND ITS WITHDRAWAL ON THE PERFORMANCE OF RATS ON SIGNALLED AND UNSIGNALLED AVOIDANCE SCHEDULES.
190331 04-04
EFFECTS OF NICOTINE ON THE OBSERVED BEHAVIOUR OF RATS DURING SIGNALLED AND UNSIGNALLED AVOIDANCE EXPERIMENTS.
190332 04-04

UNTREATED
TESTOSTERONE AND LUTEINIZING HORMONE (LH) IN UNTREATED AND METHADONE MAINTAINED NARCOTIC ADDICTS.
182166 02-13

UPDATING
UPDATING THE SLEEPING PILL.
176011 02-11

UPTAKE
THE UPTAKE, RETENTION AND METABOLISM OF 3H-5-HYDROXYTRYPTAMINE IN BRAIN SLICES AND ILEUM FROM THE RAT: EFFECTS OF COCAINE, DESMETHYLIMIPRAMINE AND RESERPINE. (PH.D. DISSERTATION).
168131 01-03
THE UPTAKE OF DOPAMINE AND SEROTONIN IN RAT BRAIN DURING PROGESTERONE DECLINE.
171307 01-03
CORTICAL SYNAPTOSOMAL UPTAKE AND SUBSYNAPTOSOMAL DISTRIBUTION OF 3H-NOREPINEPHRINE AND 3H-AMPHETAMINE: MODIFICATION BY TRICYCLIC AND PSYCHOACTIVE AGENTS IN VITRO. (PH.D. DISSERTATION).
172020 01-03
THE INHIBITION OF 3H-DOPAMINE UPTAKE INTO RAT STRIATAL BY VERATRIDINE AND BATRACHOTOXIN. (UNPUBLISHED PAPER).
173380 01-03
STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF 5-HT UPTAKE INTO RAT HYPOTHALAMIC HOMOGENATES BY SEROTONIN AND TRYPTAMINE ANALOGUES.
175233 02-03
DOPAMINE IN THE MESOLIMBIC SYSTEM OF THE RAT BRAIN: ENDOGENOUS LEVELS AND THE EFFECTS OF DRUGS ON THE UPTAKE MECHANISM AND STIMULATION OF ADENYLATE CYCLASE ACTIVITY.
177131 02-03
TRANSPORT OF SYNAPTOSOMAL TRYPTOPHAN AND CEREBRAL TYROSINE: INCREASE IN THE SPEED OF UPTAKE OF RESERPINE OR THE INHIBITION OF MONOAMINE OXIDASE.
179988 02-13
EFFECTS OF CHLORPROMAZINE AND ACTINOMYCIN D ON UPTAKE AND INCORPORATION OF CERTAIN AMINO ACIDS, HYPOXANTHINE AND THYMIDINE IN CULTURES OF HUMAN SKIN EPITHELIAL CELLS.
179989 02-13
A NEW MODIFICATION FOR STUDYING 5-HT UPTAKE BY BLOOD PLATELETS: A RE-EVALUATION OF TRICYCLIC ANTIDEPRESSANTS AS UPTAKE INHIBITORS.
180055 02-06
IN VIVO INHIBITION OF NEURONAL UPTAKE OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY COCAINE AND BY DESMETHYLIMIPRAMINE (DMI).
182150 02-03
INHIBITION OF C14-ACH UPTAKE IN RAT BRAIN SLICES BY DESMETHYLIMIPRAMINE.
182170 02-03
UPTAKE, STORAGE AND RELEASE IN VIVO OF A DOPAMINE DERIVED TETRAHYDROISOQUINOLINE (TIQ) ALKALOID BY SYMPATHETIC NERVES OF THE IRIS.
182204 02-03
INHIBITION OF THE SYNAPTOSOMAL UPTAKE MECHANISMS FOR L-NOREPINEPHRINE AND DOPAMINE BY N-ARYLALKYL DL-AMPHETAMINE DERIVATIVES.
182250 03-03
UPTAKE AND RELEASE OF NORADRENALINE IN RAT CEREBRAL CORTEX IN VITRO: NO EFFECT OF BENZODIAZEPINES AND BARBITURATES.
182347 03-03
PHARMACOLOGICAL ANALYSIS OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE REMOVAL FROM THE PULMONARY CIRCULATION: DIFFERENTIATION OF UPTAKE SITES FOR EACH AMINE.
182717 03-03
METHADONE INHIBITION OF 3H-5-HYDROXYTRYPTAMINE UPTAKE BY SYNAPTOSOMES.
183896 03-03
THE INHIBITION BY BETA-ADRENOCEPTOR BLOCKING AGENTS OF CALCIUM UPTAKE INTO AND EFFLUX FROM ISOLATED SARCOPLASMIC VESICLES.
184223 03-03
THE EFFECTS OF ACUTE ADMINISTRATION OF PROPRANOLOL AND PRACTOLOL ON THE UPTAKE, CONTENT, RELEASE AND TURNOVER OF NORADRENALINE IN THE RAT HEART IN VIVO.
184232 03-03
EFFECT OF ANTIDEPRESSANT AND ANTIMANIC DRUGS ON AMINE UPTAKE IN MAN.
184654 03-13
THE EFFECT OF P-CHLOROAMPHETAMINE ON MOTILITY IN RATS AFTER INHIBITION OF MONOAMINE SYNTHESIS, STORAGE, UPTAKE AND RECEPTOR INTERACTION.
185959 03-04
EFFECTS OF LITHIUM ON ADRENERGIC AMINE UPTAKE IN RAT BRAIN SYNAPTOSOMES.
186633 03-03
A COMPARISON OF THE EFFECTS OF AMPHETAMINE AND ITS METABOLITES, P-HYDROXYAMPHETAMINE AND P-HYDROXYNOREPHEDRINE, ON UPTAKE, RELEASE AND CATABOLISM OF 3H-NOREPINEPHRINE IN CEREBRAL CORTEX OF RAT BRAIN.
186669 03-03
EVIDENCE FOR A SPECIFIC UPTAKE OF DOPAMINE BY DOPAMINERGIC TERMINALS OF THE RAT CEREBRAL CORTEX.
188978 04-03

EFFECT OF PENTOBARBITAL ON UPTAKE AND RELEASE OF (3H)GABA AND (14C)GLUTAMATE BY BRAIN SLICES.
189031 04-03

INFLUENCE OF DIFFERENT ANIONS ON TYRAMINE AND AMPHETAMINE UPTAKE BY COW ADRENAL MEDULLA CHROMAFFIN VESICLES.
190907 04-03

5-HYDROXYTRYPTAMINE AND NORADRENALINE IN THE HIPPOCAMPAL REGION: EFFECT OF TRANSECTION OF AFFERENT PATHWAYS ON ENDOGENOUS LEVELS, HIGH AFFINITY UPTAKE AND SOME TRANSMITTER RELATED ENZYMES.
191319 04-03

THE MODE OF MORPHINE UPTAKE INTO BRAIN SLICES.
191413 04-03

INFLUENCE OF VARIOUS SUBSTANCES WHICH INDUCE AND INHIBIT AGGREGATION ON THE UPTAKE OF DEOXYGLUCOSE BY HUMAN BLOOD PLATELETS.
191770 04-13

INHIBITION OF CHOLINE UPTAKE INTO SYNAPTOSOMES BY CHOLINE ANALOGUES.
191999 04-03

URINARY

STUDIES ON THE URINARY EXCRETION OF CATECHOLAMINES AND 17-KETOSTEROID IN MANIC-DEPRESSIVE PSYCHOSIS.
178623 02-09

ANTICHOLINERGICS: THEIR EFFECTS ON FEAR MOTIVATED BEHAVIOR, URINARY 11-HYDROXYCORTICOSTEROIDS, URINARY VOLUME, AND HEART RATE IN THE DOG.
178720 02-03

BLOOD LEVEL AND URINARY EXCRETION OF BROMAZEPAM IN MAN.
182556 03-13

ASSAY PROCEDURES FOR THIORIDAZINE, TRIFLUOPERAZINE, AND THEIR SULFOXIDES AND DETERMINATION OF URINARY EXCRETION OF THESE COMPOUNDS IN MENTAL PATIENTS.
183602 03-01

ESTIMATION OF THE CONTRIBUTION OF PERIPHERAL AND CENTRAL NORADRENERGIC NEURONES TO URINARY 3-METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT.
192335 04-03

URINE

SIMULTANEOUS ANALYSIS OF A 1,5 BENZODIAZEPINE AND ITS METABOLITE IN BLOOD AND URINE BY SPECTRODENSITOMETRY.
176871 02-16

IDENTIFICATION AND QUANTITATIVE DETERMINATION OF PHENOTHIAZINE DRUGS IN URINE SAMPLES OF PSYCHIATRIC PATIENTS.
183599 03-02

GLC DETERMINATION OF MEPROBAMATE IN WATER, PLASMA AND URINE.
185977 03-16

A STUDY OF BIOGENIC AMINE METABOLITES IN THE CEREBROSPINAL FLUID AND URINE OF MONKEYS WITH CHLORPROMAZINE INDUCED DYSKINESIA.
189210 04-03

USAGE

ACUTE ADVERSE REACTIONS TO PSYCHOACTIVE DRUGS, DRUG USAGE, AND PERSONALITY. (UNPUBLISHED PAPER).
167832 01-15

THE PROBLEMS OF THE CLINICAL USAGE OF NITRAZEPAM: SUPPRESSIVE EFFECTS ON THE PHARYNGEAL REFLEX AND THE COMA, USING OTHER TRANQUILIZERS AT THE SAME TIME.
188450 04-15

PERFORMANCE ON A VERBAL LEARNING TASK BY SUBJECTS OF HEAVY PAST MARIJUANA USAGE.
190308 04-14

USERS

CYTOGENETIC STUDIES IN THE OFFSPRING OF LSD USERS.
185083 03-12

RESPONSE TO INCREMENTAL DOSES OF DITRAN IN ABSTINENT ALCOHOLICS AND DRUG USERS.
185875 03-11

UTILIZATION

EFFECTS OF SOME TETRAHYDROCANNABINOLS ON THE BIOSYNTHESIS AND UTILIZATION OF CATECHOLAMINES IN THE RAT BRAIN.
172917 01-03

EVIDENCE THAT MORPHINE INCREASES DOPAMINE UTILIZATION IN CORPORA-STRIATA OF RATS.
176746 02-03

UTILIZING

FUNCTIONAL EVALUATION OF PITUITARY RESERVE IN PATIENTS WITH THE AMENORRHEA GALACTORRHEA SYNDROME UTILIZING LUTEINIZING HORMONE RELEASING HORMONE (LH-RH), L-DOPA AND CHLORPROMAZINE.
175245 02-13

PRELIMINARY EXPERIENCES WITH THE TREATMENT OF SOME MENTAL CASES UTILIZING AN ENZYME COMBINATION.
180298 02-17

VA-NIMH

PROPHYLACTIC EFFICACY OF LITHIUM CARBONATE IN MANIC-DEPRESSIVE ILLNESS: REPORT OF THE VETERANS ADMINISTRATION AND NATIONAL INSTITUTE OF MENTAL HEALTH (VA-NIMH) COLLABORATIVE STUDY GROUP.
189735 04-09

LITHIUM IN TREATMENT AND PREVENTION OF AFFECTIVE DISORDER: A VA-NIMH COLLABORATIVE STUDY.
190381 04-09

VACCINE

DEVELOPMENT OF A VACCINE AGAINST MENTAL RETARDATION CAUSED BY CYTOMEGALOVIRUS INFECTION IN UTERO.
178549 02-11

VAGUS

THE EFFECT OF DIAZEPAM ON SOME CARDIOVASCULAR AND RESPIRATORY REFLEXES ELICITED BY AFFERENT ABDOMINAL VAGUS STIMULATION.
178945 02-03

VALIDITY

VALIDITY OF SCREENING METHODS FOR DRUGS OF ABUSE IN BIOLOGICAL FLUIDS. II. HEROIN IN PLASMA AND SALIVA.
187256 03-15

VALIUM

A DOUBLE-BLIND COMPARISON OF THIORIDAZINE (MELLARIL) VERSUS DIAZEPAM (VALIUM) IN PATIENTS WITH CHRONIC MIXED ANXIETY AND DEPRESSIVE SYMPTOMS.
172486 01-10

PSYCHOPHYSIOLOGICAL EFFECTS OF DIAZEPAM (VALIUM) COMBINED WITH A MODERATE DOSE OF ALCOHOL IN MAN.
180699 02-14

VALUABLE

AMPHETAMINES: VALUABLE ADJUNCT IN TREATMENT OF PARKINSONISM.
169220 01-11

VALUE

5-HYDROXYTRYPTOPHAN AS AN ANTIDEPRESSANT: THE PREDICTIVE VALUE OF THE PROBENECID TEST.
184652 03-09

TO SPRITZ OR NOT TO SPRITZ: THE DOUBTFUL VALUE OF AIMLESS IONTOPHORESIS.
187132 03-06

THE PREDICTIVE VALUE OF THE ANTIAPOMORPHINE TEST IN DOGS FOR NEUROLEPTIC THERAPY IN MAN.
192421 04-04

LABORATORY ASSESSMENTS OF ANTIDEPRESSIVE ACTIVITY -- THEIR VALUE FOR CLINICAL PSYCHIATRY AND THE UNDERSTANDING OF DEPRESSION.
192422 04-09

VALUES

INHALATION, PARENTERAL AND ORAL LD50 VALUES OF DELTA9-TETRAHYDROCANNABINOL IN FISCHER RATS.
189588 04-05

VAPOR

INDUCTION OF A DIETHYLETHER WITHDRAWAL SYNDROME IN MICE BY EXPOSURE TO ETHER VAPOR.
192006 04-03

VARIABILITY

SOURCES OF VARIABILITY IN THE PHARMACODYNAMICS OF 14C-IMIPRAMINE INCLUDING INTERACTION WITH DIAZEPAM OR THIORIDAZINE.
191925 04-03

VARIABLE

THE STANDARDIZED VIDEOTAPE INTERVIEW AS AN OBJECTIVE DEPENDENT VARIABLE IN PSYCHOTROPIC DRUG RESEARCH.
183635 03-17

COMPARISON OF CODEINE AND ETHYL ALCOHOL SELF-ADMINISTRATION UNDER A VARIABLE INTERVAL (VI) SCHEDULE IN MONKEYS.
191983 04-04

VARIABLES

ORTHOGONAL FACTORS VS. INTERDEPENDENT VARIABLES AS PREDICTORS OF DRUG TREATMENT RESPONSE IN ANXIOUS OUTPATIENTS.
171299 01-14

VARIANT

VESTA VARIANT OF TOURETTES DISEASE: TREATMENT WITH HALOPERIDOL.
169286 01-10

HUNTINGTONS CHOREA: THE RIGID FORM (WESTPHAL VARIANT) TREATED WITH LEVODOPA.
187618 04-11

A CASE OF A NONSPECIFIC MENTAL ILLNESS WITH PSYCHOMOTOR VARIANT.
188517 04-09

VARIATION

THE EFFECTS OF DALMANE (FLURAZEPAM HYDROCHLORIDE) ON THE CONTINGENT NEGATIVE VARIATION. (AMSTERDAM).
177645 02-16

THE EFFECTS OF METHAMPHETAMINE AND SECOBARBITAL ON THE CONTINGENT NEGATIVE VARIATION AMPLITUDE.
185932 03-13
THE EFFECT OF CAFFEINE, NITRAZEPAM AND CIGARETTE SMOKING ON THE CONTINGENT NEGATIVE VARIATION IN MAN.
187350 04-13

VASCULAR
EFFECTS OF PSYCHOTOMIMETICS ON VASCULAR STRIPS: STUDIES OF METHOXYLATED AMPHETAMINES AND OPTICAL ISOMERS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE AND 2,5 DIMETHOXY-4-BROMOAMPHETAMINE.
177734 02-03

VASCULATURE
EVIDENCE FOR THE ACTION OF D-LYSERGIC ACID DIETHYLAMIDE, MESCALINE AND BUFOTENINE ON 5-HYDROXYTRYPTAMINE RECEPTORS IN UMBILICAL VASCULATURE.
182716 03-03

VASOCONSTRICTOR
MECHANISM OF THE VASOCONSTRICTOR ACTION OF PROSTAGLANDIN B.
189394 04-03
EFFECTS OF PROSTAGLANDINS B1 AND B2 ON VASOCONSTRICTOR RESPONSES OF THE CANINE HINDPAW.
189395 04-03

VASOPRESSIN
LOCALIZED BEHAVIORAL EFFECTS OF VASOPRESSIN ON MAINTENANCE OF AN ACTIVE AVOIDANCE RESPONSE IN RATS.
187697 04-04

VEHICLE
EFFECTS OF PHENOBARBITAL AND SKF-525-A PRETREATMENT, SEX, LIVER INJURY, AND VEHICLE ON DELTA9-TETRAHYDROCANNABINOL TOXICITY.
189598 04-05

VELOCITY
NERVE CONDUCTION VELOCITY IN PATIENTS ON LONG-TERM DIPHENYLHYDANTOIN THERAPY.
189173 04-15

VENTRICLE
EFFECT OF D-AMPHETAMINE (D-A) AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) ON THE IN VIVO RELEASE OF 14C-NOREPINEPHRINE (NE) INTO THE LATERAL VENTRICLE OF RATS.
182251 03-03

VENTRICLES
HYPERTHERMIC EFFECT OF PALMITATE SODIUM, STEARATE SODIUM AND OLEATE SODIUM INJECTED INTO THE CEREBRAL VENTRICLES OF CONSCIOUS CATS.
186640 03-03

VERATRIDINE
THE INHIBITION OF 3H-DOPAMINE UPTAKE INTO RAT STRIATAL BY VERATRIDINE AND BATRACHOTOXIN. (UNPUBLISHED PAPER).
173380 01-03

VERBAL
INFLUENCE OF AFFECTIVE STATES AND PSYCHOACTIVE DRUGS ON VERBAL LEARNING AND MEMORY.
169504 01-09
AN INVESTIGATION OF INTERACTIONS AMONG LSD, DEXTROAMPHETAMINE, AND VERBAL BEHAVIOR IN MONOLOGUES AND DIALOGUES. (PH.D. DISSERTATION).
185600 03-14
PERFORMANCE ON A VERBAL LEARNING TASK BY SUBJECTS OF HEAVY PAST MARIJUANA USAGE.
190308 04-14

VESICLE
EVIDENCE FOR PERSISTENT RESERPINE BINDING TO AMINE STORAGE VESICLE MEMBRANES.
182234 03-03

VESICLES
THE INHIBITION BY BETA-ADRENOCEPTOR BLOCKING AGENTS OF CALCIUM UPTAKE INTO AND EFFLUX FROM ISOLATED SARCOPLASMIC VESICLES.
184223 03-03
INFLUENCE OF DIFFERENT ANIONS ON TYRAMINE AND AMPHETAMINE UPTAKE BY COW ADRENAL MEDULLA CHROMAFFIN VESICLES.
190907 04-03

VESPRIN
AUTOCRITICISM AND REAL PLACE OF THE SAME MEDICATION (VESPRIN).
184964 03-11

VESSELS
ALTERED NOREPINEPHRINE SYNTHESIS OF SPLANCHNIC VESSELS IN NEUROGENIC HYPERTENSION.
188198 04-03
CONTROL OF NOREPINEPHRINE SYNTHESIS IN BLOOD VESSELS AND THE EFFECTS OF MONOAMINE OXIDASE INHIBITION.
189390 04-03

VESTA
VESTA VARIANT OF TOURETTES DISEASE: TREATMENT WITH HALOPERIDOL.
169286 01-10

VETERANS
PROPHYLACTIC EFFICACY OF LITHIUM CARBONATE IN MANIC-DEPRESSIVE ILLNESS: REPORT OF THE VETERANS ADMINISTRATION AND NATIONAL INSTITUTE OF MENTAL HEALTH (VA-NIMH) COLLABORATIVE STUDY GROUP.
189735 04-09

VIDEOTAPE
THE STANDARDIZED VIDEOTAPE INTERVIEW AS AN OBJECTIVE DEPENDENT VARIABLE IN PSYCHOTROPIC DRUG RESEARCH.
183635 03-17

VIET-NAM
STATUS OF PSYCHOTROPIC MEDICATION IN VIET-NAM.
180320 02-17

VIGILANCE
EFFECTS OF TWO LEVELS OF ATTENTION DEMAND ON VIGILANCE PERFORMANCE UNDER MARIHUANA.
189359 04-14

VISUAL
LSD EFFECTS ON SIGNAL-TO-NOISE RATIO AND LATERALIZATION OF VISUAL CORTEX AND LATERAL GENICULATE DURING PHOTIC STIMULATION.
167449 01-03
BEHAVIORAL AND VISUAL EVOKED POTENTIAL INVESTIGATIONS DURING TRIHEXYPHENIDYL AND THIOTHIXENE TREATMENT IN PSYCHOTIC BOYS.
187115 03-09
COMPARATIVE EFFECTS OF SCOPOLAMINE AND AMPHETAMINE UPON BEHAVIORAL REACTIVITY AND VISUAL EVOKED POTENTIALS TO FLASHES IN RATS.
187700 04-04

VISUALLY
EFFECTS OF SCOPOLAMINE UPON BEHAVIORAL REACTIVITY AND VISUALLY EVOKED POTENTIAL TO FLASHES IN RATS.
173032 01-04

VITAMIN-D
ANTICONVULSANT ACTION OF VITAMIN-D IN EPILEPTIC PATIENTS? A CONTROLLED PILOT STUDY.
188889 04-11

VOCALIZATION
VOCALIZATION: A CHARACTERISTIC CANNABIS INDUCED BEHAVIOR IN THE RAT?
175884 02-04

VOLTAGE
VOLTAGE CLAMP ANALYSIS OF PENTYLENETETRAZOL EFFECTS ON APLYSIA NEURONS.
189032 04-03

VOLUNTEER
EFFECT OF ORAL ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL ON MEMORY, SPEECH, AND PERCEPTION OF THERMAL STIMULATION: RESULTS WITH FOUR NORMAL HUMAN VOLUNTEER SUBJECTS. PRELIMINARY REPORT.
177674 02-14

VOLUNTEERS
OPERANT BEHAVIOR AND NEUROPHYSIOLOGICAL OBSERVATIONS OF NORMAL HUMAN VOLUNTEERS RECEIVING CL-1848C, A NEW DISSOCIATIVE ANESTHETIC.
167334 01-07
LOW DOSAGE HALOPERIDOL AND INDUCED ANXIETY IN NORMAL VOLUNTEERS.
169745 01-14
DRUGS AND PLACEBOS: DRUG GUESSING BY NORMAL VOLUNTEERS.
174210 01-14
DOUBLE-BLIND PSYCHOMETRIC EVALUATION OF PIMOZIDE AND HALOPERIDOL VERSUS PLACEBO IN EMOTIONALLY LABILE VOLUNTEERS UNDER TWO DIFFERENT WORK LOAD CONDITIONS.
180065 02-14
MANIFEST ANXIETY AND ANTIANXIETY DRUG EFFECTS IN NORMAL VOLUNTEERS.
182118 02-14
DIAZEPAM AND MEPERIDINE ON ARTERIAL BLOOD GASES IN HEALTHY VOLUNTEERS.
190147 04-13

W-801
LONG-TERM APPLICATION OF CLOZAPINE (W-801) IN SCHIZOPHRENIC PATIENTS.
174680 01-08

WAKEFULNESS
EFFECTS OF PHENOTHIAZINES, ANTIHISTAMINES, BENZODIAZEPINES AND BUTYROPHENONES ON THE RHYTHMS OF WAKEFULNESS SLEEP CYCLE IN RATS.
182553 03-04

WARD
END OF A BACK WARD: THE RAPID REHABILITATION AND RELEASE OF CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS.
181153 02-08

WATER
SHOULD WE PUT BENZODIAZEPINES IN OUR DRINKING WATER
168361 01-17

EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF WATER SOLUBLE 1iDELTA9-TETRAHYDROCANNABINOL (W THC) ON WEB-BUILDING OF SPIDERS.
182193 02-04

GLC DETERMINATION OF MEPROBAMATE IN WATER, PLASMA AND URINE.
185977 03-16

EFFECTS OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL ON SOCIAL BEHAVIOR OF SQUIRREL MONKEY DYADS IN A WATER COMPETITION SITUATION.
187640 04-04

EFFECTS OF DELTA9-THC ON FOOD AND WATER INTAKE OF DEPRIVATION EXPERIENCED RATS.
191375 04-04

ALPHA-METHYL-P-TYROSINE INHIBITION OF SELF-ADMINISTERED INTRAVENOUS MORPHINE AND ORAL WATER IN RATS.
191940 04-04

THE EFFECTS OF DELTA9-THC AND A WATER SOLUBLE DERIVATIVE ON PGE1 SYNTHESIS IN THE CORPUS-STRIATUM.
191964 04-03

WAVE

ON THE STUPOROUS AND HYPOMANIC EPISODES ASSOCIATED WITH SPIKE AND WAVE IN ELECTROENCEPHALOGRAM.
181388 02-11

WAVES

THE EFFECTS OF INTRAVENTRICULARLY ADMINISTERED CATECHOLAMINES AND SEROTONIN ON THE RESERPINE INDUCED SPIKE WAVES RECORDED FROM THE MEDICAL NUCLEUS TRAPEZOIDES IN THE RABBIT.
182094 02-03

PGO WAVES IN THE LATERAL GENICULATE NUCLEUS TRIGGERED BY BARBITURATE.
187835 04-03

WEB-BUILDING

EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF WATER SOLUBLE 1-DELTA9-TETRAHYDROCANNABINOL (W THC) ON WEB-BUILDING OF SPIDERS.
182193 02-04

WEIGHT

EXCITANT AND DEPRESSANT DRUGS MODULATE EFFECTS OF ENVIRONMENT ON BRAIN WEIGHT AND CHOLINESTERASES.
174036 01-03

WEIGHT GAIN IN LITHIUM TREATED RATS.
174133 01-04

EFFECT OF A CARNITINE CYPROHEPTADINE COMBINATION ON ANOREXIA AND WEIGHT GAIN IN CHILDREN.
178811 02-10

WELLBATRIN

WELLBATRIN IN THE TREATMENT OF DEPRESSION.
191978 04-10

WERNERS

A CASE OF WERNERS SYNDROME WITH SCHIZOPHRENIA-LIKE SYMPTOMS.
175120 02-09

WESTPHAL

HUNTINGTONS CHOREA: THE RIGID FORM (WESTPHAL VARIANT) TREATED WITH LEVODOPA.
187618 04-11

WITHDRAWAL

MESORIDAZINE AND CHLORPROMAZINE IN THE TREATMENT OF ALCOHOL WITHDRAWAL SYNDROME.
168314 01-11

DEVELOPMENT OF PHYSICAL DEPENDENCE ON MORPHINE IN RESPECT TO TIME AND DOSAGE AND QUANTIFICATION OF THE PRECIPITATED WITHDRAWAL SYNDROME IN RATS.
169474 01-03

EFFECT OF DOPAMINERGIC STIMULATION OR BLOCKADE ON MORPHINE WITHDRAWAL AGGRESSION.
171300 01-04

CHRONIC HYPNOTIC DRUG USE: INEFFECTIVENESS, DRUG WITHDRAWAL INSOMNIA, AND DEPENDENCE.
172114 01-15

PREVENTION OF ALCOHOL WITHDRAWAL SEIZURES: THE ROLES OF DIPHENYLHYDANTOIN AND CHLORDIAZEPOXIDE.
172275 01-11

STUDIES ON SIDE-EFFECTS AND WITHDRAWAL SYMPTOMS OF IMINODIBENZYL DERIVATIVES.
173080 01-15

WITHDRAWAL OF MAINTENANCE DRUGS WITH LONG-TERM HOSPITALIZED MENTAL PATIENTS: A CRITICAL REVIEW.
175862 02-17

IMIPRAMINE WITHDRAWAL: AN AKATHISIA LIKE SYNDROME.
177710 02-15

EFFECTS OF CONSECUTIVE ADMINISTRATION OF DIAZEPAM AND DOXEPIN ON BOTH APPROACH WITHDRAWAL AND APPROACH AVOIDANCE RESPONSES IN RATS.
182117 02-04

CHANGES IN THE NEUROEXCITABILITY OF ALCOHOL DEPENDENT RATS UNDERGOING WITHDRAWAL AS MEASURED BY THE PENTYLENETETRAZOL SEIZURE THRESHOLD.
182348 03-03

NEUROLOGICAL CONSEQUENCES OF PSYCHOTROPIC DRUG WITHDRAWAL IN SCHIZOPHRENIC CHILDREN.
183275 03-08

THE ABRUPT WITHDRAWAL OF ANTIPARKINSONIAN DRUGS IN SCHIZOPHRENIC PATIENTS.
185005 03-08

ABSENCE OF REM REBOUND AFTER BARBITURATE WITHDRAWAL.
189884 04-14

EFFECTS OF NICOTINE AND ITS WITHDRAWAL ON THE PERFORMANCE OF RATS ON SIGNALLED AND UNSIGNALLED AVOIDANCE SCHEDULES.
190331 04-04

TARDIVE AND WITHDRAWAL DYSKINESIA ASSOCIATED WITH HALOPERIDOL.
191035 04-15

LONG-TERM ALTERATION OF SLEEP-WAKEFULNESS CYCLE DURING CHRONIC PENTOBARBITAL DOSING AND WITHDRAWAL IN CAT.
191952 04-04

MORPHINE TOLERANCE, DEPENDENCE AND WITHDRAWAL AND BRAIN ACETYLCHOLINE.
191985 04-03

LITHIUM TREATMENT DURING ETHANOL INGESTION AND WITHDRAWAL.
192005 04-11

INDUCTION OF A DIETHYLETHER WITHDRAWAL SYNDROME IN MICE BY EXPOSURE TO ETHER VAPOR.
192006 04-03

SUPERSENSITIVITY TO DOPAMINERGIC AGONISTS FOLLOWING WITHDRAWAL OF A CHRONIC DIET CONTAINING HALOPERIDOL OR PIMOZIDE.
192012 04-04

CONDITIONING IN THE PREDICTION OF DRUG WITHDRAWAL EFFECTS IN CHRONIC SCHIZOPHRENIC PATIENTS.
192412 04-17

WOMEN

THE EFFECTS OF PHENOTHIAZINES ON ENDOCRINE FUNCTION: II. EFFECTS IN MEN AND POST-MENOPAUSAL WOMEN.
184437 03-13

EFFECTS OF CONCURRENT BEHAVIOR MODIFICATION AND CHLORPROMAZINE ADMINISTRATION IN MENTALLY RETARDED WOMEN. (PH.D. DISSERTATION).
185604 03-14

THE EFFECT OF CONJUGATED ESTROGENS ON PLASMA BUTAPERAZINE LEVELS IN WOMEN.
191959 04-15

WORD

WORD RECOGNITION OF SCHIZOPHRENICS AS A FUNCTION OF PHENOTHIAZINE LEVEL AND AUTONOMIC RESPONSIVITY. (PH.D. DISSERTATION).
182524 03-08

WORK

DOUBLE-BLIND PSYCHOMETRIC EVALUATION OF PIMOZIDE AND HALOPERIDOL VERSUS PLACEBO IN EMOTIONALLY LABILE VOLUNTEERS UNDER TWO DIFFERENT WORK LOAD CONDITIONS.
180065 02-14

WY-4036

WY-4036 (LORAZEPAM) -- A NEW TRANQUILIZER.
180146 02-10

A STUDY OF ANTIANXIETY EFFECTS OF WY-4036.
185874 03-10

XANTHENES

D-(R)- AND L-(S) 3-ALKYLAMINOPYRROLIDINO-SUBSTITUTED DIHYDRODIBENZOTHIEPINS, XANTHENES, AND DIPHENYLMETHANES.
187937 04-01

Y-MAZE

EFFECTS OF DELTA9-THC, LSD-25 AND SCOPOLAMINE ON CONTINUOUS, SPONTANEOUS ALTERNATION IN THE Y-MAZE.
171306 01-04

Y-4153

COMPARISON OF THE EFFECTS OF Y-4153 AND CARPIPRAMINE ON SCHIZOPHRENIA BY A DOUBLE-BLIND METHOD.
178053 02-08

Y-6047

A CLINICAL EVALUATION OF A NEW ANXIOLYTIC DRUG (THIENODIAZEPINE DERIVATIVE Y-6047) IN NEUROTICS AND PSYCHOSOMATIC DISORDERS -- A PRELIMINARY REPORT.
181771 02-07

YESTERDAY

YESTERDAY, TODAY AND TOMORROW: A POINT OF VIEW.
168312 01-17

YIELD

METABOLISM OF CHLORPHENTERMINE AND PHENTERMINE IN MAN TO YIELD HYDROXYLAMINO, C-NITROSO AND NITRO COMPOUNDS.
183796 03-13

YOHIMBANS
ALKALOID STUDIES. 9. PREPARATION OF 18-ACYLYOHIMBAN-17-ONES AND THEIR CONVERSION TO NEW HETEROCYCLIC YOHIMBANS.
185033 03-04

YOHIMBINE
CARDIOVASCULAR EFFECTS OF RESERPINE, YOHIMBINE, AND RESERPINE YOHIMBINE MIXTURES ON INTACT ANESTHETIZED DOG.
167328 01-03
BEHAVIOURAL EFFECTS OF YOHIMBINE ADMINISTERED INTRAVENTRICULARLY IN THE RAT.
177721 02-04
DRUG-INDUCED CATALEPSY AS INFLUENCED BY PSYCHOSTIMULANTS, APOMORPHINE, L-DOPA, AND YOHIMBINE.
177730 02-13

YOUNG
FATAL INTOXICATION OF A YOUNG DRUG ADDICT WITH DIAZEPAM.
178619 02-05
CHANGES IN BRAIN ACETYLCHOLINESTERASE ACTIVITY OF YOUNG RATS AFTER CHRONIC TREATMENT WITH TREMORINE.
178814 02-03

ZINC
THE EFFECT OF ZINC N TETRACOSACTRIN ON GROWTH HORMONE RELEASE DURING SLEEP.
183490 03-13
SAFETY AND EFFICACY OF ZINC SULFATE IN GERIATRIC PATIENTS.
184177 03-11

ZISEPRON
CLINICAL EFFECT OF A NEW PSYCHOTROPIC DRUG, ZISEPRON, IN TREATMENT OF PSYCHIATRIC DISEASES IN COMPARISON WITH THIORIDAZINE.
176467 02-08

1-AMINOTETRALINES
1-AMINOTETRALINES -- CNS AGENTS AND ALPHA-BLOCKERS.
175762 02-17

1-DELTA9-TETRAHYDROCANNABINOL
EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF WATER SOLUBLE 1-DELTA9-TETRAHYDROCANNABINOL (W THC) ON WEB-BUILDING OF SPIDERS.
182193 02-04
THE EFFECT OF HYPOTHERMIC DOSES OF 1-DELTA9-TETRAHYDROCANNABINOL ON BIOGENIC AMINE METABOLISM IN SELECTED PARTS OF THE RAT BRAIN.
188231 04-03

1-METHYL-D-LYSERGIC
EFFECT OF LSD-25 AND 1-METHYL-D-LYSERGIC ACID BUTANOLAMIDE ON RAT BRAIN AND PLATELET SEROTONIN LEVELS.
184975 03-03

1-METHYL-5-PHENYL-5-PROPYL
THE SITE OF ACTION ON THE OPTICAL ISOMERS OF 1-METHYL-5-PHENYL-5-PROPYL BARBITURIC ACID.
185901 03-03

11-HYDROXY-DELTA9-TETRAHYDROCANNABINOL
DELTA9-TETRAHYDROCANNABINOL AND 11-HYDROXY-DELTA9-TETRAHYDROCANNABINOL: BEHAVIORAL EFFECTS AND TOLERANCE DEVELOPMENT.
183893 03-04

11-HYDROXYCORTICOSTEROIDS
ANTICHOLINERGICS: THEIR EFFECTS ON FEAR MOTIVATED BEHAVIOR, URINARY 11-HYDROXYCORTICOSTEROIDS, URINARY VOLUME, AND HEART RATE IN THE DOG.
178720 02-03

11-OH-DELTA8-TETRAHYDROCANNABINOL
HYPOTHERMIC ACTION OF DELTA9-TETRAHYDROCANNABINOL, 11-OH-DELTA9-TETRAHYDROCANNABINOL AND 11-OH-DELTA8-TETRAHYDROCANNABINOL (DELTA9-THC, 11-OH-DELTA9-THC AND 11-OH-DELTA8-THC) IN MICE.
182220 03-03

11-OH-DELTA8-THC
HYPOTHERMIC ACTION OF DELTA9-TETRAHYDROCANNABINOL, 11-OH-DELTA9-TETRAHYDROCANNABINOL AND 11-OH-DELTA8-TETRAHYDROCANNABINOL (DELTA9-THC, 11-OH-DELTA9-THC AND 11-OH-DELTA8-THC) IN MICE.
182220 03-03

11-OH-DELTA9-TETRAHYDROCANNABINOL
HYPOTHERMIC ACTION OF DELTA9-TETRAHYDROCANNABINOL, 11-OH-DELTA9-TETRAHYDROCANNABINOL AND 11-OH-DELTA8-TETRAHYDROCANNABINOL (DELTA9-THC, 11-OH-DELTA9-THC AND 11-OH-DELTA8-THC) IN MICE.
182220 03-03

11-OH-DELTA9-THC
HYPOTHERMIC ACTION OF DELTA9-TETRAHYDROCANNABINOL, 11-OH-DELTA9-TETRAHYDROCANNABINOL AND 11-OH-DELTA8-TETRAHYDROCANNABINOL (DELTA9-THC, 11-OH-DELTA9-THC AND 11-OH-DELTA8-THC) IN MICE.
182220 03-03

11B-PYRIDYL
STUDIES ON BENZODIAZEPINOOXAZOLES. VI. SYNTHESIS AND PHARMACOLOGY OF 11B-PYRIDYL AND 11B-THIENYL DERIVATIVES OF BENZODIAZEPINOOXAZOLES.
180490 02-02

11B-THIENYL
STUDIES ON BENZODIAZEPINOOXAZOLES. VI. SYNTHESIS AND PHARMACOLOGY OF 11B-PYRIDYL AND 11B-THIENYL DERIVATIVES OF BENZODIAZEPINOOXAZOLES.
180490 02-02

14C-CHOLINE
INCORPORATION OF 14C-DIHYDROPHENYLALANINE AND 14C-CHOLINE INTO RAT BRAIN SUBCELLULAR PARTICLES AND THE EFFECT OF PSYCHOACTIVE DRUGS.
192426 04-03

14C-DELTA9-THC
DISTRIBUTION OF 14C-DELTA9-THC IN MALE AND FEMALE RATS.
191969 04-03

14C-DIHYDROPHENYLALANINE
INCORPORATION OF 14C-DIHYDROPHENYLALANINE AND 14C-CHOLINE INTO RAT BRAIN SUBCELLULAR PARTICLES AND THE EFFECT OF PSYCHOACTIVE DRUGS.
192426 04-03

14C-IMIPRAMINE
SOURCES OF VARIABILITY IN THE PHARMACODYNAMICS OF 14C-IMIPRAMINE INCLUDING INTERACTION WITH DIAZEPAM OR THIORIDAZINE.
191925 04-03

14C-NOREPINEPHRINE
EFFECT OF D-AMPHETAMINE (D-A) AND 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) ON THE IN VIVO RELEASE OF 14C-NOREPINEPHRINE (NE) INTO THE LATERAL VENTRICLE OF RATS.
182251 03-03

14C-PSILOCIN
DISTRIBUTION OF 14C-PSILOCIN IN THE BRAINS OF VARIOUS ANIMALS.
192425 04-03

17-KETOSTEROID
STUDIES ON THE URINARY EXCRETION OF CATECHOLAMINES AND 17-KETOSTEROID IN MANIC-DEPRESSIVE PSYCHOSIS.
178623 02-09

18-ACYLYOHIMBAN-17-ONES
ALKALOID STUDIES. 9. PREPARATION OF 18-ACYLYOHIMBAN-17-ONES AND THEIR CONVERSION TO NEW HETEROCYCLIC YOHIMBANS.
185033 03-04

2-AMINOINDANE
THE EFFECTS OF AMPHETAMINE, 2-AMINOINDANE AND 2-AMINOTETRALIN ON THE CONCENTRATIONS OF WHOLE BRAIN NORADRENALINE, DOPAMINE, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC ACID IN THE MOUSE.
174828 01-03

2-AMINOPROPANE
CHEMICAL CONVERSION OF THE PSYCHOTOMIMETIC AMINE 1-(2,5 DIMETHOXY-4-METHYLPHENYL) 2-AMINOPROPANE TO 5-HYDROXYDIMETHYLINDOLE.
187941 04-01

2-AMINOTETRALIN
THE EFFECTS OF AMPHETAMINE, 2-AMINOINDANE AND 2-AMINOTETRALIN ON THE CONCENTRATIONS OF WHOLE BRAIN NORADRENALINE, DOPAMINE, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC ACID IN THE MOUSE.
174828 01-03

2-ARYLALANINES
EFFECT OF 2-ARYLALANINES, 2-ARYLSERINES, TETRAPHENYLBORON AND 1,2 DL(2,4 DICHLOROPHENYL) ETHANOLAMINE ON LEVELS OF SEROTONIN (5-HT), NOREPINEPHRINE (NE) AND DOPAMINE (DM) IN WHOLE BRAIN OF MICE.
182254 03-03

2-ARYLSERINES
EFFECT OF 2-ARYLALANINES, 2-ARYLSERINES, TETRAPHENYLBORON AND 1,2 DL(2,4 DICHLOROPHENYL) ETHANOLAMINE ON LEVELS OF SEROTONIN (5-HT), NOREPINEPHRINE (NE) AND DOPAMINE (DM) IN WHOLE BRAIN OF MICE.
182254 03-03

2-BENZYLMETHYLAMINOETHYL
A NOVEL SPASMOLYTIC AND CNS ACTIVE AGENT: 3-(2-BENZYLMETHYLAMINOETHYL) BENZOIC ACID METHYL ESTER HYDROCHLORIDE.
184581 03-02

2-BUTYLAMINO-1-P-HYDROXYPHENYL
TREATMENT OF CEREBROVASCULAR DISTURBANCES WITH 2-BUTYLAMINO-1-P-HYDROXYPHENYL ETHANOL SULFATE (BAMETHAN).
182790 03-11

2-DEOXY-D-GLUCOSE
CENTRAL HYPOTHERMIA BY 2-DEOXY-D-GLUCOSE: ANTAGONISM BY ALPHA-ADRENERGIC ACTIVATION.
188200 04-03

2-DIETHYLAMINOETHYL
N-(2-DIETHYLAMINOETHYL) 2 (P-HYDROXYPHENOXY) ACETAMIDE, A METABOLITE OF MEFEXAMIDE IN MAN.
187577 04-01

2-IMIDAZOLIN-2-YL-THIO
INTERACTION OF SEROTONIN ANTAGONISTS WITH 3,4-DICHLORO-2-(2-IMIDAZOLIN-2-YL-THIO) 2 ACETOPHENONE HYDROBROMIDE (DITA) AND D-AMPHETAMINE HYDROBROMIDE (DITA) AND D-AMPHETAMINE ON CERTAIN BEHAVIORAL PARAMETERS OF MALE MICE.
192014 04-04

2-OXYAMINO-5-PHENYLBENZODIAZEPINES
BENZODIAZEPINES. 4.2-OXYAMINO-5-PHENYLBENZODIAZEPINES.
185032 03-01

2-PHENYLETHYLAMINE
FURTHER EVIDENCE FOR A ROLE OF 2-PHENYLETHYLAMINE IN THE MODE OF ACTION OF DELTA9-TETRAHYDROCANNABINOL.
179992 02-03
THE INFLUENCE OF PSYCHOTROPIC DRUGS ON THE LEVELS OF ENDOGENOUS 2-PHENYLETHYLAMINE IN RABBIT BRAIN.
187112 03-03

2-THIOUREA
EFFECT OF L-PHENYL-3-2-THIAZOLYL 2-THIOUREA, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON MORPHINE ANALGESIA, TOLERANCE AND PHYSICAL DEPENDENCE.
191769 04-03

3-ALKYLAMINOPYRROLIDINO-SUBSTITUTED
D-(R)- AND L-(S) 3-ALKYLAMINOPYRROLIDINO-SUBSTITUTED DIHYDRODIBENZOTHIEPINS, XANTHENES, AND DIPHENYLMETHANES.
187937 04-01

3-ARYL-3-HYDROXYQUINOLIZIDINES
3-ARYL-3-HYDROXYQUINOLIZIDINES WITH POTENTIAL HYPOTENSIVE, ANTIDEPRESSANT, AND ANALGETIC ACTIVITY.
187938 04-01

3-KETOBUTOBARBITONE
BUTOBARBITONE METABOLISM IN MAN: IDENTIFICATION OF 3-KETOBUTOBARBITONE.
183793 03-13

3-METHOXY-4-HYDROXYPHENYLGLYCOL
EFFECTS OF PHENOXYBENZAMINE, ACEPERONE AND CLONIDINE ON THE LEVEL OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL, (MOPEG) IN RAT BRAIN.
180059 02-03
ESTIMATION OF THE CONTRIBUTION OF PERIPHERAL AND CENTRAL NORADRENERGIC NEURONES TO URINARY 3-METHOXY-4-HYDROXYPHENYLGLYCOL IN THE RAT.
192335 04-03

3-METHOXYTYRAMINE
CACTUS ALKALOIDS. XIX. CRYSTALLIZATION OF MESCALINE HCL AND 3-METHOXYTYRAMINE HCL FROM TRICHOCEREUS-PACHANOI.
192878 04-01

3-METHYLCHOLANTHRENE
EFFECT OF PHENOBARBITAL AND 3-METHYLCHOLANTHRENE PRETREATMENT ON THE HEPATOTOXICITY OF 1,1,1 TRICHLOROETHANE AND 1,1,2 TRICHLOROETHANE.
167361 01-05

3-ONIUM
3-ONIUM DERIVATIVES OF 1,4 BENZODIAZEPIN-2-ONES WITH TERTIARY ORGANIC BASES.
187942 04-01

3-QUINUCLIDINYLBENZILATE
THE INFLUENCE OF 3-QUINUCLIDINYLBENZILATE ON THE BEHAVIOUR OF RATS IN A CIRCULAR RUNWAY.
187259 04-04

3-SUBSTITUTED
SYNTHESIS AND CNS ACTIVITY OF 3-SUBSTITUTED 7-CHLORO-5-PHENYLBENZOTRIAZEPIN-2-ONES.
185978 03-01

3H-AMPHETAMINE
CORTICAL SYNAPTOSOMAL UPTAKE AND SUBSYNAPTOSOMAL DISTRIBUTION OF 3H-NOREPINEPHRINE AND 3H-AMPHETAMINE: MODIFICATION BY TRICYCLIC AND PSYCHOACTIVE AGENTS IN VITRO. (PH.D. DISSERTATION).
172020 01-03

3H-D-AMPHETAMINE
BRAIN TO SERUM DISTRIBUTION OF RADIOACTIVITY OF INJECTED 3H-D-AMPHETAMINE IN DIFFERENTIALLY HOUSED MICE.
168418 01-03

3H-DELTA9-TETRAHYDROCANNABINOL
3H-DELTA9-TETRAHYDROCANNABINOL (THC) METABOLISM IN RHESUS AND SQUIRREL MONKEYS.
175751 02-03

3H-DOPAMINE
THE INHIBITION OF 3H-DOPAMINE UPTAKE INTO RAT STRIATAL BY VERATRIDINE AND BATRACHOTOXIN. (UNPUBLISHED PAPER).
173380 01-03
EFFECT OF DESIPRAMINE ON RAT CORTEX SLICES INCUBATED WITH 3H-DOPAMINE.
190310 04-03

3H-NOREPINEPHRINE
CORTICAL SYNAPTOSOMAL UPTAKE AND SUBSYNAPTOSOMAL DISTRIBUTION OF 3H-NOREPINEPHRINE AND 3H-AMPHETAMINE: MODIFICATION BY TRICYCLIC AND PSYCHOACTIVE AGENTS IN VITRO. (PH.D. DISSERTATION).
172020 01-03
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON THE METABOLISM OF 3H-5-HYDROXYTRYPTAMINE AND 3H-NOREPINEPHRINE IN THE RAT BRAIN.
183787 03-03
A COMPARISON OF THE EFFECTS OF AMPHETAMINE AND ITS METABOLITES, P-HYDROXYAMPHETAMINE AND P-HYDROXYNOREPHEDRINE, ON UPTAKE, RELEASE AND CATABOLISM OF 3H-NOREPINEPHRINE IN CEREBRAL CORTEX OF RAT BRAIN.
186669 03-03
SPECIFICITY OF BLOCKADE OF THE NICOTINE INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ADRENERGIC NEURONS OF THE GUINEA-PIG HEART BY VARIOUS PHARMACOLOGICAL AGENTS.
186676 03-03

3H-PROCHLORPERAZINE
IN VIVO 3H-PROCHLORPERAZINE METABOLISM IN THE GUINEA-PIG AND RABBIT.
173875 01-03

3H-SEROTONIN
EFFECT OF LILLY-110140, 3-(P-TRIFLUOROMETHYLPHENOXY) N METHYL-3-PHENYLPROPYLAMINE ON SYNTHESIS OF 3H-SEROTONIN FROM 3H-TRYPTOPHAN IN RAT BRAIN.
191951 04-03

3H-TRYPTOPHAN
EFFECT OF LILLY-110140, 3-(P-TRIFLUOROMETHYLPHENOXY) N METHYL-3-PHENYLPROPYLAMINE ON SYNTHESIS OF 3H-SEROTONIN FROM 3H-TRYPTOPHAN IN RAT BRAIN.
191951 04-03

3H-5-HT
CHLORIMIPRAMINE AND LSD: DIFFERENTIAL EFFECTS ON THE IN VIVO RELEASE OF 3H-5-HT.
191949 04-03

3H-5-HYDROXYTRYPTAMINE
THE UPTAKE, RETENTION AND METABOLISM OF 3H-5-HYDROXYTRYPTAMINE IN BRAIN SLICES AND ILEUM FROM THE RAT: EFFECTS OF COCAINE, DESMETHYLIMIPRAMINE AND RESERPINE. (PH.D. DISSERTATION).
168131 01-03
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON THE METABOLISM OF 3H-5-HYDROXYTRYPTAMINE AND 3H-NOREPINEPHRINE IN THE RAT BRAIN.
183787 03-03
METHADONE INHIBITION OF 3H-5-HYDROXYTRYPTAMINE UPTAKE BY SYNAPTOSOMES.
183896 03-03

32P
DDT EFFECT ON 32P INCORPORATION FROM GAMMA-LABELLED ATP INTO PROTEINS FROM LOBSTER NERVE.
191315 04-03

4-CHLOROAMPHETAMINE
LONG-TERM EFFECTS OF 4-CHLOROAMPHETAMINE ON BRAIN 5-HYDROXYINDOLE METABOLISM IN RATS.
183869 03-03

4-HYDROXYLATION
THE 4-HYDROXYLATION OF AMPHETAMINE AND PHENTERMINE BY RAT LIVER MICROSOMES.
191921 04-03

5-DIAZOIMIDAZOLE-4-CARBOXAMIDE
POTENTIATION OF BARBITURATE HYPNOSIS BY 5-DIAZOIMIDAZOLE-4-CARBOXAMIDE AND ITS DERIVATIVES.
182113 02-03

5-HT
THE EFFECTS OF 6-OH-DOPAMINE ON THE REPRODUCTION AND NA AND 5-HT CONTENTS OF SOME TISSUES IN MICE.
171613 01-03
EFFECTS OF P-CHLOROPHENYLALANINE (PCPA) AND NIALAMIDE ON 5-HYDROXYTRYPTAMINE (5-HT) IN THE TRANSECTED SPINAL CORD.
171623 01-03
EFFECT OF IMIPRAMINE ON THE TURNOVER OF BRAIN 5-HT IN POSTNATAL RATS.
171624 01-03
ANTAGONISM OF P-CHLOROAMPHETAMINE (PCA) INDUCED DEPLETION OF 5-HT FROM RAT BRAIN BY SOME THYMOLEPTICS AND OTHER PSYCHOTROPIC DRUGS.
171628 01-03
STRUCTURE-ACTIVITY RELATIONS FOR THE INHIBITION OF 5-HT UPTAKE INTO RAT HYPOTHALAMIC HOMOGENATES BY SEROTONIN AND TRYPTAMINE ANALOGUES.
175233 02-03
ROLE OF 5-HT IN THE ACTION OF SOME DRUGS AFFECTING EXTRAPYRAMIDAL SYSTEM.
178757 02-04

A NEW MODIFICATION FOR STUDYING 5-HT UPTAKE BY BLOOD PLATELETS: A RE-EVALUATION OF TRICYCLIC ANTIDEPRESSANTS AS UPTAKE INHIBITORS.
180055 02-06

ORAL 5-HTP IN PRIMARY AUTISM WITH 5-HT BINDING DEFECT.
181392 02-13

IN VIVO MEASUREMENT OF THE RELEASE OF 5-HYDROXYTRYPTAMINE (5-HT) FROM THE HIPPOCAMPUS OF THE RAT: EFFECT OF RO-4-1284, PARGYLINE AND P-CHLOROAMPHETAMINE (PCA).
182140 02-03

ANALYSIS OF DRUG BLOCK OF LSD/5-HT/GABA BY MONITORING NEURONAL MEMBRANE CHANGES.
182143 02-03

EFFECT OF 2-ARYLALANINES, 2-ARYLSERINES, TETRAPHENYLBORON AND 1,2 DL(2,4 DICHLOROPHENYL) ETHANOLAMINE ON LEVELS OF SEROTONIN (5-HT), NOREPINEPHRINE (NE) AND DOPAMINE (DM) IN WHOLE BRAIN OF MICE.
182254 03-03

EFFECTS OF LSD ON SYNTHESIS AND RELEASE OF 5-HT IN RAT BRAIN SLICES.
188164 04-03

ESTIMATION OF THE RATE OF 5-HT SYNTHESIS IN THE MOUSE BRAIN BY VARIOUS METHODS.
188976 04-03

BLOCKADE OF EXCITATORY 5-HT SYNAPSE BY LSD.
191950 04-03

5-HTP

BEHAVIORAL EFFECT OF TRICYCLIC THYMOLEPTICS AND CHLORPHENIRAMINE IN MICE AFTER PRETREATMENT WITH 5 HYDROXYTRYPTOPHAN (5-HTP).
171609 01-04

ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN DIMETHYLAMINOPROPYLTHIOCINNAMANILIDE HYDROCHLORIDE), A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN (5-HTP) AND ALPHA-METHYLTRYPTAMINE.
176861 02-04

SLEEP CHANGES IN CHRONIC SCHIZOPHRENICS: EFFECTS OF 5-HYDROXYTRYPTOPHAN (5-HTP). (UNPUBLISHED PAPER
178578 02-08

ORAL 5-HTP IN PRIMARY AUTISM WITH 5-HT BINDING DEFECT.
181392 02-13

DOSE DEPENDENT POTENTIATION OR INHIBITION BY RO-4-4602 OF 5-HTP HYPERTHERMIA IN RABBITS.
185996 03-03

5-HYDROXYDIMETHYLINDOLE

CHEMICAL CONVERSION OF THE PSYCHOTOMIMETIC AMINE 1-(2,5 DIMETHOXY-4-METHYLPHENYL) 2-AMINOPROPANE TO 5-HYDROXYDIMETHYLINDOLE.
187941 04-01

5-HYDROXYINDOLE

LONG-TERM EFFECTS OF 4-CHLOROAMPHETAMINE ON BRAIN 5-HYDROXYINDOLE METABOLISM IN RATS.
183869 03-03

5-HYDROXYINDOLEACETIC

THE EFFECTS OF AMPHETAMINE, 2-AMINOINDANE AND 2-AMINOTETRALIN ON THE CONCENTRATIONS OF WHOLE BRAIN NORADRENALINE, DOPAMINE, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC ACID IN THE MOUSE.
174828 01-03

AMITRIPTYLINE IN MAN: DECREASED FORMATION OF CENTRAL 5-HYDROXYINDOLEACETIC ACID.
177736 02-13

THE ELIMINATION OF 5-HYDROXYINDOLEACETIC ACID FROM CEREBROSPINAL FLUID: CHARACTERISTICS OF THE ACID TRANSPORT SYSTEM OF THE CHOROID PLEXUS.
182718 03-03

METHIOTHEPIN ELEVATION OF 5-HYDROXYINDOLEACETIC ACID LEVELS IN VARIOUS ANATOMIC REGIONS OF RAT BRAIN.
187831 04-03

5-HYDROXYTRYPTAMINE

THE EFFECT OF D- AND L-P-CHLOROPHENYLALANINE ON THE METABOLISM OF 5-HYDROXYTRYPTAMINE IN BRAIN.
168748 01-03

DOPAMINE AND 5-HYDROXYTRYPTAMINE INHIBIT FEEDING IN RATS.
170177 01-04

EFFECTS OF P-CHLOROPHENYLALANINE (PCPA) AND NIALAMIDE ON 5-HYDROXYTRYPTAMINE (5-HT) IN THE TRANSECTED SPINAL CORD.
171623 01-03

A SENSITIVE GAS CHROMATOGRAPHIC PROCEDURE FOR THE ESTIMATION OF NORADRENALINE, DOPAMINE AND 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
171971 01-01

THE EFFECTS OF AMPHETAMINE, 2-AMINOINDANE AND 2-AMINOTETRALIN ON THE CONCENTRATIONS OF WHOLE BRAIN NORADRENALINE, DOPAMINE, 5-HYDROXYTRYPTAMINE AND 5-HYDROXYINDOLEACETIC ACID IN THE MOUSE.
174828 01-03

THE EFFECT OF PHENIRAMINE AND ITS STRUCTURAL ANALOGUES ON 5-HYDROXYTRYPTAMINE IN RAT AND MOUSE BRAIN.
175240 02-03

5-HYDROXYTRYPTAMINE AND HISTAMINE EFFECTS ON RETICULOCEREBELLAR EVOKED POTENTIALS.
182121 02-03

IN VIVO MEASUREMENT OF THE RELEASE OF 5-HYDROXYTRYPTAMINE (5-HT) FROM THE HIPPOCAMPUS OF THE RAT: EFFECT OF RO-4-1284, PARGYLINE AND P-CHLOROAMPHETAMINE (PCA).
182140 02-03

EVIDENCE FOR THE ACTION OF D-LYSERGIC ACID DIETHYLAMIDE, MESCALINE AND BUFOTENINE ON 5-HYDROXYTRYPTAMINE RECEPTORS IN UMBILICAL VASCULATURE.
182716 03-03

PHARMACOLOGICAL ANALYSIS OF NOREPINEPHRINE AND 5-HYDROXYTRYPTAMINE REMOVAL FROM THE PULMONARY CIRCULATION: DIFFERENTIATION OF UPTAKE SITES FOR EACH AMINE.
182717 03-03

THE EFFECTS OF 5-HYDROXYTRYPTAMINE AND SOME RELATED COMPOUNDS ON THE CAT SUPERIOR CERVICAL GANGLION IN SITU.
184197 03-03

HISTO-AUTORADIOGRAPHIC INVESTIGATIONS ON THE DISTRIBUTION OF INJECTED 5-HYDROXYTRYPTAMINE (SEROTONIN) IN THE BRAIN AND THE PITUITARY OF MICE.
185900 03-03

EFFECTS OF AMPHETAMINES ON REGIONAL TRYPTOPHAN HYDROXYLASE ACTIVITY AND SYNAPTOSOMAL CONVERSION OF TRYPTOPHAN TO 5-HYDROXYTRYPTAMINE IN RAT BRAIN.
186674 03-03

INTESTINAL EFFECTS OF 5-HYDROXYTRYPTAMINE AND MORPHINE IN GUINEA-PIGS, DOGS, CATS AND MONKEYS.
188202 04-03

BENZODIAZEPINES AND BARBITURATES: TURNOVER CHANGES IN CENTRAL 5-HYDROXYTRYPTAMINE PATHWAYS.
189611 04-03

EFFECT OF LITHIUM ON CENTRAL METABOLISM OF 5-HYDROXYTRYPTAMINE.
190337 04-03

5-HYDROXYTRYPTAMINE AND NORADRENALINE IN THE HIPPOCAMPAL REGION: EFFECT OF TRANSECTION OF AFFERENT PATHWAYS ON ENDOGENOUS LEVELS, HIGH AFFINITY UPTAKE AND SOME TRANSMITTER RELATED ENZYMES.
191319 04-03

PERMANENT ALTERATIONS IN 5-HYDROXYTRYPTAMINE METABOLISM IN DISCRETE AREAS OF RAT BRAIN FOLLOWING EXPOSURE TO DRUGS DURING THE PERIOD OF DEVELOPMENT.
191383 04-03

5-HYDROXYTRYPTAMINE-14C

ALTERATION OF 5-HYDROXYTRYPTAMINE-14C EFFLUX BY NICOTINE IN RAT BRAIN AREA SLICES.
172925 01-03

5-HYDROXYTRYPTOPHAN

PARADOXICAL BLOCKADE BY P-CHLOROPHENYLALANINE OF 5-HYDROXYTRYPTOPHAN FACILITATORY ACTIONS ON SPINAL REFLEXES.
168436 01-03

P-CHLOROPHENYLALANINE INDUCED ALTERATIONS IN THE BEHAVIORAL EFFECTS OF 5-HYDROXYTRYPTOPHAN.
174034 01-04

ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN DIMETHYLAMINOPROPYLTHIOCINNAMANILIDE HYDROCHLORIDE), A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN (5-HTP) AND ALPHA-METHYLTRYPTAMINE.
176861 02-04

ATTENUATION OF CONFLICT BEHAVIOR WITH CINANSERIN, A SEROTONIN ANTAGONIST: REVERSAL OF THE EFFECT WITH 5-HYDROXYTRYPTOPHAN AND ALPHA-METHYLTRYPTAMINE.
176873 02-04

SLEEP CHANGES IN CHRONIC SCHIZOPHRENICS: EFFECTS OF 5-HYDROXYTRYPTOPHAN (5-HTP). (UNPUBLISHED PAPER
178578 02-08

NON-SPECIFICITY OF 5-HYDROXYTRYPTOPHAN IN REPLETING BRAIN SEROTONIN IN RATS WITH MFB LESIONS.
182725 03-03

5-HYDROXYTRYPTOPHAN AS AN ANTIDEPRESSANT: THE PREDICTIVE VALUE OF THE PROBENECID TEST.
184652 03-09

ONE CASE OF AGRYPNIA (4 MONTHS WITHOUT SLEEP) IN A MORVAN DISEASE: FAVORABLE ACTION OF 5-HYDROXYTRYPTOPHAN.
187237 03-14

5-METHOXYTRYPTAMINE

EFFECT OF 5-METHOXYTRYPTAMINE ON SERUM CALCIUM AND PHOSPHATE IN RATS.
186678 03-03

5-OTD

THE INFLUENCE OF NEUROTROPIC DRUGS ON MONOAMINE OXIDASE (MAO) AND 5-OXYTRYPTOPHANE DECARBOXYLASE (5-OTD) ACTIVITY IN THE BRAIN.
183142 03-13

5-OXYTRYPTOPHANE
THE INFLUENCE OF NEUROTROPIC DRUGS ON MONOAMINE OXIDASE (MAO) AND 5-OXYTRYPTOPHANE DECARBOXYLASE (5-OTD) ACTIVITY IN THE BRAIN.
183142 03-13

5-PROPIONOXYBARBITURIC
ANALGESICS. I. SELECTED 5-SUBSTITUTED 5-PROPIONOXYBARBITURIC ACIDS.
187939 04-01

6-HDA
RECOVERY OF FEEDING AFTER 6-HYDROXYDOPAMINE (6-HDA) OR LATERAL HYPOTHALAMIC LESIONS: THE ROLE OF CATECHOLAMINES.
182213 03-03

6-HYDROXYDOPA
BEHAVIOURAL AND BIOCHEMICAL EFFECTS OF 6-HYDROXYDOPA IN RATS.
186571 03-04
ON THE BEHAVIORAL AND NEUROCHEMICAL ACTIONS OF 6-HYDROXYDOPA AND 5,6 DIHYDROXYTRYPTAMINE IN RATS.
187380 04-03

6-HYDROXYDOPAMINE
EFFECT OF 6-HYDROXYDOPAMINE ON DARK ADAPTATION IN THE RAT RETINA.
167358 01-03
RECOVERY OF FEEDING AND DRINKING BY RATS AFTER INTRAVENTRICULAR 6-HYDROXYDOPAMINE OR LATERAL HYPOTHALAMIC LESIONS.
168484 01-03
COMPARATIVE EFFECTS OF 6-HYDROXYDOPAMINE AND OF RESERPINE ON OUABAIN TOXICITY IN THE RAT.
172598 01-05
ADRENALINE, NORADRENALINE AND DOPAMINE LEVELS IN BRAIN AND HEART AFTER ADMINISTRATION OF 6-HYDROXYDOPAMINE AND GUANETHIDINE TO NEWBORN MICE.
177338 02-03
EFFECT OF 6-HYDROXYDOPAMINE ON THE DURATION OF HEXOBARBITAL SLEEP IN RATS.
178558 02-03
EXCRETION OF NOREPINEPHRINE AND DOPAMINE ALCOHOLIC METABOLITES AFTER 6-HYDROXYDOPAMINE.
179986 02-03
DECREASED ANOREXIA, EXCITEMENT AND STEREOTYPY TO D-AMPHETAMINE AFTER LATERAL HYPOTHALAMIC 6-HYDROXYDOPAMINE (6-OHDA) INJECTIONS.
182136 02-04
LEARNING AND MEMORY AFTER 6-HYDROXYDOPAMINE (6-OHDA).
182210 02-04
RECOVERY OF FEEDING AFTER 6-HYDROXYDOPAMINE (6-HDA) OR LATERAL HYPOTHALAMIC LESIONS: THE ROLE OF CATECHOLAMINES.
182213 03-03
COMPARISON OF TYROSINE HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE INHIBITION WITH THE EFFECTS OF VARIOUS 6-HYDROXYDOPAMINE TREATMENTS ON D-AMPHETAMINE INDUCED MOTOR ACTIVITY.
186699 03-03
LEARNING IMPAIRMENT IN RATS AFTER 6-HYDROXYDOPAMINE INDUCED DEPLETION OF BRAIN CATECHOLAMINES.
187420 04-04
EFFECTS ON HOMEOSTASIS OF INTRAVENTRICULAR INJECTIONS OF 6-HYDROXYDOPAMINE IN RATS.
187695 04-03
EFFECTS OF INTRACISTERNAL 6-HYDROXYDOPAMINE TREATMENT ON ACQUISITION AND PERFORMANCE OF RATS IN A DOUBLE T-MAZE.
187696 04-04
CARDIOVASCULAR REACTIVITY IN THE DOG AFTER CHEMICAL SYMPATHECTOMY WITH 6-HYDROXYDOPAMINE.
187807 04-03
INTRACEREBRAL INJECTION OF 6-HYDROXYDOPAMINE AND HYDROGEN PEROXIDE IN CATS: SPECIFIC AND NONSPECIFIC EFFECTS ON STRIATAL BIOGENIC AMINES.
188426 04-03
EFFECTS OF CATECHOLAMINE DEPLETING DRUGS AND AMPHETAMINE ON SELF-STIMULATION OF BRAIN FOLLOWING VARIOUS 6-HYDROXYDOPAMINE TREATMENTS.
189515 04-04
AN OVERVIEW OF THE 6-HYDROXYDOPAMINE THEORY OF SCHIZOPHRENIA.
190239 04-08
RELATIONSHIP OF CATECHOLAMINE NEURAL SYSTEMS TO THE BEHAVIORAL ALTERATIONS PRODUCED BY 6-HYDROXYDOPAMINE ADMINISTRATION INTO BRAIN.
191518 04-03
EFFECTS OF 6-HYDROXYDOPAMINE ON ANOREXIA PRODUCED BY D-AMPHETAMINE AND RELATED PHENYLETHYLAMINES.
191905 04-03

6-HYDROXYTRYPTAMINE
EFFECTS OF INTRACEREBRAL INJECTION OF 5,6-HYDROXYTRYPTAMINE ON CEREBRAL MONOAMINES AND SLEEP STATES IN THE CAT/.
189023 04-02

6-OH-DOPAMINE
THE EFFECTS OF 6-OH-DOPAMINE ON THE REPRODUCTION AND NA AND 5-HT CONTENTS OF SOME TISSUES IN MICE.
171613 01-03

6-OHDA
DECREASED ANOREXIA, EXCITEMENT AND STEREOTYPY TO D-AMPHETAMINE AFTER LATERAL HYPOTHALAMIC 6-HYDROXYDOPAMINE (6-OHDA) INJECTIONS.
182136 02-04
LEARNING AND MEMORY AFTER 6-HYDROXYDOPAMINE (6-OHDA).
182210 02-04

7-CHLORO-5-PHENYLBENZOTRIAZEPIN-2-ONES
SYNTHESIS AND CNS ACTIVITY OF 3-SUBSTITUTED 7-CHLORO-5-PHENYLBENZOTRIAZEPIN-2-ONES.
185978 03-01

7-HYDROXY-DELTA1-TETRAHYDROCANNABINOL
THE DISTRIBUTION OF DELTA1-TETRAHYDROCANNABINOL AND 7-HYDROXY-DELTA1-TETRAHYDROCANNABINOL IN THE MOUSE BRAIN AFTER INTRAVENTRICULAR INJECTION.
172596 01-03
BLOOD AND BRAIN LEVELS OF DELTA1-TETRAHYDROCANNABINOL IN MICE -- THE EFFECT OF 7-HYDROXY-DELTA1-TETRAHYDROCANNABINOL.
177333 02-03

7-OXO-DELTA1-TETRAHYDROCANNABINOL
7-OXO-DELTA1-TETRAHYDROCANNABINOL: A NOVEL METABOLITE OF DELTA1-TETRAHYDROCANNABINOL.
187574 04-01

8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE
ACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MICE, RATS, RABBITS AND DOGS.
173548 01-05
SUBACUTE TOXICITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) IN MALE AND FEMALE RATS: ORAL ADMINISTRATION FOR ONE MONTH.
177097 02-05
ANTICONVULSIVE ACTIVITY OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) AND ITS EFFECT ON LIMBIC SYSTEM.
177099 02-02
EFFECT OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) ON THE DAYTIME SLEEP-WAKEFULNESS PATTERNS IN MONKEYS.
181657 02-02
EFFECT OF 8-CHLORO-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D-40TA) ON THE DAYTIME SLEEP-WAKEFULNESS PATTERNS IN NORMAL AND P-CHLOROPHENYLALANINE INSOMNIAC CATS.
181658 02-02

8-HYDROXYCHLORPROMAZINES
TISSUE LOCALIZATION OF 7- AND 8-HYDROXYCHLORPROMAZINES.
189589 04-03

☆ U. S. GOVERNMENT PRINTING OFFICE : 1975 630-236/390

Computer Information Services of the National Clearinghouse for Mental Health Information

Searches of the NCMHI computer-based information system will be done on request. These reader-generated bibliographies are available without charge to anyone within the mental health community.

Requests for a printout on a topic not covered by the abstracts in this issue or other NCMHI publications should be sent directly to the Clearinghouse. The request should include the inquirer's name, address, professional affiliation, and phone number, along with a clear and specific statement of the information desired. Either a letter or the order blank below should be sent to the following address:

National Clearinghouse for Mental
Health Information
Alcohol, Drug Abuse, and
Mental Health Administration
5600 Fishers Lane
Rockville, Maryland 20852

Date _____

Name of requester _____

Address _____

Organization _____

Phone number (include area code) _____

Information requested (please be as specific as possible) _____

_____

_____

_____

_____

PSYCHOPHARMACOLOGY ABSTRACTS

Questions about Clearinghouse service should be addressed to:

Psychopharmacology Abstracts
National Clearinghouse for Mental Health Information
Alcohol, Drug Abuse, and Mental Health Administration
5600 Fishers Lane
Rockville, Maryland 20852

For information on subscriptions and the purchase of single copies of the *Abstracts* (Vol. 7 onward), please refer to page ii of this issue.

DEPARTMENT OF
HEALTH, EDUCATION, AND WELFARE
PUBLIC HEALTH SERVICE

ALCOHOL, DRUG ABUSE, AND
MENTAL HEALTH ADMINISTRATION
5600 FISHERS LANE
ROCKVILLE, MARYLAND 20852

OFFICIAL BUSINESS
Penalty for private use, $300

POSTAGE AND FEES PAID
U.S. DEPARTMENT OF H.E.W.
HEW 389

U.S.MAIL

NOTICE OF MAILING CHANGE

☐ Check here if you wish to discontinue receiving this type of publication.

☐ Check here if your address has changed and you wish to continue receiving this type of publication. (Be sure to furnish your complete address including zip code.)

Tear off cover with address label still affixed and send to:

Alcohol, Drug Abuse, and Mental Health Administration
Printing and Publications Management Section
5600 Fishers Lane (Rm. 6-105)
Rockville, Maryland 20852

DHEW Publication No. (ADM) 75-150
Printed 1975

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
PUBLIC HEALTH SERVICE

ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION